<?xml version="1.0" encoding="UTF-8"?>
<corpus source="DS3">
    <document id="DS3.d0" origId="9931486">
        <sentence id="DS3.d0.s0" origId="9931486-3" text="The catA1 gene was clustered with catB1 encoding MC I, catC1 encoding muconolactone isomerase (MI), catD encoding beta-ketoadipate enol-lactone hydrolase (ELH), and ORFR1 encoding a putative LysR-type regulator.">
            <entity id="DS3.d0.s0.e0" origId="P62577,Q6J0R8" charOffset="4-9" type="protein" text="catA1"/>
            <entity id="DS3.d0.s0.e1" origId="542" charOffset="70-83" type="compound" text="muconolactone"/>
            <entity id="DS3.d0.s0.e2" origId="93" charOffset="114-130" type="compound" text="beta-ketoadipate"/>
            <entity id="DS3.d0.s0.e3" origId="104" charOffset="131-143" type="compound" text="enol-lactone"/>
            <pair e1="DS3.d0.s0.e2" e2="DS3.d0.s0.e0" id="DS3.d0.s0.i0" interaction="False" />
            <pair e1="DS3.d0.s0.e1" e2="DS3.d0.s0.e0" id="DS3.d0.s0.i1" interaction="False" />
            <pair e1="DS3.d0.s0.e3" e2="DS3.d0.s0.e0" id="DS3.d0.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1" origId="9931487">
        <sentence id="DS3.d1.s0" origId="9931487-3" text="GPR55 was identified from the expressed sequence tags (EST) database whereas GPR52 and pseudogene PsiGPR53 originated from the high throughput genome (HTG) database.">
            <entity id="DS3.d1.s0.e0" origId="Q9Y2T6,A8K858" charOffset="0-5" type="protein" text="GPR55"/>
            <entity id="DS3.d1.s0.e1" origId="Q9Y2T5,F2YGU0" charOffset="77-82" type="protein" text="GPR52"/>
            <entity id="DS3.d1.s0.e2" origId="656917" charOffset="151-154" type="compound" text="HTG"/>
            <pair e1="DS3.d1.s0.e2" e2="DS3.d1.s0.e1" id="DS3.d1.s0.i0" interaction="False" />
            <pair e1="DS3.d1.s0.e2" e2="DS3.d1.s0.e0" id="DS3.d1.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1.s1" origId="9931487-5" text="GPR52 and PsiGPR53 were amplified from human genomic DNA using primers based on the HTG sequences.">
            <entity id="DS3.d1.s1.e0" origId="Q9Y2T5,F2YGU0" charOffset="0-5" type="protein" text="GPR52"/>
            <entity id="DS3.d1.s1.e1" origId="656917" charOffset="84-87" type="compound" text="HTG"/>
            <pair e1="DS3.d1.s1.e1" e2="DS3.d1.s1.e0" id="DS3.d1.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1.s2" origId="9931487-9" text="GPR52 gene localized to chromosome 1q24 shares the highest identity with GPR21 (71%), histamine H2 (27%) and 5-HT4 (26%) human receptors.">
            <entity id="DS3.d1.s2.e0" origId="Q9Y2T5,F2YGU0" charOffset="0-5" type="protein" text="GPR52"/>
            <entity id="DS3.d1.s2.e1" origId="Q99679,H9NIL4,B4DSD1" charOffset="73-78" type="protein" text="GPR21"/>
            <entity id="DS3.d1.s2.e2" origId="774" charOffset="86-95" type="compound" text="histamine"/>
            <entity id="DS3.d1.s2.e3" origId="783" charOffset="96-98" type="compound" text="H2"/>
            <entity id="DS3.d1.s2.e4" origId="Q13639" charOffset="109-114" type="protein" text="5-HT4"/>
            <pair e1="DS3.d1.s2.e3" e2="DS3.d1.s2.e0" id="DS3.d1.s2.i0" interaction="False" />
            <pair e1="DS3.d1.s2.e3" e2="DS3.d1.s2.e1" id="DS3.d1.s2.i1" interaction="False" />
            <pair e1="DS3.d1.s2.e3" e2="DS3.d1.s2.e4" id="DS3.d1.s2.i2" interaction="False" />
            <pair e1="DS3.d1.s2.e2" e2="DS3.d1.s2.e0" id="DS3.d1.s2.i3" interaction="False" />
            <pair e1="DS3.d1.s2.e2" e2="DS3.d1.s2.e1" id="DS3.d1.s2.i4" interaction="False" />
            <pair e1="DS3.d1.s2.e2" e2="DS3.d1.s2.e4" id="DS3.d1.s2.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d2" origId="9931492">
        <sentence id="DS3.d2.s0" origId="9931492-3" text="Out of the expressed PKC isoforms alpha, gamma, epsilon, zeta and lambda only the conventional isoforms PKC alpha and gamma responded to glutamate.">
            <entity id="DS3.d2.s0.e0" origId="P17252,Q7Z727,Q02156,L7RTI5,Q05513" charOffset="21-61" type="protein" text="PKC isoforms alpha, gamma, epsilon, zeta"/>
            <entity id="DS3.d2.s0.e1" origId="P17252,Q7Z727" charOffset="104-113" type="protein" text="PKC alpha"/>
            <entity id="DS3.d2.s0.e2" origId="23327,33032,611,57109091" charOffset="137-146" type="compound" text="glutamate"/>
            <pair e1="DS3.d2.s0.e2" e2="DS3.d2.s0.e1" id="DS3.d2.s0.i0" interaction="False" />
            <pair e1="DS3.d2.s0.e2" e2="DS3.d2.s0.e0" id="DS3.d2.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d2.s1" origId="9931492-4" text="Using subcellular fractionation and Western blotting with isoform-specific antibodies and immunocytochemical localization with confocal laser scanning microscopy, we observed that phorbol ester and glutamate have different effects on PKC isoform redistribution: Whereas phorbol ester resulted in translocation of PKC alpha and PKC gamma toward a membrane fraction, the glutamate-mediated rise in intracellular calcium concentration induced a translocation mainly toward a detergent-insoluble, cytoskeletal fraction.">
            <entity id="DS3.d2.s1.e0" origId="22833501,27924,70702034" charOffset="180-193" type="compound" text="phorbol ester"/>
            <entity id="DS3.d2.s1.e1" origId="23327,33032,611,57109091" charOffset="198-207" type="compound" text="glutamate"/>
            <entity id="DS3.d2.s1.e2" origId="22833501,27924,70702034" charOffset="270-283" type="compound" text="phorbol ester"/>
            <entity id="DS3.d2.s1.e3" origId="P17252,Q7Z727" charOffset="313-322" type="protein" text="PKC alpha"/>
            <entity id="DS3.d2.s1.e4" origId="P05129" charOffset="327-336" type="protein" text="PKC gamma"/>
            <entity id="DS3.d2.s1.e5" origId="23327,33032,611,57109091" charOffset="369-378" type="compound" text="glutamate"/>
            <entity id="DS3.d2.s1.e6" origId="22044544,5460341" charOffset="410-417" type="compound" text="calcium"/>
            <pair e1="DS3.d2.s1.e6" e2="DS3.d2.s1.e4" id="DS3.d2.s1.i0" interaction="False" />
            <pair e1="DS3.d2.s1.e6" e2="DS3.d2.s1.e3" id="DS3.d2.s1.i1" interaction="False" />
            <pair e1="DS3.d2.s1.e0" e2="DS3.d2.s1.e4" id="DS3.d2.s1.i2" interaction="False" />
            <pair e1="DS3.d2.s1.e0" e2="DS3.d2.s1.e3" id="DS3.d2.s1.i3" interaction="False" />
            <pair e1="DS3.d2.s1.e1" e2="DS3.d2.s1.e4" id="DS3.d2.s1.i4" interaction="False" />
            <pair e1="DS3.d2.s1.e1" e2="DS3.d2.s1.e3" id="DS3.d2.s1.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d2.s2" origId="9931492-5" text="Immunocytochemical analysis revealed an isoform-specific translocation following glutamate treatment: PKC gamma was translocated mainly to cytoplasmic, organelle-like structures, whereas PKC alpha redistributed to the plasma membrane and into the cell nucleus.">
            <entity id="DS3.d2.s2.e0" origId="23327,33032,611,57109091" charOffset="81-90" type="compound" text="glutamate"/>
            <entity id="DS3.d2.s2.e1" origId="P05129" charOffset="102-111" type="protein" text="PKC gamma"/>
            <entity id="DS3.d2.s2.e2" origId="P17252,Q7Z727" charOffset="187-196" type="protein" text="PKC alpha"/>
            <pair e1="DS3.d2.s2.e0" e2="DS3.d2.s2.e1" id="DS3.d2.s2.i0" interaction="False" />
            <pair e1="DS3.d2.s2.e0" e2="DS3.d2.s2.e2" id="DS3.d2.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d3" origId="9931493">
        <sentence id="DS3.d3.s0" origId="9931493-1" text="The human CASP8 gene, whose product is also known as caspase 8 and FLICE, encodes an interleukin-1beta converting enzyme (ICE)-related cysteine protease that is activated by the engagement of several different death receptors.">
            <entity id="DS3.d3.s0.e0" origId="Q14790,A0A024R3Z8" charOffset="10-15" type="protein" text="CASP8"/>
            <entity id="DS3.d3.s0.e1" origId="Q14790,A0A024R3Z8" charOffset="53-62" type="protein" text="caspase 8"/>
            <entity id="DS3.d3.s0.e2" origId="Q14790,A0A024R3Z8" charOffset="67-72" type="protein" text="FLICE"/>
            <entity id="DS3.d3.s0.e3" origId="5862,90793998" charOffset="135-143" type="compound" text="cysteine"/>
            <pair e1="DS3.d3.s0.e3" e2="DS3.d3.s0.e1" id="DS3.d3.s0.i0" interaction="False" />
            <pair e1="DS3.d3.s0.e3" e2="DS3.d3.s0.e2" id="DS3.d3.s0.i1" interaction="False" />
            <pair e1="DS3.d3.s0.e3" e2="DS3.d3.s0.e0" id="DS3.d3.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d3.s1" origId="9931493-7" text="Both caspases 8 and 10 contain long pro-domains with duplicated death effector domains (DEDs), as well as their corresponding cysteine protease catalytic domains.">
            <entity id="DS3.d3.s1.e0" origId="Q92851" charOffset="5-22" type="protein" text="caspases 8 and 10"/>
            <entity id="DS3.d3.s1.e1" origId="5862,90793998" charOffset="126-134" type="compound" text="cysteine"/>
            <pair e1="DS3.d3.s1.e1" e2="DS3.d3.s1.e0" id="DS3.d3.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d4" origId="9931499">
        <sentence id="DS3.d4.s0" origId="9931499-1" text="The complexity of the 5-hydroxytryptamine (5-HT) (serotonin) receptor family has been increased by the findings that isoforms or splice variants exist for subtypes such as the 5-HT2B, 5-HT2C, 5-HT4 and 5-HT7 subtypes.">
            <entity id="DS3.d4.s0.e0" origId="5202" charOffset="22-41" type="compound" text="5-hydroxytryptamine"/>
            <entity id="DS3.d4.s0.e1" origId="Q13639" charOffset="192-197" type="protein" text="5-HT4"/>
            <entity id="DS3.d4.s0.e2" origId="P34969" charOffset="202-207" type="protein" text="5-HT7"/>
            <pair e1="DS3.d4.s0.e0" e2="DS3.d4.s0.e2" id="DS3.d4.s0.i0" interaction="False" />
            <pair e1="DS3.d4.s0.e0" e2="DS3.d4.s0.e1" id="DS3.d4.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d5" origId="9931508">
        <sentence id="DS3.d5.s0" origId="9931508-0" text="Poly(ADP-ribose) polymerase interacts with novel Drosophila ribosomal proteins, L22 and l23a, with unique histone-like amino-terminal extensions.">
            <entity id="DS3.d5.s0.e0" origId="192,44415180,445794" charOffset="5-15" type="compound" text="ADP-ribose"/>
            <entity id="DS3.d5.s0.e1" origId="P50887,P35268" charOffset="80-83" type="protein" text="L22"/>
            <entity id="DS3.d5.s0.e2" origId="P62750" charOffset="88-92" type="protein" text="l23a"/>
            <pair e1="DS3.d5.s0.e0" e2="DS3.d5.s0.e1" id="DS3.d5.s0.i0" interaction="False" />
            <pair e1="DS3.d5.s0.e0" e2="DS3.d5.s0.e2" id="DS3.d5.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d5.s1" origId="9931508-8" text="These Drosophila ribosomal protein L22 and l23a have additional Ala-, Lys- and Pro-rich sequences at the amino terminus, which have a resemblance to the carboxy-terminal portion of histone H1.">
            <entity id="DS3.d5.s1.e0" origId="P50887,P35268" charOffset="35-38" type="protein" text="L22"/>
            <entity id="DS3.d5.s1.e1" origId="P62750" charOffset="43-47" type="protein" text="l23a"/>
            <entity id="DS3.d5.s1.e2" origId="5962" charOffset="70-73" type="compound" text="Lys"/>
            <pair e1="DS3.d5.s1.e2" e2="DS3.d5.s1.e0" id="DS3.d5.s1.i0" interaction="False" />
            <pair e1="DS3.d5.s1.e2" e2="DS3.d5.s1.e1" id="DS3.d5.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d6" origId="9931627">
        <sentence id="DS3.d6.s0" origId="9931627-11" text="Neoadjuvant RTx/CTx, although associated with substantial morbidity, is a promising approach for patients with locally advanced esophageal cancer located at or above the tracheal bifurcation in responding patients, provided an R0 resection can be achieved.">
            <entity id="DS3.d6.s0.e0" origId="Q02318" charOffset="16-19" type="protein" text="CTx"/>
            <entity id="DS3.d6.s0.e1" origId="80006" charOffset="179-190" type="compound" text="bifurcation"/>
            <pair e1="DS3.d6.s0.e1" e2="DS3.d6.s0.e0" id="DS3.d6.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d7" origId="9931653">
        <sentence id="DS3.d7.s0" origId="9931653-5" text='The "gold standard" up to now has been imaging procedures (contrast-enhanced CT and MRI) which should be preserved for the severe cases to estimate the extent of pancreatic necrosis.'>
            <entity id="DS3.d7.s0.e0" origId="23985" charOffset="5-9" type="compound" text="gold"/>
            <entity id="DS3.d7.s0.e1" origId="Q9BWK5,A0A024R780,A0A087WWQ8" charOffset="84-87" type="protein" text="MRI"/>
            <pair e1="DS3.d7.s0.e0" e2="DS3.d7.s0.e1" id="DS3.d7.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d8" origId="9931762">
        <sentence id="DS3.d8.s0" origId="9931762-1" text="The DIEP flap was introduced to autogenous breast reconstruction to avoid defects in the abdominal rectus muscle as created in pedicled and free TRAM flaps.">
            <entity id="DS3.d8.s0.e0" origId="3033" charOffset="4-8" type="compound" text="DIEP"/>
            <entity id="DS3.d8.s0.e1" origId="Q15629,Q6FHL3,G3XAN4" charOffset="145-149" type="protein" text="TRAM"/>
            <pair e1="DS3.d8.s0.e0" e2="DS3.d8.s0.e1" id="DS3.d8.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d9" origId="9931797">
        <sentence id="DS3.d9.s0" origId="9931797-5" text="According to the results, an arginine, omega-3-fatty acids and nucleotide-enriched diet during early enteral feeding leads to reduction of SIRS and MOF scores after severe multiple injury.">
            <entity id="DS3.d9.s0.e0" origId="6322,90867653" charOffset="29-37" type="compound" text="arginine"/>
            <entity id="DS3.d9.s0.e1" origId="Q9H7Z6" charOffset="148-151" type="protein" text="MOF"/>
            <pair e1="DS3.d9.s0.e0" e2="DS3.d9.s0.e1" id="DS3.d9.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d10" origId="9931884">
        <sentence id="DS3.d10.s0" origId="9931884-2" text="MRI showed better correlation with the pathohistological evaluation at the T3, T4, N and M stage than the other two test procedures.">
            <entity id="DS3.d10.s0.e0" origId="Q9BWK5,A0A024R780,A0A087WWQ8" charOffset="0-3" type="protein" text="MRI"/>
            <entity id="DS3.d10.s0.e1" origId="5920" charOffset="75-77" type="compound" text="T3"/>
            <pair e1="DS3.d10.s0.e1" e2="DS3.d10.s0.e0" id="DS3.d10.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d11" origId="9932018">
        <sentence id="DS3.d11.s0" origId="9932018-5" text="The response to CCK was mediated via the CCKA receptor as shown by the antagonistic action of devazepide.">
            <entity id="DS3.d11.s0.e0" origId="P32238" charOffset="41-54" type="protein" text="CCKA receptor"/>
            <entity id="DS3.d11.s0.e1" origId="443375" charOffset="94-104" type="compound" text="devazepide"/>
            <pair e1="DS3.d11.s0.e1" e2="DS3.d11.s0.e0" id="DS3.d11.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d12" origId="9932079">
        <sentence id="DS3.d12.s0" origId="9932079-10" text="A recently identified metabolite is the 7-ethyl-10-(4-N-(5-aminopentanoic acid)-1-piperidino)-carbonyloxy-camptothecin (APC), which is formed by the action of cytochrome P450 3A4.">
            <entity id="DS3.d12.s0.e0" origId="23134249" charOffset="42-47" type="compound" text="ethyl"/>
            <entity id="DS3.d12.s0.e1" origId="138,57200850" charOffset="57-78" type="compound" text="5-aminopentanoic acid"/>
            <entity id="DS3.d12.s0.e2" origId="24360" charOffset="106-118" type="compound" text="camptothecin"/>
            <entity id="DS3.d12.s0.e3" origId="P08684,Q6GRK0" charOffset="159-178" type="protein" text="cytochrome P450 3A4"/>
            <pair e1="DS3.d12.s0.e2" e2="DS3.d12.s0.e3" id="DS3.d12.s0.i0" interaction="False" />
            <pair e1="DS3.d12.s0.e1" e2="DS3.d12.s0.e3" id="DS3.d12.s0.i1" interaction="False" />
            <pair e1="DS3.d12.s0.e0" e2="DS3.d12.s0.e3" id="DS3.d12.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d13" origId="9932109">
        <sentence id="DS3.d13.s0" origId="9932109-5" text="RESULTS: We show here that the cAMP-dependent protein kinase (PKA) effectors, dibutyryl-cAMP (dBut-cAMP) and forskolin, but not the inactive analog dideoxyforskolin, enhance the secretion of APP alpha and the intracellular production of its C-terminal counterpart (p10) in stably transfected HEK293 cells.">
            <entity id="DS3.d13.s0.e0" origId="P49913,J3KNB4" charOffset="31-35" type="protein" text="cAMP"/>
            <entity id="DS3.d13.s0.e1" origId="P49913,J3KNB4" charOffset="88-92" type="protein" text="cAMP"/>
            <entity id="DS3.d13.s0.e2" origId="P49913,J3KNB4" charOffset="88-92" type="protein" text="cAMP"/>
            <entity id="DS3.d13.s0.e3" origId="47936" charOffset="109-118" type="compound" text="forskolin"/>
            <entity id="DS3.d13.s0.e4" origId="Q9NQT5,Q9NYS3" charOffset="265-268" type="protein" text="p10"/>
            <pair e1="DS3.d13.s0.e3" e2="DS3.d13.s0.e4" id="DS3.d13.s0.i0" interaction="False" />
            <pair e1="DS3.d13.s0.e3" e2="DS3.d13.s0.e0" id="DS3.d13.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d13.s1" origId="9932109-9" text="We show here that the dBut-cAMP and forskolin-induced increase of APP alpha and A beta s secretions is not prevented by the transcription inhibitor actinomycin D. CONCLUSION: Our data suggest a major contribution of post-transcriptional events in the cAMP-dependent effect on beta APP maturation.">
            <entity id="DS3.d13.s1.e0" origId="P49913,J3KNB4" charOffset="27-31" type="protein" text="cAMP"/>
            <entity id="DS3.d13.s1.e1" origId="47936" charOffset="36-45" type="compound" text="forskolin"/>
            <entity id="DS3.d13.s1.e2" origId="P49913,J3KNB4" charOffset="251-255" type="protein" text="cAMP"/>
            <pair e1="DS3.d13.s1.e1" e2="DS3.d13.s1.e0" id="DS3.d13.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d14" origId="9932142">
        <sentence id="DS3.d14.s0" origId="9932142-6" text="At 18 months, osteocalcin and deoxypyridinoline levels fell significantly in both groups, indicating a decrease in bone turnover, whereas bone specific alkaline phosphatase rose indicating beneficial effects of calcium given to all the patients.">
            <entity id="DS3.d14.s0.e0" origId="P02818" charOffset="14-25" type="protein" text="osteocalcin"/>
            <entity id="DS3.d14.s0.e1" origId="3034763" charOffset="30-47" type="compound" text="deoxypyridinoline"/>
            <entity id="DS3.d14.s0.e2" origId="22044544,5460341" charOffset="211-218" type="compound" text="calcium"/>
            <pair e1="DS3.d14.s0.e1" e2="DS3.d14.s0.e0" id="DS3.d14.s0.i0" interaction="False" />
            <pair e1="DS3.d14.s0.e2" e2="DS3.d14.s0.e0" id="DS3.d14.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d15" origId="9932163">
        <sentence id="DS3.d15.s0" origId="9932163-0" text="Clinical and pharmacologic phase I study of Cemadotin-HCl (LU103793), a novel antimitotic peptide, given as 24-hour infusion in patients with advanced cancer. A study of the Arbeitsgemeinschaft Internistische Onkologie (AIO) Phase I Group and Arbeitsgruppe Pharmakologie in der Onkologie und Haematologie (APOH) Group of the German Cancer Society.">
            <entity id="DS3.d15.s0.e0" origId="9812632" charOffset="44-53" type="compound" text="Cemadotin"/>
            <entity id="DS3.d15.s0.e1" origId="24178107" charOffset="220-223" type="compound" text="AIO"/>
            <entity id="DS3.d15.s0.e2" origId="P02749" charOffset="306-310" type="protein" text="APOH"/>
            <pair e1="DS3.d15.s0.e1" e2="DS3.d15.s0.e2" id="DS3.d15.s0.i0" interaction="False" />
            <pair e1="DS3.d15.s0.e0" e2="DS3.d15.s0.e2" id="DS3.d15.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d16" origId="9932164">
        <sentence id="DS3.d16.s0" origId="9932164-3" text="RESULTS: Eight to 15 days after the start of each cytostatic drug infusion concentrations of various plasma antioxidants were measured and compared to pretreatment values: vitamin C and E, uric acid and ceruloplasmin levels fell significantly (P &amp;lt; 0.01-0.005) and returned to baseline levels before the start of the next chemotherapy cycle.">
            <entity id="DS3.d16.s0.e0" origId="54670067" charOffset="172-181" type="compound" text="vitamin C"/>
            <entity id="DS3.d16.s0.e1" origId="1175" charOffset="189-198" type="compound" text="uric acid"/>
            <entity id="DS3.d16.s0.e2" origId="P00450,A5PL27" charOffset="203-216" type="protein" text="ceruloplasmin"/>
            <pair e1="DS3.d16.s0.e0" e2="DS3.d16.s0.e2" id="DS3.d16.s0.i0" interaction="False" />
            <pair e1="DS3.d16.s0.e1" e2="DS3.d16.s0.e2" id="DS3.d16.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d16.s1" origId="9932164-4" text="Levels of the antioxidants bilirubin albumin and the ratio vitamin E/cholesterol + triglycerides measured three weeks after the start of chemotherapy significantly decreased compared to pretreatment levels and remained low thereafter (P &amp;lt; 0.001-0.002).">
            <entity id="DS3.d16.s1.e0" origId="5280352" charOffset="27-36" type="compound" text="bilirubin"/>
            <entity id="DS3.d16.s1.e1" origId="P02768" charOffset="37-44" type="protein" text="albumin"/>
            <entity id="DS3.d16.s1.e2" origId="14985,1548900,1742129,2116" charOffset="59-68" type="compound" text="vitamin E"/>
            <entity id="DS3.d16.s1.e3" origId="5997" charOffset="69-80" type="compound" text="cholesterol"/>
            <pair e1="DS3.d16.s1.e0" e2="DS3.d16.s1.e1" id="DS3.d16.s1.i0" interaction="False" />
            <pair e1="DS3.d16.s1.e2" e2="DS3.d16.s1.e1" id="DS3.d16.s1.i1" interaction="False" />
            <pair e1="DS3.d16.s1.e3" e2="DS3.d16.s1.e1" id="DS3.d16.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d17" origId="9932214">
        <sentence id="DS3.d17.s0" origId="9932214-2" text="The insulin receptor is a membrane receptor possessing tyrosine kinase activity.">
            <entity id="DS3.d17.s0.e0" origId="P06213" charOffset="4-20" type="protein" text="insulin receptor"/>
            <entity id="DS3.d17.s0.e1" origId="6057,90983769" charOffset="55-63" type="compound" text="tyrosine"/>
            <pair e1="DS3.d17.s0.e1" e2="DS3.d17.s0.e0" id="DS3.d17.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d17.s1" origId="9932214-3" text="The binding of insulin to its receptor induces autophosphorylation of the receptor on tyrosine residues and thereby stimulates its tyrosine kinase activity towards intracellular substrates such as Shc or IRS1.">
            <entity id="DS3.d17.s1.e0" origId="6057,90983769" charOffset="86-94" type="compound" text="tyrosine"/>
            <entity id="DS3.d17.s1.e1" origId="6057,90983769" charOffset="131-139" type="compound" text="tyrosine"/>
            <entity id="DS3.d17.s1.e2" origId="P29353" charOffset="197-200" type="protein" text="Shc"/>
            <entity id="DS3.d17.s1.e3" origId="P35568,A0A024R499" charOffset="204-208" type="protein" text="IRS1"/>
            <pair e1="DS3.d17.s1.e0" e2="DS3.d17.s1.e2" id="DS3.d17.s1.i0" interaction="False" />
            <pair e1="DS3.d17.s1.e0" e2="DS3.d17.s1.e3" id="DS3.d17.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d17.s2" origId="9932214-6" text="Tyrosine phosphorylation of IRSs and Shc by the insulin receptor permits the activation of two major signalling pathways, the MAP kinase pathway and the Pl 3-kinase pathway.">
            <entity id="DS3.d17.s2.e0" origId="6057,90983769" charOffset="0-8" type="compound" text="Tyrosine"/>
            <entity id="DS3.d17.s2.e1" origId="P29353" charOffset="37-40" type="protein" text="Shc"/>
            <entity id="DS3.d17.s2.e2" origId="P06213" charOffset="48-64" type="protein" text="insulin receptor"/>
            <pair e1="DS3.d17.s2.e0" e2="DS3.d17.s2.e2" id="DS3.d17.s2.i0" interaction="False" />
            <pair e1="DS3.d17.s2.e0" e2="DS3.d17.s2.e1" id="DS3.d17.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d18" origId="9932215">
        <sentence id="DS3.d18.s0" origId="9932215-9" text="ApoCIII decreases TRL catabolism by inhibiting lipoprotein lipase activity and reducing ApoE-dependent hepatic uptake of TRL and remnants.">
            <entity id="DS3.d18.s0.e0" origId="P02656,A3KPE2" charOffset="0-7" type="protein" text="ApoCIII"/>
            <entity id="DS3.d18.s0.e1" origId="5474737" charOffset="59-65" type="compound" text="lipase"/>
            <entity id="DS3.d18.s0.e2" origId="P02649" charOffset="88-92" type="protein" text="ApoE"/>
            <pair e1="DS3.d18.s0.e1" e2="DS3.d18.s0.e2" id="DS3.d18.s0.i0" interaction="False" />
            <pair e1="DS3.d18.s0.e1" e2="DS3.d18.s0.e0" id="DS3.d18.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d19" origId="9932217">
        <sentence id="DS3.d19.s0" origId="9932217-4" text="Comparison of baseline data with measurements at the 4-year follow-up examination showed that relative HbA1c (= HbA1c/mean normal) improved (1.9 +/- 0.51 vs 1.55 +/- 0.3*, p &amp;lt; 0.001, *excluding 4 patients with diabetes manifestation at baseline) and that frequencies of daily insulin injections (3.73 +/- 1.23 vs 4.9 +/- 0.69*, p &amp;lt; 0.001) and weekly blood glucose self-tests (6.6 +/- 10.1 vs 25.5 +/- 8.7*, p &amp;lt; 0.001) increased, whereas the incidence of severe hypoglycaemia (intravenous glucose, glucagon injection) remained stable (0.19 vs 0.24, p = 0.48).">
            <entity id="DS3.d19.s0.e0" origId="206,5793,64689,79025" charOffset="362-369" type="compound" text="glucose"/>
            <entity id="DS3.d19.s0.e1" origId="206,5793,64689,79025" charOffset="497-504" type="compound" text="glucose"/>
            <entity id="DS3.d19.s0.e2" origId="P01275" charOffset="506-514" type="protein" text="glucagon"/>
            <pair e1="DS3.d19.s0.e0" e2="DS3.d19.s0.e2" id="DS3.d19.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d20" origId="9932222">
        <sentence id="DS3.d20.s0" origId="9932222-3" text="Even though the patient had very thin subcutaneous tissue, CSII was initiated and proved highly efficient, improving blood glucose control considerably (HbA1c ranging from 7.5 to 8.5%), but with no decrease in the daily insulin requirement (2 IU/kg/day).">
            <entity id="DS3.d20.s0.e0" origId="Q9H4D0" charOffset="59-63" type="protein" text="CSII"/>
            <entity id="DS3.d20.s0.e1" origId="206,5793,64689,79025" charOffset="123-130" type="compound" text="glucose"/>
            <pair e1="DS3.d20.s0.e1" e2="DS3.d20.s0.e0" id="DS3.d20.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d21" origId="9932229">
        <sentence id="DS3.d21.s0" origId="9932229-0" text="Mutation of C-terminal tyrosine residues Y497/Y504 of the Src-family member Bsk/Iyk decreases NIH3T3 cell proliferation.">
            <entity id="DS3.d21.s0.e0" origId="90983769" charOffset="23-31" type="compound" text="tyrosine"/>
            <entity id="DS3.d21.s0.e1" origId="Q922K9" charOffset="76-83" type="protein" text="Bsk/Iyk"/>
            <pair e1="DS3.d21.s0.e0" e2="DS3.d21.s0.e1" id="DS3.d21.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d21.s1" origId="9932229-8" text="The Y497F Bsk/Iyk mutant not only increased the relative amount of p57 Bsk/Iyk but also transferred this isoform to the nuclear subcellular fraction.">
            <entity id="DS3.d21.s1.e0" origId="Q922K9" charOffset="10-17" type="protein" text="Bsk/Iyk"/>
            <entity id="DS3.d21.s1.e1" origId="9962786" charOffset="67-70" type="compound" text="p57"/>
            <entity id="DS3.d21.s1.e2" origId="Q922K9" charOffset="71-78" type="protein" text="Bsk/Iyk"/>
            <pair e1="DS3.d21.s1.e1" e2="DS3.d21.s1.e0" id="DS3.d21.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d22" origId="9932281">
        <sentence id="DS3.d22.s0" origId="9932281-11" text="The data suggest that Ref-1 and Max may normally function as negative modulators of retinal apoptosis.">
            <entity id="DS3.d22.s0.e0" origId="P27695,Q5TZP7" charOffset="22-27" type="protein" text="Ref-1"/>
            <entity id="DS3.d22.s0.e1" origId="P61244,Q8TAX8,A0A024R682" charOffset="32-35" type="protein" text="Max"/>
            <entity id="DS3.d22.s0.e2" origId="638015" charOffset="84-91" type="compound" text="retinal"/>
            <pair e1="DS3.d22.s0.e2" e2="DS3.d22.s0.e1" id="DS3.d22.s0.i0" interaction="False" />
            <pair e1="DS3.d22.s0.e2" e2="DS3.d22.s0.e0" id="DS3.d22.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d22.s1" origId="9932281-9" text="The transcription factors c-Jun, c-Fos and c-Myc were found associated with apoptosis in retinal cells, but their sub-cellular location in apoptotic bodies is not consistent with their canonical functions in the control of gene expression.">
            <entity id="DS3.d22.s1.e0" origId="P05412" charOffset="26-31" type="protein" text="c-Jun"/>
            <entity id="DS3.d22.s1.e1" origId="P01100,Q6FG41" charOffset="33-38" type="protein" text="c-Fos"/>
            <entity id="DS3.d22.s1.e2" origId="P01106" charOffset="43-48" type="protein" text="c-Myc"/>
            <entity id="DS3.d22.s1.e3" origId="638015" charOffset="89-96" type="compound" text="retinal"/>
            <pair e1="DS3.d22.s1.e3" e2="DS3.d22.s1.e2" id="DS3.d22.s1.i0" interaction="False" />
            <pair e1="DS3.d22.s1.e3" e2="DS3.d22.s1.e1" id="DS3.d22.s1.i1" interaction="False" />
            <pair e1="DS3.d22.s1.e3" e2="DS3.d22.s1.e0" id="DS3.d22.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d23" origId="9932286">
        <sentence id="DS3.d23.s0" origId="9932286-0" text="N-type voltage-sensitive calcium channel interacts with syntaxin, synaptotagmin and SNAP-25 in a multiprotein complex.">
            <entity id="DS3.d23.s0.e0" origId="22044544,5460341" charOffset="25-32" type="compound" text="calcium"/>
            <entity id="DS3.d23.s0.e1" origId="Q8AXM1" charOffset="84-91" type="protein" text="SNAP-25"/>
            <pair e1="DS3.d23.s0.e0" e2="DS3.d23.s0.e1" id="DS3.d23.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d24" origId="9932300">
        <sentence id="DS3.d24.s0" origId="9932300-2" text="First, using indirect immunofluorescence staining with specific monoclonal antibodies (mAbs) against elements of this cycle, the presence of inositol trisphosphate receptors (IP3Rs) (IP3R-1 or IP3R-3) or phosphoinositide-phospholipase (PLC) isoforms (PLC beta 1 or PLC gamma 1) was monitored in the germinal vesicle (GV).">
            <entity id="DS3.d24.s0.e0" origId="892" charOffset="141-149" type="compound" text="inositol"/>
            <entity id="DS3.d24.s0.e1" origId="19432134" charOffset="150-163" type="compound" text="trisphosphate"/>
            <entity id="DS3.d24.s0.e2" origId="P11881,Q8C7X9,Q8BQN0,Q3UVA1,Q8C8N0" charOffset="183-189" type="protein" text="IP3R-1"/>
            <entity id="DS3.d24.s0.e3" origId="P70227" charOffset="193-199" type="protein" text="IP3R-3"/>
            <entity id="DS3.d24.s0.e4" origId="Q9Z1B3,F6X322,Q3UPW0" charOffset="251-261" type="protein" text="PLC beta 1"/>
            <entity id="DS3.d24.s0.e5" origId="Q62077" charOffset="265-276" type="protein" text="PLC gamma 1"/>
            <pair e1="DS3.d24.s0.e0" e2="DS3.d24.s0.e4" id="DS3.d24.s0.i0" interaction="False" />
            <pair e1="DS3.d24.s0.e0" e2="DS3.d24.s0.e2" id="DS3.d24.s0.i1" interaction="False" />
            <pair e1="DS3.d24.s0.e0" e2="DS3.d24.s0.e5" id="DS3.d24.s0.i2" interaction="False" />
            <pair e1="DS3.d24.s0.e0" e2="DS3.d24.s0.e3" id="DS3.d24.s0.i3" interaction="False" />
            <pair e1="DS3.d24.s0.e1" e2="DS3.d24.s0.e4" id="DS3.d24.s0.i4" interaction="False" />
            <pair e1="DS3.d24.s0.e1" e2="DS3.d24.s0.e2" id="DS3.d24.s0.i5" interaction="False" />
            <pair e1="DS3.d24.s0.e1" e2="DS3.d24.s0.e5" id="DS3.d24.s0.i6" interaction="False" />
            <pair e1="DS3.d24.s0.e1" e2="DS3.d24.s0.e3" id="DS3.d24.s0.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d25" origId="9932334">
        <sentence id="DS3.d25.s0" origId="9932334-0" text="Glucose effectiveness and insulin sensitivity from the minimal models: consequences of undermodeling assessed by Monte Carlo simulation.">
            <entity id="DS3.d25.s0.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS3.d25.s0.e1" origId="P01308,I3WAC9" charOffset="26-33" type="protein" text="insulin"/>
            <pair e1="DS3.d25.s0.e0" e2="DS3.d25.s0.e1" id="DS3.d25.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d25.s1" origId="9932334-1" text="The unlabeled (cold) minimal model (MM) and the labeled (hot) minimal model (HMM) are a powerful tool to investigate in vivo metabolism from a standard intravenous glucose tolerance test (IVGTT) or hot IVGTT (HIVGTT).">
            <entity id="DS3.d25.s1.e0" origId="Q8IWW8" charOffset="57-60" type="protein" text="hot"/>
            <entity id="DS3.d25.s1.e1" origId="206,5793,64689,79025" charOffset="164-171" type="compound" text="glucose"/>
            <entity id="DS3.d25.s1.e2" origId="Q8IWW8" charOffset="198-201" type="protein" text="hot"/>
            <pair e1="DS3.d25.s1.e1" e2="DS3.d25.s1.e0" id="DS3.d25.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d25.s2" origId="9932334-2" text="They allow to estimate metabolic indexes of the glucose-insulin system, namely glucose effectiveness (GE) and insulin sensitivity (IS) (of uptake and production those of MM, and of uptake only those of HMM).">
            <entity id="DS3.d25.s2.e0" origId="206,5793,64689,79025" charOffset="48-55" type="compound" text="glucose"/>
            <entity id="DS3.d25.s2.e1" origId="P01308,I3WAC9" charOffset="56-63" type="protein" text="insulin"/>
            <entity id="DS3.d25.s2.e2" origId="206,5793,64689,79025" charOffset="79-86" type="compound" text="glucose"/>
            <entity id="DS3.d25.s2.e3" origId="P01308,I3WAC9" charOffset="110-117" type="protein" text="insulin"/>
            <pair e1="DS3.d25.s2.e0" e2="DS3.d25.s2.e1" id="DS3.d25.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d25.s3" origId="9932334-4" text="RM allows to generate noisy synthetic plasma concentrations of glucose, tracer glucose, and insulin during IVGTT and HIVGTT, which are then analyzed with MM and HMM.">
            <entity id="DS3.d25.s3.e0" origId="206,5793,64689,79025" charOffset="63-70" type="compound" text="glucose"/>
            <entity id="DS3.d25.s3.e1" origId="206,5793,64689,79025" charOffset="79-86" type="compound" text="glucose"/>
            <entity id="DS3.d25.s3.e2" origId="P01308,I3WAC9" charOffset="92-99" type="protein" text="insulin"/>
            <pair e1="DS3.d25.s3.e0" e2="DS3.d25.s3.e2" id="DS3.d25.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d26" origId="9932348">
        <sentence id="DS3.d26.s0" origId="9932348-1" text="Nitric oxide (NO) is synthetized from L-arginine by the aid of an enzyme--NO synthase (NOS).">
            <entity id="DS3.d26.s0.e0" origId="145068" charOffset="0-12" type="compound" text="Nitric oxide"/>
            <entity id="DS3.d26.s0.e1" origId="6322,90867653" charOffset="40-48" type="compound" text="arginine"/>
            <entity id="DS3.d26.s0.e2" origId="P35228" charOffset="66-85" type="protein" text="enzyme--NO synthase"/>
            <entity id="DS3.d26.s0.e3" origId="P35228" charOffset="87-90" type="protein" text="NOS"/>
            <pair e1="DS3.d26.s0.e0" e2="DS3.d26.s0.e2" id="DS3.d26.s0.i0" interaction="False" />
            <pair e1="DS3.d26.s0.e0" e2="DS3.d26.s0.e3" id="DS3.d26.s0.i1" interaction="False" />
            <pair e1="DS3.d26.s0.e1" e2="DS3.d26.s0.e2" id="DS3.d26.s0.i2" interaction="False" />
            <pair e1="DS3.d26.s0.e1" e2="DS3.d26.s0.e3" id="DS3.d26.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d26.s1" origId="9932348-4" text="NO produced in small amounts by nNOS and eNOS is involved in neurotransmission in the retina and in the regulation of retinal arteriolar tonicity.">
            <entity id="DS3.d26.s1.e0" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="32-36" type="protein" text="nNOS"/>
            <entity id="DS3.d26.s1.e1" origId="P29474,A0A0A0MTA6,A0S0A6" charOffset="41-45" type="protein" text="eNOS"/>
            <entity id="DS3.d26.s1.e2" origId="638015" charOffset="118-125" type="compound" text="retinal"/>
            <pair e1="DS3.d26.s1.e2" e2="DS3.d26.s1.e1" id="DS3.d26.s1.i0" interaction="False" />
            <pair e1="DS3.d26.s1.e2" e2="DS3.d26.s1.e0" id="DS3.d26.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d26.s2" origId="9932348-5" text="NO produced in large quantities by iNOS is a bactericidal agent but can also generate inflammation of the retina and even retinal degeneration.">
            <entity id="DS3.d26.s2.e0" origId="P35228" charOffset="35-39" type="protein" text="iNOS"/>
            <entity id="DS3.d26.s2.e1" origId="638015" charOffset="122-129" type="compound" text="retinal"/>
            <pair e1="DS3.d26.s2.e1" e2="DS3.d26.s2.e0" id="DS3.d26.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d27" origId="9932400">
        <sentence id="DS3.d27.s0" origId="9932400-2" text="We have investigated the pathways through which neuronal activity stimulated by kainic acid regulates BDNF mRNA levels in cultured hippocampal neurons and transgenic mice.">
            <entity id="DS3.d27.s0.e0" origId="10255" charOffset="80-91" type="compound" text="kainic acid"/>
            <entity id="DS3.d27.s0.e1" origId="P21237,Q541P3,A2AII2" charOffset="102-106" type="protein" text="BDNF"/>
            <pair e1="DS3.d27.s0.e0" e2="DS3.d27.s0.e1" id="DS3.d27.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d27.s1" origId="9932400-3" text="Kainic acid induced the transcription of BDNF mRNA without influencing the mRNA stability.">
            <entity id="DS3.d27.s1.e0" origId="10255" charOffset="0-11" type="compound" text="Kainic acid"/>
            <entity id="DS3.d27.s1.e1" origId="P21237,Q541P3,A2AII2" charOffset="41-45" type="protein" text="BDNF"/>
            <pair e1="DS3.d27.s1.e0" e2="DS3.d27.s1.e1" id="DS3.d27.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d27.s2" origId="9932400-6" text="Increase in the BDNF mRNA levels by kainic acid was not blocked by the protein synthesis inhibitor cycloheximide demonstrating that BDNF is regulated as an immediate early gene in hippocampal neurons.">
            <entity id="DS3.d27.s2.e0" origId="P21237,Q541P3,A2AII2" charOffset="16-20" type="protein" text="BDNF"/>
            <entity id="DS3.d27.s2.e1" origId="10255" charOffset="36-47" type="compound" text="kainic acid"/>
            <entity id="DS3.d27.s2.e2" origId="6197" charOffset="99-112" type="compound" text="cycloheximide"/>
            <entity id="DS3.d27.s2.e3" origId="P21237,Q541P3,A2AII2" charOffset="132-136" type="protein" text="BDNF"/>
            <pair e1="DS3.d27.s2.e2" e2="DS3.d27.s2.e0" id="DS3.d27.s2.i0" interaction="False" />
            <pair e1="DS3.d27.s2.e1" e2="DS3.d27.s2.e0" id="DS3.d27.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d27.s3" origId="9932400-7" text="Although calmodulin antagonists are known to abolish the effect of kainic acid on BDNF mRNA, this effect was very similar in Ca(+2)-calmodulin-dependent protein kinase II alpha knock-out mice and in wild-type mice.">
            <entity id="DS3.d27.s3.e0" origId="10255" charOffset="67-78" type="compound" text="kainic acid"/>
            <entity id="DS3.d27.s3.e1" origId="P21237,Q541P3,A2AII2" charOffset="82-86" type="protein" text="BDNF"/>
            <pair e1="DS3.d27.s3.e0" e2="DS3.d27.s3.e1" id="DS3.d27.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d28" origId="9932411">
        <sentence id="DS3.d28.s0" origId="9932411-11" text="TRN and DCN neurons) upregulate GAP-43, L1 and the transcription factor c-jun in response to a graft, whereas those neurons which do not regenerate well (e.g.">
            <entity id="DS3.d28.s0.e0" origId="18807" charOffset="8-11" type="compound" text="DCN"/>
            <entity id="DS3.d28.s0.e1" origId="P17677,Q5U058" charOffset="32-38" type="protein" text="GAP-43"/>
            <entity id="DS3.d28.s0.e2" origId="P05412" charOffset="72-77" type="protein" text="c-jun"/>
            <pair e1="DS3.d28.s0.e0" e2="DS3.d28.s0.e1" id="DS3.d28.s0.i0" interaction="False" />
            <pair e1="DS3.d28.s0.e0" e2="DS3.d28.s0.e2" id="DS3.d28.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d28.s1" origId="9932411-5" text="The axons also express polysialic acid and, unlike regenerating peripheral axons, bind tenascin-C derived from Schwann cells.">
            <entity id="DS3.d28.s1.e0" origId="444885" charOffset="23-38" type="compound" text="polysialic acid"/>
            <entity id="DS3.d28.s1.e1" origId="P24821,F5H7V9,Q4LE33,B4E1W8,E9PC84,J3QSU6" charOffset="87-97" type="protein" text="tenascin-C"/>
            <pair e1="DS3.d28.s1.e0" e2="DS3.d28.s1.e1" id="DS3.d28.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d29" origId="9932420">
        <sentence id="DS3.d29.s0" origId="9932420-15" text="The observation that the administration of glucose or insulin enhances memory in Alzheimer patients also supports the view that Alzheimer's disease is basically a metabolic disease.">
            <entity id="DS3.d29.s0.e0" origId="206,5793,64689,79025" charOffset="43-50" type="compound" text="glucose"/>
            <entity id="DS3.d29.s0.e1" origId="P01308,I3WAC9" charOffset="54-61" type="protein" text="insulin"/>
            <pair e1="DS3.d29.s0.e0" e2="DS3.d29.s0.e1" id="DS3.d29.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d30" origId="9932430">
        <sentence id="DS3.d30.s0" origId="9932430-0" text="Regulation of neuronal nitric oxide synthase and identification of novel nitric oxide signaling pathways.">
            <entity id="DS3.d30.s0.e0" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="14-44" type="protein" text="neuronal nitric oxide synthase"/>
            <entity id="DS3.d30.s0.e1" origId="145068" charOffset="23-35" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d30.s0.e1" e2="DS3.d30.s0.e0" id="DS3.d30.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d31" origId="9932433">
        <sentence id="DS3.d31.s0" origId="9932433-3" text="In addition, choline acetyltransferase (ChAT) immunocytochemistry was used to identify cholinergic cells because many of the NADPHd positive cells were thought to colocalize acetylcholine.">
            <entity id="DS3.d31.s0.e0" origId="Q8BQV2" charOffset="13-38" type="protein" text="choline acetyltransferase"/>
            <entity id="DS3.d31.s0.e1" origId="187" charOffset="174-187" type="compound" text="acetylcholine"/>
            <pair e1="DS3.d31.s0.e1" e2="DS3.d31.s0.e0" id="DS3.d31.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d32" origId="9932436">
        <sentence id="DS3.d32.s0" origId="9932436-0" text="The subcellular distribution of nitric oxide synthase relative to the NR1 subunit of NMDA receptors in the cerebral cortex.">
            <entity id="DS3.d32.s0.e0" origId="145068" charOffset="32-44" type="compound" text="nitric oxide"/>
            <entity id="DS3.d32.s0.e1" origId="Q05586,Q59GW0,Q5VSF9" charOffset="70-73" type="protein" text="NR1"/>
            <pair e1="DS3.d32.s0.e0" e2="DS3.d32.s0.e1" id="DS3.d32.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d32.s1" origId="9932436-2" text="On the other hand, light microscopic neuroanatomical detection of nNOS within pyramidal neurons has been difficult, suggesting that these neurons contain nNOS at levels below threshold for detection.">
            <entity id="DS3.d32.s1.e0" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="66-70" type="protein" text="nNOS"/>
            <entity id="DS3.d32.s1.e1" origId="18648446" charOffset="78-87" type="compound" text="pyramidal"/>
            <entity id="DS3.d32.s1.e2" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="154-158" type="protein" text="nNOS"/>
            <pair e1="DS3.d32.s1.e1" e2="DS3.d32.s1.e0" id="DS3.d32.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d32.s2" origId="9932436-3" text="Our results obtained by electron microscopic immunocytochemistry indicate that nNOS occurs within spiny neurons, such as those of pyramidal neurons, albeit discretely within their spines.">
            <entity id="DS3.d32.s2.e0" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="79-83" type="protein" text="nNOS"/>
            <entity id="DS3.d32.s2.e1" origId="18648446" charOffset="130-139" type="compound" text="pyramidal"/>
            <pair e1="DS3.d32.s2.e1" e2="DS3.d32.s2.e0" id="DS3.d32.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d33" origId="9932438">
        <sentence id="DS3.d33.s0" origId="9932438-13" text="Furthermore, tectal cells normally express high levels of nitric oxide synthase (NOS) during the period of refinement, and blocking nitric oxide (NO) synthesis also preserved inappropriate projections.">
            <entity id="DS3.d33.s0.e0" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="58-79" type="protein" text="nitric oxide synthase"/>
            <entity id="DS3.d33.s0.e1" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="81-84" type="protein" text="NOS"/>
            <entity id="DS3.d33.s0.e2" origId="145068" charOffset="58-70" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d33.s0.e2" e2="DS3.d33.s0.e0" id="DS3.d33.s0.i0" interaction="False" />
            <pair e1="DS3.d33.s0.e2" e2="DS3.d33.s0.e1" id="DS3.d33.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d33.s1" origId="9932438-7" text="Blocking expression of EphA3, a receptor tyrosine kinase, in the developing retina resulted in disruption of the topography of the retinotectal connections, further supporting the role of these, molecules.">
            <entity id="DS3.d33.s1.e0" origId="P29320,Q6P4R6,C9JXA2" charOffset="23-28" type="protein" text="EphA3"/>
            <entity id="DS3.d33.s1.e1" origId="6057,90983769" charOffset="41-49" type="compound" text="tyrosine"/>
            <pair e1="DS3.d33.s1.e1" e2="DS3.d33.s1.e0" id="DS3.d33.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d34" origId="9932439">
        <sentence id="DS3.d34.s0" origId="9932439-5" text="We have used both nitric oxide synthase inhibition (nw-nitro-L-arginine, NoArg) and single (nNOS) and double (nNOS and eNOS) gene knockout mice to examine the effect that reduction in NOS has upon the development of these two systems.">
            <entity id="DS3.d34.s0.e0" origId="145068" charOffset="18-30" type="compound" text="nitric oxide"/>
            <entity id="DS3.d34.s0.e1" origId="4367" charOffset="55-71" type="compound" text="nitro-L-arginine"/>
            <entity id="DS3.d34.s0.e2" origId="Q9Z0J4,F8WGF2" charOffset="92-96" type="protein" text="nNOS"/>
            <entity id="DS3.d34.s0.e3" origId="Q9Z0J4,F8WGF2" charOffset="110-114" type="protein" text="nNOS"/>
            <entity id="DS3.d34.s0.e4" origId="P70313,Q8C5P3" charOffset="119-123" type="protein" text="eNOS"/>
            <pair e1="DS3.d34.s0.e1" e2="DS3.d34.s0.e4" id="DS3.d34.s0.i0" interaction="False" />
            <pair e1="DS3.d34.s0.e1" e2="DS3.d34.s0.e2" id="DS3.d34.s0.i1" interaction="False" />
            <pair e1="DS3.d34.s0.e0" e2="DS3.d34.s0.e4" id="DS3.d34.s0.i2" interaction="False" />
            <pair e1="DS3.d34.s0.e0" e2="DS3.d34.s0.e2" id="DS3.d34.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d34.s1" origId="9932439-6" text="The onset of NOS expression in rat, as revealed by nicotinamide adenine dinucleotide phosphate diaphorase (NADPH-d) labeling, occurred in igl cells as early as postnatal day P5, with clusters being well-established by P14.">
            <entity id="DS3.d34.s1.e0" origId="5886,929,44415116" charOffset="51-94" type="compound" text="nicotinamide adenine dinucleotide phosphate"/>
            <entity id="DS3.d34.s1.e1" origId="57369863" charOffset="107-114" type="compound" text="NADPH-d"/>
            <entity id="DS3.d34.s1.e2" origId="Q61398,Q3UIP2,Q3UN82,D3YUE2" charOffset="218-221" type="protein" text="P14"/>
            <pair e1="DS3.d34.s1.e1" e2="DS3.d34.s1.e2" id="DS3.d34.s1.i0" interaction="False" />
            <pair e1="DS3.d34.s1.e0" e2="DS3.d34.s1.e2" id="DS3.d34.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d35" origId="9932449">
        <sentence id="DS3.d35.s0" origId="9932449-11" text="BN 50730, a potent intracellular PAF antagonist, blocks COX-2 induction.">
            <entity id="DS3.d35.s0.e0" origId="3033963" charOffset="0-8" type="compound" text="BN 50730"/>
            <entity id="DS3.d35.s0.e1" origId="P00403,U5Z487" charOffset="56-61" type="protein" text="COX-2"/>
            <pair e1="DS3.d35.s0.e0" e2="DS3.d35.s0.e1" id="DS3.d35.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d35.s1" origId="9932449-12" text="COX-2 transcription and protein expression are upregulated in the hippocampus in kainic acid induced epileptogenesis.">
            <entity id="DS3.d35.s1.e0" origId="P00403,U5Z487" charOffset="0-5" type="protein" text="COX-2"/>
            <entity id="DS3.d35.s1.e1" origId="10255" charOffset="81-92" type="compound" text="kainic acid"/>
            <pair e1="DS3.d35.s1.e1" e2="DS3.d35.s1.e0" id="DS3.d35.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d35.s2" origId="9932449-13" text="There is a selectively elevated induction of COX-2 (72-fold) by kainic acid preceding neuronal cell death.">
            <entity id="DS3.d35.s2.e0" origId="P00403,U5Z487" charOffset="45-50" type="protein" text="COX-2"/>
            <entity id="DS3.d35.s2.e1" origId="10255" charOffset="64-75" type="compound" text="kainic acid"/>
            <pair e1="DS3.d35.s2.e1" e2="DS3.d35.s2.e0" id="DS3.d35.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d35.s3" origId="9932449-4" text="PAF also couples synaptic events with gene expression by stimulating a FOS/JUN/AP-1 transcriptional signaling system, as well as transcription of COX-2 (inducible prostaglandin synthase).">
            <entity id="DS3.d35.s3.e0" origId="P00403,U5Z487" charOffset="146-151" type="protein" text="COX-2"/>
            <entity id="DS3.d35.s3.e1" origId="285703,6145931" charOffset="163-176" type="compound" text="prostaglandin"/>
            <pair e1="DS3.d35.s3.e1" e2="DS3.d35.s3.e0" id="DS3.d35.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d35.s4" origId="9932449-7" text="PAF, under these pathological conditions, behaves as a neuronal injury messenger by at least two mechanisms: (a) enhancing glutamate release; and, (b) by sustained augmentation of COX-2 transcription.">
            <entity id="DS3.d35.s4.e0" origId="23327,33032,611,57109091" charOffset="123-132" type="compound" text="glutamate"/>
            <entity id="DS3.d35.s4.e1" origId="P00403,U5Z487" charOffset="180-185" type="protein" text="COX-2"/>
            <pair e1="DS3.d35.s4.e0" e2="DS3.d35.s4.e1" id="DS3.d35.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d36" origId="9932450">
        <sentence id="DS3.d36.s0" origId="9932450-5" text="Its mammalian homolog, Dyrk1A, is activated by tyrosine phosphorylation in the activation loop between subdomains VII and VIII of the catalytic domain.">
            <entity id="DS3.d36.s0.e0" origId="Q13627" charOffset="23-29" type="protein" text="Dyrk1A"/>
            <entity id="DS3.d36.s0.e1" origId="6057,90983769" charOffset="47-55" type="compound" text="tyrosine"/>
            <entity id="DS3.d36.s0.e2" origId="P10176,Q53XN1" charOffset="122-126" type="protein" text="VIII"/>
            <pair e1="DS3.d36.s0.e1" e2="DS3.d36.s0.e0" id="DS3.d36.s0.i0" interaction="False" />
            <pair e1="DS3.d36.s0.e1" e2="DS3.d36.s0.e2" id="DS3.d36.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d37" origId="9932467">
        <sentence id="DS3.d37.s0" origId="9932467-11" text='The second part of this review is devoted to the Italian hadrontherapy programme, based on the development of the network RITA, the construction in Rome by the "Istituto Superiore di Sanit" of a novel proton accelerator based on a 3 GHz linac, the design of a linac to boost the energy of protons extracted from a 50-70 MeV cyclotron and the construction in Mirasole, near Milano, of a center for protons and ions known as "CNAO".'>
            <entity id="DS3.d37.s0.e0" origId="Q9NQX6,Q71QC6,Q71QC5,A0A024R4J5,Q68D63" charOffset="122-126" type="protein" text="RITA"/>
            <entity id="DS3.d37.s0.e1" origId="71458556" charOffset="148-152" type="compound" text="Rome"/>
            <entity id="DS3.d37.s0.e2" origId="1038,5460653" charOffset="202-208" type="compound" text="proton"/>
            <pair e1="DS3.d37.s0.e1" e2="DS3.d37.s0.e0" id="DS3.d37.s0.i0" interaction="False" />
            <pair e1="DS3.d37.s0.e2" e2="DS3.d37.s0.e0" id="DS3.d37.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d37.s1" origId="9932467-12" text="This center will have a synchrotron, which is under design at CERN in the framework of a collaboration of TERA with AUSTRON and GSI which is called PIMMS (Proton Ion Medical Machine Study) and is headed by Dr. Phyl Bryant.">
            <entity id="DS3.d37.s1.e0" origId="P55072,V9HW80,Q96IF9" charOffset="106-110" type="protein" text="TERA"/>
            <entity id="DS3.d37.s1.e1" origId="1038,5460653" charOffset="155-161" type="compound" text="Proton"/>
            <pair e1="DS3.d37.s1.e1" e2="DS3.d37.s1.e0" id="DS3.d37.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d38" origId="9932471">
        <sentence id="DS3.d38.s0" origId="9932471-4" text="84 patients (T2: 47%, T3: 49.4%, T4: 3.6%) underwent concomitant ERT (dose to pelvic volume: 45 Gy; mean dose to prostatic volume: 65 Gy) and neoadjuvant hormonotherapy (flutamide: 250 mg three times/daily for 30 days; LH-RH analogue: 1 oral dose every 28 days starting 2 months prior to radiotherapy and for its whole duration).">
            <entity id="DS3.d38.s0.e0" origId="5920" charOffset="22-24" type="compound" text="T3"/>
            <entity id="DS3.d38.s0.e1" origId="3397" charOffset="170-179" type="compound" text="flutamide"/>
            <entity id="DS3.d38.s0.e2" origId="P01148" charOffset="219-224" type="protein" text="LH-RH"/>
            <pair e1="DS3.d38.s0.e1" e2="DS3.d38.s0.e2" id="DS3.d38.s0.i0" interaction="False" />
            <pair e1="DS3.d38.s0.e0" e2="DS3.d38.s0.e2" id="DS3.d38.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d39" origId="9932491">
        <sentence id="DS3.d39.s0" origId="9932491-3" text="Keratin glycosylation, via O-GlcNAc, is a dynamic modification that has been conclusively identified in K13, K8, and K18.">
            <entity id="DS3.d39.s0.e0" origId="11861101,24139,439174,899" charOffset="29-35" type="compound" text="GlcNAc"/>
            <entity id="DS3.d39.s0.e1" origId="P13646,A1A4E9" charOffset="104-107" type="protein" text="K13"/>
            <entity id="DS3.d39.s0.e2" origId="P05783,A0A024RAY2" charOffset="117-120" type="protein" text="K18"/>
            <pair e1="DS3.d39.s0.e0" e2="DS3.d39.s0.e1" id="DS3.d39.s0.i0" interaction="False" />
            <pair e1="DS3.d39.s0.e0" e2="DS3.d39.s0.e2" id="DS3.d39.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d39.s1" origId="9932491-4" text="Three serine glycosylation sites in the head domain of K18 have been identified, and it is possible that all keratins are glycosylated.">
            <entity id="DS3.d39.s1.e0" origId="5951" charOffset="6-12" type="compound" text="serine"/>
            <entity id="DS3.d39.s1.e1" origId="P05783,A0A024RAY2" charOffset="55-58" type="protein" text="K18"/>
            <pair e1="DS3.d39.s1.e0" e2="DS3.d39.s1.e1" id="DS3.d39.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d39.s2" origId="9932491-8" text="Several serine phosphorylation sites and some of the relevant kinases have been characterized in K8, K6, and K18, and serine/threonine sites have been identified in K1.">
            <entity id="DS3.d39.s2.e0" origId="5951" charOffset="8-14" type="compound" text="serine"/>
            <entity id="DS3.d39.s2.e1" origId="P05783,A0A024RAY2" charOffset="109-112" type="protein" text="K18"/>
            <entity id="DS3.d39.s2.e2" origId="5951" charOffset="118-124" type="compound" text="serine"/>
            <entity id="DS3.d39.s2.e3" origId="194239,6288" charOffset="125-134" type="compound" text="threonine"/>
            <pair e1="DS3.d39.s2.e3" e2="DS3.d39.s2.e1" id="DS3.d39.s2.i0" interaction="False" />
            <pair e1="DS3.d39.s2.e0" e2="DS3.d39.s2.e1" id="DS3.d39.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d40" origId="9932502">
        <sentence id="DS3.d40.s0" origId="9932502-4" text="Conversely, an effect of Vimentin on the metabolism of lipoprotein-derived cholesterol observed in adrenal cells is not apparent in preadipose cells.">
            <entity id="DS3.d40.s0.e0" origId="P08670,V9HWE1" charOffset="25-33" type="protein" text="Vimentin"/>
            <entity id="DS3.d40.s0.e1" origId="5997" charOffset="75-86" type="compound" text="cholesterol"/>
            <pair e1="DS3.d40.s0.e1" e2="DS3.d40.s0.e0" id="DS3.d40.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d40.s1" origId="9932502-5" text="While the complexity of the phenotypes observed in these cells might be associated with cell-type-specific differences in the metabolism of triglycerides or lipoprotein-derived cholesterol, these studies have not yet revealed a general role of Vimentin in lipid metabolism that would indicate a common mechanism in all cell types.">
            <entity id="DS3.d40.s1.e0" origId="5997" charOffset="177-188" type="compound" text="cholesterol"/>
            <entity id="DS3.d40.s1.e1" origId="P08670,V9HWE1" charOffset="244-252" type="protein" text="Vimentin"/>
            <pair e1="DS3.d40.s1.e0" e2="DS3.d40.s1.e1" id="DS3.d40.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d40.s2" origId="9932502-6" text="A key issue that needs to be addressed is whether the effect of Vimentin IFs on the stability of triglycerides or the trafficking of GSLs and lysosomal cholesterol is due to a direct participation of Vimentin IFs in some aspect of these processes, or perhaps reflects an indirect response of the lipid metabolism of these cells to an effect of Vimentin on some other cellular process.">
            <entity id="DS3.d40.s2.e0" origId="P08670,V9HWE1" charOffset="64-72" type="protein" text="Vimentin"/>
            <entity id="DS3.d40.s2.e1" origId="5997" charOffset="152-163" type="compound" text="cholesterol"/>
            <entity id="DS3.d40.s2.e2" origId="P08670,V9HWE1" charOffset="200-208" type="protein" text="Vimentin"/>
            <entity id="DS3.d40.s2.e3" origId="P08670,V9HWE1" charOffset="200-208" type="protein" text="Vimentin"/>
            <pair e1="DS3.d40.s2.e1" e2="DS3.d40.s2.e0" id="DS3.d40.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d41" origId="9932567">
        <sentence id="DS3.d41.s0" origId="9932567-11" text="The fact that androgen receptor mRNA levels were consistently up-regulated by a combined E2 plus testosterone treatment while E2 treatment alone had little or no effect shows that a collaborative action of E2 and testosterone enhances androgen receptor expression in the monkey uterus.">
            <entity id="DS3.d41.s0.e0" origId="Q6QT55" charOffset="14-31" type="protein" text="androgen receptor"/>
            <entity id="DS3.d41.s0.e1" origId="6013" charOffset="97-109" type="compound" text="testosterone"/>
            <entity id="DS3.d41.s0.e2" origId="6013" charOffset="213-225" type="compound" text="testosterone"/>
            <entity id="DS3.d41.s0.e3" origId="Q6QT55" charOffset="235-252" type="protein" text="androgen receptor"/>
            <pair e1="DS3.d41.s0.e1" e2="DS3.d41.s0.e0" id="DS3.d41.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d41.s1" origId="9932567-5" text="Both E2 and E2 plus progesterone treatment doubled androgen receptor mRNA levels in stromal cells (P &amp;lt; .01), whereas E2 plus testosterone treatment increased stromal androgen receptor mRNA levels by about five-fold (P &amp;lt; .001) compared with placebo treatment.">
            <entity id="DS3.d41.s1.e0" origId="5994" charOffset="20-32" type="compound" text="progesterone"/>
            <entity id="DS3.d41.s1.e1" origId="Q6QT55" charOffset="51-68" type="protein" text="androgen receptor"/>
            <entity id="DS3.d41.s1.e2" origId="6013" charOffset="128-140" type="compound" text="testosterone"/>
            <entity id="DS3.d41.s1.e3" origId="Q6QT55" charOffset="169-186" type="protein" text="androgen receptor"/>
            <pair e1="DS3.d41.s1.e2" e2="DS3.d41.s1.e1" id="DS3.d41.s1.i0" interaction="False" />
            <pair e1="DS3.d41.s1.e0" e2="DS3.d41.s1.e1" id="DS3.d41.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d41.s2" origId="9932567-7" text="However, the E2 plus progesterone and E2 plus testosterone treatments increased epithelial androgen receptor mRNA levels by 4.3 and 5 times, respectively (P = .008 and P &amp;lt; .002, respectively).">
            <entity id="DS3.d41.s2.e0" origId="5994" charOffset="21-33" type="compound" text="progesterone"/>
            <entity id="DS3.d41.s2.e1" origId="6013" charOffset="46-58" type="compound" text="testosterone"/>
            <entity id="DS3.d41.s2.e2" origId="Q6QT55" charOffset="91-108" type="protein" text="androgen receptor"/>
            <pair e1="DS3.d41.s2.e1" e2="DS3.d41.s2.e2" id="DS3.d41.s2.i0" interaction="False" />
            <pair e1="DS3.d41.s2.e0" e2="DS3.d41.s2.e2" id="DS3.d41.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d41.s3" origId="9932567-9" text="Estradiol treatment alone did not increase myometrial androgen receptor mRNA levels significantly, but the E2 plus progesterone and E2 plus testosterone treatments increased myometrial androgen receptor mRNA levels by 1.8 and 2 times, respectively (P = .001 and P &amp;lt; .001, respectively).">
            <entity id="DS3.d41.s3.e0" origId="5757" charOffset="0-9" type="compound" text="Estradiol"/>
            <entity id="DS3.d41.s3.e1" origId="Q6QT55" charOffset="54-71" type="protein" text="androgen receptor"/>
            <entity id="DS3.d41.s3.e2" origId="5994" charOffset="115-127" type="compound" text="progesterone"/>
            <entity id="DS3.d41.s3.e3" origId="6013" charOffset="140-152" type="compound" text="testosterone"/>
            <entity id="DS3.d41.s3.e4" origId="Q6QT55" charOffset="185-202" type="protein" text="androgen receptor"/>
            <pair e1="DS3.d41.s3.e3" e2="DS3.d41.s3.e1" id="DS3.d41.s3.i0" interaction="False" />
            <pair e1="DS3.d41.s3.e0" e2="DS3.d41.s3.e1" id="DS3.d41.s3.i1" interaction="False" />
            <pair e1="DS3.d41.s3.e2" e2="DS3.d41.s3.e1" id="DS3.d41.s3.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d42" origId="9932604">
        <sentence id="DS3.d42.s0" origId="9932604-1" text="The purpose of this study was to investigate the association among matrix metalloproteinases (gelatinases A and B, stromelysin-3 (ST3) and matrilysin) mRNAs expressed in primary breast carcinomas and standard prognostic parameters and clinical outcome.">
            <entity id="DS3.d42.s0.e0" origId="P24347,B3KQS8" charOffset="115-128" type="protein" text="stromelysin-3"/>
            <entity id="DS3.d42.s0.e1" origId="446367" charOffset="130-133" type="compound" text="ST3"/>
            <entity id="DS3.d42.s0.e2" origId="P09237" charOffset="139-149" type="protein" text="matrilysin"/>
            <pair e1="DS3.d42.s0.e1" e2="DS3.d42.s0.e2" id="DS3.d42.s0.i0" interaction="False" />
            <pair e1="DS3.d42.s0.e1" e2="DS3.d42.s0.e0" id="DS3.d42.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d42.s1" origId="9932604-4" text="ST3, gelatinase A and matrilysin mRNAs were more often expressed at high levels in carcinomatous than in normal breast tissues.">
            <entity id="DS3.d42.s1.e0" origId="446367" charOffset="0-3" type="compound" text="ST3"/>
            <entity id="DS3.d42.s1.e1" origId="P08253,A0A024R6R4" charOffset="5-17" type="protein" text="gelatinase A"/>
            <entity id="DS3.d42.s1.e2" origId="P09237" charOffset="22-32" type="protein" text="matrilysin"/>
            <pair e1="DS3.d42.s1.e0" e2="DS3.d42.s1.e2" id="DS3.d42.s1.i0" interaction="False" />
            <pair e1="DS3.d42.s1.e0" e2="DS3.d42.s1.e1" id="DS3.d42.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d43" origId="9932606">
        <sentence id="DS3.d43.s0" origId="9932606-8" text="Finally, non-small cell lung carcinomas that expressed nm23-H1 protein were more frequently sensitive to doxorubicin than carcinomas that did not express this protein.">
            <entity id="DS3.d43.s0.e0" origId="P15531" charOffset="55-62" type="protein" text="nm23-H1"/>
            <entity id="DS3.d43.s0.e1" origId="31703" charOffset="105-116" type="compound" text="doxorubicin"/>
            <pair e1="DS3.d43.s0.e1" e2="DS3.d43.s0.e0" id="DS3.d43.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d44" origId="9932607">
        <sentence id="DS3.d44.s0" origId="9932607-5" text="We have applied this technique to determine gelatinase A (Gel A) mRNA expression in the MXT mouse mammary carcinoma system.">
            <entity id="DS3.d44.s0.e0" origId="P33434,Q3UG07" charOffset="44-56" type="protein" text="gelatinase A"/>
            <entity id="DS3.d44.s0.e1" origId="P33434,Q3UG07" charOffset="58-63" type="protein" text="Gel A"/>
            <entity id="DS3.d44.s0.e2" origId="17749734" charOffset="88-91" type="compound" text="MXT"/>
            <pair e1="DS3.d44.s0.e2" e2="DS3.d44.s0.e1" id="DS3.d44.s0.i0" interaction="False" />
            <pair e1="DS3.d44.s0.e2" e2="DS3.d44.s0.e0" id="DS3.d44.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d44.s1" origId="9932607-7" text="Highly metastatic MXT subclones show an increased Gel A expression.">
            <entity id="DS3.d44.s1.e0" origId="17749734" charOffset="18-21" type="compound" text="MXT"/>
            <entity id="DS3.d44.s1.e1" origId="P33434,Q3UG07" charOffset="50-55" type="protein" text="Gel A"/>
            <pair e1="DS3.d44.s1.e0" e2="DS3.d44.s1.e1" id="DS3.d44.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d45" origId="9932619">
        <sentence id="DS3.d45.s0" origId="9932619-6" text="They include calcium channel antagonists, NMDA receptor antagonists, lubeluzole, CDP-choline, the free radical scavenger tirilizad, anti-intercellular adhesion molecule-1 (ICAM-1) antibody, GM-1 ganglioside, clomethiazole, the sodium channel antagonist fosphenytoin, and piracetam.">
            <entity id="DS3.d45.s0.e0" origId="22044544,5460341" charOffset="13-20" type="compound" text="calcium"/>
            <entity id="DS3.d45.s0.e1" origId="65998" charOffset="69-79" type="compound" text="lubeluzole"/>
            <entity id="DS3.d45.s0.e2" origId="Q13948,P39880,Q3LIA3" charOffset="81-84" type="protein" text="CDP"/>
            <entity id="DS3.d45.s0.e3" origId="305,57080826" charOffset="85-92" type="compound" text="choline"/>
            <entity id="DS3.d45.s0.e4" origId="104903" charOffset="121-130" type="compound" text="tirilizad"/>
            <entity id="DS3.d45.s0.e5" origId="P05362" charOffset="132-170" type="protein" text="anti-intercellular adhesion molecule-1"/>
            <entity id="DS3.d45.s0.e6" origId="P05362" charOffset="172-178" type="protein" text="ICAM-1"/>
            <entity id="DS3.d45.s0.e7" origId="10783" charOffset="208-221" type="compound" text="clomethiazole"/>
            <entity id="DS3.d45.s0.e8" origId="5360545" charOffset="227-233" type="compound" text="sodium"/>
            <entity id="DS3.d45.s0.e9" origId="56339" charOffset="253-265" type="compound" text="fosphenytoin"/>
            <entity id="DS3.d45.s0.e10" origId="4843" charOffset="271-280" type="compound" text="piracetam"/>
            <pair e1="DS3.d45.s0.e9" e2="DS3.d45.s0.e5" id="DS3.d45.s0.i0" interaction="False" />
            <pair e1="DS3.d45.s0.e9" e2="DS3.d45.s0.e6" id="DS3.d45.s0.i1" interaction="False" />
            <pair e1="DS3.d45.s0.e9" e2="DS3.d45.s0.e2" id="DS3.d45.s0.i2" interaction="False" />
            <pair e1="DS3.d45.s0.e8" e2="DS3.d45.s0.e5" id="DS3.d45.s0.i3" interaction="False" />
            <pair e1="DS3.d45.s0.e8" e2="DS3.d45.s0.e6" id="DS3.d45.s0.i4" interaction="False" />
            <pair e1="DS3.d45.s0.e8" e2="DS3.d45.s0.e2" id="DS3.d45.s0.i5" interaction="False" />
            <pair e1="DS3.d45.s0.e1" e2="DS3.d45.s0.e5" id="DS3.d45.s0.i6" interaction="False" />
            <pair e1="DS3.d45.s0.e1" e2="DS3.d45.s0.e6" id="DS3.d45.s0.i7" interaction="False" />
            <pair e1="DS3.d45.s0.e1" e2="DS3.d45.s0.e2" id="DS3.d45.s0.i8" interaction="False" />
            <pair e1="DS3.d45.s0.e10" e2="DS3.d45.s0.e5" id="DS3.d45.s0.i9" interaction="False" />
            <pair e1="DS3.d45.s0.e10" e2="DS3.d45.s0.e6" id="DS3.d45.s0.i10" interaction="False" />
            <pair e1="DS3.d45.s0.e10" e2="DS3.d45.s0.e2" id="DS3.d45.s0.i11" interaction="False" />
            <pair e1="DS3.d45.s0.e4" e2="DS3.d45.s0.e5" id="DS3.d45.s0.i12" interaction="False" />
            <pair e1="DS3.d45.s0.e4" e2="DS3.d45.s0.e6" id="DS3.d45.s0.i13" interaction="False" />
            <pair e1="DS3.d45.s0.e4" e2="DS3.d45.s0.e2" id="DS3.d45.s0.i14" interaction="False" />
            <pair e1="DS3.d45.s0.e0" e2="DS3.d45.s0.e5" id="DS3.d45.s0.i15" interaction="False" />
            <pair e1="DS3.d45.s0.e0" e2="DS3.d45.s0.e6" id="DS3.d45.s0.i16" interaction="False" />
            <pair e1="DS3.d45.s0.e0" e2="DS3.d45.s0.e2" id="DS3.d45.s0.i17" interaction="False" />
            <pair e1="DS3.d45.s0.e3" e2="DS3.d45.s0.e5" id="DS3.d45.s0.i18" interaction="False" />
            <pair e1="DS3.d45.s0.e3" e2="DS3.d45.s0.e6" id="DS3.d45.s0.i19" interaction="False" />
            <pair e1="DS3.d45.s0.e3" e2="DS3.d45.s0.e2" id="DS3.d45.s0.i20" interaction="False" />
            <pair e1="DS3.d45.s0.e7" e2="DS3.d45.s0.e5" id="DS3.d45.s0.i21" interaction="False" />
            <pair e1="DS3.d45.s0.e7" e2="DS3.d45.s0.e6" id="DS3.d45.s0.i22" interaction="False" />
            <pair e1="DS3.d45.s0.e7" e2="DS3.d45.s0.e2" id="DS3.d45.s0.i23" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d46" origId="9932640">
        <sentence id="DS3.d46.s0" origId="9932640-3" text="Then, the patient received allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from his human lymphocyte antigen (HL A)-identical brother following high-dose cyclophosphamide and 12 Gy total body irradiation, and the patient achieved CR with the disappearance of Bcl-2 rearrangement.">
            <entity id="DS3.d46.s0.e0" origId="2907" charOffset="173-189" type="compound" text="cyclophosphamide"/>
            <entity id="DS3.d46.s0.e1" origId="P10415,A0A024R2B3,A0A024R2C4" charOffset="278-283" type="protein" text="Bcl-2"/>
            <pair e1="DS3.d46.s0.e0" e2="DS3.d46.s0.e1" id="DS3.d46.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d47" origId="9932654">
        <sentence id="DS3.d47.s0" origId="9932654-11" text="No significant correlation was observed between leptin concentration and residual renal function, dialysis adequacy (Kt/V), dietary protein or caloric intake, or serum levels of albumin, prealbumin, C-reactive protein, glucose, and insulin-like growth factor-I.">
            <entity id="DS3.d47.s0.e0" origId="P41159,A4D0Y8" charOffset="48-54" type="protein" text="leptin"/>
            <entity id="DS3.d47.s0.e1" origId="P02768" charOffset="178-185" type="protein" text="albumin"/>
            <entity id="DS3.d47.s0.e2" origId="206,5793,64689,79025" charOffset="219-226" type="compound" text="glucose"/>
            <pair e1="DS3.d47.s0.e2" e2="DS3.d47.s0.e0" id="DS3.d47.s0.i0" interaction="False" />
            <pair e1="DS3.d47.s0.e2" e2="DS3.d47.s0.e1" id="DS3.d47.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d48" origId="9932655">
        <sentence id="DS3.d48.s0" origId="9932655-7" text="After a 4-week baseline period using solutions containing 40 mmol/L lactate, the patients were dialyzed with either 33 mmol/L bicarbonate solutions or 40 mmol/L lactate solutions.">
            <entity id="DS3.d48.s0.e0" origId="612" charOffset="68-75" type="compound" text="lactate"/>
            <entity id="DS3.d48.s0.e1" origId="767" charOffset="126-137" type="compound" text="bicarbonate"/>
            <entity id="DS3.d48.s0.e2" origId="P47881" charOffset="148-153" type="protein" text="or 40"/>
            <entity id="DS3.d48.s0.e3" origId="612" charOffset="161-168" type="compound" text="lactate"/>
            <pair e1="DS3.d48.s0.e1" e2="DS3.d48.s0.e2" id="DS3.d48.s0.i0" interaction="False" />
            <pair e1="DS3.d48.s0.e0" e2="DS3.d48.s0.e2" id="DS3.d48.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d49" origId="9932659">
        <sentence id="DS3.d49.s0" origId="9932659-14" text="The glucose dehydrogenase characterizing the Accutrend Sensor, an enzyme of the pyrroloquinolinequinone class, very likely reacts with the free reducing group of the glucose molecule located at the end of each saccharide chain.">
            <entity id="DS3.d49.s0.e0" origId="O95479,R4GMU1" charOffset="4-25" type="protein" text="glucose dehydrogenase"/>
            <entity id="DS3.d49.s0.e1" origId="1024" charOffset="80-103" type="compound" text="pyrroloquinolinequinone"/>
            <entity id="DS3.d49.s0.e2" origId="206,5793,64689,79025" charOffset="4-11" type="compound" text="glucose"/>
            <pair e1="DS3.d49.s0.e1" e2="DS3.d49.s0.e0" id="DS3.d49.s0.i0" interaction="False" />
            <pair e1="DS3.d49.s0.e2" e2="DS3.d49.s0.e0" id="DS3.d49.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d49.s1" origId="9932659-15" text="This would not be the case for the Glucocard monitor using glucose oxidase, for other kits using glucose dehydrogenase, and for the reference method based on hexokinase.">
            <entity id="DS3.d49.s1.e0" origId="206,5793,64689,79025" charOffset="59-66" type="compound" text="glucose"/>
            <entity id="DS3.d49.s1.e1" origId="O95479,R4GMU1" charOffset="97-118" type="protein" text="glucose dehydrogenase"/>
            <pair e1="DS3.d49.s1.e0" e2="DS3.d49.s1.e1" id="DS3.d49.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d49.s2" origId="9932659-1" text="OBJECTIVE: Serious discrepancies between glycemia measurements obtained with an Accutrend Sensor (Boehringer Mannheim GmbH, Mannheim, Germany) type analyzer (based on a glucose dehydrogenase enzymatic reaction) and measurements obtained in the laboratory by a reference method (hexokinase) have been found in an insulin-requiring, diabetic, continuous ambulatory peritoneal dialysis (CAPD) patient treated with icodextrin 7.5% (Extraneal; Baxter Healthcare SA, Castlebar, Ireland), a new osmotic agent for peritoneal dialysis.">
            <entity id="DS3.d49.s2.e0" origId="O95479,R4GMU1" charOffset="169-190" type="protein" text="glucose dehydrogenase"/>
            <entity id="DS3.d49.s2.e1" origId="P01308,I3WAC9" charOffset="312-319" type="protein" text="insulin"/>
            <entity id="DS3.d49.s2.e2" origId="3517" charOffset="411-421" type="compound" text="icodextrin"/>
            <pair e1="DS3.d49.s2.e2" e2="DS3.d49.s2.e1" id="DS3.d49.s2.i0" interaction="False" />
            <pair e1="DS3.d49.s2.e2" e2="DS3.d49.s2.e0" id="DS3.d49.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d50" origId="9932681">
        <sentence id="DS3.d50.s0" origId="9932681-12" text="Administration of L-arginine after trauma-hemorrhage, however, improved splenic and peritoneal macrophage IL-1beta and IL-6 release.">
            <entity id="DS3.d50.s0.e0" origId="6322,90867653" charOffset="20-28" type="compound" text="arginine"/>
            <entity id="DS3.d50.s0.e1" origId="Q5BKB0" charOffset="106-114" type="protein" text="IL-1beta"/>
            <entity id="DS3.d50.s0.e2" origId="P20607" charOffset="119-123" type="protein" text="IL-6"/>
            <pair e1="DS3.d50.s0.e0" e2="DS3.d50.s0.e2" id="DS3.d50.s0.i0" interaction="False" />
            <pair e1="DS3.d50.s0.e0" e2="DS3.d50.s0.e1" id="DS3.d50.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d50.s1" origId="9932681-13" text="Moreover, the up-regulated plasma levels of IL-6 were attenuated by L-arginine administration.">
            <entity id="DS3.d50.s1.e0" origId="P20607" charOffset="44-48" type="protein" text="IL-6"/>
            <entity id="DS3.d50.s1.e1" origId="6322,90867653" charOffset="70-78" type="compound" text="arginine"/>
            <pair e1="DS3.d50.s1.e1" e2="DS3.d50.s1.e0" id="DS3.d50.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d50.s2" origId="9932681-14" text="CONCLUSION: L-Arginine administration after trauma-hemorrhage significantly improves the depressed macrophage function, presumably by decreasing the increased plasma IL-6 levels and improving organ blood flow.">
            <entity id="DS3.d50.s2.e0" origId="6322,90867653" charOffset="14-22" type="compound" text="Arginine"/>
            <entity id="DS3.d50.s2.e1" origId="P20607" charOffset="166-170" type="protein" text="IL-6"/>
            <pair e1="DS3.d50.s2.e0" e2="DS3.d50.s2.e1" id="DS3.d50.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d50.s3" origId="9932681-15" text="Early enhancement of the depressed constitutive nitric oxide synthase activity by provision of L-arginine after trauma-hemorrhage, therefore, represents a novel and safe approach for improving the depressed immune function and decreasing plasma IL-6 levels under such conditions.">
            <entity id="DS3.d50.s3.e0" origId="145068" charOffset="48-60" type="compound" text="nitric oxide"/>
            <entity id="DS3.d50.s3.e1" origId="6322,90867653" charOffset="97-105" type="compound" text="arginine"/>
            <entity id="DS3.d50.s3.e2" origId="P20607" charOffset="245-249" type="protein" text="IL-6"/>
            <pair e1="DS3.d50.s3.e0" e2="DS3.d50.s3.e2" id="DS3.d50.s3.i0" interaction="False" />
            <pair e1="DS3.d50.s3.e1" e2="DS3.d50.s3.e2" id="DS3.d50.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d51" origId="9932682">
        <sentence id="DS3.d51.s0" origId="9932682-10" text="RESULTS: Postinjury PMNs were primed for both platelet-activating factor/N-formyl-methionyl-leucyl-phenylalanine-stimulated and lipopolysaccharide-stimulated IL-8 and TNF release at 2 hours after injury (fourfold increase of IL-8 release and fivefold increase of TNF release), whereas elective surgical patients demonstrated no priming.">
            <entity id="DS3.d51.s0.e0" origId="108157,5313888" charOffset="46-72" type="compound" text="platelet-activating factor"/>
            <entity id="DS3.d51.s0.e1" origId="443295" charOffset="73-112" type="compound" text="N-formyl-methionyl-leucyl-phenylalanine"/>
            <entity id="DS3.d51.s0.e2" origId="11970143" charOffset="128-146" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d51.s0.e3" origId="P10145,A0A024RDA5" charOffset="158-162" type="protein" text="IL-8"/>
            <entity id="DS3.d51.s0.e4" origId="P10145,A0A024RDA5" charOffset="225-229" type="protein" text="IL-8"/>
            <pair e1="DS3.d51.s0.e2" e2="DS3.d51.s0.e3" id="DS3.d51.s0.i0" interaction="False" />
            <pair e1="DS3.d51.s0.e1" e2="DS3.d51.s0.e3" id="DS3.d51.s0.i1" interaction="False" />
            <pair e1="DS3.d51.s0.e0" e2="DS3.d51.s0.e3" id="DS3.d51.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d51.s1" origId="9932682-9" text="The PMNs were stimulated with platelet-activating factor (200 nM)/N-formyl-methionyl-leucyl-phenylalanine (1 micromol/L) or lipopolysaccharide (100 ng/mL) incubated for 24 hours in RPMI-1640, and release of IL-8, TNF, and IL-1ra were measured.">
            <entity id="DS3.d51.s1.e0" origId="108157,5313888" charOffset="30-56" type="compound" text="platelet-activating factor"/>
            <entity id="DS3.d51.s1.e1" origId="443295" charOffset="66-105" type="compound" text="N-formyl-methionyl-leucyl-phenylalanine"/>
            <entity id="DS3.d51.s1.e2" origId="11970143" charOffset="124-142" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d51.s1.e3" origId="P10145,A0A024RDA5" charOffset="207-211" type="protein" text="IL-8"/>
            <entity id="DS3.d51.s1.e4" origId="P14778,B8ZZW4" charOffset="222-228" type="protein" text="IL-1ra"/>
            <pair e1="DS3.d51.s1.e2" e2="DS3.d51.s1.e4" id="DS3.d51.s1.i0" interaction="False" />
            <pair e1="DS3.d51.s1.e2" e2="DS3.d51.s1.e3" id="DS3.d51.s1.i1" interaction="False" />
            <pair e1="DS3.d51.s1.e1" e2="DS3.d51.s1.e4" id="DS3.d51.s1.i2" interaction="False" />
            <pair e1="DS3.d51.s1.e1" e2="DS3.d51.s1.e3" id="DS3.d51.s1.i3" interaction="False" />
            <pair e1="DS3.d51.s1.e0" e2="DS3.d51.s1.e4" id="DS3.d51.s1.i4" interaction="False" />
            <pair e1="DS3.d51.s1.e0" e2="DS3.d51.s1.e3" id="DS3.d51.s1.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d52" origId="9932696">
        <sentence id="DS3.d52.s0" origId="9932696-1" text="A subform of alpha2-macroglobulin, (inhibiteur de rejet de greffe (IRG), present at a low rate in healthy rat, increased with rate-related suppressive activity on complement during inflammatory processes.">
            <entity id="DS3.d52.s0.e0" origId="P01023" charOffset="13-33" type="protein" text="alpha2-macroglobulin"/>
            <entity id="DS3.d52.s0.e1" origId="70678412" charOffset="67-70" type="compound" text="IRG"/>
            <pair e1="DS3.d52.s0.e1" e2="DS3.d52.s0.e0" id="DS3.d52.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d53" origId="9932709">
        <sentence id="DS3.d53.s0" origId="9932709-0" text="Blockade of accumbens 5-HT3 receptor down-regulation by ondansetron administered during continuous cocaine administration.">
            <entity id="DS3.d53.s0.e0" origId="P35563,Q62999" charOffset="22-36" type="protein" text="5-HT3 receptor"/>
            <entity id="DS3.d53.s0.e1" origId="4595" charOffset="56-67" type="compound" text="ondansetron"/>
            <entity id="DS3.d53.s0.e2" origId="446220" charOffset="99-106" type="compound" text="cocaine"/>
            <pair e1="DS3.d53.s0.e1" e2="DS3.d53.s0.e0" id="DS3.d53.s0.i0" interaction="False" />
            <pair e1="DS3.d53.s0.e2" e2="DS3.d53.s0.e0" id="DS3.d53.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d54" origId="9932710">
        <sentence id="DS3.d54.s0" origId="9932710-1" text="Effects of the 5-HT3 receptor agonist, m-chlorophenylbiguanide (10.0-40.0 microg), on sleep and waking were studied in control, vehicle-treated and 6-hydroxydopamine-injected rats.">
            <entity id="DS3.d54.s0.e0" origId="P35563,Q62999" charOffset="15-29" type="protein" text="5-HT3 receptor"/>
            <entity id="DS3.d54.s0.e1" origId="1354" charOffset="41-62" type="compound" text="chlorophenylbiguanide"/>
            <entity id="DS3.d54.s0.e2" origId="4624" charOffset="148-165" type="compound" text="6-hydroxydopamine"/>
            <pair e1="DS3.d54.s0.e1" e2="DS3.d54.s0.e0" id="DS3.d54.s0.i0" interaction="False" />
            <pair e1="DS3.d54.s0.e2" e2="DS3.d54.s0.e0" id="DS3.d54.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d54.s1" origId="9932710-4" text="Pretreatment with the selective 5-HT3 receptor antagonist, MDL 72222 (1aH,3a,5a, H-tropan-3-yl-3,5-dichloro-benzoate) (0.5 mg/kg, s.c.), reversed the effects of m-chlorophenylbiguanide (10.0-20.0 microg) on sleep and waking in the control group.">
            <entity id="DS3.d54.s1.e0" origId="P35563,Q62999" charOffset="32-46" type="protein" text="5-HT3 receptor"/>
            <entity id="DS3.d54.s1.e1" origId="11513133" charOffset="70-73" type="compound" text="1aH"/>
            <entity id="DS3.d54.s1.e2" origId="2981881,91293124" charOffset="74-76" type="compound" text="3a"/>
            <entity id="DS3.d54.s1.e3" origId="79037" charOffset="83-89" type="compound" text="tropan"/>
            <entity id="DS3.d54.s1.e4" origId="243" charOffset="108-116" type="compound" text="benzoate"/>
            <entity id="DS3.d54.s1.e5" origId="1354" charOffset="163-184" type="compound" text="chlorophenylbiguanide"/>
            <pair e1="DS3.d54.s1.e5" e2="DS3.d54.s1.e0" id="DS3.d54.s1.i0" interaction="False" />
            <pair e1="DS3.d54.s1.e2" e2="DS3.d54.s1.e0" id="DS3.d54.s1.i1" interaction="False" />
            <pair e1="DS3.d54.s1.e3" e2="DS3.d54.s1.e0" id="DS3.d54.s1.i2" interaction="False" />
            <pair e1="DS3.d54.s1.e1" e2="DS3.d54.s1.e0" id="DS3.d54.s1.i3" interaction="False" />
            <pair e1="DS3.d54.s1.e4" e2="DS3.d54.s1.e0" id="DS3.d54.s1.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d54.s2" origId="9932710-5" text="Administration of the 5-HT3 receptor agonist to the 6-hydroxydopamine-treated animals modified only slightly the time spent in wakefulness and slow wave sleep, while REM sleep was significantly and dose dependently reduced.">
            <entity id="DS3.d54.s2.e0" origId="P35563,Q62999" charOffset="22-36" type="protein" text="5-HT3 receptor"/>
            <entity id="DS3.d54.s2.e1" origId="4624" charOffset="52-69" type="compound" text="6-hydroxydopamine"/>
            <pair e1="DS3.d54.s2.e1" e2="DS3.d54.s2.e0" id="DS3.d54.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d55" origId="9932713">
        <sentence id="DS3.d55.s0" origId="9932713-0" text="Vasopressin receptor antagonist OPC-31260 prevents cerebral oedema after subarachnoid haemorrhage.">
            <entity id="DS3.d55.s0.e0" origId="P01185,X5DQP6" charOffset="0-11" type="protein" text="Vasopressin"/>
            <entity id="DS3.d55.s0.e1" origId="119369" charOffset="32-41" type="compound" text="OPC-31260"/>
            <pair e1="DS3.d55.s0.e1" e2="DS3.d55.s0.e0" id="DS3.d55.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d55.s1" origId="9932713-1" text="The effects of the non-peptide Vasopressin V2 receptor antagonist, 5-dimethylamino-1-(4-(2-methylbenzoylamino)benzoyl)-2,3,4,5-tetrah ydro-1 H-benzazepine hydrochloride (OPC-31260) on the cerebral oedema induced by subarachnoid haemorrhage were studied in rats.">
            <entity id="DS3.d55.s1.e0" origId="P01185,X5DQP6" charOffset="31-42" type="protein" text="Vasopressin"/>
            <entity id="DS3.d55.s1.e1" origId="15559658" charOffset="143-168" type="compound" text="benzazepine hydrochloride"/>
            <entity id="DS3.d55.s1.e2" origId="119369" charOffset="170-179" type="compound" text="OPC-31260"/>
            <pair e1="DS3.d55.s1.e2" e2="DS3.d55.s1.e0" id="DS3.d55.s1.i0" interaction="False" />
            <pair e1="DS3.d55.s1.e1" e2="DS3.d55.s1.e0" id="DS3.d55.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d55.s2" origId="9932713-2" text="Subarachnoid haemorrhage induced significant water retention after water loading, increased the brain content of water and Na+ and increased plasma Vasopressin levels.">
            <entity id="DS3.d55.s2.e0" origId="962" charOffset="45-50" type="compound" text="water"/>
            <entity id="DS3.d55.s2.e1" origId="962" charOffset="67-72" type="compound" text="water"/>
            <entity id="DS3.d55.s2.e2" origId="962" charOffset="67-72" type="compound" text="water"/>
            <entity id="DS3.d55.s2.e3" origId="P01185,X5DQP6" charOffset="148-159" type="protein" text="Vasopressin"/>
            <pair e1="DS3.d55.s2.e0" e2="DS3.d55.s2.e3" id="DS3.d55.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d55.s3" origId="9932713-3" text="The water retention and brain water and Na+ accumulation were prevented by OPC-31260 administration, but the plasma Vasopressin levels were further enhanced by OPC-31260.">
            <entity id="DS3.d55.s3.e0" origId="962" charOffset="4-9" type="compound" text="water"/>
            <entity id="DS3.d55.s3.e1" origId="962" charOffset="30-35" type="compound" text="water"/>
            <entity id="DS3.d55.s3.e2" origId="119369" charOffset="75-84" type="compound" text="OPC-31260"/>
            <entity id="DS3.d55.s3.e3" origId="P01185,X5DQP6" charOffset="116-127" type="protein" text="Vasopressin"/>
            <entity id="DS3.d55.s3.e4" origId="119369" charOffset="160-169" type="compound" text="OPC-31260"/>
            <pair e1="DS3.d55.s3.e0" e2="DS3.d55.s3.e3" id="DS3.d55.s3.i0" interaction="False" />
            <pair e1="DS3.d55.s3.e2" e2="DS3.d55.s3.e3" id="DS3.d55.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d55.s4" origId="9932713-4" text="These results demonstrate the important role of Vasopressin in the development of antidiuresis and disturbances in brain water and electrolyte balance in response to subarachnoid haemorrhage.">
            <entity id="DS3.d55.s4.e0" origId="P01185,X5DQP6" charOffset="48-59" type="protein" text="Vasopressin"/>
            <entity id="DS3.d55.s4.e1" origId="962" charOffset="121-126" type="compound" text="water"/>
            <pair e1="DS3.d55.s4.e1" e2="DS3.d55.s4.e0" id="DS3.d55.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d55.s5" origId="9932713-6" text="The protective mechanism exerted by OPC-31260 stems from its influence on renal tubular function: it blocks the renal Vasopressin V2 receptors.">
            <entity id="DS3.d55.s5.e0" origId="119369" charOffset="36-45" type="compound" text="OPC-31260"/>
            <entity id="DS3.d55.s5.e1" origId="P01185,X5DQP6" charOffset="118-129" type="protein" text="Vasopressin"/>
            <pair e1="DS3.d55.s5.e0" e2="DS3.d55.s5.e1" id="DS3.d55.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d56" origId="9932719">
        <sentence id="DS3.d56.s0" origId="9932719-4" text="Myocardial necrosis, myocardial myeloperoxidase activity (MPO), serum creatinine phosphokinase activity (CPK), serum tumor necrosis factor (TNF-alpha), cardiac mRNA for TNF-alpha, cardiac intercellular adhesion molecule-1 (ICAM-1) immunostaining and myocardial contractility (left ventricle dP/dtmax) were evaluated.">
            <entity id="DS3.d56.s0.e0" origId="D3ZGE2,A0A0G2K1A2" charOffset="32-56" type="protein" text="myeloperoxidase activity"/>
            <entity id="DS3.d56.s0.e1" origId="D3ZGE2,A0A0G2K1A2" charOffset="58-61" type="protein" text="MPO"/>
            <entity id="DS3.d56.s0.e2" origId="588" charOffset="70-80" type="compound" text="creatinine"/>
            <entity id="DS3.d56.s0.e3" origId="P16599" charOffset="140-149" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d56.s0.e4" origId="P16599" charOffset="169-178" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d56.s0.e5" origId="Q00238" charOffset="223-229" type="protein" text="ICAM-1"/>
            <pair e1="DS3.d56.s0.e2" e2="DS3.d56.s0.e1" id="DS3.d56.s0.i0" interaction="False" />
            <pair e1="DS3.d56.s0.e2" e2="DS3.d56.s0.e3" id="DS3.d56.s0.i1" interaction="False" />
            <pair e1="DS3.d56.s0.e2" e2="DS3.d56.s0.e0" id="DS3.d56.s0.i2" interaction="False" />
            <pair e1="DS3.d56.s0.e2" e2="DS3.d56.s0.e5" id="DS3.d56.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d57" origId="9932811">
        <sentence id="DS3.d57.s0" origId="9932811-5" text="For the model cationic peptides (gonadorelin, angiotensin II) good linearity and reproducibility is observed in the 20 to 100 ng/mL concentration range.">
            <entity id="DS3.d57.s0.e0" origId="36523,57321499,638793" charOffset="33-44" type="compound" text="gonadorelin"/>
            <entity id="DS3.d57.s0.e1" origId="P01019,B0ZBE2,B2R5S1" charOffset="46-60" type="protein" text="angiotensin II"/>
            <pair e1="DS3.d57.s0.e0" e2="DS3.d57.s0.e1" id="DS3.d57.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d58" origId="9932816">
        <sentence id="DS3.d58.s0" origId="9932816-8" text="The cholangiocyte 2-D protein pattern is markedly different from that of isolated rat hepatocytes or whole rat liver, with high levels of proteins previously known to be expressed by cholangiocytes (e.g., cytokeratins, actins) as well as protein not previously demonstrated to be expressed at high levels (e.g., annexin V, selenium binding protein).">
            <entity id="DS3.d58.s0.e0" origId="P14668,Q66HH8" charOffset="312-321" type="protein" text="annexin V"/>
            <entity id="DS3.d58.s0.e1" origId="6326970" charOffset="323-331" type="compound" text="selenium"/>
            <pair e1="DS3.d58.s0.e1" e2="DS3.d58.s0.e0" id="DS3.d58.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d59" origId="9932843">
        <sentence id="DS3.d59.s0" origId="9932843-1" text="BACKGROUND: The purpose of this study was to determine if sacrosidase, a liquid produced from Saccharomyces cerevisiae containing 6000 IU of sucrase activity per mg protein, prevented symptoms of diarrhea, abdominal cramps, gas, and bloating in patients with congenital sucrase-isomaltase deficiency (CSID) consuming a normal sucrose and carbohydrate-containing diet.">
            <entity id="DS3.d59.s0.e0" origId="P01350,A0A0E3VY36" charOffset="224-227" type="protein" text="gas"/>
            <entity id="DS3.d59.s0.e1" origId="5988" charOffset="326-333" type="compound" text="sucrose"/>
            <pair e1="DS3.d59.s0.e1" e2="DS3.d59.s0.e0" id="DS3.d59.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d60" origId="9932853">
        <sentence id="DS3.d60.s0" origId="9932853-5" text="All copper metabolism test results (total serum copper, 24-hour urine excretion, serum ceruloplasmin) were abnormal in 62%, two in 27%, and one in 11%.">
            <entity id="DS3.d60.s0.e0" origId="23978" charOffset="4-10" type="compound" text="copper"/>
            <entity id="DS3.d60.s0.e1" origId="23978" charOffset="48-54" type="compound" text="copper"/>
            <entity id="DS3.d60.s0.e2" origId="P00450,A5PL27" charOffset="87-100" type="protein" text="ceruloplasmin"/>
            <pair e1="DS3.d60.s0.e0" e2="DS3.d60.s0.e2" id="DS3.d60.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d61" origId="9932870">
        <sentence id="DS3.d61.s0" origId="9932870-0" text="Effect of TPA on Aquaporin 4 mRNA expression in cultured rat astrocytes.">
            <entity id="DS3.d61.s0.e0" origId="122634" charOffset="10-13" type="compound" text="TPA"/>
            <entity id="DS3.d61.s0.e1" origId="P55087,F1DSG4" charOffset="17-28" type="protein" text="Aquaporin 4"/>
            <pair e1="DS3.d61.s0.e0" e2="DS3.d61.s0.e1" id="DS3.d61.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d61.s1" origId="9932870-11" text="Pretreatment of the cells with cycloheximide did not inhibit the decrease in AQP4 mRNA induced by TPA.">
            <entity id="DS3.d61.s1.e0" origId="6197" charOffset="31-44" type="compound" text="cycloheximide"/>
            <entity id="DS3.d61.s1.e1" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="77-81" type="protein" text="AQP4"/>
            <entity id="DS3.d61.s1.e2" origId="122634" charOffset="98-101" type="compound" text="TPA"/>
            <pair e1="DS3.d61.s1.e2" e2="DS3.d61.s1.e1" id="DS3.d61.s1.i0" interaction="False" />
            <pair e1="DS3.d61.s1.e0" e2="DS3.d61.s1.e1" id="DS3.d61.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d61.s2" origId="9932870-12" text="To test whether the TPA-induced decrease in AQP4 was due to a decrease in the mRNA stability, we examined the effect of actinomycin D, an inhibitor of transcription, on TPA-treated cells.">
            <entity id="DS3.d61.s2.e0" origId="122634" charOffset="20-23" type="compound" text="TPA"/>
            <entity id="DS3.d61.s2.e1" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="44-48" type="protein" text="AQP4"/>
            <entity id="DS3.d61.s2.e2" origId="122634" charOffset="169-172" type="compound" text="TPA"/>
            <pair e1="DS3.d61.s2.e0" e2="DS3.d61.s2.e1" id="DS3.d61.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d61.s3" origId="9932870-13" text="The stability of AQP4 mRNA was not decreased by the pretreatment of the cells with actinomycin D. The results suggest that AQP4 mRNA is inhibited by TPA via PKC activation without de novo protein synthesis, and that the inhibition of AQP4 mRNA could be at the transcriptional level.">
            <entity id="DS3.d61.s3.e0" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="17-21" type="protein" text="AQP4"/>
            <entity id="DS3.d61.s3.e1" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="123-127" type="protein" text="AQP4"/>
            <entity id="DS3.d61.s3.e2" origId="122634" charOffset="149-152" type="compound" text="TPA"/>
            <entity id="DS3.d61.s3.e3" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="123-127" type="protein" text="AQP4"/>
            <pair e1="DS3.d61.s3.e2" e2="DS3.d61.s3.e0" id="DS3.d61.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d61.s4" origId="9932870-1" text="Aquaporin 4 (AQP4) is a predominant water channel protein in mammalian brains, localized in the astrocyte plasma membrane.">
            <entity id="DS3.d61.s4.e0" origId="P55087,F1DSG4" charOffset="0-11" type="protein" text="Aquaporin 4"/>
            <entity id="DS3.d61.s4.e1" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="13-17" type="protein" text="AQP4"/>
            <entity id="DS3.d61.s4.e2" origId="962" charOffset="36-41" type="compound" text="water"/>
            <pair e1="DS3.d61.s4.e2" e2="DS3.d61.s4.e1" id="DS3.d61.s4.i0" interaction="False" />
            <pair e1="DS3.d61.s4.e2" e2="DS3.d61.s4.e0" id="DS3.d61.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d61.s5" origId="9932870-2" text="The regulation of AQP4 is believed to be important for the homeostasis of water in the brain, but the AQP4 regulatory mechanisms are not yet known.">
            <entity id="DS3.d61.s5.e0" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="18-22" type="protein" text="AQP4"/>
            <entity id="DS3.d61.s5.e1" origId="962" charOffset="74-79" type="compound" text="water"/>
            <entity id="DS3.d61.s5.e2" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="102-106" type="protein" text="AQP4"/>
            <pair e1="DS3.d61.s5.e1" e2="DS3.d61.s5.e0" id="DS3.d61.s5.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d61.s6" origId="9932870-5" text="Treatment of the cells with 0.1 microM of phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA), an activator of PKC, caused a rapid decrease in AQP4 mRNA.">
            <entity id="DS3.d61.s6.e0" origId="27924,70702034" charOffset="42-55" type="compound" text="phorbol ester"/>
            <entity id="DS3.d61.s6.e1" origId="107854" charOffset="56-81" type="compound" text="12-O-tetradecanoylphorbol"/>
            <entity id="DS3.d61.s6.e2" origId="176" charOffset="85-92" type="compound" text="acetate"/>
            <entity id="DS3.d61.s6.e3" origId="122634" charOffset="94-97" type="compound" text="TPA"/>
            <entity id="DS3.d61.s6.e4" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="148-152" type="protein" text="AQP4"/>
            <pair e1="DS3.d61.s6.e1" e2="DS3.d61.s6.e4" id="DS3.d61.s6.i0" interaction="False" />
            <pair e1="DS3.d61.s6.e0" e2="DS3.d61.s6.e4" id="DS3.d61.s6.i1" interaction="False" />
            <pair e1="DS3.d61.s6.e3" e2="DS3.d61.s6.e4" id="DS3.d61.s6.i2" interaction="False" />
            <pair e1="DS3.d61.s6.e2" e2="DS3.d61.s6.e4" id="DS3.d61.s6.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d61.s7" origId="9932870-7" text="The TPA-induced decrease in AQP4 mRNA was inhibited by a relatively specific PKC inhibitor, 1-(5-isoquinoline sulfonyl)-2-methylpiperazine (H7) in a dose-dependent manner.">
            <entity id="DS3.d61.s7.e0" origId="122634" charOffset="4-7" type="compound" text="TPA"/>
            <entity id="DS3.d61.s7.e1" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="28-32" type="protein" text="AQP4"/>
            <entity id="DS3.d61.s7.e2" origId="21802677" charOffset="95-118" type="compound" text="5-isoquinoline sulfonyl"/>
            <entity id="DS3.d61.s7.e3" origId="66057" charOffset="120-138" type="compound" text="2-methylpiperazine"/>
            <pair e1="DS3.d61.s7.e2" e2="DS3.d61.s7.e1" id="DS3.d61.s7.i0" interaction="False" />
            <pair e1="DS3.d61.s7.e3" e2="DS3.d61.s7.e1" id="DS3.d61.s7.i1" interaction="False" />
            <pair e1="DS3.d61.s7.e0" e2="DS3.d61.s7.e1" id="DS3.d61.s7.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d61.s8" origId="9932870-8" text="Moreover, prolonged treatment of the cells with TPA eliminated the subsequent decrease in AQP4 mRNA by TPA.">
            <entity id="DS3.d61.s8.e0" origId="122634" charOffset="48-51" type="compound" text="TPA"/>
            <entity id="DS3.d61.s8.e1" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="90-94" type="protein" text="AQP4"/>
            <entity id="DS3.d61.s8.e2" origId="122634" charOffset="103-106" type="compound" text="TPA"/>
            <pair e1="DS3.d61.s8.e0" e2="DS3.d61.s8.e1" id="DS3.d61.s8.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d61.s9" origId="9932870-9" text="These results strongly suggest that the TPA-induced decrease in AQP4 mRNA is mediated by PKC activation.">
            <entity id="DS3.d61.s9.e0" origId="122634" charOffset="40-43" type="compound" text="TPA"/>
            <entity id="DS3.d61.s9.e1" origId="P47863,A0A0G2K4I1,A0A0H2UHZ1" charOffset="64-68" type="protein" text="AQP4"/>
            <pair e1="DS3.d61.s9.e0" e2="DS3.d61.s9.e1" id="DS3.d61.s9.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d62" origId="9932872">
        <sentence id="DS3.d62.s0" origId="9932872-5" text="Combinations of ensheathing cell-conditioned medium and substrates of laminin, merosin, or 3T3 cells also failed to show the release of factors enhancing either survival or neurite outgrowth from retinal ganglion cells.">
            <entity id="DS3.d62.s0.e0" origId="44342165" charOffset="70-77" type="compound" text="laminin"/>
            <entity id="DS3.d62.s0.e1" origId="Q60675,Q5DTP0" charOffset="79-86" type="protein" text="merosin"/>
            <entity id="DS3.d62.s0.e2" origId="638015" charOffset="196-203" type="compound" text="retinal"/>
            <pair e1="DS3.d62.s0.e0" e2="DS3.d62.s0.e1" id="DS3.d62.s0.i0" interaction="False" />
            <pair e1="DS3.d62.s0.e2" e2="DS3.d62.s0.e1" id="DS3.d62.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d63" origId="9932873">
        <sentence id="DS3.d63.s0" origId="9932873-3" text="Acute or chronic exposure of astrocytes to the mGluR agonist trans-1-aminocyclopentane-1,3-dicarboxylic acid (trans-ACPD) or its active isomer 1S,3R-ACPD reduced (Glu)o in a time- and dose-dependent manner (44.5 +/- 3.6% reductions of (Glu)o in astrocytes from P0-P10 rats and 65.9 +/- 4.1% from rats P20 by 100 microM 1S,3R-ACPD, EC50 approximately 5 microM).">
            <entity id="DS3.d63.s0.e0" origId="1310" charOffset="67-108" type="compound" text="1-aminocyclopentane-1,3-dicarboxylic acid"/>
            <entity id="DS3.d63.s0.e1" origId="Q42807" charOffset="116-120" type="protein" text="ACPD"/>
            <entity id="DS3.d63.s0.e2" origId="Q42807" charOffset="149-153" type="protein" text="ACPD"/>
            <entity id="DS3.d63.s0.e3" origId="Q42807" charOffset="149-153" type="protein" text="ACPD"/>
            <pair e1="DS3.d63.s0.e0" e2="DS3.d63.s0.e1" id="DS3.d63.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d63.s1" origId="9932873-6" text="ACPD effects persisted in the presence of the glutamate uptake inhibitors D,L-threo-beta-hydroxyaspartate (THA) and L-trans-pyrrolidine-2,4-dicarboxylate (PDC) but were impaired by disruption of the transmembrane Na+, K+, or H+ gradients.">
            <entity id="DS3.d63.s1.e0" origId="Q42807" charOffset="0-4" type="protein" text="ACPD"/>
            <entity id="DS3.d63.s1.e1" origId="23327,33032,57109091,611" charOffset="46-55" type="compound" text="glutamate"/>
            <entity id="DS3.d63.s1.e2" origId="443239" charOffset="76-105" type="compound" text="L-threo-beta-hydroxyaspartate"/>
            <entity id="DS3.d63.s1.e3" origId="1935" charOffset="107-110" type="compound" text="THA"/>
            <entity id="DS3.d63.s1.e4" origId="3868" charOffset="124-153" type="compound" text="pyrrolidine-2,4-dicarboxylate"/>
            <pair e1="DS3.d63.s1.e2" e2="DS3.d63.s1.e0" id="DS3.d63.s1.i0" interaction="False" />
            <pair e1="DS3.d63.s1.e4" e2="DS3.d63.s1.e0" id="DS3.d63.s1.i1" interaction="False" />
            <pair e1="DS3.d63.s1.e1" e2="DS3.d63.s1.e0" id="DS3.d63.s1.i2" interaction="False" />
            <pair e1="DS3.d63.s1.e3" e2="DS3.d63.s1.e0" id="DS3.d63.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d63.s2" origId="9932873-7" text="In addition, 1S,3R-ACPD had no effects on intracellular glutamate content and did not directly block glutamate transport.">
            <entity id="DS3.d63.s2.e0" origId="Q42807" charOffset="19-23" type="protein" text="ACPD"/>
            <entity id="DS3.d63.s2.e1" origId="23327,33032,57109091,611" charOffset="56-65" type="compound" text="glutamate"/>
            <entity id="DS3.d63.s2.e2" origId="23327,33032,57109091,611" charOffset="101-110" type="compound" text="glutamate"/>
            <pair e1="DS3.d63.s2.e1" e2="DS3.d63.s2.e0" id="DS3.d63.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d63.s3" origId="9932873-8" text="Furthermore, ACPD effects could be mimicked by glutamate per se and several other compounds presumed to be mGluR agonists, although (S)-3,5-dihydroxyphenylglycine (DHPG), (2S,2R,3R)-2-(2,3-dicarboxycyclopropyl)glycine (DCG-IV), and L-(+)-2-amino-4-phosphonobutyric acid (L-AP4) were without effect.">
            <entity id="DS3.d63.s3.e0" origId="Q42807" charOffset="13-17" type="protein" text="ACPD"/>
            <entity id="DS3.d63.s3.e1" origId="23327,33032,57109091,611" charOffset="47-56" type="compound" text="glutamate"/>
            <entity id="DS3.d63.s3.e2" origId="108001" charOffset="136-162" type="compound" text="3,5-dihydroxyphenylglycine"/>
            <entity id="DS3.d63.s3.e3" origId="3454" charOffset="164-168" type="compound" text="DHPG"/>
            <entity id="DS3.d63.s3.e4" origId="115114" charOffset="182-217" type="compound" text="2-(2,3-dicarboxycyclopropyl)glycine"/>
            <entity id="DS3.d63.s3.e5" origId="5310979" charOffset="219-225" type="compound" text="DCG-IV"/>
            <entity id="DS3.d63.s3.e6" origId="2207" charOffset="238-269" type="compound" text="2-amino-4-phosphonobutyric acid"/>
            <entity id="DS3.d63.s3.e7" origId="179394" charOffset="271-276" type="compound" text="L-AP4"/>
            <pair e1="DS3.d63.s3.e5" e2="DS3.d63.s3.e0" id="DS3.d63.s3.i0" interaction="False" />
            <pair e1="DS3.d63.s3.e4" e2="DS3.d63.s3.e0" id="DS3.d63.s3.i1" interaction="False" />
            <pair e1="DS3.d63.s3.e7" e2="DS3.d63.s3.e0" id="DS3.d63.s3.i2" interaction="False" />
            <pair e1="DS3.d63.s3.e6" e2="DS3.d63.s3.e0" id="DS3.d63.s3.i3" interaction="False" />
            <pair e1="DS3.d63.s3.e2" e2="DS3.d63.s3.e0" id="DS3.d63.s3.i4" interaction="False" />
            <pair e1="DS3.d63.s3.e3" e2="DS3.d63.s3.e0" id="DS3.d63.s3.i5" interaction="False" />
            <pair e1="DS3.d63.s3.e1" e2="DS3.d63.s3.e0" id="DS3.d63.s3.i6" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d64" origId="9932874">
        <sentence id="DS3.d64.s0" origId="9932874-0" text="Astrocytic glutamate uptake and prion protein expression.">
            <entity id="DS3.d64.s0.e0" origId="23327,33032,611,57109091" charOffset="11-20" type="compound" text="glutamate"/>
            <entity id="DS3.d64.s0.e1" origId="F7VJQ1,P04156,Q53YK7" charOffset="32-45" type="protein" text="prion protein"/>
            <pair e1="DS3.d64.s0.e0" e2="DS3.d64.s0.e1" id="DS3.d64.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d64.s1" origId="9932874-10" text="These results show that glutamate uptake from astrocytes is dependent on PrPc expression which in turn may be related to copper metabolism.">
            <entity id="DS3.d64.s1.e0" origId="23327,33032,611,57109091" charOffset="24-33" type="compound" text="glutamate"/>
            <entity id="DS3.d64.s1.e1" origId="F7VJQ1,P04156,Q53YK7" charOffset="73-77" type="protein" text="PrPc"/>
            <entity id="DS3.d64.s1.e2" origId="23978" charOffset="121-127" type="compound" text="copper"/>
            <pair e1="DS3.d64.s1.e2" e2="DS3.d64.s1.e1" id="DS3.d64.s1.i0" interaction="False" />
            <pair e1="DS3.d64.s1.e0" e2="DS3.d64.s1.e1" id="DS3.d64.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d64.s2" origId="9932874-3" text="By using a cell culture model, we have investigated the influence of astrocytic prion protein (PrPc) expression on glutamate uptake.">
            <entity id="DS3.d64.s2.e0" origId="F7VJQ1,P04156,Q53YK7" charOffset="80-93" type="protein" text="prion protein"/>
            <entity id="DS3.d64.s2.e1" origId="F7VJQ1,P04156,Q53YK7" charOffset="95-99" type="protein" text="PrPc"/>
            <entity id="DS3.d64.s2.e2" origId="23327,33032,611,57109091" charOffset="115-124" type="compound" text="glutamate"/>
            <pair e1="DS3.d64.s2.e2" e2="DS3.d64.s2.e0" id="DS3.d64.s2.i0" interaction="False" />
            <pair e1="DS3.d64.s2.e2" e2="DS3.d64.s2.e1" id="DS3.d64.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d64.s3" origId="9932874-4" text="Type 1 astrocytes expressing PrPc have a higher rate of Na+-dependent glutamate uptake than PrPc-deficient type 1 astrocytes.">
            <entity id="DS3.d64.s3.e0" origId="F7VJQ1,P04156,Q53YK7" charOffset="29-33" type="protein" text="PrPc"/>
            <entity id="DS3.d64.s3.e1" origId="23327,33032,611,57109091" charOffset="70-79" type="compound" text="glutamate"/>
            <entity id="DS3.d64.s3.e2" origId="F7VJQ1,P04156,Q53YK7" charOffset="92-96" type="protein" text="PrPc"/>
            <pair e1="DS3.d64.s3.e1" e2="DS3.d64.s3.e0" id="DS3.d64.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d64.s4" origId="9932874-7" text="PrPc has been shown to bind copper.">
            <entity id="DS3.d64.s4.e0" origId="F7VJQ1,P04156,Q53YK7" charOffset="0-4" type="protein" text="PrPc"/>
            <entity id="DS3.d64.s4.e1" origId="23978" charOffset="28-34" type="compound" text="copper"/>
            <pair e1="DS3.d64.s4.e1" e2="DS3.d64.s4.e0" id="DS3.d64.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d64.s5" origId="9932874-9" text="PrPc-deficient cerebellar cells are more sensitive to glutamate toxicity in the presence of copper.">
            <entity id="DS3.d64.s5.e0" origId="F7VJQ1,P04156,Q53YK7" charOffset="0-4" type="protein" text="PrPc"/>
            <entity id="DS3.d64.s5.e1" origId="23327,33032,611,57109091" charOffset="54-63" type="compound" text="glutamate"/>
            <entity id="DS3.d64.s5.e2" origId="23978" charOffset="92-98" type="compound" text="copper"/>
            <pair e1="DS3.d64.s5.e2" e2="DS3.d64.s5.e0" id="DS3.d64.s5.i0" interaction="False" />
            <pair e1="DS3.d64.s5.e1" e2="DS3.d64.s5.e0" id="DS3.d64.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d65" origId="9932891">
        <sentence id="DS3.d65.s0" origId="9932891-10" text="CONCLUSION: Ebselen suppressed ET-1-induced contraction and synergetic interaction between oxyhemoglobin and ET-1, where free radical formation was involved.">
            <entity id="DS3.d65.s0.e0" origId="3194" charOffset="12-19" type="compound" text="Ebselen"/>
            <entity id="DS3.d65.s0.e1" origId="P29560" charOffset="31-35" type="protein" text="ET-1"/>
            <entity id="DS3.d65.s0.e2" origId="P29560" charOffset="109-113" type="protein" text="ET-1"/>
            <pair e1="DS3.d65.s0.e0" e2="DS3.d65.s0.e1" id="DS3.d65.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d65.s1" origId="9932891-4" text="RESULTS: Ebselen, in a certain concentration range (3 x 10(-6) and 10(-5) mol/L), significantly reduced the contractile response to ET-1 (10(-10) to 10(-8) mol/L) but not the contraction induced by 40 mmol/L potassium.">
            <entity id="DS3.d65.s1.e0" origId="3194" charOffset="9-16" type="compound" text="Ebselen"/>
            <entity id="DS3.d65.s1.e1" origId="P29560" charOffset="132-136" type="protein" text="ET-1"/>
            <entity id="DS3.d65.s1.e2" origId="5462222" charOffset="208-217" type="compound" text="potassium"/>
            <pair e1="DS3.d65.s1.e0" e2="DS3.d65.s1.e1" id="DS3.d65.s1.i0" interaction="False" />
            <pair e1="DS3.d65.s1.e2" e2="DS3.d65.s1.e1" id="DS3.d65.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d65.s2" origId="9932891-6" text="Addition of 10(-5) mol/L dithiothreitol, a sulfhydryl-reducing agent, partially reversed the inhibitory effects of ebselen on ET-1- and 1,2-dioctanoyl-sn-glycerol-induced contractions.">
            <entity id="DS3.d65.s2.e0" origId="22799231" charOffset="23-39" type="compound" text="L dithiothreitol"/>
            <entity id="DS3.d65.s2.e1" origId="5460613" charOffset="43-53" type="compound" text="sulfhydryl"/>
            <entity id="DS3.d65.s2.e2" origId="3194" charOffset="115-122" type="compound" text="ebselen"/>
            <entity id="DS3.d65.s2.e3" origId="P29560" charOffset="126-130" type="protein" text="ET-1"/>
            <entity id="DS3.d65.s2.e4" origId="148879" charOffset="136-162" type="compound" text="1,2-dioctanoyl-sn-glycerol"/>
            <pair e1="DS3.d65.s2.e1" e2="DS3.d65.s2.e3" id="DS3.d65.s2.i0" interaction="False" />
            <pair e1="DS3.d65.s2.e2" e2="DS3.d65.s2.e3" id="DS3.d65.s2.i1" interaction="False" />
            <pair e1="DS3.d65.s2.e0" e2="DS3.d65.s2.e3" id="DS3.d65.s2.i2" interaction="False" />
            <pair e1="DS3.d65.s2.e4" e2="DS3.d65.s2.e3" id="DS3.d65.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d65.s3" origId="9932891-7" text="Ebselen (10(-5) mol/L) as well as a combination of catalase (1000 units/mL) and superoxide dismutase (150 units/mL) inhibited the potentiating effects of oxyhemoglobin (10(-5) mol/L) on ET-1-induced contraction.">
            <entity id="DS3.d65.s3.e0" origId="3194" charOffset="0-7" type="compound" text="Ebselen"/>
            <entity id="DS3.d65.s3.e1" origId="G1T6W7" charOffset="51-59" type="protein" text="catalase"/>
            <entity id="DS3.d65.s3.e2" origId="5359597" charOffset="80-90" type="compound" text="superoxide"/>
            <entity id="DS3.d65.s3.e3" origId="P29560" charOffset="186-190" type="protein" text="ET-1"/>
            <pair e1="DS3.d65.s3.e0" e2="DS3.d65.s3.e3" id="DS3.d65.s3.i0" interaction="False" />
            <pair e1="DS3.d65.s3.e0" e2="DS3.d65.s3.e1" id="DS3.d65.s3.i1" interaction="False" />
            <pair e1="DS3.d65.s3.e2" e2="DS3.d65.s3.e3" id="DS3.d65.s3.i2" interaction="False" />
            <pair e1="DS3.d65.s3.e2" e2="DS3.d65.s3.e1" id="DS3.d65.s3.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d65.s4" origId="9932891-8" text="Both ebselen and catalase inhibited the contractile response to hydroxyl radical generated by ferrous ion (10(-3) mol/L) plus hydrogen peroxide (10(-2) mol/L).">
            <entity id="DS3.d65.s4.e0" origId="3194" charOffset="5-12" type="compound" text="ebselen"/>
            <entity id="DS3.d65.s4.e1" origId="G1T6W7" charOffset="17-25" type="protein" text="catalase"/>
            <entity id="DS3.d65.s4.e2" origId="27284" charOffset="94-105" type="compound" text="ferrous ion"/>
            <entity id="DS3.d65.s4.e3" origId="784" charOffset="126-143" type="compound" text="hydrogen peroxide"/>
            <pair e1="DS3.d65.s4.e0" e2="DS3.d65.s4.e1" id="DS3.d65.s4.i0" interaction="False" />
            <pair e1="DS3.d65.s4.e3" e2="DS3.d65.s4.e1" id="DS3.d65.s4.i1" interaction="False" />
            <pair e1="DS3.d65.s4.e2" e2="DS3.d65.s4.e1" id="DS3.d65.s4.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d66" origId="9932937">
        <sentence id="DS3.d66.s0" origId="9932937-0" text="Tacrine use in nursing homes: implications for prescribing new cholinesterase inhibitors. SAGE Study Group. Systematic Assessment of Geriatric Drug Use via Epidemiology.">
            <entity id="DS3.d66.s0.e0" origId="1935" charOffset="0-7" type="compound" text="Tacrine"/>
            <entity id="DS3.d66.s0.e1" origId="Q9NXZ1" charOffset="90-94" type="protein" text="SAGE"/>
            <pair e1="DS3.d66.s0.e0" e2="DS3.d66.s0.e1" id="DS3.d66.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d67" origId="9932955">
        <sentence id="DS3.d67.s0" origId="9932955-6" text="Under both culture conditions, addition of 10(-6) M eliprodil did not modify significantly the total number of either microtubule associated protein-2-positive neurons or MBP-positive oligodendrocytes.">
            <entity id="DS3.d67.s0.e0" origId="60703" charOffset="52-61" type="compound" text="eliprodil"/>
            <entity id="DS3.d67.s0.e1" origId="P11137,A0A024R3Y8,A0A024R407,A0A024R409,Q6NYC5" charOffset="118-150" type="protein" text="microtubule associated protein-2"/>
            <entity id="DS3.d67.s0.e2" origId="P02686,A0A024R384" charOffset="171-174" type="protein" text="MBP"/>
            <pair e1="DS3.d67.s0.e0" e2="DS3.d67.s0.e1" id="DS3.d67.s0.i0" interaction="False" />
            <pair e1="DS3.d67.s0.e0" e2="DS3.d67.s0.e2" id="DS3.d67.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d67.s1" origId="9932955-7" text="However, eliprodil induced a twofold (p &amp;lt; 0.01) increase in myelination when added to B-S medium, and a 4.7-fold (p &amp;lt; 0.0001) increase when added to D medium.">
            <entity id="DS3.d67.s1.e0" origId="60703" charOffset="9-18" type="compound" text="eliprodil"/>
            <entity id="DS3.d67.s1.e1" origId="P50616" charOffset="86-90" type="protein" text="to B"/>
            <pair e1="DS3.d67.s1.e0" e2="DS3.d67.s1.e1" id="DS3.d67.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d68" origId="9932956">
        <sentence id="DS3.d68.s0" origId="9932956-6" text="METHODS: The authors studied the effect of alternate-day therapy with 8.0 mIU (high dose (HD)) or 1.6 mIU (low dose (LD)) IFN-beta on NK cell FA, assessed by an in vitro 51Cr release K-562 target cell assay, and phenotype determination in RRMS patients.">
            <entity id="DS3.d68.s0.e0" origId="P01574" charOffset="122-130" type="protein" text="IFN-beta"/>
            <entity id="DS3.d68.s0.e1" origId="104786" charOffset="170-174" type="compound" text="51Cr"/>
            <pair e1="DS3.d68.s0.e1" e2="DS3.d68.s0.e0" id="DS3.d68.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d69" origId="9932958">
        <sentence id="DS3.d69.s0" origId="9932958-7" text="Electron-transferring flavoprotein-linked reduction enzymatic assay of fibroblasts with butyryl-coenzyme A (CoA) as substrate, after immunoinactivation of medium-chain acyl-CoA dehydrogenase activity, revealed a complete absence of Short-chain acyl-CoA dehydrogenase (SCAD) activity.">
            <entity id="DS3.d69.s0.e0" origId="317,44216777,44246472,6816,6914636,87642" charOffset="96-106" type="compound" text="coenzyme A"/>
            <entity id="DS3.d69.s0.e1" origId="444624,445126,447444,448506,46936280,5326877" charOffset="108-111" type="compound" text="CoA"/>
            <entity id="DS3.d69.s0.e2" origId="P11310,Q5T4U5,B7Z9I1,B4DJE7,Q5HYG7" charOffset="155-190" type="protein" text="medium-chain acyl-CoA dehydrogenase"/>
            <entity id="DS3.d69.s0.e3" origId="P16219,E5KSD5,E9PE82,B4DUH1" charOffset="232-266" type="protein" text="Short-chain acyl-CoA dehydrogenase"/>
            <pair e1="DS3.d69.s0.e1" e2="DS3.d69.s0.e2" id="DS3.d69.s0.i0" interaction="False" />
            <pair e1="DS3.d69.s0.e1" e2="DS3.d69.s0.e3" id="DS3.d69.s0.i1" interaction="False" />
            <pair e1="DS3.d69.s0.e0" e2="DS3.d69.s0.e2" id="DS3.d69.s0.i2" interaction="False" />
            <pair e1="DS3.d69.s0.e0" e2="DS3.d69.s0.e3" id="DS3.d69.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d70" origId="9933021">
        <sentence id="DS3.d70.s0" origId="9933021-2" text="Molecular O2 is an obligatory substrate for the successive syntheses of 17alpha-OH pregnenolone and dehydroepiandrosterone (DHEA) by cytochrome P450c17 in the zona reticularis of the adrenal cortex, in which it is suggested that arteriosclerosis --&amp;gt; decreased blood flow --&amp;gt; O2 and glucose deficit --&amp;gt; decreased O2-requiring synthesis of DHEA --&amp;gt; eventual decrease in number of DHEA-synthesizing cells.">
            <entity id="DS3.d70.s0.e0" origId="8955" charOffset="83-95" type="compound" text="pregnenolone"/>
            <entity id="DS3.d70.s0.e1" origId="5881" charOffset="100-122" type="compound" text="dehydroepiandrosterone"/>
            <entity id="DS3.d70.s0.e2" origId="P05093,Q1HB44" charOffset="144-151" type="protein" text="P450c17"/>
            <entity id="DS3.d70.s0.e3" origId="206,5793,64689,79025" charOffset="288-295" type="compound" text="glucose"/>
            <pair e1="DS3.d70.s0.e1" e2="DS3.d70.s0.e2" id="DS3.d70.s0.i0" interaction="False" />
            <pair e1="DS3.d70.s0.e0" e2="DS3.d70.s0.e2" id="DS3.d70.s0.i1" interaction="False" />
            <pair e1="DS3.d70.s0.e3" e2="DS3.d70.s0.e2" id="DS3.d70.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d70.s1" origId="9933021-3" text="Aging changes in the zona reticularis synergize with those in the hypothalamo-hypophyseal machinery that controls it neurally and hormonally, with ACTH-evoked pulsatile floods of cortisol coming from the adrenal zona fasciculata, with the onslaught of free radicals generated by the metabolism of catecholamines released from interdigitating cells of the adrenal medulla, and with age-correlated disabilities of erythrocytes to bind and release O2 to decrease the viability of the DHEA and dehydroepiandrosterone sulfate (DHEAS)-forming cells.">
            <entity id="DS3.d70.s1.e0" origId="P01189,Q6FHC8" charOffset="147-151" type="protein" text="ACTH"/>
            <entity id="DS3.d70.s1.e1" origId="5754" charOffset="179-187" type="compound" text="cortisol"/>
            <entity id="DS3.d70.s1.e2" origId="Q06520,A8K015" charOffset="490-520" type="protein" text="dehydroepiandrosterone sulfate"/>
            <entity id="DS3.d70.s1.e3" origId="Q06520,A8K015" charOffset="522-527" type="protein" text="DHEAS"/>
            <pair e1="DS3.d70.s1.e1" e2="DS3.d70.s1.e0" id="DS3.d70.s1.i0" interaction="False" />
            <pair e1="DS3.d70.s1.e1" e2="DS3.d70.s1.e2" id="DS3.d70.s1.i1" interaction="False" />
            <pair e1="DS3.d70.s1.e1" e2="DS3.d70.s1.e3" id="DS3.d70.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d70.s2" origId="9933021-4" text="One of the chief functions of serum DHEAS in the male may be to act as an allosteric facilitator of the binding of testosterone (T) to serum albumin, thereby helping target T to specific receptors and to allosteric sites for rapid and efficient action at the cellular level.">
            <entity id="DS3.d70.s2.e0" origId="Q06520,A8K015" charOffset="36-41" type="protein" text="DHEAS"/>
            <entity id="DS3.d70.s2.e1" origId="6013" charOffset="115-127" type="compound" text="testosterone"/>
            <entity id="DS3.d70.s2.e2" origId="P02768" charOffset="141-148" type="protein" text="albumin"/>
            <pair e1="DS3.d70.s2.e1" e2="DS3.d70.s2.e0" id="DS3.d70.s2.i0" interaction="False" />
            <pair e1="DS3.d70.s2.e1" e2="DS3.d70.s2.e2" id="DS3.d70.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d71" origId="9933022">
        <sentence id="DS3.d71.s0" origId="9933022-6" text="Cyclosporin A and herbimycin A, which suppress c-fos and c-jun gene expressions, respectively, blocked the cisplatin-induced increase in ERCC-1 mRNA.">
            <entity id="DS3.d71.s0.e0" origId="16760502,3591,5311102" charOffset="18-30" type="compound" text="herbimycin A"/>
            <entity id="DS3.d71.s0.e1" origId="P01100,Q6FG41" charOffset="47-52" type="protein" text="c-fos"/>
            <entity id="DS3.d71.s0.e2" origId="P07992,A0A024R0Q6" charOffset="137-143" type="protein" text="ERCC-1"/>
            <pair e1="DS3.d71.s0.e0" e2="DS3.d71.s0.e1" id="DS3.d71.s0.i0" interaction="False" />
            <pair e1="DS3.d71.s0.e0" e2="DS3.d71.s0.e2" id="DS3.d71.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d71.s1" origId="9933022-7" text="This effect of cyclosporin A or herbimycin A on the down-regulation of ERCC-1 correlates with enhanced cytotoxicity of cisplatin in this system.">
            <entity id="DS3.d71.s1.e0" origId="16760502,3591,5311102" charOffset="32-44" type="compound" text="herbimycin A"/>
            <entity id="DS3.d71.s1.e1" origId="P07992,A0A024R0Q6" charOffset="71-77" type="protein" text="ERCC-1"/>
            <pair e1="DS3.d71.s1.e0" e2="DS3.d71.s1.e1" id="DS3.d71.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d71.s2" origId="9933022-9" text="12-O-Tetradecanoylphorbol 13-acetate (TPA), a known AP-1 agonist, induced ERCC-1 mRNA to the same extent as cisplatin, but did not synergize with cisplatin in this regard.">
            <entity id="DS3.d71.s2.e0" origId="18633279" charOffset="3-25" type="compound" text="O-Tetradecanoylphorbol"/>
            <entity id="DS3.d71.s2.e1" origId="176" charOffset="29-36" type="compound" text="acetate"/>
            <entity id="DS3.d71.s2.e2" origId="122634" charOffset="38-41" type="compound" text="TPA"/>
            <entity id="DS3.d71.s2.e3" origId="P07992,A0A024R0Q6" charOffset="74-80" type="protein" text="ERCC-1"/>
            <pair e1="DS3.d71.s2.e0" e2="DS3.d71.s2.e3" id="DS3.d71.s2.i0" interaction="False" />
            <pair e1="DS3.d71.s2.e2" e2="DS3.d71.s2.e3" id="DS3.d71.s2.i1" interaction="False" />
            <pair e1="DS3.d71.s2.e1" e2="DS3.d71.s2.e3" id="DS3.d71.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d72" origId="9933023">
        <sentence id="DS3.d72.s0" origId="9933023-8" text="Adenosine deaminase (ADA, EC 3.5.44, 1 U/mL) reduced the intracellular cyclic AMP response to forskolin by 68%, whereas the adenosine transport inhibitor, dipyridamole (10 microM), significantly increased 1 and 10 microM forskolin-dependent cyclic AMP accumulation.">
            <entity id="DS3.d72.s0.e0" origId="Q920P6" charOffset="0-19" type="protein" text="Adenosine deaminase"/>
            <entity id="DS3.d72.s0.e1" origId="Q920P6" charOffset="21-24" type="protein" text="ADA"/>
            <entity id="DS3.d72.s0.e2" origId="57476835,60961" charOffset="124-133" type="compound" text="adenosine"/>
            <entity id="DS3.d72.s0.e3" origId="3108" charOffset="155-167" type="compound" text="dipyridamole"/>
            <pair e1="DS3.d72.s0.e3" e2="DS3.d72.s0.e0" id="DS3.d72.s0.i0" interaction="False" />
            <pair e1="DS3.d72.s0.e3" e2="DS3.d72.s0.e1" id="DS3.d72.s0.i1" interaction="False" />
            <pair e1="DS3.d72.s0.e2" e2="DS3.d72.s0.e0" id="DS3.d72.s0.i2" interaction="False" />
            <pair e1="DS3.d72.s0.e2" e2="DS3.d72.s0.e1" id="DS3.d72.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d72.s1" origId="9933023-9" text="Erythro-9-(2-hydroxy-3-nonyl)adenine (10 microM), an inhibitor of ADA, and alpha,beta-methyleneadenosine 5'-diphosphate (100 microM), an inhibitor of ecto-5'-nucleotidase, did not alter forskolin activity.">
            <entity id="DS3.d72.s1.e0" origId="3206" charOffset="0-36" type="compound" text="Erythro-9-(2-hydroxy-3-nonyl)adenine"/>
            <entity id="DS3.d72.s1.e1" origId="Q920P6" charOffset="66-69" type="protein" text="ADA"/>
            <entity id="DS3.d72.s1.e2" origId="92199" charOffset="75-119" type="compound" text="alpha,beta-methyleneadenosine 5'-diphosphate"/>
            <pair e1="DS3.d72.s1.e2" e2="DS3.d72.s1.e1" id="DS3.d72.s1.i0" interaction="False" />
            <pair e1="DS3.d72.s1.e0" e2="DS3.d72.s1.e1" id="DS3.d72.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d73" origId="9933024">
        <sentence id="DS3.d73.s0" origId="9933024-2" text="Several farnesyl pyrophosphate (FPP) analogues were synthesized and tested in vitro for their specificity in inhibiting squalene synthase (SS), PFT, or protein:geranylgeranyl transferase-1 (PGGT-1) activities (the latter was determined using a newly designed assay).">
            <entity id="DS3.d73.s0.e0" origId="445713" charOffset="32-35" type="compound" text="FPP"/>
            <entity id="DS3.d73.s0.e1" origId="P37268,B4DND3,Q6IAX1,B4DWP0,B7Z9R8" charOffset="120-137" type="protein" text="squalene synthase"/>
            <pair e1="DS3.d73.s0.e0" e2="DS3.d73.s0.e1" id="DS3.d73.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d74" origId="9933026">
        <sentence id="DS3.d74.s0" origId="9933026-0" text="The expression of the lectin-like oxidized low-density lipoprotein receptor (LOX-1) on human vascular smooth muscle cells and monocytes and its down-regulation by lovastatin.">
            <entity id="DS3.d74.s0.e0" origId="P01130,A0A024R7D5" charOffset="43-75" type="protein" text="low-density lipoprotein receptor"/>
            <entity id="DS3.d74.s0.e1" origId="P79391,A1L4Z7" charOffset="77-82" type="protein" text="LOX-1"/>
            <entity id="DS3.d74.s0.e2" origId="53232" charOffset="163-173" type="compound" text="lovastatin"/>
            <pair e1="DS3.d74.s0.e2" e2="DS3.d74.s0.e0" id="DS3.d74.s0.i0" interaction="False" />
            <pair e1="DS3.d74.s0.e2" e2="DS3.d74.s0.e1" id="DS3.d74.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d74.s1" origId="9933026-6" text="LOX-1 mRNA expression in monocytes could be significantly suppressed by lovastatin.">
            <entity id="DS3.d74.s1.e0" origId="P79391,A1L4Z7" charOffset="0-5" type="protein" text="LOX-1"/>
            <entity id="DS3.d74.s1.e1" origId="53232" charOffset="72-82" type="compound" text="lovastatin"/>
            <pair e1="DS3.d74.s1.e1" e2="DS3.d74.s1.e0" id="DS3.d74.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d74.s2" origId="9933026-7" text="Thus, LOX-1 expression is not restricted to endothelial cells and its down-regulation by HMG-CoA reductase inhibitors could contribute to the clinical benefits of these drugs.">
            <entity id="DS3.d74.s2.e0" origId="P79391,A1L4Z7" charOffset="6-11" type="protein" text="LOX-1"/>
            <entity id="DS3.d74.s2.e1" origId="439218,52922021" charOffset="89-96" type="compound" text="HMG-CoA"/>
            <pair e1="DS3.d74.s2.e1" e2="DS3.d74.s2.e0" id="DS3.d74.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d75" origId="9933027">
        <sentence id="DS3.d75.s0" origId="9933027-0" text="Distinct regulation of glucose transport by interleukin-3 and oncogenes in a murine bone marrow-derived cell line.">
            <entity id="DS3.d75.s0.e0" origId="206,5793,64689,79025" charOffset="23-30" type="compound" text="glucose"/>
            <entity id="DS3.d75.s0.e1" origId="P01586,Q5SX77" charOffset="44-57" type="protein" text="interleukin-3"/>
            <pair e1="DS3.d75.s0.e0" e2="DS3.d75.s0.e1" id="DS3.d75.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d75.s1" origId="9933027-11" text="Thus, IL-3 responses are dependent upon tyrosine, serine/threonine, and PI-3 kinases, whereas ras and abl effects on glucose transport depend upon tyrosine phosphorylation but are compromised in their dependence upon serine/threonine and PI-3 kinases.">
            <entity id="DS3.d75.s1.e0" origId="Q9BDX4" charOffset="6-10" type="protein" text="IL-3"/>
            <entity id="DS3.d75.s1.e1" origId="6057,90983769" charOffset="40-48" type="compound" text="tyrosine"/>
            <entity id="DS3.d75.s1.e2" origId="194239,6288" charOffset="57-66" type="compound" text="threonine"/>
            <entity id="DS3.d75.s1.e3" origId="206,5793,64689,79025" charOffset="117-124" type="compound" text="glucose"/>
            <entity id="DS3.d75.s1.e4" origId="6057,90983769" charOffset="147-155" type="compound" text="tyrosine"/>
            <entity id="DS3.d75.s1.e5" origId="194239,6288" charOffset="224-233" type="compound" text="threonine"/>
            <pair e1="DS3.d75.s1.e3" e2="DS3.d75.s1.e0" id="DS3.d75.s1.i0" interaction="False" />
            <pair e1="DS3.d75.s1.e2" e2="DS3.d75.s1.e0" id="DS3.d75.s1.i1" interaction="False" />
            <pair e1="DS3.d75.s1.e1" e2="DS3.d75.s1.e0" id="DS3.d75.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d75.s2" origId="9933027-2" text="In this paper, we show that interleukin-3 (IL-3), a cytokine growth factor, and the transforming oncogenes ras and abl alter the activation state of glucose transporters by distinct mechanisms.">
            <entity id="DS3.d75.s2.e0" origId="P01586,Q5SX77" charOffset="28-41" type="protein" text="interleukin-3"/>
            <entity id="DS3.d75.s2.e1" origId="Q9BDX4" charOffset="43-47" type="protein" text="IL-3"/>
            <entity id="DS3.d75.s2.e2" origId="206,5793,64689,79025" charOffset="149-156" type="compound" text="glucose"/>
            <pair e1="DS3.d75.s2.e2" e2="DS3.d75.s2.e0" id="DS3.d75.s2.i0" interaction="False" />
            <pair e1="DS3.d75.s2.e2" e2="DS3.d75.s2.e1" id="DS3.d75.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d75.s3" origId="9933027-3" text="Using bone marrow-derived IL-3-dependent 32Dc13 (32D clone 3) cells and 32D cells transformed with ras and abl oncogenes, we demonstrated that IL-3 enhanced (3H)-2-deoxyglucose (2-DOG) uptake in parental 32Dc13 cells by 40-50% at 0.2 mM 2-DOG, and this was associated with a 2.5-fold increase in transporter affinity for glucose (reduced Km).">
            <entity id="DS3.d75.s3.e0" origId="Q9BDX4" charOffset="26-30" type="protein" text="IL-3"/>
            <entity id="DS3.d75.s3.e1" origId="60210951" charOffset="41-44" type="compound" text="32D"/>
            <entity id="DS3.d75.s3.e2" origId="60210951" charOffset="49-52" type="compound" text="32D"/>
            <entity id="DS3.d75.s3.e3" origId="Q9BDX4" charOffset="143-147" type="protein" text="IL-3"/>
            <entity id="DS3.d75.s3.e4" origId="108223" charOffset="162-176" type="compound" text="2-deoxyglucose"/>
            <entity id="DS3.d75.s3.e5" origId="206,5793,64689,79025" charOffset="169-176" type="compound" text="glucose"/>
            <pair e1="DS3.d75.s3.e4" e2="DS3.d75.s3.e0" id="DS3.d75.s3.i0" interaction="False" />
            <pair e1="DS3.d75.s3.e1" e2="DS3.d75.s3.e0" id="DS3.d75.s3.i1" interaction="False" />
            <pair e1="DS3.d75.s3.e5" e2="DS3.d75.s3.e0" id="DS3.d75.s3.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d75.s4" origId="9933027-5" text="The tyrosine kinase inhibitor genistein reversed the effects of both IL-3 and oncogenes on glucose uptake and reduced transporter affinity for glucose.">
            <entity id="DS3.d75.s4.e0" origId="6057,90983769" charOffset="4-12" type="compound" text="tyrosine"/>
            <entity id="DS3.d75.s4.e1" origId="53378893" charOffset="13-29" type="compound" text="kinase inhibitor"/>
            <entity id="DS3.d75.s4.e2" origId="5280961" charOffset="30-39" type="compound" text="genistein"/>
            <entity id="DS3.d75.s4.e3" origId="Q9BDX4" charOffset="69-73" type="protein" text="IL-3"/>
            <entity id="DS3.d75.s4.e4" origId="206,5793,64689,79025" charOffset="91-98" type="compound" text="glucose"/>
            <entity id="DS3.d75.s4.e5" origId="206,5793,64689,79025" charOffset="143-150" type="compound" text="glucose"/>
            <pair e1="DS3.d75.s4.e1" e2="DS3.d75.s4.e3" id="DS3.d75.s4.i0" interaction="False" />
            <pair e1="DS3.d75.s4.e2" e2="DS3.d75.s4.e3" id="DS3.d75.s4.i1" interaction="False" />
            <pair e1="DS3.d75.s4.e4" e2="DS3.d75.s4.e3" id="DS3.d75.s4.i2" interaction="False" />
            <pair e1="DS3.d75.s4.e0" e2="DS3.d75.s4.e3" id="DS3.d75.s4.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d75.s5" origId="9933027-6" text="Likewise, with exponentially growing 32D cells in the presence of IL-3, a protein kinase C inhibitor, staurosporine, and a phosphatidylinositol 3-kinase (PI-3) kinase inhibitor, wortmannin, inhibited 2-DOG uptake and decreased transporter affinity for glucose.">
            <entity id="DS3.d75.s5.e0" origId="60210951" charOffset="37-40" type="compound" text="32D"/>
            <entity id="DS3.d75.s5.e1" origId="Q9BDX4" charOffset="66-70" type="protein" text="IL-3"/>
            <entity id="DS3.d75.s5.e2" origId="44120114,44259,451705,44299148,5279,5311103,5459111,6419748,6711321,9937179,9956178" charOffset="102-115" type="compound" text="staurosporine"/>
            <entity id="DS3.d75.s5.e3" origId="16738692,53477912" charOffset="123-143" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d75.s5.e4" origId="53378893" charOffset="160-176" type="compound" text="kinase inhibitor"/>
            <entity id="DS3.d75.s5.e5" origId="312145" charOffset="178-188" type="compound" text="wortmannin"/>
            <entity id="DS3.d75.s5.e6" origId="206,5793,64689,79025" charOffset="252-259" type="compound" text="glucose"/>
            <pair e1="DS3.d75.s5.e5" e2="DS3.d75.s5.e1" id="DS3.d75.s5.i0" interaction="False" />
            <pair e1="DS3.d75.s5.e2" e2="DS3.d75.s5.e1" id="DS3.d75.s5.i1" interaction="False" />
            <pair e1="DS3.d75.s5.e0" e2="DS3.d75.s5.e1" id="DS3.d75.s5.i2" interaction="False" />
            <pair e1="DS3.d75.s5.e4" e2="DS3.d75.s5.e1" id="DS3.d75.s5.i3" interaction="False" />
            <pair e1="DS3.d75.s5.e3" e2="DS3.d75.s5.e1" id="DS3.d75.s5.i4" interaction="False" />
            <pair e1="DS3.d75.s5.e6" e2="DS3.d75.s5.e1" id="DS3.d75.s5.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d76" origId="9933028">
        <sentence id="DS3.d76.s0" origId="9933028-0" text="Decreased resistance to gemcitabine (2',2'-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinase.">
            <entity id="DS3.d76.s0.e0" origId="6253" charOffset="69-89" type="compound" text="cytosine arabinoside"/>
            <entity id="DS3.d76.s0.e1" origId="P48769" charOffset="203-223" type="protein" text="deoxycytidine kinase"/>
            <pair e1="DS3.d76.s0.e0" e2="DS3.d76.s0.e1" id="DS3.d76.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d76.s1" origId="9933028-12" text="The sensitivity of the wild-type cell lines correlates with the accumulation of dFdCTP and ara-CTP, but is independent of dCK.">
            <entity id="DS3.d76.s1.e0" origId="130659" charOffset="80-86" type="compound" text="dFdCTP"/>
            <entity id="DS3.d76.s1.e1" origId="25774" charOffset="91-98" type="compound" text="ara-CTP"/>
            <entity id="DS3.d76.s1.e2" origId="Q9VPU1,Q8IPW2" charOffset="122-125" type="protein" text="dCK"/>
            <pair e1="DS3.d76.s1.e1" e2="DS3.d76.s1.e2" id="DS3.d76.s1.i0" interaction="False" />
            <pair e1="DS3.d76.s1.e0" e2="DS3.d76.s1.e2" id="DS3.d76.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d76.s2" origId="9933028-13" text="However, both resistant variants had decreased dCK activities, but were relatively more sensitive to dFdC than to ara-C.">
            <entity id="DS3.d76.s2.e0" origId="Q9VPU1,Q8IPW2" charOffset="47-50" type="protein" text="dCK"/>
            <entity id="DS3.d76.s2.e1" origId="60750" charOffset="101-105" type="compound" text="dFdC"/>
            <pair e1="DS3.d76.s2.e1" e2="DS3.d76.s2.e0" id="DS3.d76.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d76.s3" origId="9933028-2" text="Both drugs are phosphorylated by deoxycytidine kinase (dCK); the triphosphates, dFdCTP and ara-CTP, respectively, are incorporated into DNA.">
            <entity id="DS3.d76.s3.e0" origId="P48769" charOffset="33-53" type="protein" text="deoxycytidine kinase"/>
            <entity id="DS3.d76.s3.e1" origId="Q9VPU1,Q8IPW2" charOffset="55-58" type="protein" text="dCK"/>
            <entity id="DS3.d76.s3.e2" origId="130659" charOffset="80-86" type="compound" text="dFdCTP"/>
            <entity id="DS3.d76.s3.e3" origId="25774" charOffset="91-98" type="compound" text="ara-CTP"/>
            <pair e1="DS3.d76.s3.e3" e2="DS3.d76.s3.e0" id="DS3.d76.s3.i0" interaction="False" />
            <pair e1="DS3.d76.s3.e3" e2="DS3.d76.s3.e1" id="DS3.d76.s3.i1" interaction="False" />
            <pair e1="DS3.d76.s3.e2" e2="DS3.d76.s3.e0" id="DS3.d76.s3.i2" interaction="False" />
            <pair e1="DS3.d76.s3.e2" e2="DS3.d76.s3.e1" id="DS3.d76.s3.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d77" origId="9933029">
        <sentence id="DS3.d77.s0" origId="9933029-10" text="dCTP levels were decreased by VP-16 alone as well as by the combination of both compounds, which may favor phosphorylation of dFdC, thereby increasing dFdCTP accumulation.">
            <entity id="DS3.d77.s0.e0" origId="65091" charOffset="0-4" type="compound" text="dCTP"/>
            <entity id="DS3.d77.s0.e1" origId="P51610,A6NEM2" charOffset="30-35" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s0.e2" origId="60750" charOffset="126-130" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s0.e3" origId="130659" charOffset="151-157" type="compound" text="dFdCTP"/>
            <pair e1="DS3.d77.s0.e2" e2="DS3.d77.s0.e1" id="DS3.d77.s0.i0" interaction="False" />
            <pair e1="DS3.d77.s0.e3" e2="DS3.d77.s0.e1" id="DS3.d77.s0.i1" interaction="False" />
            <pair e1="DS3.d77.s0.e0" e2="DS3.d77.s0.e1" id="DS3.d77.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d77.s1" origId="9933029-11" text="DNA strand break (DSB) formation was increased for exposure to both compounds together compared to exposure to each compound separately, this effect being most pronounced when cells were exposed to VP-16 prior to dFdC (38% and 0% DSB for dFdC and VP-16 alone, respectively and 97% DSB for the combination).">
            <entity id="DS3.d77.s1.e0" origId="P51610,A6NEM2" charOffset="198-203" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s1.e1" origId="60750" charOffset="213-217" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s1.e2" origId="60750" charOffset="238-242" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s1.e3" origId="P51610,A6NEM2" charOffset="247-252" type="protein" text="VP-16"/>
            <pair e1="DS3.d77.s1.e1" e2="DS3.d77.s1.e0" id="DS3.d77.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d77.s2" origId="9933029-13" text="Provided the right schedule is used, VP-16 is certainly a compound eligible for combination with dFdC.">
            <entity id="DS3.d77.s2.e0" origId="P51610,A6NEM2" charOffset="37-42" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s2.e1" origId="60750" charOffset="97-101" type="compound" text="dFdC"/>
            <pair e1="DS3.d77.s2.e1" e2="DS3.d77.s2.e0" id="DS3.d77.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d77.s3" origId="9933029-1" text="Gemcitabine (2',2'-difluorodeoxycytidine, dFdC) and etoposide (4'-demethylepipodo-phyllo-toxin-9-4,6-O-ethylidene-beta-D-g lucopyranoside, VP-16) are antineoplastic agents with clinical activity against various types of solid tumors.">
            <entity id="DS3.d77.s3.e0" origId="53898275" charOffset="19-40" type="compound" text="difluorodeoxycytidine"/>
            <entity id="DS3.d77.s3.e1" origId="60750" charOffset="42-46" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s3.e2" origId="11758093,17571827,3310,439525,45356822,50989217,5284558,59360017,6419930,6610299,6708815,90657341,9916469" charOffset="52-61" type="compound" text="etoposide"/>
            <entity id="DS3.d77.s3.e3" origId="59061983" charOffset="103-113" type="compound" text="ethylidene"/>
            <entity id="DS3.d77.s3.e4" origId="P51610,A6NEM2" charOffset="139-144" type="protein" text="VP-16"/>
            <pair e1="DS3.d77.s3.e1" e2="DS3.d77.s3.e4" id="DS3.d77.s3.i0" interaction="False" />
            <pair e1="DS3.d77.s3.e3" e2="DS3.d77.s3.e4" id="DS3.d77.s3.i1" interaction="False" />
            <pair e1="DS3.d77.s3.e0" e2="DS3.d77.s3.e4" id="DS3.d77.s3.i2" interaction="False" />
            <pair e1="DS3.d77.s3.e2" e2="DS3.d77.s3.e4" id="DS3.d77.s3.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d77.s4" origId="9933029-3" text="For this purpose, we used the human ovarian cancer cell line A2780, its cis-diammine-dichloroplatinum-resistant and VP-16 cross-resistant variant ADDP, and two non-small cell lung cancer cell lines, Lewis Lung (LL, murine) and H322 (human).">
            <entity id="DS3.d77.s4.e0" origId="2770" charOffset="85-101" type="compound" text="dichloroplatinum"/>
            <entity id="DS3.d77.s4.e1" origId="P51610,A6NEM2" charOffset="116-121" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s4.e2" origId="5702657" charOffset="146-150" type="compound" text="ADDP"/>
            <pair e1="DS3.d77.s4.e0" e2="DS3.d77.s4.e1" id="DS3.d77.s4.i0" interaction="False" />
            <pair e1="DS3.d77.s4.e2" e2="DS3.d77.s4.e1" id="DS3.d77.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d77.s5" origId="9933029-5" text="In the LL cell line, the combination of dFdC and VP-16 at a constant molar ratio (dFdC:VP-16 = 1:4 or 1:0.125 after 4- or 24-hr exposure, respectively) was synergistic (combination index (CI), calculated at 50% growth inhibition = 0.7 and 0.8, respectively; CI &amp;lt;1 indicating synergism).">
            <entity id="DS3.d77.s5.e0" origId="60750" charOffset="40-44" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s5.e1" origId="P51610,A6NEM2" charOffset="49-54" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s5.e2" origId="60750" charOffset="82-86" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s5.e3" origId="P51610,A6NEM2" charOffset="87-92" type="protein" text="VP-16"/>
            <pair e1="DS3.d77.s5.e0" e2="DS3.d77.s5.e1" id="DS3.d77.s5.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d77.s6" origId="9933029-6" text="After 24- and 72-hr exposure to both drugs at a constant ratio, additivity was found in the A2780, ADDP, and H322 cell lines (dFdC:VP-16 = 1:500 for both exposure times in these cell lines).">
            <entity id="DS3.d77.s6.e0" origId="5702657" charOffset="99-103" type="compound" text="ADDP"/>
            <entity id="DS3.d77.s6.e1" origId="60750" charOffset="126-130" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s6.e2" origId="P51610,A6NEM2" charOffset="131-136" type="protein" text="VP-16"/>
            <pair e1="DS3.d77.s6.e1" e2="DS3.d77.s6.e2" id="DS3.d77.s6.i0" interaction="False" />
            <pair e1="DS3.d77.s6.e0" e2="DS3.d77.s6.e2" id="DS3.d77.s6.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d77.s7" origId="9933029-7" text="When cells were exposed to a combination of dFdC and VP-16 for 24 or 72 hr, with VP-16 at its IC25 and dFdC in a concentration range, additivity was found in both the LL and H322 cells; synergism was observed in the A2780 and ADDP cells, which are the least sensitive to VP-16.">
            <entity id="DS3.d77.s7.e0" origId="60750" charOffset="44-48" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s7.e1" origId="P51610,A6NEM2" charOffset="53-58" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s7.e2" origId="P51610,A6NEM2" charOffset="81-86" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s7.e3" origId="60750" charOffset="103-107" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s7.e4" origId="5702657" charOffset="226-230" type="compound" text="ADDP"/>
            <entity id="DS3.d77.s7.e5" origId="P51610,A6NEM2" charOffset="81-86" type="protein" text="VP-16"/>
            <pair e1="DS3.d77.s7.e0" e2="DS3.d77.s7.e1" id="DS3.d77.s7.i0" interaction="False" />
            <pair e1="DS3.d77.s7.e4" e2="DS3.d77.s7.e1" id="DS3.d77.s7.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d77.s8" origId="9933029-8" text="Schedule dependency was found in the LL cell line; when cells were exposed to dFdC 4 hr prior to VP-16 (constant molar ratio, total exposure 24 hr), synergism was found (CI = 0.5), whereas additivity was found when cells were exposed to VP-16 prior to dFdC (CI = 1.6).">
            <entity id="DS3.d77.s8.e0" origId="60750" charOffset="78-82" type="compound" text="dFdC"/>
            <entity id="DS3.d77.s8.e1" origId="P51610,A6NEM2" charOffset="97-102" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s8.e2" origId="P51610,A6NEM2" charOffset="237-242" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s8.e3" origId="60750" charOffset="252-256" type="compound" text="dFdC"/>
            <pair e1="DS3.d77.s8.e0" e2="DS3.d77.s8.e1" id="DS3.d77.s8.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d77.s9" origId="9933029-9" text="The mechanism of interaction between the drugs was studied in more detail in the LL cell line; dFdCTP accumulation was 1.2-fold enhanced by co-incubation with VP-16, and was even more pronounced (1.4-fold) when cells were exposed to VP-16 prior to dFdC.">
            <entity id="DS3.d77.s9.e0" origId="130659" charOffset="95-101" type="compound" text="dFdCTP"/>
            <entity id="DS3.d77.s9.e1" origId="P51610,A6NEM2" charOffset="159-164" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s9.e2" origId="P51610,A6NEM2" charOffset="233-238" type="protein" text="VP-16"/>
            <entity id="DS3.d77.s9.e3" origId="60750" charOffset="95-99" type="compound" text="dFdC"/>
            <pair e1="DS3.d77.s9.e3" e2="DS3.d77.s9.e1" id="DS3.d77.s9.i0" interaction="False" />
            <pair e1="DS3.d77.s9.e0" e2="DS3.d77.s9.e1" id="DS3.d77.s9.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d78" origId="9933031">
        <sentence id="DS3.d78.s0" origId="9933031-2" text="In the present study, rat liver epithelial WB cells were used to investigate the relative roles of Ca2+, protein kinase C (PKC), and protein tyrosine phosphorylation in mitogenesis and activation of the ERK pathway stimulated by epidermal growth factor (EGF) and angiotensin II (Ang II).">
            <entity id="DS3.d78.s0.e0" origId="6057,90983769" charOffset="141-149" type="compound" text="tyrosine"/>
            <entity id="DS3.d78.s0.e1" origId="Q5GAM5" charOffset="263-285" type="protein" text="angiotensin II (Ang II"/>
            <pair e1="DS3.d78.s0.e0" e2="DS3.d78.s0.e1" id="DS3.d78.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d78.s1" origId="9933031-7" text="On the other hand, an obligatory tyrosine phosphorylation step for activation of ERK was indicated by the use of protein tyrosine kinase inhibitors, which profoundly inhibited the activation of ERK by EGF, Ang II, and PMA.">
            <entity id="DS3.d78.s1.e0" origId="6057,90983769" charOffset="33-41" type="compound" text="tyrosine"/>
            <entity id="DS3.d78.s1.e1" origId="6057,90983769" charOffset="121-129" type="compound" text="tyrosine"/>
            <entity id="DS3.d78.s1.e2" origId="P01015" charOffset="206-212" type="protein" text="Ang II"/>
            <entity id="DS3.d78.s1.e3" origId="122634,27924" charOffset="218-221" type="compound" text="PMA"/>
            <pair e1="DS3.d78.s1.e3" e2="DS3.d78.s1.e2" id="DS3.d78.s1.i0" interaction="False" />
            <pair e1="DS3.d78.s1.e0" e2="DS3.d78.s1.e2" id="DS3.d78.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d79" origId="9933033">
        <sentence id="DS3.d79.s0" origId="9933033-2" text="In intact rat peritoneal leukocytes stimulated with calcium ionophore, all four phenolics inhibited leukotriene B4 generation at the 5-lipoxygenase level with effectiveness hydroxytyrosol &amp;gt; oleuropein &amp;gt; caffeic acid &amp;gt; tyrosol (approximate EC50 values: 15, 80, 200, and 500 microM, respectively).">
            <entity id="DS3.d79.s0.e0" origId="22044544,5460341" charOffset="52-59" type="compound" text="calcium"/>
            <entity id="DS3.d79.s0.e1" origId="5280492" charOffset="100-114" type="compound" text="leukotriene B4"/>
            <entity id="DS3.d79.s0.e2" origId="P12527,F1LMM5" charOffset="133-147" type="protein" text="5-lipoxygenase"/>
            <entity id="DS3.d79.s0.e3" origId="82755" charOffset="173-187" type="compound" text="hydroxytyrosol"/>
            <entity id="DS3.d79.s0.e4" origId="3789874,5281544,53297357,6325757,6426698,9807309" charOffset="193-203" type="compound" text="oleuropein"/>
            <entity id="DS3.d79.s0.e5" origId="689043" charOffset="209-221" type="compound" text="caffeic acid"/>
            <entity id="DS3.d79.s0.e6" origId="10393" charOffset="180-187" type="compound" text="tyrosol"/>
            <pair e1="DS3.d79.s0.e6" e2="DS3.d79.s0.e2" id="DS3.d79.s0.i0" interaction="False" />
            <pair e1="DS3.d79.s0.e3" e2="DS3.d79.s0.e2" id="DS3.d79.s0.i1" interaction="False" />
            <pair e1="DS3.d79.s0.e0" e2="DS3.d79.s0.e2" id="DS3.d79.s0.i2" interaction="False" />
            <pair e1="DS3.d79.s0.e5" e2="DS3.d79.s0.e2" id="DS3.d79.s0.i3" interaction="False" />
            <pair e1="DS3.d79.s0.e1" e2="DS3.d79.s0.e2" id="DS3.d79.s0.i4" interaction="False" />
            <pair e1="DS3.d79.s0.e4" e2="DS3.d79.s0.e2" id="DS3.d79.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d80" origId="9933036">
        <sentence id="DS3.d80.s0" origId="9933036-5" text="End points included toxicity, serum PSA rise related to serum testosterone restoration, and immunologic effects measured by Western blot analysis for anti-PSA antibody induction.">
            <entity id="DS3.d80.s0.e0" origId="P07225" charOffset="36-39" type="protein" text="PSA"/>
            <entity id="DS3.d80.s0.e1" origId="6013" charOffset="62-74" type="compound" text="testosterone"/>
            <entity id="DS3.d80.s0.e2" origId="P07225" charOffset="155-158" type="protein" text="PSA"/>
            <pair e1="DS3.d80.s0.e1" e2="DS3.d80.s0.e0" id="DS3.d80.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d80.s1" origId="9933036-8" text="One subject showed continued undetectable serum PSA (less than 0.2 ng/mL) for over 8 months after testosterone restoration, an interval longer than those reported in previous androgen deprivation interruption studies.">
            <entity id="DS3.d80.s1.e0" origId="P07225" charOffset="48-51" type="protein" text="PSA"/>
            <entity id="DS3.d80.s1.e1" origId="6013" charOffset="98-110" type="compound" text="testosterone"/>
            <pair e1="DS3.d80.s1.e1" e2="DS3.d80.s1.e0" id="DS3.d80.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d81" origId="9933076">
        <sentence id="DS3.d81.s0" origId="9933076-4" text="Each biopsy was analyzed for the following enzyme activities: malate dehydrogenase and citrate synthase (mitochondrial markers) and the sarcoplasmic reticular enzyme Ca2+ -dependent adenosine triphosphatase (ATPase).">
            <entity id="DS3.d81.s0.e0" origId="525" charOffset="62-68" type="compound" text="malate"/>
            <entity id="DS3.d81.s0.e1" origId="O75390,A0A024RB75" charOffset="87-103" type="protein" text="citrate synthase"/>
            <entity id="DS3.d81.s0.e2" origId="P00919" charOffset="166-169" type="protein" text="Ca2"/>
            <entity id="DS3.d81.s0.e3" origId="57476835,60961" charOffset="182-191" type="compound" text="adenosine"/>
            <pair e1="DS3.d81.s0.e0" e2="DS3.d81.s0.e1" id="DS3.d81.s0.i0" interaction="False" />
            <pair e1="DS3.d81.s0.e0" e2="DS3.d81.s0.e2" id="DS3.d81.s0.i1" interaction="False" />
            <pair e1="DS3.d81.s0.e3" e2="DS3.d81.s0.e1" id="DS3.d81.s0.i2" interaction="False" />
            <pair e1="DS3.d81.s0.e3" e2="DS3.d81.s0.e2" id="DS3.d81.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d82" origId="9933081">
        <sentence id="DS3.d82.s0" origId="9933081-3" text="Basophils also express several chemoattractant receptors, including high levels of C5a receptors, macrophage chemotactic protein (MCP) receptors (CCR2) and eotaxin receptors (CCR3), intermediate levels of CXCR1, CXCR2 and platelet-activating factor receptors, and lower levels of N-formyl-Met-Leu-Phe (fMLP) receptors.">
            <entity id="DS3.d82.s0.e0" origId="P21730" charOffset="83-86" type="protein" text="C5a"/>
            <entity id="DS3.d82.s0.e1" origId="P41597,A0A024R2Q0" charOffset="146-150" type="protein" text="CCR2"/>
            <entity id="DS3.d82.s0.e2" origId="P51677,Q8TDP5,Q8TDP4,A0A024R2Z3" charOffset="175-179" type="protein" text="CCR3"/>
            <entity id="DS3.d82.s0.e3" origId="P25024" charOffset="205-210" type="protein" text="CXCR1"/>
            <entity id="DS3.d82.s0.e4" origId="P25025,Q53PC4" charOffset="212-217" type="protein" text="CXCR2"/>
            <entity id="DS3.d82.s0.e5" origId="108157,5313888" charOffset="222-248" type="compound" text="platelet-activating factor"/>
            <entity id="DS3.d82.s0.e6" origId="P21462" charOffset="280-300" type="protein" text="N-formyl-Met-Leu-Phe"/>
            <entity id="DS3.d82.s0.e7" origId="P21462" charOffset="302-306" type="protein" text="fMLP"/>
            <pair e1="DS3.d82.s0.e5" e2="DS3.d82.s0.e6" id="DS3.d82.s0.i0" interaction="False" />
            <pair e1="DS3.d82.s0.e5" e2="DS3.d82.s0.e7" id="DS3.d82.s0.i1" interaction="False" />
            <pair e1="DS3.d82.s0.e5" e2="DS3.d82.s0.e3" id="DS3.d82.s0.i2" interaction="False" />
            <pair e1="DS3.d82.s0.e5" e2="DS3.d82.s0.e4" id="DS3.d82.s0.i3" interaction="False" />
            <pair e1="DS3.d82.s0.e5" e2="DS3.d82.s0.e1" id="DS3.d82.s0.i4" interaction="False" />
            <pair e1="DS3.d82.s0.e5" e2="DS3.d82.s0.e2" id="DS3.d82.s0.i5" interaction="False" />
            <pair e1="DS3.d82.s0.e5" e2="DS3.d82.s0.e0" id="DS3.d82.s0.i6" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d83" origId="9933100">
        <sentence id="DS3.d83.s0" origId="9933100-1" text="The IgG2a(b) heavy chain allopeptide determinant gamma2a(b) 436-451 (Kabat numbering) presented by the major histocompatibility complex (MHC) class II molecule I-Ad is recognized by T cells which cross-react with a corneal self antigen and with the UL6 protein of the herpes simplex virus which induce autoimmune keratitis, and is the target of Th1 clones that suppress IgG2a(b) production in vivo.">
            <entity id="DS3.d83.s0.e0" origId="5366546" charOffset="69-74" type="compound" text="Kabat"/>
            <entity id="DS3.d83.s0.e1" origId="Q8IXH7,H0UI80" charOffset="345-348" type="protein" text="Th1"/>
            <pair e1="DS3.d83.s0.e0" e2="DS3.d83.s0.e1" id="DS3.d83.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d84" origId="9933103">
        <sentence id="DS3.d84.s0" origId="9933103-0" text="Expression of multiple forms of IL-1 receptor antagonist (IL-1ra) by human retinal pigment epithelial cells: identification of a new IL-1ra exon.">
            <entity id="DS3.d84.s0.e0" origId="P18510,A0A024R528" charOffset="32-56" type="protein" text="IL-1 receptor antagonist"/>
            <entity id="DS3.d84.s0.e1" origId="P18510,A0A024R528" charOffset="58-64" type="protein" text="IL-1ra"/>
            <entity id="DS3.d84.s0.e2" origId="638015" charOffset="75-82" type="compound" text="retinal"/>
            <entity id="DS3.d84.s0.e3" origId="P18510,A0A024R528" charOffset="133-139" type="protein" text="IL-1ra"/>
            <pair e1="DS3.d84.s0.e2" e2="DS3.d84.s0.e1" id="DS3.d84.s0.i0" interaction="False" />
            <pair e1="DS3.d84.s0.e2" e2="DS3.d84.s0.e0" id="DS3.d84.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d84.s1" origId="9933103-5" text="Expression of both the intracellular and secreted IL-1ra was detected in unstimulated and IL-1beta- or phorbol 12-myristate 13-acetate-exposed RPE.">
            <entity id="DS3.d84.s1.e0" origId="P18510,A0A024R528" charOffset="50-56" type="protein" text="IL-1ra"/>
            <entity id="DS3.d84.s1.e1" origId="P01584" charOffset="90-98" type="protein" text="IL-1beta"/>
            <entity id="DS3.d84.s1.e2" origId="27924" charOffset="103-134" type="compound" text="phorbol 12-myristate 13-acetate"/>
            <pair e1="DS3.d84.s1.e2" e2="DS3.d84.s1.e1" id="DS3.d84.s1.i0" interaction="False" />
            <pair e1="DS3.d84.s1.e2" e2="DS3.d84.s1.e0" id="DS3.d84.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d85" origId="9933109">
        <sentence id="DS3.d85.s0" origId="9933109-7" text="In addition, binding of an ILT2-Ig fusion protein to the .221-AEH, expressing only HLA-E, and the .221-G1(Eneg) transfectants was analyzed.">
            <entity id="DS3.d85.s0.e0" origId="Q8NHL6,A0A087WSV6,D9IDM5,A8MVE2,A0A0G2JNR3,A0A0B4J1W1,A0A087WSX8" charOffset="27-31" type="protein" text="ILT2"/>
            <entity id="DS3.d85.s0.e1" origId="24748050" charOffset="62-65" type="compound" text="AEH"/>
            <entity id="DS3.d85.s0.e2" origId="P13747,Q6DU44,O19682,A8K8M6" charOffset="83-88" type="protein" text="HLA-E"/>
            <pair e1="DS3.d85.s0.e1" e2="DS3.d85.s0.e0" id="DS3.d85.s0.i0" interaction="False" />
            <pair e1="DS3.d85.s0.e1" e2="DS3.d85.s0.e2" id="DS3.d85.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d86" origId="9933114">
        <sentence id="DS3.d86.s0" origId="9933114-6" text="IFN-gamma did not restore the expression of Th1-related cytokine mRNA or the activated macrophage product inducible nitric oxide synthase in allografts.">
            <entity id="DS3.d86.s0.e0" origId="P01581" charOffset="0-9" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d86.s0.e1" origId="145068" charOffset="116-128" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d86.s0.e1" e2="DS3.d86.s0.e0" id="DS3.d86.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d87" origId="9933116">
        <sentence id="DS3.d87.s0" origId="9933116-5" text="Further, as a result of Bcl-2 overexpression, we found that hGH greatly depressed Fas-induced activation of the cysteine protease caspase-3 (CPP32), which in turn affected the cleavage of poly(ADP-ribose) polymerase.">
            <entity id="DS3.d87.s0.e0" origId="5862,90793998" charOffset="112-120" type="compound" text="cysteine"/>
            <entity id="DS3.d87.s0.e1" origId="P42574" charOffset="130-139" type="protein" text="caspase-3"/>
            <entity id="DS3.d87.s0.e2" origId="P42574" charOffset="141-146" type="protein" text="CPP32"/>
            <entity id="DS3.d87.s0.e3" origId="192,44415180,445794" charOffset="193-203" type="compound" text="ADP-ribose"/>
            <pair e1="DS3.d87.s0.e0" e2="DS3.d87.s0.e2" id="DS3.d87.s0.i0" interaction="False" />
            <pair e1="DS3.d87.s0.e0" e2="DS3.d87.s0.e1" id="DS3.d87.s0.i1" interaction="False" />
            <pair e1="DS3.d87.s0.e3" e2="DS3.d87.s0.e2" id="DS3.d87.s0.i2" interaction="False" />
            <pair e1="DS3.d87.s0.e3" e2="DS3.d87.s0.e1" id="DS3.d87.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d88" origId="9933129">
        <sentence id="DS3.d88.s0" origId="9933129-4" text="The purified CD34+ cells were cultured for 14 days with saturating doses of cytokines, including recombinant human macrophage colony stimulating factor (rM-CSF), granulocyte-CSF (rG-CSF), granulocyte/macrophage-CSF (rGM-CSF), interleukin-3 (rIL-3) and rSCF.">
            <entity id="DS3.d88.s0.e0" origId="Q6GMN4,A0A0G2K4Q6" charOffset="153-159" type="protein" text="rM-CSF"/>
            <entity id="DS3.d88.s0.e1" origId="P09919,Q6FH65,Q8N4W3" charOffset="162-185" type="protein" text="granulocyte-CSF (rG-CSF"/>
            <entity id="DS3.d88.s0.e2" origId="16122568,16750043,4369303,448383" charOffset="156-159" type="compound" text="CSF"/>
            <entity id="DS3.d88.s0.e3" origId="P48750" charOffset="216-223" type="protein" text="rGM-CSF"/>
            <pair e1="DS3.d88.s0.e2" e2="DS3.d88.s0.e0" id="DS3.d88.s0.i0" interaction="False" />
            <pair e1="DS3.d88.s0.e2" e2="DS3.d88.s0.e3" id="DS3.d88.s0.i1" interaction="False" />
            <pair e1="DS3.d88.s0.e2" e2="DS3.d88.s0.e1" id="DS3.d88.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d89" origId="9933130">
        <sentence id="DS3.d89.s0" origId="9933130-3" text="After 2-5 days, approximately 38-50% of the suspension cells became macrophage-like and acquired CD21, alpha-naphthyl acetate reactivity and immune adherence capability.">
            <entity id="DS3.d89.s0.e0" origId="P20023" charOffset="97-101" type="protein" text="CD21"/>
            <entity id="DS3.d89.s0.e1" origId="13247" charOffset="103-125" type="compound" text="alpha-naphthyl acetate"/>
            <pair e1="DS3.d89.s0.e1" e2="DS3.d89.s0.e0" id="DS3.d89.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d90" origId="9933137">
        <sentence id="DS3.d90.s0" origId="9933137-7" text="Specifically, patients with favorable cytogenetic groups (t(8;21), inv16, and t(15;17)) had lower c-mpl protein expression (median 1.7 times normal), whereas patients with unfavorable abnormalities (+8, -5 or -7, and del(11)(q23)) and normal cytogenetics had high expression (3.1 and 2.85 times normal, respectively).">
            <entity id="DS3.d90.s0.e0" origId="P40238" charOffset="98-103" type="protein" text="c-mpl"/>
            <entity id="DS3.d90.s0.e1" origId="445801" charOffset="217-220" type="compound" text="del"/>
            <pair e1="DS3.d90.s0.e1" e2="DS3.d90.s0.e0" id="DS3.d90.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d91" origId="9933145">
        <sentence id="DS3.d91.s0" origId="9933145-3" text="In mouse brain cortex membranes, the binding of the ORL1 receptor agonist (3H)nociceptin was equipotently inhibited by Mr 2266 and its enantiomer Mr 2267 (pK(i) 4.82 and 5.14, respectively), whereas the binding of the kappa-opioid receptor agonist (3H)U-69,593 was inhibited by Mr 2266 more potently (pK(i) 9.11) than by its enantiomer Mr 2267 (pK(i)7.15).">
            <entity id="DS3.d91.s0.e0" origId="P35377,Q542U1" charOffset="52-56" type="protein" text="ORL1"/>
            <entity id="DS3.d91.s0.e1" origId="Q64387,B7ZMX9,Q543U6" charOffset="78-88" type="protein" text="nociceptin"/>
            <entity id="DS3.d91.s0.e2" origId="3034816" charOffset="146-153" type="compound" text="Mr 2267"/>
            <entity id="DS3.d91.s0.e3" origId="3034816" charOffset="336-343" type="compound" text="Mr 2267"/>
            <pair e1="DS3.d91.s0.e2" e2="DS3.d91.s0.e1" id="DS3.d91.s0.i0" interaction="False" />
            <pair e1="DS3.d91.s0.e2" e2="DS3.d91.s0.e0" id="DS3.d91.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d91.s1" origId="9933145-4" text="In mouse brain cortex slices preincubated with (3H)noradrenaline, the concentration-response curve of nociceptin for inhibition of the electrically evoked overflow of tritium was equipotently shifted to the right by Mr 2266 and Mr 2267 (pA2 5.77 and 5.64, respectively).">
            <entity id="DS3.d91.s1.e0" origId="439260" charOffset="51-64" type="compound" text="noradrenaline"/>
            <entity id="DS3.d91.s1.e1" origId="Q64387,B7ZMX9,Q543U6" charOffset="102-112" type="protein" text="nociceptin"/>
            <entity id="DS3.d91.s1.e2" origId="119434" charOffset="167-174" type="compound" text="tritium"/>
            <entity id="DS3.d91.s1.e3" origId="3034816" charOffset="228-235" type="compound" text="Mr 2267"/>
            <pair e1="DS3.d91.s1.e0" e2="DS3.d91.s1.e1" id="DS3.d91.s1.i0" interaction="False" />
            <pair e1="DS3.d91.s1.e3" e2="DS3.d91.s1.e1" id="DS3.d91.s1.i1" interaction="False" />
            <pair e1="DS3.d91.s1.e2" e2="DS3.d91.s1.e1" id="DS3.d91.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d92" origId="9933146">
        <sentence id="DS3.d92.s0" origId="9933146-1" text="5-Hydroxytryptamine 5-HT2A and 5-HT2C receptors share many properties, including a common ability to stimulate phospholipase C. Traditionally, this activation was thought to be initiated only after agonist binding, in accordance with the ternary complex model of receptor function.">
            <entity id="DS3.d92.s0.e0" origId="5202" charOffset="0-19" type="compound" text="5-Hydroxytryptamine"/>
            <entity id="DS3.d92.s0.e1" origId="P35363,Q543D4" charOffset="20-26" type="protein" text="5-HT2A"/>
            <pair e1="DS3.d92.s0.e0" e2="DS3.d92.s0.e1" id="DS3.d92.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d93" origId="9933147">
        <sentence id="DS3.d93.s0" origId="9933147-0" text="Signaling via A2A adenosine receptor in four PC12 cell clones.">
            <entity id="DS3.d93.s0.e0" origId="P16086,Q6IRK8,A0A0G2K1Y8" charOffset="14-17" type="protein" text="A2A"/>
            <entity id="DS3.d93.s0.e1" origId="60961,57476835" charOffset="18-27" type="compound" text="adenosine"/>
            <pair e1="DS3.d93.s0.e1" e2="DS3.d93.s0.e0" id="DS3.d93.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d93.s1" origId="9933147-10" text="The present results show that different clones of PC 12 cells differ widely in the cAMP increase induced by adenosine analogues and that this is due to differences in the amount of adenosine A2A receptor, G protein and effector.">
            <entity id="DS3.d93.s1.e0" origId="60961,57476835" charOffset="108-117" type="compound" text="adenosine"/>
            <entity id="DS3.d93.s1.e1" origId="60961,57476835" charOffset="181-190" type="compound" text="adenosine"/>
            <entity id="DS3.d93.s1.e2" origId="P16086,Q6IRK8,A0A0G2K1Y8" charOffset="191-194" type="protein" text="A2A"/>
            <pair e1="DS3.d93.s1.e0" e2="DS3.d93.s1.e2" id="DS3.d93.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d93.s2" origId="9933147-2" text="We have examined the A2A adenosine receptor signal transduction pathways in four such clones (denoted clones 1, 19, 21 and 27) of PC12 cells.">
            <entity id="DS3.d93.s2.e0" origId="P16086,Q6IRK8,A0A0G2K1Y8" charOffset="21-24" type="protein" text="A2A"/>
            <entity id="DS3.d93.s2.e1" origId="60961,57476835" charOffset="25-34" type="compound" text="adenosine"/>
            <pair e1="DS3.d93.s2.e1" e2="DS3.d93.s2.e0" id="DS3.d93.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d93.s3" origId="9933147-3" text="Adenosine A2A, A2B and A1 receptor mRNAs were detected in all four clones by RT-PCR, whereas no A3 receptor mRNA was found.">
            <entity id="DS3.d93.s3.e0" origId="60961,57476835" charOffset="0-9" type="compound" text="Adenosine"/>
            <entity id="DS3.d93.s3.e1" origId="P16086,Q6IRK8,A0A0G2K1Y8" charOffset="10-13" type="protein" text="A2A"/>
            <pair e1="DS3.d93.s3.e0" e2="DS3.d93.s3.e1" id="DS3.d93.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d93.s4" origId="9933147-4" text="A2A receptors were quantitated by radioligand binding using the antagonist radioligand (3H)SCH 58261 ((3H)-5-amino-7(2-phenylethyl)-2-(2-furyl)-pyrazolo(4,3-e)-1,2,4 triazolo (1,5-c) pyrimidine).">
            <entity id="DS3.d93.s4.e0" origId="P16086,Q6IRK8,A0A0G2K1Y8" charOffset="0-3" type="protein" text="A2A"/>
            <entity id="DS3.d93.s4.e1" origId="176408" charOffset="91-100" type="compound" text="SCH 58261"/>
            <pair e1="DS3.d93.s4.e1" e2="DS3.d93.s4.e0" id="DS3.d93.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d93.s5" origId="9933147-7" text="Maximal responses to the non-selective adenosine analogue NECA (5'-N-ethylcarboxamidoadenosine) were similar to those observed with the selective adenosine A2A receptor agonist CGS 21680 (2-(p-(2-carbonylethyl) phenylethylamino)-5'-N-ethylcarboxamidoadenosine), and were approximately equal in clones I and 21, but lower in clone 19 and very low in clone 27.">
            <entity id="DS3.d93.s5.e0" origId="60961,57476835" charOffset="39-48" type="compound" text="adenosine"/>
            <entity id="DS3.d93.s5.e1" origId="11957539,24867503,2868392" charOffset="64-94" type="compound" text="5'-N-ethylcarboxamidoadenosine"/>
            <entity id="DS3.d93.s5.e2" origId="60961,57476835" charOffset="85-94" type="compound" text="adenosine"/>
            <entity id="DS3.d93.s5.e3" origId="P16086,Q6IRK8,A0A0G2K1Y8" charOffset="156-159" type="protein" text="A2A"/>
            <entity id="DS3.d93.s5.e4" origId="11957539,24867503,2868392" charOffset="229-259" type="compound" text="5'-N-ethylcarboxamidoadenosine"/>
            <pair e1="DS3.d93.s5.e1" e2="DS3.d93.s5.e3" id="DS3.d93.s5.i0" interaction="False" />
            <pair e1="DS3.d93.s5.e0" e2="DS3.d93.s5.e3" id="DS3.d93.s5.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d93.s6" origId="9933147-9" text="In both clones the response to NECA could be competitively antagonized by a selective adenosine A2A antagonist, SCH 58261.">
            <entity id="DS3.d93.s6.e0" origId="60961,57476835" charOffset="86-95" type="compound" text="adenosine"/>
            <entity id="DS3.d93.s6.e1" origId="P16086,Q6IRK8,A0A0G2K1Y8" charOffset="96-99" type="protein" text="A2A"/>
            <entity id="DS3.d93.s6.e2" origId="176408" charOffset="112-121" type="compound" text="SCH 58261"/>
            <pair e1="DS3.d93.s6.e2" e2="DS3.d93.s6.e1" id="DS3.d93.s6.i0" interaction="False" />
            <pair e1="DS3.d93.s6.e0" e2="DS3.d93.s6.e1" id="DS3.d93.s6.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d94" origId="9933149">
        <sentence id="DS3.d94.s0" origId="9933149-0" text="5-HT1B receptors modulate release of (3H)dopamine from rat striatal synaptosomes.">
            <entity id="DS3.d94.s0.e0" origId="P28564" charOffset="0-6" type="protein" text="5-HT1B"/>
            <entity id="DS3.d94.s0.e1" origId="681" charOffset="41-49" type="compound" text="dopamine"/>
            <pair e1="DS3.d94.s0.e1" e2="DS3.d94.s0.e0" id="DS3.d94.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d94.s1" origId="9933149-4" text="(+/-)8-OH-DPAT, a 5-HT(1A) receptor agonist, (+/-)DOI, a 5-HT2 receptor agonist, and 2-methyl-5-hydroxytryptamine, a 5-HT3 receptor agonist, at concentrations ranging from 0.01 microM to 100 microM did not show any significant effect.">
            <entity id="DS3.d94.s1.e0" origId="1220" charOffset="5-14" type="compound" text="8-OH-DPAT"/>
            <entity id="DS3.d94.s1.e1" origId="5202" charOffset="18-22" type="compound" text="5-HT"/>
            <entity id="DS3.d94.s1.e2" origId="1574" charOffset="85-113" type="compound" text="2-methyl-5-hydroxytryptamine"/>
            <entity id="DS3.d94.s1.e3" origId="P35563,Q62999" charOffset="117-131" type="protein" text="5-HT3 receptor"/>
            <pair e1="DS3.d94.s1.e2" e2="DS3.d94.s1.e3" id="DS3.d94.s1.i0" interaction="False" />
            <pair e1="DS3.d94.s1.e1" e2="DS3.d94.s1.e3" id="DS3.d94.s1.i1" interaction="False" />
            <pair e1="DS3.d94.s1.e0" e2="DS3.d94.s1.e3" id="DS3.d94.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d94.s2" origId="9933149-5" text="Neither ketanserin (1 microM and 5 microM), a selective 5-HT2/5-HT1D receptor antagonist, nor ondansetron (1 microM), a 5-HT3 receptor antagonist, changed the inhibitory effect of CP93,129.">
            <entity id="DS3.d94.s2.e0" origId="3822" charOffset="8-18" type="compound" text="ketanserin"/>
            <entity id="DS3.d94.s2.e1" origId="4595" charOffset="94-105" type="compound" text="ondansetron"/>
            <entity id="DS3.d94.s2.e2" origId="P35563,Q62999" charOffset="120-134" type="protein" text="5-HT3 receptor"/>
            <pair e1="DS3.d94.s2.e0" e2="DS3.d94.s2.e2" id="DS3.d94.s2.i0" interaction="False" />
            <pair e1="DS3.d94.s2.e1" e2="DS3.d94.s2.e2" id="DS3.d94.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d94.s3" origId="9933149-6" text="SB224289, GR55562, GR127935, isamoltane and metergoline, selective and non-selective 5-HT1B receptor antagonists, in contrast, used at a concentration of 1 microM, antagonized the inhibitory effect of CP93,129 (3 microM and 10 microM).">
            <entity id="DS3.d94.s3.e0" origId="3378093" charOffset="0-8" type="compound" text="SB224289"/>
            <entity id="DS3.d94.s3.e1" origId="128018" charOffset="10-17" type="compound" text="GR55562"/>
            <entity id="DS3.d94.s3.e2" origId="127404" charOffset="29-39" type="compound" text="isamoltane"/>
            <entity id="DS3.d94.s3.e3" origId="28693" charOffset="44-55" type="compound" text="metergoline"/>
            <entity id="DS3.d94.s3.e4" origId="P28564" charOffset="85-91" type="protein" text="5-HT1B"/>
            <pair e1="DS3.d94.s3.e3" e2="DS3.d94.s3.e4" id="DS3.d94.s3.i0" interaction="False" />
            <pair e1="DS3.d94.s3.e2" e2="DS3.d94.s3.e4" id="DS3.d94.s3.i1" interaction="False" />
            <pair e1="DS3.d94.s3.e0" e2="DS3.d94.s3.e4" id="DS3.d94.s3.i2" interaction="False" />
            <pair e1="DS3.d94.s3.e1" e2="DS3.d94.s3.e4" id="DS3.d94.s3.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d94.s4" origId="9933149-7" text="SB224289, a selective 5-HT1B receptor antagonist, inhibited the effect of CP93,129 in a concentration-dependent manner; the calculated K(i) value was 1.8 nM.">
            <entity id="DS3.d94.s4.e0" origId="3378093" charOffset="0-8" type="compound" text="SB224289"/>
            <entity id="DS3.d94.s4.e1" origId="P28564" charOffset="22-28" type="protein" text="5-HT1B"/>
            <pair e1="DS3.d94.s4.e0" e2="DS3.d94.s4.e1" id="DS3.d94.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d94.s5" origId="9933149-8" text="Our results indicate that in rat striatal axon terminals the K(+)-evoked release of dopamine is regulated by the presynaptic 5-HT1B heteroreceptors.">
            <entity id="DS3.d94.s5.e0" origId="681" charOffset="84-92" type="compound" text="dopamine"/>
            <entity id="DS3.d94.s5.e1" origId="P28564" charOffset="125-131" type="protein" text="5-HT1B"/>
            <pair e1="DS3.d94.s5.e0" e2="DS3.d94.s5.e1" id="DS3.d94.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d95" origId="9933150">
        <sentence id="DS3.d95.s0" origId="9933150-2" text="EDHF-mediated vasorelaxations to carbachol (ED50=3.26+/-0.57 nmol; the maximum relaxation, Rmax = 87.0+/-2.5%) were opposed by the selective cannabinoid CB1 antagonist, LY320135: at 2 microM ED50 for carbachol was 10.4+/-2.6 nmol and Rmax was 66.9+/-6.2%, at 10 microM ED50 was 15.9+/-4.0 nmol and Rmax was 34.0+/-4.3%.">
            <entity id="DS3.d95.s0.e0" origId="2551" charOffset="33-42" type="compound" text="carbachol"/>
            <entity id="DS3.d95.s0.e1" origId="P21554,V5KA96,S5TLS4" charOffset="153-156" type="protein" text="CB1"/>
            <entity id="DS3.d95.s0.e2" origId="5311257" charOffset="169-177" type="compound" text="LY320135"/>
            <entity id="DS3.d95.s0.e3" origId="2551" charOffset="200-209" type="compound" text="carbachol"/>
            <pair e1="DS3.d95.s0.e0" e2="DS3.d95.s0.e1" id="DS3.d95.s0.i0" interaction="False" />
            <pair e1="DS3.d95.s0.e2" e2="DS3.d95.s0.e1" id="DS3.d95.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d95.s1" origId="9933150-3" text="However, these responses were unaffected by another putative CB1 ligand, AM630 (10 microM), or a CB2 selective antagonist, SR 144528 (100 nM-1 microM).">
            <entity id="DS3.d95.s1.e0" origId="P21554,V5KA96,S5TLS4" charOffset="61-64" type="protein" text="CB1"/>
            <entity id="DS3.d95.s1.e1" origId="4302963" charOffset="73-78" type="compound" text="AM630"/>
            <entity id="DS3.d95.s1.e2" origId="P34972,A0A024RAH7" charOffset="97-100" type="protein" text="CB2"/>
            <entity id="DS3.d95.s1.e3" origId="3081355" charOffset="123-132" type="compound" text="SR 144528"/>
            <pair e1="DS3.d95.s1.e1" e2="DS3.d95.s1.e2" id="DS3.d95.s1.i0" interaction="False" />
            <pair e1="DS3.d95.s1.e1" e2="DS3.d95.s1.e0" id="DS3.d95.s1.i1" interaction="False" />
            <pair e1="DS3.d95.s1.e3" e2="DS3.d95.s1.e2" id="DS3.d95.s1.i2" interaction="False" />
            <pair e1="DS3.d95.s1.e3" e2="DS3.d95.s1.e0" id="DS3.d95.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d95.s2" origId="9933150-5" text="Coupled to our previous observation that the CB1 receptor antagonist SR141716A opposes EDHF-mediated relaxation, the present observations point to the involvement of a cannabinoid receptor, which may be CB or CB1-like, in EDHF-mediated vasorelaxation.">
            <entity id="DS3.d95.s2.e0" origId="P21554,V5KA96,S5TLS4" charOffset="45-48" type="protein" text="CB1"/>
            <entity id="DS3.d95.s2.e1" origId="104850" charOffset="69-78" type="compound" text="SR141716A"/>
            <entity id="DS3.d95.s2.e2" origId="P21554,V5KA96,S5TLS4" charOffset="209-212" type="protein" text="CB1"/>
            <pair e1="DS3.d95.s2.e1" e2="DS3.d95.s2.e0" id="DS3.d95.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d96" origId="9933154">
        <sentence id="DS3.d96.s0" origId="9933154-3" text="In Ussing chamber experiments substance P (SP), the NK1-receptor agonist (SAR9,Met(O2)11)-SP and the NK-3-receptor agonist (MePhe7)-NKB increased dose-dependently short-circuit currents.">
            <entity id="DS3.d96.s0.e0" origId="P30547,Q547C3,Q8R1R6" charOffset="52-64" type="protein" text="NK1-receptor"/>
            <entity id="DS3.d96.s0.e1" origId="P30098" charOffset="101-114" type="protein" text="NK-3-receptor"/>
            <entity id="DS3.d96.s0.e2" origId="5311312" charOffset="132-135" type="compound" text="NKB"/>
            <pair e1="DS3.d96.s0.e2" e2="DS3.d96.s0.e1" id="DS3.d96.s0.i0" interaction="False" />
            <pair e1="DS3.d96.s0.e2" e2="DS3.d96.s0.e0" id="DS3.d96.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d96.s1" origId="9933154-4" text="The NK-2-receptor agonist (betaAla8)-NKA(4-10) had no effect.">
            <entity id="DS3.d96.s1.e0" origId="Q64077" charOffset="4-17" type="protein" text="NK-2-receptor"/>
            <entity id="DS3.d96.s1.e1" origId="5311311" charOffset="37-40" type="compound" text="NKA"/>
            <pair e1="DS3.d96.s1.e1" e2="DS3.d96.s1.e0" id="DS3.d96.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d97" origId="9933164">
        <sentence id="DS3.d97.s0" origId="9933164-0" text="Oligomeric structure of the human EphB2 receptor SAM domain.">
            <entity id="DS3.d97.s0.e0" origId="P29323,Q6NVW1,Q4LE53,B4DSE0" charOffset="34-39" type="protein" text="EphB2"/>
            <entity id="DS3.d97.s0.e1" origId="34756" charOffset="49-52" type="compound" text="SAM"/>
            <pair e1="DS3.d97.s0.e1" e2="DS3.d97.s0.e0" id="DS3.d97.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d97.s1" origId="9933164-3" text="The crystal structure of the SAM domain from an Eph receptor tyrosine kinase, EphB2, reveals two large interfaces.">
            <entity id="DS3.d97.s1.e0" origId="34756" charOffset="29-32" type="compound" text="SAM"/>
            <entity id="DS3.d97.s1.e1" origId="6057,90983769" charOffset="61-69" type="compound" text="tyrosine"/>
            <entity id="DS3.d97.s1.e2" origId="P29323,Q6NVW1,Q4LE53,B4DSE0" charOffset="78-83" type="protein" text="EphB2"/>
            <pair e1="DS3.d97.s1.e0" e2="DS3.d97.s1.e2" id="DS3.d97.s1.i0" interaction="False" />
            <pair e1="DS3.d97.s1.e1" e2="DS3.d97.s1.e2" id="DS3.d97.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d98" origId="9933165">
        <sentence id="DS3.d98.s0" origId="9933165-1" text="In T lymphocytes, a store-operated calcium ion (Ca2+) entry mechanism termed the calcium release-activated Ca2+ channel (CRAC channel) underlies the sustained or oscillatory intracellular calcium concentration signal required for interleukin-2 gene expression and cell proliferation.">
            <entity id="DS3.d98.s0.e0" origId="271" charOffset="35-46" type="compound" text="calcium ion"/>
            <entity id="DS3.d98.s0.e1" origId="22044544,5460341" charOffset="35-42" type="compound" text="calcium"/>
            <entity id="DS3.d98.s0.e2" origId="22044544,5460341" charOffset="81-88" type="compound" text="calcium"/>
            <entity id="DS3.d98.s0.e3" origId="P60568,Q0GK43" charOffset="230-243" type="protein" text="interleukin-2"/>
            <pair e1="DS3.d98.s0.e1" e2="DS3.d98.s0.e3" id="DS3.d98.s0.i0" interaction="False" />
            <pair e1="DS3.d98.s0.e0" e2="DS3.d98.s0.e3" id="DS3.d98.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d99" origId="9933169">
        <sentence id="DS3.d99.s0" origId="9933169-2" text="Induction of adenosine 3',5'-monophosphate (cAMP)-specific phosphodiesterase-7 (PDE7) was found to be a consequence of such costimulation.">
            <entity id="DS3.d99.s0.e0" origId="57476835,60961" charOffset="13-22" type="compound" text="adenosine"/>
            <entity id="DS3.d99.s0.e1" origId="Q13946" charOffset="80-84" type="protein" text="PDE7"/>
            <pair e1="DS3.d99.s0.e0" e2="DS3.d99.s0.e1" id="DS3.d99.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d100" origId="993323">
        <sentence id="DS3.d100.s0" origId="993323-0" text="Increased insulin binding by lymphocyte receptors induced by beta-OH butyrate.">
            <entity id="DS3.d100.s0.e0" origId="P01308,I3WAC9" charOffset="10-17" type="protein" text="insulin"/>
            <entity id="DS3.d100.s0.e1" origId="264" charOffset="69-77" type="compound" text="butyrate"/>
            <pair e1="DS3.d100.s0.e1" e2="DS3.d100.s0.e0" id="DS3.d100.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d100.s1" origId="993323-2" text="Whether ketones alter, independent of changes in pH, in number and affinity of insulin receptors is not known.">
            <entity id="DS3.d100.s1.e0" origId="114522" charOffset="8-15" type="compound" text="ketones"/>
            <entity id="DS3.d100.s1.e1" origId="P01308,I3WAC9" charOffset="79-86" type="protein" text="insulin"/>
            <pair e1="DS3.d100.s1.e0" e2="DS3.d100.s1.e1" id="DS3.d100.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d100.s2" origId="993323-3" text="The binding of insulin 125I by 24 X 10(6)IM-9 lymphocyte cells was examined in both the presence and absence of 8 mM beta-OH butyrate.">
            <entity id="DS3.d100.s2.e0" origId="P01308,I3WAC9" charOffset="15-22" type="protein" text="insulin"/>
            <entity id="DS3.d100.s2.e1" origId="264" charOffset="125-133" type="compound" text="butyrate"/>
            <pair e1="DS3.d100.s2.e1" e2="DS3.d100.s2.e0" id="DS3.d100.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d100.s3" origId="993323-5" text="A consistent increase of insulin binding was induced by beta-OH butyrate.">
            <entity id="DS3.d100.s3.e0" origId="P01308,I3WAC9" charOffset="25-32" type="protein" text="insulin"/>
            <entity id="DS3.d100.s3.e1" origId="264" charOffset="64-72" type="compound" text="butyrate"/>
            <pair e1="DS3.d100.s3.e1" e2="DS3.d100.s3.e0" id="DS3.d100.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d101" origId="9933243">
        <sentence id="DS3.d101.s0" origId="9933243-3" text="Orthologues of the DGS candidate gene HIRA are expressed in the neural crest and in neural crest-derived tissues in both chick and mouse embryos.">
            <entity id="DS3.d101.s0.e0" origId="446806" charOffset="19-22" type="compound" text="DGS"/>
            <entity id="DS3.d101.s0.e1" origId="P79987" charOffset="38-42" type="protein" text="HIRA"/>
            <pair e1="DS3.d101.s0.e0" e2="DS3.d101.s0.e1" id="DS3.d101.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d101.s1" origId="9933243-4" text="By exposing a portion of the premigratory chick neural crest to phosphorothioate end-protected antisense oligonucleotides, ex ovo, followed by orthotopic backtransplantation to the untreated embryos, we have shown that the functional attenuation of cHIRA in the chick cardiac neural crest results in a significantly increased incidence of persistent truncus arteriosus, a phenotypic change characteristic of DGS, but does not affect the repatterning aortic arch arteries, the ventricular function, or the alignment of the outflow tract.">
            <entity id="DS3.d101.s1.e0" origId="P79987" charOffset="249-254" type="protein" text="cHIRA"/>
            <entity id="DS3.d101.s1.e1" origId="446806" charOffset="408-411" type="compound" text="DGS"/>
            <pair e1="DS3.d101.s1.e1" e2="DS3.d101.s1.e0" id="DS3.d101.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d102" origId="9933245">
        <sentence id="DS3.d102.s0" origId="9933245-1" text="The minK gene encodes a 129-amino acid peptide the expression of which modulates function of cardiac delayed rectifier currents (IKr and IKs), and mutations in minK are now recognized as one cause of the congenital long-QT syndrome.">
            <entity id="DS3.d102.s0.e0" origId="P23299,Q545H6" charOffset="4-8" type="protein" text="minK"/>
            <entity id="DS3.d102.s0.e1" origId="25229560" charOffset="129-132" type="compound" text="IKr"/>
            <entity id="DS3.d102.s0.e2" origId="P23299,Q545H6" charOffset="160-164" type="protein" text="minK"/>
            <pair e1="DS3.d102.s0.e1" e2="DS3.d102.s0.e0" id="DS3.d102.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d102.s1" origId="9933245-4" text="In minK (-/-) myocytes, IKs is absent and IKr is significantly reduced and its deactivation slowed; these results further support a role for minK in modulating both IKs and IKr.">
            <entity id="DS3.d102.s1.e0" origId="P23299,Q545H6" charOffset="3-7" type="protein" text="minK"/>
            <entity id="DS3.d102.s1.e1" origId="25229560" charOffset="42-45" type="compound" text="IKr"/>
            <entity id="DS3.d102.s1.e2" origId="P23299,Q545H6" charOffset="141-145" type="protein" text="minK"/>
            <entity id="DS3.d102.s1.e3" origId="25229560" charOffset="173-176" type="compound" text="IKr"/>
            <pair e1="DS3.d102.s1.e1" e2="DS3.d102.s1.e0" id="DS3.d102.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d103" origId="9933248">
        <sentence id="DS3.d103.s0" origId="9933248-10" text="Moreover, using high-resolution, colloidal-gold immunocytochemistry, osteopontin was found intimately associated with growing apatite crystals.">
            <entity id="DS3.d103.s0.e0" origId="P31096" charOffset="69-80" type="protein" text="osteopontin"/>
            <entity id="DS3.d103.s0.e1" origId="10207414" charOffset="126-133" type="compound" text="apatite"/>
            <pair e1="DS3.d103.s0.e1" e2="DS3.d103.s0.e0" id="DS3.d103.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d103.s1" origId="9933248-11" text="These data indicate that the effect of osteopontin, although calcium-dependent, was not mediated by simple calcium chelation but most likely by direct interaction of osteopontin with crystal surfaces.">
            <entity id="DS3.d103.s1.e0" origId="P31096" charOffset="39-50" type="protein" text="osteopontin"/>
            <entity id="DS3.d103.s1.e1" origId="22044544,5460341" charOffset="61-68" type="compound" text="calcium"/>
            <entity id="DS3.d103.s1.e2" origId="22044544,5460341" charOffset="107-114" type="compound" text="calcium"/>
            <entity id="DS3.d103.s1.e3" origId="P31096" charOffset="166-177" type="protein" text="osteopontin"/>
            <pair e1="DS3.d103.s1.e1" e2="DS3.d103.s1.e0" id="DS3.d103.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d103.s2" origId="9933248-8" text="In contrast to the inhibitory mechanism of levamisole on mineral deposition, osteopontin did not inhibit alkaline phosphatase activity or reduce phosphorus levels in the culture medium.">
            <entity id="DS3.d103.s2.e0" origId="26879" charOffset="43-53" type="compound" text="levamisole"/>
            <entity id="DS3.d103.s2.e1" origId="P31096" charOffset="77-88" type="protein" text="osteopontin"/>
            <pair e1="DS3.d103.s2.e0" e2="DS3.d103.s2.e1" id="DS3.d103.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d103.s3" origId="9933248-9" text="Addition of calcium to the cultures overcame the inhibitory effect of osteopontin on BASMC culture calcification and resulted in decreased levels of calcium in the culture medium and increased levels in the cell layer.">
            <entity id="DS3.d103.s3.e0" origId="22044544,5460341" charOffset="12-19" type="compound" text="calcium"/>
            <entity id="DS3.d103.s3.e1" origId="P31096" charOffset="70-81" type="protein" text="osteopontin"/>
            <entity id="DS3.d103.s3.e2" origId="22044544,5460341" charOffset="149-156" type="compound" text="calcium"/>
            <pair e1="DS3.d103.s3.e0" e2="DS3.d103.s3.e1" id="DS3.d103.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d104" origId="9933249">
        <sentence id="DS3.d104.s0" origId="9933249-9" text="Moreover, treatment with the selective AT1 antagonist CV-11974 before injury significantly decreased the formation of neointima in only WT mice, whereas treatment with the selective AT2 antagonist PD-123319 before injury had no effects in both animal groups.">
            <entity id="DS3.d104.s0.e0" origId="Q8BMT0,O08801" charOffset="182-185" type="protein" text="AT2"/>
            <entity id="DS3.d104.s0.e1" origId="5311345" charOffset="197-206" type="compound" text="PD-123319"/>
            <pair e1="DS3.d104.s0.e1" e2="DS3.d104.s0.e0" id="DS3.d104.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d105" origId="9933250">
        <sentence id="DS3.d105.s0" origId="9933250-0" text="Nitric oxide/cAMP interactions in the control of rat renal vascular resistance.">
            <entity id="DS3.d105.s0.e0" origId="145068" charOffset="0-12" type="compound" text="Nitric oxide"/>
            <entity id="DS3.d105.s0.e1" origId="G3V8S9" charOffset="13-17" type="protein" text="cAMP"/>
            <pair e1="DS3.d105.s0.e0" e2="DS3.d105.s0.e1" id="DS3.d105.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d105.s1" origId="9933250-1" text="This study aimed to characterize the interaction between nitric oxide (NO)- and cAMP-related pathways in the control of renal blood flow.">
            <entity id="DS3.d105.s1.e0" origId="145068" charOffset="57-69" type="compound" text="nitric oxide"/>
            <entity id="DS3.d105.s1.e1" origId="G3V8S9" charOffset="80-84" type="protein" text="cAMP"/>
            <pair e1="DS3.d105.s1.e0" e2="DS3.d105.s1.e1" id="DS3.d105.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d105.s2" origId="9933250-2" text="Using the isolated perfused rat kidney model, we determined the effects of inhibition of NO formation by Nomega-nitro-L-arginine methyl ester (L-NAME; 1 mmol/L) and of NO administration by sodium nitroprusside (SNP, 10 micromol/L) on renal vascular resistance under conditions of elevated vascular cAMP levels.">
            <entity id="DS3.d105.s2.e0" origId="440005" charOffset="105-128" type="compound" text="Nomega-nitro-L-arginine"/>
            <entity id="DS3.d105.s2.e1" origId="13468584" charOffset="129-141" type="compound" text="methyl ester"/>
            <entity id="DS3.d105.s2.e2" origId="5360545" charOffset="189-195" type="compound" text="sodium"/>
            <entity id="DS3.d105.s2.e3" origId="11963622" charOffset="196-209" type="compound" text="nitroprusside"/>
            <entity id="DS3.d105.s2.e4" origId="G3V8S9" charOffset="298-302" type="protein" text="cAMP"/>
            <pair e1="DS3.d105.s2.e1" e2="DS3.d105.s2.e4" id="DS3.d105.s2.i0" interaction="False" />
            <pair e1="DS3.d105.s2.e0" e2="DS3.d105.s2.e4" id="DS3.d105.s2.i1" interaction="False" />
            <pair e1="DS3.d105.s2.e3" e2="DS3.d105.s2.e4" id="DS3.d105.s2.i2" interaction="False" />
            <pair e1="DS3.d105.s2.e2" e2="DS3.d105.s2.e4" id="DS3.d105.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d105.s3" origId="9933250-3" text="cAMP levels were increased either by adenylate cyclase activation via isoproterenol or by inhibition of cAMP phosphodiesterases (PDEs) 1, 3, and 4.">
            <entity id="DS3.d105.s3.e0" origId="G3V8S9" charOffset="0-4" type="protein" text="cAMP"/>
            <entity id="DS3.d105.s3.e1" origId="6083" charOffset="37-46" type="compound" text="adenylate"/>
            <entity id="DS3.d105.s3.e2" origId="3779" charOffset="70-83" type="compound" text="isoproterenol"/>
            <entity id="DS3.d105.s3.e3" origId="G3V8S9" charOffset="104-108" type="protein" text="cAMP"/>
            <pair e1="DS3.d105.s3.e2" e2="DS3.d105.s3.e0" id="DS3.d105.s3.i0" interaction="False" />
            <pair e1="DS3.d105.s3.e1" e2="DS3.d105.s3.e0" id="DS3.d105.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d105.s4" origId="9933250-5" text="Both isoproterenol and inhibitors of the cAMP PDEs lowered basal vascular resistance.">
            <entity id="DS3.d105.s4.e0" origId="3779" charOffset="5-18" type="compound" text="isoproterenol"/>
            <entity id="DS3.d105.s4.e1" origId="G3V8S9" charOffset="41-45" type="protein" text="cAMP"/>
            <pair e1="DS3.d105.s4.e0" e2="DS3.d105.s4.e1" id="DS3.d105.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d105.s5" origId="9933250-8" text="Because PDE-3 is a cGMP-inhibited cAMP PDE and because the vasodilatory effect of SNP was abrogated by the guanylate cyclase inhibitor 1H-(1,2,4)oxadiazolo-(4,3-a)quinoxalin-1-one (ODQ) (20 micromol/L), our findings are compatible with the idea that an action of NO on PDE-3 could account for the vasodilatory properties of NO on the renal vasculature.">
            <entity id="DS3.d105.s5.e0" origId="G3V8S9" charOffset="34-38" type="protein" text="cAMP"/>
            <entity id="DS3.d105.s5.e1" origId="10197612" charOffset="145-155" type="compound" text="oxadiazolo"/>
            <pair e1="DS3.d105.s5.e1" e2="DS3.d105.s5.e0" id="DS3.d105.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d106" origId="9933251">
        <sentence id="DS3.d106.s0" origId="9933251-7" text="DEX alone (10(-8) mol/L for 48 hours) caused a 93% fall in basal PGI2 production, and bradykinin- and A23187-stimulated PGI2 were diminished 96% and 94%, respectively.">
            <entity id="DS3.d106.s0.e0" origId="5280427,5353608" charOffset="65-69" type="compound" text="PGI2"/>
            <entity id="DS3.d106.s0.e1" origId="P01042" charOffset="86-96" type="protein" text="bradykinin"/>
            <entity id="DS3.d106.s0.e2" origId="40486" charOffset="102-108" type="compound" text="A23187"/>
            <entity id="DS3.d106.s0.e3" origId="5280427,5353608" charOffset="120-124" type="compound" text="PGI2"/>
            <pair e1="DS3.d106.s0.e2" e2="DS3.d106.s0.e1" id="DS3.d106.s0.i0" interaction="False" />
            <pair e1="DS3.d106.s0.e0" e2="DS3.d106.s0.e1" id="DS3.d106.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d106.s1" origId="9933251-9" text="The glucocorticoid receptor (GR) antagonist mifepristone (RU-486; 10(-6) mol/L) blocked the inhibitory effect of DEX, and GR expression was evident by immunoblot analysis.">
            <entity id="DS3.d106.s1.e0" origId="P04150,E5KQF5,E5KQF6,F1D8N4,B7Z7I2" charOffset="4-27" type="protein" text="glucocorticoid receptor"/>
            <entity id="DS3.d106.s1.e1" origId="55245" charOffset="58-64" type="compound" text="RU-486"/>
            <pair e1="DS3.d106.s1.e1" e2="DS3.d106.s1.e0" id="DS3.d106.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d107" origId="9933255">
        <sentence id="DS3.d107.s0" origId="9933255-1" text="The goal of this study was to test the hypothesis that antioxidant estrogens, by a mechanism independent of the estrogen receptor, protect phospholipids residing in the plasma membrane of vascular smooth muscle cells from peroxidation and peroxidation-induced cell growth and migration.">
            <entity id="DS3.d107.s0.e0" origId="3001028" charOffset="67-76" type="compound" text="estrogens"/>
            <entity id="DS3.d107.s0.e1" origId="P06211,D0FYH4" charOffset="112-129" type="protein" text="estrogen receptor"/>
            <pair e1="DS3.d107.s0.e0" e2="DS3.d107.s0.e1" id="DS3.d107.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d107.s1" origId="9933255-4" text="This effect was attenuated by pretreating cells for 15 minutes with 50 to 5000 ng/mL of 2-hydroxyestradiol (strong antioxidant but weak estrogen-receptor ligand) or 4-hydroxytamoxifen (strong antioxidant and potent estrogen-receptor ligand), but not by estrone or droloxifene (both weak antioxidants but potent estrogen-receptor ligands).">
            <entity id="DS3.d107.s1.e0" origId="247304" charOffset="88-106" type="compound" text="2-hydroxyestradiol"/>
            <entity id="DS3.d107.s1.e1" origId="P06211,D0FYH4" charOffset="136-166" type="protein" text="estrogen-receptor ligand) or 4"/>
            <entity id="DS3.d107.s1.e2" origId="449459" charOffset="167-183" type="compound" text="hydroxytamoxifen"/>
            <entity id="DS3.d107.s1.e3" origId="P06211,D0FYH4" charOffset="136-153" type="protein" text="estrogen-receptor"/>
            <entity id="DS3.d107.s1.e4" origId="5870" charOffset="253-260" type="compound" text="estrone"/>
            <entity id="DS3.d107.s1.e5" origId="3033767" charOffset="264-275" type="compound" text="droloxifene"/>
            <entity id="DS3.d107.s1.e6" origId="P06211,D0FYH4" charOffset="215-232" type="protein" text="estrogen-receptor"/>
            <pair e1="DS3.d107.s1.e5" e2="DS3.d107.s1.e1" id="DS3.d107.s1.i0" interaction="False" />
            <pair e1="DS3.d107.s1.e5" e2="DS3.d107.s1.e3" id="DS3.d107.s1.i1" interaction="False" />
            <pair e1="DS3.d107.s1.e0" e2="DS3.d107.s1.e1" id="DS3.d107.s1.i2" interaction="False" />
            <pair e1="DS3.d107.s1.e0" e2="DS3.d107.s1.e3" id="DS3.d107.s1.i3" interaction="False" />
            <pair e1="DS3.d107.s1.e4" e2="DS3.d107.s1.e1" id="DS3.d107.s1.i4" interaction="False" />
            <pair e1="DS3.d107.s1.e4" e2="DS3.d107.s1.e3" id="DS3.d107.s1.i5" interaction="False" />
            <pair e1="DS3.d107.s1.e2" e2="DS3.d107.s1.e1" id="DS3.d107.s1.i6" interaction="False" />
            <pair e1="DS3.d107.s1.e2" e2="DS3.d107.s1.e3" id="DS3.d107.s1.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d107.s2" origId="9933255-8" text="These studies demonstrate in vascular smooth muscle cells that antioxidant estrogens via a non-estrogen receptor-dependent mechanism attenuate peroxidation of membrane phospholipids and peroxidation-induced cell growth and migration.">
            <entity id="DS3.d107.s2.e0" origId="3001028" charOffset="75-84" type="compound" text="estrogens"/>
            <entity id="DS3.d107.s2.e1" origId="P06211,D0FYH4" charOffset="95-112" type="protein" text="estrogen receptor"/>
            <pair e1="DS3.d107.s2.e0" e2="DS3.d107.s2.e1" id="DS3.d107.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d108" origId="9933264">
        <sentence id="DS3.d108.s0" origId="9933264-0" text="Concentration changes of malondialdehyde across the cerebral vascular bed and shedding of L-selectin during carotid endarterectomy.">
            <entity id="DS3.d108.s0.e0" origId="10964" charOffset="25-40" type="compound" text="malondialdehyde"/>
            <entity id="DS3.d108.s0.e1" origId="P14151,A0A024R8Z0" charOffset="90-100" type="protein" text="L-selectin"/>
            <pair e1="DS3.d108.s0.e0" e2="DS3.d108.s0.e1" id="DS3.d108.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d108.s1" origId="9933264-3" text="METHODS: In 25 patients undergoing carotid endarterectomy, jugular venous-arterial concentration differences of brain metabolites, malondialdehyde, plasma total antioxidant status, and soluble P-selectin and L-selectin were measured.">
            <entity id="DS3.d108.s1.e0" origId="10964" charOffset="131-146" type="compound" text="malondialdehyde"/>
            <entity id="DS3.d108.s1.e1" origId="P16109,Q5R341,A0A024R8Y9,Q6NUL9" charOffset="193-203" type="protein" text="P-selectin"/>
            <entity id="DS3.d108.s1.e2" origId="P14151,A0A024R8Z0" charOffset="208-218" type="protein" text="L-selectin"/>
            <pair e1="DS3.d108.s1.e0" e2="DS3.d108.s1.e2" id="DS3.d108.s1.i0" interaction="False" />
            <pair e1="DS3.d108.s1.e0" e2="DS3.d108.s1.e1" id="DS3.d108.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d108.s2" origId="9933264-7" text="While jugular venous-arterial concentration differences of soluble P-selectin showed changes similar to those of malondialdehyde, the concentration difference for soluble L-selectin was enhanced exclusively at 15 minutes after reperfusion.">
            <entity id="DS3.d108.s2.e0" origId="P16109,Q5R341,A0A024R8Y9,Q6NUL9" charOffset="67-77" type="protein" text="P-selectin"/>
            <entity id="DS3.d108.s2.e1" origId="10964" charOffset="113-128" type="compound" text="malondialdehyde"/>
            <entity id="DS3.d108.s2.e2" origId="P14151,A0A024R8Z0" charOffset="171-181" type="protein" text="L-selectin"/>
            <pair e1="DS3.d108.s2.e1" e2="DS3.d108.s2.e2" id="DS3.d108.s2.i0" interaction="False" />
            <pair e1="DS3.d108.s2.e1" e2="DS3.d108.s2.e0" id="DS3.d108.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d109" origId="9933267">
        <sentence id="DS3.d109.s0" origId="9933267-4" text="METHODS: Thirty stroke patients were studied prospectively on days 0 to 4, 7 to 9, 21 to 26, and after day 90 with clinical evaluation, radiological assessment, and analysis of cerebrospinal fluid (CSF) levels of soluble (s) Fas/APO-1 and sbcl-2, 2 proteins that regulate apoptosis.">
            <entity id="DS3.d109.s0.e0" origId="16122568,16750043,4369303,448383" charOffset="198-201" type="compound" text="CSF"/>
            <entity id="DS3.d109.s0.e1" origId="P25445,Q59FU8" charOffset="229-234" type="protein" text="APO-1"/>
            <pair e1="DS3.d109.s0.e0" e2="DS3.d109.s0.e1" id="DS3.d109.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d109.s1" origId="9933267-7" text="The patients were examined with MRI 1 to 3 months after stroke onset for measurement of infarct volume RESULTS: Significantly decreased CSF levels of sFas/APO-1 were observed during the entire observation period, with a maximal decrease on day 21 after the onset of stroke.">
            <entity id="DS3.d109.s1.e0" origId="Q9BV20" charOffset="32-37" type="protein" text="MRI 1"/>
            <entity id="DS3.d109.s1.e1" origId="16122568,16750043,4369303,448383" charOffset="136-139" type="compound" text="CSF"/>
            <entity id="DS3.d109.s1.e2" origId="P25445,Q59FU8" charOffset="155-160" type="protein" text="APO-1"/>
            <pair e1="DS3.d109.s1.e1" e2="DS3.d109.s1.e2" id="DS3.d109.s1.i0" interaction="False" />
            <pair e1="DS3.d109.s1.e1" e2="DS3.d109.s1.e0" id="DS3.d109.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d110" origId="9933268">
        <sentence id="DS3.d110.s0" origId="9933268-6" text="Total cholesterol, insulin, and Leptin were analyzed in stored samples.">
            <entity id="DS3.d110.s0.e0" origId="5997" charOffset="6-17" type="compound" text="cholesterol"/>
            <entity id="DS3.d110.s0.e1" origId="P41159,A4D0Y8" charOffset="32-38" type="protein" text="Leptin"/>
            <pair e1="DS3.d110.s0.e0" e2="DS3.d110.s0.e1" id="DS3.d110.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d111" origId="9933282">
        <sentence id="DS3.d111.s0" origId="9933282-10" text="CONCLUSIONS: It was thus demonstrated that the gene transfer of human PGIS expression-vector into rat carotid arteries resulted in the increased production of human PGI2 in the vascular wall, the expression of human PGIS in the developing neointima and significantly inhibited the neointimal formation generated after balloon injury.">
            <entity id="DS3.d111.s0.e0" origId="Q16647" charOffset="70-74" type="protein" text="PGIS"/>
            <entity id="DS3.d111.s0.e1" origId="5280427,5353608,6434194" charOffset="165-169" type="compound" text="PGI2"/>
            <entity id="DS3.d111.s0.e2" origId="Q16647" charOffset="216-220" type="protein" text="PGIS"/>
            <pair e1="DS3.d111.s0.e1" e2="DS3.d111.s0.e0" id="DS3.d111.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d111.s1" origId="9933282-2" text="A growth inhibitory property of overexpressed prostacyclin (PGI2) synthase (PGIS) was recently implicated in the pathological proliferation of vascular smooth muscle cells (VSMC) in vitro.">
            <entity id="DS3.d111.s1.e0" origId="5282411" charOffset="46-58" type="compound" text="prostacyclin"/>
            <entity id="DS3.d111.s1.e1" origId="5280427,5353608,6434194" charOffset="60-64" type="compound" text="PGI2"/>
            <entity id="DS3.d111.s1.e2" origId="Q16647" charOffset="76-80" type="protein" text="PGIS"/>
            <pair e1="DS3.d111.s1.e0" e2="DS3.d111.s1.e2" id="DS3.d111.s1.i0" interaction="False" />
            <pair e1="DS3.d111.s1.e1" e2="DS3.d111.s1.e2" id="DS3.d111.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d111.s2" origId="9933282-6" text="The level of 6-keto PGF1alpha, a stable hydrolyzed metabolite of PGI2, the histological distribution of the immunoreactivity for human PGIS and the ratio of neointimal/medial area were analyzed.">
            <entity id="DS3.d111.s2.e0" origId="5280939" charOffset="20-29" type="compound" text="PGF1alpha"/>
            <entity id="DS3.d111.s2.e1" origId="5280427,5353608,6434194" charOffset="65-69" type="compound" text="PGI2"/>
            <entity id="DS3.d111.s2.e2" origId="Q16647" charOffset="135-139" type="protein" text="PGIS"/>
            <pair e1="DS3.d111.s2.e1" e2="DS3.d111.s2.e2" id="DS3.d111.s2.i0" interaction="False" />
            <pair e1="DS3.d111.s2.e0" e2="DS3.d111.s2.e2" id="DS3.d111.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d111.s3" origId="9933282-7" text="RESULTS: In the analyses of 6-keto PGF1alpha, the level in the carotid arteries was significantly elevated 3 days after PGIS expression-vector transfection compared with that in the arteries after vehicle transfection.">
            <entity id="DS3.d111.s3.e0" origId="5280939" charOffset="35-44" type="compound" text="PGF1alpha"/>
            <entity id="DS3.d111.s3.e1" origId="Q16647" charOffset="120-124" type="protein" text="PGIS"/>
            <pair e1="DS3.d111.s3.e0" e2="DS3.d111.s3.e1" id="DS3.d111.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d112" origId="9933283">
        <sentence id="DS3.d112.s0" origId="9933283-0" text="Synergistic effects of a combination of low-dose basic fibroblast growth factor and citicoline after temporary experimental focal ischemia.">
            <entity id="DS3.d112.s0.e0" origId="P09038" charOffset="49-79" type="protein" text="basic fibroblast growth factor"/>
            <entity id="DS3.d112.s0.e1" origId="13805" charOffset="84-94" type="compound" text="citicoline"/>
            <pair e1="DS3.d112.s0.e1" e2="DS3.d112.s0.e0" id="DS3.d112.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d112.s1" origId="9933283-11" text="5+/-25.4 mm3) versus placebo (172.6+/-48.9 mm3; P=0.036, Fisher test), versus citicoline alone (186.0+/-35.7 mm3; P=0.005, Fisher test), and versus bFGF alone (176.0+/-49.2 mm3; P=0.023, Fisher test).">
            <entity id="DS3.d112.s1.e0" origId="13805" charOffset="78-88" type="compound" text="citicoline"/>
            <entity id="DS3.d112.s1.e1" origId="P09038" charOffset="148-152" type="protein" text="bFGF"/>
            <pair e1="DS3.d112.s1.e0" e2="DS3.d112.s1.e1" id="DS3.d112.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d112.s2" origId="9933283-12" text="CONCLUSIONS: These results demonstrate synergistic effects of a low-dose combination of the growth factor bFGF and citicoline after temporary experimental focal cerebral ischemia and furthermore support the effectiveness of a combination treatment regimen for the management of acute stroke.">
            <entity id="DS3.d112.s2.e0" origId="P09038" charOffset="106-110" type="protein" text="bFGF"/>
            <entity id="DS3.d112.s2.e1" origId="13805" charOffset="115-125" type="compound" text="citicoline"/>
            <pair e1="DS3.d112.s2.e1" e2="DS3.d112.s2.e0" id="DS3.d112.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d112.s3" origId="9933283-1" text="BACKGROUND AND PURPOSE: basic fibroblast growth factor (bFGF) and citicoline (cytidine 5'-diphosphate choline, an endogenous compound that stabilizes membrane function) have demonstrated neuroprotective effects after focal cerebral ischemia.">
            <entity id="DS3.d112.s3.e0" origId="P09038" charOffset="24-54" type="protein" text="basic fibroblast growth factor"/>
            <entity id="DS3.d112.s3.e1" origId="P09038" charOffset="56-60" type="protein" text="bFGF"/>
            <entity id="DS3.d112.s3.e2" origId="13805" charOffset="66-76" type="compound" text="citicoline"/>
            <entity id="DS3.d112.s3.e3" origId="6175" charOffset="78-86" type="compound" text="cytidine"/>
            <entity id="DS3.d112.s3.e4" origId="13292816" charOffset="90-109" type="compound" text="diphosphate choline"/>
            <pair e1="DS3.d112.s3.e2" e2="DS3.d112.s3.e0" id="DS3.d112.s3.i0" interaction="False" />
            <pair e1="DS3.d112.s3.e2" e2="DS3.d112.s3.e1" id="DS3.d112.s3.i1" interaction="False" />
            <pair e1="DS3.d112.s3.e4" e2="DS3.d112.s3.e0" id="DS3.d112.s3.i2" interaction="False" />
            <pair e1="DS3.d112.s3.e4" e2="DS3.d112.s3.e1" id="DS3.d112.s3.i3" interaction="False" />
            <pair e1="DS3.d112.s3.e3" e2="DS3.d112.s3.e0" id="DS3.d112.s3.i4" interaction="False" />
            <pair e1="DS3.d112.s3.e3" e2="DS3.d112.s3.e1" id="DS3.d112.s3.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d112.s4" origId="9933283-3" text="For evaluation of synergistic effects of bFGF and citicoline, a low-dose combination of both compounds was tested against each compound alone and placebo.">
            <entity id="DS3.d112.s4.e0" origId="P09038" charOffset="41-45" type="protein" text="bFGF"/>
            <entity id="DS3.d112.s4.e1" origId="13805" charOffset="50-60" type="compound" text="citicoline"/>
            <pair e1="DS3.d112.s4.e1" e2="DS3.d112.s4.e0" id="DS3.d112.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d112.s5" origId="9933283-5" text="Animals were randomly and blindly assigned to one of the following treatment groups: placebo, low-dose citicoline (250 mg/kg IP daily for 4 days), low-dose bFGF (10 microg/kg per hour IV for 3 hours), and the combination of both (250 mg/kg citicoline and 10 microg/kg per hour bFGF).">
            <entity id="DS3.d112.s5.e0" origId="13805" charOffset="103-113" type="compound" text="citicoline"/>
            <entity id="DS3.d112.s5.e1" origId="P09038" charOffset="156-160" type="protein" text="bFGF"/>
            <entity id="DS3.d112.s5.e2" origId="13805" charOffset="240-250" type="compound" text="citicoline"/>
            <entity id="DS3.d112.s5.e3" origId="P09038" charOffset="277-281" type="protein" text="bFGF"/>
            <pair e1="DS3.d112.s5.e0" e2="DS3.d112.s5.e1" id="DS3.d112.s5.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d112.s6" origId="9933283-8" text="RESULTS: The premature mortality rate was 41.7% in the placebo and citicoline groups, 33.3% in the bFGF group, and 25% (P=NS) in the combination group.">
            <entity id="DS3.d112.s6.e0" origId="13805" charOffset="67-77" type="compound" text="citicoline"/>
            <entity id="DS3.d112.s6.e1" origId="P09038" charOffset="99-103" type="protein" text="bFGF"/>
            <pair e1="DS3.d112.s6.e0" e2="DS3.d112.s6.e1" id="DS3.d112.s6.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d112.s7" origId="9933283-9" text="The mean neurological score on day 4 was 3.1+/-1.6 (placebo), 3.1+/-1.6 (citicoline), 2.9+/-1.5 (bFGF), and 2.4+/-1.4 (combination) (P=NS).">
            <entity id="DS3.d112.s7.e0" origId="13805" charOffset="73-83" type="compound" text="citicoline"/>
            <entity id="DS3.d112.s7.e1" origId="P09038" charOffset="97-101" type="protein" text="bFGF"/>
            <pair e1="DS3.d112.s7.e0" e2="DS3.d112.s7.e1" id="DS3.d112.s7.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d113" origId="9933297">
        <sentence id="DS3.d113.s0" origId="9933297-3" text="The expected associations of multiple sclerosis with the DR15 (p=8.7E-18), DQ6 (p=2.0E-09) and DR51 (p=2.8E-16) phenotypes were confirmed, and excess transmission of the DRB1*1501 and DQB1*0602 alleles was demonstrated.">
            <entity id="DS3.d113.s0.e0" origId="57325589" charOffset="75-78" type="compound" text="DQ6"/>
            <entity id="DS3.d113.s0.e1" origId="P01912,P01911,Q29974,D7RIH8,Q5Y7D1,X5DNQ0" charOffset="170-174" type="protein" text="DRB1"/>
            <entity id="DS3.d113.s0.e2" origId="P01920,Q5Y7A9,Q5SU54,Q5Y7D6,Q5Y7D3" charOffset="184-188" type="protein" text="DQB1"/>
            <pair e1="DS3.d113.s0.e0" e2="DS3.d113.s0.e2" id="DS3.d113.s0.i0" interaction="False" />
            <pair e1="DS3.d113.s0.e0" e2="DS3.d113.s0.e1" id="DS3.d113.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d114" origId="9933407">
        <sentence id="DS3.d114.s0" origId="9933407-7" text="There was a small but significant difference between the labeling pattern obtained with an anti-SCP3 serum and the pattern obtained with either of the two antisera against fragments of SCP2; although for all three antisera the peak of the immunogold label coincided with the center of the LE, the distributions of label obtained with the antisera against fragments of SCP2 were asymmetrical, with a shoulder at the inner side of the LE, whereas the distribution of label obtained with anti-SCP3 serum was symmetrical.">
            <entity id="DS3.d114.s0.e0" origId="Q63520,F1M9G5" charOffset="96-100" type="protein" text="SCP3"/>
            <entity id="DS3.d114.s0.e1" origId="P11915" charOffset="185-189" type="protein" text="SCP2"/>
            <entity id="DS3.d114.s0.e2" origId="7009630" charOffset="289-291" type="compound" text="LE"/>
            <entity id="DS3.d114.s0.e3" origId="P11915" charOffset="368-372" type="protein" text="SCP2"/>
            <entity id="DS3.d114.s0.e4" origId="7009630" charOffset="433-435" type="compound" text="LE"/>
            <entity id="DS3.d114.s0.e5" origId="Q63520,F1M9G5" charOffset="490-494" type="protein" text="SCP3"/>
            <pair e1="DS3.d114.s0.e2" e2="DS3.d114.s0.e1" id="DS3.d114.s0.i0" interaction="False" />
            <pair e1="DS3.d114.s0.e2" e2="DS3.d114.s0.e0" id="DS3.d114.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d114.s1" origId="9933407-9" text="It is possible that labeling of these fuzzy bridges caused the shoulder in the gold label distributions obtained with anti-SCP2 antibodies.">
            <entity id="DS3.d114.s1.e0" origId="23985" charOffset="79-83" type="compound" text="gold"/>
            <entity id="DS3.d114.s1.e1" origId="P11915" charOffset="123-127" type="protein" text="SCP2"/>
            <pair e1="DS3.d114.s1.e0" e2="DS3.d114.s1.e1" id="DS3.d114.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d115" origId="9933431">
        <sentence id="DS3.d115.s0" origId="9933431-1" text="CD8 deficiency is a rare primary immunodeficiency caused by the defect of a tyrosine kinase, ZAP-70, which transduces signals from the T cell receptor.">
            <entity id="DS3.d115.s0.e0" origId="6057,90983769" charOffset="76-84" type="compound" text="tyrosine"/>
            <entity id="DS3.d115.s0.e1" origId="P43403" charOffset="93-99" type="protein" text="ZAP-70"/>
            <pair e1="DS3.d115.s0.e0" e2="DS3.d115.s0.e1" id="DS3.d115.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d116" origId="9933433">
        <sentence id="DS3.d116.s0" origId="9933433-6" text="Furthermore, pooled serum obtained after IVIG infusion suppressed lipopolysaccharide- and staphylococcal enterotoxin B-stimulated, but not phorbol myristate acetate-stimulated, release of IL-1alpha and IL-1beta from PBMC isolated from healthy controls.">
            <entity id="DS3.d116.s0.e0" origId="11970143" charOffset="66-84" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d116.s0.e1" origId="22833501,27924,4792" charOffset="139-164" type="compound" text="phorbol myristate acetate"/>
            <entity id="DS3.d116.s0.e2" origId="P01583" charOffset="188-197" type="protein" text="IL-1alpha"/>
            <entity id="DS3.d116.s0.e3" origId="P01584" charOffset="202-210" type="protein" text="IL-1beta"/>
            <pair e1="DS3.d116.s0.e1" e2="DS3.d116.s0.e3" id="DS3.d116.s0.i0" interaction="False" />
            <pair e1="DS3.d116.s0.e1" e2="DS3.d116.s0.e2" id="DS3.d116.s0.i1" interaction="False" />
            <pair e1="DS3.d116.s0.e0" e2="DS3.d116.s0.e3" id="DS3.d116.s0.i2" interaction="False" />
            <pair e1="DS3.d116.s0.e0" e2="DS3.d116.s0.e2" id="DS3.d116.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d117" origId="9933434">
        <sentence id="DS3.d117.s0" origId="9933434-1" text="Based on the positive therapeutic results with ursodeoxycholic acid (UDCA) in patients with primary biliary cirrhosis, in whom we observed a clinical improvement in conjunction with the normalization of the low pretreatment dipeptidyl peptidase (DPIV, CD26) expression of peripheral blood lymphocytes (PBL), we hypothesized that the very low DPIV expression in AIDS patients could be positively influenced by UDCA.">
            <entity id="DS3.d117.s0.e0" origId="31401" charOffset="47-67" type="compound" text="ursodeoxycholic acid"/>
            <entity id="DS3.d117.s0.e1" origId="P27487" charOffset="252-256" type="protein" text="CD26"/>
            <pair e1="DS3.d117.s0.e0" e2="DS3.d117.s0.e1" id="DS3.d117.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d118" origId="9933435">
        <sentence id="DS3.d118.s0" origId="9933435-3" text="Lymphoproliferation following phytohaemagglutinin (PHA) stimulation was studied by thymidine incorporation, and production of IL-2, interferon-gamma (IFN-gamma) and IL-4 was assessed by ELISA in 12 patients receiving ritonavir and seven receiving placebo in the context of randomized, blinded clinical trials.">
            <entity id="DS3.d118.s0.e0" origId="5789" charOffset="83-92" type="compound" text="thymidine"/>
            <entity id="DS3.d118.s0.e1" origId="P60568,Q0GK43" charOffset="126-130" type="protein" text="IL-2"/>
            <entity id="DS3.d118.s0.e2" origId="P01579" charOffset="132-148" type="protein" text="interferon-gamma"/>
            <entity id="DS3.d118.s0.e3" origId="P01579" charOffset="150-159" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d118.s0.e4" origId="P05112,D4HNR6,Q5FC01" charOffset="165-169" type="protein" text="IL-4"/>
            <entity id="DS3.d118.s0.e5" origId="392622" charOffset="217-226" type="compound" text="ritonavir"/>
            <pair e1="DS3.d118.s0.e5" e2="DS3.d118.s0.e3" id="DS3.d118.s0.i0" interaction="False" />
            <pair e1="DS3.d118.s0.e5" e2="DS3.d118.s0.e4" id="DS3.d118.s0.i1" interaction="False" />
            <pair e1="DS3.d118.s0.e5" e2="DS3.d118.s0.e2" id="DS3.d118.s0.i2" interaction="False" />
            <pair e1="DS3.d118.s0.e5" e2="DS3.d118.s0.e1" id="DS3.d118.s0.i3" interaction="False" />
            <pair e1="DS3.d118.s0.e0" e2="DS3.d118.s0.e3" id="DS3.d118.s0.i4" interaction="False" />
            <pair e1="DS3.d118.s0.e0" e2="DS3.d118.s0.e4" id="DS3.d118.s0.i5" interaction="False" />
            <pair e1="DS3.d118.s0.e0" e2="DS3.d118.s0.e2" id="DS3.d118.s0.i6" interaction="False" />
            <pair e1="DS3.d118.s0.e0" e2="DS3.d118.s0.e1" id="DS3.d118.s0.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d119" origId="9933438">
        <sentence id="DS3.d119.s0" origId="9933438-3" text="The IgVH genes of the B cell hybridomas belonged to the VH3 family (DP42; DP47, n = 2; DP53), the VH1 family (DP75), the VH4 family (DP71) and the VH5 family (DP73); 7/7 IgVH genes showed somatic mutations, the R/S ratio (CDR) was &amp;gt; 3 in 4/7 IgVH genes and the mean R/S ratio of all IgVH genes was 9.3 (CDR) and 1.0 (FR), suggesting an antigen-dependent selection.">
            <entity id="DS3.d119.s0.e0" origId="53313335" charOffset="98-101" type="compound" text="VH1"/>
            <entity id="DS3.d119.s0.e1" origId="P51861" charOffset="222-225" type="protein" text="CDR"/>
            <entity id="DS3.d119.s0.e2" origId="P51861" charOffset="306-309" type="protein" text="CDR"/>
            <pair e1="DS3.d119.s0.e0" e2="DS3.d119.s0.e1" id="DS3.d119.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d120" origId="9933441">
        <sentence id="DS3.d120.s0" origId="9933441-2" text="Basal and mitogen-stimulated (lipopolysaccharide and phytohaemagglutinin (LPS + PHA)) cytokine production was determined in a whole blood assay (WBA).">
            <entity id="DS3.d120.s0.e0" origId="11970143" charOffset="30-48" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d120.s0.e1" origId="O14896,G0Z349" charOffset="74-77" type="protein" text="LPS"/>
            <entity id="DS3.d120.s0.e2" origId="Q14739" charOffset="80-83" type="protein" text="PHA"/>
            <pair e1="DS3.d120.s0.e0" e2="DS3.d120.s0.e2" id="DS3.d120.s0.i0" interaction="False" />
            <pair e1="DS3.d120.s0.e0" e2="DS3.d120.s0.e1" id="DS3.d120.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d121" origId="9933443">
        <sentence id="DS3.d121.s0" origId="9933443-1" text="The aim of this study was to investigate the production of anti-Ro/SS-A antibodies in labial salivary glands (LSG) and peripheral blood (PB) of Sjgren's syndrome (SS) patients.">
            <entity id="DS3.d121.s0.e0" origId="P19474" charOffset="64-71" type="protein" text="Ro/SS-A"/>
            <entity id="DS3.d121.s0.e1" origId="24784164" charOffset="110-113" type="compound" text="LSG"/>
            <pair e1="DS3.d121.s0.e1" e2="DS3.d121.s0.e0" id="DS3.d121.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d121.s1" origId="9933443-2" text="The ELISPOT method was performed to quantify the frequency of LSG lymphocytes and PB lymphocytes spontaneously secreting anti-Ro/SS-A antibodies.">
            <entity id="DS3.d121.s1.e0" origId="24784164" charOffset="62-65" type="compound" text="LSG"/>
            <entity id="DS3.d121.s1.e1" origId="P19474" charOffset="126-133" type="protein" text="Ro/SS-A"/>
            <pair e1="DS3.d121.s1.e0" e2="DS3.d121.s1.e1" id="DS3.d121.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d121.s2" origId="9933443-6" text="The six patients who had IgG antibodies against the Ro/SS-A antigen in LSG all had focus scores of &amp;gt;/= 7 in biopsies of LSG.">
            <entity id="DS3.d121.s2.e0" origId="P19474" charOffset="52-59" type="protein" text="Ro/SS-A"/>
            <entity id="DS3.d121.s2.e1" origId="24784164" charOffset="71-74" type="compound" text="LSG"/>
            <entity id="DS3.d121.s2.e2" origId="24784164" charOffset="123-126" type="compound" text="LSG"/>
            <pair e1="DS3.d121.s2.e1" e2="DS3.d121.s2.e0" id="DS3.d121.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d121.s3" origId="9933443-7" text="The results indicate that SS patients with a high degree of local inflammation in LSG have B cells producing anti-Ro/SS-A antibodies in both LSG and PB.">
            <entity id="DS3.d121.s3.e0" origId="24784164" charOffset="82-85" type="compound" text="LSG"/>
            <entity id="DS3.d121.s3.e1" origId="P19474" charOffset="114-121" type="protein" text="Ro/SS-A"/>
            <entity id="DS3.d121.s3.e2" origId="24784164" charOffset="141-144" type="compound" text="LSG"/>
            <pair e1="DS3.d121.s3.e0" e2="DS3.d121.s3.e1" id="DS3.d121.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d122" origId="9933444">
        <sentence id="DS3.d122.s0" origId="9933444-9" text="The results indicate that only SS patients with severe disease and high degree of local inflammation in LSG have B cells producing anti-Ro/SS-A antibodies in PB.">
            <entity id="DS3.d122.s0.e0" origId="24784164" charOffset="104-107" type="compound" text="LSG"/>
            <entity id="DS3.d122.s0.e1" origId="P19474" charOffset="139-143" type="protein" text="SS-A"/>
            <pair e1="DS3.d122.s0.e0" e2="DS3.d122.s0.e1" id="DS3.d122.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d123" origId="9933446">
        <sentence id="DS3.d123.s0" origId="9933446-0" text="Inhibition of murine IgE and immediate cutaneous hypersensitivity responses to ovalbumin by the immunomodulatory agent leflunomide.">
            <entity id="DS3.d123.s0.e0" origId="P12388,Q542A3" charOffset="79-88" type="protein" text="ovalbumin"/>
            <entity id="DS3.d123.s0.e1" origId="3899" charOffset="119-130" type="compound" text="leflunomide"/>
            <pair e1="DS3.d123.s0.e1" e2="DS3.d123.s0.e0" id="DS3.d123.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d123.s1" origId="9933446-11" text="In adoptive transfer experiments leflunomide did not induce tolerance in allergen-reactive Th2 populations, contrary to animal disease models of transplantation and autoimmunity, where leflunomide was shown to induce tolerance in the effector T cell population.">
            <entity id="DS3.d123.s1.e0" origId="3899" charOffset="33-44" type="compound" text="leflunomide"/>
            <entity id="DS3.d123.s1.e1" origId="Q61039" charOffset="91-94" type="protein" text="Th2"/>
            <entity id="DS3.d123.s1.e2" origId="3899" charOffset="185-196" type="compound" text="leflunomide"/>
            <pair e1="DS3.d123.s1.e0" e2="DS3.d123.s1.e1" id="DS3.d123.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d123.s2" origId="9933446-4" text="Mice receiving leflunomide (45 mg/kg) orally at the time of primary immunization with ovalbumin adsorbed to aluminium hydroxide adjuvant, showed a reduction in total serum IgE levels of 95%, 41% and 32% following primary, secondary and tertiary immunizations, respectively (P &amp;lt; 0.05).">
            <entity id="DS3.d123.s2.e0" origId="3899" charOffset="15-26" type="compound" text="leflunomide"/>
            <entity id="DS3.d123.s2.e1" origId="P12388,Q542A3" charOffset="86-95" type="protein" text="ovalbumin"/>
            <entity id="DS3.d123.s2.e2" origId="5359268" charOffset="108-117" type="compound" text="aluminium"/>
            <pair e1="DS3.d123.s2.e0" e2="DS3.d123.s2.e1" id="DS3.d123.s2.i0" interaction="False" />
            <pair e1="DS3.d123.s2.e2" e2="DS3.d123.s2.e1" id="DS3.d123.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d124" origId="9933447">
        <sentence id="DS3.d124.s0" origId="9933447-10" text="These data suggest that NK cell recognition of class I suppresses CR3/tyrosine kinase-dependent cytotoxicity in the same way as it suppresses cytotoxicity mediated by other tyrosine kinase-linked receptors such as FcgammaRIIIA (CD16).">
            <entity id="DS3.d124.s0.e0" origId="6057,90983769" charOffset="70-78" type="compound" text="tyrosine"/>
            <entity id="DS3.d124.s0.e1" origId="6057,90983769" charOffset="173-181" type="compound" text="tyrosine"/>
            <entity id="DS3.d124.s0.e2" origId="P08637,M9MML0" charOffset="214-226" type="protein" text="FcgammaRIIIA"/>
            <entity id="DS3.d124.s0.e3" origId="P08637,M9MML0" charOffset="228-232" type="protein" text="CD16"/>
            <pair e1="DS3.d124.s0.e0" e2="DS3.d124.s0.e3" id="DS3.d124.s0.i0" interaction="False" />
            <pair e1="DS3.d124.s0.e0" e2="DS3.d124.s0.e2" id="DS3.d124.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d124.s1" origId="9933447-5" text="Because CR3 signalling requires several tyrosine phosphorylation events, it appeared possible that CR3-dependent killing of autologous tumour cells might be suppressed by NK cell inhibitory receptors for MHC class I (KIR and CD94/NKG2) whose action involves recruitment of SHP-1 and SHP-2 tyrosine phosphatases.">
            <entity id="DS3.d124.s1.e0" origId="6057,90983769" charOffset="40-48" type="compound" text="tyrosine"/>
            <entity id="DS3.d124.s1.e1" origId="Q13241,Q53ZY6" charOffset="225-229" type="protein" text="CD94"/>
            <entity id="DS3.d124.s1.e2" origId="P26715" charOffset="230-234" type="protein" text="NKG2"/>
            <entity id="DS3.d124.s1.e3" origId="Q15466" charOffset="273-278" type="protein" text="SHP-1"/>
            <entity id="DS3.d124.s1.e4" origId="22805691" charOffset="287-297" type="compound" text="2 tyrosine"/>
            <pair e1="DS3.d124.s1.e4" e2="DS3.d124.s1.e3" id="DS3.d124.s1.i0" interaction="False" />
            <pair e1="DS3.d124.s1.e4" e2="DS3.d124.s1.e1" id="DS3.d124.s1.i1" interaction="False" />
            <pair e1="DS3.d124.s1.e4" e2="DS3.d124.s1.e2" id="DS3.d124.s1.i2" interaction="False" />
            <pair e1="DS3.d124.s1.e0" e2="DS3.d124.s1.e3" id="DS3.d124.s1.i3" interaction="False" />
            <pair e1="DS3.d124.s1.e0" e2="DS3.d124.s1.e1" id="DS3.d124.s1.i4" interaction="False" />
            <pair e1="DS3.d124.s1.e0" e2="DS3.d124.s1.e2" id="DS3.d124.s1.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d125" origId="9933448">
        <sentence id="DS3.d125.s0" origId="9933448-5" text="While sera from CMP patients and healthy individuals displayed comparable IgG reactivity to a variety of human proteins, cardiac myosin represented the prominent antigen detected strongly and preferentially by sera from CMP patients.">
            <entity id="DS3.d125.s0.e0" origId="314,6131" charOffset="16-19" type="compound" text="CMP"/>
            <entity id="DS3.d125.s0.e1" origId="Q7Z406,A1L2Z2,B3KWH4" charOffset="129-135" type="protein" text="myosin"/>
            <entity id="DS3.d125.s0.e2" origId="314,6131" charOffset="220-223" type="compound" text="CMP"/>
            <pair e1="DS3.d125.s0.e0" e2="DS3.d125.s0.e1" id="DS3.d125.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d125.s1" origId="9933448-6" text="Pronounced IgG anti-cardiac myosin reactivity was frequently found in sera from patients with dilatative CMP and reduced ventricular function.">
            <entity id="DS3.d125.s1.e0" origId="Q7Z406,A1L2Z2,B3KWH4" charOffset="28-34" type="protein" text="myosin"/>
            <entity id="DS3.d125.s1.e1" origId="314,6131" charOffset="105-108" type="compound" text="CMP"/>
            <pair e1="DS3.d125.s1.e1" e2="DS3.d125.s1.e0" id="DS3.d125.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d125.s2" origId="9933448-7" text="ELISA analyses revealed a prominent IgG2/IgG3 anti-cardiac myosin reactivity in CMP sera, indicating a preferential Th1-like immune response.">
            <entity id="DS3.d125.s2.e0" origId="Q7Z406,A1L2Z2,B3KWH4" charOffset="59-65" type="protein" text="myosin"/>
            <entity id="DS3.d125.s2.e1" origId="314,6131" charOffset="80-83" type="compound" text="CMP"/>
            <entity id="DS3.d125.s2.e2" origId="Q8IXH7,H0UI80" charOffset="116-119" type="protein" text="Th1"/>
            <pair e1="DS3.d125.s2.e1" e2="DS3.d125.s2.e2" id="DS3.d125.s2.i0" interaction="False" />
            <pair e1="DS3.d125.s2.e1" e2="DS3.d125.s2.e0" id="DS3.d125.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d125.s3" origId="9933448-9" text="If further work can support the hypothesis that autoreactivity to cardiac myosin represents a pathogenic factor in CMP, specific immunomodulation of this Th1- towards a Th2-like immune response may represent a promising therapeutic strategy for CMP.">
            <entity id="DS3.d125.s3.e0" origId="Q7Z406,A1L2Z2,B3KWH4" charOffset="74-80" type="protein" text="myosin"/>
            <entity id="DS3.d125.s3.e1" origId="314,6131" charOffset="115-118" type="compound" text="CMP"/>
            <entity id="DS3.d125.s3.e2" origId="Q8IXH7,H0UI80" charOffset="154-157" type="protein" text="Th1"/>
            <entity id="DS3.d125.s3.e3" origId="314,6131" charOffset="245-248" type="compound" text="CMP"/>
            <pair e1="DS3.d125.s3.e1" e2="DS3.d125.s3.e2" id="DS3.d125.s3.i0" interaction="False" />
            <pair e1="DS3.d125.s3.e1" e2="DS3.d125.s3.e0" id="DS3.d125.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d126" origId="9933452">
        <sentence id="DS3.d126.s0" origId="9933452-3" text="All Ro52 and Ro60 immune sera immunoblotted the inducible glucose-regulated protein grp78 and hsp70 species but not constitutive hsc70 or hsp90.">
            <entity id="DS3.d126.s0.e0" origId="Q3U7K7,Q3UCL2" charOffset="4-8" type="protein" text="Ro52"/>
            <entity id="DS3.d126.s0.e1" origId="206,5793,64689,79025" charOffset="58-65" type="compound" text="glucose"/>
            <entity id="DS3.d126.s0.e2" origId="P20029,Q3U7T8" charOffset="84-89" type="protein" text="grp78"/>
            <entity id="DS3.d126.s0.e3" origId="P63017" charOffset="129-134" type="protein" text="hsc70"/>
            <pair e1="DS3.d126.s0.e1" e2="DS3.d126.s0.e0" id="DS3.d126.s0.i0" interaction="False" />
            <pair e1="DS3.d126.s0.e1" e2="DS3.d126.s0.e2" id="DS3.d126.s0.i1" interaction="False" />
            <pair e1="DS3.d126.s0.e1" e2="DS3.d126.s0.e3" id="DS3.d126.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d127" origId="9933453">
        <sentence id="DS3.d127.s0" origId="9933453-6" text="Anti-idiotype antisera against two monoclonal anti-DNA autoantibodies were used, derived from MRL-lpr/lpr mice, i. e. clone H241 and clone H130.">
            <entity id="DS3.d127.s0.e0" origId="P25446,Q8C350" charOffset="98-101" type="protein" text="lpr"/>
            <entity id="DS3.d127.s0.e1" origId="P25446,Q8C350" charOffset="102-105" type="protein" text="lpr"/>
            <entity id="DS3.d127.s0.e2" origId="119043,164779" charOffset="124-128" type="compound" text="H241"/>
            <entity id="DS3.d127.s0.e3" origId="86583197" charOffset="139-143" type="compound" text="H130"/>
            <pair e1="DS3.d127.s0.e2" e2="DS3.d127.s0.e0" id="DS3.d127.s0.i0" interaction="False" />
            <pair e1="DS3.d127.s0.e3" e2="DS3.d127.s0.e0" id="DS3.d127.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d128" origId="9933455">
        <sentence id="DS3.d128.s0" origId="9933455-5" text="IL-1beta, tumour necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) all stimulated GM-CSF production by RPE cells and a combination of these cytokines increased GM-CSF production over five-fold compared with that with the individual cytokines alone.">
            <entity id="DS3.d128.s0.e0" origId="P01584" charOffset="0-8" type="protein" text="IL-1beta"/>
            <entity id="DS3.d128.s0.e1" origId="P01375,Q5STB3" charOffset="10-38" type="protein" text="tumour necrosis factor-alpha"/>
            <entity id="DS3.d128.s0.e2" origId="P01375,Q5STB3" charOffset="40-49" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d128.s0.e3" origId="16122568,16750043,4369303,448383" charOffset="116-119" type="compound" text="CSF"/>
            <entity id="DS3.d128.s0.e4" origId="16122568,16750043,4369303,448383" charOffset="194-197" type="compound" text="CSF"/>
            <pair e1="DS3.d128.s0.e3" e2="DS3.d128.s0.e2" id="DS3.d128.s0.i0" interaction="False" />
            <pair e1="DS3.d128.s0.e3" e2="DS3.d128.s0.e0" id="DS3.d128.s0.i1" interaction="False" />
            <pair e1="DS3.d128.s0.e3" e2="DS3.d128.s0.e1" id="DS3.d128.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d128.s1" origId="9933455-8" text="GM-CSF mRNA expression showed the same pattern of response to these cytokines, indicating transcriptional or pre-transcriptional regulation, and there was no evidence that IFN-gamma was acting by destabilizing GM-CSF mRNA.">
            <entity id="DS3.d128.s1.e0" origId="16122568,4369303,448383,16750043" charOffset="3-6" type="compound" text="CSF"/>
            <entity id="DS3.d128.s1.e1" origId="P01579" charOffset="172-181" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d128.s1.e2" origId="16122568,4369303,448383,16750043" charOffset="213-216" type="compound" text="CSF"/>
            <pair e1="DS3.d128.s1.e0" e2="DS3.d128.s1.e1" id="DS3.d128.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d129" origId="9933461">
        <sentence id="DS3.d129.s0" origId="9933461-8" text="CD25, CD71 and HLA-DR, memory cells and sCD23 positively correlated with biochemical parameters (AST, ALT, urea, alpha2-globulin) during the acute phase of HFRS.">
            <entity id="DS3.d129.s0.e0" origId="P01589,Q5W005" charOffset="0-4" type="protein" text="CD25"/>
            <entity id="DS3.d129.s0.e1" origId="P02786" charOffset="6-10" type="protein" text="CD71"/>
            <entity id="DS3.d129.s0.e2" origId="1176" charOffset="107-111" type="compound" text="urea"/>
            <pair e1="DS3.d129.s0.e2" e2="DS3.d129.s0.e1" id="DS3.d129.s0.i0" interaction="False" />
            <pair e1="DS3.d129.s0.e2" e2="DS3.d129.s0.e0" id="DS3.d129.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d130" origId="9933466">
        <sentence id="DS3.d130.s0" origId="9933466-8" text="Some epitopes were lost after trypsin-EDTA digestion and formaldehyde fixation of cells, whereas anti-PR3 targeted unfixed HUVEC.">
            <entity id="DS3.d130.s0.e0" origId="6049" charOffset="38-42" type="compound" text="EDTA"/>
            <entity id="DS3.d130.s0.e1" origId="712" charOffset="57-69" type="compound" text="formaldehyde"/>
            <entity id="DS3.d130.s0.e2" origId="P24158" charOffset="102-105" type="protein" text="PR3"/>
            <pair e1="DS3.d130.s0.e0" e2="DS3.d130.s0.e2" id="DS3.d130.s0.i0" interaction="False" />
            <pair e1="DS3.d130.s0.e1" e2="DS3.d130.s0.e2" id="DS3.d130.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d131" origId="9933468">
        <sentence id="DS3.d131.s0" origId="9933468-0" text="Comparison of recombinant human PTH(1-34) (LY333334) with a C-terminally substituted analog of human PTH-related protein(1-34) (RS-66271): In vitro activity and in vivo pharmacological effects in rats.">
            <entity id="DS3.d131.s0.e0" origId="P01270" charOffset="32-35" type="protein" text="PTH"/>
            <entity id="DS3.d131.s0.e1" origId="P01270" charOffset="101-104" type="protein" text="PTH"/>
            <entity id="DS3.d131.s0.e2" origId="7021454" charOffset="128-130" type="compound" text="RS"/>
            <pair e1="DS3.d131.s0.e2" e2="DS3.d131.s0.e0" id="DS3.d131.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d131.s1" origId="9933468-14" text="There were no consistent significant differences in the comparative effects of PTH(1-34) and RS-66271 on the measured bone parameters.">
            <entity id="DS3.d131.s1.e0" origId="P01270" charOffset="79-82" type="protein" text="PTH"/>
            <entity id="DS3.d131.s1.e1" origId="7021454" charOffset="93-95" type="compound" text="RS"/>
            <pair e1="DS3.d131.s1.e1" e2="DS3.d131.s1.e0" id="DS3.d131.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d131.s2" origId="9933468-15" text="In conclusion, despite the reduced binding affinity of RS-66271 for the PTH/PTHrP receptor compared with human PTH(1-34), both peptides displayed similar in vitro and in vivo pharmacological effects.">
            <entity id="DS3.d131.s2.e0" origId="7021454" charOffset="55-57" type="compound" text="RS"/>
            <entity id="DS3.d131.s2.e1" origId="P01270" charOffset="72-75" type="protein" text="PTH"/>
            <entity id="DS3.d131.s2.e2" origId="P01270" charOffset="76-79" type="protein" text="PTH"/>
            <pair e1="DS3.d131.s2.e0" e2="DS3.d131.s2.e1" id="DS3.d131.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d131.s3" origId="9933468-2" text="Recently, an analog of PTHrP (RS-66271), was described that demonstrated reduced binding affinity for the PTH/PTHrP receptor compared with bovine PTH(1-34) but retained equal biological activity.">
            <entity id="DS3.d131.s3.e0" origId="7021454" charOffset="30-32" type="compound" text="RS"/>
            <entity id="DS3.d131.s3.e1" origId="P01270" charOffset="23-26" type="protein" text="PTH"/>
            <entity id="DS3.d131.s3.e2" origId="P01270" charOffset="106-109" type="protein" text="PTH"/>
            <pair e1="DS3.d131.s3.e0" e2="DS3.d131.s3.e1" id="DS3.d131.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d131.s4" origId="9933468-3" text="The present study investigated the receptor binding affinities of synthetic RS-66271 and recombinant human PTH(1-34) (LY333334) and compared their in vitro and in vivo pharmacological effects.">
            <entity id="DS3.d131.s4.e0" origId="7021454" charOffset="76-78" type="compound" text="RS"/>
            <entity id="DS3.d131.s4.e1" origId="P01270" charOffset="107-110" type="protein" text="PTH"/>
            <pair e1="DS3.d131.s4.e0" e2="DS3.d131.s4.e1" id="DS3.d131.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d131.s5" origId="9933468-4" text="RS-66271 had one hundredth the activity of PTH(1-34) in competing for the binding of (125I) (Nle8,18, Tyr34)human PTH(1-34) to the human PTH/PTHrP receptor stably expressed in a human kidney cell line.">
            <entity id="DS3.d131.s5.e0" origId="7021454" charOffset="0-2" type="compound" text="RS"/>
            <entity id="DS3.d131.s5.e1" origId="P01270" charOffset="43-46" type="protein" text="PTH"/>
            <entity id="DS3.d131.s5.e2" origId="P01270" charOffset="114-117" type="protein" text="PTH"/>
            <entity id="DS3.d131.s5.e3" origId="P01270" charOffset="114-117" type="protein" text="PTH"/>
            <pair e1="DS3.d131.s5.e0" e2="DS3.d131.s5.e1" id="DS3.d131.s5.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d131.s6" origId="9933468-5" text="Despite this reduced binding affinity, RS-66271 had equivalent activity in increasing both cAMP production in osteoblast-like cells and bone resorption in neonatal mouse calvariae.">
            <entity id="DS3.d131.s6.e0" origId="7021454" charOffset="39-41" type="compound" text="RS"/>
            <entity id="DS3.d131.s6.e1" origId="P51437" charOffset="91-95" type="protein" text="cAMP"/>
            <pair e1="DS3.d131.s6.e0" e2="DS3.d131.s6.e1" id="DS3.d131.s6.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d132" origId="9933478">
        <sentence id="DS3.d132.s0" origId="9933478-1" text="The actions of 1,25-dihydroxyvitamin D3 (1,25(OH)2 D3) are mediated through the nuclear vitamin D receptor (VDR).">
            <entity id="DS3.d132.s0.e0" origId="5280453" charOffset="15-39" type="compound" text="1,25-dihydroxyvitamin D3"/>
            <entity id="DS3.d132.s0.e1" origId="P11473,F1D8P8" charOffset="88-106" type="protein" text="vitamin D receptor"/>
            <entity id="DS3.d132.s0.e2" origId="P11473,F1D8P8" charOffset="108-111" type="protein" text="VDR"/>
            <pair e1="DS3.d132.s0.e0" e2="DS3.d132.s0.e2" id="DS3.d132.s0.i0" interaction="False" />
            <pair e1="DS3.d132.s0.e0" e2="DS3.d132.s0.e1" id="DS3.d132.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d132.s1" origId="9933478-3" text="The major physiological activity of 1,25(OH)2D3 is the regulation of calcium absorption in the small intestine, and the level of VDR is an important factor in this regulation.">
            <entity id="DS3.d132.s1.e0" origId="22044544,5460341" charOffset="69-76" type="compound" text="calcium"/>
            <entity id="DS3.d132.s1.e1" origId="P11473,F1D8P8" charOffset="129-132" type="protein" text="VDR"/>
            <pair e1="DS3.d132.s1.e0" e2="DS3.d132.s1.e1" id="DS3.d132.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d133" origId="9933479">
        <sentence id="DS3.d133.s0" origId="9933479-1" text="The presence of bone-specific estrogen agonists and discovery of the osteoblast-specific transcription factor (TF), Cbfa1, together with the discovery of synergism between a TF Pit-1 and estrogen receptor alpha (ERalpha) on rat prolactin gene, led to investigation of Cbfa1 in the modulation of osteoblast-specific actions of estrogen.">
            <entity id="DS3.d133.s0.e0" origId="F1M9C5,Q13950,Q32MY8,A0A0D9SEN7" charOffset="116-121" type="protein" text="Cbfa1"/>
            <entity id="DS3.d133.s0.e1" origId="3664359" charOffset="177-182" type="compound" text="Pit-1"/>
            <entity id="DS3.d133.s0.e2" origId="P06211,D0FYH4" charOffset="187-210" type="protein" text="estrogen receptor alpha"/>
            <entity id="DS3.d133.s0.e3" origId="P06211,D0FYH4" charOffset="212-219" type="protein" text="ERalpha"/>
            <entity id="DS3.d133.s0.e4" origId="P01237,B5DEM6,B2RYT1" charOffset="228-237" type="protein" text="prolactin"/>
            <entity id="DS3.d133.s0.e5" origId="F1M9C5,Q13950,Q32MY8,A0A0D9SEN7" charOffset="268-273" type="protein" text="Cbfa1"/>
            <pair e1="DS3.d133.s0.e1" e2="DS3.d133.s0.e0" id="DS3.d133.s0.i0" interaction="False" />
            <pair e1="DS3.d133.s0.e1" e2="DS3.d133.s0.e3" id="DS3.d133.s0.i1" interaction="False" />
            <pair e1="DS3.d133.s0.e1" e2="DS3.d133.s0.e2" id="DS3.d133.s0.i2" interaction="False" />
            <pair e1="DS3.d133.s0.e1" e2="DS3.d133.s0.e4" id="DS3.d133.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d134" origId="9933485">
        <sentence id="DS3.d134.s0" origId="9933485-12" text="Of the biochemical parameters measured (including renal function, serum calcium, phosphorus, vitamin D metabolites, osteocalcin, urinary calcium, and markers of bone resorption), only intact parathyroid hormone (PTH) levels, which were 40% lower in patients with low serum magnesium levels differed significantly (45 +/- 23 pg/ml vs. 74 +/- 60 pg/ml; p = 0.019).">
            <entity id="DS3.d134.s0.e0" origId="5460341,22044544" charOffset="72-79" type="compound" text="calcium"/>
            <entity id="DS3.d134.s0.e1" origId="5280795,5283711" charOffset="93-102" type="compound" text="vitamin D"/>
            <entity id="DS3.d134.s0.e2" origId="P02818" charOffset="116-127" type="protein" text="osteocalcin"/>
            <entity id="DS3.d134.s0.e3" origId="5460341,22044544" charOffset="137-144" type="compound" text="calcium"/>
            <entity id="DS3.d134.s0.e4" origId="5462224" charOffset="273-282" type="compound" text="magnesium"/>
            <pair e1="DS3.d134.s0.e0" e2="DS3.d134.s0.e2" id="DS3.d134.s0.i0" interaction="False" />
            <pair e1="DS3.d134.s0.e4" e2="DS3.d134.s0.e2" id="DS3.d134.s0.i1" interaction="False" />
            <pair e1="DS3.d134.s0.e1" e2="DS3.d134.s0.e2" id="DS3.d134.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d135" origId="9933502">
        <sentence id="DS3.d135.s0" origId="9933502-0" text="Prostaglandin E2 mediates activation of hypothalamic histamine by interleukin-1beta in rats.">
            <entity id="DS3.d135.s0.e0" origId="5280360" charOffset="0-16" type="compound" text="Prostaglandin E2"/>
            <entity id="DS3.d135.s0.e1" origId="774" charOffset="53-62" type="compound" text="histamine"/>
            <entity id="DS3.d135.s0.e2" origId="Q5BKB0" charOffset="66-83" type="protein" text="interleukin-1beta"/>
            <pair e1="DS3.d135.s0.e1" e2="DS3.d135.s0.e2" id="DS3.d135.s0.i0" interaction="False" />
            <pair e1="DS3.d135.s0.e0" e2="DS3.d135.s0.e2" id="DS3.d135.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d135.s1" origId="9933502-1" text="The present study was designed to investigate the effects of peripheral interleukin-1beta (IL-1beta) on hypothalamic histamine (HA) systems.">
            <entity id="DS3.d135.s1.e0" origId="Q5BKB0" charOffset="72-89" type="protein" text="interleukin-1beta"/>
            <entity id="DS3.d135.s1.e1" origId="Q5BKB0" charOffset="91-99" type="protein" text="IL-1beta"/>
            <entity id="DS3.d135.s1.e2" origId="774" charOffset="117-126" type="compound" text="histamine"/>
            <pair e1="DS3.d135.s1.e2" e2="DS3.d135.s1.e0" id="DS3.d135.s1.i0" interaction="False" />
            <pair e1="DS3.d135.s1.e2" e2="DS3.d135.s1.e1" id="DS3.d135.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d135.s2" origId="9933502-2" text="Intraperitoneal injection of IL-1beta increased the turnover rate of hypothalamic HA, which was assessed by accumulation of tele-methylhistamine after pargyline treatment.">
            <entity id="DS3.d135.s2.e0" origId="Q5BKB0" charOffset="29-37" type="protein" text="IL-1beta"/>
            <entity id="DS3.d135.s2.e1" origId="3614" charOffset="124-144" type="compound" text="tele-methylhistamine"/>
            <entity id="DS3.d135.s2.e2" origId="4688" charOffset="151-160" type="compound" text="pargyline"/>
            <pair e1="DS3.d135.s2.e1" e2="DS3.d135.s2.e0" id="DS3.d135.s2.i0" interaction="False" />
            <pair e1="DS3.d135.s2.e2" e2="DS3.d135.s2.e0" id="DS3.d135.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d135.s3" origId="9933502-3" text="IL-1beta increased the activities of both histidine decarboxylase (HDC), an HA synthesizing enzyme, and HA-N-methyltransferase (HMT), an HA catabolizing enzyme.">
            <entity id="DS3.d135.s3.e0" origId="Q5BKB0" charOffset="0-8" type="protein" text="IL-1beta"/>
            <entity id="DS3.d135.s3.e1" origId="6274" charOffset="42-51" type="compound" text="histidine"/>
            <pair e1="DS3.d135.s3.e1" e2="DS3.d135.s3.e0" id="DS3.d135.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d135.s4" origId="9933502-4" text="Pretreatment with indomethacin completely blocked the effects induced by IL-1beta on hypothalamic HA.">
            <entity id="DS3.d135.s4.e0" origId="3715" charOffset="18-30" type="compound" text="indomethacin"/>
            <entity id="DS3.d135.s4.e1" origId="Q5BKB0" charOffset="73-81" type="protein" text="IL-1beta"/>
            <pair e1="DS3.d135.s4.e0" e2="DS3.d135.s4.e1" id="DS3.d135.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d135.s5" origId="9933502-6" text="These results indicate that hypothalamic PGE2 activated by peripheral administration of IL-1beta, but not by peripheral PGE2, may enhance synthesis and release of hypothalamic HA by activation of HDC, and may facilitate degradation of extracellular histamine by activation of HMT.">
            <entity id="DS3.d135.s5.e0" origId="Q5BKB0" charOffset="88-96" type="protein" text="IL-1beta"/>
            <entity id="DS3.d135.s5.e1" origId="774" charOffset="249-258" type="compound" text="histamine"/>
            <pair e1="DS3.d135.s5.e1" e2="DS3.d135.s5.e0" id="DS3.d135.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d136" origId="9933504">
        <sentence id="DS3.d136.s0" origId="9933504-11" text="Whereas a physiologic action for lactate within the hypothalamus is possible, the present findings indicate that lactate is an inhibitor of CRH release.">
            <entity id="DS3.d136.s0.e0" origId="612" charOffset="33-40" type="compound" text="lactate"/>
            <entity id="DS3.d136.s0.e1" origId="612" charOffset="113-120" type="compound" text="lactate"/>
            <entity id="DS3.d136.s0.e2" origId="P01143" charOffset="140-143" type="protein" text="CRH"/>
            <pair e1="DS3.d136.s0.e0" e2="DS3.d136.s0.e2" id="DS3.d136.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d136.s1" origId="9933504-3" text="Specifically, beta-endorphin secretion was measured from AtT-20 (D-16) mouse corticotroph tumor cells treated either acutely (15 min - 180 min) or chronically (1 day - 3 day) with physiologic levels of lactate (0.">
            <entity id="DS3.d136.s1.e0" origId="P01193" charOffset="14-28" type="protein" text="beta-endorphin"/>
            <entity id="DS3.d136.s1.e1" origId="612" charOffset="202-209" type="compound" text="lactate"/>
            <pair e1="DS3.d136.s1.e1" e2="DS3.d136.s1.e0" id="DS3.d136.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d136.s2" origId="9933504-4" text="5 x 10-3 M to 5 x 10-2 M) or lactate in combination with the corticotroph releasing factors: corticotroph releasing hormone (CRH), arginine vasopressin (AVP), norepinephrine and/or epinephrine.">
            <entity id="DS3.d136.s2.e0" origId="612" charOffset="29-36" type="compound" text="lactate"/>
            <entity id="DS3.d136.s2.e1" origId="Q8CIT0" charOffset="93-123" type="protein" text="corticotroph releasing hormone"/>
            <entity id="DS3.d136.s2.e2" origId="P01143" charOffset="125-128" type="protein" text="CRH"/>
            <entity id="DS3.d136.s2.e3" origId="6322,90867653" charOffset="131-139" type="compound" text="arginine"/>
            <entity id="DS3.d136.s2.e4" origId="439260" charOffset="159-173" type="compound" text="norepinephrine"/>
            <entity id="DS3.d136.s2.e5" origId="5816" charOffset="162-173" type="compound" text="epinephrine"/>
            <pair e1="DS3.d136.s2.e4" e2="DS3.d136.s2.e1" id="DS3.d136.s2.i0" interaction="False" />
            <pair e1="DS3.d136.s2.e4" e2="DS3.d136.s2.e2" id="DS3.d136.s2.i1" interaction="False" />
            <pair e1="DS3.d136.s2.e5" e2="DS3.d136.s2.e1" id="DS3.d136.s2.i2" interaction="False" />
            <pair e1="DS3.d136.s2.e5" e2="DS3.d136.s2.e2" id="DS3.d136.s2.i3" interaction="False" />
            <pair e1="DS3.d136.s2.e3" e2="DS3.d136.s2.e1" id="DS3.d136.s2.i4" interaction="False" />
            <pair e1="DS3.d136.s2.e3" e2="DS3.d136.s2.e2" id="DS3.d136.s2.i5" interaction="False" />
            <pair e1="DS3.d136.s2.e0" e2="DS3.d136.s2.e1" id="DS3.d136.s2.i6" interaction="False" />
            <pair e1="DS3.d136.s2.e0" e2="DS3.d136.s2.e2" id="DS3.d136.s2.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d136.s3" origId="9933504-7" text="While CRH, norepinephrine, and epinephrine evoked significant increases in beta-endorphin release, lactate, in combination with these secretagogues did not alter their effects.">
            <entity id="DS3.d136.s3.e0" origId="P01143" charOffset="6-9" type="protein" text="CRH"/>
            <entity id="DS3.d136.s3.e1" origId="439260" charOffset="11-25" type="compound" text="norepinephrine"/>
            <entity id="DS3.d136.s3.e2" origId="5816" charOffset="14-25" type="compound" text="epinephrine"/>
            <entity id="DS3.d136.s3.e3" origId="P01193" charOffset="75-89" type="protein" text="beta-endorphin"/>
            <entity id="DS3.d136.s3.e4" origId="612" charOffset="99-106" type="compound" text="lactate"/>
            <pair e1="DS3.d136.s3.e1" e2="DS3.d136.s3.e0" id="DS3.d136.s3.i0" interaction="False" />
            <pair e1="DS3.d136.s3.e1" e2="DS3.d136.s3.e3" id="DS3.d136.s3.i1" interaction="False" />
            <pair e1="DS3.d136.s3.e2" e2="DS3.d136.s3.e0" id="DS3.d136.s3.i2" interaction="False" />
            <pair e1="DS3.d136.s3.e2" e2="DS3.d136.s3.e3" id="DS3.d136.s3.i3" interaction="False" />
            <pair e1="DS3.d136.s3.e4" e2="DS3.d136.s3.e0" id="DS3.d136.s3.i4" interaction="False" />
            <pair e1="DS3.d136.s3.e4" e2="DS3.d136.s3.e3" id="DS3.d136.s3.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d136.s4" origId="9933504-9" text="The addition of lactate (3 x 103 M) to rat hypothalamic explants did, however, produce a modest but significant reduction in spontaneous CRH release, suggesting that lactate may facilitate the return to basal secretion following exercise.">
            <entity id="DS3.d136.s4.e0" origId="612" charOffset="16-23" type="compound" text="lactate"/>
            <entity id="DS3.d136.s4.e1" origId="P01143" charOffset="137-140" type="protein" text="CRH"/>
            <entity id="DS3.d136.s4.e2" origId="612" charOffset="166-173" type="compound" text="lactate"/>
            <pair e1="DS3.d136.s4.e0" e2="DS3.d136.s4.e1" id="DS3.d136.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d137" origId="9933506">
        <sentence id="DS3.d137.s0" origId="9933506-1" text="This study investigated the in vitro dose effects of ethanol (EtOH), adenosine (ADO), and urate (URA) on the basal and CRF stimulated ACTH production of pituitary tissue culture (PTC).">
            <entity id="DS3.d137.s0.e0" origId="57476835,60961" charOffset="69-78" type="compound" text="adenosine"/>
            <entity id="DS3.d137.s0.e1" origId="29645" charOffset="90-95" type="compound" text="urate"/>
            <entity id="DS3.d137.s0.e2" origId="1174" charOffset="97-100" type="compound" text="URA"/>
            <entity id="DS3.d137.s0.e3" origId="P01143" charOffset="119-122" type="protein" text="CRF"/>
            <pair e1="DS3.d137.s0.e1" e2="DS3.d137.s0.e3" id="DS3.d137.s0.i0" interaction="False" />
            <pair e1="DS3.d137.s0.e2" e2="DS3.d137.s0.e3" id="DS3.d137.s0.i1" interaction="False" />
            <pair e1="DS3.d137.s0.e0" e2="DS3.d137.s0.e3" id="DS3.d137.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d137.s1" origId="9933506-4" text="ADO significantly increased only basal ACTH secretion whereas URA increased both basal and CRF-stimulated ACTH secretion.">
            <entity id="DS3.d137.s1.e0" origId="1174" charOffset="62-65" type="compound" text="URA"/>
            <entity id="DS3.d137.s1.e1" origId="P01143" charOffset="91-94" type="protein" text="CRF"/>
            <pair e1="DS3.d137.s1.e0" e2="DS3.d137.s1.e1" id="DS3.d137.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d138" origId="9933513">
        <sentence id="DS3.d138.s0" origId="9933513-0" text="Quantitative model for Gal4p-mediated expression of the galactose/melibiose regulon in Saccharomyces cerevisiae.">
            <entity id="DS3.d138.s0.e0" origId="P04386" charOffset="23-28" type="protein" text="Gal4p"/>
            <entity id="DS3.d138.s0.e1" origId="206,439353,6036" charOffset="56-65" type="compound" text="galactose"/>
            <entity id="DS3.d138.s0.e2" origId="440658,46905267,872" charOffset="66-75" type="compound" text="melibiose"/>
            <pair e1="DS3.d138.s0.e1" e2="DS3.d138.s0.e0" id="DS3.d138.s0.i0" interaction="False" />
            <pair e1="DS3.d138.s0.e2" e2="DS3.d138.s0.e0" id="DS3.d138.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d138.s1" origId="9933513-4" text="Parameters determined from the above simulation were then used to represent a physiological status of gene expression in response to glucose (in terms of Gal4p concentration) and galactose in a wild-type strain.">
            <entity id="DS3.d138.s1.e0" origId="5793,64689,79025" charOffset="133-140" type="compound" text="glucose"/>
            <entity id="DS3.d138.s1.e1" origId="P04386" charOffset="154-159" type="protein" text="Gal4p"/>
            <entity id="DS3.d138.s1.e2" origId="206,439353,6036" charOffset="179-188" type="compound" text="galactose"/>
            <pair e1="DS3.d138.s1.e2" e2="DS3.d138.s1.e1" id="DS3.d138.s1.i0" interaction="False" />
            <pair e1="DS3.d138.s1.e0" e2="DS3.d138.s1.e1" id="DS3.d138.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d139" origId="9933568">
        <sentence id="DS3.d139.s0" origId="9933568-0" text="Cloning of the mouse and human solute carrier 22a3 (Slc22a3/Slc22a3) identifies a conserved cluster of three organic cation transporters on mouse chromosome 17 and human 6q26-q27.">
            <entity id="DS3.d139.s0.e0" origId="O75751,Q9WTW5,Q547K2" charOffset="52-59" type="protein" text="Slc22a3"/>
            <entity id="DS3.d139.s0.e1" origId="O75751,Q9WTW5,Q547K2" charOffset="60-67" type="protein" text="Slc22a3"/>
            <entity id="DS3.d139.s0.e2" origId="53346511" charOffset="175-178" type="compound" text="q27"/>
            <pair e1="DS3.d139.s0.e2" e2="DS3.d139.s0.e0" id="DS3.d139.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d139.s1" origId="9933568-6" text="Using a somatic cell hybrid panel and a human YAC clone, Slc22a3 was mapped to the syntenic region on human chromosome 6q26-q27, between the IGF2R and APO(a)-like genes.">
            <entity id="DS3.d139.s1.e0" origId="O75751,Q9WTW5,Q547K2" charOffset="57-64" type="protein" text="Slc22a3"/>
            <entity id="DS3.d139.s1.e1" origId="53346511" charOffset="124-127" type="compound" text="q27"/>
            <entity id="DS3.d139.s1.e2" origId="Q07113,Q8C6V9" charOffset="141-146" type="protein" text="IGF2R"/>
            <pair e1="DS3.d139.s1.e1" e2="DS3.d139.s1.e2" id="DS3.d139.s1.i0" interaction="False" />
            <pair e1="DS3.d139.s1.e1" e2="DS3.d139.s1.e0" id="DS3.d139.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d140" origId="9933569">
        <sentence id="DS3.d140.s0" origId="9933569-9" text="Using FISH and analysis of a panel of rodent-human cell hybrids, the human RAD17Sp gene (HGMW-approved symbol RAD17 could be localized on human chromosome 5q13-q14, a region implicated in the etiology of small cell lung carcinoma, non-small-cell lung carcinoma, duodenal adenocarcinoma, and head and neck squamous cell carcinoma.">
            <entity id="DS3.d140.s0.e0" origId="O75943,A0A0G2JNH5" charOffset="75-82" type="protein" text="RAD17Sp"/>
            <entity id="DS3.d140.s0.e1" origId="O75943,A0A0G2JNH5" charOffset="75-80" type="protein" text="RAD17"/>
            <entity id="DS3.d140.s0.e2" origId="71710902" charOffset="160-163" type="compound" text="q14"/>
            <pair e1="DS3.d140.s0.e2" e2="DS3.d140.s0.e1" id="DS3.d140.s0.i0" interaction="False" />
            <pair e1="DS3.d140.s0.e2" e2="DS3.d140.s0.e0" id="DS3.d140.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d141" origId="9933571">
        <sentence id="DS3.d141.s0" origId="9933571-1" text="Serine/threonine kinase ROCK II/Rho kinase, which is an isozyme of ROCK I, is one of the targets for the small GTPase Rho.">
            <entity id="DS3.d141.s0.e0" origId="5951" charOffset="0-6" type="compound" text="Serine"/>
            <entity id="DS3.d141.s0.e1" origId="194239,6288" charOffset="7-16" type="compound" text="threonine"/>
            <entity id="DS3.d141.s0.e2" origId="O75116" charOffset="24-31" type="protein" text="ROCK II"/>
            <pair e1="DS3.d141.s0.e1" e2="DS3.d141.s0.e2" id="DS3.d141.s0.i0" interaction="False" />
            <pair e1="DS3.d141.s0.e0" e2="DS3.d141.s0.e2" id="DS3.d141.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d142" origId="9933572">
        <sentence id="DS3.d142.s0" origId="9933572-1" text="TBX6 is a member of the T-box family of proteins, which share a region of homology corresponding to the DNA-binding domain of the transcription factor T. Previous expression studies and knockout experiments in mice indicate that TBX6 is important for specification of paraxial mesoderm structures.">
            <entity id="DS3.d142.s0.e0" origId="O95947,P70327" charOffset="0-4" type="protein" text="TBX6"/>
            <entity id="DS3.d142.s0.e1" origId="452319" charOffset="144-152" type="compound" text="factor T"/>
            <entity id="DS3.d142.s0.e2" origId="O95947,P70327" charOffset="229-233" type="protein" text="TBX6"/>
            <pair e1="DS3.d142.s0.e1" e2="DS3.d142.s0.e0" id="DS3.d142.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d143" origId="9933573">
        <sentence id="DS3.d143.s0" origId="9933573-3" text="From this region, we identified four genes including NBS1, a gene coding for a 27-kDa vitamin D-dependent calcium-binding protein (27-kDa calbindin), the mitochondrial 2,4-dienoyl-CoA reductase gene, and a novel gene, C8orf1/hT41.">
            <entity id="DS3.d143.s0.e0" origId="O60934,A0A0C4DG07" charOffset="53-57" type="protein" text="NBS1"/>
            <entity id="DS3.d143.s0.e1" origId="5280795,5283711" charOffset="86-95" type="compound" text="vitamin D"/>
            <entity id="DS3.d143.s0.e2" origId="22044544,5460341" charOffset="106-113" type="compound" text="calcium"/>
            <entity id="DS3.d143.s0.e3" origId="317,44246472,444624,445126,447444,448506,46936280,5326877,6816,87642" charOffset="180-183" type="compound" text="CoA"/>
            <entity id="DS3.d143.s0.e4" origId="Q9Y236,A0A024R9D5" charOffset="218-224" type="protein" text="C8orf1"/>
            <entity id="DS3.d143.s0.e5" origId="Q9Y236,A0A024R9D5" charOffset="225-229" type="protein" text="hT41"/>
            <pair e1="DS3.d143.s0.e3" e2="DS3.d143.s0.e4" id="DS3.d143.s0.i0" interaction="False" />
            <pair e1="DS3.d143.s0.e3" e2="DS3.d143.s0.e0" id="DS3.d143.s0.i1" interaction="False" />
            <pair e1="DS3.d143.s0.e3" e2="DS3.d143.s0.e5" id="DS3.d143.s0.i2" interaction="False" />
            <pair e1="DS3.d143.s0.e2" e2="DS3.d143.s0.e4" id="DS3.d143.s0.i3" interaction="False" />
            <pair e1="DS3.d143.s0.e2" e2="DS3.d143.s0.e0" id="DS3.d143.s0.i4" interaction="False" />
            <pair e1="DS3.d143.s0.e2" e2="DS3.d143.s0.e5" id="DS3.d143.s0.i5" interaction="False" />
            <pair e1="DS3.d143.s0.e1" e2="DS3.d143.s0.e4" id="DS3.d143.s0.i6" interaction="False" />
            <pair e1="DS3.d143.s0.e1" e2="DS3.d143.s0.e0" id="DS3.d143.s0.i7" interaction="False" />
            <pair e1="DS3.d143.s0.e1" e2="DS3.d143.s0.e5" id="DS3.d143.s0.i8" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d144" origId="9933579">
        <sentence id="DS3.d144.s0" origId="9933579-2" text="This resistance is mediated by the chimeric tyrosine kinase oncogene Bcr-Abl.">
            <entity id="DS3.d144.s0.e0" origId="6057,90983769" charOffset="44-52" type="compound" text="tyrosine"/>
            <entity id="DS3.d144.s0.e1" origId="P00519,Q59FK4,A0A024R8E2" charOffset="69-76" type="protein" text="Bcr-Abl"/>
            <pair e1="DS3.d144.s0.e0" e2="DS3.d144.s0.e1" id="DS3.d144.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d144.s1" origId="9933579-9" text="Treatment of K562 cells with tyrphostin AG957, a selective Bcr-Abl inhibitor, blocks taxol-induced PKCiota activation and sensitizes these cells to taxol-induced apoptosis, indicating that PKCiota is a relevant downstream target of Bcr-Abl-mediated resistance.">
            <entity id="DS3.d144.s1.e0" origId="2064" charOffset="40-45" type="compound" text="AG957"/>
            <entity id="DS3.d144.s1.e1" origId="P00519,Q59FK4,A0A024R8E2" charOffset="59-66" type="protein" text="Bcr-Abl"/>
            <entity id="DS3.d144.s1.e2" origId="P00519,Q59FK4,A0A024R8E2" charOffset="232-239" type="protein" text="Bcr-Abl"/>
            <pair e1="DS3.d144.s1.e0" e2="DS3.d144.s1.e1" id="DS3.d144.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d145" origId="9933580">
        <sentence id="DS3.d145.s0" origId="9933580-0" text="Direct photoaffinity labeling of the Kir6.2 subunit of the ATP-sensitive K+ channel by 8-azido-ATP.">
            <entity id="DS3.d145.s0.e0" origId="Q14654,B2RC52" charOffset="37-43" type="protein" text="Kir6.2"/>
            <entity id="DS3.d145.s0.e1" origId="2735431" charOffset="87-98" type="compound" text="8-azido-ATP"/>
            <pair e1="DS3.d145.s0.e1" e2="DS3.d145.s0.e0" id="DS3.d145.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d145.s1" origId="9933580-2" text="The potentiating effect of MgADP is conferred by the sulfonylurea receptor subunit of the channel, SUR, whereas the inhibitory effect of ATP appears to be mediated via the pore-forming subunit, Kir6.2.">
            <entity id="DS3.d145.s1.e0" origId="6022" charOffset="27-32" type="compound" text="MgADP"/>
            <entity id="DS3.d145.s1.e1" origId="Q09428" charOffset="99-102" type="protein" text="SUR"/>
            <entity id="DS3.d145.s1.e2" origId="Q14654,B2RC52" charOffset="194-200" type="protein" text="Kir6.2"/>
            <pair e1="DS3.d145.s1.e0" e2="DS3.d145.s1.e1" id="DS3.d145.s1.i0" interaction="False" />
            <pair e1="DS3.d145.s1.e0" e2="DS3.d145.s1.e2" id="DS3.d145.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d145.s2" origId="9933580-3" text="We determined whether ATP directly interacts with a binding site on the Kir6.2 subunit to mediate channel inhibition by analyzing binding of a photoaffinity analog of ATP (8-azido-(gamma-32P)ATP) to membranes from COS-7 cells transiently expressing Kir6.2.">
            <entity id="DS3.d145.s2.e0" origId="Q14654,B2RC52" charOffset="72-78" type="protein" text="Kir6.2"/>
            <entity id="DS3.d145.s2.e1" origId="644363" charOffset="172-194" type="compound" text="8-azido-(gamma-32P)ATP"/>
            <entity id="DS3.d145.s2.e2" origId="Q14654,B2RC52" charOffset="249-255" type="protein" text="Kir6.2"/>
            <pair e1="DS3.d145.s2.e2" e2="DS3.d145.s2.e0" id="DS3.d145.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d145.s3" origId="9933580-4" text="We demonstrate that Kir6.2 can be directly labeled by 8-azido-(gamma-32P)ATP but that the related subunit Kir4.1, which is not inhibited by ATP, is not labeled.">
            <entity id="DS3.d145.s3.e0" origId="Q14654,B2RC52" charOffset="20-26" type="protein" text="Kir6.2"/>
            <entity id="DS3.d145.s3.e1" origId="644363" charOffset="54-76" type="compound" text="8-azido-(gamma-32P)ATP"/>
            <entity id="DS3.d145.s3.e2" origId="P78508" charOffset="106-112" type="protein" text="Kir4.1"/>
            <pair e1="DS3.d145.s3.e2" e2="DS3.d145.s3.e0" id="DS3.d145.s3.i0" interaction="False" />
            <pair e1="DS3.d145.s3.e2" e2="DS3.d145.s3.e2" id="DS3.d145.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d146" origId="9933581">
        <sentence id="DS3.d146.s0" origId="9933581-10" text="When the alpha4-L285C subunit was co-expressed with the 5-HT3R subunit, both MTSET and silver nitrate (AgNO3), another cysteine-modifying reagent, significantly reduced the serotonin-induced current.">
            <entity id="DS3.d146.s0.e0" origId="P78318" charOffset="9-15" type="protein" text="alpha4"/>
            <entity id="DS3.d146.s0.e1" origId="P46098,B4E398" charOffset="56-62" type="protein" text="5-HT3R"/>
            <entity id="DS3.d146.s0.e2" origId="23954" charOffset="87-93" type="compound" text="silver"/>
            <entity id="DS3.d146.s0.e3" origId="10313259,943" charOffset="94-101" type="compound" text="nitrate"/>
            <entity id="DS3.d146.s0.e4" origId="24470" charOffset="103-108" type="compound" text="AgNO3"/>
            <entity id="DS3.d146.s0.e5" origId="5862,90793998" charOffset="119-127" type="compound" text="cysteine"/>
            <entity id="DS3.d146.s0.e6" origId="5202" charOffset="173-182" type="compound" text="serotonin"/>
            <pair e1="DS3.d146.s0.e3" e2="DS3.d146.s0.e0" id="DS3.d146.s0.i0" interaction="False" />
            <pair e1="DS3.d146.s0.e3" e2="DS3.d146.s0.e1" id="DS3.d146.s0.i1" interaction="False" />
            <pair e1="DS3.d146.s0.e6" e2="DS3.d146.s0.e0" id="DS3.d146.s0.i2" interaction="False" />
            <pair e1="DS3.d146.s0.e6" e2="DS3.d146.s0.e1" id="DS3.d146.s0.i3" interaction="False" />
            <pair e1="DS3.d146.s0.e5" e2="DS3.d146.s0.e0" id="DS3.d146.s0.i4" interaction="False" />
            <pair e1="DS3.d146.s0.e5" e2="DS3.d146.s0.e1" id="DS3.d146.s0.i5" interaction="False" />
            <pair e1="DS3.d146.s0.e2" e2="DS3.d146.s0.e0" id="DS3.d146.s0.i6" interaction="False" />
            <pair e1="DS3.d146.s0.e2" e2="DS3.d146.s0.e1" id="DS3.d146.s0.i7" interaction="False" />
            <pair e1="DS3.d146.s0.e4" e2="DS3.d146.s0.e0" id="DS3.d146.s0.i8" interaction="False" />
            <pair e1="DS3.d146.s0.e4" e2="DS3.d146.s0.e1" id="DS3.d146.s0.i9" interaction="False" />
        </sentence>
        <sentence id="DS3.d146.s1" origId="9933581-1" text="To understand the wide variation of calcium permeability seen in native and recombinant 5-HT3 receptor (5-HT3R) channels, we reported previously the novel hypothesis that the serotonin 5-HT3R subunit can co-assemble with the alpha4 subunit of the nicotinic acetylcholine receptor (van Hooft, J.">
            <entity id="DS3.d146.s1.e0" origId="22044544,5460341" charOffset="36-43" type="compound" text="calcium"/>
            <entity id="DS3.d146.s1.e1" origId="P46098,B4E398" charOffset="88-102" type="protein" text="5-HT3 receptor"/>
            <entity id="DS3.d146.s1.e2" origId="P46098,B4E398" charOffset="104-110" type="protein" text="5-HT3R"/>
            <entity id="DS3.d146.s1.e3" origId="5202" charOffset="175-184" type="compound" text="serotonin"/>
            <entity id="DS3.d146.s1.e4" origId="P46098,B4E398" charOffset="185-191" type="protein" text="5-HT3R"/>
            <entity id="DS3.d146.s1.e5" origId="P78318" charOffset="225-231" type="protein" text="alpha4"/>
            <entity id="DS3.d146.s1.e6" origId="187" charOffset="257-270" type="compound" text="acetylcholine"/>
            <pair e1="DS3.d146.s1.e3" e2="DS3.d146.s1.e1" id="DS3.d146.s1.i0" interaction="False" />
            <pair e1="DS3.d146.s1.e3" e2="DS3.d146.s1.e5" id="DS3.d146.s1.i1" interaction="False" />
            <pair e1="DS3.d146.s1.e3" e2="DS3.d146.s1.e2" id="DS3.d146.s1.i2" interaction="False" />
            <pair e1="DS3.d146.s1.e0" e2="DS3.d146.s1.e1" id="DS3.d146.s1.i3" interaction="False" />
            <pair e1="DS3.d146.s1.e0" e2="DS3.d146.s1.e5" id="DS3.d146.s1.i4" interaction="False" />
            <pair e1="DS3.d146.s1.e0" e2="DS3.d146.s1.e2" id="DS3.d146.s1.i5" interaction="False" />
            <pair e1="DS3.d146.s1.e6" e2="DS3.d146.s1.e1" id="DS3.d146.s1.i6" interaction="False" />
            <pair e1="DS3.d146.s1.e6" e2="DS3.d146.s1.e5" id="DS3.d146.s1.i7" interaction="False" />
            <pair e1="DS3.d146.s1.e6" e2="DS3.d146.s1.e2" id="DS3.d146.s1.i8" interaction="False" />
        </sentence>
        <sentence id="DS3.d146.s2" origId="9933581-8" text="To test the hypothesis that the alpha4 subunit contributes to the lining of the pore of the resulting 5-HT3R channel, a mutant nicotinic alpha4 subunit with a reactive cysteine residue engineered into the putative pore region was constructed by substituting the leucine at position 285 (alpha4-L285C).">
            <entity id="DS3.d146.s2.e0" origId="P78318" charOffset="32-38" type="protein" text="alpha4"/>
            <entity id="DS3.d146.s2.e1" origId="P46098,B4E398" charOffset="102-108" type="protein" text="5-HT3R"/>
            <entity id="DS3.d146.s2.e2" origId="P78318" charOffset="137-143" type="protein" text="alpha4"/>
            <entity id="DS3.d146.s2.e3" origId="5862,90793998" charOffset="168-176" type="compound" text="cysteine"/>
            <entity id="DS3.d146.s2.e4" origId="6106" charOffset="262-269" type="compound" text="leucine"/>
            <entity id="DS3.d146.s2.e5" origId="P78318" charOffset="137-143" type="protein" text="alpha4"/>
            <pair e1="DS3.d146.s2.e4" e2="DS3.d146.s2.e0" id="DS3.d146.s2.i0" interaction="False" />
            <pair e1="DS3.d146.s2.e4" e2="DS3.d146.s2.e1" id="DS3.d146.s2.i1" interaction="False" />
            <pair e1="DS3.d146.s2.e3" e2="DS3.d146.s2.e0" id="DS3.d146.s2.i2" interaction="False" />
            <pair e1="DS3.d146.s2.e3" e2="DS3.d146.s2.e1" id="DS3.d146.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d146.s3" origId="9933581-9" text="The sulfhydryl-modifying reagent (2-(trimethylammonium) ethyl)methanethiosulfonate (MTSET) reduced the acetylcholine-induced current in oocytes expressing this mutant nicotinic alpha4-L285C subunit along with the nicotinic beta2 subunit by approximately 60%.">
            <entity id="DS3.d146.s3.e0" origId="5460613" charOffset="4-14" type="compound" text="sulfhydryl"/>
            <entity id="DS3.d146.s3.e1" origId="23134249" charOffset="41-46" type="compound" text="ethyl"/>
            <entity id="DS3.d146.s3.e2" origId="5256168" charOffset="62-82" type="compound" text="methanethiosulfonate"/>
            <entity id="DS3.d146.s3.e3" origId="187" charOffset="103-116" type="compound" text="acetylcholine"/>
            <entity id="DS3.d146.s3.e4" origId="P78318" charOffset="177-183" type="protein" text="alpha4"/>
            <entity id="DS3.d146.s3.e5" origId="Q13562" charOffset="223-228" type="protein" text="beta2"/>
            <pair e1="DS3.d146.s3.e0" e2="DS3.d146.s3.e5" id="DS3.d146.s3.i0" interaction="False" />
            <pair e1="DS3.d146.s3.e0" e2="DS3.d146.s3.e4" id="DS3.d146.s3.i1" interaction="False" />
            <pair e1="DS3.d146.s3.e2" e2="DS3.d146.s3.e5" id="DS3.d146.s3.i2" interaction="False" />
            <pair e1="DS3.d146.s3.e2" e2="DS3.d146.s3.e4" id="DS3.d146.s3.i3" interaction="False" />
            <pair e1="DS3.d146.s3.e3" e2="DS3.d146.s3.e5" id="DS3.d146.s3.i4" interaction="False" />
            <pair e1="DS3.d146.s3.e3" e2="DS3.d146.s3.e4" id="DS3.d146.s3.i5" interaction="False" />
            <pair e1="DS3.d146.s3.e1" e2="DS3.d146.s3.e5" id="DS3.d146.s3.i6" interaction="False" />
            <pair e1="DS3.d146.s3.e1" e2="DS3.d146.s3.e4" id="DS3.d146.s3.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d147" origId="9933582">
        <sentence id="DS3.d147.s0" origId="9933582-5" text="Whereas the precise function of hTRFP remains to be determined, the hTRFP-containing RNA polymerase II-SRB complex supports basal level transcription and, relative to RNA polymerase II alone, enhances transcriptional activation by Gal4-VP16 in the presence of cofactor PC4.">
            <entity id="DS3.d147.s0.e0" origId="Q9H944,B3KUJ9" charOffset="32-37" type="protein" text="hTRFP"/>
            <entity id="DS3.d147.s0.e1" origId="Q9H944,B3KUJ9" charOffset="68-73" type="protein" text="hTRFP"/>
            <entity id="DS3.d147.s0.e2" origId="P51610,A6NEM2" charOffset="236-240" type="protein" text="VP16"/>
            <entity id="DS3.d147.s0.e3" origId="108194" charOffset="260-268" type="compound" text="cofactor"/>
            <entity id="DS3.d147.s0.e4" origId="O00458,A4D0U1" charOffset="269-272" type="protein" text="PC4"/>
            <pair e1="DS3.d147.s0.e3" e2="DS3.d147.s0.e0" id="DS3.d147.s0.i0" interaction="False" />
            <pair e1="DS3.d147.s0.e3" e2="DS3.d147.s0.e4" id="DS3.d147.s0.i1" interaction="False" />
            <pair e1="DS3.d147.s0.e3" e2="DS3.d147.s0.e2" id="DS3.d147.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d148" origId="9933584">
        <sentence id="DS3.d148.s0" origId="9933584-3" text="Insensitivity to leptomycin B indicates that its export is not mediated by a leucine-rich nuclear export signal-specific receptor, CRM1.">
            <entity id="DS3.d148.s0.e0" origId="435143,5458861,6436291,6917907" charOffset="17-29" type="compound" text="leptomycin B"/>
            <entity id="DS3.d148.s0.e1" origId="6106" charOffset="77-84" type="compound" text="leucine"/>
            <entity id="DS3.d148.s0.e2" origId="O14980,B3KWD0" charOffset="131-135" type="protein" text="CRM1"/>
            <pair e1="DS3.d148.s0.e1" e2="DS3.d148.s0.e2" id="DS3.d148.s0.i0" interaction="False" />
            <pair e1="DS3.d148.s0.e0" e2="DS3.d148.s0.e2" id="DS3.d148.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d148.s1" origId="9933584-5" text="The cell line tsBN2 contains a temperature-sensitive point mutation in the RCC1 gene, which encodes a guanine nucleotide exchange factor of Ran.">
            <entity id="DS3.d148.s1.e0" origId="P18754,Q5T081" charOffset="75-79" type="protein" text="RCC1"/>
            <entity id="DS3.d148.s1.e1" origId="764" charOffset="102-109" type="compound" text="guanine"/>
            <pair e1="DS3.d148.s1.e1" e2="DS3.d148.s1.e0" id="DS3.d148.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d149" origId="9933587">
        <sentence id="DS3.d149.s0" origId="9933587-15" text="To correlate the expression of FATP to its physiological function, treatment of 3T3-L1 adipocytes with PPARgamma and RXRalpha activators resulted in an increased uptake of oleate.">
            <entity id="DS3.d149.s0.e0" origId="P37238,Q6GU14,M1VPI1" charOffset="103-112" type="protein" text="PPARgamma"/>
            <entity id="DS3.d149.s0.e1" origId="P28700,Q6LC96,A2AJP1,Q3UMU4" charOffset="117-125" type="protein" text="RXRalpha"/>
            <entity id="DS3.d149.s0.e2" origId="445639" charOffset="172-178" type="compound" text="oleate"/>
            <pair e1="DS3.d149.s0.e2" e2="DS3.d149.s0.e0" id="DS3.d149.s0.i0" interaction="False" />
            <pair e1="DS3.d149.s0.e2" e2="DS3.d149.s0.e1" id="DS3.d149.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d149.s1" origId="9933587-18" text="Moreover, these results have implications for the mechanism by which certain PPARgamma activators such as the antidiabetic thiazolidinedione drugs affect adipose lipid metabolism.">
            <entity id="DS3.d149.s1.e0" origId="P37238,Q6GU14,M1VPI1" charOffset="77-86" type="protein" text="PPARgamma"/>
            <entity id="DS3.d149.s1.e1" origId="5437" charOffset="123-140" type="compound" text="thiazolidinedione"/>
            <pair e1="DS3.d149.s1.e1" e2="DS3.d149.s1.e0" id="DS3.d149.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d150" origId="9933589">
        <sentence id="DS3.d150.s0" origId="9933589-8" text="Thus, NH2-terminal truncation of MDC by CD26/DPP IV has profound biological consequences and may be an important regulatory mechanism during the migration of Th2 lymphocytes and dendritic cells to germinal centers and to sites of inflammation.">
            <entity id="DS3.d150.s0.e0" origId="6329" charOffset="6-10" type="compound" text="NH2-"/>
            <entity id="DS3.d150.s0.e1" origId="O00626" charOffset="33-36" type="protein" text="MDC"/>
            <entity id="DS3.d150.s0.e2" origId="P27487" charOffset="40-44" type="protein" text="CD26"/>
            <pair e1="DS3.d150.s0.e0" e2="DS3.d150.s0.e1" id="DS3.d150.s0.i0" interaction="False" />
            <pair e1="DS3.d150.s0.e0" e2="DS3.d150.s0.e2" id="DS3.d150.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d151" origId="9933591">
        <sentence id="DS3.d151.s0" origId="9933591-1" text="Candida albicans glucosamine-6-phosphate (GlcN-6-P) synthase was purified to apparent homogeneity with 52% yield from recombinant yeast YRSC-65 cells efficiently overexpressing the GFA1 gene.">
            <entity id="DS3.d151.s0.e0" origId="439217" charOffset="17-40" type="compound" text="glucosamine-6-phosphate"/>
            <entity id="DS3.d151.s0.e1" origId="P14742" charOffset="181-185" type="protein" text="GFA1"/>
            <pair e1="DS3.d151.s0.e0" e2="DS3.d151.s0.e1" id="DS3.d151.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d152" origId="9933594">
        <sentence id="DS3.d152.s0" origId="9933594-1" text="Munc18a, a mammalian neuronal homologue of Saccharomyces cerevisiae Sec1p protein, is essential for secretion, likely as a result of its high affinity interaction with the target SNARE protein syntaxin 1a (where SNARE is derived from SNAP receptor (the soluble N-ethylmaleimide-sensitive fusion protein)).">
            <entity id="DS3.d152.s0.e0" origId="P30619" charOffset="68-73" type="protein" text="Sec1p"/>
            <entity id="DS3.d152.s0.e1" origId="Q16623,Q75ME0" charOffset="193-204" type="protein" text="syntaxin 1a"/>
            <entity id="DS3.d152.s0.e2" origId="4362" charOffset="263-277" type="compound" text="ethylmaleimide"/>
            <pair e1="DS3.d152.s0.e2" e2="DS3.d152.s0.e0" id="DS3.d152.s0.i0" interaction="False" />
            <pair e1="DS3.d152.s0.e2" e2="DS3.d152.s0.e1" id="DS3.d152.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d152.s1" origId="9933594-8" text="Inhibition of Cdk5 with olomoucine decreased evoked norepinephrine secretion from chromaffin cells, an effect not observed with the inactive analogue iso-olomoucine.">
            <entity id="DS3.d152.s1.e0" origId="Q00535,A0A090N7W4" charOffset="14-18" type="protein" text="Cdk5"/>
            <entity id="DS3.d152.s1.e1" origId="4592" charOffset="24-34" type="compound" text="olomoucine"/>
            <entity id="DS3.d152.s1.e2" origId="439260" charOffset="52-66" type="compound" text="norepinephrine"/>
            <entity id="DS3.d152.s1.e3" origId="512292" charOffset="150-164" type="compound" text="iso-olomoucine"/>
            <pair e1="DS3.d152.s1.e1" e2="DS3.d152.s1.e0" id="DS3.d152.s1.i0" interaction="False" />
            <pair e1="DS3.d152.s1.e2" e2="DS3.d152.s1.e0" id="DS3.d152.s1.i1" interaction="False" />
            <pair e1="DS3.d152.s1.e3" e2="DS3.d152.s1.e0" id="DS3.d152.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d153" origId="9933595">
        <sentence id="DS3.d153.s0" origId="9933595-3" text="As revealed by molecular cloning, chicken clusterin is a 428-residue protein that migrates at 70 kDa on SDS-polyacrylamide gel electrophoresis and possesses most of the structural features of its mammalian successors.">
            <entity id="DS3.d153.s0.e0" origId="Q9YGP0,P10909" charOffset="42-51" type="protein" text="clusterin"/>
            <entity id="DS3.d153.s0.e1" origId="6579" charOffset="108-122" type="compound" text="polyacrylamide"/>
            <pair e1="DS3.d153.s0.e1" e2="DS3.d153.s0.e0" id="DS3.d153.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d154" origId="9933596">
        <sentence id="DS3.d154.s0" origId="9933596-0" text="The proximal tyrosines of the cytoplasmic domain of the beta chain of the type I interferon receptor are essential for signal transducer and activator of transcription (Stat) 2 activation. Evidence that two Stat2 sites are required to reach a threshold of interferon alpha-induced Stat2 tyrosine phosphorylation that allows normal formation of interferon-stimulated gene factor 3.">
            <entity id="DS3.d154.s0.e0" origId="P52630,R9QE65" charOffset="119-176" type="protein" text="signal transducer and activator of transcription (Stat) 2"/>
            <entity id="DS3.d154.s0.e1" origId="P52630,R9QE65" charOffset="207-212" type="protein" text="Stat2"/>
            <entity id="DS3.d154.s0.e2" origId="P52630,R9QE65" charOffset="281-286" type="protein" text="Stat2"/>
            <entity id="DS3.d154.s0.e3" origId="6057,90983769" charOffset="13-21" type="compound" text="tyrosine"/>
            <entity id="DS3.d154.s0.e4" origId="P52630,R9QE65" charOffset="344-379" type="protein" text="interferon-stimulated gene factor 3"/>
            <pair e1="DS3.d154.s0.e3" e2="DS3.d154.s0.e4" id="DS3.d154.s0.i0" interaction="False" />
            <pair e1="DS3.d154.s0.e3" e2="DS3.d154.s0.e0" id="DS3.d154.s0.i1" interaction="False" />
            <pair e1="DS3.d154.s0.e3" e2="DS3.d154.s0.e1" id="DS3.d154.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d154.s1" origId="9933596-2" text="In this report we demonstrate that there are functionally redundant phosphotyrosine-dependent and -independent binding sites for Stat2 in the alpha and beta subunits of the type I IFN-R.">
            <entity id="DS3.d154.s1.e0" origId="30819" charOffset="68-84" type="compound" text="phosphotyrosine-"/>
            <entity id="DS3.d154.s1.e1" origId="P52630,R9QE65" charOffset="129-134" type="protein" text="Stat2"/>
            <pair e1="DS3.d154.s1.e0" e2="DS3.d154.s1.e1" id="DS3.d154.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d154.s2" origId="9933596-5" text="Normal levels of Stat2 tyrosine phosphorylation, induction of ISGF3, and an antiviral effect always required the proximal tyrosines of betaL and at least one of the other Stat2 sites (Tyralpha466, 481 or betaL404-462).">
            <entity id="DS3.d154.s2.e0" origId="P52630,R9QE65" charOffset="17-22" type="protein" text="Stat2"/>
            <entity id="DS3.d154.s2.e1" origId="6057,90983769" charOffset="23-31" type="compound" text="tyrosine"/>
            <entity id="DS3.d154.s2.e2" origId="P52630,R9QE65" charOffset="62-67" type="protein" text="ISGF3"/>
            <entity id="DS3.d154.s2.e3" origId="P52630,R9QE65" charOffset="171-176" type="protein" text="Stat2"/>
            <pair e1="DS3.d154.s2.e1" e2="DS3.d154.s2.e0" id="DS3.d154.s2.i0" interaction="False" />
            <pair e1="DS3.d154.s2.e1" e2="DS3.d154.s2.e2" id="DS3.d154.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d154.s3" origId="9933596-6" text="These data suggest that a threshold of Stat2 tyrosine phosphorylation is required for complete activation of ISGF3.">
            <entity id="DS3.d154.s3.e0" origId="P52630,R9QE65" charOffset="39-44" type="protein" text="Stat2"/>
            <entity id="DS3.d154.s3.e1" origId="6057,90983769" charOffset="45-53" type="compound" text="tyrosine"/>
            <entity id="DS3.d154.s3.e2" origId="P52630,R9QE65" charOffset="109-114" type="protein" text="ISGF3"/>
            <pair e1="DS3.d154.s3.e1" e2="DS3.d154.s3.e0" id="DS3.d154.s3.i0" interaction="False" />
            <pair e1="DS3.d154.s3.e1" e2="DS3.d154.s3.e2" id="DS3.d154.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d154.s4" origId="9933596-7" text="Interestingly, a receptor in which all tyrosines were mutated to phenylalanine shows normal Stat3 phosphorylation and low levels of activation of Stat1.">
            <entity id="DS3.d154.s4.e0" origId="6140,71567,89654470,994" charOffset="65-78" type="compound" text="phenylalanine"/>
            <entity id="DS3.d154.s4.e1" origId="P40763" charOffset="92-97" type="protein" text="Stat3"/>
            <entity id="DS3.d154.s4.e2" origId="P42224" charOffset="146-151" type="protein" text="Stat1"/>
            <pair e1="DS3.d154.s4.e0" e2="DS3.d154.s4.e1" id="DS3.d154.s4.i0" interaction="False" />
            <pair e1="DS3.d154.s4.e0" e2="DS3.d154.s4.e2" id="DS3.d154.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d155" origId="9933597">
        <sentence id="DS3.d155.s0" origId="9933597-3" text="ECE-1 is a zinc metalloendopeptidase related in amino acid sequence to neprilysin, a mammalian cell-surface peptidase involved in the metabolism of numerous biologically active peptides.">
            <entity id="DS3.d155.s0.e0" origId="P42892,A0A024RAB0,A0A024RAF7,A0A024RAB2" charOffset="0-5" type="protein" text="ECE-1"/>
            <entity id="DS3.d155.s0.e1" origId="23994" charOffset="11-15" type="compound" text="zinc"/>
            <entity id="DS3.d155.s0.e2" origId="P08473" charOffset="71-81" type="protein" text="neprilysin"/>
            <pair e1="DS3.d155.s0.e1" e2="DS3.d155.s0.e2" id="DS3.d155.s0.i0" interaction="False" />
            <pair e1="DS3.d155.s0.e1" e2="DS3.d155.s0.e0" id="DS3.d155.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d155.s1" origId="9933597-6" text="ECE-1, unlike neprilysin, was found to have minimal activity against substrates smaller than hexapeptides, such as Leu-enkephalin.">
            <entity id="DS3.d155.s1.e0" origId="P42892,A0A024RAB0,A0A024RAF7,A0A024RAB2" charOffset="0-5" type="protein" text="ECE-1"/>
            <entity id="DS3.d155.s1.e1" origId="P08473" charOffset="14-24" type="protein" text="neprilysin"/>
            <entity id="DS3.d155.s1.e2" origId="57282044" charOffset="115-129" type="compound" text="Leu-enkephalin"/>
            <pair e1="DS3.d155.s1.e2" e2="DS3.d155.s1.e1" id="DS3.d155.s1.i0" interaction="False" />
            <pair e1="DS3.d155.s1.e2" e2="DS3.d155.s1.e0" id="DS3.d155.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d156" origId="9933599">
        <sentence id="DS3.d156.s0" origId="9933599-0" text="Functional and cooperative interactions between the homeodomain PDX1, Pbx, and Prep1 factors on the somatostatin promoter.">
            <entity id="DS3.d156.s0.e0" origId="P52945" charOffset="64-68" type="protein" text="PDX1"/>
            <entity id="DS3.d156.s0.e1" origId="21951637" charOffset="70-73" type="compound" text="Pbx"/>
            <entity id="DS3.d156.s0.e2" origId="P55347,Q96I87,E7EPN6,B4DGV5,Q6PKH2" charOffset="79-84" type="protein" text="Prep1"/>
            <entity id="DS3.d156.s0.e3" origId="P61278" charOffset="100-112" type="protein" text="somatostatin"/>
            <pair e1="DS3.d156.s0.e1" e2="DS3.d156.s0.e3" id="DS3.d156.s0.i0" interaction="False" />
            <pair e1="DS3.d156.s0.e1" e2="DS3.d156.s0.e0" id="DS3.d156.s0.i1" interaction="False" />
            <pair e1="DS3.d156.s0.e1" e2="DS3.d156.s0.e2" id="DS3.d156.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d156.s1" origId="9933599-4" text="In the present study, we show that the UE-A element binds a heterodimeric complex composed of a Pbx factor and the Prep1 protein, both belonging to the atypical three-amino acid loop extension homeodomain family.">
            <entity id="DS3.d156.s1.e0" origId="21951637" charOffset="96-99" type="compound" text="Pbx"/>
            <entity id="DS3.d156.s1.e1" origId="P55347,Q96I87,E7EPN6,B4DGV5,Q6PKH2" charOffset="115-120" type="protein" text="Prep1"/>
            <pair e1="DS3.d156.s1.e0" e2="DS3.d156.s1.e1" id="DS3.d156.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d156.s2" origId="9933599-8" text="Thus, the activity of the somatostatin mini-enhancer is mediated by a cooperative interaction between the Pbx-Prep1 heterodimeric complex and the pancreatic factor PDX1.">
            <entity id="DS3.d156.s2.e0" origId="P61278" charOffset="26-38" type="protein" text="somatostatin"/>
            <entity id="DS3.d156.s2.e1" origId="21951637" charOffset="106-109" type="compound" text="Pbx"/>
            <entity id="DS3.d156.s2.e2" origId="P55347,Q96I87,E7EPN6,B4DGV5,Q6PKH2" charOffset="110-115" type="protein" text="Prep1"/>
            <entity id="DS3.d156.s2.e3" origId="P52945" charOffset="164-168" type="protein" text="PDX1"/>
            <pair e1="DS3.d156.s2.e1" e2="DS3.d156.s2.e0" id="DS3.d156.s2.i0" interaction="False" />
            <pair e1="DS3.d156.s2.e1" e2="DS3.d156.s2.e3" id="DS3.d156.s2.i1" interaction="False" />
            <pair e1="DS3.d156.s2.e1" e2="DS3.d156.s2.e2" id="DS3.d156.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d157" origId="9933605">
        <sentence id="DS3.d157.s0" origId="9933605-7" text="One of these, a ternary complex composed of gp120, its receptor CD4, and the Fab of the human neutralizing monoclonal antibody 17b, diffracts to a minimum Bragg spacing of at least 2.2 A and is suitable for structural analysis.">
            <entity id="DS3.d157.s0.e0" origId="Q14624,B7ZKJ8,B2RMS9" charOffset="44-49" type="protein" text="gp120"/>
            <entity id="DS3.d157.s0.e1" origId="Q8NB91,A0A024RBW1" charOffset="77-80" type="protein" text="Fab"/>
            <entity id="DS3.d157.s0.e2" origId="11288092" charOffset="127-130" type="compound" text="17b"/>
            <pair e1="DS3.d157.s0.e2" e2="DS3.d157.s0.e1" id="DS3.d157.s0.i0" interaction="False" />
            <pair e1="DS3.d157.s0.e2" e2="DS3.d157.s0.e0" id="DS3.d157.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d158" origId="9933607">
        <sentence id="DS3.d158.s0" origId="9933607-8" text="ATP and geldanamycin, both known to bind to the same pocket of Hsp90, are inhibitors of this process, whereas molybdate, vanadate, and Nonidet P-40, which are thought to increase surface hydrophobicity of the protein, are activators.">
            <entity id="DS3.d158.s0.e0" origId="24196291,3460,13017912,5281885,45073431,5288382,46936377,5288451,56840921,5702269,57288407,71308206,71307093,73554183" charOffset="8-20" type="compound" text="geldanamycin"/>
            <entity id="DS3.d158.s0.e1" origId="24621" charOffset="110-119" type="compound" text="molybdate"/>
            <entity id="DS3.d158.s0.e2" origId="P15248" charOffset="143-147" type="protein" text="P-40"/>
            <pair e1="DS3.d158.s0.e1" e2="DS3.d158.s0.e2" id="DS3.d158.s0.i0" interaction="False" />
            <pair e1="DS3.d158.s0.e0" e2="DS3.d158.s0.e2" id="DS3.d158.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d159" origId="9933608">
        <sentence id="DS3.d159.s0" origId="9933608-4" text="ob/ob mice were found to have increased HDL cholesterol (2-fold), apoA-I (1.3-fold), and ApoA-II (4-fold).">
            <entity id="DS3.d159.s0.e0" origId="5997" charOffset="44-55" type="compound" text="cholesterol"/>
            <entity id="DS3.d159.s0.e1" origId="P09813" charOffset="89-96" type="protein" text="ApoA-II"/>
            <pair e1="DS3.d159.s0.e0" e2="DS3.d159.s0.e1" id="DS3.d159.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d159.s1" origId="9933608-7" text="Low dose leptin treatment markedly lowered HDL cholesterol and ApoA-II levels in both ob/ob mice and in lean wild-type mice, and it restored apoA-I mRNA to normal levels in ob/ob mice.">
            <entity id="DS3.d159.s1.e0" origId="P41160,Q544U0" charOffset="9-15" type="protein" text="leptin"/>
            <entity id="DS3.d159.s1.e1" origId="5997" charOffset="47-58" type="compound" text="cholesterol"/>
            <entity id="DS3.d159.s1.e2" origId="P09813" charOffset="63-70" type="protein" text="ApoA-II"/>
            <pair e1="DS3.d159.s1.e1" e2="DS3.d159.s1.e2" id="DS3.d159.s1.i0" interaction="False" />
            <pair e1="DS3.d159.s1.e1" e2="DS3.d159.s1.e0" id="DS3.d159.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d160" origId="9933611">
        <sentence id="DS3.d160.s0" origId="9933611-0" text="Ser-534 in the hinge 1 region of Arabidopsis nitrate reductase is conditionally required for binding of 14-3-3 proteins and in vitro inhibition.">
            <entity id="DS3.d160.s0.e0" origId="5951" charOffset="0-3" type="compound" text="Ser"/>
            <entity id="DS3.d160.s0.e1" origId="P11035,Q0WLH2" charOffset="33-62" type="protein" text="Arabidopsis nitrate reductase"/>
            <pair e1="DS3.d160.s0.e0" e2="DS3.d160.s0.e1" id="DS3.d160.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d161" origId="9933612">
        <sentence id="DS3.d161.s0" origId="9933612-3" text="The CBC represents a 20- and 80-kDa heterodimer (the subunits independently referred to as CBP20 and CBP80, respectively) that binds the 7-methylguanosine cap on RNAs transcribed by RNA polymerase II.">
            <entity id="DS3.d161.s0.e0" origId="P52298,B3KSB0" charOffset="91-96" type="protein" text="CBP20"/>
            <entity id="DS3.d161.s0.e1" origId="Q09161,A0A024R179" charOffset="101-106" type="protein" text="CBP80"/>
            <entity id="DS3.d161.s0.e2" origId="445404" charOffset="137-154" type="compound" text="7-methylguanosine"/>
            <pair e1="DS3.d161.s0.e2" e2="DS3.d161.s0.e1" id="DS3.d161.s0.i0" interaction="False" />
            <pair e1="DS3.d161.s0.e2" e2="DS3.d161.s0.e0" id="DS3.d161.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d162" origId="9933618">
        <sentence id="DS3.d162.s0" origId="9933618-9" text="This stabilization is confirmed by the dramatic decrease in the oxygen dissociation rate compared with sperm whale myoglobin.">
            <entity id="DS3.d162.s0.e0" origId="977" charOffset="64-70" type="compound" text="oxygen"/>
            <entity id="DS3.d162.s0.e1" origId="P02185" charOffset="115-124" type="protein" text="myoglobin"/>
            <pair e1="DS3.d162.s0.e0" e2="DS3.d162.s0.e1" id="DS3.d162.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d163" origId="9933619">
        <sentence id="DS3.d163.s0" origId="9933619-0" text="TGF-beta3, but not TGF-beta1, protects keratinocytes against 12-O-tetradecanoylphorbol-13-acetate-induced cell death in vitro and in vivo.">
            <entity id="DS3.d163.s0.e0" origId="Q91YU7,Q3TRQ9" charOffset="0-9" type="protein" text="TGF-beta3"/>
            <entity id="DS3.d163.s0.e1" origId="P04202,Q3UNK5" charOffset="19-28" type="protein" text="TGF-beta1"/>
            <entity id="DS3.d163.s0.e2" origId="27924" charOffset="61-97" type="compound" text="12-O-tetradecanoylphorbol-13-acetate"/>
            <pair e1="DS3.d163.s0.e2" e2="DS3.d163.s0.e0" id="DS3.d163.s0.i0" interaction="False" />
            <pair e1="DS3.d163.s0.e2" e2="DS3.d163.s0.e1" id="DS3.d163.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d163.s1" origId="9933619-10" text="Instead, TGF-beta3 treatment led to a significant reduction in TPA-induced c-Jun N-terminal kinase activity, which was associated and possibly explained by specific counteracting effects of TGF-beta3 on TPA-induced disruption of keratinocyte focal adhesions.">
            <entity id="DS3.d163.s1.e0" origId="Q91YU7,Q3TRQ9" charOffset="9-18" type="protein" text="TGF-beta3"/>
            <entity id="DS3.d163.s1.e1" origId="122634" charOffset="63-66" type="compound" text="TPA"/>
            <entity id="DS3.d163.s1.e2" origId="Q91YU7,Q3TRQ9" charOffset="190-199" type="protein" text="TGF-beta3"/>
            <entity id="DS3.d163.s1.e3" origId="122634" charOffset="203-206" type="compound" text="TPA"/>
            <pair e1="DS3.d163.s1.e1" e2="DS3.d163.s1.e0" id="DS3.d163.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d163.s2" origId="9933619-6" text="When exposed to TPA, the grafted skin of wild type and TGF-beta1 knockout mice underwent a hyperplastic response similar to that of normal mouse skin.">
            <entity id="DS3.d163.s2.e0" origId="122634" charOffset="16-19" type="compound" text="TPA"/>
            <entity id="DS3.d163.s2.e1" origId="P04202,Q3UNK5" charOffset="55-64" type="protein" text="TGF-beta1"/>
            <pair e1="DS3.d163.s2.e0" e2="DS3.d163.s2.e1" id="DS3.d163.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d163.s3" origId="9933619-7" text="In marked contrast, TPA treatment of TGF-beta3 knockout grafts induced widespread areas of keratinocyte cell death.">
            <entity id="DS3.d163.s3.e0" origId="122634" charOffset="20-23" type="compound" text="TPA"/>
            <entity id="DS3.d163.s3.e1" origId="Q91YU7,Q3TRQ9" charOffset="37-46" type="protein" text="TGF-beta3"/>
            <pair e1="DS3.d163.s3.e0" e2="DS3.d163.s3.e1" id="DS3.d163.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d163.s4" origId="9933619-8" text="Analysis of cultured keratinocytes treated with purified TGF-beta isoforms revealed that TGF-beta3 plays a direct and specific function in protecting keratinocytes against TPA-induced cell death.">
            <entity id="DS3.d163.s4.e0" origId="Q91YU7,Q3TRQ9" charOffset="89-98" type="protein" text="TGF-beta3"/>
            <entity id="DS3.d163.s4.e1" origId="122634" charOffset="172-175" type="compound" text="TPA"/>
            <pair e1="DS3.d163.s4.e1" e2="DS3.d163.s4.e0" id="DS3.d163.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d163.s5" origId="9933619-9" text="The protective function of TGF-beta3 on TPA-induced cell death was not because of general suppression of the signaling pathways triggered by this agent, as ERK1/2 activation occurred to a similar if not greater extent in TGF-beta3-treated versus control keratinocytes.">
            <entity id="DS3.d163.s5.e0" origId="Q91YU7,Q3TRQ9" charOffset="27-36" type="protein" text="TGF-beta3"/>
            <entity id="DS3.d163.s5.e1" origId="122634" charOffset="40-43" type="compound" text="TPA"/>
            <entity id="DS3.d163.s5.e2" origId="P63085" charOffset="156-162" type="protein" text="ERK1/2"/>
            <entity id="DS3.d163.s5.e3" origId="Q91YU7,Q3TRQ9" charOffset="221-230" type="protein" text="TGF-beta3"/>
            <pair e1="DS3.d163.s5.e1" e2="DS3.d163.s5.e0" id="DS3.d163.s5.i0" interaction="False" />
            <pair e1="DS3.d163.s5.e1" e2="DS3.d163.s5.e2" id="DS3.d163.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d164" origId="9933625">
        <sentence id="DS3.d164.s0" origId="9933625-3" text="In the search for a less complex system that is more amenable to genetic manipulation, we have identified a family of three genes (mca-1, mca-2, and mca-3) encoding putative calcium ATPases in the Caenorhabditis elegans Genome Project data and completed their transcript structure.">
            <entity id="DS3.d164.s0.e0" origId="G5EFR6,G5EC39,G5EC04,F5GU98" charOffset="131-136" type="protein" text="mca-1"/>
            <entity id="DS3.d164.s0.e1" origId="Q9TYP9" charOffset="138-143" type="protein" text="mca-2"/>
            <entity id="DS3.d164.s0.e2" origId="B7CED8,Q8MXS0,Q95XP5,Q95XP6,U4PMD6" charOffset="149-154" type="protein" text="mca-3"/>
            <entity id="DS3.d164.s0.e3" origId="22044544,5460341" charOffset="174-181" type="compound" text="calcium"/>
            <pair e1="DS3.d164.s0.e3" e2="DS3.d164.s0.e2" id="DS3.d164.s0.i0" interaction="False" />
            <pair e1="DS3.d164.s0.e3" e2="DS3.d164.s0.e1" id="DS3.d164.s0.i1" interaction="False" />
            <pair e1="DS3.d164.s0.e3" e2="DS3.d164.s0.e0" id="DS3.d164.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d164.s1" origId="9933625-4" text="In this work, we report the cloning and functional expression of the mca-1 gene, which encodes a calcium-stimulated ATPase whose features resemble those of the plasma membrane calcium adenosine triphosphatase family of mammalian cells and appears to be regulated by a multipartite promoter.">
            <entity id="DS3.d164.s1.e0" origId="G5EFR6,G5EC39,G5EC04,F5GU98" charOffset="69-74" type="protein" text="mca-1"/>
            <entity id="DS3.d164.s1.e1" origId="22044544,5460341" charOffset="97-104" type="compound" text="calcium"/>
            <entity id="DS3.d164.s1.e2" origId="22044544,5460341" charOffset="176-183" type="compound" text="calcium"/>
            <entity id="DS3.d164.s1.e3" origId="57476835,60961" charOffset="184-193" type="compound" text="adenosine"/>
            <pair e1="DS3.d164.s1.e1" e2="DS3.d164.s1.e0" id="DS3.d164.s1.i0" interaction="False" />
            <pair e1="DS3.d164.s1.e3" e2="DS3.d164.s1.e0" id="DS3.d164.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d165" origId="9933626">
        <sentence id="DS3.d165.s0" origId="9933626-2" text="To address the possibility that actin also participates in the transduction of an apoptotic signal, we have studied the response of the murine interleukin 2 (IL-2)-dependent T cell line CTLL-20 to treatment with the actin-binding compound jasplakinolide upon IL-2 deprivation.">
            <entity id="DS3.d165.s0.e0" origId="P04351" charOffset="143-156" type="protein" text="interleukin 2"/>
            <entity id="DS3.d165.s0.e1" origId="P60568,Q0GK43" charOffset="158-162" type="protein" text="IL-2"/>
            <entity id="DS3.d165.s0.e2" origId="25241877,3800,5351343,5386503,6436289,9831636" charOffset="239-253" type="compound" text="jasplakinolide"/>
            <entity id="DS3.d165.s0.e3" origId="P60568,Q0GK43" charOffset="259-263" type="protein" text="IL-2"/>
            <pair e1="DS3.d165.s0.e2" e2="DS3.d165.s0.e0" id="DS3.d165.s0.i0" interaction="False" />
            <pair e1="DS3.d165.s0.e2" e2="DS3.d165.s0.e1" id="DS3.d165.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d165.s1" origId="9933626-4" text="Treatment of CTLL-20 cells with jasplakinolide, in the presence or absence of recombinant human IL-2, altered actin morphology as assessed by confocal fluorescence microscopy.">
            <entity id="DS3.d165.s1.e0" origId="25241877,3800,5351343,5386503,6436289,9831636" charOffset="32-46" type="compound" text="jasplakinolide"/>
            <entity id="DS3.d165.s1.e1" origId="P60568,Q0GK43" charOffset="96-100" type="protein" text="IL-2"/>
            <pair e1="DS3.d165.s1.e0" e2="DS3.d165.s1.e1" id="DS3.d165.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d165.s2" origId="9933626-5" text="Jasplakinolide was not toxic to CTLL-20 cells, nor was apoptosis induced in the presence of exogenous recombinant human IL-2.">
            <entity id="DS3.d165.s2.e0" origId="25241877,3800,5351343,5386503,6436289,9831636" charOffset="0-14" type="compound" text="Jasplakinolide"/>
            <entity id="DS3.d165.s2.e1" origId="P60568,Q0GK43" charOffset="120-124" type="protein" text="IL-2"/>
            <pair e1="DS3.d165.s2.e0" e2="DS3.d165.s2.e1" id="DS3.d165.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d166" origId="9933627">
        <sentence id="DS3.d166.s0" origId="9933627-0" text="The FKBP12-rapamycin-binding domain is required for FKBP12-rapamycin-associated protein kinase activity and G1 progression.">
            <entity id="DS3.d166.s0.e0" origId="P62942,Q0VDC6,A0A087WTS4" charOffset="4-10" type="protein" text="FKBP12"/>
            <entity id="DS3.d166.s0.e1" origId="16760631,478951,5040,5358081,53627520,5374464,5497196,60150249,71296106,86583604,91454826,9854380,9962928" charOffset="11-20" type="compound" text="rapamycin"/>
            <entity id="DS3.d166.s0.e2" origId="P62942,Q0VDC6,A0A087WTS4" charOffset="52-58" type="protein" text="FKBP12"/>
            <entity id="DS3.d166.s0.e3" origId="16760631,478951,5040,5358081,53627520,5374464,5497196,60150249,71296106,86583604,91454826,9854380,9962928" charOffset="59-68" type="compound" text="rapamycin"/>
            <pair e1="DS3.d166.s0.e1" e2="DS3.d166.s0.e0" id="DS3.d166.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d166.s1" origId="9933627-1" text="The immunosuppressant rapamycin, in complex with its cellular receptor FKBP12, targets the cellular protein FKBP12-rapamycin-associated protein/mammalian target of rapamycin/rapamycin and FKBP12 target 1 (FRAP/mTOR/RAFT1) and inhibits/delays G1 cell cycle progression in mammalian cells.">
            <entity id="DS3.d166.s1.e0" origId="16760631,478951,5040,5358081,53627520,5374464,5497196,60150249,71296106,86583604,91454826,9854380,9962928" charOffset="22-31" type="compound" text="rapamycin"/>
            <entity id="DS3.d166.s1.e1" origId="P62942,Q0VDC6,A0A087WTS4" charOffset="71-77" type="protein" text="FKBP12"/>
            <entity id="DS3.d166.s1.e2" origId="P62942,Q0VDC6,A0A087WTS4" charOffset="108-114" type="protein" text="FKBP12"/>
            <entity id="DS3.d166.s1.e3" origId="16760631,478951,5040,5358081,53627520,5374464,5497196,60150249,71296106,86583604,91454826,9854380,9962928" charOffset="115-124" type="compound" text="rapamycin"/>
            <entity id="DS3.d166.s1.e4" origId="16760631,478951,5040,5358081,53627520,5374464,5497196,60150249,71296106,86583604,91454826,9854380,9962928" charOffset="115-124" type="compound" text="rapamycin"/>
            <entity id="DS3.d166.s1.e5" origId="16760631,478951,5040,5358081,53627520,5374464,5497196,60150249,71296106,86583604,91454826,9854380,9962928" charOffset="115-124" type="compound" text="rapamycin"/>
            <entity id="DS3.d166.s1.e6" origId="P62942,Q0VDC6,A0A087WTS4" charOffset="108-114" type="protein" text="FKBP12"/>
            <entity id="DS3.d166.s1.e7" origId="P42345" charOffset="205-209" type="protein" text="FRAP"/>
            <entity id="DS3.d166.s1.e8" origId="Q9JLN9" charOffset="210-214" type="protein" text="mTOR"/>
            <entity id="DS3.d166.s1.e9" origId="P42345" charOffset="215-220" type="protein" text="RAFT1"/>
            <pair e1="DS3.d166.s1.e0" e2="DS3.d166.s1.e8" id="DS3.d166.s1.i0" interaction="False" />
            <pair e1="DS3.d166.s1.e0" e2="DS3.d166.s1.e9" id="DS3.d166.s1.i1" interaction="False" />
            <pair e1="DS3.d166.s1.e0" e2="DS3.d166.s1.e1" id="DS3.d166.s1.i2" interaction="False" />
            <pair e1="DS3.d166.s1.e0" e2="DS3.d166.s1.e7" id="DS3.d166.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d166.s2" origId="9933627-2" text="As a member of the novel phosphatidylinositol kinase-related kinase family, FRAP's kinase activity is essential for its signaling function.">
            <entity id="DS3.d166.s2.e0" origId="16738692,53477912" charOffset="25-45" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d166.s2.e1" origId="P42345" charOffset="76-80" type="protein" text="FRAP"/>
            <pair e1="DS3.d166.s2.e0" e2="DS3.d166.s2.e1" id="DS3.d166.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d166.s3" origId="9933627-3" text="The FKBP12-rapamycin binding (FRB) domain in FRAP is also speculated to play an important role in FRAP function and signaling.">
            <entity id="DS3.d166.s3.e0" origId="P62942,Q0VDC6,A0A087WTS4" charOffset="4-10" type="protein" text="FKBP12"/>
            <entity id="DS3.d166.s3.e1" origId="16760631,478951,5040,5358081,53627520,5374464,5497196,60150249,71296106,86583604,91454826,9854380,9962928" charOffset="11-20" type="compound" text="rapamycin"/>
            <entity id="DS3.d166.s3.e2" origId="P14207" charOffset="30-33" type="protein" text="FRB"/>
            <entity id="DS3.d166.s3.e3" origId="P42345" charOffset="45-49" type="protein" text="FRAP"/>
            <entity id="DS3.d166.s3.e4" origId="P42345" charOffset="98-102" type="protein" text="FRAP"/>
            <pair e1="DS3.d166.s3.e1" e2="DS3.d166.s3.e2" id="DS3.d166.s3.i0" interaction="False" />
            <pair e1="DS3.d166.s3.e1" e2="DS3.d166.s3.e0" id="DS3.d166.s3.i1" interaction="False" />
            <pair e1="DS3.d166.s3.e1" e2="DS3.d166.s3.e3" id="DS3.d166.s3.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d166.s4" origId="9933627-4" text="However, the biochemical and physiological functions of FRB, as well as the mechanism for rapamycin inhibition, have been unclear.">
            <entity id="DS3.d166.s4.e0" origId="P14207" charOffset="56-59" type="protein" text="FRB"/>
            <entity id="DS3.d166.s4.e1" origId="16760631,478951,5040,5358081,53627520,5374464,5497196,60150249,71296106,86583604,91454826,9854380,9962928" charOffset="90-99" type="compound" text="rapamycin"/>
            <pair e1="DS3.d166.s4.e1" e2="DS3.d166.s4.e0" id="DS3.d166.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d166.s5" origId="9933627-7" text="The same mutation also abolishes kinase activity of FRAP without affecting ATP binding, and truncation studies suggest that upstream sequences including FRB are required for kinase activity in vitro.">
            <entity id="DS3.d166.s5.e0" origId="P42345" charOffset="52-56" type="protein" text="FRAP"/>
            <entity id="DS3.d166.s5.e1" origId="5957" charOffset="75-78" type="compound" text="ATP"/>
            <entity id="DS3.d166.s5.e2" origId="P14207" charOffset="153-156" type="protein" text="FRB"/>
            <pair e1="DS3.d166.s5.e1" e2="DS3.d166.s5.e2" id="DS3.d166.s5.i0" interaction="False" />
            <pair e1="DS3.d166.s5.e1" e2="DS3.d166.s5.e0" id="DS3.d166.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d167" origId="9933630">
        <sentence id="DS3.d167.s0" origId="9933630-2" text="Here we demonstrate that marked elevations of cyclic GMP induced by C-type natriuretic peptide (CNP), the ligand of GC-B, blocks activation of the mitogen-activated protein kinase cascade in fibroblasts.">
            <entity id="DS3.d167.s0.e0" origId="6804" charOffset="53-56" type="compound" text="GMP"/>
            <entity id="DS3.d167.s0.e1" origId="P23582,E5LCN7" charOffset="68-94" type="protein" text="C-type natriuretic peptide"/>
            <entity id="DS3.d167.s0.e2" origId="P04062,A0A0G2JLB3,A0A068F658,B7Z6S9" charOffset="116-120" type="protein" text="GC-B"/>
            <pair e1="DS3.d167.s0.e0" e2="DS3.d167.s0.e1" id="DS3.d167.s0.i0" interaction="False" />
            <pair e1="DS3.d167.s0.e0" e2="DS3.d167.s0.e2" id="DS3.d167.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d167.s1" origId="9933630-6" text="The effects of the mitogens on cellular cyclic GMP are fully explained by a direct and stable inactivation of GC-B.">
            <entity id="DS3.d167.s1.e0" origId="6804" charOffset="47-50" type="compound" text="GMP"/>
            <entity id="DS3.d167.s1.e1" origId="P04062,A0A0G2JLB3,A0A068F658,B7Z6S9" charOffset="110-114" type="protein" text="GC-B"/>
            <pair e1="DS3.d167.s1.e0" e2="DS3.d167.s1.e1" id="DS3.d167.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d167.s2" origId="9933630-9" text="These results not only establish a specific and reciprocal antagonistic relationship between mitogen-activated and GC-B-regulated signaling pathways in the fibroblast but also suggest that one of the earliest events following mitogen activation of a fibroblast is an interruption of cyclic GMP production from this receptor.">
            <entity id="DS3.d167.s2.e0" origId="P04062,A0A0G2JLB3,A0A068F658,B7Z6S9" charOffset="115-119" type="protein" text="GC-B"/>
            <entity id="DS3.d167.s2.e1" origId="6804" charOffset="290-293" type="compound" text="GMP"/>
            <pair e1="DS3.d167.s2.e1" e2="DS3.d167.s2.e0" id="DS3.d167.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d168" origId="9933631">
        <sentence id="DS3.d168.s0" origId="9933631-10" text="These results provide first evidence for cytokine-mediated activation of Sp1 in synovial fibroblast cells and its participation in regulating SAA expression by acting in conjunction with SAF.">
            <entity id="DS3.d168.s0.e0" origId="P08047" charOffset="73-76" type="protein" text="Sp1"/>
            <entity id="DS3.d168.s0.e1" origId="445892" charOffset="187-190" type="compound" text="SAF"/>
            <pair e1="DS3.d168.s0.e1" e2="DS3.d168.s0.e0" id="DS3.d168.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d168.s1" origId="9933631-4" text="Induction of SAA under this condition is mediated by promoter elements located between -254 and -226, which contains binding sites for transcription factors Sp1 and SAA activating sequence binding factor (SAF).">
            <entity id="DS3.d168.s1.e0" origId="P08047" charOffset="157-160" type="protein" text="Sp1"/>
            <entity id="DS3.d168.s1.e1" origId="445892" charOffset="205-208" type="compound" text="SAF"/>
            <pair e1="DS3.d168.s1.e1" e2="DS3.d168.s1.e0" id="DS3.d168.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d168.s2" origId="9933631-7" text="Sp1 interacts with the SAA promoter in association with SAF as an SAF.">
            <entity id="DS3.d168.s2.e0" origId="P08047" charOffset="0-3" type="protein" text="Sp1"/>
            <entity id="DS3.d168.s2.e1" origId="445892" charOffset="56-59" type="compound" text="SAF"/>
            <entity id="DS3.d168.s2.e2" origId="445892" charOffset="66-69" type="compound" text="SAF"/>
            <pair e1="DS3.d168.s2.e1" e2="DS3.d168.s2.e0" id="DS3.d168.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d168.s3" origId="9933631-9" text="Furthermore, using a phosphatase inhibitor, we demonstrated increased transactivation potential of both Sp1 and SAF as a consequence of a phosphorylation event.">
            <entity id="DS3.d168.s3.e0" origId="P08047" charOffset="104-107" type="protein" text="Sp1"/>
            <entity id="DS3.d168.s3.e1" origId="445892" charOffset="112-115" type="compound" text="SAF"/>
            <pair e1="DS3.d168.s3.e1" e2="DS3.d168.s3.e0" id="DS3.d168.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d169" origId="9933632">
        <sentence id="DS3.d169.s0" origId="9933632-3" text="This induction of apoptosis was abolished by the caspase inhibitor zVAD-fmk, correlated with the inhibition of nuclear factor-kappa B (NF-kappaB), and was mimicked by a cell permeable inhibitory peptide of NF-kappaB, SN-50; other NF-kappaB inhibitors, curcumin and pyrrolidine dithiocarbamate; and the proteasome inhibitor, MG-132.">
            <entity id="DS3.d169.s0.e0" origId="P19838,A0A024RDJ4" charOffset="111-133" type="protein" text="nuclear factor-kappa B"/>
            <entity id="DS3.d169.s0.e1" origId="969516" charOffset="252-260" type="compound" text="curcumin"/>
            <entity id="DS3.d169.s0.e2" origId="65351" charOffset="265-292" type="compound" text="pyrrolidine dithiocarbamate"/>
            <pair e1="DS3.d169.s0.e2" e2="DS3.d169.s0.e0" id="DS3.d169.s0.i0" interaction="False" />
            <pair e1="DS3.d169.s0.e1" e2="DS3.d169.s0.e0" id="DS3.d169.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d169.s1" origId="9933632-4" text="Gliotoxin also augmented dramatically the early (2-6 h) pro-apoptotic effects of tumor necrosis factor-alpha (TNF-alpha) in neutrophils and unmasked the ability of TNF-alpha to induce eosinophil apoptosis.">
            <entity id="DS3.d169.s1.e0" origId="6223" charOffset="0-9" type="compound" text="Gliotoxin"/>
            <entity id="DS3.d169.s1.e1" origId="P01375,Q5STB3" charOffset="81-108" type="protein" text="tumor necrosis factor-alpha"/>
            <entity id="DS3.d169.s1.e2" origId="P01375,Q5STB3" charOffset="110-119" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d169.s1.e3" origId="P01375,Q5STB3" charOffset="164-173" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d169.s1.e0" e2="DS3.d169.s1.e1" id="DS3.d169.s1.i0" interaction="False" />
            <pair e1="DS3.d169.s1.e0" e2="DS3.d169.s1.e2" id="DS3.d169.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d169.s2" origId="9933632-5" text="In neutrophils, TNF-alpha caused a gliotoxin-inhibitable activation of an inducible form of NF-kappaB, a response that may underlie the ability of TNF-alpha to delay apoptosis at later times (12-24 h) and limit its early killing effect.">
            <entity id="DS3.d169.s2.e0" origId="P01375,Q5STB3" charOffset="16-25" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d169.s2.e1" origId="6223" charOffset="35-44" type="compound" text="gliotoxin"/>
            <entity id="DS3.d169.s2.e2" origId="P01375,Q5STB3" charOffset="147-156" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d169.s2.e1" e2="DS3.d169.s2.e0" id="DS3.d169.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d169.s3" origId="9933632-6" text="Furthermore, cycloheximide displayed a similar capacity to enhance TNF-alpha induced neutrophil apoptosis even at time points when cycloheximide alone had no pro-apoptotic effect, suggesting that NF-kappaB may regulate the production of protein(s) which protect neutrophils from the cytotoxic effects of TNF-alpha.">
            <entity id="DS3.d169.s3.e0" origId="6197" charOffset="13-26" type="compound" text="cycloheximide"/>
            <entity id="DS3.d169.s3.e1" origId="P01375,Q5STB3" charOffset="67-76" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d169.s3.e2" origId="6197" charOffset="131-144" type="compound" text="cycloheximide"/>
            <entity id="DS3.d169.s3.e3" origId="P01375,Q5STB3" charOffset="304-313" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d169.s3.e0" e2="DS3.d169.s3.e1" id="DS3.d169.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d170" origId="9933633">
        <sentence id="DS3.d170.s0" origId="9933633-5" text="Here we show that extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38-mitogen-activated protein kinase (MAPK) pathways control the transcription and synthesis of TNF-alpha in A3.01 T cells that produce the cytokine upon T cell activation by costimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA) and ionomycin.">
            <entity id="DS3.d170.s0.e0" origId="P28482,Q1HBJ4,Q499G7" charOffset="18-55" type="protein" text="extracellular signal-regulated kinase"/>
            <entity id="DS3.d170.s0.e1" origId="P28482,Q1HBJ4,Q499G7" charOffset="57-60" type="protein" text="ERK"/>
            <entity id="DS3.d170.s0.e2" origId="P45983,A1L4K2" charOffset="63-86" type="protein" text="c-Jun N-terminal kinase"/>
            <entity id="DS3.d170.s0.e3" origId="P28482,Q1HBJ4,Q499G7" charOffset="98-101" type="protein" text="p38"/>
            <entity id="DS3.d170.s0.e4" origId="P01375,Q5STB3" charOffset="194-203" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d170.s0.e5" origId="18633279" charOffset="297-317" type="compound" text="tetradecanoylphorbol"/>
            <entity id="DS3.d170.s0.e6" origId="176" charOffset="321-328" type="compound" text="acetate"/>
            <entity id="DS3.d170.s0.e7" origId="122634" charOffset="330-333" type="compound" text="TPA"/>
            <entity id="DS3.d170.s0.e8" origId="25134244,3733,5353687,6434517,6912226" charOffset="339-348" type="compound" text="ionomycin"/>
            <pair e1="DS3.d170.s0.e8" e2="DS3.d170.s0.e2" id="DS3.d170.s0.i0" interaction="False" />
            <pair e1="DS3.d170.s0.e8" e2="DS3.d170.s0.e0" id="DS3.d170.s0.i1" interaction="False" />
            <pair e1="DS3.d170.s0.e8" e2="DS3.d170.s0.e3" id="DS3.d170.s0.i2" interaction="False" />
            <pair e1="DS3.d170.s0.e8" e2="DS3.d170.s0.e4" id="DS3.d170.s0.i3" interaction="False" />
            <pair e1="DS3.d170.s0.e8" e2="DS3.d170.s0.e1" id="DS3.d170.s0.i4" interaction="False" />
            <pair e1="DS3.d170.s0.e5" e2="DS3.d170.s0.e2" id="DS3.d170.s0.i5" interaction="False" />
            <pair e1="DS3.d170.s0.e5" e2="DS3.d170.s0.e0" id="DS3.d170.s0.i6" interaction="False" />
            <pair e1="DS3.d170.s0.e5" e2="DS3.d170.s0.e3" id="DS3.d170.s0.i7" interaction="False" />
            <pair e1="DS3.d170.s0.e5" e2="DS3.d170.s0.e4" id="DS3.d170.s0.i8" interaction="False" />
            <pair e1="DS3.d170.s0.e5" e2="DS3.d170.s0.e1" id="DS3.d170.s0.i9" interaction="False" />
            <pair e1="DS3.d170.s0.e7" e2="DS3.d170.s0.e2" id="DS3.d170.s0.i10" interaction="False" />
            <pair e1="DS3.d170.s0.e7" e2="DS3.d170.s0.e0" id="DS3.d170.s0.i11" interaction="False" />
            <pair e1="DS3.d170.s0.e7" e2="DS3.d170.s0.e3" id="DS3.d170.s0.i12" interaction="False" />
            <pair e1="DS3.d170.s0.e7" e2="DS3.d170.s0.e4" id="DS3.d170.s0.i13" interaction="False" />
            <pair e1="DS3.d170.s0.e7" e2="DS3.d170.s0.e1" id="DS3.d170.s0.i14" interaction="False" />
            <pair e1="DS3.d170.s0.e6" e2="DS3.d170.s0.e2" id="DS3.d170.s0.i15" interaction="False" />
            <pair e1="DS3.d170.s0.e6" e2="DS3.d170.s0.e0" id="DS3.d170.s0.i16" interaction="False" />
            <pair e1="DS3.d170.s0.e6" e2="DS3.d170.s0.e3" id="DS3.d170.s0.i17" interaction="False" />
            <pair e1="DS3.d170.s0.e6" e2="DS3.d170.s0.e4" id="DS3.d170.s0.i18" interaction="False" />
            <pair e1="DS3.d170.s0.e6" e2="DS3.d170.s0.e1" id="DS3.d170.s0.i19" interaction="False" />
        </sentence>
        <sentence id="DS3.d170.s1" origId="9933633-7" text="Furthermore, blockage of all three pathways almost abolishes TPA/ionomycin-induced transcriptional activation of the TNF-alpha promoter.">
            <entity id="DS3.d170.s1.e0" origId="122634" charOffset="61-64" type="compound" text="TPA"/>
            <entity id="DS3.d170.s1.e1" origId="25134244,3733,5353687,6434517,6912226" charOffset="65-74" type="compound" text="ionomycin"/>
            <entity id="DS3.d170.s1.e2" origId="P01375,Q5STB3" charOffset="117-126" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d170.s1.e1" e2="DS3.d170.s1.e2" id="DS3.d170.s1.i0" interaction="False" />
            <pair e1="DS3.d170.s1.e0" e2="DS3.d170.s1.e2" id="DS3.d170.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d170.s2" origId="9933633-8" text="Selective inhibition of one or more MAPK pathways impairs TNF-alpha induction by TPA/ionomycin, indicating a cooperation between these signal transduction pathways.">
            <entity id="DS3.d170.s2.e0" origId="P01375,Q5STB3" charOffset="58-67" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d170.s2.e1" origId="122634" charOffset="81-84" type="compound" text="TPA"/>
            <entity id="DS3.d170.s2.e2" origId="25134244,3733,5353687,6434517,6912226" charOffset="85-94" type="compound" text="ionomycin"/>
            <pair e1="DS3.d170.s2.e2" e2="DS3.d170.s2.e0" id="DS3.d170.s2.i0" interaction="False" />
            <pair e1="DS3.d170.s2.e1" e2="DS3.d170.s2.e0" id="DS3.d170.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d171" origId="9933634">
        <sentence id="DS3.d171.s0" origId="9933634-5" text="The most substantial change involves the essential factor SL1, which is a multisubunit complex that contains the TATA-binding protein and three TATA-binding protein-associated factors (TAFs).">
            <entity id="DS3.d171.s0.e0" origId="24794390" charOffset="58-61" type="compound" text="SL1"/>
            <entity id="DS3.d171.s0.e1" origId="P29037,Q6RI65" charOffset="113-133" type="protein" text="TATA-binding protein"/>
            <entity id="DS3.d171.s0.e2" origId="P29037,Q6RI65" charOffset="144-164" type="protein" text="TATA-binding protein"/>
            <pair e1="DS3.d171.s0.e0" e2="DS3.d171.s0.e1" id="DS3.d171.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d172" origId="9933635">
        <sentence id="DS3.d172.s0" origId="9933635-3" text="After treatment of Jurkat T lymphocytic leukemia cells with anti-Fas antibody or A549 lung cancer cells with topotecan, etoposide, or paclitaxel, the topoisomerase I fragment comigrated with the product that resulted from caspase-3 cleavage at DDVD146 downward arrowY.">
            <entity id="DS3.d172.s0.e0" origId="60700" charOffset="109-118" type="compound" text="topotecan"/>
            <entity id="DS3.d172.s0.e1" origId="11758093,17571827,3310,439525,45356822,50989217,59360017,5284558,6419930,6610299,90657341,9916469,6708815" charOffset="120-129" type="compound" text="etoposide"/>
            <entity id="DS3.d172.s0.e2" origId="36314,44155032,4666,441276,5352019,53313247,6915727,6713921" charOffset="134-144" type="compound" text="paclitaxel"/>
            <entity id="DS3.d172.s0.e3" origId="P42574" charOffset="222-231" type="protein" text="caspase-3"/>
            <pair e1="DS3.d172.s0.e0" e2="DS3.d172.s0.e3" id="DS3.d172.s0.i0" interaction="False" />
            <pair e1="DS3.d172.s0.e1" e2="DS3.d172.s0.e3" id="DS3.d172.s0.i1" interaction="False" />
            <pair e1="DS3.d172.s0.e2" e2="DS3.d172.s0.e3" id="DS3.d172.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d172.s1" origId="9933635-7" text="These observations indicate that topoisomerase I is a substrate of caspase-3 and possibly caspase-6, but is cleaved at sequences that differ from those ordinarily preferred by these enzymes, thereby providing a potential explanation why topoisomerase I cleavage lags behind that of classical caspase substrates such as poly(ADP-ribose) polymerase and lamin B1.">
            <entity id="DS3.d172.s1.e0" origId="P42574" charOffset="67-76" type="protein" text="caspase-3"/>
            <entity id="DS3.d172.s1.e1" origId="P55212" charOffset="90-99" type="protein" text="caspase-6"/>
            <entity id="DS3.d172.s1.e2" origId="192,44415180,445794" charOffset="324-334" type="compound" text="ADP-ribose"/>
            <pair e1="DS3.d172.s1.e2" e2="DS3.d172.s1.e0" id="DS3.d172.s1.i0" interaction="False" />
            <pair e1="DS3.d172.s1.e2" e2="DS3.d172.s1.e1" id="DS3.d172.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d173" origId="9933636">
        <sentence id="DS3.d173.s0" origId="9933636-0" text="Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis.">
            <entity id="DS3.d173.s0.e0" origId="P47811,Q5U421" charOffset="34-37" type="protein" text="p38"/>
            <entity id="DS3.d173.s0.e1" origId="16760631,478951,49652385,5040,5358081,53627520,5374464,5460439,60150249,70789198,71296106,86583604,91454826,9854380" charOffset="44-53" type="compound" text="rapamycin"/>
            <pair e1="DS3.d173.s0.e1" e2="DS3.d173.s0.e0" id="DS3.d173.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d173.s1" origId="9933636-2" text="Consistent with these findings, SB 203580 (a specific inhibitor of SAPK2/p38) or rapamycin (which blocks the activation of p70 S6 kinase) prevented the formation of multinucleated myotubes, as well as the expression of muscle-specific proteins that included SAPK3 (another MAPK family member).">
            <entity id="DS3.d173.s1.e0" origId="Q9WUI1" charOffset="67-72" type="protein" text="SAPK2"/>
            <entity id="DS3.d173.s1.e1" origId="P47811,Q5U421" charOffset="73-76" type="protein" text="p38"/>
            <entity id="DS3.d173.s1.e2" origId="16760631,478951,49652385,5040,5358081,53627520,5374464,5460439,60150249,70789198,71296106,86583604,91454826,9854380" charOffset="81-90" type="compound" text="rapamycin"/>
            <entity id="DS3.d173.s1.e3" origId="O08911" charOffset="258-263" type="protein" text="SAPK3"/>
            <pair e1="DS3.d173.s1.e2" e2="DS3.d173.s1.e1" id="DS3.d173.s1.i0" interaction="False" />
            <pair e1="DS3.d173.s1.e2" e2="DS3.d173.s1.e0" id="DS3.d173.s1.i1" interaction="False" />
            <pair e1="DS3.d173.s1.e2" e2="DS3.d173.s1.e3" id="DS3.d173.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d173.s2" origId="9933636-4" text="Surprisingly, the slow activation of p70 S6 kinase during differentiation was not only prevented by rapamycin but also by SB 203580, and the activation of MAPKAP kinase-2 (an in vivo substrate of SAPK2/p38) was not only prevented by SB 203580 but also by rapamycin.">
            <entity id="DS3.d173.s2.e0" origId="16760631,478951,49652385,5040,5358081,53627520,5374464,5460439,60150249,70789198,71296106,86583604,91454826,9854380" charOffset="100-109" type="compound" text="rapamycin"/>
            <entity id="DS3.d173.s2.e1" origId="P49138,Q3U2P8" charOffset="155-170" type="protein" text="MAPKAP kinase-2"/>
            <entity id="DS3.d173.s2.e2" origId="Q9WUI1" charOffset="196-201" type="protein" text="SAPK2"/>
            <entity id="DS3.d173.s2.e3" origId="P47811,Q5U421" charOffset="202-205" type="protein" text="p38"/>
            <entity id="DS3.d173.s2.e4" origId="16760631,478951,49652385,5040,5358081,53627520,5374464,5460439,60150249,70789198,71296106,86583604,91454826,9854380" charOffset="255-264" type="compound" text="rapamycin"/>
            <pair e1="DS3.d173.s2.e0" e2="DS3.d173.s2.e3" id="DS3.d173.s2.i0" interaction="False" />
            <pair e1="DS3.d173.s2.e0" e2="DS3.d173.s2.e1" id="DS3.d173.s2.i1" interaction="False" />
            <pair e1="DS3.d173.s2.e0" e2="DS3.d173.s2.e2" id="DS3.d173.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d173.s3" origId="9933636-5" text="In contrast, the acute activation of p70 S6 kinase in C2C12 myoblasts induced by phorbol esters was unaffected by SB 203580 and the acute activation of MAPKAP kinase-2 induced by anisomycin was unaffected by rapamycin.">
            <entity id="DS3.d173.s3.e0" origId="442070" charOffset="81-88" type="compound" text="phorbol"/>
            <entity id="DS3.d173.s3.e1" origId="P49138,Q3U2P8" charOffset="152-167" type="protein" text="MAPKAP kinase-2"/>
            <entity id="DS3.d173.s3.e2" origId="253602" charOffset="179-189" type="compound" text="anisomycin"/>
            <entity id="DS3.d173.s3.e3" origId="16760631,478951,49652385,5040,5358081,5374464,53627520,5460439,60150249,70789198,71296106,86583604,91454826,9854380" charOffset="208-217" type="compound" text="rapamycin"/>
            <pair e1="DS3.d173.s3.e3" e2="DS3.d173.s3.e1" id="DS3.d173.s3.i0" interaction="False" />
            <pair e1="DS3.d173.s3.e0" e2="DS3.d173.s3.e1" id="DS3.d173.s3.i1" interaction="False" />
            <pair e1="DS3.d173.s3.e2" e2="DS3.d173.s3.e1" id="DS3.d173.s3.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d174" origId="9933637">
        <sentence id="DS3.d174.s0" origId="9933637-0" text="Sustained activation of the mitogen-activated protein kinase pathway. A mechanism underlying receptor tyrosine kinase specificity for matrix metalloproteinase-9 induction and cell migration.">
            <entity id="DS3.d174.s0.e0" origId="6057,90983769" charOffset="102-110" type="compound" text="tyrosine"/>
            <entity id="DS3.d174.s0.e1" origId="P14780" charOffset="134-160" type="protein" text="matrix metalloproteinase-9"/>
            <pair e1="DS3.d174.s0.e0" e2="DS3.d174.s0.e1" id="DS3.d174.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d174.s1" origId="9933637-2" text="We have shown previously that although many receptor tyrosine kinase ligands are mitogens for keratinocytes, cell migration and induction of the 92-kilodalton gelatinase/matrix metalloproteinase (MMP)-9 are selectively regulated by the epidermal growth factor and scatter factor/hepatocyte growth factor receptors.">
            <entity id="DS3.d174.s1.e0" origId="6057,90983769" charOffset="53-61" type="compound" text="tyrosine"/>
            <entity id="DS3.d174.s1.e1" origId="P14780" charOffset="159-202" type="protein" text="gelatinase/matrix metalloproteinase (MMP)-9"/>
            <pair e1="DS3.d174.s1.e0" e2="DS3.d174.s1.e1" id="DS3.d174.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d175" origId="9933640">
        <sentence id="DS3.d175.s0" origId="9933640-5" text="The assay is based on highly active MxA GTPase as effector molecules, Thogoto virus nucleocapsids as viral targets, and guanosine 5'-O-(3-thiotriphosphate) (GTPgammaS) as a stabilizing factor.">
            <entity id="DS3.d175.s0.e0" origId="P20591" charOffset="36-39" type="protein" text="MxA"/>
            <entity id="DS3.d175.s0.e1" origId="6802" charOffset="120-129" type="compound" text="guanosine"/>
            <entity id="DS3.d175.s0.e2" origId="1764" charOffset="157-166" type="compound" text="GTPgammaS"/>
            <pair e1="DS3.d175.s0.e2" e2="DS3.d175.s0.e0" id="DS3.d175.s0.i0" interaction="False" />
            <pair e1="DS3.d175.s0.e1" e2="DS3.d175.s0.e0" id="DS3.d175.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d175.s1" origId="9933640-7" text="This interaction requires the presence of GTPgammaS and is mediated by domains in the carboxyl-terminal moiety of MxA.">
            <entity id="DS3.d175.s1.e0" origId="1764" charOffset="42-51" type="compound" text="GTPgammaS"/>
            <entity id="DS3.d175.s1.e1" origId="P20591" charOffset="114-117" type="protein" text="MxA"/>
            <pair e1="DS3.d175.s1.e0" e2="DS3.d175.s1.e1" id="DS3.d175.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d176" origId="9933642">
        <sentence id="DS3.d176.s0" origId="9933642-6" text="Transfection of the coding region of rat NHE5 into NHE-deficient PS120 cells resulted in Na+/H+ exchange activity that was relatively insensitive to the amiloride analogue, 5-(N-ethyl-N-isopropyl) amiloride, with a half-maximal inhibitory concentration (IC50) of 1.">
            <entity id="DS3.d176.s0.e0" origId="Q14940,Q9NSW9" charOffset="41-45" type="protein" text="NHE5"/>
            <entity id="DS3.d176.s0.e1" origId="16231" charOffset="153-162" type="compound" text="amiloride"/>
            <entity id="DS3.d176.s0.e2" origId="23134249" charOffset="178-183" type="compound" text="ethyl"/>
            <entity id="DS3.d176.s0.e3" origId="16231" charOffset="197-206" type="compound" text="amiloride"/>
            <pair e1="DS3.d176.s0.e2" e2="DS3.d176.s0.e0" id="DS3.d176.s0.i0" interaction="False" />
            <pair e1="DS3.d176.s0.e1" e2="DS3.d176.s0.e0" id="DS3.d176.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d177" origId="9933643">
        <sentence id="DS3.d177.s0" origId="9933643-3" text="The ER accumulation of vesicular stomatitis glycoprotein (VSV-G), a transmembrane protein, or the soluble PiZ variant of alpha1-antitrypsin, reduced levels of general COPII vesicle formation in vivo.">
            <entity id="DS3.d177.s0.e0" origId="11029524" charOffset="106-109" type="compound" text="PiZ"/>
            <entity id="DS3.d177.s0.e1" origId="P01009,E9KL23" charOffset="121-139" type="protein" text="alpha1-antitrypsin"/>
            <pair e1="DS3.d177.s0.e0" e2="DS3.d177.s0.e1" id="DS3.d177.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d178" origId="9933644">
        <sentence id="DS3.d178.s0" origId="9933644-0" text="The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1.">
            <entity id="DS3.d178.s0.e0" origId="P18146,Q546S1" charOffset="25-30" type="protein" text="EGR-1"/>
            <entity id="DS3.d178.s0.e1" origId="24820487" charOffset="79-85" type="compound" text="HT1080"/>
            <entity id="DS3.d178.s0.e2" origId="P01137" charOffset="120-152" type="protein" text="transforming growth factor-beta1"/>
            <entity id="DS3.d178.s0.e3" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="154-165" type="protein" text="fibronectin"/>
            <entity id="DS3.d178.s0.e4" origId="P05121,A0A024QYT5" charOffset="171-204" type="protein" text="plasminogen activator inhibitor-1"/>
            <pair e1="DS3.d178.s0.e1" e2="DS3.d178.s0.e3" id="DS3.d178.s0.i0" interaction="False" />
            <pair e1="DS3.d178.s0.e1" e2="DS3.d178.s0.e0" id="DS3.d178.s0.i1" interaction="False" />
            <pair e1="DS3.d178.s0.e1" e2="DS3.d178.s0.e2" id="DS3.d178.s0.i2" interaction="False" />
            <pair e1="DS3.d178.s0.e1" e2="DS3.d178.s0.e4" id="DS3.d178.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d178.s1" origId="9933644-13" text="Moreover, adhesion was greatly enhanced in EGR-1-regulated cells and was reversed by treatment with Arg-Gly-Asp (RGD) or PAI-1 antibody indicating that the secreted proteins are functional.">
            <entity id="DS3.d178.s1.e0" origId="P18146,Q546S1" charOffset="43-48" type="protein" text="EGR-1"/>
            <entity id="DS3.d178.s1.e1" origId="104802" charOffset="100-111" type="compound" text="Arg-Gly-Asp"/>
            <entity id="DS3.d178.s1.e2" origId="P05121,A0A024QYT5" charOffset="121-126" type="protein" text="PAI-1"/>
            <pair e1="DS3.d178.s1.e1" e2="DS3.d178.s1.e0" id="DS3.d178.s1.i0" interaction="False" />
            <pair e1="DS3.d178.s1.e1" e2="DS3.d178.s1.e2" id="DS3.d178.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d178.s2" origId="9933644-1" text="Re-expression of EGR-1 in fibrosarcoma HT1080 suppresses transformation including tumorigenicity (Huang, R.-P., Liu, C., Fan, Y., Mercola, D., and Adamson, E. (1995) Cancer Res.">
            <entity id="DS3.d178.s2.e0" origId="P18146,Q546S1" charOffset="17-22" type="protein" text="EGR-1"/>
            <entity id="DS3.d178.s2.e1" origId="24820487" charOffset="39-45" type="compound" text="HT1080"/>
            <entity id="DS3.d178.s2.e2" origId="Q92636" charOffset="121-124" type="protein" text="Fan"/>
            <pair e1="DS3.d178.s2.e1" e2="DS3.d178.s2.e2" id="DS3.d178.s2.i0" interaction="False" />
            <pair e1="DS3.d178.s2.e1" e2="DS3.d178.s2.e0" id="DS3.d178.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d179" origId="9933646">
        <sentence id="DS3.d179.s0" origId="9933646-4" text="Notably, single alanine substitutions at Lys547 and Lys617 reduced TIMP-2 binding by an order of magnitude from that of the recombinant wild-type C domain.">
            <entity id="DS3.d179.s0.e0" origId="5950,602" charOffset="16-23" type="compound" text="alanine"/>
            <entity id="DS3.d179.s0.e1" origId="P16035" charOffset="67-73" type="protein" text="TIMP-2"/>
            <pair e1="DS3.d179.s0.e0" e2="DS3.d179.s0.e1" id="DS3.d179.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d179.s1" origId="9933646-7" text="Because the double mutation K566A/K568A also did not alter TIMP-2 binding, these data do not confirm previously reported chimera studies that indicated the importance of the triple lysine cluster at positions 566/567/568 in TIMP-2 binding.">
            <entity id="DS3.d179.s1.e0" origId="P16035" charOffset="59-65" type="protein" text="TIMP-2"/>
            <entity id="DS3.d179.s1.e1" origId="57449,5962,866" charOffset="181-187" type="compound" text="lysine"/>
            <entity id="DS3.d179.s1.e2" origId="P16035" charOffset="224-230" type="protein" text="TIMP-2"/>
            <pair e1="DS3.d179.s1.e1" e2="DS3.d179.s1.e0" id="DS3.d179.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d179.s2" origId="9933646-8" text="Nonetheless, a subtle role in TIMP-2 interaction for the 566/567/568-lysine triad is indicated from the enhanced reduction in TIMP-2 binding that occurs when mutations here were combined with K617A.">
            <entity id="DS3.d179.s2.e0" origId="P16035" charOffset="30-36" type="protein" text="TIMP-2"/>
            <entity id="DS3.d179.s2.e1" origId="57449,5962,866" charOffset="69-75" type="compound" text="lysine"/>
            <entity id="DS3.d179.s2.e2" origId="P16035" charOffset="126-132" type="protein" text="TIMP-2"/>
            <pair e1="DS3.d179.s2.e1" e2="DS3.d179.s2.e0" id="DS3.d179.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d180" origId="9933647">
        <sentence id="DS3.d180.s0" origId="9933647-2" text="Our results indicate that the primary locus of activation lies in the carboxyl-half of the molecule, although the extent of activation can be influenced by the amino-proximal region, particularly by the Raf-1 zinc finger.">
            <entity id="DS3.d180.s0.e0" origId="P04049,L7RRS6,B4E0X2" charOffset="203-208" type="protein" text="Raf-1"/>
            <entity id="DS3.d180.s0.e1" origId="23994" charOffset="209-213" type="compound" text="zinc"/>
            <pair e1="DS3.d180.s0.e1" e2="DS3.d180.s0.e0" id="DS3.d180.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d180.s1" origId="9933647-4" text="In addition, neither Mek1 nor Mek2 are stably activated in coordination with Raf-1 in nocodazole-arrested cells.">
            <entity id="DS3.d180.s1.e0" origId="Q02750,A4QPA9,B4DFY5" charOffset="21-25" type="protein" text="Mek1"/>
            <entity id="DS3.d180.s1.e1" origId="P36507,B3KS97" charOffset="30-34" type="protein" text="Mek2"/>
            <entity id="DS3.d180.s1.e2" origId="P04049,L7RRS6,B4E0X2" charOffset="77-82" type="protein" text="Raf-1"/>
            <entity id="DS3.d180.s1.e3" origId="4122" charOffset="86-96" type="compound" text="nocodazole"/>
            <pair e1="DS3.d180.s1.e3" e2="DS3.d180.s1.e2" id="DS3.d180.s1.i0" interaction="False" />
            <pair e1="DS3.d180.s1.e3" e2="DS3.d180.s1.e1" id="DS3.d180.s1.i1" interaction="False" />
            <pair e1="DS3.d180.s1.e3" e2="DS3.d180.s1.e0" id="DS3.d180.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d181" origId="9933650">
        <sentence id="DS3.d181.s0" origId="9933650-10" text="Removal of either the sulfate residue or the N-acetylgalactosamine residue from the oligosaccharides abolished both the proliferation-inhibition and IL-1beta binding activities.">
            <entity id="DS3.d181.s0.e0" origId="1117" charOffset="22-29" type="compound" text="sulfate"/>
            <entity id="DS3.d181.s0.e1" origId="35717,440552,84265,899,57455154" charOffset="45-66" type="compound" text="N-acetylgalactosamine"/>
            <entity id="DS3.d181.s0.e2" origId="P01584" charOffset="149-157" type="protein" text="IL-1beta"/>
            <pair e1="DS3.d181.s0.e0" e2="DS3.d181.s0.e2" id="DS3.d181.s0.i0" interaction="False" />
            <pair e1="DS3.d181.s0.e1" e2="DS3.d181.s0.e2" id="DS3.d181.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d181.s1" origId="9933650-11" text="Since IL-1beta did not bind to thyroid-stimulating hormone, which has the sulfate group at C-4 of the N-acetylgalactosamine residue in its N-linked sugar chains, the binding of IL-1beta toward oligosaccharides in fraction AR was considered to be highly specific.">
            <entity id="DS3.d181.s1.e0" origId="P01584" charOffset="6-14" type="protein" text="IL-1beta"/>
            <entity id="DS3.d181.s1.e1" origId="1117" charOffset="74-81" type="compound" text="sulfate"/>
            <entity id="DS3.d181.s1.e2" origId="35717,440552,84265,899,57455154" charOffset="102-123" type="compound" text="N-acetylgalactosamine"/>
            <entity id="DS3.d181.s1.e3" origId="P01584" charOffset="177-185" type="protein" text="IL-1beta"/>
            <pair e1="DS3.d181.s1.e1" e2="DS3.d181.s1.e0" id="DS3.d181.s1.i0" interaction="False" />
            <pair e1="DS3.d181.s1.e2" e2="DS3.d181.s1.e0" id="DS3.d181.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d181.s2" origId="9933650-9" text="Fractionation of the oligosaccharides indicated that only oligosaccharides containing an N-acetylgalactosamine residue and a sulfate residue bound specifically to IL-1beta.">
            <entity id="DS3.d181.s2.e0" origId="35717,440552,84265,899,57455154" charOffset="89-110" type="compound" text="N-acetylgalactosamine"/>
            <entity id="DS3.d181.s2.e1" origId="1117" charOffset="125-132" type="compound" text="sulfate"/>
            <entity id="DS3.d181.s2.e2" origId="P01584" charOffset="163-171" type="protein" text="IL-1beta"/>
            <pair e1="DS3.d181.s2.e1" e2="DS3.d181.s2.e2" id="DS3.d181.s2.i0" interaction="False" />
            <pair e1="DS3.d181.s2.e0" e2="DS3.d181.s2.e2" id="DS3.d181.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d182" origId="9933651">
        <sentence id="DS3.d182.s0" origId="9933651-0" text="Hypoxia alters iron-regulatory protein-1 binding capacity and modulates cellular iron homeostasis in human hepatoma and erythroleukemia cells.">
            <entity id="DS3.d182.s0.e0" origId="P21399,V9HWB7,Q9HBB2" charOffset="15-40" type="protein" text="iron-regulatory protein-1"/>
            <entity id="DS3.d182.s0.e1" origId="23925,67172434" charOffset="15-19" type="compound" text="iron"/>
            <pair e1="DS3.d182.s0.e1" e2="DS3.d182.s0.e0" id="DS3.d182.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d182.s1" origId="9933651-11" text="273, 7588-7593) in which a 3% oxygen atmosphere reduced IRE/IRP-1 binding in rat hepatoma cells.">
            <entity id="DS3.d182.s1.e0" origId="977" charOffset="30-36" type="compound" text="oxygen"/>
            <entity id="DS3.d182.s1.e1" origId="Q63270" charOffset="56-65" type="protein" text="IRE/IRP-1"/>
            <pair e1="DS3.d182.s1.e0" e2="DS3.d182.s1.e1" id="DS3.d182.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d182.s2" origId="9933651-13" text="In aggregate with other investigations involving responses to hypoxia, iron, or nitric oxide, our data indicate that cellular iron metabolic responses are complex and that IRE/IRP-1 interactions vary between cell lines and perhaps between species.">
            <entity id="DS3.d182.s2.e0" origId="23925,67172434" charOffset="71-75" type="compound" text="iron"/>
            <entity id="DS3.d182.s2.e1" origId="145068" charOffset="80-92" type="compound" text="nitric oxide"/>
            <entity id="DS3.d182.s2.e2" origId="23925,67172434" charOffset="126-130" type="compound" text="iron"/>
            <entity id="DS3.d182.s2.e3" origId="Q63270" charOffset="172-181" type="protein" text="IRE/IRP-1"/>
            <pair e1="DS3.d182.s2.e1" e2="DS3.d182.s2.e3" id="DS3.d182.s2.i0" interaction="False" />
            <pair e1="DS3.d182.s2.e0" e2="DS3.d182.s2.e3" id="DS3.d182.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d182.s3" origId="9933651-1" text="Ferritin and transferrin receptor expression is post-transcriptionally regulated by a conserved mRNA sequence termed the iron-responsive element (IRE), to which a transacting protein called the iron-regulatory protein (IRP) is bound.">
            <entity id="DS3.d182.s3.e0" origId="P02786" charOffset="13-33" type="protein" text="transferrin receptor"/>
            <entity id="DS3.d182.s3.e1" origId="23925,67172434" charOffset="121-125" type="compound" text="iron"/>
            <entity id="DS3.d182.s3.e2" origId="23925,67172434" charOffset="194-198" type="compound" text="iron"/>
            <entity id="DS3.d182.s3.e3" origId="444833" charOffset="219-222" type="compound" text="IRP"/>
            <pair e1="DS3.d182.s3.e3" e2="DS3.d182.s3.e0" id="DS3.d182.s3.i0" interaction="False" />
            <pair e1="DS3.d182.s3.e1" e2="DS3.d182.s3.e0" id="DS3.d182.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d182.s4" origId="9933651-3" text="Using the human hepatoma cell line Hep3B as a model, we found that 16 h in a 1% oxygen atmosphere markedly increases IRE/IRP-1 binding as assessed by electromobility shift assay.">
            <entity id="DS3.d182.s4.e0" origId="977" charOffset="80-86" type="compound" text="oxygen"/>
            <entity id="DS3.d182.s4.e1" origId="Q63270" charOffset="117-126" type="protein" text="IRE/IRP-1"/>
            <pair e1="DS3.d182.s4.e0" e2="DS3.d182.s4.e1" id="DS3.d182.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d183" origId="9933659">
        <sentence id="DS3.d183.s0" origId="9933659-1" text="Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) has been shown to improve the diagnostic accuracy in the staging of malignant lymphomas, based on the metabolic signal of the lesions.">
            <entity id="DS3.d183.s0.e0" origId="68614" charOffset="0-30" type="compound" text="Fluorine-18 fluorodeoxyglucose"/>
            <entity id="DS3.d183.s0.e1" origId="Q53HV7,A0A024RAZ8" charOffset="61-64" type="protein" text="FDG"/>
            <pair e1="DS3.d183.s0.e0" e2="DS3.d183.s0.e1" id="DS3.d183.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d184" origId="9933660">
        <sentence id="DS3.d184.s0" origId="9933660-1" text="The capabilities and limitations of two-(2D) and three-dimensional (3D) fluorine-18 fluorodeoxyglucose positron emission tomography (FDG-PET) in detecting small tumors and lymph nodes were studied in a phantom modeling the human chest and axilla.">
            <entity id="DS3.d184.s0.e0" origId="68614" charOffset="72-102" type="compound" text="fluorine-18 fluorodeoxyglucose"/>
            <entity id="DS3.d184.s0.e1" origId="Q53HV7,A0A024RAZ8" charOffset="133-136" type="protein" text="FDG"/>
            <pair e1="DS3.d184.s0.e0" e2="DS3.d184.s0.e1" id="DS3.d184.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d184.s1" origId="9933660-3" text="Five hollow spheres ranging in diameter from 3 mm to 15 mm were filled with carbon-11 and placed in the axillary and mediastinal regions of an anthropomorphic phantom containing hollow organs filled with 18F to simulate FDG uptake 1 h after injection.">
            <entity id="DS3.d184.s1.e0" origId="114789" charOffset="76-85" type="compound" text="carbon-11"/>
            <entity id="DS3.d184.s1.e1" origId="Q53HV7,A0A024RAZ8" charOffset="220-223" type="protein" text="FDG"/>
            <pair e1="DS3.d184.s1.e0" e2="DS3.d184.s1.e1" id="DS3.d184.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d185" origId="9933661">
        <sentence id="DS3.d185.s0" origId="9933661-0" text="Comparison of iodine-123 epidepride and iodine-123 IBZM for dopamine D2 receptor imaging in clinically non-functioning pituitary macroadenomas and macroprolactinomas.">
            <entity id="DS3.d185.s0.e0" origId="105140" charOffset="14-24" type="compound" text="iodine-123"/>
            <entity id="DS3.d185.s0.e1" origId="86101" charOffset="25-35" type="compound" text="epidepride"/>
            <entity id="DS3.d185.s0.e2" origId="105140" charOffset="40-50" type="compound" text="iodine-123"/>
            <entity id="DS3.d185.s0.e3" origId="107995" charOffset="51-55" type="compound" text="IBZM"/>
            <entity id="DS3.d185.s0.e4" origId="P14416,A0A024R3C5,A0A024R3I6" charOffset="60-80" type="protein" text="dopamine D2 receptor"/>
            <pair e1="DS3.d185.s0.e3" e2="DS3.d185.s0.e4" id="DS3.d185.s0.i0" interaction="False" />
            <pair e1="DS3.d185.s0.e1" e2="DS3.d185.s0.e4" id="DS3.d185.s0.i1" interaction="False" />
            <pair e1="DS3.d185.s0.e0" e2="DS3.d185.s0.e4" id="DS3.d185.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d186" origId="9933674">
        <sentence id="DS3.d186.s0" origId="9933674-0" text="Fan-shaped hepatic parenchymal damage after ethanol injection therapy for hepatocellular carcinoma: MRI appearances.">
            <entity id="DS3.d186.s0.e0" origId="Q92636" charOffset="0-3" type="protein" text="Fan"/>
            <entity id="DS3.d186.s0.e1" origId="702" charOffset="44-51" type="compound" text="ethanol"/>
            <pair e1="DS3.d186.s0.e1" e2="DS3.d186.s0.e0" id="DS3.d186.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d186.s1" origId="9933674-12" text="CONCLUSION: The Fan-shaped areas of abnormal intensity on T1- and T2-weighted images and contrast enhancement on dynamic MR images seem to be attributable to pathologic changes in the normal liver parenchyma induced by the toxic reaction of ethanol.">
            <entity id="DS3.d186.s1.e0" origId="Q92636" charOffset="16-19" type="protein" text="Fan"/>
            <entity id="DS3.d186.s1.e1" origId="702" charOffset="241-248" type="compound" text="ethanol"/>
            <pair e1="DS3.d186.s1.e1" e2="DS3.d186.s1.e0" id="DS3.d186.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d186.s2" origId="9933674-1" text="BACKGROUND: T1- and T2-weighted magnetic resonance (MR) images frequently show Fan-shaped areas of hypo- or hyperintensity in the hepatic parenchyma adjacent to a treated hepatocellular carcinoma after percutaneous ethanol injection (PEI) therapy.">
            <entity id="DS3.d186.s2.e0" origId="Q92636" charOffset="79-82" type="protein" text="Fan"/>
            <entity id="DS3.d186.s2.e1" origId="702" charOffset="215-222" type="compound" text="ethanol"/>
            <pair e1="DS3.d186.s2.e1" e2="DS3.d186.s2.e0" id="DS3.d186.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d187" origId="9933699">
        <sentence id="DS3.d187.s0" origId="9933699-7" text="TNM staging was similar between groups, there being 43% stage II and 45% stage III lesions among the ILO patients and 53% stage II and 32% stage III disease in the THO group.">
            <entity id="DS3.d187.s0.e0" origId="Q9UKZ4,B7ZMH4" charOffset="0-3" type="protein" text="TNM"/>
            <entity id="DS3.d187.s0.e1" origId="107984" charOffset="101-104" type="compound" text="ILO"/>
            <pair e1="DS3.d187.s0.e1" e2="DS3.d187.s0.e0" id="DS3.d187.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d188" origId="9933703">
        <sentence id="DS3.d188.s0" origId="9933703-6" text="Among the preoperative laboratory data, the serum glutamic oxaloacetate and glutamate pyruvate transaminoses (GOT, GPT) levels were statistically lower in the non-BC patients (32.8 +/- 4.8 and 28.0 +/- 4.4 IU/L, respectively) than in the HB and HC patients.">
            <entity id="DS3.d188.s0.e0" origId="970" charOffset="59-71" type="compound" text="oxaloacetate"/>
            <entity id="DS3.d188.s0.e1" origId="33032,23327,611,57109091" charOffset="76-85" type="compound" text="glutamate"/>
            <entity id="DS3.d188.s0.e2" origId="1060" charOffset="86-94" type="compound" text="pyruvate"/>
            <entity id="DS3.d188.s0.e3" origId="P24298" charOffset="115-118" type="protein" text="GPT"/>
            <pair e1="DS3.d188.s0.e2" e2="DS3.d188.s0.e3" id="DS3.d188.s0.i0" interaction="False" />
            <pair e1="DS3.d188.s0.e1" e2="DS3.d188.s0.e3" id="DS3.d188.s0.i1" interaction="False" />
            <pair e1="DS3.d188.s0.e0" e2="DS3.d188.s0.e3" id="DS3.d188.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d189" origId="9933732">
        <sentence id="DS3.d189.s0" origId="9933732-5" text="The effect of exogenous thiamine pyrophosphate (TPP) addition on the blood transketolase (TK) activity (TPP TK effect) served to estimate thiamine deficiency.">
            <entity id="DS3.d189.s0.e0" origId="1132" charOffset="24-46" type="compound" text="thiamine pyrophosphate"/>
            <entity id="DS3.d189.s0.e1" origId="P29401,V9HWD9,A0A0B4J1R6" charOffset="75-88" type="protein" text="transketolase"/>
            <entity id="DS3.d189.s0.e2" origId="1130,57466011,87120568,88241550" charOffset="24-32" type="compound" text="thiamine"/>
            <pair e1="DS3.d189.s0.e2" e2="DS3.d189.s0.e1" id="DS3.d189.s0.i0" interaction="False" />
            <pair e1="DS3.d189.s0.e0" e2="DS3.d189.s0.e1" id="DS3.d189.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d190" origId="9933738">
        <sentence id="DS3.d190.s0" origId="9933738-0" text="A PstI polymorphism detects the mutation of serine128 to arginine in CD 62E gene - a risk factor for coronary artery disease.">
            <entity id="DS3.d190.s0.e0" origId="P00995" charOffset="2-6" type="protein" text="PstI"/>
            <entity id="DS3.d190.s0.e1" origId="6322,90867653" charOffset="57-65" type="compound" text="arginine"/>
            <entity id="DS3.d190.s0.e2" origId="P16581" charOffset="69-75" type="protein" text="CD 62E"/>
            <pair e1="DS3.d190.s0.e1" e2="DS3.d190.s0.e0" id="DS3.d190.s0.i0" interaction="False" />
            <pair e1="DS3.d190.s0.e1" e2="DS3.d190.s0.e2" id="DS3.d190.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d190.s1" origId="9933738-1" text="The mutation of serine128 to arginine in the CD 62E gene is a risk factor for coronary artery disease (CAD).">
            <entity id="DS3.d190.s1.e0" origId="6322,90867653" charOffset="29-37" type="compound" text="arginine"/>
            <entity id="DS3.d190.s1.e1" origId="P16581" charOffset="45-51" type="protein" text="CD 62E"/>
            <pair e1="DS3.d190.s1.e0" e2="DS3.d190.s1.e1" id="DS3.d190.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d190.s2" origId="9933738-2" text="We designed a new method to detect this mutation based on the observation that it is due to a transversion of nucleotide A561 to C, which abolishes a PstI recognition site.">
            <entity id="DS3.d190.s2.e0" origId="343461" charOffset="121-125" type="compound" text="A561"/>
            <entity id="DS3.d190.s2.e1" origId="P00995" charOffset="150-154" type="protein" text="PstI"/>
            <pair e1="DS3.d190.s2.e0" e2="DS3.d190.s2.e1" id="DS3.d190.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d190.s3" origId="9933738-3" text="Two alleles, A and C, are easily typed when genomic DNA is amplified by PCR, digested with PstI, and separated on agarose gels.">
            <entity id="DS3.d190.s3.e0" origId="P00995" charOffset="91-95" type="protein" text="PstI"/>
            <entity id="DS3.d190.s3.e1" origId="11966311" charOffset="114-121" type="compound" text="agarose"/>
            <pair e1="DS3.d190.s3.e1" e2="DS3.d190.s3.e0" id="DS3.d190.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d191" origId="9933740">
        <sentence id="DS3.d191.s0" origId="9933740-12" text="These agents included Nomega-nitro-L-arginine methyl ester (L-NAME, 10 mg/kg), a constitutive NOS and iNOS inhibitor; S, S'-1,4-phenylene-bis-(1,2-ethanedinyl) bis-isothiourea dihydrobromide (1,4-PBIT, 10 mg/kg), a relatively specific iNOS inhibitor, and dexamethasone (3 mg/kg), an inhibitor of iNOS expression.">
            <entity id="DS3.d191.s0.e0" origId="10220272" charOffset="29-58" type="compound" text="nitro-L-arginine methyl ester"/>
            <entity id="DS3.d191.s0.e1" origId="39836" charOffset="60-66" type="compound" text="L-NAME"/>
            <entity id="DS3.d191.s0.e2" origId="Q06518" charOffset="102-106" type="protein" text="iNOS"/>
            <entity id="DS3.d191.s0.e3" origId="2723790" charOffset="164-175" type="compound" text="isothiourea"/>
            <entity id="DS3.d191.s0.e4" origId="Q06518" charOffset="235-239" type="protein" text="iNOS"/>
            <entity id="DS3.d191.s0.e5" origId="5743" charOffset="255-268" type="compound" text="dexamethasone"/>
            <entity id="DS3.d191.s0.e6" origId="Q06518" charOffset="235-239" type="protein" text="iNOS"/>
            <pair e1="DS3.d191.s0.e3" e2="DS3.d191.s0.e2" id="DS3.d191.s0.i0" interaction="False" />
            <pair e1="DS3.d191.s0.e1" e2="DS3.d191.s0.e2" id="DS3.d191.s0.i1" interaction="False" />
            <pair e1="DS3.d191.s0.e0" e2="DS3.d191.s0.e2" id="DS3.d191.s0.i2" interaction="False" />
            <pair e1="DS3.d191.s0.e5" e2="DS3.d191.s0.e2" id="DS3.d191.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d192" origId="9933744">
        <sentence id="DS3.d192.s0" origId="9933744-5" text="Here, we report that the expression of traT protein, fused either with a partial pre-S antigen of hepatitis B virus (60 and 98 amino acids, respectively) or with the snake venom rhodostomin (72 amino acids), was successfully achieved on the outer membrane of E. coli, using the pT2 plasmid.">
            <entity id="DS3.d192.s0.e0" origId="P15177,B1VCB1" charOffset="39-43" type="protein" text="traT"/>
            <entity id="DS3.d192.s0.e1" origId="56842075" charOffset="178-189" type="compound" text="rhodostomin"/>
            <pair e1="DS3.d192.s0.e1" e2="DS3.d192.s0.e0" id="DS3.d192.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d193" origId="9933751">
        <sentence id="DS3.d193.s0" origId="9933751-1" text="uroguanylin, a new natriuretic peptide originally isolated from urine, stimulates the membrane guanylate cyclase C receptor.">
            <entity id="DS3.d193.s0.e0" origId="Q16661" charOffset="0-11" type="protein" text="uroguanylin"/>
            <entity id="DS3.d193.s0.e1" origId="6804" charOffset="95-104" type="compound" text="guanylate"/>
            <pair e1="DS3.d193.s0.e1" e2="DS3.d193.s0.e0" id="DS3.d193.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d193.s1" origId="9933751-2" text="No information, however, is available on the plasma and urine levels of uroguanylin in nephrotic syndrome (NS), the state associated with sodium and water retention.">
            <entity id="DS3.d193.s1.e0" origId="Q16661" charOffset="72-83" type="protein" text="uroguanylin"/>
            <entity id="DS3.d193.s1.e1" origId="5360545" charOffset="138-144" type="compound" text="sodium"/>
            <entity id="DS3.d193.s1.e2" origId="962" charOffset="149-154" type="compound" text="water"/>
            <pair e1="DS3.d193.s1.e2" e2="DS3.d193.s1.e0" id="DS3.d193.s1.i0" interaction="False" />
            <pair e1="DS3.d193.s1.e1" e2="DS3.d193.s1.e0" id="DS3.d193.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d194" origId="9933759">
        <sentence id="DS3.d194.s0" origId="9933759-4" text="Blood pressure, urinary albumin, nitrite and nitrate levels, plasma ANP, and plasma renin activity were measured.">
            <entity id="DS3.d194.s0.e0" origId="946" charOffset="33-40" type="compound" text="nitrite"/>
            <entity id="DS3.d194.s0.e1" origId="10313259,943" charOffset="45-52" type="compound" text="nitrate"/>
            <entity id="DS3.d194.s0.e2" origId="P01161,B0BMW5" charOffset="68-71" type="protein" text="ANP"/>
            <entity id="DS3.d194.s0.e3" origId="P08424" charOffset="84-89" type="protein" text="renin"/>
            <pair e1="DS3.d194.s0.e0" e2="DS3.d194.s0.e2" id="DS3.d194.s0.i0" interaction="False" />
            <pair e1="DS3.d194.s0.e0" e2="DS3.d194.s0.e3" id="DS3.d194.s0.i1" interaction="False" />
            <pair e1="DS3.d194.s0.e1" e2="DS3.d194.s0.e2" id="DS3.d194.s0.i2" interaction="False" />
            <pair e1="DS3.d194.s0.e1" e2="DS3.d194.s0.e3" id="DS3.d194.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d195" origId="9933818">
        <sentence id="DS3.d195.s0" origId="9933818-5" text="RESULTS: The median free beta-hCG MOM levels of Down syndrome (4.02 MOM) and other chromosomally abnormal pregnancies (2.03 MOM) are significantly higher than that of normal pregnancies (0.99 MOM) (p = 0.002 and p = 0.024, respectively).">
            <entity id="DS3.d195.s0.e0" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="30-33" type="protein" text="hCG"/>
            <entity id="DS3.d195.s0.e1" origId="5282188" charOffset="34-37" type="compound" text="MOM"/>
            <entity id="DS3.d195.s0.e2" origId="5282188" charOffset="68-71" type="compound" text="MOM"/>
            <entity id="DS3.d195.s0.e3" origId="5282188" charOffset="68-71" type="compound" text="MOM"/>
            <entity id="DS3.d195.s0.e4" origId="5282188" charOffset="68-71" type="compound" text="MOM"/>
            <pair e1="DS3.d195.s0.e1" e2="DS3.d195.s0.e0" id="DS3.d195.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d196" origId="9933820">
        <sentence id="DS3.d196.s0" origId="9933820-6" text="PCR products for S100B and insulin-like growth factor-I (IGF-I) as an internal control were subjected to agarose gel (2%) electrophoresis and the relative amounts of radioactivity in their products were measured to assess the quantitation of template DNA.">
            <entity id="DS3.d196.s0.e0" origId="P04271" charOffset="17-22" type="protein" text="S100B"/>
            <entity id="DS3.d196.s0.e1" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="27-55" type="protein" text="insulin-like growth factor-I"/>
            <entity id="DS3.d196.s0.e2" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="57-62" type="protein" text="IGF-I"/>
            <entity id="DS3.d196.s0.e3" origId="11966311" charOffset="105-112" type="compound" text="agarose"/>
            <pair e1="DS3.d196.s0.e3" e2="DS3.d196.s0.e1" id="DS3.d196.s0.i0" interaction="False" />
            <pair e1="DS3.d196.s0.e3" e2="DS3.d196.s0.e2" id="DS3.d196.s0.i1" interaction="False" />
            <pair e1="DS3.d196.s0.e3" e2="DS3.d196.s0.e0" id="DS3.d196.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d197" origId="9933826">
        <sentence id="DS3.d197.s0" origId="9933826-6" text="Urinary protein excretion, glomerular filtration rate (determined by 99mTc-DTPA clearance), systemic blood pressure, plasma ANP concentration and urinary cyclic GMP excretion were not changed by SCH34826 treatment.">
            <entity id="DS3.d197.s0.e0" origId="3053" charOffset="75-79" type="compound" text="DTPA"/>
            <entity id="DS3.d197.s0.e1" origId="P01161,B0BMW5" charOffset="124-127" type="protein" text="ANP"/>
            <entity id="DS3.d197.s0.e2" origId="6804" charOffset="161-164" type="compound" text="GMP"/>
            <pair e1="DS3.d197.s0.e2" e2="DS3.d197.s0.e1" id="DS3.d197.s0.i0" interaction="False" />
            <pair e1="DS3.d197.s0.e0" e2="DS3.d197.s0.e1" id="DS3.d197.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d198" origId="9933830">
        <sentence id="DS3.d198.s0" origId="9933830-3" text="AT1-antagonist losartan and ACE inhibitor perindopril) have a long-term effect on blood pressure leading to values of systolic blood pressure (SBP) of 174.5+/-14.5 and 169.8+/-15.3 mmHg, respectively, at week 30.">
            <entity id="DS3.d198.s0.e0" origId="P25095" charOffset="0-3" type="protein" text="AT1"/>
            <entity id="DS3.d198.s0.e1" origId="3961" charOffset="15-23" type="compound" text="losartan"/>
            <entity id="DS3.d198.s0.e2" origId="107807" charOffset="42-53" type="compound" text="perindopril"/>
            <pair e1="DS3.d198.s0.e1" e2="DS3.d198.s0.e0" id="DS3.d198.s0.i0" interaction="False" />
            <pair e1="DS3.d198.s0.e2" e2="DS3.d198.s0.e0" id="DS3.d198.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d199" origId="9933831">
        <sentence id="DS3.d199.s0" origId="9933831-8" text="CONCLUSION: The functional improvement under the action of enalaprilat suggests that the advantages of the drug may be mediated mainly through an increase in myocardial blood flow and that angiotensin II might be involved in the restricted increase in coronary blood flow during dynamic exercise in hypertensives with coronary microangiopathy.">
            <entity id="DS3.d199.s0.e0" origId="5462501" charOffset="59-70" type="compound" text="enalaprilat"/>
            <entity id="DS3.d199.s0.e1" origId="P01019,B0ZBE2,B2R5S1" charOffset="189-203" type="protein" text="angiotensin II"/>
            <pair e1="DS3.d199.s0.e0" e2="DS3.d199.s0.e1" id="DS3.d199.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d200" origId="9933837">
        <sentence id="DS3.d200.s0" origId="9933837-5" text="Plasma luteinizing hormone (LH), prolactin (PRL), follicle-stimulating hormone (FSH), adrenocorticotrophic hormone (ACTH), cortisol, aldosterone, dihydroepiandrosterone sulfate (DHEA-S) and testosterone levels were assessed in all patients before and after 3 weeks and 3 months following the aforementioned procedures.">
            <entity id="DS3.d200.s0.e0" origId="P01236,Q5I0G2,Q5THQ0" charOffset="33-42" type="protein" text="prolactin"/>
            <entity id="DS3.d200.s0.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="44-47" type="protein" text="PRL"/>
            <entity id="DS3.d200.s0.e2" origId="5754" charOffset="123-131" type="compound" text="cortisol"/>
            <entity id="DS3.d200.s0.e3" origId="5839" charOffset="133-144" type="compound" text="aldosterone"/>
            <entity id="DS3.d200.s0.e4" origId="20709120" charOffset="146-176" type="compound" text="dihydroepiandrosterone sulfate"/>
            <entity id="DS3.d200.s0.e5" origId="12594" charOffset="178-184" type="compound" text="DHEA-S"/>
            <entity id="DS3.d200.s0.e6" origId="6013" charOffset="190-202" type="compound" text="testosterone"/>
            <pair e1="DS3.d200.s0.e4" e2="DS3.d200.s0.e0" id="DS3.d200.s0.i0" interaction="False" />
            <pair e1="DS3.d200.s0.e4" e2="DS3.d200.s0.e1" id="DS3.d200.s0.i1" interaction="False" />
            <pair e1="DS3.d200.s0.e6" e2="DS3.d200.s0.e0" id="DS3.d200.s0.i2" interaction="False" />
            <pair e1="DS3.d200.s0.e6" e2="DS3.d200.s0.e1" id="DS3.d200.s0.i3" interaction="False" />
            <pair e1="DS3.d200.s0.e5" e2="DS3.d200.s0.e0" id="DS3.d200.s0.i4" interaction="False" />
            <pair e1="DS3.d200.s0.e5" e2="DS3.d200.s0.e1" id="DS3.d200.s0.i5" interaction="False" />
            <pair e1="DS3.d200.s0.e2" e2="DS3.d200.s0.e0" id="DS3.d200.s0.i6" interaction="False" />
            <pair e1="DS3.d200.s0.e2" e2="DS3.d200.s0.e1" id="DS3.d200.s0.i7" interaction="False" />
            <pair e1="DS3.d200.s0.e3" e2="DS3.d200.s0.e0" id="DS3.d200.s0.i8" interaction="False" />
            <pair e1="DS3.d200.s0.e3" e2="DS3.d200.s0.e1" id="DS3.d200.s0.i9" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d201" origId="9933849">
        <sentence id="DS3.d201.s0" origId="9933849-13" text="The RHA inhibition (-) PCR (+) B19 antibody (+) sera did not affect the erythroid colony formation and protected CFU-e from injury by the B19 virus.">
            <entity id="DS3.d201.s0.e0" origId="P58658,B3KWG0" charOffset="31-34" type="protein" text="B19"/>
            <entity id="DS3.d201.s0.e1" origId="77620543" charOffset="113-116" type="compound" text="CFU"/>
            <entity id="DS3.d201.s0.e2" origId="P58658,B3KWG0" charOffset="138-141" type="protein" text="B19"/>
            <pair e1="DS3.d201.s0.e1" e2="DS3.d201.s0.e0" id="DS3.d201.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d201.s1" origId="9933849-9" text="To examine the detection limits of the B19 virus by RHA, B19-viremic sera were purified by sucrose gradient ultracentrifugation.">
            <entity id="DS3.d201.s1.e0" origId="P58658,B3KWG0" charOffset="39-42" type="protein" text="B19"/>
            <entity id="DS3.d201.s1.e1" origId="P58658,B3KWG0" charOffset="57-60" type="protein" text="B19"/>
            <entity id="DS3.d201.s1.e2" origId="5988" charOffset="91-98" type="compound" text="sucrose"/>
            <pair e1="DS3.d201.s1.e2" e2="DS3.d201.s1.e0" id="DS3.d201.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d202" origId="9933919">
        <sentence id="DS3.d202.s0" origId="9933919-5" text="Given a previously reported contiguous five amino acid shared region between ns4b and myelin basic protein, a purified recombinant histidine-tagged ns4b protein and (or) human myelin basic protein were injected into mice to evaluate whether myelin-viral protein cross-reactive antibody responses could be generated.">
            <entity id="DS3.d202.s0.e0" origId="P02686,A0A024R384" charOffset="86-106" type="protein" text="myelin basic protein"/>
            <entity id="DS3.d202.s0.e1" origId="773" charOffset="131-141" type="compound" text="histidine-"/>
            <entity id="DS3.d202.s0.e2" origId="P02686,A0A024R384" charOffset="176-196" type="protein" text="myelin basic protein"/>
            <pair e1="DS3.d202.s0.e1" e2="DS3.d202.s0.e0" id="DS3.d202.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d203" origId="9933923">
        <sentence id="DS3.d203.s0" origId="9933923-4" text="We also show that quantitative measurements of paramagnetic relaxation enhancements induced by small amounts of spin-labeled phospholipids on peptide proton signals provide a meaningful insight on the location of both PMP1 and annexin fragments in DPC micelles.">
            <entity id="DS3.d203.s0.e0" origId="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5" charOffset="112-116" type="protein" text="spin"/>
            <entity id="DS3.d203.s0.e1" origId="1038,5460653" charOffset="150-156" type="compound" text="proton"/>
            <entity id="DS3.d203.s0.e2" origId="P40855" charOffset="218-222" type="protein" text="PMP1"/>
            <pair e1="DS3.d203.s0.e1" e2="DS3.d203.s0.e2" id="DS3.d203.s0.i0" interaction="False" />
            <pair e1="DS3.d203.s0.e1" e2="DS3.d203.s0.e0" id="DS3.d203.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d204" origId="9933924">
        <sentence id="DS3.d204.s0" origId="9933924-0" text="Effects of pulmonary surfactant proteins SP-B and SP-C and calcium ions on the surface properties of hydrophobic fractions of lung surfactant.">
            <entity id="DS3.d204.s0.e0" origId="F1SVC0,A7MAK5" charOffset="41-45" type="protein" text="SP-B"/>
            <entity id="DS3.d204.s0.e1" origId="Q3MSM2,Q1XFL4" charOffset="50-54" type="protein" text="SP-C"/>
            <entity id="DS3.d204.s0.e2" origId="22044544,5460341" charOffset="59-66" type="compound" text="calcium"/>
            <pair e1="DS3.d204.s0.e2" e2="DS3.d204.s0.e0" id="DS3.d204.s0.i0" interaction="False" />
            <pair e1="DS3.d204.s0.e2" e2="DS3.d204.s0.e1" id="DS3.d204.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d205" origId="9933931">
        <sentence id="DS3.d205.s0" origId="9933931-3" text="Type 1 fimbriae are surface organelles of Escherichia coli which mediate D-mannose sensitive binding to different host surfaces through the FimH adhesin, an integral part of these organelles.">
            <entity id="DS3.d205.s0.e0" origId="185698,18950,46780441" charOffset="73-82" type="compound" text="D-mannose"/>
            <entity id="DS3.d205.s0.e1" origId="Q3ZU01" charOffset="145-152" type="protein" text="adhesin"/>
            <pair e1="DS3.d205.s0.e0" e2="DS3.d205.s0.e1" id="DS3.d205.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d206" origId="9933971">
        <sentence id="DS3.d206.s0" origId="9933971-0" text="L-phenylalanine effect on rat diaphragm acetylcholinesterase and Na+,K(+)-ATPase.">
            <entity id="DS3.d206.s0.e0" origId="6140" charOffset="0-15" type="compound" text="L-phenylalanine"/>
            <entity id="DS3.d206.s0.e1" origId="P37136" charOffset="40-60" type="protein" text="acetylcholinesterase"/>
            <pair e1="DS3.d206.s0.e0" e2="DS3.d206.s0.e1" id="DS3.d206.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d206.s1" origId="9933971-1" text="The effect of different L-phenylalanine (Phe) concentrations (0.24-12.1 mM), on acetylcholinesterase (AChE) and Na+,K(+)-ATPase activities of diaphragm homogenates from 21-day old rats and pure enzymes, was investigated at 37 degrees C. AChE and Na+,K(+)-ATPase activities were determined after preincubation with Phe.">
            <entity id="DS3.d206.s1.e0" origId="6140" charOffset="24-39" type="compound" text="L-phenylalanine"/>
            <entity id="DS3.d206.s1.e1" origId="P37136" charOffset="80-100" type="protein" text="acetylcholinesterase"/>
            <entity id="DS3.d206.s1.e2" origId="P37136" charOffset="102-106" type="protein" text="AChE"/>
            <entity id="DS3.d206.s1.e3" origId="P37136" charOffset="237-241" type="protein" text="AChE"/>
            <pair e1="DS3.d206.s1.e0" e2="DS3.d206.s1.e2" id="DS3.d206.s1.i0" interaction="False" />
            <pair e1="DS3.d206.s1.e0" e2="DS3.d206.s1.e1" id="DS3.d206.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d206.s2" origId="9933971-8" text="c) The combination of high Phe concentrations effects on AChE and Na+,K(+)-ATPase could influence the levels of the diaphragm synaptic ACh.">
            <entity id="DS3.d206.s2.e0" origId="P37136" charOffset="57-61" type="protein" text="AChE"/>
            <entity id="DS3.d206.s2.e1" origId="187" charOffset="57-60" type="compound" text="ACh"/>
            <pair e1="DS3.d206.s2.e1" e2="DS3.d206.s2.e0" id="DS3.d206.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d207" origId="9933987">
        <sentence id="DS3.d207.s0" origId="9933987-0" text="Antimetastatic efficacy of orally administered ginsenoside Rb1 in dependence on intestinal bacterial hydrolyzing potential and significance of treatment with an active bacterial metabolite.">
            <entity id="DS3.d207.s0.e0" origId="441923" charOffset="47-58" type="compound" text="ginsenoside"/>
            <entity id="DS3.d207.s0.e1" origId="P13405" charOffset="59-62" type="protein" text="Rb1"/>
            <pair e1="DS3.d207.s0.e0" e2="DS3.d207.s0.e1" id="DS3.d207.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d207.s1" origId="9933987-1" text="The antimetastatic effects of orally administered ginsenoside Rb1 (Rb1) and an active metabolite by intestinal bacteria, 20-O-beta-D-glucopyranosyl-20(S)-protopanaxadiol (I), were studied, by using a spontaneous metastasis model produced by subcutaneous injection of Lewis lung carcinoma (LLC) in syngeneic C57BL/6 mice.">
            <entity id="DS3.d207.s1.e0" origId="441923" charOffset="50-61" type="compound" text="ginsenoside"/>
            <entity id="DS3.d207.s1.e1" origId="P13405" charOffset="62-65" type="protein" text="Rb1"/>
            <entity id="DS3.d207.s1.e2" origId="P13405" charOffset="67-70" type="protein" text="Rb1"/>
            <entity id="DS3.d207.s1.e3" origId="57076893" charOffset="124-147" type="compound" text="O-beta-D-glucopyranosyl"/>
            <entity id="DS3.d207.s1.e4" origId="11213350" charOffset="148-169" type="compound" text="20(S)-protopanaxadiol"/>
            <pair e1="DS3.d207.s1.e0" e2="DS3.d207.s1.e1" id="DS3.d207.s1.i0" interaction="False" />
            <pair e1="DS3.d207.s1.e3" e2="DS3.d207.s1.e1" id="DS3.d207.s1.i1" interaction="False" />
            <pair e1="DS3.d207.s1.e4" e2="DS3.d207.s1.e1" id="DS3.d207.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d208" origId="9933990">
        <sentence id="DS3.d208.s0" origId="9933990-6" text="ALR-5IIa-1-1 consisted mainly of Ara and Gal (molar ratio; 0.6: 1.0) in addition to a trace amount of uronic acid whereas ALR-5IIb-2-2 and ALR-5IIc-3-1 mainly comprised Ara, Gal, GlcA, and GalA (molar ratio; 0.2: 1.0: 0.2: 0.8, and 0.5: 1.0: 0.7: 1.5, respectively).">
            <entity id="DS3.d208.s0.e0" origId="94715" charOffset="179-183" type="compound" text="GlcA"/>
            <entity id="DS3.d208.s0.e1" origId="P06280,Q53Y83" charOffset="189-193" type="protein" text="GalA"/>
            <pair e1="DS3.d208.s0.e0" e2="DS3.d208.s0.e1" id="DS3.d208.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d208.s1" origId="9933990-8" text="ALR-5IIb-2-2 and ALR-5IIc-3-1 were composed mainly of terminal Araf, 4- or 5-linked Ara, 4-linked Gal, 4-linked GalA, and terminal GlcA.">
            <entity id="DS3.d208.s1.e0" origId="P10398,Q96II5,A0A024R178" charOffset="63-116" type="protein" text="Araf, 4- or 5-linked Ara, 4-linked Gal, 4-linked GalA"/>
            <entity id="DS3.d208.s1.e1" origId="94715" charOffset="131-135" type="compound" text="GlcA"/>
            <pair e1="DS3.d208.s1.e1" e2="DS3.d208.s1.e0" id="DS3.d208.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d209" origId="9934342">
        <sentence id="DS3.d209.s0" origId="9934342-5" text="METHODS: The authors examined all outpatient prescriptions for antihypertensive medications filled in Saskatchewan between 1989 and 1994 by over 22,000 patients with newly diagnosed hypertension whose initial treatment was with a diuretic, beta-blocker, calcium-channel blocker or angiotensin-converting-enzyme (ACE) inhibitor.">
            <entity id="DS3.d209.s0.e0" origId="22044544,5460341" charOffset="254-261" type="compound" text="calcium"/>
            <entity id="DS3.d209.s0.e1" origId="P12821,B4DKH4" charOffset="281-310" type="protein" text="angiotensin-converting-enzyme"/>
            <entity id="DS3.d209.s0.e2" origId="P12821,B4DKH4" charOffset="312-315" type="protein" text="ACE"/>
            <pair e1="DS3.d209.s0.e0" e2="DS3.d209.s0.e2" id="DS3.d209.s0.i0" interaction="False" />
            <pair e1="DS3.d209.s0.e0" e2="DS3.d209.s0.e1" id="DS3.d209.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d209.s1" origId="9934342-7" text="RESULTS: After 6 months, persistence with therapy was poor and differed according to the class of initial therapeutic agent: 80% for diuretics, 85% for beta-blockers, 86% for calcium-channel blockers and 89% for ACE inhibitors (p &amp;lt; 0.001).">
            <entity id="DS3.d209.s1.e0" origId="22044544,5460341" charOffset="175-182" type="compound" text="calcium"/>
            <entity id="DS3.d209.s1.e1" origId="P12821,B4DKH4" charOffset="212-215" type="protein" text="ACE"/>
            <pair e1="DS3.d209.s1.e0" e2="DS3.d209.s1.e1" id="DS3.d209.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d210" origId="9934359">
        <sentence id="DS3.d210.s0" origId="9934359-5" text="Very obvious was the lack of vasoconstriction after cocaine application, and the vessels also showed a lack of staining with factor VIII, possibly indicating a disruption of the endothelium.">
            <entity id="DS3.d210.s0.e0" origId="446220" charOffset="52-59" type="compound" text="cocaine"/>
            <entity id="DS3.d210.s0.e1" origId="P10176,Q53XN1" charOffset="132-136" type="protein" text="VIII"/>
            <pair e1="DS3.d210.s0.e0" e2="DS3.d210.s0.e1" id="DS3.d210.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d211" origId="9934363">
        <sentence id="DS3.d211.s0" origId="9934363-5" text="Killing of MLM did not revert the macrophages' failure to release ROI upon ingestion of the microorganism, nor were macrophages able to produce these toxic metabolites when pre-incubated in the presence of murine gamma interferon (IFN-gamma).">
            <entity id="DS3.d211.s0.e0" origId="75367" charOffset="11-14" type="compound" text="MLM"/>
            <entity id="DS3.d211.s0.e1" origId="P01580" charOffset="231-240" type="protein" text="IFN-gamma"/>
            <pair e1="DS3.d211.s0.e0" e2="DS3.d211.s0.e1" id="DS3.d211.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d212" origId="9934407">
        <sentence id="DS3.d212.s0" origId="9934407-2" text="Three forms of the illness were defined according to clinical criteria: minor (EMm), intermediate (EMt) and major (EMM).">
            <entity id="DS3.d212.s0.e0" origId="445893" charOffset="79-82" type="compound" text="EMm"/>
            <entity id="DS3.d212.s0.e1" origId="Q08881" charOffset="99-102" type="protein" text="EMt"/>
            <entity id="DS3.d212.s0.e2" origId="445893" charOffset="115-118" type="compound" text="EMM"/>
            <pair e1="DS3.d212.s0.e0" e2="DS3.d212.s0.e1" id="DS3.d212.s0.i0" interaction="False" />
            <pair e1="DS3.d212.s0.e2" e2="DS3.d212.s0.e1" id="DS3.d212.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d213" origId="9934453">
        <sentence id="DS3.d213.s0" origId="9934453-0" text="An improved route to 1,2-dideoxy-beta-1-phenyl-D-ribofuranose.">
            <entity id="DS3.d213.s0.e0" origId="Q16558" charOffset="33-39" type="protein" text="beta-1"/>
            <entity id="DS3.d213.s0.e1" origId="5779" charOffset="47-61" type="compound" text="D-ribofuranose"/>
            <pair e1="DS3.d213.s0.e1" e2="DS3.d213.s0.e0" id="DS3.d213.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d213.s1" origId="9934453-1" text="An efficient synthesis of the aryl nucleoside analogue 1,2-dideoxy-beta-1-phenyl-D-ribofuranose (1) is described.">
            <entity id="DS3.d213.s1.e0" origId="Q16558" charOffset="67-73" type="protein" text="beta-1"/>
            <entity id="DS3.d213.s1.e1" origId="5779" charOffset="81-95" type="compound" text="D-ribofuranose"/>
            <pair e1="DS3.d213.s1.e1" e2="DS3.d213.s1.e0" id="DS3.d213.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d214" origId="9934454">
        <sentence id="DS3.d214.s0" origId="9934454-1" text="A series of N-acyl-4-(5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin- 11-ylidene)piperazines is described that are dual antagonists of PAF and histamine.">
            <entity id="DS3.d214.s0.e0" origId="66534" charOffset="34-37" type="compound" text="11H"/>
            <entity id="DS3.d214.s0.e1" origId="9265" charOffset="48-58" type="compound" text="cyclohepta"/>
            <entity id="DS3.d214.s0.e2" origId="Q15004" charOffset="139-142" type="protein" text="PAF"/>
            <entity id="DS3.d214.s0.e3" origId="774" charOffset="147-156" type="compound" text="histamine"/>
            <pair e1="DS3.d214.s0.e1" e2="DS3.d214.s0.e2" id="DS3.d214.s0.i0" interaction="False" />
            <pair e1="DS3.d214.s0.e0" e2="DS3.d214.s0.e2" id="DS3.d214.s0.i1" interaction="False" />
            <pair e1="DS3.d214.s0.e3" e2="DS3.d214.s0.e2" id="DS3.d214.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d215" origId="9934458">
        <sentence id="DS3.d215.s0" origId="9934458-4" text="By this new technique, Glu-3 and Asp-23 were identified as active-site residues, the side chains of which potentially may serve as counter ions for the ammonium functionalities at positions 6', and 1 and 3 of the antibiotic substrates, respectively.">
            <entity id="DS3.d215.s0.e0" origId="223" charOffset="152-160" type="compound" text="ammonium"/>
            <entity id="DS3.d215.s0.e1" origId="O75717" charOffset="194-205" type="protein" text="and 1 and 3"/>
            <pair e1="DS3.d215.s0.e0" e2="DS3.d215.s0.e1" id="DS3.d215.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d216" origId="9934465">
        <sentence id="DS3.d216.s0" origId="9934465-1" text="Crystal structure and evolving SAR considerations of potent, selective benzylsulfonamide lactam thrombin inhibitors and related serine protease inhibitors have led to the design of novel thrombin inhibitors 1a-g, featuring hydrophobic, basic, P4-alkylaminolactam scaffolds that serve as novel types of P3-P4 dipeptide mimics.">
            <entity id="DS3.d216.s0.e0" origId="Q9UL12,A8K596" charOffset="31-34" type="protein" text="SAR"/>
            <entity id="DS3.d216.s0.e1" origId="78318" charOffset="71-88" type="compound" text="benzylsulfonamide"/>
            <entity id="DS3.d216.s0.e2" origId="90470996" charOffset="96-104" type="compound" text="thrombin"/>
            <entity id="DS3.d216.s0.e3" origId="5951" charOffset="128-134" type="compound" text="serine"/>
            <entity id="DS3.d216.s0.e4" origId="90470996" charOffset="187-195" type="compound" text="thrombin"/>
            <pair e1="DS3.d216.s0.e1" e2="DS3.d216.s0.e0" id="DS3.d216.s0.i0" interaction="False" />
            <pair e1="DS3.d216.s0.e2" e2="DS3.d216.s0.e0" id="DS3.d216.s0.i1" interaction="False" />
            <pair e1="DS3.d216.s0.e3" e2="DS3.d216.s0.e0" id="DS3.d216.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d217" origId="9934472">
        <sentence id="DS3.d217.s0" origId="9934472-0" text="Phenylpiperazine derivatives with strong affinity for 5HT1A, D2A and D3 receptors.">
            <entity id="DS3.d217.s0.e0" origId="7096" charOffset="0-16" type="compound" text="Phenylpiperazine"/>
            <entity id="DS3.d217.s0.e1" origId="P08908,Q5ZGX3,A8K5W4" charOffset="54-59" type="protein" text="5HT1A"/>
            <entity id="DS3.d217.s0.e2" origId="20039" charOffset="61-64" type="compound" text="D2A"/>
            <pair e1="DS3.d217.s0.e2" e2="DS3.d217.s0.e1" id="DS3.d217.s0.i0" interaction="False" />
            <pair e1="DS3.d217.s0.e0" e2="DS3.d217.s0.e1" id="DS3.d217.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d217.s1" origId="9934472-2" text="The affinities of these compounds for DA (D2A, D3) and 5HT1A receptors were evaluated for their ability to displace (3H)-raclopride and (3H)-8-OH-DPAT respectively from their specific binding sites.">
            <entity id="DS3.d217.s1.e0" origId="20039" charOffset="42-45" type="compound" text="D2A"/>
            <entity id="DS3.d217.s1.e1" origId="P08908,Q5ZGX3,A8K5W4" charOffset="55-60" type="protein" text="5HT1A"/>
            <entity id="DS3.d217.s1.e2" origId="3033769" charOffset="121-131" type="compound" text="raclopride"/>
            <entity id="DS3.d217.s1.e3" origId="1220" charOffset="141-150" type="compound" text="8-OH-DPAT"/>
            <pair e1="DS3.d217.s1.e0" e2="DS3.d217.s1.e1" id="DS3.d217.s1.i0" interaction="False" />
            <pair e1="DS3.d217.s1.e3" e2="DS3.d217.s1.e1" id="DS3.d217.s1.i1" interaction="False" />
            <pair e1="DS3.d217.s1.e2" e2="DS3.d217.s1.e1" id="DS3.d217.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d218" origId="9934473">
        <sentence id="DS3.d218.s0" origId="9934473-0" text="Butyrophenone analogues in the carbazole series: synthesis and determination of affinities at D2 and 5-HT2A receptors.">
            <entity id="DS3.d218.s0.e0" origId="10315" charOffset="0-13" type="compound" text="Butyrophenone"/>
            <entity id="DS3.d218.s0.e1" origId="6854" charOffset="31-40" type="compound" text="carbazole"/>
            <entity id="DS3.d218.s0.e2" origId="P28223" charOffset="103-107" type="protein" text="HT2A"/>
            <pair e1="DS3.d218.s0.e1" e2="DS3.d218.s0.e2" id="DS3.d218.s0.i0" interaction="False" />
            <pair e1="DS3.d218.s0.e0" e2="DS3.d218.s0.e2" id="DS3.d218.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d219" origId="9934476">
        <sentence id="DS3.d219.s0" origId="9934476-0" text="Facile synthesis of high affinity styrylpyridine systems as inherently fluorescent ligands for the estrogen receptor.">
            <entity id="DS3.d219.s0.e0" origId="136350" charOffset="34-48" type="compound" text="styrylpyridine"/>
            <entity id="DS3.d219.s0.e1" origId="P03372,Q9UBT1,G4XH65,A8KAF4" charOffset="99-116" type="protein" text="estrogen receptor"/>
            <pair e1="DS3.d219.s0.e0" e2="DS3.d219.s0.e1" id="DS3.d219.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d220" origId="9934486">
        <sentence id="DS3.d220.s0" origId="9934486-1" text="A series of gem-difluoro-avermectin derivatives was synthesized from the corresponding ketones at positions 4&quot;, 4', 13, and 23 using diethylaminosulfur trifluoride (DAST).">
            <entity id="DS3.d220.s0.e0" origId="P55041,Q3TH76" charOffset="12-15" type="protein" text="gem"/>
            <entity id="DS3.d220.s0.e1" origId="114522" charOffset="87-94" type="compound" text="ketones"/>
            <entity id="DS3.d220.s0.e2" origId="18359574" charOffset="133-151" type="compound" text="diethylaminosulfur"/>
            <entity id="DS3.d220.s0.e3" origId="123472" charOffset="165-169" type="compound" text="DAST"/>
            <pair e1="DS3.d220.s0.e1" e2="DS3.d220.s0.e0" id="DS3.d220.s0.i0" interaction="False" />
            <pair e1="DS3.d220.s0.e2" e2="DS3.d220.s0.e0" id="DS3.d220.s0.i1" interaction="False" />
            <pair e1="DS3.d220.s0.e3" e2="DS3.d220.s0.e0" id="DS3.d220.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d221" origId="9934490">
        <sentence id="DS3.d221.s0" origId="9934490-0" text="Differential activity of rosiglitazone enantiomers at PPAR gamma.">
            <entity id="DS3.d221.s0.e0" origId="77999" charOffset="25-38" type="compound" text="rosiglitazone"/>
            <entity id="DS3.d221.s0.e1" origId="P37231,D2KUA6,E9PFX5" charOffset="54-64" type="protein" text="PPAR gamma"/>
            <pair e1="DS3.d221.s0.e0" e2="DS3.d221.s0.e1" id="DS3.d221.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d221.s1" origId="9934490-1" text="Analysis of the enantiomers of rosiglitazone in a PPAR gamma binding assay suggests that the (S)-(-)-isomer is responsible for the antidiabetic activity.">
            <entity id="DS3.d221.s1.e0" origId="77999" charOffset="31-44" type="compound" text="rosiglitazone"/>
            <entity id="DS3.d221.s1.e1" origId="P37231,D2KUA6,E9PFX5" charOffset="50-60" type="protein" text="PPAR gamma"/>
            <pair e1="DS3.d221.s1.e0" e2="DS3.d221.s1.e1" id="DS3.d221.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d222" origId="9934491">
        <sentence id="DS3.d222.s0" origId="9934491-1" text="Truncated analogs of tripterine as cytokine (IL-1 alpha, IL-1 beta, TNF-alpha, IL-6, and IL-8) release inhibitors are discussed.">
            <entity id="DS3.d222.s0.e0" origId="122724" charOffset="21-31" type="compound" text="tripterine"/>
            <entity id="DS3.d222.s0.e1" origId="P01584" charOffset="57-66" type="protein" text="IL-1 beta"/>
            <entity id="DS3.d222.s0.e2" origId="P01375,Q5STB3" charOffset="68-77" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d222.s0.e3" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="79-83" type="protein" text="IL-6"/>
            <entity id="DS3.d222.s0.e4" origId="P10145,A0A024RDA5" charOffset="89-93" type="protein" text="IL-8"/>
            <pair e1="DS3.d222.s0.e0" e2="DS3.d222.s0.e1" id="DS3.d222.s0.i0" interaction="False" />
            <pair e1="DS3.d222.s0.e0" e2="DS3.d222.s0.e2" id="DS3.d222.s0.i1" interaction="False" />
            <pair e1="DS3.d222.s0.e0" e2="DS3.d222.s0.e4" id="DS3.d222.s0.i2" interaction="False" />
            <pair e1="DS3.d222.s0.e0" e2="DS3.d222.s0.e3" id="DS3.d222.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d223" origId="9934533">
        <sentence id="DS3.d223.s0" origId="9934533-3" text="This review will focus on the nitric oxide synthase gene family and recent progress on molecular genetic analysis of NOS1, NOS2 and NOS3 genes.">
            <entity id="DS3.d223.s0.e0" origId="145068" charOffset="30-42" type="compound" text="nitric oxide"/>
            <entity id="DS3.d223.s0.e1" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="117-121" type="protein" text="NOS1"/>
            <entity id="DS3.d223.s0.e2" origId="P35228" charOffset="123-127" type="protein" text="NOS2"/>
            <entity id="DS3.d223.s0.e3" origId="P29474,A0A0A0MTA6,A0S0A6" charOffset="132-136" type="protein" text="NOS3"/>
            <pair e1="DS3.d223.s0.e0" e2="DS3.d223.s0.e1" id="DS3.d223.s0.i0" interaction="False" />
            <pair e1="DS3.d223.s0.e0" e2="DS3.d223.s0.e2" id="DS3.d223.s0.i1" interaction="False" />
            <pair e1="DS3.d223.s0.e0" e2="DS3.d223.s0.e3" id="DS3.d223.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d224" origId="9934545">
        <sentence id="DS3.d224.s0" origId="9934545-4" text="The use of cefpodoxime MIC &amp;gt; 2.0 micrograms/mL as a marker for extended-spectrum beta-lactamase production by Escherichia coli and Klebsiella spp.">
            <entity id="DS3.d224.s0.e0" origId="123816,6335986" charOffset="11-22" type="compound" text="cefpodoxime"/>
            <entity id="DS3.d224.s0.e1" origId="P62593,Q6SJ61" charOffset="84-98" type="protein" text="beta-lactamase"/>
            <pair e1="DS3.d224.s0.e0" e2="DS3.d224.s0.e1" id="DS3.d224.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d225" origId="9934550">
        <sentence id="DS3.d225.s0" origId="9934550-0" text="Extended spectrum beta-lactamase production and fluorquinolone resistance in pathogens associated with community acquired urinary tract infection.">
            <entity id="DS3.d225.s0.e0" origId="P62593,Q6SJ61" charOffset="18-32" type="protein" text="beta-lactamase"/>
            <entity id="DS3.d225.s0.e1" origId="11094963" charOffset="48-62" type="compound" text="fluorquinolone"/>
            <pair e1="DS3.d225.s0.e1" e2="DS3.d225.s0.e0" id="DS3.d225.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d225.s1" origId="9934550-3" text="Ciprofloxacin resistance and production of extended spectrum beta-lactamase enzymes were detected in Escherichia coli strains isolated from patients in the community.">
            <entity id="DS3.d225.s1.e0" origId="2764" charOffset="0-13" type="compound" text="Ciprofloxacin"/>
            <entity id="DS3.d225.s1.e1" origId="P62593,Q6SJ61" charOffset="61-75" type="protein" text="beta-lactamase"/>
            <pair e1="DS3.d225.s1.e0" e2="DS3.d225.s1.e1" id="DS3.d225.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d226" origId="9934573">
        <sentence id="DS3.d226.s0" origId="9934573-4" text="To evaluate the effect of this treatment on plasma Met-enkephalin (ME) levels we studied 15 patients, all women with fibromyalgia under local treatment in the tender points, grouped as follows: 5 were treated with local injection of lidocaine hydrochloride, 5 were treated with local injection of saline and 5 treated with dry needling.">
            <entity id="DS3.d226.s0.e0" origId="P01189,Q6FHC8" charOffset="51-65" type="protein" text="Met-enkephalin"/>
            <entity id="DS3.d226.s0.e1" origId="3676" charOffset="233-256" type="compound" text="lidocaine hydrochloride"/>
            <pair e1="DS3.d226.s0.e1" e2="DS3.d226.s0.e0" id="DS3.d226.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d227" origId="9934678">
        <sentence id="DS3.d227.s0" origId="9934678-1" text="A tetracycline-inducible expression system has been established for the prion protein (PrP) in murine neuroblastoma cells (N2a).">
            <entity id="DS3.d227.s0.e0" origId="54675776" charOffset="2-14" type="compound" text="tetracycline"/>
            <entity id="DS3.d227.s0.e1" origId="P04925,Q4FJQ7,Q3UG89" charOffset="72-85" type="protein" text="prion protein"/>
            <entity id="DS3.d227.s0.e2" origId="P04925,Q4FJQ7,Q3UG89" charOffset="87-90" type="protein" text="PrP"/>
            <pair e1="DS3.d227.s0.e0" e2="DS3.d227.s0.e1" id="DS3.d227.s0.i0" interaction="False" />
            <pair e1="DS3.d227.s0.e0" e2="DS3.d227.s0.e2" id="DS3.d227.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d227.s1" origId="9934678-6" text="Furthermore, the selected N2a clones allowed the Prnp expression level to be quantitatively controlled by varying the level of the effector substance, the tetracycline-derivative doxycycline.">
            <entity id="DS3.d227.s1.e0" origId="P04925,Q4FJQ7,Q3UG89" charOffset="49-53" type="protein" text="Prnp"/>
            <entity id="DS3.d227.s1.e1" origId="54675776" charOffset="155-167" type="compound" text="tetracycline"/>
            <entity id="DS3.d227.s1.e2" origId="54671203" charOffset="179-190" type="compound" text="doxycycline"/>
            <pair e1="DS3.d227.s1.e2" e2="DS3.d227.s1.e0" id="DS3.d227.s1.i0" interaction="False" />
            <pair e1="DS3.d227.s1.e1" e2="DS3.d227.s1.e0" id="DS3.d227.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d227.s2" origId="9934678-8" text="These N2a clones may become an important tool for elucidation of the cellular function of PrP and may pave the way for the tetracycline-inducible expression of many genes in this neuroblastoma cell line.">
            <entity id="DS3.d227.s2.e0" origId="P04925,Q4FJQ7,Q3UG89" charOffset="90-93" type="protein" text="PrP"/>
            <entity id="DS3.d227.s2.e1" origId="54675776" charOffset="123-135" type="compound" text="tetracycline"/>
            <pair e1="DS3.d227.s2.e1" e2="DS3.d227.s2.e0" id="DS3.d227.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d228" origId="9934688">
        <sentence id="DS3.d228.s0" origId="9934688-4" text="Butyrate induces much higher levels of multiple class II and class III transcripts than does TPA, including v-MIPI, v-IL-6, v-Bcl-2, vGPCR and ORF26.">
            <entity id="DS3.d228.s0.e0" origId="122634" charOffset="93-96" type="compound" text="TPA"/>
            <entity id="DS3.d228.s0.e1" origId="F5HET8,Q76RJ0" charOffset="108-114" type="protein" text="v-MIPI"/>
            <entity id="DS3.d228.s0.e2" origId="Q2HRC7" charOffset="116-122" type="protein" text="v-IL-6"/>
            <entity id="DS3.d228.s0.e3" origId="F5HGJ3,Q76RI8" charOffset="124-131" type="protein" text="v-Bcl-2"/>
            <entity id="DS3.d228.s0.e4" origId="F5HGN8,C7E599" charOffset="143-148" type="protein" text="ORF26"/>
            <pair e1="DS3.d228.s0.e0" e2="DS3.d228.s0.e3" id="DS3.d228.s0.i0" interaction="False" />
            <pair e1="DS3.d228.s0.e0" e2="DS3.d228.s0.e4" id="DS3.d228.s0.i1" interaction="False" />
            <pair e1="DS3.d228.s0.e0" e2="DS3.d228.s0.e1" id="DS3.d228.s0.i2" interaction="False" />
            <pair e1="DS3.d228.s0.e0" e2="DS3.d228.s0.e2" id="DS3.d228.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d229" origId="9934696">
        <sentence id="DS3.d229.s0" origId="9934696-2" text="In both cases, apoptosis could be partially blocked by treatment with three anti-neuraminidase compounds (4-amino-(GR121158A) and 4-guanidino- (GG167; Zanamivir) 2,3-dehydro-N-acetylneuraminic acid and 2,3-dehydro-2-deoxy-N-acetylneuraminic acid (DANA)) when they were given to cells during the virus attachment/entry phase, but not subsequent to this phase.">
            <entity id="DS3.d229.s0.e0" origId="Q99519,Q5JQI0" charOffset="81-94" type="protein" text="neuraminidase"/>
            <entity id="DS3.d229.s0.e1" origId="3520" charOffset="132-141" type="compound" text="guanidino"/>
            <entity id="DS3.d229.s0.e2" origId="60855" charOffset="151-160" type="compound" text="Zanamivir"/>
            <entity id="DS3.d229.s0.e3" origId="439197,444885,53661354,68260278,8565,906" charOffset="174-197" type="compound" text="N-acetylneuraminic acid"/>
            <entity id="DS3.d229.s0.e4" origId="439197,444885,53661354,68260278,8565,906" charOffset="222-245" type="compound" text="N-acetylneuraminic acid"/>
            <entity id="DS3.d229.s0.e5" origId="65309" charOffset="247-251" type="compound" text="DANA"/>
            <pair e1="DS3.d229.s0.e3" e2="DS3.d229.s0.e0" id="DS3.d229.s0.i0" interaction="False" />
            <pair e1="DS3.d229.s0.e1" e2="DS3.d229.s0.e0" id="DS3.d229.s0.i1" interaction="False" />
            <pair e1="DS3.d229.s0.e2" e2="DS3.d229.s0.e0" id="DS3.d229.s0.i2" interaction="False" />
            <pair e1="DS3.d229.s0.e5" e2="DS3.d229.s0.e0" id="DS3.d229.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d230" origId="9934705">
        <sentence id="DS3.d230.s0" origId="9934705-3" text="To increase the immunogenicity of the Env antigen, a VV recombinant was generated that expresses a chimeric antigen consisting of the Env protein fused to an immunostimulatory cytokine, granulocyte-macrophage colony-stimulating factor (GM-CSF).">
            <entity id="DS3.d230.s0.e0" origId="Q9UQF0,D0EYG5" charOffset="38-41" type="protein" text="Env"/>
            <entity id="DS3.d230.s0.e1" origId="Q9UQF0,D0EYG5" charOffset="134-137" type="protein" text="Env"/>
            <entity id="DS3.d230.s0.e2" origId="16122568,16750043,4369303,448383" charOffset="239-242" type="compound" text="CSF"/>
            <pair e1="DS3.d230.s0.e2" e2="DS3.d230.s0.e0" id="DS3.d230.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d230.s1" origId="9934705-7" text="These results indicate that HIV Env antigen fusion to GM-CSF provides a means to improve the anti-HIV immune response.">
            <entity id="DS3.d230.s1.e0" origId="Q9UQF0,D0EYG5" charOffset="32-35" type="protein" text="Env"/>
            <entity id="DS3.d230.s1.e1" origId="16122568,16750043,4369303,448383" charOffset="57-60" type="compound" text="CSF"/>
            <pair e1="DS3.d230.s1.e1" e2="DS3.d230.s1.e0" id="DS3.d230.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d231" origId="9934732">
        <sentence id="DS3.d231.s0" origId="9934732-1" text="OBJECTIVE: Octreotide, a somatostatin analog, is antinociceptive and increases perception threshold in the rectum.">
            <entity id="DS3.d231.s0.e0" origId="383414,44420813,448601,86289069,6400441,57181882" charOffset="11-21" type="compound" text="Octreotide"/>
            <entity id="DS3.d231.s0.e1" origId="P61278" charOffset="25-37" type="protein" text="somatostatin"/>
            <pair e1="DS3.d231.s0.e0" e2="DS3.d231.s0.e1" id="DS3.d231.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d232" origId="9934750">
        <sentence id="DS3.d232.s0" origId="9934750-0" text="Interleukin-6, nitric oxide, and the clinical and hemodynamic alterations of patients with liver cirrhosis.">
            <entity id="DS3.d232.s0.e0" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="0-13" type="protein" text="Interleukin-6"/>
            <entity id="DS3.d232.s0.e1" origId="145068" charOffset="15-27" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d232.s0.e1" e2="DS3.d232.s0.e0" id="DS3.d232.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d232.s1" origId="9934750-12" text="Only Interleukin-6 levels had significant correlations with Child score, plasma renin activity, serum and urinary sodium, and mean arterial pressure (r &amp;gt; or = 0.4, p &amp;lt; 0.005).">
            <entity id="DS3.d232.s1.e0" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="5-18" type="protein" text="Interleukin-6"/>
            <entity id="DS3.d232.s1.e1" origId="P00797" charOffset="80-85" type="protein" text="renin"/>
            <entity id="DS3.d232.s1.e2" origId="5360545" charOffset="114-120" type="compound" text="sodium"/>
            <pair e1="DS3.d232.s1.e2" e2="DS3.d232.s1.e0" id="DS3.d232.s1.i0" interaction="False" />
            <pair e1="DS3.d232.s1.e2" e2="DS3.d232.s1.e1" id="DS3.d232.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d232.s2" origId="9934750-14" text="Interleukin-6, possibly through nitric oxide-independent mechanisms, also might play a role in the vasodilatation of cirrhosis and the pathogenesis of hepatic encephalopathy.">
            <entity id="DS3.d232.s2.e0" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="0-13" type="protein" text="Interleukin-6"/>
            <entity id="DS3.d232.s2.e1" origId="145068" charOffset="32-44" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d232.s2.e1" e2="DS3.d232.s2.e0" id="DS3.d232.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d233" origId="9934763">
        <sentence id="DS3.d233.s0" origId="9934763-8" text="Liver function tests peaked at the following values: prothrombin time of 24.5 s, total bilirubin of 18.0 mg/dL, and transaminases in excess of 5000 IU/L.">
            <entity id="DS3.d233.s0.e0" origId="P00734" charOffset="53-64" type="protein" text="prothrombin"/>
            <entity id="DS3.d233.s0.e1" origId="5280352" charOffset="87-96" type="compound" text="bilirubin"/>
            <pair e1="DS3.d233.s0.e1" e2="DS3.d233.s0.e0" id="DS3.d233.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d234" origId="9934767">
        <sentence id="DS3.d234.s0" origId="9934767-0" text="Peutz-Jeghers syndrome: molecular analysis of a three-generation kindred with a novel defect in the serine threonine kinase gene STK11.">
            <entity id="DS3.d234.s0.e0" origId="194239,6288" charOffset="107-116" type="compound" text="threonine"/>
            <entity id="DS3.d234.s0.e1" origId="Q15831" charOffset="129-134" type="protein" text="STK11"/>
            <pair e1="DS3.d234.s0.e0" e2="DS3.d234.s0.e1" id="DS3.d234.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d234.s1" origId="9934767-3" text="Recently, a mutated gene encoding abnormal forms of the novel serine threonine kinase STK11 has been identified as a genetic cause of Peutz-Jeghers syndrome.">
            <entity id="DS3.d234.s1.e0" origId="194239,6288" charOffset="69-78" type="compound" text="threonine"/>
            <entity id="DS3.d234.s1.e1" origId="Q15831" charOffset="86-91" type="protein" text="STK11"/>
            <pair e1="DS3.d234.s1.e0" e2="DS3.d234.s1.e1" id="DS3.d234.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d234.s2" origId="9934767-4" text="Here, we report the molecular analysis of the STK11 gene in a patient with Peutz-Jeghers syndrome, which in exon 1 revealed a guanine (G) insertion in the 5 G repeat of codons 51-53.">
            <entity id="DS3.d234.s2.e0" origId="Q15831" charOffset="46-51" type="protein" text="STK11"/>
            <entity id="DS3.d234.s2.e1" origId="764" charOffset="126-133" type="compound" text="guanine"/>
            <pair e1="DS3.d234.s2.e1" e2="DS3.d234.s2.e0" id="DS3.d234.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d235" origId="9934769">
        <sentence id="DS3.d235.s0" origId="9934769-1" text="A 34-yr-old woman developed simultaneous pancreatitis and hepatitis following exposure to trimethoprim-sulfamethoxazole (TMP/SMX).">
            <entity id="DS3.d235.s0.e0" origId="5578" charOffset="90-102" type="compound" text="trimethoprim"/>
            <entity id="DS3.d235.s0.e1" origId="5329" charOffset="103-119" type="compound" text="sulfamethoxazole"/>
            <entity id="DS3.d235.s0.e2" origId="P54849,A0A024RAT0" charOffset="121-124" type="protein" text="TMP"/>
            <pair e1="DS3.d235.s0.e0" e2="DS3.d235.s0.e2" id="DS3.d235.s0.i0" interaction="False" />
            <pair e1="DS3.d235.s0.e1" e2="DS3.d235.s0.e2" id="DS3.d235.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d236" origId="9934773">
        <sentence id="DS3.d236.s0" origId="9934773-1" text="Ever since the identification of the colony-stimulating factor (CSF), granulocyte-CSF (G-CSF)-producing tumors have often been reported, and have been attracting attention, especially in pulmonary cancer.">
            <entity id="DS3.d236.s0.e0" origId="16122568,16750043,4369303,448383" charOffset="64-67" type="compound" text="CSF"/>
            <entity id="DS3.d236.s0.e1" origId="P09919,Q6FH65,Q8N4W3" charOffset="70-92" type="protein" text="granulocyte-CSF (G-CSF"/>
            <pair e1="DS3.d236.s0.e0" e2="DS3.d236.s0.e1" id="DS3.d236.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d237" origId="9934776">
        <sentence id="DS3.d237.s0" origId="9934776-0" text="Successful treatment of an advanced hepatocellular carcinoma with the long-acting somatostatin analog lanreotide.">
            <entity id="DS3.d237.s0.e0" origId="P61278" charOffset="82-94" type="protein" text="somatostatin"/>
            <entity id="DS3.d237.s0.e1" origId="71349" charOffset="102-112" type="compound" text="lanreotide"/>
            <pair e1="DS3.d237.s0.e1" e2="DS3.d237.s0.e0" id="DS3.d237.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d237.s1" origId="9934776-3" text="We present the case of a 68-yr-old male, who was successfully treated with the long-acting somatostatin analog lanreotide.">
            <entity id="DS3.d237.s1.e0" origId="P61278" charOffset="91-103" type="protein" text="somatostatin"/>
            <entity id="DS3.d237.s1.e1" origId="71349" charOffset="111-121" type="compound" text="lanreotide"/>
            <pair e1="DS3.d237.s1.e1" e2="DS3.d237.s1.e0" id="DS3.d237.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d238" origId="9934802">
        <sentence id="DS3.d238.s0" origId="9934802-5" text="IMX assay was used for PSA determination in all patients.">
            <entity id="DS3.d238.s0.e0" origId="11508600" charOffset="0-3" type="compound" text="IMX"/>
            <entity id="DS3.d238.s0.e1" origId="P07225" charOffset="23-26" type="protein" text="PSA"/>
            <pair e1="DS3.d238.s0.e0" e2="DS3.d238.s0.e1" id="DS3.d238.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d239" origId="9934809">
        <sentence id="DS3.d239.s0" origId="9934809-10" text="Markedly elevated urinary TPA-like levels in all patients studied (HFM, BEN, BEN-RF, GN) suggest that urinary TPA may not be a reliable tumour marker.">
            <entity id="DS3.d239.s0.e0" origId="122634,22833501" charOffset="26-29" type="compound" text="TPA"/>
            <entity id="DS3.d239.s0.e1" origId="Q9UHL9,E9PFE2" charOffset="72-75" type="protein" text="BEN"/>
            <entity id="DS3.d239.s0.e2" origId="Q9UHL9,E9PFE2" charOffset="77-80" type="protein" text="BEN"/>
            <entity id="DS3.d239.s0.e3" origId="122634,22833501" charOffset="110-113" type="compound" text="TPA"/>
            <pair e1="DS3.d239.s0.e0" e2="DS3.d239.s0.e1" id="DS3.d239.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d239.s1" origId="9934809-11" text="However, the clinical relevance of high TPA levels in BEN patients should be evaluated.">
            <entity id="DS3.d239.s1.e0" origId="122634,22833501" charOffset="40-43" type="compound" text="TPA"/>
            <entity id="DS3.d239.s1.e1" origId="Q9UHL9,E9PFE2" charOffset="54-57" type="protein" text="BEN"/>
            <pair e1="DS3.d239.s1.e0" e2="DS3.d239.s1.e1" id="DS3.d239.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d239.s2" origId="9934809-3" text="The aim of this study was to facilitate early detection of urothelial cancer in BEN patients and their family members living in an endemic region by using tumour markers, carcinoembryonic antigen (CEA) and tissue polypeptide antigen (TPA), and a putative marker, ferritin.">
            <entity id="DS3.d239.s2.e0" origId="Q9UHL9,E9PFE2" charOffset="80-83" type="protein" text="BEN"/>
            <entity id="DS3.d239.s2.e1" origId="P06731,A0A024R0K5,Q53G30" charOffset="171-195" type="protein" text="carcinoembryonic antigen"/>
            <entity id="DS3.d239.s2.e2" origId="P06731,A0A024R0K5,Q53G30" charOffset="197-200" type="protein" text="CEA"/>
            <entity id="DS3.d239.s2.e3" origId="122634,22833501" charOffset="234-237" type="compound" text="TPA"/>
            <pair e1="DS3.d239.s2.e3" e2="DS3.d239.s2.e1" id="DS3.d239.s2.i0" interaction="False" />
            <pair e1="DS3.d239.s2.e3" e2="DS3.d239.s2.e0" id="DS3.d239.s2.i1" interaction="False" />
            <pair e1="DS3.d239.s2.e3" e2="DS3.d239.s2.e2" id="DS3.d239.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d239.s3" origId="9934809-6" text="Serum TPA levels in BEN and BEN-RF patients were significantly higher than in the C and HFM groups (p&amp;lt;0.05).">
            <entity id="DS3.d239.s3.e0" origId="122634,22833501" charOffset="6-9" type="compound" text="TPA"/>
            <entity id="DS3.d239.s3.e1" origId="Q9UHL9,E9PFE2" charOffset="20-23" type="protein" text="BEN"/>
            <entity id="DS3.d239.s3.e2" origId="Q9UHL9,E9PFE2" charOffset="28-31" type="protein" text="BEN"/>
            <pair e1="DS3.d239.s3.e0" e2="DS3.d239.s3.e1" id="DS3.d239.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d239.s4" origId="9934809-8" text="Urinary TPA levels in HFM (median 125 U/l, BEN (236 U/l) and BEN-RF (275 U/l) were significantly increased over C (30 U/l), however, TPA levels were increased also in GN patients (437 U/l).">
            <entity id="DS3.d239.s4.e0" origId="122634,22833501" charOffset="8-11" type="compound" text="TPA"/>
            <entity id="DS3.d239.s4.e1" origId="Q9UHL9,E9PFE2" charOffset="43-46" type="protein" text="BEN"/>
            <entity id="DS3.d239.s4.e2" origId="Q9UHL9,E9PFE2" charOffset="61-64" type="protein" text="BEN"/>
            <entity id="DS3.d239.s4.e3" origId="122634,22833501" charOffset="133-136" type="compound" text="TPA"/>
            <pair e1="DS3.d239.s4.e0" e2="DS3.d239.s4.e1" id="DS3.d239.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d240" origId="9934812">
        <sentence id="DS3.d240.s0" origId="9934812-0" text="The importance of serum transferrin receptor level in the diagnosis of functional iron deficiency due to recombinant human erythropoietin treatment in haemodialysis patients.">
            <entity id="DS3.d240.s0.e0" origId="23925,67172434" charOffset="82-86" type="compound" text="iron"/>
            <entity id="DS3.d240.s0.e1" origId="P01588,G9JKG7" charOffset="105-137" type="protein" text="recombinant human erythropoietin"/>
            <pair e1="DS3.d240.s0.e0" e2="DS3.d240.s0.e1" id="DS3.d240.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d240.s1" origId="9934812-1" text="In haemodialysis (HD) patients, functional iron deficiency frequently appears due to recombinant human erythropoietin (r-HuEPO) treatment.">
            <entity id="DS3.d240.s1.e0" origId="23925,67172434" charOffset="43-47" type="compound" text="iron"/>
            <entity id="DS3.d240.s1.e1" origId="P01588,G9JKG7" charOffset="85-117" type="protein" text="recombinant human erythropoietin"/>
            <pair e1="DS3.d240.s1.e0" e2="DS3.d240.s1.e1" id="DS3.d240.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d241" origId="9934814">
        <sentence id="DS3.d241.s0" origId="9934814-5" text="The patients reporting symptoms were less likely to be insulin resistant with longer time post-PTX, lower body mass index (BMI), and on lower doses of prednisone.">
            <entity id="DS3.d241.s0.e0" origId="P01308,I3WAC9" charOffset="55-62" type="protein" text="insulin"/>
            <entity id="DS3.d241.s0.e1" origId="5865" charOffset="151-161" type="compound" text="prednisone"/>
            <pair e1="DS3.d241.s0.e1" e2="DS3.d241.s0.e0" id="DS3.d241.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d241.s1" origId="9934814-7" text="Fasting glucose, free and total immunoreactive insulin (IRI), C-peptide, proinsulin and glucagon were measured following a 4 h Sustacal challenge.">
            <entity id="DS3.d241.s1.e0" origId="206,5793,64689,79025" charOffset="8-15" type="compound" text="glucose"/>
            <entity id="DS3.d241.s1.e1" origId="P01308,I3WAC9" charOffset="47-54" type="protein" text="insulin"/>
            <entity id="DS3.d241.s1.e2" origId="P01308,I3WAC9" charOffset="62-71" type="protein" text="C-peptide"/>
            <entity id="DS3.d241.s1.e3" origId="P01308,I3WAC9" charOffset="73-83" type="protein" text="proinsulin"/>
            <pair e1="DS3.d241.s1.e0" e2="DS3.d241.s1.e1" id="DS3.d241.s1.i0" interaction="False" />
            <pair e1="DS3.d241.s1.e0" e2="DS3.d241.s1.e2" id="DS3.d241.s1.i1" interaction="False" />
            <pair e1="DS3.d241.s1.e0" e2="DS3.d241.s1.e3" id="DS3.d241.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d242" origId="9934816">
        <sentence id="DS3.d242.s0" origId="9934816-5" text="Such a goal is feasible as long as (1) a rational plan of insulin therapy is adopted, including appropriate use of the short-acting insulin analogue lispro, (2) blood glucose is properly monitored, (3) blood glucose targets are individualized, and (4) education programs are widely implemented.">
            <entity id="DS3.d242.s0.e0" origId="P01308,I3WAC9" charOffset="58-65" type="protein" text="insulin"/>
            <entity id="DS3.d242.s0.e1" origId="P01308,I3WAC9" charOffset="132-139" type="protein" text="insulin"/>
            <entity id="DS3.d242.s0.e2" origId="5793,206,64689,79025" charOffset="167-174" type="compound" text="glucose"/>
            <entity id="DS3.d242.s0.e3" origId="5793,206,64689,79025" charOffset="208-215" type="compound" text="glucose"/>
            <pair e1="DS3.d242.s0.e2" e2="DS3.d242.s0.e0" id="DS3.d242.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d243" origId="9934818">
        <sentence id="DS3.d243.s0" origId="9934818-9" text="The gold standard was the albumin excretion rate measured by a nephelometric method in a 24-h urine collection.">
            <entity id="DS3.d243.s0.e0" origId="23985" charOffset="4-8" type="compound" text="gold"/>
            <entity id="DS3.d243.s0.e1" origId="P02768" charOffset="26-33" type="protein" text="albumin"/>
            <pair e1="DS3.d243.s0.e0" e2="DS3.d243.s0.e1" id="DS3.d243.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d244" origId="9934819">
        <sentence id="DS3.d244.s0" origId="9934819-12" text="In conclusion, the early course of Insulin-mediated glucose uptake in the human forearm was mainly due to an increase in glucose extraction.">
            <entity id="DS3.d244.s0.e0" origId="P01308,I3WAC9" charOffset="35-42" type="protein" text="Insulin"/>
            <entity id="DS3.d244.s0.e1" origId="206,5793,64689,79025" charOffset="52-59" type="compound" text="glucose"/>
            <entity id="DS3.d244.s0.e2" origId="206,5793,64689,79025" charOffset="121-128" type="compound" text="glucose"/>
            <pair e1="DS3.d244.s0.e1" e2="DS3.d244.s0.e0" id="DS3.d244.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d244.s1" origId="9934819-13" text="However, with time the Insulin-mediated increase in blood flow increased in importance and after 100 min of hyperinsulinaemia FBF was the major determinant of glucose uptake.">
            <entity id="DS3.d244.s1.e0" origId="P01308,I3WAC9" charOffset="23-30" type="protein" text="Insulin"/>
            <entity id="DS3.d244.s1.e1" origId="206,5793,64689,79025" charOffset="159-166" type="compound" text="glucose"/>
            <pair e1="DS3.d244.s1.e1" e2="DS3.d244.s1.e0" id="DS3.d244.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d244.s2" origId="9934819-1" text="Insulin-mediated stimulation of blood flow to skeletal muscle has been proposed to be of major importance for Insulin-mediated glucose uptake.">
            <entity id="DS3.d244.s2.e0" origId="P01308,I3WAC9" charOffset="0-7" type="protein" text="Insulin"/>
            <entity id="DS3.d244.s2.e1" origId="P01308,I3WAC9" charOffset="110-117" type="protein" text="Insulin"/>
            <entity id="DS3.d244.s2.e2" origId="206,5793,64689,79025" charOffset="127-134" type="compound" text="glucose"/>
            <pair e1="DS3.d244.s2.e2" e2="DS3.d244.s2.e0" id="DS3.d244.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d244.s3" origId="9934819-2" text="The aim of this study was to investigate the relative importance of blood flow and glucose extraction as determinants of Insulin-mediated glucose uptake in the human forearm.">
            <entity id="DS3.d244.s3.e0" origId="206,5793,64689,79025" charOffset="83-90" type="compound" text="glucose"/>
            <entity id="DS3.d244.s3.e1" origId="P01308,I3WAC9" charOffset="121-128" type="protein" text="Insulin"/>
            <entity id="DS3.d244.s3.e2" origId="206,5793,64689,79025" charOffset="138-145" type="compound" text="glucose"/>
            <pair e1="DS3.d244.s3.e0" e2="DS3.d244.s3.e1" id="DS3.d244.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d245" origId="9934825">
        <sentence id="DS3.d245.s0" origId="9934825-0" text="Tumor necrosis factor-alpha production after esophageal cancer surgery: differences in the response to lipopolysaccharide stimulation among whole blood, pleural effusion cells, and bronchoalveolar lavage fluid cells.">
            <entity id="DS3.d245.s0.e0" origId="P01375,Q5STB3" charOffset="0-27" type="protein" text="Tumor necrosis factor-alpha"/>
            <entity id="DS3.d245.s0.e1" origId="11970143" charOffset="103-121" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS3.d245.s0.e1" e2="DS3.d245.s0.e0" id="DS3.d245.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d245.s1" origId="9934825-4" text="Whole blood was stimulated with Escherichia coli (1 microg/ml), Staphylococcus aureus (10 microg/ml), and lipopolysaccharide (LPS) (1 microg/ml), and pleural effusion cells and BALF cells were stimulated with LPS; 24-H incubation and TNF-alpha concentration in supernate was measured by enzyme-linked immunosorbent assay (ELISA).">
            <entity id="DS3.d245.s1.e0" origId="11970143" charOffset="106-124" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d245.s1.e1" origId="P01375,Q5STB3" charOffset="234-243" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d245.s1.e0" e2="DS3.d245.s1.e1" id="DS3.d245.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d246" origId="9934832">
        <sentence id="DS3.d246.s0" origId="9934832-9" text="Serum bFGF and TGF-beta1 levels in the tranilast group were lower at the time of surgery than those in the control group, and bFGF levels were lower at the endpoint of this study in the tranilast group than in the control group.">
            <entity id="DS3.d246.s0.e0" origId="P13109" charOffset="6-10" type="protein" text="bFGF"/>
            <entity id="DS3.d246.s0.e1" origId="P17246" charOffset="15-24" type="protein" text="TGF-beta1"/>
            <entity id="DS3.d246.s0.e2" origId="5282230" charOffset="39-48" type="compound" text="tranilast"/>
            <entity id="DS3.d246.s0.e3" origId="P13109" charOffset="126-130" type="protein" text="bFGF"/>
            <entity id="DS3.d246.s0.e4" origId="5282230" charOffset="186-195" type="compound" text="tranilast"/>
            <pair e1="DS3.d246.s0.e2" e2="DS3.d246.s0.e1" id="DS3.d246.s0.i0" interaction="False" />
            <pair e1="DS3.d246.s0.e2" e2="DS3.d246.s0.e0" id="DS3.d246.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d247" origId="9934833">
        <sentence id="DS3.d247.s0" origId="9934833-3" text="In the present study, DLN cells, obtained from C57BL/6 mice with fibrosarcoma (MC-1), were activated and expanded with anti-CD3 monoclonal antibody followed by culture with recombinant interleukin-2 (rIL-2).">
            <entity id="DS3.d247.s0.e0" origId="44475985" charOffset="22-25" type="compound" text="DLN"/>
            <entity id="DS3.d247.s0.e1" origId="P17108" charOffset="200-205" type="protein" text="rIL-2"/>
            <pair e1="DS3.d247.s0.e0" e2="DS3.d247.s0.e1" id="DS3.d247.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d247.s1" origId="9934833-5" text="The supernatant, obtained by coculturing the activated DLN cells with MC-1 cells, exhibited the specific production of interferon-gamma (IFN-gamma) which was enhanced by rIL-2.">
            <entity id="DS3.d247.s1.e0" origId="44475985" charOffset="55-58" type="compound" text="DLN"/>
            <entity id="DS3.d247.s1.e1" origId="P01580" charOffset="119-146" type="protein" text="interferon-gamma (IFN-gamma"/>
            <entity id="DS3.d247.s1.e2" origId="P17108" charOffset="170-175" type="protein" text="rIL-2"/>
            <pair e1="DS3.d247.s1.e0" e2="DS3.d247.s1.e1" id="DS3.d247.s1.i0" interaction="False" />
            <pair e1="DS3.d247.s1.e0" e2="DS3.d247.s1.e2" id="DS3.d247.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d247.s2" origId="9934833-6" text="The therapeutic effect of the activated DLN cells correlated with the specific IFN-gamma production better than with the cytolytic activity.">
            <entity id="DS3.d247.s2.e0" origId="44475985" charOffset="40-43" type="compound" text="DLN"/>
            <entity id="DS3.d247.s2.e1" origId="P01580" charOffset="79-88" type="protein" text="IFN-gamma"/>
            <pair e1="DS3.d247.s2.e0" e2="DS3.d247.s2.e1" id="DS3.d247.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d248" origId="9934845">
        <sentence id="DS3.d248.s0" origId="9934845-6" text="We have examined the host cell reactivation (HCR) of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ in non-irradiated and UV-irradiated normal, XP-B, XP-C, XP-D, XP-F, XP-G, CS-A and CS-B fibroblasts.">
            <entity id="DS3.d248.s0.e0" origId="473141" charOffset="45-48" type="compound" text="HCR"/>
            <entity id="DS3.d248.s0.e1" origId="P16278" charOffset="53-71" type="protein" text="beta-galactosidase"/>
            <entity id="DS3.d248.s0.e2" origId="P19447,G3V1S1,B3KRG2,B3KTH1" charOffset="158-162" type="protein" text="XP-B"/>
            <entity id="DS3.d248.s0.e3" origId="Q01831,X5DRB1" charOffset="164-168" type="protein" text="XP-C"/>
            <entity id="DS3.d248.s0.e4" origId="Q92889,B4DXD8" charOffset="176-180" type="protein" text="XP-F"/>
            <entity id="DS3.d248.s0.e5" origId="P28715" charOffset="182-186" type="protein" text="XP-G"/>
            <entity id="DS3.d248.s0.e6" origId="P0DML2,P0DML3,A8K6C2" charOffset="188-192" type="protein" text="CS-A"/>
            <entity id="DS3.d248.s0.e7" origId="Q03468,Q59FF6" charOffset="197-201" type="protein" text="CS-B"/>
            <pair e1="DS3.d248.s0.e0" e2="DS3.d248.s0.e1" id="DS3.d248.s0.i0" interaction="False" />
            <pair e1="DS3.d248.s0.e0" e2="DS3.d248.s0.e3" id="DS3.d248.s0.i1" interaction="False" />
            <pair e1="DS3.d248.s0.e0" e2="DS3.d248.s0.e2" id="DS3.d248.s0.i2" interaction="False" />
            <pair e1="DS3.d248.s0.e0" e2="DS3.d248.s0.e6" id="DS3.d248.s0.i3" interaction="False" />
            <pair e1="DS3.d248.s0.e0" e2="DS3.d248.s0.e5" id="DS3.d248.s0.i4" interaction="False" />
            <pair e1="DS3.d248.s0.e0" e2="DS3.d248.s0.e4" id="DS3.d248.s0.i5" interaction="False" />
            <pair e1="DS3.d248.s0.e0" e2="DS3.d248.s0.e7" id="DS3.d248.s0.i6" interaction="False" />
        </sentence>
        <sentence id="DS3.d248.s1" origId="9934845-7" text="HCR of beta-galactosidase activity for UV-irradiated Ad5HCMVsp1lacZ was reduced in non-irradiated cells from each of the repair-deficient groups examined (including XP-C) relative to that in non-irradiated normal cells.">
            <entity id="DS3.d248.s1.e0" origId="473141" charOffset="0-3" type="compound" text="HCR"/>
            <entity id="DS3.d248.s1.e1" origId="P16278" charOffset="7-25" type="protein" text="beta-galactosidase"/>
            <entity id="DS3.d248.s1.e2" origId="Q01831,X5DRB1" charOffset="165-169" type="protein" text="XP-C"/>
            <pair e1="DS3.d248.s1.e0" e2="DS3.d248.s1.e2" id="DS3.d248.s1.i0" interaction="False" />
            <pair e1="DS3.d248.s1.e0" e2="DS3.d248.s1.e1" id="DS3.d248.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d248.s2" origId="9934845-8" text="Prior irradiation of cells with low UV fluences resulted in an enhancement of HCR for normal and XP-C strains, but not for the remaining XP and CS strains.">
            <entity id="DS3.d248.s2.e0" origId="473141" charOffset="78-81" type="compound" text="HCR"/>
            <entity id="DS3.d248.s2.e1" origId="Q01831,X5DRB1" charOffset="97-101" type="protein" text="XP-C"/>
            <pair e1="DS3.d248.s2.e0" e2="DS3.d248.s2.e1" id="DS3.d248.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d249" origId="9934848">
        <sentence id="DS3.d249.s0" origId="9934848-0" text="Phenobarbital promotes liver growth in c-myc/TGF-alpha transgenic mice by inducing hypertrophy and inhibiting apoptosis.">
            <entity id="DS3.d249.s0.e0" origId="4763" charOffset="0-13" type="compound" text="Phenobarbital"/>
            <entity id="DS3.d249.s0.e1" origId="P48030,Q545E4" charOffset="45-54" type="protein" text="TGF-alpha"/>
            <pair e1="DS3.d249.s0.e0" e2="DS3.d249.s0.e1" id="DS3.d249.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d250" origId="9934851">
        <sentence id="DS3.d250.s0" origId="9934851-12" text="Cadmium treatment had no effects on either Bcl-2 or Bax protein expression in tumor xenografts, indicating that apoptotic pathways probably do not contribute to this anti-neoplastic effect.">
            <entity id="DS3.d250.s0.e0" origId="23973" charOffset="0-7" type="compound" text="Cadmium"/>
            <entity id="DS3.d250.s0.e1" origId="P10415,A0A024R2B3,A0A024R2C4" charOffset="43-48" type="protein" text="Bcl-2"/>
            <entity id="DS3.d250.s0.e2" origId="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0" charOffset="52-55" type="protein" text="Bax"/>
            <pair e1="DS3.d250.s0.e0" e2="DS3.d250.s0.e1" id="DS3.d250.s0.i0" interaction="False" />
            <pair e1="DS3.d250.s0.e0" e2="DS3.d250.s0.e2" id="DS3.d250.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d251" origId="9934856">
        <sentence id="DS3.d251.s0" origId="9934856-0" text="Expression of the inactive C145A mutant human O6-alkylguanine-DNA alkyltransferase in E.coli increases cell killing and mutations by N-methyl-N'-nitro-N-nitrosoguanidine.">
            <entity id="DS3.d251.s0.e0" origId="P01019,B0ZBE2,B2R5S1" charOffset="46-82" type="protein" text="O6-alkylguanine-DNA alkyltransferase"/>
            <entity id="DS3.d251.s0.e1" origId="12660" charOffset="151-169" type="compound" text="N-nitrosoguanidine"/>
            <pair e1="DS3.d251.s0.e1" e2="DS3.d251.s0.e0" id="DS3.d251.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d251.s1" origId="9934856-1" text="Human O6-alkylguanine-DNA alkyltransferase (AGT) counteracts the mutagenic and toxic effects of methylating agents such as N-methyl-N'-nitro-N-nitrosoguanidine (MNNG) by removing the methyl group from O6-methylguanine lesions in DNA.">
            <entity id="DS3.d251.s1.e0" origId="P01019,B0ZBE2,B2R5S1" charOffset="6-42" type="protein" text="O6-alkylguanine-DNA alkyltransferase"/>
            <entity id="DS3.d251.s1.e1" origId="P01019,B0ZBE2,B2R5S1" charOffset="44-47" type="protein" text="AGT"/>
            <entity id="DS3.d251.s1.e2" origId="12660" charOffset="141-159" type="compound" text="N-nitrosoguanidine"/>
            <entity id="DS3.d251.s1.e3" origId="65275" charOffset="201-217" type="compound" text="O6-methylguanine"/>
            <pair e1="DS3.d251.s1.e3" e2="DS3.d251.s1.e1" id="DS3.d251.s1.i0" interaction="False" />
            <pair e1="DS3.d251.s1.e3" e2="DS3.d251.s1.e0" id="DS3.d251.s1.i1" interaction="False" />
            <pair e1="DS3.d251.s1.e2" e2="DS3.d251.s1.e1" id="DS3.d251.s1.i2" interaction="False" />
            <pair e1="DS3.d251.s1.e2" e2="DS3.d251.s1.e0" id="DS3.d251.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d251.s2" origId="9934856-2" text="The methyl group is transferred to a cysteine acceptor residue in the AGT protein, which is located at residue 145.">
            <entity id="DS3.d251.s2.e0" origId="5862,90793998" charOffset="37-45" type="compound" text="cysteine"/>
            <entity id="DS3.d251.s2.e1" origId="P01019,B0ZBE2,B2R5S1" charOffset="70-73" type="protein" text="AGT"/>
            <pair e1="DS3.d251.s2.e0" e2="DS3.d251.s2.e1" id="DS3.d251.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d251.s3" origId="9934856-3" text="The C145A mutant of AGT in which this cysteine is converted to an alanine residue is therefore inactive.">
            <entity id="DS3.d251.s3.e0" origId="P01019,B0ZBE2,B2R5S1" charOffset="20-23" type="protein" text="AGT"/>
            <entity id="DS3.d251.s3.e1" origId="5862,90793998" charOffset="38-46" type="compound" text="cysteine"/>
            <entity id="DS3.d251.s3.e2" origId="5950" charOffset="66-73" type="compound" text="alanine"/>
            <pair e1="DS3.d251.s3.e2" e2="DS3.d251.s3.e0" id="DS3.d251.s3.i0" interaction="False" />
            <pair e1="DS3.d251.s3.e1" e2="DS3.d251.s3.e0" id="DS3.d251.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d251.s4" origId="9934856-7" text="These results suggest that the C145A mutant AGT binds to O6-methylguanine lesions in DNA and prevents their repair by NER.">
            <entity id="DS3.d251.s4.e0" origId="P01019,B0ZBE2,B2R5S1" charOffset="44-47" type="protein" text="AGT"/>
            <entity id="DS3.d251.s4.e1" origId="65275" charOffset="57-73" type="compound" text="O6-methylguanine"/>
            <pair e1="DS3.d251.s4.e1" e2="DS3.d251.s4.e0" id="DS3.d251.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d252" origId="9934857">
        <sentence id="DS3.d252.s0" origId="9934857-1" text="We have investigated the mutagenicity of benzo(a)pyrene (B(a)P) in small intestine using the Dlb-1 locus assay in the mouse.">
            <entity id="DS3.d252.s0.e0" origId="31423" charOffset="49-55" type="compound" text="pyrene"/>
            <entity id="DS3.d252.s0.e1" origId="Q09199,A2A615" charOffset="93-98" type="protein" text="Dlb-1"/>
            <pair e1="DS3.d252.s0.e0" e2="DS3.d252.s0.e1" id="DS3.d252.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d253" origId="9934858">
        <sentence id="DS3.d253.s0" origId="9934858-1" text="3,3',4,4'-Tetrachlorobiphenyl (tetraCB) binds to the aryl hydrocarbon receptor (AhR), and several reports have demonstrated that AhR agonists exhibit antiestrogenic and antitumorigenic activities in human breast cancer cells, the rodent uterus and breast.">
            <entity id="DS3.d253.s0.e0" origId="36187" charOffset="0-29" type="compound" text="3,3',4,4'-Tetrachlorobiphenyl"/>
            <entity id="DS3.d253.s0.e1" origId="P35869,A0A024R9Z8" charOffset="53-78" type="protein" text="aryl hydrocarbon receptor"/>
            <entity id="DS3.d253.s0.e2" origId="P35869,A0A024R9Z8" charOffset="80-83" type="protein" text="AhR"/>
            <entity id="DS3.d253.s0.e3" origId="P35869,A0A024R9Z8" charOffset="129-132" type="protein" text="AhR"/>
            <pair e1="DS3.d253.s0.e0" e2="DS3.d253.s0.e1" id="DS3.d253.s0.i0" interaction="False" />
            <pair e1="DS3.d253.s0.e0" e2="DS3.d253.s0.e2" id="DS3.d253.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d253.s1" origId="9934858-5" text="In contrast, both compounds inhibited 17beta-estradiol (E2)-induced cell proliferation and transactivation in MCF-7/T47D cells and uterine responses in B6C3F1 mice; surprisingly inhibition of E2-induced reporter gene activity was not observed in T47D cells transfected with pCKB, and this was observed as a cell-specific response with other AhR agonists.">
            <entity id="DS3.d253.s1.e0" origId="56981346,5757" charOffset="38-54" type="compound" text="17beta-estradiol"/>
            <entity id="DS3.d253.s1.e1" origId="P35869,A0A024R9Z8" charOffset="341-344" type="protein" text="AhR"/>
            <pair e1="DS3.d253.s1.e0" e2="DS3.d253.s1.e1" id="DS3.d253.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d254" origId="9934861">
        <sentence id="DS3.d254.s0" origId="9934861-12" text="Collectively, these results indicate that B(a)PDE inhibits serum-induced SAE cell differentiation, possibly involving activating signals through a PI-3K/MEK1 mediated MAPK pathway, whereas myo-inositol protects SAE cells against this inhibitory effect of B(a)PDE perhaps through both PI-3K/MEK1 and p38 MAPK pathways.">
            <entity id="DS3.d254.s0.e0" origId="444451" charOffset="73-76" type="compound" text="SAE"/>
            <entity id="DS3.d254.s0.e1" origId="Q02750,A4QPA9,B4DFY5" charOffset="153-157" type="protein" text="MEK1"/>
            <entity id="DS3.d254.s0.e2" origId="892" charOffset="193-201" type="compound" text="inositol"/>
            <entity id="DS3.d254.s0.e3" origId="444451" charOffset="211-214" type="compound" text="SAE"/>
            <entity id="DS3.d254.s0.e4" origId="Q02750,A4QPA9,B4DFY5" charOffset="290-294" type="protein" text="MEK1"/>
            <pair e1="DS3.d254.s0.e2" e2="DS3.d254.s0.e1" id="DS3.d254.s0.i0" interaction="False" />
            <pair e1="DS3.d254.s0.e0" e2="DS3.d254.s0.e1" id="DS3.d254.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d254.s1" origId="9934861-7" text="SAE cells retain the features of basal cells in serum-free, low Ca2+ (4 nM) medium up to 4-5 passages, but in serum-supplemented or serum-free, high Ca2+ (1 mM) cultures, they differentiate into non-ciliated epithelial cells expressing Clara cell secretory protein (CCSP).">
            <entity id="DS3.d254.s1.e0" origId="444451" charOffset="0-3" type="compound" text="SAE"/>
            <entity id="DS3.d254.s1.e1" origId="P11684" charOffset="236-264" type="protein" text="Clara cell secretory protein"/>
            <entity id="DS3.d254.s1.e2" origId="P11684" charOffset="266-270" type="protein" text="CCSP"/>
            <pair e1="DS3.d254.s1.e0" e2="DS3.d254.s1.e2" id="DS3.d254.s1.i0" interaction="False" />
            <pair e1="DS3.d254.s1.e0" e2="DS3.d254.s1.e1" id="DS3.d254.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d254.s2" origId="9934861-9" text="This effect was abolished by wortmannin, a phosphatidylinositol-3 kinase (PI-3K) inhibitor, and PD98059, a mitogen activated protein kinase (MAPK) kinase-1 (MEK1) inhibitor, but not by SB202190, a p38 MAPK inhibitor, or melittin, a protein kinase C inhibitor.">
            <entity id="DS3.d254.s2.e0" origId="312145" charOffset="29-39" type="compound" text="wortmannin"/>
            <entity id="DS3.d254.s2.e1" origId="16738692,53477912" charOffset="43-63" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d254.s2.e2" origId="4713" charOffset="96-103" type="compound" text="PD98059"/>
            <entity id="DS3.d254.s2.e3" origId="Q02750,A4QPA9,B4DFY5" charOffset="157-161" type="protein" text="MEK1"/>
            <entity id="DS3.d254.s2.e4" origId="5353940" charOffset="185-193" type="compound" text="SB202190"/>
            <entity id="DS3.d254.s2.e5" origId="16129627,16133648" charOffset="220-228" type="compound" text="melittin"/>
            <pair e1="DS3.d254.s2.e2" e2="DS3.d254.s2.e3" id="DS3.d254.s2.i0" interaction="False" />
            <pair e1="DS3.d254.s2.e0" e2="DS3.d254.s2.e3" id="DS3.d254.s2.i1" interaction="False" />
            <pair e1="DS3.d254.s2.e5" e2="DS3.d254.s2.e3" id="DS3.d254.s2.i2" interaction="False" />
            <pair e1="DS3.d254.s2.e1" e2="DS3.d254.s2.e3" id="DS3.d254.s2.i3" interaction="False" />
            <pair e1="DS3.d254.s2.e4" e2="DS3.d254.s2.e3" id="DS3.d254.s2.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d255" origId="9934864">
        <sentence id="DS3.d255.s0" origId="9934864-10" text="Liver sections were analyzed for glutathione S-transferase placental form (GST-P) expression, and subjected to histopathological examination for phenotypic alteration of hepatocellular foci.">
            <entity id="DS3.d255.s0.e0" origId="124886,20725278" charOffset="33-44" type="compound" text="glutathione"/>
            <entity id="DS3.d255.s0.e1" origId="P04906,B6DYQ7" charOffset="75-80" type="protein" text="GST-P"/>
            <pair e1="DS3.d255.s0.e0" e2="DS3.d255.s0.e1" id="DS3.d255.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d255.s1" origId="9934864-11" text="In rats that did not receive DEN, MC-LR did not cause a significant increase in the numbers of GST-P-positive foci, whereas AFB1 induced a slight increase in GST-P-positive foci development.">
            <entity id="DS3.d255.s1.e0" origId="P04906,B6DYQ7" charOffset="95-100" type="protein" text="GST-P"/>
            <entity id="DS3.d255.s1.e1" origId="14403" charOffset="124-128" type="compound" text="AFB1"/>
            <entity id="DS3.d255.s1.e2" origId="P04906,B6DYQ7" charOffset="158-163" type="protein" text="GST-P"/>
            <pair e1="DS3.d255.s1.e1" e2="DS3.d255.s1.e0" id="DS3.d255.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d255.s2" origId="9934864-12" text="In rats given DEN, MC-LR enhanced the expression of GST-P-positive foci, as did AFB1 but no synergism was observed.">
            <entity id="DS3.d255.s2.e0" origId="P04906,B6DYQ7" charOffset="52-57" type="protein" text="GST-P"/>
            <entity id="DS3.d255.s2.e1" origId="14403" charOffset="80-84" type="compound" text="AFB1"/>
            <pair e1="DS3.d255.s2.e1" e2="DS3.d255.s2.e0" id="DS3.d255.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d255.s3" origId="9934864-14" text="In rats given AFB1 as an initiator, treatment with MC-LR resulted in a synergistic increase in the development of GST-P-positive foci.">
            <entity id="DS3.d255.s3.e0" origId="14403" charOffset="14-18" type="compound" text="AFB1"/>
            <entity id="DS3.d255.s3.e1" origId="P04906,B6DYQ7" charOffset="114-119" type="protein" text="GST-P"/>
            <pair e1="DS3.d255.s3.e0" e2="DS3.d255.s3.e1" id="DS3.d255.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d256" origId="9934866">
        <sentence id="DS3.d256.s0" origId="9934866-12" text="These results suggest that thyroid proliferative lesions were induced by KA administration due to continuous serum TSH stimulation through the negative feedback mechanism of the pituitary-thyroid axis, with decreases of T3 and T4 caused by a mechanism independent of T4-UDP-GT activity.">
            <entity id="DS3.d256.s0.e0" origId="5920" charOffset="220-222" type="compound" text="T3"/>
            <entity id="DS3.d256.s0.e1" origId="Q64550,Q5DT04" charOffset="270-276" type="protein" text="UDP-GT"/>
            <pair e1="DS3.d256.s0.e0" e2="DS3.d256.s0.e1" id="DS3.d256.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d257" origId="9934892">
        <sentence id="DS3.d257.s0" origId="9934892-7" text="PV and ECFV were measured by dilution of 131I-albumin and 35S sodium sulfate, respectively.">
            <entity id="DS3.d257.s0.e0" origId="167195" charOffset="41-45" type="compound" text="131I"/>
            <entity id="DS3.d257.s0.e1" origId="P02768" charOffset="46-53" type="protein" text="albumin"/>
            <entity id="DS3.d257.s0.e2" origId="24436,71373" charOffset="62-76" type="compound" text="sodium sulfate"/>
            <pair e1="DS3.d257.s0.e2" e2="DS3.d257.s0.e1" id="DS3.d257.s0.i0" interaction="False" />
            <pair e1="DS3.d257.s0.e0" e2="DS3.d257.s0.e1" id="DS3.d257.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d258" origId="9934901">
        <sentence id="DS3.d258.s0" origId="9934901-12" text="The most commonly used agents for SUP were ranitidine (31%), famotidine (24%), sucralfate (24%), and cimetidine (12%).">
            <entity id="DS3.d258.s0.e0" origId="Q15011,Q53FP9,A4UAE9" charOffset="34-37" type="protein" text="SUP"/>
            <entity id="DS3.d258.s0.e1" origId="3001055,9883333" charOffset="43-53" type="compound" text="ranitidine"/>
            <entity id="DS3.d258.s0.e2" origId="5702160" charOffset="61-71" type="compound" text="famotidine"/>
            <entity id="DS3.d258.s0.e3" origId="2756" charOffset="101-111" type="compound" text="cimetidine"/>
            <pair e1="DS3.d258.s0.e2" e2="DS3.d258.s0.e0" id="DS3.d258.s0.i0" interaction="False" />
            <pair e1="DS3.d258.s0.e1" e2="DS3.d258.s0.e0" id="DS3.d258.s0.i1" interaction="False" />
            <pair e1="DS3.d258.s0.e3" e2="DS3.d258.s0.e0" id="DS3.d258.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d258.s1" origId="9934901-14" text="Eighty-two percent of respondents considered the presence of bright red blood in the nasogastric tube as failure of SUP.">
            <entity id="DS3.d258.s1.e0" origId="6857872" charOffset="61-71" type="compound" text="bright red"/>
            <entity id="DS3.d258.s1.e1" origId="Q15011,Q53FP9,A4UAE9" charOffset="116-119" type="protein" text="SUP"/>
            <pair e1="DS3.d258.s1.e0" e2="DS3.d258.s1.e1" id="DS3.d258.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d258.s2" origId="9934901-17" text="Of those respondents who used sucralfate, 77% would add an H2-antagonist when SUP failed.">
            <entity id="DS3.d258.s2.e0" origId="783" charOffset="59-61" type="compound" text="H2"/>
            <entity id="DS3.d258.s2.e1" origId="Q15011,Q53FP9,A4UAE9" charOffset="78-81" type="protein" text="SUP"/>
            <pair e1="DS3.d258.s2.e0" e2="DS3.d258.s2.e1" id="DS3.d258.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d259" origId="9934904">
        <sentence id="DS3.d259.s0" origId="9934904-9" text="Administration of pentoxifylline at 5 mg/kg/day also down regulated the production of IL-6 messenger RNA (mRNA) in liver and lipopolysaccharide binding protein mRNA in the liver and intestine of septic animals given the high-protein liquid diet.">
            <entity id="DS3.d259.s0.e0" origId="4740" charOffset="18-32" type="compound" text="pentoxifylline"/>
            <entity id="DS3.d259.s0.e1" origId="P20607" charOffset="86-90" type="protein" text="IL-6"/>
            <entity id="DS3.d259.s0.e2" origId="11970143" charOffset="125-143" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS3.d259.s0.e0" e2="DS3.d259.s0.e1" id="DS3.d259.s0.i0" interaction="False" />
            <pair e1="DS3.d259.s0.e2" e2="DS3.d259.s0.e1" id="DS3.d259.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d260" origId="9934906">
        <sentence id="DS3.d260.s0" origId="9934906-12" text="From a TNF-alpha-raised permeability level (about 50% above control) and from a histamine-raised permeability level (about 60% above control), both drugs induced small reductions in the capillary filtration coefficient.">
            <entity id="DS3.d260.s0.e0" origId="Q06599" charOffset="7-16" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d260.s0.e1" origId="774" charOffset="80-89" type="compound" text="histamine"/>
            <pair e1="DS3.d260.s0.e1" e2="DS3.d260.s0.e0" id="DS3.d260.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d260.s1" origId="9934906-7" text="These analyses were made from normal and from raised permeability levels, the latter by prior and simultaneous infusion of tumor necrosis factor-a (TNF-a) or histamine.">
            <entity id="DS3.d260.s1.e0" origId="Q06599" charOffset="123-146" type="protein" text="tumor necrosis factor-a"/>
            <entity id="DS3.d260.s1.e1" origId="Q06599" charOffset="148-153" type="protein" text="TNF-a"/>
            <entity id="DS3.d260.s1.e2" origId="774" charOffset="158-167" type="compound" text="histamine"/>
            <pair e1="DS3.d260.s1.e2" e2="DS3.d260.s1.e1" id="DS3.d260.s1.i0" interaction="False" />
            <pair e1="DS3.d260.s1.e2" e2="DS3.d260.s1.e0" id="DS3.d260.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d261" origId="9934909">
        <sentence id="DS3.d261.s0" origId="9934909-10" text="In contrast, the receptor antagonist prevented LPS-induced metabolic acidosis and hypoxemia, and improved LPS-induced decreases in urine volume, renal blood flow, creatinine clearance, and urine osmolality, whereas TAK-044 or vehicle administered alone resulted in no significant hemodynamic or blood gas changes.">
            <entity id="DS3.d261.s0.e0" origId="588" charOffset="163-173" type="compound" text="creatinine"/>
            <entity id="DS3.d261.s0.e1" origId="123883" charOffset="215-222" type="compound" text="TAK-044"/>
            <entity id="DS3.d261.s0.e2" origId="P01353" charOffset="301-304" type="protein" text="gas"/>
            <pair e1="DS3.d261.s0.e0" e2="DS3.d261.s0.e2" id="DS3.d261.s0.i0" interaction="False" />
            <pair e1="DS3.d261.s0.e1" e2="DS3.d261.s0.e2" id="DS3.d261.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d261.s1" origId="9934909-11" text="Plasma endothelin-1 concentrations significantly increased after LPS infusion, with or without TAK-044.">
            <entity id="DS3.d261.s1.e0" origId="P13206" charOffset="7-19" type="protein" text="endothelin-1"/>
            <entity id="DS3.d261.s1.e1" origId="123883" charOffset="95-102" type="compound" text="TAK-044"/>
            <pair e1="DS3.d261.s1.e1" e2="DS3.d261.s1.e0" id="DS3.d261.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d261.s2" origId="9934909-12" text="CONCLUSIONS: The present study suggests that endothelin-1 plays an important role in the impaired renal hemodynamics and renal function associated with endotoxemia, and that endothelin receptor antagonists may be useful as therapeutic agents for acute renal failure during endotoxemia.">
            <entity id="DS3.d261.s2.e0" origId="P13206" charOffset="45-57" type="protein" text="endothelin-1"/>
            <entity id="DS3.d261.s2.e1" origId="44284481" charOffset="45-55" type="compound" text="endothelin"/>
            <pair e1="DS3.d261.s2.e1" e2="DS3.d261.s2.e0" id="DS3.d261.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d262" origId="9934912">
        <sentence id="DS3.d262.s0" origId="9934912-13" text="However, TNF-alpha infusion significantly increased the oxygen cost of contractility by 40% (1.25+/-0.13 vs. 1.75+/-0.24 mL oxygen.mL/mm Hg/beat, p&amp;lt; .05), indicating that MVo2 for the excitation-contraction coupling increased.">
            <entity id="DS3.d262.s0.e0" origId="P01375,Q5STB3" charOffset="9-18" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d262.s0.e1" origId="977" charOffset="56-62" type="compound" text="oxygen"/>
            <entity id="DS3.d262.s0.e2" origId="977" charOffset="124-130" type="compound" text="oxygen"/>
            <pair e1="DS3.d262.s0.e1" e2="DS3.d262.s0.e0" id="DS3.d262.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d263" origId="9934942">
        <sentence id="DS3.d263.s0" origId="9934942-1" text="The occurrence of acute dystonia was prospectively monitored in 39 schizophrenic patients (18 male and 21 female) treated with 9 to 27 mg/day of nemonapride, a selective dopamine antagonist, and the relationship of acute dystonia with characteristics of patients and plasma concentrations of the drug and prolactin was investigated.">
            <entity id="DS3.d263.s0.e0" origId="156333,4452,9952220" charOffset="145-156" type="compound" text="nemonapride"/>
            <entity id="DS3.d263.s0.e1" origId="681" charOffset="170-178" type="compound" text="dopamine"/>
            <entity id="DS3.d263.s0.e2" origId="P01236,Q5I0G2,Q5THQ0" charOffset="305-314" type="protein" text="prolactin"/>
            <pair e1="DS3.d263.s0.e0" e2="DS3.d263.s0.e2" id="DS3.d263.s0.i0" interaction="False" />
            <pair e1="DS3.d263.s0.e1" e2="DS3.d263.s0.e2" id="DS3.d263.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d263.s1" origId="9934942-7" text="prolactin response after 1 week of treatment as an index of dopamine blockade may reflect vulnerability to the development of acute dystonia at least in male patients treated with nemonapride.">
            <entity id="DS3.d263.s1.e0" origId="P01236,Q5I0G2,Q5THQ0" charOffset="0-9" type="protein" text="prolactin"/>
            <entity id="DS3.d263.s1.e1" origId="681" charOffset="60-68" type="compound" text="dopamine"/>
            <entity id="DS3.d263.s1.e2" origId="156333,4452,9952220" charOffset="180-191" type="compound" text="nemonapride"/>
            <pair e1="DS3.d263.s1.e2" e2="DS3.d263.s1.e0" id="DS3.d263.s1.i0" interaction="False" />
            <pair e1="DS3.d263.s1.e1" e2="DS3.d263.s1.e0" id="DS3.d263.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d264" origId="9934944">
        <sentence id="DS3.d264.s0" origId="9934944-0" text="Prolactin levels and adverse events in patients treated with risperidone.">
            <entity id="DS3.d264.s0.e0" origId="P01236,Q5I0G2,Q5THQ0" charOffset="0-9" type="protein" text="Prolactin"/>
            <entity id="DS3.d264.s0.e1" origId="5073" charOffset="61-72" type="compound" text="risperidone"/>
            <pair e1="DS3.d264.s0.e1" e2="DS3.d264.s0.e0" id="DS3.d264.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d264.s1" origId="9934944-10" text="Risperidone-associated increase in serum Prolactin levels was not significantly correlated to the emergence of possible Prolactin-related side effects.">
            <entity id="DS3.d264.s1.e0" origId="5073" charOffset="0-11" type="compound" text="Risperidone"/>
            <entity id="DS3.d264.s1.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="41-50" type="protein" text="Prolactin"/>
            <entity id="DS3.d264.s1.e2" origId="P01236,Q5I0G2,Q5THQ0" charOffset="120-129" type="protein" text="Prolactin"/>
            <pair e1="DS3.d264.s1.e0" e2="DS3.d264.s1.e1" id="DS3.d264.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d264.s2" origId="9934944-3" text="This analysis was designed to characterize the relationship between risperidone, serum Prolactin levels, and possible clinical sequelae.">
            <entity id="DS3.d264.s2.e0" origId="5073" charOffset="68-79" type="compound" text="risperidone"/>
            <entity id="DS3.d264.s2.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="87-96" type="protein" text="Prolactin"/>
            <pair e1="DS3.d264.s2.e0" e2="DS3.d264.s2.e1" id="DS3.d264.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d264.s3" origId="9934944-6" text="Both risperidone and haloperidol produced dose-related increases in plasma Prolactin levels in men and women.">
            <entity id="DS3.d264.s3.e0" origId="5073" charOffset="5-16" type="compound" text="risperidone"/>
            <entity id="DS3.d264.s3.e1" origId="3559" charOffset="21-32" type="compound" text="haloperidol"/>
            <entity id="DS3.d264.s3.e2" origId="P01236,Q5I0G2,Q5THQ0" charOffset="75-84" type="protein" text="Prolactin"/>
            <pair e1="DS3.d264.s3.e1" e2="DS3.d264.s3.e2" id="DS3.d264.s3.i0" interaction="False" />
            <pair e1="DS3.d264.s3.e0" e2="DS3.d264.s3.e2" id="DS3.d264.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d264.s4" origId="9934944-7" text="Among women, the risperidone dose was not correlated with adverse events, nor were the adverse events correlated with endpoint Prolactin levels.">
            <entity id="DS3.d264.s4.e0" origId="5073" charOffset="17-28" type="compound" text="risperidone"/>
            <entity id="DS3.d264.s4.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="127-136" type="protein" text="Prolactin"/>
            <pair e1="DS3.d264.s4.e0" e2="DS3.d264.s4.e1" id="DS3.d264.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d265" origId="9934946">
        <sentence id="DS3.d265.s0" origId="9934946-8" text="A variety of strategies have been reported in the management of SSRI-induced sexual dysfunction, including waiting for tolerance to develop, dosage reduction, drug holidays, substitution of another antidepressant drug, and various augmentation strategies with 5-hydroxytryptamine-2 (5-HT2), 5-HT3, and alpha2 adrenergic receptor antagonists, 5-HT1A and dopamine receptor agonists, and phosphodiesterase (PDE5) enzyme inhibitors.">
            <entity id="DS3.d265.s0.e0" origId="5202" charOffset="260-279" type="compound" text="5-hydroxytryptamine"/>
            <entity id="DS3.d265.s0.e1" origId="681" charOffset="353-361" type="compound" text="dopamine"/>
            <entity id="DS3.d265.s0.e2" origId="O76074,G5E9C5" charOffset="404-408" type="protein" text="PDE5"/>
            <pair e1="DS3.d265.s0.e0" e2="DS3.d265.s0.e2" id="DS3.d265.s0.i0" interaction="False" />
            <pair e1="DS3.d265.s0.e1" e2="DS3.d265.s0.e2" id="DS3.d265.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d266" origId="9934992">
        <sentence id="DS3.d266.s0" origId="9934992-2" text="By in situ hybridization combined with retrograde Fast Blue labeling, expression of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor (GluR-A to -D) and N-methyl-D-aspartate (NMDA) receptor (NR1 and NR2A-D) subunit mRNAs were examined in visceromotor and somatomotor neurons of the rat lumbosacral spinal cord.">
            <entity id="DS3.d266.s0.e0" origId="66685" charOffset="50-59" type="compound" text="Fast Blue"/>
            <entity id="DS3.d266.s0.e1" origId="10125119" charOffset="90-141" type="compound" text="amino-3-hydroxy-5-methyl-4-isoxazole propionic acid"/>
            <entity id="DS3.d266.s0.e2" origId="P19490" charOffset="159-165" type="protein" text="GluR-A"/>
            <entity id="DS3.d266.s0.e3" origId="83887" charOffset="186-197" type="compound" text="D-aspartate"/>
            <entity id="DS3.d266.s0.e4" origId="P35439,Q62648" charOffset="215-218" type="protein" text="NR1"/>
            <entity id="DS3.d266.s0.e5" origId="Q00959" charOffset="223-227" type="protein" text="NR2A"/>
            <pair e1="DS3.d266.s0.e3" e2="DS3.d266.s0.e2" id="DS3.d266.s0.i0" interaction="False" />
            <pair e1="DS3.d266.s0.e3" e2="DS3.d266.s0.e4" id="DS3.d266.s0.i1" interaction="False" />
            <pair e1="DS3.d266.s0.e3" e2="DS3.d266.s0.e5" id="DS3.d266.s0.i2" interaction="False" />
            <pair e1="DS3.d266.s0.e1" e2="DS3.d266.s0.e2" id="DS3.d266.s0.i3" interaction="False" />
            <pair e1="DS3.d266.s0.e1" e2="DS3.d266.s0.e4" id="DS3.d266.s0.i4" interaction="False" />
            <pair e1="DS3.d266.s0.e1" e2="DS3.d266.s0.e5" id="DS3.d266.s0.i5" interaction="False" />
            <pair e1="DS3.d266.s0.e0" e2="DS3.d266.s0.e2" id="DS3.d266.s0.i6" interaction="False" />
            <pair e1="DS3.d266.s0.e0" e2="DS3.d266.s0.e4" id="DS3.d266.s0.i7" interaction="False" />
            <pair e1="DS3.d266.s0.e0" e2="DS3.d266.s0.e5" id="DS3.d266.s0.i8" interaction="False" />
        </sentence>
        <sentence id="DS3.d266.s1" origId="9934992-4" text="As for the NMDA receptor, PGNs were associated with abundant signals for NR1 subunit mRNA, but without any NR2 subunit mRNAs.">
            <entity id="DS3.d266.s1.e0" origId="P35439,Q62648" charOffset="73-76" type="protein" text="NR1"/>
            <entity id="DS3.d266.s1.e1" origId="6852128" charOffset="107-110" type="compound" text="NR2"/>
            <pair e1="DS3.d266.s1.e1" e2="DS3.d266.s1.e0" id="DS3.d266.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d266.s2" origId="9934992-8" text="Considering that native NMDA receptors are heteromeric channels composed of NR1 and NR2 subunits, it seems likely that dorsolateral nucleus neurons, not PGNs, are provided with functional NMDA receptors, which could induce activity-dependent changes in synaptic transmission in the efferent pathway for the lower urinary tract.">
            <entity id="DS3.d266.s2.e0" origId="P35439,Q62648" charOffset="76-79" type="protein" text="NR1"/>
            <entity id="DS3.d266.s2.e1" origId="6852128" charOffset="84-87" type="compound" text="NR2"/>
            <pair e1="DS3.d266.s2.e1" e2="DS3.d266.s2.e0" id="DS3.d266.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d267" origId="9934994">
        <sentence id="DS3.d267.s0" origId="9934994-1" text="The expression of the terminal saccharide determinant CD15 (3(a1-3)-fucosyl-N-acetyl-lactosamine) was evaluated in the central auditory system of the human developing brain by using monoclonal antibodies against this epitope.">
            <entity id="DS3.d267.s0.e0" origId="P22083" charOffset="54-58" type="protein" text="CD15"/>
            <entity id="DS3.d267.s0.e1" origId="90864978" charOffset="68-75" type="compound" text="fucosyl"/>
            <entity id="DS3.d267.s0.e2" origId="9800166" charOffset="76-96" type="compound" text="N-acetyl-lactosamine"/>
            <pair e1="DS3.d267.s0.e1" e2="DS3.d267.s0.e0" id="DS3.d267.s0.i0" interaction="False" />
            <pair e1="DS3.d267.s0.e2" e2="DS3.d267.s0.e0" id="DS3.d267.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d268" origId="9934996">
        <sentence id="DS3.d268.s0" origId="9934996-1" text="An immunohistochemically distinct zone was identified in the superficial aspect of trigeminal nucleus caudalis of the New World owl monkey that is not immunoreactive for substance P or serotonin, in stark contrast to the dense staining present in the surrounding laminae I and II.">
            <entity id="DS3.d268.s0.e0" origId="P20366,Q9Y494" charOffset="170-181" type="protein" text="substance P"/>
            <entity id="DS3.d268.s0.e1" origId="5202" charOffset="185-194" type="compound" text="serotonin"/>
            <pair e1="DS3.d268.s0.e1" e2="DS3.d268.s0.e0" id="DS3.d268.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d268.s1" origId="9934996-6" text="In addition, these observations corroborate other findings that have indicated that lamina I COLD cells are pyramidal neurons and are not physiologically modulated by substance P or serotonin, in contrast to nociceptive neurons.">
            <entity id="DS3.d268.s1.e0" origId="18648446" charOffset="108-117" type="compound" text="pyramidal"/>
            <entity id="DS3.d268.s1.e1" origId="P20366,Q9Y494" charOffset="167-178" type="protein" text="substance P"/>
            <entity id="DS3.d268.s1.e2" origId="5202" charOffset="182-191" type="compound" text="serotonin"/>
            <pair e1="DS3.d268.s1.e2" e2="DS3.d268.s1.e1" id="DS3.d268.s1.i0" interaction="False" />
            <pair e1="DS3.d268.s1.e0" e2="DS3.d268.s1.e1" id="DS3.d268.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d269" origId="9934997">
        <sentence id="DS3.d269.s0" origId="9934997-0" text="Distribution of a specific calcium-binding protein of the S100 protein family, S100A6 (calcyclin), in subpopulations of neurons and glial cells of the adult rat nervous system.">
            <entity id="DS3.d269.s0.e0" origId="22044544,5460341" charOffset="27-34" type="compound" text="calcium"/>
            <entity id="DS3.d269.s0.e1" origId="P05964,B2GVB1,P06703" charOffset="79-85" type="protein" text="S100A6"/>
            <entity id="DS3.d269.s0.e2" origId="P05964,B2GVB1" charOffset="87-96" type="protein" text="calcyclin"/>
            <pair e1="DS3.d269.s0.e0" e2="DS3.d269.s0.e2" id="DS3.d269.s0.i0" interaction="False" />
            <pair e1="DS3.d269.s0.e0" e2="DS3.d269.s0.e1" id="DS3.d269.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d269.s1" origId="9934997-1" text="S100A6 (calcyclin) is a member of the large S100 Ca2+-binding protein family, considered to activate several processes along the calcium signal transduction pathway including the regulation of cell growth, proliferation, secretion, and exocytosis.">
            <entity id="DS3.d269.s1.e0" origId="P05964,B2GVB1,P06703" charOffset="0-6" type="protein" text="S100A6"/>
            <entity id="DS3.d269.s1.e1" origId="P05964,B2GVB1" charOffset="8-17" type="protein" text="calcyclin"/>
            <entity id="DS3.d269.s1.e2" origId="22044544,5460341" charOffset="129-136" type="compound" text="calcium"/>
            <pair e1="DS3.d269.s1.e2" e2="DS3.d269.s1.e1" id="DS3.d269.s1.i0" interaction="False" />
            <pair e1="DS3.d269.s1.e2" e2="DS3.d269.s1.e0" id="DS3.d269.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d269.s2" origId="9934997-3" text="The main S100A6-immunoreactive elements were 1) neuronal somata and dendrites in some specific regions of the limbic system (e.g., the basolateral amygdaloid nucleus, ventral tip of the CA1-subicular border region, entorhinal cortex, and parasubiculum), most of which were identified as a subpopulation of pyramidal cells; 2) olfactory receptor cells and olfactory nerve fibers and terminals in the olfactory bulb; 3) some tracts of the hindbrain and spinal cord (e.g., the spinal trigeminal tract, solitary tract, dorsal root fibers, and the tract of Lissauer) and their terminals (e.g., the principal sensory trigeminal nucleus, spinal trigeminal nucleus, nucleus of the solitary tract, marginal zone, substantia gelatinosa, and proper sensory nucleus of the dorsal horn), as well as some sensory neurons of their origins in the dorsal root and trigeminal ganglia; 4) a subpopulation of astrocytes in the white matter (e.g., the corpus callosum, cingulum, external capsule, internal capsule, and fimbria of the hippocampus) and around the ventricles; 5) some ependymal cells, especially around the central canal; and 6) Schwann cells.">
            <entity id="DS3.d269.s2.e0" origId="P05964,B2GVB1,P06703" charOffset="9-15" type="protein" text="S100A6"/>
            <entity id="DS3.d269.s2.e1" origId="B0BNN3" charOffset="186-189" type="protein" text="CA1"/>
            <entity id="DS3.d269.s2.e2" origId="18648446" charOffset="306-315" type="compound" text="pyramidal"/>
            <pair e1="DS3.d269.s2.e2" e2="DS3.d269.s2.e1" id="DS3.d269.s2.i0" interaction="False" />
            <pair e1="DS3.d269.s2.e2" e2="DS3.d269.s2.e0" id="DS3.d269.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d270" origId="9935007">
        <sentence id="DS3.d270.s0" origId="9935007-10" text="In nine patients, 17% of the sotalol group, an ICD was implanted after VT/VF recurrence, three patients (5.7%) received amiodarone.">
            <entity id="DS3.d270.s0.e0" origId="5253" charOffset="29-36" type="compound" text="sotalol"/>
            <entity id="DS3.d270.s0.e1" origId="Q3T906" charOffset="47-50" type="protein" text="ICD"/>
            <entity id="DS3.d270.s0.e2" origId="2157" charOffset="120-130" type="compound" text="amiodarone"/>
            <pair e1="DS3.d270.s0.e0" e2="DS3.d270.s0.e1" id="DS3.d270.s0.i0" interaction="False" />
            <pair e1="DS3.d270.s0.e2" e2="DS3.d270.s0.e1" id="DS3.d270.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d270.s1" origId="9935007-7" text="After implantation of the device patients were randomly assigned to oral treatment with d,l-sotalol (ICD/sotalol group, n=46) or no antiarrhythmic medication (n=47, ICD-only group).">
            <entity id="DS3.d270.s1.e0" origId="6101895" charOffset="90-99" type="compound" text="l-sotalol"/>
            <entity id="DS3.d270.s1.e1" origId="Q3T906" charOffset="101-104" type="protein" text="ICD"/>
            <entity id="DS3.d270.s1.e2" origId="5253" charOffset="92-99" type="compound" text="sotalol"/>
            <entity id="DS3.d270.s1.e3" origId="Q3T906" charOffset="165-168" type="protein" text="ICD"/>
            <pair e1="DS3.d270.s1.e2" e2="DS3.d270.s1.e1" id="DS3.d270.s1.i0" interaction="False" />
            <pair e1="DS3.d270.s1.e0" e2="DS3.d270.s1.e1" id="DS3.d270.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d270.s2" origId="9935007-8" text="RESULTS: During follow-up, 25 patients (53.2%) in the ICD-only group had a VT/VF recurrence in comparison to 15 patients (28.3%) in the sotalol group and 15 patients (32.6%) in the ICD/sotalol group (p=0.0013).">
            <entity id="DS3.d270.s2.e0" origId="Q3T906" charOffset="54-57" type="protein" text="ICD"/>
            <entity id="DS3.d270.s2.e1" origId="5253" charOffset="136-143" type="compound" text="sotalol"/>
            <entity id="DS3.d270.s2.e2" origId="Q3T906" charOffset="181-184" type="protein" text="ICD"/>
            <entity id="DS3.d270.s2.e3" origId="5253" charOffset="185-192" type="compound" text="sotalol"/>
            <pair e1="DS3.d270.s2.e1" e2="DS3.d270.s2.e0" id="DS3.d270.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d270.s3" origId="9935007-9" text="Therapy with d,l-sotalol, amiodarone or metoprolol was instituted in 12 patients (25.5%) of the ICD-only group due to frequent VT/VF recurrences or symptomatic supraventricular tachyarrhythmias.">
            <entity id="DS3.d270.s3.e0" origId="6101895" charOffset="15-24" type="compound" text="l-sotalol"/>
            <entity id="DS3.d270.s3.e1" origId="2157" charOffset="26-36" type="compound" text="amiodarone"/>
            <entity id="DS3.d270.s3.e2" origId="4171" charOffset="40-50" type="compound" text="metoprolol"/>
            <entity id="DS3.d270.s3.e3" origId="Q3T906" charOffset="96-99" type="protein" text="ICD"/>
            <pair e1="DS3.d270.s3.e2" e2="DS3.d270.s3.e3" id="DS3.d270.s3.i0" interaction="False" />
            <pair e1="DS3.d270.s3.e1" e2="DS3.d270.s3.e3" id="DS3.d270.s3.i1" interaction="False" />
            <pair e1="DS3.d270.s3.e0" e2="DS3.d270.s3.e3" id="DS3.d270.s3.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d271" origId="9935015">
        <sentence id="DS3.d271.s0" origId="9935015-3" text="Thrombin-activated platelets adhere via P-selectin to monocytes and neutrophils.">
            <entity id="DS3.d271.s0.e0" origId="90470996" charOffset="0-8" type="compound" text="Thrombin"/>
            <entity id="DS3.d271.s0.e1" origId="P16109,Q5R341,A0A024R8Y9,Q6NUL9" charOffset="40-50" type="protein" text="P-selectin"/>
            <pair e1="DS3.d271.s0.e0" e2="DS3.d271.s0.e1" id="DS3.d271.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d271.s1" origId="9935015-6" text="RESULTS: Leukocyte CD11b expression increased after angioplasty in control patients (neutrophils 171+/-25 to 255+/-31 mean fluorescence intensity (MFI, mean+/-SEM), n=25, p &amp;lt; 0.0001; monocytes 200+/-40 to 248+/-36 MFI, n=17, p &amp;lt; 0.05) and decreased in the patients selected to receive chimeric 7E3 Fab (neutrophils 146+/-30 to 82+/-22 MFI, n=25, p &amp;lt; 0.0001; monocytes 256+/- 53 to 160+/-38 MFI, n= 17, p &amp;lt; 0.05).">
            <entity id="DS3.d271.s1.e0" origId="P11215" charOffset="19-24" type="protein" text="CD11b"/>
            <entity id="DS3.d271.s1.e1" origId="5289348" charOffset="159-162" type="compound" text="SEM"/>
            <pair e1="DS3.d271.s1.e1" e2="DS3.d271.s1.e0" id="DS3.d271.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d272" origId="9935026">
        <sentence id="DS3.d272.s0" origId="9935026-1" text="OBJECTIVES: This study was designed to analyze the effect of iNOS on mitochondrial creatine kinase (mi-CK) expression and exercise capacity in chronic heart failure (CHF).">
            <entity id="DS3.d272.s0.e0" origId="Q9NPH2" charOffset="61-65" type="protein" text="iNOS"/>
            <entity id="DS3.d272.s0.e1" origId="586" charOffset="83-91" type="compound" text="creatine"/>
            <pair e1="DS3.d272.s0.e1" e2="DS3.d272.s0.e0" id="DS3.d272.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d272.s1" origId="9935026-3" text="Expression of inducible nitric oxide synthase (iNOS) and reduced phosphocreatine resynthesis have been described in skeletal muscle of patients with CHF.">
            <entity id="DS3.d272.s1.e0" origId="Q9NPH2" charOffset="14-45" type="protein" text="inducible nitric oxide synthase"/>
            <entity id="DS3.d272.s1.e1" origId="Q9NPH2" charOffset="47-51" type="protein" text="iNOS"/>
            <entity id="DS3.d272.s1.e2" origId="587,9548602" charOffset="65-80" type="compound" text="phosphocreatine"/>
            <pair e1="DS3.d272.s1.e2" e2="DS3.d272.s1.e0" id="DS3.d272.s1.i0" interaction="False" />
            <pair e1="DS3.d272.s1.e2" e2="DS3.d272.s1.e1" id="DS3.d272.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d272.s2" origId="9935026-9" text="RESULTS: Expression of iNOS was significantly increased in CHF (4.0+/-2.8 vs. 0.8+/-0.7% iNOS positive tissue area, p &amp;lt; 0.001 vs. C) and inversely correlated to maximal oxygen uptake (r=-0.65, p &amp;lt; 0.001).">
            <entity id="DS3.d272.s2.e0" origId="Q9NPH2" charOffset="23-27" type="protein" text="iNOS"/>
            <entity id="DS3.d272.s2.e1" origId="Q9NPH2" charOffset="89-93" type="protein" text="iNOS"/>
            <entity id="DS3.d272.s2.e2" origId="977" charOffset="172-178" type="compound" text="oxygen"/>
            <pair e1="DS3.d272.s2.e2" e2="DS3.d272.s2.e0" id="DS3.d272.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d273" origId="9935028">
        <sentence id="DS3.d273.s0" origId="9935028-10" text="Clonidine also caused a significant increase in tau, as measured by the method of Weiss (65+/-3 vs. 74+/-4 ms, p &amp;lt; 0.01) and the direct pressure half-time technique (48+/-2 vs. 54+/-3 ms, p &amp;lt; 0.01).">
            <entity id="DS3.d273.s0.e0" origId="2803" charOffset="0-9" type="compound" text="Clonidine"/>
            <entity id="DS3.d273.s0.e1" origId="P10636,A0A024R9Y0,A0A024RA17,A0A024R9Y1,A0A024RA19,B3KTM0" charOffset="48-51" type="protein" text="tau"/>
            <pair e1="DS3.d273.s0.e0" e2="DS3.d273.s0.e1" id="DS3.d273.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d273.s1" origId="9935028-5" text="Study measurements included right and left heart hemodynamics, cardiac output, rate of rise in left ventricular peak positive pressure (LV + dP/dt) and tau, along with cardiac and total body norepinephrine spillover.">
            <entity id="DS3.d273.s1.e0" origId="P10636,A0A024R9Y0,A0A024RA17,A0A024R9Y1,A0A024RA19,B3KTM0" charOffset="152-155" type="protein" text="tau"/>
            <entity id="DS3.d273.s1.e1" origId="439260" charOffset="191-205" type="compound" text="norepinephrine"/>
            <pair e1="DS3.d273.s1.e1" e2="DS3.d273.s1.e0" id="DS3.d273.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d274" origId="9935036">
        <sentence id="DS3.d274.s0" origId="9935036-0" text="Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions.">
            <entity id="DS3.d274.s0.e0" origId="54687" charOffset="0-18" type="compound" text="Pravastatin sodium"/>
            <entity id="DS3.d274.s0.e1" origId="F1MY54" charOffset="29-62" type="protein" text="endothelial nitric oxide synthase"/>
            <entity id="DS3.d274.s0.e2" origId="5997" charOffset="82-93" type="compound" text="cholesterol"/>
            <pair e1="DS3.d274.s0.e0" e2="DS3.d274.s0.e1" id="DS3.d274.s0.i0" interaction="False" />
            <pair e1="DS3.d274.s0.e2" e2="DS3.d274.s0.e1" id="DS3.d274.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d275" origId="9935041">
        <sentence id="DS3.d275.s0" origId="9935041-0" text="ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association.">
            <entity id="DS3.d275.s0.e0" origId="Q13085,B2ZZ90,A0A024R0Y2,Q7Z5W8" charOffset="0-3" type="protein" text="ACC"/>
            <entity id="DS3.d275.s0.e1" origId="5212" charOffset="54-60" type="compound" text="Viagra"/>
            <pair e1="DS3.d275.s0.e1" e2="DS3.d275.s0.e0" id="DS3.d275.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d276" origId="9935052">
        <sentence id="DS3.d276.s0" origId="9935052-0" text="Parametric PET imaging of 5HT2A receptor distribution with 18F-setoperone in the normal human neocortex.">
            <entity id="DS3.d276.s0.e0" origId="P28223" charOffset="26-40" type="protein" text="5HT2A receptor"/>
            <entity id="DS3.d276.s0.e1" origId="68604" charOffset="63-73" type="compound" text="setoperone"/>
            <pair e1="DS3.d276.s0.e1" e2="DS3.d276.s0.e0" id="DS3.d276.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d277" origId="9935054">
        <sentence id="DS3.d277.s0" origId="9935054-0" text="67Ga scintigraphy in B-cell non-Hodgkin's lymphoma: correlation of 67Ga uptake with histology and transferrin receptor expression.">
            <entity id="DS3.d277.s0.e0" origId="5464084" charOffset="0-4" type="compound" text="67Ga"/>
            <entity id="DS3.d277.s0.e1" origId="5464084" charOffset="67-71" type="compound" text="67Ga"/>
            <entity id="DS3.d277.s0.e2" origId="P02786" charOffset="98-118" type="protein" text="transferrin receptor"/>
            <pair e1="DS3.d277.s0.e0" e2="DS3.d277.s0.e2" id="DS3.d277.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d277.s1" origId="9935054-12" text="CONCLUSION: There were three factors influencing 67Ga uptake in NHL: histology, TfR/CD71 expression and the presence of a large cells component.">
            <entity id="DS3.d277.s1.e0" origId="5464084" charOffset="49-53" type="compound" text="67Ga"/>
            <entity id="DS3.d277.s1.e1" origId="Q9NZ71,R4IXY3" charOffset="64-67" type="protein" text="NHL"/>
            <entity id="DS3.d277.s1.e2" origId="P02786" charOffset="80-83" type="protein" text="TfR"/>
            <entity id="DS3.d277.s1.e3" origId="P02786" charOffset="84-88" type="protein" text="CD71"/>
            <pair e1="DS3.d277.s1.e0" e2="DS3.d277.s1.e1" id="DS3.d277.s1.i0" interaction="False" />
            <pair e1="DS3.d277.s1.e0" e2="DS3.d277.s1.e3" id="DS3.d277.s1.i1" interaction="False" />
            <pair e1="DS3.d277.s1.e0" e2="DS3.d277.s1.e2" id="DS3.d277.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d277.s2" origId="9935054-13" text="This justifies the usefulness of 67Ga scintigraphy in staging the TfR/CD71-positive lymphomas.">
            <entity id="DS3.d277.s2.e0" origId="5464084" charOffset="33-37" type="compound" text="67Ga"/>
            <entity id="DS3.d277.s2.e1" origId="P02786" charOffset="66-69" type="protein" text="TfR"/>
            <entity id="DS3.d277.s2.e2" origId="P02786" charOffset="70-74" type="protein" text="CD71"/>
            <pair e1="DS3.d277.s2.e0" e2="DS3.d277.s2.e2" id="DS3.d277.s2.i0" interaction="False" />
            <pair e1="DS3.d277.s2.e0" e2="DS3.d277.s2.e1" id="DS3.d277.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d277.s3" origId="9935054-1" text="67Ga scintigraphy is routinely used in the management of non-Hodgkin's lymphomas (NHLs), but the heterogeneity of 67Ga uptake in the different NHL histological subtypes has not been clearly explained.">
            <entity id="DS3.d277.s3.e0" origId="5464084" charOffset="0-4" type="compound" text="67Ga"/>
            <entity id="DS3.d277.s3.e1" origId="5464084" charOffset="114-118" type="compound" text="67Ga"/>
            <entity id="DS3.d277.s3.e2" origId="Q9NZ71,R4IXY3" charOffset="82-85" type="protein" text="NHL"/>
            <pair e1="DS3.d277.s3.e0" e2="DS3.d277.s3.e2" id="DS3.d277.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d277.s4" origId="9935054-2" text="The transferrin receptors (TfR/CD71) play an important role in the mechanisms of 67Ga uptake by tumor cells.">
            <entity id="DS3.d277.s4.e0" origId="P02786" charOffset="27-30" type="protein" text="TfR"/>
            <entity id="DS3.d277.s4.e1" origId="P02786" charOffset="31-35" type="protein" text="CD71"/>
            <entity id="DS3.d277.s4.e2" origId="5464084" charOffset="81-85" type="compound" text="67Ga"/>
            <pair e1="DS3.d277.s4.e2" e2="DS3.d277.s4.e1" id="DS3.d277.s4.i0" interaction="False" />
            <pair e1="DS3.d277.s4.e2" e2="DS3.d277.s4.e0" id="DS3.d277.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d277.s5" origId="9935054-3" text="However, the relationship between the 67Ga uptake in NHL and the TfR/CD71 expression in lymphomatous cells remains to be defined.">
            <entity id="DS3.d277.s5.e0" origId="5464084" charOffset="38-42" type="compound" text="67Ga"/>
            <entity id="DS3.d277.s5.e1" origId="Q9NZ71,R4IXY3" charOffset="53-56" type="protein" text="NHL"/>
            <entity id="DS3.d277.s5.e2" origId="P02786" charOffset="65-68" type="protein" text="TfR"/>
            <entity id="DS3.d277.s5.e3" origId="P02786" charOffset="69-73" type="protein" text="CD71"/>
            <pair e1="DS3.d277.s5.e0" e2="DS3.d277.s5.e1" id="DS3.d277.s5.i0" interaction="False" />
            <pair e1="DS3.d277.s5.e0" e2="DS3.d277.s5.e3" id="DS3.d277.s5.i1" interaction="False" />
            <pair e1="DS3.d277.s5.e0" e2="DS3.d277.s5.e2" id="DS3.d277.s5.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d277.s6" origId="9935054-4" text="The aim of this study was to determine the intensity of 67Ga uptake in different histological subtypes of B-cell NHL (B-NHL) and to compare this uptake with the expression of TfR/CD71 on lymphomatous cells.">
            <entity id="DS3.d277.s6.e0" origId="5464084" charOffset="56-60" type="compound" text="67Ga"/>
            <entity id="DS3.d277.s6.e1" origId="Q9NZ71,R4IXY3" charOffset="113-116" type="protein" text="NHL"/>
            <entity id="DS3.d277.s6.e2" origId="Q9NZ71,R4IXY3" charOffset="120-123" type="protein" text="NHL"/>
            <entity id="DS3.d277.s6.e3" origId="P02786" charOffset="175-178" type="protein" text="TfR"/>
            <entity id="DS3.d277.s6.e4" origId="P02786" charOffset="179-183" type="protein" text="CD71"/>
            <pair e1="DS3.d277.s6.e0" e2="DS3.d277.s6.e1" id="DS3.d277.s6.i0" interaction="False" />
            <pair e1="DS3.d277.s6.e0" e2="DS3.d277.s6.e4" id="DS3.d277.s6.i1" interaction="False" />
            <pair e1="DS3.d277.s6.e0" e2="DS3.d277.s6.e3" id="DS3.d277.s6.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d278" origId="9935069">
        <sentence id="DS3.d278.s0" origId="9935069-3" text="Kinetic modeling of 99mTc-labeled diethylenetriamine pentaacetic acid-galactosyl-human serum albumin (TcGSA) time-activity data yields estimates of ASGP-R concentration (R)o and amount R0, which are directly related to functional liver mass.">
            <entity id="DS3.d278.s0.e0" origId="8111" charOffset="34-52" type="compound" text="diethylenetriamine"/>
            <entity id="DS3.d278.s0.e1" origId="446996" charOffset="70-80" type="compound" text="galactosyl"/>
            <entity id="DS3.d278.s0.e2" origId="P02768" charOffset="93-100" type="protein" text="albumin"/>
            <pair e1="DS3.d278.s0.e0" e2="DS3.d278.s0.e2" id="DS3.d278.s0.i0" interaction="False" />
            <pair e1="DS3.d278.s0.e1" e2="DS3.d278.s0.e2" id="DS3.d278.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d279" origId="9935072">
        <sentence id="DS3.d279.s0" origId="9935072-0" text="Photodegraded nifedipine promotes transferrin-independent gallium uptake by cultured tumor cells.">
            <entity id="DS3.d279.s0.e0" origId="4485" charOffset="14-24" type="compound" text="nifedipine"/>
            <entity id="DS3.d279.s0.e1" origId="P02787,Q06AH7,A0PJA6" charOffset="34-45" type="protein" text="transferrin"/>
            <entity id="DS3.d279.s0.e2" origId="5360835" charOffset="58-65" type="compound" text="gallium"/>
            <pair e1="DS3.d279.s0.e0" e2="DS3.d279.s0.e1" id="DS3.d279.s0.i0" interaction="False" />
            <pair e1="DS3.d279.s0.e2" e2="DS3.d279.s0.e1" id="DS3.d279.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d279.s1" origId="9935072-10" text="light-shielded nifedipine has no effect on 67Ga uptake.">
            <entity id="DS3.d279.s1.e0" origId="O43557" charOffset="0-5" type="protein" text="light"/>
            <entity id="DS3.d279.s1.e1" origId="4485" charOffset="15-25" type="compound" text="nifedipine"/>
            <entity id="DS3.d279.s1.e2" origId="5464084" charOffset="43-47" type="compound" text="67Ga"/>
            <pair e1="DS3.d279.s1.e1" e2="DS3.d279.s1.e0" id="DS3.d279.s1.i0" interaction="False" />
            <pair e1="DS3.d279.s1.e2" e2="DS3.d279.s1.e0" id="DS3.d279.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d279.s2" origId="9935072-11" text="CONCLUSION: The effect of photodegraded nifedipine on the uptake of 67Ga is independent of expression of the transferrin receptor.">
            <entity id="DS3.d279.s2.e0" origId="4485" charOffset="40-50" type="compound" text="nifedipine"/>
            <entity id="DS3.d279.s2.e1" origId="5464084" charOffset="68-72" type="compound" text="67Ga"/>
            <entity id="DS3.d279.s2.e2" origId="P02786" charOffset="109-129" type="protein" text="transferrin receptor"/>
            <pair e1="DS3.d279.s2.e0" e2="DS3.d279.s2.e2" id="DS3.d279.s2.i0" interaction="False" />
            <pair e1="DS3.d279.s2.e1" e2="DS3.d279.s2.e2" id="DS3.d279.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d279.s3" origId="9935072-1" text="It was reported previously that normal soft tissues accumulate 67Ga by a transferrin-dependent route, but uptake by tumors can be transferrin independent.">
            <entity id="DS3.d279.s3.e0" origId="5464084" charOffset="63-67" type="compound" text="67Ga"/>
            <entity id="DS3.d279.s3.e1" origId="P02787,Q06AH7,A0PJA6" charOffset="73-84" type="protein" text="transferrin"/>
            <entity id="DS3.d279.s3.e2" origId="P02787,Q06AH7,A0PJA6" charOffset="130-141" type="protein" text="transferrin"/>
            <pair e1="DS3.d279.s3.e0" e2="DS3.d279.s3.e1" id="DS3.d279.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d279.s4" origId="9935072-2" text="It was also reported that, although overexpression of the transferrin receptor can promote Ga avidity, the transferrin-independent uptake of 67Ga is significant and can be augmented to exceed transferrin-mediated levels by increasing extracellular calcium.">
            <entity id="DS3.d279.s4.e0" origId="P02786" charOffset="58-78" type="protein" text="transferrin receptor"/>
            <entity id="DS3.d279.s4.e1" origId="P02787,Q06AH7,A0PJA6" charOffset="58-69" type="protein" text="transferrin"/>
            <entity id="DS3.d279.s4.e2" origId="5464084" charOffset="141-145" type="compound" text="67Ga"/>
            <entity id="DS3.d279.s4.e3" origId="P02787,Q06AH7,A0PJA6" charOffset="107-118" type="protein" text="transferrin"/>
            <entity id="DS3.d279.s4.e4" origId="22044544,5460341" charOffset="248-255" type="compound" text="calcium"/>
            <pair e1="DS3.d279.s4.e4" e2="DS3.d279.s4.e0" id="DS3.d279.s4.i0" interaction="False" />
            <pair e1="DS3.d279.s4.e4" e2="DS3.d279.s4.e1" id="DS3.d279.s4.i1" interaction="False" />
            <pair e1="DS3.d279.s4.e2" e2="DS3.d279.s4.e0" id="DS3.d279.s4.i2" interaction="False" />
            <pair e1="DS3.d279.s4.e2" e2="DS3.d279.s4.e1" id="DS3.d279.s4.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d279.s5" origId="9935072-3" text="In assessing the effect of calcium channel blockers on uptake of 67Ga, it was observed that, after exposure to light (either visible or ultraviolet (UV)), nifedipine strongly potentiates the cellular uptake of 67Ga by a transferrin-independent process.">
            <entity id="DS3.d279.s5.e0" origId="22044544,5460341" charOffset="27-34" type="compound" text="calcium"/>
            <entity id="DS3.d279.s5.e1" origId="5464084" charOffset="65-69" type="compound" text="67Ga"/>
            <entity id="DS3.d279.s5.e2" origId="O43557" charOffset="111-116" type="protein" text="light"/>
            <entity id="DS3.d279.s5.e3" origId="4485" charOffset="155-165" type="compound" text="nifedipine"/>
            <entity id="DS3.d279.s5.e4" origId="5464084" charOffset="210-214" type="compound" text="67Ga"/>
            <entity id="DS3.d279.s5.e5" origId="P02787,Q06AH7,A0PJA6" charOffset="220-231" type="protein" text="transferrin"/>
            <pair e1="DS3.d279.s5.e0" e2="DS3.d279.s5.e2" id="DS3.d279.s5.i0" interaction="False" />
            <pair e1="DS3.d279.s5.e0" e2="DS3.d279.s5.e5" id="DS3.d279.s5.i1" interaction="False" />
            <pair e1="DS3.d279.s5.e1" e2="DS3.d279.s5.e2" id="DS3.d279.s5.i2" interaction="False" />
            <pair e1="DS3.d279.s5.e1" e2="DS3.d279.s5.e5" id="DS3.d279.s5.i3" interaction="False" />
            <pair e1="DS3.d279.s5.e3" e2="DS3.d279.s5.e2" id="DS3.d279.s5.i4" interaction="False" />
            <pair e1="DS3.d279.s5.e3" e2="DS3.d279.s5.e5" id="DS3.d279.s5.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d279.s6" origId="9935072-4" text="METHODS: The effect of nifedipine on 67Ga uptake as a function of time, concentration, duration and type of preexposure to light was determined in two cultured Chinese hamster ovary cell lines.">
            <entity id="DS3.d279.s6.e0" origId="4485" charOffset="23-33" type="compound" text="nifedipine"/>
            <entity id="DS3.d279.s6.e1" origId="5464084" charOffset="37-41" type="compound" text="67Ga"/>
            <entity id="DS3.d279.s6.e2" origId="O43557" charOffset="123-128" type="protein" text="light"/>
            <pair e1="DS3.d279.s6.e0" e2="DS3.d279.s6.e2" id="DS3.d279.s6.i0" interaction="False" />
            <pair e1="DS3.d279.s6.e1" e2="DS3.d279.s6.e2" id="DS3.d279.s6.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d279.s7" origId="9935072-7" text="RESULTS: Although there are some differences in pattern of stimulation of uptake, nifedipine subjected to either UV or fluorescent light strongly promotes the uptake of 67Ga in the cultured cells in a time-dependent and concentration-dependent manner.">
            <entity id="DS3.d279.s7.e0" origId="4485" charOffset="82-92" type="compound" text="nifedipine"/>
            <entity id="DS3.d279.s7.e1" origId="O43557" charOffset="131-136" type="protein" text="light"/>
            <entity id="DS3.d279.s7.e2" origId="5464084" charOffset="169-173" type="compound" text="67Ga"/>
            <pair e1="DS3.d279.s7.e0" e2="DS3.d279.s7.e1" id="DS3.d279.s7.i0" interaction="False" />
            <pair e1="DS3.d279.s7.e2" e2="DS3.d279.s7.e1" id="DS3.d279.s7.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d279.s8" origId="9935072-8" text="Maximal uptake of 67Ga occurs when the cells are incubated for 30 min with 25 micromol/L nifedipine preexposed to either 4h of fluorescent or 1h of UV light.">
            <entity id="DS3.d279.s8.e0" origId="5464084" charOffset="18-22" type="compound" text="67Ga"/>
            <entity id="DS3.d279.s8.e1" origId="54167661" charOffset="87-99" type="compound" text="L nifedipine"/>
            <entity id="DS3.d279.s8.e2" origId="O43557" charOffset="151-156" type="protein" text="light"/>
            <pair e1="DS3.d279.s8.e1" e2="DS3.d279.s8.e2" id="DS3.d279.s8.i0" interaction="False" />
            <pair e1="DS3.d279.s8.e0" e2="DS3.d279.s8.e2" id="DS3.d279.s8.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d279.s9" origId="9935072-9" text="Under these conditions, uptake of 67Ga is 1000-fold greater than basal levels and 50-fold greater than can be achieved by the transferrin-dependent route.">
            <entity id="DS3.d279.s9.e0" origId="5464084" charOffset="34-38" type="compound" text="67Ga"/>
            <entity id="DS3.d279.s9.e1" origId="P02787,Q06AH7,A0PJA6" charOffset="126-137" type="protein" text="transferrin"/>
            <pair e1="DS3.d279.s9.e0" e2="DS3.d279.s9.e1" id="DS3.d279.s9.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d280" origId="9935073">
        <sentence id="DS3.d280.s0" origId="9935073-0" text="Alpha-emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry.">
            <entity id="DS3.d280.s0.e0" origId="5359367" charOffset="15-22" type="compound" text="bismuth"/>
            <entity id="DS3.d280.s0.e1" origId="20444" charOffset="23-39" type="compound" text="cyclohexylbenzyl"/>
            <entity id="DS3.d280.s0.e2" origId="3053" charOffset="40-44" type="compound" text="DTPA"/>
            <entity id="DS3.d280.s0.e3" origId="P20138,Q546G0" charOffset="86-90" type="protein" text="CD33"/>
            <pair e1="DS3.d280.s0.e1" e2="DS3.d280.s0.e3" id="DS3.d280.s0.i0" interaction="False" />
            <pair e1="DS3.d280.s0.e0" e2="DS3.d280.s0.e3" id="DS3.d280.s0.i1" interaction="False" />
            <pair e1="DS3.d280.s0.e2" e2="DS3.d280.s0.e3" id="DS3.d280.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d280.s1" origId="9935073-2" text="This article describes the pharmacokinetic, bioactivity, toxicity and chemical characteristics of alpha-particle-emitting, 213Bi and 212Bi radiometal conjugated HuM195 (anti-CD33) constructs.">
            <entity id="DS3.d280.s1.e0" origId="6337093" charOffset="123-128" type="compound" text="213Bi"/>
            <entity id="DS3.d280.s1.e1" origId="6335500" charOffset="133-138" type="compound" text="212Bi"/>
            <entity id="DS3.d280.s1.e2" origId="P20138,Q546G0" charOffset="174-178" type="protein" text="CD33"/>
            <pair e1="DS3.d280.s1.e1" e2="DS3.d280.s1.e2" id="DS3.d280.s1.i0" interaction="False" />
            <pair e1="DS3.d280.s1.e0" e2="DS3.d280.s1.e2" id="DS3.d280.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d280.s2" origId="9935073-6" text="The bismuth-labeled CHX-A-DTPA-HuM195 construct was rapidly internalized into the cell in a time-dependent manner ranging from 50% at 1 h to 65% at 24 h. 205Bi/206Bi-labeled constructs were stable for at least 2 d in vitro in the presence of human serum at 37 degrees C. After injection into mice, there was no uptake or loss of bismuth to mouse tissues, which do not express CD33, or to the kidney, which has avidity for free bismuth.">
            <entity id="DS3.d280.s2.e0" origId="5359367" charOffset="4-11" type="compound" text="bismuth"/>
            <entity id="DS3.d280.s2.e1" origId="3053" charOffset="26-30" type="compound" text="DTPA"/>
            <entity id="DS3.d280.s2.e2" origId="6337623" charOffset="154-159" type="compound" text="205Bi"/>
            <entity id="DS3.d280.s2.e3" origId="6336623" charOffset="160-165" type="compound" text="206Bi"/>
            <entity id="DS3.d280.s2.e4" origId="5359367" charOffset="329-336" type="compound" text="bismuth"/>
            <entity id="DS3.d280.s2.e5" origId="P20138,Q546G0" charOffset="376-380" type="protein" text="CD33"/>
            <entity id="DS3.d280.s2.e6" origId="5359367" charOffset="329-336" type="compound" text="bismuth"/>
            <pair e1="DS3.d280.s2.e2" e2="DS3.d280.s2.e5" id="DS3.d280.s2.i0" interaction="False" />
            <pair e1="DS3.d280.s2.e0" e2="DS3.d280.s2.e5" id="DS3.d280.s2.i1" interaction="False" />
            <pair e1="DS3.d280.s2.e1" e2="DS3.d280.s2.e5" id="DS3.d280.s2.i2" interaction="False" />
            <pair e1="DS3.d280.s2.e3" e2="DS3.d280.s2.e5" id="DS3.d280.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d280.s3" origId="9935073-9" text="Leukemia cell killing in vitro with bismuth-labeled HuM1 95 showed dose- and specific activity-dependent killing of CD33+ HL60 cells; approximately 50% killing was observed when two bismuth atoms (50 fM radiolabeled antibody) were initially bound onto the target cell surface.">
            <entity id="DS3.d280.s3.e0" origId="5359367" charOffset="36-43" type="compound" text="bismuth"/>
            <entity id="DS3.d280.s3.e1" origId="P20138,Q546G0" charOffset="116-120" type="protein" text="CD33"/>
            <entity id="DS3.d280.s3.e2" origId="5359367" charOffset="182-189" type="compound" text="bismuth"/>
            <pair e1="DS3.d280.s3.e0" e2="DS3.d280.s3.e1" id="DS3.d280.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d281" origId="9935075">
        <sentence id="DS3.d281.s0" origId="9935075-10" text="In addition, the uptake of FITC annexin V and 99mTc-HYNIC annexin V was studied in heat-treated necrotic Jurkat T-cell cultures.">
            <entity id="DS3.d281.s0.e0" origId="18730" charOffset="27-31" type="compound" text="FITC"/>
            <entity id="DS3.d281.s0.e1" origId="P08758,V9HWE0,P48036" charOffset="32-41" type="protein" text="annexin V"/>
            <entity id="DS3.d281.s0.e2" origId="P08758,V9HWE0,P48036" charOffset="58-67" type="protein" text="annexin V"/>
            <pair e1="DS3.d281.s0.e0" e2="DS3.d281.s0.e1" id="DS3.d281.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d281.s1" origId="9935075-12" text="RESULTS: Membrane-bound radiolabeled annexin V activity linearly correlated to total fluorescence as observed by FITC annexin V flow cytometry in Jurkat T-cell cultures induced to undergo apoptosis in response to growth factor deprivation (N = 10, r2 = 0.987), antiFas antibody (N = 8, r2 = 0.836) and doxorubicin (N = 10, r2 = 0.804); and in ex vivo experiments on thymic cell suspensions with dexamethasone-induced apoptosis from Balb/c mice (N = 6, r2 = 0.989).">
            <entity id="DS3.d281.s1.e0" origId="P08758,V9HWE0,P48036" charOffset="37-46" type="protein" text="annexin V"/>
            <entity id="DS3.d281.s1.e1" origId="18730" charOffset="113-117" type="compound" text="FITC"/>
            <entity id="DS3.d281.s1.e2" origId="P08758,V9HWE0,P48036" charOffset="118-127" type="protein" text="annexin V"/>
            <entity id="DS3.d281.s1.e3" origId="31703" charOffset="302-313" type="compound" text="doxorubicin"/>
            <entity id="DS3.d281.s1.e4" origId="5743" charOffset="395-408" type="compound" text="dexamethasone"/>
            <pair e1="DS3.d281.s1.e1" e2="DS3.d281.s1.e0" id="DS3.d281.s1.i0" interaction="False" />
            <pair e1="DS3.d281.s1.e3" e2="DS3.d281.s1.e0" id="DS3.d281.s1.i1" interaction="False" />
            <pair e1="DS3.d281.s1.e4" e2="DS3.d281.s1.e0" id="DS3.d281.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d281.s2" origId="9935075-8" text="METHODS: annexin V was coupled to hydrazinonicotinamide (HYNIC) and radiolabeled with 99mTc.">
            <entity id="DS3.d281.s2.e0" origId="P08758,V9HWE0,P48036" charOffset="9-18" type="protein" text="annexin V"/>
            <entity id="DS3.d281.s2.e1" origId="20077770" charOffset="34-55" type="compound" text="hydrazinonicotinamide"/>
            <pair e1="DS3.d281.s2.e1" e2="DS3.d281.s2.e0" id="DS3.d281.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d281.s3" origId="9935075-9" text="Bioreactivity of 99mTc-HYNIC annexin V was compared with fluorescein isothiocyanate (FITC)-labeled annexin V in cultures of Jurkat T-cell lymphoblasts and in ex vivo thymic cell suspensions undergoing apoptosis in response to different stimuli.">
            <entity id="DS3.d281.s3.e0" origId="P08758,V9HWE0,P48036" charOffset="29-38" type="protein" text="annexin V"/>
            <entity id="DS3.d281.s3.e1" origId="16850" charOffset="57-68" type="compound" text="fluorescein"/>
            <entity id="DS3.d281.s3.e2" origId="781" charOffset="69-83" type="compound" text="isothiocyanate"/>
            <entity id="DS3.d281.s3.e3" origId="18730" charOffset="85-89" type="compound" text="FITC"/>
            <entity id="DS3.d281.s3.e4" origId="P08758,V9HWE0,P48036" charOffset="99-108" type="protein" text="annexin V"/>
            <pair e1="DS3.d281.s3.e3" e2="DS3.d281.s3.e0" id="DS3.d281.s3.i0" interaction="False" />
            <pair e1="DS3.d281.s3.e1" e2="DS3.d281.s3.e0" id="DS3.d281.s3.i1" interaction="False" />
            <pair e1="DS3.d281.s3.e2" e2="DS3.d281.s3.e0" id="DS3.d281.s3.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d282" origId="9935077">
        <sentence id="DS3.d282.s0" origId="9935077-1" text="The purpose of this study was to compare the toxicity and efficacy of two-step radioimmunotherapy using a bispecific anticarcinoembryonic antigen (CEA)/anti-diethylenetriamine pentaacetic acid (DTPA) antibody (F6-734 bispecific monoclonal antibodies (BsMAbs) and an 131I-di-DTPA-TL bivalent hapten with F(ab')2 fragments of the same directly labeled anti-CEA 131-F6.">
            <entity id="DS3.d282.s0.e0" origId="P11465,A0A024R0M4" charOffset="147-150" type="protein" text="CEA"/>
            <entity id="DS3.d282.s0.e1" origId="8111" charOffset="157-175" type="compound" text="diethylenetriamine"/>
            <entity id="DS3.d282.s0.e2" origId="3053" charOffset="194-198" type="compound" text="DTPA"/>
            <entity id="DS3.d282.s0.e3" origId="167195" charOffset="266-270" type="compound" text="131I"/>
            <entity id="DS3.d282.s0.e4" origId="3053" charOffset="274-278" type="compound" text="DTPA"/>
            <entity id="DS3.d282.s0.e5" origId="P11465,A0A024R0M4" charOffset="355-358" type="protein" text="CEA"/>
            <pair e1="DS3.d282.s0.e1" e2="DS3.d282.s0.e0" id="DS3.d282.s0.i0" interaction="False" />
            <pair e1="DS3.d282.s0.e2" e2="DS3.d282.s0.e0" id="DS3.d282.s0.i1" interaction="False" />
            <pair e1="DS3.d282.s0.e3" e2="DS3.d282.s0.e0" id="DS3.d282.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d282.s1" origId="9935077-4" text="Four control groups were treated respectively with (a) 92.5 MBq nonspecific 131I-734 fragments, (b) 92.5 MBq 131I-di-DTPA-TL 48 h after injection of a mixture of irrelevant F6-679 (anti-CEA/anti-histamine) and G7A5-734 (anti-melanoma/anti-DTPA) BsMAb, (c) 250 microg nonradiolabeled F6, and 250 microg F6-734 BsMAb and then 48 h later 1.25 nmol of nonradiolabeled hapten.">
            <entity id="DS3.d282.s1.e0" origId="167195" charOffset="76-80" type="compound" text="131I"/>
            <entity id="DS3.d282.s1.e1" origId="167195" charOffset="109-113" type="compound" text="131I"/>
            <entity id="DS3.d282.s1.e2" origId="3053" charOffset="117-121" type="compound" text="DTPA"/>
            <entity id="DS3.d282.s1.e3" origId="P11465,A0A024R0M4" charOffset="186-189" type="protein" text="CEA"/>
            <entity id="DS3.d282.s1.e4" origId="774" charOffset="195-204" type="compound" text="histamine"/>
            <entity id="DS3.d282.s1.e5" origId="3053" charOffset="239-243" type="compound" text="DTPA"/>
            <pair e1="DS3.d282.s1.e2" e2="DS3.d282.s1.e3" id="DS3.d282.s1.i0" interaction="False" />
            <pair e1="DS3.d282.s1.e0" e2="DS3.d282.s1.e3" id="DS3.d282.s1.i1" interaction="False" />
            <pair e1="DS3.d282.s1.e4" e2="DS3.d282.s1.e3" id="DS3.d282.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d283" origId="9935086">
        <sentence id="DS3.d283.s0" origId="9935086-1" text="BACKGROUND: Transient hyperpigmentation is the most common complication seen following cutaneous carbon dioxide (CO2) laser resurfacing.">
            <entity id="DS3.d283.s0.e0" origId="5462310" charOffset="97-103" type="compound" text="carbon"/>
            <entity id="DS3.d283.s0.e1" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="113-116" type="protein" text="CO2"/>
            <pair e1="DS3.d283.s0.e0" e2="DS3.d283.s0.e1" id="DS3.d283.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d283.s1" origId="9935086-3" text="METHODS: One hundred consecutive CO2 laser resurfacing patients (skin types I-III) were randomized to receive preoperative treatment with 10% glycolic acid cream twice daily (n=25), hydroquinone 4% cream qHS and tretinoin 0.025% cream twice daily (n=25) or no pretreatment (n=50, control) for at least 2 weeks.">
            <entity id="DS3.d283.s1.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="33-36" type="protein" text="CO2"/>
            <entity id="DS3.d283.s1.e1" origId="757" charOffset="142-155" type="compound" text="glycolic acid"/>
            <entity id="DS3.d283.s1.e2" origId="785,91156575" charOffset="182-194" type="compound" text="hydroquinone"/>
            <entity id="DS3.d283.s1.e3" origId="444795" charOffset="212-221" type="compound" text="tretinoin"/>
            <pair e1="DS3.d283.s1.e2" e2="DS3.d283.s1.e0" id="DS3.d283.s1.i0" interaction="False" />
            <pair e1="DS3.d283.s1.e3" e2="DS3.d283.s1.e0" id="DS3.d283.s1.i1" interaction="False" />
            <pair e1="DS3.d283.s1.e1" e2="DS3.d283.s1.e0" id="DS3.d283.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d283.s2" origId="9935086-5" text="RESULTS: There was no significant difference in the incidence of post-CO2 laser resurfacing hyperpigmentation between subjects who received pretreatment with either topical glycolic acid cream or combination tretinoin/hydroquinone creams and those who received no pretreatment regimen.">
            <entity id="DS3.d283.s2.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="70-73" type="protein" text="CO2"/>
            <entity id="DS3.d283.s2.e1" origId="757" charOffset="173-186" type="compound" text="glycolic acid"/>
            <entity id="DS3.d283.s2.e2" origId="444795" charOffset="208-217" type="compound" text="tretinoin"/>
            <entity id="DS3.d283.s2.e3" origId="785,91156575" charOffset="218-230" type="compound" text="hydroquinone"/>
            <pair e1="DS3.d283.s2.e2" e2="DS3.d283.s2.e0" id="DS3.d283.s2.i0" interaction="False" />
            <pair e1="DS3.d283.s2.e1" e2="DS3.d283.s2.e0" id="DS3.d283.s2.i1" interaction="False" />
            <pair e1="DS3.d283.s2.e3" e2="DS3.d283.s2.e0" id="DS3.d283.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d284" origId="9935109">
        <sentence id="DS3.d284.s0" origId="9935109-1" text="OBJECTIVE: To compare the efficacy of two clinically accepted methods of progesterone supplementation during IVF.">
            <entity id="DS3.d284.s0.e0" origId="5994" charOffset="73-85" type="compound" text="progesterone"/>
            <entity id="DS3.d284.s0.e1" origId="Q14524,K4DIA1,Q86V90,E9PG18,H9KVD2,E9PHB6" charOffset="109-112" type="protein" text="IVF"/>
            <pair e1="DS3.d284.s0.e0" e2="DS3.d284.s0.e1" id="DS3.d284.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d285" origId="9935117">
        <sentence id="DS3.d285.s0" origId="9935117-10" text="Progesterone production was increased in the medium with FBS supplemented with FSH alone, hCG alone, and FSH with LH compared with control.">
            <entity id="DS3.d285.s0.e0" origId="5994" charOffset="0-12" type="compound" text="Progesterone"/>
            <entity id="DS3.d285.s0.e1" origId="P25440,X5CF57,A0A024RCR5" charOffset="79-82" type="protein" text="FSH"/>
            <entity id="DS3.d285.s0.e2" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="90-93" type="protein" text="hCG"/>
            <entity id="DS3.d285.s0.e3" origId="P25440,X5CF57,A0A024RCR5" charOffset="105-108" type="protein" text="FSH"/>
            <pair e1="DS3.d285.s0.e0" e2="DS3.d285.s0.e1" id="DS3.d285.s0.i0" interaction="False" />
            <pair e1="DS3.d285.s0.e0" e2="DS3.d285.s0.e2" id="DS3.d285.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d285.s1" origId="9935117-11" text="There was no difference in progesterone levels in the culture medium without FBS supplemented with both concentrations of FSH alone and hCG alone compared with control.">
            <entity id="DS3.d285.s1.e0" origId="5994" charOffset="27-39" type="compound" text="progesterone"/>
            <entity id="DS3.d285.s1.e1" origId="P25440,X5CF57,A0A024RCR5" charOffset="122-125" type="protein" text="FSH"/>
            <entity id="DS3.d285.s1.e2" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="136-139" type="protein" text="hCG"/>
            <pair e1="DS3.d285.s1.e0" e2="DS3.d285.s1.e1" id="DS3.d285.s1.i0" interaction="False" />
            <pair e1="DS3.d285.s1.e0" e2="DS3.d285.s1.e2" id="DS3.d285.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d285.s2" origId="9935117-12" text="However, progesterone secretion was increased in the medium without FBS supplemented with a physiologic concentration of FSH with LH.">
            <entity id="DS3.d285.s2.e0" origId="5994" charOffset="9-21" type="compound" text="progesterone"/>
            <entity id="DS3.d285.s2.e1" origId="P25440,X5CF57,A0A024RCR5" charOffset="121-124" type="protein" text="FSH"/>
            <pair e1="DS3.d285.s2.e0" e2="DS3.d285.s2.e1" id="DS3.d285.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d285.s3" origId="9935117-7" text="RESULT(S): Estradiol secretion was significantly increased in the culture medium with FBS supplemented with both concentrations of FSH alone compared with control.">
            <entity id="DS3.d285.s3.e0" origId="5757" charOffset="11-20" type="compound" text="Estradiol"/>
            <entity id="DS3.d285.s3.e1" origId="P25440,X5CF57,A0A024RCR5" charOffset="131-134" type="protein" text="FSH"/>
            <pair e1="DS3.d285.s3.e0" e2="DS3.d285.s3.e1" id="DS3.d285.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d286" origId="9935118">
        <sentence id="DS3.d286.s0" origId="9935118-0" text="Immunomodulation with interleukin-10 and interleukin-4 compared with ketorolac tromethamine for prevention of postoperative adhesions in a murine model.">
            <entity id="DS3.d286.s0.e0" origId="P18893,Q3U879" charOffset="22-36" type="protein" text="interleukin-10"/>
            <entity id="DS3.d286.s0.e1" origId="P07750" charOffset="41-54" type="protein" text="interleukin-4"/>
            <entity id="DS3.d286.s0.e2" origId="3826" charOffset="69-91" type="compound" text="ketorolac tromethamine"/>
            <pair e1="DS3.d286.s0.e2" e2="DS3.d286.s0.e0" id="DS3.d286.s0.i0" interaction="False" />
            <pair e1="DS3.d286.s0.e2" e2="DS3.d286.s0.e1" id="DS3.d286.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d286.s1" origId="9935118-1" text="OBJECTIVE: To assess the effects of two macrophage down-regulating cytokines (interleukin (IL)-10 and IL-4) and the nonsteroidal anti-inflammatory drug ketorolac tromethamine on postoperative adhesion formation.">
            <entity id="DS3.d286.s1.e0" origId="P18893,Q3U879" charOffset="91-97" type="protein" text="IL)-10"/>
            <entity id="DS3.d286.s1.e1" origId="3826" charOffset="152-174" type="compound" text="ketorolac tromethamine"/>
            <pair e1="DS3.d286.s1.e1" e2="DS3.d286.s1.e1" id="DS3.d286.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d286.s2" origId="9935118-6" text="Subsequently, animals were randomized to nine different treatment groups to receive no injections, phosphate-buffered saline (PBS) only, IL-10, IL-4, ketorolac, IL-10 plus IL-4, IL-10 plus ketorolac, IL-4 plus ketorolac, or all three agents.">
            <entity id="DS3.d286.s2.e0" origId="24978514" charOffset="99-124" type="compound" text="phosphate-buffered saline"/>
            <entity id="DS3.d286.s2.e1" origId="P18893,Q3U879" charOffset="137-142" type="protein" text="IL-10"/>
            <entity id="DS3.d286.s2.e2" origId="P18893,Q3U879" charOffset="161-166" type="protein" text="IL-10"/>
            <entity id="DS3.d286.s2.e3" origId="P18893,Q3U879" charOffset="161-166" type="protein" text="IL-10"/>
            <pair e1="DS3.d286.s2.e0" e2="DS3.d286.s2.e1" id="DS3.d286.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d287" origId="9935122">
        <sentence id="DS3.d287.s0" origId="9935122-14" text="Interim analysis showed that the 95% confidence intervals of an ovulation rate of 0 were 0-17% for the dexamethasone arm (n = 19) and 0-19% for the placebo arm (n = 17).">
            <entity id="DS3.d287.s0.e0" origId="5743" charOffset="103-116" type="compound" text="dexamethasone"/>
            <entity id="DS3.d287.s0.e1" origId="P14550,V9HWI0" charOffset="117-120" type="protein" text="arm"/>
            <entity id="DS3.d287.s0.e2" origId="P14550,V9HWI0" charOffset="156-159" type="protein" text="arm"/>
            <pair e1="DS3.d287.s0.e0" e2="DS3.d287.s0.e1" id="DS3.d287.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d288" origId="9935125">
        <sentence id="DS3.d288.s0" origId="9935125-1" text="OBJECTIVE: To determine whether a starting dose of 50 units of recombinant FSH (follitropin beta, Puregon; Organon Laboratories Limited, Cambridge, United Kingdom) produces a follicular response in patients with clomiphene citrate-resistant polycystic ovary syndrome (PCOS).">
            <entity id="DS3.d288.s0.e0" origId="P25440,X5CF57,A0A024RCR5" charOffset="75-78" type="protein" text="FSH"/>
            <entity id="DS3.d288.s0.e1" origId="235905" charOffset="107-114" type="compound" text="Organon"/>
            <entity id="DS3.d288.s0.e2" origId="3033832,60974,6420009" charOffset="212-230" type="compound" text="clomiphene citrate"/>
            <pair e1="DS3.d288.s0.e1" e2="DS3.d288.s0.e0" id="DS3.d288.s0.i0" interaction="False" />
            <pair e1="DS3.d288.s0.e2" e2="DS3.d288.s0.e0" id="DS3.d288.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d289" origId="9935127">
        <sentence id="DS3.d289.s0" origId="9935127-12" text="CONCLUSION(S): Naltrexone treatment improves GHRH-induced GH secretion in patients with PCOS.">
            <entity id="DS3.d289.s0.e0" origId="5360515" charOffset="15-25" type="compound" text="Naltrexone"/>
            <entity id="DS3.d289.s0.e1" origId="P01286" charOffset="45-49" type="protein" text="GHRH"/>
            <pair e1="DS3.d289.s0.e0" e2="DS3.d289.s0.e1" id="DS3.d289.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d289.s1" origId="9935127-5" text="INTERVENTION(S): Patients underwent a GH-releasing hormone (GHRH) test and an oral glucose tolerance test before and after 4-5 weeks of treatment with 50 mg/d of naltrexone.">
            <entity id="DS3.d289.s1.e0" origId="P01286" charOffset="38-58" type="protein" text="GH-releasing hormone"/>
            <entity id="DS3.d289.s1.e1" origId="P01286" charOffset="60-64" type="protein" text="GHRH"/>
            <entity id="DS3.d289.s1.e2" origId="206,5793,64689,79025" charOffset="83-90" type="compound" text="glucose"/>
            <entity id="DS3.d289.s1.e3" origId="5360515" charOffset="162-172" type="compound" text="naltrexone"/>
            <pair e1="DS3.d289.s1.e3" e2="DS3.d289.s1.e0" id="DS3.d289.s1.i0" interaction="False" />
            <pair e1="DS3.d289.s1.e3" e2="DS3.d289.s1.e1" id="DS3.d289.s1.i1" interaction="False" />
            <pair e1="DS3.d289.s1.e2" e2="DS3.d289.s1.e0" id="DS3.d289.s1.i2" interaction="False" />
            <pair e1="DS3.d289.s1.e2" e2="DS3.d289.s1.e1" id="DS3.d289.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d289.s2" origId="9935127-6" text="MAIN OUTCOME MEASURE(S): Serum concentrations of GH, insulin, glucose, steroids, and gonadotropins, as well as the GH area under the curve (AUC-GH) and the insulin area under the curve (AUC-I), were measured before and after naltrexone treatment.">
            <entity id="DS3.d289.s2.e0" origId="P01308,I3WAC9" charOffset="53-60" type="protein" text="insulin"/>
            <entity id="DS3.d289.s2.e1" origId="206,5793,64689,79025" charOffset="62-69" type="compound" text="glucose"/>
            <entity id="DS3.d289.s2.e2" origId="P01308,I3WAC9" charOffset="156-163" type="protein" text="insulin"/>
            <entity id="DS3.d289.s2.e3" origId="5360515" charOffset="225-235" type="compound" text="naltrexone"/>
            <pair e1="DS3.d289.s2.e3" e2="DS3.d289.s2.e0" id="DS3.d289.s2.i0" interaction="False" />
            <pair e1="DS3.d289.s2.e1" e2="DS3.d289.s2.e0" id="DS3.d289.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d289.s3" origId="9935127-7" text="RESULT(S): In patients with PCOS, the administration of naltrexone increased the GH response to the GHRH test without interfering with the insulin response to the oral glucose tolerance test.">
            <entity id="DS3.d289.s3.e0" origId="5360515" charOffset="56-66" type="compound" text="naltrexone"/>
            <entity id="DS3.d289.s3.e1" origId="P01286" charOffset="100-104" type="protein" text="GHRH"/>
            <entity id="DS3.d289.s3.e2" origId="P01308,I3WAC9" charOffset="139-146" type="protein" text="insulin"/>
            <entity id="DS3.d289.s3.e3" origId="206,5793,64689,79025" charOffset="168-175" type="compound" text="glucose"/>
            <pair e1="DS3.d289.s3.e0" e2="DS3.d289.s3.e1" id="DS3.d289.s3.i0" interaction="False" />
            <pair e1="DS3.d289.s3.e0" e2="DS3.d289.s3.e2" id="DS3.d289.s3.i1" interaction="False" />
            <pair e1="DS3.d289.s3.e3" e2="DS3.d289.s3.e1" id="DS3.d289.s3.i2" interaction="False" />
            <pair e1="DS3.d289.s3.e3" e2="DS3.d289.s3.e2" id="DS3.d289.s3.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d290" origId="9935138">
        <sentence id="DS3.d290.s0" origId="9935138-10" text="RESULT(S): On the day of hCG administration, the degree of endometrial echogenicity was similar in both groups (41% vs. 40%), but after hCG administration, it increased significantly faster in the high progesterone group than in the low progesterone group (70% vs. 63% at oocyte retrieval and 90% vs. 79% at ET, respectively).">
            <entity id="DS3.d290.s0.e0" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="25-28" type="protein" text="hCG"/>
            <entity id="DS3.d290.s0.e1" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="136-139" type="protein" text="hCG"/>
            <entity id="DS3.d290.s0.e2" origId="5994" charOffset="202-214" type="compound" text="progesterone"/>
            <entity id="DS3.d290.s0.e3" origId="5994" charOffset="237-249" type="compound" text="progesterone"/>
            <pair e1="DS3.d290.s0.e2" e2="DS3.d290.s0.e0" id="DS3.d290.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d290.s1" origId="9935138-11" text="CONCLUSION(S): End-follicular phase elevation in plasma progesterone (&amp;gt;0.9 ng/mL on the day of hCG administration) was associated with a faster increase in endometrial echogenicity during the early luteal phase of COH cycles.">
            <entity id="DS3.d290.s1.e0" origId="5994" charOffset="56-68" type="compound" text="progesterone"/>
            <entity id="DS3.d290.s1.e1" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="98-101" type="protein" text="hCG"/>
            <pair e1="DS3.d290.s1.e0" e2="DS3.d290.s1.e1" id="DS3.d290.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d290.s2" origId="9935138-8" text="Patients were sorted according to whether their plasma progesterone level exceeded 0.9 ng/mL (n = 26) or not (n = 33) on the day of hCG administration.">
            <entity id="DS3.d290.s2.e0" origId="5994" charOffset="55-67" type="compound" text="progesterone"/>
            <entity id="DS3.d290.s2.e1" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="132-135" type="protein" text="hCG"/>
            <pair e1="DS3.d290.s2.e0" e2="DS3.d290.s2.e1" id="DS3.d290.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d291" origId="9935140">
        <sentence id="DS3.d291.s0" origId="9935140-0" text="Predictive value of serum estradiol levels for IVF pregnancy outcome after gonadotropin stimulation?">
            <entity id="DS3.d291.s0.e0" origId="5757" charOffset="26-35" type="compound" text="estradiol"/>
            <entity id="DS3.d291.s0.e1" origId="Q14524,K4DIA1,Q86V90,E9PG18,H9KVD2,E9PHB6" charOffset="47-50" type="protein" text="IVF"/>
            <pair e1="DS3.d291.s0.e0" e2="DS3.d291.s0.e1" id="DS3.d291.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d292" origId="9935151">
        <sentence id="DS3.d292.s0" origId="9935151-5" text="Data were also analyzed using multiple logistic regression with adjustment for known risk factors for the development of breast cancer as well as anthropometric, demographic and hormonal variables, including estradiol, prolactin, IGF-I and IGF-binding protein-3.">
            <entity id="DS3.d292.s0.e0" origId="5757" charOffset="208-217" type="compound" text="estradiol"/>
            <entity id="DS3.d292.s0.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="219-228" type="protein" text="prolactin"/>
            <entity id="DS3.d292.s0.e2" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="230-235" type="protein" text="IGF-I"/>
            <entity id="DS3.d292.s0.e3" origId="P17936,B3KPF0" charOffset="240-261" type="protein" text="IGF-binding protein-3"/>
            <pair e1="DS3.d292.s0.e0" e2="DS3.d292.s0.e1" id="DS3.d292.s0.i0" interaction="False" />
            <pair e1="DS3.d292.s0.e0" e2="DS3.d292.s0.e3" id="DS3.d292.s0.i1" interaction="False" />
            <pair e1="DS3.d292.s0.e0" e2="DS3.d292.s0.e2" id="DS3.d292.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d293" origId="9935153">
        <sentence id="DS3.d293.s0" origId="9935153-4" text="The deduced human UPK1b protein sequence has 92% and 93% amino-acid homology with bovine UPK1b and mink TI1 proteins respectively.">
            <entity id="DS3.d293.s0.e0" origId="O75841" charOffset="18-23" type="protein" text="UPK1b"/>
            <entity id="DS3.d293.s0.e1" origId="O75841" charOffset="89-94" type="protein" text="UPK1b"/>
            <entity id="DS3.d293.s0.e2" origId="5289469" charOffset="104-107" type="compound" text="TI1"/>
            <pair e1="DS3.d293.s0.e2" e2="DS3.d293.s0.e0" id="DS3.d293.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d294" origId="9935156">
        <sentence id="DS3.d294.s0" origId="9935156-4" text="Then, 3 cell lines with the major types of K-ras point mutation, i.e.,HuP-T1, HuP-T3 and PANC-1, and 1 without mutation, BxPC-3, were used for the experiments.">
            <entity id="DS3.d294.s0.e0" origId="P01116,L7RSL8,A0A024RAV5,I1SRC5" charOffset="43-48" type="protein" text="K-ras"/>
            <entity id="DS3.d294.s0.e1" origId="4369233,59922556" charOffset="70-73" type="compound" text="HuP"/>
            <entity id="DS3.d294.s0.e2" origId="4369233,59922556" charOffset="78-81" type="compound" text="HuP"/>
            <entity id="DS3.d294.s0.e3" origId="5920" charOffset="82-84" type="compound" text="T3"/>
            <pair e1="DS3.d294.s0.e1" e2="DS3.d294.s0.e0" id="DS3.d294.s0.i0" interaction="False" />
            <pair e1="DS3.d294.s0.e3" e2="DS3.d294.s0.e0" id="DS3.d294.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d295" origId="9935157">
        <sentence id="DS3.d295.s0" origId="9935157-3" text="The biodistribution of 111In-K1 was studied in athymic nude mice bearing 2 s.c. tumors, one expressing a stably transfected plasmid encoding mesothelin and one composed of the parental untransfected A431 epidermoid carcinoma cells which do not express mesothelin.">
            <entity id="DS3.d295.s0.e0" origId="5462099" charOffset="23-28" type="compound" text="111In"/>
            <entity id="DS3.d295.s0.e1" origId="Q13421" charOffset="141-151" type="protein" text="mesothelin"/>
            <entity id="DS3.d295.s0.e2" origId="Q13421" charOffset="252-262" type="protein" text="mesothelin"/>
            <pair e1="DS3.d295.s0.e0" e2="DS3.d295.s0.e1" id="DS3.d295.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d296" origId="9935160">
        <sentence id="DS3.d296.s0" origId="9935160-4" text="Indeed, in a representative panel of 12 human osteosarcoma cell lines, in addition to the IGF-IR-mediated circuit, we demonstrated also a loop mediated by epidermal growth factor receptor as well as the presence of nerve growth factor, low-affinity nerve growth factor receptor as well as tyrosine receptor kinase A in the great majority of osteosarcomas.">
            <entity id="DS3.d296.s0.e0" origId="P08069,C9J5X1" charOffset="90-96" type="protein" text="IGF-IR"/>
            <entity id="DS3.d296.s0.e1" origId="P00533" charOffset="155-187" type="protein" text="epidermal growth factor receptor"/>
            <entity id="DS3.d296.s0.e2" origId="P08138" charOffset="236-277" type="protein" text="low-affinity nerve growth factor receptor"/>
            <entity id="DS3.d296.s0.e3" origId="6057,90983769" charOffset="289-297" type="compound" text="tyrosine"/>
            <pair e1="DS3.d296.s0.e3" e2="DS3.d296.s0.e1" id="DS3.d296.s0.i0" interaction="False" />
            <pair e1="DS3.d296.s0.e3" e2="DS3.d296.s0.e0" id="DS3.d296.s0.i1" interaction="False" />
            <pair e1="DS3.d296.s0.e3" e2="DS3.d296.s0.e2" id="DS3.d296.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d297" origId="9935163">
        <sentence id="DS3.d297.s0" origId="9935163-0" text="Ectopic expression of RET results in microphthalmia and tumors in the retinal pigment epithelium.">
            <entity id="DS3.d297.s0.e0" origId="P35546" charOffset="22-25" type="protein" text="RET"/>
            <entity id="DS3.d297.s0.e1" origId="638015" charOffset="70-77" type="compound" text="retinal"/>
            <pair e1="DS3.d297.s0.e1" e2="DS3.d297.s0.e0" id="DS3.d297.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d298" origId="9935164">
        <sentence id="DS3.d298.s0" origId="9935164-10" text="Our results indicate that FTA and FTB fucosylate distinct glycan chains in the same cell, leading to opposite effects, under control of the immune system.">
            <entity id="DS3.d298.s0.e0" origId="Q61239,Q541Z2" charOffset="26-29" type="protein" text="FTA"/>
            <entity id="DS3.d298.s0.e1" origId="447371" charOffset="34-37" type="compound" text="FTB"/>
            <entity id="DS3.d298.s0.e2" origId="54302978" charOffset="38-48" type="compound" text="fucosylate"/>
            <pair e1="DS3.d298.s0.e2" e2="DS3.d298.s0.e0" id="DS3.d298.s0.i0" interaction="False" />
            <pair e1="DS3.d298.s0.e1" e2="DS3.d298.s0.e0" id="DS3.d298.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d298.s1" origId="9935164-3" text="Two alpha1,2-fucosyltransferases, expressed in colorectal carcinomas, have been characterized (FUT1 and FUT2 in humans, FTA and FTB in rats).">
            <entity id="DS3.d298.s1.e0" origId="P19526,Q6IZA2" charOffset="95-99" type="protein" text="FUT1"/>
            <entity id="DS3.d298.s1.e1" origId="Q10981,A8K2L2" charOffset="104-108" type="protein" text="FUT2"/>
            <entity id="DS3.d298.s1.e2" origId="Q61239,Q541Z2" charOffset="120-123" type="protein" text="FTA"/>
            <entity id="DS3.d298.s1.e3" origId="447371" charOffset="128-131" type="compound" text="FTB"/>
            <pair e1="DS3.d298.s1.e3" e2="DS3.d298.s1.e2" id="DS3.d298.s1.i0" interaction="False" />
            <pair e1="DS3.d298.s1.e3" e2="DS3.d298.s1.e1" id="DS3.d298.s1.i1" interaction="False" />
            <pair e1="DS3.d298.s1.e3" e2="DS3.d298.s1.e0" id="DS3.d298.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d298.s2" origId="9935164-7" text="We now report the anti-sense transfection of an FTA cDNA fragment into PROb cells, which resulted in decreased enzymatic activity on a type 2 precursor and decreased cell-surface H type 2 antigen exclusively.">
            <entity id="DS3.d298.s2.e0" origId="Q61239,Q541Z2" charOffset="48-51" type="protein" text="FTA"/>
            <entity id="DS3.d298.s2.e1" origId="5288910" charOffset="179-187" type="compound" text="H type 2"/>
            <pair e1="DS3.d298.s2.e1" e2="DS3.d298.s2.e0" id="DS3.d298.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d299" origId="9935165">
        <sentence id="DS3.d299.s0" origId="9935165-2" text="Here we report the pre-clinical characterization of bispecific-antibody fragments (bsFab2) directed to 2 different glioblastoma-associated antigens: the EGF receptor (EGFR) and a chondroitin-sulfate proteoglycan (CSPG).">
            <entity id="DS3.d299.s0.e0" origId="P00533" charOffset="153-165" type="protein" text="EGF receptor"/>
            <entity id="DS3.d299.s0.e1" origId="P00533" charOffset="167-171" type="protein" text="EGFR"/>
            <entity id="DS3.d299.s0.e2" origId="53477707" charOffset="179-190" type="compound" text="chondroitin"/>
            <entity id="DS3.d299.s0.e3" origId="1117" charOffset="191-198" type="compound" text="sulfate"/>
            <pair e1="DS3.d299.s0.e2" e2="DS3.d299.s0.e0" id="DS3.d299.s0.i0" interaction="False" />
            <pair e1="DS3.d299.s0.e2" e2="DS3.d299.s0.e1" id="DS3.d299.s0.i1" interaction="False" />
            <pair e1="DS3.d299.s0.e3" e2="DS3.d299.s0.e0" id="DS3.d299.s0.i2" interaction="False" />
            <pair e1="DS3.d299.s0.e3" e2="DS3.d299.s0.e1" id="DS3.d299.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d300" origId="9935166">
        <sentence id="DS3.d300.s0" origId="9935166-10" text="Our findings indicate that hypoxia stimulates carcinoma cell invasiveness by upregulating uPAR expression on the cell surface through a mechanism that requires a putative heme protein.">
            <entity id="DS3.d300.s0.e0" origId="Q03405,M0R1I2" charOffset="90-94" type="protein" text="uPAR"/>
            <entity id="DS3.d300.s0.e1" origId="4971" charOffset="171-175" type="compound" text="heme"/>
            <pair e1="DS3.d300.s0.e1" e2="DS3.d300.s0.e0" id="DS3.d300.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d300.s1" origId="9935166-6" text="Furthermore, incubation with cobalt chloride or with an iron chelator also resulted in elevated uPAR expression, while presence of 30% carbon monoxide in the hypoxic atmosphere reduced the hypoxia-mediated uPAR mRNA upregulation.">
            <entity id="DS3.d300.s1.e0" origId="66297" charOffset="29-44" type="compound" text="cobalt chloride"/>
            <entity id="DS3.d300.s1.e1" origId="23925,67172434" charOffset="56-60" type="compound" text="iron"/>
            <entity id="DS3.d300.s1.e2" origId="Q03405,M0R1I2" charOffset="96-100" type="protein" text="uPAR"/>
            <entity id="DS3.d300.s1.e3" origId="281" charOffset="135-150" type="compound" text="carbon monoxide"/>
            <entity id="DS3.d300.s1.e4" origId="Q03405,M0R1I2" charOffset="206-210" type="protein" text="uPAR"/>
            <pair e1="DS3.d300.s1.e0" e2="DS3.d300.s1.e2" id="DS3.d300.s1.i0" interaction="False" />
            <pair e1="DS3.d300.s1.e1" e2="DS3.d300.s1.e2" id="DS3.d300.s1.i1" interaction="False" />
            <pair e1="DS3.d300.s1.e3" e2="DS3.d300.s1.e2" id="DS3.d300.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d301" origId="9935167">
        <sentence id="DS3.d301.s0" origId="9935167-5" text="One cDNA corresponds to the murine guanylate-binding protein gene Gbp-1/Mag-1.">
            <entity id="DS3.d301.s0.e0" origId="6804" charOffset="35-44" type="compound" text="guanylate"/>
            <entity id="DS3.d301.s0.e1" origId="A4UUI2" charOffset="66-71" type="protein" text="Gbp-1"/>
            <entity id="DS3.d301.s0.e2" origId="A4UUI2" charOffset="72-77" type="protein" text="Mag-1"/>
            <pair e1="DS3.d301.s0.e0" e2="DS3.d301.s0.e1" id="DS3.d301.s0.i0" interaction="False" />
            <pair e1="DS3.d301.s0.e0" e2="DS3.d301.s0.e2" id="DS3.d301.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d302" origId="9935174">
        <sentence id="DS3.d302.s0" origId="9935174-4" text="Whilst the majority of EBV strains in either normal or tumour tissues were type 1 viruses with similar numbers of LMP1 repeats, a marked predominance of LMP1 deletion (del-LMP1) over non-deleted/wild-type LMP1 (wt-LMP1) variants was observed in nasal T/NK-cell lymphoma.">
            <entity id="DS3.d302.s0.e0" origId="P03230,A0A0B6VKE3" charOffset="114-118" type="protein" text="LMP1"/>
            <entity id="DS3.d302.s0.e1" origId="P03230,A0A0B6VKE3" charOffset="153-157" type="protein" text="LMP1"/>
            <entity id="DS3.d302.s0.e2" origId="445801" charOffset="158-161" type="compound" text="del"/>
            <entity id="DS3.d302.s0.e3" origId="P03230,A0A0B6VKE3" charOffset="153-157" type="protein" text="LMP1"/>
            <entity id="DS3.d302.s0.e4" origId="P03230,A0A0B6VKE3" charOffset="153-157" type="protein" text="LMP1"/>
            <entity id="DS3.d302.s0.e5" origId="P03230,A0A0B6VKE3" charOffset="153-157" type="protein" text="LMP1"/>
            <pair e1="DS3.d302.s0.e2" e2="DS3.d302.s0.e0" id="DS3.d302.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d302.s1" origId="9935174-5" text="Although del-LMP1 variants were also prevalent in the normal carriers of our population, wt-LMP1 was detected at a significantly higher frequency in normal vs. tumour tissues (p = 0.036).">
            <entity id="DS3.d302.s1.e0" origId="445801" charOffset="9-12" type="compound" text="del"/>
            <entity id="DS3.d302.s1.e1" origId="P03230,A0A0B6VKE3" charOffset="13-17" type="protein" text="LMP1"/>
            <entity id="DS3.d302.s1.e2" origId="P03230,A0A0B6VKE3" charOffset="92-96" type="protein" text="LMP1"/>
            <pair e1="DS3.d302.s1.e0" e2="DS3.d302.s1.e1" id="DS3.d302.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d302.s2" origId="9935174-6" text="More critically, wt-LMP1 variants were found frequently in mixed infection with del-LMP1 variants in the normal carriers.">
            <entity id="DS3.d302.s2.e0" origId="P03230,A0A0B6VKE3" charOffset="20-24" type="protein" text="LMP1"/>
            <entity id="DS3.d302.s2.e1" origId="445801" charOffset="80-83" type="compound" text="del"/>
            <entity id="DS3.d302.s2.e2" origId="P03230,A0A0B6VKE3" charOffset="84-88" type="protein" text="LMP1"/>
            <pair e1="DS3.d302.s2.e1" e2="DS3.d302.s2.e0" id="DS3.d302.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d302.s3" origId="9935174-7" text="Sequence analysis identified 2 major del-LMP1 (and several wt-LMP1) variants containing signatory nucleotide changes in relation to the prototype B95-8 sequence in both normal and neoplastic nasal tissues.">
            <entity id="DS3.d302.s3.e0" origId="445801" charOffset="37-40" type="compound" text="del"/>
            <entity id="DS3.d302.s3.e1" origId="P03230,A0A0B6VKE3" charOffset="41-45" type="protein" text="LMP1"/>
            <entity id="DS3.d302.s3.e2" origId="P03230,A0A0B6VKE3" charOffset="62-66" type="protein" text="LMP1"/>
            <pair e1="DS3.d302.s3.e0" e2="DS3.d302.s3.e1" id="DS3.d302.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d302.s4" origId="9935174-8" text="Together, our data provide strong evidence for a selection mechanism for del-LMP1 over the wt-LMP1 variants in tumours.">
            <entity id="DS3.d302.s4.e0" origId="445801" charOffset="73-76" type="compound" text="del"/>
            <entity id="DS3.d302.s4.e1" origId="P03230,A0A0B6VKE3" charOffset="77-81" type="protein" text="LMP1"/>
            <entity id="DS3.d302.s4.e2" origId="P03230,A0A0B6VKE3" charOffset="94-98" type="protein" text="LMP1"/>
            <pair e1="DS3.d302.s4.e0" e2="DS3.d302.s4.e1" id="DS3.d302.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d303" origId="9935176">
        <sentence id="DS3.d303.s0" origId="9935176-0" text="Amplification and over-expression of OZF, a gene encoding a zinc finger protein, in human pancreatic carcinomas.">
            <entity id="DS3.d303.s0.e0" origId="Q15072" charOffset="37-40" type="protein" text="OZF"/>
            <entity id="DS3.d303.s0.e1" origId="23994" charOffset="60-64" type="compound" text="zinc"/>
            <pair e1="DS3.d303.s0.e1" e2="DS3.d303.s0.e0" id="DS3.d303.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d303.s1" origId="9935176-1" text="The OZF gene encodes a protein consisting of 10 zinc finger motifs and is located on chromosome 19q3.1.">
            <entity id="DS3.d303.s1.e0" origId="Q15072" charOffset="4-7" type="protein" text="OZF"/>
            <entity id="DS3.d303.s1.e1" origId="23994" charOffset="48-52" type="compound" text="zinc"/>
            <pair e1="DS3.d303.s1.e1" e2="DS3.d303.s1.e0" id="DS3.d303.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d304" origId="9935180">
        <sentence id="DS3.d304.s0" origId="9935180-2" text="After 25 weeks of the carcinogen treatment, rats were fed chow pellets containing 10% sodium chloride and were given s.c. injections of genistein at dosages of 15 mg/kg or 30 mg/kg body weight every other day.">
            <entity id="DS3.d304.s0.e0" origId="5234" charOffset="86-101" type="compound" text="sodium chloride"/>
            <entity id="DS3.d304.s0.e1" origId="5280961" charOffset="136-145" type="compound" text="genistein"/>
            <entity id="DS3.d304.s0.e2" origId="Q6ZM99" charOffset="169-174" type="protein" text="or 30"/>
            <pair e1="DS3.d304.s0.e0" e2="DS3.d304.s0.e2" id="DS3.d304.s0.i0" interaction="False" />
            <pair e1="DS3.d304.s0.e1" e2="DS3.d304.s0.e2" id="DS3.d304.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d305" origId="9935181">
        <sentence id="DS3.d305.s0" origId="9935181-7" text="To study the relationship between PKC-alpha, p53 and cell death, cells were treated either with TPA, to down-regulate PKC or with staurosporine, to inhibit PKC activity.">
            <entity id="DS3.d305.s0.e0" origId="O09185" charOffset="45-48" type="protein" text="p53"/>
            <entity id="DS3.d305.s0.e1" origId="122634" charOffset="96-99" type="compound" text="TPA"/>
            <entity id="DS3.d305.s0.e2" origId="44299148,451705,5311103,5459111,6419748,6711321,44259,9937179,9956178,5279,44120114" charOffset="130-143" type="compound" text="staurosporine"/>
            <pair e1="DS3.d305.s0.e2" e2="DS3.d305.s0.e0" id="DS3.d305.s0.i0" interaction="False" />
            <pair e1="DS3.d305.s0.e1" e2="DS3.d305.s0.e0" id="DS3.d305.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d305.s1" origId="9935181-8" text="Staurosporine, a potent PKC inhibitor and inducer of programmed cell death, caused the appearance of new PKC-alpha and p53 bands similar to those induced by serum starvation.">
            <entity id="DS3.d305.s1.e0" origId="44299148,451705,5311103,5459111,6419748,6711321,44259,9937179,9956178,5279,44120114" charOffset="0-13" type="compound" text="Staurosporine"/>
            <entity id="DS3.d305.s1.e1" origId="O09185" charOffset="119-122" type="protein" text="p53"/>
            <pair e1="DS3.d305.s1.e0" e2="DS3.d305.s1.e1" id="DS3.d305.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d306" origId="9935184">
        <sentence id="DS3.d306.s0" origId="9935184-1" text="We report here that stress stimuli such as gamma-irradiation or the anticancer drug doxorubicin activate expression of the death-inducing ligands (DILs) CD95-L, TNF-alpha and TRAIL.">
            <entity id="DS3.d306.s0.e0" origId="31703" charOffset="84-95" type="compound" text="doxorubicin"/>
            <entity id="DS3.d306.s0.e1" origId="P48023,Q53ZZ1" charOffset="153-159" type="protein" text="CD95-L"/>
            <entity id="DS3.d306.s0.e2" origId="P01375,Q5STB3" charOffset="161-170" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d306.s0.e3" origId="P50591,Q6IBA9" charOffset="175-180" type="protein" text="TRAIL"/>
            <pair e1="DS3.d306.s0.e0" e2="DS3.d306.s0.e3" id="DS3.d306.s0.i0" interaction="False" />
            <pair e1="DS3.d306.s0.e0" e2="DS3.d306.s0.e1" id="DS3.d306.s0.i1" interaction="False" />
            <pair e1="DS3.d306.s0.e0" e2="DS3.d306.s0.e2" id="DS3.d306.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d306.s1" origId="9935184-2" text="Apoptosis induced by gamma-irradiation or doxorubicin engages a FADD- and caspase-dependent apoptosis pathway which is inhibited by dominant negative FADD or the caspase inhibitor zVAD.">
            <entity id="DS3.d306.s1.e0" origId="31703" charOffset="42-53" type="compound" text="doxorubicin"/>
            <entity id="DS3.d306.s1.e1" origId="Q13158" charOffset="64-68" type="protein" text="FADD"/>
            <entity id="DS3.d306.s1.e2" origId="Q13158" charOffset="150-154" type="protein" text="FADD"/>
            <pair e1="DS3.d306.s1.e0" e2="DS3.d306.s1.e1" id="DS3.d306.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d307" origId="9935186">
        <sentence id="DS3.d307.s0" origId="9935186-9" text="This survival function of the IGF-1 receptor in response to UVB irradiation was influenced by activation of phosphatidylinositol-3 kinase and MAP kinase.">
            <entity id="DS3.d307.s0.e0" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="30-35" type="protein" text="IGF-1"/>
            <entity id="DS3.d307.s0.e1" origId="16738692,53477912" charOffset="108-128" type="compound" text="phosphatidylinositol"/>
            <pair e1="DS3.d307.s0.e1" e2="DS3.d307.s0.e0" id="DS3.d307.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d308" origId="9935187">
        <sentence id="DS3.d308.s0" origId="9935187-7" text="Furthermore, treatment of a PC346C culture with the demethylating agent 5-azacytidine resulted in re-expression of CD44 mRNA.">
            <entity id="DS3.d308.s0.e0" origId="9444" charOffset="74-85" type="compound" text="azacytidine"/>
            <entity id="DS3.d308.s0.e1" origId="P16070" charOffset="115-119" type="protein" text="CD44"/>
            <pair e1="DS3.d308.s0.e0" e2="DS3.d308.s0.e1" id="DS3.d308.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d309" origId="9935188">
        <sentence id="DS3.d309.s0" origId="9935188-2" text="Induction of lipolysis was attenuated by the adenylate cyclase inhibitor MDL12330A and the protein kinase A inhibitor H8, suggesting that cAMP was the intracellular mediator of induction.">
            <entity id="DS3.d309.s0.e0" origId="6083" charOffset="45-54" type="compound" text="adenylate"/>
            <entity id="DS3.d309.s0.e1" origId="3540" charOffset="118-120" type="compound" text="H8"/>
            <entity id="DS3.d309.s0.e2" origId="P51437" charOffset="138-142" type="protein" text="cAMP"/>
            <pair e1="DS3.d309.s0.e1" e2="DS3.d309.s0.e2" id="DS3.d309.s0.i0" interaction="False" />
            <pair e1="DS3.d309.s0.e0" e2="DS3.d309.s0.e2" id="DS3.d309.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d310" origId="9935189">
        <sentence id="DS3.d310.s0" origId="9935189-3" text="In cell culture, Neurotensin stimulates the growth of human colon cancer cell lines (SW480, SW620, HT29, HCT116 and Cl.19A) expressing the Neurotensin receptor NTR1 but does not change the growth of Caco2 cells, which do not express NTR1.">
            <entity id="DS3.d310.s0.e0" origId="P30990,Q6FH20,Q9D3P9" charOffset="17-28" type="protein" text="Neurotensin"/>
            <entity id="DS3.d310.s0.e1" origId="6096886" charOffset="119-122" type="compound" text="19A"/>
            <entity id="DS3.d310.s0.e2" origId="P30990,Q6FH20,Q9D3P9" charOffset="139-150" type="protein" text="Neurotensin"/>
            <entity id="DS3.d310.s0.e3" origId="Q9UBB9,A0A024R1I7" charOffset="160-164" type="protein" text="NTR1"/>
            <entity id="DS3.d310.s0.e4" origId="Q9UBB9,A0A024R1I7" charOffset="233-237" type="protein" text="NTR1"/>
            <pair e1="DS3.d310.s0.e1" e2="DS3.d310.s0.e0" id="DS3.d310.s0.i0" interaction="False" />
            <pair e1="DS3.d310.s0.e1" e2="DS3.d310.s0.e3" id="DS3.d310.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d311" origId="9935190">
        <sentence id="DS3.d311.s0" origId="9935190-7" text="We show that compaction depends on extracellular calcium, E-cadherin-mediated adhesion and F-actin but not on protein synthesis, microtubules or substratum adhesion.">
            <entity id="DS3.d311.s0.e0" origId="22044544,5460341" charOffset="49-56" type="compound" text="calcium"/>
            <entity id="DS3.d311.s0.e1" origId="P12830" charOffset="58-68" type="protein" text="E-cadherin"/>
            <pair e1="DS3.d311.s0.e0" e2="DS3.d311.s0.e1" id="DS3.d311.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d311.s1" origId="9935190-9" text="TPA treatment causes rapid translocation of PKC-alpha to the insoluble fraction.">
            <entity id="DS3.d311.s1.e0" origId="122634,22833501" charOffset="0-3" type="compound" text="TPA"/>
            <entity id="DS3.d311.s1.e1" origId="P17252,Q7Z727" charOffset="44-53" type="protein" text="PKC-alpha"/>
            <pair e1="DS3.d311.s1.e0" e2="DS3.d311.s1.e1" id="DS3.d311.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d312" origId="9935191">
        <sentence id="DS3.d312.s0" origId="9935191-0" text="Enhancement of 5-fluorouracil cytotoxicity by human thymidine-phosphorylase expression in cancer cells: in vitro and in vivo study.">
            <entity id="DS3.d312.s0.e0" origId="3385" charOffset="17-29" type="compound" text="fluorouracil"/>
            <entity id="DS3.d312.s0.e1" origId="P19971,E5KRG5,B2RBL3" charOffset="52-75" type="protein" text="thymidine-phosphorylase"/>
            <pair e1="DS3.d312.s0.e0" e2="DS3.d312.s0.e1" id="DS3.d312.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d312.s1" origId="9935191-2" text="Thymidine phosphorylase (TP) is the first enzyme in the metabolic activation pathway of 5-fluorouracil (5-FU) to fluorodeoxyribonucleotides, thus, it could be used to increase the sensitivity of cancer cells to this anti-pyrimidine agent.">
            <entity id="DS3.d312.s1.e0" origId="P19971,E5KRG5,B2RBL3" charOffset="0-23" type="protein" text="Thymidine phosphorylase"/>
            <entity id="DS3.d312.s1.e1" origId="3385" charOffset="90-102" type="compound" text="fluorouracil"/>
            <pair e1="DS3.d312.s1.e1" e2="DS3.d312.s1.e0" id="DS3.d312.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d313" origId="9935193">
        <sentence id="DS3.d313.s0" origId="9935193-4" text="Transformation by overexpression of ErbB-2 correlated with ligand-independent tyrosine phosphorylation of ErbB-2 and the adaptor protein Shc.">
            <entity id="DS3.d313.s0.e0" origId="P04626,J3QLU9,F5H1T4,X5DNK3" charOffset="36-42" type="protein" text="ErbB-2"/>
            <entity id="DS3.d313.s0.e1" origId="6057,90983769" charOffset="78-86" type="compound" text="tyrosine"/>
            <entity id="DS3.d313.s0.e2" origId="P04626,J3QLU9,F5H1T4,X5DNK3" charOffset="106-112" type="protein" text="ErbB-2"/>
            <entity id="DS3.d313.s0.e3" origId="P29353" charOffset="137-140" type="protein" text="Shc"/>
            <pair e1="DS3.d313.s0.e1" e2="DS3.d313.s0.e0" id="DS3.d313.s0.i0" interaction="False" />
            <pair e1="DS3.d313.s0.e1" e2="DS3.d313.s0.e3" id="DS3.d313.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d314" origId="9935194">
        <sentence id="DS3.d314.s0" origId="9935194-0" text="A MAGE-1-encoded HLA-A24-binding synthetic peptide induces specific anti-tumor cytotoxic T lymphocytes.">
            <entity id="DS3.d314.s0.e0" origId="P43355" charOffset="2-8" type="protein" text="MAGE-1"/>
            <entity id="DS3.d314.s0.e1" origId="446539" charOffset="21-24" type="compound" text="A24"/>
            <pair e1="DS3.d314.s0.e1" e2="DS3.d314.s0.e0" id="DS3.d314.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d314.s1" origId="9935194-1" text="Although several MAGE-1 peptides have already been identified, the MAGE-1-encoded peptide presented by HLA-A24, which is the most common allele in Japanese population and is also frequently present in Caucasians, might have a wide applicability for immunotherapy using these peptides.">
            <entity id="DS3.d314.s1.e0" origId="P43355" charOffset="17-23" type="protein" text="MAGE-1"/>
            <entity id="DS3.d314.s1.e1" origId="P43355" charOffset="67-73" type="protein" text="MAGE-1"/>
            <entity id="DS3.d314.s1.e2" origId="446539" charOffset="107-110" type="compound" text="A24"/>
            <pair e1="DS3.d314.s1.e2" e2="DS3.d314.s1.e0" id="DS3.d314.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d314.s2" origId="9935194-2" text="To identify this potential peptide, we examined the induction of specific cytotoxic T lymphocytes (CTL) from the peripheral-blood mononuclear cells (PBMC) in HLA-A24 healthy donors by in vitro stimulation with MAGE-1-encoded synthetic peptides with a binding affinity for HLA-A24, by a simplified method.">
            <entity id="DS3.d314.s2.e0" origId="446539" charOffset="162-165" type="compound" text="A24"/>
            <entity id="DS3.d314.s2.e1" origId="P43355" charOffset="210-216" type="protein" text="MAGE-1"/>
            <entity id="DS3.d314.s2.e2" origId="446539" charOffset="276-279" type="compound" text="A24"/>
            <pair e1="DS3.d314.s2.e0" e2="DS3.d314.s2.e1" id="DS3.d314.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d314.s3" origId="9935194-4" text="The induced CTL could thus lyse HLA-A24 tumor cells expressing MAGE-1, as well as the peptide-pulsed target cells, in an HLA-class-I-restricted manner.">
            <entity id="DS3.d314.s3.e0" origId="446539" charOffset="36-39" type="compound" text="A24"/>
            <entity id="DS3.d314.s3.e1" origId="P43355" charOffset="63-69" type="protein" text="MAGE-1"/>
            <pair e1="DS3.d314.s3.e0" e2="DS3.d314.s3.e1" id="DS3.d314.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d314.s4" origId="9935194-5" text="By using the MAGE-1/HLA-A24 peptide, NYKHCFPEI, we found it possible to immunize many more patients, especially Japanese patients, by means of such peptide-based immunotherapeutic approaches to MAGE-1-positive malignant tumors.">
            <entity id="DS3.d314.s4.e0" origId="P43355" charOffset="13-19" type="protein" text="MAGE-1"/>
            <entity id="DS3.d314.s4.e1" origId="446539" charOffset="24-27" type="compound" text="A24"/>
            <entity id="DS3.d314.s4.e2" origId="P43355" charOffset="194-200" type="protein" text="MAGE-1"/>
            <pair e1="DS3.d314.s4.e1" e2="DS3.d314.s4.e0" id="DS3.d314.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d315" origId="9935198">
        <sentence id="DS3.d315.s0" origId="9935198-3" text="In view of decreased expression of transforming growth factor-beta1 (TGF-beta1), an antagonist of IGF-I, in endometrial carcinoma, we investigated the expression of IGF-I, at both the mRNA and protein levels, and the immunoreactivity for type I IGF-I receptor in 30 formalin-fixed, paraffin-embedded tissue samples of normal and neoplastic endometrium, in order to possibly clarify the role of IGF-I in endometrial proliferation and differentiation.">
            <entity id="DS3.d315.s0.e0" origId="P01137" charOffset="35-67" type="protein" text="transforming growth factor-beta1"/>
            <entity id="DS3.d315.s0.e1" origId="P01137" charOffset="69-78" type="protein" text="TGF-beta1"/>
            <entity id="DS3.d315.s0.e2" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="98-103" type="protein" text="IGF-I"/>
            <entity id="DS3.d315.s0.e3" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="165-170" type="protein" text="IGF-I"/>
            <entity id="DS3.d315.s0.e4" origId="P08069,C9J5X1" charOffset="245-259" type="protein" text="IGF-I receptor"/>
            <entity id="DS3.d315.s0.e5" origId="712" charOffset="266-274" type="compound" text="formalin"/>
            <entity id="DS3.d315.s0.e6" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="165-170" type="protein" text="IGF-I"/>
            <pair e1="DS3.d315.s0.e5" e2="DS3.d315.s0.e4" id="DS3.d315.s0.i0" interaction="False" />
            <pair e1="DS3.d315.s0.e5" e2="DS3.d315.s0.e1" id="DS3.d315.s0.i1" interaction="False" />
            <pair e1="DS3.d315.s0.e5" e2="DS3.d315.s0.e2" id="DS3.d315.s0.i2" interaction="False" />
            <pair e1="DS3.d315.s0.e5" e2="DS3.d315.s0.e0" id="DS3.d315.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d316" origId="9935199">
        <sentence id="DS3.d316.s0" origId="9935199-4" text="We have studied the expression of different facilitating glucose transport proteins (GLUT 1, 2, 3 and 4) by immunohistochemistry in a variety of preneoplastic and neoplastic mucosal lesions of the head and neck.">
            <entity id="DS3.d316.s0.e0" origId="206,5793,64689,79025" charOffset="57-64" type="compound" text="glucose"/>
            <entity id="DS3.d316.s0.e1" origId="P11166,Q59GX2" charOffset="85-91" type="protein" text="GLUT 1"/>
            <pair e1="DS3.d316.s0.e0" e2="DS3.d316.s0.e1" id="DS3.d316.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d317" origId="9935206">
        <sentence id="DS3.d317.s0" origId="9935206-7" text="HD-3 LCLs were able to grow in vitro at low serum concentrations (up to 0.1%) and were significantly more clonogenic in soft agarose than B95.8 LCLs.">
            <entity id="DS3.d317.s0.e0" origId="O15379" charOffset="0-4" type="protein" text="HD-3"/>
            <entity id="DS3.d317.s0.e1" origId="11966311" charOffset="125-132" type="compound" text="agarose"/>
            <pair e1="DS3.d317.s0.e1" e2="DS3.d317.s0.e0" id="DS3.d317.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d318" origId="9935207">
        <sentence id="DS3.d318.s0" origId="9935207-4" text="The level of BMP-6 mRNA decreased upon serum starvation, whereas epidermal growth factor (EGF) treatment led to elevation of BMP-6 mRNA levels in a dose-dependent manner, with a maximum at 50 ng/ml EGF under serum-free conditions in hormone-sensitive (MCF-7) and in hormone-insensitive (SK-BR-3) breast cancer cell lines.">
            <entity id="DS3.d318.s0.e0" origId="P22004,Q4VBA3" charOffset="13-18" type="protein" text="BMP-6"/>
            <entity id="DS3.d318.s0.e1" origId="P22004,Q4VBA3" charOffset="125-130" type="protein" text="BMP-6"/>
            <entity id="DS3.d318.s0.e2" origId="259" charOffset="290-293" type="compound" text="BR-"/>
            <pair e1="DS3.d318.s0.e2" e2="DS3.d318.s0.e0" id="DS3.d318.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d318.s1" origId="9935207-6" text="Inhibition of EGF receptor tyrosine kinase with tyrphostine AG 1517 repressed the inductive effect of these growth factors, indicating an EGF receptor-mediated regulation of BMP-6 mRNA.">
            <entity id="DS3.d318.s1.e0" origId="P00533" charOffset="14-26" type="protein" text="EGF receptor"/>
            <entity id="DS3.d318.s1.e1" origId="6057,90983769" charOffset="27-35" type="compound" text="tyrosine"/>
            <entity id="DS3.d318.s1.e2" origId="4705" charOffset="60-67" type="compound" text="AG 1517"/>
            <entity id="DS3.d318.s1.e3" origId="P00533" charOffset="138-150" type="protein" text="EGF receptor"/>
            <entity id="DS3.d318.s1.e4" origId="P22004,Q4VBA3" charOffset="174-179" type="protein" text="BMP-6"/>
            <pair e1="DS3.d318.s1.e2" e2="DS3.d318.s1.e4" id="DS3.d318.s1.i0" interaction="False" />
            <pair e1="DS3.d318.s1.e2" e2="DS3.d318.s1.e0" id="DS3.d318.s1.i1" interaction="False" />
            <pair e1="DS3.d318.s1.e1" e2="DS3.d318.s1.e4" id="DS3.d318.s1.i2" interaction="False" />
            <pair e1="DS3.d318.s1.e1" e2="DS3.d318.s1.e0" id="DS3.d318.s1.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d319" origId="9935269">
        <sentence id="DS3.d319.s0" origId="9935269-4" text="The responses were not influenced by the pretreatment with L-365,260, a type B CCK receptor (CCKBR) antagonist, while they were significantly diminished by pretreatment with MK-329, a CCKAR antagonist.">
            <entity id="DS3.d319.s0.e0" origId="P01355" charOffset="79-82" type="protein" text="CCK"/>
            <entity id="DS3.d319.s0.e1" origId="P30553" charOffset="93-98" type="protein" text="CCKBR"/>
            <entity id="DS3.d319.s0.e2" origId="443375,59751" charOffset="174-180" type="compound" text="MK-329"/>
            <entity id="DS3.d319.s0.e3" origId="P30551,F1LQR7" charOffset="184-189" type="protein" text="CCKAR"/>
            <pair e1="DS3.d319.s0.e2" e2="DS3.d319.s0.e1" id="DS3.d319.s0.i0" interaction="False" />
            <pair e1="DS3.d319.s0.e2" e2="DS3.d319.s0.e3" id="DS3.d319.s0.i1" interaction="False" />
            <pair e1="DS3.d319.s0.e2" e2="DS3.d319.s0.e0" id="DS3.d319.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d319.s1" origId="9935269-5" text="After pretreatment with MK-329, 3 nmol kg(-1) (but not 300 pmol kg(-1)) of CCK still elicited a small but significant increase in the activity.">
            <entity id="DS3.d319.s1.e0" origId="443375,59751" charOffset="24-30" type="compound" text="MK-329"/>
            <entity id="DS3.d319.s1.e1" origId="P01355" charOffset="75-78" type="protein" text="CCK"/>
            <pair e1="DS3.d319.s1.e0" e2="DS3.d319.s1.e1" id="DS3.d319.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d319.s2" origId="9935269-6" text="In the OLETF rats, both 300 pmol kg(-1) and 3 nmol kg(-1) of CCK produced small increases in the vagal afferent activity, and the responses were not influenced by pretreatment with either L-365,260 or MK-329.">
            <entity id="DS3.d319.s2.e0" origId="P01355" charOffset="61-64" type="protein" text="CCK"/>
            <entity id="DS3.d319.s2.e1" origId="443375,59751" charOffset="201-207" type="compound" text="MK-329"/>
            <pair e1="DS3.d319.s2.e1" e2="DS3.d319.s2.e0" id="DS3.d319.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d320" origId="9935306">
        <sentence id="DS3.d320.s0" origId="9935306-3" text="After parvalbumin, a three EF-hand fish allergen, calcium-binding allergens were discovered in pollens of trees.">
            <entity id="DS3.d320.s0.e0" origId="P20472,A0A024R1K9" charOffset="6-17" type="protein" text="parvalbumin"/>
            <entity id="DS3.d320.s0.e1" origId="22044544,5460341" charOffset="50-57" type="compound" text="calcium"/>
            <pair e1="DS3.d320.s0.e1" e2="DS3.d320.s0.e0" id="DS3.d320.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d321" origId="994465">
        <sentence id="DS3.d321.s0" origId="994465-6" text="Cyclic nucleotides (AMP or GMP) or insulin do not regulate the expression of Tissue factor in these cells.">
            <entity id="DS3.d321.s0.e0" origId="6804" charOffset="27-30" type="compound" text="GMP"/>
            <entity id="DS3.d321.s0.e1" origId="P01308,I3WAC9" charOffset="35-42" type="protein" text="insulin"/>
            <entity id="DS3.d321.s0.e2" origId="P13726" charOffset="77-90" type="protein" text="Tissue factor"/>
            <pair e1="DS3.d321.s0.e0" e2="DS3.d321.s0.e1" id="DS3.d321.s0.i0" interaction="False" />
            <pair e1="DS3.d321.s0.e0" e2="DS3.d321.s0.e2" id="DS3.d321.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d322" origId="9945502">
        <sentence id="DS3.d322.s0" origId="9945502-0" text="Trapping of gas mixtures by amorphous water ice.">
            <entity id="DS3.d322.s0.e0" origId="P01350,A0A0E3VY36" charOffset="12-15" type="protein" text="gas"/>
            <entity id="DS3.d322.s0.e1" origId="962" charOffset="38-43" type="compound" text="water"/>
            <pair e1="DS3.d322.s0.e1" e2="DS3.d322.s0.e0" id="DS3.d322.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d322.s1" origId="9945502-1" text="Our studies on gas trapping in amorphous water ice at 24-100 K were extended, by using mixtures of CH4, CO, N2, and Ar, rather than single gases.">
            <entity id="DS3.d322.s1.e0" origId="P01350,A0A0E3VY36" charOffset="15-18" type="protein" text="gas"/>
            <entity id="DS3.d322.s1.e1" origId="962" charOffset="41-46" type="compound" text="water"/>
            <pair e1="DS3.d322.s1.e1" e2="DS3.d322.s1.e0" id="DS3.d322.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d322.s2" origId="9945502-2" text="In 1:1 gas:(water vapor) mixtures, the competition among these gases on the available sites in the ice showed that the trapping capacity for the various gases is determined not only by the structure and dynamics of the ice, but is also influenced by the gas itself.">
            <entity id="DS3.d322.s2.e0" origId="P01350,A0A0E3VY36" charOffset="7-10" type="protein" text="gas"/>
            <entity id="DS3.d322.s2.e1" origId="962" charOffset="12-17" type="compound" text="water"/>
            <entity id="DS3.d322.s2.e2" origId="P01350,A0A0E3VY36" charOffset="63-66" type="protein" text="gas"/>
            <pair e1="DS3.d322.s2.e1" e2="DS3.d322.s2.e0" id="DS3.d322.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d322.s3" origId="9945502-4" text="This order is influenced by the gas-water interaction energy, the size of the trapped gas atom or molecule, the type of clathrate-hydrate formed (I or II) and, possibly, other factors.">
            <entity id="DS3.d322.s3.e0" origId="P01350,A0A0E3VY36" charOffset="32-35" type="protein" text="gas"/>
            <entity id="DS3.d322.s3.e1" origId="962" charOffset="36-41" type="compound" text="water"/>
            <entity id="DS3.d322.s3.e2" origId="P01350,A0A0E3VY36" charOffset="86-89" type="protein" text="gas"/>
            <pair e1="DS3.d322.s3.e1" e2="DS3.d322.s3.e0" id="DS3.d322.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d323" origId="9947">
        <sentence id="DS3.d323.s0" origId="9947-0" text="Critical role of lipid peroxidation in carbon tetrachloride-induced loss of aminopyrine demethylase, cytochrome P-450 and glucose 6-phosphatase.">
            <entity id="DS3.d323.s0.e0" origId="5943" charOffset="39-59" type="compound" text="carbon tetrachloride"/>
            <entity id="DS3.d323.s0.e1" origId="P35575" charOffset="101-143" type="protein" text="cytochrome P-450 and glucose 6-phosphatase"/>
            <pair e1="DS3.d323.s0.e0" e2="DS3.d323.s0.e1" id="DS3.d323.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d324" origId="9949157">
        <sentence id="DS3.d324.s0" origId="9949157-1" text="The relationship between stem cell mobilization with granulocyte colony-stimulating factor (G-CSF) and the endogenous production of interleukin-8 (IL-8), macrophage inflammatory protein-1alpha (MIP-1alpha), tumor necrosis factor-alpha (TNF-alpha), and interferon-gamma (IFN-gamma) was studied in normal donors for allogeneic peripheral blood stem cell (PBSC) transplantation.">
            <entity id="DS3.d324.s0.e0" origId="16122568,16750043,4369303,448383" charOffset="94-97" type="compound" text="CSF"/>
            <entity id="DS3.d324.s0.e1" origId="P10145,A0A024RDA5" charOffset="132-145" type="protein" text="interleukin-8"/>
            <entity id="DS3.d324.s0.e2" origId="P10145,A0A024RDA5" charOffset="147-151" type="protein" text="IL-8"/>
            <entity id="DS3.d324.s0.e3" origId="P10147,A0N0R1" charOffset="154-192" type="protein" text="macrophage inflammatory protein-1alpha"/>
            <entity id="DS3.d324.s0.e4" origId="P10147,A0N0R1" charOffset="194-204" type="protein" text="MIP-1alpha"/>
            <entity id="DS3.d324.s0.e5" origId="P01375,Q5STB3" charOffset="207-234" type="protein" text="tumor necrosis factor-alpha"/>
            <entity id="DS3.d324.s0.e6" origId="P01375,Q5STB3" charOffset="236-245" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d324.s0.e7" origId="P01579" charOffset="252-268" type="protein" text="interferon-gamma"/>
            <entity id="DS3.d324.s0.e8" origId="P01579" charOffset="270-279" type="protein" text="IFN-gamma"/>
            <pair e1="DS3.d324.s0.e0" e2="DS3.d324.s0.e5" id="DS3.d324.s0.i0" interaction="False" />
            <pair e1="DS3.d324.s0.e0" e2="DS3.d324.s0.e2" id="DS3.d324.s0.i1" interaction="False" />
            <pair e1="DS3.d324.s0.e0" e2="DS3.d324.s0.e4" id="DS3.d324.s0.i2" interaction="False" />
            <pair e1="DS3.d324.s0.e0" e2="DS3.d324.s0.e8" id="DS3.d324.s0.i3" interaction="False" />
            <pair e1="DS3.d324.s0.e0" e2="DS3.d324.s0.e1" id="DS3.d324.s0.i4" interaction="False" />
            <pair e1="DS3.d324.s0.e0" e2="DS3.d324.s0.e6" id="DS3.d324.s0.i5" interaction="False" />
            <pair e1="DS3.d324.s0.e0" e2="DS3.d324.s0.e7" id="DS3.d324.s0.i6" interaction="False" />
            <pair e1="DS3.d324.s0.e0" e2="DS3.d324.s0.e3" id="DS3.d324.s0.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d324.s1" origId="9949157-5" text="Serum IL-8 levels correlated CD34(+) cell numbers (P =.0151 and P =.0005 on days 5 and 6, respectively) and colony-forming unit-granulocyte-macrophage (CFU-GM) numbers (P =.0019 and P =.0010 on days 5 and 6, respectively).">
            <entity id="DS3.d324.s1.e0" origId="P10145,A0A024RDA5" charOffset="6-10" type="protein" text="IL-8"/>
            <entity id="DS3.d324.s1.e1" origId="77620543" charOffset="152-155" type="compound" text="CFU"/>
            <pair e1="DS3.d324.s1.e1" e2="DS3.d324.s1.e0" id="DS3.d324.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d324.s2" origId="9949157-7" text="In contrast, before treatment, the average levels of MIP-1alpha, TNF-alpha, and IFN-gamma were 70.1, 4.03, and 3.84 pg/mL, respectively, and no significant changes in the levels of these cytokines were observed during G-CSF treatment.">
            <entity id="DS3.d324.s2.e0" origId="P10147,A0N0R1" charOffset="53-63" type="protein" text="MIP-1alpha"/>
            <entity id="DS3.d324.s2.e1" origId="P01375,Q5STB3" charOffset="65-74" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d324.s2.e2" origId="P01579" charOffset="80-89" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d324.s2.e3" origId="16122568,16750043,4369303,448383" charOffset="220-223" type="compound" text="CSF"/>
            <pair e1="DS3.d324.s2.e3" e2="DS3.d324.s2.e2" id="DS3.d324.s2.i0" interaction="False" />
            <pair e1="DS3.d324.s2.e3" e2="DS3.d324.s2.e1" id="DS3.d324.s2.i1" interaction="False" />
            <pair e1="DS3.d324.s2.e3" e2="DS3.d324.s2.e0" id="DS3.d324.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d324.s3" origId="9949157-8" text="These studies suggest that IL-8 production may be critical to G-CSF-induced stem cell mobilization, although the underlying mechanism could not be clarified.">
            <entity id="DS3.d324.s3.e0" origId="P10145,A0A024RDA5" charOffset="27-31" type="protein" text="IL-8"/>
            <entity id="DS3.d324.s3.e1" origId="16122568,16750043,4369303,448383" charOffset="64-67" type="compound" text="CSF"/>
            <pair e1="DS3.d324.s3.e1" e2="DS3.d324.s3.e0" id="DS3.d324.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d325" origId="9949160">
        <sentence id="DS3.d325.s0" origId="9949160-1" text="The pattern of expression of several protein kinase C (PKC) isoforms (alpha, betaI, delta, epsilon, eta, and zeta) during the course of hematopoietic development was investigated using primary human CD34(+) hematopoietic cells and stable cell lines subcloned from the growth factor-dependent 32D murine hematopoietic cell line.">
            <entity id="DS3.d325.s0.e0" origId="P28066" charOffset="109-113" type="protein" text="zeta"/>
            <entity id="DS3.d325.s0.e1" origId="60210951" charOffset="292-295" type="compound" text="32D"/>
            <pair e1="DS3.d325.s0.e1" e2="DS3.d325.s0.e0" id="DS3.d325.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d325.s1" origId="9949160-9" text="(5) All 32D cell lines expressed the mRNA for PKC-epsilon, indicating that the downmodulation of the epsilon isoform occurred at a posttranscriptional level.">
            <entity id="DS3.d325.s1.e0" origId="60210951" charOffset="8-11" type="compound" text="32D"/>
            <entity id="DS3.d325.s1.e1" origId="Q02156,L7RTI5" charOffset="46-57" type="protein" text="PKC-epsilon"/>
            <pair e1="DS3.d325.s1.e0" e2="DS3.d325.s1.e1" id="DS3.d325.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d326" origId="9949161">
        <sentence id="DS3.d326.s0" origId="9949161-10" text="These results indicated the inhibitory effect of mi-MITF on the transactivation of particular genes in CMCs.">
            <entity id="DS3.d326.s0.e0" origId="Q08874,Q32MU7,Q3U2D2,Q8C6Y4,E9QL92" charOffset="52-56" type="protein" text="MITF"/>
            <entity id="DS3.d326.s0.e1" origId="71595676" charOffset="103-107" type="compound" text="CMCs"/>
            <pair e1="DS3.d326.s0.e1" e2="DS3.d326.s0.e0" id="DS3.d326.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d326.s1" origId="9949161-1" text="The mi locus of mice encodes a transcription factor of the basic-helix-loop-helix-leucine zipper protein family (MITF).">
            <entity id="DS3.d326.s1.e0" origId="6106" charOffset="82-89" type="compound" text="leucine"/>
            <entity id="DS3.d326.s1.e1" origId="Q08874,Q32MU7,Q3U2D2,Q8C6Y4,E9QL92" charOffset="113-117" type="protein" text="MITF"/>
            <pair e1="DS3.d326.s1.e0" e2="DS3.d326.s1.e1" id="DS3.d326.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d326.s2" origId="9949161-4" text="To investigate the function of mi-MITF in cultured mast cells (CMCs), we took two approaches.">
            <entity id="DS3.d326.s2.e0" origId="Q08874,Q32MU7,Q3U2D2,Q8C6Y4,E9QL92" charOffset="34-38" type="protein" text="MITF"/>
            <entity id="DS3.d326.s2.e1" origId="71595676" charOffset="63-67" type="compound" text="CMCs"/>
            <pair e1="DS3.d326.s2.e1" e2="DS3.d326.s2.e0" id="DS3.d326.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d326.s3" origId="9949161-9" text="On the other hand, the transcription of three genes encoding c-kit receptor, tryptophan hydroxylase, and granzyme B was markedly reduced in mi/mi CMCs, but the reduction was significantly smaller in tg/tg CMCs.">
            <entity id="DS3.d326.s3.e0" origId="57175189,6305" charOffset="77-87" type="compound" text="tryptophan"/>
            <entity id="DS3.d326.s3.e1" origId="P04187,Q3TZH4" charOffset="105-115" type="protein" text="granzyme B"/>
            <entity id="DS3.d326.s3.e2" origId="71595676" charOffset="146-150" type="compound" text="CMCs"/>
            <entity id="DS3.d326.s3.e3" origId="71595676" charOffset="205-209" type="compound" text="CMCs"/>
            <pair e1="DS3.d326.s3.e0" e2="DS3.d326.s3.e1" id="DS3.d326.s3.i0" interaction="False" />
            <pair e1="DS3.d326.s3.e2" e2="DS3.d326.s3.e1" id="DS3.d326.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d327" origId="9949163">
        <sentence id="DS3.d327.s0" origId="9949163-1" text="We have recently demonstrated that CD11b-/dullCD11c+ and CD11b+hiCD11c+ dendritic cell (DC) precursor subsets represent two distinct DC differentiation pathways from murine bone marrow lineage-phenotype negative (Lin-)c-kit+ hematopoietic progenitor cells (HPCs) stimulated with granulocyte-macrophage colony-stimulating factor (GM-CSF) + stem cell factor (SCF) + tumor necrosis factor alpha (TNFalpha).">
            <entity id="DS3.d327.s0.e0" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="35-40" type="protein" text="CD11b"/>
            <entity id="DS3.d327.s0.e1" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="57-62" type="protein" text="CD11b"/>
            <entity id="DS3.d327.s0.e2" origId="521017" charOffset="257-261" type="compound" text="HPCs"/>
            <entity id="DS3.d327.s0.e3" origId="P01587,Q5SX78" charOffset="279-327" type="protein" text="granulocyte-macrophage colony-stimulating factor"/>
            <entity id="DS3.d327.s0.e4" origId="P01587,Q5SX78" charOffset="329-335" type="protein" text="GM-CSF"/>
            <entity id="DS3.d327.s0.e5" origId="P20826" charOffset="339-355" type="protein" text="stem cell factor"/>
            <entity id="DS3.d327.s0.e6" origId="P20826" charOffset="357-360" type="protein" text="SCF"/>
            <entity id="DS3.d327.s0.e7" origId="P06804,Q3U593" charOffset="364-391" type="protein" text="tumor necrosis factor alpha"/>
            <entity id="DS3.d327.s0.e8" origId="P06804,Q3U593" charOffset="393-401" type="protein" text="TNFalpha"/>
            <pair e1="DS3.d327.s0.e2" e2="DS3.d327.s0.e8" id="DS3.d327.s0.i0" interaction="False" />
            <pair e1="DS3.d327.s0.e2" e2="DS3.d327.s0.e4" id="DS3.d327.s0.i1" interaction="False" />
            <pair e1="DS3.d327.s0.e2" e2="DS3.d327.s0.e3" id="DS3.d327.s0.i2" interaction="False" />
            <pair e1="DS3.d327.s0.e2" e2="DS3.d327.s0.e6" id="DS3.d327.s0.i3" interaction="False" />
            <pair e1="DS3.d327.s0.e2" e2="DS3.d327.s0.e7" id="DS3.d327.s0.i4" interaction="False" />
            <pair e1="DS3.d327.s0.e2" e2="DS3.d327.s0.e5" id="DS3.d327.s0.i5" interaction="False" />
            <pair e1="DS3.d327.s0.e2" e2="DS3.d327.s0.e0" id="DS3.d327.s0.i6" interaction="False" />
        </sentence>
        <sentence id="DS3.d327.s1" origId="9949163-5" text="In the absence of TNFalpha, TGF-beta1 markedly suppressed the expression of CIITA and CCR7 mRNAs in GM-CSF + SCF-stimulated Lin-c-kit+ HPCs at either day 6 or day 12 and induced the differentiation solely into monocytes/macrophages as evident in morphology, active phagocytic, and endocytic activities.">
            <entity id="DS3.d327.s1.e0" origId="P06804,Q3U593" charOffset="18-26" type="protein" text="TNFalpha"/>
            <entity id="DS3.d327.s1.e1" origId="P04202,Q3UNK5" charOffset="28-37" type="protein" text="TGF-beta1"/>
            <entity id="DS3.d327.s1.e2" origId="P79621,Q3U5G4,Q3KNE0,Q8HW99,Q3UNW8,Q3UU40" charOffset="76-81" type="protein" text="CIITA"/>
            <entity id="DS3.d327.s1.e3" origId="P47774" charOffset="86-90" type="protein" text="CCR7"/>
            <entity id="DS3.d327.s1.e4" origId="P01587,Q5SX78" charOffset="100-106" type="protein" text="GM-CSF"/>
            <entity id="DS3.d327.s1.e5" origId="P20826" charOffset="109-112" type="protein" text="SCF"/>
            <entity id="DS3.d327.s1.e6" origId="521017" charOffset="135-139" type="compound" text="HPCs"/>
            <pair e1="DS3.d327.s1.e6" e2="DS3.d327.s1.e1" id="DS3.d327.s1.i0" interaction="False" />
            <pair e1="DS3.d327.s1.e6" e2="DS3.d327.s1.e0" id="DS3.d327.s1.i1" interaction="False" />
            <pair e1="DS3.d327.s1.e6" e2="DS3.d327.s1.e4" id="DS3.d327.s1.i2" interaction="False" />
            <pair e1="DS3.d327.s1.e6" e2="DS3.d327.s1.e2" id="DS3.d327.s1.i3" interaction="False" />
            <pair e1="DS3.d327.s1.e6" e2="DS3.d327.s1.e5" id="DS3.d327.s1.i4" interaction="False" />
            <pair e1="DS3.d327.s1.e6" e2="DS3.d327.s1.e3" id="DS3.d327.s1.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d327.s2" origId="9949163-8" text="Taken together, all of these findings suggest that TGF-beta1 polarizes murine HPCs to generate LC-like DCs through a monocyte/macrophage differentiation pathway.">
            <entity id="DS3.d327.s2.e0" origId="P04202,Q3UNK5" charOffset="51-60" type="protein" text="TGF-beta1"/>
            <entity id="DS3.d327.s2.e1" origId="521017" charOffset="78-82" type="compound" text="HPCs"/>
            <pair e1="DS3.d327.s2.e1" e2="DS3.d327.s2.e0" id="DS3.d327.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d328" origId="9949164">
        <sentence id="DS3.d328.s0" origId="9949164-5" text="The use of 3Fn (according to the nomenclature proposed by Bork and Koonin (Curr Opin Struct Biol 6:366, 1996) for the type III fibronectin modules) module-specific antibodies and recombinant polypeptides showed that alpha4 integrins recognized both the RGD sequence (3Fn10) and an apparently novel synergistic site located within the 3Fn8 module; even in this case, the integrins displayed a distinct binding site preference.">
            <entity id="DS3.d328.s0.e0" origId="11406590" charOffset="11-14" type="compound" text="3Fn"/>
            <entity id="DS3.d328.s0.e1" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="127-138" type="protein" text="fibronectin"/>
            <pair e1="DS3.d328.s0.e0" e2="DS3.d328.s0.e1" id="DS3.d328.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d329" origId="9949167">
        <sentence id="DS3.d329.s0" origId="9949167-0" text="Sialylation of the sialic acid binding lectin sialoadhesin regulates its ability to mediate cell adhesion.">
            <entity id="DS3.d329.s0.e0" origId="444885,656387,906,445063" charOffset="19-30" type="compound" text="sialic acid"/>
            <entity id="DS3.d329.s0.e1" origId="Q9BZZ2" charOffset="46-58" type="protein" text="sialoadhesin"/>
            <pair e1="DS3.d329.s0.e0" e2="DS3.d329.s0.e1" id="DS3.d329.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d329.s1" origId="9949167-1" text="The macrophage-specific cell surface receptor sialoadhesin, which is a member of the newly recognized family of sialic acid binding lectins called siglecs, binds glycoprotein and glycolipid ligands containing a2-3-linked sialic acid on the surface of several leukocyte subsets.">
            <entity id="DS3.d329.s1.e0" origId="Q9BZZ2" charOffset="46-58" type="protein" text="sialoadhesin"/>
            <entity id="DS3.d329.s1.e1" origId="444885,656387,906,445063" charOffset="112-123" type="compound" text="sialic acid"/>
            <entity id="DS3.d329.s1.e2" origId="444885,656387,906,445063" charOffset="221-232" type="compound" text="sialic acid"/>
            <pair e1="DS3.d329.s1.e1" e2="DS3.d329.s1.e0" id="DS3.d329.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d329.s2" origId="9949167-2" text="Recently, the sialic acid binding activity of the siglec CD22 has been demonstrated to be regulated by sialylation of the CD22 receptor molecule.">
            <entity id="DS3.d329.s2.e0" origId="444885,445063,656387,906" charOffset="14-25" type="compound" text="sialic acid"/>
            <entity id="DS3.d329.s2.e1" origId="P20273,Q0EAF5" charOffset="57-61" type="protein" text="CD22"/>
            <entity id="DS3.d329.s2.e2" origId="P20273,Q0EAF5" charOffset="122-126" type="protein" text="CD22"/>
            <pair e1="DS3.d329.s2.e0" e2="DS3.d329.s2.e1" id="DS3.d329.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d330" origId="9949172">
        <sentence id="DS3.d330.s0" origId="9949172-0" text="Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.">
            <entity id="DS3.d330.s0.e0" origId="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5" charOffset="0-5" type="protein" text="Muc-1"/>
            <entity id="DS3.d330.s0.e1" origId="5743" charOffset="76-89" type="compound" text="dexamethasone"/>
            <pair e1="DS3.d330.s0.e1" e2="DS3.d330.s0.e0" id="DS3.d330.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d330.s1" origId="9949172-10" text="Dex induced Muc-1 upregulation could be blocked with a 10-fold excess of the glucocorticoid receptor antagonist RU486, confirming that Dex was acting via the glucocorticoid receptor.">
            <entity id="DS3.d330.s1.e0" origId="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5" charOffset="12-17" type="protein" text="Muc-1"/>
            <entity id="DS3.d330.s1.e1" origId="55245" charOffset="112-117" type="compound" text="RU486"/>
            <pair e1="DS3.d330.s1.e1" e2="DS3.d330.s1.e0" id="DS3.d330.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d330.s2" origId="9949172-11" text="No changes in Muc-1 expression were observed on MM cells treated with estrogen and progesterone receptor agonists and antagonists or with RU486.">
            <entity id="DS3.d330.s2.e0" origId="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5" charOffset="14-19" type="protein" text="Muc-1"/>
            <entity id="DS3.d330.s2.e1" origId="P06401" charOffset="83-104" type="protein" text="progesterone receptor"/>
            <entity id="DS3.d330.s2.e2" origId="55245" charOffset="138-143" type="compound" text="RU486"/>
            <pair e1="DS3.d330.s2.e2" e2="DS3.d330.s2.e0" id="DS3.d330.s2.i0" interaction="False" />
            <pair e1="DS3.d330.s2.e2" e2="DS3.d330.s2.e1" id="DS3.d330.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d330.s3" origId="9949172-1" text="Monoclonal antibodies (MoAbs) that selectively identify Muc-1 core protein (MoAbs DF3-P, VU-4H5) determinants were used to identify the Muc-1 glycoform present on 7 multiple myeloma (MM) cell lines, 5 MM patient plasma cells, 12 MM patient B cells, as well as 32 non-MM cell lines and normal hematopoietic cells.">
            <entity id="DS3.d330.s3.e0" origId="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5" charOffset="56-61" type="protein" text="Muc-1"/>
            <entity id="DS3.d330.s3.e1" origId="4405380" charOffset="82-85" type="compound" text="DF3"/>
            <entity id="DS3.d330.s3.e2" origId="91664024" charOffset="92-95" type="compound" text="4H5"/>
            <entity id="DS3.d330.s3.e3" origId="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5" charOffset="136-141" type="protein" text="Muc-1"/>
            <pair e1="DS3.d330.s3.e2" e2="DS3.d330.s3.e0" id="DS3.d330.s3.i0" interaction="False" />
            <pair e1="DS3.d330.s3.e1" e2="DS3.d330.s3.e0" id="DS3.d330.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d330.s4" origId="9949172-6" text="We next studied the effects of estrogen, progesterone, and glucocorticoid receptor agonists and antagonists on Muc-1 expression, because consensus sequences for the response elements of these steroids are present on the Muc-1 gene promoter.">
            <entity id="DS3.d330.s4.e0" origId="5994" charOffset="41-53" type="compound" text="progesterone"/>
            <entity id="DS3.d330.s4.e1" origId="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5" charOffset="111-116" type="protein" text="Muc-1"/>
            <entity id="DS3.d330.s4.e2" origId="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5" charOffset="220-225" type="protein" text="Muc-1"/>
            <pair e1="DS3.d330.s4.e0" e2="DS3.d330.s4.e1" id="DS3.d330.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d330.s5" origId="9949172-7" text="These studies showed that dexamethasone (Dex) induced Muc-1 expression on MM cell lines, as determined by both flow cytometry and Western blot analyses.">
            <entity id="DS3.d330.s5.e0" origId="5743" charOffset="26-39" type="compound" text="dexamethasone"/>
            <entity id="DS3.d330.s5.e1" origId="P15941,A6ZIE4,Q7Z551,A5YRU7,A6ZID7,A6ZID6,A0A087X0L2,A5YRV0,Q7Z538,A0A0A0MRB3,A0A087X2A4,A5YRV2,A0A0C4DGW3,B6ECB3,A6ZIE6,A5YRU5" charOffset="54-59" type="protein" text="Muc-1"/>
            <pair e1="DS3.d330.s5.e0" e2="DS3.d330.s5.e1" id="DS3.d330.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d331" origId="9949175">
        <sentence id="DS3.d331.s0" origId="9949175-1" text="The c-KIT receptor tyrosine kinase (KIT) is constitutively activated by naturally occurring mutations in either the juxtamembrane domain or the kinase domain.">
            <entity id="DS3.d331.s0.e0" origId="P05532,F7DD14" charOffset="4-9" type="protein" text="c-KIT"/>
            <entity id="DS3.d331.s0.e1" origId="90983769" charOffset="19-27" type="compound" text="tyrosine"/>
            <entity id="DS3.d331.s0.e2" origId="P05532,F7DD14" charOffset="6-9" type="protein" text="KIT"/>
            <pair e1="DS3.d331.s0.e1" e2="DS3.d331.s0.e0" id="DS3.d331.s0.i0" interaction="False" />
            <pair e1="DS3.d331.s0.e1" e2="DS3.d331.s0.e2" id="DS3.d331.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d331.s1" origId="9949175-2" text="Although the juxtamembrane domain mutations led to ligand-independent KIT dimerization, the kinase domain mutations (Asp814 --&amp;gt; Val or Tyr) did not.">
            <entity id="DS3.d331.s1.e0" origId="P05532,F7DD14" charOffset="70-73" type="protein" text="KIT"/>
            <entity id="DS3.d331.s1.e1" origId="6057" charOffset="138-141" type="compound" text="Tyr"/>
            <pair e1="DS3.d331.s1.e1" e2="DS3.d331.s1.e0" id="DS3.d331.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d331.s2" origId="9949175-4" text="When c-kitDel-Wild and c-kitDel-Tyr814 genes were introduced into a murine interleukin-3 (IL-3)-dependent cell line Ba/F3, KITDel-Tyr814 was constitutively phosphorylated on tyrosine and activated, whereas KITDel-Wild was not.">
            <entity id="DS3.d331.s2.e0" origId="P01586,Q5SX77" charOffset="90-94" type="protein" text="IL-3"/>
            <entity id="DS3.d331.s2.e1" origId="90983769" charOffset="174-182" type="compound" text="tyrosine"/>
            <pair e1="DS3.d331.s2.e1" e2="DS3.d331.s2.e0" id="DS3.d331.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d331.s3" origId="9949175-5" text="In addition, Ba/F3 cells expressing KITDel-Tyr814 (Ba/F3(Del-Tyr814)) grew in suspension culture without the addition of exogenous growth factor, whereas Ba/F3 cells expressing KITDel-Wild (Ba/F3(Del-Wild)) required IL-3 for growth.">
            <entity id="DS3.d331.s3.e0" origId="445801" charOffset="39-42" type="compound" text="Del"/>
            <entity id="DS3.d331.s3.e1" origId="445801" charOffset="57-60" type="compound" text="Del"/>
            <entity id="DS3.d331.s3.e2" origId="P01586,Q5SX77" charOffset="216-220" type="protein" text="IL-3"/>
            <pair e1="DS3.d331.s3.e0" e2="DS3.d331.s3.e2" id="DS3.d331.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d331.s4" origId="9949175-6" text="The factor-independent growth of Ba/F3(Del-Tyr814) cells was virtually abrogated by coexpression of KITW42 that is a dominant-negative form of KIT, but not by that of KITWild, suggesting that KITDel-Tyr814 may not function as a monomer but may require receptor dimerization for inducing factor-independent growth.">
            <entity id="DS3.d331.s4.e0" origId="445801" charOffset="39-42" type="compound" text="Del"/>
            <entity id="DS3.d331.s4.e1" origId="P05532,F7DD14" charOffset="100-103" type="protein" text="KIT"/>
            <pair e1="DS3.d331.s4.e0" e2="DS3.d331.s4.e1" id="DS3.d331.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d332" origId="9949177">
        <sentence id="DS3.d332.s0" origId="9949177-3" text="Here, we report that Bcr-Abl through a Ras-dependent pathway signals the serine/threonine protein kinase GCKR (Germinal Center Kinase Related) leading to SAPK activation.">
            <entity id="DS3.d332.s0.e0" origId="P00519,Q59FK4,A0A024R8E2" charOffset="21-28" type="protein" text="Bcr-Abl"/>
            <entity id="DS3.d332.s0.e1" origId="194239,6288" charOffset="80-89" type="compound" text="threonine"/>
            <entity id="DS3.d332.s0.e2" origId="Q9Y4K4,B3KWC4" charOffset="111-141" type="protein" text="Germinal Center Kinase Related"/>
            <pair e1="DS3.d332.s0.e1" e2="DS3.d332.s0.e2" id="DS3.d332.s0.i0" interaction="False" />
            <pair e1="DS3.d332.s0.e1" e2="DS3.d332.s0.e0" id="DS3.d332.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d333" origId="9949178">
        <sentence id="DS3.d333.s0" origId="9949178-0" text="Both Stat3-activation and Stat3-independent BCL2 downregulation are important for interleukin-6-induced apoptosis of 1A9-M cells.">
            <entity id="DS3.d333.s0.e0" origId="P40763" charOffset="5-10" type="protein" text="Stat3"/>
            <entity id="DS3.d333.s0.e1" origId="P40763" charOffset="26-31" type="protein" text="Stat3"/>
            <entity id="DS3.d333.s0.e2" origId="P10415,A0A024R2B3,A0A024R2C4" charOffset="44-48" type="protein" text="BCL2"/>
            <entity id="DS3.d333.s0.e3" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="82-95" type="protein" text="interleukin-6"/>
            <entity id="DS3.d333.s0.e4" origId="71297182" charOffset="117-120" type="compound" text="1A9"/>
            <pair e1="DS3.d333.s0.e4" e2="DS3.d333.s0.e0" id="DS3.d333.s0.i0" interaction="False" />
            <pair e1="DS3.d333.s0.e4" e2="DS3.d333.s0.e3" id="DS3.d333.s0.i1" interaction="False" />
            <pair e1="DS3.d333.s0.e4" e2="DS3.d333.s0.e2" id="DS3.d333.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d333.s1" origId="9949178-3" text="We used expression cloning to identify interleukin-6 (IL-6) as one factor that suppressed growth of a pre-B-cell variant line, 1A9-M.">
            <entity id="DS3.d333.s1.e0" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="39-52" type="protein" text="interleukin-6"/>
            <entity id="DS3.d333.s1.e1" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="54-58" type="protein" text="IL-6"/>
            <entity id="DS3.d333.s1.e2" origId="71297182" charOffset="127-130" type="compound" text="1A9"/>
            <pair e1="DS3.d333.s1.e2" e2="DS3.d333.s1.e1" id="DS3.d333.s1.i0" interaction="False" />
            <pair e1="DS3.d333.s1.e2" e2="DS3.d333.s1.e0" id="DS3.d333.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d333.s2" origId="9949178-4" text="Moreover, IL-6 induced macrophage-differentiation and apoptosis of 1A9-M cells.">
            <entity id="DS3.d333.s2.e0" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="10-14" type="protein" text="IL-6"/>
            <entity id="DS3.d333.s2.e1" origId="71297182" charOffset="67-70" type="compound" text="1A9"/>
            <pair e1="DS3.d333.s2.e1" e2="DS3.d333.s2.e0" id="DS3.d333.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d333.s3" origId="9949178-5" text="During this process, IL-6 downregulated expression of BCL2 in 1A9-M cells and stimulated BCL-XL expression, but had no effect on p53, Bax, or Bak gene expression.">
            <entity id="DS3.d333.s3.e0" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="21-25" type="protein" text="IL-6"/>
            <entity id="DS3.d333.s3.e1" origId="P10415,A0A024R2B3,A0A024R2C4" charOffset="54-58" type="protein" text="BCL2"/>
            <entity id="DS3.d333.s3.e2" origId="71297182" charOffset="62-65" type="compound" text="1A9"/>
            <entity id="DS3.d333.s3.e3" origId="Q07817,Q5TE63" charOffset="89-95" type="protein" text="BCL-XL"/>
            <entity id="DS3.d333.s3.e4" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="129-132" type="protein" text="p53"/>
            <entity id="DS3.d333.s3.e5" origId="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0" charOffset="134-137" type="protein" text="Bax"/>
            <entity id="DS3.d333.s3.e6" origId="Q16611" charOffset="142-145" type="protein" text="Bak"/>
            <pair e1="DS3.d333.s3.e2" e2="DS3.d333.s3.e0" id="DS3.d333.s3.i0" interaction="False" />
            <pair e1="DS3.d333.s3.e2" e2="DS3.d333.s3.e5" id="DS3.d333.s3.i1" interaction="False" />
            <pair e1="DS3.d333.s3.e2" e2="DS3.d333.s3.e3" id="DS3.d333.s3.i2" interaction="False" />
            <pair e1="DS3.d333.s3.e2" e2="DS3.d333.s3.e1" id="DS3.d333.s3.i3" interaction="False" />
            <pair e1="DS3.d333.s3.e2" e2="DS3.d333.s3.e6" id="DS3.d333.s3.i4" interaction="False" />
            <pair e1="DS3.d333.s3.e2" e2="DS3.d333.s3.e4" id="DS3.d333.s3.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d333.s4" origId="9949178-6" text="Mechanisms for transduction of IL-6-induced signals were then evaluated in IL-6-stimulated 1A9-M cells.">
            <entity id="DS3.d333.s4.e0" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="31-35" type="protein" text="IL-6"/>
            <entity id="DS3.d333.s4.e1" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="75-79" type="protein" text="IL-6"/>
            <entity id="DS3.d333.s4.e2" origId="71297182" charOffset="91-94" type="compound" text="1A9"/>
            <pair e1="DS3.d333.s4.e2" e2="DS3.d333.s4.e0" id="DS3.d333.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d333.s5" origId="9949178-8" text="The importance of BCL2 and Stat3 on IL-6-induced macrophage-differentiation and apoptosis was studied with 1A9-M cells expressing human BCL2 or a dominant-negative form of Stat3, respectively.">
            <entity id="DS3.d333.s5.e0" origId="P10415,A0A024R2B3,A0A024R2C4" charOffset="18-22" type="protein" text="BCL2"/>
            <entity id="DS3.d333.s5.e1" origId="P40763" charOffset="27-32" type="protein" text="Stat3"/>
            <entity id="DS3.d333.s5.e2" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="36-40" type="protein" text="IL-6"/>
            <entity id="DS3.d333.s5.e3" origId="71297182" charOffset="107-110" type="compound" text="1A9"/>
            <entity id="DS3.d333.s5.e4" origId="P10415,A0A024R2B3,A0A024R2C4" charOffset="136-140" type="protein" text="BCL2"/>
            <entity id="DS3.d333.s5.e5" origId="P40763" charOffset="172-177" type="protein" text="Stat3"/>
            <pair e1="DS3.d333.s5.e3" e2="DS3.d333.s5.e2" id="DS3.d333.s5.i0" interaction="False" />
            <pair e1="DS3.d333.s5.e3" e2="DS3.d333.s5.e1" id="DS3.d333.s5.i1" interaction="False" />
            <pair e1="DS3.d333.s5.e3" e2="DS3.d333.s5.e0" id="DS3.d333.s5.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d334" origId="9949179">
        <sentence id="DS3.d334.s0" origId="9949179-5" text="TRKC is a receptor tyrosine kinase that is activated by neurotrophin-3 (NT-3).">
            <entity id="DS3.d334.s0.e0" origId="Q16288,X5D2R1,B7Z7U4,Q96CY4,X5D7M5,X5DNW6" charOffset="0-4" type="protein" text="TRKC"/>
            <entity id="DS3.d334.s0.e1" origId="6057,90983769" charOffset="19-27" type="compound" text="tyrosine"/>
            <entity id="DS3.d334.s0.e2" origId="P20783" charOffset="56-70" type="protein" text="neurotrophin-3"/>
            <pair e1="DS3.d334.s0.e1" e2="DS3.d334.s0.e2" id="DS3.d334.s0.i0" interaction="False" />
            <pair e1="DS3.d334.s0.e1" e2="DS3.d334.s0.e0" id="DS3.d334.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d334.s1" origId="9949179-7" text="ETV6-TRKC chimeric transcript encoded the pointed (PNT) domain of the ETV6 gene that fused to the protein-tyrosine kinase (PTK) domain of the TRKC gene.">
            <entity id="DS3.d334.s1.e0" origId="P41212" charOffset="0-4" type="protein" text="ETV6"/>
            <entity id="DS3.d334.s1.e1" origId="Q16288,X5D2R1,B7Z7U4,Q96CY4,X5D7M5,X5DNW6" charOffset="5-9" type="protein" text="TRKC"/>
            <entity id="DS3.d334.s1.e2" origId="P41212" charOffset="70-74" type="protein" text="ETV6"/>
            <entity id="DS3.d334.s1.e3" origId="6057,90983769" charOffset="106-114" type="compound" text="tyrosine"/>
            <entity id="DS3.d334.s1.e4" origId="Q16288,X5D2R1,B7Z7U4,Q96CY4,X5D7M5,X5DNW6" charOffset="142-146" type="protein" text="TRKC"/>
            <pair e1="DS3.d334.s1.e3" e2="DS3.d334.s1.e1" id="DS3.d334.s1.i0" interaction="False" />
            <pair e1="DS3.d334.s1.e3" e2="DS3.d334.s1.e0" id="DS3.d334.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d335" origId="9949182">
        <sentence id="DS3.d335.s0" origId="9949182-0" text="The t(6;8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1.">
            <entity id="DS3.d335.s0.e0" origId="53346511" charOffset="11-14" type="compound" text="q27"/>
            <entity id="DS3.d335.s0.e1" origId="O95684,B4DH64,A0A087WV25" charOffset="97-100" type="protein" text="FOP"/>
            <entity id="DS3.d335.s0.e2" origId="P11362" charOffset="105-140" type="protein" text="fibroblast growth factor receptor 1"/>
            <pair e1="DS3.d335.s0.e0" e2="DS3.d335.s0.e2" id="DS3.d335.s0.i0" interaction="False" />
            <pair e1="DS3.d335.s0.e0" e2="DS3.d335.s0.e1" id="DS3.d335.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d335.s1" origId="9949182-3" text="The t(8;13) translocation has recently been shown to result in a fusion between the FGFR1 gene that encodes a tyrosine kinase receptor for fibroblast growth factors and a novel gene, FIM (also called RAMP or ZNF198), belonging to a novel family of zinc finger genes.">
            <entity id="DS3.d335.s1.e0" origId="P11362" charOffset="84-89" type="protein" text="FGFR1"/>
            <entity id="DS3.d335.s1.e1" origId="6057,90983769" charOffset="110-118" type="compound" text="tyrosine"/>
            <entity id="DS3.d335.s1.e2" origId="Q9UBW7,A0A024RDS3,A8K126" charOffset="183-186" type="protein" text="FIM"/>
            <entity id="DS3.d335.s1.e3" origId="Q9UBW7,A0A024RDS3,A8K126" charOffset="208-214" type="protein" text="ZNF198"/>
            <entity id="DS3.d335.s1.e4" origId="23994" charOffset="248-252" type="compound" text="zinc"/>
            <pair e1="DS3.d335.s1.e4" e2="DS3.d335.s1.e2" id="DS3.d335.s1.i0" interaction="False" />
            <pair e1="DS3.d335.s1.e4" e2="DS3.d335.s1.e3" id="DS3.d335.s1.i1" interaction="False" />
            <pair e1="DS3.d335.s1.e4" e2="DS3.d335.s1.e0" id="DS3.d335.s1.i2" interaction="False" />
            <pair e1="DS3.d335.s1.e1" e2="DS3.d335.s1.e2" id="DS3.d335.s1.i3" interaction="False" />
            <pair e1="DS3.d335.s1.e1" e2="DS3.d335.s1.e3" id="DS3.d335.s1.i4" interaction="False" />
            <pair e1="DS3.d335.s1.e1" e2="DS3.d335.s1.e0" id="DS3.d335.s1.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d335.s2" origId="9949182-4" text="In the present study, we have cloned the t(6;8)(q27;p11) translocation in two patients and found a fusion between FGFR1 and a novel gene, FOP (FGFR1 Oncogene Partner), located on chromosome band 6q27.">
            <entity id="DS3.d335.s2.e0" origId="53346511" charOffset="48-51" type="compound" text="q27"/>
            <entity id="DS3.d335.s2.e1" origId="P11362" charOffset="114-119" type="protein" text="FGFR1"/>
            <entity id="DS3.d335.s2.e2" origId="O95684,B4DH64,A0A087WV25" charOffset="138-141" type="protein" text="FOP"/>
            <entity id="DS3.d335.s2.e3" origId="O95684,B4DH64,A0A087WV25" charOffset="143-165" type="protein" text="FGFR1 Oncogene Partner"/>
            <pair e1="DS3.d335.s2.e0" e2="DS3.d335.s2.e3" id="DS3.d335.s2.i0" interaction="False" />
            <pair e1="DS3.d335.s2.e0" e2="DS3.d335.s2.e2" id="DS3.d335.s2.i1" interaction="False" />
            <pair e1="DS3.d335.s2.e0" e2="DS3.d335.s2.e1" id="DS3.d335.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d335.s3" origId="9949182-8" text="The predicted chimeric FOP-FGFR1 protein contains the FOP N-terminus leucine-rich region fused to the catalytic domain of FGFR1.">
            <entity id="DS3.d335.s3.e0" origId="O95684,B4DH64,A0A087WV25" charOffset="23-26" type="protein" text="FOP"/>
            <entity id="DS3.d335.s3.e1" origId="P11362" charOffset="27-32" type="protein" text="FGFR1"/>
            <entity id="DS3.d335.s3.e2" origId="O95684,B4DH64,A0A087WV25" charOffset="54-57" type="protein" text="FOP"/>
            <entity id="DS3.d335.s3.e3" origId="6106" charOffset="69-76" type="compound" text="leucine"/>
            <entity id="DS3.d335.s3.e4" origId="P11362" charOffset="122-127" type="protein" text="FGFR1"/>
            <pair e1="DS3.d335.s3.e3" e2="DS3.d335.s3.e0" id="DS3.d335.s3.i0" interaction="False" />
            <pair e1="DS3.d335.s3.e3" e2="DS3.d335.s3.e1" id="DS3.d335.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d336" origId="9949183">
        <sentence id="DS3.d336.s0" origId="9949183-4" text="We present here evidence that p21(cip-1/waf-1) deficiency relaxes the G1 phase microtubule checkpoint that is activated by microtubule damage induced with nocodazole.">
            <entity id="DS3.d336.s0.e0" origId="P38936,A0A024RCX5" charOffset="30-33" type="protein" text="p21"/>
            <entity id="DS3.d336.s0.e1" origId="P38936,A0A024RCX5" charOffset="34-39" type="protein" text="cip-1"/>
            <entity id="DS3.d336.s0.e2" origId="P38936,A0A024RCX5" charOffset="40-45" type="protein" text="waf-1"/>
            <entity id="DS3.d336.s0.e3" origId="4122" charOffset="155-165" type="compound" text="nocodazole"/>
            <pair e1="DS3.d336.s0.e3" e2="DS3.d336.s0.e1" id="DS3.d336.s0.i0" interaction="False" />
            <pair e1="DS3.d336.s0.e3" e2="DS3.d336.s0.e0" id="DS3.d336.s0.i1" interaction="False" />
            <pair e1="DS3.d336.s0.e3" e2="DS3.d336.s0.e2" id="DS3.d336.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d337" origId="9949184">
        <sentence id="DS3.d337.s0" origId="9949184-0" text="Activation of nitric oxide release and oxidative metabolism by leukotrienes B4, C4, and D4 in human polymorphonuclear leukocytes.">
            <entity id="DS3.d337.s0.e0" origId="145068" charOffset="14-26" type="compound" text="nitric oxide"/>
            <entity id="DS3.d337.s0.e1" origId="P0C0L4" charOffset="80-90" type="protein" text="C4, and D4"/>
            <pair e1="DS3.d337.s0.e0" e2="DS3.d337.s0.e1" id="DS3.d337.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d338" origId="9949185">
        <sentence id="DS3.d338.s0" origId="9949185-5" text="It was inhibitable by the tetrapeptide arg-gly-gln-ser (RGDS), therefore implicating the alphavbeta3/CD36/thrombospondin pathway.">
            <entity id="DS3.d338.s0.e0" origId="123913" charOffset="43-50" type="compound" text="gly-gln"/>
            <entity id="DS3.d338.s0.e1" origId="5951" charOffset="51-54" type="compound" text="ser"/>
            <entity id="DS3.d338.s0.e2" origId="Q03386,F1LN84" charOffset="56-60" type="protein" text="RGDS"/>
            <entity id="DS3.d338.s0.e3" origId="Q6IMX5" charOffset="101-105" type="protein" text="CD36"/>
            <pair e1="DS3.d338.s0.e0" e2="DS3.d338.s0.e2" id="DS3.d338.s0.i0" interaction="False" />
            <pair e1="DS3.d338.s0.e0" e2="DS3.d338.s0.e3" id="DS3.d338.s0.i1" interaction="False" />
            <pair e1="DS3.d338.s0.e1" e2="DS3.d338.s0.e2" id="DS3.d338.s0.i2" interaction="False" />
            <pair e1="DS3.d338.s0.e1" e2="DS3.d338.s0.e3" id="DS3.d338.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d339" origId="9949186">
        <sentence id="DS3.d339.s0" origId="9949186-3" text="Highly purified PMN were found to contain an intracellular stock of preformed OSM that was rapidly mobilized by degranulating agents such as phorbol myristate acetate and granulocyte-macrophage colony-stimulating factor (GM-CSF).">
            <entity id="DS3.d339.s0.e0" origId="P13725,B5MCX1" charOffset="78-81" type="protein" text="OSM"/>
            <entity id="DS3.d339.s0.e1" origId="22833501,27924,4792" charOffset="141-166" type="compound" text="phorbol myristate acetate"/>
            <entity id="DS3.d339.s0.e2" origId="P04141" charOffset="171-219" type="protein" text="granulocyte-macrophage colony-stimulating factor"/>
            <entity id="DS3.d339.s0.e3" origId="P04141" charOffset="221-227" type="protein" text="GM-CSF"/>
            <pair e1="DS3.d339.s0.e1" e2="DS3.d339.s0.e2" id="DS3.d339.s0.i0" interaction="False" />
            <pair e1="DS3.d339.s0.e1" e2="DS3.d339.s0.e0" id="DS3.d339.s0.i1" interaction="False" />
            <pair e1="DS3.d339.s0.e1" e2="DS3.d339.s0.e3" id="DS3.d339.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d339.s1" origId="9949186-5" text="The most potent effect was observed with the combination of lipopolysaccharide and GM-CSF, which had a concentration- and time-dependent effect at both the protein and mRNA levels.">
            <entity id="DS3.d339.s1.e0" origId="11970143" charOffset="60-78" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d339.s1.e1" origId="P04141" charOffset="83-89" type="protein" text="GM-CSF"/>
            <pair e1="DS3.d339.s1.e0" e2="DS3.d339.s1.e1" id="DS3.d339.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d339.s2" origId="9949186-7" text="Cycloheximide inhibited OSM protein synthesis but did not affect the release of preformed stores.">
            <entity id="DS3.d339.s2.e0" origId="6197" charOffset="0-13" type="compound" text="Cycloheximide"/>
            <entity id="DS3.d339.s2.e1" origId="P13725,B5MCX1" charOffset="24-27" type="protein" text="OSM"/>
            <pair e1="DS3.d339.s2.e0" e2="DS3.d339.s2.e1" id="DS3.d339.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d339.s3" origId="9949186-8" text="In addition, OSM production was downregulated by dexamethasone, whereas IL-10 had no effect.">
            <entity id="DS3.d339.s3.e0" origId="P13725,B5MCX1" charOffset="13-16" type="protein" text="OSM"/>
            <entity id="DS3.d339.s3.e1" origId="5743" charOffset="49-62" type="compound" text="dexamethasone"/>
            <entity id="DS3.d339.s3.e2" origId="P22301,Q6FGW4" charOffset="72-77" type="protein" text="IL-10"/>
            <pair e1="DS3.d339.s3.e1" e2="DS3.d339.s3.e0" id="DS3.d339.s3.i0" interaction="False" />
            <pair e1="DS3.d339.s3.e1" e2="DS3.d339.s3.e2" id="DS3.d339.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d340" origId="9949187">
        <sentence id="DS3.d340.s0" origId="9949187-11" text="Thus, anionic polysaccharides can inhibit SS RBC-endothelium interaction in the presence or absence of soluble TSP.">
            <entity id="DS3.d340.s0.e0" origId="871" charOffset="14-29" type="compound" text="polysaccharides"/>
            <entity id="DS3.d340.s0.e1" origId="P07996" charOffset="111-114" type="protein" text="TSP"/>
            <pair e1="DS3.d340.s0.e0" e2="DS3.d340.s0.e1" id="DS3.d340.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d340.s1" origId="9949187-2" text="Thrombospondin (TSP), unusually large molecular weight forms of von Willebrand factor, and laminin are known to enhance adhesion of SS RBC.">
            <entity id="DS3.d340.s1.e0" origId="P07996" charOffset="0-14" type="protein" text="Thrombospondin"/>
            <entity id="DS3.d340.s1.e1" origId="P07996" charOffset="16-19" type="protein" text="TSP"/>
            <entity id="DS3.d340.s1.e2" origId="P04275" charOffset="64-85" type="protein" text="von Willebrand factor"/>
            <entity id="DS3.d340.s1.e3" origId="44342165" charOffset="91-98" type="compound" text="laminin"/>
            <pair e1="DS3.d340.s1.e3" e2="DS3.d340.s1.e2" id="DS3.d340.s1.i0" interaction="False" />
            <pair e1="DS3.d340.s1.e3" e2="DS3.d340.s1.e0" id="DS3.d340.s1.i1" interaction="False" />
            <pair e1="DS3.d340.s1.e3" e2="DS3.d340.s1.e1" id="DS3.d340.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d340.s2" origId="9949187-5" text="In this study, we have investigated the effect of anionic polysaccharides, in the presence or absence of TSP, on SS RBC adhesion to the endothelium, using cultured human umbilical vein endothelial cells (HUVEC) (for the adhesion assay) and the ex vivo mesocecum of the rat (for hemodynamic evaluation).">
            <entity id="DS3.d340.s2.e0" origId="871" charOffset="58-73" type="compound" text="polysaccharides"/>
            <entity id="DS3.d340.s2.e1" origId="P07996" charOffset="105-108" type="protein" text="TSP"/>
            <pair e1="DS3.d340.s2.e0" e2="DS3.d340.s2.e1" id="DS3.d340.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d340.s3" origId="9949187-6" text="The baseline adhesion (ie, without added TSP) of SS RBC to HUVEC was most effectively inhibited by high molecular weight dextran sulfate (HDS), whereas low molecular weight dextran sulfate (LDS) and the glycosaminoglycan chondroitin sulfate A (CSA) also had significant inhibitory effects.">
            <entity id="DS3.d340.s3.e0" origId="P07996" charOffset="41-44" type="protein" text="TSP"/>
            <entity id="DS3.d340.s3.e1" origId="4125253,5460037" charOffset="121-128" type="compound" text="dextran"/>
            <entity id="DS3.d340.s3.e2" origId="1117" charOffset="129-136" type="compound" text="sulfate"/>
            <entity id="DS3.d340.s3.e3" origId="Q86SQ9" charOffset="138-141" type="protein" text="HDS"/>
            <entity id="DS3.d340.s3.e4" origId="4125253,5460037" charOffset="173-180" type="compound" text="dextran"/>
            <entity id="DS3.d340.s3.e5" origId="1117" charOffset="181-188" type="compound" text="sulfate"/>
            <entity id="DS3.d340.s3.e6" origId="53477711" charOffset="221-242" type="compound" text="chondroitin sulfate A"/>
            <pair e1="DS3.d340.s3.e1" e2="DS3.d340.s3.e3" id="DS3.d340.s3.i0" interaction="False" />
            <pair e1="DS3.d340.s3.e1" e2="DS3.d340.s3.e0" id="DS3.d340.s3.i1" interaction="False" />
            <pair e1="DS3.d340.s3.e2" e2="DS3.d340.s3.e3" id="DS3.d340.s3.i2" interaction="False" />
            <pair e1="DS3.d340.s3.e2" e2="DS3.d340.s3.e0" id="DS3.d340.s3.i3" interaction="False" />
            <pair e1="DS3.d340.s3.e6" e2="DS3.d340.s3.e3" id="DS3.d340.s3.i4" interaction="False" />
            <pair e1="DS3.d340.s3.e6" e2="DS3.d340.s3.e0" id="DS3.d340.s3.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d341" origId="9949188">
        <sentence id="DS3.d341.s0" origId="9949188-5" text="Similar to Tenascin-C, immobilized antibody to GD2 (3F8) or sphingosine, a protein kinase C inhibitor, strongly inhibited RGD-dependent cell spreading.">
            <entity id="DS3.d341.s0.e0" origId="P24821,F5H7V9,Q4LE33,B4E1W8,E9PC84,J3QSU6" charOffset="11-21" type="protein" text="Tenascin-C"/>
            <entity id="DS3.d341.s0.e1" origId="6450346" charOffset="47-50" type="compound" text="GD2"/>
            <entity id="DS3.d341.s0.e2" origId="86287509" charOffset="52-55" type="compound" text="3F8"/>
            <entity id="DS3.d341.s0.e3" origId="31270,5280335" charOffset="60-71" type="compound" text="sphingosine"/>
            <pair e1="DS3.d341.s0.e1" e2="DS3.d341.s0.e0" id="DS3.d341.s0.i0" interaction="False" />
            <pair e1="DS3.d341.s0.e3" e2="DS3.d341.s0.e0" id="DS3.d341.s0.i1" interaction="False" />
            <pair e1="DS3.d341.s0.e2" e2="DS3.d341.s0.e0" id="DS3.d341.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d342" origId="9949189">
        <sentence id="DS3.d342.s0" origId="9949189-0" text="Bovine mammary gland UDP-GalNAc:GlcNAcbeta-R beta1--&amp;gt;4-N-acetylgalactosaminyltransferase is glycoprotein hormone nonspecific and shows interaction with alpha-lactalbumin.">
            <entity id="DS3.d342.s0.e0" origId="439185" charOffset="21-31" type="compound" text="UDP-GalNAc"/>
            <entity id="DS3.d342.s0.e1" origId="P00711,B6V3I5,P00709,A0A080YV01" charOffset="155-172" type="protein" text="alpha-lactalbumin"/>
            <pair e1="DS3.d342.s0.e0" e2="DS3.d342.s0.e1" id="DS3.d342.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d342.s1" origId="9949189-3" text="Therefore, the enzyme can be identified as a UDP-GalNAc:GlcNAcbeta-R beta1--&amp;gt;4-N-acetylgalactosaminyltransferase (beta4-GalNAcT).">
            <entity id="DS3.d342.s1.e0" origId="439185" charOffset="45-55" type="compound" text="UDP-GalNAc"/>
            <entity id="DS3.d342.s1.e1" origId="Q8TDX6" charOffset="117-130" type="protein" text="beta4-GalNAcT"/>
            <pair e1="DS3.d342.s1.e0" e2="DS3.d342.s1.e1" id="DS3.d342.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d342.s2" origId="9949189-6" text="Furthermore, the GalNAcT activity appeared not to be due to a promiscuous action of a beta4-GalT as could be demonstrated by comparing the beta4-GalNAcT and beta4-GalT activities of the mammary gland, bovine colostrum, and purified beta4-GalT, by competition studies with UDP-GalNAc and UDP-Gal, and by use of an anti-beta4-GalT polyclonal inhibiting antibody.">
            <entity id="DS3.d342.s2.e0" origId="Q8TDX6" charOffset="139-152" type="protein" text="beta4-GalNAcT"/>
            <entity id="DS3.d342.s2.e1" origId="439185" charOffset="272-282" type="compound" text="UDP-GalNAc"/>
            <entity id="DS3.d342.s2.e2" origId="439158,16220068,16760700,18068,46936243" charOffset="272-279" type="compound" text="UDP-Gal"/>
            <pair e1="DS3.d342.s2.e2" e2="DS3.d342.s2.e0" id="DS3.d342.s2.i0" interaction="False" />
            <pair e1="DS3.d342.s2.e1" e2="DS3.d342.s2.e0" id="DS3.d342.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d342.s3" origId="9949189-7" text="Interestingly, under conditions where mammalian beta4-GalT forms with alpha-lactalbumin (alpha-LA) the lactose synthase complex, the mammary gland beta4-GalNAcT was similarly induced by alpha-LA to act on Glc with an increased efficiency yielding the lactose analog GalNAcbeta1--&amp;gt;4Glc.">
            <entity id="DS3.d342.s3.e0" origId="P00711,B6V3I5,P00709,A0A080YV01" charOffset="70-87" type="protein" text="alpha-lactalbumin"/>
            <entity id="DS3.d342.s3.e1" origId="294,440995,6134,84571" charOffset="103-110" type="compound" text="lactose"/>
            <entity id="DS3.d342.s3.e2" origId="Q8TDX6" charOffset="147-160" type="protein" text="beta4-GalNAcT"/>
            <entity id="DS3.d342.s3.e3" origId="3034742,57288387,6971003" charOffset="205-208" type="compound" text="Glc"/>
            <entity id="DS3.d342.s3.e4" origId="294,440995,6134,84571" charOffset="251-258" type="compound" text="lactose"/>
            <pair e1="DS3.d342.s3.e1" e2="DS3.d342.s3.e2" id="DS3.d342.s3.i0" interaction="False" />
            <pair e1="DS3.d342.s3.e1" e2="DS3.d342.s3.e0" id="DS3.d342.s3.i1" interaction="False" />
            <pair e1="DS3.d342.s3.e3" e2="DS3.d342.s3.e2" id="DS3.d342.s3.i2" interaction="False" />
            <pair e1="DS3.d342.s3.e3" e2="DS3.d342.s3.e0" id="DS3.d342.s3.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d342.s4" origId="9949189-9" text="It is proposed that the mammary gland beta4-GalNAcT functions in the synthesis of lacdiNAc-based, complex-type glycans frequently occurring on bovine milk glycoproteins.">
            <entity id="DS3.d342.s4.e0" origId="Q8TDX6" charOffset="38-51" type="protein" text="beta4-GalNAcT"/>
            <entity id="DS3.d342.s4.e1" origId="871" charOffset="111-118" type="compound" text="glycans"/>
            <pair e1="DS3.d342.s4.e1" e2="DS3.d342.s4.e0" id="DS3.d342.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d343" origId="9949191">
        <sentence id="DS3.d343.s0" origId="9949191-3" text="Detection by fluorescence labeled alpha-galactose specific lectin revealed that 50% of the cells incorporated galactose to cell surface mannoproteins only when the gma12(+) and hUGT2 genes were coexpressed in galactose media.">
            <entity id="DS3.d343.s0.e0" origId="206,439353" charOffset="40-49" type="compound" text="galactose"/>
            <entity id="DS3.d343.s0.e1" origId="206,439353" charOffset="110-119" type="compound" text="galactose"/>
            <entity id="DS3.d343.s0.e2" origId="Q9NYU1,Q05D90" charOffset="177-182" type="protein" text="hUGT2"/>
            <entity id="DS3.d343.s0.e3" origId="206,439353" charOffset="110-119" type="compound" text="galactose"/>
            <pair e1="DS3.d343.s0.e0" e2="DS3.d343.s0.e2" id="DS3.d343.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d344" origId="9949192">
        <sentence id="DS3.d344.s0" origId="9949192-3" text="All nine proteins-laminin-1, fibronectin, thrombospondin-1, NCAM, L1, protease nexin-1, urokinase plasminogen activator, thrombin, and fibroblast growth factor-2-bound brain heparan sulfate less strongly than heparin, but the degree of difference in affinity varied considerably.">
            <entity id="DS3.d344.s0.e0" origId="D4A409" charOffset="18-27" type="protein" text="laminin-1"/>
            <entity id="DS3.d344.s0.e1" origId="F1LST1,A0A096P6L8" charOffset="29-40" type="protein" text="fibronectin"/>
            <entity id="DS3.d344.s0.e2" origId="Q71SA3" charOffset="42-58" type="protein" text="thrombospondin-1"/>
            <entity id="DS3.d344.s0.e3" origId="P13596,Q3T1H3" charOffset="60-64" type="protein" text="NCAM"/>
            <entity id="DS3.d344.s0.e4" origId="90470996" charOffset="121-129" type="compound" text="thrombin"/>
            <entity id="DS3.d344.s0.e5" origId="P13109" charOffset="135-161" type="protein" text="fibroblast growth factor-2"/>
            <entity id="DS3.d344.s0.e6" origId="53477715" charOffset="174-189" type="compound" text="heparan sulfate"/>
            <pair e1="DS3.d344.s0.e4" e2="DS3.d344.s0.e2" id="DS3.d344.s0.i0" interaction="False" />
            <pair e1="DS3.d344.s0.e4" e2="DS3.d344.s0.e5" id="DS3.d344.s0.i1" interaction="False" />
            <pair e1="DS3.d344.s0.e4" e2="DS3.d344.s0.e1" id="DS3.d344.s0.i2" interaction="False" />
            <pair e1="DS3.d344.s0.e4" e2="DS3.d344.s0.e0" id="DS3.d344.s0.i3" interaction="False" />
            <pair e1="DS3.d344.s0.e4" e2="DS3.d344.s0.e3" id="DS3.d344.s0.i4" interaction="False" />
            <pair e1="DS3.d344.s0.e6" e2="DS3.d344.s0.e2" id="DS3.d344.s0.i5" interaction="False" />
            <pair e1="DS3.d344.s0.e6" e2="DS3.d344.s0.e5" id="DS3.d344.s0.i6" interaction="False" />
            <pair e1="DS3.d344.s0.e6" e2="DS3.d344.s0.e1" id="DS3.d344.s0.i7" interaction="False" />
            <pair e1="DS3.d344.s0.e6" e2="DS3.d344.s0.e0" id="DS3.d344.s0.i8" interaction="False" />
            <pair e1="DS3.d344.s0.e6" e2="DS3.d344.s0.e3" id="DS3.d344.s0.i9" interaction="False" />
        </sentence>
        <sentence id="DS3.d344.s1" origId="9949192-4" text="Protease nexin-1 bound brain heparan sulfate only 1.8-fold less tightly than heparin (Kdvalues of 35 vs. 20 nM, respectively), whereas NCAM and L1 bound heparin well (Kd approximately 140 nM) but failed to bind detectably to brain heparan sulfate (Kd&amp;gt;3 microM).">
            <entity id="DS3.d344.s1.e0" origId="53477715" charOffset="29-44" type="compound" text="heparan sulfate"/>
            <entity id="DS3.d344.s1.e1" origId="P13596,Q3T1H3" charOffset="135-139" type="protein" text="NCAM"/>
            <entity id="DS3.d344.s1.e2" origId="53477715" charOffset="231-246" type="compound" text="heparan sulfate"/>
            <pair e1="DS3.d344.s1.e0" e2="DS3.d344.s1.e1" id="DS3.d344.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d344.s2" origId="9949192-6" text="Overall, the highest affinities were observed with intact heparan sulfate proteoglycans: laminin-1's affinities for the proteoglycans cerebroglycan (glypican-2), glypican-1 and syndecan-3 were 300- to 1800-fold stronger than its affinity for brain heparan sulfate.">
            <entity id="DS3.d344.s2.e0" origId="53477715" charOffset="58-73" type="compound" text="heparan sulfate"/>
            <entity id="DS3.d344.s2.e1" origId="D4A409" charOffset="89-98" type="protein" text="laminin-1"/>
            <entity id="DS3.d344.s2.e2" origId="P51653" charOffset="134-147" type="protein" text="cerebroglycan"/>
            <entity id="DS3.d344.s2.e3" origId="P51653" charOffset="149-159" type="protein" text="glypican-2"/>
            <entity id="DS3.d344.s2.e4" origId="P35053" charOffset="162-172" type="protein" text="glypican-1"/>
            <entity id="DS3.d344.s2.e5" origId="P33671,G3V9B7" charOffset="177-187" type="protein" text="syndecan-3"/>
            <entity id="DS3.d344.s2.e6" origId="53477715" charOffset="248-263" type="compound" text="heparan sulfate"/>
            <pair e1="DS3.d344.s2.e0" e2="DS3.d344.s2.e5" id="DS3.d344.s2.i0" interaction="False" />
            <pair e1="DS3.d344.s2.e0" e2="DS3.d344.s2.e4" id="DS3.d344.s2.i1" interaction="False" />
            <pair e1="DS3.d344.s2.e0" e2="DS3.d344.s2.e3" id="DS3.d344.s2.i2" interaction="False" />
            <pair e1="DS3.d344.s2.e0" e2="DS3.d344.s2.e1" id="DS3.d344.s2.i3" interaction="False" />
            <pair e1="DS3.d344.s2.e0" e2="DS3.d344.s2.e2" id="DS3.d344.s2.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d344.s3" origId="9949192-7" text="In contrast, the affinities of fibroblast growth factor-2 for cerebroglycan and for brain heparan sulfate were similar.">
            <entity id="DS3.d344.s3.e0" origId="P13109" charOffset="31-57" type="protein" text="fibroblast growth factor-2"/>
            <entity id="DS3.d344.s3.e1" origId="P51653" charOffset="62-75" type="protein" text="cerebroglycan"/>
            <entity id="DS3.d344.s3.e2" origId="53477715" charOffset="90-105" type="compound" text="heparan sulfate"/>
            <pair e1="DS3.d344.s3.e2" e2="DS3.d344.s3.e0" id="DS3.d344.s3.i0" interaction="False" />
            <pair e1="DS3.d344.s3.e2" e2="DS3.d344.s3.e1" id="DS3.d344.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d344.s4" origId="9949192-8" text="Interestingly, partial proteolysis of cerebroglycan resulted in a &amp;gt;400-fold loss of laminin affinity.">
            <entity id="DS3.d344.s4.e0" origId="P51653" charOffset="38-51" type="protein" text="cerebroglycan"/>
            <entity id="DS3.d344.s4.e1" origId="44342165" charOffset="87-94" type="compound" text="laminin"/>
            <pair e1="DS3.d344.s4.e1" e2="DS3.d344.s4.e0" id="DS3.d344.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d345" origId="9949196">
        <sentence id="DS3.d345.s0" origId="9949196-4" text="Although FUT1 is expressed in the COS cell mRNA, it has not been possible to demonstrate alpha1,2-fucosyltransferase activity in cell extracts but the presence of Le(y) and blood-group A antigenic determinants on the cell surface imply the formation of H-precursor structures at some stage.">
            <entity id="DS3.d345.s0.e0" origId="P19526,Q6IZA2" charOffset="9-13" type="protein" text="FUT1"/>
            <entity id="DS3.d345.s0.e1" origId="7009630" charOffset="163-165" type="compound" text="Le"/>
            <pair e1="DS3.d345.s0.e1" e2="DS3.d345.s0.e0" id="DS3.d345.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d345.s1" origId="9949196-5" text="The most strongly expressed fucosyltransferase in the COS cells is the alpha1,6-enzyme transferring fucose to the innermost N -acetylglucosamine unit in N -glycan chains; this enzyme is similar in its properties to the product of the human FUT8 gene.">
            <entity id="DS3.d345.s1.e0" origId="17106,19466,439554,6713579,71315513,840" charOffset="100-106" type="compound" text="fucose"/>
            <entity id="DS3.d345.s1.e1" origId="24139" charOffset="127-144" type="compound" text="acetylglucosamine"/>
            <entity id="DS3.d345.s1.e2" origId="Q9BYC5,Q546E0,A8K8P8" charOffset="240-244" type="protein" text="FUT8"/>
            <pair e1="DS3.d345.s1.e1" e2="DS3.d345.s1.e2" id="DS3.d345.s1.i0" interaction="False" />
            <pair e1="DS3.d345.s1.e0" e2="DS3.d345.s1.e2" id="DS3.d345.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d345.s2" origId="9949196-6" text="The enzymes resembling the human FUT4 and FUT8 gene products both had pH optima of 7.0 and were resistant to 10 mM NEM.">
            <entity id="DS3.d345.s2.e0" origId="P22083" charOffset="33-37" type="protein" text="FUT4"/>
            <entity id="DS3.d345.s2.e1" origId="Q9BYC5,Q546E0,A8K8P8" charOffset="42-46" type="protein" text="FUT8"/>
            <entity id="DS3.d345.s2.e2" origId="4362" charOffset="115-118" type="compound" text="NEM"/>
            <pair e1="DS3.d345.s2.e2" e2="DS3.d345.s2.e0" id="DS3.d345.s2.i0" interaction="False" />
            <pair e1="DS3.d345.s2.e2" e2="DS3.d345.s2.e1" id="DS3.d345.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d345.s3" origId="9949196-8" text="This result initially suggested the presence of a third fucosyltransferase expressed in the COS cells but we have now shown that triantennary N- glycans with terminal nonreducing galactose units, similar to those present in asialo-fetuin, are modified by a weak endogenous beta-galactosidase in the COS cell extracts and thereby rendered suitable substrates for the alpha1,6-fucosyltransferase.">
            <entity id="DS3.d345.s3.e0" origId="871" charOffset="145-152" type="compound" text="glycans"/>
            <entity id="DS3.d345.s3.e1" origId="206,439353,439357,6036" charOffset="179-188" type="compound" text="galactose"/>
            <entity id="DS3.d345.s3.e2" origId="P16278" charOffset="273-291" type="protein" text="beta-galactosidase"/>
            <entity id="DS3.d345.s3.e3" origId="Q9BYC5,Q546E0,A8K8P8" charOffset="366-393" type="protein" text="alpha1,6-fucosyltransferase"/>
            <pair e1="DS3.d345.s3.e0" e2="DS3.d345.s3.e3" id="DS3.d345.s3.i0" interaction="False" />
            <pair e1="DS3.d345.s3.e0" e2="DS3.d345.s3.e2" id="DS3.d345.s3.i1" interaction="False" />
            <pair e1="DS3.d345.s3.e1" e2="DS3.d345.s3.e3" id="DS3.d345.s3.i2" interaction="False" />
            <pair e1="DS3.d345.s3.e1" e2="DS3.d345.s3.e2" id="DS3.d345.s3.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d346" origId="9949197">
        <sentence id="DS3.d346.s0" origId="9949197-0" text="Distribution of emerin and lamins in the heart and implications for Emery-Dreifuss muscular dystrophy.">
            <entity id="DS3.d346.s0.e0" origId="B7NZQ0,P50402" charOffset="16-22" type="protein" text="emerin"/>
            <entity id="DS3.d346.s0.e1" origId="14769" charOffset="68-73" type="compound" text="Emery"/>
            <pair e1="DS3.d346.s0.e1" e2="DS3.d346.s0.e0" id="DS3.d346.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d346.s1" origId="9949197-1" text="emerin is a nuclear membrane protein which is missing or defective in Emery-Dreifuss muscular dystrophy (EDMD).">
            <entity id="DS3.d346.s1.e0" origId="B7NZQ0,P50402" charOffset="0-6" type="protein" text="emerin"/>
            <entity id="DS3.d346.s1.e1" origId="14769" charOffset="70-75" type="compound" text="Emery"/>
            <pair e1="DS3.d346.s1.e1" e2="DS3.d346.s1.e0" id="DS3.d346.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d347" origId="9949198">
        <sentence id="DS3.d347.s0" origId="9949198-6" text="These results implicate a crucial role for CBP in mammalian LTM.">
            <entity id="DS3.d347.s0.e0" origId="Q6GQV9,F8VPR5,Q92793" charOffset="43-46" type="protein" text="CBP"/>
            <entity id="DS3.d347.s0.e1" origId="15386579" charOffset="60-63" type="compound" text="LTM"/>
            <pair e1="DS3.d347.s0.e1" e2="DS3.d347.s0.e0" id="DS3.d347.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d348" origId="9949199">
        <sentence id="DS3.d348.s0" origId="9949199-1" text="Huntington's disease (HD) is an inherited, neurodegenerative disorder caused by the expansion of a glutamine repeat in the N-terminus of the huntingtin protein.">
            <entity id="DS3.d348.s0.e0" origId="5961" charOffset="99-108" type="compound" text="glutamine"/>
            <entity id="DS3.d348.s0.e1" origId="G3X9H5" charOffset="141-151" type="protein" text="huntingtin"/>
            <pair e1="DS3.d348.s0.e0" e2="DS3.d348.s0.e1" id="DS3.d348.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d348.s1" origId="9949199-3" text="Mice expressing relatively low steady-state levels of N171 huntingtin with 82 glutamine repeats (N171-82Q) develop behavioral abnormalities, including loss of coordination, tremors, hypokinesis and abnormal gait, before dying prematurely.">
            <entity id="DS3.d348.s1.e0" origId="G3X9H5" charOffset="59-69" type="protein" text="huntingtin"/>
            <entity id="DS3.d348.s1.e1" origId="5961" charOffset="78-87" type="compound" text="glutamine"/>
            <pair e1="DS3.d348.s1.e1" e2="DS3.d348.s1.e0" id="DS3.d348.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d349" origId="9949201">
        <sentence id="DS3.d349.s0" origId="9949201-0" text="The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis.">
            <entity id="DS3.d349.s0.e0" origId="Q16595" charOffset="4-23" type="protein" text="Friedreich's ataxia"/>
            <entity id="DS3.d349.s0.e1" origId="23925,67172434" charOffset="113-117" type="compound" text="iron"/>
            <entity id="DS3.d349.s0.e2" origId="22044544,5460341" charOffset="122-129" type="compound" text="calcium"/>
            <pair e1="DS3.d349.s0.e2" e2="DS3.d349.s0.e0" id="DS3.d349.s0.i0" interaction="False" />
            <pair e1="DS3.d349.s0.e1" e2="DS3.d349.s0.e0" id="DS3.d349.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d349.s1" origId="9949201-2" text="frataxin is a mitochondrial protein, and disruption of a frataxin homolog in yeast results in increased sensitivity to oxidant stress, increased mitochondrial iron and respiration deficiency.">
            <entity id="DS3.d349.s1.e0" origId="Q16595" charOffset="0-8" type="protein" text="frataxin"/>
            <entity id="DS3.d349.s1.e1" origId="Q16595" charOffset="57-65" type="protein" text="frataxin"/>
            <entity id="DS3.d349.s1.e2" origId="23925,67172434" charOffset="159-163" type="compound" text="iron"/>
            <pair e1="DS3.d349.s1.e2" e2="DS3.d349.s1.e0" id="DS3.d349.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d349.s2" origId="9949201-4" text="FRDA fibroblasts were hypersensitive to iron stress and significantly more sensitive to hydrogen peroxide than controls.">
            <entity id="DS3.d349.s2.e0" origId="Q16595" charOffset="0-4" type="protein" text="FRDA"/>
            <entity id="DS3.d349.s2.e1" origId="23925,67172434" charOffset="40-44" type="compound" text="iron"/>
            <entity id="DS3.d349.s2.e2" origId="784" charOffset="88-105" type="compound" text="hydrogen peroxide"/>
            <pair e1="DS3.d349.s2.e2" e2="DS3.d349.s2.e0" id="DS3.d349.s2.i0" interaction="False" />
            <pair e1="DS3.d349.s2.e1" e2="DS3.d349.s2.e0" id="DS3.d349.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d349.s3" origId="9949201-5" text="The iron chelator deferoxamine rescued FRDA fibroblasts more than controls from oxidant-induced death, consistent with a role for iron in the differential kinetics of death; however, mean mitochondrial iron content in FRDA fibroblasts was increased by only 40%.">
            <entity id="DS3.d349.s3.e0" origId="23925,67172434" charOffset="4-8" type="compound" text="iron"/>
            <entity id="DS3.d349.s3.e1" origId="2973" charOffset="18-30" type="compound" text="deferoxamine"/>
            <entity id="DS3.d349.s3.e2" origId="Q16595" charOffset="39-43" type="protein" text="FRDA"/>
            <entity id="DS3.d349.s3.e3" origId="23925,67172434" charOffset="130-134" type="compound" text="iron"/>
            <entity id="DS3.d349.s3.e4" origId="23925,67172434" charOffset="130-134" type="compound" text="iron"/>
            <entity id="DS3.d349.s3.e5" origId="Q16595" charOffset="218-222" type="protein" text="FRDA"/>
            <pair e1="DS3.d349.s3.e1" e2="DS3.d349.s3.e2" id="DS3.d349.s3.i0" interaction="False" />
            <pair e1="DS3.d349.s3.e0" e2="DS3.d349.s3.e2" id="DS3.d349.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d349.s4" origId="9949201-6" text="Treatment of cells with the intracellular Ca2+chelator BAPTA-AM rescued both FRDA fibroblasts and controls from oxidant-induced death.">
            <entity id="DS3.d349.s4.e0" origId="6102758" charOffset="42-45" type="compound" text="Ca2"/>
            <entity id="DS3.d349.s4.e1" origId="104751" charOffset="55-60" type="compound" text="BAPTA"/>
            <entity id="DS3.d349.s4.e2" origId="Q16595" charOffset="77-81" type="protein" text="FRDA"/>
            <pair e1="DS3.d349.s4.e0" e2="DS3.d349.s4.e2" id="DS3.d349.s4.i0" interaction="False" />
            <pair e1="DS3.d349.s4.e1" e2="DS3.d349.s4.e2" id="DS3.d349.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d349.s5" origId="9949201-7" text="Treatment with apoptosis inhibitors rescued FRDA but not control fibroblasts from oxidant stress, and staurosporine-induced caspase 3 activity was higher in FRDA fibroblasts, consistent with the possibility that an apoptotic step upstream of caspase 3 is activated in FRDA fibroblasts.">
            <entity id="DS3.d349.s5.e0" origId="Q16595" charOffset="44-48" type="protein" text="FRDA"/>
            <entity id="DS3.d349.s5.e1" origId="44120114,44259,44299148,451705,5279,5311103,5459111,6419748,6711321,9937179,9956178" charOffset="102-115" type="compound" text="staurosporine"/>
            <entity id="DS3.d349.s5.e2" origId="P42574" charOffset="124-133" type="protein" text="caspase 3"/>
            <entity id="DS3.d349.s5.e3" origId="Q16595" charOffset="157-161" type="protein" text="FRDA"/>
            <entity id="DS3.d349.s5.e4" origId="P42574" charOffset="242-251" type="protein" text="caspase 3"/>
            <entity id="DS3.d349.s5.e5" origId="Q16595" charOffset="157-161" type="protein" text="FRDA"/>
            <pair e1="DS3.d349.s5.e1" e2="DS3.d349.s5.e2" id="DS3.d349.s5.i0" interaction="False" />
            <pair e1="DS3.d349.s5.e1" e2="DS3.d349.s5.e0" id="DS3.d349.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d350" origId="9949202">
        <sentence id="DS3.d350.s0" origId="9949202-1" text="FRA3B at 3p14.2 is the most active of the common fragile sites in the human genome and is expressed when cells are exposed to the DNA replication inhibitor, aphidicolin.">
            <entity id="DS3.d350.s0.e0" origId="P49789,A0A024R366" charOffset="0-5" type="protein" text="FRA3B"/>
            <entity id="DS3.d350.s0.e1" origId="457964" charOffset="157-168" type="compound" text="aphidicolin"/>
            <pair e1="DS3.d350.s0.e1" e2="DS3.d350.s0.e0" id="DS3.d350.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d350.s1" origId="9949202-3" text="To elucidate the relationship between the timing of replication across the FRA3B region and its corresponding fragility, we labeled cells with 5-bromo-2'-deoxyuridine (BrdU) and adopted an immunofluorescent procedure to visualize late replicating DNA (BrdU-substituted DNA) in metaphase chromosomes.">
            <entity id="DS3.d350.s1.e0" origId="P49789,A0A024R366" charOffset="75-80" type="protein" text="FRA3B"/>
            <entity id="DS3.d350.s1.e1" origId="6035" charOffset="168-172" type="compound" text="BrdU"/>
            <entity id="DS3.d350.s1.e2" origId="6035" charOffset="252-256" type="compound" text="BrdU"/>
            <pair e1="DS3.d350.s1.e1" e2="DS3.d350.s1.e0" id="DS3.d350.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d350.s2" origId="9949202-4" text="We also chose 21 markers along the FRA3B region and analyzed the timing of replication using BrdU-labeled DNA from different stages of the cell cycle sorted by flow cytometry.">
            <entity id="DS3.d350.s2.e0" origId="P49789,A0A024R366" charOffset="35-40" type="protein" text="FRA3B"/>
            <entity id="DS3.d350.s2.e1" origId="6035" charOffset="93-97" type="compound" text="BrdU"/>
            <pair e1="DS3.d350.s2.e1" e2="DS3.d350.s2.e0" id="DS3.d350.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d351" origId="9949206">
        <sentence id="DS3.d351.s0" origId="9949206-0" text="Dystonia associated with mutation of the neuronal sodium channel Scn8a and identification of the modifier locus SCNM1 on mouse chromosome 3.">
            <entity id="DS3.d351.s0.e0" origId="5360545" charOffset="50-56" type="compound" text="sodium"/>
            <entity id="DS3.d351.s0.e1" origId="Q9WTU3,F7D6K4,F6U329,A0A0J9YUW5,Q9UQD0" charOffset="65-70" type="protein" text="Scn8a"/>
            <entity id="DS3.d351.s0.e2" origId="Q8K136" charOffset="112-117" type="protein" text="SCNM1"/>
            <pair e1="DS3.d351.s0.e0" e2="DS3.d351.s0.e2" id="DS3.d351.s0.i0" interaction="False" />
            <pair e1="DS3.d351.s0.e0" e2="DS3.d351.s0.e1" id="DS3.d351.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d351.s1" origId="9949206-1" text="The mouse mutant medJ contains a splice site mutation in the neuronal sodium channel Scn8a that results in a very low level of expression.">
            <entity id="DS3.d351.s1.e0" origId="5360545" charOffset="70-76" type="compound" text="sodium"/>
            <entity id="DS3.d351.s1.e1" origId="Q9WTU3,F7D6K4,F6U329,A0A0J9YUW5,Q9UQD0" charOffset="85-90" type="protein" text="Scn8a"/>
            <pair e1="DS3.d351.s1.e0" e2="DS3.d351.s1.e1" id="DS3.d351.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d352" origId="9949209">
        <sentence id="DS3.d352.s0" origId="9949209-2" text="The major cause of hepatic copper accumulation in man is a dysfunctional ATP7B gene, causing Wilson disease (WD).">
            <entity id="DS3.d352.s0.e0" origId="23978" charOffset="27-33" type="compound" text="copper"/>
            <entity id="DS3.d352.s0.e1" origId="P35670,A0A024RDX3,B7ZLR4,E7ET55,Q64446" charOffset="73-78" type="protein" text="ATP7B"/>
            <pair e1="DS3.d352.s0.e0" e2="DS3.d352.s0.e1" id="DS3.d352.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d352.s1" origId="9949209-4" text="The ATP7B gene has been excluded in the much rarer human copper overload disease non-Indian childhood cirrhosis, indicating genetic heterogeneity.">
            <entity id="DS3.d352.s1.e0" origId="P35670,A0A024RDX3,B7ZLR4,E7ET55,Q64446" charOffset="4-9" type="protein" text="ATP7B"/>
            <entity id="DS3.d352.s1.e1" origId="23978" charOffset="57-63" type="compound" text="copper"/>
            <pair e1="DS3.d352.s1.e1" e2="DS3.d352.s1.e0" id="DS3.d352.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d352.s2" origId="9949209-9" text="The copper transport genes CTR1 and CTR2 were also excluded as candidate genes for CT since they both mapped to canine chromosome region CFA11q22.">
            <entity id="DS3.d352.s2.e0" origId="23978" charOffset="4-10" type="compound" text="copper"/>
            <entity id="DS3.d352.s2.e1" origId="O15431,A0A024R824" charOffset="27-31" type="protein" text="CTR1"/>
            <entity id="DS3.d352.s2.e2" origId="O15432,Q53X94" charOffset="36-40" type="protein" text="CTR2"/>
            <pair e1="DS3.d352.s2.e0" e2="DS3.d352.s2.e2" id="DS3.d352.s2.i0" interaction="False" />
            <pair e1="DS3.d352.s2.e0" e2="DS3.d352.s2.e1" id="DS3.d352.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d353" origId="9949213">
        <sentence id="DS3.d353.s0" origId="9949213-3" text="This gene encodes a highly conserved giant protein, HERC2, that is distantly related to p532 (HERC1), a guanine nucleotide exchange factor (GEF) implicated in vesicular trafficking.">
            <entity id="DS3.d353.s0.e0" origId="Q4U2R1" charOffset="52-57" type="protein" text="HERC2"/>
            <entity id="DS3.d353.s0.e1" origId="57500583" charOffset="88-92" type="compound" text="p532"/>
            <entity id="DS3.d353.s0.e2" origId="E9PZP8" charOffset="94-99" type="protein" text="HERC1"/>
            <entity id="DS3.d353.s0.e3" origId="764" charOffset="104-111" type="compound" text="guanine"/>
            <pair e1="DS3.d353.s0.e1" e2="DS3.d353.s0.e2" id="DS3.d353.s0.i0" interaction="False" />
            <pair e1="DS3.d353.s0.e1" e2="DS3.d353.s0.e0" id="DS3.d353.s0.i1" interaction="False" />
            <pair e1="DS3.d353.s0.e3" e2="DS3.d353.s0.e2" id="DS3.d353.s0.i2" interaction="False" />
            <pair e1="DS3.d353.s0.e3" e2="DS3.d353.s0.e0" id="DS3.d353.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d353.s1" origId="9949213-5" text="We have identified single nucleotide splice junction mutations in HERC2 in three independent N-ethyl-N-nitrosourea-induced jdf2 mutant alleles, each leading to exon skipping with premature termination of translation and/or deletion of conserved amino acids.">
            <entity id="DS3.d353.s1.e0" origId="Q4U2R1" charOffset="66-71" type="protein" text="HERC2"/>
            <entity id="DS3.d353.s1.e1" origId="12967" charOffset="93-114" type="compound" text="N-ethyl-N-nitrosourea"/>
            <entity id="DS3.d353.s1.e2" origId="Q4U2R1" charOffset="123-127" type="protein" text="jdf2"/>
            <pair e1="DS3.d353.s1.e1" e2="DS3.d353.s1.e0" id="DS3.d353.s1.i0" interaction="False" />
            <pair e1="DS3.d353.s1.e1" e2="DS3.d353.s1.e2" id="DS3.d353.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d354" origId="9949214">
        <sentence id="DS3.d354.s0" origId="9949214-6" text="The predicted human PKDREJ protein has 2253 amino acids (calculated molecular mass 255 kDa) and sequence similarity over approximately 2000 amino acids with polycystin-1, corresponding to the predicted membrane associated region and the area of homology ( approximately 1000 amino acids) with the suREJ protein (the REJ module).">
            <entity id="DS3.d354.s0.e0" origId="F8VQF3" charOffset="20-26" type="protein" text="PKDREJ"/>
            <entity id="DS3.d354.s0.e1" origId="P98161" charOffset="157-169" type="protein" text="polycystin-1"/>
            <entity id="DS3.d354.s0.e2" origId="54765325" charOffset="23-26" type="compound" text="REJ"/>
            <pair e1="DS3.d354.s0.e2" e2="DS3.d354.s0.e0" id="DS3.d354.s0.i0" interaction="False" />
            <pair e1="DS3.d354.s0.e2" e2="DS3.d354.s0.e1" id="DS3.d354.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d355" origId="9949226">
        <sentence id="DS3.d355.s0" origId="9949226-4" text="Fusion of these two genes results in the production of a putative oncogenic protein composed of the zinc finger DNA-binding domains of WT1 linked to the potential transcriptional regulatory domains of EWS.">
            <entity id="DS3.d355.s0.e0" origId="23994" charOffset="100-104" type="compound" text="zinc"/>
            <entity id="DS3.d355.s0.e1" origId="P19544,Q6PI38" charOffset="135-138" type="protein" text="WT1"/>
            <entity id="DS3.d355.s0.e2" origId="Q01844" charOffset="201-204" type="protein" text="EWS"/>
            <pair e1="DS3.d355.s0.e0" e2="DS3.d355.s0.e2" id="DS3.d355.s0.i0" interaction="False" />
            <pair e1="DS3.d355.s0.e0" e2="DS3.d355.s0.e1" id="DS3.d355.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d356" origId="9949234">
        <sentence id="DS3.d356.s0" origId="9949234-3" text="RESULTS: All patients carried the same glycine-to-arginine mutation at codon 380(G380R) of the transmembrane domain of FGFR3.">
            <entity id="DS3.d356.s0.e0" origId="45934207,750" charOffset="39-46" type="compound" text="glycine"/>
            <entity id="DS3.d356.s0.e1" origId="6322,90867653" charOffset="50-58" type="compound" text="arginine"/>
            <entity id="DS3.d356.s0.e2" origId="P22607,Q0IJ44,X5D2G8" charOffset="119-124" type="protein" text="FGFR3"/>
            <pair e1="DS3.d356.s0.e1" e2="DS3.d356.s0.e2" id="DS3.d356.s0.i0" interaction="False" />
            <pair e1="DS3.d356.s0.e0" e2="DS3.d356.s0.e2" id="DS3.d356.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d357" origId="9949257">
        <sentence id="DS3.d357.s0" origId="9949257-11" text="The increase in cAMP levels did not affect the effect of PMA on pHi recovery, but it blocked the effect of thapsigargin.">
            <entity id="DS3.d357.s0.e0" origId="G3V8S9" charOffset="16-20" type="protein" text="cAMP"/>
            <entity id="DS3.d357.s0.e1" origId="122634,27924" charOffset="57-60" type="compound" text="PMA"/>
            <entity id="DS3.d357.s0.e2" origId="Q6P6V0" charOffset="64-67" type="protein" text="pHi"/>
            <entity id="DS3.d357.s0.e3" origId="49926,446378" charOffset="107-119" type="compound" text="thapsigargin"/>
            <pair e1="DS3.d357.s0.e3" e2="DS3.d357.s0.e2" id="DS3.d357.s0.i0" interaction="False" />
            <pair e1="DS3.d357.s0.e3" e2="DS3.d357.s0.e0" id="DS3.d357.s0.i1" interaction="False" />
            <pair e1="DS3.d357.s0.e1" e2="DS3.d357.s0.e2" id="DS3.d357.s0.i2" interaction="False" />
            <pair e1="DS3.d357.s0.e1" e2="DS3.d357.s0.e0" id="DS3.d357.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d357.s1" origId="9949257-13" text="And also that the modulation of this exchanger is the consequence of the connection between different intracellular mechanisms, Na+/K+-ATPase-PKC-calcium, among which cAMP seems not to have a direct role.">
            <entity id="DS3.d357.s1.e0" origId="22044544,5460341" charOffset="146-153" type="compound" text="calcium"/>
            <entity id="DS3.d357.s1.e1" origId="G3V8S9" charOffset="167-171" type="protein" text="cAMP"/>
            <pair e1="DS3.d357.s1.e0" e2="DS3.d357.s1.e1" id="DS3.d357.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d357.s2" origId="9949257-2" text="After promoting an artificial acidification with sodium propionate we determined the variations on pHi rate recovery.">
            <entity id="DS3.d357.s2.e0" origId="1032" charOffset="49-66" type="compound" text="sodium propionate"/>
            <entity id="DS3.d357.s2.e1" origId="Q6P6V0" charOffset="99-102" type="protein" text="pHi"/>
            <pair e1="DS3.d357.s2.e0" e2="DS3.d357.s2.e1" id="DS3.d357.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d357.s3" origId="9949257-3" text="pHi was measured with the dye 2, 7-bis(carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester.">
            <entity id="DS3.d357.s3.e0" origId="Q6P6V0" charOffset="0-3" type="protein" text="pHi"/>
            <entity id="DS3.d357.s3.e1" origId="22244731" charOffset="58-96" type="compound" text="carboxyfluorescein acetoxymethyl ester"/>
            <pair e1="DS3.d357.s3.e1" e2="DS3.d357.s3.e0" id="DS3.d357.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d357.s4" origId="9949257-8" text="The suppression of intracellular and extracellular calcium did not induced any change in pHi.">
            <entity id="DS3.d357.s4.e0" origId="22044544,5460341" charOffset="51-58" type="compound" text="calcium"/>
            <entity id="DS3.d357.s4.e1" origId="Q6P6V0" charOffset="89-92" type="protein" text="pHi"/>
            <pair e1="DS3.d357.s4.e0" e2="DS3.d357.s4.e1" id="DS3.d357.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d358" origId="9949282">
        <sentence id="DS3.d358.s0" origId="9949282-5" text="The progesterone/estradiol ratio was lower in the patients expressing immunoreactive c-fos (median = 13.1 ng/ml) compared to those who did not (median = 84.5 ng/ml, p &amp;lt; 0.05).">
            <entity id="DS3.d358.s0.e0" origId="5994" charOffset="4-16" type="compound" text="progesterone"/>
            <entity id="DS3.d358.s0.e1" origId="5757" charOffset="17-26" type="compound" text="estradiol"/>
            <entity id="DS3.d358.s0.e2" origId="P01100,Q6FG41" charOffset="85-90" type="protein" text="c-fos"/>
            <pair e1="DS3.d358.s0.e1" e2="DS3.d358.s0.e2" id="DS3.d358.s0.i0" interaction="False" />
            <pair e1="DS3.d358.s0.e0" e2="DS3.d358.s0.e2" id="DS3.d358.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d358.s1" origId="9949282-6" text="We conclude that immunoreactive c-fos is found mostly in stromal cells during the proliferative phase of the menstrual cycle, and is sharply reduced during the secretory phase, when the endometrium is under progesterone stimulation - attested by PRL production.">
            <entity id="DS3.d358.s1.e0" origId="P01100,Q6FG41" charOffset="32-37" type="protein" text="c-fos"/>
            <entity id="DS3.d358.s1.e1" origId="5994" charOffset="207-219" type="compound" text="progesterone"/>
            <entity id="DS3.d358.s1.e2" origId="P01236,Q5I0G2,Q5THQ0" charOffset="246-249" type="protein" text="PRL"/>
            <pair e1="DS3.d358.s1.e1" e2="DS3.d358.s1.e2" id="DS3.d358.s1.i0" interaction="False" />
            <pair e1="DS3.d358.s1.e1" e2="DS3.d358.s1.e0" id="DS3.d358.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d359" origId="9949285">
        <sentence id="DS3.d359.s0" origId="9949285-1" text="BACKGROUND AND METHODS: Because the use of immunohistochemistry in the diagnosis of granulosa cell tumor (GCT) has not been fully explored, routinely processed (formalin-fixed, paraffin-embedded) tissue from 11 GCT, adult type, was investigated immunohistochemically (ABC method) with a broad spectrum of antibodies against various markers, including p53 and Ki-67.">
            <entity id="DS3.d359.s0.e0" origId="712" charOffset="161-169" type="compound" text="formalin"/>
            <entity id="DS3.d359.s0.e1" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="351-354" type="protein" text="p53"/>
            <pair e1="DS3.d359.s0.e0" e2="DS3.d359.s0.e1" id="DS3.d359.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d360" origId="9949291">
        <sentence id="DS3.d360.s0" origId="9949291-3" text="Laminin contributed most to the action of plasmin.">
            <entity id="DS3.d360.s0.e0" origId="44342165" charOffset="0-7" type="compound" text="Laminin"/>
            <entity id="DS3.d360.s0.e1" origId="P00747,Q5TEH5" charOffset="42-49" type="protein" text="plasmin"/>
            <pair e1="DS3.d360.s0.e0" e2="DS3.d360.s0.e1" id="DS3.d360.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d360.s1" origId="9949291-4" text="The cell motility induced by plasmin and laminin was chemokinetic in nature and was almost completely suppressed by alpha2-antiplasmin.">
            <entity id="DS3.d360.s1.e0" origId="P00747,Q5TEH5" charOffset="29-36" type="protein" text="plasmin"/>
            <entity id="DS3.d360.s1.e1" origId="44342165" charOffset="41-48" type="compound" text="laminin"/>
            <pair e1="DS3.d360.s1.e1" e2="DS3.d360.s1.e0" id="DS3.d360.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d360.s2" origId="9949291-6" text="The results suggested that plasmin may modulate cell motility through protein kinase C and mitogen-activated protein kinase cascades in cooperation with laminin.">
            <entity id="DS3.d360.s2.e0" origId="P00747,Q5TEH5" charOffset="27-34" type="protein" text="plasmin"/>
            <entity id="DS3.d360.s2.e1" origId="44342165" charOffset="153-160" type="compound" text="laminin"/>
            <pair e1="DS3.d360.s2.e1" e2="DS3.d360.s2.e0" id="DS3.d360.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d361" origId="9949294">
        <sentence id="DS3.d361.s0" origId="9949294-11" text="We conclude that intravenous CMF with a cyclophosphamide dose of 1,500 mg/m2 given at 3-week intervals with the selective use of prophylactic G-CSF is feasible as adjuvant treatment for patients with breast cancer.">
            <entity id="DS3.d361.s0.e0" origId="2907" charOffset="40-56" type="compound" text="cyclophosphamide"/>
            <entity id="DS3.d361.s0.e1" origId="P09919,Q6FH65,Q8N4W3" charOffset="142-147" type="protein" text="G-CSF"/>
            <pair e1="DS3.d361.s0.e0" e2="DS3.d361.s0.e1" id="DS3.d361.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d361.s1" origId="9949294-1" text="Escalating doses of cyclophosphamide were given every 3 weeks as adjuvant treatment for women operated for breast cancer to determine the maximum tolerated dose of cyclophosphamide that can be given with constant doses of methotrexate (40 mg/m2) and 5-FU (600 mg/m2; CMF) as an outpatient treatment without the routine use of granulocyte colony-stimulating growth factor (G-CSF).">
            <entity id="DS3.d361.s1.e0" origId="2907" charOffset="20-36" type="compound" text="cyclophosphamide"/>
            <entity id="DS3.d361.s1.e1" origId="2907" charOffset="164-180" type="compound" text="cyclophosphamide"/>
            <entity id="DS3.d361.s1.e2" origId="126941" charOffset="222-234" type="compound" text="methotrexate"/>
            <entity id="DS3.d361.s1.e3" origId="P09919,Q6FH65,Q8N4W3" charOffset="326-370" type="protein" text="granulocyte colony-stimulating growth factor"/>
            <entity id="DS3.d361.s1.e4" origId="P09919,Q6FH65,Q8N4W3" charOffset="372-377" type="protein" text="G-CSF"/>
            <pair e1="DS3.d361.s1.e2" e2="DS3.d361.s1.e3" id="DS3.d361.s1.i0" interaction="False" />
            <pair e1="DS3.d361.s1.e2" e2="DS3.d361.s1.e4" id="DS3.d361.s1.i1" interaction="False" />
            <pair e1="DS3.d361.s1.e0" e2="DS3.d361.s1.e3" id="DS3.d361.s1.i2" interaction="False" />
            <pair e1="DS3.d361.s1.e0" e2="DS3.d361.s1.e4" id="DS3.d361.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d361.s2" origId="9949294-5" text="G-CSF and ofloxacin were used if grade IV granulocytopenia continued for longer than 48 h or if granulocytopenic infection occurred.">
            <entity id="DS3.d361.s2.e0" origId="P09919,Q6FH65,Q8N4W3" charOffset="0-5" type="protein" text="G-CSF"/>
            <entity id="DS3.d361.s2.e1" origId="4583" charOffset="10-19" type="compound" text="ofloxacin"/>
            <pair e1="DS3.d361.s2.e1" e2="DS3.d361.s2.e0" id="DS3.d361.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d362" origId="9949297">
        <sentence id="DS3.d362.s0" origId="9949297-8" text="ACTH stimulation tests demonstrated that Rivizor does not interfere with adrenal mineralocorticoid and glucocorticoid steroid synthesis.">
            <entity id="DS3.d362.s0.e0" origId="P01189,Q6FHC8" charOffset="0-4" type="protein" text="ACTH"/>
            <entity id="DS3.d362.s0.e1" origId="6918191" charOffset="41-48" type="compound" text="Rivizor"/>
            <pair e1="DS3.d362.s0.e1" e2="DS3.d362.s0.e0" id="DS3.d362.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d363" origId="9949299">
        <sentence id="DS3.d363.s0" origId="9949299-1" text="To clarify the host immune response and explore a new serological marker of lung cancer, we examined serum c-Myc antigens and auto-antibodies against c-Myc in 68 lung cancer patients and 30 healthy volunteers using bacterially synthesized glutathione S-transferase c-Myc fusion proteins and immunoblotting.">
            <entity id="DS3.d363.s0.e0" origId="P01106" charOffset="107-112" type="protein" text="c-Myc"/>
            <entity id="DS3.d363.s0.e1" origId="P01106" charOffset="150-155" type="protein" text="c-Myc"/>
            <entity id="DS3.d363.s0.e2" origId="124886,20725278" charOffset="239-250" type="compound" text="glutathione"/>
            <entity id="DS3.d363.s0.e3" origId="P01106" charOffset="150-155" type="protein" text="c-Myc"/>
            <pair e1="DS3.d363.s0.e2" e2="DS3.d363.s0.e0" id="DS3.d363.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d364" origId="9949305">
        <sentence id="DS3.d364.s0" origId="9949305-10" text="At passage 12 SNAT and N-acetylserotonin were unaffected but a depletion of plasma tryptophan (-34%, p &amp;lt; 0.0001), the precursor amino acid of melatonin, was found.">
            <entity id="DS3.d364.s0.e0" origId="Q16613,F1T0I5" charOffset="14-18" type="protein" text="SNAT"/>
            <entity id="DS3.d364.s0.e1" origId="903" charOffset="23-40" type="compound" text="N-acetylserotonin"/>
            <entity id="DS3.d364.s0.e2" origId="57175189" charOffset="83-93" type="compound" text="tryptophan"/>
            <entity id="DS3.d364.s0.e3" origId="896" charOffset="145-154" type="compound" text="melatonin"/>
            <pair e1="DS3.d364.s0.e1" e2="DS3.d364.s0.e0" id="DS3.d364.s0.i0" interaction="False" />
            <pair e1="DS3.d364.s0.e3" e2="DS3.d364.s0.e0" id="DS3.d364.s0.i1" interaction="False" />
            <pair e1="DS3.d364.s0.e2" e2="DS3.d364.s0.e0" id="DS3.d364.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d364.s1" origId="9949305-12" text="Therefore, the involvement of an additional mechanism has to be postulated, such as a degradation of melatonin via indoleamine 2,3-dioxygenase, an extrahepatic enzyme which has been detected in tumor tissue and is related to tryptophan 2,3-dioxygenase (TDO).">
            <entity id="DS3.d364.s1.e0" origId="896" charOffset="101-110" type="compound" text="melatonin"/>
            <entity id="DS3.d364.s1.e1" origId="P48775" charOffset="225-251" type="protein" text="tryptophan 2,3-dioxygenase"/>
            <entity id="DS3.d364.s1.e2" origId="P48775" charOffset="253-256" type="protein" text="TDO"/>
            <pair e1="DS3.d364.s1.e0" e2="DS3.d364.s1.e1" id="DS3.d364.s1.i0" interaction="False" />
            <pair e1="DS3.d364.s1.e0" e2="DS3.d364.s1.e2" id="DS3.d364.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d364.s2" origId="9949305-13" text="TDO occurs only in the liver, is highly specific for L-tryptophan and is induced by glucocorticoids which would account for the observed depletion of plasma tryptophan resulting from a tumor-associated activation of the hypothalamo-pituitary-adrenal axis (urinary corticosterone +208%, p &amp;lt; 0.01).">
            <entity id="DS3.d364.s2.e0" origId="P48775" charOffset="0-3" type="protein" text="TDO"/>
            <entity id="DS3.d364.s2.e1" origId="57175189" charOffset="55-65" type="compound" text="tryptophan"/>
            <entity id="DS3.d364.s2.e2" origId="57175189" charOffset="157-167" type="compound" text="tryptophan"/>
            <entity id="DS3.d364.s2.e3" origId="5753" charOffset="264-278" type="compound" text="corticosterone"/>
            <pair e1="DS3.d364.s2.e1" e2="DS3.d364.s2.e0" id="DS3.d364.s2.i0" interaction="False" />
            <pair e1="DS3.d364.s2.e3" e2="DS3.d364.s2.e0" id="DS3.d364.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d364.s3" origId="9949305-8" text="At passage 2 nocturnal pineal N-acetylserotonin (02.00-03.00 h) was significantly enhanced (+62%, p &amp;lt; 0.05) probably due to an increased activity of serotonin-N-acetyltransferase (SNAT, +45%), the rate-limiting step of pineal melatonin biosynthesis converting serotonin to N-acetylserotonin.">
            <entity id="DS3.d364.s3.e0" origId="903" charOffset="30-47" type="compound" text="N-acetylserotonin"/>
            <entity id="DS3.d364.s3.e1" origId="Q16613,F1T0I5" charOffset="152-181" type="protein" text="serotonin-N-acetyltransferase"/>
            <entity id="DS3.d364.s3.e2" origId="Q16613,F1T0I5" charOffset="183-187" type="protein" text="SNAT"/>
            <entity id="DS3.d364.s3.e3" origId="896" charOffset="229-238" type="compound" text="melatonin"/>
            <entity id="DS3.d364.s3.e4" origId="5202" charOffset="38-47" type="compound" text="serotonin"/>
            <entity id="DS3.d364.s3.e5" origId="903" charOffset="276-293" type="compound" text="N-acetylserotonin"/>
            <pair e1="DS3.d364.s3.e4" e2="DS3.d364.s3.e1" id="DS3.d364.s3.i0" interaction="False" />
            <pair e1="DS3.d364.s3.e4" e2="DS3.d364.s3.e2" id="DS3.d364.s3.i1" interaction="False" />
            <pair e1="DS3.d364.s3.e0" e2="DS3.d364.s3.e1" id="DS3.d364.s3.i2" interaction="False" />
            <pair e1="DS3.d364.s3.e0" e2="DS3.d364.s3.e2" id="DS3.d364.s3.i3" interaction="False" />
            <pair e1="DS3.d364.s3.e3" e2="DS3.d364.s3.e1" id="DS3.d364.s3.i4" interaction="False" />
            <pair e1="DS3.d364.s3.e3" e2="DS3.d364.s3.e2" id="DS3.d364.s3.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d364.s4" origId="9949305-9" text="The activation of SNAT may be due to a stimulation of the sympathetic nervous system (urinary noradrenaline; NA: +243%, p &amp;lt; 0.005) when the cellular immune system responded towards tumor growth (urinary biopterin, +214%, p &amp;lt; 0.005).">
            <entity id="DS3.d364.s4.e0" origId="Q16613,F1T0I5" charOffset="18-22" type="protein" text="SNAT"/>
            <entity id="DS3.d364.s4.e1" origId="439260" charOffset="94-107" type="compound" text="noradrenaline"/>
            <entity id="DS3.d364.s4.e2" origId="2380,444475,445040" charOffset="206-215" type="compound" text="biopterin"/>
            <pair e1="DS3.d364.s4.e1" e2="DS3.d364.s4.e0" id="DS3.d364.s4.i0" interaction="False" />
            <pair e1="DS3.d364.s4.e2" e2="DS3.d364.s4.e0" id="DS3.d364.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d365" origId="9949313">
        <sentence id="DS3.d365.s0" origId="9949313-5" text="RESULTS: Most patients were nonobstructed (FEV1, 91% +/- 20%); a low level of bronchial reversibility (FEV1 increase after beta2 -agonist, 7.8% +/- 9.2%) and BHR (histamine PC20 FEV1 geometric mean, 0.98 mg/mL) were found.">
            <entity id="DS3.d365.s0.e0" origId="Q13562" charOffset="123-128" type="protein" text="beta2"/>
            <entity id="DS3.d365.s0.e1" origId="774" charOffset="163-172" type="compound" text="histamine"/>
            <pair e1="DS3.d365.s0.e1" e2="DS3.d365.s0.e0" id="DS3.d365.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d366" origId="9949315">
        <sentence id="DS3.d366.s0" origId="9949315-11" text="Significant treatment-by-strata interactions (P &amp;lt;.05), favoring zafirlukast, were noted for various outcome measures in subgroups with the greatest amount of baseline beta2 -agonist use (&amp;gt;8 puffs/day) and with greater baseline peak flow variability (&amp;gt;/=20%) and baseline airflow obstruction (FEV1 /forced vital capacity ratio, &amp;lt;0.70).">
            <entity id="DS3.d366.s0.e0" origId="5717" charOffset="67-78" type="compound" text="zafirlukast"/>
            <entity id="DS3.d366.s0.e1" origId="Q13562" charOffset="170-175" type="protein" text="beta2"/>
            <pair e1="DS3.d366.s0.e0" e2="DS3.d366.s0.e1" id="DS3.d366.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d366.s1" origId="9949315-7" text="Significant overall treatment effects, favoring zafirlukast, were noted for measures of daytime and nighttime symptoms, beta2 -agonist use, and pulmonary function (P &amp;lt;.05).">
            <entity id="DS3.d366.s1.e0" origId="5717" charOffset="48-59" type="compound" text="zafirlukast"/>
            <entity id="DS3.d366.s1.e1" origId="Q13562" charOffset="120-125" type="protein" text="beta2"/>
            <pair e1="DS3.d366.s1.e0" e2="DS3.d366.s1.e1" id="DS3.d366.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d367" origId="9949326">
        <sentence id="DS3.d367.s0" origId="9949326-0" text="Decreased release of histamine and sulfidoleukotrienes by human peripheral blood leukocytes after wasp venom immunotherapy is partially due to induction of IL-10 and IFN-gamma production of T cells.">
            <entity id="DS3.d367.s0.e0" origId="774" charOffset="21-30" type="compound" text="histamine"/>
            <entity id="DS3.d367.s0.e1" origId="P22301,Q6FGW4" charOffset="156-161" type="protein" text="IL-10"/>
            <entity id="DS3.d367.s0.e2" origId="P01579" charOffset="166-175" type="protein" text="IFN-gamma"/>
            <pair e1="DS3.d367.s0.e0" e2="DS3.d367.s0.e2" id="DS3.d367.s0.i0" interaction="False" />
            <pair e1="DS3.d367.s0.e0" e2="DS3.d367.s0.e1" id="DS3.d367.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d367.s1" origId="9949326-7" text="This was at least partially due to the induction of IFN-gamma and IL-10 production, because (1) neutralization of IL-10 and IFN-gamma by mAbs partially restored the release after the initiation of VIT and (2) the addition of exogenous IFN-gamma and IL-10 caused a statistically significant diminution of the venom-induced histamine and sulfidoleukotriene release before VIT.">
            <entity id="DS3.d367.s1.e0" origId="P01579" charOffset="52-61" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d367.s1.e1" origId="P22301,Q6FGW4" charOffset="66-71" type="protein" text="IL-10"/>
            <entity id="DS3.d367.s1.e2" origId="P22301,Q6FGW4" charOffset="114-119" type="protein" text="IL-10"/>
            <entity id="DS3.d367.s1.e3" origId="P01579" charOffset="124-133" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d367.s1.e4" origId="P01579" charOffset="124-133" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d367.s1.e5" origId="P22301,Q6FGW4" charOffset="114-119" type="protein" text="IL-10"/>
            <entity id="DS3.d367.s1.e6" origId="774" charOffset="322-331" type="compound" text="histamine"/>
            <pair e1="DS3.d367.s1.e6" e2="DS3.d367.s1.e0" id="DS3.d367.s1.i0" interaction="False" />
            <pair e1="DS3.d367.s1.e6" e2="DS3.d367.s1.e1" id="DS3.d367.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d367.s2" origId="9949326-9" text="CONCLUSION: These data indicate that T cells (producing IL-10 and IFN-gamma after VIT) play a key role for the inhibition of histamine and sulfidoleukotriene release of effector cells.">
            <entity id="DS3.d367.s2.e0" origId="P22301,Q6FGW4" charOffset="56-61" type="protein" text="IL-10"/>
            <entity id="DS3.d367.s2.e1" origId="P01579" charOffset="66-75" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d367.s2.e2" origId="774" charOffset="125-134" type="compound" text="histamine"/>
            <pair e1="DS3.d367.s2.e2" e2="DS3.d367.s2.e1" id="DS3.d367.s2.i0" interaction="False" />
            <pair e1="DS3.d367.s2.e2" e2="DS3.d367.s2.e0" id="DS3.d367.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d368" origId="9949327">
        <sentence id="DS3.d368.s0" origId="9949327-10" text="CONCLUSION: These data show that overproduction of IgE and IgG4 can be regulated by a number of cytokines affecting the IL-4-dependent pathway of IgE/IgG4 production in HIE and suggest new targets for therapeutic intervention.">
            <entity id="DS3.d368.s0.e0" origId="P05112,D4HNR6,Q5FC01" charOffset="120-124" type="protein" text="IL-4"/>
            <entity id="DS3.d368.s0.e1" origId="24772860" charOffset="169-172" type="compound" text="HIE"/>
            <pair e1="DS3.d368.s0.e1" e2="DS3.d368.s0.e0" id="DS3.d368.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d368.s1" origId="9949327-5" text="METHODS: PBMCs were isolated from patients with HIE (n = 9) and normal individuals (n = 8), and IgE and IgG4 production was assessed spontaneously, in the presence of recombinant IL-4, IL-13, IL-6, IL-8, IL-12, and IFN-gamma, under conditions in which the IL-4R was blocked or when these cytokines were neutralized by specific monoclonal or polyclonal antibodies.">
            <entity id="DS3.d368.s1.e0" origId="24772860" charOffset="48-51" type="compound" text="HIE"/>
            <entity id="DS3.d368.s1.e1" origId="P05112,D4HNR6,Q5FC01" charOffset="179-183" type="protein" text="IL-4"/>
            <entity id="DS3.d368.s1.e2" origId="P35225" charOffset="185-190" type="protein" text="IL-13"/>
            <entity id="DS3.d368.s1.e3" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="192-196" type="protein" text="IL-6"/>
            <entity id="DS3.d368.s1.e4" origId="P10145,A0A024RDA5" charOffset="198-202" type="protein" text="IL-8"/>
            <entity id="DS3.d368.s1.e5" origId="P01579" charOffset="215-224" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d368.s1.e6" origId="P24394,B2RBY1" charOffset="256-261" type="protein" text="IL-4R"/>
            <pair e1="DS3.d368.s1.e0" e2="DS3.d368.s1.e4" id="DS3.d368.s1.i0" interaction="False" />
            <pair e1="DS3.d368.s1.e0" e2="DS3.d368.s1.e1" id="DS3.d368.s1.i1" interaction="False" />
            <pair e1="DS3.d368.s1.e0" e2="DS3.d368.s1.e3" id="DS3.d368.s1.i2" interaction="False" />
            <pair e1="DS3.d368.s1.e0" e2="DS3.d368.s1.e2" id="DS3.d368.s1.i3" interaction="False" />
            <pair e1="DS3.d368.s1.e0" e2="DS3.d368.s1.e5" id="DS3.d368.s1.i4" interaction="False" />
            <pair e1="DS3.d368.s1.e0" e2="DS3.d368.s1.e6" id="DS3.d368.s1.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d368.s2" origId="9949327-6" text="RESULTS: In PBMCs from patients with HIE, a significant (P &amp;lt;.01) reduction in the spontaneously produced IgE (and IgG4) was induced by either IFN-gamma or IL-12, although neither cytokine could totally abrogate the immunoglobulin production.">
            <entity id="DS3.d368.s2.e0" origId="24772860" charOffset="37-40" type="compound" text="HIE"/>
            <entity id="DS3.d368.s2.e1" origId="P01579" charOffset="145-154" type="protein" text="IFN-gamma"/>
            <pair e1="DS3.d368.s2.e0" e2="DS3.d368.s2.e1" id="DS3.d368.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d368.s3" origId="9949327-8" text="In contrast to the neutralization of IL-4 and IL-13 protein, anti-IL-4R antibodies or soluble IL-4R completely suppressed IgE and IgG4 production in HIE.">
            <entity id="DS3.d368.s3.e0" origId="P05112,D4HNR6,Q5FC01" charOffset="37-41" type="protein" text="IL-4"/>
            <entity id="DS3.d368.s3.e1" origId="P35225" charOffset="46-51" type="protein" text="IL-13"/>
            <entity id="DS3.d368.s3.e2" origId="P24394,B2RBY1" charOffset="66-71" type="protein" text="IL-4R"/>
            <entity id="DS3.d368.s3.e3" origId="P24394,B2RBY1" charOffset="94-99" type="protein" text="IL-4R"/>
            <entity id="DS3.d368.s3.e4" origId="24772860" charOffset="149-152" type="compound" text="HIE"/>
            <pair e1="DS3.d368.s3.e4" e2="DS3.d368.s3.e0" id="DS3.d368.s3.i0" interaction="False" />
            <pair e1="DS3.d368.s3.e4" e2="DS3.d368.s3.e2" id="DS3.d368.s3.i1" interaction="False" />
            <pair e1="DS3.d368.s3.e4" e2="DS3.d368.s3.e1" id="DS3.d368.s3.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d369" origId="9949353">
        <sentence id="DS3.d369.s0" origId="9949353-6" text="To explore the role played by Cyclin D1 in the pathogenesis of thyroid papillary carcinoma, we have quantitated, by computerized image analysis, the immunohistochemical expression of Cyclin D1 in formalin-fixed, paraffin-embedded tissue from 35 conventional papillary carcinomas of the thyroid and correlated the results with established clinicopathologic parameters and available survival data.">
            <entity id="DS3.d369.s0.e0" origId="P24385,Q6FI00" charOffset="30-39" type="protein" text="Cyclin D1"/>
            <entity id="DS3.d369.s0.e1" origId="P24385,Q6FI00" charOffset="183-192" type="protein" text="Cyclin D1"/>
            <entity id="DS3.d369.s0.e2" origId="712" charOffset="196-204" type="compound" text="formalin"/>
            <pair e1="DS3.d369.s0.e2" e2="DS3.d369.s0.e0" id="DS3.d369.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d370" origId="9949357">
        <sentence id="DS3.d370.s0" origId="9949357-9" text="The mast-cell mediators tryptase and prostaglandin D2 were analyzed, as was a marker of epithelial cell permeability, albumin.">
            <entity id="DS3.d370.s0.e0" origId="448457" charOffset="37-53" type="compound" text="prostaglandin D2"/>
            <entity id="DS3.d370.s0.e1" origId="P02768" charOffset="118-125" type="protein" text="albumin"/>
            <pair e1="DS3.d370.s0.e0" e2="DS3.d370.s0.e1" id="DS3.d370.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d371" origId="9949365">
        <sentence id="DS3.d371.s0" origId="9949365-0" text="Effect of parenteral pentoxifylline and topical nitroglycerin on skin flap survival.">
            <entity id="DS3.d371.s0.e0" origId="4740" charOffset="21-35" type="compound" text="pentoxifylline"/>
            <entity id="DS3.d371.s0.e1" origId="4510" charOffset="48-61" type="compound" text="nitroglycerin"/>
            <entity id="DS3.d371.s0.e2" origId="P20291" charOffset="70-74" type="protein" text="flap"/>
            <pair e1="DS3.d371.s0.e0" e2="DS3.d371.s0.e2" id="DS3.d371.s0.i0" interaction="False" />
            <pair e1="DS3.d371.s0.e1" e2="DS3.d371.s0.e2" id="DS3.d371.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d371.s1" origId="9949365-4" text="In the group treated with pentoxifylline and nitroglycerin (n = 15), the mean viable length of the flap was calculated to be 6.907 +/- 0.617, and the mean nonnecrotic flap area was found to be 2078.5 +/- 172.7.">
            <entity id="DS3.d371.s1.e0" origId="4740" charOffset="26-40" type="compound" text="pentoxifylline"/>
            <entity id="DS3.d371.s1.e1" origId="4510" charOffset="45-58" type="compound" text="nitroglycerin"/>
            <entity id="DS3.d371.s1.e2" origId="P20291" charOffset="99-103" type="protein" text="flap"/>
            <entity id="DS3.d371.s1.e3" origId="P20291" charOffset="167-171" type="protein" text="flap"/>
            <pair e1="DS3.d371.s1.e0" e2="DS3.d371.s1.e2" id="DS3.d371.s1.i0" interaction="False" />
            <pair e1="DS3.d371.s1.e1" e2="DS3.d371.s1.e2" id="DS3.d371.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d371.s2" origId="9949365-5" text="In this study results showed that the use of parenteral pentoxifylline and topical nitroglycerin is effective on skin flap survival.">
            <entity id="DS3.d371.s2.e0" origId="4740" charOffset="56-70" type="compound" text="pentoxifylline"/>
            <entity id="DS3.d371.s2.e1" origId="4510" charOffset="83-96" type="compound" text="nitroglycerin"/>
            <entity id="DS3.d371.s2.e2" origId="P20291" charOffset="118-122" type="protein" text="flap"/>
            <pair e1="DS3.d371.s2.e0" e2="DS3.d371.s2.e2" id="DS3.d371.s2.i0" interaction="False" />
            <pair e1="DS3.d371.s2.e1" e2="DS3.d371.s2.e2" id="DS3.d371.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d372" origId="9949414">
        <sentence id="DS3.d372.s0" origId="9949414-1" text="Adding normal saline (NS) separately before 99Tcm-sodium pertechnetate to MDP cold kits has been shown to reduce substantially the radiation dose to the hand.">
            <entity id="DS3.d372.s0.e0" origId="74086836" charOffset="50-70" type="compound" text="sodium pertechnetate"/>
            <entity id="DS3.d372.s0.e1" origId="P16444" charOffset="74-77" type="protein" text="MDP"/>
            <pair e1="DS3.d372.s0.e0" e2="DS3.d372.s0.e1" id="DS3.d372.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d373" origId="9949425">
        <sentence id="DS3.d373.s0" origId="9949425-5" text="RESULTS: The mean reference ratio for fluorodeoxyglucose F18 metabolism was significantly elevated in the striatum compared with the frontal, temporal, or parietal regions.">
            <entity id="DS3.d373.s0.e0" origId="54303434" charOffset="38-56" type="compound" text="fluorodeoxyglucose"/>
            <entity id="DS3.d373.s0.e1" origId="Q13495" charOffset="57-60" type="protein" text="F18"/>
            <pair e1="DS3.d373.s0.e0" e2="DS3.d373.s0.e1" id="DS3.d373.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d374" origId="9949435">
        <sentence id="DS3.d374.s0" origId="9949435-7" text="When congenital bilateral absence of the vas deferens with azoospermia is encountered, cystic fibrosis transmembrane conductance regulator (CFTR) gene mutations are commonly the underlying cause.">
            <entity id="DS3.d374.s0.e0" origId="6323535" charOffset="41-44" type="compound" text="vas"/>
            <entity id="DS3.d374.s0.e1" origId="P13569,A0A024R730" charOffset="87-138" type="protein" text="cystic fibrosis transmembrane conductance regulator"/>
            <pair e1="DS3.d374.s0.e0" e2="DS3.d374.s0.e1" id="DS3.d374.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d375" origId="9949468">
        <sentence id="DS3.d375.s0" origId="9949468-7" text="RESULTS: Emoxipine-treated patients had reduced content of primary lipid peroxidation products and schiff bases in AM, catalase level in them returned to normal, blood levels of alpha-tocopherol went up.">
            <entity id="DS3.d375.s0.e0" origId="114681" charOffset="9-18" type="compound" text="Emoxipine"/>
            <entity id="DS3.d375.s0.e1" origId="P04040" charOffset="119-127" type="protein" text="catalase"/>
            <pair e1="DS3.d375.s0.e0" e2="DS3.d375.s0.e1" id="DS3.d375.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d376" origId="9949474">
        <sentence id="DS3.d376.s0" origId="9949474-6" text="Statistical differences observed in serum chloride and albumin, amylase activities, spun packed-cell volumes, red blood cell counts, hemoglobin concentrations, and hematocrit values between control and moniliformin-dosed mink were considered biologically insignificant because values were within ranges reported for normal mink.">
            <entity id="DS3.d376.s0.e0" origId="312" charOffset="42-50" type="compound" text="chloride"/>
            <entity id="DS3.d376.s0.e1" origId="P02768" charOffset="55-62" type="protein" text="albumin"/>
            <entity id="DS3.d376.s0.e2" origId="40452" charOffset="202-214" type="compound" text="moniliformin"/>
            <pair e1="DS3.d376.s0.e0" e2="DS3.d376.s0.e1" id="DS3.d376.s0.i0" interaction="False" />
            <pair e1="DS3.d376.s0.e2" e2="DS3.d376.s0.e1" id="DS3.d376.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d377" origId="9949475">
        <sentence id="DS3.d377.s0" origId="9949475-3" text="Fifty percent Rhazya was fatal to rats, and hepatorenal lesions at 3 and 6 w confirmed changes in serum enzyme activity and in total protein, albumin, bilirubin and urea concentrations.">
            <entity id="DS3.d377.s0.e0" origId="P02770,A0A0G2JSH5" charOffset="142-149" type="protein" text="albumin"/>
            <entity id="DS3.d377.s0.e1" origId="5280352" charOffset="151-160" type="compound" text="bilirubin"/>
            <entity id="DS3.d377.s0.e2" origId="1176" charOffset="165-169" type="compound" text="urea"/>
            <pair e1="DS3.d377.s0.e1" e2="DS3.d377.s0.e0" id="DS3.d377.s0.i0" interaction="False" />
            <pair e1="DS3.d377.s0.e2" e2="DS3.d377.s0.e0" id="DS3.d377.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d378" origId="9949481">
        <sentence id="DS3.d378.s0" origId="9949481-2" text="A view of the plants in the region and blood examination (hemogram, albumin, total protein, calcium and phosphorus) and determination of bone calcium were done.">
            <entity id="DS3.d378.s0.e0" origId="P02769" charOffset="68-75" type="protein" text="albumin"/>
            <entity id="DS3.d378.s0.e1" origId="22044544,5460341" charOffset="92-99" type="compound" text="calcium"/>
            <entity id="DS3.d378.s0.e2" origId="22044544,5460341" charOffset="142-149" type="compound" text="calcium"/>
            <pair e1="DS3.d378.s0.e1" e2="DS3.d378.s0.e0" id="DS3.d378.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d379" origId="9949488">
        <sentence id="DS3.d379.s0" origId="9949488-10" text="ABMT/ACMT members favored the use of syrup of ipecac in this scenario (P &amp;lt; 0.005), while the CSPI's did not (P &amp;lt; 0.005), and the ABAT's did not have statistical difference.">
            <entity id="DS3.d379.s0.e0" origId="11162923" charOffset="37-42" type="compound" text="syrup"/>
            <entity id="DS3.d379.s0.e1" origId="P80404,X5D8S1" charOffset="135-139" type="protein" text="ABAT"/>
            <pair e1="DS3.d379.s0.e0" e2="DS3.d379.s0.e1" id="DS3.d379.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d379.s1" origId="9949488-2" text="A survey compared syrup of ipecac use by CSPI, ABAT, and ABMT/ACMT members as the first response decontamination.">
            <entity id="DS3.d379.s1.e0" origId="11162923" charOffset="18-23" type="compound" text="syrup"/>
            <entity id="DS3.d379.s1.e1" origId="P80404,X5D8S1" charOffset="47-51" type="protein" text="ABAT"/>
            <pair e1="DS3.d379.s1.e0" e2="DS3.d379.s1.e1" id="DS3.d379.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d379.s2" origId="9949488-3" text="The survey asked CSPI, ABAT, and ABMT/ACMT members their professional opinion on the use of syrup of ipecac in a potentially toxic ingestion.">
            <entity id="DS3.d379.s2.e0" origId="P80404,X5D8S1" charOffset="23-27" type="protein" text="ABAT"/>
            <entity id="DS3.d379.s2.e1" origId="11162923" charOffset="92-97" type="compound" text="syrup"/>
            <pair e1="DS3.d379.s2.e1" e2="DS3.d379.s2.e0" id="DS3.d379.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d380" origId="9949493">
        <sentence id="DS3.d380.s0" origId="9949493-3" text="In monocytes, the toxin in a dose of 0.2 microgram/4 x 10(4) cells inhibited the formation of active forms of oxygen (AFO) and activated the production of superoxide dismutase (SOD).">
            <entity id="DS3.d380.s0.e0" origId="977" charOffset="110-116" type="compound" text="oxygen"/>
            <entity id="DS3.d380.s0.e1" origId="49795070" charOffset="118-121" type="compound" text="AFO"/>
            <entity id="DS3.d380.s0.e2" origId="5359597" charOffset="155-165" type="compound" text="superoxide"/>
            <entity id="DS3.d380.s0.e3" origId="P00441,V9HWC9" charOffset="177-180" type="protein" text="SOD"/>
            <pair e1="DS3.d380.s0.e1" e2="DS3.d380.s0.e3" id="DS3.d380.s0.i0" interaction="False" />
            <pair e1="DS3.d380.s0.e2" e2="DS3.d380.s0.e3" id="DS3.d380.s0.i1" interaction="False" />
            <pair e1="DS3.d380.s0.e0" e2="DS3.d380.s0.e3" id="DS3.d380.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d380.s1" origId="9949493-7" text="Indomethacin prevented the action of the toxin on mononuclears with respect to AFO, SOD and cAMP, which was indicative of the mediating role of prostaglandins in the mechanism of the action of the toxin.">
            <entity id="DS3.d380.s1.e0" origId="3715" charOffset="0-12" type="compound" text="Indomethacin"/>
            <entity id="DS3.d380.s1.e1" origId="49795070" charOffset="79-82" type="compound" text="AFO"/>
            <entity id="DS3.d380.s1.e2" origId="P00441,V9HWC9" charOffset="84-87" type="protein" text="SOD"/>
            <pair e1="DS3.d380.s1.e1" e2="DS3.d380.s1.e2" id="DS3.d380.s1.i0" interaction="False" />
            <pair e1="DS3.d380.s1.e0" e2="DS3.d380.s1.e2" id="DS3.d380.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d381" origId="9949505">
        <sentence id="DS3.d381.s0" origId="9949505-4" text="Experiments on the inhibition of the immunoenzyme reaction of McAb with A-PS indicate that CR determinants include rhamnose and beta-N-acetyl-D-glucosamine of rhamnose alone.">
            <entity id="DS3.d381.s0.e0" origId="P07288,Q546G3" charOffset="72-76" type="protein" text="A-PS"/>
            <entity id="DS3.d381.s0.e1" origId="6713579" charOffset="115-123" type="compound" text="rhamnose"/>
            <entity id="DS3.d381.s0.e2" origId="45933887,739" charOffset="142-155" type="compound" text="D-glucosamine"/>
            <entity id="DS3.d381.s0.e3" origId="6713579" charOffset="159-167" type="compound" text="rhamnose"/>
            <pair e1="DS3.d381.s0.e1" e2="DS3.d381.s0.e0" id="DS3.d381.s0.i0" interaction="False" />
            <pair e1="DS3.d381.s0.e2" e2="DS3.d381.s0.e0" id="DS3.d381.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d382" origId="9949527">
        <sentence id="DS3.d382.s0" origId="9949527-4" text="Color and brightness components (N87 and P120, respectively) were reasonably reliably detected in all cases of substitution of stimuli with identical or different spectra.">
            <entity id="DS3.d382.s0.e0" origId="51351826" charOffset="33-36" type="compound" text="N87"/>
            <entity id="DS3.d382.s0.e1" origId="Q8N6C5" charOffset="41-45" type="protein" text="P120"/>
            <pair e1="DS3.d382.s0.e0" e2="DS3.d382.s0.e1" id="DS3.d382.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d382.s1" origId="9949527-5" text="However, the latency and amplitude analysis of N87 and P120 components in these cases showed that N87 reflects not only color but also brightness information.">
            <entity id="DS3.d382.s1.e0" origId="51351826" charOffset="47-50" type="compound" text="N87"/>
            <entity id="DS3.d382.s1.e1" origId="Q8N6C5" charOffset="55-59" type="protein" text="P120"/>
            <entity id="DS3.d382.s1.e2" origId="51351826" charOffset="98-101" type="compound" text="N87"/>
            <pair e1="DS3.d382.s1.e0" e2="DS3.d382.s1.e1" id="DS3.d382.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d383" origId="9949572">
        <sentence id="DS3.d383.s0" origId="9949572-0" text="(Effect of finasteride on the percentage of free PSA: implications in the early diagnosis of prostatic cancer).">
            <entity id="DS3.d383.s0.e0" origId="57363" charOffset="11-22" type="compound" text="finasteride"/>
            <entity id="DS3.d383.s0.e1" origId="P07288,Q546G3" charOffset="49-52" type="protein" text="PSA"/>
            <pair e1="DS3.d383.s0.e0" e2="DS3.d383.s0.e1" id="DS3.d383.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d383.s1" origId="9949572-11" text="CONCLUSION: Long-term treatment with finasteride reduces PSA serum concentration about 50% without changing the free PSA ratio.">
            <entity id="DS3.d383.s1.e0" origId="57363" charOffset="37-48" type="compound" text="finasteride"/>
            <entity id="DS3.d383.s1.e1" origId="P07288,Q546G3" charOffset="57-60" type="protein" text="PSA"/>
            <entity id="DS3.d383.s1.e2" origId="P07288,Q546G3" charOffset="117-120" type="protein" text="PSA"/>
            <pair e1="DS3.d383.s1.e0" e2="DS3.d383.s1.e1" id="DS3.d383.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d383.s2" origId="9949572-13" text="Free PSA ratio allows to increase PSA specificity and avoid unnecessary biopsied also in finasteride-treated patients.">
            <entity id="DS3.d383.s2.e0" origId="P07288,Q546G3" charOffset="5-8" type="protein" text="PSA"/>
            <entity id="DS3.d383.s2.e1" origId="P07288,Q546G3" charOffset="34-37" type="protein" text="PSA"/>
            <entity id="DS3.d383.s2.e2" origId="57363" charOffset="89-100" type="compound" text="finasteride"/>
            <pair e1="DS3.d383.s2.e2" e2="DS3.d383.s2.e0" id="DS3.d383.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d383.s3" origId="9949572-1" text="OBJECTIVE: To analyze the behaviour of free PSA percentage in finasteride-treated patients and to evaluate whether this ratio allows an increased PSA specificity in the early diagnosis of prostate cancer.">
            <entity id="DS3.d383.s3.e0" origId="P07288,Q546G3" charOffset="44-47" type="protein" text="PSA"/>
            <entity id="DS3.d383.s3.e1" origId="57363" charOffset="62-73" type="compound" text="finasteride"/>
            <entity id="DS3.d383.s3.e2" origId="P07288,Q546G3" charOffset="146-149" type="protein" text="PSA"/>
            <pair e1="DS3.d383.s3.e1" e2="DS3.d383.s3.e0" id="DS3.d383.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d383.s4" origId="9949572-2" text="MATERIAL AND METHODS: Evaluation of PSA serum levels and free PSA ratio in 336 patients initially diagnosed with prostate benign hyperplasia (PBH).">
            <entity id="DS3.d383.s4.e0" origId="P07288,Q546G3" charOffset="36-39" type="protein" text="PSA"/>
            <entity id="DS3.d383.s4.e1" origId="P07288,Q546G3" charOffset="62-65" type="protein" text="PSA"/>
            <entity id="DS3.d383.s4.e2" origId="44820610" charOffset="142-145" type="compound" text="PBH"/>
            <pair e1="DS3.d383.s4.e2" e2="DS3.d383.s4.e0" id="DS3.d383.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d383.s5" origId="9949572-7" text="RESULTS: Median PSA level in PBH patients was 1.6 ng/mL for the finasteride-treated group and 3.5 for the untreated group, p &amp;lt; 0.0001.">
            <entity id="DS3.d383.s5.e0" origId="P07288,Q546G3" charOffset="16-19" type="protein" text="PSA"/>
            <entity id="DS3.d383.s5.e1" origId="44820610" charOffset="29-32" type="compound" text="PBH"/>
            <entity id="DS3.d383.s5.e2" origId="57363" charOffset="64-75" type="compound" text="finasteride"/>
            <pair e1="DS3.d383.s5.e2" e2="DS3.d383.s5.e0" id="DS3.d383.s5.i0" interaction="False" />
            <pair e1="DS3.d383.s5.e1" e2="DS3.d383.s5.e0" id="DS3.d383.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d384" origId="9949588">
        <sentence id="DS3.d384.s0" origId="9949588-3" text="Epidemiological characteristics were evaluated, as well as hemostatic tests including: platelet count, mean platelet volume, plasmatic fibrinogen level, prothrombine time, activated partial thromboplastin time, thrombin time, bleeding time, von Willebrand factor antigen and ristocetin cofactor, factor VIII coagulant, and platelet aggregation to different agents.">
            <entity id="DS3.d384.s0.e0" origId="P02675,V9HVY1" charOffset="135-145" type="protein" text="fibrinogen"/>
            <entity id="DS3.d384.s0.e1" origId="90470996" charOffset="156-164" type="compound" text="thrombin"/>
            <entity id="DS3.d384.s0.e2" origId="108194" charOffset="286-294" type="compound" text="cofactor"/>
            <pair e1="DS3.d384.s0.e1" e2="DS3.d384.s0.e0" id="DS3.d384.s0.i0" interaction="False" />
            <pair e1="DS3.d384.s0.e2" e2="DS3.d384.s0.e0" id="DS3.d384.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d385" origId="9949621">
        <sentence id="DS3.d385.s0" origId="9949621-4" text="DESIGN AND METHODS: LTC-IC were evaluated in long-term cultures, comparing two types of murine stromal cell lines: M2-10B4 and M2-10B4 transfected with cDNAs for human G-CSF and IL-3.">
            <entity id="DS3.d385.s0.e0" origId="16122568,16750043,4369303,448383" charOffset="170-173" type="compound" text="CSF"/>
            <entity id="DS3.d385.s0.e1" origId="P08700" charOffset="178-182" type="protein" text="IL-3"/>
            <pair e1="DS3.d385.s0.e0" e2="DS3.d385.s0.e1" id="DS3.d385.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d385.s1" origId="9949621-5" text="RESULTS: Two and five fold higher numbers of terminally differentiated cells were produced during nine weeks of culture of CB mononuclear or CD34+ cells respectively, in cultures containing a M2-10B4 IL-3 G-CSF cell line compared to cultures containing the parental cell line.">
            <entity id="DS3.d385.s1.e0" origId="P08700" charOffset="200-204" type="protein" text="IL-3"/>
            <entity id="DS3.d385.s1.e1" origId="16122568,16750043,4369303,448383" charOffset="207-210" type="compound" text="CSF"/>
            <pair e1="DS3.d385.s1.e1" e2="DS3.d385.s1.e0" id="DS3.d385.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d385.s2" origId="9949621-7" text="In contrast, the number of CFC generated within the stromal layer, after 5 or 9 weeks of culture, was significantly higher in cultures on M2-10B4 cells than those on M2-10B4 IL-3 G-CSF.">
            <entity id="DS3.d385.s2.e0" origId="P08700" charOffset="174-178" type="protein" text="IL-3"/>
            <entity id="DS3.d385.s2.e1" origId="16122568,16750043,4369303,448383" charOffset="181-184" type="compound" text="CSF"/>
            <pair e1="DS3.d385.s2.e1" e2="DS3.d385.s2.e0" id="DS3.d385.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d386" origId="9949625">
        <sentence id="DS3.d386.s0" origId="9949625-11" text="In our study, increased levels of TNF-alpha, IL-6 and especially IL-8 correlated with hepatic or renal dysfunction as evaluated by increased bilirubin and creatinine in plasma, while pulmonary complications correlated only with increased IL-6 levels.">
            <entity id="DS3.d386.s0.e0" origId="P01375,Q5STB3" charOffset="34-43" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d386.s0.e1" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="45-49" type="protein" text="IL-6"/>
            <entity id="DS3.d386.s0.e2" origId="P10145,A0A024RDA5" charOffset="65-69" type="protein" text="IL-8"/>
            <entity id="DS3.d386.s0.e3" origId="5280352" charOffset="141-150" type="compound" text="bilirubin"/>
            <entity id="DS3.d386.s0.e4" origId="588" charOffset="155-165" type="compound" text="creatinine"/>
            <entity id="DS3.d386.s0.e5" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="238-242" type="protein" text="IL-6"/>
            <pair e1="DS3.d386.s0.e3" e2="DS3.d386.s0.e0" id="DS3.d386.s0.i0" interaction="False" />
            <pair e1="DS3.d386.s0.e3" e2="DS3.d386.s0.e2" id="DS3.d386.s0.i1" interaction="False" />
            <pair e1="DS3.d386.s0.e3" e2="DS3.d386.s0.e1" id="DS3.d386.s0.i2" interaction="False" />
            <pair e1="DS3.d386.s0.e4" e2="DS3.d386.s0.e0" id="DS3.d386.s0.i3" interaction="False" />
            <pair e1="DS3.d386.s0.e4" e2="DS3.d386.s0.e2" id="DS3.d386.s0.i4" interaction="False" />
            <pair e1="DS3.d386.s0.e4" e2="DS3.d386.s0.e1" id="DS3.d386.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d387" origId="9949668">
        <sentence id="DS3.d387.s0" origId="9949668-0" text="Effects of metformin on fibrinogen levels in obese patients with type 2 diabetes.">
            <entity id="DS3.d387.s0.e0" origId="4091" charOffset="11-20" type="compound" text="metformin"/>
            <entity id="DS3.d387.s0.e1" origId="P02675,V9HVY1" charOffset="24-34" type="protein" text="fibrinogen"/>
            <pair e1="DS3.d387.s0.e0" e2="DS3.d387.s0.e1" id="DS3.d387.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d387.s1" origId="9949668-11" text="Only glucose decreased in the insulin subgroup.">
            <entity id="DS3.d387.s1.e0" origId="206,5793,79025,64689" charOffset="5-12" type="compound" text="glucose"/>
            <entity id="DS3.d387.s1.e1" origId="P01308,I3WAC9" charOffset="30-37" type="protein" text="insulin"/>
            <pair e1="DS3.d387.s1.e0" e2="DS3.d387.s1.e1" id="DS3.d387.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d387.s2" origId="9949668-13" text="CONCLUSIONS: In addition to improving metabolic control, metformin showed to be a good therapeutic alternative in modifying fibrinogen levels in type 2 diabetic patients.">
            <entity id="DS3.d387.s2.e0" origId="4091" charOffset="57-66" type="compound" text="metformin"/>
            <entity id="DS3.d387.s2.e1" origId="P02675,V9HVY1" charOffset="124-134" type="protein" text="fibrinogen"/>
            <pair e1="DS3.d387.s2.e0" e2="DS3.d387.s2.e1" id="DS3.d387.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d387.s3" origId="9949668-1" text="OBJECTIVE: To determine fibrinogen levels in obese patients with type 2 diabetes and assess its changes with the use of metformin.">
            <entity id="DS3.d387.s3.e0" origId="P02675,V9HVY1" charOffset="24-34" type="protein" text="fibrinogen"/>
            <entity id="DS3.d387.s3.e1" origId="4091" charOffset="120-129" type="compound" text="metformin"/>
            <pair e1="DS3.d387.s3.e1" e2="DS3.d387.s3.e0" id="DS3.d387.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d387.s4" origId="9949668-9" text="RESULTS: The mean values of plasma glucose, fibrinogen levels and body mass index did not change in the pretreatment phase in controls and diabetics.">
            <entity id="DS3.d387.s4.e0" origId="206,5793,64689,79025" charOffset="35-42" type="compound" text="glucose"/>
            <entity id="DS3.d387.s4.e1" origId="P02675,V9HVY1" charOffset="44-54" type="protein" text="fibrinogen"/>
            <pair e1="DS3.d387.s4.e0" e2="DS3.d387.s4.e1" id="DS3.d387.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d388" origId="9949700">
        <sentence id="DS3.d388.s0" origId="9949700-10" text="N14 DNA hybridizes to 63F/64A on the left arm of chromosome 3.">
            <entity id="DS3.d388.s0.e0" origId="Q7KGH1,A0A0B4LEJ6" charOffset="0-3" type="protein" text="N14"/>
            <entity id="DS3.d388.s0.e1" origId="51035437" charOffset="22-25" type="compound" text="63F"/>
            <pair e1="DS3.d388.s0.e1" e2="DS3.d388.s0.e0" id="DS3.d388.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d389" origId="9949723">
        <sentence id="DS3.d389.s0" origId="9949723-7" text="An additional gene, termed Rlp-3, which is highly related to Rlp-1 and Rlp-2, was found in the GenBank Data Base.">
            <entity id="DS3.d389.s0.e0" origId="185679" charOffset="27-30" type="compound" text="Rlp"/>
            <entity id="DS3.d389.s0.e1" origId="Q96KN8,B4DY88,Q8NE88" charOffset="61-66" type="protein" text="Rlp-1"/>
            <entity id="DS3.d389.s0.e2" origId="Q969X0" charOffset="71-76" type="protein" text="Rlp-2"/>
            <pair e1="DS3.d389.s0.e0" e2="DS3.d389.s0.e1" id="DS3.d389.s0.i0" interaction="False" />
            <pair e1="DS3.d389.s0.e0" e2="DS3.d389.s0.e2" id="DS3.d389.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d389.s1" origId="9949723-8" text="The predicted molecular mass for Rlp is approximately 31 kDa and is consistent with that of Rlp-1 synthesized in Escherichia coli.">
            <entity id="DS3.d389.s1.e0" origId="185679" charOffset="33-36" type="compound" text="Rlp"/>
            <entity id="DS3.d389.s1.e1" origId="Q96KN8,B4DY88,Q8NE88" charOffset="92-97" type="protein" text="Rlp-1"/>
            <pair e1="DS3.d389.s1.e0" e2="DS3.d389.s1.e1" id="DS3.d389.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d390" origId="9949786">
        <sentence id="DS3.d390.s0" origId="9949786-8" text="The heat shock proteins (HSP) Hsp60 and Hsp70 are decreased in alcohol-fed rats, as is desmin.">
            <entity id="DS3.d390.s0.e0" origId="P63039" charOffset="30-35" type="protein" text="Hsp60"/>
            <entity id="DS3.d390.s0.e1" origId="10982484" charOffset="63-70" type="compound" text="alcohol"/>
            <pair e1="DS3.d390.s0.e1" e2="DS3.d390.s0.e0" id="DS3.d390.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d391" origId="9949792">
        <sentence id="DS3.d391.s0" origId="9949792-3" text="Some evidence also suggests moderate alcohol consumption may reduce insulin resistance.">
            <entity id="DS3.d391.s0.e0" origId="10982484,702" charOffset="37-44" type="compound" text="alcohol"/>
            <entity id="DS3.d391.s0.e1" origId="P01308,I3WAC9" charOffset="68-75" type="protein" text="insulin"/>
            <pair e1="DS3.d391.s0.e0" e2="DS3.d391.s0.e1" id="DS3.d391.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d392" origId="9949802">
        <sentence id="DS3.d392.s0" origId="9949802-10" text="The roles of Th2, inflammatory cytokines, common antigens and changes in cortisol metabolism suggest several strategies for immunotherapy, and several sites where genetic polymorphisms may affect susceptibility.">
            <entity id="DS3.d392.s0.e0" origId="Q61039" charOffset="13-16" type="protein" text="Th2"/>
            <entity id="DS3.d392.s0.e1" origId="5754" charOffset="73-81" type="compound" text="cortisol"/>
            <pair e1="DS3.d392.s0.e1" e2="DS3.d392.s0.e0" id="DS3.d392.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d392.s1" origId="9949802-7" text="The balance of Th1 to Th2 and the function of inflammatory cytokines are also regulated by cortisol.">
            <entity id="DS3.d392.s1.e0" origId="Q61039" charOffset="22-25" type="protein" text="Th2"/>
            <entity id="DS3.d392.s1.e1" origId="5754" charOffset="91-99" type="compound" text="cortisol"/>
            <pair e1="DS3.d392.s1.e1" e2="DS3.d392.s1.e0" id="DS3.d392.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d393" origId="9949859">
        <sentence id="DS3.d393.s0" origId="9949859-0" text="Insulin resistance, impaired glucose tolerance and non-Insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities.">
            <entity id="DS3.d393.s0.e0" origId="P01308,I3WAC9" charOffset="0-7" type="protein" text="Insulin"/>
            <entity id="DS3.d393.s0.e1" origId="206,5793,64689,79025" charOffset="29-36" type="compound" text="glucose"/>
            <entity id="DS3.d393.s0.e2" origId="P01308,I3WAC9" charOffset="55-62" type="protein" text="Insulin"/>
            <pair e1="DS3.d393.s0.e1" e2="DS3.d393.s0.e0" id="DS3.d393.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d393.s1" origId="9949859-1" text="Impaired glucose tolerance and non-Insulin-dependent diabetes (NIDDM) are the pathologic consequence of two co-incident and interacting conditions, namely Insulin resistance and relative Insulin deficiency.">
            <entity id="DS3.d393.s1.e0" origId="206,5793,64689,79025" charOffset="9-16" type="compound" text="glucose"/>
            <entity id="DS3.d393.s1.e1" origId="P01308,I3WAC9" charOffset="35-42" type="protein" text="Insulin"/>
            <entity id="DS3.d393.s1.e2" origId="P01308,I3WAC9" charOffset="155-162" type="protein" text="Insulin"/>
            <entity id="DS3.d393.s1.e3" origId="P01308,I3WAC9" charOffset="155-162" type="protein" text="Insulin"/>
            <pair e1="DS3.d393.s1.e0" e2="DS3.d393.s1.e1" id="DS3.d393.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d393.s2" origId="9949859-4" text="Insulin resistance is established as the characteristic pathologic feature of patients with glucose intolerance and NIDDM describing a state in which Insulin stimulated glucose uptake and utilisation in liver, skeletal muscle and adipose tissue is impaired and coupled to impaired suppression of hepatic glucose output.">
            <entity id="DS3.d393.s2.e0" origId="P01308,I3WAC9" charOffset="0-7" type="protein" text="Insulin"/>
            <entity id="DS3.d393.s2.e1" origId="206,5793,64689,79025" charOffset="92-99" type="compound" text="glucose"/>
            <entity id="DS3.d393.s2.e2" origId="P01308,I3WAC9" charOffset="150-157" type="protein" text="Insulin"/>
            <entity id="DS3.d393.s2.e3" origId="206,5793,64689,79025" charOffset="169-176" type="compound" text="glucose"/>
            <entity id="DS3.d393.s2.e4" origId="206,5793,64689,79025" charOffset="169-176" type="compound" text="glucose"/>
            <pair e1="DS3.d393.s2.e1" e2="DS3.d393.s2.e0" id="DS3.d393.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d393.s3" origId="9949859-6" text="In this article we review the biochemical and molecular nature of the defects in Insulin sensitivity and glucose uptake, and discuss some of the potential causative mechanisms.">
            <entity id="DS3.d393.s3.e0" origId="P01308,I3WAC9" charOffset="81-88" type="protein" text="Insulin"/>
            <entity id="DS3.d393.s3.e1" origId="206,5793,64689,79025" charOffset="105-112" type="compound" text="glucose"/>
            <pair e1="DS3.d393.s3.e1" e2="DS3.d393.s3.e0" id="DS3.d393.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d394" origId="9949863">
        <sentence id="DS3.d394.s0" origId="9949863-16" text="Sumatriptan is an agonist at 5-HT1D and 5-HT1B receptor subtypes, and effective in treating migraine pain and associated symptoms.">
            <entity id="DS3.d394.s0.e0" origId="5358" charOffset="0-11" type="compound" text="Sumatriptan"/>
            <entity id="DS3.d394.s0.e1" origId="P28221" charOffset="29-35" type="protein" text="5-HT1D"/>
            <pair e1="DS3.d394.s0.e0" e2="DS3.d394.s0.e1" id="DS3.d394.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d394.s1" origId="9949863-8" text="Substance P, calcitonin gene related peptide and nitric oxide are all though to play a role in the dural inflammatory cascade.">
            <entity id="DS3.d394.s1.e0" origId="P20366,Q9Y494" charOffset="0-11" type="protein" text="Substance P"/>
            <entity id="DS3.d394.s1.e1" origId="P06881,P01258" charOffset="13-23" type="protein" text="calcitonin"/>
            <entity id="DS3.d394.s1.e2" origId="145068" charOffset="49-61" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d394.s1.e2" e2="DS3.d394.s1.e0" id="DS3.d394.s1.i0" interaction="False" />
            <pair e1="DS3.d394.s1.e2" e2="DS3.d394.s1.e1" id="DS3.d394.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d395" origId="9949883">
        <sentence id="DS3.d395.s0" origId="9949883-4" text="However, it significantly increased curvilinear velocity (VCL), amplitude of lateral head displacement (ALH) and hyperactivated motility (HA), and significantly decreased linearity (LIN) of spermatozoa from both samples.">
            <entity id="DS3.d395.s0.e0" origId="P18206,A0A024QZN4,V9HWK2,B3KXA2" charOffset="58-61" type="protein" text="VCL"/>
            <entity id="DS3.d395.s0.e1" origId="5326843" charOffset="104-107" type="compound" text="ALH"/>
            <pair e1="DS3.d395.s0.e1" e2="DS3.d395.s0.e0" id="DS3.d395.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d396" origId="9949887">
        <sentence id="DS3.d396.s0" origId="9949887-5" text="The substrate for subtilisin may play a role in andrology, because subtilisin is a serine protease like acrosin.">
            <entity id="DS3.d396.s0.e0" origId="5951" charOffset="83-89" type="compound" text="serine"/>
            <entity id="DS3.d396.s0.e1" origId="P10323" charOffset="104-111" type="protein" text="acrosin"/>
            <pair e1="DS3.d396.s0.e0" e2="DS3.d396.s0.e1" id="DS3.d396.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d397" origId="9949893">
        <sentence id="DS3.d397.s0" origId="9949893-3" text="Nomegestrol acetate, alone, had no significant effect on glycemia, antithrombin III, triglycerides, total cholesterol, apoprotein A1, and LpA1 values compared to those at baseline but apoprotein B and Lp (a) values tended to decrease slightly.">
            <entity id="DS3.d397.s0.e0" origId="68783" charOffset="0-11" type="compound" text="Nomegestrol"/>
            <entity id="DS3.d397.s0.e1" origId="176" charOffset="12-19" type="compound" text="acetate"/>
            <entity id="DS3.d397.s0.e2" origId="P01008,A0A024R944" charOffset="67-83" type="protein" text="antithrombin III"/>
            <entity id="DS3.d397.s0.e3" origId="5997" charOffset="106-117" type="compound" text="cholesterol"/>
            <entity id="DS3.d397.s0.e4" origId="Q92633,Q5VZX0" charOffset="138-142" type="protein" text="LpA1"/>
            <pair e1="DS3.d397.s0.e0" e2="DS3.d397.s0.e2" id="DS3.d397.s0.i0" interaction="False" />
            <pair e1="DS3.d397.s0.e0" e2="DS3.d397.s0.e4" id="DS3.d397.s0.i1" interaction="False" />
            <pair e1="DS3.d397.s0.e1" e2="DS3.d397.s0.e2" id="DS3.d397.s0.i2" interaction="False" />
            <pair e1="DS3.d397.s0.e1" e2="DS3.d397.s0.e4" id="DS3.d397.s0.i3" interaction="False" />
            <pair e1="DS3.d397.s0.e3" e2="DS3.d397.s0.e2" id="DS3.d397.s0.i4" interaction="False" />
            <pair e1="DS3.d397.s0.e3" e2="DS3.d397.s0.e4" id="DS3.d397.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d398" origId="9949944">
        <sentence id="DS3.d398.s0" origId="9949944-2" text="We describe here an HLA-B*27 allele (B*2712) encoding an antigen that lacks reactivity with B27 monoclonal antibodies (moabs) and alloantisera but reacts with some B40/B60 moabs and alloantisera and expresses the Bw6 public epitope.">
            <entity id="DS3.d398.s0.e0" origId="P01889,P30460,Q5SS57,E5FQ95" charOffset="20-25" type="protein" text="HLA-B"/>
            <entity id="DS3.d398.s0.e1" origId="Q8TCY5" charOffset="92-95" type="protein" text="B27"/>
            <entity id="DS3.d398.s0.e2" origId="44475970" charOffset="168-171" type="compound" text="B60"/>
            <pair e1="DS3.d398.s0.e2" e2="DS3.d398.s0.e1" id="DS3.d398.s0.i0" interaction="False" />
            <pair e1="DS3.d398.s0.e2" e2="DS3.d398.s0.e0" id="DS3.d398.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d398.s1" origId="9949944-4" text="Serological typing showed a lack of reactivity with four B27 moabs and four alloantisera but positive reactivity with moabs and alloantisera specific for B40/B60 and Bw6 public epitopes.">
            <entity id="DS3.d398.s1.e0" origId="Q8TCY5" charOffset="57-60" type="protein" text="B27"/>
            <entity id="DS3.d398.s1.e1" origId="44475970" charOffset="158-161" type="compound" text="B60"/>
            <pair e1="DS3.d398.s1.e1" e2="DS3.d398.s1.e0" id="DS3.d398.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d398.s2" origId="9949944-7" text="The relationship between HLA-B*2712 and reported B60 associations with susceptibility to AS remains to be determined.">
            <entity id="DS3.d398.s2.e0" origId="P01889,P30460,Q5SS57,E5FQ95" charOffset="25-30" type="protein" text="HLA-B"/>
            <entity id="DS3.d398.s2.e1" origId="44475970" charOffset="49-52" type="compound" text="B60"/>
            <pair e1="DS3.d398.s2.e1" e2="DS3.d398.s2.e0" id="DS3.d398.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d399" origId="9950019">
        <sentence id="DS3.d399.s0" origId="9950019-3" text="Patients were randomized to dressing type on postoperative day (POD) 1, completed a pain and distress visual analogue scale (VAS) on PODs 1, 3 and 5, and a cosmetic result VAS upon discharge.">
            <entity id="DS3.d399.s0.e0" origId="6323535" charOffset="125-128" type="compound" text="VAS"/>
            <entity id="DS3.d399.s0.e1" origId="O43680" charOffset="133-148" type="protein" text="PODs 1, 3 and 5"/>
            <entity id="DS3.d399.s0.e2" origId="6323535" charOffset="172-175" type="compound" text="VAS"/>
            <pair e1="DS3.d399.s0.e0" e2="DS3.d399.s0.e1" id="DS3.d399.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d400" origId="9950057">
        <sentence id="DS3.d400.s0" origId="9950057-0" text="Immunohistochemical localization of serotonin transporter in normal and colchicine treated rat brain.">
            <entity id="DS3.d400.s0.e0" origId="P31652" charOffset="36-57" type="protein" text="serotonin transporter"/>
            <entity id="DS3.d400.s0.e1" origId="6167" charOffset="72-82" type="compound" text="colchicine"/>
            <pair e1="DS3.d400.s0.e1" e2="DS3.d400.s0.e0" id="DS3.d400.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d401" origId="9950058">
        <sentence id="DS3.d401.s0" origId="9950058-0" text="Cloning and chromosomal mapping of the human gene of Neuroglycan C (NGC), a neural transmembrane chondroitin sulfate proteoglycan with an EGF module.">
            <entity id="DS3.d401.s0.e0" origId="Q9ERQ6" charOffset="53-66" type="protein" text="Neuroglycan C"/>
            <entity id="DS3.d401.s0.e1" origId="O95196,B7Z2E0,A0A087WUT8,Q9ERQ6" charOffset="68-71" type="protein" text="NGC"/>
            <entity id="DS3.d401.s0.e2" origId="53477707" charOffset="97-108" type="compound" text="chondroitin"/>
            <entity id="DS3.d401.s0.e3" origId="1117" charOffset="109-116" type="compound" text="sulfate"/>
            <pair e1="DS3.d401.s0.e2" e2="DS3.d401.s0.e0" id="DS3.d401.s0.i0" interaction="False" />
            <pair e1="DS3.d401.s0.e2" e2="DS3.d401.s0.e1" id="DS3.d401.s0.i1" interaction="False" />
            <pair e1="DS3.d401.s0.e3" e2="DS3.d401.s0.e0" id="DS3.d401.s0.i2" interaction="False" />
            <pair e1="DS3.d401.s0.e3" e2="DS3.d401.s0.e1" id="DS3.d401.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d401.s1" origId="9950058-1" text="Neuroglycan C (NGC) is a 150 kDa transmembrane chondroitin sulfate proteoglycan with a 120 kDa core glycoprotein that was originally isolated from the developing rat brain.">
            <entity id="DS3.d401.s1.e0" origId="Q9ERQ6" charOffset="0-13" type="protein" text="Neuroglycan C"/>
            <entity id="DS3.d401.s1.e1" origId="O95196,B7Z2E0,A0A087WUT8,Q9ERQ6" charOffset="15-18" type="protein" text="NGC"/>
            <entity id="DS3.d401.s1.e2" origId="53477707" charOffset="47-58" type="compound" text="chondroitin"/>
            <entity id="DS3.d401.s1.e3" origId="1117" charOffset="59-66" type="compound" text="sulfate"/>
            <pair e1="DS3.d401.s1.e2" e2="DS3.d401.s1.e0" id="DS3.d401.s1.i0" interaction="False" />
            <pair e1="DS3.d401.s1.e2" e2="DS3.d401.s1.e1" id="DS3.d401.s1.i1" interaction="False" />
            <pair e1="DS3.d401.s1.e3" e2="DS3.d401.s1.e0" id="DS3.d401.s1.i2" interaction="False" />
            <pair e1="DS3.d401.s1.e3" e2="DS3.d401.s1.e1" id="DS3.d401.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d401.s2" origId="9950058-5" text="The domain structure characteristic of rat NGC was completely conserved in human NGC, which consisted of an N-terminal signal sequence, a chondroitin sulfate-attachment domain, an acidic amino acid cluster, an EGF-like domain, a transmembrane domain and a cytoplasmic tail.">
            <entity id="DS3.d401.s2.e0" origId="O95196,B7Z2E0,A0A087WUT8,Q9ERQ6" charOffset="43-46" type="protein" text="NGC"/>
            <entity id="DS3.d401.s2.e1" origId="O95196,B7Z2E0,A0A087WUT8,Q9ERQ6" charOffset="81-84" type="protein" text="NGC"/>
            <entity id="DS3.d401.s2.e2" origId="53477707" charOffset="138-149" type="compound" text="chondroitin"/>
            <entity id="DS3.d401.s2.e3" origId="1117" charOffset="150-157" type="compound" text="sulfate"/>
            <pair e1="DS3.d401.s2.e2" e2="DS3.d401.s2.e0" id="DS3.d401.s2.i0" interaction="False" />
            <pair e1="DS3.d401.s2.e3" e2="DS3.d401.s2.e0" id="DS3.d401.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d402" origId="9950060">
        <sentence id="DS3.d402.s0" origId="9950060-7" text="Moreover, double-labeling immunohistochemistry revealed that: (1) many FosB-positive nuclei were observed in oxytocin and vasopressin neurons of the SON and PVN in parturient rats; (2) within FosB-positive neurons, 89.5% in the MPA, 86.8% in the MLT of parturient rats, and 92% in the MPA and 90.8% in the MLT of lactating animals were also Fos-positive.">
            <entity id="DS3.d402.s0.e0" origId="D3ZLB7,S5NB67" charOffset="71-75" type="protein" text="FosB"/>
            <entity id="DS3.d402.s0.e1" origId="439302" charOffset="109-117" type="compound" text="oxytocin"/>
            <entity id="DS3.d402.s0.e2" origId="D3ZLB7,S5NB67" charOffset="192-196" type="protein" text="FosB"/>
            <pair e1="DS3.d402.s0.e1" e2="DS3.d402.s0.e0" id="DS3.d402.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d403" origId="9950067">
        <sentence id="DS3.d403.s0" origId="9950067-8" text="It is concluded that the (H2)15O PET method may measure CBF distribution in the meditative state as well as during the resting state of normal consciousness, and that characteristic patterns of neural activity support each state.">
            <entity id="DS3.d403.s0.e0" origId="783" charOffset="26-28" type="compound" text="H2"/>
            <entity id="DS3.d403.s0.e1" origId="Q03701" charOffset="56-59" type="protein" text="CBF"/>
            <pair e1="DS3.d403.s0.e0" e2="DS3.d403.s0.e1" id="DS3.d403.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d404" origId="9950072">
        <sentence id="DS3.d404.s0" origId="9950072-0" text="Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen.">
            <entity id="DS3.d404.s0.e0" origId="Q95L75,Q63120" charOffset="21-25" type="protein" text="mrp2"/>
            <entity id="DS3.d404.s0.e1" origId="16043998,24871024,44419043,45356263,5381226,57020413,5388984" charOffset="89-99" type="compound" text="rifampicin"/>
            <entity id="DS3.d404.s0.e2" origId="2733526" charOffset="103-112" type="compound" text="tamoxifen"/>
            <pair e1="DS3.d404.s0.e1" e2="DS3.d404.s0.e0" id="DS3.d404.s0.i0" interaction="False" />
            <pair e1="DS3.d404.s0.e2" e2="DS3.d404.s0.e0" id="DS3.d404.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d404.s1" origId="9950072-2" text="mrp2 transports a broad spectrum of organic anions including glucuronides, glutathione conjugates, and organic sulphates into bile.">
            <entity id="DS3.d404.s1.e0" origId="Q95L75,Q63120" charOffset="0-4" type="protein" text="mrp2"/>
            <entity id="DS3.d404.s1.e1" origId="124886,20725278,745" charOffset="75-86" type="compound" text="glutathione"/>
            <pair e1="DS3.d404.s1.e1" e2="DS3.d404.s1.e0" id="DS3.d404.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d404.s2" origId="9950072-3" text="Based on previous observations in rat hepatocytes, the inducibility of mrp2 gene expression in primate liver was investigated in rhesus monkeys treated with tamoxifen or rifampicin.">
            <entity id="DS3.d404.s2.e0" origId="Q95L75,Q63120" charOffset="71-75" type="protein" text="mrp2"/>
            <entity id="DS3.d404.s2.e1" origId="2733526" charOffset="157-166" type="compound" text="tamoxifen"/>
            <entity id="DS3.d404.s2.e2" origId="16043998,24871024,44419043,45356263,5381226,57020413,5388984" charOffset="170-180" type="compound" text="rifampicin"/>
            <pair e1="DS3.d404.s2.e2" e2="DS3.d404.s2.e0" id="DS3.d404.s2.i0" interaction="False" />
            <pair e1="DS3.d404.s2.e1" e2="DS3.d404.s2.e0" id="DS3.d404.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d404.s3" origId="9950072-4" text="It was found that treatment with tamoxifen (25 mg/kg per day; over 7 days) or rifampicin (15 mg/kg per day; over 7 days) leading to an induction of cytochrome P450 3A4, resulted in a strong increase in mrp2 mRNA in the liver of male and female rhesus monkeys.">
            <entity id="DS3.d404.s3.e0" origId="2733526" charOffset="33-42" type="compound" text="tamoxifen"/>
            <entity id="DS3.d404.s3.e1" origId="16043998,24871024,44419043,45356263,5381226,57020413,5388984" charOffset="78-88" type="compound" text="rifampicin"/>
            <entity id="DS3.d404.s3.e2" origId="Q95L75,Q63120" charOffset="202-206" type="protein" text="mrp2"/>
            <pair e1="DS3.d404.s3.e1" e2="DS3.d404.s3.e2" id="DS3.d404.s3.i0" interaction="False" />
            <pair e1="DS3.d404.s3.e0" e2="DS3.d404.s3.e2" id="DS3.d404.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d405" origId="9950073">
        <sentence id="DS3.d405.s0" origId="9950073-1" text="We compared the effects of 2,3,7,8-tetra (TCDD), 1,2,3,7,8-penta (PeCDD), 1,2,3,4,7,8-hexa (HxCDD) and 1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin (HpCDD) on brain serotonin metabolism, plasma tryptophan and liver tryptophan pyrrolase activity in two rat strains, TCDD-sensitive Long-Evans (Turku AB; L-E) and TCDD-resistant Han/Wistar (Kuopio; H/W).">
            <entity id="DS3.d405.s0.e0" origId="29575" charOffset="92-97" type="compound" text="HxCDD"/>
            <entity id="DS3.d405.s0.e1" origId="37270" charOffset="103-144" type="compound" text="1,2,3,4,6,7,8-heptachlorodibenzo-p-dioxin"/>
            <entity id="DS3.d405.s0.e2" origId="5202" charOffset="162-171" type="compound" text="serotonin"/>
            <entity id="DS3.d405.s0.e3" origId="57175189,6305" charOffset="191-201" type="compound" text="tryptophan"/>
            <entity id="DS3.d405.s0.e4" origId="P21643" charOffset="212-232" type="protein" text="tryptophan pyrrolase"/>
            <pair e1="DS3.d405.s0.e1" e2="DS3.d405.s0.e4" id="DS3.d405.s0.i0" interaction="False" />
            <pair e1="DS3.d405.s0.e2" e2="DS3.d405.s0.e4" id="DS3.d405.s0.i1" interaction="False" />
            <pair e1="DS3.d405.s0.e0" e2="DS3.d405.s0.e4" id="DS3.d405.s0.i2" interaction="False" />
            <pair e1="DS3.d405.s0.e3" e2="DS3.d405.s0.e4" id="DS3.d405.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d405.s1" origId="9950073-5" text="The same rank order was recorded for elevations in brain tryptophan and plasma free tryptophan concentrations as well as for inhibition of the main hepatic tryptophan metabolizing enzyme, tryptophan pyrrolase.">
            <entity id="DS3.d405.s1.e0" origId="57175189,6305" charOffset="57-67" type="compound" text="tryptophan"/>
            <entity id="DS3.d405.s1.e1" origId="57175189,6305" charOffset="84-94" type="compound" text="tryptophan"/>
            <entity id="DS3.d405.s1.e2" origId="57175189,6305" charOffset="84-94" type="compound" text="tryptophan"/>
            <entity id="DS3.d405.s1.e3" origId="P21643" charOffset="188-208" type="protein" text="tryptophan pyrrolase"/>
            <pair e1="DS3.d405.s1.e0" e2="DS3.d405.s1.e3" id="DS3.d405.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d406" origId="9950075">
        <sentence id="DS3.d406.s0" origId="9950075-5" text="In rat hepatocytes in vitro, MEHP (the active metabolite of DEHP) induced DNA synthesis 2.5-fold (P = 0.001) and suppressed 10- and 4-fold, respectively both spontaneous (P = 0.0008) and transforming growth factor beta1 (TGFbeta1)-induced (P = 0.0001) apoptosis.">
            <entity id="DS3.d406.s0.e0" origId="20393" charOffset="29-33" type="compound" text="MEHP"/>
            <entity id="DS3.d406.s0.e1" origId="8343" charOffset="60-64" type="compound" text="DEHP"/>
            <entity id="DS3.d406.s0.e2" origId="P17246" charOffset="187-219" type="protein" text="transforming growth factor beta1"/>
            <entity id="DS3.d406.s0.e3" origId="P17246" charOffset="221-229" type="protein" text="TGFbeta1"/>
            <pair e1="DS3.d406.s0.e1" e2="DS3.d406.s0.e2" id="DS3.d406.s0.i0" interaction="False" />
            <pair e1="DS3.d406.s0.e1" e2="DS3.d406.s0.e3" id="DS3.d406.s0.i1" interaction="False" />
            <pair e1="DS3.d406.s0.e0" e2="DS3.d406.s0.e2" id="DS3.d406.s0.i2" interaction="False" />
            <pair e1="DS3.d406.s0.e0" e2="DS3.d406.s0.e3" id="DS3.d406.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d407" origId="9950079">
        <sentence id="DS3.d407.s0" origId="9950079-0" text="Determination of glutathione transferase (GSTT1-1) activities in different tissues based on formation of radioactive metabolites using 35S-glutathione.">
            <entity id="DS3.d407.s0.e0" origId="124886,20725278" charOffset="17-28" type="compound" text="glutathione"/>
            <entity id="DS3.d407.s0.e1" origId="Q64471,Q9DCY6" charOffset="42-49" type="protein" text="GSTT1-1"/>
            <entity id="DS3.d407.s0.e2" origId="124886,20725278" charOffset="139-150" type="compound" text="glutathione"/>
            <pair e1="DS3.d407.s0.e0" e2="DS3.d407.s0.e1" id="DS3.d407.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d407.s1" origId="9950079-1" text="A new system has been developed to determine enzyme activities of glutathione transferase theta (GSTT1-1) based on radiometric product detection resulting from the enzymic reaction of methyl chloride with 35S-labelled glutathione.">
            <entity id="DS3.d407.s1.e0" origId="124886,20725278" charOffset="66-77" type="compound" text="glutathione"/>
            <entity id="DS3.d407.s1.e1" origId="Q64471,Q9DCY6" charOffset="97-104" type="protein" text="GSTT1-1"/>
            <entity id="DS3.d407.s1.e2" origId="6327" charOffset="184-199" type="compound" text="methyl chloride"/>
            <entity id="DS3.d407.s1.e3" origId="124886,20725278" charOffset="218-229" type="compound" text="glutathione"/>
            <pair e1="DS3.d407.s1.e0" e2="DS3.d407.s1.e1" id="DS3.d407.s1.i0" interaction="False" />
            <pair e1="DS3.d407.s1.e2" e2="DS3.d407.s1.e1" id="DS3.d407.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d408" origId="9950082">
        <sentence id="DS3.d408.s0" origId="9950082-4" text="Altered liver function was evidenced by the increased activity of alcohol dehydrogenase, aldehyde dehydrogenase, glutamic oxaloacetic transaminase (aspartate amino transferase (GOT)), glutamic pyruvic transaminase (alanine amino transferase (GPT)).">
            <entity id="DS3.d408.s0.e0" origId="10982484,702" charOffset="66-73" type="compound" text="alcohol"/>
            <entity id="DS3.d408.s0.e1" origId="5960" charOffset="148-157" type="compound" text="aspartate"/>
            <entity id="DS3.d408.s0.e2" origId="22878841" charOffset="215-228" type="compound" text="alanine amino"/>
            <entity id="DS3.d408.s0.e3" origId="P25409" charOffset="242-245" type="protein" text="GPT"/>
            <pair e1="DS3.d408.s0.e2" e2="DS3.d408.s0.e3" id="DS3.d408.s0.i0" interaction="False" />
            <pair e1="DS3.d408.s0.e1" e2="DS3.d408.s0.e3" id="DS3.d408.s0.i1" interaction="False" />
            <pair e1="DS3.d408.s0.e0" e2="DS3.d408.s0.e3" id="DS3.d408.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d408.s1" origId="9950082-5" text="Hyperlipidemia was caused by increased biosynthesis since the incorporation of 14C acetate into lipids and activities of HMG CoA reductase and lipogenic enzymes were elevated.">
            <entity id="DS3.d408.s1.e0" origId="176" charOffset="83-90" type="compound" text="acetate"/>
            <entity id="DS3.d408.s1.e1" origId="P51639" charOffset="121-138" type="protein" text="HMG CoA reductase"/>
            <pair e1="DS3.d408.s1.e0" e2="DS3.d408.s1.e1" id="DS3.d408.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d409" origId="9950101">
        <sentence id="DS3.d409.s0" origId="9950101-0" text="Levamisole and interleukin-2 for advanced malignancy.">
            <entity id="DS3.d409.s0.e0" origId="26879" charOffset="0-10" type="compound" text="Levamisole"/>
            <entity id="DS3.d409.s0.e1" origId="P60568,Q0GK43" charOffset="15-28" type="protein" text="interleukin-2"/>
            <pair e1="DS3.d409.s0.e0" e2="DS3.d409.s0.e1" id="DS3.d409.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d409.s1" origId="9950101-2" text="interleukin-2 (IL2) stimulates T-cells and natural killer (NK) cells to kill tumor cells and levamisole (LMS) is an immunostimulant which has been shown to increase NK cells and activated T-cells in patients receiving this adjuvantly along with 5FU for Stage III colon cancer.">
            <entity id="DS3.d409.s1.e0" origId="P60568,Q0GK43" charOffset="0-13" type="protein" text="interleukin-2"/>
            <entity id="DS3.d409.s1.e1" origId="P60568,Q0GK43" charOffset="15-18" type="protein" text="IL2"/>
            <entity id="DS3.d409.s1.e2" origId="26879" charOffset="93-103" type="compound" text="levamisole"/>
            <pair e1="DS3.d409.s1.e2" e2="DS3.d409.s1.e0" id="DS3.d409.s1.i0" interaction="False" />
            <pair e1="DS3.d409.s1.e2" e2="DS3.d409.s1.e1" id="DS3.d409.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d410" origId="9950148">
        <sentence id="DS3.d410.s0" origId="9950148-2" text="Ultrastructural enzyme-histochemical analysis of G6Pase was performed using cerium and lead as capturing agents.">
            <entity id="DS3.d410.s0.e0" origId="P35575" charOffset="49-55" type="protein" text="G6Pase"/>
            <entity id="DS3.d410.s0.e1" origId="23974" charOffset="76-82" type="compound" text="cerium"/>
            <pair e1="DS3.d410.s0.e1" e2="DS3.d410.s0.e0" id="DS3.d410.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d411" origId="9950149">
        <sentence id="DS3.d411.s0" origId="9950149-10" text="The study provides direct in vivo evidence for IRP regulation of TfR expression in the human placenta.">
            <entity id="DS3.d411.s0.e0" origId="444833" charOffset="47-50" type="compound" text="IRP"/>
            <entity id="DS3.d411.s0.e1" origId="P02786" charOffset="65-68" type="protein" text="TfR"/>
            <pair e1="DS3.d411.s0.e0" e2="DS3.d411.s0.e1" id="DS3.d411.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d411.s1" origId="9950149-1" text="Placental transferrin receptor (TfR) protein expression is increased in diabetic pregnancies that are complicated by low fetal iron stores, suggesting regulation of placental iron transport by fetoplacental iron status.">
            <entity id="DS3.d411.s1.e0" origId="P02786" charOffset="10-30" type="protein" text="transferrin receptor"/>
            <entity id="DS3.d411.s1.e1" origId="P02786" charOffset="32-35" type="protein" text="TfR"/>
            <entity id="DS3.d411.s1.e2" origId="23925,67172434" charOffset="127-131" type="compound" text="iron"/>
            <entity id="DS3.d411.s1.e3" origId="23925,67172434" charOffset="175-179" type="compound" text="iron"/>
            <entity id="DS3.d411.s1.e4" origId="23925,67172434" charOffset="175-179" type="compound" text="iron"/>
            <pair e1="DS3.d411.s1.e2" e2="DS3.d411.s1.e0" id="DS3.d411.s1.i0" interaction="False" />
            <pair e1="DS3.d411.s1.e2" e2="DS3.d411.s1.e1" id="DS3.d411.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d411.s2" origId="9950149-2" text="In cell culture, iron homeostasis is regulated by coordinate stabilization of TfR mRNA and translation inactivation of ferritin mRNA by iron regulatory proteins (IRP-1 and -2) which bind to iron-responsive elements (IREs) on the respective mRNAs.">
            <entity id="DS3.d411.s2.e0" origId="23925,67172434" charOffset="17-21" type="compound" text="iron"/>
            <entity id="DS3.d411.s2.e1" origId="P02786" charOffset="78-81" type="protein" text="TfR"/>
            <entity id="DS3.d411.s2.e2" origId="23925,67172434" charOffset="136-140" type="compound" text="iron"/>
            <entity id="DS3.d411.s2.e3" origId="P21399,V9HWB7,Q9HBB2" charOffset="162-167" type="protein" text="IRP-1"/>
            <entity id="DS3.d411.s2.e4" origId="23925,67172434" charOffset="136-140" type="compound" text="iron"/>
            <pair e1="DS3.d411.s2.e0" e2="DS3.d411.s2.e3" id="DS3.d411.s2.i0" interaction="False" />
            <pair e1="DS3.d411.s2.e0" e2="DS3.d411.s2.e1" id="DS3.d411.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d411.s3" origId="9950149-3" text="Concentrations of IRP-1, IRP-2 and TfR mRNA were measured in 10 placentae obtained from diabetic and non-diabetic human pregnancies with a wide range of fetoplacental iron status.">
            <entity id="DS3.d411.s3.e0" origId="P21399,V9HWB7,Q9HBB2" charOffset="18-23" type="protein" text="IRP-1"/>
            <entity id="DS3.d411.s3.e1" origId="P48200,D3DW85" charOffset="25-30" type="protein" text="IRP-2"/>
            <entity id="DS3.d411.s3.e2" origId="P02786" charOffset="35-38" type="protein" text="TfR"/>
            <entity id="DS3.d411.s3.e3" origId="23925,67172434" charOffset="167-171" type="compound" text="iron"/>
            <pair e1="DS3.d411.s3.e3" e2="DS3.d411.s3.e0" id="DS3.d411.s3.i0" interaction="False" />
            <pair e1="DS3.d411.s3.e3" e2="DS3.d411.s3.e1" id="DS3.d411.s3.i1" interaction="False" />
            <pair e1="DS3.d411.s3.e3" e2="DS3.d411.s3.e2" id="DS3.d411.s3.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d411.s4" origId="9950149-7" text="IRP-1 activity and TfR Bmax for diferric transferrin were greater in the iron-deficient group (P&amp;lt;0.05).">
            <entity id="DS3.d411.s4.e0" origId="P21399,V9HWB7,Q9HBB2" charOffset="0-5" type="protein" text="IRP-1"/>
            <entity id="DS3.d411.s4.e1" origId="P02786" charOffset="19-22" type="protein" text="TfR"/>
            <entity id="DS3.d411.s4.e2" origId="P02787,Q06AH7,A0PJA6" charOffset="41-52" type="protein" text="transferrin"/>
            <entity id="DS3.d411.s4.e3" origId="23925,67172434" charOffset="73-77" type="compound" text="iron"/>
            <pair e1="DS3.d411.s4.e3" e2="DS3.d411.s4.e0" id="DS3.d411.s4.i0" interaction="False" />
            <pair e1="DS3.d411.s4.e3" e2="DS3.d411.s4.e2" id="DS3.d411.s4.i1" interaction="False" />
            <pair e1="DS3.d411.s4.e3" e2="DS3.d411.s4.e1" id="DS3.d411.s4.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d411.s5" origId="9950149-8" text="IRP-1 activity correlated inversely with cord serum ferritin (r=0.75; P&amp;lt;0.01) and placental non-heme iron (r=0.61; P=0.05) concentration.">
            <entity id="DS3.d411.s5.e0" origId="P21399,V9HWB7,Q9HBB2" charOffset="0-5" type="protein" text="IRP-1"/>
            <entity id="DS3.d411.s5.e1" origId="4971" charOffset="99-103" type="compound" text="heme"/>
            <entity id="DS3.d411.s5.e2" origId="23925,67172434" charOffset="104-108" type="compound" text="iron"/>
            <pair e1="DS3.d411.s5.e2" e2="DS3.d411.s5.e0" id="DS3.d411.s5.i0" interaction="False" />
            <pair e1="DS3.d411.s5.e1" e2="DS3.d411.s5.e0" id="DS3.d411.s5.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d411.s6" origId="9950149-9" text="Placental IRP-1 activity is directly related to TfR mRNA concentration and is more highly expressed in iron-deficient placentae.">
            <entity id="DS3.d411.s6.e0" origId="P21399,V9HWB7,Q9HBB2" charOffset="10-15" type="protein" text="IRP-1"/>
            <entity id="DS3.d411.s6.e1" origId="P02786" charOffset="48-51" type="protein" text="TfR"/>
            <entity id="DS3.d411.s6.e2" origId="23925,67172434" charOffset="103-107" type="compound" text="iron"/>
            <pair e1="DS3.d411.s6.e2" e2="DS3.d411.s6.e0" id="DS3.d411.s6.i0" interaction="False" />
            <pair e1="DS3.d411.s6.e2" e2="DS3.d411.s6.e1" id="DS3.d411.s6.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d412" origId="9950150">
        <sentence id="DS3.d412.s0" origId="9950150-4" text="Furthermore, it studied the defence mechanism of the thioredoxin-thioredoxin reductase system against oxidative stress in mitochondria of normal human placenta where reactive oxygen species are primarily produced.">
            <entity id="DS3.d412.s0.e0" origId="P10599,H9ZYJ2" charOffset="53-64" type="protein" text="thioredoxin"/>
            <entity id="DS3.d412.s0.e1" origId="P30044" charOffset="65-86" type="protein" text="thioredoxin reductase"/>
            <entity id="DS3.d412.s0.e2" origId="977" charOffset="175-181" type="compound" text="oxygen"/>
            <pair e1="DS3.d412.s0.e2" e2="DS3.d412.s0.e1" id="DS3.d412.s0.i0" interaction="False" />
            <pair e1="DS3.d412.s0.e2" e2="DS3.d412.s0.e0" id="DS3.d412.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d413" origId="9950152">
        <sentence id="DS3.d413.s0" origId="9950152-3" text="The expression of ERV-3 env mRNA increased after 48 h forskolin treatment, concurrently with increased intercellular fusion and production of human chorionic gonadotropin (beta-hCG) mRNA, a hormonal differentiation marker for trophoblast.">
            <entity id="DS3.d413.s0.e0" origId="Q14264" charOffset="18-23" type="protein" text="ERV-3"/>
            <entity id="DS3.d413.s0.e1" origId="47936" charOffset="54-63" type="compound" text="forskolin"/>
            <pair e1="DS3.d413.s0.e1" e2="DS3.d413.s0.e0" id="DS3.d413.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d414" origId="9950160">
        <sentence id="DS3.d414.s0" origId="9950160-3" text="Renal biopsy specimens from 13 patients with glomerular disease (6 with Alport's syndrome, 5 with focal glomerulosclerosis, 2 with membranoproliferative glomerulonephritis, Type 1) showing interstitial FCs were investigated by histochemical means for neutral lipid (oil red O stain); immunohistochemical means for monocytes/macrophages (CD68), apolipoproteins (Apo) A-I, B, and E, and oxidized low-density lipoprotein (LDL); and by electron microscopic examination.">
            <entity id="DS3.d414.s0.e0" origId="6046885,6821284" charOffset="266-275" type="compound" text="oil red O"/>
            <entity id="DS3.d414.s0.e1" origId="P34810" charOffset="337-341" type="protein" text="CD68"/>
            <entity id="DS3.d414.s0.e2" origId="P02647,A0A024R3E3" charOffset="344-372" type="protein" text="apolipoproteins (Apo) A-I, B"/>
            <pair e1="DS3.d414.s0.e0" e2="DS3.d414.s0.e2" id="DS3.d414.s0.i0" interaction="False" />
            <pair e1="DS3.d414.s0.e0" e2="DS3.d414.s0.e1" id="DS3.d414.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d415" origId="9950174">
        <sentence id="DS3.d415.s0" origId="9950174-6" text="This was proven for the following 3 representative hemocompatibility parameters: complement C5a generation, thrombin-antithrombin (TAT) III formation, and platelet count (PC).">
            <entity id="DS3.d415.s0.e0" origId="P01031" charOffset="92-95" type="protein" text="C5a"/>
            <entity id="DS3.d415.s0.e1" origId="90470996" charOffset="108-116" type="compound" text="thrombin"/>
            <pair e1="DS3.d415.s0.e1" e2="DS3.d415.s0.e0" id="DS3.d415.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d416" origId="9950176">
        <sentence id="DS3.d416.s0" origId="9950176-10" text="However, only polysulfone induced an increase in CD11b expression and fibrinogen binding to monocytes.">
            <entity id="DS3.d416.s0.e0" origId="16211415" charOffset="14-25" type="compound" text="polysulfone"/>
            <entity id="DS3.d416.s0.e1" origId="P11215" charOffset="49-54" type="protein" text="CD11b"/>
            <entity id="DS3.d416.s0.e2" origId="P02675,V9HVY1" charOffset="70-80" type="protein" text="fibrinogen"/>
            <pair e1="DS3.d416.s0.e0" e2="DS3.d416.s0.e2" id="DS3.d416.s0.i0" interaction="False" />
            <pair e1="DS3.d416.s0.e0" e2="DS3.d416.s0.e1" id="DS3.d416.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d416.s1" origId="9950176-3" text="To evaluate this process, we examined respectively platelet activation (anti-CD41, anti-CD62, and antifibrinogen monoclonal antibodies (MoAb) binding), leukocyte activation (CD11b expression), and the appearance of platelet specific antigens on leukocytes as an index of platelet-leukocyte aggregation during HD using 3 different membrane materials, Cuprophan, Hemophan, and polysulfone.">
            <entity id="DS3.d416.s1.e0" origId="P08514" charOffset="77-81" type="protein" text="CD41"/>
            <entity id="DS3.d416.s1.e1" origId="P16109,Q5R341,A0A024R8Y9,Q6NUL9" charOffset="88-92" type="protein" text="CD62"/>
            <entity id="DS3.d416.s1.e2" origId="P11215" charOffset="174-179" type="protein" text="CD11b"/>
            <entity id="DS3.d416.s1.e3" origId="16211415" charOffset="375-386" type="compound" text="polysulfone"/>
            <pair e1="DS3.d416.s1.e3" e2="DS3.d416.s1.e0" id="DS3.d416.s1.i0" interaction="False" />
            <pair e1="DS3.d416.s1.e3" e2="DS3.d416.s1.e1" id="DS3.d416.s1.i1" interaction="False" />
            <pair e1="DS3.d416.s1.e3" e2="DS3.d416.s1.e2" id="DS3.d416.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d417" origId="9950184">
        <sentence id="DS3.d417.s0" origId="9950184-3" text="The most important contribution to the FPSA system was the development of a new polysulfone hollow-fiber filter, which is characterized by a sieving coefficient of 0.89 for human serum albumin (HSA) but only of 0.17 for fibrinogen, and 0 (zero) for IgM immunoglobulins.">
            <entity id="DS3.d417.s0.e0" origId="16211415" charOffset="80-91" type="compound" text="polysulfone"/>
            <entity id="DS3.d417.s0.e1" origId="P02768" charOffset="185-192" type="protein" text="albumin"/>
            <entity id="DS3.d417.s0.e2" origId="P02675,V9HVY1" charOffset="220-237" type="protein" text="fibrinogen, and 0"/>
            <pair e1="DS3.d417.s0.e0" e2="DS3.d417.s0.e2" id="DS3.d417.s0.i0" interaction="False" />
            <pair e1="DS3.d417.s0.e0" e2="DS3.d417.s0.e1" id="DS3.d417.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d417.s1" origId="9950184-4" text="Using a closed filtrate circuit connected to the new polysulfone filter which integrates 1 or 2 adsorption columns and also a high flux dialyzer adapted to a dialysis machine, the FPSA system opens excellent possibilities for the relatively specific removal of albumin bound substances from the blood such as albumin bound bilirubin or even tryptophan.">
            <entity id="DS3.d417.s1.e0" origId="16211415" charOffset="53-64" type="compound" text="polysulfone"/>
            <entity id="DS3.d417.s1.e1" origId="P02768" charOffset="261-268" type="protein" text="albumin"/>
            <entity id="DS3.d417.s1.e2" origId="P02768" charOffset="309-316" type="protein" text="albumin"/>
            <entity id="DS3.d417.s1.e3" origId="5280352" charOffset="323-332" type="compound" text="bilirubin"/>
            <entity id="DS3.d417.s1.e4" origId="57175189,6305" charOffset="341-351" type="compound" text="tryptophan"/>
            <pair e1="DS3.d417.s1.e3" e2="DS3.d417.s1.e1" id="DS3.d417.s1.i0" interaction="False" />
            <pair e1="DS3.d417.s1.e4" e2="DS3.d417.s1.e1" id="DS3.d417.s1.i1" interaction="False" />
            <pair e1="DS3.d417.s1.e0" e2="DS3.d417.s1.e1" id="DS3.d417.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d418" origId="9950187">
        <sentence id="DS3.d418.s0" origId="9950187-2" text="Plasticized polyvinyl chloride before and after treatment with methanol to reduce the plasticizer surface level was assessed in terms of fibrinogen and albumin adsorption with unplasticized polyvinyl chloride acting as a control.">
            <entity id="DS3.d418.s0.e0" origId="6338" charOffset="12-30" type="compound" text="polyvinyl chloride"/>
            <entity id="DS3.d418.s0.e1" origId="11686950,887" charOffset="63-71" type="compound" text="methanol"/>
            <entity id="DS3.d418.s0.e2" origId="P02675,V9HVY1" charOffset="137-147" type="protein" text="fibrinogen"/>
            <entity id="DS3.d418.s0.e3" origId="P02768" charOffset="152-159" type="protein" text="albumin"/>
            <entity id="DS3.d418.s0.e4" origId="6338" charOffset="190-208" type="compound" text="polyvinyl chloride"/>
            <pair e1="DS3.d418.s0.e0" e2="DS3.d418.s0.e3" id="DS3.d418.s0.i0" interaction="False" />
            <pair e1="DS3.d418.s0.e0" e2="DS3.d418.s0.e2" id="DS3.d418.s0.i1" interaction="False" />
            <pair e1="DS3.d418.s0.e1" e2="DS3.d418.s0.e3" id="DS3.d418.s0.i2" interaction="False" />
            <pair e1="DS3.d418.s0.e1" e2="DS3.d418.s0.e2" id="DS3.d418.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d419" origId="9950188">
        <sentence id="DS3.d419.s0" origId="9950188-3" text="Flow cytometry demonstrated that the SSLF initiated significantly smaller effects in terms of mean fluorescence intensity of CD63 (p&amp;lt;0.03) and of the amount of CD62P expressing platelets (p&amp;lt;0.002) compared to the polyurethane filters.">
            <entity id="DS3.d419.s0.e0" origId="P08962,A0A024RB05" charOffset="125-129" type="protein" text="CD63"/>
            <entity id="DS3.d419.s0.e1" origId="P16109,Q5R341,A0A024R8Y9,Q6NUL9" charOffset="163-168" type="protein" text="CD62P"/>
            <entity id="DS3.d419.s0.e2" origId="12254" charOffset="219-231" type="compound" text="polyurethane"/>
            <pair e1="DS3.d419.s0.e2" e2="DS3.d419.s0.e0" id="DS3.d419.s0.i0" interaction="False" />
            <pair e1="DS3.d419.s0.e2" e2="DS3.d419.s0.e1" id="DS3.d419.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d420" origId="9950189">
        <sentence id="DS3.d420.s0" origId="9950189-3" text="MDCK cells and KU-2 cells were seeded onto 96 well plates which had been precoated with collagen types I and IV, laminin, and fibronectin.">
            <entity id="DS3.d420.s0.e0" origId="44342165" charOffset="113-120" type="compound" text="laminin"/>
            <entity id="DS3.d420.s0.e1" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="126-137" type="protein" text="fibronectin"/>
            <pair e1="DS3.d420.s0.e0" e2="DS3.d420.s0.e1" id="DS3.d420.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d420.s1" origId="9950189-6" text="In the MDCK cell culture, better cell attachment was observed between 60 min and 24 h after incubation start time with the use of laminin at a concentration of 5 microg/ml, 60 min and more after incubation start time with the use of fibronectin at the concentrations of 1 and 4 microg/ml, or 30 min and more after incubation start time with the use of fibronectin at the concentrations of 16 and 32 microg/ml.">
            <entity id="DS3.d420.s1.e0" origId="44342165" charOffset="130-137" type="compound" text="laminin"/>
            <entity id="DS3.d420.s1.e1" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="233-244" type="protein" text="fibronectin"/>
            <entity id="DS3.d420.s1.e2" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="352-363" type="protein" text="fibronectin"/>
            <pair e1="DS3.d420.s1.e0" e2="DS3.d420.s1.e1" id="DS3.d420.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d421" origId="9950195">
        <sentence id="DS3.d421.s0" origId="9950195-4" text="PROCEDURE: Mean glomerular filtration rate (GFR) was determined by inulin or iothalamate clearance; proximal tubular function was evaluated by measuring fractional excretion of glucose (FEglu), tubular maximum phosphate reabsorption per GFR (TMP/GFR), FE of urate, and 24-hour amino acid excretion.">
            <entity id="DS3.d421.s0.e0" origId="Q92565,A8MQ07,Q5JPD2" charOffset="44-47" type="protein" text="GFR"/>
            <entity id="DS3.d421.s0.e1" origId="18772499,24763" charOffset="67-73" type="compound" text="inulin"/>
            <entity id="DS3.d421.s0.e2" origId="2140" charOffset="77-88" type="compound" text="iothalamate"/>
            <entity id="DS3.d421.s0.e3" origId="206,5793,64689,79025" charOffset="177-184" type="compound" text="glucose"/>
            <entity id="DS3.d421.s0.e4" origId="1061,167704,644102" charOffset="210-219" type="compound" text="phosphate"/>
            <entity id="DS3.d421.s0.e5" origId="Q92565,A8MQ07,Q5JPD2" charOffset="237-240" type="protein" text="GFR"/>
            <entity id="DS3.d421.s0.e6" origId="Q92565,A8MQ07,Q5JPD2" charOffset="237-240" type="protein" text="GFR"/>
            <entity id="DS3.d421.s0.e7" origId="1175,29645" charOffset="258-263" type="compound" text="urate"/>
            <pair e1="DS3.d421.s0.e2" e2="DS3.d421.s0.e0" id="DS3.d421.s0.i0" interaction="False" />
            <pair e1="DS3.d421.s0.e7" e2="DS3.d421.s0.e0" id="DS3.d421.s0.i1" interaction="False" />
            <pair e1="DS3.d421.s0.e4" e2="DS3.d421.s0.e0" id="DS3.d421.s0.i2" interaction="False" />
            <pair e1="DS3.d421.s0.e1" e2="DS3.d421.s0.e0" id="DS3.d421.s0.i3" interaction="False" />
            <pair e1="DS3.d421.s0.e3" e2="DS3.d421.s0.e0" id="DS3.d421.s0.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d421.s1" origId="9950195-9" text="Proximal tubular function evaluation revealed normal FEglu, normal mean TMP/GFR values, and high FE of urate (1 5.7%).">
            <entity id="DS3.d421.s1.e0" origId="Q92565,A8MQ07,Q5JPD2" charOffset="76-79" type="protein" text="GFR"/>
            <entity id="DS3.d421.s1.e1" origId="1175,29645" charOffset="103-108" type="compound" text="urate"/>
            <pair e1="DS3.d421.s1.e1" e2="DS3.d421.s1.e0" id="DS3.d421.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d422" origId="9950217">
        <sentence id="DS3.d422.s0" origId="9950217-7" text="Its deletion blunted the response of PPARgamma2 promoter to cotransfected C/EBPbeta or methylisobutylxanthine treatment.">
            <entity id="DS3.d422.s0.e0" origId="P17676" charOffset="74-83" type="protein" text="C/EBPbeta"/>
            <entity id="DS3.d422.s0.e1" origId="3758" charOffset="87-109" type="compound" text="methylisobutylxanthine"/>
            <pair e1="DS3.d422.s0.e1" e2="DS3.d422.s0.e0" id="DS3.d422.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d423" origId="9950218">
        <sentence id="DS3.d423.s0" origId="9950218-0" text="Retinoic acid-mediated G1-S-phase arrest of normal human mammary epithelial cells is independent of the level of p53 protein expression.">
            <entity id="DS3.d423.s0.e0" origId="444795" charOffset="0-13" type="compound" text="Retinoic acid"/>
            <entity id="DS3.d423.s0.e1" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="113-116" type="protein" text="p53"/>
            <pair e1="DS3.d423.s0.e0" e2="DS3.d423.s0.e1" id="DS3.d423.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d424" origId="9950219">
        <sentence id="DS3.d424.s0" origId="9950219-1" text="The Shc protein helps to transmit signals from receptor and cytoplasmic tyrosine kinases to Ras.">
            <entity id="DS3.d424.s0.e0" origId="P29353" charOffset="4-7" type="protein" text="Shc"/>
            <entity id="DS3.d424.s0.e1" origId="6057,90983769" charOffset="72-80" type="compound" text="tyrosine"/>
            <pair e1="DS3.d424.s0.e1" e2="DS3.d424.s0.e0" id="DS3.d424.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d424.s1" origId="9950219-2" text="We have shown that several breast cancer cell lines (MDA-MB-453, BT474, MDA-MB-361, and SKBR3), which overexpress the ErbB2 receptor tyrosine kinase, contain constitutively tyrosine phosphorylated Shc.">
            <entity id="DS3.d424.s1.e0" origId="P04626,J3QLU9,F5H1T4,X5DNK3" charOffset="118-123" type="protein" text="ErbB2"/>
            <entity id="DS3.d424.s1.e1" origId="6057,90983769" charOffset="133-141" type="compound" text="tyrosine"/>
            <entity id="DS3.d424.s1.e2" origId="6057,90983769" charOffset="173-181" type="compound" text="tyrosine"/>
            <entity id="DS3.d424.s1.e3" origId="P29353" charOffset="197-200" type="protein" text="Shc"/>
            <pair e1="DS3.d424.s1.e1" e2="DS3.d424.s1.e0" id="DS3.d424.s1.i0" interaction="False" />
            <pair e1="DS3.d424.s1.e1" e2="DS3.d424.s1.e3" id="DS3.d424.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d424.s2" origId="9950219-7" text="The G2-M block was unexpected because Shc-Y317 is downstream of receptor tyrosine kinases that drive the early events in the cell cycle.">
            <entity id="DS3.d424.s2.e0" origId="P29353" charOffset="38-41" type="protein" text="Shc"/>
            <entity id="DS3.d424.s2.e1" origId="6057,90983769" charOffset="73-81" type="compound" text="tyrosine"/>
            <pair e1="DS3.d424.s2.e1" e2="DS3.d424.s2.e0" id="DS3.d424.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d424.s3" origId="9950219-8" text="Both the G0-G1 and G2-M arrest were rescued by transfection with wild-type Shc or oncogenic Ras 12V.">
            <entity id="DS3.d424.s3.e0" origId="P29353" charOffset="75-78" type="protein" text="Shc"/>
            <entity id="DS3.d424.s3.e1" origId="49835811" charOffset="96-99" type="compound" text="12V"/>
            <pair e1="DS3.d424.s3.e1" e2="DS3.d424.s3.e0" id="DS3.d424.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d425" origId="9950258">
        <sentence id="DS3.d425.s0" origId="9950258-5" text="Therefore, the basal fibrinogen binding to GP IIb/IIIa and CD 62p expression and the thrombin-concentration for half-maximal platelet activation before and after exercise testing were determined.">
            <entity id="DS3.d425.s0.e0" origId="P16109,Q5R341,A0A024R8Y9,Q6NUL9" charOffset="59-65" type="protein" text="CD 62p"/>
            <entity id="DS3.d425.s0.e1" origId="90470996" charOffset="85-93" type="compound" text="thrombin"/>
            <pair e1="DS3.d425.s0.e1" e2="DS3.d425.s0.e0" id="DS3.d425.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d425.s1" origId="9950258-6" text="Additionally, inhibition of thrombin-induced platelet activation by increasing concentrations of the prostacyclin-analog iloprost and the NO-donor SIN-1 was examined.">
            <entity id="DS3.d425.s1.e0" origId="90470996" charOffset="28-36" type="compound" text="thrombin"/>
            <entity id="DS3.d425.s1.e1" origId="5280427" charOffset="101-113" type="compound" text="prostacyclin"/>
            <entity id="DS3.d425.s1.e2" origId="10937300,5311181,53394043,53486260,6435378,6443959" charOffset="121-129" type="compound" text="iloprost"/>
            <entity id="DS3.d425.s1.e3" origId="Q9BPZ7,A0A024R863" charOffset="147-152" type="protein" text="SIN-1"/>
            <pair e1="DS3.d425.s1.e0" e2="DS3.d425.s1.e3" id="DS3.d425.s1.i0" interaction="False" />
            <pair e1="DS3.d425.s1.e2" e2="DS3.d425.s1.e3" id="DS3.d425.s1.i1" interaction="False" />
            <pair e1="DS3.d425.s1.e1" e2="DS3.d425.s1.e3" id="DS3.d425.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d425.s2" origId="9950258-8" text="The thrombin-induced expression of GP IIb/IIIa and CD 62p was significantly diminished in patients with CAD after physical exercise and their platelets were significantly more sensitive towards the inhibitory effects of iloprost and SIN-1.">
            <entity id="DS3.d425.s2.e0" origId="90470996" charOffset="4-12" type="compound" text="thrombin"/>
            <entity id="DS3.d425.s2.e1" origId="P16109,Q5R341,A0A024R8Y9,Q6NUL9" charOffset="51-57" type="protein" text="CD 62p"/>
            <entity id="DS3.d425.s2.e2" origId="10937300,5311181,53394043,53486260,6435378,6443959" charOffset="220-228" type="compound" text="iloprost"/>
            <entity id="DS3.d425.s2.e3" origId="Q9BPZ7,A0A024R863" charOffset="233-238" type="protein" text="SIN-1"/>
            <pair e1="DS3.d425.s2.e0" e2="DS3.d425.s2.e3" id="DS3.d425.s2.i0" interaction="False" />
            <pair e1="DS3.d425.s2.e0" e2="DS3.d425.s2.e1" id="DS3.d425.s2.i1" interaction="False" />
            <pair e1="DS3.d425.s2.e2" e2="DS3.d425.s2.e3" id="DS3.d425.s2.i2" interaction="False" />
            <pair e1="DS3.d425.s2.e2" e2="DS3.d425.s2.e1" id="DS3.d425.s2.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d426" origId="9950259">
        <sentence id="DS3.d426.s0" origId="9950259-1" text="A common C677T mutation in the gene for the enzyme 5,10-methylenetetrahydrofolate reductase (5,10-MTHFR) has been linked to elevated levels of homocysteine and was therefore suspected to be a candidate genetic risk factor for arterial occlusive disease.">
            <entity id="DS3.d426.s0.e0" origId="108194,439175,445117,884" charOffset="51-81" type="compound" text="5,10-methylenetetrahydrofolate"/>
            <entity id="DS3.d426.s0.e1" origId="P42898,Q8IU67,Q59GJ6" charOffset="98-103" type="protein" text="MTHFR"/>
            <entity id="DS3.d426.s0.e2" origId="91552" charOffset="143-155" type="compound" text="homocysteine"/>
            <pair e1="DS3.d426.s0.e2" e2="DS3.d426.s0.e1" id="DS3.d426.s0.i0" interaction="False" />
            <pair e1="DS3.d426.s0.e0" e2="DS3.d426.s0.e1" id="DS3.d426.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d427" origId="9950260">
        <sentence id="DS3.d427.s0" origId="9950260-3" text="The parameters assayed were: prothrombin fragment 1+2 (F1+2), thrombin-antithrombin III complexes (TAT), fibrinopeptide A (FPA), plasmin-alpha2 antiplasmin complexes (PAP) and D-Dimer.">
            <entity id="DS3.d427.s0.e0" origId="P00748,Q8IZZ5" charOffset="55-59" type="protein" text="F1+2"/>
            <entity id="DS3.d427.s0.e1" origId="90470996" charOffset="32-40" type="compound" text="thrombin"/>
            <entity id="DS3.d427.s0.e2" origId="25078015,25081464" charOffset="105-121" type="compound" text="fibrinopeptide A"/>
            <pair e1="DS3.d427.s0.e1" e2="DS3.d427.s0.e0" id="DS3.d427.s0.i0" interaction="False" />
            <pair e1="DS3.d427.s0.e2" e2="DS3.d427.s0.e0" id="DS3.d427.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d428" origId="9950264">
        <sentence id="DS3.d428.s0" origId="9950264-2" text="NSF-60 cells proliferate in response to interleukin-3 (IL-3) and undergo apoptosis when deprived of exogenous IL-3, as demonstrated by the appearance of characteristic DNA 'ladders' following agarose gel electrophoresis.">
            <entity id="DS3.d428.s0.e0" origId="P01586,Q5SX77" charOffset="40-59" type="protein" text="interleukin-3 (IL-3"/>
            <entity id="DS3.d428.s0.e1" origId="P01586,Q5SX77" charOffset="55-59" type="protein" text="IL-3"/>
            <entity id="DS3.d428.s0.e2" origId="11966311" charOffset="192-199" type="compound" text="agarose"/>
            <pair e1="DS3.d428.s0.e2" e2="DS3.d428.s0.e0" id="DS3.d428.s0.i0" interaction="False" />
            <pair e1="DS3.d428.s0.e2" e2="DS3.d428.s0.e1" id="DS3.d428.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d428.s1" origId="9950264-6" text="ATA and IL-3 induced proliferation was inhibited by the kinase inhibitors genistein, staurosporine and H-7.">
            <entity id="DS3.d428.s1.e0" origId="P01586,Q5SX77" charOffset="8-12" type="protein" text="IL-3"/>
            <entity id="DS3.d428.s1.e1" origId="5280961" charOffset="74-83" type="compound" text="genistein"/>
            <entity id="DS3.d428.s1.e2" origId="44120114,44299148,451705,5311103,5459111,5279,6419748,6711321,9937179,9956178" charOffset="85-98" type="compound" text="staurosporine"/>
            <pair e1="DS3.d428.s1.e2" e2="DS3.d428.s1.e0" id="DS3.d428.s1.i0" interaction="False" />
            <pair e1="DS3.d428.s1.e1" e2="DS3.d428.s1.e0" id="DS3.d428.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d429" origId="9950265">
        <sentence id="DS3.d429.s0" origId="9950265-0" text="The role of aminopeptidase N in Met-enkephalin modulated superoxide anion release.">
            <entity id="DS3.d429.s0.e0" origId="P15144,A0A024RC61,Q59E93" charOffset="12-28" type="protein" text="aminopeptidase N"/>
            <entity id="DS3.d429.s0.e1" origId="461776" charOffset="36-46" type="compound" text="enkephalin"/>
            <entity id="DS3.d429.s0.e2" origId="5359597" charOffset="57-67" type="compound" text="superoxide"/>
            <pair e1="DS3.d429.s0.e1" e2="DS3.d429.s0.e0" id="DS3.d429.s0.i0" interaction="False" />
            <pair e1="DS3.d429.s0.e2" e2="DS3.d429.s0.e0" id="DS3.d429.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d429.s1" origId="9950265-6" text="The level of APN activity from different donors correlated with the effect of MENK on superoxide anion release.">
            <entity id="DS3.d429.s1.e0" origId="P15144,A0A024RC61,Q59E93" charOffset="13-16" type="protein" text="APN"/>
            <entity id="DS3.d429.s1.e1" origId="5359597" charOffset="86-96" type="compound" text="superoxide"/>
            <pair e1="DS3.d429.s1.e1" e2="DS3.d429.s1.e0" id="DS3.d429.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d429.s2" origId="9950265-7" text="Neutrophils with low APN activity, if preincubated with MENK, released reduced amounts of superoxide anion.">
            <entity id="DS3.d429.s2.e0" origId="P15144,A0A024RC61,Q59E93" charOffset="21-24" type="protein" text="APN"/>
            <entity id="DS3.d429.s2.e1" origId="5359597" charOffset="90-100" type="compound" text="superoxide"/>
            <pair e1="DS3.d429.s2.e1" e2="DS3.d429.s2.e0" id="DS3.d429.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d429.s3" origId="9950265-8" text="In contrast, neutrophils with high APN activity released increased amounts of superoxide anion after preincubation with MENK.">
            <entity id="DS3.d429.s3.e0" origId="P15144,A0A024RC61,Q59E93" charOffset="35-38" type="protein" text="APN"/>
            <entity id="DS3.d429.s3.e1" origId="5359597" charOffset="78-88" type="compound" text="superoxide"/>
            <pair e1="DS3.d429.s3.e1" e2="DS3.d429.s3.e0" id="DS3.d429.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d430" origId="9950266">
        <sentence id="DS3.d430.s0" origId="9950266-0" text="Alpha 1-acid glycoprotein-induced tumor necrosis factor-alpha secretion of human monocytes is enhanced by serum binding proteins and depends on protein tyrosine kinase activation.">
            <entity id="DS3.d430.s0.e0" origId="P01375,Q5STB3" charOffset="34-61" type="protein" text="tumor necrosis factor-alpha"/>
            <entity id="DS3.d430.s0.e1" origId="6057,90983769" charOffset="152-160" type="compound" text="tyrosine"/>
            <pair e1="DS3.d430.s0.e1" e2="DS3.d430.s0.e0" id="DS3.d430.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d430.s1" origId="9950266-2" text="AGP-induced TNFalpha secretion of monocytes was enhanced in the presence of human plasma and inhibited by protein kinase inhibitors, indicating it is serum and tyrosine kinase dependent.">
            <entity id="DS3.d430.s1.e0" origId="P01375,Q5STB3" charOffset="12-20" type="protein" text="TNFalpha"/>
            <entity id="DS3.d430.s1.e1" origId="6057,90983769" charOffset="160-168" type="compound" text="tyrosine"/>
            <pair e1="DS3.d430.s1.e1" e2="DS3.d430.s1.e0" id="DS3.d430.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d431" origId="9950267">
        <sentence id="DS3.d431.s0" origId="9950267-2" text="T cells treated for 48 h with immobilized anti-CD3 monoclonal antibody upregulated expression of the interleukin-2 receptor alpha-chain (CD25), transferrin receptor (CD71), the apoptosis-regulating Fas receptor (CD95), contained a greater level of the anti-apoptotic protein Bcl-2 and accumulated significantly more BPD-MA than their unactivated counterparts.">
            <entity id="DS3.d431.s0.e0" origId="P01590,Q544I2" charOffset="101-135" type="protein" text="interleukin-2 receptor alpha-chain"/>
            <entity id="DS3.d431.s0.e1" origId="P01590,Q544I2" charOffset="137-141" type="protein" text="CD25"/>
            <entity id="DS3.d431.s0.e2" origId="Q62351,Q542D9" charOffset="144-164" type="protein" text="transferrin receptor"/>
            <entity id="DS3.d431.s0.e3" origId="Q62351,Q542D9" charOffset="166-170" type="protein" text="CD71"/>
            <entity id="DS3.d431.s0.e4" origId="P25446,Q8C350" charOffset="212-216" type="protein" text="CD95"/>
            <entity id="DS3.d431.s0.e5" origId="P10417,Q6NTH7" charOffset="275-280" type="protein" text="Bcl-2"/>
            <entity id="DS3.d431.s0.e6" origId="5485223" charOffset="316-322" type="compound" text="BPD-MA"/>
            <pair e1="DS3.d431.s0.e6" e2="DS3.d431.s0.e3" id="DS3.d431.s0.i0" interaction="False" />
            <pair e1="DS3.d431.s0.e6" e2="DS3.d431.s0.e2" id="DS3.d431.s0.i1" interaction="False" />
            <pair e1="DS3.d431.s0.e6" e2="DS3.d431.s0.e4" id="DS3.d431.s0.i2" interaction="False" />
            <pair e1="DS3.d431.s0.e6" e2="DS3.d431.s0.e1" id="DS3.d431.s0.i3" interaction="False" />
            <pair e1="DS3.d431.s0.e6" e2="DS3.d431.s0.e5" id="DS3.d431.s0.i4" interaction="False" />
            <pair e1="DS3.d431.s0.e6" e2="DS3.d431.s0.e0" id="DS3.d431.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d431.s1" origId="9950267-4" text="Resting T cells treated with sub-lethal levels of BPD-MA and light did not exhibit changes in surface levels of CD3, CD4, CD8, CD28, CD45 or T cell receptor (TCR) beta-chain structures.">
            <entity id="DS3.d431.s1.e0" origId="5485223" charOffset="50-56" type="compound" text="BPD-MA"/>
            <entity id="DS3.d431.s1.e1" origId="P06332,Q3TSV7" charOffset="117-120" type="protein" text="CD4"/>
            <entity id="DS3.d431.s1.e2" origId="P31041,Q8CDB3" charOffset="127-131" type="protein" text="CD28"/>
            <entity id="DS3.d431.s1.e3" origId="S4R2V1,Q8C6Q7,S4R1S4,S4R1M0" charOffset="133-137" type="protein" text="CD45"/>
            <pair e1="DS3.d431.s1.e0" e2="DS3.d431.s1.e1" id="DS3.d431.s1.i0" interaction="False" />
            <pair e1="DS3.d431.s1.e0" e2="DS3.d431.s1.e3" id="DS3.d431.s1.i1" interaction="False" />
            <pair e1="DS3.d431.s1.e0" e2="DS3.d431.s1.e2" id="DS3.d431.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d431.s2" origId="9950267-7" text="Activated T cells treated with sub-lethal levels of BPD-MA and light exhibited lower CD25 levels, a temporary block in cell cycle transition, but unaltered expression of MHC Class I, CD3, CD4, CD8, CD45, CD54, CD71, CD122 (IL-2R beta-chain) or TCR beta-chain antigens 24 h afterward.">
            <entity id="DS3.d431.s2.e0" origId="5485223" charOffset="52-58" type="compound" text="BPD-MA"/>
            <entity id="DS3.d431.s2.e1" origId="P01590,Q544I2" charOffset="85-89" type="protein" text="CD25"/>
            <entity id="DS3.d431.s2.e2" origId="P06332,Q3TSV7" charOffset="188-191" type="protein" text="CD4"/>
            <entity id="DS3.d431.s2.e3" origId="S4R2V1,Q8C6Q7,S4R1S4,S4R1M0" charOffset="198-202" type="protein" text="CD45"/>
            <entity id="DS3.d431.s2.e4" origId="P13597,Q3U8M7" charOffset="204-208" type="protein" text="CD54"/>
            <entity id="DS3.d431.s2.e5" origId="Q62351,Q542D9" charOffset="210-214" type="protein" text="CD71"/>
            <entity id="DS3.d431.s2.e6" origId="P16297" charOffset="216-221" type="protein" text="CD122"/>
            <pair e1="DS3.d431.s2.e0" e2="DS3.d431.s2.e5" id="DS3.d431.s2.i0" interaction="False" />
            <pair e1="DS3.d431.s2.e0" e2="DS3.d431.s2.e4" id="DS3.d431.s2.i1" interaction="False" />
            <pair e1="DS3.d431.s2.e0" e2="DS3.d431.s2.e6" id="DS3.d431.s2.i2" interaction="False" />
            <pair e1="DS3.d431.s2.e0" e2="DS3.d431.s2.e3" id="DS3.d431.s2.i3" interaction="False" />
            <pair e1="DS3.d431.s2.e0" e2="DS3.d431.s2.e1" id="DS3.d431.s2.i4" interaction="False" />
            <pair e1="DS3.d431.s2.e0" e2="DS3.d431.s2.e2" id="DS3.d431.s2.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d432" origId="9950270">
        <sentence id="DS3.d432.s0" origId="9950270-1" text="In the present study, we investigated the effects of the anti-inflammatory drug pentoxifylline (PTX) on activation of endothelial cells for enhanced adhesion and transmigration of neutrophils by lipopolysaccharide (LPS), tumor necrosis factor-alpha (TNF), interleukin-1 (IL-1) and granulocyte colony-stimulating factor (G-CSF).">
            <entity id="DS3.d432.s0.e0" origId="4740" charOffset="80-94" type="compound" text="pentoxifylline"/>
            <entity id="DS3.d432.s0.e1" origId="11970143" charOffset="195-213" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d432.s0.e2" origId="P01375,Q5STB3" charOffset="221-248" type="protein" text="tumor necrosis factor-alpha"/>
            <entity id="DS3.d432.s0.e3" origId="P01583" charOffset="271-275" type="protein" text="IL-1"/>
            <entity id="DS3.d432.s0.e4" origId="P09919,Q6FH65,Q8N4W3" charOffset="281-325" type="protein" text="granulocyte colony-stimulating factor (G-CSF"/>
            <pair e1="DS3.d432.s0.e0" e2="DS3.d432.s0.e4" id="DS3.d432.s0.i0" interaction="False" />
            <pair e1="DS3.d432.s0.e0" e2="DS3.d432.s0.e2" id="DS3.d432.s0.i1" interaction="False" />
            <pair e1="DS3.d432.s0.e0" e2="DS3.d432.s0.e3" id="DS3.d432.s0.i2" interaction="False" />
            <pair e1="DS3.d432.s0.e1" e2="DS3.d432.s0.e4" id="DS3.d432.s0.i3" interaction="False" />
            <pair e1="DS3.d432.s0.e1" e2="DS3.d432.s0.e2" id="DS3.d432.s0.i4" interaction="False" />
            <pair e1="DS3.d432.s0.e1" e2="DS3.d432.s0.e3" id="DS3.d432.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d432.s1" origId="9950270-2" text="To evaluate the mechanism by which PTX exerts its effect, human umbilical vein endothelial cells (HUVEC) were pretreated with theophylline, 2'-O-dibutyryl-3', 5'-cyclic adenosine monophosphate (db cAMP), and 3-isobutyl-1-methylxanthine, respectively, prior to stimulation.">
            <entity id="DS3.d432.s1.e0" origId="2153" charOffset="126-138" type="compound" text="theophylline"/>
            <entity id="DS3.d432.s1.e1" origId="6076" charOffset="162-192" type="compound" text="cyclic adenosine monophosphate"/>
            <entity id="DS3.d432.s1.e2" origId="P49913,J3KNB4" charOffset="197-201" type="protein" text="cAMP"/>
            <entity id="DS3.d432.s1.e3" origId="3758" charOffset="208-235" type="compound" text="3-isobutyl-1-methylxanthine"/>
            <pair e1="DS3.d432.s1.e1" e2="DS3.d432.s1.e2" id="DS3.d432.s1.i0" interaction="False" />
            <pair e1="DS3.d432.s1.e0" e2="DS3.d432.s1.e2" id="DS3.d432.s1.i1" interaction="False" />
            <pair e1="DS3.d432.s1.e3" e2="DS3.d432.s1.e2" id="DS3.d432.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d432.s2" origId="9950270-5" text="With the exception of theophylline, all other test cAMP-raising agents stimulated transmigration in similar fashion to PTX.">
            <entity id="DS3.d432.s2.e0" origId="2153" charOffset="22-34" type="compound" text="theophylline"/>
            <entity id="DS3.d432.s2.e1" origId="P49913,J3KNB4" charOffset="51-55" type="protein" text="cAMP"/>
            <pair e1="DS3.d432.s2.e0" e2="DS3.d432.s2.e1" id="DS3.d432.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d433" origId="9950279">
        <sentence id="DS3.d433.s0" origId="9950279-3" text="RESULTS: Ceftibuten and cyclacillin were recognized by PEPT1 with affinity constants comparable to those of natural dipeptides (K(i) = 0.3 and 0.5 mM, respectively).">
            <entity id="DS3.d433.s0.e0" origId="5282242" charOffset="9-19" type="compound" text="Ceftibuten"/>
            <entity id="DS3.d433.s0.e1" origId="19003" charOffset="24-35" type="compound" text="cyclacillin"/>
            <entity id="DS3.d433.s0.e2" origId="P46059,B2CQT6" charOffset="55-60" type="protein" text="PEPT1"/>
            <pair e1="DS3.d433.s0.e1" e2="DS3.d433.s0.e2" id="DS3.d433.s0.i0" interaction="False" />
            <pair e1="DS3.d433.s0.e0" e2="DS3.d433.s0.e2" id="DS3.d433.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d433.s1" origId="9950279-4" text="Cefadroxil, cefamandole, cephradine, cefaclor, cefuroxime-axetil, cefixime, cephalotin, cephalexin and ampicillin also interacted with PEPTI (K(i) = 7-14 mM).">
            <entity id="DS3.d433.s1.e0" origId="47965" charOffset="0-10" type="compound" text="Cefadroxil"/>
            <entity id="DS3.d433.s1.e1" origId="456255" charOffset="12-23" type="compound" text="cefamandole"/>
            <entity id="DS3.d433.s1.e2" origId="38103" charOffset="25-35" type="compound" text="cephradine"/>
            <entity id="DS3.d433.s1.e3" origId="51039" charOffset="37-45" type="compound" text="cefaclor"/>
            <entity id="DS3.d433.s1.e4" origId="2659,41375,5361202,53952828,5479529,6604560" charOffset="47-57" type="compound" text="cefuroxime"/>
            <entity id="DS3.d433.s1.e5" origId="2675,5353520,5362065,54362,5943039,6321411" charOffset="66-74" type="compound" text="cefixime"/>
            <entity id="DS3.d433.s1.e6" origId="6024" charOffset="76-86" type="compound" text="cephalotin"/>
            <entity id="DS3.d433.s1.e7" origId="27447" charOffset="88-98" type="compound" text="cephalexin"/>
            <entity id="DS3.d433.s1.e8" origId="6249" charOffset="103-113" type="compound" text="ampicillin"/>
            <entity id="DS3.d433.s1.e9" origId="P46059,B2CQT6" charOffset="135-140" type="protein" text="PEPTI"/>
            <pair e1="DS3.d433.s1.e5" e2="DS3.d433.s1.e9" id="DS3.d433.s1.i0" interaction="False" />
            <pair e1="DS3.d433.s1.e7" e2="DS3.d433.s1.e9" id="DS3.d433.s1.i1" interaction="False" />
            <pair e1="DS3.d433.s1.e1" e2="DS3.d433.s1.e9" id="DS3.d433.s1.i2" interaction="False" />
            <pair e1="DS3.d433.s1.e6" e2="DS3.d433.s1.e9" id="DS3.d433.s1.i3" interaction="False" />
            <pair e1="DS3.d433.s1.e0" e2="DS3.d433.s1.e9" id="DS3.d433.s1.i4" interaction="False" />
            <pair e1="DS3.d433.s1.e3" e2="DS3.d433.s1.e9" id="DS3.d433.s1.i5" interaction="False" />
            <pair e1="DS3.d433.s1.e2" e2="DS3.d433.s1.e9" id="DS3.d433.s1.i6" interaction="False" />
            <pair e1="DS3.d433.s1.e8" e2="DS3.d433.s1.e9" id="DS3.d433.s1.i7" interaction="False" />
            <pair e1="DS3.d433.s1.e4" e2="DS3.d433.s1.e9" id="DS3.d433.s1.i8" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d434" origId="9950281">
        <sentence id="DS3.d434.s0" origId="9950281-10" text="CONCLUSIONS: ACVbeta(glc) is stable and absorbable, but it is not transported by SGLT1.">
            <entity id="DS3.d434.s0.e0" origId="3034742,57288387,6971003" charOffset="21-24" type="compound" text="glc"/>
            <entity id="DS3.d434.s0.e1" origId="P53790" charOffset="81-86" type="protein" text="SGLT1"/>
            <pair e1="DS3.d434.s0.e0" e2="DS3.d434.s0.e1" id="DS3.d434.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d434.s1" origId="9950281-11" text="No involvement of SGLT1 in the ACVbeta(glc) transport is not due to glucose conformation.">
            <entity id="DS3.d434.s1.e0" origId="P53790" charOffset="18-23" type="protein" text="SGLT1"/>
            <entity id="DS3.d434.s1.e1" origId="3034742,57288387,6971003" charOffset="39-42" type="compound" text="glc"/>
            <entity id="DS3.d434.s1.e2" origId="206,5793,64689,79025" charOffset="68-75" type="compound" text="glucose"/>
            <pair e1="DS3.d434.s1.e1" e2="DS3.d434.s1.e0" id="DS3.d434.s1.i0" interaction="False" />
            <pair e1="DS3.d434.s1.e2" e2="DS3.d434.s1.e0" id="DS3.d434.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d434.s2" origId="9950281-1" text="PURPOSE: To characterize the intestinal absorption of a beta-glucose conjugate of acyclovir (9-((2-hydroxyethoxy) methyl) guanine, ACV) and compare it to ACV and its analogues in terms of stability and transport by Na+/glucose cotransporter (SGLTI).">
            <entity id="DS3.d434.s2.e0" origId="206,5793,64689,79025" charOffset="61-68" type="compound" text="glucose"/>
            <entity id="DS3.d434.s2.e1" origId="2022" charOffset="82-91" type="compound" text="acyclovir"/>
            <entity id="DS3.d434.s2.e2" origId="764" charOffset="122-129" type="compound" text="guanine"/>
            <entity id="DS3.d434.s2.e3" origId="206,5793,64689,79025" charOffset="219-226" type="compound" text="glucose"/>
            <entity id="DS3.d434.s2.e4" origId="P53790" charOffset="242-247" type="protein" text="SGLTI"/>
            <pair e1="DS3.d434.s2.e1" e2="DS3.d434.s2.e4" id="DS3.d434.s2.i0" interaction="False" />
            <pair e1="DS3.d434.s2.e2" e2="DS3.d434.s2.e4" id="DS3.d434.s2.i1" interaction="False" />
            <pair e1="DS3.d434.s2.e0" e2="DS3.d434.s2.e4" id="DS3.d434.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d434.s3" origId="9950281-7" text="NMR spectroscopic analysis indicated that the glucose conformation of ACVbeta(glc) was the 4C1 chair form, identical to beta-glucose or SGLT1-transportable beta-glucosides reported previously.">
            <entity id="DS3.d434.s3.e0" origId="206,5793,64689,79025" charOffset="46-53" type="compound" text="glucose"/>
            <entity id="DS3.d434.s3.e1" origId="3034742,57288387,6971003" charOffset="78-81" type="compound" text="glc"/>
            <entity id="DS3.d434.s3.e2" origId="206,5793,64689,79025" charOffset="125-132" type="compound" text="glucose"/>
            <entity id="DS3.d434.s3.e3" origId="P53790" charOffset="136-141" type="protein" text="SGLT1"/>
            <pair e1="DS3.d434.s3.e1" e2="DS3.d434.s3.e3" id="DS3.d434.s3.i0" interaction="False" />
            <pair e1="DS3.d434.s3.e0" e2="DS3.d434.s3.e3" id="DS3.d434.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d434.s4" origId="9950281-8" text="Therefore, other factors such as molecular size and charge due to aglycone may cause no transport of ACVbeta(glc) by SGLT1.">
            <entity id="DS3.d434.s4.e0" origId="3034742,57288387,6971003" charOffset="109-112" type="compound" text="glc"/>
            <entity id="DS3.d434.s4.e1" origId="P53790" charOffset="117-122" type="protein" text="SGLT1"/>
            <pair e1="DS3.d434.s4.e0" e2="DS3.d434.s4.e1" id="DS3.d434.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d435" origId="9950293">
        <sentence id="DS3.d435.s0" origId="9950293-0" text="Molecular mechanisms of the adsorption of a model protein (human serum albumin) on poly(methylidene malonate 2.1.2) nanoparticles.">
            <entity id="DS3.d435.s0.e0" origId="P02768" charOffset="71-78" type="protein" text="albumin"/>
            <entity id="DS3.d435.s0.e1" origId="242818" charOffset="88-108" type="compound" text="methylidene malonate"/>
            <pair e1="DS3.d435.s0.e1" e2="DS3.d435.s0.e0" id="DS3.d435.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d436" origId="9950295">
        <sentence id="DS3.d436.s0" origId="9950295-1" text="PURPOSE: To determine whether human vasoactive intestinal peptide (VIP)-poly(ethylene glycol) (PEG)-grafted distearoyl-phosphatidylethanolamine (DSPE) micelles elicit potent and stable vasodilation in vivo.">
            <entity id="DS3.d436.s0.e0" origId="P01282" charOffset="67-70" type="protein" text="VIP"/>
            <entity id="DS3.d436.s0.e1" origId="53675528,6325" charOffset="77-85" type="compound" text="ethylene"/>
            <entity id="DS3.d436.s0.e2" origId="174" charOffset="86-92" type="compound" text="glycol"/>
            <entity id="DS3.d436.s0.e3" origId="102547" charOffset="145-149" type="compound" text="DSPE"/>
            <pair e1="DS3.d436.s0.e1" e2="DS3.d436.s0.e0" id="DS3.d436.s0.i0" interaction="False" />
            <pair e1="DS3.d436.s0.e2" e2="DS3.d436.s0.e0" id="DS3.d436.s0.i1" interaction="False" />
            <pair e1="DS3.d436.s0.e3" e2="DS3.d436.s0.e0" id="DS3.d436.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d436.s1" origId="9950295-4" text="Vasoactivity of VIP in SSM was determined by monitoring changes in diameter of resistance arterioles in the in situ hamster cheek pouch using intravital microscopy.">
            <entity id="DS3.d436.s1.e0" origId="P01282" charOffset="16-19" type="protein" text="VIP"/>
            <entity id="DS3.d436.s1.e1" origId="19092" charOffset="23-26" type="compound" text="SSM"/>
            <pair e1="DS3.d436.s1.e1" e2="DS3.d436.s1.e0" id="DS3.d436.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d436.s2" origId="9950295-5" text="RESULTS: VIP easily undergoes self-assembly into small PEG-DSPE micelles (mean (+/-SEM) size, 18+/-1 nm) in a time-dependent fashion.">
            <entity id="DS3.d436.s2.e0" origId="P01282" charOffset="9-12" type="protein" text="VIP"/>
            <entity id="DS3.d436.s2.e1" origId="102547" charOffset="59-63" type="compound" text="DSPE"/>
            <entity id="DS3.d436.s2.e2" origId="5289348" charOffset="83-86" type="compound" text="SEM"/>
            <pair e1="DS3.d436.s2.e2" e2="DS3.d436.s2.e0" id="DS3.d436.s2.i0" interaction="False" />
            <pair e1="DS3.d436.s2.e1" e2="DS3.d436.s2.e0" id="DS3.d436.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d436.s3" origId="9950295-8" text="Micellar VIP dispersion remains vasoactive for at least 14 days after preparation and storage at 4 degrees C. CONCLUSIONS: A novel, self-associated, small and stable PEG-DSPE micellar formulation of VIP amplifies vasodilation in the in situ peripheral microcirculation in a specific fashion by elaborating NO.">
            <entity id="DS3.d436.s3.e0" origId="P01282" charOffset="9-12" type="protein" text="VIP"/>
            <entity id="DS3.d436.s3.e1" origId="102547" charOffset="170-174" type="compound" text="DSPE"/>
            <entity id="DS3.d436.s3.e2" origId="P01282" charOffset="199-202" type="protein" text="VIP"/>
            <pair e1="DS3.d436.s3.e1" e2="DS3.d436.s3.e0" id="DS3.d436.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d437" origId="9950303">
        <sentence id="DS3.d437.s0" origId="9950303-3" text="Tests of thyroid peroxidase antibody, thyroglobulin antibody, TSH receptor antibody and free thyroxine (fT4) gave normal results.">
            <entity id="DS3.d437.s0.e0" origId="P01266" charOffset="38-51" type="protein" text="thyroglobulin"/>
            <entity id="DS3.d437.s0.e1" origId="5819,853" charOffset="93-102" type="compound" text="thyroxine"/>
            <pair e1="DS3.d437.s0.e1" e2="DS3.d437.s0.e0" id="DS3.d437.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d438" origId="9950308">
        <sentence id="DS3.d438.s0" origId="9950308-1" text="Treatment of hyperphenylalaninaemias due to phenylalanine hydroxylase deficiency with a low phenylalanine (Phe) diet is highly successful in preventing neurological impairment and mental retardation.">
            <entity id="DS3.d438.s0.e0" origId="P00439,A0A024RBG4" charOffset="44-69" type="protein" text="phenylalanine hydroxylase"/>
            <entity id="DS3.d438.s0.e1" origId="6140,71567,89654470,994" charOffset="44-57" type="compound" text="phenylalanine"/>
            <pair e1="DS3.d438.s0.e1" e2="DS3.d438.s0.e0" id="DS3.d438.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d439" origId="9950359">
        <sentence id="DS3.d439.s0" origId="9950359-1" text="A recurrent point mutation in the fibroblast growth factor receptor 3 (FGFR3) gene that converts proline 250 into arginine is commonly associated with coronal craniosynostosis and has allowed definition of a new syndrome on a molecular basis.">
            <entity id="DS3.d439.s0.e0" origId="P22607,Q0IJ44,X5D2G8" charOffset="34-69" type="protein" text="fibroblast growth factor receptor 3"/>
            <entity id="DS3.d439.s0.e1" origId="P22607,Q0IJ44,X5D2G8" charOffset="71-76" type="protein" text="FGFR3"/>
            <entity id="DS3.d439.s0.e2" origId="145742,57240853,614,8988" charOffset="97-104" type="compound" text="proline"/>
            <entity id="DS3.d439.s0.e3" origId="6322,90867653" charOffset="114-122" type="compound" text="arginine"/>
            <pair e1="DS3.d439.s0.e2" e2="DS3.d439.s0.e0" id="DS3.d439.s0.i0" interaction="False" />
            <pair e1="DS3.d439.s0.e2" e2="DS3.d439.s0.e1" id="DS3.d439.s0.i1" interaction="False" />
            <pair e1="DS3.d439.s0.e3" e2="DS3.d439.s0.e0" id="DS3.d439.s0.i2" interaction="False" />
            <pair e1="DS3.d439.s0.e3" e2="DS3.d439.s0.e1" id="DS3.d439.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d440" origId="9950371">
        <sentence id="DS3.d440.s0" origId="9950371-1" text="The RET proto-oncogene encodes a receptor tyrosine kinase expressed in neural crest derived tissues.">
            <entity id="DS3.d440.s0.e0" origId="P07949,Q9BTX6,A0A024R7T2" charOffset="4-7" type="protein" text="RET"/>
            <entity id="DS3.d440.s0.e1" origId="6057,90983769" charOffset="42-50" type="compound" text="tyrosine"/>
            <pair e1="DS3.d440.s0.e1" e2="DS3.d440.s0.e0" id="DS3.d440.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d440.s1" origId="9950371-5" text='Germline missense mutations in one of six cysteine codons (609, 611, 618, and 620 in exon 10, and codons 630 and 634 in exon 11), which encode part of the extracellular cysteine rich domain of RET, have been detected in the majority of these families: 100% of MEN 2A families, 67% of FMTC families, and 54% of families classified as "other".'>
            <entity id="DS3.d440.s1.e0" origId="5862,90793998" charOffset="42-50" type="compound" text="cysteine"/>
            <entity id="DS3.d440.s1.e1" origId="5862,90793998" charOffset="169-177" type="compound" text="cysteine"/>
            <entity id="DS3.d440.s1.e2" origId="P07949,Q9BTX6,A0A024R7T2" charOffset="193-196" type="protein" text="RET"/>
            <entity id="DS3.d440.s1.e3" origId="P07949,Q9BTX6,A0A024R7T2" charOffset="260-266" type="protein" text="MEN 2A"/>
            <pair e1="DS3.d440.s1.e0" e2="DS3.d440.s1.e3" id="DS3.d440.s1.i0" interaction="False" />
            <pair e1="DS3.d440.s1.e0" e2="DS3.d440.s1.e2" id="DS3.d440.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d441" origId="9950392">
        <sentence id="DS3.d441.s0" origId="9950392-4" text="The test was considered positive whenever total CK-MB was elevated (&amp;gt;6 U/L) or the cardiac isoform MB2 was relatively increased (MB2 &amp;gt; 2 U/L and MB2/MB1 &amp;gt; 1.7).">
            <entity id="DS3.d441.s0.e0" origId="74766010" charOffset="102-105" type="compound" text="MB2"/>
            <entity id="DS3.d441.s0.e1" origId="74766010" charOffset="132-135" type="compound" text="MB2"/>
            <entity id="DS3.d441.s0.e2" origId="74766010" charOffset="132-135" type="compound" text="MB2"/>
            <entity id="DS3.d441.s0.e3" origId="P11912" charOffset="155-158" type="protein" text="MB1"/>
            <pair e1="DS3.d441.s0.e0" e2="DS3.d441.s0.e3" id="DS3.d441.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d442" origId="9950427">
        <sentence id="DS3.d442.s0" origId="9950427-2" text="The intracellular calcium concentration ((Ca2+)i) of growth cones correlates with motility in vitro, but the physiological links between environmental cues and axon growth in vivo are unknown.">
            <entity id="DS3.d442.s0.e0" origId="22044544,5460341" charOffset="18-25" type="compound" text="calcium"/>
            <entity id="DS3.d442.s0.e1" origId="P00918,V9HW21" charOffset="42-45" type="protein" text="Ca2"/>
            <pair e1="DS3.d442.s0.e0" e2="DS3.d442.s0.e1" id="DS3.d442.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d443" origId="9950429">
        <sentence id="DS3.d443.s0" origId="9950429-7" text="Heteromeric assemblies of 5-HT3A and 5-HT3B subunits display a large single-channel conductance (16 pS), low permeability to calcium ions, and a current-voltage relationship which resembles that of characterized neuronal 5-HT3 channels.">
            <entity id="DS3.d443.s0.e0" origId="P46098,B4E398" charOffset="26-32" type="protein" text="5-HT3A"/>
            <entity id="DS3.d443.s0.e1" origId="O95264" charOffset="37-43" type="protein" text="5-HT3B"/>
            <entity id="DS3.d443.s0.e2" origId="271" charOffset="125-137" type="compound" text="calcium ions"/>
            <pair e1="DS3.d443.s0.e2" e2="DS3.d443.s0.e0" id="DS3.d443.s0.i0" interaction="False" />
            <pair e1="DS3.d443.s0.e2" e2="DS3.d443.s0.e1" id="DS3.d443.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d444" origId="9950551">
        <sentence id="DS3.d444.s0" origId="9950551-0" text="CO2 and erbium:YAG laser resurfacing: current status and personal perspective.">
            <entity id="DS3.d444.s0.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="0-3" type="protein" text="CO2"/>
            <entity id="DS3.d444.s0.e1" origId="23980" charOffset="8-14" type="compound" text="erbium"/>
            <pair e1="DS3.d444.s0.e1" e2="DS3.d444.s0.e0" id="DS3.d444.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d445" origId="9950554">
        <sentence id="DS3.d445.s0" origId="9950554-0" text="Cutaneous resurfacing with CO2 and erbium: YAG lasers: preoperative, intraoperative, and postoperative considerations.">
            <entity id="DS3.d445.s0.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="27-30" type="protein" text="CO2"/>
            <entity id="DS3.d445.s0.e1" origId="23980" charOffset="35-41" type="compound" text="erbium"/>
            <pair e1="DS3.d445.s0.e1" e2="DS3.d445.s0.e0" id="DS3.d445.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d445.s1" origId="9950554-1" text="The development and integration of pulsed and scanned CO2 and erbium:YAG laser systems into mainstream surgical practice over the past years has revolutionized cutaneous resurfacing.">
            <entity id="DS3.d445.s1.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="54-57" type="protein" text="CO2"/>
            <entity id="DS3.d445.s1.e1" origId="23980" charOffset="62-68" type="compound" text="erbium"/>
            <pair e1="DS3.d445.s1.e1" e2="DS3.d445.s1.e0" id="DS3.d445.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d445.s2" origId="9950554-4" text="This article reviews the basic principles of CO2 and erbium:YAG laser resurfacing, including preoperative, intraoperative, and postoperative patient considerations.">
            <entity id="DS3.d445.s2.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="45-48" type="protein" text="CO2"/>
            <entity id="DS3.d445.s2.e1" origId="23980" charOffset="53-59" type="compound" text="erbium"/>
            <pair e1="DS3.d445.s2.e1" e2="DS3.d445.s2.e0" id="DS3.d445.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d446" origId="9950583">
        <sentence id="DS3.d446.s0" origId="9950583-1" text="PURPOSE: The purpose was to determine the potential of gene therapy for retinoblastoma using transfer of the herpes simplex virus thymidine kinase (HSV-TK) gene into retinoblastoma cells (Y79 cell line).">
            <entity id="DS3.d446.s0.e0" origId="P06400,A0A024RDV3" charOffset="72-86" type="protein" text="retinoblastoma"/>
            <entity id="DS3.d446.s0.e1" origId="5789" charOffset="130-139" type="compound" text="thymidine"/>
            <entity id="DS3.d446.s0.e2" origId="P06400,A0A024RDV3" charOffset="166-180" type="protein" text="retinoblastoma"/>
            <pair e1="DS3.d446.s0.e1" e2="DS3.d446.s0.e0" id="DS3.d446.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d447" origId="9950584">
        <sentence id="DS3.d447.s0" origId="9950584-10" text="Gene therapy with a bFGF-expressing recombinant adenoviral vector may provide a new strategy with which to target retinal degenerative diseases.">
            <entity id="DS3.d447.s0.e0" origId="P09038" charOffset="20-24" type="protein" text="bFGF"/>
            <entity id="DS3.d447.s0.e1" origId="638015" charOffset="114-121" type="compound" text="retinal"/>
            <pair e1="DS3.d447.s0.e1" e2="DS3.d447.s0.e0" id="DS3.d447.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d447.s1" origId="9950584-1" text="PURPOSE: To evaluate the abilities of recombinant adenovirus carrying the basic fibroblast growth factor (bFGF) gene to (1) produce bFGF protein in vitro and (2) rescue retinal photoreceptors in Royal College of Surgeons (RCS) rats in vivo.">
            <entity id="DS3.d447.s1.e0" origId="P13109" charOffset="74-104" type="protein" text="basic fibroblast growth factor"/>
            <entity id="DS3.d447.s1.e1" origId="P09038" charOffset="106-110" type="protein" text="bFGF"/>
            <entity id="DS3.d447.s1.e2" origId="P09038" charOffset="132-136" type="protein" text="bFGF"/>
            <entity id="DS3.d447.s1.e3" origId="638015" charOffset="169-176" type="compound" text="retinal"/>
            <pair e1="DS3.d447.s1.e3" e2="DS3.d447.s1.e0" id="DS3.d447.s1.i0" interaction="False" />
            <pair e1="DS3.d447.s1.e3" e2="DS3.d447.s1.e1" id="DS3.d447.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d447.s2" origId="9950584-2" text="METHODS: Cultured human retinal pigment epithelial cells were infected with one of the following two replication-deficient adenoviral vectors that drive inserted genes by beta-actin promoter with cytomegalovirus enhancer: AxCAJSbFGF, which expresses the human bFGF gene, and AxCAlacZ, carrying the cDNA of bacterial beta-galactosidase as a viral control.">
            <entity id="DS3.d447.s2.e0" origId="638015" charOffset="24-31" type="compound" text="retinal"/>
            <entity id="DS3.d447.s2.e1" origId="A5A3E0" charOffset="171-181" type="protein" text="beta-actin"/>
            <entity id="DS3.d447.s2.e2" origId="P09038" charOffset="228-232" type="protein" text="bFGF"/>
            <entity id="DS3.d447.s2.e3" origId="P16278" charOffset="316-334" type="protein" text="beta-galactosidase"/>
            <pair e1="DS3.d447.s2.e0" e2="DS3.d447.s2.e1" id="DS3.d447.s2.i0" interaction="False" />
            <pair e1="DS3.d447.s2.e0" e2="DS3.d447.s2.e3" id="DS3.d447.s2.i1" interaction="False" />
            <pair e1="DS3.d447.s2.e0" e2="DS3.d447.s2.e2" id="DS3.d447.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d448" origId="9950605">
        <sentence id="DS3.d448.s0" origId="9950605-4" text="Gene expression for endothelial and neuronal nitric oxide synthases (eNOS and nNOS) was studied by reverse transcription-polymerase chain reaction (RT-PCR).">
            <entity id="DS3.d448.s0.e0" origId="145068" charOffset="45-57" type="compound" text="nitric oxide"/>
            <entity id="DS3.d448.s0.e1" origId="Q62600" charOffset="69-73" type="protein" text="eNOS"/>
            <entity id="DS3.d448.s0.e2" origId="P29476,D3ZEW7" charOffset="78-82" type="protein" text="nNOS"/>
            <pair e1="DS3.d448.s0.e0" e2="DS3.d448.s0.e1" id="DS3.d448.s0.i0" interaction="False" />
            <pair e1="DS3.d448.s0.e0" e2="DS3.d448.s0.e2" id="DS3.d448.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d448.s1" origId="9950605-5" text="To inhibit cNOS, NG-nitro-L-arginine (L-NNA) was injected intraperitoneally four times (every 6 hours) beginning 2 hours after reperfusion, for a total dose of 80 mg/kg.">
            <entity id="DS3.d448.s1.e0" origId="Q62600" charOffset="11-15" type="protein" text="cNOS"/>
            <entity id="DS3.d448.s1.e1" origId="440005" charOffset="17-36" type="compound" text="NG-nitro-L-arginine"/>
            <pair e1="DS3.d448.s1.e1" e2="DS3.d448.s1.e0" id="DS3.d448.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d449" origId="9950608">
        <sentence id="DS3.d449.s0" origId="9950608-10" text="MG-132 suppressed MGSA/gro-alpha, RANTES, MCP-1, IL-1beta, M-CSF, and ICAM-1 mRNA expression and secreted RANTES, MCP-1, and M-CSF protein, and cell-surface ICAM-1 that were induced by IL-1beta, TNF-alpha, and TII.">
            <entity id="DS3.d449.s0.e0" origId="P09341" charOffset="18-22" type="protein" text="MGSA"/>
            <entity id="DS3.d449.s0.e1" origId="P09341" charOffset="23-32" type="protein" text="gro-alpha"/>
            <entity id="DS3.d449.s0.e2" origId="P13501,D0EI67" charOffset="34-40" type="protein" text="RANTES"/>
            <entity id="DS3.d449.s0.e3" origId="P13500" charOffset="42-47" type="protein" text="MCP-1"/>
            <entity id="DS3.d449.s0.e4" origId="P01584" charOffset="49-57" type="protein" text="IL-1beta"/>
            <entity id="DS3.d449.s0.e5" origId="16122568,16750043,4369303,448383" charOffset="61-64" type="compound" text="CSF"/>
            <entity id="DS3.d449.s0.e6" origId="P05362" charOffset="70-76" type="protein" text="ICAM-1"/>
            <entity id="DS3.d449.s0.e7" origId="P13501,D0EI67" charOffset="106-112" type="protein" text="RANTES"/>
            <entity id="DS3.d449.s0.e8" origId="P13500" charOffset="114-119" type="protein" text="MCP-1"/>
            <entity id="DS3.d449.s0.e9" origId="16122568,16750043,4369303,448383" charOffset="127-130" type="compound" text="CSF"/>
            <entity id="DS3.d449.s0.e10" origId="P05362" charOffset="157-163" type="protein" text="ICAM-1"/>
            <entity id="DS3.d449.s0.e11" origId="P01584" charOffset="185-193" type="protein" text="IL-1beta"/>
            <entity id="DS3.d449.s0.e12" origId="P01375,Q5STB3" charOffset="195-204" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d449.s0.e5" e2="DS3.d449.s0.e1" id="DS3.d449.s0.i0" interaction="False" />
            <pair e1="DS3.d449.s0.e5" e2="DS3.d449.s0.e4" id="DS3.d449.s0.i1" interaction="False" />
            <pair e1="DS3.d449.s0.e5" e2="DS3.d449.s0.e6" id="DS3.d449.s0.i2" interaction="False" />
            <pair e1="DS3.d449.s0.e5" e2="DS3.d449.s0.e2" id="DS3.d449.s0.i3" interaction="False" />
            <pair e1="DS3.d449.s0.e5" e2="DS3.d449.s0.e0" id="DS3.d449.s0.i4" interaction="False" />
            <pair e1="DS3.d449.s0.e5" e2="DS3.d449.s0.e12" id="DS3.d449.s0.i5" interaction="False" />
            <pair e1="DS3.d449.s0.e5" e2="DS3.d449.s0.e3" id="DS3.d449.s0.i6" interaction="False" />
        </sentence>
        <sentence id="DS3.d449.s1" origId="9950608-1" text="PURPOSE: To determine whether nuclear transcription factor-kappaB (NF-kappaB) is activated in human retinal pigment epithelial (hRPE) cells in response to interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), or interferon-gamma (IFN-gamma) alone or in combination and if so, whether expression of proinflammatory genes induced by these agents can be blocked by a proteasome inhibitor, MG-132, which inhibits the degradation of I kappaB, an NF-kappaB inhibitor, thereby preventing nuclear translocation of NF-kappaB.">
            <entity id="DS3.d449.s1.e0" origId="P19838,A0A024RDJ4" charOffset="30-65" type="protein" text="nuclear transcription factor-kappaB"/>
            <entity id="DS3.d449.s1.e1" origId="638015" charOffset="100-107" type="compound" text="retinal"/>
            <entity id="DS3.d449.s1.e2" origId="P01584" charOffset="155-172" type="protein" text="interleukin-1beta"/>
            <entity id="DS3.d449.s1.e3" origId="P01584" charOffset="174-182" type="protein" text="IL-1beta"/>
            <entity id="DS3.d449.s1.e4" origId="P01375,Q5STB3" charOffset="185-212" type="protein" text="tumor necrosis factor-alpha"/>
            <entity id="DS3.d449.s1.e5" origId="P01375,Q5STB3" charOffset="214-223" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d449.s1.e6" origId="P01579" charOffset="247-256" type="protein" text="IFN-gamma"/>
            <pair e1="DS3.d449.s1.e1" e2="DS3.d449.s1.e4" id="DS3.d449.s1.i0" interaction="False" />
            <pair e1="DS3.d449.s1.e1" e2="DS3.d449.s1.e0" id="DS3.d449.s1.i1" interaction="False" />
            <pair e1="DS3.d449.s1.e1" e2="DS3.d449.s1.e3" id="DS3.d449.s1.i2" interaction="False" />
            <pair e1="DS3.d449.s1.e1" e2="DS3.d449.s1.e6" id="DS3.d449.s1.i3" interaction="False" />
            <pair e1="DS3.d449.s1.e1" e2="DS3.d449.s1.e2" id="DS3.d449.s1.i4" interaction="False" />
            <pair e1="DS3.d449.s1.e1" e2="DS3.d449.s1.e5" id="DS3.d449.s1.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d449.s2" origId="9950608-6" text="Steady state mRNA expression of the chemokines melanoma growth stimulating activity (MGSA)/gro-alpha, regulated on activation normal T-cell expression and secreted (RANTES), and monocyte chemoattractant protein (MCP-1), the cytokines IL-1beta and macrophage colony stimulating factor (M-CSF) and intercellular adhesion molecule-1 (ICAM-1) was evaluated by semiquantitative reverse transcription-polymerase chain reaction.">
            <entity id="DS3.d449.s2.e0" origId="P09341" charOffset="47-83" type="protein" text="melanoma growth stimulating activity"/>
            <entity id="DS3.d449.s2.e1" origId="P09341" charOffset="85-89" type="protein" text="MGSA"/>
            <entity id="DS3.d449.s2.e2" origId="P09341" charOffset="91-100" type="protein" text="gro-alpha"/>
            <entity id="DS3.d449.s2.e3" origId="P13501,D0EI67" charOffset="102-163" type="protein" text="regulated on activation normal T-cell expression and secreted"/>
            <entity id="DS3.d449.s2.e4" origId="P13501,D0EI67" charOffset="165-171" type="protein" text="RANTES"/>
            <entity id="DS3.d449.s2.e5" origId="P13500" charOffset="212-217" type="protein" text="MCP-1"/>
            <entity id="DS3.d449.s2.e6" origId="P01584" charOffset="234-242" type="protein" text="IL-1beta"/>
            <entity id="DS3.d449.s2.e7" origId="16122568,16750043,4369303,448383" charOffset="287-290" type="compound" text="CSF"/>
            <entity id="DS3.d449.s2.e8" origId="P05362" charOffset="296-329" type="protein" text="intercellular adhesion molecule-1"/>
            <entity id="DS3.d449.s2.e9" origId="P05362" charOffset="331-337" type="protein" text="ICAM-1"/>
            <pair e1="DS3.d449.s2.e7" e2="DS3.d449.s2.e2" id="DS3.d449.s2.i0" interaction="False" />
            <pair e1="DS3.d449.s2.e7" e2="DS3.d449.s2.e0" id="DS3.d449.s2.i1" interaction="False" />
            <pair e1="DS3.d449.s2.e7" e2="DS3.d449.s2.e8" id="DS3.d449.s2.i2" interaction="False" />
            <pair e1="DS3.d449.s2.e7" e2="DS3.d449.s2.e3" id="DS3.d449.s2.i3" interaction="False" />
            <pair e1="DS3.d449.s2.e7" e2="DS3.d449.s2.e9" id="DS3.d449.s2.i4" interaction="False" />
            <pair e1="DS3.d449.s2.e7" e2="DS3.d449.s2.e4" id="DS3.d449.s2.i5" interaction="False" />
            <pair e1="DS3.d449.s2.e7" e2="DS3.d449.s2.e1" id="DS3.d449.s2.i6" interaction="False" />
            <pair e1="DS3.d449.s2.e7" e2="DS3.d449.s2.e6" id="DS3.d449.s2.i7" interaction="False" />
            <pair e1="DS3.d449.s2.e7" e2="DS3.d449.s2.e5" id="DS3.d449.s2.i8" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d450" origId="9950613">
        <sentence id="DS3.d450.s0" origId="9950613-2" text="To develop such a model, the distribution of 5I2 antigen, a protein possessing the functions of the human decay-accelerating factor (DAF (CD55)) and membrane cofactor protein (MCP (CD46)), and rat inhibitory protein (CD59), the homologue of the human membrane inhibitor of reactive lysis (MIRL(CD59)) were characterized in the rat eye and ocular adnexal structures.">
            <entity id="DS3.d450.s0.e0" origId="Q63135,A0A096MIS6,O35520" charOffset="45-56" type="protein" text="5I2 antigen"/>
            <entity id="DS3.d450.s0.e1" origId="Q9Z0M0,A0A0G2QC50,Q9Z0L9" charOffset="133-136" type="protein" text="DAF"/>
            <entity id="DS3.d450.s0.e2" origId="P08174,B1AP13" charOffset="138-142" type="protein" text="CD55"/>
            <entity id="DS3.d450.s0.e3" origId="108194" charOffset="158-166" type="compound" text="cofactor"/>
            <entity id="DS3.d450.s0.e4" origId="P15529" charOffset="181-185" type="protein" text="CD46"/>
            <entity id="DS3.d450.s0.e5" origId="P13987,Q6FHM9" charOffset="217-221" type="protein" text="CD59"/>
            <entity id="DS3.d450.s0.e6" origId="P13987,Q6FHM9" charOffset="251-287" type="protein" text="membrane inhibitor of reactive lysis"/>
            <entity id="DS3.d450.s0.e7" origId="P13987,Q6FHM9" charOffset="289-293" type="protein" text="MIRL"/>
            <entity id="DS3.d450.s0.e8" origId="P13987,Q6FHM9" charOffset="294-298" type="protein" text="CD59"/>
            <pair e1="DS3.d450.s0.e3" e2="DS3.d450.s0.e7" id="DS3.d450.s0.i0" interaction="False" />
            <pair e1="DS3.d450.s0.e3" e2="DS3.d450.s0.e1" id="DS3.d450.s0.i1" interaction="False" />
            <pair e1="DS3.d450.s0.e3" e2="DS3.d450.s0.e5" id="DS3.d450.s0.i2" interaction="False" />
            <pair e1="DS3.d450.s0.e3" e2="DS3.d450.s0.e2" id="DS3.d450.s0.i3" interaction="False" />
            <pair e1="DS3.d450.s0.e3" e2="DS3.d450.s0.e6" id="DS3.d450.s0.i4" interaction="False" />
            <pair e1="DS3.d450.s0.e3" e2="DS3.d450.s0.e4" id="DS3.d450.s0.i5" interaction="False" />
            <pair e1="DS3.d450.s0.e3" e2="DS3.d450.s0.e0" id="DS3.d450.s0.i6" interaction="False" />
        </sentence>
        <sentence id="DS3.d450.s1" origId="9950613-3" text="METHODS: After euthanasia of female Wistar rats, followed by orbital exenteration, eyelids and orbital tissue including the lacrimal gland were separated from the globes and immediately snap-frozen in liquid nitrogen at -70 degrees C. Tissues then were sectioned at -20 degrees C and examined immunohistochemically for 5I2 antigen and rat CD59.">
            <entity id="DS3.d450.s1.e0" origId="947" charOffset="208-216" type="compound" text="nitrogen"/>
            <entity id="DS3.d450.s1.e1" origId="Q63135,A0A096MIS6,O35520" charOffset="319-330" type="protein" text="5I2 antigen"/>
            <entity id="DS3.d450.s1.e2" origId="P13987,Q6FHM9" charOffset="339-343" type="protein" text="CD59"/>
            <pair e1="DS3.d450.s1.e0" e2="DS3.d450.s1.e2" id="DS3.d450.s1.i0" interaction="False" />
            <pair e1="DS3.d450.s1.e0" e2="DS3.d450.s1.e1" id="DS3.d450.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d451" origId="9950621">
        <sentence id="DS3.d451.s0" origId="9950621-0" text="Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses.">
            <entity id="DS3.d451.s0.e0" origId="P28564" charOffset="28-45" type="protein" text="5HT1B/1D receptor"/>
            <entity id="DS3.d451.s0.e1" origId="4440" charOffset="54-65" type="compound" text="naratriptan"/>
            <pair e1="DS3.d451.s0.e1" e2="DS3.d451.s0.e0" id="DS3.d451.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d451.s1" origId="9950621-1" text="In vivo electrophysiological assays in anesthetized rats have been used to compare the effects of the 5HT1B/1D receptor agonist, naratriptan, on central trigeminal nociceptive processing from dural and cutaneous inputs with its effects on nociceptive processing in the spinal cord.">
            <entity id="DS3.d451.s1.e0" origId="P28564" charOffset="102-119" type="protein" text="5HT1B/1D receptor"/>
            <entity id="DS3.d451.s1.e1" origId="4440" charOffset="129-140" type="compound" text="naratriptan"/>
            <pair e1="DS3.d451.s1.e1" e2="DS3.d451.s1.e0" id="DS3.d451.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d452" origId="9950636">
        <sentence id="DS3.d452.s0" origId="9950636-1" text="The purpose of these studies was to determine the distribution of a lipophilic antimalarial agent, halofantrine hydrochloride (Hf), in fasted plasma from hypo-, normo-, and hyperlipidemic patients that displayed differences in lipoprotein concentration and lipid transfer protein I (LTP I) activity.">
            <entity id="DS3.d452.s0.e0" origId="P11597,B4DMZ5" charOffset="257-281" type="protein" text="lipid transfer protein I"/>
            <entity id="DS3.d452.s0.e1" origId="56846361" charOffset="283-286" type="compound" text="LTP"/>
            <pair e1="DS3.d452.s0.e1" e2="DS3.d452.s0.e0" id="DS3.d452.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d453" origId="9950646">
        <sentence id="DS3.d453.s0" origId="9950646-11" text="In contrast, coating the liposome's surface with mucin did not affect either the MTT or DTT of liposomes in the intestine.">
            <entity id="DS3.d453.s0.e0" origId="O35055" charOffset="49-54" type="protein" text="mucin"/>
            <entity id="DS3.d453.s0.e1" origId="64966" charOffset="81-84" type="compound" text="MTT"/>
            <entity id="DS3.d453.s0.e2" origId="439196,446094" charOffset="88-91" type="compound" text="DTT"/>
            <pair e1="DS3.d453.s0.e1" e2="DS3.d453.s0.e0" id="DS3.d453.s0.i0" interaction="False" />
            <pair e1="DS3.d453.s0.e2" e2="DS3.d453.s0.e0" id="DS3.d453.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d453.s1" origId="9950646-13" text="Both the MTT and DTT values of insulin encapsulated in PEG-Lip and mucin-Lip were almost the same as those of liposomes themselves, suggesting that surface-coated liposomes retained insulin in the intestinal tract.">
            <entity id="DS3.d453.s1.e0" origId="64966" charOffset="9-12" type="compound" text="MTT"/>
            <entity id="DS3.d453.s1.e1" origId="439196,446094" charOffset="17-20" type="compound" text="DTT"/>
            <entity id="DS3.d453.s1.e2" origId="O35055" charOffset="67-72" type="protein" text="mucin"/>
            <pair e1="DS3.d453.s1.e0" e2="DS3.d453.s1.e2" id="DS3.d453.s1.i0" interaction="False" />
            <pair e1="DS3.d453.s1.e1" e2="DS3.d453.s1.e2" id="DS3.d453.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d453.s2" origId="9950646-2" text="The surface of the liposomes was coated with poly(ethylene glycol) 2000 (PEG-Lip) or the sugar chain of mucin (mucin-Lip).">
            <entity id="DS3.d453.s2.e0" origId="53675528,6325" charOffset="50-58" type="compound" text="ethylene"/>
            <entity id="DS3.d453.s2.e1" origId="174" charOffset="59-65" type="compound" text="glycol"/>
            <entity id="DS3.d453.s2.e2" origId="O35055" charOffset="104-109" type="protein" text="mucin"/>
            <entity id="DS3.d453.s2.e3" origId="O35055" charOffset="111-116" type="protein" text="mucin"/>
            <pair e1="DS3.d453.s2.e0" e2="DS3.d453.s2.e2" id="DS3.d453.s2.i0" interaction="False" />
            <pair e1="DS3.d453.s2.e1" e2="DS3.d453.s2.e2" id="DS3.d453.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d453.s3" origId="9950646-9" text="The MTT of PEG-Lip was much longer than those of uncoated liposomes and mucin-Lip and was significantly shortened after removal of the intestinal mucous layer.">
            <entity id="DS3.d453.s3.e0" origId="64966" charOffset="4-7" type="compound" text="MTT"/>
            <entity id="DS3.d453.s3.e1" origId="O35055" charOffset="72-77" type="protein" text="mucin"/>
            <pair e1="DS3.d453.s3.e0" e2="DS3.d453.s3.e1" id="DS3.d453.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d454" origId="9950655">
        <sentence id="DS3.d454.s0" origId="9950655-1" text="BACKGROUND: Mice in which the gene encoding NPR-A, a guanylyl cyclase-linked natriuretic peptide receptor, has been disrupted were used to examine the contribution of natriuretic peptides to maintaining pulmonary vascular homeostasis in normal- and low-oxygen environments.">
            <entity id="DS3.d454.s0.e0" origId="P18293,Q2TAY4,Q3UY30" charOffset="44-49" type="protein" text="NPR-A"/>
            <entity id="DS3.d454.s0.e1" origId="977" charOffset="253-259" type="compound" text="oxygen"/>
            <pair e1="DS3.d454.s0.e1" e2="DS3.d454.s0.e0" id="DS3.d454.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d455" origId="9950656">
        <sentence id="DS3.d455.s0" origId="9950656-5" text="The observed values (mean+/-SD) were 47.6+/-17.8% versus 30.1+/-9.9% at 10 800 s-1 (P&amp;lt;0.01) and 32.9+/-14.1% versus 17.5+/-9.5% at 7200 s-1 (P&amp;lt;0.01), respectively, and were positively correlated with plasma vWF antigen levels and ristocetin cofactor activities.">
            <entity id="DS3.d455.s0.e0" origId="P04275" charOffset="213-216" type="protein" text="vWF"/>
            <entity id="DS3.d455.s0.e1" origId="108194" charOffset="247-255" type="compound" text="cofactor"/>
            <pair e1="DS3.d455.s0.e1" e2="DS3.d455.s0.e0" id="DS3.d455.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d456" origId="9950667">
        <sentence id="DS3.d456.s0" origId="9950667-4" text="METHODS AND RESULTS: Vasoflux is prepared by depolymerization of heparin, restricting molecular size to between 3000 and 8000 Da, and reducing antithrombin affinity by periodate oxidation.">
            <entity id="DS3.d456.s0.e0" origId="P01008,A0A024R944" charOffset="143-155" type="protein" text="antithrombin"/>
            <entity id="DS3.d456.s0.e1" origId="167232" charOffset="168-177" type="compound" text="periodate"/>
            <pair e1="DS3.d456.s0.e1" e2="DS3.d456.s0.e0" id="DS3.d456.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d456.s1" origId="9950667-5" text="Vasoflux catalyzes fibrin-bound thrombin inactivation by heparin cofactor II (HCII) and inhibits factor IXa activation of factor X independently of antithrombin and HCII.">
            <entity id="DS3.d456.s1.e0" origId="90470996" charOffset="32-40" type="compound" text="thrombin"/>
            <entity id="DS3.d456.s1.e1" origId="P05546,Q8IVC0" charOffset="57-76" type="protein" text="heparin cofactor II"/>
            <entity id="DS3.d456.s1.e2" origId="P05546,Q8IVC0" charOffset="78-82" type="protein" text="HCII"/>
            <entity id="DS3.d456.s1.e3" origId="P01008,A0A024R944" charOffset="148-160" type="protein" text="antithrombin"/>
            <entity id="DS3.d456.s1.e4" origId="P05546,Q8IVC0" charOffset="165-169" type="protein" text="HCII"/>
            <pair e1="DS3.d456.s1.e0" e2="DS3.d456.s1.e2" id="DS3.d456.s1.i0" interaction="False" />
            <pair e1="DS3.d456.s1.e0" e2="DS3.d456.s1.e3" id="DS3.d456.s1.i1" interaction="False" />
            <pair e1="DS3.d456.s1.e0" e2="DS3.d456.s1.e1" id="DS3.d456.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d457" origId="9950671">
        <sentence id="DS3.d457.s0" origId="9950671-2" text="Clenbuterol (clen), a beta2-adrenergic receptor agonist, was used to improve the performance of trained skeletal muscle in sheep.">
            <entity id="DS3.d457.s0.e0" origId="2783" charOffset="0-11" type="compound" text="Clenbuterol"/>
            <entity id="DS3.d457.s0.e1" origId="B3GN12" charOffset="22-47" type="protein" text="beta2-adrenergic receptor"/>
            <pair e1="DS3.d457.s0.e0" e2="DS3.d457.s0.e1" id="DS3.d457.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d458" origId="9950677">
        <sentence id="DS3.d458.s0" origId="9950677-7" text="Deletion of the domain harboring the eight IQ motifs abolishes the localization of Cyk1p/Iqg1p to the bud neck, suggesting that Cyk1p/Iqg1p may be localized through interactions with a calmodulin-like protein.">
            <entity id="DS3.d458.s0.e0" origId="53462" charOffset="43-45" type="compound" text="IQ"/>
            <entity id="DS3.d458.s0.e1" origId="Q12280" charOffset="83-88" type="protein" text="Cyk1p"/>
            <entity id="DS3.d458.s0.e2" origId="Q12280" charOffset="89-94" type="protein" text="Iqg1p"/>
            <entity id="DS3.d458.s0.e3" origId="Q12280" charOffset="128-133" type="protein" text="Cyk1p"/>
            <entity id="DS3.d458.s0.e4" origId="Q12280" charOffset="134-139" type="protein" text="Iqg1p"/>
            <pair e1="DS3.d458.s0.e0" e2="DS3.d458.s0.e2" id="DS3.d458.s0.i0" interaction="False" />
            <pair e1="DS3.d458.s0.e0" e2="DS3.d458.s0.e1" id="DS3.d458.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d458.s1" origId="9950677-9" text="In vitro binding experiments show that Cyk1p/Iqg1p binds to calmodulin, Cmd1p, in a calcium-dependent manner, and to Tem1p, a small GTP-binding protein previously found to be required for the completion of anaphase.">
            <entity id="DS3.d458.s1.e0" origId="Q12280" charOffset="39-44" type="protein" text="Cyk1p"/>
            <entity id="DS3.d458.s1.e1" origId="Q12280" charOffset="45-50" type="protein" text="Iqg1p"/>
            <entity id="DS3.d458.s1.e2" origId="P06787" charOffset="72-77" type="protein" text="Cmd1p"/>
            <entity id="DS3.d458.s1.e3" origId="22044544,5460341" charOffset="84-91" type="compound" text="calcium"/>
            <entity id="DS3.d458.s1.e4" origId="P38987" charOffset="117-122" type="protein" text="Tem1p"/>
            <entity id="DS3.d458.s1.e5" origId="6830" charOffset="132-135" type="compound" text="GTP"/>
            <pair e1="DS3.d458.s1.e5" e2="DS3.d458.s1.e1" id="DS3.d458.s1.i0" interaction="False" />
            <pair e1="DS3.d458.s1.e5" e2="DS3.d458.s1.e4" id="DS3.d458.s1.i1" interaction="False" />
            <pair e1="DS3.d458.s1.e5" e2="DS3.d458.s1.e0" id="DS3.d458.s1.i2" interaction="False" />
            <pair e1="DS3.d458.s1.e5" e2="DS3.d458.s1.e2" id="DS3.d458.s1.i3" interaction="False" />
            <pair e1="DS3.d458.s1.e3" e2="DS3.d458.s1.e1" id="DS3.d458.s1.i4" interaction="False" />
            <pair e1="DS3.d458.s1.e3" e2="DS3.d458.s1.e4" id="DS3.d458.s1.i5" interaction="False" />
            <pair e1="DS3.d458.s1.e3" e2="DS3.d458.s1.e0" id="DS3.d458.s1.i6" interaction="False" />
            <pair e1="DS3.d458.s1.e3" e2="DS3.d458.s1.e2" id="DS3.d458.s1.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d459" origId="9950679">
        <sentence id="DS3.d459.s0" origId="9950679-10" text="Accordingly, GT1b,GD1b, GM1, and GM2, but not GM3 and asialo-GM1, prevent the binding of 125I-FGF-2 to a soluble, recombinant form of extracellular FGFR-1.">
            <entity id="DS3.d459.s0.e0" origId="45259176" charOffset="13-17" type="compound" text="GT1b"/>
            <entity id="DS3.d459.s0.e1" origId="P09038" charOffset="94-99" type="protein" text="FGF-2"/>
            <entity id="DS3.d459.s0.e2" origId="P11362" charOffset="148-154" type="protein" text="FGFR-1"/>
            <pair e1="DS3.d459.s0.e0" e2="DS3.d459.s0.e1" id="DS3.d459.s0.i0" interaction="False" />
            <pair e1="DS3.d459.s0.e0" e2="DS3.d459.s0.e2" id="DS3.d459.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d459.s1" origId="9950679-15" text="This interaction involves the COOH terminus of the FGF-2 molecule and depends on the structure of the oligosaccharide chain and on the presence of sialic acid residue(s) in the ganglioside molecule.">
            <entity id="DS3.d459.s1.e0" origId="P09038" charOffset="51-56" type="protein" text="FGF-2"/>
            <entity id="DS3.d459.s1.e1" origId="444885,445063,656387,906" charOffset="147-158" type="compound" text="sialic acid"/>
            <pair e1="DS3.d459.s1.e1" e2="DS3.d459.s1.e0" id="DS3.d459.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d459.s2" origId="9950679-3" text="Size exclusion chromatography demonstrates that native, but not heat-denatured, 125I-FGF-2 binds to micelles formed by gangliosides GT1b, GD1b, or GM1.">
            <entity id="DS3.d459.s2.e0" origId="P09038" charOffset="85-90" type="protein" text="FGF-2"/>
            <entity id="DS3.d459.s2.e1" origId="45259176" charOffset="132-136" type="compound" text="GT1b"/>
            <pair e1="DS3.d459.s2.e1" e2="DS3.d459.s2.e0" id="DS3.d459.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d459.s3" origId="9950679-4" text="Also, gangliosides protect native FGF-2 from trypsin digestion at micromolar concentrations, the order of relative potency being GT1b &amp;gt; GD1b &amp;gt; GM1 = GM2 = sulfatide &amp;gt; GM3 = galactosyl-ceramide, whereas asialo-GM1, neuraminic acid, and N-acetylneuramin-lactose were ineffective.">
            <entity id="DS3.d459.s3.e0" origId="P09038" charOffset="34-39" type="protein" text="FGF-2"/>
            <entity id="DS3.d459.s3.e1" origId="45259176" charOffset="129-133" type="compound" text="GT1b"/>
            <entity id="DS3.d459.s3.e2" origId="446996" charOffset="182-192" type="compound" text="galactosyl"/>
            <entity id="DS3.d459.s3.e3" origId="441037,3083551,513472,5229254" charOffset="223-238" type="compound" text="neuraminic acid"/>
            <entity id="DS3.d459.s3.e4" origId="18729306" charOffset="244-260" type="compound" text="N-acetylneuramin"/>
            <entity id="DS3.d459.s3.e5" origId="294,6134,84571" charOffset="261-268" type="compound" text="lactose"/>
            <pair e1="DS3.d459.s3.e1" e2="DS3.d459.s3.e0" id="DS3.d459.s3.i0" interaction="False" />
            <pair e1="DS3.d459.s3.e3" e2="DS3.d459.s3.e0" id="DS3.d459.s3.i1" interaction="False" />
            <pair e1="DS3.d459.s3.e4" e2="DS3.d459.s3.e0" id="DS3.d459.s3.i2" interaction="False" />
            <pair e1="DS3.d459.s3.e2" e2="DS3.d459.s3.e0" id="DS3.d459.s3.i3" interaction="False" />
            <pair e1="DS3.d459.s3.e5" e2="DS3.d459.s3.e0" id="DS3.d459.s3.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d459.s4" origId="9950679-6" text="This interaction is inhibited by the sialic acid-binding peptide mastoparan and by the synthetic fragments FGF-2(112-129) and, to a lesser extent, FGF-2(130-155), whereas peptides FGF-2(10-33), FGF-2(39-59), FGF-2(86-96), and the basic peptide HIV-1 Tat(41-60) were ineffective.">
            <entity id="DS3.d459.s4.e0" origId="444885,445063,656387,906" charOffset="37-48" type="compound" text="sialic acid"/>
            <entity id="DS3.d459.s4.e1" origId="4016,5464497,6324633" charOffset="65-75" type="compound" text="mastoparan"/>
            <entity id="DS3.d459.s4.e2" origId="P09038" charOffset="107-112" type="protein" text="FGF-2"/>
            <entity id="DS3.d459.s4.e3" origId="P09038" charOffset="147-152" type="protein" text="FGF-2"/>
            <entity id="DS3.d459.s4.e4" origId="P09038" charOffset="147-152" type="protein" text="FGF-2"/>
            <entity id="DS3.d459.s4.e5" origId="P09038" charOffset="147-152" type="protein" text="FGF-2"/>
            <entity id="DS3.d459.s4.e6" origId="P09038" charOffset="147-152" type="protein" text="FGF-2"/>
            <pair e1="DS3.d459.s4.e0" e2="DS3.d459.s4.e2" id="DS3.d459.s4.i0" interaction="False" />
            <pair e1="DS3.d459.s4.e1" e2="DS3.d459.s4.e2" id="DS3.d459.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d459.s5" origId="9950679-8" text="Exogenous gangliosides inhibit the binding of 125I-FGF-2 to high-affinity tyrosine-kinase FGF-receptors (FGFRs) of endothelial GM 7373 cells at micromolar concentrations.">
            <entity id="DS3.d459.s5.e0" origId="P09038" charOffset="51-56" type="protein" text="FGF-2"/>
            <entity id="DS3.d459.s5.e1" origId="6057,90983769" charOffset="74-82" type="compound" text="tyrosine"/>
            <pair e1="DS3.d459.s5.e1" e2="DS3.d459.s5.e0" id="DS3.d459.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d460" origId="9950680">
        <sentence id="DS3.d460.s0" origId="9950680-5" text="Using this assay, we show that Sec62p is spatially close to the signal sequence of the prepro-alpha-factor in vivo.">
            <entity id="DS3.d460.s0.e0" origId="P21825" charOffset="31-37" type="protein" text="Sec62p"/>
            <entity id="DS3.d460.s0.e1" origId="86289906" charOffset="94-106" type="compound" text="alpha-factor"/>
            <pair e1="DS3.d460.s0.e1" e2="DS3.d460.s0.e0" id="DS3.d460.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d460.s1" origId="9950680-8" text="Cub fusions that bore the signal sequence of invertase resulted in a much lower Ub reconstitution with Nub-Sec62p than otherwise identical test proteins bearing the signal sequence of prepro-alpha-factor.">
            <entity id="DS3.d460.s1.e0" origId="P21825" charOffset="107-113" type="protein" text="Sec62p"/>
            <entity id="DS3.d460.s1.e1" origId="86289906" charOffset="191-203" type="compound" text="alpha-factor"/>
            <pair e1="DS3.d460.s1.e1" e2="DS3.d460.s1.e0" id="DS3.d460.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d461" origId="9950682">
        <sentence id="DS3.d461.s0" origId="9950682-1" text="A toxic dose of the nitric oxide (NO) donor S-nitrosoglutathione (GSNO; 1 mM) promoted apoptotic cell death of RAW 264.7 macrophages, which was attenuated by cellular preactivation with a nontoxic dose of GSNO (200 microM) or with lipopolysaccharide, interferon-gamma, and NG-monomethyl-L-arginine (LPS/IFN-gamma/NMMA) for 15 h. Protection from apoptosis was achieved by expression of cyclooxygenase-2 (Cox-2).">
            <entity id="DS3.d461.s0.e0" origId="145068" charOffset="20-32" type="compound" text="nitric oxide"/>
            <entity id="DS3.d461.s0.e1" origId="10404739" charOffset="44-64" type="compound" text="S-nitrosoglutathione"/>
            <entity id="DS3.d461.s0.e2" origId="104858" charOffset="66-70" type="compound" text="GSNO"/>
            <entity id="DS3.d461.s0.e3" origId="104858" charOffset="205-209" type="compound" text="GSNO"/>
            <entity id="DS3.d461.s0.e4" origId="11970143" charOffset="231-249" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d461.s0.e5" origId="P01580" charOffset="251-267" type="protein" text="interferon-gamma"/>
            <entity id="DS3.d461.s0.e6" origId="4366" charOffset="273-297" type="compound" text="NG-monomethyl-L-arginine"/>
            <entity id="DS3.d461.s0.e7" origId="P01580" charOffset="299-312" type="protein" text="LPS/IFN-gamma"/>
            <entity id="DS3.d461.s0.e8" origId="Q05769" charOffset="385-401" type="protein" text="cyclooxygenase-2"/>
            <pair e1="DS3.d461.s0.e0" e2="DS3.d461.s0.e5" id="DS3.d461.s0.i0" interaction="False" />
            <pair e1="DS3.d461.s0.e0" e2="DS3.d461.s0.e8" id="DS3.d461.s0.i1" interaction="False" />
            <pair e1="DS3.d461.s0.e0" e2="DS3.d461.s0.e7" id="DS3.d461.s0.i2" interaction="False" />
            <pair e1="DS3.d461.s0.e4" e2="DS3.d461.s0.e5" id="DS3.d461.s0.i3" interaction="False" />
            <pair e1="DS3.d461.s0.e4" e2="DS3.d461.s0.e8" id="DS3.d461.s0.i4" interaction="False" />
            <pair e1="DS3.d461.s0.e4" e2="DS3.d461.s0.e7" id="DS3.d461.s0.i5" interaction="False" />
            <pair e1="DS3.d461.s0.e6" e2="DS3.d461.s0.e5" id="DS3.d461.s0.i6" interaction="False" />
            <pair e1="DS3.d461.s0.e6" e2="DS3.d461.s0.e8" id="DS3.d461.s0.i7" interaction="False" />
            <pair e1="DS3.d461.s0.e6" e2="DS3.d461.s0.e7" id="DS3.d461.s0.i8" interaction="False" />
            <pair e1="DS3.d461.s0.e1" e2="DS3.d461.s0.e5" id="DS3.d461.s0.i9" interaction="False" />
            <pair e1="DS3.d461.s0.e1" e2="DS3.d461.s0.e8" id="DS3.d461.s0.i10" interaction="False" />
            <pair e1="DS3.d461.s0.e1" e2="DS3.d461.s0.e7" id="DS3.d461.s0.i11" interaction="False" />
            <pair e1="DS3.d461.s0.e2" e2="DS3.d461.s0.e5" id="DS3.d461.s0.i12" interaction="False" />
            <pair e1="DS3.d461.s0.e2" e2="DS3.d461.s0.e8" id="DS3.d461.s0.i13" interaction="False" />
            <pair e1="DS3.d461.s0.e2" e2="DS3.d461.s0.e7" id="DS3.d461.s0.i14" interaction="False" />
        </sentence>
        <sentence id="DS3.d461.s1" origId="9950682-4" text="Cox-2 induction by low-dose GSNO demanded activation of both NF-kappaB and activator protein-1 (AP-1).">
            <entity id="DS3.d461.s1.e0" origId="104858" charOffset="28-32" type="compound" text="GSNO"/>
            <entity id="DS3.d461.s1.e1" origId="P05627,Q52L79" charOffset="75-94" type="protein" text="activator protein-1"/>
            <pair e1="DS3.d461.s1.e0" e2="DS3.d461.s1.e1" id="DS3.d461.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d462" origId="9950686">
        <sentence id="DS3.d462.s0" origId="9950686-1" text="Eps15 is a substrate for the tyrosine kinase of the epidermal growth factor receptor (EGFR) and is characterized by the presence of a novel protein:protein interaction domain, the EH domain.">
            <entity id="DS3.d462.s0.e0" origId="P42566,B7Z240" charOffset="0-5" type="protein" text="Eps15"/>
            <entity id="DS3.d462.s0.e1" origId="6057,90983769" charOffset="29-37" type="compound" text="tyrosine"/>
            <entity id="DS3.d462.s0.e2" origId="P00533" charOffset="52-84" type="protein" text="epidermal growth factor receptor"/>
            <entity id="DS3.d462.s0.e3" origId="P00533" charOffset="86-90" type="protein" text="EGFR"/>
            <pair e1="DS3.d462.s0.e1" e2="DS3.d462.s0.e0" id="DS3.d462.s0.i0" interaction="False" />
            <pair e1="DS3.d462.s0.e1" e2="DS3.d462.s0.e3" id="DS3.d462.s0.i1" interaction="False" />
            <pair e1="DS3.d462.s0.e1" e2="DS3.d462.s0.e2" id="DS3.d462.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d462.s1" origId="9950686-6" text="Furthermore, Eps15 appears to undergo tyrosine phosphorylation both at the plasma membrane and in a nocodazole-sensitive compartment, suggesting sustained phosphorylation in endocytic compartments.">
            <entity id="DS3.d462.s1.e0" origId="P42566,B7Z240" charOffset="13-18" type="protein" text="Eps15"/>
            <entity id="DS3.d462.s1.e1" origId="6057,90983769" charOffset="38-46" type="compound" text="tyrosine"/>
            <entity id="DS3.d462.s1.e2" origId="4122" charOffset="100-110" type="compound" text="nocodazole"/>
            <pair e1="DS3.d462.s1.e2" e2="DS3.d462.s1.e0" id="DS3.d462.s1.i0" interaction="False" />
            <pair e1="DS3.d462.s1.e1" e2="DS3.d462.s1.e0" id="DS3.d462.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d463" origId="9950687">
        <sentence id="DS3.d463.s0" origId="9950687-1" text="Yeast Sec22p participates in both anterograde and retrograde vesicular transport between the endoplasmic reticulum (ER) and the Golgi apparatus by functioning as a v-SNARE (soluble N-ethylmaleimide-sensitive factor (NSF) attachment protein receptor) of transport vesicles.">
            <entity id="DS3.d463.s0.e0" origId="P22214" charOffset="6-12" type="protein" text="Sec22p"/>
            <entity id="DS3.d463.s0.e1" origId="4362" charOffset="181-197" type="compound" text="N-ethylmaleimide"/>
            <pair e1="DS3.d463.s0.e1" e2="DS3.d463.s0.e0" id="DS3.d463.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d463.s1" origId="9950687-6" text="Colabeling experiments for Sec22b/ERS-24 with Golgi mannosidase II, the KDEL receptor, and the envelope glycoprotein G (VSVG) of vesicular stomatitis virus (VSV) en route from the ER to the Golgi under normal, brefeldin A, or nocodazole-treated cells suggest that Sec22b/ERS-24 is enriched in the pre-Golgi intermediate compartment (IC).">
            <entity id="DS3.d463.s1.e0" origId="O75396" charOffset="27-33" type="protein" text="Sec22b"/>
            <entity id="DS3.d463.s1.e1" origId="O75396" charOffset="34-40" type="protein" text="ERS-24"/>
            <entity id="DS3.d463.s1.e2" origId="P24390" charOffset="72-85" type="protein" text="KDEL receptor"/>
            <entity id="DS3.d463.s1.e3" origId="24123450,2430,5351204,5353446,6364669,6436187,71308166" charOffset="210-221" type="compound" text="brefeldin A"/>
            <entity id="DS3.d463.s1.e4" origId="4122" charOffset="226-236" type="compound" text="nocodazole"/>
            <entity id="DS3.d463.s1.e5" origId="O75396" charOffset="264-270" type="protein" text="Sec22b"/>
            <entity id="DS3.d463.s1.e6" origId="O75396" charOffset="271-277" type="protein" text="ERS-24"/>
            <pair e1="DS3.d463.s1.e3" e2="DS3.d463.s1.e0" id="DS3.d463.s1.i0" interaction="False" />
            <pair e1="DS3.d463.s1.e3" e2="DS3.d463.s1.e2" id="DS3.d463.s1.i1" interaction="False" />
            <pair e1="DS3.d463.s1.e3" e2="DS3.d463.s1.e1" id="DS3.d463.s1.i2" interaction="False" />
            <pair e1="DS3.d463.s1.e4" e2="DS3.d463.s1.e0" id="DS3.d463.s1.i3" interaction="False" />
            <pair e1="DS3.d463.s1.e4" e2="DS3.d463.s1.e2" id="DS3.d463.s1.i4" interaction="False" />
            <pair e1="DS3.d463.s1.e4" e2="DS3.d463.s1.e1" id="DS3.d463.s1.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d463.s2" origId="9950687-9" text="Antibodies against Sec22b/ERS-24 inhibit ER-Golgi transport only when they are added before the EGTA-sensitive stage.">
            <entity id="DS3.d463.s2.e0" origId="O75396" charOffset="19-25" type="protein" text="Sec22b"/>
            <entity id="DS3.d463.s2.e1" origId="O75396" charOffset="26-32" type="protein" text="ERS-24"/>
            <entity id="DS3.d463.s2.e2" origId="6207" charOffset="96-100" type="compound" text="EGTA"/>
            <pair e1="DS3.d463.s2.e2" e2="DS3.d463.s2.e0" id="DS3.d463.s2.i0" interaction="False" />
            <pair e1="DS3.d463.s2.e2" e2="DS3.d463.s2.e1" id="DS3.d463.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d464" origId="9950688">
        <sentence id="DS3.d464.s0" origId="9950688-10" text="This perinuclear AE1-containing compartment is also stained by ankyrin antibodies and partially overlaps the membrane compartment stained by NBD C6-ceramide, a Golgi marker.">
            <entity id="DS3.d464.s0.e0" origId="P15575" charOffset="17-20" type="protein" text="AE1"/>
            <entity id="DS3.d464.s0.e1" origId="5702613" charOffset="145-156" type="compound" text="C6-ceramide"/>
            <pair e1="DS3.d464.s0.e1" e2="DS3.d464.s0.e0" id="DS3.d464.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d464.s1" origId="9950688-6" text="Furthermore, AE1 anion exchangers become detergent insoluble more rapidly than they acquire endo F-resistant modifications in cells recovering from an ammonium chloride block.">
            <entity id="DS3.d464.s1.e0" origId="P15575" charOffset="13-16" type="protein" text="AE1"/>
            <entity id="DS3.d464.s1.e1" origId="25517" charOffset="151-168" type="compound" text="ammonium chloride"/>
            <pair e1="DS3.d464.s1.e1" e2="DS3.d464.s1.e0" id="DS3.d464.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d465" origId="9950757">
        <sentence id="DS3.d465.s0" origId="9950757-1" text="We have shown that endocytosis at the apical plasma membrane of pancreatic acinar cells is regulated by the pH of the acinar lumen and is associated with cleavage of GP2, a glycosyl phosphatidylinositol-anchored protein.">
            <entity id="DS3.d465.s0.e0" origId="F1M9X2" charOffset="166-169" type="protein" text="GP2"/>
            <entity id="DS3.d465.s0.e1" origId="16738692,53477912" charOffset="182-202" type="compound" text="phosphatidylinositol"/>
            <pair e1="DS3.d465.s0.e1" e2="DS3.d465.s0.e0" id="DS3.d465.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d466" origId="9950759">
        <sentence id="DS3.d466.s0" origId="9950759-5" text="The following treatments enhanced mechanosensitivity: actin depolymerization (cytochalasin B), N-ethylmaleimide, an inhibitor of ATPases including myosin, elevated Ca (using A-23187), and osmotic swelling (acutely and after 24 h).">
            <entity id="DS3.d466.s0.e0" origId="2724383,2919,5311281,5368686,5836499,6364615,6433621" charOffset="78-92" type="compound" text="cytochalasin B"/>
            <entity id="DS3.d466.s0.e1" origId="Q7Z406,A1L2Z2,B3KWH4" charOffset="147-153" type="protein" text="myosin"/>
            <pair e1="DS3.d466.s0.e0" e2="DS3.d466.s0.e1" id="DS3.d466.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d467" origId="9950761">
        <sentence id="DS3.d467.s0" origId="9950761-4" text="1) An endothelial NO synthase (eNOS)-, NO-, and cGMP-related, Ca2+-dependent decrease in permeability was activated by nanomolar concentrations of estradiol, resulting in enhanced Cl- influx, increased cell size, and increases in the resistance of the lateral intercellular space (RLIS) and in the resistance of the tight junctions (RTJ); these effects appeared to be limited by the ability of cells to generate cGMP in response to NO.">
            <entity id="DS3.d467.s0.e0" origId="P29474,A0A0A0MTA6,A0S0A6" charOffset="6-29" type="protein" text="endothelial NO synthase"/>
            <entity id="DS3.d467.s0.e1" origId="P29474,A0A0A0MTA6,A0S0A6" charOffset="31-35" type="protein" text="eNOS"/>
            <entity id="DS3.d467.s0.e2" origId="5757" charOffset="147-156" type="compound" text="estradiol"/>
            <pair e1="DS3.d467.s0.e2" e2="DS3.d467.s0.e1" id="DS3.d467.s0.i0" interaction="False" />
            <pair e1="DS3.d467.s0.e2" e2="DS3.d467.s0.e0" id="DS3.d467.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d467.s1" origId="9950761-5" text="2) An inducible NO synthase (iNOS)- and NO-related, Ca2+-independent increase in permeability was activated by micromolar concentrations of estradiol, resulting in enhanced Cl- efflux, decreased cell size, and decreased RLIS and RTJ.">
            <entity id="DS3.d467.s1.e0" origId="P35228" charOffset="6-27" type="protein" text="inducible NO synthase"/>
            <entity id="DS3.d467.s1.e1" origId="P35228" charOffset="29-33" type="protein" text="iNOS"/>
            <entity id="DS3.d467.s1.e2" origId="5757" charOffset="140-149" type="compound" text="estradiol"/>
            <pair e1="DS3.d467.s1.e2" e2="DS3.d467.s1.e0" id="DS3.d467.s1.i0" interaction="False" />
            <pair e1="DS3.d467.s1.e2" e2="DS3.d467.s1.e1" id="DS3.d467.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d468" origId="9950763">
        <sentence id="DS3.d468.s0" origId="9950763-3" text="In a simplified model using COS-7 cells, we demonstrate acquisition of an ATP-, ADP-, AMP-, and adenosine (ADO)-regulated halide permeability specifically following expression of wild-type (wt) cystic fibrosis transmembrane conductance regulator (CFTR).">
            <entity id="DS3.d468.s0.e0" origId="5957" charOffset="74-77" type="compound" text="ATP"/>
            <entity id="DS3.d468.s0.e1" origId="6022" charOffset="80-83" type="compound" text="ADP"/>
            <entity id="DS3.d468.s0.e2" origId="57476835,60961" charOffset="96-105" type="compound" text="adenosine"/>
            <entity id="DS3.d468.s0.e3" origId="P13569,A0A024R730" charOffset="194-245" type="protein" text="cystic fibrosis transmembrane conductance regulator"/>
            <pair e1="DS3.d468.s0.e1" e2="DS3.d468.s0.e3" id="DS3.d468.s0.i0" interaction="False" />
            <pair e1="DS3.d468.s0.e0" e2="DS3.d468.s0.e3" id="DS3.d468.s0.i1" interaction="False" />
            <pair e1="DS3.d468.s0.e2" e2="DS3.d468.s0.e3" id="DS3.d468.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d469" origId="9950764">
        <sentence id="DS3.d469.s0" origId="9950764-10" text="In summary, it is likely that phosphorylation of MDR1 by PKA and by PKC alters swelling-activated Cl- channels by independent mechanisms and that Ser-661, Ser-667, and Ser-671 are involved in the responses of ICl,swell to stimulation of PKA and PKC.">
            <entity id="DS3.d469.s0.e0" origId="P08183,A4D1D2" charOffset="49-53" type="protein" text="MDR1"/>
            <entity id="DS3.d469.s0.e1" origId="5951" charOffset="146-149" type="compound" text="Ser"/>
            <entity id="DS3.d469.s0.e2" origId="5951" charOffset="155-158" type="compound" text="Ser"/>
            <entity id="DS3.d469.s0.e3" origId="5951" charOffset="155-158" type="compound" text="Ser"/>
            <pair e1="DS3.d469.s0.e1" e2="DS3.d469.s0.e0" id="DS3.d469.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d469.s1" origId="9950764-3" text="We measured whole cell swelling-activated Cl- currents (ICl,swell) in parental cells and cells expressing wild-type MDR1 or a phosphorylation-defective mutant (Ser-661, Ser-667, and Ser-671 replaced by Ala).">
            <entity id="DS3.d469.s1.e0" origId="P08183,A4D1D2" charOffset="116-120" type="protein" text="MDR1"/>
            <entity id="DS3.d469.s1.e1" origId="5951" charOffset="160-163" type="compound" text="Ser"/>
            <entity id="DS3.d469.s1.e2" origId="5951" charOffset="169-172" type="compound" text="Ser"/>
            <entity id="DS3.d469.s1.e3" origId="5951" charOffset="169-172" type="compound" text="Ser"/>
            <pair e1="DS3.d469.s1.e1" e2="DS3.d469.s1.e0" id="DS3.d469.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d469.s2" origId="9950764-4" text="Stimulation of protein kinase C (PKC) with a phorbol ester reduced the rate of increase in ICl,swell only in cells that express MDR1.">
            <entity id="DS3.d469.s2.e0" origId="22833501,27924,70702034" charOffset="45-58" type="compound" text="phorbol ester"/>
            <entity id="DS3.d469.s2.e1" origId="P08183,A4D1D2" charOffset="128-132" type="protein" text="MDR1"/>
            <pair e1="DS3.d469.s2.e0" e2="DS3.d469.s2.e1" id="DS3.d469.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d469.s3" origId="9950764-6" text="Stimulation of protein kinase A (PKA) with 8-bromoadenosine 3',5'-cyclic monophosphate reduced steady-state ICl, swell only in MDR1-expressing cells.">
            <entity id="DS3.d469.s3.e0" origId="32014" charOffset="43-86" type="compound" text="8-bromoadenosine 3',5'-cyclic monophosphate"/>
            <entity id="DS3.d469.s3.e1" origId="P08183,A4D1D2" charOffset="127-131" type="protein" text="MDR1"/>
            <pair e1="DS3.d469.s3.e0" e2="DS3.d469.s3.e1" id="DS3.d469.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d470" origId="9950765">
        <sentence id="DS3.d470.s0" origId="9950765-3" text="Cells were treated with vehicle or the progesterone analog medroxyprogesterone acetate (MPA) for 5 days, and intracellular free Ca2+ concentration ((Ca2+)i) was quantified after treatment with oxytocin (OX) or endothelin (ET)-1.">
            <entity id="DS3.d470.s0.e0" origId="5994" charOffset="39-51" type="compound" text="progesterone"/>
            <entity id="DS3.d470.s0.e1" origId="6279" charOffset="59-86" type="compound" text="medroxyprogesterone acetate"/>
            <entity id="DS3.d470.s0.e2" origId="P01178,X5D7M6" charOffset="193-201" type="protein" text="oxytocin"/>
            <entity id="DS3.d470.s0.e3" origId="44284481" charOffset="210-220" type="compound" text="endothelin"/>
            <pair e1="DS3.d470.s0.e3" e2="DS3.d470.s0.e2" id="DS3.d470.s0.i0" interaction="False" />
            <pair e1="DS3.d470.s0.e1" e2="DS3.d470.s0.e2" id="DS3.d470.s0.i1" interaction="False" />
            <pair e1="DS3.d470.s0.e0" e2="DS3.d470.s0.e2" id="DS3.d470.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d471" origId="9950766">
        <sentence id="DS3.d471.s0" origId="9950766-6" text="Consistent with this concept, the present study identifies several phenotypic abnormalities in macrophages from ob/ob mice, including decreased steady-state levels of uncoupling protein-2 mRNA, increased mitochondrial production of superoxide and hydrogen peroxide, constitutive activation of CCAAT enhancer binding protein (C/EBP)-beta, an oxidant-sensitive transcription factor, increased expression of interleukin-6 and cyclooxygenase (COX)-2, two C/EBP-beta target genes, and increased COX-2-dependent production of PGE2.">
            <entity id="DS3.d471.s0.e0" origId="5359597" charOffset="232-242" type="compound" text="superoxide"/>
            <entity id="DS3.d471.s0.e1" origId="784" charOffset="247-264" type="compound" text="hydrogen peroxide"/>
            <entity id="DS3.d471.s0.e2" origId="P28033,Q3UPN9" charOffset="325-336" type="protein" text="C/EBP)-beta"/>
            <entity id="DS3.d471.s0.e3" origId="P00405,Q7JCZ1" charOffset="405-445" type="protein" text="interleukin-6 and cyclooxygenase (COX)-2"/>
            <entity id="DS3.d471.s0.e4" origId="P00405,Q7JCZ1" charOffset="490-495" type="protein" text="COX-2"/>
            <pair e1="DS3.d471.s0.e1" e2="DS3.d471.s0.e4" id="DS3.d471.s0.i0" interaction="False" />
            <pair e1="DS3.d471.s0.e1" e2="DS3.d471.s0.e2" id="DS3.d471.s0.i1" interaction="False" />
            <pair e1="DS3.d471.s0.e1" e2="DS3.d471.s0.e3" id="DS3.d471.s0.i2" interaction="False" />
            <pair e1="DS3.d471.s0.e0" e2="DS3.d471.s0.e4" id="DS3.d471.s0.i3" interaction="False" />
            <pair e1="DS3.d471.s0.e0" e2="DS3.d471.s0.e2" id="DS3.d471.s0.i4" interaction="False" />
            <pair e1="DS3.d471.s0.e0" e2="DS3.d471.s0.e3" id="DS3.d471.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d472" origId="9950767">
        <sentence id="DS3.d472.s0" origId="9950767-1" text="The calcium-binding protein parvalbumin (PV) occurs at high concentrations in fast-contracting vertebrate muscle fibers.">
            <entity id="DS3.d472.s0.e0" origId="22044544,5460341" charOffset="4-11" type="compound" text="calcium"/>
            <entity id="DS3.d472.s0.e1" origId="P32848,Q545M7" charOffset="28-39" type="protein" text="parvalbumin"/>
            <pair e1="DS3.d472.s0.e0" e2="DS3.d472.s0.e1" id="DS3.d472.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d473" origId="9950768">
        <sentence id="DS3.d473.s0" origId="9950768-1" text="The role of E-cadherin, a calcium-dependent adhesion protein, in organizing and maintaining epithelial junctions was examined in detail by expressing a fusion protein (GP2-Cad1) composed of the extracellular domain of a nonadherent glycoprotein (GP2) and the transmembrane and cytoplasmic domains of E-cadherin.">
            <entity id="DS3.d473.s0.e0" origId="P12830" charOffset="12-22" type="protein" text="E-cadherin"/>
            <entity id="DS3.d473.s0.e1" origId="22044544,5460341" charOffset="26-33" type="compound" text="calcium"/>
            <entity id="DS3.d473.s0.e2" origId="P55259,Q68D34,B7Z1G2" charOffset="168-176" type="protein" text="GP2-Cad1"/>
            <entity id="DS3.d473.s0.e3" origId="P55259,Q68D34,B7Z1G2" charOffset="168-171" type="protein" text="GP2"/>
            <entity id="DS3.d473.s0.e4" origId="P12830" charOffset="300-310" type="protein" text="E-cadherin"/>
            <pair e1="DS3.d473.s0.e1" e2="DS3.d473.s0.e2" id="DS3.d473.s0.i0" interaction="False" />
            <pair e1="DS3.d473.s0.e1" e2="DS3.d473.s0.e0" id="DS3.d473.s0.i1" interaction="False" />
            <pair e1="DS3.d473.s0.e1" e2="DS3.d473.s0.e3" id="DS3.d473.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d473.s1" origId="9950768-4" text="However, GP2-Cad1 accelerated the disassembly of epithelial junctional complexes and delayed their reassembly in calcium switch experiments.">
            <entity id="DS3.d473.s1.e0" origId="P55259,Q68D34,B7Z1G2" charOffset="9-17" type="protein" text="GP2-Cad1"/>
            <entity id="DS3.d473.s1.e1" origId="22044544,5460341" charOffset="113-120" type="compound" text="calcium"/>
            <pair e1="DS3.d473.s1.e1" e2="DS3.d473.s1.e0" id="DS3.d473.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d474" origId="9950769">
        <sentence id="DS3.d474.s0" origId="9950769-0" text="EGF induces nuclear translocation of STAT2 without tyrosine phosphorylation in intestinal epithelial cells.">
            <entity id="DS3.d474.s0.e0" origId="Q5XI26,P52630,R9QE65" charOffset="37-42" type="protein" text="STAT2"/>
            <entity id="DS3.d474.s0.e1" origId="6057,90983769" charOffset="51-59" type="compound" text="tyrosine"/>
            <pair e1="DS3.d474.s0.e1" e2="DS3.d474.s0.e0" id="DS3.d474.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d474.s1" origId="9950769-5" text="First, EGF promoted the tyrosine phosphorylation of STAT1 in IEC-6 cells and caused its translocation to the nucleus.">
            <entity id="DS3.d474.s1.e0" origId="6057,90983769" charOffset="24-32" type="compound" text="tyrosine"/>
            <entity id="DS3.d474.s1.e1" origId="F1M9D6,Q6P6Q7,Q9QXK0" charOffset="52-57" type="protein" text="STAT1"/>
            <pair e1="DS3.d474.s1.e0" e2="DS3.d474.s1.e1" id="DS3.d474.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d474.s2" origId="9950769-7" text="Third, EGF caused the translocation of STAT2 to the nucleus in both IEC-6 and HeLa cells without inducing the tyrosine phosphorylation of STAT2.">
            <entity id="DS3.d474.s2.e0" origId="Q5XI26,P52630,R9QE65" charOffset="39-44" type="protein" text="STAT2"/>
            <entity id="DS3.d474.s2.e1" origId="6057,90983769" charOffset="110-118" type="compound" text="tyrosine"/>
            <entity id="DS3.d474.s2.e2" origId="Q5XI26,P52630,R9QE65" charOffset="138-143" type="protein" text="STAT2"/>
            <pair e1="DS3.d474.s2.e1" e2="DS3.d474.s2.e0" id="DS3.d474.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d475" origId="9950771">
        <sentence id="DS3.d475.s0" origId="9950771-11" text="Although originally characterized as a PKC inhibitor, Ro-318220 inhibited TNF-alpha-induced MKP-1 expression through a mechanism other than blocking the PKC pathway.">
            <entity id="DS3.d475.s0.e0" origId="5083" charOffset="54-63" type="compound" text="Ro-318220"/>
            <entity id="DS3.d475.s0.e1" origId="P16599" charOffset="74-83" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d475.s0.e2" origId="Q64623,Q63683" charOffset="92-97" type="protein" text="MKP-1"/>
            <pair e1="DS3.d475.s0.e0" e2="DS3.d475.s0.e1" id="DS3.d475.s0.i0" interaction="False" />
            <pair e1="DS3.d475.s0.e0" e2="DS3.d475.s0.e2" id="DS3.d475.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d475.s1" origId="9950771-14" text="However, activation of PKC by phorbol 12-myristate 13-acetate (PMA) dramatically increased cellular resistance to the apoptotic effect of TNF-alpha.">
            <entity id="DS3.d475.s1.e0" origId="71308525" charOffset="30-50" type="compound" text="phorbol 12-myristate"/>
            <entity id="DS3.d475.s1.e1" origId="176" charOffset="54-61" type="compound" text="acetate"/>
            <entity id="DS3.d475.s1.e2" origId="122634,22833501,27924,4792" charOffset="63-66" type="compound" text="PMA"/>
            <entity id="DS3.d475.s1.e3" origId="P16599" charOffset="138-147" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d475.s1.e0" e2="DS3.d475.s1.e3" id="DS3.d475.s1.i0" interaction="False" />
            <pair e1="DS3.d475.s1.e2" e2="DS3.d475.s1.e3" id="DS3.d475.s1.i1" interaction="False" />
            <pair e1="DS3.d475.s1.e1" e2="DS3.d475.s1.e3" id="DS3.d475.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d475.s2" origId="9950771-15" text="Coincidentally, PMA stimulated MKP-1 expression and suppressed JNK activation.">
            <entity id="DS3.d475.s2.e0" origId="122634,22833501,27924,4792" charOffset="16-19" type="compound" text="PMA"/>
            <entity id="DS3.d475.s2.e1" origId="Q64623,Q63683" charOffset="31-36" type="protein" text="MKP-1"/>
            <pair e1="DS3.d475.s2.e0" e2="DS3.d475.s2.e1" id="DS3.d475.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d475.s3" origId="9950771-16" text="Therefore, PMA-induced MKP-1 expression may contribute to the protective effect of PMA.">
            <entity id="DS3.d475.s3.e0" origId="122634,22833501,27924,4792" charOffset="11-14" type="compound" text="PMA"/>
            <entity id="DS3.d475.s3.e1" origId="Q64623,Q63683" charOffset="23-28" type="protein" text="MKP-1"/>
            <entity id="DS3.d475.s3.e2" origId="122634,22833501,27924,4792" charOffset="83-86" type="compound" text="PMA"/>
            <pair e1="DS3.d475.s3.e0" e2="DS3.d475.s3.e1" id="DS3.d475.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d475.s4" origId="9950771-1" text="We reported previously that Ro-318220 blocked expression of mitogen-activated protein kinase phosphatase-1 (MKP-1) induced by tumor necrosis factor-alpha (TNF-alpha) and subsequently caused apopotosis in mesangial cells (Y.-L. Guo, B. Kang, and J. R. Williamson.">
            <entity id="DS3.d475.s4.e0" origId="5083" charOffset="28-37" type="compound" text="Ro-318220"/>
            <entity id="DS3.d475.s4.e1" origId="Q64623,Q63683" charOffset="60-106" type="protein" text="mitogen-activated protein kinase phosphatase-1"/>
            <entity id="DS3.d475.s4.e2" origId="Q64623,Q63683" charOffset="108-113" type="protein" text="MKP-1"/>
            <entity id="DS3.d475.s4.e3" origId="P16599" charOffset="126-153" type="protein" text="tumor necrosis factor-alpha"/>
            <entity id="DS3.d475.s4.e4" origId="P16599" charOffset="155-164" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d475.s4.e5" origId="6802" charOffset="227-230" type="compound" text="Guo"/>
            <pair e1="DS3.d475.s4.e5" e2="DS3.d475.s4.e3" id="DS3.d475.s4.i0" interaction="False" />
            <pair e1="DS3.d475.s4.e5" e2="DS3.d475.s4.e2" id="DS3.d475.s4.i1" interaction="False" />
            <pair e1="DS3.d475.s4.e5" e2="DS3.d475.s4.e4" id="DS3.d475.s4.i2" interaction="False" />
            <pair e1="DS3.d475.s4.e5" e2="DS3.d475.s4.e1" id="DS3.d475.s4.i3" interaction="False" />
            <pair e1="DS3.d475.s4.e0" e2="DS3.d475.s4.e3" id="DS3.d475.s4.i4" interaction="False" />
            <pair e1="DS3.d475.s4.e0" e2="DS3.d475.s4.e2" id="DS3.d475.s4.i5" interaction="False" />
            <pair e1="DS3.d475.s4.e0" e2="DS3.d475.s4.e4" id="DS3.d475.s4.i6" interaction="False" />
            <pair e1="DS3.d475.s4.e0" e2="DS3.d475.s4.e1" id="DS3.d475.s4.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d475.s5" origId="9950771-5" text="These data support our hypothesis that a TNF-alpha-inducible phosphatase may be responsible for preventing sustained activation of c-Jun NH2-terminal protein kinase (JNK) and consequent cell death in these cells (Y.-L. Guo, K. Baysal, B. Kang, L.-J.">
            <entity id="DS3.d475.s5.e0" origId="P16599" charOffset="41-50" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d475.s5.e1" origId="P49185" charOffset="131-164" type="protein" text="c-Jun NH2-terminal protein kinase"/>
            <entity id="DS3.d475.s5.e2" origId="6802" charOffset="219-222" type="compound" text="Guo"/>
            <pair e1="DS3.d475.s5.e2" e2="DS3.d475.s5.e1" id="DS3.d475.s5.i0" interaction="False" />
            <pair e1="DS3.d475.s5.e2" e2="DS3.d475.s5.e0" id="DS3.d475.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d476" origId="9950772">
        <sentence id="DS3.d476.s0" origId="9950772-4" text="When shark NPR-B and human CFTR were coexpressed in Xenopus oocytes, CNP increased the cGMP content of oocytes (EC50 12 nM) and activated CFTR Cl- channels (EC50 8 nM).">
            <entity id="DS3.d476.s0.e0" origId="P20594" charOffset="11-16" type="protein" text="NPR-B"/>
            <entity id="DS3.d476.s0.e1" origId="24316" charOffset="87-91" type="compound" text="cGMP"/>
            <pair e1="DS3.d476.s0.e1" e2="DS3.d476.s0.e0" id="DS3.d476.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d477" origId="9950773">
        <sentence id="DS3.d477.s0" origId="9950773-10" text="Hypoxic HUVECs bound immune complexes and acted as a cofactor for factor I-mediated cleavage of C3b.">
            <entity id="DS3.d477.s0.e0" origId="108194" charOffset="53-61" type="compound" text="cofactor"/>
            <entity id="DS3.d477.s0.e1" origId="P01024,V9HWA9,B4DR57" charOffset="96-99" type="protein" text="C3b"/>
            <pair e1="DS3.d477.s0.e0" e2="DS3.d477.s0.e1" id="DS3.d477.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d477.s1" origId="9950773-6" text="Lipopolysaccharide or tumor necrosis factor-alpha also significantly increased HUVEC CR1 protein expression.">
            <entity id="DS3.d477.s1.e0" origId="11970143" charOffset="0-18" type="compound" text="Lipopolysaccharide"/>
            <entity id="DS3.d477.s1.e1" origId="P01375,Q5STB3" charOffset="22-49" type="protein" text="tumor necrosis factor-alpha"/>
            <entity id="DS3.d477.s1.e2" origId="P17927,E9PDY4" charOffset="85-88" type="protein" text="CR1"/>
            <pair e1="DS3.d477.s1.e0" e2="DS3.d477.s1.e1" id="DS3.d477.s1.i0" interaction="False" />
            <pair e1="DS3.d477.s1.e0" e2="DS3.d477.s1.e2" id="DS3.d477.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d478" origId="9950774">
        <sentence id="DS3.d478.s0" origId="9950774-2" text="We depleted polyamines with alpha-difluoromethylornithine (DFMO) in migrating cells with or without stimulation by epidermal growth factor (EGF) and investigated filamentous (F-) actin, monomeric (G-) actin, and thymosin beta4 (Tbeta4), using immunofluorescent confocal microscopy, DNase assay, and immunoblot analysis.">
            <entity id="DS3.d478.s0.e0" origId="9812937" charOffset="34-57" type="compound" text="difluoromethylornithine"/>
            <entity id="DS3.d478.s0.e1" origId="3009" charOffset="59-63" type="compound" text="DFMO"/>
            <entity id="DS3.d478.s0.e2" origId="P62329" charOffset="212-226" type="protein" text="thymosin beta4"/>
            <entity id="DS3.d478.s0.e3" origId="P62329" charOffset="228-234" type="protein" text="Tbeta4"/>
            <pair e1="DS3.d478.s0.e0" e2="DS3.d478.s0.e3" id="DS3.d478.s0.i0" interaction="False" />
            <pair e1="DS3.d478.s0.e0" e2="DS3.d478.s0.e2" id="DS3.d478.s0.i1" interaction="False" />
            <pair e1="DS3.d478.s0.e1" e2="DS3.d478.s0.e3" id="DS3.d478.s0.i2" interaction="False" />
            <pair e1="DS3.d478.s0.e1" e2="DS3.d478.s0.e2" id="DS3.d478.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d478.s1" origId="9950774-3" text="DFMO reduced F-actin in the cell interior, increased it in the cell cortex, redistributed G-actin, and increased nuclear staining of Tbeta4.">
            <entity id="DS3.d478.s1.e0" origId="3009" charOffset="0-4" type="compound" text="DFMO"/>
            <entity id="DS3.d478.s1.e1" origId="P62329" charOffset="133-139" type="protein" text="Tbeta4"/>
            <pair e1="DS3.d478.s1.e0" e2="DS3.d478.s1.e1" id="DS3.d478.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d478.s2" origId="9950774-4" text="However, DFMO did not affect the amount of Tbeta4 mRNA.">
            <entity id="DS3.d478.s2.e0" origId="3009" charOffset="9-13" type="compound" text="DFMO"/>
            <entity id="DS3.d478.s2.e1" origId="P62329" charOffset="43-49" type="protein" text="Tbeta4"/>
            <pair e1="DS3.d478.s2.e0" e2="DS3.d478.s2.e1" id="DS3.d478.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d478.s3" origId="9950774-7" text="We propose that DFMO reduces migration by interfering with the sequestration of G-actin by Tbeta4 and the association of F-actin with activated EGF receptors.">
            <entity id="DS3.d478.s3.e0" origId="3009" charOffset="16-20" type="compound" text="DFMO"/>
            <entity id="DS3.d478.s3.e1" origId="P62329" charOffset="91-97" type="protein" text="Tbeta4"/>
            <pair e1="DS3.d478.s3.e0" e2="DS3.d478.s3.e1" id="DS3.d478.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d479" origId="9950777">
        <sentence id="DS3.d479.s0" origId="9950777-2" text="A differentiation response substantially more complete and rapid than that obtained with insulin and 3,5,3'-triiodothyronine was observed with established inhibitors of adenylyl cyclases: 2', 5'-dideoxyadenosine (2',5'-dd-Ado), 9-(cyclopentyl)adenine (9-CP-Ade), and 9-(arabinofuranosyl)adenine (9-Ara-Ade), coincident with decreased cellular cAMP levels.">
            <entity id="DS3.d479.s0.e0" origId="P01308,I3WAC9" charOffset="89-96" type="protein" text="insulin"/>
            <entity id="DS3.d479.s0.e1" origId="5920" charOffset="108-124" type="compound" text="triiodothyronine"/>
            <entity id="DS3.d479.s0.e2" origId="20039" charOffset="195-211" type="compound" text="dideoxyadenosine"/>
            <entity id="DS3.d479.s0.e3" origId="Q96SZ5,B3KXN9" charOffset="222-225" type="protein" text="Ado"/>
            <entity id="DS3.d479.s0.e4" origId="190,57060554" charOffset="243-250" type="compound" text="adenine"/>
            <entity id="DS3.d479.s0.e5" origId="12852" charOffset="252-260" type="compound" text="9-CP-Ade"/>
            <entity id="DS3.d479.s0.e6" origId="12444981" charOffset="270-286" type="compound" text="arabinofuranosyl"/>
            <entity id="DS3.d479.s0.e7" origId="190,57060554" charOffset="287-294" type="compound" text="adenine"/>
            <pair e1="DS3.d479.s0.e2" e2="DS3.d479.s0.e3" id="DS3.d479.s0.i0" interaction="False" />
            <pair e1="DS3.d479.s0.e2" e2="DS3.d479.s0.e0" id="DS3.d479.s0.i1" interaction="False" />
            <pair e1="DS3.d479.s0.e6" e2="DS3.d479.s0.e3" id="DS3.d479.s0.i2" interaction="False" />
            <pair e1="DS3.d479.s0.e6" e2="DS3.d479.s0.e0" id="DS3.d479.s0.i3" interaction="False" />
            <pair e1="DS3.d479.s0.e1" e2="DS3.d479.s0.e3" id="DS3.d479.s0.i4" interaction="False" />
            <pair e1="DS3.d479.s0.e1" e2="DS3.d479.s0.e0" id="DS3.d479.s0.i5" interaction="False" />
            <pair e1="DS3.d479.s0.e5" e2="DS3.d479.s0.e3" id="DS3.d479.s0.i6" interaction="False" />
            <pair e1="DS3.d479.s0.e5" e2="DS3.d479.s0.e0" id="DS3.d479.s0.i7" interaction="False" />
            <pair e1="DS3.d479.s0.e4" e2="DS3.d479.s0.e3" id="DS3.d479.s0.i8" interaction="False" />
            <pair e1="DS3.d479.s0.e4" e2="DS3.d479.s0.e0" id="DS3.d479.s0.i9" interaction="False" />
        </sentence>
        <sentence id="DS3.d479.s1" origId="9950777-6" text="Potency of the differentiation response followed the order 2',5'-dd-Ado (1-20 microM) &amp;gt; 9-CP-Ade (10-100 microM) = 9-Ara-Ade (10-100 microM) &amp;gt;&amp;gt; inosine, consistent with their potencies to inhibit adenylyl cyclases.">
            <entity id="DS3.d479.s1.e0" origId="Q96SZ5,B3KXN9" charOffset="68-71" type="protein" text="Ado"/>
            <entity id="DS3.d479.s1.e1" origId="12852" charOffset="91-99" type="compound" text="9-CP-Ade"/>
            <entity id="DS3.d479.s1.e2" origId="6021" charOffset="153-160" type="compound" text="inosine"/>
            <pair e1="DS3.d479.s1.e2" e2="DS3.d479.s1.e0" id="DS3.d479.s1.i0" interaction="False" />
            <pair e1="DS3.d479.s1.e1" e2="DS3.d479.s1.e0" id="DS3.d479.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d480" origId="9950781">
        <sentence id="DS3.d480.s0" origId="9950781-9" text="During glucose infusion, there was apparently a relative increase in the fraction of glycerol derived from the action of lipoprotein lipase and an increase in reesterification in situ.">
            <entity id="DS3.d480.s0.e0" origId="206,5793,64689,79025" charOffset="7-14" type="compound" text="glucose"/>
            <entity id="DS3.d480.s0.e1" origId="24759880,753" charOffset="85-93" type="compound" text="glycerol"/>
            <entity id="DS3.d480.s0.e2" origId="P06858" charOffset="121-139" type="protein" text="lipoprotein lipase"/>
            <pair e1="DS3.d480.s0.e1" e2="DS3.d480.s0.e2" id="DS3.d480.s0.i0" interaction="False" />
            <pair e1="DS3.d480.s0.e0" e2="DS3.d480.s0.e2" id="DS3.d480.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d481" origId="9950782">
        <sentence id="DS3.d481.s0" origId="9950782-2" text="Six subjects were fasted overnight and were then given 40 g of triacylglycerol either orally or as an intravenous infusion over 4 h. Intracellular lipolysis (hormone-sensitive lipase action; HSL) was suppressed after both oral and intravenous fat loads (P &amp;lt; 0.001).">
            <entity id="DS3.d481.s0.e0" origId="11146" charOffset="63-78" type="compound" text="triacylglycerol"/>
            <entity id="DS3.d481.s0.e1" origId="5474737" charOffset="176-182" type="compound" text="lipase"/>
            <entity id="DS3.d481.s0.e2" origId="Q05469,A8K8W7" charOffset="191-194" type="protein" text="HSL"/>
            <pair e1="DS3.d481.s0.e1" e2="DS3.d481.s0.e2" id="DS3.d481.s0.i0" interaction="False" />
            <pair e1="DS3.d481.s0.e0" e2="DS3.d481.s0.e2" id="DS3.d481.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d481.s1" origId="9950782-4" text="The rate of action of LPL (measured as triacylglycerol extraction) increased with both oral and intravenous fat loads in adipose tissue (P = 0.002) and skeletal muscle (P = 0.001).">
            <entity id="DS3.d481.s1.e0" origId="P06858" charOffset="22-25" type="protein" text="LPL"/>
            <entity id="DS3.d481.s1.e1" origId="11146" charOffset="39-54" type="compound" text="triacylglycerol"/>
            <pair e1="DS3.d481.s1.e1" e2="DS3.d481.s1.e0" id="DS3.d481.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d481.s2" origId="9950782-7" text="These results suggest that Insulin is not essential for HSL suppression or increased triacylglycerol clearance but is important in reesterification of fatty acids in adipose tissue but not uptake by skeletal muscle, thus affecting fatty acid partitioning between adipose tissue and the circulation, postprandial nonesterified fatty acid concentrations, and hepatic very low density lipoprotein secretion.">
            <entity id="DS3.d481.s2.e0" origId="P01308,I3WAC9" charOffset="27-34" type="protein" text="Insulin"/>
            <entity id="DS3.d481.s2.e1" origId="Q05469,A8K8W7" charOffset="56-59" type="protein" text="HSL"/>
            <entity id="DS3.d481.s2.e2" origId="11146" charOffset="85-100" type="compound" text="triacylglycerol"/>
            <pair e1="DS3.d481.s2.e2" e2="DS3.d481.s2.e0" id="DS3.d481.s2.i0" interaction="False" />
            <pair e1="DS3.d481.s2.e2" e2="DS3.d481.s2.e1" id="DS3.d481.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d482" origId="9950784">
        <sentence id="DS3.d482.s0" origId="9950784-1" text="The present study examined the effect of high-intensity exercise training on muscle sarcolemmal lactate/H+ transport and the monocarboxylate transporters (MCT1 and MCT4) as well as lactate and H+ release during intense exercise in humans.">
            <entity id="DS3.d482.s0.e0" origId="612" charOffset="96-103" type="compound" text="lactate"/>
            <entity id="DS3.d482.s0.e1" origId="P53985,B4DKS0,A0A024R0H1" charOffset="155-159" type="protein" text="MCT1"/>
            <entity id="DS3.d482.s0.e2" origId="O15374" charOffset="164-168" type="protein" text="MCT4"/>
            <entity id="DS3.d482.s0.e3" origId="612" charOffset="181-188" type="compound" text="lactate"/>
            <pair e1="DS3.d482.s0.e0" e2="DS3.d482.s0.e2" id="DS3.d482.s0.i0" interaction="False" />
            <pair e1="DS3.d482.s0.e0" e2="DS3.d482.s0.e1" id="DS3.d482.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d483" origId="9950787">
        <sentence id="DS3.d483.s0" origId="9950787-4" text="The percent increase in glycerol Ra correlated closely with the percent decline in plasma insulin in both groups (r2 = 0.85; P &amp;lt; 0.05).">
            <entity id="DS3.d483.s0.e0" origId="24759880,753" charOffset="24-32" type="compound" text="glycerol"/>
            <entity id="DS3.d483.s0.e1" origId="P01308,I3WAC9" charOffset="90-97" type="protein" text="insulin"/>
            <pair e1="DS3.d483.s0.e0" e2="DS3.d483.s0.e1" id="DS3.d483.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d484" origId="9950788">
        <sentence id="DS3.d484.s0" origId="9950788-12" text="An insulin-modified (0.03 U/kg body wt infused over 5 min) (6,6-2H2)glucose-labeled IVGTT (0.33 g/kg of glucose) was performed in 10 normal subjects.">
            <entity id="DS3.d484.s0.e0" origId="P01308,I3WAC9" charOffset="3-10" type="protein" text="insulin"/>
            <entity id="DS3.d484.s0.e1" origId="73505242" charOffset="64-67" type="compound" text="2H2"/>
            <entity id="DS3.d484.s0.e2" origId="206,5793,64689,79025" charOffset="68-75" type="compound" text="glucose"/>
            <entity id="DS3.d484.s0.e3" origId="206,5793,64689,79025" charOffset="104-111" type="compound" text="glucose"/>
            <pair e1="DS3.d484.s0.e1" e2="DS3.d484.s0.e0" id="DS3.d484.s0.i0" interaction="False" />
            <pair e1="DS3.d484.s0.e2" e2="DS3.d484.s0.e0" id="DS3.d484.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d485" origId="9950789">
        <sentence id="DS3.d485.s0" origId="9950789-2" text="To determine whether this effect on NHGU is specific to the portal route of GNGAA delivery, somatostatin, intraportal insulin (3-fold basal) and glucagon (basal), and intraportal glucose (to increase the hepatic glucose load by approximately 50%) were infused for 240 min.">
            <entity id="DS3.d485.s0.e0" origId="P01321" charOffset="118-125" type="protein" text="insulin"/>
            <entity id="DS3.d485.s0.e1" origId="206,64689,79025,5793" charOffset="179-186" type="compound" text="glucose"/>
            <entity id="DS3.d485.s0.e2" origId="206,64689,79025,5793" charOffset="212-219" type="compound" text="glucose"/>
            <pair e1="DS3.d485.s0.e1" e2="DS3.d485.s0.e0" id="DS3.d485.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d486" origId="9950790">
        <sentence id="DS3.d486.s0" origId="9950790-0" text="Control of adrenal cell proliferation by AT1 receptors in response to angiotensin II and low-sodium diet.">
            <entity id="DS3.d486.s0.e0" origId="P01015" charOffset="70-84" type="protein" text="angiotensin II"/>
            <entity id="DS3.d486.s0.e1" origId="5360545" charOffset="93-99" type="compound" text="sodium"/>
            <pair e1="DS3.d486.s0.e1" e2="DS3.d486.s0.e0" id="DS3.d486.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d486.s1" origId="9950790-1" text="The effects of angiotensin II (ANG II), the angiotensin type 1 (AT1) receptor antagonist losartan, and low-sodium diet on rat adrenal cell proliferation were studied in vivo with immunocytochemistry.">
            <entity id="DS3.d486.s1.e0" origId="P01015" charOffset="15-29" type="protein" text="angiotensin II"/>
            <entity id="DS3.d486.s1.e1" origId="P01015" charOffset="31-37" type="protein" text="ANG II"/>
            <entity id="DS3.d486.s1.e2" origId="3961" charOffset="89-97" type="compound" text="losartan"/>
            <entity id="DS3.d486.s1.e3" origId="5360545" charOffset="107-113" type="compound" text="sodium"/>
            <pair e1="DS3.d486.s1.e2" e2="DS3.d486.s1.e0" id="DS3.d486.s1.i0" interaction="False" />
            <pair e1="DS3.d486.s1.e2" e2="DS3.d486.s1.e1" id="DS3.d486.s1.i1" interaction="False" />
            <pair e1="DS3.d486.s1.e3" e2="DS3.d486.s1.e0" id="DS3.d486.s1.i2" interaction="False" />
            <pair e1="DS3.d486.s1.e3" e2="DS3.d486.s1.e1" id="DS3.d486.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d486.s2" origId="9950790-2" text="Both ANG II and low-sodium diet increased proliferation of endothelial cells of the zona glomerulosa.">
            <entity id="DS3.d486.s2.e0" origId="P01015" charOffset="5-11" type="protein" text="ANG II"/>
            <entity id="DS3.d486.s2.e1" origId="5360545" charOffset="20-26" type="compound" text="sodium"/>
            <pair e1="DS3.d486.s2.e1" e2="DS3.d486.s2.e0" id="DS3.d486.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d486.s3" origId="9950790-3" text="Losartan prevented ANG II-induced hyperplasia of glomerulosa cells but not the effects of a low-sodium diet.">
            <entity id="DS3.d486.s3.e0" origId="3961" charOffset="0-8" type="compound" text="Losartan"/>
            <entity id="DS3.d486.s3.e1" origId="P01015" charOffset="19-25" type="protein" text="ANG II"/>
            <entity id="DS3.d486.s3.e2" origId="5360545" charOffset="96-102" type="compound" text="sodium"/>
            <pair e1="DS3.d486.s3.e0" e2="DS3.d486.s3.e1" id="DS3.d486.s3.i0" interaction="False" />
            <pair e1="DS3.d486.s3.e2" e2="DS3.d486.s3.e1" id="DS3.d486.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d486.s4" origId="9950790-4" text="Glomerulosa cells after ANG II + losartan treatment appeared hypertrophied compared with those of controls.">
            <entity id="DS3.d486.s4.e0" origId="P01015" charOffset="24-30" type="protein" text="ANG II"/>
            <entity id="DS3.d486.s4.e1" origId="3961" charOffset="33-41" type="compound" text="losartan"/>
            <pair e1="DS3.d486.s4.e1" e2="DS3.d486.s4.e0" id="DS3.d486.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d486.s5" origId="9950790-5" text="Proliferative effects of ANG II and low-sodium diet in the reticularis were blocked by losartan.">
            <entity id="DS3.d486.s5.e0" origId="P01015" charOffset="25-31" type="protein" text="ANG II"/>
            <entity id="DS3.d486.s5.e1" origId="5360545" charOffset="40-46" type="compound" text="sodium"/>
            <entity id="DS3.d486.s5.e2" origId="3961" charOffset="87-95" type="compound" text="losartan"/>
            <pair e1="DS3.d486.s5.e2" e2="DS3.d486.s5.e0" id="DS3.d486.s5.i0" interaction="False" />
            <pair e1="DS3.d486.s5.e1" e2="DS3.d486.s5.e0" id="DS3.d486.s5.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d486.s6" origId="9950790-7" text="Proliferation in the medulla was increased with losartan, was decreased by ANG II, but was unaffected by low-sodium diet.">
            <entity id="DS3.d486.s6.e0" origId="3961" charOffset="48-56" type="compound" text="losartan"/>
            <entity id="DS3.d486.s6.e1" origId="P01015" charOffset="75-81" type="protein" text="ANG II"/>
            <entity id="DS3.d486.s6.e2" origId="5360545" charOffset="109-115" type="compound" text="sodium"/>
            <pair e1="DS3.d486.s6.e0" e2="DS3.d486.s6.e1" id="DS3.d486.s6.i0" interaction="False" />
            <pair e1="DS3.d486.s6.e2" e2="DS3.d486.s6.e1" id="DS3.d486.s6.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d487" origId="9950793">
        <sentence id="DS3.d487.s0" origId="9950793-1" text="Little is known about mechanisms of regulation of cysteine dioxygenase (CDO), gamma-glutamylcysteine synthetase (GCS), and cysteine-sulfinate decarboxylase (CSDC) in response to diet.">
            <entity id="DS3.d487.s0.e0" origId="5862,90793998" charOffset="50-58" type="compound" text="cysteine"/>
            <entity id="DS3.d487.s0.e1" origId="P19468" charOffset="78-111" type="protein" text="gamma-glutamylcysteine synthetase"/>
            <entity id="DS3.d487.s0.e2" origId="Q64611,B5LSW7" charOffset="123-155" type="protein" text="cysteine-sulfinate decarboxylase"/>
            <pair e1="DS3.d487.s0.e0" e2="DS3.d487.s0.e2" id="DS3.d487.s0.i0" interaction="False" />
            <pair e1="DS3.d487.s0.e0" e2="DS3.d487.s0.e1" id="DS3.d487.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d488" origId="9950797">
        <sentence id="DS3.d488.s0" origId="9950797-0" text="Plasma insulin rise precedes rise in ob mRNA expression and plasma leptin in gold thioglucose-obese mice.">
            <entity id="DS3.d488.s0.e0" origId="P41160,Q544U0" charOffset="67-73" type="protein" text="leptin"/>
            <entity id="DS3.d488.s0.e1" origId="446466" charOffset="77-93" type="compound" text="gold thioglucose"/>
            <pair e1="DS3.d488.s0.e1" e2="DS3.d488.s0.e0" id="DS3.d488.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d488.s1" origId="9950797-4" text="The ratio of serum leptin to fat pad weight was significantly higher in GTG mice 12 wk postinjection.">
            <entity id="DS3.d488.s1.e0" origId="P41160,Q544U0" charOffset="19-25" type="protein" text="leptin"/>
            <entity id="DS3.d488.s1.e1" origId="19805081,5492869" charOffset="33-36" type="compound" text="pad"/>
            <pair e1="DS3.d488.s1.e1" e2="DS3.d488.s1.e0" id="DS3.d488.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d488.s2" origId="9950797-5" text="Starvation-induced reductions in serum leptin (50%), glucose (50%), and insulin (74%) were greater than decreases in fat pad weight (18%).">
            <entity id="DS3.d488.s2.e0" origId="P41160,Q544U0" charOffset="39-45" type="protein" text="leptin"/>
            <entity id="DS3.d488.s2.e1" origId="206,5793,64689,79025" charOffset="53-60" type="compound" text="glucose"/>
            <entity id="DS3.d488.s2.e2" origId="19805081,5492869" charOffset="121-124" type="compound" text="pad"/>
            <pair e1="DS3.d488.s2.e2" e2="DS3.d488.s2.e0" id="DS3.d488.s2.i0" interaction="False" />
            <pair e1="DS3.d488.s2.e1" e2="DS3.d488.s2.e0" id="DS3.d488.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d488.s3" origId="9950797-6" text="Adrenalectomy decreased both adiposity and serum leptin within 1 wk in both CON and GTG and altered the serum leptin level-to-fat pad weight ratio in CON.">
            <entity id="DS3.d488.s3.e0" origId="P41160,Q544U0" charOffset="49-55" type="protein" text="leptin"/>
            <entity id="DS3.d488.s3.e1" origId="P41160,Q544U0" charOffset="110-116" type="protein" text="leptin"/>
            <entity id="DS3.d488.s3.e2" origId="19805081,5492869" charOffset="130-133" type="compound" text="pad"/>
            <pair e1="DS3.d488.s3.e2" e2="DS3.d488.s3.e0" id="DS3.d488.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d489" origId="9950798">
        <sentence id="DS3.d489.s0" origId="9950798-3" text="The following five alternative methods for assessing glucose tolerance were compared: fasting plasma glucose (FPG) as a single sample or as the mean of three 5-min samples (FPG3); the 1- and 2-h glucose during a low-dose intravenous glucose infusion (CIG); and the 2-h plasma glucose from a 75-g oral glucose tolerance test (OGTT).">
            <entity id="DS3.d489.s0.e0" origId="206,5793,64689,79025" charOffset="53-60" type="compound" text="glucose"/>
            <entity id="DS3.d489.s0.e1" origId="206,5793,64689,79025" charOffset="101-108" type="compound" text="glucose"/>
            <entity id="DS3.d489.s0.e2" origId="206,5793,64689,79025" charOffset="101-108" type="compound" text="glucose"/>
            <entity id="DS3.d489.s0.e3" origId="206,5793,64689,79025" charOffset="101-108" type="compound" text="glucose"/>
            <entity id="DS3.d489.s0.e4" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="251-254" type="protein" text="CIG"/>
            <entity id="DS3.d489.s0.e5" origId="206,5793,64689,79025" charOffset="101-108" type="compound" text="glucose"/>
            <entity id="DS3.d489.s0.e6" origId="206,5793,64689,79025" charOffset="101-108" type="compound" text="glucose"/>
            <pair e1="DS3.d489.s0.e0" e2="DS3.d489.s0.e4" id="DS3.d489.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d490" origId="9950799">
        <sentence id="DS3.d490.s0" origId="9950799-3" text="PGE2 increased both parameters, peaking at 100 nM, an effect that was mimicked by forskolin and was abolished by 2',3'-dideoxyadenosine (an adenylate cyclase inhibitor) and was thus cAMP dependent, pointing to the involvement of EP2 or EP4.">
            <entity id="DS3.d490.s0.e0" origId="47936" charOffset="82-91" type="compound" text="forskolin"/>
            <entity id="DS3.d490.s0.e1" origId="20039" charOffset="113-135" type="compound" text="2',3'-dideoxyadenosine"/>
            <entity id="DS3.d490.s0.e2" origId="6083" charOffset="140-149" type="compound" text="adenylate"/>
            <entity id="DS3.d490.s0.e3" origId="Q62928" charOffset="229-232" type="protein" text="EP2"/>
            <entity id="DS3.d490.s0.e4" origId="P43114,A0A0G2JSM6" charOffset="236-239" type="protein" text="EP4"/>
            <pair e1="DS3.d490.s0.e0" e2="DS3.d490.s0.e4" id="DS3.d490.s0.i0" interaction="False" />
            <pair e1="DS3.d490.s0.e0" e2="DS3.d490.s0.e3" id="DS3.d490.s0.i1" interaction="False" />
            <pair e1="DS3.d490.s0.e1" e2="DS3.d490.s0.e4" id="DS3.d490.s0.i2" interaction="False" />
            <pair e1="DS3.d490.s0.e1" e2="DS3.d490.s0.e3" id="DS3.d490.s0.i3" interaction="False" />
            <pair e1="DS3.d490.s0.e2" e2="DS3.d490.s0.e4" id="DS3.d490.s0.i4" interaction="False" />
            <pair e1="DS3.d490.s0.e2" e2="DS3.d490.s0.e3" id="DS3.d490.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d490.s1" origId="9950799-4" text="Consistently, 17-phenyl-omega-trinor PGE2 (EP1 agonist) and sulprostone (EP3/EP1 agonist) lacked any anabolic activity.">
            <entity id="DS3.d490.s1.e0" origId="P70597" charOffset="43-46" type="protein" text="EP1"/>
            <entity id="DS3.d490.s1.e1" origId="13532635,20980918,43251,51668574,5312153,6917982,71311734" charOffset="60-71" type="compound" text="sulprostone"/>
            <entity id="DS3.d490.s1.e2" origId="P34980,G3V7D9,A0A0G2JSK4" charOffset="73-76" type="protein" text="EP3"/>
            <entity id="DS3.d490.s1.e3" origId="P70597" charOffset="77-80" type="protein" text="EP1"/>
            <pair e1="DS3.d490.s1.e1" e2="DS3.d490.s1.e2" id="DS3.d490.s1.i0" interaction="False" />
            <pair e1="DS3.d490.s1.e1" e2="DS3.d490.s1.e0" id="DS3.d490.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d490.s2" origId="9950799-5" text="Furthermore, butaprost (EP2 agonist) was inactive, 11-deoxy-PGE1 (EP4/EP2 agonist) was as effective as PGE2, and the PGE2 effect was abolished dose dependently by the selective EP4 antagonist AH-23848B, suggesting the involvement of EP4.">
            <entity id="DS3.d490.s2.e0" origId="Q62928" charOffset="24-27" type="protein" text="EP2"/>
            <entity id="DS3.d490.s2.e1" origId="5283055" charOffset="51-64" type="compound" text="11-deoxy-PGE1"/>
            <entity id="DS3.d490.s2.e2" origId="P43114,A0A0G2JSM6" charOffset="66-69" type="protein" text="EP4"/>
            <entity id="DS3.d490.s2.e3" origId="Q62928" charOffset="70-73" type="protein" text="EP2"/>
            <entity id="DS3.d490.s2.e4" origId="P43114,A0A0G2JSM6" charOffset="177-180" type="protein" text="EP4"/>
            <entity id="DS3.d490.s2.e5" origId="5310999" charOffset="192-201" type="compound" text="AH-23848B"/>
            <entity id="DS3.d490.s2.e6" origId="P43114,A0A0G2JSM6" charOffset="177-180" type="protein" text="EP4"/>
            <pair e1="DS3.d490.s2.e1" e2="DS3.d490.s2.e2" id="DS3.d490.s2.i0" interaction="False" />
            <pair e1="DS3.d490.s2.e1" e2="DS3.d490.s2.e0" id="DS3.d490.s2.i1" interaction="False" />
            <pair e1="DS3.d490.s2.e5" e2="DS3.d490.s2.e2" id="DS3.d490.s2.i2" interaction="False" />
            <pair e1="DS3.d490.s2.e5" e2="DS3.d490.s2.e0" id="DS3.d490.s2.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d491" origId="9950801">
        <sentence id="DS3.d491.s0" origId="9950801-0" text="GLUT-1 or GLUT-4 transgenes in obese mice improve glucose tolerance but do not prevent Insulin resistance.">
            <entity id="DS3.d491.s0.e0" origId="P17809" charOffset="0-6" type="protein" text="GLUT-1"/>
            <entity id="DS3.d491.s0.e1" origId="P14142" charOffset="10-16" type="protein" text="GLUT-4"/>
            <entity id="DS3.d491.s0.e2" origId="P41160,Q544U0" charOffset="31-36" type="protein" text="obese"/>
            <entity id="DS3.d491.s0.e3" origId="206,5793,64689,79025" charOffset="50-57" type="compound" text="glucose"/>
            <entity id="DS3.d491.s0.e4" origId="P01308,I3WAC9" charOffset="87-94" type="protein" text="Insulin"/>
            <pair e1="DS3.d491.s0.e3" e2="DS3.d491.s0.e2" id="DS3.d491.s0.i0" interaction="False" />
            <pair e1="DS3.d491.s0.e3" e2="DS3.d491.s0.e0" id="DS3.d491.s0.i1" interaction="False" />
            <pair e1="DS3.d491.s0.e3" e2="DS3.d491.s0.e4" id="DS3.d491.s0.i2" interaction="False" />
            <pair e1="DS3.d491.s0.e3" e2="DS3.d491.s0.e1" id="DS3.d491.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d491.s1" origId="9950801-11" text="On the high-fat, high-sugar diet, wild-type and GLUT-1 mice developed marked Insulin resistance, but GLUT-4 and GLUT-1 and -4 mice were somewhat protected (glucose utilization during hyperinsulinemic clamp of 28.5 +/- 3.4 vs. 42.4 +/- 5.9, 51.2 +/- 8.1, and 55.9 +/- 4.">
            <entity id="DS3.d491.s1.e0" origId="P17809" charOffset="48-54" type="protein" text="GLUT-1"/>
            <entity id="DS3.d491.s1.e1" origId="P01308,I3WAC9" charOffset="77-84" type="protein" text="Insulin"/>
            <entity id="DS3.d491.s1.e2" origId="P14142" charOffset="101-107" type="protein" text="GLUT-4"/>
            <entity id="DS3.d491.s1.e3" origId="P17809" charOffset="112-118" type="protein" text="GLUT-1"/>
            <entity id="DS3.d491.s1.e4" origId="206,5793,64689,79025" charOffset="156-163" type="compound" text="glucose"/>
            <pair e1="DS3.d491.s1.e4" e2="DS3.d491.s1.e0" id="DS3.d491.s1.i0" interaction="False" />
            <pair e1="DS3.d491.s1.e4" e2="DS3.d491.s1.e1" id="DS3.d491.s1.i1" interaction="False" />
            <pair e1="DS3.d491.s1.e4" e2="DS3.d491.s1.e2" id="DS3.d491.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d491.s2" origId="9950801-14" text="These data demonstrate that overexpression of GLUT-1 and/or GLUT-4 enhances whole body glucose utilization and prevents the development of fasting hyperglycemia and glucose intolerance induced by a high-fat, high-sugar diet.">
            <entity id="DS3.d491.s2.e0" origId="P17809" charOffset="46-52" type="protein" text="GLUT-1"/>
            <entity id="DS3.d491.s2.e1" origId="P14142" charOffset="60-66" type="protein" text="GLUT-4"/>
            <entity id="DS3.d491.s2.e2" origId="206,5793,64689,79025" charOffset="87-94" type="compound" text="glucose"/>
            <entity id="DS3.d491.s2.e3" origId="206,5793,64689,79025" charOffset="165-172" type="compound" text="glucose"/>
            <pair e1="DS3.d491.s2.e2" e2="DS3.d491.s2.e0" id="DS3.d491.s2.i0" interaction="False" />
            <pair e1="DS3.d491.s2.e2" e2="DS3.d491.s2.e1" id="DS3.d491.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d491.s3" origId="9950801-1" text="Insulin-stimulated glucose uptake is defective in patients with type 2 diabetes.">
            <entity id="DS3.d491.s3.e0" origId="P01308,I3WAC9" charOffset="0-7" type="protein" text="Insulin"/>
            <entity id="DS3.d491.s3.e1" origId="206,5793,64689,79025" charOffset="19-26" type="compound" text="glucose"/>
            <pair e1="DS3.d491.s3.e1" e2="DS3.d491.s3.e0" id="DS3.d491.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d491.s4" origId="9950801-2" text="To determine whether transgenic glucose transporter overexpression in muscle can prevent diabetes induced by a high-fat, high-sugar diet, singly (GLUT-1, GLUT-4) and doubly (GLUT-1 and -4) transgenic mice were placed on a high-fat, high-sugar diet or a standard chow diet.">
            <entity id="DS3.d491.s4.e0" origId="206,5793,64689,79025" charOffset="32-39" type="compound" text="glucose"/>
            <entity id="DS3.d491.s4.e1" origId="P17809" charOffset="146-152" type="protein" text="GLUT-1"/>
            <entity id="DS3.d491.s4.e2" origId="P14142" charOffset="154-160" type="protein" text="GLUT-4"/>
            <entity id="DS3.d491.s4.e3" origId="P17809" charOffset="174-180" type="protein" text="GLUT-1"/>
            <pair e1="DS3.d491.s4.e0" e2="DS3.d491.s4.e1" id="DS3.d491.s4.i0" interaction="False" />
            <pair e1="DS3.d491.s4.e0" e2="DS3.d491.s4.e2" id="DS3.d491.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d491.s5" origId="9950801-4" text="Hyperinsulinemic clamps showed that transporter overexpression elevated Insulin-stimulated glucose utilization on standard chow (49 +/- 4 mg. kg-1.">
            <entity id="DS3.d491.s5.e0" origId="P01308,I3WAC9" charOffset="72-79" type="protein" text="Insulin"/>
            <entity id="DS3.d491.s5.e1" origId="206,5793,64689,79025" charOffset="91-98" type="compound" text="glucose"/>
            <pair e1="DS3.d491.s5.e1" e2="DS3.d491.s5.e0" id="DS3.d491.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d492" origId="9950808">
        <sentence id="DS3.d492.s0" origId="9950808-2" text="In the present study in a newborn swine intestinal epithelial cell line (IPEC-1), taurocholate and phosphatidylcholine were found to have no effect on apolipoprotein B (apo B) secretion but did significantly increase the basolateral secretion of apo A-I.">
            <entity id="DS3.d492.s0.e0" origId="6675" charOffset="82-94" type="compound" text="taurocholate"/>
            <entity id="DS3.d492.s0.e1" origId="P18648" charOffset="246-253" type="protein" text="apo A-I"/>
            <pair e1="DS3.d492.s0.e0" e2="DS3.d492.s0.e1" id="DS3.d492.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d492.s1" origId="9950808-3" text="This regulation of apo A-I secretion occurred at the pretranslational level for taurocholate and at the posttranslational level for phosphatidylcholine.">
            <entity id="DS3.d492.s1.e0" origId="P18648" charOffset="19-26" type="protein" text="apo A-I"/>
            <entity id="DS3.d492.s1.e1" origId="6675" charOffset="80-92" type="compound" text="taurocholate"/>
            <pair e1="DS3.d492.s1.e1" e2="DS3.d492.s1.e0" id="DS3.d492.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d492.s2" origId="9950808-5" text="Cholesterol, whether solubilized with taurocholate or phosphatidylcholine, had no effect on the secretion of either apo B or apo A-I.">
            <entity id="DS3.d492.s2.e0" origId="5997" charOffset="0-11" type="compound" text="Cholesterol"/>
            <entity id="DS3.d492.s2.e1" origId="6675" charOffset="38-50" type="compound" text="taurocholate"/>
            <entity id="DS3.d492.s2.e2" origId="P18648" charOffset="125-132" type="protein" text="apo A-I"/>
            <pair e1="DS3.d492.s2.e1" e2="DS3.d492.s2.e2" id="DS3.d492.s2.i0" interaction="False" />
            <pair e1="DS3.d492.s2.e0" e2="DS3.d492.s2.e2" id="DS3.d492.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d492.s3" origId="9950808-6" text="However, when taurocholate, phosphatidylcholine, and cholesterol were combined, apo B secretion was decreased, and the increase in apo A-I secretion noted with taurocholate and phosphatidylcholine alone was ablated.">
            <entity id="DS3.d492.s3.e0" origId="6675" charOffset="14-26" type="compound" text="taurocholate"/>
            <entity id="DS3.d492.s3.e1" origId="5997" charOffset="53-64" type="compound" text="cholesterol"/>
            <entity id="DS3.d492.s3.e2" origId="P18648" charOffset="131-138" type="protein" text="apo A-I"/>
            <entity id="DS3.d492.s3.e3" origId="6675" charOffset="160-172" type="compound" text="taurocholate"/>
            <pair e1="DS3.d492.s3.e0" e2="DS3.d492.s3.e2" id="DS3.d492.s3.i0" interaction="False" />
            <pair e1="DS3.d492.s3.e1" e2="DS3.d492.s3.e2" id="DS3.d492.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d492.s4" origId="9950808-7" text="Another primary bile acid, taurochenodeoxycholate, was found to decrease apo B secretion but had no effect on apo A-I secretion.">
            <entity id="DS3.d492.s4.e0" origId="387316" charOffset="27-49" type="compound" text="taurochenodeoxycholate"/>
            <entity id="DS3.d492.s4.e1" origId="P18648" charOffset="110-117" type="protein" text="apo A-I"/>
            <pair e1="DS3.d492.s4.e0" e2="DS3.d492.s4.e1" id="DS3.d492.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d493" origId="9950809">
        <sentence id="DS3.d493.s0" origId="9950809-2" text="Because nitric oxide (NO) may be increased in PVS and has been recognized as a negative inotropic agent, we investigated the induction of NO synthase (NOS2) and/or changes in constitutive NOS (NOS3) as factors in the cardiac dysfunction of the PVS rat.">
            <entity id="DS3.d493.s0.e0" origId="145068" charOffset="8-20" type="compound" text="nitric oxide"/>
            <entity id="DS3.d493.s0.e1" origId="Q06518" charOffset="151-155" type="protein" text="NOS2"/>
            <entity id="DS3.d493.s0.e2" origId="Q62600" charOffset="193-197" type="protein" text="NOS3"/>
            <pair e1="DS3.d493.s0.e0" e2="DS3.d493.s0.e1" id="DS3.d493.s0.i0" interaction="False" />
            <pair e1="DS3.d493.s0.e0" e2="DS3.d493.s0.e2" id="DS3.d493.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d493.s1" origId="9950809-5" text="Cardiac tissue NOS2 and NOS3 activities were assayed, Western blot analyses of NOS2 and NOS3 expression were performed, and circulating nitrate-nitrite (NOX) levels (an indicator of in vivo NOS activity) were assayed.">
            <entity id="DS3.d493.s1.e0" origId="Q06518" charOffset="15-19" type="protein" text="NOS2"/>
            <entity id="DS3.d493.s1.e1" origId="Q62600" charOffset="24-28" type="protein" text="NOS3"/>
            <entity id="DS3.d493.s1.e2" origId="Q06518" charOffset="79-83" type="protein" text="NOS2"/>
            <entity id="DS3.d493.s1.e3" origId="Q62600" charOffset="88-92" type="protein" text="NOS3"/>
            <entity id="DS3.d493.s1.e4" origId="10313259,943" charOffset="136-143" type="compound" text="nitrate"/>
            <entity id="DS3.d493.s1.e5" origId="946" charOffset="144-151" type="compound" text="nitrite"/>
            <pair e1="DS3.d493.s1.e4" e2="DS3.d493.s1.e0" id="DS3.d493.s1.i0" interaction="False" />
            <pair e1="DS3.d493.s1.e4" e2="DS3.d493.s1.e1" id="DS3.d493.s1.i1" interaction="False" />
            <pair e1="DS3.d493.s1.e5" e2="DS3.d493.s1.e0" id="DS3.d493.s1.i2" interaction="False" />
            <pair e1="DS3.d493.s1.e5" e2="DS3.d493.s1.e1" id="DS3.d493.s1.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d494" origId="9950811">
        <sentence id="DS3.d494.s0" origId="9950811-11" text="The vesicle contained immunoidentifiable apolipoprotein (apo) B48 and apo A-IV but very little apo A-I, although apo A-I was present in the ER and Golgi.">
            <entity id="DS3.d494.s0.e0" origId="2744426" charOffset="62-65" type="compound" text="B48"/>
            <entity id="DS3.d494.s0.e1" origId="P02651" charOffset="70-78" type="protein" text="apo A-IV"/>
            <pair e1="DS3.d494.s0.e0" e2="DS3.d494.s0.e1" id="DS3.d494.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d495" origId="9950815">
        <sentence id="DS3.d495.s0" origId="9950815-3" text="G17 led to a sixfold induction in luciferase activity in cells transfected with plasmids containing the -356+109 sequence of the murine c-fos promoter, which includes the Sis-inducible element (SIE), serum response element (SRE), and the Ca2+/cAMP response element (CRE) regulatory elements.">
            <entity id="DS3.d495.s0.e0" origId="O35984,Q4FJL3" charOffset="0-3" type="protein" text="G17"/>
            <entity id="DS3.d495.s0.e1" origId="P01101" charOffset="136-141" type="protein" text="c-fos"/>
            <entity id="DS3.d495.s0.e2" origId="6540269" charOffset="194-197" type="compound" text="SIE"/>
            <entity id="DS3.d495.s0.e3" origId="P00920" charOffset="238-264" type="protein" text="Ca2+/cAMP response element"/>
            <pair e1="DS3.d495.s0.e2" e2="DS3.d495.s0.e0" id="DS3.d495.s0.i0" interaction="False" />
            <pair e1="DS3.d495.s0.e2" e2="DS3.d495.s0.e1" id="DS3.d495.s0.i1" interaction="False" />
            <pair e1="DS3.d495.s0.e2" e2="DS3.d495.s0.e3" id="DS3.d495.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d495.s1" origId="9950815-9" text="Because activation of the SRE involves the small GTP-binding protein Rho A, we examined the role of Rho A in G17 induction of c-fos transcription.">
            <entity id="DS3.d495.s1.e0" origId="6830" charOffset="49-52" type="compound" text="GTP"/>
            <entity id="DS3.d495.s1.e1" origId="O35984,Q4FJL3" charOffset="109-112" type="protein" text="G17"/>
            <entity id="DS3.d495.s1.e2" origId="P01101" charOffset="126-131" type="protein" text="c-fos"/>
            <pair e1="DS3.d495.s1.e0" e2="DS3.d495.s1.e1" id="DS3.d495.s1.i0" interaction="False" />
            <pair e1="DS3.d495.s1.e0" e2="DS3.d495.s1.e2" id="DS3.d495.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d496" origId="9950818">
        <sentence id="DS3.d496.s0" origId="9950818-10" text="The increase in JunD/AP-1 activity in DFMO-treated cells was associated with a significant decrease in cell division.">
            <entity id="DS3.d496.s0.e0" origId="P52909" charOffset="16-20" type="protein" text="JunD"/>
            <entity id="DS3.d496.s0.e1" origId="3009" charOffset="38-42" type="compound" text="DFMO"/>
            <pair e1="DS3.d496.s0.e1" e2="DS3.d496.s0.e0" id="DS3.d496.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d496.s1" origId="9950818-13" text="These results indicate that 1) polyamine depletion is associated with an increase in AP-1 binding activity and 2) the increase in AP-1 activity in the DFMO-treated cells was primarily contributed by an increase in the JunD/AP-1.">
            <entity id="DS3.d496.s1.e0" origId="3009" charOffset="151-155" type="compound" text="DFMO"/>
            <entity id="DS3.d496.s1.e1" origId="P52909" charOffset="218-222" type="protein" text="JunD"/>
            <pair e1="DS3.d496.s1.e0" e2="DS3.d496.s1.e1" id="DS3.d496.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d496.s2" origId="9950818-9" text="There were significant increases in JunD mRNA and protein in DFMO-treated cells, although expression of the c-Fos, c-jun, and JunB genes decreased.">
            <entity id="DS3.d496.s2.e0" origId="P52909" charOffset="36-40" type="protein" text="JunD"/>
            <entity id="DS3.d496.s2.e1" origId="3009" charOffset="61-65" type="compound" text="DFMO"/>
            <entity id="DS3.d496.s2.e2" origId="P12841" charOffset="110-113" type="protein" text="Fos"/>
            <entity id="DS3.d496.s2.e3" origId="P24898,A0A0G2JSY8" charOffset="126-130" type="protein" text="JunB"/>
            <pair e1="DS3.d496.s2.e1" e2="DS3.d496.s2.e3" id="DS3.d496.s2.i0" interaction="False" />
            <pair e1="DS3.d496.s2.e1" e2="DS3.d496.s2.e0" id="DS3.d496.s2.i1" interaction="False" />
            <pair e1="DS3.d496.s2.e1" e2="DS3.d496.s2.e2" id="DS3.d496.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d497" origId="9950819">
        <sentence id="DS3.d497.s0" origId="9950819-9" text="A1R immunoreactivity colocalized in synaptophysin-immunoreactive presynaptic varicose nerve terminals.">
            <entity id="DS3.d497.s0.e0" origId="6918639" charOffset="0-3" type="compound" text="A1R"/>
            <entity id="DS3.d497.s0.e1" origId="H0V8Y9" charOffset="36-49" type="protein" text="synaptophysin"/>
            <pair e1="DS3.d497.s0.e0" e2="DS3.d497.s0.e1" id="DS3.d497.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d498" origId="9950821">
        <sentence id="DS3.d498.s0" origId="9950821-3" text="In acinar cells superfused with a physiological salt solution (145 mM Na+), Na+/H+ exchanger activity was inhibited by low concentrations of the amiloride derivative ethylisopropyl amiloride (EIPA; IC50 = 0.014 +/- 0.005 microM), suggesting the expression of amiloride-sensitive isoforms NHE1 and/or NHE2.">
            <entity id="DS3.d498.s0.e0" origId="16231" charOffset="145-154" type="compound" text="amiloride"/>
            <entity id="DS3.d498.s0.e1" origId="138194" charOffset="166-180" type="compound" text="ethylisopropyl"/>
            <entity id="DS3.d498.s0.e2" origId="16231" charOffset="181-190" type="compound" text="amiloride"/>
            <entity id="DS3.d498.s0.e3" origId="1795" charOffset="192-196" type="compound" text="EIPA"/>
            <entity id="DS3.d498.s0.e4" origId="16231" charOffset="181-190" type="compound" text="amiloride"/>
            <entity id="DS3.d498.s0.e5" origId="P26431" charOffset="288-292" type="protein" text="NHE1"/>
            <entity id="DS3.d498.s0.e6" origId="P48763" charOffset="300-304" type="protein" text="NHE2"/>
            <pair e1="DS3.d498.s0.e3" e2="DS3.d498.s0.e5" id="DS3.d498.s0.i0" interaction="False" />
            <pair e1="DS3.d498.s0.e3" e2="DS3.d498.s0.e6" id="DS3.d498.s0.i1" interaction="False" />
            <pair e1="DS3.d498.s0.e1" e2="DS3.d498.s0.e5" id="DS3.d498.s0.i2" interaction="False" />
            <pair e1="DS3.d498.s0.e1" e2="DS3.d498.s0.e6" id="DS3.d498.s0.i3" interaction="False" />
            <pair e1="DS3.d498.s0.e0" e2="DS3.d498.s0.e5" id="DS3.d498.s0.i4" interaction="False" />
            <pair e1="DS3.d498.s0.e0" e2="DS3.d498.s0.e6" id="DS3.d498.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d498.s1" origId="9950821-6" text="Ductal cells were about one order of magnitude more resistant to EIPA (IC50 = 0.754 +/- 0.104 microM) than cell lines expressing NHE1 or NHE2 (IC50 = 0.076 +/- 0.013 or 0.055 +/- 0.015 microM, respectively).">
            <entity id="DS3.d498.s1.e0" origId="1795" charOffset="65-69" type="compound" text="EIPA"/>
            <entity id="DS3.d498.s1.e1" origId="P26431" charOffset="129-133" type="protein" text="NHE1"/>
            <entity id="DS3.d498.s1.e2" origId="P48763" charOffset="137-141" type="protein" text="NHE2"/>
            <pair e1="DS3.d498.s1.e0" e2="DS3.d498.s1.e1" id="DS3.d498.s1.i0" interaction="False" />
            <pair e1="DS3.d498.s1.e0" e2="DS3.d498.s1.e2" id="DS3.d498.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d498.s2" origId="9950821-7" text="Conversely, ductal cells were nearly one order of magnitude more sensitive to EIPA than a cell line expressing the NHE3 isoform (IC50 = 6.25 +/- 1.89 microM).">
            <entity id="DS3.d498.s2.e0" origId="1795" charOffset="78-82" type="compound" text="EIPA"/>
            <entity id="DS3.d498.s2.e1" origId="P26433,G3V7Y7" charOffset="115-119" type="protein" text="NHE3"/>
            <pair e1="DS3.d498.s2.e0" e2="DS3.d498.s2.e1" id="DS3.d498.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d499" origId="9950824">
        <sentence id="DS3.d499.s0" origId="9950824-12" text="Glucocorticoid receptor-specific amounts of RU-28362 in combination with mineralocorticoid receptor-specific amounts of aldosterone or of the mineralocorticoid antagonist spironolactone showed cooperative action, suggesting a heterodimeric activation of JNa by the glucocorticoid receptor and mineralocorticoid receptor.">
            <entity id="DS3.d499.s0.e0" origId="123790" charOffset="44-52" type="compound" text="RU-28362"/>
            <entity id="DS3.d499.s0.e1" origId="P22199" charOffset="73-99" type="protein" text="mineralocorticoid receptor"/>
            <entity id="DS3.d499.s0.e2" origId="5833" charOffset="171-185" type="compound" text="spironolactone"/>
            <entity id="DS3.d499.s0.e3" origId="P22199" charOffset="293-319" type="protein" text="mineralocorticoid receptor"/>
            <pair e1="DS3.d499.s0.e2" e2="DS3.d499.s0.e1" id="DS3.d499.s0.i0" interaction="False" />
            <pair e1="DS3.d499.s0.e0" e2="DS3.d499.s0.e1" id="DS3.d499.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d500" origId="9950829">
        <sentence id="DS3.d500.s0" origId="9950829-3" text="HOE-694 inhibition studies establish that 25 microM HOE-694-sensitive (NHE2) and 25 microM HOE-694-insensitive (NHE3) Na+/H+ exchange activities are present in AMV of both proximal and distal colon of normal rats.">
            <entity id="DS3.d500.s0.e0" origId="123841" charOffset="0-7" type="compound" text="HOE-694"/>
            <entity id="DS3.d500.s0.e1" origId="123841" charOffset="52-59" type="compound" text="HOE-694"/>
            <entity id="DS3.d500.s0.e2" origId="P48763" charOffset="71-75" type="protein" text="NHE2"/>
            <entity id="DS3.d500.s0.e3" origId="123841" charOffset="52-59" type="compound" text="HOE-694"/>
            <entity id="DS3.d500.s0.e4" origId="P26433,G3V7Y7" charOffset="112-116" type="protein" text="NHE3"/>
            <pair e1="DS3.d500.s0.e0" e2="DS3.d500.s0.e4" id="DS3.d500.s0.i0" interaction="False" />
            <pair e1="DS3.d500.s0.e0" e2="DS3.d500.s0.e2" id="DS3.d500.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d500.s1" origId="9950829-4" text="In proximal colon, dietary sodium depletion enhanced both NHE2 and NHE3 isoform-specific Na+/H+ exchange activities, protein expression, and mRNA abundance.">
            <entity id="DS3.d500.s1.e0" origId="5360545" charOffset="27-33" type="compound" text="sodium"/>
            <entity id="DS3.d500.s1.e1" origId="P48763" charOffset="58-62" type="protein" text="NHE2"/>
            <entity id="DS3.d500.s1.e2" origId="P26433,G3V7Y7" charOffset="67-71" type="protein" text="NHE3"/>
            <pair e1="DS3.d500.s1.e0" e2="DS3.d500.s1.e2" id="DS3.d500.s1.i0" interaction="False" />
            <pair e1="DS3.d500.s1.e0" e2="DS3.d500.s1.e1" id="DS3.d500.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d500.s2" origId="9950829-5" text="In contrast, in distal colon both NHE2 and NHE3 isoform-specific Na+/H+ exchange activities, protein expression, and mRNA abundance were inhibited by sodium depletion.">
            <entity id="DS3.d500.s2.e0" origId="P48763" charOffset="34-38" type="protein" text="NHE2"/>
            <entity id="DS3.d500.s2.e1" origId="P26433,G3V7Y7" charOffset="43-47" type="protein" text="NHE3"/>
            <entity id="DS3.d500.s2.e2" origId="5360545" charOffset="150-156" type="compound" text="sodium"/>
            <pair e1="DS3.d500.s2.e2" e2="DS3.d500.s2.e1" id="DS3.d500.s2.i0" interaction="False" />
            <pair e1="DS3.d500.s2.e2" e2="DS3.d500.s2.e0" id="DS3.d500.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d500.s3" origId="9950829-6" text="NHE1 isoform-specific mRNA abundance in proximal or distal colon was not altered by sodium depletion.">
            <entity id="DS3.d500.s3.e0" origId="P26431" charOffset="0-4" type="protein" text="NHE1"/>
            <entity id="DS3.d500.s3.e1" origId="5360545" charOffset="84-90" type="compound" text="sodium"/>
            <pair e1="DS3.d500.s3.e1" e2="DS3.d500.s3.e0" id="DS3.d500.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d501" origId="9950830">
        <sentence id="DS3.d501.s0" origId="9950830-5" text="PYY antibody (anti-PYY) at a dose of 0.5 mg/kg or CCK-A receptor antagonist (devazepide) at a dose of 0.1 mg/kg was administered alone or in combination 10 min before the proximal half of the gut was perfused with 60 mM oleate or buffer.">
            <entity id="DS3.d501.s0.e0" origId="Q5D0K2" charOffset="50-64" type="protein" text="CCK-A receptor"/>
            <entity id="DS3.d501.s0.e1" origId="443375" charOffset="77-87" type="compound" text="devazepide"/>
            <entity id="DS3.d501.s0.e2" origId="445639" charOffset="220-226" type="compound" text="oleate"/>
            <pair e1="DS3.d501.s0.e2" e2="DS3.d501.s0.e0" id="DS3.d501.s0.i0" interaction="False" />
            <pair e1="DS3.d501.s0.e1" e2="DS3.d501.s0.e0" id="DS3.d501.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d502" origId="9950831">
        <sentence id="DS3.d502.s0" origId="9950831-11" text="In conclusion, these studies demonstrated that decreased sodium-dependent bile salt uptake in female hepatocytes was due to decreased membrane lipid fluidity and a selective decrease in Ntcp.">
            <entity id="DS3.d502.s0.e0" origId="5360545" charOffset="57-63" type="compound" text="sodium"/>
            <entity id="DS3.d502.s0.e1" origId="P26435" charOffset="186-190" type="protein" text="Ntcp"/>
            <pair e1="DS3.d502.s0.e0" e2="DS3.d502.s0.e1" id="DS3.d502.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d502.s1" origId="9950831-9" text="In females, expression of the sodium-dependent taurocholate peptide (Ntcp) and mRNA were selectively decreased to 46 +/- 9 and 54 +/- 4% (P &amp;lt; 0.01), respectively, and the organic anion transporter peptide (Oatp) and Na+-K+-ATPase alpha-subunit were not significantly different.">
            <entity id="DS3.d502.s1.e0" origId="5360545" charOffset="30-36" type="compound" text="sodium"/>
            <entity id="DS3.d502.s1.e1" origId="6675" charOffset="47-59" type="compound" text="taurocholate"/>
            <entity id="DS3.d502.s1.e2" origId="P26435" charOffset="69-73" type="protein" text="Ntcp"/>
            <pair e1="DS3.d502.s1.e1" e2="DS3.d502.s1.e2" id="DS3.d502.s1.i0" interaction="False" />
            <pair e1="DS3.d502.s1.e0" e2="DS3.d502.s1.e2" id="DS3.d502.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d503" origId="9950832">
        <sentence id="DS3.d503.s0" origId="9950832-0" text="Adenosine A1 receptor-mediated antiadrenergic effects are modulated by A2a receptor activation in rat heart.">
            <entity id="DS3.d503.s0.e0" origId="P25099" charOffset="0-21" type="protein" text="Adenosine A1 receptor"/>
            <entity id="DS3.d503.s0.e1" origId="11618368" charOffset="71-74" type="compound" text="A2a"/>
            <pair e1="DS3.d503.s0.e1" e2="DS3.d503.s0.e0" id="DS3.d503.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d504" origId="9950834">
        <sentence id="DS3.d504.s0" origId="9950834-1" text="The aim of this project was to investigate the role of ETA and ETB receptors in the mediation of endothelin (ET)-1-induced vasoconstriction in human skin.">
            <entity id="DS3.d504.s0.e0" origId="P25101" charOffset="55-58" type="protein" text="ETA"/>
            <entity id="DS3.d504.s0.e1" origId="44284481" charOffset="97-107" type="compound" text="endothelin"/>
            <pair e1="DS3.d504.s0.e1" e2="DS3.d504.s0.e0" id="DS3.d504.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d504.s1" origId="9950834-4" text="It was observed that ET-1 (10(-10) to 10(-8) M) and norepinephrine (NE, 10(-8) to 10(-5) M) caused skin vasoconstriction in a concentration-dependent manner, with the vasoconstrictor potency of ET-1 approximately 200-fold higher than NE.">
            <entity id="DS3.d504.s1.e0" origId="P05305,Q6FH53" charOffset="21-25" type="protein" text="ET-1"/>
            <entity id="DS3.d504.s1.e1" origId="439260" charOffset="52-66" type="compound" text="norepinephrine"/>
            <entity id="DS3.d504.s1.e2" origId="P05305,Q6FH53" charOffset="194-198" type="protein" text="ET-1"/>
            <pair e1="DS3.d504.s1.e1" e2="DS3.d504.s1.e0" id="DS3.d504.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d504.s2" origId="9950834-5" text="The ETA-receptor antagonist BQ-123 but not the ETB-receptor antagonist BQ-788 blocked the vasoconstrictor effect of ET-1.">
            <entity id="DS3.d504.s2.e0" origId="P25101" charOffset="4-7" type="protein" text="ETA"/>
            <entity id="DS3.d504.s2.e1" origId="16219006,443289,52943236" charOffset="28-34" type="compound" text="BQ-123"/>
            <entity id="DS3.d504.s2.e2" origId="5311032,44283453" charOffset="71-77" type="compound" text="BQ-788"/>
            <entity id="DS3.d504.s2.e3" origId="P05305,Q6FH53" charOffset="116-120" type="protein" text="ET-1"/>
            <pair e1="DS3.d504.s2.e2" e2="DS3.d504.s2.e3" id="DS3.d504.s2.i0" interaction="False" />
            <pair e1="DS3.d504.s2.e2" e2="DS3.d504.s2.e0" id="DS3.d504.s2.i1" interaction="False" />
            <pair e1="DS3.d504.s2.e1" e2="DS3.d504.s2.e3" id="DS3.d504.s2.i2" interaction="False" />
            <pair e1="DS3.d504.s2.e1" e2="DS3.d504.s2.e0" id="DS3.d504.s2.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d505" origId="9950836">
        <sentence id="DS3.d505.s0" origId="9950836-0" text="Metabolism of cAMP to adenosine: role in vasodilation of rat pial artery in response to hypotension.">
            <entity id="DS3.d505.s0.e0" origId="G3V8S9" charOffset="14-18" type="protein" text="cAMP"/>
            <entity id="DS3.d505.s0.e1" origId="57476835,60961" charOffset="22-31" type="compound" text="adenosine"/>
            <pair e1="DS3.d505.s0.e1" e2="DS3.d505.s0.e0" id="DS3.d505.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d505.s1" origId="9950836-1" text="The purpose of this experiment was to examine whether the cAMP-adenosine pathway is implicated in the autoregulatory vasodilation in response to hypotension.">
            <entity id="DS3.d505.s1.e0" origId="G3V8S9" charOffset="58-62" type="protein" text="cAMP"/>
            <entity id="DS3.d505.s1.e1" origId="57476835,60961" charOffset="63-72" type="compound" text="adenosine"/>
            <pair e1="DS3.d505.s1.e1" e2="DS3.d505.s1.e0" id="DS3.d505.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d505.s2" origId="9950836-2" text="Suffusion with cAMP (1-100 micromol/l) or adenosine (0.01-10 micromol/l) caused a sustained vasodilation of the resting pial arteries in a concentration-dependent manner.">
            <entity id="DS3.d505.s2.e0" origId="G3V8S9" charOffset="15-19" type="protein" text="cAMP"/>
            <entity id="DS3.d505.s2.e1" origId="57476835,60961" charOffset="42-51" type="compound" text="adenosine"/>
            <pair e1="DS3.d505.s2.e1" e2="DS3.d505.s2.e0" id="DS3.d505.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d505.s3" origId="9950836-4" text="The vasodilation to cAMP (1-100 micromol/l), adenosine (0.01-10 micromol/l), and hypotension was significantly reduced by pretreatment with 3,7-dimethyl-1-propargylxanthine (1 micromol/l), an A2 receptor antagonist, as well as 3-isobutyl-1-methylxanthine (3 micromol/l), an inhibitor of endo- and ectophosphodiesterase, 1, 3-dipropyl-8-p-sulfophenylxanthine (100 micromol/l), an inhibitor of ecto-5'-phosphodiesterase, or alpha,beta-methylene-adenosine 5'-diphosphate (100 micromol/l), an inhibitor of ecto-5'-nucleotidase.">
            <entity id="DS3.d505.s3.e0" origId="G3V8S9" charOffset="20-24" type="protein" text="cAMP"/>
            <entity id="DS3.d505.s3.e1" origId="57476835,60961" charOffset="45-54" type="compound" text="adenosine"/>
            <entity id="DS3.d505.s3.e2" origId="99562" charOffset="140-172" type="compound" text="3,7-dimethyl-1-propargylxanthine"/>
            <entity id="DS3.d505.s3.e3" origId="3758" charOffset="227-254" type="compound" text="3-isobutyl-1-methylxanthine"/>
            <entity id="DS3.d505.s3.e4" origId="88042895" charOffset="336-357" type="compound" text="p-sulfophenylxanthine"/>
            <entity id="DS3.d505.s3.e5" origId="123164" charOffset="433-442" type="compound" text="methylene"/>
            <entity id="DS3.d505.s3.e6" origId="57476835,60961" charOffset="443-452" type="compound" text="adenosine"/>
            <entity id="DS3.d505.s3.e7" origId="644102" charOffset="456-467" type="compound" text="diphosphate"/>
            <pair e1="DS3.d505.s3.e7" e2="DS3.d505.s3.e0" id="DS3.d505.s3.i0" interaction="False" />
            <pair e1="DS3.d505.s3.e4" e2="DS3.d505.s3.e0" id="DS3.d505.s3.i1" interaction="False" />
            <pair e1="DS3.d505.s3.e1" e2="DS3.d505.s3.e0" id="DS3.d505.s3.i2" interaction="False" />
            <pair e1="DS3.d505.s3.e5" e2="DS3.d505.s3.e0" id="DS3.d505.s3.i3" interaction="False" />
            <pair e1="DS3.d505.s3.e3" e2="DS3.d505.s3.e0" id="DS3.d505.s3.i4" interaction="False" />
            <pair e1="DS3.d505.s3.e2" e2="DS3.d505.s3.e0" id="DS3.d505.s3.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d505.s4" origId="9950836-6" text="The increased release of adenosine when the cortical surface was suffused with cAMP (100 micromol/l) was significantly reduced by 3-isobutyl-1-methylxanthine, 1,3-dipropyl-8-p-sulfophenylxanthine, and alpha,beta-methylene-adenosine 5'-diphosphate (each 100 micromol/l).">
            <entity id="DS3.d505.s4.e0" origId="57476835,60961" charOffset="25-34" type="compound" text="adenosine"/>
            <entity id="DS3.d505.s4.e1" origId="G3V8S9" charOffset="79-83" type="protein" text="cAMP"/>
            <entity id="DS3.d505.s4.e2" origId="3758" charOffset="130-157" type="compound" text="3-isobutyl-1-methylxanthine"/>
            <entity id="DS3.d505.s4.e3" origId="1330" charOffset="159-195" type="compound" text="1,3-dipropyl-8-p-sulfophenylxanthine"/>
            <entity id="DS3.d505.s4.e4" origId="123164" charOffset="212-221" type="compound" text="methylene"/>
            <entity id="DS3.d505.s4.e5" origId="57476835,60961" charOffset="222-231" type="compound" text="adenosine"/>
            <entity id="DS3.d505.s4.e6" origId="644102" charOffset="235-246" type="compound" text="diphosphate"/>
            <pair e1="DS3.d505.s4.e6" e2="DS3.d505.s4.e1" id="DS3.d505.s4.i0" interaction="False" />
            <pair e1="DS3.d505.s4.e3" e2="DS3.d505.s4.e1" id="DS3.d505.s4.i1" interaction="False" />
            <pair e1="DS3.d505.s4.e4" e2="DS3.d505.s4.e1" id="DS3.d505.s4.i2" interaction="False" />
            <pair e1="DS3.d505.s4.e2" e2="DS3.d505.s4.e1" id="DS3.d505.s4.i3" interaction="False" />
            <pair e1="DS3.d505.s4.e0" e2="DS3.d505.s4.e1" id="DS3.d505.s4.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d505.s5" origId="9950836-7" text="These results indicate that the cAMP-adenosine pathway as a viable metabolic mechanism is implicated in the production of adenosine in the rat pial artery and contributes to the regulation of vasodilation in response to hypotension.">
            <entity id="DS3.d505.s5.e0" origId="G3V8S9" charOffset="32-36" type="protein" text="cAMP"/>
            <entity id="DS3.d505.s5.e1" origId="57476835,60961" charOffset="37-46" type="compound" text="adenosine"/>
            <entity id="DS3.d505.s5.e2" origId="57476835,60961" charOffset="122-131" type="compound" text="adenosine"/>
            <pair e1="DS3.d505.s5.e1" e2="DS3.d505.s5.e0" id="DS3.d505.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d506" origId="9950848">
        <sentence id="DS3.d506.s0" origId="9950848-1" text="Current evidence suggests that nitric oxide (NO) and vasodilating prostanoids, possibly via the actions of cGMP and cAMP, play permissive roles in hypercapnic cerebral vasodilation.">
            <entity id="DS3.d506.s0.e0" origId="145068" charOffset="31-43" type="compound" text="nitric oxide"/>
            <entity id="DS3.d506.s0.e1" origId="G3V8S9" charOffset="116-120" type="protein" text="cAMP"/>
            <pair e1="DS3.d506.s0.e0" e2="DS3.d506.s0.e1" id="DS3.d506.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d506.s1" origId="9950848-4" text="Also, we measured cGMP and cAMP contents in primary neuronal and astrocyte cultures, at different levels of CO2.">
            <entity id="DS3.d506.s1.e0" origId="G3V8S9" charOffset="27-31" type="protein" text="cAMP"/>
            <entity id="DS3.d506.s1.e1" origId="280" charOffset="108-111" type="compound" text="CO2"/>
            <pair e1="DS3.d506.s1.e1" e2="DS3.d506.s1.e0" id="DS3.d506.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d506.s2" origId="9950848-6" text="Inhibition of nNOS with 7-nitroindazole (7-NI) significantly reduced both the CO2-induced arteriolar dilation (by 77%) and the pCSF cGMP and cAMP increases (by 60-70%).">
            <entity id="DS3.d506.s2.e0" origId="P29476,D3ZEW7" charOffset="14-18" type="protein" text="nNOS"/>
            <entity id="DS3.d506.s2.e1" origId="1893" charOffset="24-39" type="compound" text="7-nitroindazole"/>
            <entity id="DS3.d506.s2.e2" origId="280" charOffset="78-81" type="compound" text="CO2"/>
            <entity id="DS3.d506.s2.e3" origId="G3V8S9" charOffset="141-145" type="protein" text="cAMP"/>
            <pair e1="DS3.d506.s2.e2" e2="DS3.d506.s2.e3" id="DS3.d506.s2.i0" interaction="False" />
            <pair e1="DS3.d506.s2.e2" e2="DS3.d506.s2.e0" id="DS3.d506.s2.i1" interaction="False" />
            <pair e1="DS3.d506.s2.e1" e2="DS3.d506.s2.e3" id="DS3.d506.s2.i2" interaction="False" />
            <pair e1="DS3.d506.s2.e1" e2="DS3.d506.s2.e0" id="DS3.d506.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d506.s3" origId="9950848-8" text="In neuronal cultures a transient NO-dependent increase in cGMP, but not cAMP, was seen when the CO2 level was raised from 5 to 14%.">
            <entity id="DS3.d506.s3.e0" origId="G3V8S9" charOffset="72-76" type="protein" text="cAMP"/>
            <entity id="DS3.d506.s3.e1" origId="280" charOffset="96-99" type="compound" text="CO2"/>
            <pair e1="DS3.d506.s3.e1" e2="DS3.d506.s3.e0" id="DS3.d506.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d507" origId="9950850">
        <sentence id="DS3.d507.s0" origId="9950850-9" text="We suggest that pyruvate may inhibit the MPT by decreasing pHi and scavenging free radicals, thus protecting hearts from reperfusion injury.">
            <entity id="DS3.d507.s0.e0" origId="1060" charOffset="16-24" type="compound" text="pyruvate"/>
            <entity id="DS3.d507.s0.e1" origId="Q6P6V0" charOffset="59-62" type="protein" text="pHi"/>
            <pair e1="DS3.d507.s0.e0" e2="DS3.d507.s0.e1" id="DS3.d507.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d508" origId="9950853">
        <sentence id="DS3.d508.s0" origId="9950853-5" text="To test this hypothesis, we used dual-label quantitative autoradiography (QAR) to measure extracellular fluid volume (thetaec) and intravascular volume (thetaiv) in the AAM of rats within the Pip range from -2.8 to +8 mmHg.">
            <entity id="DS3.d508.s0.e0" origId="46892845" charOffset="74-77" type="compound" text="QAR"/>
            <entity id="DS3.d508.s0.e1" origId="O70417" charOffset="192-195" type="protein" text="Pip"/>
            <pair e1="DS3.d508.s0.e0" e2="DS3.d508.s0.e1" id="DS3.d508.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d509" origId="9950855">
        <sentence id="DS3.d509.s0" origId="9950855-0" text="Role of phospholipase C, protein kinase C, and calcium in VEGF-induced venular hyperpermeability.">
            <entity id="DS3.d509.s0.e0" origId="22044544,5460341" charOffset="47-54" type="compound" text="calcium"/>
            <entity id="DS3.d509.s0.e1" origId="P15692,A0A024RD37,A0A024RD33,A2A2V4" charOffset="58-62" type="protein" text="VEGF"/>
            <pair e1="DS3.d509.s0.e0" e2="DS3.d509.s0.e1" id="DS3.d509.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d509.s1" origId="9950855-1" text="We previously demonstrated that vascular endothelial growth factor (VEGF)-elicited increase in the permeability of coronary venules was blocked by the nitric oxide (NO) synthase inhibitor NG-monomethyl-L-arginine (L-NMMA).">
            <entity id="DS3.d509.s1.e0" origId="P15692,A0A024RD37,A0A024RD33,A2A2V4" charOffset="32-66" type="protein" text="vascular endothelial growth factor"/>
            <entity id="DS3.d509.s1.e1" origId="P15692,A0A024RD37,A0A024RD33,A2A2V4" charOffset="68-72" type="protein" text="VEGF"/>
            <entity id="DS3.d509.s1.e2" origId="145068" charOffset="151-163" type="compound" text="nitric oxide"/>
            <entity id="DS3.d509.s1.e3" origId="4366" charOffset="188-212" type="compound" text="NG-monomethyl-L-arginine"/>
            <entity id="DS3.d509.s1.e4" origId="132862" charOffset="214-220" type="compound" text="L-NMMA"/>
            <pair e1="DS3.d509.s1.e2" e2="DS3.d509.s1.e0" id="DS3.d509.s1.i0" interaction="False" />
            <pair e1="DS3.d509.s1.e2" e2="DS3.d509.s1.e1" id="DS3.d509.s1.i1" interaction="False" />
            <pair e1="DS3.d509.s1.e3" e2="DS3.d509.s1.e0" id="DS3.d509.s1.i2" interaction="False" />
            <pair e1="DS3.d509.s1.e3" e2="DS3.d509.s1.e1" id="DS3.d509.s1.i3" interaction="False" />
            <pair e1="DS3.d509.s1.e4" e2="DS3.d509.s1.e0" id="DS3.d509.s1.i4" interaction="False" />
            <pair e1="DS3.d509.s1.e4" e2="DS3.d509.s1.e1" id="DS3.d509.s1.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d509.s2" origId="9950855-4" text="VEGF (10(-10) M) induced a two- to threefold increase in Pa, which was blocked by a monoclonal antibody directed against the VEGF receptor Flk-1/KDR, the phospholipase C (PLC) antagonist U-73122, or the protein kinase C (PKC) antagonist bisindolylmaleimide (BIM).">
            <entity id="DS3.d509.s2.e0" origId="P15692,A0A024RD37,A0A024RD33,A2A2V4" charOffset="0-4" type="protein" text="VEGF"/>
            <entity id="DS3.d509.s2.e1" origId="P15692,A0A024RD37,A0A024RD33,A2A2V4" charOffset="125-129" type="protein" text="VEGF"/>
            <entity id="DS3.d509.s2.e2" origId="P35968,A0A024RD88" charOffset="139-144" type="protein" text="Flk-1"/>
            <entity id="DS3.d509.s2.e3" origId="P35968,A0A024RD88" charOffset="145-148" type="protein" text="KDR"/>
            <entity id="DS3.d509.s2.e4" origId="2396" charOffset="237-256" type="compound" text="bisindolylmaleimide"/>
            <pair e1="DS3.d509.s2.e4" e2="DS3.d509.s2.e0" id="DS3.d509.s2.i0" interaction="False" />
            <pair e1="DS3.d509.s2.e4" e2="DS3.d509.s2.e3" id="DS3.d509.s2.i1" interaction="False" />
            <pair e1="DS3.d509.s2.e4" e2="DS3.d509.s2.e2" id="DS3.d509.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d509.s3" origId="9950855-5" text="In 12 venules that displayed the (Ca2+)i response to bradykinin (10(-6) M) and ionomycin (10(-6) M), only 4 vessels responded to VEGF with a transient increase in (Ca2+)i.">
            <entity id="DS3.d509.s3.e0" origId="P01042" charOffset="53-63" type="protein" text="bradykinin"/>
            <entity id="DS3.d509.s3.e1" origId="25134244,3733,5353687,6434517,6912226" charOffset="79-88" type="compound" text="ionomycin"/>
            <entity id="DS3.d509.s3.e2" origId="P15692,A0A024RD37,A0A024RD33,A2A2V4" charOffset="129-133" type="protein" text="VEGF"/>
            <pair e1="DS3.d509.s3.e1" e2="DS3.d509.s3.e2" id="DS3.d509.s3.i0" interaction="False" />
            <pair e1="DS3.d509.s3.e1" e2="DS3.d509.s3.e0" id="DS3.d509.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d509.s4" origId="9950855-6" text="Furthermore, Western blot analysis of cultured human umbilical vein endothelial cells showed that VEGF increased tyrosine phosphorylation of PLC-gamma and serine phosphorylation of endothelial constitutive NO synthase (ecNOS).">
            <entity id="DS3.d509.s4.e0" origId="P15692,A0A024RD37,A0A024RD33,A2A2V4" charOffset="98-102" type="protein" text="VEGF"/>
            <entity id="DS3.d509.s4.e1" origId="6057,90983769" charOffset="113-121" type="compound" text="tyrosine"/>
            <entity id="DS3.d509.s4.e2" origId="P29474,A0A0A0MTA6,A0S0A6" charOffset="181-217" type="protein" text="endothelial constitutive NO synthase"/>
            <entity id="DS3.d509.s4.e3" origId="P29474,A0A0A0MTA6,A0S0A6" charOffset="219-224" type="protein" text="ecNOS"/>
            <pair e1="DS3.d509.s4.e1" e2="DS3.d509.s4.e2" id="DS3.d509.s4.i0" interaction="False" />
            <pair e1="DS3.d509.s4.e1" e2="DS3.d509.s4.e0" id="DS3.d509.s4.i1" interaction="False" />
            <pair e1="DS3.d509.s4.e1" e2="DS3.d509.s4.e3" id="DS3.d509.s4.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d509.s5" origId="9950855-7" text="The hyperphosphorylation of PLC-gamma was greatly attenuated by the KDR receptor antibody and U-73122, but not by BIM or L-NMMA.">
            <entity id="DS3.d509.s5.e0" origId="P35968,A0A024RD88" charOffset="68-71" type="protein" text="KDR"/>
            <entity id="DS3.d509.s5.e1" origId="132862" charOffset="121-127" type="compound" text="L-NMMA"/>
            <pair e1="DS3.d509.s5.e1" e2="DS3.d509.s5.e0" id="DS3.d509.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d510" origId="9950856">
        <sentence id="DS3.d510.s0" origId="9950856-8" text="Pyrrolidine dithiocarbamate, an antioxidant, significantly inhibited the loss of IkappaBalpha protein from the cytoplasm and prevented NF-kappaB binding activity in the nucleus.">
            <entity id="DS3.d510.s0.e0" origId="18967899,65351" charOffset="0-27" type="compound" text="Pyrrolidine dithiocarbamate"/>
            <entity id="DS3.d510.s0.e1" origId="Q63746" charOffset="81-93" type="protein" text="IkappaBalpha"/>
            <pair e1="DS3.d510.s0.e0" e2="DS3.d510.s0.e1" id="DS3.d510.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d511" origId="9950863">
        <sentence id="DS3.d511.s0" origId="9950863-4" text="A specific ERK1/ERK2 kinase inhibitor, PD-98059, inhibited phosphorylation and activation of ERK1/ERK2 but did not inhibit the increased cell proliferation and cell alignment induced by strain.">
            <entity id="DS3.d511.s0.e0" origId="E1B8P9" charOffset="11-15" type="protein" text="ERK1"/>
            <entity id="DS3.d511.s0.e1" origId="P46196" charOffset="16-20" type="protein" text="ERK2"/>
            <entity id="DS3.d511.s0.e2" origId="53378893" charOffset="21-37" type="compound" text="kinase inhibitor"/>
            <entity id="DS3.d511.s0.e3" origId="4713" charOffset="39-47" type="compound" text="PD-98059"/>
            <entity id="DS3.d511.s0.e4" origId="E1B8P9" charOffset="93-97" type="protein" text="ERK1"/>
            <entity id="DS3.d511.s0.e5" origId="P46196" charOffset="98-102" type="protein" text="ERK2"/>
            <pair e1="DS3.d511.s0.e3" e2="DS3.d511.s0.e0" id="DS3.d511.s0.i0" interaction="False" />
            <pair e1="DS3.d511.s0.e3" e2="DS3.d511.s0.e1" id="DS3.d511.s0.i1" interaction="False" />
            <pair e1="DS3.d511.s0.e2" e2="DS3.d511.s0.e0" id="DS3.d511.s0.i2" interaction="False" />
            <pair e1="DS3.d511.s0.e2" e2="DS3.d511.s0.e1" id="DS3.d511.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d511.s1" origId="9950863-5" text="Treatment of BAEC with 2,5-di-tert-butyl-1, 4-benzohydroquinone, to deplete inositol trisphosphate-sensitive calcium storage, and gadolinium chloride, a Ca2+ channel blocker, did not inhibit the activation of ERK1/ERK2.">
            <entity id="DS3.d511.s1.e0" origId="90937099" charOffset="30-40" type="compound" text="tert-butyl"/>
            <entity id="DS3.d511.s1.e1" origId="892" charOffset="76-84" type="compound" text="inositol"/>
            <entity id="DS3.d511.s1.e2" origId="19432134" charOffset="85-98" type="compound" text="trisphosphate"/>
            <entity id="DS3.d511.s1.e3" origId="22044544,5460341" charOffset="109-116" type="compound" text="calcium"/>
            <entity id="DS3.d511.s1.e4" origId="61486" charOffset="130-149" type="compound" text="gadolinium chloride"/>
            <entity id="DS3.d511.s1.e5" origId="E1B8P9" charOffset="209-213" type="protein" text="ERK1"/>
            <entity id="DS3.d511.s1.e6" origId="P46196" charOffset="214-218" type="protein" text="ERK2"/>
            <pair e1="DS3.d511.s1.e3" e2="DS3.d511.s1.e5" id="DS3.d511.s1.i0" interaction="False" />
            <pair e1="DS3.d511.s1.e3" e2="DS3.d511.s1.e6" id="DS3.d511.s1.i1" interaction="False" />
            <pair e1="DS3.d511.s1.e0" e2="DS3.d511.s1.e5" id="DS3.d511.s1.i2" interaction="False" />
            <pair e1="DS3.d511.s1.e0" e2="DS3.d511.s1.e6" id="DS3.d511.s1.i3" interaction="False" />
            <pair e1="DS3.d511.s1.e1" e2="DS3.d511.s1.e5" id="DS3.d511.s1.i4" interaction="False" />
            <pair e1="DS3.d511.s1.e1" e2="DS3.d511.s1.e6" id="DS3.d511.s1.i5" interaction="False" />
            <pair e1="DS3.d511.s1.e4" e2="DS3.d511.s1.e5" id="DS3.d511.s1.i6" interaction="False" />
            <pair e1="DS3.d511.s1.e4" e2="DS3.d511.s1.e6" id="DS3.d511.s1.i7" interaction="False" />
            <pair e1="DS3.d511.s1.e2" e2="DS3.d511.s1.e5" id="DS3.d511.s1.i8" interaction="False" />
            <pair e1="DS3.d511.s1.e2" e2="DS3.d511.s1.e6" id="DS3.d511.s1.i9" interaction="False" />
        </sentence>
        <sentence id="DS3.d511.s2" origId="9950863-6" text="Strain-induced ERK1/ERK2 activation was partly inhibited by the protein kinase C inhibitor calphostin C and completely inhibited by the tyrosine kinase inhibitor genistein.">
            <entity id="DS3.d511.s2.e0" origId="E1B8P9" charOffset="15-19" type="protein" text="ERK1"/>
            <entity id="DS3.d511.s2.e1" origId="P46196" charOffset="20-24" type="protein" text="ERK2"/>
            <entity id="DS3.d511.s2.e2" origId="2533" charOffset="91-103" type="compound" text="calphostin C"/>
            <entity id="DS3.d511.s2.e3" origId="6057,90983769" charOffset="136-144" type="compound" text="tyrosine"/>
            <entity id="DS3.d511.s2.e4" origId="53378893" charOffset="145-161" type="compound" text="kinase inhibitor"/>
            <entity id="DS3.d511.s2.e5" origId="5280961" charOffset="162-171" type="compound" text="genistein"/>
            <pair e1="DS3.d511.s2.e4" e2="DS3.d511.s2.e0" id="DS3.d511.s2.i0" interaction="False" />
            <pair e1="DS3.d511.s2.e4" e2="DS3.d511.s2.e1" id="DS3.d511.s2.i1" interaction="False" />
            <pair e1="DS3.d511.s2.e5" e2="DS3.d511.s2.e0" id="DS3.d511.s2.i2" interaction="False" />
            <pair e1="DS3.d511.s2.e5" e2="DS3.d511.s2.e1" id="DS3.d511.s2.i3" interaction="False" />
            <pair e1="DS3.d511.s2.e2" e2="DS3.d511.s2.e0" id="DS3.d511.s2.i4" interaction="False" />
            <pair e1="DS3.d511.s2.e2" e2="DS3.d511.s2.e1" id="DS3.d511.s2.i5" interaction="False" />
            <pair e1="DS3.d511.s2.e3" e2="DS3.d511.s2.e0" id="DS3.d511.s2.i6" interaction="False" />
            <pair e1="DS3.d511.s2.e3" e2="DS3.d511.s2.e1" id="DS3.d511.s2.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d511.s3" origId="9950863-7" text="These data suggest that 1) ERK1/ERK2 are not critically involved in the strain-induced cell proliferation and orientation, 2) strain-dependent activation of ERK1/ERK2 is independent of intracellular and extracellular calcium mobilization, and 3) protein kinase C activation and tyrosine kinase regulate strain-induced activation of ERK1/ERK2.">
            <entity id="DS3.d511.s3.e0" origId="E1B8P9" charOffset="27-31" type="protein" text="ERK1"/>
            <entity id="DS3.d511.s3.e1" origId="P46196" charOffset="32-36" type="protein" text="ERK2"/>
            <entity id="DS3.d511.s3.e2" origId="E1B8P9" charOffset="157-161" type="protein" text="ERK1"/>
            <entity id="DS3.d511.s3.e3" origId="P46196" charOffset="162-166" type="protein" text="ERK2"/>
            <entity id="DS3.d511.s3.e4" origId="22044544,5460341" charOffset="217-224" type="compound" text="calcium"/>
            <entity id="DS3.d511.s3.e5" origId="6057,90983769" charOffset="278-286" type="compound" text="tyrosine"/>
            <entity id="DS3.d511.s3.e6" origId="E1B8P9" charOffset="157-161" type="protein" text="ERK1"/>
            <entity id="DS3.d511.s3.e7" origId="P46196" charOffset="162-166" type="protein" text="ERK2"/>
            <pair e1="DS3.d511.s3.e4" e2="DS3.d511.s3.e0" id="DS3.d511.s3.i0" interaction="False" />
            <pair e1="DS3.d511.s3.e4" e2="DS3.d511.s3.e1" id="DS3.d511.s3.i1" interaction="False" />
            <pair e1="DS3.d511.s3.e5" e2="DS3.d511.s3.e0" id="DS3.d511.s3.i2" interaction="False" />
            <pair e1="DS3.d511.s3.e5" e2="DS3.d511.s3.e1" id="DS3.d511.s3.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d512" origId="9950865">
        <sentence id="DS3.d512.s0" origId="9950865-5" text="Atropine and pirenzepine blocked both the positive and the negative effects of ACh.">
            <entity id="DS3.d512.s0.e0" origId="174174" charOffset="0-8" type="compound" text="Atropine"/>
            <entity id="DS3.d512.s0.e1" origId="4848" charOffset="13-24" type="compound" text="pirenzepine"/>
            <entity id="DS3.d512.s0.e2" origId="P22607,Q0IJ44,X5D2G8" charOffset="79-82" type="protein" text="ACh"/>
            <pair e1="DS3.d512.s0.e0" e2="DS3.d512.s0.e2" id="DS3.d512.s0.i0" interaction="False" />
            <pair e1="DS3.d512.s0.e1" e2="DS3.d512.s0.e2" id="DS3.d512.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d512.s1" origId="9950865-7" text="Infusion of 8-bromoguanosine 3', 5'-cyclic monophosphate reverted the positive effect of ACh to a negative effect.">
            <entity id="DS3.d512.s1.e0" origId="92977" charOffset="12-28" type="compound" text="8-bromoguanosine"/>
            <entity id="DS3.d512.s1.e1" origId="P22607,Q0IJ44,X5D2G8" charOffset="89-92" type="protein" text="ACh"/>
            <pair e1="DS3.d512.s1.e0" e2="DS3.d512.s1.e1" id="DS3.d512.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d513" origId="9950884">
        <sentence id="DS3.d513.s0" origId="9950884-6" text="Mice administered (Sar9,Met(O2)11)substance P, an NK1-receptor agonist, after each JP-8 exposure had the appearance of normal pulmonary values and tissue morphology.">
            <entity id="DS3.d513.s0.e0" origId="P30548" charOffset="50-62" type="protein" text="NK1-receptor"/>
            <entity id="DS3.d513.s0.e1" origId="56840896" charOffset="83-87" type="compound" text="JP-8"/>
            <pair e1="DS3.d513.s0.e1" e2="DS3.d513.s0.e0" id="DS3.d513.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d513.s1" origId="9950884-7" text="In contrast, endogenous NK1-receptor antagonism by CP-96345 administration exacerbated JP-8-enhanced permeability, alveolar macrophage toxicity, and bronchiolar epithelial injury.">
            <entity id="DS3.d513.s1.e0" origId="P30548" charOffset="24-36" type="protein" text="NK1-receptor"/>
            <entity id="DS3.d513.s1.e1" origId="56840896" charOffset="87-91" type="compound" text="JP-8"/>
            <pair e1="DS3.d513.s1.e1" e2="DS3.d513.s1.e0" id="DS3.d513.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d514" origId="9950886">
        <sentence id="DS3.d514.s0" origId="9950886-0" text="EGF activates ErbB-2 and stimulates phosphatidylinositol 3-kinase in human airway smooth muscle cells.">
            <entity id="DS3.d514.s0.e0" origId="P04626,J3QLU9,F5H1T4,X5DNK3,Q92731,Q7LCB3,F1D8N3,Q0PTK2" charOffset="14-20" type="protein" text="ErbB-2"/>
            <entity id="DS3.d514.s0.e1" origId="16738692,53477912" charOffset="36-56" type="compound" text="phosphatidylinositol"/>
            <pair e1="DS3.d514.s0.e1" e2="DS3.d514.s0.e0" id="DS3.d514.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d514.s1" origId="9950886-1" text="The epidermal growth factor (EGF)-receptor (EGFR) family includes four homologous transmembrane receptor protein tyrosine kinases, EGFR, ErbB-2, ErbB-3, and ErbB-4.">
            <entity id="DS3.d514.s1.e0" origId="6057,90983769" charOffset="113-121" type="compound" text="tyrosine"/>
            <entity id="DS3.d514.s1.e1" origId="P04626,J3QLU9,F5H1T4,X5DNK3,Q92731,Q7LCB3,F1D8N3,Q0PTK2" charOffset="137-143" type="protein" text="ErbB-2"/>
            <entity id="DS3.d514.s1.e2" origId="P21860" charOffset="145-151" type="protein" text="ErbB-3"/>
            <entity id="DS3.d514.s1.e3" origId="Q15303" charOffset="157-163" type="protein" text="ErbB-4"/>
            <pair e1="DS3.d514.s1.e0" e2="DS3.d514.s1.e1" id="DS3.d514.s1.i0" interaction="False" />
            <pair e1="DS3.d514.s1.e0" e2="DS3.d514.s1.e2" id="DS3.d514.s1.i1" interaction="False" />
            <pair e1="DS3.d514.s1.e0" e2="DS3.d514.s1.e3" id="DS3.d514.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d514.s2" origId="9950886-6" text="Phosphatidylinositol (PI) 3-kinase, a critical signaling enzyme that modulates HASM cell growth, is preferentially associated with ErbB-2, and EGF-stimulated transactivation of ErbB-2 induces PI 3-kinase activation.">
            <entity id="DS3.d514.s2.e0" origId="16738692,53477912" charOffset="0-20" type="compound" text="Phosphatidylinositol"/>
            <entity id="DS3.d514.s2.e1" origId="P04626,J3QLU9,F5H1T4,X5DNK3,Q92731,Q7LCB3,F1D8N3,Q0PTK2" charOffset="131-137" type="protein" text="ErbB-2"/>
            <entity id="DS3.d514.s2.e2" origId="P04626,J3QLU9,F5H1T4,X5DNK3,Q92731,Q7LCB3,F1D8N3,Q0PTK2" charOffset="177-183" type="protein" text="ErbB-2"/>
            <pair e1="DS3.d514.s2.e0" e2="DS3.d514.s2.e1" id="DS3.d514.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d515" origId="9950888">
        <sentence id="DS3.d515.s0" origId="9950888-5" text="NO) synthase (iNOS)-selective inhibitor aminoguanidine (AG) initiated 24 h after NNMU administration improve the survival of NNMU-treated animals.">
            <entity id="DS3.d515.s0.e0" origId="Q06518" charOffset="14-18" type="protein" text="iNOS"/>
            <entity id="DS3.d515.s0.e1" origId="2146" charOffset="40-54" type="compound" text="aminoguanidine"/>
            <pair e1="DS3.d515.s0.e1" e2="DS3.d515.s0.e0" id="DS3.d515.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d516" origId="9950892">
        <sentence id="DS3.d516.s0" origId="9950892-1" text="Endothelial nitric oxide (NO) synthase (eNOS) mRNA and protein and NO production are increased in hypoxia-induced hypertensive rat lungs, but it is uncertain whether eNOS gene expression and activity are increased in other forms of rat pulmonary hypertension.">
            <entity id="DS3.d516.s0.e0" origId="145068" charOffset="12-24" type="compound" text="nitric oxide"/>
            <entity id="DS3.d516.s0.e1" origId="Q62600,P29474,A0A0A0MTA6,A0S0A6" charOffset="40-44" type="protein" text="eNOS"/>
            <entity id="DS3.d516.s0.e2" origId="Q62600,P29474,A0A0A0MTA6,A0S0A6" charOffset="166-170" type="protein" text="eNOS"/>
            <pair e1="DS3.d516.s0.e0" e2="DS3.d516.s0.e1" id="DS3.d516.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d516.s1" origId="9950892-2" text="To investigate these questions, we measured eNOS mRNA and protein, eNOS immunohistochemical localization, perfusate NO product levels, and NO-mediated suppression of resting vascular tone in chronically hypoxic (3-4 wk at barometric pressure of 410 mmHg), monocrotaline-treated (4 wk after 60 mg/kg), and fawn-hooded (6-9 mo old) rats.">
            <entity id="DS3.d516.s1.e0" origId="Q62600,P29474,A0A0A0MTA6,A0S0A6" charOffset="44-48" type="protein" text="eNOS"/>
            <entity id="DS3.d516.s1.e1" origId="Q62600,P29474,A0A0A0MTA6,A0S0A6" charOffset="67-71" type="protein" text="eNOS"/>
            <entity id="DS3.d516.s1.e2" origId="9415" charOffset="256-269" type="compound" text="monocrotaline"/>
            <pair e1="DS3.d516.s1.e2" e2="DS3.d516.s1.e0" id="DS3.d516.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d516.s2" origId="9950892-3" text="eNOS mRNA levels (Northern blot) were greater in hypoxic and monocrotaline-treated lungs (130 and 125% of control lungs, respectively; P &amp;lt; 0.05) but not in fawn-hooded lungs.">
            <entity id="DS3.d516.s2.e0" origId="Q62600,P29474,A0A0A0MTA6,A0S0A6" charOffset="0-4" type="protein" text="eNOS"/>
            <entity id="DS3.d516.s2.e1" origId="9415" charOffset="61-74" type="compound" text="monocrotaline"/>
            <pair e1="DS3.d516.s2.e1" e2="DS3.d516.s2.e0" id="DS3.d516.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d516.s3" origId="9950892-4" text="Western blotting indicated that eNOS protein levels increased to 300 +/- 46% of control levels in hypoxic lungs (P &amp;lt; 0.05) but were decreased by 50 +/- 5 and 60 +/- 11%, respectively, in monocrotaline-treated and fawn-hooded lungs (P &amp;lt; 0.05).">
            <entity id="DS3.d516.s3.e0" origId="Q62600,P29474,A0A0A0MTA6,A0S0A6" charOffset="32-36" type="protein" text="eNOS"/>
            <entity id="DS3.d516.s3.e1" origId="9415" charOffset="190-203" type="compound" text="monocrotaline"/>
            <pair e1="DS3.d516.s3.e1" e2="DS3.d516.s3.e0" id="DS3.d516.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d516.s4" origId="9950892-5" text="Immunostaining showed prominent eNOS expression in small neomuscularized arterioles in all groups, whereas perfusate NO product levels increased in chronically hypoxic lungs (3.4 +/- 1.4 microM; P &amp;lt; 0.05) but not in either monocrotaline-treated (0.7 +/- 0.3 microM) or fawn-hooded (0.45 +/- 0.1 microM) lungs vs. normotensive lungs (0.12 +/- 0.07 microM).">
            <entity id="DS3.d516.s4.e0" origId="Q62600,P29474,A0A0A0MTA6,A0S0A6" charOffset="32-36" type="protein" text="eNOS"/>
            <entity id="DS3.d516.s4.e1" origId="9415" charOffset="226-239" type="compound" text="monocrotaline"/>
            <pair e1="DS3.d516.s4.e1" e2="DS3.d516.s4.e0" id="DS3.d516.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d517" origId="9950893">
        <sentence id="DS3.d517.s0" origId="9950893-0" text="Endothelin-1 is elevated in monocrotaline pulmonary hypertension.">
            <entity id="DS3.d517.s0.e0" origId="P22388" charOffset="0-12" type="protein" text="Endothelin-1"/>
            <entity id="DS3.d517.s0.e1" origId="9415" charOffset="28-41" type="compound" text="monocrotaline"/>
            <pair e1="DS3.d517.s0.e1" e2="DS3.d517.s0.e0" id="DS3.d517.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d517.s1" origId="9950893-4" text="MCT-injected rats developed pulmonary hypertension, right ventricular hypertrophy, and heightened pulmonary vasoconstriction to ANG II and the NOS inhibitor NG-monomethyl-L-arginine (L-NMMA).">
            <entity id="DS3.d517.s1.e0" origId="P01015" charOffset="128-134" type="protein" text="ANG II"/>
            <entity id="DS3.d517.s1.e1" origId="90867653" charOffset="173-181" type="compound" text="arginine"/>
            <entity id="DS3.d517.s1.e2" origId="132862" charOffset="183-189" type="compound" text="L-NMMA"/>
            <pair e1="DS3.d517.s1.e1" e2="DS3.d517.s1.e0" id="DS3.d517.s1.i0" interaction="False" />
            <pair e1="DS3.d517.s1.e2" e2="DS3.d517.s1.e0" id="DS3.d517.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d517.s2" origId="9950893-6" text="Pretreatment of isolated MCT-injected lungs with combined ETA (BQ-123) plus ETB (BQ-788) antagonists or ETA antagonist alone prevented the L-NMMA-induced constriction.">
            <entity id="DS3.d517.s2.e0" origId="P26684,A1Y2B8,A0A0G2JSX5" charOffset="58-61" type="protein" text="ETA"/>
            <entity id="DS3.d517.s2.e1" origId="16219006,443289,52943236" charOffset="63-69" type="compound" text="BQ-123"/>
            <entity id="DS3.d517.s2.e2" origId="P21451" charOffset="76-79" type="protein" text="ETB"/>
            <entity id="DS3.d517.s2.e3" origId="5311032,44283453" charOffset="81-87" type="compound" text="BQ-788"/>
            <entity id="DS3.d517.s2.e4" origId="P26684,A1Y2B8,A0A0G2JSX5" charOffset="104-107" type="protein" text="ETA"/>
            <entity id="DS3.d517.s2.e5" origId="132862" charOffset="139-145" type="compound" text="L-NMMA"/>
            <pair e1="DS3.d517.s2.e3" e2="DS3.d517.s2.e2" id="DS3.d517.s2.i0" interaction="False" />
            <pair e1="DS3.d517.s2.e3" e2="DS3.d517.s2.e0" id="DS3.d517.s2.i1" interaction="False" />
            <pair e1="DS3.d517.s2.e5" e2="DS3.d517.s2.e2" id="DS3.d517.s2.i2" interaction="False" />
            <pair e1="DS3.d517.s2.e5" e2="DS3.d517.s2.e0" id="DS3.d517.s2.i3" interaction="False" />
            <pair e1="DS3.d517.s2.e1" e2="DS3.d517.s2.e2" id="DS3.d517.s2.i4" interaction="False" />
            <pair e1="DS3.d517.s2.e1" e2="DS3.d517.s2.e0" id="DS3.d517.s2.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d517.s3" origId="9950893-7" text="Addition of ETA antagonist reversed established L-NMMA-induced constriction; ETB antagonist did not.">
            <entity id="DS3.d517.s3.e0" origId="P26684,A1Y2B8,A0A0G2JSX5" charOffset="12-15" type="protein" text="ETA"/>
            <entity id="DS3.d517.s3.e1" origId="132862" charOffset="48-54" type="compound" text="L-NMMA"/>
            <entity id="DS3.d517.s3.e2" origId="P21451" charOffset="77-80" type="protein" text="ETB"/>
            <pair e1="DS3.d517.s3.e1" e2="DS3.d517.s3.e2" id="DS3.d517.s3.i0" interaction="False" />
            <pair e1="DS3.d517.s3.e1" e2="DS3.d517.s3.e0" id="DS3.d517.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d518" origId="9950895">
        <sentence id="DS3.d518.s0" origId="9950895-3" text="A rat lung epithelial cell line (L2) and a glucocorticoid receptor-deficient human prostate cancer cell line (PC3), together with GS reporter gene constructs, were utilized in gene transfer experiments to identify two regions within the rat genomic clone gGS3 that imparted dexamethasone (Dex) responsiveness to both the homologous GS promoter and the heterologous herpes simplex virus thymidine kinase promoter in glucocorticoid receptor-dependent fashions.">
            <entity id="DS3.d518.s0.e0" origId="P06536" charOffset="43-66" type="protein" text="glucocorticoid receptor"/>
            <entity id="DS3.d518.s0.e1" origId="5743" charOffset="274-287" type="compound" text="dexamethasone"/>
            <entity id="DS3.d518.s0.e2" origId="5789" charOffset="386-395" type="compound" text="thymidine"/>
            <entity id="DS3.d518.s0.e3" origId="P06536" charOffset="415-438" type="protein" text="glucocorticoid receptor"/>
            <pair e1="DS3.d518.s0.e2" e2="DS3.d518.s0.e0" id="DS3.d518.s0.i0" interaction="False" />
            <pair e1="DS3.d518.s0.e1" e2="DS3.d518.s0.e0" id="DS3.d518.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d519" origId="9950898">
        <sentence id="DS3.d519.s0" origId="9950898-2" text="Vascular permeability and neutrophil accumulation were assessed by the percent area occupied by Monastral blue-labeled blood vessels and by myeloperoxidase-containing granulocytes, respectively, in whole mounts of the trachea and main bronchus.">
            <entity id="DS3.d519.s0.e0" origId="14670364" charOffset="96-110" type="compound" text="Monastral blue"/>
            <entity id="DS3.d519.s0.e1" origId="D3ZGE2,A0A0G2K1A2" charOffset="140-155" type="protein" text="myeloperoxidase"/>
            <pair e1="DS3.d519.s0.e0" e2="DS3.d519.s0.e1" id="DS3.d519.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d519.s1" origId="9950898-3" text="Intravenous PAF caused dose-dependent increases in the area density of Monastral blue-labeled vessels and neutrophil influx, and the former effect was inhibited by depletion of circulating neutrophils by cyclophosphamide or treatment with the neutrophil elastase inhibitor ONO-5046.">
            <entity id="DS3.d519.s1.e0" origId="14670364" charOffset="71-85" type="compound" text="Monastral blue"/>
            <entity id="DS3.d519.s1.e1" origId="2907" charOffset="204-220" type="compound" text="cyclophosphamide"/>
            <entity id="DS3.d519.s1.e2" origId="D4A488" charOffset="243-262" type="protein" text="neutrophil elastase"/>
            <entity id="DS3.d519.s1.e3" origId="107706" charOffset="273-281" type="compound" text="ONO-5046"/>
            <pair e1="DS3.d519.s1.e3" e2="DS3.d519.s1.e2" id="DS3.d519.s1.i0" interaction="False" />
            <pair e1="DS3.d519.s1.e0" e2="DS3.d519.s1.e2" id="DS3.d519.s1.i1" interaction="False" />
            <pair e1="DS3.d519.s1.e1" e2="DS3.d519.s1.e2" id="DS3.d519.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d519.s2" origId="9950898-6" text="PAF increased neutrophil elastase contents in bronchoalveolar lavage fluid, an effect that was inhibited by azelastine.">
            <entity id="DS3.d519.s2.e0" origId="D4A488" charOffset="14-33" type="protein" text="neutrophil elastase"/>
            <entity id="DS3.d519.s2.e1" origId="2267" charOffset="108-118" type="compound" text="azelastine"/>
            <pair e1="DS3.d519.s2.e1" e2="DS3.d519.s2.e0" id="DS3.d519.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d519.s3" origId="9950898-7" text="Therefore, azelastine attenuates PAF-induced airway mucosal microvascular leakage, probably involving inhibition of the release of neutrophil elastase from activated neutrophils.">
            <entity id="DS3.d519.s3.e0" origId="2267" charOffset="11-21" type="compound" text="azelastine"/>
            <entity id="DS3.d519.s3.e1" origId="D4A488" charOffset="131-150" type="protein" text="neutrophil elastase"/>
            <pair e1="DS3.d519.s3.e0" e2="DS3.d519.s3.e1" id="DS3.d519.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d520" origId="9950899">
        <sentence id="DS3.d520.s0" origId="9950899-1" text="To investigate whether chronic hypoxia affects endothelin-B (ETB) receptor-mediated pulmonary vasodilation, we compared the vasodilator responses to IRL-1620, a selective ETB-receptor agonist, in isolated perfused lungs from normoxic and chronically hypoxic adult male rats.">
            <entity id="DS3.d520.s0.e0" origId="44284481" charOffset="47-57" type="compound" text="endothelin"/>
            <entity id="DS3.d520.s0.e1" origId="P21451" charOffset="61-64" type="protein" text="ETB"/>
            <entity id="DS3.d520.s0.e2" origId="16133819" charOffset="149-157" type="compound" text="IRL-1620"/>
            <entity id="DS3.d520.s0.e3" origId="P21451" charOffset="171-174" type="protein" text="ETB"/>
            <pair e1="DS3.d520.s0.e0" e2="DS3.d520.s0.e1" id="DS3.d520.s0.i0" interaction="False" />
            <pair e1="DS3.d520.s0.e2" e2="DS3.d520.s0.e1" id="DS3.d520.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d521" origId="9950902">
        <sentence id="DS3.d521.s0" origId="9950902-1" text="Nitric oxide (NO), generated by NO synthase (NOS), is an important mediator of physiological processes in the airway and lung parenchyma, and there is evidence that the pulmonary expression of the endothelial isoform of NOS (eNOS) is developmentally regulated.">
            <entity id="DS3.d521.s0.e0" origId="145068" charOffset="0-12" type="compound" text="Nitric oxide"/>
            <entity id="DS3.d521.s0.e1" origId="Q4U3W6" charOffset="197-223" type="protein" text="endothelial isoform of NOS"/>
            <entity id="DS3.d521.s0.e2" origId="Q4U3W6" charOffset="225-229" type="protein" text="eNOS"/>
            <pair e1="DS3.d521.s0.e0" e2="DS3.d521.s0.e2" id="DS3.d521.s0.i0" interaction="False" />
            <pair e1="DS3.d521.s0.e0" e2="DS3.d521.s0.e1" id="DS3.d521.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d522" origId="9950908">
        <sentence id="DS3.d522.s0" origId="9950908-1" text="To provide additional support to the hypothesis that only dietary protein (Pro; chicken egg albumin) and not amino acids (AA; patterned after albumin), carbohydrates (CHO; cornstarch), or fats (Fat; corn oil) produces a satiating effect via CCK receptors, two CCK-A receptor antagonists (PD-140,548 and devazepide) were coadministered with each nutrient.">
            <entity id="DS3.d522.s0.e0" origId="24836924" charOffset="172-182" type="compound" text="cornstarch"/>
            <entity id="DS3.d522.s0.e1" origId="P30551,F1LQR7" charOffset="260-274" type="protein" text="CCK-A receptor"/>
            <entity id="DS3.d522.s0.e2" origId="9915756" charOffset="288-298" type="compound" text="PD-140,548"/>
            <entity id="DS3.d522.s0.e3" origId="443375" charOffset="303-313" type="compound" text="devazepide"/>
            <pair e1="DS3.d522.s0.e0" e2="DS3.d522.s0.e1" id="DS3.d522.s0.i0" interaction="False" />
            <pair e1="DS3.d522.s0.e3" e2="DS3.d522.s0.e1" id="DS3.d522.s0.i1" interaction="False" />
            <pair e1="DS3.d522.s0.e2" e2="DS3.d522.s0.e1" id="DS3.d522.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d523" origId="9950914">
        <sentence id="DS3.d523.s0" origId="9950914-5" text="For 13 days, one-half of the animals in each dietary group received intraperitoneal human leptin (2.5 mg/kg twice daily), while the other one-half received phosphate-buffered saline.">
            <entity id="DS3.d523.s0.e0" origId="P41159,A4D0Y8" charOffset="90-96" type="protein" text="leptin"/>
            <entity id="DS3.d523.s0.e1" origId="24978514" charOffset="156-181" type="compound" text="phosphate-buffered saline"/>
            <pair e1="DS3.d523.s0.e1" e2="DS3.d523.s0.e0" id="DS3.d523.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d524" origId="9950915">
        <sentence id="DS3.d524.s0" origId="9950915-2" text="Both outbred and inbred strains of rats that develop diet-induced obesity (DIO) or are diet resistant (DR) when fed a diet relatively high in energy, fat, and sucrose content (HE diet) were used to study arcuate NPY mRNA expression during long-term changes in energy balance.">
            <entity id="DS3.d524.s0.e0" origId="5988" charOffset="159-166" type="compound" text="sucrose"/>
            <entity id="DS3.d524.s0.e1" origId="P07808,F2W8A6" charOffset="212-215" type="protein" text="NPY"/>
            <pair e1="DS3.d524.s0.e0" e2="DS3.d524.s0.e1" id="DS3.d524.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d525" origId="9950921">
        <sentence id="DS3.d525.s0" origId="9950921-6" text="CCK and 5-HT involvement in fat-induced satiety was investigated by preceding the 80% fat infusate with CCK and/or 5-HT3 receptor antagonists Devazepide (Dev) and Tropisetron (Trop).">
            <entity id="DS3.d525.s0.e0" origId="5202" charOffset="8-12" type="compound" text="5-HT"/>
            <entity id="DS3.d525.s0.e1" origId="P35563,Q62999" charOffset="115-129" type="protein" text="5-HT3 receptor"/>
            <entity id="DS3.d525.s0.e2" origId="443375" charOffset="142-152" type="compound" text="Devazepide"/>
            <entity id="DS3.d525.s0.e3" origId="656665" charOffset="163-174" type="compound" text="Tropisetron"/>
            <pair e1="DS3.d525.s0.e0" e2="DS3.d525.s0.e1" id="DS3.d525.s0.i0" interaction="False" />
            <pair e1="DS3.d525.s0.e3" e2="DS3.d525.s0.e1" id="DS3.d525.s0.i1" interaction="False" />
            <pair e1="DS3.d525.s0.e2" e2="DS3.d525.s0.e1" id="DS3.d525.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d526" origId="9950924">
        <sentence id="DS3.d526.s0" origId="9950924-0" text="Arginine vasopressin does not mediate the attenuated febrile response to intravenous IL-1beta in pregnant rats.">
            <entity id="DS3.d526.s0.e0" origId="6322,90867653" charOffset="0-8" type="compound" text="Arginine"/>
            <entity id="DS3.d526.s0.e1" origId="Q5BKB0" charOffset="85-93" type="protein" text="IL-1beta"/>
            <pair e1="DS3.d526.s0.e0" e2="DS3.d526.s0.e1" id="DS3.d526.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d527" origId="9950928">
        <sentence id="DS3.d527.s0" origId="9950928-10" text="While L-NMMA did block the exercise-induced increase in cytolysis, exercise did not increase NO-2 or iNOS gene expression in the old mice, indicating perhaps the contribution of other cytolytic mechanisms in old mice.">
            <entity id="DS3.d527.s0.e0" origId="132862" charOffset="6-12" type="compound" text="L-NMMA"/>
            <entity id="DS3.d527.s0.e1" origId="P29477" charOffset="101-105" type="protein" text="iNOS"/>
            <pair e1="DS3.d527.s0.e0" e2="DS3.d527.s0.e1" id="DS3.d527.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d527.s1" origId="9950928-1" text="In this study, we determined the effects of age and chronic treadmill running (16 wk; 5 days/wk; 45 min/day; 18-22 m/min) on resident peritoneal macrophage responsiveness to interferon-gamma (IFN-gamma) and lipopolysaccharide (LPS) in young (6 mo) and aged (22 mo) male BALB/cByJ mice by measuring cytolytic ability and production of reactive nitrogen products.">
            <entity id="DS3.d527.s1.e0" origId="P01580" charOffset="174-190" type="protein" text="interferon-gamma"/>
            <entity id="DS3.d527.s1.e1" origId="P01580" charOffset="192-201" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d527.s1.e2" origId="Q9QUK6,L0CL36" charOffset="207-225" type="protein" text="lipopolysaccharide"/>
            <entity id="DS3.d527.s1.e3" origId="Q9QUK6,L0CL36" charOffset="227-230" type="protein" text="LPS"/>
            <entity id="DS3.d527.s1.e4" origId="947" charOffset="343-351" type="compound" text="nitrogen"/>
            <pair e1="DS3.d527.s1.e4" e2="DS3.d527.s1.e1" id="DS3.d527.s1.i0" interaction="False" />
            <pair e1="DS3.d527.s1.e4" e2="DS3.d527.s1.e0" id="DS3.d527.s1.i1" interaction="False" />
            <pair e1="DS3.d527.s1.e4" e2="DS3.d527.s1.e2" id="DS3.d527.s1.i2" interaction="False" />
            <pair e1="DS3.d527.s1.e4" e2="DS3.d527.s1.e3" id="DS3.d527.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d527.s2" origId="9950928-2" text="Macrophages (&amp;gt;90% Mac-3(+)) were incubated with various concentrations of IFN-gamma and LPS for 24 h. After washing, P815 tumor cells were utilized as targets in a 16-h 51Cr release assay.">
            <entity id="DS3.d527.s2.e0" origId="P17047,Q8C5K0" charOffset="21-26" type="protein" text="Mac-3"/>
            <entity id="DS3.d527.s2.e1" origId="P01580" charOffset="77-86" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d527.s2.e2" origId="Q9QUK6,L0CL36" charOffset="91-94" type="protein" text="LPS"/>
            <entity id="DS3.d527.s2.e3" origId="104786" charOffset="172-176" type="compound" text="51Cr"/>
            <pair e1="DS3.d527.s2.e3" e2="DS3.d527.s2.e1" id="DS3.d527.s2.i0" interaction="False" />
            <pair e1="DS3.d527.s2.e3" e2="DS3.d527.s2.e2" id="DS3.d527.s2.i1" interaction="False" />
            <pair e1="DS3.d527.s2.e3" e2="DS3.d527.s2.e0" id="DS3.d527.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d527.s3" origId="9950928-6" text="The inducible nitric oxide synthase (iNOS) inhibitor NG-monomethyl-L-arginine (L-NMMA) significantly reduced macrophage cytolysis and NO-2 production and completely abrogated exercise-induced increases in these measures.">
            <entity id="DS3.d527.s3.e0" origId="P29477" charOffset="4-35" type="protein" text="inducible nitric oxide synthase"/>
            <entity id="DS3.d527.s3.e1" origId="P29477" charOffset="37-41" type="protein" text="iNOS"/>
            <entity id="DS3.d527.s3.e2" origId="90867653" charOffset="69-77" type="compound" text="arginine"/>
            <entity id="DS3.d527.s3.e3" origId="132862" charOffset="79-85" type="compound" text="L-NMMA"/>
            <pair e1="DS3.d527.s3.e2" e2="DS3.d527.s3.e0" id="DS3.d527.s3.i0" interaction="False" />
            <pair e1="DS3.d527.s3.e2" e2="DS3.d527.s3.e1" id="DS3.d527.s3.i1" interaction="False" />
            <pair e1="DS3.d527.s3.e3" e2="DS3.d527.s3.e0" id="DS3.d527.s3.i2" interaction="False" />
            <pair e1="DS3.d527.s3.e3" e2="DS3.d527.s3.e1" id="DS3.d527.s3.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d528" origId="9950929">
        <sentence id="DS3.d528.s0" origId="9950929-9" text="Ca2+ transport may depend on the high-capacity Na+/Ca2+ exchanger coupled to the versatile sodium pump.">
            <entity id="DS3.d528.s0.e0" origId="Q9H009" charOffset="47-54" type="protein" text="Na+/Ca2"/>
            <entity id="DS3.d528.s0.e1" origId="5360545" charOffset="91-97" type="compound" text="sodium"/>
            <pair e1="DS3.d528.s0.e1" e2="DS3.d528.s0.e0" id="DS3.d528.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d529" origId="9950932">
        <sentence id="DS3.d529.s0" origId="9950932-5" text="The excitatory effect of amylin was completely blocked by coapplication of the selective amylin receptor antagonist AC-187 (10(-6)-10(-5) M) but was not affected by losartan (10(-5) M).">
            <entity id="DS3.d529.s0.e0" origId="P12969" charOffset="25-31" type="protein" text="amylin"/>
            <entity id="DS3.d529.s0.e1" origId="P12969" charOffset="89-95" type="protein" text="amylin"/>
            <entity id="DS3.d529.s0.e2" origId="3961" charOffset="165-173" type="compound" text="losartan"/>
            <pair e1="DS3.d529.s0.e2" e2="DS3.d529.s0.e0" id="DS3.d529.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d529.s1" origId="9950932-6" text="Subcutaneous injections of 40 nmol of amylin significantly increased water intake in euhydrated rats, as did an equimolar dose of ANG II, which is a well-described SFO-mediated effect of circulating ANG II.">
            <entity id="DS3.d529.s1.e0" origId="P12969" charOffset="38-44" type="protein" text="amylin"/>
            <entity id="DS3.d529.s1.e1" origId="962" charOffset="69-74" type="compound" text="water"/>
            <entity id="DS3.d529.s1.e2" origId="P01015" charOffset="130-136" type="protein" text="ANG II"/>
            <entity id="DS3.d529.s1.e3" origId="P01015" charOffset="199-205" type="protein" text="ANG II"/>
            <pair e1="DS3.d529.s1.e1" e2="DS3.d529.s1.e0" id="DS3.d529.s1.i0" interaction="False" />
            <pair e1="DS3.d529.s1.e1" e2="DS3.d529.s1.e2" id="DS3.d529.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d530" origId="9950936">
        <sentence id="DS3.d530.s0" origId="9950936-6" text="The steady-state levels of Ca2+-ATPase and phospholamban mRNAs and the expression of the encoded proteins Ca2+-ATPase (SERCA) and phospholamban (PLB) were measured, using semi-quantitative RT-PCR and Western immunoblotting, respectively.">
            <entity id="DS3.d530.s0.e0" origId="P61016" charOffset="43-56" type="protein" text="phospholamban"/>
            <entity id="DS3.d530.s0.e1" origId="P61016" charOffset="130-143" type="protein" text="phospholamban"/>
            <entity id="DS3.d530.s0.e2" origId="5289162" charOffset="145-148" type="compound" text="PLB"/>
            <pair e1="DS3.d530.s0.e2" e2="DS3.d530.s0.e0" id="DS3.d530.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d530.s1" origId="9950936-8" text="Heat acclimation, which brought about a reduced thyroxine level, led to downregulation of Ca2+-ATPase mRNA expression and translation and upregulation of phospholamban mRNA and PLB.">
            <entity id="DS3.d530.s1.e0" origId="5819,853" charOffset="48-57" type="compound" text="thyroxine"/>
            <entity id="DS3.d530.s1.e1" origId="P61016" charOffset="154-167" type="protein" text="phospholamban"/>
            <entity id="DS3.d530.s1.e2" origId="5289162" charOffset="177-180" type="compound" text="PLB"/>
            <pair e1="DS3.d530.s1.e0" e2="DS3.d530.s1.e1" id="DS3.d530.s1.i0" interaction="False" />
            <pair e1="DS3.d530.s1.e2" e2="DS3.d530.s1.e1" id="DS3.d530.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d531" origId="9950937">
        <sentence id="DS3.d531.s0" origId="9950937-3" text="CA III content and activity were measured in soleus muscles from 10- to 100-day-old rats, and the influence of CA inhibitor on fatigue and hexosemonophosphate content was quantified in vitro.">
            <entity id="DS3.d531.s0.e0" origId="P14141" charOffset="0-6" type="protein" text="CA III"/>
            <entity id="DS3.d531.s0.e1" origId="4626994" charOffset="139-158" type="compound" text="hexosemonophosphate"/>
            <pair e1="DS3.d531.s0.e1" e2="DS3.d531.s0.e0" id="DS3.d531.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d532" origId="9950939">
        <sentence id="DS3.d532.s0" origId="9950939-11" text="Dantrolene, an inhibitor of Ca2+ release, reduced the increased (Ca2+)i occurring after AVP.">
            <entity id="DS3.d532.s0.e0" origId="6914273" charOffset="0-10" type="compound" text="Dantrolene"/>
            <entity id="DS3.d532.s0.e1" origId="P01186" charOffset="88-91" type="protein" text="AVP"/>
            <pair e1="DS3.d532.s0.e0" e2="DS3.d532.s0.e1" id="DS3.d532.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d533" origId="9950947">
        <sentence id="DS3.d533.s0" origId="9950947-6" text="These results indicate that the Na+-D-glucose cotransport in the jejunum, the ileum, and the rectum of chickens is due to an SGLT-1 type protein.">
            <entity id="DS3.d533.s0.e0" origId="79025" charOffset="36-45" type="compound" text="D-glucose"/>
            <entity id="DS3.d533.s0.e1" origId="F1NZW3" charOffset="125-131" type="protein" text="SGLT-1"/>
            <pair e1="DS3.d533.s0.e0" e2="DS3.d533.s0.e1" id="DS3.d533.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d534" origId="9950948">
        <sentence id="DS3.d534.s0" origId="9950948-1" text="In the renal collecting duct, vasopressin acutely activates cAMP production, resulting in trafficking of aquaporin-2 water channels (AQP2) to the apical plasma membrane, thereby increasing water permeability.">
            <entity id="DS3.d534.s0.e0" origId="P51437" charOffset="60-64" type="protein" text="cAMP"/>
            <entity id="DS3.d534.s0.e1" origId="P56402,Q3UQD4" charOffset="105-116" type="protein" text="aquaporin-2"/>
            <entity id="DS3.d534.s0.e2" origId="962" charOffset="117-122" type="compound" text="water"/>
            <entity id="DS3.d534.s0.e3" origId="P56402,Q3UQD4" charOffset="133-137" type="protein" text="AQP2"/>
            <entity id="DS3.d534.s0.e4" origId="962" charOffset="189-194" type="compound" text="water"/>
            <pair e1="DS3.d534.s0.e2" e2="DS3.d534.s0.e1" id="DS3.d534.s0.i0" interaction="False" />
            <pair e1="DS3.d534.s0.e2" e2="DS3.d534.s0.e0" id="DS3.d534.s0.i1" interaction="False" />
            <pair e1="DS3.d534.s0.e2" e2="DS3.d534.s0.e3" id="DS3.d534.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d535" origId="9950949">
        <sentence id="DS3.d535.s0" origId="9950949-2" text="It has been suggested that the nephrotoxicity of albuminuric states may be due to the protein molecule itself or by lipids, such as lysophosphatidic acid (LPA), that albumin carries.">
            <entity id="DS3.d535.s0.e0" origId="5311263,5497152,3988,5885531" charOffset="132-153" type="compound" text="lysophosphatidic acid"/>
            <entity id="DS3.d535.s0.e1" origId="P02768" charOffset="49-56" type="protein" text="albumin"/>
            <pair e1="DS3.d535.s0.e0" e2="DS3.d535.s0.e1" id="DS3.d535.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d536" origId="9950950">
        <sentence id="DS3.d536.s0" origId="9950950-13" text="Thus VACM-1 may be involved in the regulation of endothelial permeability and water transport in the CT.">
            <entity id="DS3.d536.s0.e0" origId="Q29425,Q93034" charOffset="5-11" type="protein" text="VACM-1"/>
            <entity id="DS3.d536.s0.e1" origId="962" charOffset="78-83" type="compound" text="water"/>
            <pair e1="DS3.d536.s0.e1" e2="DS3.d536.s0.e0" id="DS3.d536.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d536.s1" origId="9950950-1" text="The vasopressin-activated calcium-mobilizing (VACM-1) protein is a novel arginine vasopressin (AVP) receptor that shares sequence homology with a cullin multigene family but not with the AVP receptors.">
            <entity id="DS3.d536.s1.e0" origId="22044544,5460341" charOffset="26-33" type="compound" text="calcium"/>
            <entity id="DS3.d536.s1.e1" origId="Q29425,Q93034" charOffset="46-52" type="protein" text="VACM-1"/>
            <entity id="DS3.d536.s1.e2" origId="6322,90867653" charOffset="73-81" type="compound" text="arginine"/>
            <pair e1="DS3.d536.s1.e0" e2="DS3.d536.s1.e1" id="DS3.d536.s1.i0" interaction="False" />
            <pair e1="DS3.d536.s1.e2" e2="DS3.d536.s1.e1" id="DS3.d536.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d537" origId="9950951">
        <sentence id="DS3.d537.s0" origId="9950951-5" text="E-cadherin mediates calcium-dependent homotypic cell-cell interactions that are stabilized by its association with catenins and the actin cytoskeleton.">
            <entity id="DS3.d537.s0.e0" origId="P09803" charOffset="0-10" type="protein" text="E-cadherin"/>
            <entity id="DS3.d537.s0.e1" origId="5460341,22044544" charOffset="20-27" type="compound" text="calcium"/>
            <pair e1="DS3.d537.s0.e1" e2="DS3.d537.s0.e0" id="DS3.d537.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d538" origId="9950952">
        <sentence id="DS3.d538.s0" origId="9950952-4" text="Autocrine RAS feedback was examined following exposure to ANG II (10(-8) M), and it was noted that angiotensinogen mRNA increases significantly by 1 h and remains elevated through 24 h. The AT1 blocker losartan prevents this increase.">
            <entity id="DS3.d538.s0.e0" origId="P01015" charOffset="58-64" type="protein" text="ANG II"/>
            <entity id="DS3.d538.s0.e1" origId="P01015" charOffset="99-114" type="protein" text="angiotensinogen"/>
            <entity id="DS3.d538.s0.e2" origId="3961" charOffset="202-210" type="compound" text="losartan"/>
            <pair e1="DS3.d538.s0.e2" e2="DS3.d538.s0.e1" id="DS3.d538.s0.i0" interaction="False" />
            <pair e1="DS3.d538.s0.e2" e2="DS3.d538.s0.e0" id="DS3.d538.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d538.s1" origId="9950952-7" text="ANG II secreted by line 93-p-2-1 is increased by isoproterenol, suggesting beta-adrenergic regulation in IRPTC.">
            <entity id="DS3.d538.s1.e0" origId="P01015" charOffset="0-6" type="protein" text="ANG II"/>
            <entity id="DS3.d538.s1.e1" origId="3779" charOffset="49-62" type="compound" text="isoproterenol"/>
            <pair e1="DS3.d538.s1.e1" e2="DS3.d538.s1.e0" id="DS3.d538.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d539" origId="9950955">
        <sentence id="DS3.d539.s0" origId="9950955-0" text="Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys.">
            <entity id="DS3.d539.s0.e0" origId="P08516" charOffset="16-44" type="protein" text="cytochrome P-450 4A1 and 4A2"/>
            <entity id="DS3.d539.s0.e1" origId="5283157" charOffset="57-88" type="compound" text="20-hydroxyeicosatetraenoic acid"/>
            <pair e1="DS3.d539.s0.e1" e2="DS3.d539.s0.e0" id="DS3.d539.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d539.s1" origId="9950955-1" text="20-Hydroxyeicosatetraenoic acids (20-HETE), a biologically active cytochrome P-450 (CYP) metabolite of arachidonic acid in the rat kidney, can be catalyzed by CYP4A isoforms including CYP4A1, CYP4A2, and CYP4A3.">
            <entity id="DS3.d539.s1.e0" origId="444899" charOffset="103-119" type="compound" text="arachidonic acid"/>
            <entity id="DS3.d539.s1.e1" origId="P08516" charOffset="184-190" type="protein" text="CYP4A1"/>
            <entity id="DS3.d539.s1.e2" origId="P20816" charOffset="192-198" type="protein" text="CYP4A2"/>
            <entity id="DS3.d539.s1.e3" origId="P20817" charOffset="204-210" type="protein" text="CYP4A3"/>
            <pair e1="DS3.d539.s1.e0" e2="DS3.d539.s1.e1" id="DS3.d539.s1.i0" interaction="False" />
            <pair e1="DS3.d539.s1.e0" e2="DS3.d539.s1.e3" id="DS3.d539.s1.i1" interaction="False" />
            <pair e1="DS3.d539.s1.e0" e2="DS3.d539.s1.e2" id="DS3.d539.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d540" origId="9950956">
        <sentence id="DS3.d540.s0" origId="9950956-11" text="The results indicate that AVP stimulates phosphorylation of AQP2 at Ser256 via activation of PKA, supporting the idea that this is one of the first steps leading to increased water permeability in collecting duct cells.">
            <entity id="DS3.d540.s0.e0" origId="P01186" charOffset="26-29" type="protein" text="AVP"/>
            <entity id="DS3.d540.s0.e1" origId="P34080" charOffset="60-64" type="protein" text="AQP2"/>
            <entity id="DS3.d540.s0.e2" origId="962" charOffset="175-180" type="compound" text="water"/>
            <pair e1="DS3.d540.s0.e2" e2="DS3.d540.s0.e1" id="DS3.d540.s0.i0" interaction="False" />
            <pair e1="DS3.d540.s0.e2" e2="DS3.d540.s0.e0" id="DS3.d540.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d540.s1" origId="9950956-1" text="aquaporin-2 (AQP2), the protein that mediates Arginine vasopressin (AVP)-regulated apical water transport in the renal collecting duct, possesses a single consensus phosphorylation site for cAMP-dependent protein kinase A (PKA) at Ser256.">
            <entity id="DS3.d540.s1.e0" origId="P34080" charOffset="0-11" type="protein" text="aquaporin-2"/>
            <entity id="DS3.d540.s1.e1" origId="P34080" charOffset="13-17" type="protein" text="AQP2"/>
            <entity id="DS3.d540.s1.e2" origId="P01186" charOffset="46-66" type="protein" text="Arginine vasopressin"/>
            <entity id="DS3.d540.s1.e3" origId="P01186" charOffset="68-71" type="protein" text="AVP"/>
            <entity id="DS3.d540.s1.e4" origId="962" charOffset="90-95" type="compound" text="water"/>
            <entity id="DS3.d540.s1.e5" origId="G3V8S9" charOffset="190-194" type="protein" text="cAMP"/>
            <pair e1="DS3.d540.s1.e4" e2="DS3.d540.s1.e0" id="DS3.d540.s1.i0" interaction="False" />
            <pair e1="DS3.d540.s1.e4" e2="DS3.d540.s1.e3" id="DS3.d540.s1.i1" interaction="False" />
            <pair e1="DS3.d540.s1.e4" e2="DS3.d540.s1.e2" id="DS3.d540.s1.i2" interaction="False" />
            <pair e1="DS3.d540.s1.e4" e2="DS3.d540.s1.e5" id="DS3.d540.s1.i3" interaction="False" />
            <pair e1="DS3.d540.s1.e4" e2="DS3.d540.s1.e1" id="DS3.d540.s1.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d540.s2" origId="9950956-8" text="This effect on AQP2 phosphorylation was mimicked by the vasopressin (V2) agonist, 1-desamino-(8-D-arginine)vasopressin (DDAVP), or forskolin.">
            <entity id="DS3.d540.s2.e0" origId="P34080" charOffset="15-19" type="protein" text="AQP2"/>
            <entity id="DS3.d540.s2.e1" origId="P01186" charOffset="98-118" type="protein" text="arginine)vasopressin"/>
            <entity id="DS3.d540.s2.e2" origId="27991" charOffset="120-125" type="compound" text="DDAVP"/>
            <entity id="DS3.d540.s2.e3" origId="47936" charOffset="131-140" type="compound" text="forskolin"/>
            <pair e1="DS3.d540.s2.e2" e2="DS3.d540.s2.e0" id="DS3.d540.s2.i0" interaction="False" />
            <pair e1="DS3.d540.s2.e2" e2="DS3.d540.s2.e3" id="DS3.d540.s2.i1" interaction="False" />
            <pair e1="DS3.d540.s2.e3" e2="DS3.d540.s2.e0" id="DS3.d540.s2.i2" interaction="False" />
            <pair e1="DS3.d540.s2.e3" e2="DS3.d540.s2.e3" id="DS3.d540.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d540.s3" origId="9950956-9" text="Two-dimensional phosphopeptide mapping indicated that AVP and forskolin stimulated the phosphorylation of the same site in AQP2.">
            <entity id="DS3.d540.s3.e0" origId="P01186" charOffset="54-57" type="protein" text="AVP"/>
            <entity id="DS3.d540.s3.e1" origId="47936" charOffset="62-71" type="compound" text="forskolin"/>
            <entity id="DS3.d540.s3.e2" origId="P34080" charOffset="123-127" type="protein" text="AQP2"/>
            <pair e1="DS3.d540.s3.e1" e2="DS3.d540.s3.e2" id="DS3.d540.s3.i0" interaction="False" />
            <pair e1="DS3.d540.s3.e1" e2="DS3.d540.s3.e0" id="DS3.d540.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d541" origId="9950957">
        <sentence id="DS3.d541.s0" origId="9950957-7" text="ANG II effects were inhibited by the AT1 receptor antagonist losartan.">
            <entity id="DS3.d541.s0.e0" origId="Q5GAM5,P01015" charOffset="0-6" type="protein" text="ANG II"/>
            <entity id="DS3.d541.s0.e1" origId="3961" charOffset="61-69" type="compound" text="losartan"/>
            <pair e1="DS3.d541.s0.e1" e2="DS3.d541.s0.e0" id="DS3.d541.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d541.s1" origId="9950957-8" text="AVP action was blocked by the V1 receptor antagonist (d(CH2)5,Tyr(NH2)9)AVP.">
            <entity id="DS3.d541.s1.e0" origId="P01186" charOffset="0-3" type="protein" text="AVP"/>
            <entity id="DS3.d541.s1.e1" origId="6057" charOffset="62-65" type="compound" text="Tyr"/>
            <entity id="DS3.d541.s1.e2" origId="P01186" charOffset="72-75" type="protein" text="AVP"/>
            <pair e1="DS3.d541.s1.e1" e2="DS3.d541.s1.e0" id="DS3.d541.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d541.s2" origId="9950957-9" text="In SMC pretreated with nifedipine, neither ANG II nor AVP elicited (Ca2+)i responses.">
            <entity id="DS3.d541.s2.e0" origId="4485" charOffset="23-33" type="compound" text="nifedipine"/>
            <entity id="DS3.d541.s2.e1" origId="Q5GAM5,P01015" charOffset="43-49" type="protein" text="ANG II"/>
            <entity id="DS3.d541.s2.e2" origId="P01186" charOffset="54-57" type="protein" text="AVP"/>
            <pair e1="DS3.d541.s2.e0" e2="DS3.d541.s2.e2" id="DS3.d541.s2.i0" interaction="False" />
            <pair e1="DS3.d541.s2.e0" e2="DS3.d541.s2.e1" id="DS3.d541.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d542" origId="9950958">
        <sentence id="DS3.d542.s0" origId="9950958-2" text="We compared the contributions of ANG II and BK to the renal medullary blood flow (MBF) responses to angiotensin-converting enzyme (ACE) inhibition (enalaprilat, 33 micrograms .">
            <entity id="DS3.d542.s0.e0" origId="A0A8J8" charOffset="33-39" type="protein" text="ANG II"/>
            <entity id="DS3.d542.s0.e1" origId="5462501" charOffset="148-159" type="compound" text="enalaprilat"/>
            <pair e1="DS3.d542.s0.e1" e2="DS3.d542.s0.e0" id="DS3.d542.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d542.s1" origId="9950958-9" text="These data indicate that under normal sodium intake, increases in MBF and CBF caused by ACE inhibition are primarily due to reduced intrarenal ANG II levels.">
            <entity id="DS3.d542.s1.e0" origId="5360545" charOffset="38-44" type="compound" text="sodium"/>
            <entity id="DS3.d542.s1.e1" origId="A0A8J8" charOffset="143-149" type="protein" text="ANG II"/>
            <pair e1="DS3.d542.s1.e0" e2="DS3.d542.s1.e1" id="DS3.d542.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d543" origId="9950960">
        <sentence id="DS3.d543.s0" origId="9950960-2" text="Because marine teleost renal sulfate secretion is associated with bicarbonate anion exchange, we investigated the effect of CA inhibition on transepithelial sulfate transport by flounder renal tubule primary monolayer cultures (PTC) and on renal sulfate secretion (QSO4) by intact flounder.">
            <entity id="DS3.d543.s0.e0" origId="1117" charOffset="29-36" type="compound" text="sulfate"/>
            <entity id="DS3.d543.s0.e1" origId="767" charOffset="66-77" type="compound" text="bicarbonate"/>
            <entity id="DS3.d543.s0.e2" origId="1117" charOffset="157-164" type="compound" text="sulfate"/>
            <entity id="DS3.d543.s0.e3" origId="P00740" charOffset="228-231" type="protein" text="PTC"/>
            <entity id="DS3.d543.s0.e4" origId="1117" charOffset="157-164" type="compound" text="sulfate"/>
            <pair e1="DS3.d543.s0.e0" e2="DS3.d543.s0.e3" id="DS3.d543.s0.i0" interaction="False" />
            <pair e1="DS3.d543.s0.e1" e2="DS3.d543.s0.e3" id="DS3.d543.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d543.s1" origId="9950960-3" text="Both methazolamide and ethoxzolamide (10 microM) inhibited PTC secretory flux by approximately 50%; reabsorptive sulfate flux, Na-dependent glucose transport, and transepithelial electrical resistance were unaffected.">
            <entity id="DS3.d543.s1.e0" origId="4100" charOffset="5-18" type="compound" text="methazolamide"/>
            <entity id="DS3.d543.s1.e1" origId="3295" charOffset="23-36" type="compound" text="ethoxzolamide"/>
            <entity id="DS3.d543.s1.e2" origId="P00740" charOffset="59-62" type="protein" text="PTC"/>
            <entity id="DS3.d543.s1.e3" origId="1117" charOffset="113-120" type="compound" text="sulfate"/>
            <entity id="DS3.d543.s1.e4" origId="206,5793,79025,64689" charOffset="140-147" type="compound" text="glucose"/>
            <pair e1="DS3.d543.s1.e0" e2="DS3.d543.s1.e2" id="DS3.d543.s1.i0" interaction="False" />
            <pair e1="DS3.d543.s1.e1" e2="DS3.d543.s1.e2" id="DS3.d543.s1.i1" interaction="False" />
            <pair e1="DS3.d543.s1.e3" e2="DS3.d543.s1.e2" id="DS3.d543.s1.i2" interaction="False" />
            <pair e1="DS3.d543.s1.e4" e2="DS3.d543.s1.e2" id="DS3.d543.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d543.s2" origId="9950960-4" text="A CA inhibitor restricted to the extracellular space (10 microM polyoxyethylene-aminobenzolamide, 3.7 kDa) had no effect on PTC sulfate transport.">
            <entity id="DS3.d543.s2.e0" origId="P00740" charOffset="124-127" type="protein" text="PTC"/>
            <entity id="DS3.d543.s2.e1" origId="1117" charOffset="128-135" type="compound" text="sulfate"/>
            <pair e1="DS3.d543.s2.e1" e2="DS3.d543.s2.e0" id="DS3.d543.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d544" origId="9950961">
        <sentence id="DS3.d544.s0" origId="9950961-10" text="Like rat OAT1 organic anion transporter, hPAHT was inhibited by furosemide, indomethacin, probenecid, and alpha-ketoglutarate.">
            <entity id="DS3.d544.s0.e0" origId="Q4U2R8" charOffset="9-13" type="protein" text="OAT1"/>
            <entity id="DS3.d544.s0.e1" origId="Q4U2R8" charOffset="41-46" type="protein" text="hPAHT"/>
            <entity id="DS3.d544.s0.e2" origId="3440" charOffset="64-74" type="compound" text="furosemide"/>
            <entity id="DS3.d544.s0.e3" origId="3715" charOffset="76-88" type="compound" text="indomethacin"/>
            <entity id="DS3.d544.s0.e4" origId="4911" charOffset="90-100" type="compound" text="probenecid"/>
            <pair e1="DS3.d544.s0.e2" e2="DS3.d544.s0.e1" id="DS3.d544.s0.i0" interaction="False" />
            <pair e1="DS3.d544.s0.e2" e2="DS3.d544.s0.e0" id="DS3.d544.s0.i1" interaction="False" />
            <pair e1="DS3.d544.s0.e3" e2="DS3.d544.s0.e1" id="DS3.d544.s0.i2" interaction="False" />
            <pair e1="DS3.d544.s0.e3" e2="DS3.d544.s0.e0" id="DS3.d544.s0.i3" interaction="False" />
            <pair e1="DS3.d544.s0.e4" e2="DS3.d544.s0.e1" id="DS3.d544.s0.i4" interaction="False" />
            <pair e1="DS3.d544.s0.e4" e2="DS3.d544.s0.e0" id="DS3.d544.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d544.s1" origId="9950961-11" text="Unlike OAT1, hPAHT was not inhibited by prostaglandins or methotrexate (MTX).">
            <entity id="DS3.d544.s1.e0" origId="Q4U2R8" charOffset="7-11" type="protein" text="OAT1"/>
            <entity id="DS3.d544.s1.e1" origId="Q4U2R8" charOffset="13-18" type="protein" text="hPAHT"/>
            <entity id="DS3.d544.s1.e2" origId="126941" charOffset="58-70" type="compound" text="methotrexate"/>
            <pair e1="DS3.d544.s1.e2" e2="DS3.d544.s1.e1" id="DS3.d544.s1.i0" interaction="False" />
            <pair e1="DS3.d544.s1.e2" e2="DS3.d544.s1.e0" id="DS3.d544.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d545" origId="9950963">
        <sentence id="DS3.d545.s0" origId="9950963-0" text="Enhanced renal vascular responsiveness to angiotensin II in hypertensive ren-2 transgenic rats.">
            <entity id="DS3.d545.s0.e0" origId="P01015" charOffset="42-56" type="protein" text="angiotensin II"/>
            <entity id="DS3.d545.s0.e1" origId="439653" charOffset="9-12" type="compound" text="ren"/>
            <pair e1="DS3.d545.s0.e1" e2="DS3.d545.s0.e0" id="DS3.d545.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d545.s1" origId="9950963-1" text="The present study was performed to evaluate renal vascular responsiveness (RVR) to ANG II in hypertensive transgenic rats (TGR; strain TGR(mRen2)27) harboring the mouse ren-2 renin gene.">
            <entity id="DS3.d545.s1.e0" origId="P01015" charOffset="83-89" type="protein" text="ANG II"/>
            <entity id="DS3.d545.s1.e1" origId="439653" charOffset="44-47" type="compound" text="ren"/>
            <pair e1="DS3.d545.s1.e1" e2="DS3.d545.s1.e0" id="DS3.d545.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d545.s2" origId="9950963-2" text="Renal blood flow (RBF) responses to either intravenous or intrarenal arterial administration of ANG II were assessed in pentobarbital sodium-anesthetized female heterozygous TGR (9-12 wk old) and age-matched transgene-negative Hanover Sprague-Dawley rats (HanSD).">
            <entity id="DS3.d545.s2.e0" origId="P01015" charOffset="96-102" type="protein" text="ANG II"/>
            <entity id="DS3.d545.s2.e1" origId="4737" charOffset="120-140" type="compound" text="pentobarbital sodium"/>
            <pair e1="DS3.d545.s2.e1" e2="DS3.d545.s2.e0" id="DS3.d545.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d545.s3" origId="9950963-8" text="Furthermore, the enhanced RVR to ANG II does not appear to reflect an impaired RVR to endogenous vasodilator factors since intrarenal administration of bradykinin and acetylcholine elicited larger increases in RBF in TGR than in HanSD.">
            <entity id="DS3.d545.s3.e0" origId="P01015" charOffset="33-39" type="protein" text="ANG II"/>
            <entity id="DS3.d545.s3.e1" origId="187" charOffset="167-180" type="compound" text="acetylcholine"/>
            <pair e1="DS3.d545.s3.e1" e2="DS3.d545.s3.e0" id="DS3.d545.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d546" origId="9951011">
        <sentence id="DS3.d546.s0" origId="9951011-1" text="INTRODUCTION: Different studies have shown that aspirin (AAS), in low doses, may lead to a considerable frequency of hemorrhagic complications when used in the long term.">
            <entity id="DS3.d546.s0.e0" origId="2244" charOffset="48-55" type="compound" text="aspirin"/>
            <entity id="DS3.d546.s0.e1" origId="P98174,A0A024R9Y5" charOffset="57-60" type="protein" text="AAS"/>
            <pair e1="DS3.d546.s0.e0" e2="DS3.d546.s0.e1" id="DS3.d546.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d546.s1" origId="9951011-2" text="OBJECTIVE: We compare the long-term occurrence of hemorrhagic complications with low doses of AAS and high doses of triflusal.">
            <entity id="DS3.d546.s1.e0" origId="P98174,A0A024R9Y5" charOffset="94-97" type="protein" text="AAS"/>
            <entity id="DS3.d546.s1.e1" origId="9458" charOffset="116-125" type="compound" text="triflusal"/>
            <pair e1="DS3.d546.s1.e1" e2="DS3.d546.s1.e0" id="DS3.d546.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d546.s2" origId="9951011-3" text="PATIENTS AND METHODS: Our series included 106 patients who took 900 mg triflusal per day (300 mg 3 times per day) and 111 who took AAS (330 mg/day once daily).">
            <entity id="DS3.d546.s2.e0" origId="9458" charOffset="71-80" type="compound" text="triflusal"/>
            <entity id="DS3.d546.s2.e1" origId="P98174,A0A024R9Y5" charOffset="131-134" type="protein" text="AAS"/>
            <pair e1="DS3.d546.s2.e0" e2="DS3.d546.s2.e1" id="DS3.d546.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d546.s3" origId="9951011-7" text="RESULTS: Compared with AAS, triflusal led to a 76% reduction in risk of hemorrhagic complications (2.8% against 10.8%; OR 0.24; IC 0.06-0.94).">
            <entity id="DS3.d546.s3.e0" origId="P98174,A0A024R9Y5" charOffset="23-26" type="protein" text="AAS"/>
            <entity id="DS3.d546.s3.e1" origId="9458" charOffset="28-37" type="compound" text="triflusal"/>
            <pair e1="DS3.d546.s3.e1" e2="DS3.d546.s3.e0" id="DS3.d546.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d547" origId="9951020">
        <sentence id="DS3.d547.s0" origId="9951020-9" text="CSF culture grew Salmonella which was resistant to ampicillin but sensitive to cefotaxima.">
            <entity id="DS3.d547.s0.e0" origId="Q13753" charOffset="0-3" type="protein" text="CSF"/>
            <entity id="DS3.d547.s0.e1" origId="6249" charOffset="51-61" type="compound" text="ampicillin"/>
            <entity id="DS3.d547.s0.e2" origId="5742673" charOffset="79-89" type="compound" text="cefotaxima"/>
            <pair e1="DS3.d547.s0.e1" e2="DS3.d547.s0.e0" id="DS3.d547.s0.i0" interaction="False" />
            <pair e1="DS3.d547.s0.e2" e2="DS3.d547.s0.e0" id="DS3.d547.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d548" origId="9951030">
        <sentence id="DS3.d548.s0" origId="9951030-0" text="(Riluzole as a treatment for amyotrophic lateral sclerosis).">
            <entity id="DS3.d548.s0.e0" origId="5070" charOffset="1-9" type="compound" text="Riluzole"/>
            <entity id="DS3.d548.s0.e1" origId="P00441,V9HWC9" charOffset="29-58" type="protein" text="amyotrophic lateral sclerosis"/>
            <pair e1="DS3.d548.s0.e0" e2="DS3.d548.s0.e1" id="DS3.d548.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d549" origId="9951034">
        <sentence id="DS3.d549.s0" origId="9951034-1" text="OBJECTIVE: hypoxanthine-guanine phosphoribosyltransferase (HPRT) deficiency is characterized by an increase in renal uric acid excretion, usually with hyperuricemia and may be associated with more or less important neurological symptoms.">
            <entity id="DS3.d549.s0.e0" origId="P00492" charOffset="11-57" type="protein" text="hypoxanthine-guanine phosphoribosyltransferase"/>
            <entity id="DS3.d549.s0.e1" origId="P00492" charOffset="59-63" type="protein" text="HPRT"/>
            <entity id="DS3.d549.s0.e2" origId="1175" charOffset="117-126" type="compound" text="uric acid"/>
            <pair e1="DS3.d549.s0.e2" e2="DS3.d549.s0.e0" id="DS3.d549.s0.i0" interaction="False" />
            <pair e1="DS3.d549.s0.e2" e2="DS3.d549.s0.e1" id="DS3.d549.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d550" origId="9951046">
        <sentence id="DS3.d550.s0" origId="9951046-7" text="When the group of rats are considered in correlation computation positive correlation can be documented between total plasma cholesterol and plasma prolactin.">
            <entity id="DS3.d550.s0.e0" origId="5997" charOffset="125-136" type="compound" text="cholesterol"/>
            <entity id="DS3.d550.s0.e1" origId="P01237,B5DEM6,B2RYT1" charOffset="148-157" type="protein" text="prolactin"/>
            <pair e1="DS3.d550.s0.e0" e2="DS3.d550.s0.e1" id="DS3.d550.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d551" origId="9951146">
        <sentence id="DS3.d551.s0" origId="9951146-5" text="We tested 50 OLP unrelated patients (5 males) for HLA A and compared them to 1089 healthy controls.">
            <entity id="DS3.d551.s0.e0" origId="2856" charOffset="13-16" type="compound" text="OLP"/>
            <entity id="DS3.d551.s0.e1" origId="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126" charOffset="50-55" type="protein" text="HLA A"/>
            <pair e1="DS3.d551.s0.e0" e2="DS3.d551.s0.e1" id="DS3.d551.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d551.s1" origId="9951146-6" text="OLP patients had 3 times less frequently HLA A w19 and 5 times less frequently HLA A28, compared with controls.">
            <entity id="DS3.d551.s1.e0" origId="2856" charOffset="0-3" type="compound" text="OLP"/>
            <entity id="DS3.d551.s1.e1" origId="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126" charOffset="41-46" type="protein" text="HLA A"/>
            <entity id="DS3.d551.s1.e2" origId="70789251" charOffset="47-50" type="compound" text="w19"/>
            <pair e1="DS3.d551.s1.e0" e2="DS3.d551.s1.e1" id="DS3.d551.s1.i0" interaction="False" />
            <pair e1="DS3.d551.s1.e2" e2="DS3.d551.s1.e1" id="DS3.d551.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d551.s2" origId="9951146-8" text="In conclusion, HLA A w19 and A28 appeared associated with OLP in particular, while HLA A11 and A26 with erosive types of OLP.">
            <entity id="DS3.d551.s2.e0" origId="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126" charOffset="15-20" type="protein" text="HLA A"/>
            <entity id="DS3.d551.s2.e1" origId="70789251" charOffset="21-24" type="compound" text="w19"/>
            <entity id="DS3.d551.s2.e2" origId="2856" charOffset="58-61" type="compound" text="OLP"/>
            <entity id="DS3.d551.s2.e3" origId="2856" charOffset="121-124" type="compound" text="OLP"/>
            <pair e1="DS3.d551.s2.e2" e2="DS3.d551.s2.e0" id="DS3.d551.s2.i0" interaction="False" />
            <pair e1="DS3.d551.s2.e1" e2="DS3.d551.s2.e0" id="DS3.d551.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d552" origId="9951147">
        <sentence id="DS3.d552.s0" origId="9951147-3" text="As it is known that some HLA B and DR 3/4 antigens are cross-linked, we have determined the frequencies of HLA B antigens in group of 50 Croatian patients (5 males) with OLP and compared them with the 1089 healthy controls.">
            <entity id="DS3.d552.s0.e0" origId="Q93038,P13762,X5D2U9" charOffset="35-41" type="protein" text="DR 3/4"/>
            <entity id="DS3.d552.s0.e1" origId="2856" charOffset="170-173" type="compound" text="OLP"/>
            <pair e1="DS3.d552.s0.e1" e2="DS3.d552.s0.e0" id="DS3.d552.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d553" origId="9951149">
        <sentence id="DS3.d553.s0" origId="9951149-5" text="Cells were identified immunocytochemically by the presence of antigen CD68 and labeled with acid phosphatase (AP) and alpha-naphthyl acetate esterase (ANAE) techniques.">
            <entity id="DS3.d553.s0.e0" origId="P34810" charOffset="70-74" type="protein" text="CD68"/>
            <entity id="DS3.d553.s0.e1" origId="13247" charOffset="124-140" type="compound" text="naphthyl acetate"/>
            <pair e1="DS3.d553.s0.e1" e2="DS3.d553.s0.e0" id="DS3.d553.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d554" origId="9951232">
        <sentence id="DS3.d554.s0" origId="9951232-4" text="Subsequent treatment failure, after an initially satisfactory response, occurs in 5-10 per cent of patients on OHAs, and is currently treated with a combination of an OHA for daytime use and NPH insulin (isophane insulin) for use at bedtime.">
            <entity id="DS3.d554.s0.e0" origId="4998669" charOffset="111-114" type="compound" text="OHA"/>
            <entity id="DS3.d554.s0.e1" origId="P01308,I3WAC9" charOffset="195-202" type="protein" text="insulin"/>
            <entity id="DS3.d554.s0.e2" origId="P01308,I3WAC9" charOffset="213-220" type="protein" text="insulin"/>
            <pair e1="DS3.d554.s0.e0" e2="DS3.d554.s0.e1" id="DS3.d554.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d555" origId="9951242">
        <sentence id="DS3.d555.s0" origId="9951242-0" text="(Spin and pour off! Homocysteine is non-perishable when handled correctly!).">
            <entity id="DS3.d555.s0.e0" origId="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5" charOffset="1-5" type="protein" text="Spin"/>
            <entity id="DS3.d555.s0.e1" origId="778,91552" charOffset="20-32" type="compound" text="Homocysteine"/>
            <pair e1="DS3.d555.s0.e1" e2="DS3.d555.s0.e0" id="DS3.d555.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d556" origId="9951292">
        <sentence id="DS3.d556.s0" origId="9951292-1" text="The activity of alanin-aminotransferase (ALT) and aspartate-aminotransferase (AST) was measured in blood plasma of 103 patients with brain trauma.">
            <entity id="DS3.d556.s0.e0" origId="602" charOffset="16-22" type="compound" text="alanin"/>
            <entity id="DS3.d556.s0.e1" origId="Q9NRA2" charOffset="50-76" type="protein" text="aspartate-aminotransferase"/>
            <entity id="DS3.d556.s0.e2" origId="Q9NRA2" charOffset="78-81" type="protein" text="AST"/>
            <pair e1="DS3.d556.s0.e0" e2="DS3.d556.s0.e1" id="DS3.d556.s0.i0" interaction="False" />
            <pair e1="DS3.d556.s0.e0" e2="DS3.d556.s0.e2" id="DS3.d556.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d557" origId="9951387">
        <sentence id="DS3.d557.s0" origId="9951387-4" text="An intraperitoneal injection of PABA in a dose of 10 mg/kg 24 h before hypoxia virtually completely prevented accumulation of lipid peroxides and preserved catalase activity in the retina.">
            <entity id="DS3.d557.s0.e0" origId="978" charOffset="32-36" type="compound" text="PABA"/>
            <entity id="DS3.d557.s0.e1" origId="P04762" charOffset="156-164" type="protein" text="catalase"/>
            <pair e1="DS3.d557.s0.e0" e2="DS3.d557.s0.e1" id="DS3.d557.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d557.s1" origId="9951387-5" text="Parabulbar injection of 0.01% PABA solution 1 h before hypoxia prevented LPO intensification, stabilized catalase activity in hypoxia, and protected the retina starting from the moment immediately after hypoxic exposure.">
            <entity id="DS3.d557.s1.e0" origId="978" charOffset="30-34" type="compound" text="PABA"/>
            <entity id="DS3.d557.s1.e1" origId="P04762" charOffset="105-113" type="protein" text="catalase"/>
            <pair e1="DS3.d557.s1.e0" e2="DS3.d557.s1.e1" id="DS3.d557.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d557.s2" origId="9951387-7" text="PABA exerts an antioxidant effect after hypoxia by decreasing the abnormally high level of lipid peroxides and reducing catalase activity in the retina after parabulbar injection of the drug.">
            <entity id="DS3.d557.s2.e0" origId="978" charOffset="0-4" type="compound" text="PABA"/>
            <entity id="DS3.d557.s2.e1" origId="P04762" charOffset="120-128" type="protein" text="catalase"/>
            <pair e1="DS3.d557.s2.e0" e2="DS3.d557.s2.e1" id="DS3.d557.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d558" origId="9951413">
        <sentence id="DS3.d558.s0" origId="9951413-16" text="Following rain showers, there is a sharp decline in tritium activity correlated with copious drinking from temporary pools of rain water.">
            <entity id="DS3.d558.s0.e0" origId="Q5U651,Q7L251,Q8IUR2" charOffset="10-14" type="protein" text="rain"/>
            <entity id="DS3.d558.s0.e1" origId="119434" charOffset="52-59" type="compound" text="tritium"/>
            <entity id="DS3.d558.s0.e2" origId="Q5U651,Q7L251,Q8IUR2" charOffset="126-130" type="protein" text="rain"/>
            <entity id="DS3.d558.s0.e3" origId="962" charOffset="131-136" type="compound" text="water"/>
            <pair e1="DS3.d558.s0.e3" e2="DS3.d558.s0.e0" id="DS3.d558.s0.i0" interaction="False" />
            <pair e1="DS3.d558.s0.e1" e2="DS3.d558.s0.e0" id="DS3.d558.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d559" origId="9951421">
        <sentence id="DS3.d559.s0" origId="9951421-0" text="(Positron emission tomography (PET) and (F-18)-fluorodeoxyglucose in (FDG) in cancerology).">
            <entity id="DS3.d559.s0.e0" origId="Q13495" charOffset="41-45" type="protein" text="F-18"/>
            <entity id="DS3.d559.s0.e1" origId="54303434" charOffset="47-65" type="compound" text="fluorodeoxyglucose"/>
            <entity id="DS3.d559.s0.e2" origId="445226,68196650,315411" charOffset="70-73" type="compound" text="FDG"/>
            <pair e1="DS3.d559.s0.e1" e2="DS3.d559.s0.e0" id="DS3.d559.s0.i0" interaction="False" />
            <pair e1="DS3.d559.s0.e2" e2="DS3.d559.s0.e0" id="DS3.d559.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d560" origId="9951468">
        <sentence id="DS3.d560.s0" origId="9951468-7" text="MAIN OUTCOME MEASURES: The presence of early and late AMD and of subcapsular, cortical, nuclear, and mixed cataracts was assessed and related to the levels of plasma glutathione peroxidase and erythrocyte superoxide dismutase.">
            <entity id="DS3.d560.s0.e0" origId="P22352" charOffset="159-188" type="protein" text="plasma glutathione peroxidase"/>
            <entity id="DS3.d560.s0.e1" origId="5359597" charOffset="205-215" type="compound" text="superoxide"/>
            <pair e1="DS3.d560.s0.e1" e2="DS3.d560.s0.e0" id="DS3.d560.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d560.s1" origId="9951468-9" text="High levels of erythrocyte superoxide dismutase (SOD) activity were not associated with late AMD and early signs of AMD but were associated with a twofold increase in nuclear cataract.">
            <entity id="DS3.d560.s1.e0" origId="5359597" charOffset="27-37" type="compound" text="superoxide"/>
            <entity id="DS3.d560.s1.e1" origId="P00441,V9HWC9" charOffset="49-52" type="protein" text="SOD"/>
            <pair e1="DS3.d560.s1.e0" e2="DS3.d560.s1.e1" id="DS3.d560.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d561" origId="9951469">
        <sentence id="DS3.d561.s0" origId="9951469-15" text="At 3 months, flare was reduced to preoperative levels in the Surodex group but was still raised in the dexamethasone eyedrop group.">
            <entity id="DS3.d561.s0.e0" origId="P01008,A0A024R944" charOffset="0-4" type="protein" text="At 3"/>
            <entity id="DS3.d561.s0.e1" origId="5743" charOffset="103-116" type="compound" text="dexamethasone"/>
            <pair e1="DS3.d561.s0.e1" e2="DS3.d561.s0.e0" id="DS3.d561.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d562" origId="9951474">
        <sentence id="DS3.d562.s0" origId="9951474-4" text="MAIN OUTCOME MEASURES: Tests of visual function included visual acuity, dark-adaptation thresholds, dark-adapted static perimetry, and rod and cone computer-averaged electroretinograms (ERGs), which were obtained over a range of retinal illuminances.">
            <entity id="DS3.d562.s0.e0" origId="P50748" charOffset="135-138" type="protein" text="rod"/>
            <entity id="DS3.d562.s0.e1" origId="638015" charOffset="229-236" type="compound" text="retinal"/>
            <pair e1="DS3.d562.s0.e1" e2="DS3.d562.s0.e0" id="DS3.d562.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d563" origId="9951492">
        <sentence id="DS3.d563.s0" origId="9951492-4" text="INTERVENTION: Mycophenolate mofetil, at a dosage of 1 g twice daily, was given in conjunction with steroids, as a steroid-sparing agent, or as an additional agent with cyclosporine (CsA), or instead of CsA or azathioprine.">
            <entity id="DS3.d563.s0.e0" origId="4271" charOffset="14-35" type="compound" text="Mycophenolate mofetil"/>
            <entity id="DS3.d563.s0.e1" origId="Q13216,B3KPW7,B4DGZ9" charOffset="182-185" type="protein" text="CsA"/>
            <entity id="DS3.d563.s0.e2" origId="Q13216,B3KPW7,B4DGZ9" charOffset="202-205" type="protein" text="CsA"/>
            <entity id="DS3.d563.s0.e3" origId="2265" charOffset="209-221" type="compound" text="azathioprine"/>
            <pair e1="DS3.d563.s0.e3" e2="DS3.d563.s0.e1" id="DS3.d563.s0.i0" interaction="False" />
            <pair e1="DS3.d563.s0.e0" e2="DS3.d563.s0.e1" id="DS3.d563.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d564" origId="9951548">
        <sentence id="DS3.d564.s0" origId="9951548-1" text="glucose-6-phosphate dehydrogenase (G6PD) activity and the affinity for its substrate glucose-6-phosphate were investigated under conditions similar to the physiological environment in terms of ionic strength (I: 0.188), cation concentration, pH 7.34, and temperature (37 degrees C).">
            <entity id="DS3.d564.s0.e0" origId="P11413" charOffset="0-33" type="protein" text="glucose-6-phosphate dehydrogenase"/>
            <entity id="DS3.d564.s0.e1" origId="P11413" charOffset="35-39" type="protein" text="G6PD"/>
            <entity id="DS3.d564.s0.e2" origId="5793,206,64689,79025" charOffset="0-7" type="compound" text="glucose"/>
            <entity id="DS3.d564.s0.e3" origId="1061,167704,644102" charOffset="10-19" type="compound" text="phosphate"/>
            <pair e1="DS3.d564.s0.e3" e2="DS3.d564.s0.e1" id="DS3.d564.s0.i0" interaction="False" />
            <pair e1="DS3.d564.s0.e3" e2="DS3.d564.s0.e0" id="DS3.d564.s0.i1" interaction="False" />
            <pair e1="DS3.d564.s0.e2" e2="DS3.d564.s0.e1" id="DS3.d564.s0.i2" interaction="False" />
            <pair e1="DS3.d564.s0.e2" e2="DS3.d564.s0.e0" id="DS3.d564.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d565" origId="9951550">
        <sentence id="DS3.d565.s0" origId="9951550-11" text="The finding of a strong negative correlation between SHBG levels and pancreatic beta-cell secretion, mainly for the 120-min post-glucose load proinsulin levels, reinforces the concept that low SHBG levels are a suitable marker of increased pancreatic beta-cell demand.">
            <entity id="DS3.d565.s0.e0" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="53-57" type="protein" text="SHBG"/>
            <entity id="DS3.d565.s0.e1" origId="206,5793,64689,79025" charOffset="129-136" type="compound" text="glucose"/>
            <entity id="DS3.d565.s0.e2" origId="P01308,I3WAC9" charOffset="142-152" type="protein" text="proinsulin"/>
            <entity id="DS3.d565.s0.e3" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="193-197" type="protein" text="SHBG"/>
            <pair e1="DS3.d565.s0.e1" e2="DS3.d565.s0.e0" id="DS3.d565.s0.i0" interaction="False" />
            <pair e1="DS3.d565.s0.e1" e2="DS3.d565.s0.e2" id="DS3.d565.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d565.s1" origId="9951550-5" text="Eighteen young men (30.0 +/- 2.4 years) with normal glucose tolerance and body mass indexes (BMI) ranging from 22.6 to 43.2 kg/m2 were submitted to an oral glucose tolerance test (75 g) and baseline and 120-min blood samples were used to determine insulin, proinsulin and C-peptide by specific immunoassays.">
            <entity id="DS3.d565.s1.e0" origId="206,5793,64689,79025" charOffset="52-59" type="compound" text="glucose"/>
            <entity id="DS3.d565.s1.e1" origId="206,5793,64689,79025" charOffset="156-163" type="compound" text="glucose"/>
            <entity id="DS3.d565.s1.e2" origId="P01308,I3WAC9" charOffset="248-255" type="protein" text="insulin"/>
            <entity id="DS3.d565.s1.e3" origId="P01308,I3WAC9" charOffset="257-267" type="protein" text="proinsulin"/>
            <entity id="DS3.d565.s1.e4" origId="P01308,I3WAC9" charOffset="272-281" type="protein" text="C-peptide"/>
            <pair e1="DS3.d565.s1.e0" e2="DS3.d565.s1.e2" id="DS3.d565.s1.i0" interaction="False" />
            <pair e1="DS3.d565.s1.e0" e2="DS3.d565.s1.e4" id="DS3.d565.s1.i1" interaction="False" />
            <pair e1="DS3.d565.s1.e0" e2="DS3.d565.s1.e3" id="DS3.d565.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d565.s2" origId="9951550-6" text="Baseline SHBG values were significantly correlated with baseline insulin (r = -0.58, P &amp;lt; 0.05), proinsulin (r = -0.47, P &amp;lt; 0.05), C-peptide (r = -0.55, P &amp;lt; 0.05) and also with proinsulin at 120 min after glucose load (r = -0.58, P &amp;lt; 0.05).">
            <entity id="DS3.d565.s2.e0" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="9-13" type="protein" text="SHBG"/>
            <entity id="DS3.d565.s2.e1" origId="P01308,I3WAC9" charOffset="65-72" type="protein" text="insulin"/>
            <entity id="DS3.d565.s2.e2" origId="P01308,I3WAC9" charOffset="99-109" type="protein" text="proinsulin"/>
            <entity id="DS3.d565.s2.e3" origId="P01308,I3WAC9" charOffset="136-145" type="protein" text="C-peptide"/>
            <entity id="DS3.d565.s2.e4" origId="P01308,I3WAC9" charOffset="185-195" type="protein" text="proinsulin"/>
            <entity id="DS3.d565.s2.e5" origId="206,5793,64689,79025" charOffset="213-220" type="compound" text="glucose"/>
            <pair e1="DS3.d565.s2.e5" e2="DS3.d565.s2.e0" id="DS3.d565.s2.i0" interaction="False" />
            <pair e1="DS3.d565.s2.e5" e2="DS3.d565.s2.e1" id="DS3.d565.s2.i1" interaction="False" />
            <pair e1="DS3.d565.s2.e5" e2="DS3.d565.s2.e3" id="DS3.d565.s2.i2" interaction="False" />
            <pair e1="DS3.d565.s2.e5" e2="DS3.d565.s2.e2" id="DS3.d565.s2.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d566" origId="9951552">
        <sentence id="DS3.d566.s0" origId="9951552-2" text="Eighteen subjects were treated with the alpha-melanocyte-stimulating hormone (alpha-MSH) synthetic analogue (Nle4, D-Phe7)-alpha-MSH.">
            <entity id="DS3.d566.s0.e0" origId="P01189,Q6FHC8" charOffset="78-87" type="protein" text="alpha-MSH"/>
            <entity id="DS3.d566.s0.e1" origId="92432" charOffset="115-121" type="compound" text="D-Phe7"/>
            <entity id="DS3.d566.s0.e2" origId="P01189,Q6FHC8" charOffset="123-132" type="protein" text="alpha-MSH"/>
            <pair e1="DS3.d566.s0.e1" e2="DS3.d566.s0.e0" id="DS3.d566.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d567" origId="9951556">
        <sentence id="DS3.d567.s0" origId="9951556-0" text="Cytotoxic activity of BCG-activated macrophages against L929 tumor cells is nitric oxide-dependent.">
            <entity id="DS3.d567.s0.e0" origId="P41251" charOffset="22-25" type="protein" text="BCG"/>
            <entity id="DS3.d567.s0.e1" origId="145068" charOffset="76-88" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d567.s0.e1" e2="DS3.d567.s0.e0" id="DS3.d567.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d568" origId="9951557">
        <sentence id="DS3.d568.s0" origId="9951557-0" text="Role of angiotensin II and vasopressin receptors within the supraoptic nucleus in water and sodium intake induced by the injection of angiotensin II into the medial septal area.">
            <entity id="DS3.d568.s0.e0" origId="P01015" charOffset="8-22" type="protein" text="angiotensin II"/>
            <entity id="DS3.d568.s0.e1" origId="962" charOffset="82-87" type="compound" text="water"/>
            <entity id="DS3.d568.s0.e2" origId="5360545" charOffset="92-98" type="compound" text="sodium"/>
            <entity id="DS3.d568.s0.e3" origId="P01015" charOffset="134-148" type="protein" text="angiotensin II"/>
            <pair e1="DS3.d568.s0.e1" e2="DS3.d568.s0.e0" id="DS3.d568.s0.i0" interaction="False" />
            <pair e1="DS3.d568.s0.e2" e2="DS3.d568.s0.e0" id="DS3.d568.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d568.s1" origId="9951557-1" text="In this study we investigated the effects of the injection into the supraoptic nucleus (SON) of non-peptide AT1- and AT2-angiotensin II (ANG II) receptor antagonists, DuP753 and PD123319, as well as of the arginine-vasopressin (AVP) receptor antagonist d(CH2)5-Tyr(Me)-AVP, on water and 3% NaCl intake induced by the injection of ANG II into the medial septal area (MSA).">
            <entity id="DS3.d568.s1.e0" origId="P01015" charOffset="121-135" type="protein" text="angiotensin II"/>
            <entity id="DS3.d568.s1.e1" origId="P01015" charOffset="137-143" type="protein" text="ANG II"/>
            <entity id="DS3.d568.s1.e2" origId="5311345" charOffset="178-186" type="compound" text="PD123319"/>
            <entity id="DS3.d568.s1.e3" origId="6322,90867653" charOffset="206-214" type="compound" text="arginine"/>
            <entity id="DS3.d568.s1.e4" origId="6057" charOffset="261-264" type="compound" text="Tyr"/>
            <entity id="DS3.d568.s1.e5" origId="962" charOffset="277-282" type="compound" text="water"/>
            <entity id="DS3.d568.s1.e6" origId="P01015" charOffset="330-336" type="protein" text="ANG II"/>
            <pair e1="DS3.d568.s1.e5" e2="DS3.d568.s1.e0" id="DS3.d568.s1.i0" interaction="False" />
            <pair e1="DS3.d568.s1.e5" e2="DS3.d568.s1.e1" id="DS3.d568.s1.i1" interaction="False" />
            <pair e1="DS3.d568.s1.e2" e2="DS3.d568.s1.e0" id="DS3.d568.s1.i2" interaction="False" />
            <pair e1="DS3.d568.s1.e2" e2="DS3.d568.s1.e1" id="DS3.d568.s1.i3" interaction="False" />
            <pair e1="DS3.d568.s1.e4" e2="DS3.d568.s1.e0" id="DS3.d568.s1.i4" interaction="False" />
            <pair e1="DS3.d568.s1.e4" e2="DS3.d568.s1.e1" id="DS3.d568.s1.i5" interaction="False" />
            <pair e1="DS3.d568.s1.e3" e2="DS3.d568.s1.e0" id="DS3.d568.s1.i6" interaction="False" />
            <pair e1="DS3.d568.s1.e3" e2="DS3.d568.s1.e1" id="DS3.d568.s1.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d568.s2" origId="9951557-6" text="Previous administration of the AT1 receptor antagonist DuP753 into the SON decreased water (65%, N = 10, P &amp;lt; 0.01) and sodium intake (81%, N = 8, P &amp;lt; 0.01) induced by the injection of ANG II (10 nmol) into the MSA.">
            <entity id="DS3.d568.s2.e0" origId="962" charOffset="85-90" type="compound" text="water"/>
            <entity id="DS3.d568.s2.e1" origId="5360545" charOffset="122-128" type="compound" text="sodium"/>
            <entity id="DS3.d568.s2.e2" origId="P01015" charOffset="190-196" type="protein" text="ANG II"/>
            <pair e1="DS3.d568.s2.e0" e2="DS3.d568.s2.e2" id="DS3.d568.s2.i0" interaction="False" />
            <pair e1="DS3.d568.s2.e1" e2="DS3.d568.s2.e2" id="DS3.d568.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d568.s3" origId="9951557-8" text="On the other hand, while there was a decrease in water intake (45%, N = 9, P &amp;lt; 0.01), ANG II-induced sodium intake was significantly increased (70%, N = 8, P &amp;lt; 0.01) following injection of the V1-type vasopressin antagonist d(CH2)5-Tyr(Me)-AVP into the SON.">
            <entity id="DS3.d568.s3.e0" origId="962" charOffset="49-54" type="compound" text="water"/>
            <entity id="DS3.d568.s3.e1" origId="P01015" charOffset="89-95" type="protein" text="ANG II"/>
            <entity id="DS3.d568.s3.e2" origId="5360545" charOffset="104-110" type="compound" text="sodium"/>
            <entity id="DS3.d568.s3.e3" origId="6057" charOffset="238-241" type="compound" text="Tyr"/>
            <pair e1="DS3.d568.s3.e0" e2="DS3.d568.s3.e1" id="DS3.d568.s3.i0" interaction="False" />
            <pair e1="DS3.d568.s3.e3" e2="DS3.d568.s3.e1" id="DS3.d568.s3.i1" interaction="False" />
            <pair e1="DS3.d568.s3.e2" e2="DS3.d568.s3.e1" id="DS3.d568.s3.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d568.s4" origId="9951557-9" text="These results suggest that both AT1 and V1 receptors within the SON may be involved in water and sodium intake induced by the activation of ANG II receptors within the MSA.">
            <entity id="DS3.d568.s4.e0" origId="962" charOffset="87-92" type="compound" text="water"/>
            <entity id="DS3.d568.s4.e1" origId="5360545" charOffset="97-103" type="compound" text="sodium"/>
            <entity id="DS3.d568.s4.e2" origId="P01015" charOffset="140-146" type="protein" text="ANG II"/>
            <pair e1="DS3.d568.s4.e0" e2="DS3.d568.s4.e2" id="DS3.d568.s4.i0" interaction="False" />
            <pair e1="DS3.d568.s4.e1" e2="DS3.d568.s4.e2" id="DS3.d568.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d569" origId="9951562">
        <sentence id="DS3.d569.s0" origId="9951562-1" text="BACKGROUND: Whole blood serotonin (5-HT) and C-terminally directed beta-endorphin protein immunoreactivity (C-ter-beta-EP-ir) are known to be elevated in autistic subjects and might be possible markers of genetic liability to autism.">
            <entity id="DS3.d569.s0.e0" origId="5202" charOffset="35-39" type="compound" text="5-HT"/>
            <entity id="DS3.d569.s0.e1" origId="P01189,Q6FHC8" charOffset="67-81" type="protein" text="beta-endorphin"/>
            <pair e1="DS3.d569.s0.e0" e2="DS3.d569.s0.e1" id="DS3.d569.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d570" origId="9951564">
        <sentence id="DS3.d570.s0" origId="9951564-3" text="AA-NAT leads to formation of N-acetylserotonin from serotonin, and in the pineal gland, to melatonin synthesis.">
            <entity id="DS3.d570.s0.e0" origId="Q64666" charOffset="0-6" type="protein" text="AA-NAT"/>
            <entity id="DS3.d570.s0.e1" origId="903" charOffset="31-46" type="compound" text="acetylserotonin"/>
            <entity id="DS3.d570.s0.e2" origId="5202" charOffset="37-46" type="compound" text="serotonin"/>
            <entity id="DS3.d570.s0.e3" origId="896" charOffset="91-100" type="compound" text="melatonin"/>
            <pair e1="DS3.d570.s0.e2" e2="DS3.d570.s0.e0" id="DS3.d570.s0.i0" interaction="False" />
            <pair e1="DS3.d570.s0.e1" e2="DS3.d570.s0.e0" id="DS3.d570.s0.i1" interaction="False" />
            <pair e1="DS3.d570.s0.e3" e2="DS3.d570.s0.e0" id="DS3.d570.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d571" origId="9951569">
        <sentence id="DS3.d571.s0" origId="9951569-0" text="Vitamin B12 and folate levels and lithium administration in patients with affective disorders.">
            <entity id="DS3.d571.s0.e0" origId="O43676,A0A024R413" charOffset="8-11" type="protein" text="B12"/>
            <entity id="DS3.d571.s0.e1" origId="6037" charOffset="16-22" type="compound" text="folate"/>
            <entity id="DS3.d571.s0.e2" origId="3028194" charOffset="34-41" type="compound" text="lithium"/>
            <pair e1="DS3.d571.s0.e2" e2="DS3.d571.s0.e0" id="DS3.d571.s0.i0" interaction="False" />
            <pair e1="DS3.d571.s0.e1" e2="DS3.d571.s0.e0" id="DS3.d571.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d571.s1" origId="9951569-1" text="BACKGROUND: It is unclear whether there is a relationship between lithium administration and vitamin B12 metabolism.">
            <entity id="DS3.d571.s1.e0" origId="3028194" charOffset="66-73" type="compound" text="lithium"/>
            <entity id="DS3.d571.s1.e1" origId="O43676,A0A024R413" charOffset="101-104" type="protein" text="B12"/>
            <pair e1="DS3.d571.s1.e0" e2="DS3.d571.s1.e1" id="DS3.d571.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d571.s2" origId="9951569-2" text="METHODS: We compared serum B12, serum folate, and red blood cell folate concentrations in patients receiving and not receiving lithium at two Mood Disorders Clinics.">
            <entity id="DS3.d571.s2.e0" origId="O43676,A0A024R413" charOffset="27-30" type="protein" text="B12"/>
            <entity id="DS3.d571.s2.e1" origId="6037" charOffset="38-44" type="compound" text="folate"/>
            <entity id="DS3.d571.s2.e2" origId="6037" charOffset="65-71" type="compound" text="folate"/>
            <entity id="DS3.d571.s2.e3" origId="3028194" charOffset="127-134" type="compound" text="lithium"/>
            <pair e1="DS3.d571.s2.e3" e2="DS3.d571.s2.e0" id="DS3.d571.s2.i0" interaction="False" />
            <pair e1="DS3.d571.s2.e1" e2="DS3.d571.s2.e0" id="DS3.d571.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d571.s3" origId="9951569-5" text="RESULTS: Mean serum B12 concentrations were approximately 20% lower in the lithium than in the nonlithium group at each center.">
            <entity id="DS3.d571.s3.e0" origId="O43676,A0A024R413" charOffset="20-23" type="protein" text="B12"/>
            <entity id="DS3.d571.s3.e1" origId="3028194" charOffset="75-82" type="compound" text="lithium"/>
            <pair e1="DS3.d571.s3.e1" e2="DS3.d571.s3.e0" id="DS3.d571.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d571.s4" origId="9951569-8" text="There was a nonsignificant trend toward an increased prevalence of assay-defined B12 deficiency in the lithium group at one center only, with no cases in either group at the other center and a nonsignificant combined relative risk.">
            <entity id="DS3.d571.s4.e0" origId="O43676,A0A024R413" charOffset="81-84" type="protein" text="B12"/>
            <entity id="DS3.d571.s4.e1" origId="3028194" charOffset="103-110" type="compound" text="lithium"/>
            <pair e1="DS3.d571.s4.e1" e2="DS3.d571.s4.e0" id="DS3.d571.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d571.s5" origId="9951569-9" text="CONCLUSIONS: Our data may represent a lithium-associated decrease in serum B12 concentration.">
            <entity id="DS3.d571.s5.e0" origId="3028194" charOffset="38-45" type="compound" text="lithium"/>
            <entity id="DS3.d571.s5.e1" origId="O43676,A0A024R413" charOffset="75-78" type="protein" text="B12"/>
            <pair e1="DS3.d571.s5.e0" e2="DS3.d571.s5.e1" id="DS3.d571.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d572" origId="9951570">
        <sentence id="DS3.d572.s0" origId="9951570-4" text="METHODS: Ten healthy subjects underwent a standard protocol on four occasions and each time received ovine corticotropin-releasing hormone, synthetic adrenocorticotropic hormone (ACTH), cortisol, or placebo.">
            <entity id="DS3.d572.s0.e0" origId="16132344" charOffset="101-138" type="compound" text="ovine corticotropin-releasing hormone"/>
            <entity id="DS3.d572.s0.e1" origId="P01189,Q6FHC8" charOffset="179-183" type="protein" text="ACTH"/>
            <pair e1="DS3.d572.s0.e0" e2="DS3.d572.s0.e1" id="DS3.d572.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d573" origId="9951573">
        <sentence id="DS3.d573.s0" origId="9951573-1" text="BACKGROUND: The purpose of this study was to determine the role that serotonin (5-HT)3 receptors play in the prolactin and nausea responses to clomipramine challenge.">
            <entity id="DS3.d573.s0.e0" origId="5202" charOffset="69-78" type="compound" text="serotonin"/>
            <entity id="DS3.d573.s0.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="109-118" type="protein" text="prolactin"/>
            <entity id="DS3.d573.s0.e2" origId="2801" charOffset="143-155" type="compound" text="clomipramine"/>
            <pair e1="DS3.d573.s0.e0" e2="DS3.d573.s0.e1" id="DS3.d573.s0.i0" interaction="False" />
            <pair e1="DS3.d573.s0.e2" e2="DS3.d573.s0.e1" id="DS3.d573.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d573.s1" origId="9951573-3" text="RESULTS: Ondansetron pretreatment had no effect on the prolactin response to clomipramine challenge.">
            <entity id="DS3.d573.s1.e0" origId="4595" charOffset="9-20" type="compound" text="Ondansetron"/>
            <entity id="DS3.d573.s1.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="55-64" type="protein" text="prolactin"/>
            <entity id="DS3.d573.s1.e2" origId="2801" charOffset="77-89" type="compound" text="clomipramine"/>
            <pair e1="DS3.d573.s1.e2" e2="DS3.d573.s1.e1" id="DS3.d573.s1.i0" interaction="False" />
            <pair e1="DS3.d573.s1.e0" e2="DS3.d573.s1.e1" id="DS3.d573.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d574" origId="9951583">
        <sentence id="DS3.d574.s0" origId="9951583-0" text="Laboratory control of oral anticoagulant therapy: preservation of prothrombin time specimens using a polypropylene collection system.">
            <entity id="DS3.d574.s0.e0" origId="P00734" charOffset="66-77" type="protein" text="prothrombin"/>
            <entity id="DS3.d574.s0.e1" origId="8252" charOffset="101-114" type="compound" text="polypropylene"/>
            <pair e1="DS3.d574.s0.e1" e2="DS3.d574.s0.e0" id="DS3.d574.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d574.s1" origId="9951583-8" text="Overall, the results indicate that when polypropylene collection tubes are used, prothrombin time specimens can be successfully preserved for up to 24 h at room temperature or up to 48 h when refrigerated.">
            <entity id="DS3.d574.s1.e0" origId="8252" charOffset="40-53" type="compound" text="polypropylene"/>
            <entity id="DS3.d574.s1.e1" origId="P00734" charOffset="81-92" type="protein" text="prothrombin"/>
            <pair e1="DS3.d574.s1.e0" e2="DS3.d574.s1.e1" id="DS3.d574.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d575" origId="9951625">
        <sentence id="DS3.d575.s0" origId="9951625-1" text="Nitric oxide (NO), generated by endothelial (e) NO synthase (NOS) and neuronal (n) NOS, plays a ubiquitous role in the body in controlling the function of almost every, if not every, organ system.">
            <entity id="DS3.d575.s0.e0" origId="145068" charOffset="0-12" type="compound" text="Nitric oxide"/>
            <entity id="DS3.d575.s0.e1" origId="P35228" charOffset="48-59" type="protein" text="NO synthase"/>
            <entity id="DS3.d575.s0.e2" origId="P35228" charOffset="61-64" type="protein" text="NOS"/>
            <entity id="DS3.d575.s0.e3" origId="P35228" charOffset="83-86" type="protein" text="NOS"/>
            <pair e1="DS3.d575.s0.e0" e2="DS3.d575.s0.e2" id="DS3.d575.s0.i0" interaction="False" />
            <pair e1="DS3.d575.s0.e0" e2="DS3.d575.s0.e1" id="DS3.d575.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d575.s1" origId="9951625-2" text="Bacterial and viral products, such as bacterial lipopolysaccharide (LPS), induce inducible (i) NOS synthesis that produces massive amounts of NO toxic to the invading viruses and bacteria, but also host cells by inactivation of enzymes leading to cell death.">
            <entity id="DS3.d575.s1.e0" origId="11970143" charOffset="48-66" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d575.s1.e1" origId="P35228" charOffset="95-98" type="protein" text="NOS"/>
            <pair e1="DS3.d575.s1.e0" e2="DS3.d575.s1.e1" id="DS3.d575.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d575.s2" origId="9951625-3" text="The actions of all forms of NOS are mediated not only by the free radical oxidant properties of this soluble gas, but also by its activation of guanylate cyclase (GC), leading to the production of cyclic guanosine monophosphate (cGMP) that mediates many of its physiological actions.">
            <entity id="DS3.d575.s2.e0" origId="P35228" charOffset="28-31" type="protein" text="NOS"/>
            <entity id="DS3.d575.s2.e1" origId="24755530" charOffset="204-227" type="compound" text="guanosine monophosphate"/>
            <entity id="DS3.d575.s2.e2" origId="24316" charOffset="229-233" type="compound" text="cGMP"/>
            <pair e1="DS3.d575.s2.e2" e2="DS3.d575.s2.e0" id="DS3.d575.s2.i0" interaction="False" />
            <pair e1="DS3.d575.s2.e1" e2="DS3.d575.s2.e0" id="DS3.d575.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d576" origId="9951626">
        <sentence id="DS3.d576.s0" origId="9951626-1" text="The present article summarizes our data regarding: (a) the effect of sex steroids on the expression of a specific astrocytic marker in glial cell cultures (GFAP); (b) the effects of aging on two markers of the peripheral myelin (glycoprotein Po and the myelin basic protein, MBP); (c) the possible modification of the damaging effects of aging on these two markers by the in vivo administration of progesterone and its derivatives; and, finally, (d) the effect of progesterone derivatives on the gene expression of Po in cultures of rat Schwann cells.">
            <entity id="DS3.d576.s0.e0" origId="P47819" charOffset="156-160" type="protein" text="GFAP"/>
            <entity id="DS3.d576.s0.e1" origId="P02688,Q5XFW1,I7FKL4" charOffset="253-273" type="protein" text="myelin basic protein"/>
            <entity id="DS3.d576.s0.e2" origId="P02688,Q5XFW1,I7FKL4" charOffset="275-278" type="protein" text="MBP"/>
            <entity id="DS3.d576.s0.e3" origId="5994" charOffset="398-410" type="compound" text="progesterone"/>
            <entity id="DS3.d576.s0.e4" origId="5994" charOffset="464-476" type="compound" text="progesterone"/>
            <pair e1="DS3.d576.s0.e3" e2="DS3.d576.s0.e2" id="DS3.d576.s0.i0" interaction="False" />
            <pair e1="DS3.d576.s0.e3" e2="DS3.d576.s0.e0" id="DS3.d576.s0.i1" interaction="False" />
            <pair e1="DS3.d576.s0.e3" e2="DS3.d576.s0.e1" id="DS3.d576.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d576.s1" origId="9951626-2" text="The data obtained have indicated that progesterone and its 5 alpha-reduced metabolites may play an important role in the control of gene expression of GFAP and Po, respectively, in type 1 astrocytes and Schwann cells.">
            <entity id="DS3.d576.s1.e0" origId="5994" charOffset="38-50" type="compound" text="progesterone"/>
            <entity id="DS3.d576.s1.e1" origId="P47819" charOffset="151-155" type="protein" text="GFAP"/>
            <pair e1="DS3.d576.s1.e0" e2="DS3.d576.s1.e1" id="DS3.d576.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d577" origId="9951627">
        <sentence id="DS3.d577.s0" origId="9951627-9" text="Immunohistochemical staining for fibronectin and chondroitin sulfate proteoglycans revealed a substantial decrease that could account for a decrease in diffusion barriers.">
            <entity id="DS3.d577.s0.e0" origId="F1LST1,A0A096P6L8" charOffset="33-44" type="protein" text="fibronectin"/>
            <entity id="DS3.d577.s0.e1" origId="53477707" charOffset="49-60" type="compound" text="chondroitin"/>
            <entity id="DS3.d577.s0.e2" origId="1117" charOffset="61-68" type="compound" text="sulfate"/>
            <pair e1="DS3.d577.s0.e1" e2="DS3.d577.s0.e0" id="DS3.d577.s0.i0" interaction="False" />
            <pair e1="DS3.d577.s0.e2" e2="DS3.d577.s0.e0" id="DS3.d577.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d578" origId="9951628">
        <sentence id="DS3.d578.s0" origId="9951628-2" text="NCAM is found in three major forms, of which two--NCAM-140 and NCAM-180--are transmembrane proteins, while the third--NCAM-120--is attached to the membrane via a glycosylphosphatidyl inositol anchor.">
            <entity id="DS3.d578.s0.e0" origId="P13595,E9QB01,E9Q589,A0A0A6YY47" charOffset="0-4" type="protein" text="NCAM"/>
            <entity id="DS3.d578.s0.e1" origId="P13595,E9QB01,E9Q589,A0A0A6YY47" charOffset="50-54" type="protein" text="NCAM"/>
            <entity id="DS3.d578.s0.e2" origId="P13595,E9QB01,E9Q589,A0A0A6YY47" charOffset="50-54" type="protein" text="NCAM"/>
            <entity id="DS3.d578.s0.e3" origId="P13595,E9QB01,E9Q589,A0A0A6YY47" charOffset="50-54" type="protein" text="NCAM"/>
            <entity id="DS3.d578.s0.e4" origId="892" charOffset="183-191" type="compound" text="inositol"/>
            <pair e1="DS3.d578.s0.e4" e2="DS3.d578.s0.e0" id="DS3.d578.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d578.s1" origId="9951628-5" text="Following NCAM binding, transmembrane signalling is believed to be activated, resulting in increased intracellular calcium.">
            <entity id="DS3.d578.s1.e0" origId="P13595,E9QB01,E9Q589,A0A0A6YY47" charOffset="10-14" type="protein" text="NCAM"/>
            <entity id="DS3.d578.s1.e1" origId="22044544,5460341" charOffset="115-122" type="compound" text="calcium"/>
            <pair e1="DS3.d578.s1.e1" e2="DS3.d578.s1.e0" id="DS3.d578.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d579" origId="9951632">
        <sentence id="DS3.d579.s0" origId="9951632-3" text="Plasma parameters of clotting activation in vivo, such as prothrombin fragment 1 + 2, fibrinopeptide A, thrombin-antithrombin III complex, and D-dimer, are positively correlated with age.">
            <entity id="DS3.d579.s0.e0" origId="P00734" charOffset="58-69" type="protein" text="prothrombin"/>
            <entity id="DS3.d579.s0.e1" origId="25078015,25081464" charOffset="86-102" type="compound" text="fibrinopeptide A"/>
            <entity id="DS3.d579.s0.e2" origId="90470996" charOffset="61-69" type="compound" text="thrombin"/>
            <entity id="DS3.d579.s0.e3" origId="P01008,A0A024R944" charOffset="113-129" type="protein" text="antithrombin III"/>
            <pair e1="DS3.d579.s0.e2" e2="DS3.d579.s0.e3" id="DS3.d579.s0.i0" interaction="False" />
            <pair e1="DS3.d579.s0.e2" e2="DS3.d579.s0.e0" id="DS3.d579.s0.i1" interaction="False" />
            <pair e1="DS3.d579.s0.e1" e2="DS3.d579.s0.e3" id="DS3.d579.s0.i2" interaction="False" />
            <pair e1="DS3.d579.s0.e1" e2="DS3.d579.s0.e0" id="DS3.d579.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d579.s1" origId="9951632-5" text="Natural anticoagulants, including antithrombin III, heparin cofactor II, protein C, protein S, and tissue factor pathway inhibitor, can modulate the reactions of blood coagulation system.">
            <entity id="DS3.d579.s1.e0" origId="P01008,A0A024R944" charOffset="34-50" type="protein" text="antithrombin III"/>
            <entity id="DS3.d579.s1.e1" origId="P05546,Q8IVC0" charOffset="52-71" type="protein" text="heparin cofactor II"/>
            <entity id="DS3.d579.s1.e2" origId="P04070" charOffset="73-82" type="protein" text="protein C"/>
            <entity id="DS3.d579.s1.e3" origId="38003" charOffset="99-130" type="compound" text="tissue factor pathway inhibitor"/>
            <pair e1="DS3.d579.s1.e3" e2="DS3.d579.s1.e0" id="DS3.d579.s1.i0" interaction="False" />
            <pair e1="DS3.d579.s1.e3" e2="DS3.d579.s1.e2" id="DS3.d579.s1.i1" interaction="False" />
            <pair e1="DS3.d579.s1.e3" e2="DS3.d579.s1.e1" id="DS3.d579.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d580" origId="9951633">
        <sentence id="DS3.d580.s0" origId="9951633-10" text="The cortisol/DHEA-S ratio during the life span follows a U-shape curve, which may be telling us to explore these two critical adrenal steroids in tandem.">
            <entity id="DS3.d580.s0.e0" origId="5754" charOffset="4-12" type="compound" text="cortisol"/>
            <entity id="DS3.d580.s0.e1" origId="Q06520,A8K015" charOffset="13-19" type="protein" text="DHEA-S"/>
            <pair e1="DS3.d580.s0.e0" e2="DS3.d580.s0.e1" id="DS3.d580.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d580.s1" origId="9951633-8" text="The life-sustaining role of adrenal cortisol secretion and its regulation of metabolism via catabolic actions may be modulated by its partner DHEA and DHEA-S.">
            <entity id="DS3.d580.s1.e0" origId="5754" charOffset="36-44" type="compound" text="cortisol"/>
            <entity id="DS3.d580.s1.e1" origId="Q06520,A8K015" charOffset="151-157" type="protein" text="DHEA-S"/>
            <pair e1="DS3.d580.s1.e0" e2="DS3.d580.s1.e1" id="DS3.d580.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d580.s2" origId="9951633-9" text="During the anabolic growth period (childhood and early adulthood) the body is exposed to relatively high levels of DHEA/DHEA-S but to relatively or absolutely high levels of cortisol during infancy and the aging phase.">
            <entity id="DS3.d580.s2.e0" origId="Q06520,A8K015" charOffset="120-126" type="protein" text="DHEA-S"/>
            <entity id="DS3.d580.s2.e1" origId="5754" charOffset="174-182" type="compound" text="cortisol"/>
            <pair e1="DS3.d580.s2.e1" e2="DS3.d580.s2.e0" id="DS3.d580.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d581" origId="9951645">
        <sentence id="DS3.d581.s0" origId="9951645-3" text="The effect of various concentrations of Trapidil on cell viability and cell proliferation was determined using three different culture conditions: (1) serum-free medium (WM/F12), (2) serum-containing medium (WM/F12 + 10% FCS), and (3) serum-free medium + 50 ng/ml PDGF-BB.">
            <entity id="DS3.d581.s0.e0" origId="5531,57293064" charOffset="40-48" type="compound" text="Trapidil"/>
            <entity id="DS3.d581.s0.e1" origId="P98140" charOffset="173-176" type="protein" text="F12"/>
            <entity id="DS3.d581.s0.e2" origId="P98140" charOffset="211-214" type="protein" text="F12"/>
            <pair e1="DS3.d581.s0.e0" e2="DS3.d581.s0.e1" id="DS3.d581.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d582" origId="9951680">
        <sentence id="DS3.d582.s0" origId="9951680-7" text="At 2 months, total retinal detachment appeared with a large superior retinal dialysis.">
            <entity id="DS3.d582.s0.e0" origId="P50052" charOffset="0-4" type="protein" text="At 2"/>
            <entity id="DS3.d582.s0.e1" origId="638015" charOffset="19-26" type="compound" text="retinal"/>
            <entity id="DS3.d582.s0.e2" origId="638015" charOffset="69-76" type="compound" text="retinal"/>
            <pair e1="DS3.d582.s0.e1" e2="DS3.d582.s0.e0" id="DS3.d582.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d583" origId="9951685">
        <sentence id="DS3.d583.s0" origId="9951685-0" text="Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)--what is the difference?">
            <entity id="DS3.d583.s0.e0" origId="P09919,Q6FH65,Q8N4W3" charOffset="52-89" type="protein" text="granulocyte colony-stimulating factor"/>
            <entity id="DS3.d583.s0.e1" origId="16122568,16750043,4369303,448383" charOffset="95-98" type="compound" text="CSF"/>
            <pair e1="DS3.d583.s0.e1" e2="DS3.d583.s0.e0" id="DS3.d583.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d583.s1" origId="9951685-1" text="Two forms of recombinant human G-CSF (rhG-CSF) are available for clinical use: filgrastim is expressed in E coli and non-glycosylated, whereas lenograstim is derived from Chinese hamster ovary (CHO) cells and glycosylated.">
            <entity id="DS3.d583.s1.e0" origId="P09919,Q6FH65,Q8N4W3" charOffset="31-36" type="protein" text="G-CSF"/>
            <entity id="DS3.d583.s1.e1" origId="16122568,16750043,4369303,448383" charOffset="33-36" type="compound" text="CSF"/>
            <entity id="DS3.d583.s1.e2" origId="P09919,Q6FH65,Q8N4W3" charOffset="143-154" type="protein" text="lenograstim"/>
            <pair e1="DS3.d583.s1.e1" e2="DS3.d583.s1.e2" id="DS3.d583.s1.i0" interaction="False" />
            <pair e1="DS3.d583.s1.e1" e2="DS3.d583.s1.e0" id="DS3.d583.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d583.s2" origId="9951685-6" text="Correspondingly, two randomised crossover studies in normal subjects, comparing mass equivalent doses of the two rhG-CSFs, have demonstrated a 25-30% higher concentration of blood stem cells (CD34+, CFU-GM) during lenograstim administration.">
            <entity id="DS3.d583.s2.e0" origId="77620543" charOffset="199-202" type="compound" text="CFU"/>
            <entity id="DS3.d583.s2.e1" origId="P09919,Q6FH65,Q8N4W3" charOffset="214-225" type="protein" text="lenograstim"/>
            <pair e1="DS3.d583.s2.e0" e2="DS3.d583.s2.e1" id="DS3.d583.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d584" origId="9951689">
        <sentence id="DS3.d584.s0" origId="9951689-4" text="Chemosensitivity data, according to a short-term assay (FMCA), indicated that tumours with p53 mutation were more resistant to cisplatin and cyclophosphamide.">
            <entity id="DS3.d584.s0.e0" origId="71716335" charOffset="56-60" type="compound" text="FMCA"/>
            <entity id="DS3.d584.s0.e1" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="91-94" type="protein" text="p53"/>
            <entity id="DS3.d584.s0.e2" origId="2907" charOffset="141-157" type="compound" text="cyclophosphamide"/>
            <pair e1="DS3.d584.s0.e2" e2="DS3.d584.s0.e1" id="DS3.d584.s0.i0" interaction="False" />
            <pair e1="DS3.d584.s0.e0" e2="DS3.d584.s0.e1" id="DS3.d584.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d585" origId="9951690">
        <sentence id="DS3.d585.s0" origId="9951690-1" text="2-benzoyl-3-phenylquinoxaline 1,4-dioxide (BPQ) and other substituted quinoxaline 1,4-dioxides (QdO) were tested for their ability to inhibit the stimulations of ornithine decarboxylase (ODC) enzyme activity and DNA synthesis, two biochemical markers linked to skin tumour promotion by ultraviolet B (UVB) radiation.">
            <entity id="DS3.d585.s0.e0" origId="314065" charOffset="0-29" type="compound" text="2-benzoyl-3-phenylquinoxaline"/>
            <entity id="DS3.d585.s0.e1" origId="28467" charOffset="30-41" type="compound" text="1,4-dioxide"/>
            <entity id="DS3.d585.s0.e2" origId="7045" charOffset="18-29" type="compound" text="quinoxaline"/>
            <entity id="DS3.d585.s0.e3" origId="P00860" charOffset="162-185" type="protein" text="ornithine decarboxylase"/>
            <entity id="DS3.d585.s0.e4" origId="P00860" charOffset="187-190" type="protein" text="ODC"/>
            <pair e1="DS3.d585.s0.e2" e2="DS3.d585.s0.e3" id="DS3.d585.s0.i0" interaction="False" />
            <pair e1="DS3.d585.s0.e2" e2="DS3.d585.s0.e4" id="DS3.d585.s0.i1" interaction="False" />
            <pair e1="DS3.d585.s0.e0" e2="DS3.d585.s0.e3" id="DS3.d585.s0.i2" interaction="False" />
            <pair e1="DS3.d585.s0.e0" e2="DS3.d585.s0.e4" id="DS3.d585.s0.i3" interaction="False" />
            <pair e1="DS3.d585.s0.e1" e2="DS3.d585.s0.e3" id="DS3.d585.s0.i4" interaction="False" />
            <pair e1="DS3.d585.s0.e1" e2="DS3.d585.s0.e4" id="DS3.d585.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d586" origId="9951698">
        <sentence id="DS3.d586.s0" origId="9951698-6" text="In the present study, we report that by lowering growth temperature and overexpressing a rare arginyl tRNA, it is possible to boost the production in Escherichia coli of murine TdT with minimal proteolysis and high specific activity.">
            <entity id="DS3.d586.s0.e0" origId="19919009,444288" charOffset="94-101" type="compound" text="arginyl"/>
            <entity id="DS3.d586.s0.e1" origId="P09838,Q3UZ80" charOffset="177-180" type="protein" text="TdT"/>
            <pair e1="DS3.d586.s0.e0" e2="DS3.d586.s0.e1" id="DS3.d586.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d587" origId="9951729">
        <sentence id="DS3.d587.s0" origId="9951729-3" text="It consists of a nuclear-encoded, regulatory subunit ClpC, which is an ATPase, and a plastid-encoded proteolytic subunit ClpP, which is a serine protease.">
            <entity id="DS3.d587.s0.e0" origId="Q2MI76" charOffset="121-125" type="protein" text="ClpP"/>
            <entity id="DS3.d587.s0.e1" origId="5951" charOffset="138-144" type="compound" text="serine"/>
            <pair e1="DS3.d587.s0.e1" e2="DS3.d587.s0.e0" id="DS3.d587.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d588" origId="9951731">
        <sentence id="DS3.d588.s0" origId="9951731-2" text="The enzyme has an absolute requirement for reduced FMN as a cofactor, although the 1,4-anti elimination of phosphate and the C(6proR)-hydrogen does not involve a net redox change.">
            <entity id="DS3.d588.s0.e0" origId="Q68DA7,H0YM30" charOffset="51-54" type="protein" text="FMN"/>
            <entity id="DS3.d588.s0.e1" origId="108194" charOffset="60-68" type="compound" text="cofactor"/>
            <entity id="DS3.d588.s0.e2" origId="1061,167704,644102" charOffset="107-116" type="compound" text="phosphate"/>
            <entity id="DS3.d588.s0.e3" origId="783" charOffset="134-142" type="compound" text="hydrogen"/>
            <pair e1="DS3.d588.s0.e2" e2="DS3.d588.s0.e0" id="DS3.d588.s0.i0" interaction="False" />
            <pair e1="DS3.d588.s0.e3" e2="DS3.d588.s0.e0" id="DS3.d588.s0.i1" interaction="False" />
            <pair e1="DS3.d588.s0.e1" e2="DS3.d588.s0.e0" id="DS3.d588.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d588.s1" origId="9951731-5" text="Studies on chorismate synthases from bacteria, fungi and plants revealed that in these organisms the reduced FMN cofactor is made available in different ways to chorismate synthase: chorismate synthases in fungi--in contrast to those in bacteria and plants--carry a second enzymatic activity which enables them to reduce FMN at the expense of NADPH.">
            <entity id="DS3.d588.s1.e0" origId="12039" charOffset="11-21" type="compound" text="chorismate"/>
            <entity id="DS3.d588.s1.e1" origId="Q68DA7,H0YM30" charOffset="109-112" type="protein" text="FMN"/>
            <entity id="DS3.d588.s1.e2" origId="108194" charOffset="113-121" type="compound" text="cofactor"/>
            <entity id="DS3.d588.s1.e3" origId="12039" charOffset="161-171" type="compound" text="chorismate"/>
            <entity id="DS3.d588.s1.e4" origId="12039" charOffset="161-171" type="compound" text="chorismate"/>
            <entity id="DS3.d588.s1.e5" origId="Q68DA7,H0YM30" charOffset="321-324" type="protein" text="FMN"/>
            <entity id="DS3.d588.s1.e6" origId="Q16698,A0A024R9D7" charOffset="343-348" type="protein" text="NADPH"/>
            <pair e1="DS3.d588.s1.e0" e2="DS3.d588.s1.e1" id="DS3.d588.s1.i0" interaction="False" />
            <pair e1="DS3.d588.s1.e0" e2="DS3.d588.s1.e6" id="DS3.d588.s1.i1" interaction="False" />
            <pair e1="DS3.d588.s1.e2" e2="DS3.d588.s1.e1" id="DS3.d588.s1.i2" interaction="False" />
            <pair e1="DS3.d588.s1.e2" e2="DS3.d588.s1.e6" id="DS3.d588.s1.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d589" origId="9951732">
        <sentence id="DS3.d589.s0" origId="9951732-2" text="were measured in double mutants between MSG1 and AXR1, both of which are auxin-resistant and defective in hypocotyl growth curvature induced upon unilateral application of auxin.">
            <entity id="DS3.d589.s0.e0" origId="P93022,F4K5M5" charOffset="40-44" type="protein" text="MSG1"/>
            <entity id="DS3.d589.s0.e1" origId="P42744,F4I7A3,F4I7A4" charOffset="49-53" type="protein" text="AXR1"/>
            <entity id="DS3.d589.s0.e2" origId="802" charOffset="73-78" type="compound" text="auxin"/>
            <entity id="DS3.d589.s0.e3" origId="802" charOffset="172-177" type="compound" text="auxin"/>
            <pair e1="DS3.d589.s0.e2" e2="DS3.d589.s0.e1" id="DS3.d589.s0.i0" interaction="False" />
            <pair e1="DS3.d589.s0.e2" e2="DS3.d589.s0.e0" id="DS3.d589.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d589.s1" origId="9951732-3" text="The MSG1 AXR1 double mutants showed no auxin-induced growth curvature, that is, they exhibited the MSG1 phenotype, though the AXR1 defects were partial.">
            <entity id="DS3.d589.s1.e0" origId="P93022,F4K5M5" charOffset="4-8" type="protein" text="MSG1"/>
            <entity id="DS3.d589.s1.e1" origId="P42744,F4I7A3,F4I7A4" charOffset="9-13" type="protein" text="AXR1"/>
            <entity id="DS3.d589.s1.e2" origId="802" charOffset="39-44" type="compound" text="auxin"/>
            <entity id="DS3.d589.s1.e3" origId="P93022,F4K5M5" charOffset="99-103" type="protein" text="MSG1"/>
            <entity id="DS3.d589.s1.e4" origId="P42744,F4I7A3,F4I7A4" charOffset="126-130" type="protein" text="AXR1"/>
            <pair e1="DS3.d589.s1.e2" e2="DS3.d589.s1.e1" id="DS3.d589.s1.i0" interaction="False" />
            <pair e1="DS3.d589.s1.e2" e2="DS3.d589.s1.e0" id="DS3.d589.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d589.s2" origId="9951732-8" text="The hypocotyls of these mutants showed auxin resistance in the order: MSG1 AXR1 &amp;gt; AXR1 &amp;gt; MSG1 &amp;gt; wild type.">
            <entity id="DS3.d589.s2.e0" origId="802" charOffset="39-44" type="compound" text="auxin"/>
            <entity id="DS3.d589.s2.e1" origId="P93022,F4K5M5" charOffset="70-74" type="protein" text="MSG1"/>
            <entity id="DS3.d589.s2.e2" origId="P42744,F4I7A3,F4I7A4" charOffset="75-79" type="protein" text="AXR1"/>
            <entity id="DS3.d589.s2.e3" origId="P42744,F4I7A3,F4I7A4" charOffset="85-89" type="protein" text="AXR1"/>
            <entity id="DS3.d589.s2.e4" origId="P93022,F4K5M5" charOffset="95-99" type="protein" text="MSG1"/>
            <pair e1="DS3.d589.s2.e0" e2="DS3.d589.s2.e2" id="DS3.d589.s2.i0" interaction="False" />
            <pair e1="DS3.d589.s2.e0" e2="DS3.d589.s2.e1" id="DS3.d589.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d590" origId="9951738">
        <sentence id="DS3.d590.s0" origId="9951738-3" text="One isolated cDNA clone, designated Nrt2:1At, was found to code for a putative high-affinity nitrate transporter.">
            <entity id="DS3.d590.s0.e0" origId="O82811" charOffset="36-40" type="protein" text="Nrt2"/>
            <entity id="DS3.d590.s0.e1" origId="71576793" charOffset="41-44" type="compound" text="1At"/>
            <entity id="DS3.d590.s0.e2" origId="943,10313259" charOffset="93-100" type="compound" text="nitrate"/>
            <pair e1="DS3.d590.s0.e2" e2="DS3.d590.s0.e0" id="DS3.d590.s0.i0" interaction="False" />
            <pair e1="DS3.d590.s0.e1" e2="DS3.d590.s0.e0" id="DS3.d590.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d590.s1" origId="9951738-4" text="Two genomic sequences homologous to Nrt2:1At were found to be localized on the same fragment of chromosome 1 in the Arabidopsis genome.">
            <entity id="DS3.d590.s1.e0" origId="O82811" charOffset="36-40" type="protein" text="Nrt2"/>
            <entity id="DS3.d590.s1.e1" origId="71576793" charOffset="41-44" type="compound" text="1At"/>
            <pair e1="DS3.d590.s1.e1" e2="DS3.d590.s1.e0" id="DS3.d590.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d590.s2" origId="9951738-5" text="Expression analyses of both low- and high-affinity nitrate transporter genes, respectively Nrt1:1At (previously named Chl1) and Nrt2:1At, were carried out on plants grown under different nitrogen regimes.">
            <entity id="DS3.d590.s2.e0" origId="943,10313259" charOffset="51-58" type="compound" text="nitrate"/>
            <entity id="DS3.d590.s2.e1" origId="Q05085" charOffset="91-95" type="protein" text="Nrt1"/>
            <entity id="DS3.d590.s2.e2" origId="71576793" charOffset="96-99" type="compound" text="1At"/>
            <entity id="DS3.d590.s2.e3" origId="Q05085" charOffset="118-122" type="protein" text="Chl1"/>
            <entity id="DS3.d590.s2.e4" origId="O82811" charOffset="128-132" type="protein" text="Nrt2"/>
            <entity id="DS3.d590.s2.e5" origId="71576793" charOffset="133-136" type="compound" text="1At"/>
            <entity id="DS3.d590.s2.e6" origId="947" charOffset="187-195" type="compound" text="nitrogen"/>
            <pair e1="DS3.d590.s2.e0" e2="DS3.d590.s2.e3" id="DS3.d590.s2.i0" interaction="False" />
            <pair e1="DS3.d590.s2.e0" e2="DS3.d590.s2.e1" id="DS3.d590.s2.i1" interaction="False" />
            <pair e1="DS3.d590.s2.e0" e2="DS3.d590.s2.e4" id="DS3.d590.s2.i2" interaction="False" />
            <pair e1="DS3.d590.s2.e2" e2="DS3.d590.s2.e3" id="DS3.d590.s2.i3" interaction="False" />
            <pair e1="DS3.d590.s2.e2" e2="DS3.d590.s2.e1" id="DS3.d590.s2.i4" interaction="False" />
            <pair e1="DS3.d590.s2.e2" e2="DS3.d590.s2.e4" id="DS3.d590.s2.i5" interaction="False" />
            <pair e1="DS3.d590.s2.e6" e2="DS3.d590.s2.e3" id="DS3.d590.s2.i6" interaction="False" />
            <pair e1="DS3.d590.s2.e6" e2="DS3.d590.s2.e1" id="DS3.d590.s2.i7" interaction="False" />
            <pair e1="DS3.d590.s2.e6" e2="DS3.d590.s2.e4" id="DS3.d590.s2.i8" interaction="False" />
        </sentence>
        <sentence id="DS3.d590.s3" origId="9951738-7" text="However, stronger induction was observed with Nrt2:1At than with Nrt1:1At.">
            <entity id="DS3.d590.s3.e0" origId="O82811" charOffset="46-50" type="protein" text="Nrt2"/>
            <entity id="DS3.d590.s3.e1" origId="71576793" charOffset="51-54" type="compound" text="1At"/>
            <entity id="DS3.d590.s3.e2" origId="Q05085" charOffset="65-69" type="protein" text="Nrt1"/>
            <entity id="DS3.d590.s3.e3" origId="71576793" charOffset="70-73" type="compound" text="1At"/>
            <pair e1="DS3.d590.s3.e1" e2="DS3.d590.s3.e2" id="DS3.d590.s3.i0" interaction="False" />
            <pair e1="DS3.d590.s3.e1" e2="DS3.d590.s3.e0" id="DS3.d590.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d590.s4" origId="9951738-9" text="Indeed, the steady-state amounts of Nrt1:1At mRNA declined whereas the amount of Nrt2:1At mRNA increased, probably reflecting the de-repression of the high-affinity transport system during N-starvation.">
            <entity id="DS3.d590.s4.e0" origId="Q05085" charOffset="36-40" type="protein" text="Nrt1"/>
            <entity id="DS3.d590.s4.e1" origId="71576793" charOffset="41-44" type="compound" text="1At"/>
            <entity id="DS3.d590.s4.e2" origId="O82811" charOffset="81-85" type="protein" text="Nrt2"/>
            <entity id="DS3.d590.s4.e3" origId="71576793" charOffset="86-89" type="compound" text="1At"/>
            <pair e1="DS3.d590.s4.e1" e2="DS3.d590.s4.e0" id="DS3.d590.s4.i0" interaction="False" />
            <pair e1="DS3.d590.s4.e1" e2="DS3.d590.s4.e2" id="DS3.d590.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d591" origId="9951766">
        <sentence id="DS3.d591.s0" origId="9951766-0" text="In vivo 300 MHz longitudinally detected ESR-CT imaging in the head of a rat treated with a nitroxide radical.">
            <entity id="DS3.d591.s0.e0" origId="P06211,D0FYH4" charOffset="40-43" type="protein" text="ESR"/>
            <entity id="DS3.d591.s0.e1" origId="787" charOffset="91-100" type="compound" text="nitroxide"/>
            <pair e1="DS3.d591.s0.e1" e2="DS3.d591.s0.e0" id="DS3.d591.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d592" origId="9951770">
        <sentence id="DS3.d592.s0" origId="9951770-1" text="The study provides a review of the basic examination procedures and results of proton magnetic resonance spectroscopy (1H MRS) in patients suffering from mesial temporal lobe epilepsy (MTLE).">
            <entity id="DS3.d592.s0.e0" origId="1038,5460653" charOffset="79-85" type="compound" text="proton"/>
            <entity id="DS3.d592.s0.e1" origId="P59665" charOffset="122-125" type="protein" text="MRS"/>
            <pair e1="DS3.d592.s0.e0" e2="DS3.d592.s0.e1" id="DS3.d592.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d592.s1" origId="9951770-4" text="The decisive 1H MRS parameter characterizing an epileptogenic lesion is a statistically significantly decreased value of N-acetylaspartate levels compared with control values, most often associated with a decrease in the ratios of the intensities of NAA/Cr, NAA/Cho and NAA/(Cr + Cho) signals.">
            <entity id="DS3.d592.s1.e0" origId="P59665" charOffset="16-19" type="protein" text="MRS"/>
            <entity id="DS3.d592.s1.e1" origId="65065" charOffset="121-138" type="compound" text="N-acetylaspartate"/>
            <pair e1="DS3.d592.s1.e1" e2="DS3.d592.s1.e0" id="DS3.d592.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d592.s2" origId="9951770-6" text="As regards other metabolic compounds which play an important role in the pathobiochemistry of epilepsy, MRS is employed to study the action of gamma-aminobutyric acid (GABA), inositol, lactate, glutamine, and glutamate, the clinical function of which has not been fully clarified as yet.">
            <entity id="DS3.d592.s2.e0" origId="P59665" charOffset="104-107" type="protein" text="MRS"/>
            <entity id="DS3.d592.s2.e1" origId="119" charOffset="143-166" type="compound" text="gamma-aminobutyric acid"/>
            <entity id="DS3.d592.s2.e2" origId="892" charOffset="175-183" type="compound" text="inositol"/>
            <entity id="DS3.d592.s2.e3" origId="612" charOffset="185-192" type="compound" text="lactate"/>
            <entity id="DS3.d592.s2.e4" origId="5961" charOffset="194-203" type="compound" text="glutamine"/>
            <entity id="DS3.d592.s2.e5" origId="23327,33032,611,57109091" charOffset="209-218" type="compound" text="glutamate"/>
            <pair e1="DS3.d592.s2.e5" e2="DS3.d592.s2.e0" id="DS3.d592.s2.i0" interaction="False" />
            <pair e1="DS3.d592.s2.e1" e2="DS3.d592.s2.e0" id="DS3.d592.s2.i1" interaction="False" />
            <pair e1="DS3.d592.s2.e4" e2="DS3.d592.s2.e0" id="DS3.d592.s2.i2" interaction="False" />
            <pair e1="DS3.d592.s2.e2" e2="DS3.d592.s2.e0" id="DS3.d592.s2.i3" interaction="False" />
            <pair e1="DS3.d592.s2.e3" e2="DS3.d592.s2.e0" id="DS3.d592.s2.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d593" origId="9951776">
        <sentence id="DS3.d593.s0" origId="9951776-7" text="PTH treatment of ovx rats increased cancellous bone volume by 191% in the PTM, 56% in the DTM, 47% in the LV, and 22% in the CV, compared with vehicle treatment of ovx rats.">
            <entity id="DS3.d593.s0.e0" origId="P04089" charOffset="0-3" type="protein" text="PTH"/>
            <entity id="DS3.d593.s0.e1" origId="5289224" charOffset="74-77" type="compound" text="PTM"/>
            <pair e1="DS3.d593.s0.e1" e2="DS3.d593.s0.e0" id="DS3.d593.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d594" origId="9951785">
        <sentence id="DS3.d594.s0" origId="9951785-5" text="Bone-specific alkaline phosphatase and osteocalcin levels increased significantly during summer (p &amp;lt; 0.001) and urinary calcium level decreased significantly during winter (p &amp;lt; 0.05).">
            <entity id="DS3.d594.s0.e0" origId="P02818" charOffset="39-50" type="protein" text="osteocalcin"/>
            <entity id="DS3.d594.s0.e1" origId="22044544,5460341" charOffset="123-130" type="compound" text="calcium"/>
            <pair e1="DS3.d594.s0.e1" e2="DS3.d594.s0.e0" id="DS3.d594.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d595" origId="9951809">
        <sentence id="DS3.d595.s0" origId="9951809-4" text="Because MICA-1.2 and -1.4 were in strong linkage disequilibria with HLA-B52 and -B54 in the Japanese populations, respectively, we have compared the odds ratio (OR) of the risk to the diseases for individuals having both or each of the disease-associated MICA and HLA-B alleles.">
            <entity id="DS3.d595.s0.e0" origId="44475967" charOffset="72-75" type="compound" text="B52"/>
            <entity id="DS3.d595.s0.e1" origId="44373851" charOffset="81-84" type="compound" text="B54"/>
            <entity id="DS3.d595.s0.e2" origId="P01889,P30460,Q5SS57,E5FQ95" charOffset="68-73" type="protein" text="HLA-B"/>
            <pair e1="DS3.d595.s0.e0" e2="DS3.d595.s0.e2" id="DS3.d595.s0.i0" interaction="False" />
            <pair e1="DS3.d595.s0.e1" e2="DS3.d595.s0.e2" id="DS3.d595.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d596" origId="9951810">
        <sentence id="DS3.d596.s0" origId="9951810-2" text="The frequency of HLA-A31 and HLA-B52 (chi2=4.54, P&amp;lt;0.05; chi2=3.80, P&amp;lt;0.05, RR=7.5) appeared to be increased in the patient group.">
            <entity id="DS3.d596.s0.e0" origId="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126" charOffset="17-24" type="protein" text="HLA-A31"/>
            <entity id="DS3.d596.s0.e1" origId="44475967" charOffset="33-36" type="compound" text="B52"/>
            <pair e1="DS3.d596.s0.e1" e2="DS3.d596.s0.e0" id="DS3.d596.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d597" origId="9951812">
        <sentence id="DS3.d597.s0" origId="9951812-4" text="The data revealed a strong association of the disease with HLA-B5 (chi2=22.5, P&amp;lt;1 x 10(-6), RR=3.08) as well as its two common serological subtypes, B51 (chi2=20.5) and B52 (chi2=18.5).">
            <entity id="DS3.d597.s0.e0" origId="57340899" charOffset="152-155" type="compound" text="B51"/>
            <entity id="DS3.d597.s0.e1" origId="Q13247" charOffset="172-175" type="protein" text="B52"/>
            <pair e1="DS3.d597.s0.e0" e2="DS3.d597.s0.e1" id="DS3.d597.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d597.s1" origId="9951812-6" text="The observation suggest that HLA linked genes are definitely involved in the development of Takayasu arteritis and that the disease in Indian subjects is associated with HLA-B5 and its two serological subtypes, B51 as well as B52.">
            <entity id="DS3.d597.s1.e0" origId="57340899" charOffset="211-214" type="compound" text="B51"/>
            <entity id="DS3.d597.s1.e1" origId="Q13247" charOffset="226-229" type="protein" text="B52"/>
            <pair e1="DS3.d597.s1.e0" e2="DS3.d597.s1.e1" id="DS3.d597.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d598" origId="9951833">
        <sentence id="DS3.d598.s0" origId="9951833-4" text="UVC treatment during G0/G1 phase resulted in decreased incorporation of (3H)thymidine, an effect that was enhanced by pretreatment with TGF-beta1.">
            <entity id="DS3.d598.s0.e0" origId="5789" charOffset="76-85" type="compound" text="thymidine"/>
            <entity id="DS3.d598.s0.e1" origId="Q14766,B7ZLY3" charOffset="136-145" type="protein" text="TGF-beta1"/>
            <pair e1="DS3.d598.s0.e0" e2="DS3.d598.s0.e1" id="DS3.d598.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d599" origId="9951837">
        <sentence id="DS3.d599.s0" origId="9951837-0" text="The effects of cadmium on the hepatic and renal levels of reduced glutathione, the activity of glutathione S-transferase and gamma glutamyl transpeptidase.">
            <entity id="DS3.d599.s0.e0" origId="23973" charOffset="15-22" type="compound" text="cadmium"/>
            <entity id="DS3.d599.s0.e1" origId="124886" charOffset="58-77" type="compound" text="reduced glutathione"/>
            <entity id="DS3.d599.s0.e2" origId="20725278,745" charOffset="66-77" type="compound" text="glutathione"/>
            <entity id="DS3.d599.s0.e3" origId="Q60928,Q4FK56" charOffset="125-154" type="protein" text="gamma glutamyl transpeptidase"/>
            <pair e1="DS3.d599.s0.e0" e2="DS3.d599.s0.e3" id="DS3.d599.s0.i0" interaction="False" />
            <pair e1="DS3.d599.s0.e1" e2="DS3.d599.s0.e3" id="DS3.d599.s0.i1" interaction="False" />
            <pair e1="DS3.d599.s0.e2" e2="DS3.d599.s0.e3" id="DS3.d599.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d599.s1" origId="9951837-1" text="Cadmium chloride, injected subcutaneously in mice at doses of 1.0, 1.5, and 2.0 mg/Kg body weight, resulted in the alteration of body weight and relative liver and kidney weights, the hepatic and renal reduced glutathione levels, and the activity of the enzymes glutathione S-transferase and gamma-glutamyl transpeptidase in a dose-dependent manner.">
            <entity id="DS3.d599.s1.e0" origId="24633,24947" charOffset="0-16" type="compound" text="Cadmium chloride"/>
            <entity id="DS3.d599.s1.e1" origId="124886" charOffset="202-221" type="compound" text="reduced glutathione"/>
            <entity id="DS3.d599.s1.e2" origId="20725278,745" charOffset="210-221" type="compound" text="glutathione"/>
            <entity id="DS3.d599.s1.e3" origId="Q60928,Q4FK56" charOffset="292-321" type="protein" text="gamma-glutamyl transpeptidase"/>
            <pair e1="DS3.d599.s1.e0" e2="DS3.d599.s1.e3" id="DS3.d599.s1.i0" interaction="False" />
            <pair e1="DS3.d599.s1.e2" e2="DS3.d599.s1.e3" id="DS3.d599.s1.i1" interaction="False" />
            <pair e1="DS3.d599.s1.e1" e2="DS3.d599.s1.e3" id="DS3.d599.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d599.s2" origId="9951837-7" text="The present study showed that the effects of cadmium could be correlated with a decreased level of reduced glutathione and glutathione S-transferase activity and an increased activity of gamma-glutamyl transpeptidase in liver and kidney.">
            <entity id="DS3.d599.s2.e0" origId="23973" charOffset="45-52" type="compound" text="cadmium"/>
            <entity id="DS3.d599.s2.e1" origId="124886" charOffset="99-118" type="compound" text="reduced glutathione"/>
            <entity id="DS3.d599.s2.e2" origId="20725278,745" charOffset="107-118" type="compound" text="glutathione"/>
            <entity id="DS3.d599.s2.e3" origId="Q60928,Q4FK56" charOffset="187-216" type="protein" text="gamma-glutamyl transpeptidase"/>
            <pair e1="DS3.d599.s2.e0" e2="DS3.d599.s2.e3" id="DS3.d599.s2.i0" interaction="False" />
            <pair e1="DS3.d599.s2.e1" e2="DS3.d599.s2.e3" id="DS3.d599.s2.i1" interaction="False" />
            <pair e1="DS3.d599.s2.e2" e2="DS3.d599.s2.e3" id="DS3.d599.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d600" origId="9951876">
        <sentence id="DS3.d600.s0" origId="9951876-0" text="Dihydropyrimidine dehydrogenase but not thymidylate synthase expression is associated with resistance to 5-fluorouracil in colorectal cancer.">
            <entity id="DS3.d600.s0.e0" origId="Q12882" charOffset="0-31" type="protein" text="Dihydropyrimidine dehydrogenase"/>
            <entity id="DS3.d600.s0.e1" origId="P04818,Q53Y97" charOffset="40-60" type="protein" text="thymidylate synthase"/>
            <entity id="DS3.d600.s0.e2" origId="3385" charOffset="107-119" type="compound" text="fluorouracil"/>
            <pair e1="DS3.d600.s0.e2" e2="DS3.d600.s0.e1" id="DS3.d600.s0.i0" interaction="False" />
            <pair e1="DS3.d600.s0.e2" e2="DS3.d600.s0.e0" id="DS3.d600.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d600.s1" origId="9951876-2" text="thymidylate synthase (TS) and Dihydropyrimidine dehydrogenase (DPD) are key enzymes involved in the biochemical functions of the antimetabolite 5-fluorouracil (5-FU).">
            <entity id="DS3.d600.s1.e0" origId="P04818,Q53Y97" charOffset="0-20" type="protein" text="thymidylate synthase"/>
            <entity id="DS3.d600.s1.e1" origId="Q12882" charOffset="30-61" type="protein" text="Dihydropyrimidine dehydrogenase"/>
            <entity id="DS3.d600.s1.e2" origId="Q12882" charOffset="63-66" type="protein" text="DPD"/>
            <entity id="DS3.d600.s1.e3" origId="3385" charOffset="146-158" type="compound" text="fluorouracil"/>
            <pair e1="DS3.d600.s1.e3" e2="DS3.d600.s1.e0" id="DS3.d600.s1.i0" interaction="False" />
            <pair e1="DS3.d600.s1.e3" e2="DS3.d600.s1.e2" id="DS3.d600.s1.i1" interaction="False" />
            <pair e1="DS3.d600.s1.e3" e2="DS3.d600.s1.e1" id="DS3.d600.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d601" origId="9951906">
        <sentence id="DS3.d601.s0" origId="9951906-11" text="Triglycerides (TG) (p&amp;lt;0.05) and cholesterol (Chol) (p&amp;lt;0.05) were reduced as well, whereas Apolipoprotein B levels did not change.">
            <entity id="DS3.d601.s0.e0" origId="5997" charOffset="35-46" type="compound" text="cholesterol"/>
            <entity id="DS3.d601.s0.e1" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="96-112" type="protein" text="Apolipoprotein B"/>
            <pair e1="DS3.d601.s0.e0" e2="DS3.d601.s0.e1" id="DS3.d601.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d601.s1" origId="9951906-13" text="Except for cholestatic liver disease with raised serum cholesterol (p&amp;lt;0.05) and Apolipoprotein B levels (p&amp;lt;0.001), the etiology of cirrhosis had no impact on the observed serum lipid alterations.">
            <entity id="DS3.d601.s1.e0" origId="5997" charOffset="55-66" type="compound" text="cholesterol"/>
            <entity id="DS3.d601.s1.e1" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="83-99" type="protein" text="Apolipoprotein B"/>
            <pair e1="DS3.d601.s1.e0" e2="DS3.d601.s1.e1" id="DS3.d601.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d601.s2" origId="9951906-5" text="In contrast, apolipoprotein A-I (apoA-I) represents the primary protein content of the high density lipoprotein (HDL) particles, which interacts with the putative HDL-receptor, and stimulates the enzymatic reaction of lecithin-cholesterol acyltransferase (LCAT) resulting in esterified cholesterol, which is the essential step in the process of reverse cholesterol transport.">
            <entity id="DS3.d601.s2.e0" origId="P02647,A0A024R3E3" charOffset="13-31" type="protein" text="apolipoprotein A-I"/>
            <entity id="DS3.d601.s2.e1" origId="P02647,A0A024R3E3" charOffset="33-39" type="protein" text="apoA-I"/>
            <entity id="DS3.d601.s2.e2" origId="P04180" charOffset="218-254" type="protein" text="lecithin-cholesterol acyltransferase"/>
            <entity id="DS3.d601.s2.e3" origId="P04180" charOffset="256-260" type="protein" text="LCAT"/>
            <entity id="DS3.d601.s2.e4" origId="5997" charOffset="227-238" type="compound" text="cholesterol"/>
            <entity id="DS3.d601.s2.e5" origId="5997" charOffset="286-297" type="compound" text="cholesterol"/>
            <pair e1="DS3.d601.s2.e4" e2="DS3.d601.s2.e2" id="DS3.d601.s2.i0" interaction="False" />
            <pair e1="DS3.d601.s2.e4" e2="DS3.d601.s2.e3" id="DS3.d601.s2.i1" interaction="False" />
            <pair e1="DS3.d601.s2.e4" e2="DS3.d601.s2.e1" id="DS3.d601.s2.i2" interaction="False" />
            <pair e1="DS3.d601.s2.e4" e2="DS3.d601.s2.e0" id="DS3.d601.s2.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d602" origId="9951915">
        <sentence id="DS3.d602.s0" origId="9951915-11" text="One, 3 and 6 months after TIPS there was no significant deterioration of liver function as assessed by ABT, MEGX or serum bilirubin, serum albumin, and prothrombin time compared to baseline values before TIPS.">
            <entity id="DS3.d602.s0.e0" origId="5280352" charOffset="122-131" type="compound" text="bilirubin"/>
            <entity id="DS3.d602.s0.e1" origId="P00734" charOffset="152-163" type="protein" text="prothrombin"/>
            <pair e1="DS3.d602.s0.e0" e2="DS3.d602.s0.e1" id="DS3.d602.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d602.s1" origId="9951915-8" text="Liver function was quantitatively measured using the (14C)aminopyrine breath test (ABT), considered to be independent of hepatic blood flow, the monoethylglycinexylidide test (MEGX), believed to be largely dependent on hepatic blood flow, serum bilirubin, serum albumin, and prothrombin time.">
            <entity id="DS3.d602.s1.e0" origId="24415" charOffset="145-169" type="compound" text="monoethylglycinexylidide"/>
            <entity id="DS3.d602.s1.e1" origId="5280352" charOffset="245-254" type="compound" text="bilirubin"/>
            <entity id="DS3.d602.s1.e2" origId="P00734" charOffset="275-286" type="protein" text="prothrombin"/>
            <pair e1="DS3.d602.s1.e1" e2="DS3.d602.s1.e2" id="DS3.d602.s1.i0" interaction="False" />
            <pair e1="DS3.d602.s1.e0" e2="DS3.d602.s1.e2" id="DS3.d602.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d603" origId="9951918">
        <sentence id="DS3.d603.s0" origId="9951918-2" text="Visual control of the operating field is important for isolation and ligation of blood vessels and bile ducts after selective liver dissection by suitable techniques such as the water-jet dissector.">
            <entity id="DS3.d603.s0.e0" origId="962" charOffset="178-183" type="compound" text="water"/>
            <entity id="DS3.d603.s0.e1" origId="Q9H469" charOffset="184-187" type="protein" text="jet"/>
            <pair e1="DS3.d603.s0.e0" e2="DS3.d603.s0.e1" id="DS3.d603.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d604" origId="9951937">
        <sentence id="DS3.d604.s0" origId="9951937-4" text="METHODOLOGY: Liver cirrhosis has been induced in rats by 1% dimethylnitrosamine (Sigma, St. Louis, Mo) dissolved in normal saline at the dose of 10 ml of DMN/Kg, i.p., 3 consecutive days a week for 4 weeks.">
            <entity id="DS3.d604.s0.e0" origId="6124" charOffset="60-79" type="compound" text="dimethylnitrosamine"/>
            <entity id="DS3.d604.s0.e1" origId="G3V9G5,A0A096MK54" charOffset="154-157" type="protein" text="DMN"/>
            <pair e1="DS3.d604.s0.e0" e2="DS3.d604.s0.e1" id="DS3.d604.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d605" origId="9951940">
        <sentence id="DS3.d605.s0" origId="9951940-3" text="METHODOLOGY: The expression of E-cadherin was evaluated in 83 formalin-fixed, paraffin-embedded specimens of gastric cancer by immunohistochemistry.">
            <entity id="DS3.d605.s0.e0" origId="P12830" charOffset="31-41" type="protein" text="E-cadherin"/>
            <entity id="DS3.d605.s0.e1" origId="712" charOffset="62-70" type="compound" text="formalin"/>
            <pair e1="DS3.d605.s0.e1" e2="DS3.d605.s0.e0" id="DS3.d605.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d606" origId="9951948">
        <sentence id="DS3.d606.s0" origId="9951948-13" text="Recently, efforts have focused on use of alpha1A-urospecific antagonists such as tamsulosin and alfuzosin in an attempt to achieve similar clinical results as doxazosin and terazosin without systemic adverse effects.">
            <entity id="DS3.d606.s0.e0" origId="O00555,A0A087WW63,Q9NS89,B5TYJ1" charOffset="41-48" type="protein" text="alpha1A"/>
            <entity id="DS3.d606.s0.e1" origId="129211" charOffset="81-91" type="compound" text="tamsulosin"/>
            <entity id="DS3.d606.s0.e2" origId="2092" charOffset="96-105" type="compound" text="alfuzosin"/>
            <entity id="DS3.d606.s0.e3" origId="3157" charOffset="159-168" type="compound" text="doxazosin"/>
            <entity id="DS3.d606.s0.e4" origId="5401" charOffset="173-182" type="compound" text="terazosin"/>
            <pair e1="DS3.d606.s0.e2" e2="DS3.d606.s0.e0" id="DS3.d606.s0.i0" interaction="False" />
            <pair e1="DS3.d606.s0.e3" e2="DS3.d606.s0.e0" id="DS3.d606.s0.i1" interaction="False" />
            <pair e1="DS3.d606.s0.e4" e2="DS3.d606.s0.e0" id="DS3.d606.s0.i2" interaction="False" />
            <pair e1="DS3.d606.s0.e1" e2="DS3.d606.s0.e0" id="DS3.d606.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d607" origId="9951949">
        <sentence id="DS3.d607.s0" origId="9951949-10" text="Both insulin lispro and repaglinide are associated with postprandial hyperinsulinaemia.">
            <entity id="DS3.d607.s0.e0" origId="P01308,I3WAC9" charOffset="5-12" type="protein" text="insulin"/>
            <entity id="DS3.d607.s0.e1" origId="65981" charOffset="24-35" type="compound" text="repaglinide"/>
            <pair e1="DS3.d607.s0.e1" e2="DS3.d607.s0.e0" id="DS3.d607.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d607.s1" origId="9951949-12" text="alpha-glucosidase inhibitors such as acarbose, miglitol and voglibose also reduce PPHG primarily by interfering with the carbohydrate-digesting enzymes and delaying glucose absorption.">
            <entity id="DS3.d607.s1.e0" origId="O43451,E7ER45" charOffset="0-17" type="protein" text="alpha-glucosidase"/>
            <entity id="DS3.d607.s1.e1" origId="41774,441184,4432690,444254,445421,44891366,70702327,71312704" charOffset="37-45" type="compound" text="acarbose"/>
            <entity id="DS3.d607.s1.e2" origId="441314" charOffset="47-55" type="compound" text="miglitol"/>
            <entity id="DS3.d607.s1.e3" origId="444020" charOffset="60-69" type="compound" text="voglibose"/>
            <entity id="DS3.d607.s1.e4" origId="206,64689,79025" charOffset="165-172" type="compound" text="glucose"/>
            <pair e1="DS3.d607.s1.e1" e2="DS3.d607.s1.e0" id="DS3.d607.s1.i0" interaction="False" />
            <pair e1="DS3.d607.s1.e4" e2="DS3.d607.s1.e0" id="DS3.d607.s1.i1" interaction="False" />
            <pair e1="DS3.d607.s1.e2" e2="DS3.d607.s1.e0" id="DS3.d607.s1.i2" interaction="False" />
            <pair e1="DS3.d607.s1.e3" e2="DS3.d607.s1.e0" id="DS3.d607.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d607.s2" origId="9951949-5" text="These include insulin lispro, amylin analogues, alpha-glucosidase inhibitors and meglitinide analogues.">
            <entity id="DS3.d607.s2.e0" origId="P01308,I3WAC9" charOffset="14-21" type="protein" text="insulin"/>
            <entity id="DS3.d607.s2.e1" origId="P10997,A0A024RAU1" charOffset="30-36" type="protein" text="amylin"/>
            <entity id="DS3.d607.s2.e2" origId="O43451,E7ER45" charOffset="48-65" type="protein" text="alpha-glucosidase"/>
            <entity id="DS3.d607.s2.e3" origId="41214" charOffset="81-92" type="compound" text="meglitinide"/>
            <pair e1="DS3.d607.s2.e3" e2="DS3.d607.s2.e1" id="DS3.d607.s2.i0" interaction="False" />
            <pair e1="DS3.d607.s2.e3" e2="DS3.d607.s2.e2" id="DS3.d607.s2.i1" interaction="False" />
            <pair e1="DS3.d607.s2.e3" e2="DS3.d607.s2.e0" id="DS3.d607.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d608" origId="9951955">
        <sentence id="DS3.d608.s0" origId="9951955-4" text="In clinical studies, single-dose ibandronate (0.2 to 6 mg intravenously) significantly reduced albumin-corrected serum calcium levels and urinary markers of bone resorption in patients with hypercalcaemia of malignancy, and in those with bone metastases.">
            <entity id="DS3.d608.s0.e0" origId="P02768" charOffset="95-102" type="protein" text="albumin"/>
            <entity id="DS3.d608.s0.e1" origId="22044544,5460341" charOffset="119-126" type="compound" text="calcium"/>
            <pair e1="DS3.d608.s0.e1" e2="DS3.d608.s0.e0" id="DS3.d608.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d609" origId="9951956">
        <sentence id="DS3.d609.s0" origId="9951956-1" text="The 5alpha-reductase inhibitor finasteride blocks the conversion of testosterone to dihydrotestosterone (DHT), the androgen responsible for male pattern hair loss (androgenetic alopecia) in genetically predisposed men.">
            <entity id="DS3.d609.s0.e0" origId="P18405" charOffset="4-20" type="protein" text="5alpha-reductase"/>
            <entity id="DS3.d609.s0.e1" origId="57363" charOffset="31-42" type="compound" text="finasteride"/>
            <entity id="DS3.d609.s0.e2" origId="6013" charOffset="68-80" type="compound" text="testosterone"/>
            <entity id="DS3.d609.s0.e3" origId="147320,10635" charOffset="84-103" type="compound" text="dihydrotestosterone"/>
            <pair e1="DS3.d609.s0.e3" e2="DS3.d609.s0.e0" id="DS3.d609.s0.i0" interaction="False" />
            <pair e1="DS3.d609.s0.e1" e2="DS3.d609.s0.e0" id="DS3.d609.s0.i1" interaction="False" />
            <pair e1="DS3.d609.s0.e2" e2="DS3.d609.s0.e0" id="DS3.d609.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d610" origId="9951957">
        <sentence id="DS3.d610.s0" origId="9951957-2" text="Two patients with advanced stages of the disease were treated with polychemotherapy (pentamidine and allopurinol) combined with recombinant human interferon-gamma (rIFN-gamma).">
            <entity id="DS3.d610.s0.e0" origId="4735" charOffset="85-96" type="compound" text="pentamidine"/>
            <entity id="DS3.d610.s0.e1" origId="2094" charOffset="101-112" type="compound" text="allopurinol"/>
            <entity id="DS3.d610.s0.e2" origId="P01579" charOffset="128-162" type="protein" text="recombinant human interferon-gamma"/>
            <entity id="DS3.d610.s0.e3" origId="P01581" charOffset="164-174" type="protein" text="rIFN-gamma"/>
            <pair e1="DS3.d610.s0.e1" e2="DS3.d610.s0.e2" id="DS3.d610.s0.i0" interaction="False" />
            <pair e1="DS3.d610.s0.e1" e2="DS3.d610.s0.e3" id="DS3.d610.s0.i1" interaction="False" />
            <pair e1="DS3.d610.s0.e0" e2="DS3.d610.s0.e2" id="DS3.d610.s0.i2" interaction="False" />
            <pair e1="DS3.d610.s0.e0" e2="DS3.d610.s0.e3" id="DS3.d610.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d610.s1" origId="9951957-5" text="Both patients were treated and recovered rapidly, but one of them developed insulin-dependent type I diabetes because of pentamidine toxicity.">
            <entity id="DS3.d610.s1.e0" origId="P01308,I3WAC9" charOffset="76-83" type="protein" text="insulin"/>
            <entity id="DS3.d610.s1.e1" origId="4735" charOffset="121-132" type="compound" text="pentamidine"/>
            <pair e1="DS3.d610.s1.e1" e2="DS3.d610.s1.e0" id="DS3.d610.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d610.s2" origId="9951957-7" text="Our results suggest that allopurinol-pentamidine polychemotherapy, involving reduced dosage of pentamidine, combined with rIFN-gamma is an alternative for DCL patients infected with L. m. mexicana.">
            <entity id="DS3.d610.s2.e0" origId="2094" charOffset="25-36" type="compound" text="allopurinol"/>
            <entity id="DS3.d610.s2.e1" origId="4735" charOffset="37-48" type="compound" text="pentamidine"/>
            <entity id="DS3.d610.s2.e2" origId="4735" charOffset="95-106" type="compound" text="pentamidine"/>
            <entity id="DS3.d610.s2.e3" origId="P01581" charOffset="122-132" type="protein" text="rIFN-gamma"/>
            <pair e1="DS3.d610.s2.e0" e2="DS3.d610.s2.e3" id="DS3.d610.s2.i0" interaction="False" />
            <pair e1="DS3.d610.s2.e1" e2="DS3.d610.s2.e3" id="DS3.d610.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d611" origId="9952005">
        <sentence id="DS3.d611.s0" origId="9952005-1" text="The first intravascular oxygenator and carbon dioxide (CO2) removal device (IVOX), conceived by Mortensen, was capable of removing 30% of CO2 production of an adult at normocapnia with a measurable reduction in ventilator requirements.">
            <entity id="DS3.d611.s0.e0" origId="280" charOffset="39-53" type="compound" text="carbon dioxide"/>
            <entity id="DS3.d611.s0.e1" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="55-58" type="protein" text="CO2"/>
            <entity id="DS3.d611.s0.e2" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="138-141" type="protein" text="CO2"/>
            <pair e1="DS3.d611.s0.e0" e2="DS3.d611.s0.e1" id="DS3.d611.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d612" origId="9952022">
        <sentence id="DS3.d612.s0" origId="9952022-3" text="In addition, DR4 expression is upregulated on B cells of patients suffering from chronic inflammation and is reduced under prednisolone-treatment.">
            <entity id="DS3.d612.s0.e0" origId="P13762,X5D2U9" charOffset="13-16" type="protein" text="DR4"/>
            <entity id="DS3.d612.s0.e1" origId="5755" charOffset="123-135" type="compound" text="prednisolone"/>
            <pair e1="DS3.d612.s0.e1" e2="DS3.d612.s0.e0" id="DS3.d612.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d613" origId="9952023">
        <sentence id="DS3.d613.s0" origId="9952023-4" text="Specific glycolipids such as alpha-galactosylceramide (alpha-GalCer) and alpha-glucosylceramide (alpha-GlcCer) have been identified as ligand(s) recognized by murine Valpha14NKT cells in a CD1d-restricted manner, but it remains unclear whether these glycolipids are ligand(s) for Valpha24NKT cells in humans.">
            <entity id="DS3.d613.s0.e0" origId="2826713" charOffset="29-53" type="compound" text="alpha-galactosylceramide"/>
            <entity id="DS3.d613.s0.e1" origId="71317033" charOffset="61-67" type="compound" text="GalCer"/>
            <entity id="DS3.d613.s0.e2" origId="6475228" charOffset="79-95" type="compound" text="glucosylceramide"/>
            <entity id="DS3.d613.s0.e3" origId="15297626" charOffset="97-109" type="compound" text="alpha-GlcCer"/>
            <entity id="DS3.d613.s0.e4" origId="P15813,P11609" charOffset="189-193" type="protein" text="CD1d"/>
            <pair e1="DS3.d613.s0.e0" e2="DS3.d613.s0.e4" id="DS3.d613.s0.i0" interaction="False" />
            <pair e1="DS3.d613.s0.e1" e2="DS3.d613.s0.e4" id="DS3.d613.s0.i1" interaction="False" />
            <pair e1="DS3.d613.s0.e2" e2="DS3.d613.s0.e4" id="DS3.d613.s0.i2" interaction="False" />
            <pair e1="DS3.d613.s0.e3" e2="DS3.d613.s0.e4" id="DS3.d613.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d614" origId="9952026">
        <sentence id="DS3.d614.s0" origId="9952026-2" text="In the present study, we show that, in healthy individuals and immunosuppressed kidney transplant recipients, CD69 expression and intracellular cytokine production by peripheral blood T cells compare favorably to thymidine uptake as a measure of PBL response to alloantigen in mixed leukocyte culture (MLC).">
            <entity id="DS3.d614.s0.e0" origId="Q07108,Q53ZX0" charOffset="110-114" type="protein" text="CD69"/>
            <entity id="DS3.d614.s0.e1" origId="5789" charOffset="213-222" type="compound" text="thymidine"/>
            <pair e1="DS3.d614.s0.e1" e2="DS3.d614.s0.e0" id="DS3.d614.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d614.s1" origId="9952026-8" text="Two had no response to donor cells (donor-specific hyporesponsiveness), three had donor-specific anergy (CD69 expression without cytokine production in response to donor cells), five had a donor-specific Thl response (CD69 expression and IL-2 production in response to donor cells), and one had a donor-specific Th2 response (CD69 expression and IL-4 but not IL-2 production in response to donor cells).">
            <entity id="DS3.d614.s1.e0" origId="Q07108,Q53ZX0" charOffset="105-109" type="protein" text="CD69"/>
            <entity id="DS3.d614.s1.e1" origId="4599" charOffset="204-207" type="compound" text="Thl"/>
            <entity id="DS3.d614.s1.e2" origId="Q07108,Q53ZX0" charOffset="218-222" type="protein" text="CD69"/>
            <entity id="DS3.d614.s1.e3" origId="Q07108,Q53ZX0" charOffset="218-222" type="protein" text="CD69"/>
            <pair e1="DS3.d614.s1.e1" e2="DS3.d614.s1.e0" id="DS3.d614.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d615" origId="9952030">
        <sentence id="DS3.d615.s0" origId="9952030-2" text="Human cord blood CD34+ cells were plated in methylcellulose in the presence of stem cell factor (SCF), granulocyte-colony stimulating factor (G-CSF), interleukin (IL)-7, and the murine stroma cell line, MS-5.">
            <entity id="DS3.d615.s0.e0" origId="44263857" charOffset="44-59" type="compound" text="methylcellulose"/>
            <entity id="DS3.d615.s0.e1" origId="P21583,A0A024RBC0,A0A024RBF5" charOffset="79-95" type="protein" text="stem cell factor"/>
            <entity id="DS3.d615.s0.e2" origId="P21583,A0A024RBC0,A0A024RBF5" charOffset="97-100" type="protein" text="SCF"/>
            <entity id="DS3.d615.s0.e3" origId="P09919,Q6FH65,Q8N4W3" charOffset="103-140" type="protein" text="granulocyte-colony stimulating factor"/>
            <entity id="DS3.d615.s0.e4" origId="P09919,Q6FH65,Q8N4W3" charOffset="142-147" type="protein" text="G-CSF"/>
            <pair e1="DS3.d615.s0.e0" e2="DS3.d615.s0.e1" id="DS3.d615.s0.i0" interaction="False" />
            <pair e1="DS3.d615.s0.e0" e2="DS3.d615.s0.e2" id="DS3.d615.s0.i1" interaction="False" />
            <pair e1="DS3.d615.s0.e0" e2="DS3.d615.s0.e4" id="DS3.d615.s0.i2" interaction="False" />
            <pair e1="DS3.d615.s0.e0" e2="DS3.d615.s0.e3" id="DS3.d615.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d615.s1" origId="9952030-3" text="The growing primary colonies were individually examined for their potentials to differentiate along both myeloid and B-lymphoid lineages by reculturing aliquots of the primary colonies in methylcellulose culture containing IL-3, G-CSF and erythropoietin (Epo), and on a monolayer of MS-5 in the presence of SCF and G-CSF.">
            <entity id="DS3.d615.s1.e0" origId="44263857" charOffset="188-203" type="compound" text="methylcellulose"/>
            <entity id="DS3.d615.s1.e1" origId="P08700" charOffset="223-227" type="protein" text="IL-3"/>
            <entity id="DS3.d615.s1.e2" origId="P09919,Q6FH65,Q8N4W3" charOffset="229-234" type="protein" text="G-CSF"/>
            <entity id="DS3.d615.s1.e3" origId="P01588,G9JKG7" charOffset="239-253" type="protein" text="erythropoietin"/>
            <entity id="DS3.d615.s1.e4" origId="P01588,G9JKG7" charOffset="255-258" type="protein" text="Epo"/>
            <entity id="DS3.d615.s1.e5" origId="P21583,A0A024RBC0,A0A024RBF5" charOffset="307-310" type="protein" text="SCF"/>
            <entity id="DS3.d615.s1.e6" origId="P09919,Q6FH65,Q8N4W3" charOffset="315-320" type="protein" text="G-CSF"/>
            <pair e1="DS3.d615.s1.e0" e2="DS3.d615.s1.e4" id="DS3.d615.s1.i0" interaction="False" />
            <pair e1="DS3.d615.s1.e0" e2="DS3.d615.s1.e5" id="DS3.d615.s1.i1" interaction="False" />
            <pair e1="DS3.d615.s1.e0" e2="DS3.d615.s1.e3" id="DS3.d615.s1.i2" interaction="False" />
            <pair e1="DS3.d615.s1.e0" e2="DS3.d615.s1.e2" id="DS3.d615.s1.i3" interaction="False" />
            <pair e1="DS3.d615.s1.e0" e2="DS3.d615.s1.e1" id="DS3.d615.s1.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d616" origId="9952034">
        <sentence id="DS3.d616.s0" origId="9952034-0" text="Ganglioside GM1 attenuates scopolamine-induced amnesia in rats and mice.">
            <entity id="DS3.d616.s0.e0" origId="E9Q3H6" charOffset="12-15" type="protein" text="GM1"/>
            <entity id="DS3.d616.s0.e1" origId="11968014,5284456,452977,6432494" charOffset="27-38" type="compound" text="scopolamine"/>
            <pair e1="DS3.d616.s0.e1" e2="DS3.d616.s0.e0" id="DS3.d616.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d616.s1" origId="9952034-2" text="The present study investigates the effects of GM1 on the memory impairment induced by scopolamine in rats or mice tested in passive (PA) and discriminative avoidance (DA) tasks, respectively.">
            <entity id="DS3.d616.s1.e0" origId="E9Q3H6" charOffset="46-49" type="protein" text="GM1"/>
            <entity id="DS3.d616.s1.e1" origId="11968014,5284456,452977,6432494" charOffset="86-97" type="compound" text="scopolamine"/>
            <pair e1="DS3.d616.s1.e1" e2="DS3.d616.s1.e0" id="DS3.d616.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d616.s2" origId="9952034-4" text="Twenty-four hours after the last injection, GM1-treated animals received 1 mg/kg scopolamine (GM1-SCO) and saline-treated animals received 1 mg/kg scopolamine (SAL-SCO) or saline (SAL-SAL) IP.">
            <entity id="DS3.d616.s2.e0" origId="E9Q3H6" charOffset="44-47" type="protein" text="GM1"/>
            <entity id="DS3.d616.s2.e1" origId="11968014,5284456,452977,6432494" charOffset="81-92" type="compound" text="scopolamine"/>
            <entity id="DS3.d616.s2.e2" origId="E9Q3H6" charOffset="94-97" type="protein" text="GM1"/>
            <entity id="DS3.d616.s2.e3" origId="446720" charOffset="98-101" type="compound" text="SCO"/>
            <entity id="DS3.d616.s2.e4" origId="11968014,5284456,452977,6432494" charOffset="147-158" type="compound" text="scopolamine"/>
            <entity id="DS3.d616.s2.e5" origId="446720" charOffset="164-167" type="compound" text="SCO"/>
            <pair e1="DS3.d616.s2.e3" e2="DS3.d616.s2.e0" id="DS3.d616.s2.i0" interaction="False" />
            <pair e1="DS3.d616.s2.e1" e2="DS3.d616.s2.e0" id="DS3.d616.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d616.s3" origId="9952034-7" text="GM1-SCO animals showed an increased LD when compared to SAL-SCO animals and were not significantly different from SAL-SAL rats.">
            <entity id="DS3.d616.s3.e0" origId="E9Q3H6" charOffset="0-3" type="protein" text="GM1"/>
            <entity id="DS3.d616.s3.e1" origId="446720" charOffset="4-7" type="compound" text="SCO"/>
            <entity id="DS3.d616.s3.e2" origId="446720" charOffset="60-63" type="compound" text="SCO"/>
            <pair e1="DS3.d616.s3.e1" e2="DS3.d616.s3.e0" id="DS3.d616.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d616.s4" origId="9952034-8" text="GM1-SCO and SAL-SAL (but not SAL-SCO) mice spent significantly less time in the aversive enclosed arm of the discriminative avoidance apparatus when compared to the time spent in the non-aversive enclosed arm.">
            <entity id="DS3.d616.s4.e0" origId="E9Q3H6" charOffset="0-3" type="protein" text="GM1"/>
            <entity id="DS3.d616.s4.e1" origId="446720" charOffset="4-7" type="compound" text="SCO"/>
            <entity id="DS3.d616.s4.e2" origId="446720" charOffset="33-36" type="compound" text="SCO"/>
            <pair e1="DS3.d616.s4.e1" e2="DS3.d616.s4.e0" id="DS3.d616.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d616.s5" origId="9952034-9" text="The results are consistent with the interpretation that GM1 attenuates scopolamine-induced amnesia.">
            <entity id="DS3.d616.s5.e0" origId="E9Q3H6" charOffset="56-59" type="protein" text="GM1"/>
            <entity id="DS3.d616.s5.e1" origId="11968014,5284456,452977,6432494" charOffset="71-82" type="compound" text="scopolamine"/>
            <pair e1="DS3.d616.s5.e1" e2="DS3.d616.s5.e0" id="DS3.d616.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d617" origId="9952038">
        <sentence id="DS3.d617.s0" origId="9952038-8" text="This tolerance was accompanied by a significant increase in brain nicotinic receptor number assessed by quantitative auto-radiography using (3H)-cytisine (alpha4 nAChr) and (125I)-alpha-bungarotoxin (alpha7 nAChr) as radioligands.">
            <entity id="DS3.d617.s0.e0" origId="O70174,Q53YK0" charOffset="155-167" type="protein" text="alpha4 nAChr"/>
            <entity id="DS3.d617.s0.e1" origId="44264212" charOffset="180-198" type="compound" text="alpha-bungarotoxin"/>
            <entity id="DS3.d617.s0.e2" origId="P49582,Q8CC01,Q53YJ9" charOffset="200-212" type="protein" text="alpha7 nAChr"/>
            <pair e1="DS3.d617.s0.e1" e2="DS3.d617.s0.e0" id="DS3.d617.s0.i0" interaction="False" />
            <pair e1="DS3.d617.s0.e1" e2="DS3.d617.s0.e2" id="DS3.d617.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d618" origId="9952048">
        <sentence id="DS3.d618.s0" origId="9952048-0" text="Effect of nociceptin on alcohol intake in alcohol-preferring rats.">
            <entity id="DS3.d618.s0.e0" origId="Q62923" charOffset="10-20" type="protein" text="nociceptin"/>
            <entity id="DS3.d618.s0.e1" origId="10982484,702" charOffset="24-31" type="compound" text="alcohol"/>
            <entity id="DS3.d618.s0.e2" origId="10982484,702" charOffset="42-49" type="compound" text="alcohol"/>
            <pair e1="DS3.d618.s0.e1" e2="DS3.d618.s0.e0" id="DS3.d618.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d618.s1" origId="9952048-1" text="The present study investigated the effect of nociceptin (NC), the endogenous ligand of the opioid-like orphan receptor ORL1, on ethanol intake in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats.">
            <entity id="DS3.d618.s1.e0" origId="Q62923" charOffset="45-55" type="protein" text="nociceptin"/>
            <entity id="DS3.d618.s1.e1" origId="P35370" charOffset="119-123" type="protein" text="ORL1"/>
            <entity id="DS3.d618.s1.e2" origId="10982484,702" charOffset="188-195" type="compound" text="alcohol"/>
            <pair e1="DS3.d618.s1.e2" e2="DS3.d618.s1.e1" id="DS3.d618.s1.i0" interaction="False" />
            <pair e1="DS3.d618.s1.e2" e2="DS3.d618.s1.e0" id="DS3.d618.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d619" origId="9952093">
        <sentence id="DS3.d619.s0" origId="9952093-4" text="They received mepivacaine mixed with contrast agent through an indwelling catheter with the arm abducted to either 0 or 90 degrees , and with or without local digital compression.">
            <entity id="DS3.d619.s0.e0" origId="4062" charOffset="14-25" type="compound" text="mepivacaine"/>
            <entity id="DS3.d619.s0.e1" origId="P14550,V9HWI0" charOffset="92-95" type="protein" text="arm"/>
            <pair e1="DS3.d619.s0.e0" e2="DS3.d619.s0.e1" id="DS3.d619.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d619.s1" origId="9952093-7" text="They received mepivacaine with the arm abducted 0 degrees or 90 degrees .">
            <entity id="DS3.d619.s1.e0" origId="4062" charOffset="14-25" type="compound" text="mepivacaine"/>
            <entity id="DS3.d619.s1.e1" origId="P14550,V9HWI0" charOffset="35-38" type="protein" text="arm"/>
            <pair e1="DS3.d619.s1.e0" e2="DS3.d619.s1.e1" id="DS3.d619.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d620" origId="9952097">
        <sentence id="DS3.d620.s0" origId="9952097-7" text='Using a knockout strategy, we have also raised mice with a deletion of the preprotachykinin-A (PPT-A) gene, which encodes for SP and neurokinin A (NKA), and have identified a specific behavioral phenotype in which the animals do not detect a window of "pain" intensities; this window cuts across stimulus modalities.'>
            <entity id="DS3.d620.s0.e0" origId="P41539,B7ZMQ2,Q149W7" charOffset="75-93" type="protein" text="preprotachykinin-A"/>
            <entity id="DS3.d620.s0.e1" origId="P41539,B7ZMQ2,Q149W7" charOffset="95-100" type="protein" text="PPT-A"/>
            <entity id="DS3.d620.s0.e2" origId="P55099" charOffset="133-145" type="protein" text="neurokinin A"/>
            <entity id="DS3.d620.s0.e3" origId="5311311" charOffset="147-150" type="compound" text="NKA"/>
            <pair e1="DS3.d620.s0.e3" e2="DS3.d620.s0.e0" id="DS3.d620.s0.i0" interaction="False" />
            <pair e1="DS3.d620.s0.e3" e2="DS3.d620.s0.e2" id="DS3.d620.s0.i1" interaction="False" />
            <pair e1="DS3.d620.s0.e3" e2="DS3.d620.s0.e1" id="DS3.d620.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d621" origId="9952106">
        <sentence id="DS3.d621.s0" origId="9952106-8" text="Marginal zone hyperplasia led to marginal zone lymphoma (MZL), a well-differentiated lymphoma that usually expressed CD45R (B220) and CD5 at low levels and that had clonal IgH gene rearrangements.">
            <entity id="DS3.d621.s0.e0" origId="9820664" charOffset="57-60" type="compound" text="MZL"/>
            <entity id="DS3.d621.s0.e1" origId="S4R2V1,Q8C6Q7,S4R1S4,S4R1M0" charOffset="124-128" type="protein" text="B220"/>
            <pair e1="DS3.d621.s0.e0" e2="DS3.d621.s0.e1" id="DS3.d621.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d622" origId="9952108">
        <sentence id="DS3.d622.s0" origId="9952108-6" text="BB1 antibody was effective in identifying basophils in sections of mixed cells or in tissues after fixation with ethanol, Carnoy's solution, or formalin.">
            <entity id="DS3.d622.s0.e0" origId="P33681,A0N0P2" charOffset="0-3" type="protein" text="BB1"/>
            <entity id="DS3.d622.s0.e1" origId="702" charOffset="113-120" type="compound" text="ethanol"/>
            <entity id="DS3.d622.s0.e2" origId="712" charOffset="144-152" type="compound" text="formalin"/>
            <pair e1="DS3.d622.s0.e2" e2="DS3.d622.s0.e0" id="DS3.d622.s0.i0" interaction="False" />
            <pair e1="DS3.d622.s0.e1" e2="DS3.d622.s0.e0" id="DS3.d622.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d622.s1" origId="9952108-9" text="BB1 antibody did not, by itself, stimulate histamine release.">
            <entity id="DS3.d622.s1.e0" origId="P33681,A0N0P2" charOffset="0-3" type="protein" text="BB1"/>
            <entity id="DS3.d622.s1.e1" origId="774" charOffset="43-52" type="compound" text="histamine"/>
            <pair e1="DS3.d622.s1.e1" e2="DS3.d622.s1.e0" id="DS3.d622.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d623" origId="9952110">
        <sentence id="DS3.d623.s0" origId="9952110-3" text="Seven days after colitis induction with trinitrobenzenesulfonic acid/ethanol, the duodenal and ileal TJ were studied by means of transmission electron microscopy using lanthanum nitrate, freeze fractures, and immunohistochemistry of occludin, ZO-1, and cingulin.">
            <entity id="DS3.d623.s0.e0" origId="11045" charOffset="40-68" type="compound" text="trinitrobenzenesulfonic acid"/>
            <entity id="DS3.d623.s0.e1" origId="702" charOffset="69-76" type="compound" text="ethanol"/>
            <entity id="DS3.d623.s0.e2" origId="23926" charOffset="168-177" type="compound" text="lanthanum"/>
            <entity id="DS3.d623.s0.e3" origId="10313259,943" charOffset="178-185" type="compound" text="nitrate"/>
            <entity id="DS3.d623.s0.e4" origId="Q6P6T5" charOffset="233-241" type="protein" text="occludin"/>
            <entity id="DS3.d623.s0.e5" origId="F1M4A0" charOffset="243-247" type="protein" text="ZO-1"/>
            <entity id="DS3.d623.s0.e6" origId="D4A4X4" charOffset="253-261" type="protein" text="cingulin"/>
            <pair e1="DS3.d623.s0.e0" e2="DS3.d623.s0.e4" id="DS3.d623.s0.i0" interaction="False" />
            <pair e1="DS3.d623.s0.e0" e2="DS3.d623.s0.e6" id="DS3.d623.s0.i1" interaction="False" />
            <pair e1="DS3.d623.s0.e0" e2="DS3.d623.s0.e5" id="DS3.d623.s0.i2" interaction="False" />
            <pair e1="DS3.d623.s0.e3" e2="DS3.d623.s0.e4" id="DS3.d623.s0.i3" interaction="False" />
            <pair e1="DS3.d623.s0.e3" e2="DS3.d623.s0.e6" id="DS3.d623.s0.i4" interaction="False" />
            <pair e1="DS3.d623.s0.e3" e2="DS3.d623.s0.e5" id="DS3.d623.s0.i5" interaction="False" />
            <pair e1="DS3.d623.s0.e1" e2="DS3.d623.s0.e4" id="DS3.d623.s0.i6" interaction="False" />
            <pair e1="DS3.d623.s0.e1" e2="DS3.d623.s0.e6" id="DS3.d623.s0.i7" interaction="False" />
            <pair e1="DS3.d623.s0.e1" e2="DS3.d623.s0.e5" id="DS3.d623.s0.i8" interaction="False" />
            <pair e1="DS3.d623.s0.e2" e2="DS3.d623.s0.e4" id="DS3.d623.s0.i9" interaction="False" />
            <pair e1="DS3.d623.s0.e2" e2="DS3.d623.s0.e6" id="DS3.d623.s0.i10" interaction="False" />
            <pair e1="DS3.d623.s0.e2" e2="DS3.d623.s0.e5" id="DS3.d623.s0.i11" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d624" origId="9952111">
        <sentence id="DS3.d624.s0" origId="9952111-2" text="The tyrosine kinase receptor Kit is an established marker for ICC.">
            <entity id="DS3.d624.s0.e0" origId="6057,90983769" charOffset="4-12" type="compound" text="tyrosine"/>
            <entity id="DS3.d624.s0.e1" origId="P10721,A0A024RDA0" charOffset="29-32" type="protein" text="Kit"/>
            <pair e1="DS3.d624.s0.e0" e2="DS3.d624.s0.e1" id="DS3.d624.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d625" origId="9952128">
        <sentence id="DS3.d625.s0" origId="9952128-2" text="METHODS: Thirty-two patients in this study fulfilled the following criteria: ruptured anterior communicating aneurysms, computed tomography (CT) within 2 days and unilateral pterional approach within 3 days after the ictus, bilaterally symmetrical clots without intracerebral hematoma, no postoperative complication, and CBF studies with single photon emission computed tomography (SPECT) with 123I-IMP.">
            <entity id="DS3.d625.s0.e0" origId="105140" charOffset="394-398" type="compound" text="123I"/>
            <entity id="DS3.d625.s0.e1" origId="P29218,A0A024R830" charOffset="399-402" type="protein" text="IMP"/>
            <pair e1="DS3.d625.s0.e0" e2="DS3.d625.s0.e1" id="DS3.d625.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d625.s1" origId="9952128-3" text="RESULTS: Postoperative regional hypoperfusion due to brain retraction was frequently recognized on 123I-IMP-SPECT without infarction.">
            <entity id="DS3.d625.s1.e0" origId="105140" charOffset="99-103" type="compound" text="123I"/>
            <entity id="DS3.d625.s1.e1" origId="P29218,A0A024R830" charOffset="104-107" type="protein" text="IMP"/>
            <pair e1="DS3.d625.s1.e0" e2="DS3.d625.s1.e1" id="DS3.d625.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d626" origId="9952153">
        <sentence id="DS3.d626.s0" origId="9952153-6" text="RESULTS: Mercapturates and glutathione conjugates of compound A both produced renal corticomedullary necrosis similar to that caused by compound A. Aminooxyacetic acid, an inhibitor of renal cysteine conjugate beta-lyase, did not inhibit the toxicity of the mercapturates, whereas acivicin, an inhibitor of gamma-glutamyltranspeptidase, potentiated the toxicity of both classes of conjugates.">
            <entity id="DS3.d626.s0.e0" origId="20725278,124886" charOffset="27-38" type="compound" text="glutathione"/>
            <entity id="DS3.d626.s0.e1" origId="286" charOffset="148-167" type="compound" text="Aminooxyacetic acid"/>
            <entity id="DS3.d626.s0.e2" origId="5862,90793998" charOffset="191-199" type="compound" text="cysteine"/>
            <entity id="DS3.d626.s0.e3" origId="294641" charOffset="281-289" type="compound" text="acivicin"/>
            <entity id="DS3.d626.s0.e4" origId="P07314" charOffset="307-335" type="protein" text="gamma-glutamyltranspeptidase"/>
            <pair e1="DS3.d626.s0.e3" e2="DS3.d626.s0.e4" id="DS3.d626.s0.i0" interaction="False" />
            <pair e1="DS3.d626.s0.e0" e2="DS3.d626.s0.e4" id="DS3.d626.s0.i1" interaction="False" />
            <pair e1="DS3.d626.s0.e2" e2="DS3.d626.s0.e4" id="DS3.d626.s0.i2" interaction="False" />
            <pair e1="DS3.d626.s0.e1" e2="DS3.d626.s0.e4" id="DS3.d626.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d627" origId="9952154">
        <sentence id="DS3.d627.s0" origId="9952154-0" text="Nitrous oxide produces antinociceptive response via alpha2B and/or alpha2C adrenoceptor subtypes in mice.">
            <entity id="DS3.d627.s0.e0" origId="948" charOffset="0-13" type="compound" text="Nitrous oxide"/>
            <entity id="DS3.d627.s0.e1" origId="F8VQ23" charOffset="52-59" type="protein" text="alpha2B"/>
            <entity id="DS3.d627.s0.e2" origId="Q01337" charOffset="67-74" type="protein" text="alpha2C"/>
            <pair e1="DS3.d627.s0.e0" e2="DS3.d627.s0.e2" id="DS3.d627.s0.i0" interaction="False" />
            <pair e1="DS3.d627.s0.e0" e2="DS3.d627.s0.e1" id="DS3.d627.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d627.s1" origId="9952154-10" text="Whereas dexmedetomidine exhibited no antinociceptive response in the D79N mice, the robust antinociceptive response in the wild-type litter mates could not be blocked by a selective alpha2B-/alpha2C-receptor antagonist.">
            <entity id="DS3.d627.s1.e0" origId="5311068" charOffset="8-23" type="compound" text="dexmedetomidine"/>
            <entity id="DS3.d627.s1.e1" origId="Q01337" charOffset="182-207" type="protein" text="alpha2B-/alpha2C-receptor"/>
            <pair e1="DS3.d627.s1.e0" e2="DS3.d627.s1.e1" id="DS3.d627.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d627.s2" origId="9952154-5" text="The antinociceptive effect of N2O was tested after pretreatment systemically with yohimbine (nonselective alpha2 antagonist), naloxone (opiate antagonist), L659,066 (peripheral alpha2-antagonist) and prazosin (alpha2B- and alpha2C-selective antagonist).">
            <entity id="DS3.d627.s2.e0" origId="8969" charOffset="82-91" type="compound" text="yohimbine"/>
            <entity id="DS3.d627.s2.e1" origId="5284596" charOffset="126-134" type="compound" text="naloxone"/>
            <entity id="DS3.d627.s2.e2" origId="4893" charOffset="200-208" type="compound" text="prazosin"/>
            <entity id="DS3.d627.s2.e3" origId="F8VQ23" charOffset="210-217" type="protein" text="alpha2B"/>
            <entity id="DS3.d627.s2.e4" origId="Q01337" charOffset="223-230" type="protein" text="alpha2C"/>
            <pair e1="DS3.d627.s2.e2" e2="DS3.d627.s2.e4" id="DS3.d627.s2.i0" interaction="False" />
            <pair e1="DS3.d627.s2.e2" e2="DS3.d627.s2.e3" id="DS3.d627.s2.i1" interaction="False" />
            <pair e1="DS3.d627.s2.e1" e2="DS3.d627.s2.e4" id="DS3.d627.s2.i2" interaction="False" />
            <pair e1="DS3.d627.s2.e1" e2="DS3.d627.s2.e3" id="DS3.d627.s2.i3" interaction="False" />
            <pair e1="DS3.d627.s2.e0" e2="DS3.d627.s2.e4" id="DS3.d627.s2.i4" interaction="False" />
            <pair e1="DS3.d627.s2.e0" e2="DS3.d627.s2.e3" id="DS3.d627.s2.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d628" origId="9952157">
        <sentence id="DS3.d628.s0" origId="9952157-12" text="CONCLUSIONS: These experiments suggest that intrathecal edrophonium or neostigmine produces an antagonism on touch-evoked allodynia at the spinal level in a rat model of neuropathic pain and that the antiallodynic action of cholinesterase inhibitors is probably mediated by a spinal muscarinic system, especially at the M1 receptor subtype.">
            <entity id="DS3.d628.s0.e0" origId="3202" charOffset="56-67" type="compound" text="edrophonium"/>
            <entity id="DS3.d628.s0.e1" origId="4456" charOffset="71-82" type="compound" text="neostigmine"/>
            <entity id="DS3.d628.s0.e2" origId="Q9JKC1" charOffset="224-238" type="protein" text="cholinesterase"/>
            <pair e1="DS3.d628.s0.e1" e2="DS3.d628.s0.e2" id="DS3.d628.s0.i0" interaction="False" />
            <pair e1="DS3.d628.s0.e0" e2="DS3.d628.s0.e2" id="DS3.d628.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d628.s1" origId="9952157-1" text="BACKGROUND: This study determined the effect of intrathecally administered cholinesterase inhibitors, edrophonium and neostigmine, on nerve injury-induced, touch-evoked allodynia and identified the pharmacologic characteristics of this action.">
            <entity id="DS3.d628.s1.e0" origId="Q9JKC1" charOffset="75-89" type="protein" text="cholinesterase"/>
            <entity id="DS3.d628.s1.e1" origId="3202" charOffset="102-113" type="compound" text="edrophonium"/>
            <entity id="DS3.d628.s1.e2" origId="4456" charOffset="118-129" type="compound" text="neostigmine"/>
            <pair e1="DS3.d628.s1.e2" e2="DS3.d628.s1.e0" id="DS3.d628.s1.i0" interaction="False" />
            <pair e1="DS3.d628.s1.e1" e2="DS3.d628.s1.e0" id="DS3.d628.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d628.s2" origId="9952157-6" text="To compare the action of subtype antagonists, the M1 muscarinic receptor antagonist pirenzepine, the M2 antagonist methoctramine, the M3 antagonist 4-DAMP (diphenylacetoxy-N-methypiperidine), and the M4 antagonist tropicamide were administered intrathecally before cholinesterase inhibitors were injected.">
            <entity id="DS3.d628.s2.e0" origId="4848" charOffset="84-95" type="compound" text="pirenzepine"/>
            <entity id="DS3.d628.s2.e1" origId="4108" charOffset="115-128" type="compound" text="methoctramine"/>
            <entity id="DS3.d628.s2.e2" origId="1734" charOffset="148-154" type="compound" text="4-DAMP"/>
            <entity id="DS3.d628.s2.e3" origId="8333" charOffset="156-171" type="compound" text="diphenylacetoxy"/>
            <entity id="DS3.d628.s2.e4" origId="5593" charOffset="214-225" type="compound" text="tropicamide"/>
            <entity id="DS3.d628.s2.e5" origId="Q9JKC1" charOffset="265-279" type="protein" text="cholinesterase"/>
            <pair e1="DS3.d628.s2.e4" e2="DS3.d628.s2.e5" id="DS3.d628.s2.i0" interaction="False" />
            <pair e1="DS3.d628.s2.e0" e2="DS3.d628.s2.e5" id="DS3.d628.s2.i1" interaction="False" />
            <pair e1="DS3.d628.s2.e3" e2="DS3.d628.s2.e5" id="DS3.d628.s2.i2" interaction="False" />
            <pair e1="DS3.d628.s2.e2" e2="DS3.d628.s2.e5" id="DS3.d628.s2.i3" interaction="False" />
            <pair e1="DS3.d628.s2.e1" e2="DS3.d628.s2.e5" id="DS3.d628.s2.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d628.s3" origId="9952157-9" text="Pretreatment with intrathecal atropine but not mecamylamine yielded a complete antagonism of the effects of the cholinesterase inhibitors.">
            <entity id="DS3.d628.s3.e0" origId="174174" charOffset="30-38" type="compound" text="atropine"/>
            <entity id="DS3.d628.s3.e1" origId="4032" charOffset="47-59" type="compound" text="mecamylamine"/>
            <entity id="DS3.d628.s3.e2" origId="Q9JKC1" charOffset="112-126" type="protein" text="cholinesterase"/>
            <pair e1="DS3.d628.s3.e0" e2="DS3.d628.s3.e2" id="DS3.d628.s3.i0" interaction="False" />
            <pair e1="DS3.d628.s3.e1" e2="DS3.d628.s3.e2" id="DS3.d628.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d629" origId="9952163">
        <sentence id="DS3.d629.s0" origId="9952163-10" text="GAS-1(fc21) is a missense mutation replacing a strictly conserved arginine with lysine.">
            <entity id="DS3.d629.s0.e0" origId="Q93873" charOffset="0-5" type="protein" text="GAS-1"/>
            <entity id="DS3.d629.s0.e1" origId="6322,90867653" charOffset="66-74" type="compound" text="arginine"/>
            <entity id="DS3.d629.s0.e2" origId="57449,5962,866" charOffset="80-86" type="compound" text="lysine"/>
            <pair e1="DS3.d629.s0.e2" e2="DS3.d629.s0.e0" id="DS3.d629.s0.i0" interaction="False" />
            <pair e1="DS3.d629.s0.e1" e2="DS3.d629.s0.e0" id="DS3.d629.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d629.s1" origId="9952163-3" text="GAS-1 confers different sensitivities to stereoisomers of isoflurane, and thus may be a direct target for volatile anesthetics.">
            <entity id="DS3.d629.s1.e0" origId="Q93873" charOffset="0-5" type="protein" text="GAS-1"/>
            <entity id="DS3.d629.s1.e1" origId="3763" charOffset="58-68" type="compound" text="isoflurane"/>
            <pair e1="DS3.d629.s1.e1" e2="DS3.d629.s1.e0" id="DS3.d629.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d629.s2" origId="9952163-9" text="The protein GAS-1 is a homologue of the 49-kDa (IP) subunit of the mitochondrial NADH:ubiquinone-oxidoreductase (complex I of the respiratory chain).">
            <entity id="DS3.d629.s2.e0" origId="Q93873" charOffset="12-17" type="protein" text="GAS-1"/>
            <entity id="DS3.d629.s2.e1" origId="439153" charOffset="81-85" type="compound" text="NADH"/>
            <pair e1="DS3.d629.s2.e1" e2="DS3.d629.s2.e0" id="DS3.d629.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d630" origId="9952220">
        <sentence id="DS3.d630.s0" origId="9952220-0" text="Characterization of early developmental pattern of expression of neurotensin/neuromedin N gene in foregut and midgut.">
            <entity id="DS3.d630.s0.e0" origId="P30990,Q6FH20" charOffset="65-76" type="protein" text="neurotensin"/>
            <entity id="DS3.d630.s0.e1" origId="15927888,9940301" charOffset="77-89" type="compound" text="neuromedin N"/>
            <pair e1="DS3.d630.s0.e1" e2="DS3.d630.s0.e0" id="DS3.d630.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d631" origId="9952228">
        <sentence id="DS3.d631.s0" origId="9952228-4" text="In addition to mucin positivity, immunohistochemical stains demonstrated the tumor to be positive for chromogranin, synaptophysin, serotonin, gastrin, and glucagon.">
            <entity id="DS3.d631.s0.e0" origId="P08247" charOffset="116-129" type="protein" text="synaptophysin"/>
            <entity id="DS3.d631.s0.e1" origId="5202" charOffset="131-140" type="compound" text="serotonin"/>
            <entity id="DS3.d631.s0.e2" origId="P01350,A0A0E3VY36" charOffset="142-149" type="protein" text="gastrin"/>
            <pair e1="DS3.d631.s0.e1" e2="DS3.d631.s0.e0" id="DS3.d631.s0.i0" interaction="False" />
            <pair e1="DS3.d631.s0.e1" e2="DS3.d631.s0.e2" id="DS3.d631.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d632" origId="9952234">
        <sentence id="DS3.d632.s0" origId="9952234-9" text="Three patients (17%) had persistent elevations in serum gastrin levels while on omeprazole treatment, which was associated with both younger patient age and higher omeprazole dosing; however, all elevated gastrin levels returned to normal after discontinuation of the medication.">
            <entity id="DS3.d632.s0.e0" origId="P01350,A0A0E3VY36" charOffset="56-63" type="protein" text="gastrin"/>
            <entity id="DS3.d632.s0.e1" origId="4594" charOffset="80-90" type="compound" text="omeprazole"/>
            <entity id="DS3.d632.s0.e2" origId="4594" charOffset="164-174" type="compound" text="omeprazole"/>
            <entity id="DS3.d632.s0.e3" origId="P01350,A0A0E3VY36" charOffset="205-212" type="protein" text="gastrin"/>
            <pair e1="DS3.d632.s0.e1" e2="DS3.d632.s0.e0" id="DS3.d632.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d633" origId="9952239">
        <sentence id="DS3.d633.s0" origId="9952239-6" text="Moreover, serum aminopeptidase-M seems to reflect other aspects of the pathological process than those reflected by the alanine aminotransferase and gamma-glutamyltranspeptidase.">
            <entity id="DS3.d633.s0.e0" origId="P15144,A0A024RC61,Q59E93" charOffset="16-32" type="protein" text="aminopeptidase-M"/>
            <entity id="DS3.d633.s0.e1" origId="5950,602" charOffset="120-127" type="compound" text="alanine"/>
            <entity id="DS3.d633.s0.e2" origId="Q9BX51,D3DW46" charOffset="149-177" type="protein" text="gamma-glutamyltranspeptidase"/>
            <pair e1="DS3.d633.s0.e1" e2="DS3.d633.s0.e2" id="DS3.d633.s0.i0" interaction="False" />
            <pair e1="DS3.d633.s0.e1" e2="DS3.d633.s0.e0" id="DS3.d633.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d634" origId="9952243">
        <sentence id="DS3.d634.s0" origId="9952243-2" text="The present study tests whether in vitro human gallbladder contractility in response to acetylcholine and cholecystokinin is affected by UDCA therapy.">
            <entity id="DS3.d634.s0.e0" origId="187" charOffset="88-101" type="compound" text="acetylcholine"/>
            <entity id="DS3.d634.s0.e1" origId="P06307,Q6FG82" charOffset="106-121" type="protein" text="cholecystokinin"/>
            <pair e1="DS3.d634.s0.e0" e2="DS3.d634.s0.e1" id="DS3.d634.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d634.s1" origId="9952243-6" text="UDCA treatment enhanced gallbladder contractility in vitro: Dose-response curves for acetylcholine and cholecystokinin were both shifted to the left, and the maximal contractile stress generated in response to cholecystokinin was higher in the treated group, whereas the maximal acetylcholine-induced stress was not increased.">
            <entity id="DS3.d634.s1.e0" origId="187" charOffset="85-98" type="compound" text="acetylcholine"/>
            <entity id="DS3.d634.s1.e1" origId="P06307,Q6FG82" charOffset="103-118" type="protein" text="cholecystokinin"/>
            <entity id="DS3.d634.s1.e2" origId="P06307,Q6FG82" charOffset="210-225" type="protein" text="cholecystokinin"/>
            <entity id="DS3.d634.s1.e3" origId="187" charOffset="279-292" type="compound" text="acetylcholine"/>
            <pair e1="DS3.d634.s1.e0" e2="DS3.d634.s1.e1" id="DS3.d634.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d634.s2" origId="9952243-7" text="Maximal cholecystokinin-induced stress correlated positively with fasting gallbladder volume and negatively with the biliary cholesterol saturation index, but not with bile salt hydrophobicity or gallbladder wall inflammation score.">
            <entity id="DS3.d634.s2.e0" origId="P06307,Q6FG82" charOffset="8-23" type="protein" text="cholecystokinin"/>
            <entity id="DS3.d634.s2.e1" origId="5997" charOffset="125-136" type="compound" text="cholesterol"/>
            <pair e1="DS3.d634.s2.e1" e2="DS3.d634.s2.e0" id="DS3.d634.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d635" origId="9952259">
        <sentence id="DS3.d635.s0" origId="9952259-3" text="METHODS: Mice were divided into three groups: (a) six mice (FLK) were kindled with flurothyl, rechallenged with flurothyl after a 28-day incubation phase, implanted with olfactory bulb (OB) electrodes, and electrically kindled; (b) six mice (ELK) were implanted with OB electrodes, electrically kindled to six stage 5 seizures, and given one flurothyl trial 3 days later and a second flurothyl trial after a 28-day incubation period; and (c) six mice (IMP) were implanted with OB electrodes, tested with flurothyl at the same times as the ELK group, and later electrically kindled.">
            <entity id="DS3.d635.s0.e0" origId="9528" charOffset="83-92" type="compound" text="flurothyl"/>
            <entity id="DS3.d635.s0.e1" origId="9528" charOffset="112-121" type="compound" text="flurothyl"/>
            <entity id="DS3.d635.s0.e2" origId="9528" charOffset="112-121" type="compound" text="flurothyl"/>
            <entity id="DS3.d635.s0.e3" origId="9528" charOffset="112-121" type="compound" text="flurothyl"/>
            <entity id="DS3.d635.s0.e4" origId="Q99MP8" charOffset="452-455" type="protein" text="IMP"/>
            <entity id="DS3.d635.s0.e5" origId="9528" charOffset="112-121" type="compound" text="flurothyl"/>
            <pair e1="DS3.d635.s0.e0" e2="DS3.d635.s0.e4" id="DS3.d635.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d635.s1" origId="9952259-4" text="RESULTS: Mice that were previously kindled with flurothyl (FLK) had significantly faster electrical kindling rates to one stage 5 seizure or to six stage 5 seizures compared with animals in the ELK and IMP groups.">
            <entity id="DS3.d635.s1.e0" origId="9528" charOffset="48-57" type="compound" text="flurothyl"/>
            <entity id="DS3.d635.s1.e1" origId="Q99MP8" charOffset="202-205" type="protein" text="IMP"/>
            <pair e1="DS3.d635.s1.e0" e2="DS3.d635.s1.e1" id="DS3.d635.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d635.s2" origId="9952259-5" text="Mice that were previously exposed to either electrical kindling or flurothyl kindling had significantly diminished latencies to generalized seizure onset (flurothyl-induced seizure thresholds) either before or after a 28-day incubation period compared with the IMP control mice.">
            <entity id="DS3.d635.s2.e0" origId="9528" charOffset="67-76" type="compound" text="flurothyl"/>
            <entity id="DS3.d635.s2.e1" origId="9528" charOffset="155-164" type="compound" text="flurothyl"/>
            <entity id="DS3.d635.s2.e2" origId="Q99MP8" charOffset="261-264" type="protein" text="IMP"/>
            <pair e1="DS3.d635.s2.e0" e2="DS3.d635.s2.e2" id="DS3.d635.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d635.s3" origId="9952259-6" text="In addition, both the FLK and ELK groups had significantly increased percentages of mice expressing forebrain-brainstem seizures, compared with the IMP group, following either rechallenge with flurothyl after a 28-day incubation or focal electrical kindling.">
            <entity id="DS3.d635.s3.e0" origId="Q99MP8" charOffset="148-151" type="protein" text="IMP"/>
            <entity id="DS3.d635.s3.e1" origId="9528" charOffset="193-202" type="compound" text="flurothyl"/>
            <pair e1="DS3.d635.s3.e1" e2="DS3.d635.s3.e0" id="DS3.d635.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d636" origId="9952267">
        <sentence id="DS3.d636.s0" origId="9952267-6" text="The CBZ group also had a significantly lower mean DHEAS concentration than the control, untreated, and sodium valproate (VPA) monotherapy groups.">
            <entity id="DS3.d636.s0.e0" origId="Q06520,A8K015" charOffset="50-55" type="protein" text="DHEAS"/>
            <entity id="DS3.d636.s0.e1" origId="3121" charOffset="103-119" type="compound" text="sodium valproate"/>
            <pair e1="DS3.d636.s0.e1" e2="DS3.d636.s0.e0" id="DS3.d636.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d636.s1" origId="9952267-7" text="The phenytoin monotherapy group (PHT) had a significantly higher mean SHBG than both the control and untreated groups, and had a significantly higher mean total testosterone (TT) value than the control untreated, CBZ, and VPA groups, and a significantly lower mean DHEAS than the controls, untreated, and VPA groups.">
            <entity id="DS3.d636.s1.e0" origId="1775" charOffset="4-13" type="compound" text="phenytoin"/>
            <entity id="DS3.d636.s1.e1" origId="6013" charOffset="161-173" type="compound" text="testosterone"/>
            <entity id="DS3.d636.s1.e2" origId="Q06520,A8K015" charOffset="265-270" type="protein" text="DHEAS"/>
            <pair e1="DS3.d636.s1.e0" e2="DS3.d636.s1.e2" id="DS3.d636.s1.i0" interaction="False" />
            <pair e1="DS3.d636.s1.e1" e2="DS3.d636.s1.e2" id="DS3.d636.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d637" origId="9952274">
        <sentence id="DS3.d637.s0" origId="9952274-1" text="The role of the glutamate receptor GluR3 in Rasmussen's encephalitis is actively under investigation.">
            <entity id="DS3.d637.s0.e0" origId="23327,33032,611,57109091" charOffset="16-25" type="compound" text="glutamate"/>
            <entity id="DS3.d637.s0.e1" origId="P42263,Q5XKG2,Q17R51" charOffset="35-40" type="protein" text="GluR3"/>
            <pair e1="DS3.d637.s0.e0" e2="DS3.d637.s0.e1" id="DS3.d637.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d638" origId="9952286">
        <sentence id="DS3.d638.s0" origId="9952286-0" text="Intralymphocyte free magnesium and calcium and insulin tolerance test in a group of essential hypertensive patients.">
            <entity id="DS3.d638.s0.e0" origId="5462224" charOffset="21-30" type="compound" text="magnesium"/>
            <entity id="DS3.d638.s0.e1" origId="22044544,5460341" charOffset="35-42" type="compound" text="calcium"/>
            <entity id="DS3.d638.s0.e2" origId="P01308,I3WAC9" charOffset="47-54" type="protein" text="insulin"/>
            <pair e1="DS3.d638.s0.e1" e2="DS3.d638.s0.e2" id="DS3.d638.s0.i0" interaction="False" />
            <pair e1="DS3.d638.s0.e0" e2="DS3.d638.s0.e2" id="DS3.d638.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d638.s1" origId="9952286-1" text="In order to assess the links which are claimed to exist between peripheral insulin resistance and intracellular magnesium and calcium concentrations, we measured free intralymphocyte magnesium (Mg(i)) and calcium (Ca(i)) concentrations as well as the rate constant of plasma glucose disappearance (K(itt)) after insulin injection (insulin tolerance test: ITT) in a group of 16 normotensive control subjects (NC) and 34 essential hypertensive subjects (EH).">
            <entity id="DS3.d638.s1.e0" origId="P01308,I3WAC9" charOffset="75-82" type="protein" text="insulin"/>
            <entity id="DS3.d638.s1.e1" origId="5462224" charOffset="112-121" type="compound" text="magnesium"/>
            <entity id="DS3.d638.s1.e2" origId="22044544,5460341" charOffset="126-133" type="compound" text="calcium"/>
            <entity id="DS3.d638.s1.e3" origId="5462224" charOffset="183-192" type="compound" text="magnesium"/>
            <entity id="DS3.d638.s1.e4" origId="22044544,5460341" charOffset="205-212" type="compound" text="calcium"/>
            <entity id="DS3.d638.s1.e5" origId="206,5793,64689,79025" charOffset="275-282" type="compound" text="glucose"/>
            <entity id="DS3.d638.s1.e6" origId="P01308,I3WAC9" charOffset="312-319" type="protein" text="insulin"/>
            <entity id="DS3.d638.s1.e7" origId="P01308,I3WAC9" charOffset="312-319" type="protein" text="insulin"/>
            <pair e1="DS3.d638.s1.e2" e2="DS3.d638.s1.e0" id="DS3.d638.s1.i0" interaction="False" />
            <pair e1="DS3.d638.s1.e1" e2="DS3.d638.s1.e0" id="DS3.d638.s1.i1" interaction="False" />
            <pair e1="DS3.d638.s1.e5" e2="DS3.d638.s1.e0" id="DS3.d638.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d638.s2" origId="9952286-6" text="In a step-up multivariate regression analysis including blood pressure, plasma lipids, BMI, plasma magnesium, fasting insulin, fasting glucose, Mg(i) and Ca(i), the dependent variable K(itt) is statistically significantly correlated with body mass index and Mg(i).">
            <entity id="DS3.d638.s2.e0" origId="5462224" charOffset="99-108" type="compound" text="magnesium"/>
            <entity id="DS3.d638.s2.e1" origId="P01308,I3WAC9" charOffset="118-125" type="protein" text="insulin"/>
            <entity id="DS3.d638.s2.e2" origId="206,5793,64689,79025" charOffset="135-142" type="compound" text="glucose"/>
            <pair e1="DS3.d638.s2.e0" e2="DS3.d638.s2.e1" id="DS3.d638.s2.i0" interaction="False" />
            <pair e1="DS3.d638.s2.e2" e2="DS3.d638.s2.e1" id="DS3.d638.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d638.s3" origId="9952286-7" text="In a first attempt to study the relationships between insulin resistance, Mg(i) and Ca(i) in nucleated cells, the chosen index of peripheral resistance seems to be linked to intracellular free magnesium.">
            <entity id="DS3.d638.s3.e0" origId="P01308,I3WAC9" charOffset="54-61" type="protein" text="insulin"/>
            <entity id="DS3.d638.s3.e1" origId="5462224" charOffset="193-202" type="compound" text="magnesium"/>
            <pair e1="DS3.d638.s3.e1" e2="DS3.d638.s3.e0" id="DS3.d638.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d639" origId="9952297">
        <sentence id="DS3.d639.s0" origId="9952297-3" text="Here we report that transfection of PC12 neuron precursor cells with the G93A mutation of SOD1 results in increased production of hydroxyl radicals (*OH) and an enhanced rate of cell death by apoptosis.">
            <entity id="DS3.d639.s0.e0" origId="P07632" charOffset="90-94" type="protein" text="SOD1"/>
            <entity id="DS3.d639.s0.e1" origId="961" charOffset="130-147" type="compound" text="hydroxyl radicals"/>
            <pair e1="DS3.d639.s0.e1" e2="DS3.d639.s0.e0" id="DS3.d639.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d639.s1" origId="9952297-4" text="Notably, PC12 cells transfected with the H63C/G93A mutant of SOD1 with a mutation in the catalytic site that converts histidine at position 63 to cysteine showed a dramatically reduced production of *OH and rate of death by apoptosis.">
            <entity id="DS3.d639.s1.e0" origId="P07632" charOffset="61-65" type="protein" text="SOD1"/>
            <entity id="DS3.d639.s1.e1" origId="6274" charOffset="118-127" type="compound" text="histidine"/>
            <entity id="DS3.d639.s1.e2" origId="5862,90793998" charOffset="146-154" type="compound" text="cysteine"/>
            <pair e1="DS3.d639.s1.e2" e2="DS3.d639.s1.e0" id="DS3.d639.s1.i0" interaction="False" />
            <pair e1="DS3.d639.s1.e1" e2="DS3.d639.s1.e0" id="DS3.d639.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d640" origId="9952298">
        <sentence id="DS3.d640.s0" origId="9952298-5" text="Analysis of the spectrum of Kras mutations demonstrated unique mutations in both codons 13 (GGC to GAC) and 61 (CAA to CTA) in addition to the commonly identified substitution of GAT for GGT in codon 12 of Kras.">
            <entity id="DS3.d640.s0.e0" origId="P32883,Q5J7N1,Q0VDV7" charOffset="28-32" type="protein" text="Kras"/>
            <entity id="DS3.d640.s0.e1" origId="449471" charOffset="92-95" type="compound" text="GGC"/>
            <entity id="DS3.d640.s0.e2" origId="P32883,Q5J7N1,Q0VDV7" charOffset="206-210" type="protein" text="Kras"/>
            <pair e1="DS3.d640.s0.e1" e2="DS3.d640.s0.e0" id="DS3.d640.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d641" origId="9952300">
        <sentence id="DS3.d641.s0" origId="9952300-0" text="Wortmannin sensitizes mammalian cells to radiation by inhibiting the DNA-dependent protein kinase-mediated rejoining of double-strand breaks.">
            <entity id="DS3.d641.s0.e0" origId="312145" charOffset="0-10" type="compound" text="Wortmannin"/>
            <entity id="DS3.d641.s0.e1" origId="P78527" charOffset="69-97" type="protein" text="DNA-dependent protein kinase"/>
            <pair e1="DS3.d641.s0.e0" e2="DS3.d641.s0.e1" id="DS3.d641.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d641.s1" origId="9952300-2" text="Since wortmannin is able to inhibit DNA-dependent protein kinase (DNA-PK) and double-strand break (DSB) rejoining, it is believed that its mechanism of radiation sensitization is through the inhibition of DNA-PK-mediated repair of DSBs.">
            <entity id="DS3.d641.s1.e0" origId="312145" charOffset="6-16" type="compound" text="wortmannin"/>
            <entity id="DS3.d641.s1.e1" origId="P78527" charOffset="36-64" type="protein" text="DNA-dependent protein kinase"/>
            <entity id="DS3.d641.s1.e2" origId="P78527" charOffset="66-72" type="protein" text="DNA-PK"/>
            <entity id="DS3.d641.s1.e3" origId="P78527" charOffset="205-211" type="protein" text="DNA-PK"/>
            <pair e1="DS3.d641.s1.e0" e2="DS3.d641.s1.e1" id="DS3.d641.s1.i0" interaction="False" />
            <pair e1="DS3.d641.s1.e0" e2="DS3.d641.s1.e2" id="DS3.d641.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d641.s2" origId="9952300-6" text="Pretreatment with wortmannin enhanced the radiosensitivity of ataxia telangiectasia (AT) cells, thereby precluding the participation of ATM protein in the radiation sensitization by wortmannin.">
            <entity id="DS3.d641.s2.e0" origId="312145" charOffset="18-28" type="compound" text="wortmannin"/>
            <entity id="DS3.d641.s2.e1" origId="Q13315,A0A024R3C7" charOffset="136-139" type="protein" text="ATM"/>
            <entity id="DS3.d641.s2.e2" origId="312145" charOffset="182-192" type="compound" text="wortmannin"/>
            <pair e1="DS3.d641.s2.e0" e2="DS3.d641.s2.e1" id="DS3.d641.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d641.s3" origId="9952300-7" text="At the same time, irradiated DNA-PK-deficient cells were not significantly affected by pretreatment with wortmannin.">
            <entity id="DS3.d641.s3.e0" origId="P78527" charOffset="29-35" type="protein" text="DNA-PK"/>
            <entity id="DS3.d641.s3.e1" origId="312145" charOffset="105-115" type="compound" text="wortmannin"/>
            <pair e1="DS3.d641.s3.e1" e2="DS3.d641.s3.e0" id="DS3.d641.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d641.s4" origId="9952300-8" text="These observations support a likely mechanism; that is, wortmannin sensitizes cells to radiation through inhibition of the DNA-PK-mediated rejoining of DSBs.">
            <entity id="DS3.d641.s4.e0" origId="312145" charOffset="56-66" type="compound" text="wortmannin"/>
            <entity id="DS3.d641.s4.e1" origId="P78527" charOffset="123-129" type="protein" text="DNA-PK"/>
            <pair e1="DS3.d641.s4.e0" e2="DS3.d641.s4.e1" id="DS3.d641.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d642" origId="9952354">
        <sentence id="DS3.d642.s0" origId="9952354-14" text="The 2A4(+)ORN immunoreactivity was found to be due to expression of HSP70, the dominant stress-inducible member of the HSP70 family, rather than constitutively expressed HSC70.">
            <entity id="DS3.d642.s0.e0" origId="91623326" charOffset="4-7" type="compound" text="2A4"/>
            <entity id="DS3.d642.s0.e1" origId="P63018" charOffset="170-175" type="protein" text="HSC70"/>
            <pair e1="DS3.d642.s0.e0" e2="DS3.d642.s0.e1" id="DS3.d642.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d642.s1" origId="9952354-9" text="Initially, low cell numbers rise to a density of 0.1 2A4(+)ORNs/mm OE length by P14, plateau at 0.9 2A4(+)ORNs/mm by P49, then fall to adult values of 0.4 cells/mm.">
            <entity id="DS3.d642.s1.e0" origId="91623326" charOffset="53-56" type="compound" text="2A4"/>
            <entity id="DS3.d642.s1.e1" origId="P02692" charOffset="80-83" type="protein" text="P14"/>
            <entity id="DS3.d642.s1.e2" origId="91623326" charOffset="100-103" type="compound" text="2A4"/>
            <pair e1="DS3.d642.s1.e0" e2="DS3.d642.s1.e1" id="DS3.d642.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d643" origId="9952355">
        <sentence id="DS3.d643.s0" origId="9952355-3" text="FluoroGold was injected into the spinal cord, and, in the same frogs, antibodies to enkephalin, substance P, somatostatin, and serotonin were localized in adjacent sections.">
            <entity id="DS3.d643.s0.e0" origId="461776" charOffset="84-94" type="compound" text="enkephalin"/>
            <entity id="DS3.d643.s0.e1" origId="P20366,Q9Y494" charOffset="96-107" type="protein" text="substance P"/>
            <entity id="DS3.d643.s0.e2" origId="P61278" charOffset="109-121" type="protein" text="somatostatin"/>
            <entity id="DS3.d643.s0.e3" origId="5202" charOffset="127-136" type="compound" text="serotonin"/>
            <pair e1="DS3.d643.s0.e3" e2="DS3.d643.s0.e2" id="DS3.d643.s0.i0" interaction="False" />
            <pair e1="DS3.d643.s0.e3" e2="DS3.d643.s0.e1" id="DS3.d643.s0.i1" interaction="False" />
            <pair e1="DS3.d643.s0.e0" e2="DS3.d643.s0.e2" id="DS3.d643.s0.i2" interaction="False" />
            <pair e1="DS3.d643.s0.e0" e2="DS3.d643.s0.e1" id="DS3.d643.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d644" origId="9952364">
        <sentence id="DS3.d644.s0" origId="9952364-3" text="Phagocytes were stimulated by zymosan opsonized with human complement with and without priming by platelet-activating factor (PAF) or FMLP.">
            <entity id="DS3.d644.s0.e0" origId="64689" charOffset="30-37" type="compound" text="zymosan"/>
            <entity id="DS3.d644.s0.e1" origId="108157,5313888" charOffset="98-124" type="compound" text="platelet-activating factor"/>
            <entity id="DS3.d644.s0.e2" origId="P21462" charOffset="134-138" type="protein" text="FMLP"/>
            <pair e1="DS3.d644.s0.e0" e2="DS3.d644.s0.e2" id="DS3.d644.s0.i0" interaction="False" />
            <pair e1="DS3.d644.s0.e1" e2="DS3.d644.s0.e2" id="DS3.d644.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d645" origId="9952373">
        <sentence id="DS3.d645.s0" origId="9952373-6" text="Fungicidal activity triggered via FcgammaRI required in vivo priming with G-CSF, whereas FcalphaRI-mediated activity was not dependent on this growth factor.">
            <entity id="DS3.d645.s0.e0" origId="P12314" charOffset="34-43" type="protein" text="FcgammaRI"/>
            <entity id="DS3.d645.s0.e1" origId="16122568,4369303,448383,16750043" charOffset="76-79" type="compound" text="CSF"/>
            <pair e1="DS3.d645.s0.e1" e2="DS3.d645.s0.e0" id="DS3.d645.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d646" origId="9952389">
        <sentence id="DS3.d646.s0" origId="9952389-5" text="Administration of IL-11 was associated with increased production of mRNA for IL-12 and inducible nitric oxide synthase but not interferon-gamma or IL-4 in B. burgdorferi-infected mice, suggesting a predominant effect of IL-11 on the innate immune response.">
            <entity id="DS3.d646.s0.e0" origId="P47873,A3KPB8,F7A7F2,Q3V0U3" charOffset="18-23" type="protein" text="IL-11"/>
            <entity id="DS3.d646.s0.e1" origId="145068" charOffset="97-109" type="compound" text="nitric oxide"/>
            <entity id="DS3.d646.s0.e2" origId="P47873,A3KPB8,F7A7F2,Q3V0U3" charOffset="220-225" type="protein" text="IL-11"/>
            <pair e1="DS3.d646.s0.e1" e2="DS3.d646.s0.e0" id="DS3.d646.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d647" origId="9952395">
        <sentence id="DS3.d647.s0" origId="9952395-10" text="We propose that inactivation can occur after C0 dissociates from alpha-actinin by two distinct but converging calcium-dependent processes: competitive displacement of alpha-actinin by calmodulin and reduction in the affinity of alpha-actinin for C0 after binding of calcium to alpha-actinin.">
            <entity id="DS3.d647.s0.e0" origId="P12814,A0A024R694" charOffset="65-78" type="protein" text="alpha-actinin"/>
            <entity id="DS3.d647.s0.e1" origId="22044544,5460341" charOffset="110-117" type="compound" text="calcium"/>
            <entity id="DS3.d647.s0.e2" origId="P12814,A0A024R694" charOffset="167-180" type="protein" text="alpha-actinin"/>
            <entity id="DS3.d647.s0.e3" origId="P12814,A0A024R694" charOffset="167-180" type="protein" text="alpha-actinin"/>
            <entity id="DS3.d647.s0.e4" origId="22044544,5460341" charOffset="266-273" type="compound" text="calcium"/>
            <entity id="DS3.d647.s0.e5" origId="P12814,A0A024R694" charOffset="167-180" type="protein" text="alpha-actinin"/>
            <pair e1="DS3.d647.s0.e1" e2="DS3.d647.s0.e0" id="DS3.d647.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d648" origId="9952396">
        <sentence id="DS3.d648.s0" origId="9952396-4" text="Estradiol elicited rapid (within 5-15 min) tyrosine phosphorylation/activation of the mitogen-activated protein (MAP) kinases, ERK1 and ERK2, that persisted for at least 2 hr.">
            <entity id="DS3.d648.s0.e0" origId="5757" charOffset="0-9" type="compound" text="Estradiol"/>
            <entity id="DS3.d648.s0.e1" origId="6057,90983769" charOffset="43-51" type="compound" text="tyrosine"/>
            <entity id="DS3.d648.s0.e2" origId="P27361,L7RXH5,Q9BWJ1" charOffset="127-131" type="protein" text="ERK1"/>
            <entity id="DS3.d648.s0.e3" origId="P28482,Q1HBJ4,Q499G7" charOffset="136-140" type="protein" text="ERK2"/>
            <pair e1="DS3.d648.s0.e0" e2="DS3.d648.s0.e2" id="DS3.d648.s0.i0" interaction="False" />
            <pair e1="DS3.d648.s0.e0" e2="DS3.d648.s0.e3" id="DS3.d648.s0.i1" interaction="False" />
            <pair e1="DS3.d648.s0.e1" e2="DS3.d648.s0.e2" id="DS3.d648.s0.i2" interaction="False" />
            <pair e1="DS3.d648.s0.e1" e2="DS3.d648.s0.e3" id="DS3.d648.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d648.s1" origId="9952396-5" text="This extracellular signal-regulated protein kinase (ERK) activation was inhibited successfully by the MEK1 inhibitor PD98059, but not by the estrogen receptor (ER) antagonist ICI 182,780, and did not appear to result from estradiol-induced activation of trk.">
            <entity id="DS3.d648.s1.e0" origId="Q02750,A4QPA9,B4DFY5" charOffset="102-106" type="protein" text="MEK1"/>
            <entity id="DS3.d648.s1.e1" origId="4713" charOffset="117-124" type="compound" text="PD98059"/>
            <entity id="DS3.d648.s1.e2" origId="P03372,Q9UBT1,G4XH65,A8KAF4" charOffset="141-158" type="protein" text="estrogen receptor"/>
            <entity id="DS3.d648.s1.e3" origId="104741" charOffset="175-186" type="compound" text="ICI 182,780"/>
            <entity id="DS3.d648.s1.e4" origId="5757" charOffset="222-231" type="compound" text="estradiol"/>
            <entity id="DS3.d648.s1.e5" origId="54730402" charOffset="254-257" type="compound" text="trk"/>
            <pair e1="DS3.d648.s1.e1" e2="DS3.d648.s1.e0" id="DS3.d648.s1.i0" interaction="False" />
            <pair e1="DS3.d648.s1.e1" e2="DS3.d648.s1.e2" id="DS3.d648.s1.i1" interaction="False" />
            <pair e1="DS3.d648.s1.e3" e2="DS3.d648.s1.e0" id="DS3.d648.s1.i2" interaction="False" />
            <pair e1="DS3.d648.s1.e3" e2="DS3.d648.s1.e2" id="DS3.d648.s1.i3" interaction="False" />
            <pair e1="DS3.d648.s1.e5" e2="DS3.d648.s1.e0" id="DS3.d648.s1.i4" interaction="False" />
            <pair e1="DS3.d648.s1.e5" e2="DS3.d648.s1.e2" id="DS3.d648.s1.i5" interaction="False" />
            <pair e1="DS3.d648.s1.e4" e2="DS3.d648.s1.e0" id="DS3.d648.s1.i6" interaction="False" />
            <pair e1="DS3.d648.s1.e4" e2="DS3.d648.s1.e2" id="DS3.d648.s1.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d648.s2" origId="9952396-6" text="Furthermore, we also found that estradiol elicited an increase in B-Raf kinase activity.">
            <entity id="DS3.d648.s2.e0" origId="5757" charOffset="32-41" type="compound" text="estradiol"/>
            <entity id="DS3.d648.s2.e1" origId="P15056" charOffset="66-71" type="protein" text="B-Raf"/>
            <pair e1="DS3.d648.s2.e0" e2="DS3.d648.s2.e1" id="DS3.d648.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d649" origId="9952400">
        <sentence id="DS3.d649.s0" origId="9952400-0" text="Reg1ulatory role and molecular interactions of a cell-surface heparan sulfate proteoglycan (N-syndecan) in hippocampal long-term potentiation.">
            <entity id="DS3.d649.s0.e0" origId="53477715" charOffset="62-77" type="compound" text="heparan sulfate"/>
            <entity id="DS3.d649.s0.e1" origId="P33671,G3V9B7" charOffset="92-102" type="protein" text="N-syndecan"/>
            <pair e1="DS3.d649.s0.e0" e2="DS3.d649.s0.e1" id="DS3.d649.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d649.s1" origId="9952400-6" text="A prominent carrier protein for the type of glycans implicated in LTP regulation in the adult hippocampus was identified as N-syndecan (syndecan-3), a transmembrane proteoglycan that was expressed at the processes of the CA1 pyramidal neurons in an activity-dependent manner.">
            <entity id="DS3.d649.s1.e0" origId="871" charOffset="44-51" type="compound" text="glycans"/>
            <entity id="DS3.d649.s1.e1" origId="56846361" charOffset="66-69" type="compound" text="LTP"/>
            <entity id="DS3.d649.s1.e2" origId="P33671,G3V9B7" charOffset="124-134" type="protein" text="N-syndecan"/>
            <entity id="DS3.d649.s1.e3" origId="18648446" charOffset="225-234" type="compound" text="pyramidal"/>
            <pair e1="DS3.d649.s1.e0" e2="DS3.d649.s1.e2" id="DS3.d649.s1.i0" interaction="False" />
            <pair e1="DS3.d649.s1.e3" e2="DS3.d649.s1.e2" id="DS3.d649.s1.i1" interaction="False" />
            <pair e1="DS3.d649.s1.e1" e2="DS3.d649.s1.e2" id="DS3.d649.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d649.s2" origId="9952400-7" text="Addition of soluble N-syndecan into the CA1 dendritic area prevented tetanus-induced LTP.">
            <entity id="DS3.d649.s2.e0" origId="P33671,G3V9B7" charOffset="20-30" type="protein" text="N-syndecan"/>
            <entity id="DS3.d649.s2.e1" origId="56846361" charOffset="85-88" type="compound" text="LTP"/>
            <pair e1="DS3.d649.s2.e1" e2="DS3.d649.s2.e0" id="DS3.d649.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d649.s3" origId="9952400-8" text="A major substrate of src-type kinases, cortactin (p80/85), and the tyrosine kinase fyn copurified with N-syndecan from hippocampus.">
            <entity id="DS3.d649.s3.e0" origId="Q66HL2,A0A0G2JZ13,D3ZGE6" charOffset="39-48" type="protein" text="cortactin"/>
            <entity id="DS3.d649.s3.e1" origId="50904892" charOffset="50-53" type="compound" text="p80"/>
            <entity id="DS3.d649.s3.e2" origId="6057,90983769" charOffset="67-75" type="compound" text="tyrosine"/>
            <entity id="DS3.d649.s3.e3" origId="Q62844" charOffset="83-86" type="protein" text="fyn"/>
            <entity id="DS3.d649.s3.e4" origId="P33671,G3V9B7" charOffset="103-113" type="protein" text="N-syndecan"/>
            <pair e1="DS3.d649.s3.e1" e2="DS3.d649.s3.e3" id="DS3.d649.s3.i0" interaction="False" />
            <pair e1="DS3.d649.s3.e1" e2="DS3.d649.s3.e4" id="DS3.d649.s3.i1" interaction="False" />
            <pair e1="DS3.d649.s3.e1" e2="DS3.d649.s3.e0" id="DS3.d649.s3.i2" interaction="False" />
            <pair e1="DS3.d649.s3.e2" e2="DS3.d649.s3.e3" id="DS3.d649.s3.i3" interaction="False" />
            <pair e1="DS3.d649.s3.e2" e2="DS3.d649.s3.e4" id="DS3.d649.s3.i4" interaction="False" />
            <pair e1="DS3.d649.s3.e2" e2="DS3.d649.s3.e0" id="DS3.d649.s3.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d649.s4" origId="9952400-9" text="Moreover, association of both cortactin and fyn to N-syndecan was rapidly increased after induction of LTP.">
            <entity id="DS3.d649.s4.e0" origId="Q66HL2,A0A0G2JZ13,D3ZGE6" charOffset="30-39" type="protein" text="cortactin"/>
            <entity id="DS3.d649.s4.e1" origId="Q62844" charOffset="44-47" type="protein" text="fyn"/>
            <entity id="DS3.d649.s4.e2" origId="P33671,G3V9B7" charOffset="51-61" type="protein" text="N-syndecan"/>
            <entity id="DS3.d649.s4.e3" origId="56846361" charOffset="103-106" type="compound" text="LTP"/>
            <pair e1="DS3.d649.s4.e3" e2="DS3.d649.s4.e1" id="DS3.d649.s4.i0" interaction="False" />
            <pair e1="DS3.d649.s4.e3" e2="DS3.d649.s4.e2" id="DS3.d649.s4.i1" interaction="False" />
            <pair e1="DS3.d649.s4.e3" e2="DS3.d649.s4.e0" id="DS3.d649.s4.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d650" origId="9952403">
        <sentence id="DS3.d650.s0" origId="9952403-6" text="Analyses of the activation level of leukemia inhibitory factor receptor beta- and signal transducer and activator of transcription 3-signaling molecules in response to exogenous CNTF revealed an increased tyrosine phosphorylation positively correlated with the twitch tension developed by the soleus muscle of the animals.">
            <entity id="DS3.d650.s0.e0" origId="P20294" charOffset="178-182" type="protein" text="CNTF"/>
            <entity id="DS3.d650.s0.e1" origId="6057,90983769" charOffset="205-213" type="compound" text="tyrosine"/>
            <pair e1="DS3.d650.s0.e1" e2="DS3.d650.s0.e0" id="DS3.d650.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d651" origId="9952404">
        <sentence id="DS3.d651.s0" origId="9952404-3" text="Within 5 min after the addition of 100 microM glutamate to the culture medium, a rapid and selective redistribution of GluR1 subunits away from a subset of synaptic sites was observed.">
            <entity id="DS3.d651.s0.e0" origId="23327,33032,611,57109091" charOffset="46-55" type="compound" text="glutamate"/>
            <entity id="DS3.d651.s0.e1" origId="P19490" charOffset="119-124" type="protein" text="GluR1"/>
            <pair e1="DS3.d651.s0.e0" e2="DS3.d651.s0.e1" id="DS3.d651.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d652" origId="9952408">
        <sentence id="DS3.d652.s0" origId="9952408-0" text="Molecular analysis of the X11-mLin-2/CASK complex in brain.">
            <entity id="DS3.d652.s0.e0" origId="5375676" charOffset="26-29" type="compound" text="X11"/>
            <entity id="DS3.d652.s0.e1" origId="O70589,B9EJ23" charOffset="30-36" type="protein" text="mLin-2"/>
            <entity id="DS3.d652.s0.e2" origId="O14936" charOffset="37-41" type="protein" text="CASK"/>
            <pair e1="DS3.d652.s0.e0" e2="DS3.d652.s0.e1" id="DS3.d652.s0.i0" interaction="False" />
            <pair e1="DS3.d652.s0.e0" e2="DS3.d652.s0.e2" id="DS3.d652.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d652.s1" origId="9952408-2" text="In Caenorhabditis elegans, it localizes Let-23, a receptor tyrosine kinase, to the basolateral side of vulval epithelium, a step crucial for proper vulva development.">
            <entity id="DS3.d652.s1.e0" origId="P24348,B5BM27,B5BM28" charOffset="40-46" type="protein" text="Let-23"/>
            <entity id="DS3.d652.s1.e1" origId="6057,90983769" charOffset="59-67" type="compound" text="tyrosine"/>
            <pair e1="DS3.d652.s1.e1" e2="DS3.d652.s1.e0" id="DS3.d652.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d652.s2" origId="9952408-4" text="Accordingly, phosphotyrosine binding (PTB) and postsynaptic density-95/Discs large/Zona Occludens-1 domains found in X11alpha and mLin-2/CASK bind to cell-surface proteins, including amyloid precursor protein, neurexins, and syndecans.">
            <entity id="DS3.d652.s2.e0" origId="30819" charOffset="13-28" type="compound" text="phosphotyrosine"/>
            <entity id="DS3.d652.s2.e1" origId="Q02410" charOffset="117-125" type="protein" text="X11alpha"/>
            <entity id="DS3.d652.s2.e2" origId="O70589,B9EJ23" charOffset="130-136" type="protein" text="mLin-2"/>
            <entity id="DS3.d652.s2.e3" origId="O14936" charOffset="137-141" type="protein" text="CASK"/>
            <pair e1="DS3.d652.s2.e0" e2="DS3.d652.s2.e2" id="DS3.d652.s2.i0" interaction="False" />
            <pair e1="DS3.d652.s2.e0" e2="DS3.d652.s2.e1" id="DS3.d652.s2.i1" interaction="False" />
            <pair e1="DS3.d652.s2.e0" e2="DS3.d652.s2.e3" id="DS3.d652.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d652.s3" origId="9952408-8" text="A region containing the mLin-2/CASK guanylate kinase domain also interacts with X11alpha but with a lower affinity than the CKII domain.">
            <entity id="DS3.d652.s3.e0" origId="O70589,B9EJ23" charOffset="24-30" type="protein" text="mLin-2"/>
            <entity id="DS3.d652.s3.e1" origId="O14936" charOffset="31-35" type="protein" text="CASK"/>
            <entity id="DS3.d652.s3.e2" origId="6804" charOffset="36-45" type="compound" text="guanylate"/>
            <entity id="DS3.d652.s3.e3" origId="Q02410" charOffset="80-88" type="protein" text="X11alpha"/>
            <pair e1="DS3.d652.s3.e2" e2="DS3.d652.s3.e0" id="DS3.d652.s3.i0" interaction="False" />
            <pair e1="DS3.d652.s3.e2" e2="DS3.d652.s3.e3" id="DS3.d652.s3.i1" interaction="False" />
            <pair e1="DS3.d652.s3.e2" e2="DS3.d652.s3.e1" id="DS3.d652.s3.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d653" origId="9952410">
        <sentence id="DS3.d653.s0" origId="9952410-6" text="The distribution of synaptotagmin, synapsin1, sec6, and FM1-43 labeling in cultured neurons suggested that the plasma membrane localization of the sec6/8 complex preceded the arrival of synaptic markers and was downregulated in mature synapses.">
            <entity id="DS3.d653.s0.e0" origId="P09951" charOffset="35-44" type="protein" text="synapsin1"/>
            <entity id="DS3.d653.s0.e1" origId="Q62825" charOffset="46-50" type="protein" text="sec6"/>
            <entity id="DS3.d653.s0.e2" origId="446659" charOffset="56-59" type="compound" text="FM1"/>
            <entity id="DS3.d653.s0.e3" origId="Q62824,Q62825,P32855,P32844,P97694,B2GUV0" charOffset="147-153" type="protein" text="sec6/8"/>
            <pair e1="DS3.d653.s0.e2" e2="DS3.d653.s0.e1" id="DS3.d653.s0.i0" interaction="False" />
            <pair e1="DS3.d653.s0.e2" e2="DS3.d653.s0.e3" id="DS3.d653.s0.i1" interaction="False" />
            <pair e1="DS3.d653.s0.e2" e2="DS3.d653.s0.e0" id="DS3.d653.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d654" origId="9952411">
        <sentence id="DS3.d654.s0" origId="9952411-1" text="We examined the uptake and distribution of an antisense phosphorothioated oligodeoxynucleotide (s-ODN) to c-Fos, rncfosr115, infused into the left cerebral ventricle of male Long-Evans rats and the effect of this s-ODN on subsequent Fos, NGF, neurotrophin-3 (NT-3), and actin expression.">
            <entity id="DS3.d654.s0.e0" origId="78673848" charOffset="98-101" type="compound" text="ODN"/>
            <entity id="DS3.d654.s0.e1" origId="P12841" charOffset="106-111" type="protein" text="c-Fos"/>
            <entity id="DS3.d654.s0.e2" origId="78673848" charOffset="215-218" type="compound" text="ODN"/>
            <entity id="DS3.d654.s0.e3" origId="P12841" charOffset="108-111" type="protein" text="Fos"/>
            <entity id="DS3.d654.s0.e4" origId="P18280,A0A0G2JXV7,A0A0G2JVQ7" charOffset="243-257" type="protein" text="neurotrophin-3"/>
            <pair e1="DS3.d654.s0.e0" e2="DS3.d654.s0.e4" id="DS3.d654.s0.i0" interaction="False" />
            <pair e1="DS3.d654.s0.e0" e2="DS3.d654.s0.e1" id="DS3.d654.s0.i1" interaction="False" />
            <pair e1="DS3.d654.s0.e0" e2="DS3.d654.s0.e3" id="DS3.d654.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d654.s1" origId="9952411-6" text="The effectiveness of c-Fos antisense s-ODN was demonstrated by its suppression of postischemic Fos expression, which was accompanied by an inhibition of ischemia-induced NGF mRNA expression in the dentate gyrus.">
            <entity id="DS3.d654.s1.e0" origId="P12841" charOffset="21-26" type="protein" text="c-Fos"/>
            <entity id="DS3.d654.s1.e1" origId="78673848" charOffset="39-42" type="compound" text="ODN"/>
            <entity id="DS3.d654.s1.e2" origId="P12841" charOffset="23-26" type="protein" text="Fos"/>
            <pair e1="DS3.d654.s1.e1" e2="DS3.d654.s1.e0" id="DS3.d654.s1.i0" interaction="False" />
            <pair e1="DS3.d654.s1.e1" e2="DS3.d654.s1.e2" id="DS3.d654.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d654.s2" origId="9952411-7" text="Infusion of saline, the sense s-ODN, or a mismatch antisense s-ODN did not suppress Fos expression.">
            <entity id="DS3.d654.s2.e0" origId="78673848" charOffset="32-35" type="compound" text="ODN"/>
            <entity id="DS3.d654.s2.e1" origId="78673848" charOffset="63-66" type="compound" text="ODN"/>
            <entity id="DS3.d654.s2.e2" origId="P12841" charOffset="84-87" type="protein" text="Fos"/>
            <pair e1="DS3.d654.s2.e0" e2="DS3.d654.s2.e2" id="DS3.d654.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d654.s3" origId="9952411-8" text="That this effect of c-Fos antisense s-ODN was specific to NGF was demonstrated by its lack of effect on the postischemic expression of the NT-3 and beta-actin genes.">
            <entity id="DS3.d654.s3.e0" origId="P12841" charOffset="20-25" type="protein" text="c-Fos"/>
            <entity id="DS3.d654.s3.e1" origId="78673848" charOffset="38-41" type="compound" text="ODN"/>
            <entity id="DS3.d654.s3.e2" origId="P60711" charOffset="148-158" type="protein" text="beta-actin"/>
            <pair e1="DS3.d654.s3.e1" e2="DS3.d654.s3.e2" id="DS3.d654.s3.i0" interaction="False" />
            <pair e1="DS3.d654.s3.e1" e2="DS3.d654.s3.e0" id="DS3.d654.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d654.s4" origId="9952411-9" text="Our results demonstrate that c-Fos antisense s-ODN blocks selected downstream events and support the contention that postischemic Fos regulates the subsequent expression of the NGF gene and that Fos expression may have a functional component in neuroregeneration after focal cerebral ischemia-reperfusion.">
            <entity id="DS3.d654.s4.e0" origId="P12841" charOffset="29-34" type="protein" text="c-Fos"/>
            <entity id="DS3.d654.s4.e1" origId="78673848" charOffset="47-50" type="compound" text="ODN"/>
            <entity id="DS3.d654.s4.e2" origId="P12841" charOffset="31-34" type="protein" text="Fos"/>
            <entity id="DS3.d654.s4.e3" origId="P12841" charOffset="130-133" type="protein" text="Fos"/>
            <pair e1="DS3.d654.s4.e1" e2="DS3.d654.s4.e0" id="DS3.d654.s4.i0" interaction="False" />
            <pair e1="DS3.d654.s4.e1" e2="DS3.d654.s4.e2" id="DS3.d654.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d655" origId="9952416">
        <sentence id="DS3.d655.s0" origId="9952416-0" text="Stimulation of myelin basic protein gene transcription by Fyn tyrosine kinase for myelination.">
            <entity id="DS3.d655.s0.e0" origId="P04370,Q5D096,Q542T4,Q3UGF3" charOffset="15-35" type="protein" text="myelin basic protein"/>
            <entity id="DS3.d655.s0.e1" origId="P39688" charOffset="58-61" type="protein" text="Fyn"/>
            <entity id="DS3.d655.s0.e2" origId="6057,90983769" charOffset="62-70" type="compound" text="tyrosine"/>
            <pair e1="DS3.d655.s0.e2" e2="DS3.d655.s0.e1" id="DS3.d655.s0.i0" interaction="False" />
            <pair e1="DS3.d655.s0.e2" e2="DS3.d655.s0.e0" id="DS3.d655.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d655.s1" origId="9952416-2" text="The Src-family tyrosine kinase Fyn is involved in the initial events of myelination.">
            <entity id="DS3.d655.s1.e0" origId="6057,90983769" charOffset="15-23" type="compound" text="tyrosine"/>
            <entity id="DS3.d655.s1.e1" origId="P39688" charOffset="31-34" type="protein" text="Fyn"/>
            <pair e1="DS3.d655.s1.e0" e2="DS3.d655.s1.e1" id="DS3.d655.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d656" origId="9952418">
        <sentence id="DS3.d656.s0" origId="9952418-0" text="GDNF protection against 6-OHDA-induced reductions in potassium-evoked overflow of striatal dopamine.">
            <entity id="DS3.d656.s0.e0" origId="Q07731,A7UGJ1" charOffset="0-4" type="protein" text="GDNF"/>
            <entity id="DS3.d656.s0.e1" origId="5462222" charOffset="53-62" type="compound" text="potassium"/>
            <entity id="DS3.d656.s0.e2" origId="681" charOffset="91-99" type="compound" text="dopamine"/>
            <pair e1="DS3.d656.s0.e1" e2="DS3.d656.s0.e0" id="DS3.d656.s0.i0" interaction="False" />
            <pair e1="DS3.d656.s0.e2" e2="DS3.d656.s0.e0" id="DS3.d656.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d656.s1" origId="9952418-1" text="Glial cell line-derived neurotrophic factor (GDNF), when administered before 6-hydroxydopamine (6-OHDA), has been shown to prevent the reduction in nigral dopamine (DA) levels and tyrosine hydroxylase-positive neurons normally observed after 6-OHDA lesions.">
            <entity id="DS3.d656.s1.e0" origId="Q07731,A7UGJ1" charOffset="0-43" type="protein" text="Glial cell line-derived neurotrophic factor"/>
            <entity id="DS3.d656.s1.e1" origId="Q07731,A7UGJ1" charOffset="45-49" type="protein" text="GDNF"/>
            <entity id="DS3.d656.s1.e2" origId="4624" charOffset="77-94" type="compound" text="6-hydroxydopamine"/>
            <entity id="DS3.d656.s1.e3" origId="681" charOffset="86-94" type="compound" text="dopamine"/>
            <entity id="DS3.d656.s1.e4" origId="6057,90983769" charOffset="180-188" type="compound" text="tyrosine"/>
            <pair e1="DS3.d656.s1.e4" e2="DS3.d656.s1.e1" id="DS3.d656.s1.i0" interaction="False" />
            <pair e1="DS3.d656.s1.e4" e2="DS3.d656.s1.e0" id="DS3.d656.s1.i1" interaction="False" />
            <pair e1="DS3.d656.s1.e2" e2="DS3.d656.s1.e1" id="DS3.d656.s1.i2" interaction="False" />
            <pair e1="DS3.d656.s1.e2" e2="DS3.d656.s1.e0" id="DS3.d656.s1.i3" interaction="False" />
            <pair e1="DS3.d656.s1.e3" e2="DS3.d656.s1.e1" id="DS3.d656.s1.i4" interaction="False" />
            <pair e1="DS3.d656.s1.e3" e2="DS3.d656.s1.e0" id="DS3.d656.s1.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d657" origId="9952419">
        <sentence id="DS3.d657.s0" origId="9952419-2" text="In this study, we attempted to block selectively the activation of distinct neurotrophin receptors throughout kindling development in the rat via chronic intracerebroventricular administration of trk receptor bodies.">
            <entity id="DS3.d657.s0.e0" origId="P23560,A0A0E3SU01" charOffset="76-88" type="protein" text="neurotrophin"/>
            <entity id="DS3.d657.s0.e1" origId="54730402" charOffset="196-199" type="compound" text="trk"/>
            <pair e1="DS3.d657.s0.e1" e2="DS3.d657.s0.e0" id="DS3.d657.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d657.s1" origId="9952419-3" text="The efficacy and selectivity of the trk receptor bodies were established by inhibition of neurotrophin-induced trk receptor phosphorylation in pheochromocytoma (PC12) cells and primary cultures of cortical neurons.">
            <entity id="DS3.d657.s1.e0" origId="54730402" charOffset="36-39" type="compound" text="trk"/>
            <entity id="DS3.d657.s1.e1" origId="P23560,A0A0E3SU01" charOffset="90-102" type="protein" text="neurotrophin"/>
            <entity id="DS3.d657.s1.e2" origId="54730402" charOffset="111-114" type="compound" text="trk"/>
            <pair e1="DS3.d657.s1.e0" e2="DS3.d657.s1.e1" id="DS3.d657.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d658" origId="9952429">
        <sentence id="DS3.d658.s0" origId="9952429-3" text="The neurons respond, when fatty foods are being eaten, to pure Fat such as glyceryl trioleate and also to substances with a similar texture but different chemical composition such as paraffin oil (hydrocarbon) and silicone oil (Si(CH3)2O)n).">
            <entity id="DS3.d658.s0.e0" origId="P16671,A4D1B1,E9PLT1,B7Z6C3" charOffset="63-66" type="protein" text="Fat"/>
            <entity id="DS3.d658.s0.e1" origId="5497163" charOffset="75-93" type="compound" text="glyceryl trioleate"/>
            <pair e1="DS3.d658.s0.e1" e2="DS3.d658.s0.e0" id="DS3.d658.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d658.s1" origId="9952429-7" text="For example, neurons were found that responded to the mouth feel of Fat and the taste of monosodium glutamate (both found in milk), or to the mouth feel of Fat and to odor.">
            <entity id="DS3.d658.s1.e0" origId="P16671,A4D1B1,E9PLT1,B7Z6C3" charOffset="68-71" type="protein" text="Fat"/>
            <entity id="DS3.d658.s1.e1" origId="33032" charOffset="89-109" type="compound" text="monosodium glutamate"/>
            <entity id="DS3.d658.s1.e2" origId="P16671,A4D1B1,E9PLT1,B7Z6C3" charOffset="156-159" type="protein" text="Fat"/>
            <pair e1="DS3.d658.s1.e1" e2="DS3.d658.s1.e0" id="DS3.d658.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d659" origId="9952441">
        <sentence id="DS3.d659.s0" origId="9952441-8" text="Taken together, all of these data suggest that CBF2 and CBF3 may function as transcriptional activators, controlling the level of low-temperature gene expression and promoting freezing tolerance through an abscisic acid-independent pathway.">
            <entity id="DS3.d659.s0.e0" origId="Q9SYS6,B2BIW9" charOffset="47-51" type="protein" text="CBF2"/>
            <entity id="DS3.d659.s0.e1" origId="Q9M0L0,B2BIZ3" charOffset="56-60" type="protein" text="CBF3"/>
            <entity id="DS3.d659.s0.e2" origId="5375199" charOffset="206-219" type="compound" text="abscisic acid"/>
            <pair e1="DS3.d659.s0.e2" e2="DS3.d659.s0.e1" id="DS3.d659.s0.i0" interaction="False" />
            <pair e1="DS3.d659.s0.e2" e2="DS3.d659.s0.e0" id="DS3.d659.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d660" origId="9952446">
        <sentence id="DS3.d660.s0" origId="9952446-1" text="The Arabidopsis GA3 cDNA was expressed in yeast (Saccharomyces cerevisiae) and the ability of the transformed yeast cells to metabolize ent-kaurene was tested.">
            <entity id="DS3.d660.s0.e0" origId="Q93ZB2" charOffset="16-19" type="protein" text="GA3"/>
            <entity id="DS3.d660.s0.e1" origId="11966109,440911,54160126" charOffset="136-147" type="compound" text="ent-kaurene"/>
            <pair e1="DS3.d660.s0.e1" e2="DS3.d660.s0.e0" id="DS3.d660.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d660.s1" origId="9952446-2" text="We show by full-scan gas chromatography-mass spectrometry that the transformed cells produce ent-kaurenoic acid, and demonstrate that the single enzyme GA3 (ent-kaurene oxidase) catalyzes the three steps of gibberellin biosynthesis from ent-kaurene to ent-kaurenoic acid.">
            <entity id="DS3.d660.s1.e0" origId="73062" charOffset="93-111" type="compound" text="ent-kaurenoic acid"/>
            <entity id="DS3.d660.s1.e1" origId="Q93ZB2" charOffset="152-155" type="protein" text="GA3"/>
            <entity id="DS3.d660.s1.e2" origId="11966109,440911,54160126" charOffset="157-168" type="compound" text="ent-kaurene"/>
            <entity id="DS3.d660.s1.e3" origId="11966109,440911,54160126" charOffset="237-248" type="compound" text="ent-kaurene"/>
            <entity id="DS3.d660.s1.e4" origId="73062" charOffset="252-270" type="compound" text="ent-kaurenoic acid"/>
            <pair e1="DS3.d660.s1.e0" e2="DS3.d660.s1.e1" id="DS3.d660.s1.i0" interaction="False" />
            <pair e1="DS3.d660.s1.e2" e2="DS3.d660.s1.e1" id="DS3.d660.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d661" origId="9952448">
        <sentence id="DS3.d661.s0" origId="9952448-1" text="The Arabidopsis mutants eto1 (ethylene overproducer) and eto3 produce elevated levels of ethylene as etiolated seedlings.">
            <entity id="DS3.d661.s0.e0" origId="O65020,F4J4I9" charOffset="24-28" type="protein" text="eto1"/>
            <entity id="DS3.d661.s0.e1" origId="53675528,6325" charOffset="30-38" type="compound" text="ethylene"/>
            <entity id="DS3.d661.s0.e2" origId="Q9M2Y8" charOffset="57-61" type="protein" text="eto3"/>
            <entity id="DS3.d661.s0.e3" origId="53675528,6325" charOffset="89-97" type="compound" text="ethylene"/>
            <pair e1="DS3.d661.s0.e1" e2="DS3.d661.s0.e2" id="DS3.d661.s0.i0" interaction="False" />
            <pair e1="DS3.d661.s0.e1" e2="DS3.d661.s0.e0" id="DS3.d661.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d661.s1" origId="9952448-3" text="Ethylene overproduction in eto1 and eto3 is limited mainly to etiolated seedlings; light-grown seedlings and various adult tissues produce close to wild-type amounts of ethylene.">
            <entity id="DS3.d661.s1.e0" origId="53675528,6325" charOffset="0-8" type="compound" text="Ethylene"/>
            <entity id="DS3.d661.s1.e1" origId="O65020,F4J4I9" charOffset="27-31" type="protein" text="eto1"/>
            <entity id="DS3.d661.s1.e2" origId="Q9M2Y8" charOffset="36-40" type="protein" text="eto3"/>
            <entity id="DS3.d661.s1.e3" origId="53675528,6325" charOffset="169-177" type="compound" text="ethylene"/>
            <pair e1="DS3.d661.s1.e0" e2="DS3.d661.s1.e2" id="DS3.d661.s1.i0" interaction="False" />
            <pair e1="DS3.d661.s1.e0" e2="DS3.d661.s1.e1" id="DS3.d661.s1.i1" interaction="False" />
            <pair e1="DS3.d661.s1.e3" e2="DS3.d661.s1.e2" id="DS3.d661.s1.i2" interaction="False" />
            <pair e1="DS3.d661.s1.e3" e2="DS3.d661.s1.e1" id="DS3.d661.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d661.s2" origId="9952448-4" text="Several compounds that induce ethylene biosynthesis in wild-type, etiolated seedlings through distinct 1-aminocyclopropane-1-carboxylic acid (ACC) synthase (ACS) isoforms were found to act synergistically with eto1 and eto3, as did the ethylene-insensitive mutation etr1 (ethylene resistant), which blocks feedback inhibition of biosynthesis.">
            <entity id="DS3.d661.s2.e0" origId="53675528,6325" charOffset="30-38" type="compound" text="ethylene"/>
            <entity id="DS3.d661.s2.e1" origId="535" charOffset="103-140" type="compound" text="1-aminocyclopropane-1-carboxylic acid"/>
            <entity id="DS3.d661.s2.e2" origId="O65020,F4J4I9" charOffset="210-214" type="protein" text="eto1"/>
            <entity id="DS3.d661.s2.e3" origId="Q9M2Y8" charOffset="219-223" type="protein" text="eto3"/>
            <entity id="DS3.d661.s2.e4" origId="53675528,6325" charOffset="236-244" type="compound" text="ethylene"/>
            <entity id="DS3.d661.s2.e5" origId="P49333" charOffset="266-270" type="protein" text="etr1"/>
            <entity id="DS3.d661.s2.e6" origId="53675528,6325" charOffset="236-244" type="compound" text="ethylene"/>
            <pair e1="DS3.d661.s2.e0" e2="DS3.d661.s2.e5" id="DS3.d661.s2.i0" interaction="False" />
            <pair e1="DS3.d661.s2.e0" e2="DS3.d661.s2.e3" id="DS3.d661.s2.i1" interaction="False" />
            <pair e1="DS3.d661.s2.e0" e2="DS3.d661.s2.e2" id="DS3.d661.s2.i2" interaction="False" />
            <pair e1="DS3.d661.s2.e1" e2="DS3.d661.s2.e5" id="DS3.d661.s2.i3" interaction="False" />
            <pair e1="DS3.d661.s2.e1" e2="DS3.d661.s2.e3" id="DS3.d661.s2.i4" interaction="False" />
            <pair e1="DS3.d661.s2.e1" e2="DS3.d661.s2.e2" id="DS3.d661.s2.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d661.s3" origId="9952448-5" text="ACS activity, the rate-limiting step of ethylene biosynthesis, was highly elevated in both eto1 and eto3 mutant seedlings, even though RNA gel-blot analysis demonstrated that the steady-state level of ACS mRNA was not increased, including that of a novel Arabidopsis ACS gene that was identified.">
            <entity id="DS3.d661.s3.e0" origId="53675528,6325" charOffset="40-48" type="compound" text="ethylene"/>
            <entity id="DS3.d661.s3.e1" origId="O65020,F4J4I9" charOffset="91-95" type="protein" text="eto1"/>
            <entity id="DS3.d661.s3.e2" origId="Q9M2Y8" charOffset="100-104" type="protein" text="eto3"/>
            <pair e1="DS3.d661.s3.e0" e2="DS3.d661.s3.e2" id="DS3.d661.s3.i0" interaction="False" />
            <pair e1="DS3.d661.s3.e0" e2="DS3.d661.s3.e1" id="DS3.d661.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d661.s4" origId="9952448-7" text="Taken together, these data suggest that the eto1 and eto3 mutations elevate ethylene biosynthesis by affecting the posttranscriptional regulation of ACS.">
            <entity id="DS3.d661.s4.e0" origId="O65020,F4J4I9" charOffset="44-48" type="protein" text="eto1"/>
            <entity id="DS3.d661.s4.e1" origId="Q9M2Y8" charOffset="53-57" type="protein" text="eto3"/>
            <entity id="DS3.d661.s4.e2" origId="53675528,6325" charOffset="76-84" type="compound" text="ethylene"/>
            <pair e1="DS3.d661.s4.e2" e2="DS3.d661.s4.e1" id="DS3.d661.s4.i0" interaction="False" />
            <pair e1="DS3.d661.s4.e2" e2="DS3.d661.s4.e0" id="DS3.d661.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d662" origId="9952455">
        <sentence id="DS3.d662.s0" origId="9952455-5" text="The induction of Gtr mRNA in developing nodules was subsequent to that of the gene Enod2 (early nodule) and coincided with leghemoglobin mRNA accumulation.">
            <entity id="DS3.d662.s0.e0" origId="441476" charOffset="17-20" type="compound" text="Gtr"/>
            <entity id="DS3.d662.s0.e1" origId="P02238,C6T4A7" charOffset="123-136" type="protein" text="leghemoglobin"/>
            <pair e1="DS3.d662.s0.e0" e2="DS3.d662.s0.e1" id="DS3.d662.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d663" origId="9952462">
        <sentence id="DS3.d663.s0" origId="9952462-2" text="We isolated a full-length lg3 cDNA containing a knotted1-like family homeobox.">
            <entity id="DS3.d663.s0.e0" origId="67431" charOffset="26-29" type="compound" text="lg3"/>
            <entity id="DS3.d663.s0.e1" origId="P24345,Q53ZF1" charOffset="48-56" type="protein" text="knotted1"/>
            <pair e1="DS3.d663.s0.e0" e2="DS3.d663.s0.e1" id="DS3.d663.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d663.s1" origId="9952462-3" text="Six Lg3-O partial revertant alleles caused by insertion of a Mutator (Mu) transposon and two deletion derivatives were isolated and used to verify that our knotted1-like cDNA corresponds to the LG3 message.">
            <entity id="DS3.d663.s1.e0" origId="67431" charOffset="4-7" type="compound" text="Lg3"/>
            <entity id="DS3.d663.s1.e1" origId="P24345,Q53ZF1" charOffset="156-164" type="protein" text="knotted1"/>
            <entity id="DS3.d663.s1.e2" origId="67431" charOffset="194-197" type="compound" text="LG3"/>
            <pair e1="DS3.d663.s1.e0" e2="DS3.d663.s1.e1" id="DS3.d663.s1.i0" interaction="False" />
            <pair e1="DS3.d663.s1.e2" e2="DS3.d663.s1.e1" id="DS3.d663.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d664" origId="9971736">
        <sentence id="DS3.d664.s0" origId="9971736-4" text="By the yeast two-hybrid assay with various deletion mutants of PKC, FEZ1 was shown to interact with the NH2-terminal variable region (V1) of PKCzeta and weakly with that of PKCepsilon.">
            <entity id="DS3.d664.s0.e0" origId="P97577" charOffset="68-72" type="protein" text="FEZ1"/>
            <entity id="DS3.d664.s0.e1" origId="6329" charOffset="104-108" type="compound" text="NH2-"/>
            <pair e1="DS3.d664.s0.e1" e2="DS3.d664.s0.e0" id="DS3.d664.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d664.s1" origId="9971736-8" text="Upon treatment of the cells with a PKC inhibitor, staurosporin, FEZ1 was translocated from the cytoplasm to the plasma membrane, suggesting that the cytoplasmic translocation of FEZ1 is directly regulated by the PKCzeta activity.">
            <entity id="DS3.d664.s1.e0" origId="44259" charOffset="50-62" type="compound" text="staurosporin"/>
            <entity id="DS3.d664.s1.e1" origId="P97577" charOffset="64-68" type="protein" text="FEZ1"/>
            <entity id="DS3.d664.s1.e2" origId="P97577" charOffset="178-182" type="protein" text="FEZ1"/>
            <pair e1="DS3.d664.s1.e0" e2="DS3.d664.s1.e1" id="DS3.d664.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d665" origId="9971737">
        <sentence id="DS3.d665.s0" origId="9971737-3" text="Coexpression of transforming Ha-Ras L61 with kinase-defective, dominant-negative (DN) mutants of aPKC-lambda and aPKC-zeta, as well as antisense constructs encoding RNA-directed against isotype-specific 5' sequences of the corresponding mRNA, abrogates the Ha-Ras-induced reorganization of the actin cytoskeleton.">
            <entity id="DS3.d665.s0.e0" origId="28377756" charOffset="36-39" type="compound" text="L61"/>
            <entity id="DS3.d665.s0.e1" origId="Q02956,Q3V341" charOffset="113-122" type="protein" text="aPKC-zeta"/>
            <pair e1="DS3.d665.s0.e0" e2="DS3.d665.s0.e1" id="DS3.d665.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d665.s1" origId="9971737-6" text="Coexpression of (DN) Rac-1 N17 and addition of the phosphatidylinositol 3'-kinase (PI3K) inhibitors wortmannin and LY294002 are in agreement with a tentative model suggesting that, in the signaling pathway from Ha-Ras to the cytoskeleton aPKC-lambda acts upstream of PI3K and Rac-1, whereas aPKC-zeta functions downstream of PI3K and Rac-1.">
            <entity id="DS3.d665.s1.e0" origId="P63001,K7Q7T7,Q3TLP8" charOffset="21-26" type="protein" text="Rac-1"/>
            <entity id="DS3.d665.s1.e1" origId="16738692,53477912" charOffset="51-71" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d665.s1.e2" origId="312145" charOffset="100-110" type="compound" text="wortmannin"/>
            <entity id="DS3.d665.s1.e3" origId="3973" charOffset="115-123" type="compound" text="LY294002"/>
            <entity id="DS3.d665.s1.e4" origId="P63001,K7Q7T7,Q3TLP8" charOffset="276-281" type="protein" text="Rac-1"/>
            <entity id="DS3.d665.s1.e5" origId="Q02956,Q3V341" charOffset="291-300" type="protein" text="aPKC-zeta"/>
            <entity id="DS3.d665.s1.e6" origId="P63001,K7Q7T7,Q3TLP8" charOffset="276-281" type="protein" text="Rac-1"/>
            <pair e1="DS3.d665.s1.e3" e2="DS3.d665.s1.e0" id="DS3.d665.s1.i0" interaction="False" />
            <pair e1="DS3.d665.s1.e3" e2="DS3.d665.s1.e5" id="DS3.d665.s1.i1" interaction="False" />
            <pair e1="DS3.d665.s1.e2" e2="DS3.d665.s1.e0" id="DS3.d665.s1.i2" interaction="False" />
            <pair e1="DS3.d665.s1.e2" e2="DS3.d665.s1.e5" id="DS3.d665.s1.i3" interaction="False" />
            <pair e1="DS3.d665.s1.e1" e2="DS3.d665.s1.e0" id="DS3.d665.s1.i4" interaction="False" />
            <pair e1="DS3.d665.s1.e1" e2="DS3.d665.s1.e5" id="DS3.d665.s1.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d666" origId="9971738">
        <sentence id="DS3.d666.s0" origId="9971738-6" text="When dexamethasone and cAMP were further added, both iNOS and arginase II were induced, NO production was much decreased, and apoptosis was prevented.">
            <entity id="DS3.d666.s0.e0" origId="5743" charOffset="5-18" type="compound" text="dexamethasone"/>
            <entity id="DS3.d666.s0.e1" origId="P51437" charOffset="23-27" type="protein" text="cAMP"/>
            <entity id="DS3.d666.s0.e2" origId="P29477" charOffset="53-57" type="protein" text="iNOS"/>
            <pair e1="DS3.d666.s0.e0" e2="DS3.d666.s0.e1" id="DS3.d666.s0.i0" interaction="False" />
            <pair e1="DS3.d666.s0.e0" e2="DS3.d666.s0.e2" id="DS3.d666.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d667" origId="9971741">
        <sentence id="DS3.d667.s0" origId="9971741-2" text="The bifunctional PAM protein contains an NH2-terminal monooxygenase (PHM) domain followed by a lyase (PAL) domain and a transmembrane domain.">
            <entity id="DS3.d667.s0.e0" origId="P97467,A1L331,E9Q704,F8VQA4" charOffset="17-20" type="protein" text="PAM"/>
            <entity id="DS3.d667.s0.e1" origId="6329" charOffset="41-45" type="compound" text="NH2-"/>
            <entity id="DS3.d667.s0.e2" origId="P97467,A1L331,E9Q704,F8VQA4" charOffset="69-72" type="protein" text="PHM"/>
            <pair e1="DS3.d667.s0.e1" e2="DS3.d667.s0.e0" id="DS3.d667.s0.i0" interaction="False" />
            <pair e1="DS3.d667.s0.e1" e2="DS3.d667.s0.e2" id="DS3.d667.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d667.s1" origId="9971741-4" text="A reverse tetracycline-regulated inducible expression system was used to construct an AtT-20 corticotrope cell line capable of inducible PAM-1 expression.">
            <entity id="DS3.d667.s1.e0" origId="54675776" charOffset="10-22" type="compound" text="tetracycline"/>
            <entity id="DS3.d667.s1.e1" origId="P97467,A1L331,E9Q704,F8VQA4" charOffset="137-140" type="protein" text="PAM"/>
            <pair e1="DS3.d667.s1.e0" e2="DS3.d667.s1.e1" id="DS3.d667.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d668" origId="9971742">
        <sentence id="DS3.d668.s0" origId="9971742-26" text="Consistent with this, Western blots indicate that DHC1b is present in the flagellum, predominantly in the detergent- and ATP-soluble fractions.">
            <entity id="DS3.d668.s0.e0" origId="Q8NCM8" charOffset="50-55" type="protein" text="DHC1b"/>
            <entity id="DS3.d668.s0.e1" origId="5957" charOffset="121-124" type="compound" text="ATP"/>
            <pair e1="DS3.d668.s0.e1" e2="DS3.d668.s0.e0" id="DS3.d668.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d669" origId="9971748">
        <sentence id="DS3.d669.s0" origId="9971748-11" text="Our results provide the first evidence that different states of an integrin (alpha6beta1) can interact with an extracellular matrix ligand (laminin) or a membrane-anchored cell surface ligand (ADAM 2).">
            <entity id="DS3.d669.s0.e0" origId="44342165" charOffset="140-147" type="compound" text="laminin"/>
            <entity id="DS3.d669.s0.e1" origId="Q60718" charOffset="193-199" type="protein" text="ADAM 2"/>
            <pair e1="DS3.d669.s0.e0" e2="DS3.d669.s0.e1" id="DS3.d669.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d669.s1" origId="9971748-4" text="Using alpha6-transfected cells we found that treatments (e.g., with phorbol myristate acetate or MnCl2) that increased adhesion to laminin inhibited sperm binding.">
            <entity id="DS3.d669.s1.e0" origId="P16305" charOffset="6-12" type="protein" text="alpha6"/>
            <entity id="DS3.d669.s1.e1" origId="22833501,27924,4792" charOffset="68-93" type="compound" text="phorbol myristate acetate"/>
            <entity id="DS3.d669.s1.e2" origId="24480" charOffset="97-102" type="compound" text="MnCl2"/>
            <entity id="DS3.d669.s1.e3" origId="44342165" charOffset="131-138" type="compound" text="laminin"/>
            <pair e1="DS3.d669.s1.e3" e2="DS3.d669.s1.e0" id="DS3.d669.s1.i0" interaction="False" />
            <pair e1="DS3.d669.s1.e1" e2="DS3.d669.s1.e0" id="DS3.d669.s1.i1" interaction="False" />
            <pair e1="DS3.d669.s1.e2" e2="DS3.d669.s1.e0" id="DS3.d669.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d669.s2" origId="9971748-6" text="Next, we compared the ability of fluorescent beads coated with either fertilin beta or with the laminin E8 fragment to bind to eggs.">
            <entity id="DS3.d669.s2.e0" origId="Q60718" charOffset="70-83" type="protein" text="fertilin beta"/>
            <entity id="DS3.d669.s2.e1" origId="44342165" charOffset="96-103" type="compound" text="laminin"/>
            <pair e1="DS3.d669.s2.e1" e2="DS3.d669.s2.e0" id="DS3.d669.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d670" origId="9971749">
        <sentence id="DS3.d670.s0" origId="9971749-5" text="This is accompanied by a particular pattern of inhibition of early tyrosine kinases, including Zap 70 and p59(fyn) inhibition, but not overall inhibition of p56(lck).">
            <entity id="DS3.d670.s0.e0" origId="6057,90983769" charOffset="67-75" type="compound" text="tyrosine"/>
            <entity id="DS3.d670.s0.e1" origId="P43403" charOffset="95-101" type="protein" text="Zap 70"/>
            <entity id="DS3.d670.s0.e2" origId="Q13418,V9HWF0" charOffset="106-109" type="protein" text="p59"/>
            <entity id="DS3.d670.s0.e3" origId="P09914" charOffset="157-160" type="protein" text="p56"/>
            <entity id="DS3.d670.s0.e4" origId="P06239,Q573B4" charOffset="161-164" type="protein" text="lck"/>
            <pair e1="DS3.d670.s0.e0" e2="DS3.d670.s0.e1" id="DS3.d670.s0.i0" interaction="False" />
            <pair e1="DS3.d670.s0.e0" e2="DS3.d670.s0.e3" id="DS3.d670.s0.i1" interaction="False" />
            <pair e1="DS3.d670.s0.e0" e2="DS3.d670.s0.e2" id="DS3.d670.s0.i2" interaction="False" />
            <pair e1="DS3.d670.s0.e0" e2="DS3.d670.s0.e4" id="DS3.d670.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d671" origId="9971750">
        <sentence id="DS3.d671.s0" origId="9971750-0" text="Cell surface heparan sulfate proteoglycan syndecan-2 induces the maturation of dendritic spines in rat hippocampal neurons.">
            <entity id="DS3.d671.s0.e0" origId="1117" charOffset="21-28" type="compound" text="sulfate"/>
            <entity id="DS3.d671.s0.e1" origId="P34900,Q6IRK3" charOffset="42-52" type="protein" text="syndecan-2"/>
            <pair e1="DS3.d671.s0.e0" e2="DS3.d671.s0.e1" id="DS3.d671.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d671.s1" origId="9971750-2" text="We demonstrate that the cell surface heparan sulfate proteoglycan syndecan-2 plays a critical role in spine development.">
            <entity id="DS3.d671.s1.e0" origId="1117" charOffset="45-52" type="compound" text="sulfate"/>
            <entity id="DS3.d671.s1.e1" origId="P34900,Q6IRK3" charOffset="66-76" type="protein" text="syndecan-2"/>
            <pair e1="DS3.d671.s1.e0" e2="DS3.d671.s1.e1" id="DS3.d671.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d672" origId="9971752">
        <sentence id="DS3.d672.s0" origId="9971752-7" text="Additionally, despite having increased levels of inducible nitric oxide synthetase (iNOS) expression, treatment of Tg mice with the iNOS inhibitor aminoguanidine did not alter the level of protection afforded by IFN-gamma expression.">
            <entity id="DS3.d672.s0.e0" origId="145068" charOffset="59-71" type="compound" text="nitric oxide"/>
            <entity id="DS3.d672.s0.e1" origId="2146" charOffset="147-161" type="compound" text="aminoguanidine"/>
            <entity id="DS3.d672.s0.e2" origId="P01580" charOffset="212-221" type="protein" text="IFN-gamma"/>
            <pair e1="DS3.d672.s0.e0" e2="DS3.d672.s0.e2" id="DS3.d672.s0.i0" interaction="False" />
            <pair e1="DS3.d672.s0.e1" e2="DS3.d672.s0.e2" id="DS3.d672.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d673" origId="9971760">
        <sentence id="DS3.d673.s0" origId="9971760-8" text="Finally, our results suggest that efficient infectivity of vectors defective in the accessory proteins Vif, Vpr, Vpu, and Nef depends on the nature of the target cells.">
            <entity id="DS3.d673.s0.e0" origId="P69722,P69720,P69721,P69723,Q77YG0" charOffset="103-106" type="protein" text="Vif"/>
            <entity id="DS3.d673.s0.e1" origId="Q77YF9" charOffset="108-111" type="protein" text="Vpr"/>
            <entity id="DS3.d673.s0.e2" origId="42627785" charOffset="113-116" type="compound" text="Vpu"/>
            <entity id="DS3.d673.s0.e3" origId="P04601" charOffset="122-125" type="protein" text="Nef"/>
            <pair e1="DS3.d673.s0.e2" e2="DS3.d673.s0.e3" id="DS3.d673.s0.i0" interaction="False" />
            <pair e1="DS3.d673.s0.e2" e2="DS3.d673.s0.e0" id="DS3.d673.s0.i1" interaction="False" />
            <pair e1="DS3.d673.s0.e2" e2="DS3.d673.s0.e1" id="DS3.d673.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d674" origId="9971762">
        <sentence id="DS3.d674.s0" origId="9971762-10" text="This suggests that the function of vig-1 may be involved in the nonspecific virus-induced synthesis of enzymatic cofactors of the nitric oxide pathway.">
            <entity id="DS3.d674.s0.e0" origId="Q8WXG1,O93384" charOffset="35-40" type="protein" text="vig-1"/>
            <entity id="DS3.d674.s0.e1" origId="145068" charOffset="130-142" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d674.s0.e1" e2="DS3.d674.s0.e0" id="DS3.d674.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d675" origId="9971773">
        <sentence id="DS3.d675.s0" origId="9971773-7" text="Pairwise comparisons suggested that coxsackie A11 and A15 viruses should be classified as strains of the same serotype, as should coxsackie A13 and A18 viruses.">
            <entity id="DS3.d675.s0.e0" origId="P41732" charOffset="54-57" type="protein" text="A15"/>
            <entity id="DS3.d675.s0.e1" origId="2259" charOffset="140-143" type="compound" text="A13"/>
            <pair e1="DS3.d675.s0.e1" e2="DS3.d675.s0.e0" id="DS3.d675.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d676" origId="9971776">
        <sentence id="DS3.d676.s0" origId="9971776-0" text="Nef-induced CD4 and major histocompatibility complex class I (MHC-I) down-regulation are governed by distinct determinants: N-terminal alpha helix and proline repeat of Nef selectively regulate MHC-I trafficking.">
            <entity id="DS3.d676.s0.e0" origId="P04601" charOffset="0-3" type="protein" text="Nef"/>
            <entity id="DS3.d676.s0.e1" origId="145742,57240853,614,8988" charOffset="151-158" type="compound" text="proline"/>
            <entity id="DS3.d676.s0.e2" origId="P04601" charOffset="169-172" type="protein" text="Nef"/>
            <pair e1="DS3.d676.s0.e1" e2="DS3.d676.s0.e0" id="DS3.d676.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d676.s1" origId="9971776-6" text="Mutations affecting only CD4 regulation mapped to residues previously shown to mediate the binding of Nef to this receptor, such as W57 and L58, as well as to an AP-recruiting dileucine motif and to an acidic dipeptide in the C-terminal region of the protein.">
            <entity id="DS3.d676.s1.e0" origId="P04601" charOffset="102-105" type="protein" text="Nef"/>
            <entity id="DS3.d676.s1.e1" origId="59697583" charOffset="140-143" type="compound" text="L58"/>
            <pair e1="DS3.d676.s1.e1" e2="DS3.d676.s1.e0" id="DS3.d676.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d676.s2" origId="9971776-7" text="In contrast, mutation of residues in an alpha-helical region in the proximal portion of Nef and amino acid substitutions in a proline-based SH3 domain-binding motif selectively affected MHC-I down-modulation.">
            <entity id="DS3.d676.s2.e0" origId="P04601" charOffset="88-91" type="protein" text="Nef"/>
            <entity id="DS3.d676.s2.e1" origId="145742,57240853,614,8988" charOffset="126-133" type="compound" text="proline"/>
            <pair e1="DS3.d676.s2.e1" e2="DS3.d676.s2.e0" id="DS3.d676.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d676.s3" origId="9971776-8" text="Although both the N-terminal alpha-helix and the proline-rich region of Nef have been implicated in recruiting Src family protein kinases, the inhibitor herbimycin A did not block MHC-I down-regulation, suggesting that the latter process is not mediated through an activation of this family of tyrosine kinases.">
            <entity id="DS3.d676.s3.e0" origId="145742,57240853,614,8988" charOffset="49-56" type="compound" text="proline"/>
            <entity id="DS3.d676.s3.e1" origId="P04601" charOffset="72-75" type="protein" text="Nef"/>
            <entity id="DS3.d676.s3.e2" origId="3591,16760502,5311102" charOffset="153-165" type="compound" text="herbimycin A"/>
            <entity id="DS3.d676.s3.e3" origId="6057,90983769" charOffset="294-302" type="compound" text="tyrosine"/>
            <pair e1="DS3.d676.s3.e3" e2="DS3.d676.s3.e1" id="DS3.d676.s3.i0" interaction="False" />
            <pair e1="DS3.d676.s3.e0" e2="DS3.d676.s3.e1" id="DS3.d676.s3.i1" interaction="False" />
            <pair e1="DS3.d676.s3.e2" e2="DS3.d676.s3.e1" id="DS3.d676.s3.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d677" origId="9971784">
        <sentence id="DS3.d677.s0" origId="9971784-8" text="Interestingly, although PEST sequences (rich in proline, glutamine, serine, and threonine), often associated with degradation, are found in c-Myb, deletion of PEST-containing regions had no effect on protein turnover.">
            <entity id="DS3.d677.s0.e0" origId="57240853,614,8988" charOffset="48-55" type="compound" text="proline"/>
            <entity id="DS3.d677.s0.e1" origId="5961" charOffset="57-66" type="compound" text="glutamine"/>
            <entity id="DS3.d677.s0.e2" origId="5951" charOffset="68-74" type="compound" text="serine"/>
            <entity id="DS3.d677.s0.e3" origId="194239,6288" charOffset="80-89" type="compound" text="threonine"/>
            <entity id="DS3.d677.s0.e4" origId="P06876,Q3UUX5,A0A087WPA7" charOffset="140-145" type="protein" text="c-Myb"/>
            <pair e1="DS3.d677.s0.e3" e2="DS3.d677.s0.e4" id="DS3.d677.s0.i0" interaction="False" />
            <pair e1="DS3.d677.s0.e0" e2="DS3.d677.s0.e4" id="DS3.d677.s0.i1" interaction="False" />
            <pair e1="DS3.d677.s0.e2" e2="DS3.d677.s0.e4" id="DS3.d677.s0.i2" interaction="False" />
            <pair e1="DS3.d677.s0.e1" e2="DS3.d677.s0.e4" id="DS3.d677.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d678" origId="9971788">
        <sentence id="DS3.d678.s0" origId="9971788-10" text="However IL-7, a crucial factor for thymopoiesis that is secreted mainly by TEC, is a necessary cofactor for NF-kappaB activation elicited by TNF or IL-1.">
            <entity id="DS3.d678.s0.e0" origId="P13232,Q5FBX5,A0A0A0MTG5,A8K673" charOffset="8-12" type="protein" text="IL-7"/>
            <entity id="DS3.d678.s0.e1" origId="108194" charOffset="95-103" type="compound" text="cofactor"/>
            <entity id="DS3.d678.s0.e2" origId="P01583" charOffset="148-152" type="protein" text="IL-1"/>
            <pair e1="DS3.d678.s0.e1" e2="DS3.d678.s0.e0" id="DS3.d678.s0.i0" interaction="False" />
            <pair e1="DS3.d678.s0.e1" e2="DS3.d678.s0.e2" id="DS3.d678.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d679" origId="9971795">
        <sentence id="DS3.d679.s0" origId="9971795-5" text="To directly analyze the function of the mature IN protein itself, in the context of a replicating virus but independently from that of Gag-Pol, we used an approach developed in our laboratory for incorporating proteins into HIV virions by their expression in trans as fusion partners of either Vpr or Vpx.">
            <entity id="DS3.d679.s0.e0" origId="P04585" charOffset="135-142" type="protein" text="Gag-Pol"/>
            <entity id="DS3.d679.s0.e1" origId="16678473" charOffset="301-304" type="compound" text="Vpx"/>
            <pair e1="DS3.d679.s0.e1" e2="DS3.d679.s0.e0" id="DS3.d679.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d680" origId="9971806">
        <sentence id="DS3.d680.s0" origId="9971806-6" text="A second group of early genes that were slightly delayed in their appearance included viral DHFR, thymidylate synthase, vMIP I, G protein-coupled receptor, K12, vBcl2, and a lytic transcript that overlapped LANA.">
            <entity id="DS3.d680.s0.e0" origId="9700" charOffset="98-109" type="compound" text="thymidylate"/>
            <entity id="DS3.d680.s0.e1" origId="Q77Q38,D0UZT8" charOffset="156-159" type="protein" text="K12"/>
            <entity id="DS3.d680.s0.e2" origId="F5HGJ3,Q76RI8" charOffset="161-166" type="protein" text="vBcl2"/>
            <entity id="DS3.d680.s0.e3" origId="Q9QR71" charOffset="207-211" type="protein" text="LANA"/>
            <pair e1="DS3.d680.s0.e0" e2="DS3.d680.s0.e2" id="DS3.d680.s0.i0" interaction="False" />
            <pair e1="DS3.d680.s0.e0" e2="DS3.d680.s0.e1" id="DS3.d680.s0.i1" interaction="False" />
            <pair e1="DS3.d680.s0.e0" e2="DS3.d680.s0.e3" id="DS3.d680.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d680.s1" origId="9971806-7" text="The transcript of sVCA (ORF65), a late gene whose expression was abolished by Phosphonoacetic acid, an inhibitor of KSHV DNA replication, did not appear until 30 h after induction.">
            <entity id="DS3.d680.s1.e0" origId="Q2HR63,Q76RF4" charOffset="24-29" type="protein" text="ORF65"/>
            <entity id="DS3.d680.s1.e1" origId="546" charOffset="78-98" type="compound" text="Phosphonoacetic acid"/>
            <pair e1="DS3.d680.s1.e1" e2="DS3.d680.s1.e0" id="DS3.d680.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d681" origId="9971815">
        <sentence id="DS3.d681.s0" origId="9971815-7" text="Latently infected peritoneal cells consistently scored for expression of RNA derived from 4 of the 11 candidate latency-associated ORFs examined, including the regions of ORF M2, ORF M11 (encoding v-bcl-2), gene 73 (a homolog of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) gene encoding latency-associated nuclear antigen), and gene 74 (encoding a G-protein coupled receptor homolog, v-GCR).">
            <entity id="DS3.d681.s0.e0" origId="25021181" charOffset="183-186" type="compound" text="M11"/>
            <entity id="DS3.d681.s0.e1" origId="F5HGJ3,Q76RI8" charOffset="197-204" type="protein" text="v-bcl-2"/>
            <pair e1="DS3.d681.s0.e0" e2="DS3.d681.s0.e1" id="DS3.d681.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d682" origId="9971831">
        <sentence id="DS3.d682.s0" origId="9971831-5" text="The ie-2 mutant viruses exhibited delays in viral DNA synthesis, late gene expression, budded virus production, and occlusion body formation in SF-21 cells but not in TN-5B1-4 cells.">
            <entity id="DS3.d682.s0.e0" origId="P24647,A0A097PV75" charOffset="4-8" type="protein" text="ie-2"/>
            <entity id="DS3.d682.s0.e1" origId="2911646" charOffset="144-149" type="compound" text="SF-21"/>
            <pair e1="DS3.d682.s0.e1" e2="DS3.d682.s0.e0" id="DS3.d682.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d683" origId="9971832">
        <sentence id="DS3.d683.s0" origId="9971832-0" text="A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity.">
            <entity id="DS3.d683.s0.e0" origId="57175189,6305" charOffset="12-22" type="compound" text="tryptophan"/>
            <entity id="DS3.d683.s0.e1" origId="P04578" charOffset="142-145" type="protein" text="Env"/>
            <pair e1="DS3.d683.s0.e0" e2="DS3.d683.s0.e1" id="DS3.d683.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d683.s1" origId="9971832-10" text="Even the substitution of phenylalanine for a single tryptophan residue was sufficient to reduce Env incorporation and drop the efficiency of virus entry approximately 10-fold, despite the fact that the same mutation had no significant effect on syncytium formation.">
            <entity id="DS3.d683.s1.e0" origId="71567,89654470,994,6140" charOffset="25-38" type="compound" text="phenylalanine"/>
            <entity id="DS3.d683.s1.e1" origId="57175189,6305" charOffset="52-62" type="compound" text="tryptophan"/>
            <entity id="DS3.d683.s1.e2" origId="P04578" charOffset="96-99" type="protein" text="Env"/>
            <pair e1="DS3.d683.s1.e1" e2="DS3.d683.s1.e2" id="DS3.d683.s1.i0" interaction="False" />
            <pair e1="DS3.d683.s1.e0" e2="DS3.d683.s1.e2" id="DS3.d683.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d684" origId="9971877">
        <sentence id="DS3.d684.s0" origId="9971877-5" text="In the coding region, 53 simple sequence variants were found: 35 missense mutations, one 2 bp deletion (CT) resulting in a stop at codon 3364, one nonsense mutation with a stop at codon 3326, one deletion of a complete codon (AAA) resulting in the loss of leucine, and 15 silent mutations.">
            <entity id="DS3.d684.s0.e0" origId="P05067,A0A0A0MRG2,B4DGD0,B4DJT9,E9PG40" charOffset="226-229" type="protein" text="AAA"/>
            <entity id="DS3.d684.s0.e1" origId="6106" charOffset="256-263" type="compound" text="leucine"/>
            <pair e1="DS3.d684.s0.e1" e2="DS3.d684.s0.e0" id="DS3.d684.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d685" origId="9971892">
        <sentence id="DS3.d685.s0" origId="9971892-2" text="The release properties of tablets prepared from this new material, poly(acrylamido-2-methyl-1-propanesulfonate sodium -co- methyl methacrylate) (PAMPSNa/MMA), are discussed.">
            <entity id="DS3.d685.s0.e0" origId="10352978" charOffset="72-110" type="compound" text="acrylamido-2-methyl-1-propanesulfonate"/>
            <entity id="DS3.d685.s0.e1" origId="5360545" charOffset="111-117" type="compound" text="sodium"/>
            <entity id="DS3.d685.s0.e2" origId="6658" charOffset="123-142" type="compound" text="methyl methacrylate"/>
            <entity id="DS3.d685.s0.e3" origId="Q15546" charOffset="153-156" type="protein" text="MMA"/>
            <pair e1="DS3.d685.s0.e2" e2="DS3.d685.s0.e3" id="DS3.d685.s0.i0" interaction="False" />
            <pair e1="DS3.d685.s0.e0" e2="DS3.d685.s0.e3" id="DS3.d685.s0.i1" interaction="False" />
            <pair e1="DS3.d685.s0.e1" e2="DS3.d685.s0.e3" id="DS3.d685.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d686" origId="9971904">
        <sentence id="DS3.d686.s0" origId="9971904-1" text="OBJECTIVE: percutaneous ethanol injection (PEI) under general anesthesia (One Shot PEI) is a new therapy for large and multiple hepatocellular carcinoma (HCC) by the injection of large amount of ethanol in the tumor.">
            <entity id="DS3.d686.s0.e0" origId="702" charOffset="24-31" type="compound" text="ethanol"/>
            <entity id="DS3.d686.s0.e1" origId="O60902,A6NLG4" charOffset="78-82" type="protein" text="Shot"/>
            <entity id="DS3.d686.s0.e2" origId="702" charOffset="195-202" type="compound" text="ethanol"/>
            <pair e1="DS3.d686.s0.e0" e2="DS3.d686.s0.e1" id="DS3.d686.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d687" origId="9971915">
        <sentence id="DS3.d687.s0" origId="9971915-0" text="N-terminal 4-imidazolidinone prodrugs of Leu-enkephalin: synthesis, chemical and enzymatic stability studies.">
            <entity id="DS3.d687.s0.e0" origId="1502063" charOffset="11-28" type="compound" text="4-imidazolidinone"/>
            <entity id="DS3.d687.s0.e1" origId="P01213" charOffset="41-55" type="protein" text="Leu-enkephalin"/>
            <pair e1="DS3.d687.s0.e0" e2="DS3.d687.s0.e1" id="DS3.d687.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d687.s1" origId="9971915-1" text="Four N-terminal 4-imidazolidinone prodrugs of Leu-enkephalin are prepared and characterized.">
            <entity id="DS3.d687.s1.e0" origId="1502063" charOffset="16-33" type="compound" text="4-imidazolidinone"/>
            <entity id="DS3.d687.s1.e1" origId="P01213" charOffset="46-60" type="protein" text="Leu-enkephalin"/>
            <pair e1="DS3.d687.s1.e0" e2="DS3.d687.s1.e1" id="DS3.d687.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d687.s2" origId="9971915-3" text="The prodrug derivatives are shown to degrade stoichiometrically to Leu-enkephalin in phosphate buffer (t1/2 (0.05 M phosphate buffer without KCl): acetone prodrug (II) 930 min; cyclopentanone prodrug (III): 216 min; cyclohexanone prodrug (IV): 432 min; 4-methylcyclohexanone prodrug (V): 792 min).">
            <entity id="DS3.d687.s2.e0" origId="P01213" charOffset="67-81" type="protein" text="Leu-enkephalin"/>
            <entity id="DS3.d687.s2.e1" origId="1061,167704,644102" charOffset="85-94" type="compound" text="phosphate"/>
            <entity id="DS3.d687.s2.e2" origId="1061,167704,644102" charOffset="116-125" type="compound" text="phosphate"/>
            <entity id="DS3.d687.s2.e3" origId="180" charOffset="147-154" type="compound" text="acetone"/>
            <entity id="DS3.d687.s2.e4" origId="8452" charOffset="177-191" type="compound" text="cyclopentanone"/>
            <entity id="DS3.d687.s2.e5" origId="7967" charOffset="216-229" type="compound" text="cyclohexanone"/>
            <entity id="DS3.d687.s2.e6" origId="11525" charOffset="253-274" type="compound" text="4-methylcyclohexanone"/>
            <pair e1="DS3.d687.s2.e6" e2="DS3.d687.s2.e0" id="DS3.d687.s2.i0" interaction="False" />
            <pair e1="DS3.d687.s2.e1" e2="DS3.d687.s2.e0" id="DS3.d687.s2.i1" interaction="False" />
            <pair e1="DS3.d687.s2.e4" e2="DS3.d687.s2.e0" id="DS3.d687.s2.i2" interaction="False" />
            <pair e1="DS3.d687.s2.e3" e2="DS3.d687.s2.e0" id="DS3.d687.s2.i3" interaction="False" />
            <pair e1="DS3.d687.s2.e5" e2="DS3.d687.s2.e0" id="DS3.d687.s2.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d688" origId="9972044">
        <sentence id="DS3.d688.s0" origId="9972044-0" text="Hyphomycetes in rain water draining from intact trees.">
            <entity id="DS3.d688.s0.e0" origId="Q5U651,Q7L251,Q8IUR2" charOffset="16-20" type="protein" text="rain"/>
            <entity id="DS3.d688.s0.e1" origId="962" charOffset="21-26" type="compound" text="water"/>
            <pair e1="DS3.d688.s0.e1" e2="DS3.d688.s0.e0" id="DS3.d688.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d688.s1" origId="9972044-1" text="The authors investigated Hyphomycetes in rain water flowing down from leaves of 10 gymnospermous and 10 angiospermous tree species in northeastern Poland.">
            <entity id="DS3.d688.s1.e0" origId="Q5U651,Q7L251,Q8IUR2" charOffset="41-45" type="protein" text="rain"/>
            <entity id="DS3.d688.s1.e1" origId="962" charOffset="46-51" type="compound" text="water"/>
            <pair e1="DS3.d688.s1.e1" e2="DS3.d688.s1.e0" id="DS3.d688.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d688.s2" origId="9972044-3" text="Only 17 species were found to develop both on gymnospermous and angiospermous tree species out of 57 found in rain water flowing down the trees.">
            <entity id="DS3.d688.s2.e0" origId="Q5U651,Q7L251,Q8IUR2" charOffset="110-114" type="protein" text="rain"/>
            <entity id="DS3.d688.s2.e1" origId="962" charOffset="115-120" type="compound" text="water"/>
            <pair e1="DS3.d688.s2.e1" e2="DS3.d688.s2.e0" id="DS3.d688.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d688.s3" origId="9972044-4" text="16 Hyphomycetes species were observed in rain water flowing down the angiospermous trees, while 24 species in the water from the gymnospermous trees.">
            <entity id="DS3.d688.s3.e0" origId="Q5U651,Q7L251,Q8IUR2" charOffset="41-45" type="protein" text="rain"/>
            <entity id="DS3.d688.s3.e1" origId="962" charOffset="46-51" type="compound" text="water"/>
            <entity id="DS3.d688.s3.e2" origId="962" charOffset="114-119" type="compound" text="water"/>
            <pair e1="DS3.d688.s3.e1" e2="DS3.d688.s3.e0" id="DS3.d688.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d689" origId="9972053">
        <sentence id="DS3.d689.s0" origId="9972053-0" text="Involvement of nitric oxide in cardiovascular effects of cholecystokinin (CCK) in rats.">
            <entity id="DS3.d689.s0.e0" origId="145068" charOffset="15-27" type="compound" text="nitric oxide"/>
            <entity id="DS3.d689.s0.e1" origId="P01355" charOffset="57-72" type="protein" text="cholecystokinin"/>
            <pair e1="DS3.d689.s0.e0" e2="DS3.d689.s0.e1" id="DS3.d689.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d689.s1" origId="9972053-3" text="Donors NO: L-arginine (L-Arg-100.0 mg/kg i.v.)">
            <entity id="DS3.d689.s1.e0" origId="90867653" charOffset="13-21" type="compound" text="arginine"/>
            <entity id="DS3.d689.s1.e1" origId="Q5BMA6" charOffset="23-28" type="protein" text="L-Arg"/>
            <pair e1="DS3.d689.s1.e0" e2="DS3.d689.s1.e1" id="DS3.d689.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d690" origId="9972056">
        <sentence id="DS3.d690.s0" origId="9972056-0" text="Prolidase as a prodrug converting enzyme. II. Synthesis of proline analogue of anthraquinone-2-carboxylic acid and its susceptibility to the action of Prolidase.">
            <entity id="DS3.d690.s0.e0" origId="P12955" charOffset="0-9" type="protein" text="Prolidase"/>
            <entity id="DS3.d690.s0.e1" origId="57240853,614,8988" charOffset="59-66" type="compound" text="proline"/>
            <entity id="DS3.d690.s0.e2" origId="67030" charOffset="79-110" type="compound" text="anthraquinone-2-carboxylic acid"/>
            <entity id="DS3.d690.s0.e3" origId="P12955" charOffset="151-160" type="protein" text="Prolidase"/>
            <pair e1="DS3.d690.s0.e2" e2="DS3.d690.s0.e0" id="DS3.d690.s0.i0" interaction="False" />
            <pair e1="DS3.d690.s0.e1" e2="DS3.d690.s0.e0" id="DS3.d690.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d690.s1" origId="9972056-2" text="The synthesis of proline analogue of anthraquinone-2-carboxylic acid (potential antineoplastic agent) conjugated through imido-bond (potential target for Prolidase action) has been performed.">
            <entity id="DS3.d690.s1.e0" origId="57240853,614,8988" charOffset="17-24" type="compound" text="proline"/>
            <entity id="DS3.d690.s1.e1" origId="67030" charOffset="37-68" type="compound" text="anthraquinone-2-carboxylic acid"/>
            <entity id="DS3.d690.s1.e2" origId="P12955" charOffset="154-163" type="protein" text="Prolidase"/>
            <pair e1="DS3.d690.s1.e1" e2="DS3.d690.s1.e2" id="DS3.d690.s1.i0" interaction="False" />
            <pair e1="DS3.d690.s1.e0" e2="DS3.d690.s1.e2" id="DS3.d690.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d690.s2" origId="9972056-4" text="Evidence was provided that 1% DMSO does not affect Prolidase activity, thus allowing for substrate susceptibility measurement in a such conditions.">
            <entity id="DS3.d690.s2.e0" origId="679" charOffset="30-34" type="compound" text="DMSO"/>
            <entity id="DS3.d690.s2.e1" origId="P12955" charOffset="51-60" type="protein" text="Prolidase"/>
            <pair e1="DS3.d690.s2.e0" e2="DS3.d690.s2.e1" id="DS3.d690.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d690.s3" origId="9972056-5" text="It has been presented that product of synthesis, N-(anthraquinone-2-carbonyl)-L-proline evokes susceptibility to the action of purified Prolidase, comparable to the susceptibility of glycyl-L-proline (standard substrate for Prolidase).">
            <entity id="DS3.d690.s3.e0" origId="344310" charOffset="52-76" type="compound" text="anthraquinone-2-carbonyl"/>
            <entity id="DS3.d690.s3.e1" origId="57240853,614,8988" charOffset="80-87" type="compound" text="proline"/>
            <entity id="DS3.d690.s3.e2" origId="P12955" charOffset="136-145" type="protein" text="Prolidase"/>
            <entity id="DS3.d690.s3.e3" origId="3013625" charOffset="183-199" type="compound" text="glycyl-L-proline"/>
            <entity id="DS3.d690.s3.e4" origId="P12955" charOffset="224-233" type="protein" text="Prolidase"/>
            <pair e1="DS3.d690.s3.e3" e2="DS3.d690.s3.e2" id="DS3.d690.s3.i0" interaction="False" />
            <pair e1="DS3.d690.s3.e1" e2="DS3.d690.s3.e2" id="DS3.d690.s3.i1" interaction="False" />
            <pair e1="DS3.d690.s3.e0" e2="DS3.d690.s3.e2" id="DS3.d690.s3.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d690.s4" origId="9972056-6" text="Although insolubility of the proline analogue of anthraquinone-2-carboxylic acid in aqueous solutions limit its potential therapeutic value, the presented data suggest that Prolidase may have a broader substrate specificity than thought previously.">
            <entity id="DS3.d690.s4.e0" origId="57240853,614,8988" charOffset="29-36" type="compound" text="proline"/>
            <entity id="DS3.d690.s4.e1" origId="67030" charOffset="49-80" type="compound" text="anthraquinone-2-carboxylic acid"/>
            <entity id="DS3.d690.s4.e2" origId="P12955" charOffset="173-182" type="protein" text="Prolidase"/>
            <pair e1="DS3.d690.s4.e1" e2="DS3.d690.s4.e2" id="DS3.d690.s4.i0" interaction="False" />
            <pair e1="DS3.d690.s4.e0" e2="DS3.d690.s4.e2" id="DS3.d690.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d691" origId="9972058">
        <sentence id="DS3.d691.s0" origId="9972058-1" text="The activities of alcohol dehydrogenase isoenzymes (class ADH I and ADH II) and aldehyde dehydrogenase (ALDH) were measured using fluorogenic substrates in the liver of rats.">
            <entity id="DS3.d691.s0.e0" origId="10982484,702" charOffset="18-25" type="compound" text="alcohol"/>
            <entity id="DS3.d691.s0.e1" origId="A1L128" charOffset="68-74" type="protein" text="ADH II"/>
            <entity id="DS3.d691.s0.e2" origId="P11883" charOffset="80-102" type="protein" text="aldehyde dehydrogenase"/>
            <pair e1="DS3.d691.s0.e0" e2="DS3.d691.s0.e2" id="DS3.d691.s0.i0" interaction="False" />
            <pair e1="DS3.d691.s0.e0" e2="DS3.d691.s0.e1" id="DS3.d691.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d692" origId="9972062">
        <sentence id="DS3.d692.s0" origId="9972062-0" text="Effects of sulfated cholecystokinin octapeptide and cholecystokinin tetrapeptide in rat behavior after blockade of nitric oxide synthase by L-NAME.">
            <entity id="DS3.d692.s0.e0" origId="P01355" charOffset="20-35" type="protein" text="cholecystokinin"/>
            <entity id="DS3.d692.s0.e1" origId="P01355" charOffset="52-67" type="protein" text="cholecystokinin"/>
            <entity id="DS3.d692.s0.e2" origId="145068" charOffset="115-127" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d692.s0.e2" e2="DS3.d692.s0.e0" id="DS3.d692.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d692.s1" origId="9972062-1" text="This study was conducted to determine what, if any, role L-NAME (inhibitor of nitric oxide synthase) plays in the behavioral effects induced by sulfated cholecystokinin octapeptide CCK-8) and cholecystokinin tetrapeptide (CCK-4) in adult male rats.">
            <entity id="DS3.d692.s1.e0" origId="145068" charOffset="78-90" type="compound" text="nitric oxide"/>
            <entity id="DS3.d692.s1.e1" origId="P01355" charOffset="153-168" type="protein" text="cholecystokinin"/>
            <entity id="DS3.d692.s1.e2" origId="16219094" charOffset="181-186" type="compound" text="CCK-8"/>
            <entity id="DS3.d692.s1.e3" origId="P01355" charOffset="192-207" type="protein" text="cholecystokinin"/>
            <entity id="DS3.d692.s1.e4" origId="4329839,446569" charOffset="222-227" type="compound" text="CCK-4"/>
            <pair e1="DS3.d692.s1.e0" e2="DS3.d692.s1.e1" id="DS3.d692.s1.i0" interaction="False" />
            <pair e1="DS3.d692.s1.e2" e2="DS3.d692.s1.e1" id="DS3.d692.s1.i1" interaction="False" />
            <pair e1="DS3.d692.s1.e4" e2="DS3.d692.s1.e1" id="DS3.d692.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d693" origId="9972082">
        <sentence id="DS3.d693.s0" origId="9972082-5" text="Furthermore, malnourished children showed iron deficiency anaemia, which may interfere with the results of plasma transferrin determinations.">
            <entity id="DS3.d693.s0.e0" origId="23925,67172434" charOffset="42-46" type="compound" text="iron"/>
            <entity id="DS3.d693.s0.e1" origId="P02787,Q06AH7,A0PJA6" charOffset="114-125" type="protein" text="transferrin"/>
            <pair e1="DS3.d693.s0.e0" e2="DS3.d693.s0.e1" id="DS3.d693.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d694" origId="9972097">
        <sentence id="DS3.d694.s0" origId="9972097-1" text="A genetic study was performed on a sample of 146 autochthonous individuals from the province of Navarre (northern Spain) to test for 6 STR systems: CSF1PO, TPOX, TH01, F13A1, FES/FPS, and VWA31/A.">
            <entity id="DS3.d694.s0.e0" origId="703907" charOffset="162-166" type="compound" text="TH01"/>
            <entity id="DS3.d694.s0.e1" origId="P00488" charOffset="168-173" type="protein" text="F13A1"/>
            <entity id="DS3.d694.s0.e2" origId="P07332,A0A024RC92" charOffset="175-178" type="protein" text="FES"/>
            <pair e1="DS3.d694.s0.e0" e2="DS3.d694.s0.e1" id="DS3.d694.s0.i0" interaction="False" />
            <pair e1="DS3.d694.s0.e0" e2="DS3.d694.s0.e2" id="DS3.d694.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d695" origId="9972122">
        <sentence id="DS3.d695.s0" origId="9972122-6" text="Patients are placed on Doxycycline 50 mg BID for three months and then undergo repeat diagnostic arthroscopy and synovial fluid collection.">
            <entity id="DS3.d695.s0.e0" origId="54671203" charOffset="23-34" type="compound" text="Doxycycline"/>
            <entity id="DS3.d695.s0.e1" origId="P55957,A8ASI8,B2ZP79,B3KT21" charOffset="41-44" type="protein" text="BID"/>
            <pair e1="DS3.d695.s0.e0" e2="DS3.d695.s0.e1" id="DS3.d695.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d696" origId="9972133">
        <sentence id="DS3.d696.s0" origId="9972133-3" text="In this study, we show that doxycycline not only inhibits MMP-8 and MMP-9 (gelatinase B) activity, but also the synthesis of MMPs in human endothelial cells.">
            <entity id="DS3.d696.s0.e0" origId="54671203" charOffset="28-39" type="compound" text="doxycycline"/>
            <entity id="DS3.d696.s0.e1" origId="P22894,B4E0I2" charOffset="58-63" type="protein" text="MMP-8"/>
            <entity id="DS3.d696.s0.e2" origId="P14780" charOffset="68-73" type="protein" text="MMP-9"/>
            <pair e1="DS3.d696.s0.e0" e2="DS3.d696.s0.e1" id="DS3.d696.s0.i0" interaction="False" />
            <pair e1="DS3.d696.s0.e0" e2="DS3.d696.s0.e2" id="DS3.d696.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d696.s1" origId="9972133-4" text="Doxycycline (50 microM) completely inhibited the phorbol-12-myristate-13-acetate (PMA)-mediated induction of MMP-8 and MMP-9, as measured by Western blotting and gelatin zymography, respectively.">
            <entity id="DS3.d696.s1.e0" origId="54671203" charOffset="0-11" type="compound" text="Doxycycline"/>
            <entity id="DS3.d696.s1.e1" origId="442070" charOffset="49-56" type="compound" text="phorbol"/>
            <entity id="DS3.d696.s1.e2" origId="54025349" charOffset="60-80" type="compound" text="myristate-13-acetate"/>
            <entity id="DS3.d696.s1.e3" origId="122634,27924" charOffset="82-85" type="compound" text="PMA"/>
            <entity id="DS3.d696.s1.e4" origId="P22894,B4E0I2" charOffset="109-114" type="protein" text="MMP-8"/>
            <entity id="DS3.d696.s1.e5" origId="P14780" charOffset="119-124" type="protein" text="MMP-9"/>
            <pair e1="DS3.d696.s1.e0" e2="DS3.d696.s1.e4" id="DS3.d696.s1.i0" interaction="False" />
            <pair e1="DS3.d696.s1.e0" e2="DS3.d696.s1.e5" id="DS3.d696.s1.i1" interaction="False" />
            <pair e1="DS3.d696.s1.e3" e2="DS3.d696.s1.e4" id="DS3.d696.s1.i2" interaction="False" />
            <pair e1="DS3.d696.s1.e3" e2="DS3.d696.s1.e5" id="DS3.d696.s1.i3" interaction="False" />
            <pair e1="DS3.d696.s1.e1" e2="DS3.d696.s1.e4" id="DS3.d696.s1.i4" interaction="False" />
            <pair e1="DS3.d696.s1.e1" e2="DS3.d696.s1.e5" id="DS3.d696.s1.i5" interaction="False" />
            <pair e1="DS3.d696.s1.e2" e2="DS3.d696.s1.e4" id="DS3.d696.s1.i6" interaction="False" />
            <pair e1="DS3.d696.s1.e2" e2="DS3.d696.s1.e5" id="DS3.d696.s1.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d697" origId="9972134">
        <sentence id="DS3.d697.s0" origId="9972134-10" text="In vivo experiments had shown that TTC prevented mortality in LPS-treated mice, but not in mice pre-sensitized with galactosamine prior to the LPS challenge.">
            <entity id="DS3.d697.s0.e0" origId="Q9QUK6,L0CL36" charOffset="62-65" type="protein" text="LPS"/>
            <entity id="DS3.d697.s0.e1" origId="24154" charOffset="116-129" type="compound" text="galactosamine"/>
            <entity id="DS3.d697.s0.e2" origId="Q9QUK6,L0CL36" charOffset="143-146" type="protein" text="LPS"/>
            <pair e1="DS3.d697.s0.e1" e2="DS3.d697.s0.e0" id="DS3.d697.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d697.s1" origId="9972134-5" text="TTC inhibited the secretion of nitric oxide (NO) and TNF alpha from LPS-stimulated macrophages and inhibited macrophage-induced thymocyte proliferation.">
            <entity id="DS3.d697.s1.e0" origId="145068" charOffset="31-43" type="compound" text="nitric oxide"/>
            <entity id="DS3.d697.s1.e1" origId="P06804,Q3U593" charOffset="53-62" type="protein" text="TNF alpha"/>
            <entity id="DS3.d697.s1.e2" origId="Q9QUK6,L0CL36" charOffset="68-71" type="protein" text="LPS"/>
            <pair e1="DS3.d697.s1.e0" e2="DS3.d697.s1.e2" id="DS3.d697.s1.i0" interaction="False" />
            <pair e1="DS3.d697.s1.e0" e2="DS3.d697.s1.e1" id="DS3.d697.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d698" origId="9972136">
        <sentence id="DS3.d698.s0" origId="9972136-1" text="Chemically modified tetracyclines (CMTs) dose-dependently decreased inducible nitric oxide synthase (iNOS) and, consequently, nitric oxide (NO) formation by the lipopolysaccharide (LPS)-stimulated J774 line.">
            <entity id="DS3.d698.s0.e0" origId="P35228" charOffset="68-99" type="protein" text="inducible nitric oxide synthase"/>
            <entity id="DS3.d698.s0.e1" origId="P35228" charOffset="101-105" type="protein" text="iNOS"/>
            <entity id="DS3.d698.s0.e2" origId="145068" charOffset="78-90" type="compound" text="nitric oxide"/>
            <entity id="DS3.d698.s0.e3" origId="11970143" charOffset="161-179" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS3.d698.s0.e2" e2="DS3.d698.s0.e0" id="DS3.d698.s0.i0" interaction="False" />
            <pair e1="DS3.d698.s0.e2" e2="DS3.d698.s0.e1" id="DS3.d698.s0.i1" interaction="False" />
            <pair e1="DS3.d698.s0.e3" e2="DS3.d698.s0.e0" id="DS3.d698.s0.i2" interaction="False" />
            <pair e1="DS3.d698.s0.e3" e2="DS3.d698.s0.e1" id="DS3.d698.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d699" origId="9972138">
        <sentence id="DS3.d699.s0" origId="9972138-4" text="Assessment of cell viability by means of the MTT assay demonstrated a potent dose-dependent cytotoxic effect induced by compound CMT-3 and a less potent effect induced by doxycycline, but no apparent cytotoxic effect in the presence of either CMT-2 or CMT-5.">
            <entity id="DS3.d699.s0.e0" origId="64966" charOffset="45-48" type="compound" text="MTT"/>
            <entity id="DS3.d699.s0.e1" origId="54676069,54678924" charOffset="129-134" type="compound" text="CMT-3"/>
            <entity id="DS3.d699.s0.e2" origId="54671203" charOffset="171-182" type="compound" text="doxycycline"/>
            <entity id="DS3.d699.s0.e3" origId="Q15013" charOffset="243-248" type="protein" text="CMT-2"/>
            <pair e1="DS3.d699.s0.e2" e2="DS3.d699.s0.e3" id="DS3.d699.s0.i0" interaction="False" />
            <pair e1="DS3.d699.s0.e1" e2="DS3.d699.s0.e3" id="DS3.d699.s0.i1" interaction="False" />
            <pair e1="DS3.d699.s0.e0" e2="DS3.d699.s0.e3" id="DS3.d699.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d700" origId="9972145">
        <sentence id="DS3.d700.s0" origId="9972145-0" text="Effects of HEMA on water evaporation from water-HEMA mixtures.">
            <entity id="DS3.d700.s0.e0" origId="P00451" charOffset="11-15" type="protein" text="HEMA"/>
            <entity id="DS3.d700.s0.e1" origId="962" charOffset="19-24" type="compound" text="water"/>
            <entity id="DS3.d700.s0.e2" origId="962" charOffset="42-47" type="compound" text="water"/>
            <entity id="DS3.d700.s0.e3" origId="P00451" charOffset="48-52" type="protein" text="HEMA"/>
            <pair e1="DS3.d700.s0.e1" e2="DS3.d700.s0.e0" id="DS3.d700.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d700.s1" origId="9972145-1" text="OBJECTIVES: The aims of this research were: (1) to determine the relative rates of evaporation of water and HEMA, and (2) to determine the effects of increasing concentrations of HEMA on the rate of evaporation of water from water and HEMA mixtures.">
            <entity id="DS3.d700.s1.e0" origId="962" charOffset="98-103" type="compound" text="water"/>
            <entity id="DS3.d700.s1.e1" origId="P00451" charOffset="108-112" type="protein" text="HEMA"/>
            <entity id="DS3.d700.s1.e2" origId="P00451" charOffset="179-183" type="protein" text="HEMA"/>
            <entity id="DS3.d700.s1.e3" origId="962" charOffset="214-219" type="compound" text="water"/>
            <entity id="DS3.d700.s1.e4" origId="962" charOffset="214-219" type="compound" text="water"/>
            <entity id="DS3.d700.s1.e5" origId="P00451" charOffset="179-183" type="protein" text="HEMA"/>
            <pair e1="DS3.d700.s1.e0" e2="DS3.d700.s1.e1" id="DS3.d700.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d700.s2" origId="9972145-3" text="RESULTS: The rate of evaporation of pure water was 32-fold higher than that of 100% HEMA.">
            <entity id="DS3.d700.s2.e0" origId="962" charOffset="41-46" type="compound" text="water"/>
            <entity id="DS3.d700.s2.e1" origId="P00451" charOffset="84-88" type="protein" text="HEMA"/>
            <pair e1="DS3.d700.s2.e0" e2="DS3.d700.s2.e1" id="DS3.d700.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d700.s3" origId="9972145-4" text="Addition of HEMA to water lowered the rate of evaporation of water from the water-HEMA mixtures in a manner that was proportional to its effect on lowering the vapor pressure of water (p &amp;lt; 0.05 comparing 50% HEMA with 75% HEMA).">
            <entity id="DS3.d700.s3.e0" origId="P00451" charOffset="12-16" type="protein" text="HEMA"/>
            <entity id="DS3.d700.s3.e1" origId="962" charOffset="20-25" type="compound" text="water"/>
            <entity id="DS3.d700.s3.e2" origId="962" charOffset="61-66" type="compound" text="water"/>
            <entity id="DS3.d700.s3.e3" origId="962" charOffset="61-66" type="compound" text="water"/>
            <entity id="DS3.d700.s3.e4" origId="P00451" charOffset="82-86" type="protein" text="HEMA"/>
            <entity id="DS3.d700.s3.e5" origId="962" charOffset="61-66" type="compound" text="water"/>
            <entity id="DS3.d700.s3.e6" origId="P00451" charOffset="82-86" type="protein" text="HEMA"/>
            <entity id="DS3.d700.s3.e7" origId="P00451" charOffset="82-86" type="protein" text="HEMA"/>
            <pair e1="DS3.d700.s3.e1" e2="DS3.d700.s3.e0" id="DS3.d700.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d700.s4" origId="9972145-5" text="The rate of evaporation of water from water-HEMA mixtures was higher (p &amp;lt; 0.05) when the ambient gas was at 0% RH than when it was at 51% RH.">
            <entity id="DS3.d700.s4.e0" origId="962" charOffset="27-32" type="compound" text="water"/>
            <entity id="DS3.d700.s4.e1" origId="962" charOffset="38-43" type="compound" text="water"/>
            <entity id="DS3.d700.s4.e2" origId="P00451" charOffset="44-48" type="protein" text="HEMA"/>
            <pair e1="DS3.d700.s4.e0" e2="DS3.d700.s4.e2" id="DS3.d700.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d700.s5" origId="9972145-6" text="SIGNIFICANCE: The results indicate that as water evaporates from water-HEMA mixtures, the concentration of HEMA rises because it is relatively non-volatile.">
            <entity id="DS3.d700.s5.e0" origId="962" charOffset="43-48" type="compound" text="water"/>
            <entity id="DS3.d700.s5.e1" origId="962" charOffset="65-70" type="compound" text="water"/>
            <entity id="DS3.d700.s5.e2" origId="P00451" charOffset="71-75" type="protein" text="HEMA"/>
            <entity id="DS3.d700.s5.e3" origId="P00451" charOffset="107-111" type="protein" text="HEMA"/>
            <pair e1="DS3.d700.s5.e0" e2="DS3.d700.s5.e2" id="DS3.d700.s5.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d700.s6" origId="9972145-7" text="This rise in HEMA concentration lowers the vapor pressure of water making it more difficult to remove the last amounts of water.">
            <entity id="DS3.d700.s6.e0" origId="P00451" charOffset="13-17" type="protein" text="HEMA"/>
            <entity id="DS3.d700.s6.e1" origId="962" charOffset="61-66" type="compound" text="water"/>
            <entity id="DS3.d700.s6.e2" origId="962" charOffset="122-127" type="compound" text="water"/>
            <pair e1="DS3.d700.s6.e1" e2="DS3.d700.s6.e0" id="DS3.d700.s6.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d701" origId="9972147">
        <sentence id="DS3.d701.s0" origId="9972147-10" text="In particular, monomeric mixtures containing HEMA, MAN or 4-META exhibited a significant acid component of the surface free-energy.">
            <entity id="DS3.d701.s0.e0" origId="P00451" charOffset="45-49" type="protein" text="HEMA"/>
            <entity id="DS3.d701.s0.e1" origId="51027" charOffset="58-64" type="compound" text="4-META"/>
            <pair e1="DS3.d701.s0.e1" e2="DS3.d701.s0.e0" id="DS3.d701.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d702" origId="9972251">
        <sentence id="DS3.d702.s0" origId="9972251-0" text="Effects of elution (correction of eution) conditions on the separation of calpastatin, mu- and m-calpain on DEAE-Sephacel chromatography.">
            <entity id="DS3.d702.s0.e0" origId="P20810,E7EQA0,E7EQ12,E9PCH5,A0A0C4DGB5,A0A0A0MR45,Q59HE3,E9PDE4,Q86YM9,B7Z6N0" charOffset="74-85" type="protein" text="calpastatin"/>
            <entity id="DS3.d702.s0.e1" origId="P17655,Q59EF6,B4DN77" charOffset="95-104" type="protein" text="m-calpain"/>
            <entity id="DS3.d702.s0.e2" origId="7497" charOffset="108-112" type="compound" text="DEAE"/>
            <pair e1="DS3.d702.s0.e2" e2="DS3.d702.s0.e0" id="DS3.d702.s0.i0" interaction="False" />
            <pair e1="DS3.d702.s0.e2" e2="DS3.d702.s0.e1" id="DS3.d702.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d702.s1" origId="9972251-2" text="The activities of calpastatin, mu-calpain and m-calpain can be rapidly assayed following the separation on DEAE-Sephacel chromatography by a 2 stage elution with 90 mM NaCl (pH 8.5), and then by 200 and 300 mM NaCl in elution buffer (pH 7.0).">
            <entity id="DS3.d702.s1.e0" origId="P20810,E7EQA0,E7EQ12,E9PCH5,A0A0C4DGB5,A0A0A0MR45,Q59HE3,E9PDE4,Q86YM9,B7Z6N0" charOffset="18-29" type="protein" text="calpastatin"/>
            <entity id="DS3.d702.s1.e1" origId="P17655,Q59EF6,B4DN77" charOffset="46-55" type="protein" text="m-calpain"/>
            <entity id="DS3.d702.s1.e2" origId="7497" charOffset="107-111" type="compound" text="DEAE"/>
            <pair e1="DS3.d702.s1.e2" e2="DS3.d702.s1.e0" id="DS3.d702.s1.i0" interaction="False" />
            <pair e1="DS3.d702.s1.e2" e2="DS3.d702.s1.e1" id="DS3.d702.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d703" origId="9972253">
        <sentence id="DS3.d703.s0" origId="9972253-2" text="Among various tea extracts, infusions from cultivar 'Benihomare' and Taiwan lineage strongly inhibited histamine release after Fc epsilon RI cross-linking.">
            <entity id="DS3.d703.s0.e0" origId="P18581" charOffset="14-17" type="protein" text="tea"/>
            <entity id="DS3.d703.s0.e1" origId="774" charOffset="103-112" type="compound" text="histamine"/>
            <entity id="DS3.d703.s0.e2" origId="P20489" charOffset="127-140" type="protein" text="Fc epsilon RI"/>
            <pair e1="DS3.d703.s0.e1" e2="DS3.d703.s0.e0" id="DS3.d703.s0.i0" interaction="False" />
            <pair e1="DS3.d703.s0.e1" e2="DS3.d703.s0.e2" id="DS3.d703.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d703.s1" origId="9972253-3" text="Among three types of tea (from cultivar 'Benihomare'), extract from oolong tea or black tea inhibited histamine release more strongly than green tea extract.">
            <entity id="DS3.d703.s1.e0" origId="P18581" charOffset="21-24" type="protein" text="tea"/>
            <entity id="DS3.d703.s1.e1" origId="P18581" charOffset="75-78" type="protein" text="tea"/>
            <entity id="DS3.d703.s1.e2" origId="P18581" charOffset="75-78" type="protein" text="tea"/>
            <entity id="DS3.d703.s1.e3" origId="774" charOffset="102-111" type="compound" text="histamine"/>
            <entity id="DS3.d703.s1.e4" origId="P18581" charOffset="75-78" type="protein" text="tea"/>
            <pair e1="DS3.d703.s1.e3" e2="DS3.d703.s1.e0" id="DS3.d703.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d703.s2" origId="9972253-4" text="Furthermore, 'Benihomare' oolong tea extract suppressed tyrosine phosphorylation of cellular proteins after Fc epsilon RI cross-linking, but polyvinyl polypyrrolidone treatment of the extract to remove phenolic compounds, weakened the suppressive effect.">
            <entity id="DS3.d703.s2.e0" origId="P18581" charOffset="33-36" type="protein" text="tea"/>
            <entity id="DS3.d703.s2.e1" origId="6057,90983769" charOffset="56-64" type="compound" text="tyrosine"/>
            <entity id="DS3.d703.s2.e2" origId="P20489" charOffset="108-121" type="protein" text="Fc epsilon RI"/>
            <pair e1="DS3.d703.s2.e1" e2="DS3.d703.s2.e0" id="DS3.d703.s2.i0" interaction="False" />
            <pair e1="DS3.d703.s2.e1" e2="DS3.d703.s2.e2" id="DS3.d703.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d704" origId="9972254">
        <sentence id="DS3.d704.s0" origId="9972254-2" text="Using conventional genetic techniques, four mutant genes concerned in uracil biosynthesis were identified and denoted as ura1, ura2, ura3, and ura4.">
            <entity id="DS3.d704.s0.e0" origId="1174,90983865" charOffset="70-76" type="compound" text="uracil"/>
            <entity id="DS3.d704.s0.e1" origId="P28272" charOffset="121-125" type="protein" text="ura1"/>
            <entity id="DS3.d704.s0.e2" origId="P07259" charOffset="127-131" type="protein" text="ura2"/>
            <entity id="DS3.d704.s0.e3" origId="P03962" charOffset="133-137" type="protein" text="ura3"/>
            <entity id="DS3.d704.s0.e4" origId="P20051" charOffset="143-147" type="protein" text="ura4"/>
            <pair e1="DS3.d704.s0.e0" e2="DS3.d704.s0.e4" id="DS3.d704.s0.i0" interaction="False" />
            <pair e1="DS3.d704.s0.e0" e2="DS3.d704.s0.e2" id="DS3.d704.s0.i1" interaction="False" />
            <pair e1="DS3.d704.s0.e0" e2="DS3.d704.s0.e3" id="DS3.d704.s0.i2" interaction="False" />
            <pair e1="DS3.d704.s0.e0" e2="DS3.d704.s0.e1" id="DS3.d704.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d704.s1" origId="9972254-3" text="Mutations in the ura3 and ura4 genes were specifically selected with 5-fluoroorotic acid (5-FOA).">
            <entity id="DS3.d704.s1.e0" origId="P03962" charOffset="17-21" type="protein" text="ura3"/>
            <entity id="DS3.d704.s1.e1" origId="P20051" charOffset="26-30" type="protein" text="ura4"/>
            <entity id="DS3.d704.s1.e2" origId="69711" charOffset="90-95" type="compound" text="5-FOA"/>
            <pair e1="DS3.d704.s1.e2" e2="DS3.d704.s1.e1" id="DS3.d704.s1.i0" interaction="False" />
            <pair e1="DS3.d704.s1.e2" e2="DS3.d704.s1.e0" id="DS3.d704.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d705" origId="9972259">
        <sentence id="DS3.d705.s0" origId="9972259-1" text="The effects of arginine on cell proliferation and subsequent T helper (Th) 1 and Th 2 cytokine synthesis by murine Peyer's patch (PP) Th cells in vitro and the influence of arginine on the induction of antigen-specific mucosal and systemic immune responses in vivo were examined.">
            <entity id="DS3.d705.s0.e0" origId="6322,90867653" charOffset="15-23" type="compound" text="arginine"/>
            <entity id="DS3.d705.s0.e1" origId="Q61039" charOffset="81-85" type="protein" text="Th 2"/>
            <entity id="DS3.d705.s0.e2" origId="6322,90867653" charOffset="173-181" type="compound" text="arginine"/>
            <pair e1="DS3.d705.s0.e0" e2="DS3.d705.s0.e1" id="DS3.d705.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d706" origId="9972261">
        <sentence id="DS3.d706.s0" origId="9972261-4" text="An ICE-like protease inhibitor (Z-Asp-CH2-DCB) completely blocked the apoptosis, but a caspase-1 inhibitor (Ac-YVAD-CHO) and a caspase-3 inhibitor (Ac-DEVD-CHO) did not block the apoptosis, suggesting that other caspases have the critical roles in the execution process of apoptosis induced by niacin-related compounds.">
            <entity id="DS3.d706.s0.e0" origId="P29466,A8K257,A8K249" charOffset="87-96" type="protein" text="caspase-1"/>
            <entity id="DS3.d706.s0.e1" origId="4339,5311139" charOffset="108-119" type="compound" text="Ac-YVAD-CHO"/>
            <entity id="DS3.d706.s0.e2" origId="P42574" charOffset="127-136" type="protein" text="caspase-3"/>
            <entity id="DS3.d706.s0.e3" origId="644345" charOffset="148-159" type="compound" text="Ac-DEVD-CHO"/>
            <entity id="DS3.d706.s0.e4" origId="938" charOffset="294-300" type="compound" text="niacin"/>
            <pair e1="DS3.d706.s0.e4" e2="DS3.d706.s0.e0" id="DS3.d706.s0.i0" interaction="False" />
            <pair e1="DS3.d706.s0.e4" e2="DS3.d706.s0.e2" id="DS3.d706.s0.i1" interaction="False" />
            <pair e1="DS3.d706.s0.e1" e2="DS3.d706.s0.e0" id="DS3.d706.s0.i2" interaction="False" />
            <pair e1="DS3.d706.s0.e1" e2="DS3.d706.s0.e2" id="DS3.d706.s0.i3" interaction="False" />
            <pair e1="DS3.d706.s0.e3" e2="DS3.d706.s0.e0" id="DS3.d706.s0.i4" interaction="False" />
            <pair e1="DS3.d706.s0.e3" e2="DS3.d706.s0.e2" id="DS3.d706.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d707" origId="9972263">
        <sentence id="DS3.d707.s0" origId="9972263-2" text="The deduced amino acid sequence predicts a zinc finger protein of 419 amino acids in length, and its zinc finger regions show high similarity with those of Aspergillus CreAs, T. reesei Cre1, and Saccharomyces cerevisiae MIG1.">
            <entity id="DS3.d707.s0.e0" origId="23994" charOffset="43-47" type="compound" text="zinc"/>
            <entity id="DS3.d707.s0.e1" origId="23994" charOffset="101-105" type="compound" text="zinc"/>
            <entity id="DS3.d707.s0.e2" origId="P27705" charOffset="220-224" type="protein" text="MIG1"/>
            <pair e1="DS3.d707.s0.e0" e2="DS3.d707.s0.e2" id="DS3.d707.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d708" origId="9972268">
        <sentence id="DS3.d708.s0" origId="9972268-2" text="The DMCS solution inhibited the decrease of transferrin in the plasma of tumor-bearing rats when compared with the effect of an L-methionine-containing solution.">
            <entity id="DS3.d708.s0.e0" origId="6327132" charOffset="4-8" type="compound" text="DMCS"/>
            <entity id="DS3.d708.s0.e1" origId="P12346" charOffset="44-55" type="protein" text="transferrin"/>
            <entity id="DS3.d708.s0.e2" origId="84815,876" charOffset="130-140" type="compound" text="methionine"/>
            <pair e1="DS3.d708.s0.e2" e2="DS3.d708.s0.e1" id="DS3.d708.s0.i0" interaction="False" />
            <pair e1="DS3.d708.s0.e0" e2="DS3.d708.s0.e1" id="DS3.d708.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d709" origId="9972276">
        <sentence id="DS3.d709.s0" origId="9972276-3" text="Ch-P was highly soluble in the aqueous phase at neutral pH values and exerted higher antioxidative activity than alpha-tocopherol and PCh in the Fe(III)/ascorbic acid-catalyzed peroxidation of a fish oil emulsion and the autoxidation of a rat brain homogenate.">
            <entity id="DS3.d709.s0.e0" origId="P61023" charOffset="0-4" type="protein" text="Ch-P"/>
            <entity id="DS3.d709.s0.e1" origId="14985" charOffset="113-129" type="compound" text="alpha-tocopherol"/>
            <entity id="DS3.d709.s0.e2" origId="54670067" charOffset="153-166" type="compound" text="ascorbic acid"/>
            <pair e1="DS3.d709.s0.e2" e2="DS3.d709.s0.e0" id="DS3.d709.s0.i0" interaction="False" />
            <pair e1="DS3.d709.s0.e1" e2="DS3.d709.s0.e0" id="DS3.d709.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d710" origId="9972287">
        <sentence id="DS3.d710.s0" origId="9972287-2" text="Glucose, mannose, fructose, glyceraldehyde and dihydroxyacetone all at 8 mM, significantly enhanced the release of insulin elicited by basal concentrations of these carbohydrates (2 mM).">
            <entity id="DS3.d710.s0.e0" origId="5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS3.d710.s0.e1" origId="670" charOffset="47-63" type="compound" text="dihydroxyacetone"/>
            <entity id="DS3.d710.s0.e2" origId="P01308,I3WAC9" charOffset="115-122" type="protein" text="insulin"/>
            <pair e1="DS3.d710.s0.e1" e2="DS3.d710.s0.e2" id="DS3.d710.s0.i0" interaction="False" />
            <pair e1="DS3.d710.s0.e0" e2="DS3.d710.s0.e2" id="DS3.d710.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d710.s1" origId="9972287-3" text="The nonmetabolizable sugars galactose and 2-deoxyglucose failed to enhance insulin secretion.">
            <entity id="DS3.d710.s1.e0" origId="206,439353" charOffset="28-37" type="compound" text="galactose"/>
            <entity id="DS3.d710.s1.e1" origId="P01308,I3WAC9" charOffset="75-82" type="protein" text="insulin"/>
            <pair e1="DS3.d710.s1.e0" e2="DS3.d710.s1.e1" id="DS3.d710.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d710.s2" origId="9972287-4" text="N-Acetyl-glucosamine at 8 mM did not significantly affect the release of insulin.">
            <entity id="DS3.d710.s2.e0" origId="53992372" charOffset="2-20" type="compound" text="Acetyl-glucosamine"/>
            <entity id="DS3.d710.s2.e1" origId="P01308,I3WAC9" charOffset="73-80" type="protein" text="insulin"/>
            <pair e1="DS3.d710.s2.e0" e2="DS3.d710.s2.e1" id="DS3.d710.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d710.s3" origId="9972287-5" text="D-Glucose, but not L-glucose, at 8 mM stimulated insulin secretion above baseline (2 mM glucose).">
            <entity id="DS3.d710.s3.e0" origId="5793,64689,79025" charOffset="2-9" type="compound" text="Glucose"/>
            <entity id="DS3.d710.s3.e1" origId="5793,64689,79025" charOffset="21-28" type="compound" text="glucose"/>
            <entity id="DS3.d710.s3.e2" origId="P01308,I3WAC9" charOffset="49-56" type="protein" text="insulin"/>
            <entity id="DS3.d710.s3.e3" origId="5793,64689,79025" charOffset="88-95" type="compound" text="glucose"/>
            <pair e1="DS3.d710.s3.e1" e2="DS3.d710.s3.e2" id="DS3.d710.s3.i0" interaction="False" />
            <pair e1="DS3.d710.s3.e0" e2="DS3.d710.s3.e2" id="DS3.d710.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d710.s4" origId="9972287-6" text="At 8 mM, the D-glucose alpha-anomer significantly increased insulin release, while this effect was not observed using the beta-anomer.">
            <entity id="DS3.d710.s4.e0" origId="5793,64689,79025" charOffset="15-22" type="compound" text="glucose"/>
            <entity id="DS3.d710.s4.e1" origId="P01308,I3WAC9" charOffset="60-67" type="protein" text="insulin"/>
            <pair e1="DS3.d710.s4.e0" e2="DS3.d710.s4.e1" id="DS3.d710.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d710.s5" origId="9972287-8" text="Iodoacetate (5 mM), and dinitrophenol (0.3 mM) exerted an inhibitory effect upon glucose-induced insulin secretion.">
            <entity id="DS3.d710.s5.e0" origId="5240" charOffset="0-11" type="compound" text="Iodoacetate"/>
            <entity id="DS3.d710.s5.e1" origId="1493" charOffset="24-37" type="compound" text="dinitrophenol"/>
            <entity id="DS3.d710.s5.e2" origId="5793,64689,79025" charOffset="81-88" type="compound" text="glucose"/>
            <entity id="DS3.d710.s5.e3" origId="P01308,I3WAC9" charOffset="97-104" type="protein" text="insulin"/>
            <pair e1="DS3.d710.s5.e1" e2="DS3.d710.s5.e3" id="DS3.d710.s5.i0" interaction="False" />
            <pair e1="DS3.d710.s5.e2" e2="DS3.d710.s5.e3" id="DS3.d710.s5.i1" interaction="False" />
            <pair e1="DS3.d710.s5.e0" e2="DS3.d710.s5.e3" id="DS3.d710.s5.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d711" origId="9972288">
        <sentence id="DS3.d711.s0" origId="9972288-0" text="A myoglobin evolved from indoleamine 2,3-dioxygenase, a tryptophan-degrading enzyme.">
            <entity id="DS3.d711.s0.e0" origId="P02144" charOffset="2-11" type="protein" text="myoglobin"/>
            <entity id="DS3.d711.s0.e1" origId="P14902" charOffset="25-52" type="protein" text="indoleamine 2,3-dioxygenase"/>
            <entity id="DS3.d711.s0.e2" origId="57175189,6305" charOffset="56-66" type="compound" text="tryptophan"/>
            <pair e1="DS3.d711.s0.e2" e2="DS3.d711.s0.e1" id="DS3.d711.s0.i0" interaction="False" />
            <pair e1="DS3.d711.s0.e2" e2="DS3.d711.s0.e0" id="DS3.d711.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d711.s1" origId="9972288-1" text="The distribution, isolation, spectral and oxygen-binding properties, stability of ferrous state (autoxidation), amino acid sequence and gene structure of indoleamine 2,3-dioxygenase (IDO)-like myoglobins are summarized, and their evolution is discussed.">
            <entity id="DS3.d711.s1.e0" origId="977" charOffset="42-48" type="compound" text="oxygen"/>
            <entity id="DS3.d711.s1.e1" origId="P14902" charOffset="154-181" type="protein" text="indoleamine 2,3-dioxygenase"/>
            <entity id="DS3.d711.s1.e2" origId="P14902" charOffset="183-186" type="protein" text="IDO"/>
            <pair e1="DS3.d711.s1.e0" e2="DS3.d711.s1.e2" id="DS3.d711.s1.i0" interaction="False" />
            <pair e1="DS3.d711.s1.e0" e2="DS3.d711.s1.e1" id="DS3.d711.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d712" origId="9972289">
        <sentence id="DS3.d712.s0" origId="9972289-1" text="cystatin C is one of a family of proteinase inhibitors of cathepsins and other cysteine proteinases.">
            <entity id="DS3.d712.s0.e0" origId="P01034" charOffset="0-10" type="protein" text="cystatin C"/>
            <entity id="DS3.d712.s0.e1" origId="90793998,5862" charOffset="79-87" type="compound" text="cysteine"/>
            <pair e1="DS3.d712.s0.e1" e2="DS3.d712.s0.e0" id="DS3.d712.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d713" origId="9972291">
        <sentence id="DS3.d713.s0" origId="9972291-4" text="As long as this loop is closed in both lectins, they can be boiled in the presence of SDS or treated with 6 mol guanidine hydrochloride without losing their hemagglutinating activity.">
            <entity id="DS3.d713.s0.e0" origId="P20132,Q8WW81" charOffset="86-89" type="protein" text="SDS"/>
            <entity id="DS3.d713.s0.e1" origId="12211325,3520" charOffset="112-135" type="compound" text="guanidine hydrochloride"/>
            <pair e1="DS3.d713.s0.e1" e2="DS3.d713.s0.e0" id="DS3.d713.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d714" origId="9972293">
        <sentence id="DS3.d714.s0" origId="9972293-5" text="It acts as an agonist at the receptor for glucagon-like peptide-1(7-36)-amide (GLP-1), thereby stimulating secretion of insulin from pancreatic beta-cells of the islets of Langerhans.">
            <entity id="DS3.d714.s0.e0" origId="2826723" charOffset="72-77" type="compound" text="amide"/>
            <entity id="DS3.d714.s0.e1" origId="P01308,I3WAC9" charOffset="120-127" type="protein" text="insulin"/>
            <pair e1="DS3.d714.s0.e0" e2="DS3.d714.s0.e1" id="DS3.d714.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d715" origId="9972294">
        <sentence id="DS3.d715.s0" origId="9972294-5" text="Mitochondrial enzyme activities were 1.8-4.8-fold higher in rat than in bovine tissues but the citrate synthase to cytochrome-c oxidase ratio was the highest in the liver (17-38), intermediate in the heart and muscles from calves and rats (6-10) and the lowest in heart and muscles from bulls (2-3, P &amp;lt; 0.05).">
            <entity id="DS3.d715.s0.e0" origId="311,17938267" charOffset="95-102" type="compound" text="citrate"/>
            <entity id="DS3.d715.s0.e1" origId="P13182" charOffset="115-135" type="protein" text="cytochrome-c oxidase"/>
            <pair e1="DS3.d715.s0.e0" e2="DS3.d715.s0.e1" id="DS3.d715.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d715.s1" origId="9972294-6" text="In all tissues and animal groups, palmitate oxidation rates were similar per unit cytochrome-c oxidase activity, but not always per unit citrate synthase activity.">
            <entity id="DS3.d715.s1.e0" origId="985" charOffset="34-43" type="compound" text="palmitate"/>
            <entity id="DS3.d715.s1.e1" origId="P13182" charOffset="82-102" type="protein" text="cytochrome-c oxidase"/>
            <entity id="DS3.d715.s1.e2" origId="311,17938267" charOffset="137-144" type="compound" text="citrate"/>
            <pair e1="DS3.d715.s1.e0" e2="DS3.d715.s1.e1" id="DS3.d715.s1.i0" interaction="False" />
            <pair e1="DS3.d715.s1.e2" e2="DS3.d715.s1.e1" id="DS3.d715.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d716" origId="9972296">
        <sentence id="DS3.d716.s0" origId="9972296-1" text="An aminopeptidase N (apn) isozyme having the molecular weight of 90 kDa, was released by phosphatidylinositol-specific phospholipase C (PI-PLC) and purified homogeneously, from the brush border membrane of Bombyx mori.">
            <entity id="DS3.d716.s0.e0" origId="O76151" charOffset="3-19" type="protein" text="aminopeptidase N"/>
            <entity id="DS3.d716.s0.e1" origId="O76803" charOffset="21-24" type="protein" text="apn"/>
            <entity id="DS3.d716.s0.e2" origId="16738692,53477912" charOffset="89-109" type="compound" text="phosphatidylinositol"/>
            <pair e1="DS3.d716.s0.e2" e2="DS3.d716.s0.e1" id="DS3.d716.s0.i0" interaction="False" />
            <pair e1="DS3.d716.s0.e2" e2="DS3.d716.s0.e0" id="DS3.d716.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d716.s1" origId="9972296-2" text="From the result of cDNA cloning, the primary structure of 90 kDa apn proved to consist of 948 amino acid residues, containing a typical metalloprotease-specific zinc-binding motif in the deduced sequence.">
            <entity id="DS3.d716.s1.e0" origId="O76803" charOffset="65-68" type="protein" text="apn"/>
            <entity id="DS3.d716.s1.e1" origId="23994" charOffset="161-165" type="compound" text="zinc"/>
            <pair e1="DS3.d716.s1.e1" e2="DS3.d716.s1.e0" id="DS3.d716.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d716.s2" origId="9972296-4" text="The N-terminal one showed characteristics of leader peptide for secretion and the C-terminal one contained a possible glycosylphosphatidylinositol (GPI) anchoring site, suggesting that the apn encoded by the cDNA is not only a zinc-binding enzyme, but also a GPI-anchored protein.">
            <entity id="DS3.d716.s2.e0" origId="O76803" charOffset="189-192" type="protein" text="apn"/>
            <entity id="DS3.d716.s2.e1" origId="23994" charOffset="227-231" type="compound" text="zinc"/>
            <pair e1="DS3.d716.s2.e1" e2="DS3.d716.s2.e0" id="DS3.d716.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d717" origId="9972311">
        <sentence id="DS3.d717.s0" origId="9972311-1" text="The apparent high degree of homology of a blood protein with a unique dual binding affinity for two distinct hormones, thyroxin (T4) and vitamin D, isolated from a turtle, Trachemys scripta (Family Emydidae) and mammalian vitamin D binding protein (DBP) prompted further interspecific comparison to better understand the structure of functional binding sites.">
            <entity id="DS3.d717.s0.e0" origId="5280795,5283711" charOffset="137-146" type="compound" text="vitamin D"/>
            <entity id="DS3.d717.s0.e1" origId="5280795,5283711" charOffset="222-231" type="compound" text="vitamin D"/>
            <entity id="DS3.d717.s0.e2" origId="Q10586" charOffset="249-252" type="protein" text="DBP"/>
            <pair e1="DS3.d717.s0.e0" e2="DS3.d717.s0.e2" id="DS3.d717.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d718" origId="9972318">
        <sentence id="DS3.d718.s0" origId="9972318-2" text="Rats injected with a single dose of cyclophosphamide (200 mg kg-1 body weight) showed an increase in the levels of serum glutamate-oxaloacetate transaminase, serum glutamate-pyruvate transaminase, glucose-6-phosphate dehydrogenase and creatine phosphokinase isoenzyme by 53, 24, 55 and 135%, respectively.">
            <entity id="DS3.d718.s0.e0" origId="2907" charOffset="36-52" type="compound" text="cyclophosphamide"/>
            <entity id="DS3.d718.s0.e1" origId="23327,33032,611,57109091" charOffset="121-130" type="compound" text="glutamate"/>
            <entity id="DS3.d718.s0.e2" origId="970" charOffset="131-143" type="compound" text="oxaloacetate"/>
            <entity id="DS3.d718.s0.e3" origId="22790321" charOffset="164-182" type="compound" text="glutamate-pyruvate"/>
            <entity id="DS3.d718.s0.e4" origId="P05370" charOffset="197-230" type="protein" text="glucose-6-phosphate dehydrogenase"/>
            <entity id="DS3.d718.s0.e5" origId="586" charOffset="235-243" type="compound" text="creatine"/>
            <pair e1="DS3.d718.s0.e5" e2="DS3.d718.s0.e4" id="DS3.d718.s0.i0" interaction="False" />
            <pair e1="DS3.d718.s0.e0" e2="DS3.d718.s0.e4" id="DS3.d718.s0.i1" interaction="False" />
            <pair e1="DS3.d718.s0.e1" e2="DS3.d718.s0.e4" id="DS3.d718.s0.i2" interaction="False" />
            <pair e1="DS3.d718.s0.e2" e2="DS3.d718.s0.e4" id="DS3.d718.s0.i3" interaction="False" />
            <pair e1="DS3.d718.s0.e3" e2="DS3.d718.s0.e4" id="DS3.d718.s0.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d719" origId="9972320">
        <sentence id="DS3.d719.s0" origId="9972320-0" text="Serum and antral gastrin levels in fed and fasted rats: relation to aging.">
            <entity id="DS3.d719.s0.e0" origId="35864" charOffset="10-16" type="compound" text="antral"/>
            <entity id="DS3.d719.s0.e1" origId="P04563" charOffset="17-24" type="protein" text="gastrin"/>
            <pair e1="DS3.d719.s0.e0" e2="DS3.d719.s0.e1" id="DS3.d719.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d719.s1" origId="9972320-1" text="The effect of short fasting for up to 24 h on serum and antral gastrin concentrations and G cell ultrastructure has been examined in the young rat compared with the middle-aged rat.">
            <entity id="DS3.d719.s1.e0" origId="35864" charOffset="56-62" type="compound" text="antral"/>
            <entity id="DS3.d719.s1.e1" origId="P04563" charOffset="63-70" type="protein" text="gastrin"/>
            <pair e1="DS3.d719.s1.e0" e2="DS3.d719.s1.e1" id="DS3.d719.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d719.s2" origId="9972320-3" text="There was also a significant decrease in antral gastrin concentrations after 24 h of fasting in the middle-aged rats.">
            <entity id="DS3.d719.s2.e0" origId="35864" charOffset="41-47" type="compound" text="antral"/>
            <entity id="DS3.d719.s2.e1" origId="P04563" charOffset="48-55" type="protein" text="gastrin"/>
            <pair e1="DS3.d719.s2.e0" e2="DS3.d719.s2.e1" id="DS3.d719.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d719.s3" origId="9972320-4" text="By contrast, the antral gastrin concentrations in the young rats increased progressively and significantly with fasting for up to 24 h. These responses were associated with a significant increase in the content of secretory granules of G cell, which was at its greatest by 24 h. The antral gastrin level in the 48-h fasting rats was markedly reduced to a level below that for the prestarvation group.">
            <entity id="DS3.d719.s3.e0" origId="35864" charOffset="17-23" type="compound" text="antral"/>
            <entity id="DS3.d719.s3.e1" origId="P04563" charOffset="24-31" type="protein" text="gastrin"/>
            <entity id="DS3.d719.s3.e2" origId="35864" charOffset="283-289" type="compound" text="antral"/>
            <entity id="DS3.d719.s3.e3" origId="P04563" charOffset="290-297" type="protein" text="gastrin"/>
            <pair e1="DS3.d719.s3.e0" e2="DS3.d719.s3.e1" id="DS3.d719.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d719.s4" origId="9972320-6" text="These results indicate that the effects of fasting on the antral gastrin levels in young rats differ from those of the middle-aged and that starvation for up to 24 h caused a significant increase in the antral gastrin content in the young rats' stomach.">
            <entity id="DS3.d719.s4.e0" origId="35864" charOffset="58-64" type="compound" text="antral"/>
            <entity id="DS3.d719.s4.e1" origId="P04563" charOffset="65-72" type="protein" text="gastrin"/>
            <entity id="DS3.d719.s4.e2" origId="35864" charOffset="203-209" type="compound" text="antral"/>
            <entity id="DS3.d719.s4.e3" origId="P04563" charOffset="210-217" type="protein" text="gastrin"/>
            <pair e1="DS3.d719.s4.e0" e2="DS3.d719.s4.e1" id="DS3.d719.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d720" origId="9972323">
        <sentence id="DS3.d720.s0" origId="9972323-0" text="Serum prolactin and dehydroepiandrosterone concentrations during the summer and winter hair growth cycles of mink (Mustela vison).">
            <entity id="DS3.d720.s0.e0" origId="P01236,Q5I0G2,Q5THQ0" charOffset="6-15" type="protein" text="prolactin"/>
            <entity id="DS3.d720.s0.e1" origId="5881" charOffset="20-42" type="compound" text="dehydroepiandrosterone"/>
            <entity id="DS3.d720.s0.e2" origId="P15382,A8MWV9,A7LFK2,C7S316,Q6FHJ6,A7LFK4" charOffset="109-113" type="protein" text="mink"/>
            <pair e1="DS3.d720.s0.e1" e2="DS3.d720.s0.e0" id="DS3.d720.s0.i0" interaction="False" />
            <pair e1="DS3.d720.s0.e1" e2="DS3.d720.s0.e2" id="DS3.d720.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d720.s1" origId="9972323-1" text="We investigated the relationship between serum concentrations of prolactin (PRL) and dehydroepiandrosterone (DHEA) during initiation and development of summer and winter hair growth (anagen) cycles in mink.">
            <entity id="DS3.d720.s1.e0" origId="P01236,Q5I0G2,Q5THQ0" charOffset="65-74" type="protein" text="prolactin"/>
            <entity id="DS3.d720.s1.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="76-79" type="protein" text="PRL"/>
            <entity id="DS3.d720.s1.e2" origId="5881" charOffset="85-107" type="compound" text="dehydroepiandrosterone"/>
            <entity id="DS3.d720.s1.e3" origId="P15382,A8MWV9,A7LFK2,C7S316,Q6FHJ6,A7LFK4" charOffset="201-205" type="protein" text="mink"/>
            <pair e1="DS3.d720.s1.e2" e2="DS3.d720.s1.e0" id="DS3.d720.s1.i0" interaction="False" />
            <pair e1="DS3.d720.s1.e2" e2="DS3.d720.s1.e3" id="DS3.d720.s1.i1" interaction="False" />
            <pair e1="DS3.d720.s1.e2" e2="DS3.d720.s1.e1" id="DS3.d720.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d720.s2" origId="9972323-2" text="In the spring, haloperidol (HAL) increased PRL concentrations and induced summer anagen earlier than controls, whereas melatonin (MEL) inhibited PRL secretion and completely blocked summer anagen.">
            <entity id="DS3.d720.s2.e0" origId="3559" charOffset="15-26" type="compound" text="haloperidol"/>
            <entity id="DS3.d720.s2.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="43-46" type="protein" text="PRL"/>
            <entity id="DS3.d720.s2.e2" origId="896" charOffset="119-128" type="compound" text="melatonin"/>
            <entity id="DS3.d720.s2.e3" origId="P01236,Q5I0G2,Q5THQ0" charOffset="145-148" type="protein" text="PRL"/>
            <pair e1="DS3.d720.s2.e0" e2="DS3.d720.s2.e1" id="DS3.d720.s2.i0" interaction="False" />
            <pair e1="DS3.d720.s2.e2" e2="DS3.d720.s2.e1" id="DS3.d720.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d721" origId="9972324">
        <sentence id="DS3.d721.s0" origId="9972324-4" text="To estimate the degree of physical strain, possible muscle injury and regenerative processes of muscles in response to exercise in the cold, serum creatine kinase (CK), lactate dehydrogenase (LDH), muscle beta-glucuronidase and prolyl-4-hydroxylase (PH) activities were measured.">
            <entity id="DS3.d721.s0.e0" origId="586" charOffset="147-155" type="compound" text="creatine"/>
            <entity id="DS3.d721.s0.e1" origId="612" charOffset="169-176" type="compound" text="lactate"/>
            <entity id="DS3.d721.s0.e2" origId="P06760" charOffset="205-223" type="protein" text="beta-glucuronidase"/>
            <entity id="DS3.d721.s0.e3" origId="90816339" charOffset="228-236" type="compound" text="prolyl-4"/>
            <pair e1="DS3.d721.s0.e1" e2="DS3.d721.s0.e2" id="DS3.d721.s0.i0" interaction="False" />
            <pair e1="DS3.d721.s0.e3" e2="DS3.d721.s0.e2" id="DS3.d721.s0.i1" interaction="False" />
            <pair e1="DS3.d721.s0.e0" e2="DS3.d721.s0.e2" id="DS3.d721.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d722" origId="9972367">
        <sentence id="DS3.d722.s0" origId="9972367-2" text="Tc-99m hexakis-2-methoxyisobutylisonitrile (MIBI) scintimammography has been reported to indicate the expression of P-glycoprotein, which is one factor concerned with multidrug resistance.">
            <entity id="DS3.d722.s0.e0" origId="16683004" charOffset="7-14" type="compound" text="hexakis"/>
            <entity id="DS3.d722.s0.e1" origId="130600" charOffset="15-42" type="compound" text="2-methoxyisobutylisonitrile"/>
            <entity id="DS3.d722.s0.e2" origId="P08183,A4D1D2" charOffset="116-130" type="protein" text="P-glycoprotein"/>
            <pair e1="DS3.d722.s0.e0" e2="DS3.d722.s0.e2" id="DS3.d722.s0.i0" interaction="False" />
            <pair e1="DS3.d722.s0.e1" e2="DS3.d722.s0.e2" id="DS3.d722.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d723" origId="9972369">
        <sentence id="DS3.d723.s0" origId="9972369-14" text="CONCLUSION: 123I-MIBG myocardial uptake is affected by both SMD and cardiac autonomic neuropathy.">
            <entity id="DS3.d723.s0.e0" origId="105140" charOffset="12-16" type="compound" text="123I"/>
            <entity id="DS3.d723.s0.e1" origId="60860" charOffset="17-21" type="compound" text="MIBG"/>
            <entity id="DS3.d723.s0.e2" origId="P63162,X5DP00" charOffset="60-63" type="protein" text="SMD"/>
            <pair e1="DS3.d723.s0.e1" e2="DS3.d723.s0.e2" id="DS3.d723.s0.i0" interaction="False" />
            <pair e1="DS3.d723.s0.e0" e2="DS3.d723.s0.e2" id="DS3.d723.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d723.s1" origId="9972369-15" text="Based on the finding that delta TUS was much higher in AN (+) subgroups and there was no statistically significant difference between SMD (+) AN (+) and SMD (-) AN (+) subgroups, a decrease in myocardial 123I-MIBG uptake might progress independently of SMD.">
            <entity id="DS3.d723.s1.e0" origId="P63162,X5DP00" charOffset="134-137" type="protein" text="SMD"/>
            <entity id="DS3.d723.s1.e1" origId="P63162,X5DP00" charOffset="153-156" type="protein" text="SMD"/>
            <entity id="DS3.d723.s1.e2" origId="105140" charOffset="204-208" type="compound" text="123I"/>
            <entity id="DS3.d723.s1.e3" origId="60860" charOffset="209-213" type="compound" text="MIBG"/>
            <entity id="DS3.d723.s1.e4" origId="P63162,X5DP00" charOffset="153-156" type="protein" text="SMD"/>
            <pair e1="DS3.d723.s1.e3" e2="DS3.d723.s1.e0" id="DS3.d723.s1.i0" interaction="False" />
            <pair e1="DS3.d723.s1.e2" e2="DS3.d723.s1.e0" id="DS3.d723.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d723.s2" origId="9972369-1" text="PURPOSE: To investigate the influence of diabetic myocardial damage (suspected myocardial damage; SMD) diagnosed by 201Tl-SPECT and diabetic cardiac autonomic neuropathy (AN) on myocardial MIBG uptake in patients with non-insulin-dependent diabetes mellitus (NIDDM).">
            <entity id="DS3.d723.s2.e0" origId="P63162,X5DP00" charOffset="98-101" type="protein" text="SMD"/>
            <entity id="DS3.d723.s2.e1" origId="60860" charOffset="189-193" type="compound" text="MIBG"/>
            <pair e1="DS3.d723.s2.e1" e2="DS3.d723.s2.e0" id="DS3.d723.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d723.s3" origId="9972369-6" text="Similarly, the difference between the 201Tl image and the 123I-MIBG image in TUS was taken as the difference in the total uptake score (delta TUS) representing cardiac sympathetic denervation without SMD.">
            <entity id="DS3.d723.s3.e0" origId="105140" charOffset="58-62" type="compound" text="123I"/>
            <entity id="DS3.d723.s3.e1" origId="60860" charOffset="63-67" type="compound" text="MIBG"/>
            <entity id="DS3.d723.s3.e2" origId="P63162,X5DP00" charOffset="200-203" type="protein" text="SMD"/>
            <pair e1="DS3.d723.s3.e1" e2="DS3.d723.s3.e2" id="DS3.d723.s3.i0" interaction="False" />
            <pair e1="DS3.d723.s3.e0" e2="DS3.d723.s3.e2" id="DS3.d723.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d724" origId="9972374">
        <sentence id="DS3.d724.s0" origId="9972374-0" text="Glucose tolerance and myocardial F-18 fluorodeoxyglucose uptake in normal regions in coronary heart disease patients.">
            <entity id="DS3.d724.s0.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS3.d724.s0.e1" origId="Q13495" charOffset="33-37" type="protein" text="F-18"/>
            <entity id="DS3.d724.s0.e2" origId="54303434" charOffset="38-56" type="compound" text="fluorodeoxyglucose"/>
            <pair e1="DS3.d724.s0.e2" e2="DS3.d724.s0.e1" id="DS3.d724.s0.i0" interaction="False" />
            <pair e1="DS3.d724.s0.e0" e2="DS3.d724.s0.e1" id="DS3.d724.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d724.s1" origId="9972374-1" text="To elucidate the relation between glucose tolerance and myocardial uptake of F-18 fluorodeoxyglucose (FDG), FDG-PET with 75 g oral glucose loading was performed on 43 coronary artery disease patients (twice in 2 patients).">
            <entity id="DS3.d724.s1.e0" origId="206,5793,64689,79025" charOffset="34-41" type="compound" text="glucose"/>
            <entity id="DS3.d724.s1.e1" origId="Q13495" charOffset="77-81" type="protein" text="F-18"/>
            <entity id="DS3.d724.s1.e2" origId="54303434" charOffset="82-100" type="compound" text="fluorodeoxyglucose"/>
            <entity id="DS3.d724.s1.e3" origId="315411,445226,68196650" charOffset="102-105" type="compound" text="FDG"/>
            <entity id="DS3.d724.s1.e4" origId="315411,445226,68196650" charOffset="108-111" type="compound" text="FDG"/>
            <entity id="DS3.d724.s1.e5" origId="206,5793,64689,79025" charOffset="93-100" type="compound" text="glucose"/>
            <pair e1="DS3.d724.s1.e2" e2="DS3.d724.s1.e1" id="DS3.d724.s1.i0" interaction="False" />
            <pair e1="DS3.d724.s1.e3" e2="DS3.d724.s1.e1" id="DS3.d724.s1.i1" interaction="False" />
            <pair e1="DS3.d724.s1.e0" e2="DS3.d724.s1.e1" id="DS3.d724.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d725" origId="9972375">
        <sentence id="DS3.d725.s0" origId="9972375-1" text="99mTc-DTPA-galactosyl human serum albumin (99mTc-GSA) hepatic scintigraphy was performed in 32 patients with hepatocellular carcinoma before and after chemolipiodolization, which was performed from the right hepatic artery (RHA) in 15 patients and the proper hepatic artery (PHA) in 17 patients.">
            <entity id="DS3.d725.s0.e0" origId="446996" charOffset="11-21" type="compound" text="galactosyl"/>
            <entity id="DS3.d725.s0.e1" origId="P02768" charOffset="34-41" type="protein" text="albumin"/>
            <entity id="DS3.d725.s0.e2" origId="P84996,Q5JWF2,P63092,O95467,B0AZR9,Q5JWD1,Q14455,Q5FWY2" charOffset="49-52" type="protein" text="GSA"/>
            <pair e1="DS3.d725.s0.e0" e2="DS3.d725.s0.e2" id="DS3.d725.s0.i0" interaction="False" />
            <pair e1="DS3.d725.s0.e0" e2="DS3.d725.s0.e1" id="DS3.d725.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d726" origId="9972377">
        <sentence id="DS3.d726.s0" origId="9972377-2" text="METHODS: Patients of the Outpatient Clinic of Cheyenne Veterans Affairs Medical Center, Wyoming, receiving nifedipine ER for the management of hypertension (systolic BP or SBP &amp;gt; 140 mm Hg and diastolic BP or DBP &amp;gt; 90 mm Hg), participated in this study.">
            <entity id="DS3.d726.s0.e0" origId="4485" charOffset="107-117" type="compound" text="nifedipine"/>
            <entity id="DS3.d726.s0.e1" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="172-175" type="protein" text="SBP"/>
            <entity id="DS3.d726.s0.e2" origId="Q10586" charOffset="211-214" type="protein" text="DBP"/>
            <pair e1="DS3.d726.s0.e0" e2="DS3.d726.s0.e2" id="DS3.d726.s0.i0" interaction="False" />
            <pair e1="DS3.d726.s0.e0" e2="DS3.d726.s0.e1" id="DS3.d726.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d727" origId="9972380">
        <sentence id="DS3.d727.s0" origId="9972380-7" text="In most cases, the patients had preexisting risk factors for torsade de pointes and/or were receiving other medications known to inhibit the hepatic CYP3A4 enzyme system and the metabolism of cisapride.">
            <entity id="DS3.d727.s0.e0" origId="P08684,Q6GRK0" charOffset="149-155" type="protein" text="CYP3A4"/>
            <entity id="DS3.d727.s0.e1" origId="13677779,2769,5311047,6917698" charOffset="192-201" type="compound" text="cisapride"/>
            <pair e1="DS3.d727.s0.e1" e2="DS3.d727.s0.e0" id="DS3.d727.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d727.s1" origId="9972380-8" text="There is evidence that clarithromycin, a relatively new macrolide antibiotic, also inhibits the isoenzyme CYP3A4.">
            <entity id="DS3.d727.s1.e0" origId="84029" charOffset="23-37" type="compound" text="clarithromycin"/>
            <entity id="DS3.d727.s1.e1" origId="P08684,Q6GRK0" charOffset="106-112" type="protein" text="CYP3A4"/>
            <pair e1="DS3.d727.s1.e0" e2="DS3.d727.s1.e1" id="DS3.d727.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d728" origId="9972382">
        <sentence id="DS3.d728.s0" origId="9972382-5" text="The alkaline phosphatase, lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyltranspeptidase concentrations were dramatically elevated.">
            <entity id="DS3.d728.s0.e0" origId="612" charOffset="26-33" type="compound" text="lactate"/>
            <entity id="DS3.d728.s0.e1" origId="5960" charOffset="49-58" type="compound" text="aspartate"/>
            <entity id="DS3.d728.s0.e2" origId="5950" charOffset="77-84" type="compound" text="alanine"/>
            <entity id="DS3.d728.s0.e3" origId="Q9BX51,D3DW46" charOffset="107-135" type="protein" text="gamma-glutamyltranspeptidase"/>
            <pair e1="DS3.d728.s0.e2" e2="DS3.d728.s0.e3" id="DS3.d728.s0.i0" interaction="False" />
            <pair e1="DS3.d728.s0.e1" e2="DS3.d728.s0.e3" id="DS3.d728.s0.i1" interaction="False" />
            <pair e1="DS3.d728.s0.e0" e2="DS3.d728.s0.e3" id="DS3.d728.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d729" origId="9972450">
        <sentence id="DS3.d729.s0" origId="9972450-4" text="At least one study has demonstrated the induction, by ethanol, of a protein immunochemically similar to CYP2E1 in a Cricetid rodent.">
            <entity id="DS3.d729.s0.e0" origId="702" charOffset="54-61" type="compound" text="ethanol"/>
            <entity id="DS3.d729.s0.e1" origId="P05182" charOffset="104-110" type="protein" text="CYP2E1"/>
            <pair e1="DS3.d729.s0.e0" e2="DS3.d729.s0.e1" id="DS3.d729.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d730" origId="9972461">
        <sentence id="DS3.d730.s0" origId="9972461-1" text="The induction of a hepatic pleiotropic response, including increase in liver/body weight ratio, induction of hepatic CYP2B and CYP3A protein and catalytic activity, and hepatic microsomal epoxide hydration activity, was investigated in male cotton rats (Sigmodon hispidus) administered graded dietary concentrations (0-1500 ppm) of phenobarbital (PB) for 14 days.">
            <entity id="DS3.d730.s0.e0" origId="Q8CJF2" charOffset="127-132" type="protein" text="CYP3A"/>
            <entity id="DS3.d730.s0.e1" origId="4763" charOffset="332-345" type="compound" text="phenobarbital"/>
            <pair e1="DS3.d730.s0.e1" e2="DS3.d730.s0.e0" id="DS3.d730.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d730.s1" origId="9972461-5" text="Testosterone 6 beta-hydroxylation (considered to be relatively selective for CYP3A in R. norvegicus) was induced maximally less than two-fold.">
            <entity id="DS3.d730.s1.e0" origId="6013" charOffset="0-12" type="compound" text="Testosterone"/>
            <entity id="DS3.d730.s1.e1" origId="Q8CJF2" charOffset="77-82" type="protein" text="CYP3A"/>
            <pair e1="DS3.d730.s1.e0" e2="DS3.d730.s1.e1" id="DS3.d730.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d731" origId="9972464">
        <sentence id="DS3.d731.s0" origId="9972464-5" text="Treatment with vinclozolin resulted in significant induction of testosterone 2 beta- and 15 beta-hydroxylase activity in quail kidney accompanied by increases in expression of P450 enzymes cross-reactive with antibodies raised against a CYP 3A-like protein in teleost fish.">
            <entity id="DS3.d731.s0.e0" origId="39676" charOffset="15-26" type="compound" text="vinclozolin"/>
            <entity id="DS3.d731.s0.e1" origId="6013" charOffset="64-76" type="compound" text="testosterone"/>
            <entity id="DS3.d731.s0.e2" origId="Q8CJF2" charOffset="237-243" type="protein" text="CYP 3A"/>
            <pair e1="DS3.d731.s0.e0" e2="DS3.d731.s0.e2" id="DS3.d731.s0.i0" interaction="False" />
            <pair e1="DS3.d731.s0.e1" e2="DS3.d731.s0.e2" id="DS3.d731.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d731.s1" origId="9972464-7" text="Propiconazole and vinclozolin significantly induced a CYP 1A1 cross-reactive P450 enzyme in quail kidney 2-3-fold unaccompanied by significant increases in alkoxyresorufin O-dealkylase activity.">
            <entity id="DS3.d731.s1.e0" origId="43234" charOffset="0-13" type="compound" text="Propiconazole"/>
            <entity id="DS3.d731.s1.e1" origId="39676" charOffset="18-29" type="compound" text="vinclozolin"/>
            <entity id="DS3.d731.s1.e2" origId="P00185" charOffset="54-61" type="protein" text="CYP 1A1"/>
            <pair e1="DS3.d731.s1.e1" e2="DS3.d731.s1.e2" id="DS3.d731.s1.i0" interaction="False" />
            <pair e1="DS3.d731.s1.e0" e2="DS3.d731.s1.e2" id="DS3.d731.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d731.s2" origId="9972464-9" text="Quail kidney microsomes also expressed high levels of a CYP 4A1 cross-reactive apoprotein which was inducible 3-4-fold by ketoconazole.">
            <entity id="DS3.d731.s2.e0" origId="P08516" charOffset="56-63" type="protein" text="CYP 4A1"/>
            <entity id="DS3.d731.s2.e1" origId="3823,456201,47576,5702077" charOffset="122-134" type="compound" text="ketoconazole"/>
            <pair e1="DS3.d731.s2.e1" e2="DS3.d731.s2.e0" id="DS3.d731.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d732" origId="9972469">
        <sentence id="DS3.d732.s0" origId="9972469-10" text="Immunoblot analysis showed reduction of CYP1A1 content at all doses, being significant at 25 mM after 48 h, but no decrease in CYP3A-like protein, the dominant catalyst of testosterone 6 beta-hydroxylation, nor CYP2B-like protein, the major contributor to indicates significant effects of TPT at high concentrations on fish hepatic CYP1A1 protein, EROD activity and the reductases.">
            <entity id="DS3.d732.s0.e0" origId="P04798,A0N0X8" charOffset="40-46" type="protein" text="CYP1A1"/>
            <entity id="DS3.d732.s0.e1" origId="6013" charOffset="172-184" type="compound" text="testosterone"/>
            <entity id="DS3.d732.s0.e2" origId="70848" charOffset="289-292" type="compound" text="TPT"/>
            <entity id="DS3.d732.s0.e3" origId="P04798,A0N0X8" charOffset="332-338" type="protein" text="CYP1A1"/>
            <pair e1="DS3.d732.s0.e2" e2="DS3.d732.s0.e0" id="DS3.d732.s0.i0" interaction="False" />
            <pair e1="DS3.d732.s0.e1" e2="DS3.d732.s0.e0" id="DS3.d732.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d732.s1" origId="9972469-11" text="TPT seems to act more specifically on CYP1A1 than on other CYP forms.">
            <entity id="DS3.d732.s1.e0" origId="70848" charOffset="0-3" type="compound" text="TPT"/>
            <entity id="DS3.d732.s1.e1" origId="P04798,A0N0X8" charOffset="38-44" type="protein" text="CYP1A1"/>
            <pair e1="DS3.d732.s1.e0" e2="DS3.d732.s1.e1" id="DS3.d732.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d732.s2" origId="9972469-6" text="Further in vitro incubations showed that NADPH, but not NADH, cytochrome c reductase was strongly inhibited at 100 microM TPT and higher.">
            <entity id="DS3.d732.s2.e0" origId="Q16698,A0A024R9D7" charOffset="41-46" type="protein" text="NADPH"/>
            <entity id="DS3.d732.s2.e1" origId="439153" charOffset="56-60" type="compound" text="NADH"/>
            <entity id="DS3.d732.s2.e2" origId="70848" charOffset="122-125" type="compound" text="TPT"/>
            <pair e1="DS3.d732.s2.e2" e2="DS3.d732.s2.e0" id="DS3.d732.s2.i0" interaction="False" />
            <pair e1="DS3.d732.s2.e1" e2="DS3.d732.s2.e0" id="DS3.d732.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d732.s3" origId="9972469-8" text="EROD activity tended to be decreased in TPT-treated scup, with the response being stronger after 48 than 24 h. No significant conversion of spectrally determined P450 to cytochrome P420 was found, and cytochrome b5 was not affected.">
            <entity id="DS3.d732.s3.e0" origId="70848" charOffset="40-43" type="compound" text="TPT"/>
            <entity id="DS3.d732.s3.e1" origId="P00167" charOffset="201-214" type="protein" text="cytochrome b5"/>
            <pair e1="DS3.d732.s3.e0" e2="DS3.d732.s3.e1" id="DS3.d732.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d733" origId="9972473">
        <sentence id="DS3.d733.s0" origId="9972473-3" text="In addition, we also treated the flies with eight chemicals (beta-naphtoflavone, benzo-alpha-pyrene, 3-methylcholanthrene, phenobarbital, aminopyrine, rifampicin, prochloraz, and clofibrate) known to induces genes from the families CYP1, CYP2, CYP3, CYP4, and CYP6.">
            <entity id="DS3.d733.s0.e0" origId="31423" charOffset="93-99" type="compound" text="pyrene"/>
            <entity id="DS3.d733.s0.e1" origId="1674" charOffset="103-121" type="compound" text="methylcholanthrene"/>
            <entity id="DS3.d733.s0.e2" origId="4763" charOffset="123-136" type="compound" text="phenobarbital"/>
            <entity id="DS3.d733.s0.e3" origId="16043998,24871024,25141428,44419043,45356263,5381226,5388984,5458213,57020413,6243627,6842115,6913622" charOffset="151-161" type="compound" text="rifampicin"/>
            <entity id="DS3.d733.s0.e4" origId="73665" charOffset="163-173" type="compound" text="prochloraz"/>
            <entity id="DS3.d733.s0.e5" origId="2796" charOffset="179-189" type="compound" text="clofibrate"/>
            <entity id="DS3.d733.s0.e6" origId="P25007,A8E774" charOffset="232-236" type="protein" text="CYP1"/>
            <pair e1="DS3.d733.s0.e3" e2="DS3.d733.s0.e6" id="DS3.d733.s0.i0" interaction="False" />
            <pair e1="DS3.d733.s0.e1" e2="DS3.d733.s0.e6" id="DS3.d733.s0.i1" interaction="False" />
            <pair e1="DS3.d733.s0.e2" e2="DS3.d733.s0.e6" id="DS3.d733.s0.i2" interaction="False" />
            <pair e1="DS3.d733.s0.e5" e2="DS3.d733.s0.e6" id="DS3.d733.s0.i3" interaction="False" />
            <pair e1="DS3.d733.s0.e4" e2="DS3.d733.s0.e6" id="DS3.d733.s0.i4" interaction="False" />
            <pair e1="DS3.d733.s0.e0" e2="DS3.d733.s0.e6" id="DS3.d733.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d734" origId="9972479">
        <sentence id="DS3.d734.s0" origId="9972479-11" text="NADPH was the preferred cofactor for EROD activity and the NAD(P)H-EROD activity was higher in Anthopleura elegantissima than Anthopleura xanthogrammica.">
            <entity id="DS3.d734.s0.e0" origId="Q16698,A0A024R9D7" charOffset="0-5" type="protein" text="NADPH"/>
            <entity id="DS3.d734.s0.e1" origId="108194" charOffset="24-32" type="compound" text="cofactor"/>
            <entity id="DS3.d734.s0.e2" origId="5893" charOffset="0-3" type="compound" text="NAD"/>
            <pair e1="DS3.d734.s0.e2" e2="DS3.d734.s0.e0" id="DS3.d734.s0.i0" interaction="False" />
            <pair e1="DS3.d734.s0.e1" e2="DS3.d734.s0.e0" id="DS3.d734.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d734.s1" origId="9972479-12" text="The Bunodosoma cavernata NADPH-EROD activity was barely noted at the detection limit of the assay and NADH-EROD activity was not detected.">
            <entity id="DS3.d734.s1.e0" origId="Q16698,A0A024R9D7" charOffset="25-30" type="protein" text="NADPH"/>
            <entity id="DS3.d734.s1.e1" origId="439153" charOffset="102-106" type="compound" text="NADH"/>
            <pair e1="DS3.d734.s1.e1" e2="DS3.d734.s1.e0" id="DS3.d734.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d735" origId="9972481">
        <sentence id="DS3.d735.s0" origId="9972481-12" text="The differences in PHAH stimulation of UROX among the non-mammalian species have implications in the evolutionary changes in CYP1A, as well as the mechanism of development of PHAH-stimulated uroporphyria in different species.">
            <entity id="DS3.d735.s0.e0" origId="8799" charOffset="39-43" type="compound" text="UROX"/>
            <entity id="DS3.d735.s0.e1" origId="O15528" charOffset="125-130" type="protein" text="CYP1A"/>
            <pair e1="DS3.d735.s0.e0" e2="DS3.d735.s0.e1" id="DS3.d735.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d735.s1" origId="9972481-2" text="The planar biphenyl, 3,3',4,4'-tetrachlorobiphenyl (TCB) stimulates uroporphyrinogen oxidation (UROX) in chick hepatic microsomes, but inhibits UROX activity in hepatic microsomes from mice and rats pre-induced by CYP1A2.">
            <entity id="DS3.d735.s1.e0" origId="36187" charOffset="21-50" type="compound" text="3,3',4,4'-tetrachlorobiphenyl"/>
            <entity id="DS3.d735.s1.e1" origId="8799" charOffset="96-100" type="compound" text="UROX"/>
            <entity id="DS3.d735.s1.e2" origId="8799" charOffset="144-148" type="compound" text="UROX"/>
            <entity id="DS3.d735.s1.e3" origId="P04799" charOffset="214-220" type="protein" text="CYP1A2"/>
            <pair e1="DS3.d735.s1.e1" e2="DS3.d735.s1.e3" id="DS3.d735.s1.i0" interaction="False" />
            <pair e1="DS3.d735.s1.e0" e2="DS3.d735.s1.e3" id="DS3.d735.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d735.s2" origId="9972481-4" text="UROX was stimulated 1.5-3-fold by TCB and 2-4-fold by 3,3',4,4',5,5'-hexachlorobiphenyl in hepatic microsomes from duck, alligator and scup treated with inducers of CYP1A.">
            <entity id="DS3.d735.s2.e0" origId="8799" charOffset="0-4" type="compound" text="UROX"/>
            <entity id="DS3.d735.s2.e1" origId="36231" charOffset="54-87" type="compound" text="3,3',4,4',5,5'-hexachlorobiphenyl"/>
            <entity id="DS3.d735.s2.e2" origId="O15528" charOffset="165-170" type="protein" text="CYP1A"/>
            <pair e1="DS3.d735.s2.e1" e2="DS3.d735.s2.e2" id="DS3.d735.s2.i0" interaction="False" />
            <pair e1="DS3.d735.s2.e0" e2="DS3.d735.s2.e2" id="DS3.d735.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d735.s3" origId="9972481-9" text="In this post-inductional TCB treatment, cycloheximide was included to prevent further induction of CYP1A.">
            <entity id="DS3.d735.s3.e0" origId="6197" charOffset="40-53" type="compound" text="cycloheximide"/>
            <entity id="DS3.d735.s3.e1" origId="O15528" charOffset="99-104" type="protein" text="CYP1A"/>
            <pair e1="DS3.d735.s3.e0" e2="DS3.d735.s3.e1" id="DS3.d735.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d736" origId="9972491">
        <sentence id="DS3.d736.s0" origId="9972491-17" text="These results indicate that the terminal sequences of oligosaccharide side-chains in spermatocytes and, principally, in spermatids are: fucose, mannose, Neu5Ac2,3Gal1,3GalNAc, Gal1,3GalNAc, Gal1,4GlcNAc, Neu5AcGalNAc and GalNAc (in O-glycosylated proteins); mannose (in N-glycosylated proteins) and GlcNAc (in both protein types).">
            <entity id="DS3.d736.s0.e0" origId="17106,19466,439554,6713579,840" charOffset="136-142" type="compound" text="fucose"/>
            <entity id="DS3.d736.s0.e1" origId="18950" charOffset="144-151" type="compound" text="mannose"/>
            <entity id="DS3.d736.s0.e2" origId="P09382" charOffset="162-166" type="protein" text="Gal1"/>
            <entity id="DS3.d736.s0.e3" origId="P09382" charOffset="176-180" type="protein" text="Gal1"/>
            <entity id="DS3.d736.s0.e4" origId="35717" charOffset="168-174" type="compound" text="GalNAc"/>
            <entity id="DS3.d736.s0.e5" origId="18950" charOffset="258-265" type="compound" text="mannose"/>
            <entity id="DS3.d736.s0.e6" origId="11861101,24139,439174,899" charOffset="196-202" type="compound" text="GlcNAc"/>
            <pair e1="DS3.d736.s0.e6" e2="DS3.d736.s0.e2" id="DS3.d736.s0.i0" interaction="False" />
            <pair e1="DS3.d736.s0.e1" e2="DS3.d736.s0.e2" id="DS3.d736.s0.i1" interaction="False" />
            <pair e1="DS3.d736.s0.e4" e2="DS3.d736.s0.e2" id="DS3.d736.s0.i2" interaction="False" />
            <pair e1="DS3.d736.s0.e0" e2="DS3.d736.s0.e2" id="DS3.d736.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d736.s1" origId="9972491-19" text="Present findings also indicate that Sertoli cell glycoproteins are similar to those of spermatids, and that the terminal sugar residues in Leydig cells are GlcNAc, fucose, mannose, Neu5Ac2,3Gal1,3GalNAc, Gal1,3GalNAc, and Gal1,4GlcNAc.">
            <entity id="DS3.d736.s1.e0" origId="11861101,24139,439174,899" charOffset="156-162" type="compound" text="GlcNAc"/>
            <entity id="DS3.d736.s1.e1" origId="17106,19466,439554,6713579,840" charOffset="164-170" type="compound" text="fucose"/>
            <entity id="DS3.d736.s1.e2" origId="18950" charOffset="172-179" type="compound" text="mannose"/>
            <entity id="DS3.d736.s1.e3" origId="P09382" charOffset="190-194" type="protein" text="Gal1"/>
            <entity id="DS3.d736.s1.e4" origId="P09382" charOffset="204-208" type="protein" text="Gal1"/>
            <pair e1="DS3.d736.s1.e2" e2="DS3.d736.s1.e3" id="DS3.d736.s1.i0" interaction="False" />
            <pair e1="DS3.d736.s1.e0" e2="DS3.d736.s1.e3" id="DS3.d736.s1.i1" interaction="False" />
            <pair e1="DS3.d736.s1.e1" e2="DS3.d736.s1.e3" id="DS3.d736.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d737" origId="9972494">
        <sentence id="DS3.d737.s0" origId="9972494-2" text="A significant (p &amp;lt; 0.01) decrease in average path velocity (VAP), curvilinear velocity (VCL) and amplitude of lateral head displacement (ALH) was found after exposure to sauna for 2 weeks.">
            <entity id="DS3.d737.s0.e0" origId="P18206,A0A024QZN4,V9HWK2,B3KXA2" charOffset="91-94" type="protein" text="VCL"/>
            <entity id="DS3.d737.s0.e1" origId="5326843" charOffset="140-143" type="compound" text="ALH"/>
            <pair e1="DS3.d737.s0.e1" e2="DS3.d737.s0.e0" id="DS3.d737.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d738" origId="9972501">
        <sentence id="DS3.d738.s0" origId="9972501-6" text="There was only methylene chloride solvate of IMC with a small amount of amorphous form in the IMC agglomerates prepared from albumin as a protective colloid, while IMC agglomerates prepared from methylcellulose, polyvinyl alcohol or biosoluble polymer consisted of the mixture of amorphous and alpha forms, and methylene chloride solvate of IMC.">
            <entity id="DS3.d738.s0.e0" origId="6344" charOffset="15-33" type="compound" text="methylene chloride"/>
            <entity id="DS3.d738.s0.e1" origId="P02768" charOffset="125-132" type="protein" text="albumin"/>
            <entity id="DS3.d738.s0.e2" origId="44263857" charOffset="195-210" type="compound" text="methylcellulose"/>
            <entity id="DS3.d738.s0.e3" origId="11199" charOffset="212-229" type="compound" text="polyvinyl alcohol"/>
            <entity id="DS3.d738.s0.e4" origId="6344" charOffset="311-329" type="compound" text="methylene chloride"/>
            <pair e1="DS3.d738.s0.e0" e2="DS3.d738.s0.e1" id="DS3.d738.s0.i0" interaction="False" />
            <pair e1="DS3.d738.s0.e3" e2="DS3.d738.s0.e1" id="DS3.d738.s0.i1" interaction="False" />
            <pair e1="DS3.d738.s0.e2" e2="DS3.d738.s0.e1" id="DS3.d738.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d739" origId="9972502">
        <sentence id="DS3.d739.s0" origId="9972502-2" text="The preparation process was further developed in the present study to reduce the particle size and to increase the loading capacity of brilliant blue, bovine serum albumin (BSA) and tumour necrosis factor-alpha (TNF-alpha) which were used as water soluble model drug substances.">
            <entity id="DS3.d739.s0.e0" origId="17560" charOffset="135-149" type="compound" text="brilliant blue"/>
            <entity id="DS3.d739.s0.e1" origId="P02769" charOffset="151-171" type="protein" text="bovine serum albumin"/>
            <entity id="DS3.d739.s0.e2" origId="Q06599" charOffset="182-210" type="protein" text="tumour necrosis factor-alpha"/>
            <entity id="DS3.d739.s0.e3" origId="Q06599" charOffset="212-221" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d739.s0.e4" origId="962" charOffset="242-247" type="compound" text="water"/>
            <pair e1="DS3.d739.s0.e4" e2="DS3.d739.s0.e1" id="DS3.d739.s0.i0" interaction="False" />
            <pair e1="DS3.d739.s0.e4" e2="DS3.d739.s0.e3" id="DS3.d739.s0.i1" interaction="False" />
            <pair e1="DS3.d739.s0.e4" e2="DS3.d739.s0.e2" id="DS3.d739.s0.i2" interaction="False" />
            <pair e1="DS3.d739.s0.e0" e2="DS3.d739.s0.e1" id="DS3.d739.s0.i3" interaction="False" />
            <pair e1="DS3.d739.s0.e0" e2="DS3.d739.s0.e3" id="DS3.d739.s0.i4" interaction="False" />
            <pair e1="DS3.d739.s0.e0" e2="DS3.d739.s0.e2" id="DS3.d739.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d740" origId="9972519">
        <sentence id="DS3.d740.s0" origId="9972519-7" text="In contrast, 5-HT-induced relaxation of the facial vein was concentration-dependently antagonized by methysergide (10(-7) M and 10(-6) M), a non-selective 5-HT1- and 5-HT2-receptor antagonist, but not by NAN-190 (10(-6) M) and SDZ-205,557 (10(-6) M), antagonists for 5-HT1A- and 5-HT4-receptors, respectively.">
            <entity id="DS3.d740.s0.e0" origId="9681" charOffset="101-113" type="compound" text="methysergide"/>
            <entity id="DS3.d740.s0.e1" origId="4431" charOffset="204-211" type="compound" text="NAN-190"/>
            <entity id="DS3.d740.s0.e2" origId="446129" charOffset="227-230" type="compound" text="SDZ"/>
            <entity id="DS3.d740.s0.e3" origId="G1SXX7" charOffset="267-294" type="protein" text="5-HT1A- and 5-HT4-receptors"/>
            <pair e1="DS3.d740.s0.e1" e2="DS3.d740.s0.e3" id="DS3.d740.s0.i0" interaction="False" />
            <pair e1="DS3.d740.s0.e2" e2="DS3.d740.s0.e3" id="DS3.d740.s0.i1" interaction="False" />
            <pair e1="DS3.d740.s0.e0" e2="DS3.d740.s0.e3" id="DS3.d740.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d741" origId="9972566">
        <sentence id="DS3.d741.s0" origId="9972566-6" text="A single chip is used to implement the three processing stages of the model; the inner-hair cell (IHC), cochlear nucleus sustained-chopper, and CNIC coincidence-detection stages.">
            <entity id="DS3.d741.s0.e0" origId="P29972,A0A024RA31" charOffset="9-13" type="protein" text="chip"/>
            <entity id="DS3.d741.s0.e1" origId="54738" charOffset="131-138" type="compound" text="chopper"/>
            <pair e1="DS3.d741.s0.e1" e2="DS3.d741.s0.e0" id="DS3.d741.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d741.s1" origId="9972566-8" text='The input to the chip is taken from a "silicon cochlea" consisting of a cascade of filters that simulate basilar membrane mechanical frequency selectivity.'>
            <entity id="DS3.d741.s1.e0" origId="P29972,A0A024RA31" charOffset="17-21" type="protein" text="chip"/>
            <entity id="DS3.d741.s1.e1" origId="5461123,6329105" charOffset="39-46" type="compound" text="silicon"/>
            <pair e1="DS3.d741.s1.e1" e2="DS3.d741.s1.e0" id="DS3.d741.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d742" origId="9972660">
        <sentence id="DS3.d742.s0" origId="9972660-2" text="With the recent development of short-pulsed high-peak power and rapidly scanned carbon dioxide (CO2) lasers, it is now possible to remove photo-damaged skin precisely and reproducibly, while leaving behind a narrow zone of thermal damage.">
            <entity id="DS3.d742.s0.e0" origId="280" charOffset="80-94" type="compound" text="carbon dioxide"/>
            <entity id="DS3.d742.s0.e1" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="96-99" type="protein" text="CO2"/>
            <pair e1="DS3.d742.s0.e0" e2="DS3.d742.s0.e1" id="DS3.d742.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d743" origId="9972663">
        <sentence id="DS3.d743.s0" origId="9972663-2" text="The present study examines both aspects in a group of 55 patients with DVT; the presence of a hypercoagulable state was assessed by quantifying the prothrombin fragment 1+2 (F1+2) and the thrombin-antithrombin III complex (T-AT), and the main hemorheological parameters were evaluated in the acute state and 6 and 12 months later.">
            <entity id="DS3.d743.s0.e0" origId="P00748,Q8IZZ5" charOffset="174-178" type="protein" text="F1+2"/>
            <entity id="DS3.d743.s0.e1" origId="90470996" charOffset="151-159" type="compound" text="thrombin"/>
            <pair e1="DS3.d743.s0.e1" e2="DS3.d743.s0.e0" id="DS3.d743.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d744" origId="9972665">
        <sentence id="DS3.d744.s0" origId="9972665-1" text="In 24 hypertensives we evaluated, at baseline, the leukocyte filtration parameters (using the St. George's Filtrometer), polymorphonuclear (PMN) membrane fluidity (with the fluorescent probe 1-(4-(trimethylamino)phenyl)-6-phenyl-1,3,5-hexatriene (TMA-DPH)) and PMN cytosolic Ca2+ content (with the fluorescent probe Fura 2-AM).">
            <entity id="DS3.d744.s0.e0" origId="122133" charOffset="191-245" type="compound" text="1-(4-(trimethylamino)phenyl)-6-phenyl-1,3,5-hexatriene"/>
            <entity id="DS3.d744.s0.e1" origId="5706757" charOffset="247-254" type="compound" text="TMA-DPH"/>
            <entity id="DS3.d744.s0.e2" origId="P00918,V9HW21" charOffset="275-278" type="protein" text="Ca2"/>
            <pair e1="DS3.d744.s0.e2" e2="DS3.d744.s0.e2" id="DS3.d744.s0.i0" interaction="False" />
            <pair e1="DS3.d744.s0.e1" e2="DS3.d744.s0.e2" id="DS3.d744.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d744.s1" origId="9972665-2" text="In a subgroup of hypertensives (n = 17) the PMN filtration parameters, PMN membrane fluidity and cytosolic Ca2+ content were evaluated after in vitro chemotactic activation (prolonged for 5 and 15 min) with two stimulating agents (4-phorbol 12-myristate 13-acetate (PMA) and N-formyl-methionyl-leucyl-phenylalanine (fMLP)).">
            <entity id="DS3.d744.s1.e0" origId="P00918,V9HW21" charOffset="107-110" type="protein" text="Ca2"/>
            <entity id="DS3.d744.s1.e1" origId="71308525" charOffset="233-253" type="compound" text="phorbol 12-myristate"/>
            <entity id="DS3.d744.s1.e2" origId="176" charOffset="257-264" type="compound" text="acetate"/>
            <entity id="DS3.d744.s1.e3" origId="122634,22833501,27924,4792" charOffset="266-269" type="compound" text="PMA"/>
            <entity id="DS3.d744.s1.e4" origId="P21462" charOffset="275-314" type="protein" text="N-formyl-methionyl-leucyl-phenylalanine"/>
            <entity id="DS3.d744.s1.e5" origId="P21462" charOffset="316-320" type="protein" text="fMLP"/>
            <pair e1="DS3.d744.s1.e1" e2="DS3.d744.s1.e0" id="DS3.d744.s1.i0" interaction="False" />
            <pair e1="DS3.d744.s1.e1" e2="DS3.d744.s1.e4" id="DS3.d744.s1.i1" interaction="False" />
            <pair e1="DS3.d744.s1.e1" e2="DS3.d744.s1.e5" id="DS3.d744.s1.i2" interaction="False" />
            <pair e1="DS3.d744.s1.e3" e2="DS3.d744.s1.e0" id="DS3.d744.s1.i3" interaction="False" />
            <pair e1="DS3.d744.s1.e3" e2="DS3.d744.s1.e4" id="DS3.d744.s1.i4" interaction="False" />
            <pair e1="DS3.d744.s1.e3" e2="DS3.d744.s1.e5" id="DS3.d744.s1.i5" interaction="False" />
            <pair e1="DS3.d744.s1.e2" e2="DS3.d744.s1.e0" id="DS3.d744.s1.i6" interaction="False" />
            <pair e1="DS3.d744.s1.e2" e2="DS3.d744.s1.e4" id="DS3.d744.s1.i7" interaction="False" />
            <pair e1="DS3.d744.s1.e2" e2="DS3.d744.s1.e5" id="DS3.d744.s1.i8" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d745" origId="9972673">
        <sentence id="DS3.d745.s0" origId="9972673-10" text="All patients preferred the addition of metformin rather than NPH insulin.">
            <entity id="DS3.d745.s0.e0" origId="4091" charOffset="39-48" type="compound" text="metformin"/>
            <entity id="DS3.d745.s0.e1" origId="P01308,I3WAC9" charOffset="65-72" type="protein" text="insulin"/>
            <pair e1="DS3.d745.s0.e0" e2="DS3.d745.s0.e1" id="DS3.d745.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d745.s1" origId="9972673-2" text="We performed a crossover study in 50 NIDDM patients with secondary failure to glibenclamide by comparing the addition to sulphonylurea of either a low-dose bedtime NPH insulin or a t.i.d.">
            <entity id="DS3.d745.s1.e0" origId="3488" charOffset="78-91" type="compound" text="glibenclamide"/>
            <entity id="DS3.d745.s1.e1" origId="P01308,I3WAC9" charOffset="168-175" type="protein" text="insulin"/>
            <pair e1="DS3.d745.s1.e0" e2="DS3.d745.s1.e1" id="DS3.d745.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d745.s2" origId="9972673-5" text="HbA1 c were similarly reduced by the addition of either bedtime NPH insulin (7.6+/-0.34 vs 8.7+/-0.35, p&amp;lt;0.01) or metformin (7.6+/-0.22 vs 8.6+/-0.31, p&amp;lt;0.01).">
            <entity id="DS3.d745.s2.e0" origId="P01308,I3WAC9" charOffset="68-75" type="protein" text="insulin"/>
            <entity id="DS3.d745.s2.e1" origId="4091" charOffset="117-126" type="compound" text="metformin"/>
            <pair e1="DS3.d745.s2.e1" e2="DS3.d745.s2.e0" id="DS3.d745.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d745.s3" origId="9972673-7" text="Bed-time NPH insulin was more effective on FPG reduction than metformin (-36+/-2% vs -25+/-2%, p&amp;lt;0.01); in contrast, metformin addition was more effective on PPPG reduction than bedtime NPH insulin addition (-30+/-2% vs 20+/-3%, p&amp;lt;0.01).">
            <entity id="DS3.d745.s3.e0" origId="P01308,I3WAC9" charOffset="13-20" type="protein" text="insulin"/>
            <entity id="DS3.d745.s3.e1" origId="4091" charOffset="62-71" type="compound" text="metformin"/>
            <entity id="DS3.d745.s3.e2" origId="4091" charOffset="120-129" type="compound" text="metformin"/>
            <entity id="DS3.d745.s3.e3" origId="P01308,I3WAC9" charOffset="193-200" type="protein" text="insulin"/>
            <pair e1="DS3.d745.s3.e1" e2="DS3.d745.s3.e0" id="DS3.d745.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d745.s4" origId="9972673-8" text="Serum cholesterol was marginally but significantly decreased after metformin (5.49+/-0.19 vs 5.91 +/-0.18 mM, p&amp;lt;0.05) but not after NPH insulin.">
            <entity id="DS3.d745.s4.e0" origId="5997" charOffset="6-17" type="compound" text="cholesterol"/>
            <entity id="DS3.d745.s4.e1" origId="4091" charOffset="67-76" type="compound" text="metformin"/>
            <entity id="DS3.d745.s4.e2" origId="P01308,I3WAC9" charOffset="139-146" type="protein" text="insulin"/>
            <pair e1="DS3.d745.s4.e1" e2="DS3.d745.s4.e2" id="DS3.d745.s4.i0" interaction="False" />
            <pair e1="DS3.d745.s4.e0" e2="DS3.d745.s4.e2" id="DS3.d745.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d745.s5" origId="9972673-9" text="Body weight increase was significantly greater after insulin addition than after metformin (1.47+/-0.25 Kg vs 0.64+/-0.17 p=0.02).">
            <entity id="DS3.d745.s5.e0" origId="P01308,I3WAC9" charOffset="53-60" type="protein" text="insulin"/>
            <entity id="DS3.d745.s5.e1" origId="4091" charOffset="81-90" type="compound" text="metformin"/>
            <pair e1="DS3.d745.s5.e1" e2="DS3.d745.s5.e0" id="DS3.d745.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d746" origId="9972675">
        <sentence id="DS3.d746.s0" origId="9972675-1" text="The role of p53 tumor suppressor gene in the pathomechanism of adrenal tumors was investigated by measuring p53 protein and its messenger ribonucleic acid (mRNA) in 12 normal human adrenals as well as in 56 adrenal tumors (7 aldosterone-producing adenomas, 5 adrenocortical adenomas causing Cushing's syndrome, 19 non-hyperfunctioning adrenocortical adenomas, 5 adrenocortical carcinomas, 12 pheochromocytomas, 3 myelolipomas, 4 ganglioneuromas and 1 hemangioma).">
            <entity id="DS3.d746.s0.e0" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="12-15" type="protein" text="p53"/>
            <entity id="DS3.d746.s0.e1" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="108-111" type="protein" text="p53"/>
            <entity id="DS3.d746.s0.e2" origId="90741845" charOffset="225-246" type="compound" text="aldosterone-producing"/>
            <pair e1="DS3.d746.s0.e2" e2="DS3.d746.s0.e0" id="DS3.d746.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d746.s1" origId="9972675-2" text="The p53 protein concentration was significantly increased in aldosterone-producing adenomas (394+/-36 pg/mg cytosolic protein, mean+/-SE, vs 266+/-18 in normal human adrenals), whereas the concentration of this protein in Cushing's adenomas, non-hyperfunctioning adrenocortical adenomas, pheochromocytomas, and in all but one adrenocortical carcinomas was similar to that measured in normal human adrenal tissues.">
            <entity id="DS3.d746.s1.e0" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="4-7" type="protein" text="p53"/>
            <entity id="DS3.d746.s1.e1" origId="90741845" charOffset="61-82" type="compound" text="aldosterone-producing"/>
            <pair e1="DS3.d746.s1.e1" e2="DS3.d746.s1.e0" id="DS3.d746.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d746.s2" origId="9972675-5" text="Northern blot analysis revealed the presence of p53 mRNA in each adrenal tissue examined with highest levels in aldosterone-producing and Cushing's adenomas.">
            <entity id="DS3.d746.s2.e0" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="48-51" type="protein" text="p53"/>
            <entity id="DS3.d746.s2.e1" origId="90741845" charOffset="112-133" type="compound" text="aldosterone-producing"/>
            <pair e1="DS3.d746.s2.e1" e2="DS3.d746.s2.e0" id="DS3.d746.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d747" origId="9972688">
        <sentence id="DS3.d747.s0" origId="9972688-1" text="The effects of angiotensin II (AngII), the AngII analogues saralasin--(Sar1, Ala8)AngII, sarmesin--(Sar1Tyr(Me)4)AngII, the nonpeptide AngII receptor antagonists DuP753 (losartan) (for AT1 receptor subtype) and PD123319 (for AT2 receptor subtype), as well as combinations of AngII and each of its analogues and receptor antagonists, administered intracerebroventricularly (ICV), were studied on mice using the acetic acid-induced abdominal constrictions test (acetic acid 1% intraperitoneally, IP).">
            <entity id="DS3.d747.s0.e0" origId="Q64438,W0UV59" charOffset="15-36" type="protein" text="angiotensin II (AngII"/>
            <entity id="DS3.d747.s0.e1" origId="Q64438,W0UV59" charOffset="31-36" type="protein" text="AngII"/>
            <entity id="DS3.d747.s0.e2" origId="36736,5464275,6324663" charOffset="59-68" type="compound" text="saralasin"/>
            <entity id="DS3.d747.s0.e3" origId="Q64438,W0UV59" charOffset="43-48" type="protein" text="AngII"/>
            <entity id="DS3.d747.s0.e4" origId="122005" charOffset="89-97" type="compound" text="sarmesin"/>
            <entity id="DS3.d747.s0.e5" origId="Q64438,W0UV59" charOffset="43-48" type="protein" text="AngII"/>
            <entity id="DS3.d747.s0.e6" origId="Q64438,W0UV59" charOffset="43-48" type="protein" text="AngII"/>
            <entity id="DS3.d747.s0.e7" origId="3961" charOffset="170-178" type="compound" text="losartan"/>
            <entity id="DS3.d747.s0.e8" origId="Q9WVK0" charOffset="185-197" type="protein" text="AT1 receptor"/>
            <entity id="DS3.d747.s0.e9" origId="5311345" charOffset="211-219" type="compound" text="PD123319"/>
            <entity id="DS3.d747.s0.e10" origId="P35374,Q3US12" charOffset="225-237" type="protein" text="AT2 receptor"/>
            <entity id="DS3.d747.s0.e11" origId="Q64438,W0UV59" charOffset="43-48" type="protein" text="AngII"/>
            <pair e1="DS3.d747.s0.e7" e2="DS3.d747.s0.e8" id="DS3.d747.s0.i0" interaction="False" />
            <pair e1="DS3.d747.s0.e7" e2="DS3.d747.s0.e10" id="DS3.d747.s0.i1" interaction="False" />
            <pair e1="DS3.d747.s0.e7" e2="DS3.d747.s0.e0" id="DS3.d747.s0.i2" interaction="False" />
            <pair e1="DS3.d747.s0.e7" e2="DS3.d747.s0.e1" id="DS3.d747.s0.i3" interaction="False" />
            <pair e1="DS3.d747.s0.e4" e2="DS3.d747.s0.e8" id="DS3.d747.s0.i4" interaction="False" />
            <pair e1="DS3.d747.s0.e4" e2="DS3.d747.s0.e10" id="DS3.d747.s0.i5" interaction="False" />
            <pair e1="DS3.d747.s0.e4" e2="DS3.d747.s0.e0" id="DS3.d747.s0.i6" interaction="False" />
            <pair e1="DS3.d747.s0.e4" e2="DS3.d747.s0.e1" id="DS3.d747.s0.i7" interaction="False" />
            <pair e1="DS3.d747.s0.e2" e2="DS3.d747.s0.e8" id="DS3.d747.s0.i8" interaction="False" />
            <pair e1="DS3.d747.s0.e2" e2="DS3.d747.s0.e10" id="DS3.d747.s0.i9" interaction="False" />
            <pair e1="DS3.d747.s0.e2" e2="DS3.d747.s0.e0" id="DS3.d747.s0.i10" interaction="False" />
            <pair e1="DS3.d747.s0.e2" e2="DS3.d747.s0.e1" id="DS3.d747.s0.i11" interaction="False" />
            <pair e1="DS3.d747.s0.e9" e2="DS3.d747.s0.e8" id="DS3.d747.s0.i12" interaction="False" />
            <pair e1="DS3.d747.s0.e9" e2="DS3.d747.s0.e10" id="DS3.d747.s0.i13" interaction="False" />
            <pair e1="DS3.d747.s0.e9" e2="DS3.d747.s0.e0" id="DS3.d747.s0.i14" interaction="False" />
            <pair e1="DS3.d747.s0.e9" e2="DS3.d747.s0.e1" id="DS3.d747.s0.i15" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d748" origId="9972690">
        <sentence id="DS3.d748.s0" origId="9972690-3" text="apoE-deficient mice treated with Cerebrolysin showed a significant improved performance in the Morris water maze, compared to saline-treated apoE-deficient mice.">
            <entity id="DS3.d748.s0.e0" origId="P08226,Q3TXU4" charOffset="0-4" type="protein" text="apoE"/>
            <entity id="DS3.d748.s0.e1" origId="962" charOffset="102-107" type="compound" text="water"/>
            <entity id="DS3.d748.s0.e2" origId="P08226,Q3TXU4" charOffset="141-145" type="protein" text="apoE"/>
            <pair e1="DS3.d748.s0.e1" e2="DS3.d748.s0.e0" id="DS3.d748.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d749" origId="9972692">
        <sentence id="DS3.d749.s0" origId="9972692-1" text="(-)Deprenyl is an irreversible inhibitor of monoamine oxidase B (MAO-B) frequently used as an adjunct therapy in the treatment of Parkinson's Disease.">
            <entity id="DS3.d749.s0.e0" origId="26757" charOffset="3-11" type="compound" text="Deprenyl"/>
            <entity id="DS3.d749.s0.e1" origId="P27338,B7Z242" charOffset="44-63" type="protein" text="monoamine oxidase B"/>
            <entity id="DS3.d749.s0.e2" origId="P27338,B7Z242" charOffset="65-70" type="protein" text="MAO-B"/>
            <pair e1="DS3.d749.s0.e0" e2="DS3.d749.s0.e2" id="DS3.d749.s0.i0" interaction="False" />
            <pair e1="DS3.d749.s0.e0" e2="DS3.d749.s0.e1" id="DS3.d749.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d749.s1" origId="9972692-3" text="Interestingly, deprenyl's antiapoptotic actions appear not to depend upon the inhibition of MAO-B.">
            <entity id="DS3.d749.s1.e0" origId="26757" charOffset="15-23" type="compound" text="deprenyl"/>
            <entity id="DS3.d749.s1.e1" origId="P27338,B7Z242" charOffset="92-97" type="protein" text="MAO-B"/>
            <pair e1="DS3.d749.s1.e0" e2="DS3.d749.s1.e1" id="DS3.d749.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d750" origId="9972699">
        <sentence id="DS3.d750.s0" origId="9972699-1" text="Antiseizure effects of progesterone (P) and its metabolite, 5alpha-pregnan-3alpha-ol-20-one (3alpha, 5alpha-THP) were investigated following continuous vs. discontinuous P exposure.">
            <entity id="DS3.d750.s0.e0" origId="5994" charOffset="23-35" type="compound" text="progesterone"/>
            <entity id="DS3.d750.s0.e1" origId="92786" charOffset="60-91" type="compound" text="5alpha-pregnan-3alpha-ol-20-one"/>
            <entity id="DS3.d750.s0.e2" origId="P27590,A0A0G2JSP1" charOffset="108-111" type="protein" text="THP"/>
            <pair e1="DS3.d750.s0.e1" e2="DS3.d750.s0.e2" id="DS3.d750.s0.i0" interaction="False" />
            <pair e1="DS3.d750.s0.e0" e2="DS3.d750.s0.e2" id="DS3.d750.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d750.s1" origId="9972699-2" text="In Experiments 1, 32 cycling Long-Evans rats were administered kainic acid (32 mg/kg SC), ictal behavior was examined, and plasma 3alpha,5alpha-THP levels were measured by radioimmunoassay.">
            <entity id="DS3.d750.s1.e0" origId="10255" charOffset="63-74" type="compound" text="kainic acid"/>
            <entity id="DS3.d750.s1.e1" origId="P27590,A0A0G2JSP1" charOffset="144-147" type="protein" text="THP"/>
            <pair e1="DS3.d750.s1.e0" e2="DS3.d750.s1.e1" id="DS3.d750.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d750.s2" origId="9972699-3" text="Proestrus/estrus rats showed less ictal activity and had elevated 3alpha,5alpha-THP levels prior to kainic acid compared to diestrus/metestrus subjects.">
            <entity id="DS3.d750.s2.e0" origId="P27590,A0A0G2JSP1" charOffset="80-83" type="protein" text="THP"/>
            <entity id="DS3.d750.s2.e1" origId="10255" charOffset="100-111" type="compound" text="kainic acid"/>
            <pair e1="DS3.d750.s2.e1" e2="DS3.d750.s2.e0" id="DS3.d750.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d751" origId="9972701">
        <sentence id="DS3.d751.s0" origId="9972701-10" text="Although the ethanol-cocaine regimen produced a marked suppression of catalase and esterase activity compared with control-fed rats, this suppression was roughly equivalent in both rat phenotypes.">
            <entity id="DS3.d751.s0.e0" origId="702" charOffset="13-20" type="compound" text="ethanol"/>
            <entity id="DS3.d751.s0.e1" origId="446220" charOffset="21-28" type="compound" text="cocaine"/>
            <entity id="DS3.d751.s0.e2" origId="P04762" charOffset="70-78" type="protein" text="catalase"/>
            <pair e1="DS3.d751.s0.e1" e2="DS3.d751.s0.e2" id="DS3.d751.s0.i0" interaction="False" />
            <pair e1="DS3.d751.s0.e0" e2="DS3.d751.s0.e2" id="DS3.d751.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d751.s1" origId="9972701-4" text="The following parameters were evaluated: (a) ethanol consumption, (b) cocaine-induced behavioral activity, (c) blood ethanol levels, (d) blood, liver, or brain cocaine and cocaethylene levels, and (e) liver catalase and esterase activity.">
            <entity id="DS3.d751.s1.e0" origId="702" charOffset="45-52" type="compound" text="ethanol"/>
            <entity id="DS3.d751.s1.e1" origId="446220" charOffset="70-77" type="compound" text="cocaine"/>
            <entity id="DS3.d751.s1.e2" origId="702" charOffset="117-124" type="compound" text="ethanol"/>
            <entity id="DS3.d751.s1.e3" origId="446220" charOffset="160-167" type="compound" text="cocaine"/>
            <entity id="DS3.d751.s1.e4" origId="644006" charOffset="172-184" type="compound" text="cocaethylene"/>
            <entity id="DS3.d751.s1.e5" origId="P04762" charOffset="207-215" type="protein" text="catalase"/>
            <pair e1="DS3.d751.s1.e4" e2="DS3.d751.s1.e5" id="DS3.d751.s1.i0" interaction="False" />
            <pair e1="DS3.d751.s1.e1" e2="DS3.d751.s1.e5" id="DS3.d751.s1.i1" interaction="False" />
            <pair e1="DS3.d751.s1.e0" e2="DS3.d751.s1.e5" id="DS3.d751.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d752" origId="9972706">
        <sentence id="DS3.d752.s0" origId="9972706-4" text="Relative to FRL rats, FSL rats did not exhibit increases in muscarinic receptor binding until P32 in the striatum and hippocampus and P120 in the hypothalamus.">
            <entity id="DS3.d752.s0.e0" origId="5288253" charOffset="12-15" type="compound" text="FRL"/>
            <entity id="DS3.d752.s0.e1" origId="76936804" charOffset="22-25" type="compound" text="FSL"/>
            <entity id="DS3.d752.s0.e2" origId="Q5TLG7,A0A0G2JWN9" charOffset="134-138" type="protein" text="P120"/>
            <pair e1="DS3.d752.s0.e1" e2="DS3.d752.s0.e2" id="DS3.d752.s0.i0" interaction="False" />
            <pair e1="DS3.d752.s0.e0" e2="DS3.d752.s0.e2" id="DS3.d752.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d753" origId="9972708">
        <sentence id="DS3.d753.s0" origId="9972708-5" text="Both acute and repeated pyridostigmine bromide administration decreased serum cholinesterase levels by approximately 50%, but neither treatment affected brain cholinesterase levels in our assay.">
            <entity id="DS3.d753.s0.e0" origId="4991" charOffset="24-38" type="compound" text="pyridostigmine"/>
            <entity id="DS3.d753.s0.e1" origId="259" charOffset="39-46" type="compound" text="bromide"/>
            <entity id="DS3.d753.s0.e2" origId="Q9JKC1" charOffset="78-92" type="protein" text="cholinesterase"/>
            <entity id="DS3.d753.s0.e3" origId="Q9JKC1" charOffset="159-173" type="protein" text="cholinesterase"/>
            <pair e1="DS3.d753.s0.e1" e2="DS3.d753.s0.e2" id="DS3.d753.s0.i0" interaction="False" />
            <pair e1="DS3.d753.s0.e0" e2="DS3.d753.s0.e2" id="DS3.d753.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d754" origId="9972713">
        <sentence id="DS3.d754.s0" origId="9972713-0" text="Combination therapy: utilization of CO2 and Erbium:YAG lasers for skin resurfacing.">
            <entity id="DS3.d754.s0.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="36-39" type="protein" text="CO2"/>
            <entity id="DS3.d754.s0.e1" origId="23980" charOffset="44-50" type="compound" text="Erbium"/>
            <pair e1="DS3.d754.s0.e1" e2="DS3.d754.s0.e0" id="DS3.d754.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d754.s1" origId="9972713-1" text="Skin resurfacing with carbon dioxide (CO2) lasers is a commonly used method for skin rejuvenation.">
            <entity id="DS3.d754.s1.e0" origId="5462310" charOffset="22-28" type="compound" text="carbon"/>
            <entity id="DS3.d754.s1.e1" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="38-41" type="protein" text="CO2"/>
            <pair e1="DS3.d754.s1.e0" e2="DS3.d754.s1.e1" id="DS3.d754.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d754.s2" origId="9972713-5" text="The author discusses the practice of combining the CO2 and Erbium:YAG lasers for limiting thermal injury.">
            <entity id="DS3.d754.s2.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="51-54" type="protein" text="CO2"/>
            <entity id="DS3.d754.s2.e1" origId="23980" charOffset="59-65" type="compound" text="Erbium"/>
            <pair e1="DS3.d754.s2.e1" e2="DS3.d754.s2.e0" id="DS3.d754.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d754.s3" origId="9972713-7" text="For moderate rhytids, the CO2 laser can be used for the first pass followed by one to multiple passes with the Erbium:YAG laser.">
            <entity id="DS3.d754.s3.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="26-29" type="protein" text="CO2"/>
            <entity id="DS3.d754.s3.e1" origId="23980" charOffset="111-117" type="compound" text="Erbium"/>
            <pair e1="DS3.d754.s3.e1" e2="DS3.d754.s3.e0" id="DS3.d754.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d755" origId="9972740">
        <sentence id="DS3.d755.s0" origId="9972740-8" text="This was associated with an increase in coronary sinus hemoglobin oxygen saturation (30% +/- 5% at control pacing and 34% +/- 6% during pacing with NTG 2 microg x kg(-1) x min(-1); P = 0.018), which indicates that during the infusion of NTG, there was more metabolic coronary vasodilation than achievable solely on the basis of the metabolic stimulus.">
            <entity id="DS3.d755.s0.e0" origId="977" charOffset="66-72" type="compound" text="oxygen"/>
            <entity id="DS3.d755.s0.e1" origId="P13987,Q6FHM9" charOffset="172-178" type="protein" text="min(-1"/>
            <pair e1="DS3.d755.s0.e0" e2="DS3.d755.s0.e1" id="DS3.d755.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d756" origId="9972741">
        <sentence id="DS3.d756.s0" origId="9972741-10" text="In conclusion, ANP attenuates ischemic ST-segment depression and lactate release during pacing-induced myocardial ischemia in patients with CAD.">
            <entity id="DS3.d756.s0.e0" origId="P01160" charOffset="15-18" type="protein" text="ANP"/>
            <entity id="DS3.d756.s0.e1" origId="612" charOffset="65-72" type="compound" text="lactate"/>
            <pair e1="DS3.d756.s0.e1" e2="DS3.d756.s0.e0" id="DS3.d756.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d756.s1" origId="9972741-11" text="The antiischemic effect of ANP was not accompanied by any improvement in the regional myocardial oxygen supply/demand relationship.">
            <entity id="DS3.d756.s1.e0" origId="P01160" charOffset="27-30" type="protein" text="ANP"/>
            <entity id="DS3.d756.s1.e1" origId="977" charOffset="97-103" type="compound" text="oxygen"/>
            <pair e1="DS3.d756.s1.e1" e2="DS3.d756.s1.e0" id="DS3.d756.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d756.s2" origId="9972741-14" text="In contrast to placebo, Atrial natriuretic peptide attenuated ST-segment depression and myocardial lactate production and improved left ventricular function during pacing-induced ischemia.">
            <entity id="DS3.d756.s2.e0" origId="P01160" charOffset="24-50" type="protein" text="Atrial natriuretic peptide"/>
            <entity id="DS3.d756.s2.e1" origId="612" charOffset="99-106" type="compound" text="lactate"/>
            <pair e1="DS3.d756.s2.e1" e2="DS3.d756.s2.e0" id="DS3.d756.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d756.s3" origId="9972741-2" text="We investigated the effects of ANP on pacing-induced myocardial ischemia during enflurane anesthesia in patients with coronary artery disease (CAD).">
            <entity id="DS3.d756.s3.e0" origId="P01160" charOffset="31-34" type="protein" text="ANP"/>
            <entity id="DS3.d756.s3.e1" origId="3226" charOffset="80-89" type="compound" text="enflurane"/>
            <pair e1="DS3.d756.s3.e1" e2="DS3.d756.s3.e0" id="DS3.d756.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d756.s4" origId="9972741-5" text="We studied the effects of ANP or placebo on pacing-induced changes in central hemodynamics, myocardial blood flow and regional myocardial indices of lactate uptake (RMLU), and oxygen consumption (RMVO2) and extraction (RMO2E).">
            <entity id="DS3.d756.s4.e0" origId="P01160" charOffset="26-29" type="protein" text="ANP"/>
            <entity id="DS3.d756.s4.e1" origId="612" charOffset="149-156" type="compound" text="lactate"/>
            <entity id="DS3.d756.s4.e2" origId="977" charOffset="176-182" type="compound" text="oxygen"/>
            <pair e1="DS3.d756.s4.e2" e2="DS3.d756.s4.e0" id="DS3.d756.s4.i0" interaction="False" />
            <pair e1="DS3.d756.s4.e1" e2="DS3.d756.s4.e0" id="DS3.d756.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d757" origId="9972742">
        <sentence id="DS3.d757.s0" origId="9972742-3" text="The relative risk of in-hospital mortality was determined by logistic regression with in-hospital mortality as the dependent variable, and independent variables that included known risk factors and preoperative cardioactive or antithrombotic drug treatment, i.e., age; left ventricular function; left main coronary artery disease; urgent priority; gender; previous cardiac surgery; concurrent cardiovascular surgery; chronic lung disease; creatinine concentration; hemoglobin concentration; diabetes; hypertension; cerebrovascular disease; recent myocardial infarction; prior vascular surgery; number of arteries bypassed; and regular daily treatment with beta-blockers, aspirin within 5 days, calcium antagonists, angiotensin converting enzyme (ACE) inhibitors, digoxin, or warfarin.">
            <entity id="DS3.d757.s0.e0" origId="588" charOffset="439-449" type="compound" text="creatinine"/>
            <entity id="DS3.d757.s0.e1" origId="2244" charOffset="671-678" type="compound" text="aspirin"/>
            <entity id="DS3.d757.s0.e2" origId="22044544,5460341" charOffset="694-701" type="compound" text="calcium"/>
            <entity id="DS3.d757.s0.e3" origId="P12821,B4DKH4" charOffset="715-744" type="protein" text="angiotensin converting enzyme"/>
            <entity id="DS3.d757.s0.e4" origId="P12821,B4DKH4" charOffset="746-749" type="protein" text="ACE"/>
            <entity id="DS3.d757.s0.e5" origId="2724385" charOffset="763-770" type="compound" text="digoxin"/>
            <entity id="DS3.d757.s0.e6" origId="54678486" charOffset="775-783" type="compound" text="warfarin"/>
            <pair e1="DS3.d757.s0.e2" e2="DS3.d757.s0.e3" id="DS3.d757.s0.i0" interaction="False" />
            <pair e1="DS3.d757.s0.e2" e2="DS3.d757.s0.e4" id="DS3.d757.s0.i1" interaction="False" />
            <pair e1="DS3.d757.s0.e0" e2="DS3.d757.s0.e3" id="DS3.d757.s0.i2" interaction="False" />
            <pair e1="DS3.d757.s0.e0" e2="DS3.d757.s0.e4" id="DS3.d757.s0.i3" interaction="False" />
            <pair e1="DS3.d757.s0.e5" e2="DS3.d757.s0.e3" id="DS3.d757.s0.i4" interaction="False" />
            <pair e1="DS3.d757.s0.e5" e2="DS3.d757.s0.e4" id="DS3.d757.s0.i5" interaction="False" />
            <pair e1="DS3.d757.s0.e6" e2="DS3.d757.s0.e3" id="DS3.d757.s0.i6" interaction="False" />
            <pair e1="DS3.d757.s0.e6" e2="DS3.d757.s0.e4" id="DS3.d757.s0.i7" interaction="False" />
            <pair e1="DS3.d757.s0.e1" e2="DS3.d757.s0.e3" id="DS3.d757.s0.i8" interaction="False" />
            <pair e1="DS3.d757.s0.e1" e2="DS3.d757.s0.e4" id="DS3.d757.s0.i9" interaction="False" />
        </sentence>
        <sentence id="DS3.d757.s1" origId="9972742-5" text="The relative risk of in-hospital mortality (with 95% confidence intervals of the relative risk) associated with the following drug treatments was: nitrates 3.8 (1.5-9.6), beta-blockers 0.4 (0.2-0.8), aspirin within 5 days 1.0 (0.5-1.9), calcium antagonists 1.1 (0.6-2.1), ACE inhibitors 0.8 (0.4-1.5), digoxin 0.7 (0.2-1.8), and warfarin 0.3 (0.1-1.6).">
            <entity id="DS3.d757.s1.e0" origId="2244" charOffset="200-207" type="compound" text="aspirin"/>
            <entity id="DS3.d757.s1.e1" origId="22044544,5460341" charOffset="237-244" type="compound" text="calcium"/>
            <entity id="DS3.d757.s1.e2" origId="P12821,B4DKH4" charOffset="272-275" type="protein" text="ACE"/>
            <entity id="DS3.d757.s1.e3" origId="2724385" charOffset="302-309" type="compound" text="digoxin"/>
            <entity id="DS3.d757.s1.e4" origId="54678486" charOffset="329-337" type="compound" text="warfarin"/>
            <pair e1="DS3.d757.s1.e1" e2="DS3.d757.s1.e2" id="DS3.d757.s1.i0" interaction="False" />
            <pair e1="DS3.d757.s1.e3" e2="DS3.d757.s1.e2" id="DS3.d757.s1.i1" interaction="False" />
            <pair e1="DS3.d757.s1.e4" e2="DS3.d757.s1.e2" id="DS3.d757.s1.i2" interaction="False" />
            <pair e1="DS3.d757.s1.e0" e2="DS3.d757.s1.e2" id="DS3.d757.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d757.s2" origId="9972742-7" text="A significant association between in-hospital mortality and the preoperative use of calcium antagonists, ACE inhibitors, aspirin, digoxin, and warfarin was not confirmed.">
            <entity id="DS3.d757.s2.e0" origId="22044544,5460341" charOffset="84-91" type="compound" text="calcium"/>
            <entity id="DS3.d757.s2.e1" origId="P12821,B4DKH4" charOffset="105-108" type="protein" text="ACE"/>
            <entity id="DS3.d757.s2.e2" origId="2244" charOffset="121-128" type="compound" text="aspirin"/>
            <entity id="DS3.d757.s2.e3" origId="2724385" charOffset="130-137" type="compound" text="digoxin"/>
            <entity id="DS3.d757.s2.e4" origId="54678486" charOffset="143-151" type="compound" text="warfarin"/>
            <pair e1="DS3.d757.s2.e0" e2="DS3.d757.s2.e1" id="DS3.d757.s2.i0" interaction="False" />
            <pair e1="DS3.d757.s2.e3" e2="DS3.d757.s2.e1" id="DS3.d757.s2.i1" interaction="False" />
            <pair e1="DS3.d757.s2.e4" e2="DS3.d757.s2.e1" id="DS3.d757.s2.i2" interaction="False" />
            <pair e1="DS3.d757.s2.e2" e2="DS3.d757.s2.e1" id="DS3.d757.s2.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d758" origId="9972753">
        <sentence id="DS3.d758.s0" origId="9972753-7" text="Awake dRoR values were similar in the isoflurane and sevoflurane groups, 32 +/- 2%/s and 29 +/- 2%/s, respectively.">
            <entity id="DS3.d758.s0.e0" origId="Q24488,D9PTS3" charOffset="6-10" type="protein" text="dRoR"/>
            <entity id="DS3.d758.s0.e1" origId="3763" charOffset="38-48" type="compound" text="isoflurane"/>
            <entity id="DS3.d758.s0.e2" origId="5206" charOffset="53-64" type="compound" text="sevoflurane"/>
            <pair e1="DS3.d758.s0.e2" e2="DS3.d758.s0.e0" id="DS3.d758.s0.i0" interaction="False" />
            <pair e1="DS3.d758.s0.e1" e2="DS3.d758.s0.e0" id="DS3.d758.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d758.s1" origId="9972753-8" text="dRoR decreased to 5 +/- 1%/s during isoflurane anesthesia but to only 24 +/- 2%/s during sevoflurane anesthesia.">
            <entity id="DS3.d758.s1.e0" origId="Q24488,D9PTS3" charOffset="0-4" type="protein" text="dRoR"/>
            <entity id="DS3.d758.s1.e1" origId="3763" charOffset="36-46" type="compound" text="isoflurane"/>
            <entity id="DS3.d758.s1.e2" origId="5206" charOffset="89-100" type="compound" text="sevoflurane"/>
            <pair e1="DS3.d758.s1.e2" e2="DS3.d758.s1.e0" id="DS3.d758.s1.i0" interaction="False" />
            <pair e1="DS3.d758.s1.e1" e2="DS3.d758.s1.e0" id="DS3.d758.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d759" origId="9972767">
        <sentence id="DS3.d759.s0" origId="9972767-12" text="Given the observed inconsistencies between this study of Fos expression and our previous behavioral study, it is questionable whether anesthetic modulation of noxious stimulus-induced FLI parallels that of behavioral responses.">
            <entity id="DS3.d759.s0.e0" origId="P12841" charOffset="57-60" type="protein" text="Fos"/>
            <entity id="DS3.d759.s0.e1" origId="45100492" charOffset="184-187" type="compound" text="FLI"/>
            <pair e1="DS3.d759.s0.e1" e2="DS3.d759.s0.e0" id="DS3.d759.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d759.s1" origId="9972767-1" text="We evaluated the suppression of spinal Fos-like immunoreactivity (FLI) by i.v.">
            <entity id="DS3.d759.s1.e0" origId="P12841" charOffset="39-42" type="protein" text="Fos"/>
            <entity id="DS3.d759.s1.e1" origId="45100492" charOffset="66-69" type="compound" text="FLI"/>
            <pair e1="DS3.d759.s1.e1" e2="DS3.d759.s1.e0" id="DS3.d759.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d760" origId="9972771">
        <sentence id="DS3.d760.s0" origId="9972771-10" text="IMPLICATIONS: We examined the dose-response relationship of sevoflurane/Compound A and urinary excretion of albumin, glucose, and alpha-GST.">
            <entity id="DS3.d760.s0.e0" origId="5206" charOffset="60-71" type="compound" text="sevoflurane"/>
            <entity id="DS3.d760.s0.e1" origId="P02768" charOffset="108-115" type="protein" text="albumin"/>
            <entity id="DS3.d760.s0.e2" origId="206,64689,79025" charOffset="117-124" type="compound" text="glucose"/>
            <pair e1="DS3.d760.s0.e0" e2="DS3.d760.s0.e1" id="DS3.d760.s0.i0" interaction="False" />
            <pair e1="DS3.d760.s0.e2" e2="DS3.d760.s0.e1" id="DS3.d760.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d760.s1" origId="9972771-4" text="We measured inspired and expired concentrations of Compound A and urinary excretion of albumin, alpha-glutathione-S-transferase (GST), and glucose.">
            <entity id="DS3.d760.s1.e0" origId="P02768" charOffset="87-94" type="protein" text="albumin"/>
            <entity id="DS3.d760.s1.e1" origId="20725278,124886" charOffset="102-113" type="compound" text="glutathione"/>
            <entity id="DS3.d760.s1.e2" origId="206,64689,79025" charOffset="139-146" type="compound" text="glucose"/>
            <pair e1="DS3.d760.s1.e1" e2="DS3.d760.s1.e0" id="DS3.d760.s1.i0" interaction="False" />
            <pair e1="DS3.d760.s1.e2" e2="DS3.d760.s1.e0" id="DS3.d760.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d760.s2" origId="9972771-5" text="The median urinary excretion of albumin, glucose, and alpha-GST for the first 3 days after anesthesia increased significantly from preanesthetic values in the 2-L/min group.">
            <entity id="DS3.d760.s2.e0" origId="P02768" charOffset="32-39" type="protein" text="albumin"/>
            <entity id="DS3.d760.s2.e1" origId="206,64689,79025" charOffset="41-48" type="compound" text="glucose"/>
            <pair e1="DS3.d760.s2.e1" e2="DS3.d760.s2.e0" id="DS3.d760.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d760.s3" origId="9972771-6" text="Compound A doses &amp;lt; 240 ppm-h resulted in normal urinary excretion of albumin, glucose, and alpha-GST.">
            <entity id="DS3.d760.s3.e0" origId="P02768" charOffset="72-79" type="protein" text="albumin"/>
            <entity id="DS3.d760.s3.e1" origId="206,64689,79025" charOffset="81-88" type="compound" text="glucose"/>
            <pair e1="DS3.d760.s3.e1" e2="DS3.d760.s3.e0" id="DS3.d760.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d760.s4" origId="9972771-8" text="Urinary excretion of albumin, alpha-GST, and glucose was normal by 14 days after exposure.">
            <entity id="DS3.d760.s4.e0" origId="P02768" charOffset="21-28" type="protein" text="albumin"/>
            <entity id="DS3.d760.s4.e1" origId="206,64689,79025" charOffset="45-52" type="compound" text="glucose"/>
            <pair e1="DS3.d760.s4.e1" e2="DS3.d760.s4.e0" id="DS3.d760.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d761" origId="9972793">
        <sentence id="DS3.d761.s0" origId="9972793-5" text="RESULTS: It is shown that concentrations of wortmannin completely inhibiting DNA-PK activity profoundly affect the rejoining of dsb in vivo, but have no effect on dsb rejoining in vitro.">
            <entity id="DS3.d761.s0.e0" origId="312145" charOffset="44-54" type="compound" text="wortmannin"/>
            <entity id="DS3.d761.s0.e1" origId="P78527" charOffset="77-83" type="protein" text="DNA-PK"/>
            <pair e1="DS3.d761.s0.e0" e2="DS3.d761.s0.e1" id="DS3.d761.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d761.s1" origId="9972793-6" text="Furthermore, fractionation of cell extracts using ammonium sulphate precipitation, generates protein fractions that are able to support dsb rejoining, despite the fact that they do not contain detectable amounts of either DNA-PKcs or Ku80.">
            <entity id="DS3.d761.s1.e0" origId="6097028" charOffset="50-67" type="compound" text="ammonium sulphate"/>
            <entity id="DS3.d761.s1.e1" origId="P13010" charOffset="234-238" type="protein" text="Ku80"/>
            <pair e1="DS3.d761.s1.e0" e2="DS3.d761.s1.e1" id="DS3.d761.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d762" origId="9972794">
        <sentence id="DS3.d762.s0" origId="9972794-2" text="MATERIALS AND METHODS: The yields of single- (ssb) and double-strand breaks (dsb) in pBR322 DNA over a range of scavenging capacities were measured in the presence of Tris after irradiation with a single pulse of 400 keV electrons.">
            <entity id="DS3.d762.s0.e0" origId="P05455" charOffset="46-49" type="protein" text="ssb"/>
            <entity id="DS3.d762.s0.e1" origId="6503" charOffset="167-171" type="compound" text="Tris"/>
            <pair e1="DS3.d762.s0.e1" e2="DS3.d762.s0.e0" id="DS3.d762.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d763" origId="9972805">
        <sentence id="DS3.d763.s0" origId="9972805-11" text="A reduction in serum progesterone coincides with TNF-alpha increase, resulting in an increase of apoptotic deciduomal cells at the regression period, and that the life span of deciduoma is prolonged by additive supply of progesterone.">
            <entity id="DS3.d763.s0.e0" origId="5994" charOffset="21-33" type="compound" text="progesterone"/>
            <entity id="DS3.d763.s0.e1" origId="P06804,Q3U593" charOffset="49-58" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d763.s0.e2" origId="5994" charOffset="221-233" type="compound" text="progesterone"/>
            <pair e1="DS3.d763.s0.e0" e2="DS3.d763.s0.e1" id="DS3.d763.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d764" origId="9972815">
        <sentence id="DS3.d764.s0" origId="9972815-4" text="The tongue, palatine, and mouth cavity (bottom) minor salivary glands of newborn, 1- to 20-day-old, and adult magellanic penguins were studied with hematoxylin-eosin, periodic acid-Schiff, alcian blue, toluidine blue, and lectin histochemistry.">
            <entity id="DS3.d764.s0.e0" origId="Q92570,A0A024R168" charOffset="48-53" type="protein" text="minor"/>
            <entity id="DS3.d764.s0.e1" origId="10603,320930,45029742,15559608" charOffset="148-159" type="compound" text="hematoxylin"/>
            <entity id="DS3.d764.s0.e2" origId="65185" charOffset="167-180" type="compound" text="periodic acid"/>
            <entity id="DS3.d764.s0.e3" origId="7084" charOffset="202-216" type="compound" text="toluidine blue"/>
            <pair e1="DS3.d764.s0.e3" e2="DS3.d764.s0.e0" id="DS3.d764.s0.i0" interaction="False" />
            <pair e1="DS3.d764.s0.e2" e2="DS3.d764.s0.e0" id="DS3.d764.s0.i1" interaction="False" />
            <pair e1="DS3.d764.s0.e1" e2="DS3.d764.s0.e0" id="DS3.d764.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d765" origId="9972821">
        <sentence id="DS3.d765.s0" origId="9972821-4" text="Fibroblast growth factors (FGF)-1, -2, and -9 (50 ng/ml), the prostaglandins PGA2, PGE2, and PGI2 (10 microM), phorbol 12,13-didecanoate (PDD; 10 nM), okadaic acid (10 nM), dexamethasone (1 microM), and vitamin D3 (1 microm) also differentially effected GDNF release from U-87MG and SK-N-AS cells.">
            <entity id="DS3.d765.s0.e0" origId="P05230,A8K147,Q16089" charOffset="0-45" type="protein" text="Fibroblast growth factors (FGF)-1, -2, and -9"/>
            <entity id="DS3.d765.s0.e1" origId="5280880" charOffset="77-81" type="compound" text="PGA2"/>
            <entity id="DS3.d765.s0.e2" origId="5280427,5282411,5353608,6434194" charOffset="93-97" type="compound" text="PGI2"/>
            <entity id="DS3.d765.s0.e3" origId="71308620" charOffset="111-136" type="compound" text="phorbol 12,13-didecanoate"/>
            <entity id="DS3.d765.s0.e4" origId="16219908,452543,452544,537379" charOffset="138-141" type="compound" text="PDD"/>
            <entity id="DS3.d765.s0.e5" origId="11953808,42628599,446512,45356271,4584,5468826,57059112,6102351,6426933,6476659,6917781,90479758" charOffset="151-163" type="compound" text="okadaic acid"/>
            <entity id="DS3.d765.s0.e6" origId="5743" charOffset="173-186" type="compound" text="dexamethasone"/>
            <entity id="DS3.d765.s0.e7" origId="P39905" charOffset="254-258" type="protein" text="GDNF"/>
            <entity id="DS3.d765.s0.e8" origId="Q5VTY9,B7Z5N1" charOffset="283-287" type="protein" text="SK-N"/>
            <pair e1="DS3.d765.s0.e3" e2="DS3.d765.s0.e8" id="DS3.d765.s0.i0" interaction="False" />
            <pair e1="DS3.d765.s0.e3" e2="DS3.d765.s0.e7" id="DS3.d765.s0.i1" interaction="False" />
            <pair e1="DS3.d765.s0.e3" e2="DS3.d765.s0.e0" id="DS3.d765.s0.i2" interaction="False" />
            <pair e1="DS3.d765.s0.e2" e2="DS3.d765.s0.e8" id="DS3.d765.s0.i3" interaction="False" />
            <pair e1="DS3.d765.s0.e2" e2="DS3.d765.s0.e7" id="DS3.d765.s0.i4" interaction="False" />
            <pair e1="DS3.d765.s0.e2" e2="DS3.d765.s0.e0" id="DS3.d765.s0.i5" interaction="False" />
            <pair e1="DS3.d765.s0.e1" e2="DS3.d765.s0.e8" id="DS3.d765.s0.i6" interaction="False" />
            <pair e1="DS3.d765.s0.e1" e2="DS3.d765.s0.e7" id="DS3.d765.s0.i7" interaction="False" />
            <pair e1="DS3.d765.s0.e1" e2="DS3.d765.s0.e0" id="DS3.d765.s0.i8" interaction="False" />
            <pair e1="DS3.d765.s0.e4" e2="DS3.d765.s0.e8" id="DS3.d765.s0.i9" interaction="False" />
            <pair e1="DS3.d765.s0.e4" e2="DS3.d765.s0.e7" id="DS3.d765.s0.i10" interaction="False" />
            <pair e1="DS3.d765.s0.e4" e2="DS3.d765.s0.e0" id="DS3.d765.s0.i11" interaction="False" />
            <pair e1="DS3.d765.s0.e5" e2="DS3.d765.s0.e8" id="DS3.d765.s0.i12" interaction="False" />
            <pair e1="DS3.d765.s0.e5" e2="DS3.d765.s0.e7" id="DS3.d765.s0.i13" interaction="False" />
            <pair e1="DS3.d765.s0.e5" e2="DS3.d765.s0.e0" id="DS3.d765.s0.i14" interaction="False" />
            <pair e1="DS3.d765.s0.e6" e2="DS3.d765.s0.e8" id="DS3.d765.s0.i15" interaction="False" />
            <pair e1="DS3.d765.s0.e6" e2="DS3.d765.s0.e7" id="DS3.d765.s0.i16" interaction="False" />
            <pair e1="DS3.d765.s0.e6" e2="DS3.d765.s0.e0" id="DS3.d765.s0.i17" interaction="False" />
        </sentence>
        <sentence id="DS3.d765.s1" origId="9972821-5" text="A result shared by both cell lines, was a two- to threefold increase in GDNF release by db-cAMP (1 mM), or forskolin (10 microM).">
            <entity id="DS3.d765.s1.e0" origId="P39905" charOffset="72-76" type="protein" text="GDNF"/>
            <entity id="DS3.d765.s1.e1" origId="6076" charOffset="91-95" type="compound" text="cAMP"/>
            <entity id="DS3.d765.s1.e2" origId="47936" charOffset="107-116" type="compound" text="forskolin"/>
            <pair e1="DS3.d765.s1.e2" e2="DS3.d765.s1.e0" id="DS3.d765.s1.i0" interaction="False" />
            <pair e1="DS3.d765.s1.e1" e2="DS3.d765.s1.e0" id="DS3.d765.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d766" origId="9972823">
        <sentence id="DS3.d766.s0" origId="9972823-9" text="Examining the subunit expression of the kainate receptor subunits GluR6/7 and KA2 did, however, not reveal any major change during development of the cultures.">
            <entity id="DS3.d766.s0.e0" origId="10255" charOffset="40-47" type="compound" text="kainate"/>
            <entity id="DS3.d766.s0.e1" origId="Q6PAQ0,D3Z797" charOffset="66-71" type="protein" text="GluR6"/>
            <entity id="DS3.d766.s0.e2" origId="Q61626,Q80WU3" charOffset="78-81" type="protein" text="KA2"/>
            <pair e1="DS3.d766.s0.e0" e2="DS3.d766.s0.e2" id="DS3.d766.s0.i0" interaction="False" />
            <pair e1="DS3.d766.s0.e0" e2="DS3.d766.s0.e1" id="DS3.d766.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d767" origId="9972824">
        <sentence id="DS3.d767.s0" origId="9972824-0" text="Interindividual differences in the levels of the glutamate transporters GLAST and GLT, but no clear correlation with Alzheimer's disease.">
            <entity id="DS3.d767.s0.e0" origId="23327,611,57109091" charOffset="49-58" type="compound" text="glutamate"/>
            <entity id="DS3.d767.s0.e1" origId="P43003,Q8N169,Q7Z5T0,B4DF14,A0A024R050,A0A087X0U3,A0A087WT87" charOffset="72-77" type="protein" text="GLAST"/>
            <entity id="DS3.d767.s0.e2" origId="33032" charOffset="82-85" type="compound" text="GLT"/>
            <pair e1="DS3.d767.s0.e2" e2="DS3.d767.s0.e1" id="DS3.d767.s0.i0" interaction="False" />
            <pair e1="DS3.d767.s0.e0" e2="DS3.d767.s0.e1" id="DS3.d767.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d767.s1" origId="9972824-10" text="In conclusion, Alzheimer's disease brains can have both normal and reduced levels of GLAST and GLT.">
            <entity id="DS3.d767.s1.e0" origId="P43003,Q8N169,Q7Z5T0,B4DF14,A0A024R050,A0A087X0U3,A0A087WT87" charOffset="85-90" type="protein" text="GLAST"/>
            <entity id="DS3.d767.s1.e1" origId="33032" charOffset="95-98" type="compound" text="GLT"/>
            <pair e1="DS3.d767.s1.e1" e2="DS3.d767.s1.e0" id="DS3.d767.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d767.s2" origId="9972824-3" text="To determine if reduced glutamate uptake is a contributing factor, we have measured the levels of the glutamate transporter proteins GLAST (EAAT1) and GLT (EAAT2) in human autopsy samples.">
            <entity id="DS3.d767.s2.e0" origId="23327,611,57109091" charOffset="24-33" type="compound" text="glutamate"/>
            <entity id="DS3.d767.s2.e1" origId="23327,611,57109091" charOffset="102-111" type="compound" text="glutamate"/>
            <entity id="DS3.d767.s2.e2" origId="P43003,Q8N169,Q7Z5T0,B4DF14,A0A024R050,A0A087X0U3,A0A087WT87" charOffset="133-138" type="protein" text="GLAST"/>
            <entity id="DS3.d767.s2.e3" origId="P43003,Q8N169,Q7Z5T0,B4DF14,A0A024R050,A0A087X0U3,A0A087WT87" charOffset="140-145" type="protein" text="EAAT1"/>
            <entity id="DS3.d767.s2.e4" origId="33032" charOffset="151-154" type="compound" text="GLT"/>
            <entity id="DS3.d767.s2.e5" origId="P43004,A2A2U1" charOffset="156-161" type="protein" text="EAAT2"/>
            <pair e1="DS3.d767.s2.e4" e2="DS3.d767.s2.e5" id="DS3.d767.s2.i0" interaction="False" />
            <pair e1="DS3.d767.s2.e4" e2="DS3.d767.s2.e3" id="DS3.d767.s2.i1" interaction="False" />
            <pair e1="DS3.d767.s2.e4" e2="DS3.d767.s2.e2" id="DS3.d767.s2.i2" interaction="False" />
            <pair e1="DS3.d767.s2.e0" e2="DS3.d767.s2.e5" id="DS3.d767.s2.i3" interaction="False" />
            <pair e1="DS3.d767.s2.e0" e2="DS3.d767.s2.e3" id="DS3.d767.s2.i4" interaction="False" />
            <pair e1="DS3.d767.s2.e0" e2="DS3.d767.s2.e2" id="DS3.d767.s2.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d767.s3" origId="9972824-6" text="GLT (N-terminal and central parts), GLAST (C-terminal), glial fibrillary acidic protein (GFAP) and inositol (1,4,5)-triphosphate (IP3)-receptor immunoreactivities were determined in the cingulate and inferior temporal gyri by immunoblotting.">
            <entity id="DS3.d767.s3.e0" origId="33032" charOffset="0-3" type="compound" text="GLT"/>
            <entity id="DS3.d767.s3.e1" origId="P43003,Q8N169,Q7Z5T0,B4DF14,A0A024R050,A0A087X0U3,A0A087WT87" charOffset="36-41" type="protein" text="GLAST"/>
            <entity id="DS3.d767.s3.e2" origId="P14136,A7REI1" charOffset="56-87" type="protein" text="glial fibrillary acidic protein"/>
            <entity id="DS3.d767.s3.e3" origId="P14136,A7REI1" charOffset="89-93" type="protein" text="GFAP"/>
            <entity id="DS3.d767.s3.e4" origId="892" charOffset="99-107" type="compound" text="inositol"/>
            <entity id="DS3.d767.s3.e5" origId="439456" charOffset="130-133" type="compound" text="IP3"/>
            <pair e1="DS3.d767.s3.e5" e2="DS3.d767.s3.e2" id="DS3.d767.s3.i0" interaction="False" />
            <pair e1="DS3.d767.s3.e5" e2="DS3.d767.s3.e3" id="DS3.d767.s3.i1" interaction="False" />
            <pair e1="DS3.d767.s3.e5" e2="DS3.d767.s3.e1" id="DS3.d767.s3.i2" interaction="False" />
            <pair e1="DS3.d767.s3.e0" e2="DS3.d767.s3.e2" id="DS3.d767.s3.i3" interaction="False" />
            <pair e1="DS3.d767.s3.e0" e2="DS3.d767.s3.e3" id="DS3.d767.s3.i4" interaction="False" />
            <pair e1="DS3.d767.s3.e0" e2="DS3.d767.s3.e1" id="DS3.d767.s3.i5" interaction="False" />
            <pair e1="DS3.d767.s3.e4" e2="DS3.d767.s3.e2" id="DS3.d767.s3.i6" interaction="False" />
            <pair e1="DS3.d767.s3.e4" e2="DS3.d767.s3.e3" id="DS3.d767.s3.i7" interaction="False" />
            <pair e1="DS3.d767.s3.e4" e2="DS3.d767.s3.e1" id="DS3.d767.s3.i8" interaction="False" />
        </sentence>
        <sentence id="DS3.d767.s4" origId="9972824-8" text="An individual variation in GLAST and GLT levels was found, but no significant correlation with Alzheimer's disease, except for a 14% lower ratio of N-terminal to central GLT immunoreactivity (P &amp;lt; 0.04).">
            <entity id="DS3.d767.s4.e0" origId="P43003,Q8N169,Q7Z5T0,B4DF14,A0A024R050,A0A087X0U3,A0A087WT87" charOffset="27-32" type="protein" text="GLAST"/>
            <entity id="DS3.d767.s4.e1" origId="33032" charOffset="37-40" type="compound" text="GLT"/>
            <entity id="DS3.d767.s4.e2" origId="33032" charOffset="170-173" type="compound" text="GLT"/>
            <pair e1="DS3.d767.s4.e1" e2="DS3.d767.s4.e0" id="DS3.d767.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d767.s5" origId="9972824-9" text="The levels of GLAST and GLT showed negative correlation in agreement with the idea that these proteins are differentially regulated.">
            <entity id="DS3.d767.s5.e0" origId="P43003,Q8N169,Q7Z5T0,B4DF14,A0A024R050,A0A087X0U3,A0A087WT87" charOffset="14-19" type="protein" text="GLAST"/>
            <entity id="DS3.d767.s5.e1" origId="33032" charOffset="24-27" type="compound" text="GLT"/>
            <pair e1="DS3.d767.s5.e1" e2="DS3.d767.s5.e0" id="DS3.d767.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d768" origId="9972827">
        <sentence id="DS3.d768.s0" origId="9972827-7" text="Following treatment with interleukin-1beta (IL-1beta), human astrocytes demonstrated increased message and protein expression for MIP-1alpha, while other immune modulators such as interferon-gamma (IFN)-gamma, tumor necrosis factor-alpha (TNF-alpha), granulocyte-macrophage colony-stimulating factor (GM-CSF), lipopolysaccharide, or phorbol ester (a protein kinase C activator) did not induce MIP-1alpha expression in human astrocytes.">
            <entity id="DS3.d768.s0.e0" origId="P01584" charOffset="25-42" type="protein" text="interleukin-1beta"/>
            <entity id="DS3.d768.s0.e1" origId="P01584" charOffset="44-52" type="protein" text="IL-1beta"/>
            <entity id="DS3.d768.s0.e2" origId="P10147,A0N0R1" charOffset="130-140" type="protein" text="MIP-1alpha"/>
            <entity id="DS3.d768.s0.e3" origId="P01375,Q5STB3" charOffset="239-248" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d768.s0.e4" origId="P04141" charOffset="251-299" type="protein" text="granulocyte-macrophage colony-stimulating factor"/>
            <entity id="DS3.d768.s0.e5" origId="P04141" charOffset="301-307" type="protein" text="GM-CSF"/>
            <entity id="DS3.d768.s0.e6" origId="11970143" charOffset="310-328" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d768.s0.e7" origId="22833501,27924,70702034" charOffset="333-346" type="compound" text="phorbol ester"/>
            <entity id="DS3.d768.s0.e8" origId="P10147,A0N0R1" charOffset="393-403" type="protein" text="MIP-1alpha"/>
            <pair e1="DS3.d768.s0.e7" e2="DS3.d768.s0.e5" id="DS3.d768.s0.i0" interaction="False" />
            <pair e1="DS3.d768.s0.e7" e2="DS3.d768.s0.e4" id="DS3.d768.s0.i1" interaction="False" />
            <pair e1="DS3.d768.s0.e7" e2="DS3.d768.s0.e2" id="DS3.d768.s0.i2" interaction="False" />
            <pair e1="DS3.d768.s0.e7" e2="DS3.d768.s0.e1" id="DS3.d768.s0.i3" interaction="False" />
            <pair e1="DS3.d768.s0.e7" e2="DS3.d768.s0.e0" id="DS3.d768.s0.i4" interaction="False" />
            <pair e1="DS3.d768.s0.e7" e2="DS3.d768.s0.e3" id="DS3.d768.s0.i5" interaction="False" />
            <pair e1="DS3.d768.s0.e6" e2="DS3.d768.s0.e5" id="DS3.d768.s0.i6" interaction="False" />
            <pair e1="DS3.d768.s0.e6" e2="DS3.d768.s0.e4" id="DS3.d768.s0.i7" interaction="False" />
            <pair e1="DS3.d768.s0.e6" e2="DS3.d768.s0.e2" id="DS3.d768.s0.i8" interaction="False" />
            <pair e1="DS3.d768.s0.e6" e2="DS3.d768.s0.e1" id="DS3.d768.s0.i9" interaction="False" />
            <pair e1="DS3.d768.s0.e6" e2="DS3.d768.s0.e0" id="DS3.d768.s0.i10" interaction="False" />
            <pair e1="DS3.d768.s0.e6" e2="DS3.d768.s0.e3" id="DS3.d768.s0.i11" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d769" origId="9972828">
        <sentence id="DS3.d769.s0" origId="9972828-2" text="recoverin is a calcium-binding protein which inhibits rhodopsin kinase from phosphorylating rhodopsin.">
            <entity id="DS3.d769.s0.e0" origId="Q8VH47,P34057,Q2TB46" charOffset="0-9" type="protein" text="recoverin"/>
            <entity id="DS3.d769.s0.e1" origId="22044544,5460341" charOffset="15-22" type="compound" text="calcium"/>
            <entity id="DS3.d769.s0.e2" origId="P51489,A0A0G2JSY7" charOffset="54-63" type="protein" text="rhodopsin"/>
            <entity id="DS3.d769.s0.e3" origId="P51489,A0A0G2JSY7" charOffset="92-101" type="protein" text="rhodopsin"/>
            <pair e1="DS3.d769.s0.e1" e2="DS3.d769.s0.e0" id="DS3.d769.s0.i0" interaction="False" />
            <pair e1="DS3.d769.s0.e1" e2="DS3.d769.s0.e2" id="DS3.d769.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d770" origId="9972829">
        <sentence id="DS3.d770.s0" origId="9972829-4" text="Postembedding immunoelectron microscopy analysis performed in the mouse muscle showed that the PrPc-specific colloidal gold immunolabelling was concentrated over the sarcoplasmic cytoplasm.">
            <entity id="DS3.d770.s0.e0" origId="P04925,Q4FJQ7,Q3UG89" charOffset="95-99" type="protein" text="PrPc"/>
            <entity id="DS3.d770.s0.e1" origId="23985" charOffset="119-123" type="compound" text="gold"/>
            <pair e1="DS3.d770.s0.e1" e2="DS3.d770.s0.e0" id="DS3.d770.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d771" origId="9972841">
        <sentence id="DS3.d771.s0" origId="9972841-6" text="Whereas SKF 38393 failed to induce significative changes, PPHT and low doses of SCH 23390 and sulpiride improved the acquisition of CARs in those groups.">
            <entity id="DS3.d771.s0.e0" origId="3036864,5018" charOffset="80-89" type="compound" text="SCH 23390"/>
            <entity id="DS3.d771.s0.e1" origId="3018598,5355" charOffset="94-103" type="compound" text="sulpiride"/>
            <entity id="DS3.d771.s0.e2" origId="G3V9K0" charOffset="132-136" type="protein" text="CARs"/>
            <pair e1="DS3.d771.s0.e0" e2="DS3.d771.s0.e2" id="DS3.d771.s0.i0" interaction="False" />
            <pair e1="DS3.d771.s0.e1" e2="DS3.d771.s0.e2" id="DS3.d771.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d772" origId="9972845">
        <sentence id="DS3.d772.s0" origId="9972845-0" text="Sex and estrous cycle-dependent changes in neurosteroid and benzodiazepine effects on food consumption and plus-maze learning behaviors in rats.">
            <entity id="DS3.d772.s0.e0" origId="D3ZPX4" charOffset="0-3" type="protein" text="Sex"/>
            <entity id="DS3.d772.s0.e1" origId="134664" charOffset="60-74" type="compound" text="benzodiazepine"/>
            <pair e1="DS3.d772.s0.e1" e2="DS3.d772.s0.e0" id="DS3.d772.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d773" origId="9972846">
        <sentence id="DS3.d773.s0" origId="9972846-0" text="Interleukin-1alpha injection into ventromedial hypothalamic nucleus of normal rats depresses food intake and increases release of dopamine and serotonin.">
            <entity id="DS3.d773.s0.e0" origId="P16598" charOffset="0-18" type="protein" text="Interleukin-1alpha"/>
            <entity id="DS3.d773.s0.e1" origId="681" charOffset="130-138" type="compound" text="dopamine"/>
            <pair e1="DS3.d773.s0.e1" e2="DS3.d773.s0.e0" id="DS3.d773.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d773.s1" origId="9972846-10" text="During eating, VMN 5-HT in control rats significantly increased while increasing VMN 5-HIAA occurred in IL-1alpha rats.">
            <entity id="DS3.d773.s1.e0" origId="5202" charOffset="19-23" type="compound" text="5-HT"/>
            <entity id="DS3.d773.s1.e1" origId="1826" charOffset="85-91" type="compound" text="5-HIAA"/>
            <entity id="DS3.d773.s1.e2" origId="P16598" charOffset="104-113" type="protein" text="IL-1alpha"/>
            <pair e1="DS3.d773.s1.e0" e2="DS3.d773.s1.e2" id="DS3.d773.s1.i0" interaction="False" />
            <pair e1="DS3.d773.s1.e1" e2="DS3.d773.s1.e2" id="DS3.d773.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d773.s2" origId="9972846-11" text="Findings show that an IL-1alpha pathophysiological dose injected into the VMN was associated with anorexia and significantly increased dopaminergic and serotonergic activities and suggest that enhanced VMN DA and 5-HT activities may be part of an IL-1alpha-initiated cascade involved in IL-1alpha-associated anorexia.">
            <entity id="DS3.d773.s2.e0" origId="P16598" charOffset="22-31" type="protein" text="IL-1alpha"/>
            <entity id="DS3.d773.s2.e1" origId="5202" charOffset="213-217" type="compound" text="5-HT"/>
            <entity id="DS3.d773.s2.e2" origId="P16598" charOffset="247-256" type="protein" text="IL-1alpha"/>
            <entity id="DS3.d773.s2.e3" origId="P16598" charOffset="247-256" type="protein" text="IL-1alpha"/>
            <pair e1="DS3.d773.s2.e1" e2="DS3.d773.s2.e0" id="DS3.d773.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d773.s3" origId="9972846-1" text="A microdialysis injector probe administered IL-1alpha into ventromedial hypothalamus (VMN) and concurrently measured release of dopamine (DA), DOPAC, 5-HT, and 5-HIAA.">
            <entity id="DS3.d773.s3.e0" origId="P16598" charOffset="44-53" type="protein" text="IL-1alpha"/>
            <entity id="DS3.d773.s3.e1" origId="681" charOffset="128-136" type="compound" text="dopamine"/>
            <entity id="DS3.d773.s3.e2" origId="547" charOffset="143-148" type="compound" text="DOPAC"/>
            <entity id="DS3.d773.s3.e3" origId="5202" charOffset="150-154" type="compound" text="5-HT"/>
            <entity id="DS3.d773.s3.e4" origId="1826" charOffset="160-166" type="compound" text="5-HIAA"/>
            <pair e1="DS3.d773.s3.e2" e2="DS3.d773.s3.e0" id="DS3.d773.s3.i0" interaction="False" />
            <pair e1="DS3.d773.s3.e3" e2="DS3.d773.s3.e0" id="DS3.d773.s3.i1" interaction="False" />
            <pair e1="DS3.d773.s3.e4" e2="DS3.d773.s3.e0" id="DS3.d773.s3.i2" interaction="False" />
            <pair e1="DS3.d773.s3.e1" e2="DS3.d773.s3.e0" id="DS3.d773.s3.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d773.s4" origId="9972846-7" text="DA and 5-HT rose immediately on injecting IL-1alpha and remained higher (p &amp;lt; 0.05) than basal during the first 60 min and 40 min sampling period, respectively.">
            <entity id="DS3.d773.s4.e0" origId="5202" charOffset="7-11" type="compound" text="5-HT"/>
            <entity id="DS3.d773.s4.e1" origId="P16598" charOffset="42-51" type="protein" text="IL-1alpha"/>
            <pair e1="DS3.d773.s4.e0" e2="DS3.d773.s4.e1" id="DS3.d773.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d773.s5" origId="9972846-9" text="Eating decreased VMN DA in controls, and decreased VMN DOPAC in IL-1alpha-treated rats.">
            <entity id="DS3.d773.s5.e0" origId="547" charOffset="55-60" type="compound" text="DOPAC"/>
            <entity id="DS3.d773.s5.e1" origId="P16598" charOffset="64-73" type="protein" text="IL-1alpha"/>
            <pair e1="DS3.d773.s5.e0" e2="DS3.d773.s5.e1" id="DS3.d773.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d774" origId="9972849">
        <sentence id="DS3.d774.s0" origId="9972849-1" text="In the substantia nigra acetylcholinesterase is released from the dopamine cells of the pars compacta independent of cholinergic transmission.">
            <entity id="DS3.d774.s0.e0" origId="P37136" charOffset="24-44" type="protein" text="acetylcholinesterase"/>
            <entity id="DS3.d774.s0.e1" origId="681" charOffset="66-74" type="compound" text="dopamine"/>
            <pair e1="DS3.d774.s0.e1" e2="DS3.d774.s0.e0" id="DS3.d774.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d774.s1" origId="9972849-2" text="In this study the effects of local and systemic amphetamine treatment were compared on acetylcholinesterase release in the rat substantia nigra in relation to concomitant behavior.">
            <entity id="DS3.d774.s1.e0" origId="3007" charOffset="48-59" type="compound" text="amphetamine"/>
            <entity id="DS3.d774.s1.e1" origId="P37136" charOffset="87-107" type="protein" text="acetylcholinesterase"/>
            <pair e1="DS3.d774.s1.e0" e2="DS3.d774.s1.e1" id="DS3.d774.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d774.s2" origId="9972849-3" text='acetylcholinesterase release, measured "on-line" with a sensitive chemiluminescent system, was enhanced by amphetamine stimulation administered locally and could not be dissociated from simultaneous amphetamine-induced circling behavior.'>
            <entity id="DS3.d774.s2.e0" origId="P37136" charOffset="0-20" type="protein" text="acetylcholinesterase"/>
            <entity id="DS3.d774.s2.e1" origId="3007" charOffset="107-118" type="compound" text="amphetamine"/>
            <entity id="DS3.d774.s2.e2" origId="3007" charOffset="199-210" type="compound" text="amphetamine"/>
            <pair e1="DS3.d774.s2.e1" e2="DS3.d774.s2.e0" id="DS3.d774.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d774.s3" origId="9972849-4" text="On the other hand, amphetamine administered systemically resulted in a general increase in locomotor behavior followed by a subsequent increase in acetylcholinesterase release.">
            <entity id="DS3.d774.s3.e0" origId="3007" charOffset="19-30" type="compound" text="amphetamine"/>
            <entity id="DS3.d774.s3.e1" origId="P37136" charOffset="147-167" type="protein" text="acetylcholinesterase"/>
            <pair e1="DS3.d774.s3.e0" e2="DS3.d774.s3.e1" id="DS3.d774.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d775" origId="9972854">
        <sentence id="DS3.d775.s0" origId="9972854-1" text="To clarify which subtype of sigma receptors is involved in the sigma receptor-mediated neck dystonia in rats, we examined whether 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride (SA4503), a selective sigma1 receptor agonist, and 1,3-di-(2-tolyl)guanidine (DTG), a sigma1 and sigma2 receptor agonist, induce neck dystonia in rats.">
            <entity id="DS3.d775.s0.e0" origId="9907323" charOffset="130-201" type="compound" text="1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)piperazine dihydrochloride"/>
            <entity id="DS3.d775.s0.e1" origId="Q9R0C9" charOffset="224-239" type="protein" text="sigma1 receptor"/>
            <entity id="DS3.d775.s0.e2" origId="7333" charOffset="253-278" type="compound" text="1,3-di-(2-tolyl)guanidine"/>
            <entity id="DS3.d775.s0.e3" origId="Q9R0C9" charOffset="288-314" type="protein" text="sigma1 and sigma2 receptor"/>
            <pair e1="DS3.d775.s0.e0" e2="DS3.d775.s0.e3" id="DS3.d775.s0.i0" interaction="False" />
            <pair e1="DS3.d775.s0.e0" e2="DS3.d775.s0.e1" id="DS3.d775.s0.i1" interaction="False" />
            <pair e1="DS3.d775.s0.e2" e2="DS3.d775.s0.e3" id="DS3.d775.s0.i2" interaction="False" />
            <pair e1="DS3.d775.s0.e2" e2="DS3.d775.s0.e1" id="DS3.d775.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d776" origId="9972858">
        <sentence id="DS3.d776.s0" origId="9972858-1" text="The hypothesis that the selective activation of cyclic AMP (cAMP) signal transduction pathways will suppress the initiation of cocaine self-administration was examined in this investigation.">
            <entity id="DS3.d776.s0.e0" origId="P49913,J3KNB4" charOffset="60-64" type="protein" text="cAMP"/>
            <entity id="DS3.d776.s0.e1" origId="446220" charOffset="127-134" type="compound" text="cocaine"/>
            <pair e1="DS3.d776.s0.e1" e2="DS3.d776.s0.e0" id="DS3.d776.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d776.s1" origId="9972858-2" text="To test this hypothesis, the effects of the administration of the cAMP-specific (type IV) phosphodiesterase inhibitors, rolipram and Ro 20-1724, on cocaine self-administration were determined.">
            <entity id="DS3.d776.s1.e0" origId="P49913,J3KNB4" charOffset="66-70" type="protein" text="cAMP"/>
            <entity id="DS3.d776.s1.e1" origId="5092" charOffset="120-128" type="compound" text="rolipram"/>
            <entity id="DS3.d776.s1.e2" origId="446220" charOffset="148-155" type="compound" text="cocaine"/>
            <pair e1="DS3.d776.s1.e2" e2="DS3.d776.s1.e0" id="DS3.d776.s1.i0" interaction="False" />
            <pair e1="DS3.d776.s1.e1" e2="DS3.d776.s1.e0" id="DS3.d776.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d776.s2" origId="9972858-8" text="These results suggest that cAMP-specific phosphodiesterase inhibitors may inhibit the initiation of operant responding for either cocaine or food.">
            <entity id="DS3.d776.s2.e0" origId="P49913,J3KNB4" charOffset="27-31" type="protein" text="cAMP"/>
            <entity id="DS3.d776.s2.e1" origId="446220" charOffset="130-137" type="compound" text="cocaine"/>
            <pair e1="DS3.d776.s2.e1" e2="DS3.d776.s2.e0" id="DS3.d776.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d777" origId="9972861">
        <sentence id="DS3.d777.s0" origId="9972861-3" text="In a passive avoidance test synthetic TFF3/monomer or 0.9% sodium chloride (control) was injected bilaterally into the basolateral nucleus of the amygdala of male rats either immediately (consolidation test) or 23 h after a footshock (retrieval test).">
            <entity id="DS3.d777.s0.e0" origId="Q03191,A0A0G2JSY6" charOffset="38-42" type="protein" text="TFF3"/>
            <entity id="DS3.d777.s0.e1" origId="5234" charOffset="59-74" type="compound" text="sodium chloride"/>
            <pair e1="DS3.d777.s0.e1" e2="DS3.d777.s0.e0" id="DS3.d777.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d778" origId="9972869">
        <sentence id="DS3.d778.s0" origId="9972869-2" text="Although many theories for this effect have been suggested, for example, an increase in superoxide dismutase (SOD) activity, the mechanism of action has yet to be elucidated.">
            <entity id="DS3.d778.s0.e0" origId="5359597" charOffset="88-98" type="compound" text="superoxide"/>
            <entity id="DS3.d778.s0.e1" origId="P61851,M9PF91" charOffset="110-113" type="protein" text="SOD"/>
            <pair e1="DS3.d778.s0.e0" e2="DS3.d778.s0.e1" id="DS3.d778.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d779" origId="9972870">
        <sentence id="DS3.d779.s0" origId="9972870-1" text="It has been established that oligodendrocytes, the myelin forming cells, participate in iron homeostasis through the synthesis and secretion of Transferrin.">
            <entity id="DS3.d779.s0.e0" origId="23925,67172434" charOffset="88-92" type="compound" text="iron"/>
            <entity id="DS3.d779.s0.e1" origId="P12346" charOffset="144-155" type="protein" text="Transferrin"/>
            <pair e1="DS3.d779.s0.e0" e2="DS3.d779.s0.e1" id="DS3.d779.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d780" origId="9972872">
        <sentence id="DS3.d780.s0" origId="9972872-1" text="Myelin basic protein (MBP) and two peptides derived from MBP (MBP(1-44) and MBP(152-167)) stimulated Schwann cell (SC) proliferation in a cAMP-mediated process.">
            <entity id="DS3.d780.s0.e0" origId="P02686,A0A024R384" charOffset="0-20" type="protein" text="Myelin basic protein"/>
            <entity id="DS3.d780.s0.e1" origId="P02686,A0A024R384" charOffset="22-25" type="protein" text="MBP"/>
            <entity id="DS3.d780.s0.e2" origId="P02686,A0A024R384" charOffset="57-60" type="protein" text="MBP"/>
            <entity id="DS3.d780.s0.e3" origId="P02686,A0A024R384" charOffset="57-60" type="protein" text="MBP"/>
            <entity id="DS3.d780.s0.e4" origId="P02686,A0A024R384" charOffset="57-60" type="protein" text="MBP"/>
            <entity id="DS3.d780.s0.e5" origId="6076" charOffset="138-142" type="compound" text="cAMP"/>
            <pair e1="DS3.d780.s0.e5" e2="DS3.d780.s0.e1" id="DS3.d780.s0.i0" interaction="False" />
            <pair e1="DS3.d780.s0.e5" e2="DS3.d780.s0.e0" id="DS3.d780.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d781" origId="9972874">
        <sentence id="DS3.d781.s0" origId="9972874-1" text="The hydrophobic myelin proteolipid protein (PLP) contains covalently bound long-chain fatty acids which are attached to intracellular cysteine residues via thioester linkages.">
            <entity id="DS3.d781.s0.e0" origId="P60201,A8K9L3,B4DI30" charOffset="16-42" type="protein" text="myelin proteolipid protein"/>
            <entity id="DS3.d781.s0.e1" origId="P60201,A8K9L3,B4DI30" charOffset="44-47" type="protein" text="PLP"/>
            <entity id="DS3.d781.s0.e2" origId="5862,90793998" charOffset="134-142" type="compound" text="cysteine"/>
            <pair e1="DS3.d781.s0.e2" e2="DS3.d781.s0.e0" id="DS3.d781.s0.i0" interaction="False" />
            <pair e1="DS3.d781.s0.e2" e2="DS3.d781.s0.e1" id="DS3.d781.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d782" origId="9972876">
        <sentence id="DS3.d782.s0" origId="9972876-0" text="GM2 promotes ciliary neurotrophic factor-dependent rescue of immortalized motor neuron-like cell (NSC-34).">
            <entity id="DS3.d782.s0.e0" origId="Q5SSH8" charOffset="0-3" type="protein" text="GM2"/>
            <entity id="DS3.d782.s0.e1" origId="P51642,Q544D1" charOffset="13-40" type="protein" text="ciliary neurotrophic factor"/>
            <entity id="DS3.d782.s0.e2" origId="5369356" charOffset="98-104" type="compound" text="NSC-34"/>
            <pair e1="DS3.d782.s0.e2" e2="DS3.d782.s0.e0" id="DS3.d782.s0.i0" interaction="False" />
            <pair e1="DS3.d782.s0.e2" e2="DS3.d782.s0.e1" id="DS3.d782.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d782.s1" origId="9972876-2" text="One of the cell lines, NSC-34 exhibited cell survival in the presence of CNTF.">
            <entity id="DS3.d782.s1.e0" origId="5369356" charOffset="23-29" type="compound" text="NSC-34"/>
            <entity id="DS3.d782.s1.e1" origId="P51642,Q544D1" charOffset="73-77" type="protein" text="CNTF"/>
            <pair e1="DS3.d782.s1.e0" e2="DS3.d782.s1.e1" id="DS3.d782.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d782.s2" origId="9972876-4" text="GM2 ganglioside is characteristic of motor neurons, and expressed highly in NSC-34.">
            <entity id="DS3.d782.s2.e0" origId="Q5SSH8" charOffset="0-3" type="protein" text="GM2"/>
            <entity id="DS3.d782.s2.e1" origId="5369356" charOffset="76-82" type="compound" text="NSC-34"/>
            <pair e1="DS3.d782.s2.e1" e2="DS3.d782.s2.e0" id="DS3.d782.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d782.s3" origId="9972876-5" text="When NSC-34 was cultured with exogenous GM2 ganglioside and CNTF, GM2 facilitated the cell survival effect of CNTF.">
            <entity id="DS3.d782.s3.e0" origId="5369356" charOffset="5-11" type="compound" text="NSC-34"/>
            <entity id="DS3.d782.s3.e1" origId="Q5SSH8" charOffset="40-43" type="protein" text="GM2"/>
            <entity id="DS3.d782.s3.e2" origId="P51642,Q544D1" charOffset="60-64" type="protein" text="CNTF"/>
            <entity id="DS3.d782.s3.e3" origId="Q5SSH8" charOffset="66-69" type="protein" text="GM2"/>
            <entity id="DS3.d782.s3.e4" origId="P51642,Q544D1" charOffset="110-114" type="protein" text="CNTF"/>
            <pair e1="DS3.d782.s3.e0" e2="DS3.d782.s3.e1" id="DS3.d782.s3.i0" interaction="False" />
            <pair e1="DS3.d782.s3.e0" e2="DS3.d782.s3.e2" id="DS3.d782.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d783" origId="9972879">
        <sentence id="DS3.d783.s0" origId="9972879-0" text="Delivery, distribution, and neuronal uptake of exogenous mannose-terminal glucocerebrosidase in the intact rat brain.">
            <entity id="DS3.d783.s0.e0" origId="206" charOffset="57-64" type="compound" text="mannose"/>
            <entity id="DS3.d783.s0.e1" origId="B2RYC9" charOffset="74-92" type="protein" text="glucocerebrosidase"/>
            <pair e1="DS3.d783.s0.e0" e2="DS3.d783.s0.e1" id="DS3.d783.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d784" origId="9972884">
        <sentence id="DS3.d784.s0" origId="9972884-3" text="The tumor growth of C6 cells transfected with GFAP cDNA was significantly reduced compared to that of control NeoC6 cells transfected only with the neomycin resistant gene.">
            <entity id="DS3.d784.s0.e0" origId="P47819" charOffset="46-50" type="protein" text="GFAP"/>
            <entity id="DS3.d784.s0.e1" origId="8378" charOffset="148-156" type="compound" text="neomycin"/>
            <pair e1="DS3.d784.s0.e1" e2="DS3.d784.s0.e0" id="DS3.d784.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d785" origId="9972901">
        <sentence id="DS3.d785.s0" origId="9972901-5" text="TnT measurements were determined from blood samples taken before surgery (A), 1 hour after onset of CPB (B), 4 hours (C), 8 hours (D), 12 hours (E), 24 hours (F), 48 hours (G) and 72 hours after CPB (H).">
            <entity id="DS3.d785.s0.e0" origId="8376" charOffset="0-3" type="compound" text="TnT"/>
            <entity id="DS3.d785.s0.e1" origId="P15086" charOffset="100-103" type="protein" text="CPB"/>
            <entity id="DS3.d785.s0.e2" origId="P15086" charOffset="195-198" type="protein" text="CPB"/>
            <pair e1="DS3.d785.s0.e0" e2="DS3.d785.s0.e1" id="DS3.d785.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d785.s1" origId="9972901-7" text="Ischaemic preconditioning decreased TnT concentration with statistical significance 1 hour after onset of CPB (preconditioned B: median 0.12+/-0.25 vs control B: median 0.32+/-0.43, p=0.03).">
            <entity id="DS3.d785.s1.e0" origId="8376" charOffset="36-39" type="compound" text="TnT"/>
            <entity id="DS3.d785.s1.e1" origId="P15086" charOffset="106-109" type="protein" text="CPB"/>
            <pair e1="DS3.d785.s1.e0" e2="DS3.d785.s1.e1" id="DS3.d785.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d786" origId="9972921">
        <sentence id="DS3.d786.s0" origId="9972921-3" text="No increase in the incidence of tumors of any type was observed in male or female Fischer 344 rats, male or female CD-1 mice, or male Sprague-Dawley rats fed atrazine at a maximum tolerated level in their diet for 24 mo.">
            <entity id="DS3.d786.s0.e0" origId="Q63493" charOffset="115-119" type="protein" text="CD-1"/>
            <entity id="DS3.d786.s0.e1" origId="2256" charOffset="158-166" type="compound" text="atrazine"/>
            <pair e1="DS3.d786.s0.e1" e2="DS3.d786.s0.e0" id="DS3.d786.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d786.s1" origId="9972921-7" text="Therefore, the mammary tumor response in female Sprague-Dawley rats following the administration of high levels of atrazine appears to be due to an acceleration of the normal reproductive aging process resulting in increased exposure to endogenous estrogen and prolactin.">
            <entity id="DS3.d786.s1.e0" origId="2256" charOffset="115-123" type="compound" text="atrazine"/>
            <entity id="DS3.d786.s1.e1" origId="P01237,B5DEM6,B2RYT1" charOffset="261-270" type="protein" text="prolactin"/>
            <pair e1="DS3.d786.s1.e0" e2="DS3.d786.s1.e1" id="DS3.d786.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d787" origId="9972923">
        <sentence id="DS3.d787.s0" origId="9972923-1" text="Since allyl alcohol and ethanol are both metabolized by alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH), ethanol could affect allyl-alcohol induced toxicity under in vivo coexposure conditions.">
            <entity id="DS3.d787.s0.e0" origId="7858" charOffset="6-19" type="compound" text="allyl alcohol"/>
            <entity id="DS3.d787.s0.e1" origId="702" charOffset="24-31" type="compound" text="ethanol"/>
            <entity id="DS3.d787.s0.e2" origId="10982484" charOffset="12-19" type="compound" text="alcohol"/>
            <entity id="DS3.d787.s0.e3" origId="P11883" charOffset="88-110" type="protein" text="aldehyde dehydrogenase"/>
            <entity id="DS3.d787.s0.e4" origId="702" charOffset="119-126" type="compound" text="ethanol"/>
            <entity id="DS3.d787.s0.e5" origId="8252" charOffset="6-11" type="compound" text="allyl"/>
            <entity id="DS3.d787.s0.e6" origId="10982484" charOffset="56-63" type="compound" text="alcohol"/>
            <pair e1="DS3.d787.s0.e5" e2="DS3.d787.s0.e3" id="DS3.d787.s0.i0" interaction="False" />
            <pair e1="DS3.d787.s0.e0" e2="DS3.d787.s0.e3" id="DS3.d787.s0.i1" interaction="False" />
            <pair e1="DS3.d787.s0.e1" e2="DS3.d787.s0.e3" id="DS3.d787.s0.i2" interaction="False" />
            <pair e1="DS3.d787.s0.e2" e2="DS3.d787.s0.e3" id="DS3.d787.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d788" origId="9972958">
        <sentence id="DS3.d788.s0" origId="9972958-1" text="OBJECTIVE: To study the response of cortisol and of prolactin (PRL) to specific stimuli in rheumatoid arthritis (RA).">
            <entity id="DS3.d788.s0.e0" origId="5754" charOffset="36-44" type="compound" text="cortisol"/>
            <entity id="DS3.d788.s0.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="52-61" type="protein" text="prolactin"/>
            <entity id="DS3.d788.s0.e2" origId="P01236,Q5I0G2,Q5THQ0" charOffset="63-66" type="protein" text="PRL"/>
            <pair e1="DS3.d788.s0.e0" e2="DS3.d788.s0.e1" id="DS3.d788.s0.i0" interaction="False" />
            <pair e1="DS3.d788.s0.e0" e2="DS3.d788.s0.e2" id="DS3.d788.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d788.s1" origId="9972958-2" text="METHODS: We measured the response of cortisol to insulin induced hypoglycemia and of PRL to thyrotropin releasing hormone (TRH) in 10 patients with active RA and in 10 paired control subjects.">
            <entity id="DS3.d788.s1.e0" origId="5754" charOffset="37-45" type="compound" text="cortisol"/>
            <entity id="DS3.d788.s1.e1" origId="P01308,I3WAC9" charOffset="49-56" type="protein" text="insulin"/>
            <entity id="DS3.d788.s1.e2" origId="P01236,Q5I0G2,Q5THQ0" charOffset="85-88" type="protein" text="PRL"/>
            <entity id="DS3.d788.s1.e3" origId="32281,638678,7098641" charOffset="92-121" type="compound" text="thyrotropin releasing hormone"/>
            <pair e1="DS3.d788.s1.e0" e2="DS3.d788.s1.e2" id="DS3.d788.s1.i0" interaction="False" />
            <pair e1="DS3.d788.s1.e0" e2="DS3.d788.s1.e1" id="DS3.d788.s1.i1" interaction="False" />
            <pair e1="DS3.d788.s1.e3" e2="DS3.d788.s1.e2" id="DS3.d788.s1.i2" interaction="False" />
            <pair e1="DS3.d788.s1.e3" e2="DS3.d788.s1.e1" id="DS3.d788.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d788.s2" origId="9972958-5" text="The PRL concentration was assessed by chemiluminescence immune assay and the cortisol concentration by radioimmunoassay.">
            <entity id="DS3.d788.s2.e0" origId="P01236,Q5I0G2,Q5THQ0" charOffset="4-7" type="protein" text="PRL"/>
            <entity id="DS3.d788.s2.e1" origId="5754" charOffset="77-85" type="compound" text="cortisol"/>
            <pair e1="DS3.d788.s2.e1" e2="DS3.d788.s2.e0" id="DS3.d788.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d788.s3" origId="9972958-6" text="RESULTS: The basal serum levels of cortisol (14.47+/-2.5 microg/dl) and PRL (10.1+/-1.3 ng/ml) in the RA group were not significantly different from those of the control group (12.3+/-1.1 microg/dl and 13.7+/-2.4 ng/ml, respectively).">
            <entity id="DS3.d788.s3.e0" origId="5754" charOffset="35-43" type="compound" text="cortisol"/>
            <entity id="DS3.d788.s3.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="72-75" type="protein" text="PRL"/>
            <pair e1="DS3.d788.s3.e0" e2="DS3.d788.s3.e1" id="DS3.d788.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d789" origId="9972959">
        <sentence id="DS3.d789.s0" origId="9972959-2" text="METHODS: We evaluated, in 10 premenopausal patients with RA and 7 age matched controls, plasma dehydroepiandrosterone (DHEA), its sulfate (DHEAS), and cortisol concentrations, together with inflammatory cytokine levels (interleukin 6 (IL-6) and IL-12), both in basal conditions and after stimulation with ovine corticotropin releasing hormone (oCRH) and with low dose intravenous (5 microg) adrenocorticotropic hormone (ACTH).">
            <entity id="DS3.d789.s0.e0" origId="5881" charOffset="95-117" type="compound" text="dehydroepiandrosterone"/>
            <entity id="DS3.d789.s0.e1" origId="1117" charOffset="130-137" type="compound" text="sulfate"/>
            <entity id="DS3.d789.s0.e2" origId="Q06520,A8K015" charOffset="139-144" type="protein" text="DHEAS"/>
            <entity id="DS3.d789.s0.e3" origId="5754" charOffset="151-159" type="compound" text="cortisol"/>
            <entity id="DS3.d789.s0.e4" origId="16132344" charOffset="344-348" type="compound" text="oCRH"/>
            <entity id="DS3.d789.s0.e5" origId="P01189,Q6FHC8" charOffset="391-418" type="protein" text="adrenocorticotropic hormone"/>
            <entity id="DS3.d789.s0.e6" origId="P01189,Q6FHC8" charOffset="420-424" type="protein" text="ACTH"/>
            <pair e1="DS3.d789.s0.e0" e2="DS3.d789.s0.e2" id="DS3.d789.s0.i0" interaction="False" />
            <pair e1="DS3.d789.s0.e0" e2="DS3.d789.s0.e6" id="DS3.d789.s0.i1" interaction="False" />
            <pair e1="DS3.d789.s0.e0" e2="DS3.d789.s0.e5" id="DS3.d789.s0.i2" interaction="False" />
            <pair e1="DS3.d789.s0.e4" e2="DS3.d789.s0.e2" id="DS3.d789.s0.i3" interaction="False" />
            <pair e1="DS3.d789.s0.e4" e2="DS3.d789.s0.e6" id="DS3.d789.s0.i4" interaction="False" />
            <pair e1="DS3.d789.s0.e4" e2="DS3.d789.s0.e5" id="DS3.d789.s0.i5" interaction="False" />
            <pair e1="DS3.d789.s0.e1" e2="DS3.d789.s0.e2" id="DS3.d789.s0.i6" interaction="False" />
            <pair e1="DS3.d789.s0.e1" e2="DS3.d789.s0.e6" id="DS3.d789.s0.i7" interaction="False" />
            <pair e1="DS3.d789.s0.e1" e2="DS3.d789.s0.e5" id="DS3.d789.s0.i8" interaction="False" />
            <pair e1="DS3.d789.s0.e3" e2="DS3.d789.s0.e2" id="DS3.d789.s0.i9" interaction="False" />
            <pair e1="DS3.d789.s0.e3" e2="DS3.d789.s0.e6" id="DS3.d789.s0.i10" interaction="False" />
            <pair e1="DS3.d789.s0.e3" e2="DS3.d789.s0.e5" id="DS3.d789.s0.i11" interaction="False" />
        </sentence>
        <sentence id="DS3.d789.s1" origId="9972959-8" text="Normal plasma cortisol levels during oCRH and ACTH testing were found in patients with RA in spite of their inflammatory condition.">
            <entity id="DS3.d789.s1.e0" origId="5754" charOffset="14-22" type="compound" text="cortisol"/>
            <entity id="DS3.d789.s1.e1" origId="16132344" charOffset="37-41" type="compound" text="oCRH"/>
            <entity id="DS3.d789.s1.e2" origId="P01189,Q6FHC8" charOffset="46-50" type="protein" text="ACTH"/>
            <pair e1="DS3.d789.s1.e1" e2="DS3.d789.s1.e2" id="DS3.d789.s1.i0" interaction="False" />
            <pair e1="DS3.d789.s1.e0" e2="DS3.d789.s1.e2" id="DS3.d789.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d790" origId="9973015">
        <sentence id="DS3.d790.s0" origId="9973015-10" text="Atropine (0.02 mg/kg) shortened the PP interval (p &amp;lt; 0.001) and the PTa interval (p &amp;lt; 0.01).">
            <entity id="DS3.d790.s0.e0" origId="174174" charOffset="0-8" type="compound" text="Atropine"/>
            <entity id="DS3.d790.s0.e1" origId="Q6ISU1,A0A087WTE9,Q6ZNR1" charOffset="71-74" type="protein" text="PTa"/>
            <pair e1="DS3.d790.s0.e0" e2="DS3.d790.s0.e1" id="DS3.d790.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d790.s1" origId="9973015-12" text="Neither disopyramide (2.0 mg/kg) nor flecainide acetate (2.0 mg/kg) altered the PP interval, but both prolonged the PTa interval (p &amp;lt; 0.001).">
            <entity id="DS3.d790.s1.e0" origId="3114" charOffset="8-20" type="compound" text="disopyramide"/>
            <entity id="DS3.d790.s1.e1" origId="3356" charOffset="37-55" type="compound" text="flecainide acetate"/>
            <entity id="DS3.d790.s1.e2" origId="Q6ISU1,A0A087WTE9,Q6ZNR1" charOffset="116-119" type="protein" text="PTa"/>
            <pair e1="DS3.d790.s1.e0" e2="DS3.d790.s1.e2" id="DS3.d790.s1.i0" interaction="False" />
            <pair e1="DS3.d790.s1.e1" e2="DS3.d790.s1.e2" id="DS3.d790.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d791" origId="9973024">
        <sentence id="DS3.d791.s0" origId="9973024-1" text="OBJECTIVES: To examine the association between the fractional esterification rate of cholesterol (C) in low density lipoprotein- and very low density lipoprotein-depleted plasma (FER(HDL)) and coronary artery disease (CAD) and the influence of serum HDL-C levels.">
            <entity id="DS3.d791.s0.e0" origId="5997" charOffset="85-96" type="compound" text="cholesterol"/>
            <entity id="DS3.d791.s0.e1" origId="P28845,X5D2L1" charOffset="183-186" type="protein" text="HDL"/>
            <entity id="DS3.d791.s0.e2" origId="P28845,X5D2L1" charOffset="250-255" type="protein" text="HDL-C"/>
            <pair e1="DS3.d791.s0.e0" e2="DS3.d791.s0.e2" id="DS3.d791.s0.i0" interaction="False" />
            <pair e1="DS3.d791.s0.e0" e2="DS3.d791.s0.e1" id="DS3.d791.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d791.s1" origId="9973024-2" text="BACKGROUND: The function of HDL in reverse cholesterol transport is involved in the antiatherogenic action of HDL, and FER(HDL) is a newly established quantitative measure of HDL function in vivo.">
            <entity id="DS3.d791.s1.e0" origId="P28845,X5D2L1" charOffset="28-31" type="protein" text="HDL"/>
            <entity id="DS3.d791.s1.e1" origId="5997" charOffset="43-54" type="compound" text="cholesterol"/>
            <entity id="DS3.d791.s1.e2" origId="P28845,X5D2L1" charOffset="110-113" type="protein" text="HDL"/>
            <entity id="DS3.d791.s1.e3" origId="P28845,X5D2L1" charOffset="110-113" type="protein" text="HDL"/>
            <entity id="DS3.d791.s1.e4" origId="P28845,X5D2L1" charOffset="110-113" type="protein" text="HDL"/>
            <pair e1="DS3.d791.s1.e1" e2="DS3.d791.s1.e0" id="DS3.d791.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d792" origId="9973025">
        <sentence id="DS3.d792.s0" origId="9973025-10" text="Multiple logistic regression analysis determined male sex, presence of diabetes and left anterior descending (LAD) and circumflex (LCx) coronary calcium scores, independent from more distal calcium localization, as independent predictors for identification of three-vessel and/or left main CAD.">
            <entity id="DS3.d792.s0.e0" origId="Q8NFU7" charOffset="131-134" type="protein" text="LCx"/>
            <entity id="DS3.d792.s0.e1" origId="22044544,5460341" charOffset="145-152" type="compound" text="calcium"/>
            <entity id="DS3.d792.s0.e2" origId="22044544,5460341" charOffset="190-197" type="compound" text="calcium"/>
            <pair e1="DS3.d792.s0.e1" e2="DS3.d792.s0.e0" id="DS3.d792.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d793" origId="9973033">
        <sentence id="DS3.d793.s0" origId="9973033-2" text="BACKGROUND: Dobutamine-atropine stress echocardiography (DASE) accurately detects scar, reversible dysfunction and the extent of coronary artery disease in LVD.">
            <entity id="DS3.d793.s0.e0" origId="36811" charOffset="12-22" type="compound" text="Dobutamine"/>
            <entity id="DS3.d793.s0.e1" origId="174174" charOffset="23-31" type="compound" text="atropine"/>
            <entity id="DS3.d793.s0.e2" origId="P62701,B2R491" charOffset="82-86" type="protein" text="scar"/>
            <pair e1="DS3.d793.s0.e1" e2="DS3.d793.s0.e2" id="DS3.d793.s0.i0" interaction="False" />
            <pair e1="DS3.d793.s0.e0" e2="DS3.d793.s0.e2" id="DS3.d793.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d793.s1" origId="9973033-4" text="Dobutamine-atropine stress echocardiographic findings were classified according to sustained improvement in all vascular territories, scar, inducible ischemia (worsening wall motion at peak dose only or biphasic responses) and their extent.">
            <entity id="DS3.d793.s1.e0" origId="36811" charOffset="0-10" type="compound" text="Dobutamine"/>
            <entity id="DS3.d793.s1.e1" origId="174174" charOffset="11-19" type="compound" text="atropine"/>
            <entity id="DS3.d793.s1.e2" origId="P62701,B2R491" charOffset="134-138" type="protein" text="scar"/>
            <pair e1="DS3.d793.s1.e1" e2="DS3.d793.s1.e2" id="DS3.d793.s1.i0" interaction="False" />
            <pair e1="DS3.d793.s1.e0" e2="DS3.d793.s1.e2" id="DS3.d793.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d794" origId="9973096">
        <sentence id="DS3.d794.s0" origId="9973096-11" text="The shape and size of actin- and/or myosin-positive stromal cells from a 72-year-old donor culture were also usually larger and polygonal in shape as compared to thin and elongated shapes in 15-year-old donor cultures.">
            <entity id="DS3.d794.s0.e0" origId="Q7Z406,A1L2Z2,B3KWH4" charOffset="36-42" type="protein" text="myosin"/>
            <entity id="DS3.d794.s0.e1" origId="71405072" charOffset="128-137" type="compound" text="polygonal"/>
            <pair e1="DS3.d794.s0.e1" e2="DS3.d794.s0.e0" id="DS3.d794.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d794.s1" origId="9973096-4" text="Cell phenotype was assessed by immunocytochemical staining for smooth muscle alpha-actin, smooth muscle myosin, and prolyl-4-hydroxylase.">
            <entity id="DS3.d794.s1.e0" origId="Q7Z406,A1L2Z2,B3KWH4" charOffset="104-110" type="protein" text="myosin"/>
            <entity id="DS3.d794.s1.e1" origId="3323161,445997" charOffset="116-122" type="compound" text="prolyl"/>
            <pair e1="DS3.d794.s1.e1" e2="DS3.d794.s1.e0" id="DS3.d794.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d795" origId="9973101">
        <sentence id="DS3.d795.s0" origId="9973101-2" text="Doxorubicin derivative 2-pyrrolinodoxorubicin (AN-201) can be linked to carrier analog (D-Lys6)LH-RH to form the targeted cytotoxic analog of LH-RH, AN-207.">
            <entity id="DS3.d795.s0.e0" origId="31703" charOffset="0-11" type="compound" text="Doxorubicin"/>
            <entity id="DS3.d795.s0.e1" origId="119196" charOffset="23-45" type="compound" text="2-pyrrolinodoxorubicin"/>
            <entity id="DS3.d795.s0.e2" origId="P13562,Q3UTE9" charOffset="95-100" type="protein" text="LH-RH"/>
            <entity id="DS3.d795.s0.e3" origId="P13562,Q3UTE9" charOffset="142-147" type="protein" text="LH-RH"/>
            <pair e1="DS3.d795.s0.e0" e2="DS3.d795.s0.e2" id="DS3.d795.s0.i0" interaction="False" />
            <pair e1="DS3.d795.s0.e1" e2="DS3.d795.s0.e2" id="DS3.d795.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d796" origId="9973104">
        <sentence id="DS3.d796.s0" origId="9973104-12" text="The basal cells in ventral prostate might express more complex glycoconjugates, as they were also stained by PWA, RCA-I, ECA, and PHA-L, in addition to GS-I-B4, suggesting that these basal cells contained more Gal(beta1,4)GlcNAc and Gal(beta1,4)GlcNAc(alpha1,2)Man residues.">
            <entity id="DS3.d796.s0.e0" origId="24139,11861101,439174,899" charOffset="222-228" type="compound" text="GlcNAc"/>
            <entity id="DS3.d796.s0.e1" origId="24139,11861101,439174,899" charOffset="245-251" type="compound" text="GlcNAc"/>
            <entity id="DS3.d796.s0.e2" origId="P25100,B0ZBE0" charOffset="252-260" type="protein" text="alpha1,2"/>
            <pair e1="DS3.d796.s0.e0" e2="DS3.d796.s0.e2" id="DS3.d796.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d796.s1" origId="9973104-7" text="Two types of cytoplasmic belbs were also identified according to their lectin bindings: blebs stained by S-Con A, LCA, PWA, UEA-II, RCA-I, DBA, ECA, WFA, Jacalin, MPA, SJA, LTA, UEA-I, PHA-E, and PHA-L, and some blebs stained by S-WGA, SBA, HAA, HPA, VAA, BPA, MAA, and SNA.">
            <entity id="DS3.d796.s1.e0" origId="Q06332" charOffset="173-176" type="protein" text="LTA"/>
            <entity id="DS3.d796.s1.e1" origId="445811" charOffset="251-254" type="compound" text="VAA"/>
            <pair e1="DS3.d796.s1.e1" e2="DS3.d796.s1.e0" id="DS3.d796.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d797" origId="9973106">
        <sentence id="DS3.d797.s0" origId="9973106-5" text="The multivariate analysis of PICP, ICTP, ALP, PSA, and extent of disease (EOD) grade revealed that only the EOD grade was an important prognostic indicator for survival.">
            <entity id="DS3.d797.s0.e0" origId="P05187,B2R7C7" charOffset="41-44" type="protein" text="ALP"/>
            <entity id="DS3.d797.s0.e1" origId="P07225" charOffset="46-49" type="protein" text="PSA"/>
            <entity id="DS3.d797.s0.e2" origId="11963498" charOffset="74-77" type="compound" text="EOD"/>
            <entity id="DS3.d797.s0.e3" origId="11963498" charOffset="108-111" type="compound" text="EOD"/>
            <pair e1="DS3.d797.s0.e2" e2="DS3.d797.s0.e1" id="DS3.d797.s0.i0" interaction="False" />
            <pair e1="DS3.d797.s0.e2" e2="DS3.d797.s0.e0" id="DS3.d797.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d798" origId="9973140">
        <sentence id="DS3.d798.s0" origId="9973140-3" text="Spermatobioscopies were performed, and serum urea, creatinine, luteinizing hormone (LH), follicle-stimulating hormone (FSH), prolactin (PRL), and testosterone (T) levels were determined.">
            <entity id="DS3.d798.s0.e0" origId="1176" charOffset="45-49" type="compound" text="urea"/>
            <entity id="DS3.d798.s0.e1" origId="588" charOffset="51-61" type="compound" text="creatinine"/>
            <entity id="DS3.d798.s0.e2" origId="P01236,Q5I0G2,Q5THQ0" charOffset="125-134" type="protein" text="prolactin"/>
            <entity id="DS3.d798.s0.e3" origId="P01236,Q5I0G2,Q5THQ0" charOffset="136-139" type="protein" text="PRL"/>
            <entity id="DS3.d798.s0.e4" origId="6013" charOffset="146-158" type="compound" text="testosterone"/>
            <pair e1="DS3.d798.s0.e1" e2="DS3.d798.s0.e2" id="DS3.d798.s0.i0" interaction="False" />
            <pair e1="DS3.d798.s0.e1" e2="DS3.d798.s0.e3" id="DS3.d798.s0.i1" interaction="False" />
            <pair e1="DS3.d798.s0.e0" e2="DS3.d798.s0.e2" id="DS3.d798.s0.i2" interaction="False" />
            <pair e1="DS3.d798.s0.e0" e2="DS3.d798.s0.e3" id="DS3.d798.s0.i3" interaction="False" />
            <pair e1="DS3.d798.s0.e4" e2="DS3.d798.s0.e2" id="DS3.d798.s0.i4" interaction="False" />
            <pair e1="DS3.d798.s0.e4" e2="DS3.d798.s0.e3" id="DS3.d798.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d799" origId="9973150">
        <sentence id="DS3.d799.s0" origId="9973150-7" text="These two atypical ANCA became cANCA when paraformaldehyde fixation was applied.">
            <entity id="DS3.d799.s0.e0" origId="P24158" charOffset="31-36" type="protein" text="cANCA"/>
            <entity id="DS3.d799.s0.e1" origId="712" charOffset="42-58" type="compound" text="paraformaldehyde"/>
            <pair e1="DS3.d799.s0.e1" e2="DS3.d799.s0.e0" id="DS3.d799.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d800" origId="9973179">
        <sentence id="DS3.d800.s0" origId="9973179-1" text="Two model substrates, rac-1-(3-phenoxy-(ring-14C)benzoyl)-2,3-dipalmitoyl glycerol (1(3PBA)DPG) and sn-2-(3-phenoxy-(ring-14C)benzoyl)-1,3-dipalmitoyl glycerol (2(3PBA)DPG), were compared with tri(1-14C)palmitoylglycerol or tri(9,10(n)-3H)oleoylglycerol as substrates for pancreatic lipase, lipoprotein lipase, and hormone-sensitive lipase.">
            <entity id="DS3.d800.s0.e0" origId="P63000,A4D2P0,A4D2P1" charOffset="22-27" type="protein" text="rac-1"/>
            <entity id="DS3.d800.s0.e1" origId="99931" charOffset="62-82" type="compound" text="dipalmitoyl glycerol"/>
            <entity id="DS3.d800.s0.e2" origId="99931" charOffset="139-159" type="compound" text="dipalmitoyl glycerol"/>
            <entity id="DS3.d800.s0.e3" origId="53681616" charOffset="203-220" type="compound" text="palmitoylglycerol"/>
            <entity id="DS3.d800.s0.e4" origId="5283468" charOffset="239-253" type="compound" text="oleoylglycerol"/>
            <entity id="DS3.d800.s0.e5" origId="P16233" charOffset="272-289" type="protein" text="pancreatic lipase"/>
            <entity id="DS3.d800.s0.e6" origId="P06858" charOffset="291-309" type="protein" text="lipoprotein lipase"/>
            <entity id="DS3.d800.s0.e7" origId="5474737" charOffset="283-289" type="compound" text="lipase"/>
            <pair e1="DS3.d800.s0.e1" e2="DS3.d800.s0.e0" id="DS3.d800.s0.i0" interaction="False" />
            <pair e1="DS3.d800.s0.e1" e2="DS3.d800.s0.e6" id="DS3.d800.s0.i1" interaction="False" />
            <pair e1="DS3.d800.s0.e1" e2="DS3.d800.s0.e5" id="DS3.d800.s0.i2" interaction="False" />
            <pair e1="DS3.d800.s0.e3" e2="DS3.d800.s0.e0" id="DS3.d800.s0.i3" interaction="False" />
            <pair e1="DS3.d800.s0.e3" e2="DS3.d800.s0.e6" id="DS3.d800.s0.i4" interaction="False" />
            <pair e1="DS3.d800.s0.e3" e2="DS3.d800.s0.e5" id="DS3.d800.s0.i5" interaction="False" />
            <pair e1="DS3.d800.s0.e7" e2="DS3.d800.s0.e0" id="DS3.d800.s0.i6" interaction="False" />
            <pair e1="DS3.d800.s0.e7" e2="DS3.d800.s0.e6" id="DS3.d800.s0.i7" interaction="False" />
            <pair e1="DS3.d800.s0.e7" e2="DS3.d800.s0.e5" id="DS3.d800.s0.i8" interaction="False" />
            <pair e1="DS3.d800.s0.e4" e2="DS3.d800.s0.e0" id="DS3.d800.s0.i9" interaction="False" />
            <pair e1="DS3.d800.s0.e4" e2="DS3.d800.s0.e6" id="DS3.d800.s0.i10" interaction="False" />
            <pair e1="DS3.d800.s0.e4" e2="DS3.d800.s0.e5" id="DS3.d800.s0.i11" interaction="False" />
        </sentence>
        <sentence id="DS3.d800.s1" origId="9973179-3" text="The loss of 3PBA from the rac-1 position was similarly low with hormone-sensitive lipase (about 7% of the loss of oleate), but higher with pancreatic lipase (about 35% that of oleate) and lipoprotein lipase (about 23% that of oleate).">
            <entity id="DS3.d800.s1.e0" origId="P63000,A4D2P0,A4D2P1" charOffset="26-31" type="protein" text="rac-1"/>
            <entity id="DS3.d800.s1.e1" origId="5474737" charOffset="82-88" type="compound" text="lipase"/>
            <entity id="DS3.d800.s1.e2" origId="445639" charOffset="114-120" type="compound" text="oleate"/>
            <entity id="DS3.d800.s1.e3" origId="P16233" charOffset="139-156" type="protein" text="pancreatic lipase"/>
            <entity id="DS3.d800.s1.e4" origId="445639" charOffset="176-182" type="compound" text="oleate"/>
            <entity id="DS3.d800.s1.e5" origId="P06858" charOffset="188-206" type="protein" text="lipoprotein lipase"/>
            <entity id="DS3.d800.s1.e6" origId="445639" charOffset="176-182" type="compound" text="oleate"/>
            <pair e1="DS3.d800.s1.e2" e2="DS3.d800.s1.e0" id="DS3.d800.s1.i0" interaction="False" />
            <pair e1="DS3.d800.s1.e2" e2="DS3.d800.s1.e5" id="DS3.d800.s1.i1" interaction="False" />
            <pair e1="DS3.d800.s1.e2" e2="DS3.d800.s1.e3" id="DS3.d800.s1.i2" interaction="False" />
            <pair e1="DS3.d800.s1.e1" e2="DS3.d800.s1.e0" id="DS3.d800.s1.i3" interaction="False" />
            <pair e1="DS3.d800.s1.e1" e2="DS3.d800.s1.e5" id="DS3.d800.s1.i4" interaction="False" />
            <pair e1="DS3.d800.s1.e1" e2="DS3.d800.s1.e3" id="DS3.d800.s1.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d800.s2" origId="9973179-5" text="lipoprotein lipase acting on 1-(14C-3PBA)DPG produced nearly 70% of its product as nonesterified 3PBA and only 25% as the diacylglycerol.">
            <entity id="DS3.d800.s2.e0" origId="P06858" charOffset="0-18" type="protein" text="lipoprotein lipase"/>
            <entity id="DS3.d800.s2.e1" origId="6026790" charOffset="122-136" type="compound" text="diacylglycerol"/>
            <pair e1="DS3.d800.s2.e1" e2="DS3.d800.s2.e0" id="DS3.d800.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d801" origId="9973180">
        <sentence id="DS3.d801.s0" origId="9973180-0" text="The metabolism of the xenobiotic triacylglycerols, rac-1- and sn-2- (3-phenoxybenzoyl)-dipalmitoylglycerol, following intravenous administration to the rat.">
            <entity id="DS3.d801.s0.e0" origId="Q6RUV5" charOffset="51-56" type="protein" text="rac-1"/>
            <entity id="DS3.d801.s0.e1" origId="88060" charOffset="71-85" type="compound" text="phenoxybenzoyl"/>
            <entity id="DS3.d801.s0.e2" origId="18665592" charOffset="87-106" type="compound" text="dipalmitoylglycerol"/>
            <pair e1="DS3.d801.s0.e2" e2="DS3.d801.s0.e0" id="DS3.d801.s0.i0" interaction="False" />
            <pair e1="DS3.d801.s0.e1" e2="DS3.d801.s0.e0" id="DS3.d801.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d801.s1" origId="9973180-2" text='Three radiolabeled triacylglycerols (rac-1-(3-phenoxy-(ring-14C)-benzoyl)-2,3-dipalmitoylglycerol (1(3PBA)DPG), sn-2-(3-phenoxy-(ring-14C)benzoyl)-1,3-dipalmitoylglycerol (2(3PBA)DPG) and the "natural" tri-(1-14C)oleoylglycerol) were incorporated into rat VLDL.'>
            <entity id="DS3.d801.s1.e0" origId="Q6RUV5" charOffset="37-42" type="protein" text="rac-1"/>
            <entity id="DS3.d801.s1.e1" origId="18665592" charOffset="78-97" type="compound" text="dipalmitoylglycerol"/>
            <entity id="DS3.d801.s1.e2" origId="68149" charOffset="147-170" type="compound" text="1,3-dipalmitoylglycerol"/>
            <entity id="DS3.d801.s1.e3" origId="5283468" charOffset="213-227" type="compound" text="oleoylglycerol"/>
            <pair e1="DS3.d801.s1.e1" e2="DS3.d801.s1.e0" id="DS3.d801.s1.i0" interaction="False" />
            <pair e1="DS3.d801.s1.e2" e2="DS3.d801.s1.e0" id="DS3.d801.s1.i1" interaction="False" />
            <pair e1="DS3.d801.s1.e3" e2="DS3.d801.s1.e0" id="DS3.d801.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d802" origId="9973187">
        <sentence id="DS3.d802.s0" origId="9973187-0" text="Methoxyresorufin: an inappropriate substrate for CYP1A2 in the mouse.">
            <entity id="DS3.d802.s0.e0" origId="119220" charOffset="0-16" type="compound" text="Methoxyresorufin"/>
            <entity id="DS3.d802.s0.e1" origId="P00186,B6VGH4" charOffset="49-55" type="protein" text="CYP1A2"/>
            <pair e1="DS3.d802.s0.e0" e2="DS3.d802.s0.e1" id="DS3.d802.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d802.s1" origId="9973187-1" text="Hepatic microsomes derived from Cypla2(-/-) knockout (KO) and parental strains of mice, C57BL/6N and 129Sv, were used to examine the specificity of methoxyresorufin and acetanilide as substrates for CYP1A2 activity.">
            <entity id="DS3.d802.s1.e0" origId="119220" charOffset="148-164" type="compound" text="methoxyresorufin"/>
            <entity id="DS3.d802.s1.e1" origId="904" charOffset="169-180" type="compound" text="acetanilide"/>
            <entity id="DS3.d802.s1.e2" origId="P00186,B6VGH4" charOffset="199-205" type="protein" text="CYP1A2"/>
            <pair e1="DS3.d802.s1.e1" e2="DS3.d802.s1.e2" id="DS3.d802.s1.i0" interaction="False" />
            <pair e1="DS3.d802.s1.e0" e2="DS3.d802.s1.e2" id="DS3.d802.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d802.s2" origId="9973187-3" text="As expected, microsomes from untreated 1a2 KO mice did not have immunodetectable CYP1A2 protein; however, methoxyresorufin-O-demethylase (MROD, 25.5+/-6.1 pmol/min/mg protein) and acetanilide-4-hydroxylation (ACOH, 0.64+/-0.04 nmol/min/mg protein) activities were still present.">
            <entity id="DS3.d802.s2.e0" origId="P00186,B6VGH4" charOffset="81-87" type="protein" text="CYP1A2"/>
            <entity id="DS3.d802.s2.e1" origId="119220" charOffset="106-122" type="compound" text="methoxyresorufin"/>
            <entity id="DS3.d802.s2.e2" origId="904" charOffset="180-191" type="compound" text="acetanilide"/>
            <entity id="DS3.d802.s2.e3" origId="176" charOffset="209-213" type="compound" text="ACOH"/>
            <pair e1="DS3.d802.s2.e3" e2="DS3.d802.s2.e0" id="DS3.d802.s2.i0" interaction="False" />
            <pair e1="DS3.d802.s2.e2" e2="DS3.d802.s2.e0" id="DS3.d802.s2.i1" interaction="False" />
            <pair e1="DS3.d802.s2.e1" e2="DS3.d802.s2.e0" id="DS3.d802.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d802.s3" origId="9973187-8" text="Results indicate that both substrates are subject to metabolism by non-CYP1A2 sources, and the apparent contribution of CYP1A1 activity to methoxyresorufin metabolism makes MROD unsuitable for differentiating CYP1A1 and CYP1A2 activities in the mouse.">
            <entity id="DS3.d802.s3.e0" origId="P00186,B6VGH4" charOffset="71-77" type="protein" text="CYP1A2"/>
            <entity id="DS3.d802.s3.e1" origId="P00184,Q05A20" charOffset="120-126" type="protein" text="CYP1A1"/>
            <entity id="DS3.d802.s3.e2" origId="119220" charOffset="139-155" type="compound" text="methoxyresorufin"/>
            <entity id="DS3.d802.s3.e3" origId="P00184,Q05A20" charOffset="209-215" type="protein" text="CYP1A1"/>
            <entity id="DS3.d802.s3.e4" origId="P00186,B6VGH4" charOffset="220-226" type="protein" text="CYP1A2"/>
            <pair e1="DS3.d802.s3.e2" e2="DS3.d802.s3.e1" id="DS3.d802.s3.i0" interaction="False" />
            <pair e1="DS3.d802.s3.e2" e2="DS3.d802.s3.e0" id="DS3.d802.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d803" origId="9973188">
        <sentence id="DS3.d803.s0" origId="9973188-2" text="Gold sodium thiomalate (GSTM) impaired the ability of interleukin 1beta (IL-1beta)-stimulated human umbilical vein endothelial cells (HUVEC) to express E-selectin and to bind PMN but had no effect on the expression of intercellular adhesion molecule 1 (ICAM-1) or on hyperadhesivity of N-formyl-methionyl-leucyl-phenylalanine (fMLP)-stimulated PMN.">
            <entity id="DS3.d803.s0.e0" origId="23985" charOffset="0-4" type="compound" text="Gold"/>
            <entity id="DS3.d803.s0.e1" origId="11193418" charOffset="5-22" type="compound" text="sodium thiomalate"/>
            <entity id="DS3.d803.s0.e2" origId="P01584" charOffset="54-71" type="protein" text="interleukin 1beta"/>
            <entity id="DS3.d803.s0.e3" origId="P01584" charOffset="73-81" type="protein" text="IL-1beta"/>
            <entity id="DS3.d803.s0.e4" origId="P16581" charOffset="152-162" type="protein" text="E-selectin"/>
            <entity id="DS3.d803.s0.e5" origId="P05362" charOffset="218-251" type="protein" text="intercellular adhesion molecule 1"/>
            <entity id="DS3.d803.s0.e6" origId="P05362" charOffset="253-259" type="protein" text="ICAM-1"/>
            <entity id="DS3.d803.s0.e7" origId="P21462" charOffset="286-325" type="protein" text="N-formyl-methionyl-leucyl-phenylalanine"/>
            <entity id="DS3.d803.s0.e8" origId="P21462" charOffset="327-331" type="protein" text="fMLP"/>
            <pair e1="DS3.d803.s0.e1" e2="DS3.d803.s0.e4" id="DS3.d803.s0.i0" interaction="False" />
            <pair e1="DS3.d803.s0.e1" e2="DS3.d803.s0.e7" id="DS3.d803.s0.i1" interaction="False" />
            <pair e1="DS3.d803.s0.e1" e2="DS3.d803.s0.e8" id="DS3.d803.s0.i2" interaction="False" />
            <pair e1="DS3.d803.s0.e1" e2="DS3.d803.s0.e3" id="DS3.d803.s0.i3" interaction="False" />
            <pair e1="DS3.d803.s0.e1" e2="DS3.d803.s0.e5" id="DS3.d803.s0.i4" interaction="False" />
            <pair e1="DS3.d803.s0.e1" e2="DS3.d803.s0.e6" id="DS3.d803.s0.i5" interaction="False" />
            <pair e1="DS3.d803.s0.e1" e2="DS3.d803.s0.e2" id="DS3.d803.s0.i6" interaction="False" />
            <pair e1="DS3.d803.s0.e0" e2="DS3.d803.s0.e4" id="DS3.d803.s0.i7" interaction="False" />
            <pair e1="DS3.d803.s0.e0" e2="DS3.d803.s0.e7" id="DS3.d803.s0.i8" interaction="False" />
            <pair e1="DS3.d803.s0.e0" e2="DS3.d803.s0.e8" id="DS3.d803.s0.i9" interaction="False" />
            <pair e1="DS3.d803.s0.e0" e2="DS3.d803.s0.e3" id="DS3.d803.s0.i10" interaction="False" />
            <pair e1="DS3.d803.s0.e0" e2="DS3.d803.s0.e5" id="DS3.d803.s0.i11" interaction="False" />
            <pair e1="DS3.d803.s0.e0" e2="DS3.d803.s0.e6" id="DS3.d803.s0.i12" interaction="False" />
            <pair e1="DS3.d803.s0.e0" e2="DS3.d803.s0.e2" id="DS3.d803.s0.i13" interaction="False" />
        </sentence>
        <sentence id="DS3.d803.s1" origId="9973188-3" text="Auranofin (AF) interacted with HUVEC and PMN adhesiveness but in opposite directions: this drug hampered IL-1beta-induced HUVEC hyperadhesiveness and expression of E-selectin and intercellular adhesion molecule 1, but augmented PMN adherence and CD18 expression.">
            <entity id="DS3.d803.s1.e0" origId="88293" charOffset="0-9" type="compound" text="Auranofin"/>
            <entity id="DS3.d803.s1.e1" origId="P01584" charOffset="105-113" type="protein" text="IL-1beta"/>
            <entity id="DS3.d803.s1.e2" origId="P16581" charOffset="164-174" type="protein" text="E-selectin"/>
            <entity id="DS3.d803.s1.e3" origId="P05362" charOffset="179-212" type="protein" text="intercellular adhesion molecule 1"/>
            <entity id="DS3.d803.s1.e4" origId="P05107,B4E0R1" charOffset="246-250" type="protein" text="CD18"/>
            <pair e1="DS3.d803.s1.e0" e2="DS3.d803.s1.e2" id="DS3.d803.s1.i0" interaction="False" />
            <pair e1="DS3.d803.s1.e0" e2="DS3.d803.s1.e1" id="DS3.d803.s1.i1" interaction="False" />
            <pair e1="DS3.d803.s1.e0" e2="DS3.d803.s1.e4" id="DS3.d803.s1.i2" interaction="False" />
            <pair e1="DS3.d803.s1.e0" e2="DS3.d803.s1.e3" id="DS3.d803.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d803.s2" origId="9973188-5" text="Salazopyrin did not affect HUVEC or PMN adhesiveness or E-selectin and intercellular adhesion molecule 1 expression.">
            <entity id="DS3.d803.s2.e0" origId="5359476" charOffset="0-11" type="compound" text="Salazopyrin"/>
            <entity id="DS3.d803.s2.e1" origId="P16581" charOffset="56-66" type="protein" text="E-selectin"/>
            <entity id="DS3.d803.s2.e2" origId="P05362" charOffset="71-104" type="protein" text="intercellular adhesion molecule 1"/>
            <pair e1="DS3.d803.s2.e0" e2="DS3.d803.s2.e1" id="DS3.d803.s2.i0" interaction="False" />
            <pair e1="DS3.d803.s2.e0" e2="DS3.d803.s2.e2" id="DS3.d803.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d804" origId="9973190">
        <sentence id="DS3.d804.s0" origId="9973190-4" text="A novel gene designated MASL1 (MFH-amplified sequences with leucine-rich tandem repeats 1) was isolated from within this narrowly defined region.">
            <entity id="DS3.d804.s0.e0" origId="Q9Y4C4" charOffset="24-29" type="protein" text="MASL1"/>
            <entity id="DS3.d804.s0.e1" origId="6106" charOffset="60-67" type="compound" text="leucine"/>
            <pair e1="DS3.d804.s0.e1" e2="DS3.d804.s0.e0" id="DS3.d804.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d805" origId="9973196">
        <sentence id="DS3.d805.s0" origId="9973196-4" text="Expression of hMLH1 restored normal levels of mPMS2 protein, reduced spontaneous base substitution and microsatellite mutations, increased sensitivity to the toxic effects of 6-thioguanine (6-TG), and restored 6-TG-induced cell cycle arrest.">
            <entity id="DS3.d805.s0.e0" origId="P40692,A0A024R2S9,Q59EG3" charOffset="14-19" type="protein" text="hMLH1"/>
            <entity id="DS3.d805.s0.e1" origId="B9EJ22" charOffset="46-51" type="protein" text="mPMS2"/>
            <entity id="DS3.d805.s0.e2" origId="2723601" charOffset="177-188" type="compound" text="thioguanine"/>
            <pair e1="DS3.d805.s0.e2" e2="DS3.d805.s0.e1" id="DS3.d805.s0.i0" interaction="False" />
            <pair e1="DS3.d805.s0.e2" e2="DS3.d805.s0.e0" id="DS3.d805.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d806" origId="9973197">
        <sentence id="DS3.d806.s0" origId="9973197-3" text="Inhibition of PI 3-K activity by nanomolar concentrations of wortmannin and of its expression by transfection with an antisense fragment of p85alpha prevented the differentiative process.">
            <entity id="DS3.d806.s0.e0" origId="312145" charOffset="61-71" type="compound" text="wortmannin"/>
            <entity id="DS3.d806.s0.e1" origId="P27986" charOffset="140-148" type="protein" text="p85alpha"/>
            <pair e1="DS3.d806.s0.e0" e2="DS3.d806.s0.e1" id="DS3.d806.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d807" origId="9973200">
        <sentence id="DS3.d807.s0" origId="9973200-6" text="Our results indicate that the third ankyrin repeat and the NH2-terminal portion of the fourth repeat constitute the essential element necessary for the ability of p18 to bind and inhibit CDK4 and CDK6.">
            <entity id="DS3.d807.s0.e0" origId="6329" charOffset="59-63" type="compound" text="NH2-"/>
            <entity id="DS3.d807.s0.e1" origId="P42773,Q6ICV4" charOffset="163-166" type="protein" text="p18"/>
            <entity id="DS3.d807.s0.e2" origId="P11802,A0A024RBB6" charOffset="187-191" type="protein" text="CDK4"/>
            <entity id="DS3.d807.s0.e3" origId="Q00534" charOffset="196-200" type="protein" text="CDK6"/>
            <pair e1="DS3.d807.s0.e0" e2="DS3.d807.s0.e1" id="DS3.d807.s0.i0" interaction="False" />
            <pair e1="DS3.d807.s0.e0" e2="DS3.d807.s0.e2" id="DS3.d807.s0.i1" interaction="False" />
            <pair e1="DS3.d807.s0.e0" e2="DS3.d807.s0.e3" id="DS3.d807.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d808" origId="9973201">
        <sentence id="DS3.d808.s0" origId="9973201-1" text="bone sialoprotein (BSP) is an early marker of differentiated osteoblasts that has been implicated in the nucleation of hydroxyapatite crystal formation during de novo bone formation.">
            <entity id="DS3.d808.s0.e0" origId="A0JPM6" charOffset="0-17" type="protein" text="bone sialoprotein"/>
            <entity id="DS3.d808.s0.e1" origId="A0JPM6" charOffset="19-22" type="protein" text="BSP"/>
            <entity id="DS3.d808.s0.e2" origId="14781" charOffset="119-133" type="compound" text="hydroxyapatite"/>
            <pair e1="DS3.d808.s0.e2" e2="DS3.d808.s0.e0" id="DS3.d808.s0.i0" interaction="False" />
            <pair e1="DS3.d808.s0.e2" e2="DS3.d808.s0.e1" id="DS3.d808.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d809" origId="9973202">
        <sentence id="DS3.d809.s0" origId="9973202-2" text="Here we report that treatment of the SCLC cell lines H 69, H 345, and H 510 with phorbol-12,13-dibutyrate (PDB) led to a rapid and striking activation of Protein kinase D (PKD), a novel serine/threonine protein kinase distinct from all PKC isoforms.">
            <entity id="DS3.d809.s0.e0" origId="452545,500033" charOffset="81-105" type="compound" text="phorbol-12,13-dibutyrate"/>
            <entity id="DS3.d809.s0.e1" origId="Q15139,F8WBA3" charOffset="154-170" type="protein" text="Protein kinase D"/>
            <entity id="DS3.d809.s0.e2" origId="Q15139,F8WBA3" charOffset="172-175" type="protein" text="PKD"/>
            <entity id="DS3.d809.s0.e3" origId="5951" charOffset="186-192" type="compound" text="serine"/>
            <entity id="DS3.d809.s0.e4" origId="194239,6288" charOffset="193-202" type="compound" text="threonine"/>
            <pair e1="DS3.d809.s0.e0" e2="DS3.d809.s0.e1" id="DS3.d809.s0.i0" interaction="False" />
            <pair e1="DS3.d809.s0.e0" e2="DS3.d809.s0.e2" id="DS3.d809.s0.i1" interaction="False" />
            <pair e1="DS3.d809.s0.e4" e2="DS3.d809.s0.e1" id="DS3.d809.s0.i2" interaction="False" />
            <pair e1="DS3.d809.s0.e4" e2="DS3.d809.s0.e2" id="DS3.d809.s0.i3" interaction="False" />
            <pair e1="DS3.d809.s0.e3" e2="DS3.d809.s0.e1" id="DS3.d809.s0.i4" interaction="False" />
            <pair e1="DS3.d809.s0.e3" e2="DS3.d809.s0.e2" id="DS3.d809.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d809.s1" origId="9973202-4" text="Treatment with the biologically active phorbol ester 12-O-tetradecanoylphorbol-13-acetate or with membrane-permeable diacylglycerols also stimulated PKD activation, which was also completely prevented by prior exposure of the cells to GF I.">
            <entity id="DS3.d809.s1.e0" origId="22833501,70702034" charOffset="39-52" type="compound" text="phorbol ester"/>
            <entity id="DS3.d809.s1.e1" origId="107854" charOffset="53-78" type="compound" text="12-O-tetradecanoylphorbol"/>
            <entity id="DS3.d809.s1.e2" origId="176" charOffset="82-89" type="compound" text="acetate"/>
            <entity id="DS3.d809.s1.e3" origId="Q15139,F8WBA3" charOffset="149-152" type="protein" text="PKD"/>
            <pair e1="DS3.d809.s1.e1" e2="DS3.d809.s1.e3" id="DS3.d809.s1.i0" interaction="False" />
            <pair e1="DS3.d809.s1.e0" e2="DS3.d809.s1.e3" id="DS3.d809.s1.i1" interaction="False" />
            <pair e1="DS3.d809.s1.e2" e2="DS3.d809.s1.e3" id="DS3.d809.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d809.s2" origId="9973202-5" text="The PKC inhibitors Ro 31-8220 and Go 7874 also blocked PKD activation in response to PDB.">
            <entity id="DS3.d809.s2.e0" origId="214797" charOffset="19-24" type="compound" text="Ro 31"/>
            <entity id="DS3.d809.s2.e1" origId="5327863" charOffset="34-41" type="compound" text="Go 7874"/>
            <entity id="DS3.d809.s2.e2" origId="Q15139,F8WBA3" charOffset="55-58" type="protein" text="PKD"/>
            <pair e1="DS3.d809.s2.e0" e2="DS3.d809.s2.e2" id="DS3.d809.s2.i0" interaction="False" />
            <pair e1="DS3.d809.s2.e1" e2="DS3.d809.s2.e2" id="DS3.d809.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d810" origId="9973208">
        <sentence id="DS3.d810.s0" origId="9973208-0" text="Isoform-specific induction of a human aldo-keto reductase by polycyclic aromatic hydrocarbons (PAHs), electrophiles, and oxidative stress: implications for the alternative pathway of PAH activation catalyzed by human dihydrodiol dehydrogenase.">
            <entity id="DS3.d810.s0.e0" origId="2148" charOffset="95-98" type="compound" text="PAH"/>
            <entity id="DS3.d810.s0.e1" origId="Q9UQ10" charOffset="217-242" type="protein" text="dihydrodiol dehydrogenase"/>
            <pair e1="DS3.d810.s0.e0" e2="DS3.d810.s0.e1" id="DS3.d810.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d810.s1" origId="9973208-10" text="Thus, BPQ formation by AKR1C1 results in both a chemical (redox-cycling) and a genetic (AKR1C1 induction) amplification of ROS in PAH-exposed cells.">
            <entity id="DS3.d810.s1.e0" origId="Q04828" charOffset="23-29" type="protein" text="AKR1C1"/>
            <entity id="DS3.d810.s1.e1" origId="Q04828" charOffset="88-94" type="protein" text="AKR1C1"/>
            <entity id="DS3.d810.s1.e2" origId="2148" charOffset="130-133" type="compound" text="PAH"/>
            <pair e1="DS3.d810.s1.e2" e2="DS3.d810.s1.e0" id="DS3.d810.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d810.s2" origId="9973208-2" text="Of these, human AKR1C1 (DD1) and AKR1C2 (DD2) oxidize trans-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene to the cytotoxic and genotoxic metabolite benzo(a)pyrene-7,8-dione (BPQ) with the highest catalytic efficiency.">
            <entity id="DS3.d810.s2.e0" origId="Q04828" charOffset="16-22" type="protein" text="AKR1C1"/>
            <entity id="DS3.d810.s2.e1" origId="Q04828" charOffset="24-27" type="protein" text="DD1"/>
            <entity id="DS3.d810.s2.e2" origId="P52895,B4DK69" charOffset="33-39" type="protein" text="AKR1C2"/>
            <entity id="DS3.d810.s2.e3" origId="P52895,B4DK69" charOffset="41-44" type="protein" text="DD2"/>
            <entity id="DS3.d810.s2.e4" origId="20279694" charOffset="78-99" type="compound" text="dihydrobenzo(a)pyrene"/>
            <entity id="DS3.d810.s2.e5" origId="105020" charOffset="142-166" type="compound" text="benzo(a)pyrene-7,8-dione"/>
            <pair e1="DS3.d810.s2.e5" e2="DS3.d810.s2.e3" id="DS3.d810.s2.i0" interaction="False" />
            <pair e1="DS3.d810.s2.e5" e2="DS3.d810.s2.e1" id="DS3.d810.s2.i1" interaction="False" />
            <pair e1="DS3.d810.s2.e5" e2="DS3.d810.s2.e0" id="DS3.d810.s2.i2" interaction="False" />
            <pair e1="DS3.d810.s2.e5" e2="DS3.d810.s2.e2" id="DS3.d810.s2.i3" interaction="False" />
            <pair e1="DS3.d810.s2.e5" e2="DS3.d810.s2.e3" id="DS3.d810.s2.i4" interaction="False" />
            <pair e1="DS3.d810.s2.e5" e2="DS3.d810.s2.e1" id="DS3.d810.s2.i5" interaction="False" />
            <pair e1="DS3.d810.s2.e5" e2="DS3.d810.s2.e0" id="DS3.d810.s2.i6" interaction="False" />
            <pair e1="DS3.d810.s2.e5" e2="DS3.d810.s2.e2" id="DS3.d810.s2.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d810.s3" origId="9973208-7" text="The increased DD activity in HepG2 lysates was inhibited only by high concentrations of ursodeoxycholate, which suggested that AKR1C2 (DD2, bile-acid-binding protein) was not the isoform induced.">
            <entity id="DS3.d810.s3.e0" origId="31401" charOffset="88-104" type="compound" text="ursodeoxycholate"/>
            <entity id="DS3.d810.s3.e1" origId="P52895,B4DK69" charOffset="127-133" type="protein" text="AKR1C2"/>
            <entity id="DS3.d810.s3.e2" origId="P52895,B4DK69" charOffset="135-138" type="protein" text="DD2"/>
            <pair e1="DS3.d810.s3.e0" e2="DS3.d810.s3.e2" id="DS3.d810.s3.i0" interaction="False" />
            <pair e1="DS3.d810.s3.e0" e2="DS3.d810.s3.e1" id="DS3.d810.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d811" origId="9973209">
        <sentence id="DS3.d811.s0" origId="9973209-10" text="Kinetic analysis was able to remove the confounding influence of (C-11)CO2, the principal labeled metabolite of 2-(C-11)dThd, and to estimate the flux of dThd incorporation into DNA.">
            <entity id="DS3.d811.s0.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="71-74" type="protein" text="CO2"/>
            <entity id="DS3.d811.s0.e1" origId="5789" charOffset="120-124" type="compound" text="dThd"/>
            <entity id="DS3.d811.s0.e2" origId="5789" charOffset="154-158" type="compound" text="dThd"/>
            <pair e1="DS3.d811.s0.e1" e2="DS3.d811.s0.e0" id="DS3.d811.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d811.s1" origId="9973209-11" text="Sequential, same-day (C-11)CO2 and (C-11)dThd imaging demonstrated the ability of kinetic analysis to model both dThd and CO2 simultaneously.">
            <entity id="DS3.d811.s1.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="27-30" type="protein" text="CO2"/>
            <entity id="DS3.d811.s1.e1" origId="5789" charOffset="41-45" type="compound" text="dThd"/>
            <entity id="DS3.d811.s1.e2" origId="5789" charOffset="113-117" type="compound" text="dThd"/>
            <entity id="DS3.d811.s1.e3" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="122-125" type="protein" text="CO2"/>
            <pair e1="DS3.d811.s1.e1" e2="DS3.d811.s1.e0" id="DS3.d811.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d812" origId="9973211">
        <sentence id="DS3.d812.s0" origId="9973211-0" text="Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.">
            <entity id="DS3.d812.s0.e0" origId="P06804,Q3U593" charOffset="36-63" type="protein" text="tumor necrosis factor-alpha"/>
            <entity id="DS3.d812.s0.e1" origId="470396" charOffset="78-100" type="compound" text="5,6-dimethylxanthenone"/>
            <pair e1="DS3.d812.s0.e1" e2="DS3.d812.s0.e0" id="DS3.d812.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d812.s1" origId="9973211-11" text="DMXAA induced 35-fold higher TNF activity in the Colon 38 tissue than did LPS.">
            <entity id="DS3.d812.s1.e0" origId="123964" charOffset="0-5" type="compound" text="DMXAA"/>
            <entity id="DS3.d812.s1.e1" origId="Q9QUK6,L0CL36" charOffset="74-77" type="protein" text="LPS"/>
            <pair e1="DS3.d812.s1.e0" e2="DS3.d812.s1.e1" id="DS3.d812.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d812.s2" origId="9973211-7" text="The distribution of cells containing TNF mRNA in tumor tissues after DMXAA administration contrasted significantly with that obtained after lipopolysaccharide (LPS) treatment, although splenic and hepatic tissues showed a similar distribution of TNF mRNA-positive cells.">
            <entity id="DS3.d812.s2.e0" origId="123964" charOffset="69-74" type="compound" text="DMXAA"/>
            <entity id="DS3.d812.s2.e1" origId="Q9QUK6,L0CL36" charOffset="140-158" type="protein" text="lipopolysaccharide"/>
            <entity id="DS3.d812.s2.e2" origId="Q9QUK6,L0CL36" charOffset="160-163" type="protein" text="LPS"/>
            <pair e1="DS3.d812.s2.e0" e2="DS3.d812.s2.e1" id="DS3.d812.s2.i0" interaction="False" />
            <pair e1="DS3.d812.s2.e0" e2="DS3.d812.s2.e2" id="DS3.d812.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d813" origId="9973213">
        <sentence id="DS3.d813.s0" origId="9973213-2" text="To test this, we first injected into the brain of Sprague Dawley rats a 1:1 mixture of C6 rat glioblastoma cells and psi2.L4SN20 or E86.L4SN50 retroviral producer cells (RPCs), secreting 20 and 50 ng of IL-4/5 x 10(5) cells/48 h, respectively.">
            <entity id="DS3.d813.s0.e0" origId="44481490" charOffset="132-135" type="compound" text="E86"/>
            <entity id="DS3.d813.s0.e1" origId="P20096" charOffset="203-207" type="protein" text="IL-4"/>
            <pair e1="DS3.d813.s0.e0" e2="DS3.d813.s0.e1" id="DS3.d813.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d813.s1" origId="9973213-5" text="A novel IL-4 RPC clone expressing higher levels of IL-4, E86.L4SN200, coinjected with 9L cells increased to 75% the fraction of long-term survivors and induced tumor regression in 50% of rats when injected into established 9L gliosarcomas.">
            <entity id="DS3.d813.s1.e0" origId="P20096" charOffset="8-12" type="protein" text="IL-4"/>
            <entity id="DS3.d813.s1.e1" origId="P20096" charOffset="51-55" type="protein" text="IL-4"/>
            <entity id="DS3.d813.s1.e2" origId="44481490" charOffset="57-60" type="compound" text="E86"/>
            <pair e1="DS3.d813.s1.e2" e2="DS3.d813.s1.e0" id="DS3.d813.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d814" origId="9973215">
        <sentence id="DS3.d814.s0" origId="9973215-2" text="The rat sodium/iodide symporter gene (rNIS) was cloned into a retroviral vector for transfer into cancer cells to mimic the iodide uptake of thyroid follicular cells.">
            <entity id="DS3.d814.s0.e0" origId="5360545" charOffset="8-14" type="compound" text="sodium"/>
            <entity id="DS3.d814.s0.e1" origId="105054,30165" charOffset="15-21" type="compound" text="iodide"/>
            <entity id="DS3.d814.s0.e2" origId="Q63008,F1LR66" charOffset="38-42" type="protein" text="rNIS"/>
            <entity id="DS3.d814.s0.e3" origId="105054,30165" charOffset="124-130" type="compound" text="iodide"/>
            <pair e1="DS3.d814.s0.e1" e2="DS3.d814.s0.e2" id="DS3.d814.s0.i0" interaction="False" />
            <pair e1="DS3.d814.s0.e0" e2="DS3.d814.s0.e2" id="DS3.d814.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d814.s1" origId="9973215-3" text="In vitro iodide transport shows that the symporter functions similarly in rNIS-transduced tumor cells and rat thyroid follicular cells.">
            <entity id="DS3.d814.s1.e0" origId="105054,30165" charOffset="9-15" type="compound" text="iodide"/>
            <entity id="DS3.d814.s1.e1" origId="Q63008,F1LR66" charOffset="74-78" type="protein" text="rNIS"/>
            <pair e1="DS3.d814.s1.e0" e2="DS3.d814.s1.e1" id="DS3.d814.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d814.s2" origId="9973215-7" text="In vitro clonogenic assays confirm efficacy and clearly show that rNIS-transduced A375 human melanoma, BNL.1 ME murine transformed liver, CT26 murine colon carcinoma, and IGROV human ovarian carcinoma can be selectively killed by the induced accumulation of 131I.">
            <entity id="DS3.d814.s2.e0" origId="Q63008,F1LR66" charOffset="66-70" type="protein" text="rNIS"/>
            <entity id="DS3.d814.s2.e1" origId="167195" charOffset="258-262" type="compound" text="131I"/>
            <pair e1="DS3.d814.s2.e1" e2="DS3.d814.s2.e0" id="DS3.d814.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d815" origId="9973219">
        <sentence id="DS3.d815.s0" origId="9973219-0" text="N-(2-chloroethyl)-N-nitrosourea tethered to lexitropsin induces minor groove lesions at the p53 cDNA that are more cytotoxic than mutagenic.">
            <entity id="DS3.d815.s0.e0" origId="105035" charOffset="20-31" type="compound" text="nitrosourea"/>
            <entity id="DS3.d815.s0.e1" origId="119575" charOffset="44-55" type="compound" text="lexitropsin"/>
            <entity id="DS3.d815.s0.e2" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="92-95" type="protein" text="p53"/>
            <pair e1="DS3.d815.s0.e0" e2="DS3.d815.s0.e2" id="DS3.d815.s0.i0" interaction="False" />
            <pair e1="DS3.d815.s0.e1" e2="DS3.d815.s0.e2" id="DS3.d815.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d815.s1" origId="9973219-3" text="CENU-lex sequence specificity for DNA alkylation was determined using 32P-end-labeled restriction fragments of the p53 cDNA.">
            <entity id="DS3.d815.s1.e0" origId="4571095" charOffset="5-8" type="compound" text="lex"/>
            <entity id="DS3.d815.s1.e1" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="115-118" type="protein" text="p53"/>
            <pair e1="DS3.d815.s1.e0" e2="DS3.d815.s1.e1" id="DS3.d815.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d815.s2" origId="9973219-5" text="To establish the mutagenic and lethal properties of CENU-lex-specific lesions, a yeast expression vector harboring a human wild-type p53 cDNA was treated in vitro with CENU-lex and transfected into a yeast strain containing the ADE2 gene regulated by a p53-responsive promoter.">
            <entity id="DS3.d815.s2.e0" origId="4571095" charOffset="57-60" type="compound" text="lex"/>
            <entity id="DS3.d815.s2.e1" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="133-136" type="protein" text="p53"/>
            <entity id="DS3.d815.s2.e2" origId="4571095" charOffset="173-176" type="compound" text="lex"/>
            <entity id="DS3.d815.s2.e3" origId="P21264" charOffset="228-232" type="protein" text="ADE2"/>
            <entity id="DS3.d815.s2.e4" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="253-256" type="protein" text="p53"/>
            <pair e1="DS3.d815.s2.e0" e2="DS3.d815.s2.e3" id="DS3.d815.s2.i0" interaction="False" />
            <pair e1="DS3.d815.s2.e0" e2="DS3.d815.s2.e1" id="DS3.d815.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d815.s3" origId="9973219-7" text="The results revealed that: (a) CENU-lex preferentially induces N3-Alkyl-A at specific lex equilibrium binding sites, the formations of which are strongly inhibited by distamycin; (b) reactivity toward Gs is still present, albeit to a lesser extent when compared to N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea and to CENU; (c) 91% of the 49 CENU-lex p53 mutations (45 of 49) were bp substitutions, 29 of which were GC--&amp;gt;AT transitions, mainly at 5' purine G sites; (d) all AT-targeted mutations but one were AT--&amp;gt;TA transversions; (e) the distribution of the CENU-lex mutations along the p53 cDNA was not random, with position 273 (codon 91), where only GC--&amp;gt;AT transitions were observed, being a real (n = 3, P &amp;lt; 0.0002) CENU-lex mutation hot spot; and (f) a shift in DNA alkylation sites between lesion spectra induced by CENU-lex and N-(2-chloroethyl-N-cyclohexyl-N-nitrosourea was associated with an increased lethality and a decreased mutagenicity, whereas no dramatic change in mutational specificity was observed.">
            <entity id="DS3.d815.s3.e0" origId="4571095" charOffset="36-39" type="compound" text="lex"/>
            <entity id="DS3.d815.s3.e1" origId="4571095" charOffset="86-89" type="compound" text="lex"/>
            <entity id="DS3.d815.s3.e2" origId="3115" charOffset="167-177" type="compound" text="distamycin"/>
            <entity id="DS3.d815.s3.e3" origId="3041706" charOffset="265-309" type="compound" text="N-(2-chloroethyl)-N-cyclohexyl-N-nitrosourea"/>
            <entity id="DS3.d815.s3.e4" origId="4571095" charOffset="86-89" type="compound" text="lex"/>
            <entity id="DS3.d815.s3.e5" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="350-353" type="protein" text="p53"/>
            <entity id="DS3.d815.s3.e6" origId="4571095" charOffset="86-89" type="compound" text="lex"/>
            <entity id="DS3.d815.s3.e7" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="594-597" type="protein" text="p53"/>
            <entity id="DS3.d815.s3.e8" origId="4571095" charOffset="86-89" type="compound" text="lex"/>
            <entity id="DS3.d815.s3.e9" origId="4571095" charOffset="86-89" type="compound" text="lex"/>
            <entity id="DS3.d815.s3.e10" origId="160550" charOffset="285-309" type="compound" text="cyclohexyl-N-nitrosourea"/>
            <pair e1="DS3.d815.s3.e0" e2="DS3.d815.s3.e5" id="DS3.d815.s3.i0" interaction="False" />
            <pair e1="DS3.d815.s3.e2" e2="DS3.d815.s3.e5" id="DS3.d815.s3.i1" interaction="False" />
            <pair e1="DS3.d815.s3.e10" e2="DS3.d815.s3.e5" id="DS3.d815.s3.i2" interaction="False" />
            <pair e1="DS3.d815.s3.e3" e2="DS3.d815.s3.e5" id="DS3.d815.s3.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d816" origId="9973230">
        <sentence id="DS3.d816.s0" origId="9973230-0" text="The 21-aminosteroid U-74389F attenuates hyperexpression of GAP-43 and NADPH-diaphorase in the spinal cord of wobbler mouse, a model for amyotrophic lateral sclerosis.">
            <entity id="DS3.d816.s0.e0" origId="40112" charOffset="7-19" type="compound" text="aminosteroid"/>
            <entity id="DS3.d816.s0.e1" origId="104934" charOffset="20-28" type="compound" text="U-74389F"/>
            <entity id="DS3.d816.s0.e2" origId="P06837" charOffset="59-65" type="protein" text="GAP-43"/>
            <entity id="DS3.d816.s0.e3" origId="5884" charOffset="70-75" type="compound" text="NADPH"/>
            <pair e1="DS3.d816.s0.e3" e2="DS3.d816.s0.e2" id="DS3.d816.s0.i0" interaction="False" />
            <pair e1="DS3.d816.s0.e0" e2="DS3.d816.s0.e2" id="DS3.d816.s0.i1" interaction="False" />
            <pair e1="DS3.d816.s0.e1" e2="DS3.d816.s0.e2" id="DS3.d816.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d816.s1" origId="9973230-13" text="U-74389F may stop neurodegeneration and/or increase muscle trophism and stop oxidative stress, consequently GAP-43 hyperexpression was attenuated.">
            <entity id="DS3.d816.s1.e0" origId="104934" charOffset="0-8" type="compound" text="U-74389F"/>
            <entity id="DS3.d816.s1.e1" origId="P06837" charOffset="108-114" type="protein" text="GAP-43"/>
            <pair e1="DS3.d816.s1.e0" e2="DS3.d816.s1.e1" id="DS3.d816.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d816.s2" origId="9973230-3" text="We have studied in these animals the expression of two proteins, the growth-associated protein (GAP-43) and the NADPH-diaphorase, the nitric oxide synthesizing enzyme, employing immunocytochemistry and histochemistry.">
            <entity id="DS3.d816.s2.e0" origId="P06837" charOffset="96-102" type="protein" text="GAP-43"/>
            <entity id="DS3.d816.s2.e1" origId="5884" charOffset="112-117" type="compound" text="NADPH"/>
            <entity id="DS3.d816.s2.e2" origId="145068" charOffset="134-146" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d816.s2.e1" e2="DS3.d816.s2.e0" id="DS3.d816.s2.i0" interaction="False" />
            <pair e1="DS3.d816.s2.e2" e2="DS3.d816.s2.e0" id="DS3.d816.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d816.s3" origId="9973230-8" text="U-74389F slightly attenuated GAP-43 immunostaining in dorsal regions of the spinal cord from wobblers but not in controls.">
            <entity id="DS3.d816.s3.e0" origId="104934" charOffset="0-8" type="compound" text="U-74389F"/>
            <entity id="DS3.d816.s3.e1" origId="P06837" charOffset="29-35" type="protein" text="GAP-43"/>
            <pair e1="DS3.d816.s3.e0" e2="DS3.d816.s3.e1" id="DS3.d816.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d816.s4" origId="9973230-9" text="However, in motoneurons of wobbler mice number of GAP-43 immunopositive neurons, cell processes and reaction intensity were reduced by U-74389F.">
            <entity id="DS3.d816.s4.e0" origId="P06837" charOffset="50-56" type="protein" text="GAP-43"/>
            <entity id="DS3.d816.s4.e1" origId="104934" charOffset="135-143" type="compound" text="U-74389F"/>
            <pair e1="DS3.d816.s4.e1" e2="DS3.d816.s4.e0" id="DS3.d816.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d817" origId="9973237">
        <sentence id="DS3.d817.s0" origId="9973237-5" text="The Kms by Michaelis-Menten equation for the control, and in the presence of 5, or 10 mM ammonia were 32.5+/-4.52, 44.4+/-5.82, and 39.3+/-7.0 microM, respectively.">
            <entity id="DS3.d817.s0.e0" origId="P23352" charOffset="4-7" type="protein" text="Kms"/>
            <entity id="DS3.d817.s0.e1" origId="222" charOffset="89-96" type="compound" text="ammonia"/>
            <pair e1="DS3.d817.s0.e1" e2="DS3.d817.s0.e0" id="DS3.d817.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d817.s1" origId="9973237-6" text="Kms by Hanes-Woolf plot for the control, 5, or 10 mM ammonia were 25, 45, and 40 microM, respectively.">
            <entity id="DS3.d817.s1.e0" origId="P23352" charOffset="0-3" type="protein" text="Kms"/>
            <entity id="DS3.d817.s1.e1" origId="222" charOffset="53-60" type="compound" text="ammonia"/>
            <pair e1="DS3.d817.s1.e1" e2="DS3.d817.s1.e0" id="DS3.d817.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d818" origId="9973239">
        <sentence id="DS3.d818.s0" origId="9973239-3" text="U18666A also blocked LDL-stimulated downregulation of LDL receptor and caused lysosomal accumulation of cholesterol as measured by filipin staining.">
            <entity id="DS3.d818.s0.e0" origId="9954083" charOffset="0-7" type="compound" text="U18666A"/>
            <entity id="DS3.d818.s0.e1" origId="P01130,A0A024R7D5" charOffset="54-66" type="protein" text="LDL receptor"/>
            <entity id="DS3.d818.s0.e2" origId="5997" charOffset="104-115" type="compound" text="cholesterol"/>
            <entity id="DS3.d818.s0.e3" origId="5351457,57264780,6433194,6433553" charOffset="131-138" type="compound" text="filipin"/>
            <pair e1="DS3.d818.s0.e0" e2="DS3.d818.s0.e1" id="DS3.d818.s0.i0" interaction="False" />
            <pair e1="DS3.d818.s0.e3" e2="DS3.d818.s0.e1" id="DS3.d818.s0.i1" interaction="False" />
            <pair e1="DS3.d818.s0.e2" e2="DS3.d818.s0.e1" id="DS3.d818.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d818.s1" origId="9973239-5" text="These results suggest that U 18666A may preferentially block a voltage-regulated Ca2+ channel involved in norepinephrine release and that alterations in neurotransmitter secretion might be a feature of disorders such as Niemann-Pick Type C, in which intracellular cholesterol transport and distribution are impaired.">
            <entity id="DS3.d818.s1.e0" origId="Q9NRD5,A0A024R1J5" charOffset="228-232" type="protein" text="Pick"/>
            <entity id="DS3.d818.s1.e1" origId="5997" charOffset="264-275" type="compound" text="cholesterol"/>
            <pair e1="DS3.d818.s1.e1" e2="DS3.d818.s1.e0" id="DS3.d818.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d819" origId="9973244">
        <sentence id="DS3.d819.s0" origId="9973244-4" text="This paper describes a series of experimental and clinical studies demonstrating that: (1) high serum levels of some cytokines, including IL-1, IL-6, and TNF, are present in advanced-stage cancer patients, particularly those with CACS; (2) megestrol acetate (MA) has a beneficial therapeutic effect on CACS symptoms, such as appetite, body weight, and quality-of-life; (3) MA downregulates the synthesis and release of cytokines and relieves the symptoms of CACS; (4) cytokines play a key role in the onset of CACS; (5) medroxyprogesterone acetate (MPA) reduces the in vitro production of cytokines and serotonin (5-hydroxytryptamine, 5-HT) by peripheral blood mononuclear cells (PBMC) of cancer patients; and (6) MA and MPA reduce the cisplatin-induced 5-HT release in vitro from PBMC of cancer patients.">
            <entity id="DS3.d819.s0.e0" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="144-148" type="protein" text="IL-6"/>
            <entity id="DS3.d819.s0.e1" origId="11683" charOffset="240-257" type="compound" text="megestrol acetate"/>
            <entity id="DS3.d819.s0.e2" origId="6279" charOffset="520-547" type="compound" text="medroxyprogesterone acetate"/>
            <entity id="DS3.d819.s0.e3" origId="5202" charOffset="614-633" type="compound" text="5-hydroxytryptamine"/>
            <pair e1="DS3.d819.s0.e3" e2="DS3.d819.s0.e0" id="DS3.d819.s0.i0" interaction="False" />
            <pair e1="DS3.d819.s0.e2" e2="DS3.d819.s0.e0" id="DS3.d819.s0.i1" interaction="False" />
            <pair e1="DS3.d819.s0.e1" e2="DS3.d819.s0.e0" id="DS3.d819.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d820" origId="9973250">
        <sentence id="DS3.d820.s0" origId="9973250-1" text="We identified Ark, the mouse homolog of the receptor tyrosine kinase Axl (Ufo, Tyro7), in a screen for novel factors involved in GnRH neuronal migration by using differential-display PCR on cell lines derived at two windows during GnRH neuronal development.">
            <entity id="DS3.d820.s0.e0" origId="Q00993,Q6PE80,Q8CCF8" charOffset="14-17" type="protein" text="Ark"/>
            <entity id="DS3.d820.s0.e1" origId="6057,90983769" charOffset="53-61" type="compound" text="tyrosine"/>
            <entity id="DS3.d820.s0.e2" origId="Q00993,Q6PE80,Q8CCF8" charOffset="69-72" type="protein" text="Axl"/>
            <entity id="DS3.d820.s0.e3" origId="Q00993,Q6PE80,Q8CCF8" charOffset="74-77" type="protein" text="Ufo"/>
            <entity id="DS3.d820.s0.e4" origId="Q00993,Q6PE80,Q8CCF8" charOffset="79-84" type="protein" text="Tyro7"/>
            <pair e1="DS3.d820.s0.e1" e2="DS3.d820.s0.e4" id="DS3.d820.s0.i0" interaction="False" />
            <pair e1="DS3.d820.s0.e1" e2="DS3.d820.s0.e0" id="DS3.d820.s0.i1" interaction="False" />
            <pair e1="DS3.d820.s0.e1" e2="DS3.d820.s0.e2" id="DS3.d820.s0.i2" interaction="False" />
            <pair e1="DS3.d820.s0.e1" e2="DS3.d820.s0.e3" id="DS3.d820.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d820.s1" origId="9973250-2" text="Ark is expressed in Gn10 GnRH cells, developed from a tumor in the olfactory area when GnRH neurons are migrating, but not in GT1-7 cells, derived from a tumor in the forebrain when GnRH neurons are postmigratory.">
            <entity id="DS3.d820.s1.e0" origId="Q00993,Q6PE80,Q8CCF8" charOffset="0-3" type="protein" text="Ark"/>
            <entity id="DS3.d820.s1.e1" origId="46881081" charOffset="126-129" type="compound" text="GT1"/>
            <pair e1="DS3.d820.s1.e1" e2="DS3.d820.s1.e0" id="DS3.d820.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d820.s2" origId="9973250-3" text="Since Ark (Ax1) signaling protects from programmed cell death in fibroblasts, we hypothesized that it may play an antiapoptotic role in GnRH neurons.">
            <entity id="DS3.d820.s2.e0" origId="Q00993,Q6PE80,Q8CCF8" charOffset="6-9" type="protein" text="Ark"/>
            <entity id="DS3.d820.s2.e1" origId="25113143" charOffset="11-14" type="compound" text="Ax1"/>
            <pair e1="DS3.d820.s2.e1" e2="DS3.d820.s2.e0" id="DS3.d820.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d820.s3" origId="9973250-4" text="Gn10 (Ark positive) GnRH cells were more resistant to serum withdrawal-induced apoptosis than GT1-7 (Ark negative) cells, and this effect was augmented with the addition of Gas6, the Ark (Ax1) ligand.">
            <entity id="DS3.d820.s3.e0" origId="Q00993,Q6PE80,Q8CCF8" charOffset="6-9" type="protein" text="Ark"/>
            <entity id="DS3.d820.s3.e1" origId="46881081" charOffset="94-97" type="compound" text="GT1"/>
            <entity id="DS3.d820.s3.e2" origId="Q00993,Q6PE80,Q8CCF8" charOffset="101-104" type="protein" text="Ark"/>
            <entity id="DS3.d820.s3.e3" origId="Q61592" charOffset="173-177" type="protein" text="Gas6"/>
            <entity id="DS3.d820.s3.e4" origId="Q00993,Q6PE80,Q8CCF8" charOffset="101-104" type="protein" text="Ark"/>
            <entity id="DS3.d820.s3.e5" origId="25113143" charOffset="188-191" type="compound" text="Ax1"/>
            <pair e1="DS3.d820.s3.e1" e2="DS3.d820.s3.e0" id="DS3.d820.s3.i0" interaction="False" />
            <pair e1="DS3.d820.s3.e1" e2="DS3.d820.s3.e3" id="DS3.d820.s3.i1" interaction="False" />
            <pair e1="DS3.d820.s3.e5" e2="DS3.d820.s3.e0" id="DS3.d820.s3.i2" interaction="False" />
            <pair e1="DS3.d820.s3.e5" e2="DS3.d820.s3.e3" id="DS3.d820.s3.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d820.s4" origId="9973250-5" text="Gas6/Ark stimulated the extracellular signal-regulated kinase, ERK, and the serine-threonine kinase, Akt, a downstream component of the phosphoinositide 3-kinase (PI3-K) pathway.">
            <entity id="DS3.d820.s4.e0" origId="Q61592" charOffset="0-8" type="protein" text="Gas6/Ark"/>
            <entity id="DS3.d820.s4.e1" origId="5951" charOffset="76-82" type="compound" text="serine"/>
            <entity id="DS3.d820.s4.e2" origId="194239,6288" charOffset="83-92" type="compound" text="threonine"/>
            <entity id="DS3.d820.s4.e3" origId="16738692" charOffset="136-152" type="compound" text="phosphoinositide"/>
            <pair e1="DS3.d820.s4.e2" e2="DS3.d820.s4.e0" id="DS3.d820.s4.i0" interaction="False" />
            <pair e1="DS3.d820.s4.e3" e2="DS3.d820.s4.e0" id="DS3.d820.s4.i1" interaction="False" />
            <pair e1="DS3.d820.s4.e1" e2="DS3.d820.s4.e0" id="DS3.d820.s4.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d820.s5" origId="9973250-7" text="Gas6 rescued Gn10 cells from apoptosis, and this effect was blocked by coincubation of the cells with the mitogen-activated protein/ERK kinase (MEK) inhibitor, PD98059, or wortmannin (but not rapamycin).">
            <entity id="DS3.d820.s5.e0" origId="Q61592" charOffset="0-4" type="protein" text="Gas6"/>
            <entity id="DS3.d820.s5.e1" origId="4713" charOffset="160-167" type="compound" text="PD98059"/>
            <entity id="DS3.d820.s5.e2" origId="312145" charOffset="172-182" type="compound" text="wortmannin"/>
            <entity id="DS3.d820.s5.e3" origId="16760631,478951,5284616,5040,53627520,5358081,5374464,54600319,60150249,6436030,70789198,71296106,86583604,91454826,9854380" charOffset="192-201" type="compound" text="rapamycin"/>
            <pair e1="DS3.d820.s5.e1" e2="DS3.d820.s5.e0" id="DS3.d820.s5.i0" interaction="False" />
            <pair e1="DS3.d820.s5.e2" e2="DS3.d820.s5.e0" id="DS3.d820.s5.i1" interaction="False" />
            <pair e1="DS3.d820.s5.e3" e2="DS3.d820.s5.e0" id="DS3.d820.s5.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d821" origId="9973252">
        <sentence id="DS3.d821.s0" origId="9973252-2" text="The mechanism underlying this down-regulation was studied in the rat liver cell line CWSV-1, where continuous GH suppressed the level of activated (tyrosine- phosphorylated) STAT5b to approximately 10-20% of the maximal GH pulse-induced STAT5b signal within 3 h. In contrast to the robust JAK2 kinase-dependent STAT5b activation loop that is established by a GH pulse, JAK2 kinase signaling to individual STAT5b molecules was found to be short lived in cells treated with GH continuously.">
            <entity id="DS3.d821.s0.e0" origId="6057,90983769" charOffset="148-156" type="compound" text="tyrosine"/>
            <entity id="DS3.d821.s0.e1" origId="P52632,A0A0G2JSR4" charOffset="174-180" type="protein" text="STAT5b"/>
            <entity id="DS3.d821.s0.e2" origId="P52632,A0A0G2JSR4" charOffset="237-243" type="protein" text="STAT5b"/>
            <entity id="DS3.d821.s0.e3" origId="Q62689" charOffset="289-293" type="protein" text="JAK2"/>
            <entity id="DS3.d821.s0.e4" origId="P52632,A0A0G2JSR4" charOffset="237-243" type="protein" text="STAT5b"/>
            <entity id="DS3.d821.s0.e5" origId="Q62689" charOffset="369-373" type="protein" text="JAK2"/>
            <entity id="DS3.d821.s0.e6" origId="P52632,A0A0G2JSR4" charOffset="237-243" type="protein" text="STAT5b"/>
            <pair e1="DS3.d821.s0.e0" e2="DS3.d821.s0.e1" id="DS3.d821.s0.i0" interaction="False" />
            <pair e1="DS3.d821.s0.e0" e2="DS3.d821.s0.e3" id="DS3.d821.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d821.s1" origId="9973252-4" text="Increased STAT5b DNA-binding activity was observed in cells treated with the proteasome inhibitor MG132, suggesting that at least one component of the GH receptor (GHR)-JAK2-STAT5b signaling pathway becomes labile in response to continuous GH treatment.">
            <entity id="DS3.d821.s1.e0" origId="P52632,A0A0G2JSR4" charOffset="10-16" type="protein" text="STAT5b"/>
            <entity id="DS3.d821.s1.e1" origId="462382" charOffset="98-103" type="compound" text="MG132"/>
            <entity id="DS3.d821.s1.e2" origId="P16310" charOffset="151-162" type="protein" text="GH receptor"/>
            <entity id="DS3.d821.s1.e3" origId="P16310" charOffset="164-167" type="protein" text="GHR"/>
            <entity id="DS3.d821.s1.e4" origId="Q62689" charOffset="169-173" type="protein" text="JAK2"/>
            <entity id="DS3.d821.s1.e5" origId="P52632,A0A0G2JSR4" charOffset="174-180" type="protein" text="STAT5b"/>
            <pair e1="DS3.d821.s1.e1" e2="DS3.d821.s1.e0" id="DS3.d821.s1.i0" interaction="False" />
            <pair e1="DS3.d821.s1.e1" e2="DS3.d821.s1.e4" id="DS3.d821.s1.i1" interaction="False" />
            <pair e1="DS3.d821.s1.e1" e2="DS3.d821.s1.e2" id="DS3.d821.s1.i2" interaction="False" />
            <pair e1="DS3.d821.s1.e1" e2="DS3.d821.s1.e3" id="DS3.d821.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d821.s2" origId="9973252-7" text="Finally, the sustaining effect of the serine kinase inhibitor H7 on GH pulse-induced JAK2 signaling to STAT5b was not observed in continuous GH-treated cells.">
            <entity id="DS3.d821.s2.e0" origId="53378893" charOffset="45-61" type="compound" text="kinase inhibitor"/>
            <entity id="DS3.d821.s2.e1" origId="Q62689" charOffset="85-89" type="protein" text="JAK2"/>
            <entity id="DS3.d821.s2.e2" origId="P52632,A0A0G2JSR4" charOffset="103-109" type="protein" text="STAT5b"/>
            <pair e1="DS3.d821.s2.e0" e2="DS3.d821.s2.e2" id="DS3.d821.s2.i0" interaction="False" />
            <pair e1="DS3.d821.s2.e0" e2="DS3.d821.s2.e1" id="DS3.d821.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d822" origId="9973253">
        <sentence id="DS3.d822.s0" origId="9973253-0" text="Reconstitution of the protein kinase A response of the rat prolactin promoter: differential effects of distinct Pit-1 isoforms and functional interaction with Oct-1.">
            <entity id="DS3.d822.s0.e0" origId="A1L1M0" charOffset="22-38" type="protein" text="protein kinase A"/>
            <entity id="DS3.d822.s0.e1" origId="P01237,B5DEM6,B2RYT1" charOffset="59-68" type="protein" text="prolactin"/>
            <entity id="DS3.d822.s0.e2" origId="3664359" charOffset="112-117" type="compound" text="Pit-1"/>
            <entity id="DS3.d822.s0.e3" origId="Q63089" charOffset="159-164" type="protein" text="Oct-1"/>
            <pair e1="DS3.d822.s0.e2" e2="DS3.d822.s0.e3" id="DS3.d822.s0.i0" interaction="False" />
            <pair e1="DS3.d822.s0.e2" e2="DS3.d822.s0.e0" id="DS3.d822.s0.i1" interaction="False" />
            <pair e1="DS3.d822.s0.e2" e2="DS3.d822.s0.e1" id="DS3.d822.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d822.s1" origId="9973253-1" text="PRL gene transcription is primarily regulated by dopamine, which lowers cAMP levels and inhibits protein kinase A (PKA) activity.">
            <entity id="DS3.d822.s1.e0" origId="P01237,B5DEM6,B2RYT1" charOffset="0-3" type="protein" text="PRL"/>
            <entity id="DS3.d822.s1.e1" origId="681" charOffset="49-57" type="compound" text="dopamine"/>
            <entity id="DS3.d822.s1.e2" origId="A1L1M0" charOffset="97-113" type="protein" text="protein kinase A"/>
            <pair e1="DS3.d822.s1.e1" e2="DS3.d822.s1.e0" id="DS3.d822.s1.i0" interaction="False" />
            <pair e1="DS3.d822.s1.e1" e2="DS3.d822.s1.e2" id="DS3.d822.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d822.s2" origId="9973253-2" text="Current data indicate that the cAMP/PKA response maps to the most proximal Pit-1/Pit-1beta binding site footprint I (FP I) on the rat PRL (rPRL) promoter.">
            <entity id="DS3.d822.s2.e0" origId="3664359" charOffset="75-80" type="compound" text="Pit-1"/>
            <entity id="DS3.d822.s2.e1" origId="P01237,B5DEM6,B2RYT1" charOffset="134-137" type="protein" text="PRL"/>
            <entity id="DS3.d822.s2.e2" origId="P01237,B5DEM6,B2RYT1" charOffset="139-143" type="protein" text="rPRL"/>
            <pair e1="DS3.d822.s2.e0" e2="DS3.d822.s2.e2" id="DS3.d822.s2.i0" interaction="False" />
            <pair e1="DS3.d822.s2.e0" e2="DS3.d822.s2.e1" id="DS3.d822.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d822.s3" origId="9973253-3" text="Pit-1, a POU-homeo domain transcription factor, is specifically expressed in the anterior pituitary and is required both for the normal development of anterior pituitary cell types, somatotrophs, lactotrophs, and thyrotrophs, and for the expression of their hormones: GH, PRL, and TSHbeta.">
            <entity id="DS3.d822.s3.e0" origId="3664359" charOffset="0-5" type="compound" text="Pit-1"/>
            <entity id="DS3.d822.s3.e1" origId="P01237,B5DEM6,B2RYT1" charOffset="272-275" type="protein" text="PRL"/>
            <entity id="DS3.d822.s3.e2" origId="P04652,A0A0F7RQR3" charOffset="281-288" type="protein" text="TSHbeta"/>
            <pair e1="DS3.d822.s3.e0" e2="DS3.d822.s3.e2" id="DS3.d822.s3.i0" interaction="False" />
            <pair e1="DS3.d822.s3.e0" e2="DS3.d822.s3.e1" id="DS3.d822.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d822.s4" origId="9973253-4" text="Pit-1 has been shown to functionally interact, via FP I, with several transcription factors, including Oct-1, a ubiquitous homeobox protein, and thyrotroph embryonic factor, which is found in lactotrophs, to activate basal rPRL promoter activity.">
            <entity id="DS3.d822.s4.e0" origId="3664359" charOffset="0-5" type="compound" text="Pit-1"/>
            <entity id="DS3.d822.s4.e1" origId="Q63089" charOffset="103-108" type="protein" text="Oct-1"/>
            <entity id="DS3.d822.s4.e2" origId="P01237,B5DEM6,B2RYT1" charOffset="223-227" type="protein" text="rPRL"/>
            <pair e1="DS3.d822.s4.e0" e2="DS3.d822.s4.e2" id="DS3.d822.s4.i0" interaction="False" />
            <pair e1="DS3.d822.s4.e0" e2="DS3.d822.s4.e1" id="DS3.d822.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d822.s5" origId="9973253-5" text="Pit-1beta/GHF-2, a distinct splice isoform of Pit-1, acts to inhibit Ras-activated transcription from the rPRL promoter, which is mediated by a functional interaction between Pit-1 and Ets-1 at the most distal Pit-1 binding site (FP IV).">
            <entity id="DS3.d822.s5.e0" origId="3664359" charOffset="0-5" type="compound" text="Pit-1"/>
            <entity id="DS3.d822.s5.e1" origId="P01237,B5DEM6,B2RYT1" charOffset="106-110" type="protein" text="rPRL"/>
            <entity id="DS3.d822.s5.e2" origId="3664359" charOffset="46-51" type="compound" text="Pit-1"/>
            <entity id="DS3.d822.s5.e3" origId="P41156" charOffset="185-190" type="protein" text="Ets-1"/>
            <entity id="DS3.d822.s5.e4" origId="3664359" charOffset="46-51" type="compound" text="Pit-1"/>
            <pair e1="DS3.d822.s5.e0" e2="DS3.d822.s5.e1" id="DS3.d822.s5.i0" interaction="False" />
            <pair e1="DS3.d822.s5.e0" e2="DS3.d822.s5.e3" id="DS3.d822.s5.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d822.s6" origId="9973253-6" text="In this manuscript we show 1) that the Pit-1beta isoform not only fails to block PKA activation, but is, in fact, a superior mediator of the PKA response; 2) that the PKA response requires intact POU-specific and POU-homeo domains of Pit-1; and 3) that Oct-1, but not thyrotroph embryonic factor, functions as a Pit-1-interacting factor to mediate an optimal PKA response.">
            <entity id="DS3.d822.s6.e0" origId="3664359" charOffset="39-44" type="compound" text="Pit-1"/>
            <entity id="DS3.d822.s6.e1" origId="Q63089" charOffset="253-258" type="protein" text="Oct-1"/>
            <entity id="DS3.d822.s6.e2" origId="3664359" charOffset="234-239" type="compound" text="Pit-1"/>
            <pair e1="DS3.d822.s6.e0" e2="DS3.d822.s6.e1" id="DS3.d822.s6.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d823" origId="9973257">
        <sentence id="DS3.d823.s0" origId="9973257-0" text="Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization.">
            <entity id="DS3.d823.s0.e0" origId="444795" charOffset="17-30" type="compound" text="retinoic acid"/>
            <entity id="DS3.d823.s0.e1" origId="P01100,Q6FG41" charOffset="90-95" type="protein" text="c-Fos"/>
            <pair e1="DS3.d823.s0.e0" e2="DS3.d823.s0.e1" id="DS3.d823.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d823.s1" origId="9973257-1" text="In the presence of retinoic acid (RA), the retinoid receptors, retinoic acid receptor (RAR) and retinoid X receptor (RXR), are able to up-regulate transcription directly by binding to RA-responsive elements on the promoters of responsive genes.">
            <entity id="DS3.d823.s1.e0" origId="444795" charOffset="19-32" type="compound" text="retinoic acid"/>
            <entity id="DS3.d823.s1.e1" origId="444795" charOffset="63-76" type="compound" text="retinoic acid"/>
            <entity id="DS3.d823.s1.e2" origId="P19793,F1D8Q5,Q6P3U7" charOffset="96-115" type="protein" text="retinoid X receptor"/>
            <entity id="DS3.d823.s1.e3" origId="P19793,F1D8Q5,Q6P3U7" charOffset="117-120" type="protein" text="RXR"/>
            <pair e1="DS3.d823.s1.e0" e2="DS3.d823.s1.e3" id="DS3.d823.s1.i0" interaction="False" />
            <pair e1="DS3.d823.s1.e0" e2="DS3.d823.s1.e2" id="DS3.d823.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d824" origId="9973258">
        <sentence id="DS3.d824.s0" origId="9973258-4" text="We found that the interaction of E or E/F domains of the ER with full-length ER is estradiol dependent and estrogen responsive element independent, as measured by the reconstitution of GAL4 activity from GAL4-E domain-containing fusion protein interactions.">
            <entity id="DS3.d824.s0.e0" origId="5757" charOffset="83-92" type="compound" text="estradiol"/>
            <entity id="DS3.d824.s0.e1" origId="P04386" charOffset="185-189" type="protein" text="GAL4"/>
            <entity id="DS3.d824.s0.e2" origId="P04386" charOffset="204-208" type="protein" text="GAL4"/>
            <pair e1="DS3.d824.s0.e0" e2="DS3.d824.s0.e1" id="DS3.d824.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d825" origId="9973262">
        <sentence id="DS3.d825.s0" origId="9973262-0" text="Glucocorticoid receptor/signal transducer and activator of transcription 5 (STAT5) interactions enhance STAT5 activation by prolonging STAT5 DNA binding and tyrosine phosphorylation.">
            <entity id="DS3.d825.s0.e0" origId="P42229,Q59GY7,A8K6I5,K7EK35" charOffset="24-74" type="protein" text="signal transducer and activator of transcription 5"/>
            <entity id="DS3.d825.s0.e1" origId="P42229,Q59GY7,A8K6I5,K7EK35" charOffset="76-81" type="protein" text="STAT5"/>
            <entity id="DS3.d825.s0.e2" origId="P42229,Q59GY7,A8K6I5,K7EK35" charOffset="104-109" type="protein" text="STAT5"/>
            <entity id="DS3.d825.s0.e3" origId="P42229,Q59GY7,A8K6I5,K7EK35" charOffset="104-109" type="protein" text="STAT5"/>
            <entity id="DS3.d825.s0.e4" origId="6057,90983769" charOffset="157-165" type="compound" text="tyrosine"/>
            <pair e1="DS3.d825.s0.e4" e2="DS3.d825.s0.e1" id="DS3.d825.s0.i0" interaction="False" />
            <pair e1="DS3.d825.s0.e4" e2="DS3.d825.s0.e0" id="DS3.d825.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d825.s1" origId="9973262-8" text="This was correlated with increased STAT5 tyrosine phosphorylation, suggesting that GR enhances STAT5 DNA binding by modulating the rate of STAT5 dephosphorylation.">
            <entity id="DS3.d825.s1.e0" origId="P42229,Q59GY7,A8K6I5,K7EK35" charOffset="35-40" type="protein" text="STAT5"/>
            <entity id="DS3.d825.s1.e1" origId="6057,90983769" charOffset="41-49" type="compound" text="tyrosine"/>
            <entity id="DS3.d825.s1.e2" origId="P42229,Q59GY7,A8K6I5,K7EK35" charOffset="95-100" type="protein" text="STAT5"/>
            <entity id="DS3.d825.s1.e3" origId="P42229,Q59GY7,A8K6I5,K7EK35" charOffset="95-100" type="protein" text="STAT5"/>
            <pair e1="DS3.d825.s1.e1" e2="DS3.d825.s1.e0" id="DS3.d825.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d825.s2" origId="9973262-9" text="In contrast, cotransfection of the estrogen receptor resulted in an overall decrease in STAT5 tyrosine phosphorylation, without changing the kinetics of dephosphorylation.">
            <entity id="DS3.d825.s2.e0" origId="P42229,Q59GY7,A8K6I5,K7EK35" charOffset="88-93" type="protein" text="STAT5"/>
            <entity id="DS3.d825.s2.e1" origId="6057,90983769" charOffset="94-102" type="compound" text="tyrosine"/>
            <pair e1="DS3.d825.s2.e1" e2="DS3.d825.s2.e0" id="DS3.d825.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d826" origId="9973263">
        <sentence id="DS3.d826.s0" origId="9973263-3" text="Estrogen induces the expression of progesterone receptors in atrial natriuretic factor neurons and also augments neuronal functions by increasing expression of constitutively active D5 receptors that generate cAMP in a ligand-independent manner.">
            <entity id="DS3.d826.s0.e0" origId="5994" charOffset="35-47" type="compound" text="progesterone"/>
            <entity id="DS3.d826.s0.e1" origId="G3V8S9" charOffset="209-213" type="protein" text="cAMP"/>
            <pair e1="DS3.d826.s0.e0" e2="DS3.d826.s0.e1" id="DS3.d826.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d826.s1" origId="9973263-4" text="Such a cross-talk mechanism allows estrogen to exert its effects via the adenylyl cyclase-cAMP system by augmenting dopamine receptor activity, an action that may play an important integrative role in facilitating female sexual behavior.">
            <entity id="DS3.d826.s1.e0" origId="G3V8S9" charOffset="90-94" type="protein" text="cAMP"/>
            <entity id="DS3.d826.s1.e1" origId="681" charOffset="116-124" type="compound" text="dopamine"/>
            <pair e1="DS3.d826.s1.e1" e2="DS3.d826.s1.e0" id="DS3.d826.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d827" origId="9973269">
        <sentence id="DS3.d827.s0" origId="9973269-7" text="However, exogenous FSH stimulation induced a marked rise in inhibin, which correlated with an estradiol rise.">
            <entity id="DS3.d827.s0.e0" origId="P25440,X5CF57,A0A024RCR5" charOffset="19-22" type="protein" text="FSH"/>
            <entity id="DS3.d827.s0.e1" origId="5757" charOffset="94-103" type="compound" text="estradiol"/>
            <pair e1="DS3.d827.s0.e1" e2="DS3.d827.s0.e0" id="DS3.d827.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d828" origId="9973281">
        <sentence id="DS3.d828.s0" origId="9973281-2" text="Recently, we showed that mutations in the putative zinc finger transcription factor gene SALL1 cause TBS.">
            <entity id="DS3.d828.s0.e0" origId="23994" charOffset="51-55" type="compound" text="zinc"/>
            <entity id="DS3.d828.s0.e1" origId="Q9NSC2" charOffset="89-94" type="protein" text="SALL1"/>
            <pair e1="DS3.d828.s0.e0" e2="DS3.d828.s0.e1" id="DS3.d828.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d828.s1" origId="9973281-9" text="This suggests that only SALL1 mutations that remove the DZF domains result in TBS.">
            <entity id="DS3.d828.s1.e0" origId="Q9NSC2" charOffset="24-29" type="protein" text="SALL1"/>
            <entity id="DS3.d828.s1.e1" origId="6323294" charOffset="56-59" type="compound" text="DZF"/>
            <pair e1="DS3.d828.s1.e1" e2="DS3.d828.s1.e0" id="DS3.d828.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d829" origId="9973283">
        <sentence id="DS3.d829.s0" origId="9973283-6" text="The specific activity of the V94M-hGALE protein expressed in yeast was severely reduced with regard to UDP-galactose and partially reduced with regard to UDP-N-acetylgalactosamine.">
            <entity id="DS3.d829.s0.e0" origId="Q14376" charOffset="34-39" type="protein" text="hGALE"/>
            <entity id="DS3.d829.s0.e1" origId="23724458,439158,1166,46936243,18068,56845790" charOffset="103-116" type="compound" text="UDP-galactose"/>
            <entity id="DS3.d829.s0.e2" origId="6031" charOffset="103-106" type="compound" text="UDP"/>
            <entity id="DS3.d829.s0.e3" origId="440552,84265,899,57455154" charOffset="158-179" type="compound" text="N-acetylgalactosamine"/>
            <pair e1="DS3.d829.s0.e1" e2="DS3.d829.s0.e0" id="DS3.d829.s0.i0" interaction="False" />
            <pair e1="DS3.d829.s0.e2" e2="DS3.d829.s0.e0" id="DS3.d829.s0.i1" interaction="False" />
            <pair e1="DS3.d829.s0.e3" e2="DS3.d829.s0.e0" id="DS3.d829.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d830" origId="9973288">
        <sentence id="DS3.d830.s0" origId="9973288-3" text="The HPT-JT gene (HRPT2) maps to chromosome 1q25-q31.">
            <entity id="DS3.d830.s0.e0" origId="Q6P1J9" charOffset="17-22" type="protein" text="HRPT2"/>
            <entity id="DS3.d830.s0.e1" origId="72551594" charOffset="48-51" type="compound" text="q31"/>
            <pair e1="DS3.d830.s0.e1" e2="DS3.d830.s0.e0" id="DS3.d830.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d831" origId="9973309">
        <sentence id="DS3.d831.s0" origId="9973309-4" text="More recently, studies of the role of C-13 hydroxy metabolites of anthracyclines have provided new perspectives on the role of iron in the cardiotoxicity of these drugs, showing that such metabolites can impair intracellular iron handling and homeostasis.">
            <entity id="DS3.d831.s0.e0" origId="P31276" charOffset="38-42" type="protein" text="C-13"/>
            <entity id="DS3.d831.s0.e1" origId="23925,67172434" charOffset="127-131" type="compound" text="iron"/>
            <entity id="DS3.d831.s0.e2" origId="23925,67172434" charOffset="225-229" type="compound" text="iron"/>
            <pair e1="DS3.d831.s0.e1" e2="DS3.d831.s0.e0" id="DS3.d831.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d832" origId="9973311">
        <sentence id="DS3.d832.s0" origId="9973311-0" text="Glucose and free radicals impair the antioxidant properties of serum albumin.">
            <entity id="DS3.d832.s0.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS3.d832.s0.e1" origId="P02768" charOffset="69-76" type="protein" text="albumin"/>
            <pair e1="DS3.d832.s0.e0" e2="DS3.d832.s0.e1" id="DS3.d832.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d832.s1" origId="9973311-13" text="Although these results warrant further in vivo investigations, we propose that, considering the poor glucose control found in diabetics as well as the key role of oxidative stress in vascular complications, glycation-mediated and free radical-induced impairment of the antioxidant properties of albumin might be important parameters in vascular complications encountered in diabetes.">
            <entity id="DS3.d832.s1.e0" origId="206,5793,64689,79025" charOffset="101-108" type="compound" text="glucose"/>
            <entity id="DS3.d832.s1.e1" origId="P02768" charOffset="295-302" type="protein" text="albumin"/>
            <pair e1="DS3.d832.s1.e0" e2="DS3.d832.s1.e1" id="DS3.d832.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d833" origId="9973312">
        <sentence id="DS3.d833.s0" origId="9973312-0" text="Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy.">
            <entity id="DS3.d833.s0.e0" origId="P35354" charOffset="16-33" type="protein" text="cyclo-oxygenase-2"/>
            <entity id="DS3.d833.s0.e1" origId="444899" charOffset="48-64" type="compound" text="arachidonic acid"/>
            <pair e1="DS3.d833.s0.e1" e2="DS3.d833.s0.e0" id="DS3.d833.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d833.s1" origId="9973312-11" text="A., Warner, T. D. Synergy between cyclo-oxygenase-2 induction and arachidonic acid supply in vivo: consequences for nonsteroidal antiinflammatory drug efficacy.">
            <entity id="DS3.d833.s1.e0" origId="P35354" charOffset="34-51" type="protein" text="cyclo-oxygenase-2"/>
            <entity id="DS3.d833.s1.e1" origId="444899" charOffset="66-82" type="compound" text="arachidonic acid"/>
            <pair e1="DS3.d833.s1.e1" e2="DS3.d833.s1.e0" id="DS3.d833.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d833.s2" origId="9973312-4" text="Thus, only after intravenous injection of bradykinin or exogenous arachidonic acid was a marked increase in prostanoid formation seen.">
            <entity id="DS3.d833.s2.e0" origId="P01042" charOffset="42-52" type="protein" text="bradykinin"/>
            <entity id="DS3.d833.s2.e1" origId="444899" charOffset="66-82" type="compound" text="arachidonic acid"/>
            <pair e1="DS3.d833.s2.e1" e2="DS3.d833.s2.e0" id="DS3.d833.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d834" origId="9973314">
        <sentence id="DS3.d834.s0" origId="9973314-4" text="A subsequent proliferative response to stem cell factor (SCF), the ligand for the proto-oncogene receptor tyrosine kinase c-kit, is characterized by an initial maturation in immunophenotype and subsequent self-renewal of cells (SCF blasts) without differentiation for at least 50 generations.">
            <entity id="DS3.d834.s0.e0" origId="P21581,F1LYJ6,Q54A14" charOffset="39-55" type="protein" text="stem cell factor"/>
            <entity id="DS3.d834.s0.e1" origId="P21581,F1LYJ6,Q54A14" charOffset="57-60" type="protein" text="SCF"/>
            <entity id="DS3.d834.s0.e2" origId="6057,90983769" charOffset="106-114" type="compound" text="tyrosine"/>
            <entity id="DS3.d834.s0.e3" origId="P21581,F1LYJ6,Q54A14" charOffset="228-231" type="protein" text="SCF"/>
            <pair e1="DS3.d834.s0.e2" e2="DS3.d834.s0.e0" id="DS3.d834.s0.i0" interaction="False" />
            <pair e1="DS3.d834.s0.e2" e2="DS3.d834.s0.e1" id="DS3.d834.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d834.s1" origId="9973314-5" text="Although granulocyte colony-stimulating factor (G-CSF), interleukin (IL) -6, IL-7, and IL-11 synergize with SCF to increase blast colony formation, cytokines such as granulocyte-macrophage CSF or IL-3 are without significant effect.">
            <entity id="DS3.d834.s1.e0" origId="16122568,16750043,4369303,448383" charOffset="50-53" type="compound" text="CSF"/>
            <entity id="DS3.d834.s1.e1" origId="Q91Y32" charOffset="77-81" type="protein" text="IL-7"/>
            <entity id="DS3.d834.s1.e2" origId="G3V890" charOffset="87-92" type="protein" text="IL-11"/>
            <entity id="DS3.d834.s1.e3" origId="P21581,F1LYJ6,Q54A14" charOffset="108-111" type="protein" text="SCF"/>
            <entity id="DS3.d834.s1.e4" origId="16122568,16750043,4369303,448383" charOffset="189-192" type="compound" text="CSF"/>
            <entity id="DS3.d834.s1.e5" origId="P97688" charOffset="196-200" type="protein" text="IL-3"/>
            <pair e1="DS3.d834.s1.e0" e2="DS3.d834.s1.e5" id="DS3.d834.s1.i0" interaction="False" />
            <pair e1="DS3.d834.s1.e0" e2="DS3.d834.s1.e1" id="DS3.d834.s1.i1" interaction="False" />
            <pair e1="DS3.d834.s1.e0" e2="DS3.d834.s1.e3" id="DS3.d834.s1.i2" interaction="False" />
            <pair e1="DS3.d834.s1.e0" e2="DS3.d834.s1.e2" id="DS3.d834.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d834.s2" origId="9973314-8" text="Data indicate a pivotal role for SCF/c-kit interaction during antigenic maturation, self-renewal, and apoptotic protection of these lineage-restricted progenitors during non-CSF-mediated induction of differentiation.">
            <entity id="DS3.d834.s2.e0" origId="P21581,F1LYJ6,Q54A14" charOffset="33-36" type="protein" text="SCF"/>
            <entity id="DS3.d834.s2.e1" origId="16122568,16750043,4369303,448383" charOffset="174-177" type="compound" text="CSF"/>
            <pair e1="DS3.d834.s2.e1" e2="DS3.d834.s2.e0" id="DS3.d834.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d835" origId="9973315">
        <sentence id="DS3.d835.s0" origId="9973315-1" text="CD38, a transmembrane glycoprotein widely expressed in vertebrate cells, is a bifunctional ectoenzyme catalyzing the synthesis and hydrolysis of cyclic ADP-ribose (cADPR).">
            <entity id="DS3.d835.s0.e0" origId="P28907" charOffset="0-4" type="protein" text="CD38"/>
            <entity id="DS3.d835.s0.e1" origId="123847" charOffset="145-162" type="compound" text="cyclic ADP-ribose"/>
            <pair e1="DS3.d835.s0.e1" e2="DS3.d835.s0.e0" id="DS3.d835.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d835.s1" origId="9973315-4" text="Recently, we demonstrated that CD38 is a catalytically active, unidirectional transmembrane transporter of cADPR, which then reaches its receptor-operated intracellular calcium stores.">
            <entity id="DS3.d835.s1.e0" origId="P28907" charOffset="31-35" type="protein" text="CD38"/>
            <entity id="DS3.d835.s1.e1" origId="22044544,5460341" charOffset="169-176" type="compound" text="calcium"/>
            <pair e1="DS3.d835.s1.e1" e2="DS3.d835.s1.e0" id="DS3.d835.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d835.s2" origId="9973315-7" text="This effect of CD38-internalizing ligands on intracellular calcium levels was found to involve a two-step mechanism: 1) influx of cytosolic NAD+ into the endocytotic vesicles, mediated by a hitherto unrecognized dinucleotide transport system that is saturable, bidirectional, inhibitable by 8-N3-NAD+, and characterized by poor dinucleotide specificity, low affinity, and high efficiency; 2) intravesicular CD38-catalyzed conversion of NAD+ to cADPR, followed by outpumping of the cyclic nucleotide into the cytosol and subsequent release of calcium from thapsigargin-sensitive stores.">
            <entity id="DS3.d835.s2.e0" origId="P28907" charOffset="15-19" type="protein" text="CD38"/>
            <entity id="DS3.d835.s2.e1" origId="22044544,5460341" charOffset="59-66" type="compound" text="calcium"/>
            <entity id="DS3.d835.s2.e2" origId="P28907" charOffset="407-411" type="protein" text="CD38"/>
            <entity id="DS3.d835.s2.e3" origId="22044544,5460341" charOffset="542-549" type="compound" text="calcium"/>
            <entity id="DS3.d835.s2.e4" origId="446378,49926" charOffset="555-567" type="compound" text="thapsigargin"/>
            <pair e1="DS3.d835.s2.e1" e2="DS3.d835.s2.e0" id="DS3.d835.s2.i0" interaction="False" />
            <pair e1="DS3.d835.s2.e4" e2="DS3.d835.s2.e0" id="DS3.d835.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d835.s3" origId="9973315-8" text="This unknown intracellular trafficking of NAD+ and cADPR based on two distinctive and specific transmembrane carriers for either nucleotide can affect the intracellular calcium homeostasis in CD38(+) cells.">
            <entity id="DS3.d835.s3.e0" origId="22044544,5460341" charOffset="169-176" type="compound" text="calcium"/>
            <entity id="DS3.d835.s3.e1" origId="P28907" charOffset="192-196" type="protein" text="CD38"/>
            <pair e1="DS3.d835.s3.e0" e2="DS3.d835.s3.e1" id="DS3.d835.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d836" origId="9973316">
        <sentence id="DS3.d836.s0" origId="9973316-4" text="Cultivation of EBs at increasing oxygen concentrations (starting at 1% O2) did not influence the temporal expression pattern of embryonic (betaH1) globin compared to the normoxic controls (20% O2).">
            <entity id="DS3.d836.s0.e0" origId="977" charOffset="33-39" type="compound" text="oxygen"/>
            <entity id="DS3.d836.s0.e1" origId="P04444,Q5EBL1" charOffset="139-145" type="protein" text="betaH1"/>
            <pair e1="DS3.d836.s0.e0" e2="DS3.d836.s0.e1" id="DS3.d836.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d837" origId="9973319">
        <sentence id="DS3.d837.s0" origId="9973319-6" text="The NO/cGMP-mediated ICa depression was dependent on a reduction of cAMP/protein kinase A (PKA) levels since application of the catalytic subunit of PKA or of the PKA inhibitor PK) prevented the carbachol effect.">
            <entity id="DS3.d837.s0.e0" origId="24316" charOffset="7-11" type="compound" text="cGMP"/>
            <entity id="DS3.d837.s0.e1" origId="P49913,J3KNB4" charOffset="68-72" type="protein" text="cAMP"/>
            <entity id="DS3.d837.s0.e2" origId="2551" charOffset="195-204" type="compound" text="carbachol"/>
            <pair e1="DS3.d837.s0.e0" e2="DS3.d837.s0.e1" id="DS3.d837.s0.i0" interaction="False" />
            <pair e1="DS3.d837.s0.e2" e2="DS3.d837.s0.e1" id="DS3.d837.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d838" origId="9973323">
        <sentence id="DS3.d838.s0" origId="9973323-4" text="Secretion of IFN-gamma by PMA and ionomycin-stimulated clones of Th1 cells was not altered by VIP.">
            <entity id="DS3.d838.s0.e0" origId="122634,22833501,27924,4792" charOffset="26-29" type="compound" text="PMA"/>
            <entity id="DS3.d838.s0.e1" origId="25134244,3733,6434517,5353687,6912226" charOffset="34-43" type="compound" text="ionomycin"/>
            <entity id="DS3.d838.s0.e2" origId="P32648" charOffset="94-97" type="protein" text="VIP"/>
            <pair e1="DS3.d838.s0.e1" e2="DS3.d838.s0.e2" id="DS3.d838.s0.i0" interaction="False" />
            <pair e1="DS3.d838.s0.e0" e2="DS3.d838.s0.e2" id="DS3.d838.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d839" origId="9973326">
        <sentence id="DS3.d839.s0" origId="9973326-1" text="The Tie gene encodes an endothelial cell receptor tyrosine kinase necessary for normal vascular development.">
            <entity id="DS3.d839.s0.e0" origId="Q06806,P35590,B4DTW8" charOffset="4-7" type="protein" text="Tie"/>
            <entity id="DS3.d839.s0.e1" origId="6057,90983769" charOffset="50-58" type="compound" text="tyrosine"/>
            <pair e1="DS3.d839.s0.e1" e2="DS3.d839.s0.e0" id="DS3.d839.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d840" origId="9973338">
        <sentence id="DS3.d840.s0" origId="9973338-8" text="Cells unable to break down long-chain-base phosphates, due to deletion of DPL1 and LCB3, show a 500-fold increase in PHS-1-P and DHS-1-P levels, grow slowly, and survive a 44 degreesC heat stress 10-fold better than parental cells.">
            <entity id="DS3.d840.s0.e0" origId="Q05567" charOffset="74-78" type="protein" text="DPL1"/>
            <entity id="DS3.d840.s0.e1" origId="P47013" charOffset="83-87" type="protein" text="LCB3"/>
            <entity id="DS3.d840.s0.e2" origId="644260" charOffset="129-136" type="compound" text="DHS-1-P"/>
            <pair e1="DS3.d840.s0.e2" e2="DS3.d840.s0.e1" id="DS3.d840.s0.i0" interaction="False" />
            <pair e1="DS3.d840.s0.e2" e2="DS3.d840.s0.e0" id="DS3.d840.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d840.s1" origId="9973338-9" text="These and other data for DPL1 or LCB3 single-mutant strains suggest that DHS-1-P and/or PHS-1-P act as signals for resistance to heat stress.">
            <entity id="DS3.d840.s1.e0" origId="Q05567" charOffset="25-29" type="protein" text="DPL1"/>
            <entity id="DS3.d840.s1.e1" origId="P47013" charOffset="33-37" type="protein" text="LCB3"/>
            <entity id="DS3.d840.s1.e2" origId="644260" charOffset="73-80" type="compound" text="DHS-1-P"/>
            <pair e1="DS3.d840.s1.e2" e2="DS3.d840.s1.e1" id="DS3.d840.s1.i0" interaction="False" />
            <pair e1="DS3.d840.s1.e2" e2="DS3.d840.s1.e0" id="DS3.d840.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d841" origId="9973346">
        <sentence id="DS3.d841.s0" origId="9973346-6" text="ATP and ADP transport was specific since AMP, GTP, CTP, UTP, dATP, dCTP, dGTP, and dTTP did not inhibit uptake.">
            <entity id="DS3.d841.s0.e0" origId="5957" charOffset="0-3" type="compound" text="ATP"/>
            <entity id="DS3.d841.s0.e1" origId="6022" charOffset="8-11" type="compound" text="ADP"/>
            <entity id="DS3.d841.s0.e2" origId="6830" charOffset="46-49" type="compound" text="GTP"/>
            <entity id="DS3.d841.s0.e3" origId="6176" charOffset="51-54" type="compound" text="CTP"/>
            <entity id="DS3.d841.s0.e4" origId="6133" charOffset="56-59" type="compound" text="UTP"/>
            <entity id="DS3.d841.s0.e5" origId="15993" charOffset="61-65" type="compound" text="dATP"/>
            <entity id="DS3.d841.s0.e6" origId="65091" charOffset="67-71" type="compound" text="dCTP"/>
            <entity id="DS3.d841.s0.e7" origId="65103" charOffset="73-77" type="compound" text="dGTP"/>
            <entity id="DS3.d841.s0.e8" origId="P47980,B3DN56" charOffset="83-87" type="protein" text="dTTP"/>
            <pair e1="DS3.d841.s0.e3" e2="DS3.d841.s0.e8" id="DS3.d841.s0.i0" interaction="False" />
            <pair e1="DS3.d841.s0.e1" e2="DS3.d841.s0.e8" id="DS3.d841.s0.i1" interaction="False" />
            <pair e1="DS3.d841.s0.e7" e2="DS3.d841.s0.e8" id="DS3.d841.s0.i2" interaction="False" />
            <pair e1="DS3.d841.s0.e5" e2="DS3.d841.s0.e8" id="DS3.d841.s0.i3" interaction="False" />
            <pair e1="DS3.d841.s0.e2" e2="DS3.d841.s0.e8" id="DS3.d841.s0.i4" interaction="False" />
            <pair e1="DS3.d841.s0.e4" e2="DS3.d841.s0.e8" id="DS3.d841.s0.i5" interaction="False" />
            <pair e1="DS3.d841.s0.e0" e2="DS3.d841.s0.e8" id="DS3.d841.s0.i6" interaction="False" />
            <pair e1="DS3.d841.s0.e6" e2="DS3.d841.s0.e8" id="DS3.d841.s0.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d842" origId="9973353">
        <sentence id="DS3.d842.s0" origId="9973353-1" text="The eubacterial 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (EC 1.1.1.34) was purified 3,000-fold from Streptomyces sp.">
            <entity id="DS3.d842.s0.e0" origId="15983954" charOffset="16-53" type="compound" text="3-hydroxy-3-methylglutaryl coenzyme A"/>
            <entity id="DS3.d842.s0.e1" origId="P04035,A0A024RAP2" charOffset="55-73" type="protein" text="HMG-CoA) reductase"/>
            <pair e1="DS3.d842.s0.e0" e2="DS3.d842.s0.e1" id="DS3.d842.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d842.s1" origId="9973353-5" text="The enzyme showed a pH optimum of around 7.2, with apparent Km values of 62 microM for NADPH and 7.7 microM for HMG-CoA.">
            <entity id="DS3.d842.s1.e0" origId="Q16698,A0A024R9D7" charOffset="87-92" type="protein" text="NADPH"/>
            <entity id="DS3.d842.s1.e1" origId="439218,52922021" charOffset="112-119" type="compound" text="HMG-CoA"/>
            <pair e1="DS3.d842.s1.e1" e2="DS3.d842.s1.e0" id="DS3.d842.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d843" origId="9973359">
        <sentence id="DS3.d843.s0" origId="9973359-3" text="The cbzE gene appeared to be plasmid localized and was found in a region that also harbors genes encoding a transposase, a ferredoxin that was homologous to XylT, an open reading frame with similarity to a protein of a meta-cleavage pathway with unknown function, and a 2-hydroxymuconic semialdehyde dehydrogenase.">
            <entity id="DS3.d843.s0.e0" origId="Q8RMN5" charOffset="108-119" type="protein" text="transposase"/>
            <entity id="DS3.d843.s0.e1" origId="Q847G8" charOffset="123-133" type="protein" text="ferredoxin"/>
            <entity id="DS3.d843.s0.e2" origId="P23103,Q7AXV0" charOffset="157-161" type="protein" text="XylT"/>
            <entity id="DS3.d843.s0.e3" origId="5280366" charOffset="270-299" type="compound" text="2-hydroxymuconic semialdehyde"/>
            <pair e1="DS3.d843.s0.e3" e2="DS3.d843.s0.e1" id="DS3.d843.s0.i0" interaction="False" />
            <pair e1="DS3.d843.s0.e3" e2="DS3.d843.s0.e2" id="DS3.d843.s0.i1" interaction="False" />
            <pair e1="DS3.d843.s0.e3" e2="DS3.d843.s0.e0" id="DS3.d843.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d844" origId="9973367">
        <sentence id="DS3.d844.s0" origId="9973367-8" text="We conclude from the results of these physiological and genetic experiments that T4 gp2 expression, like Mu Gam expression, kills bacteria by binding to double-stranded DNA termini, the most likely mode for its protection of entering phage DNA from exonuclease V.">
            <entity id="DS3.d844.s0.e0" origId="448477" charOffset="84-87" type="compound" text="gp2"/>
            <entity id="DS3.d844.s0.e1" origId="P03702,C6ZCV5" charOffset="108-111" type="protein" text="Gam"/>
            <pair e1="DS3.d844.s0.e0" e2="DS3.d844.s0.e1" id="DS3.d844.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d845" origId="9973376">
        <sentence id="DS3.d845.s0" origId="9973376-0" text="IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells.">
            <entity id="DS3.d845.s0.e0" origId="Q16552" charOffset="0-5" type="protein" text="IL-17"/>
            <entity id="DS3.d845.s0.e1" origId="Q8IXH7,H0UI80" charOffset="42-45" type="protein" text="Th1"/>
            <entity id="DS3.d845.s0.e2" origId="12563346" charOffset="46-49" type="compound" text="Th0"/>
            <pair e1="DS3.d845.s0.e2" e2="DS3.d845.s0.e0" id="DS3.d845.s0.i0" interaction="False" />
            <pair e1="DS3.d845.s0.e2" e2="DS3.d845.s0.e1" id="DS3.d845.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d845.s1" origId="9973376-12" text="The results demonstrate that some cells of the Th1/Th0 phenotype produce IL-17 but not cells of the Th2 phenotype.">
            <entity id="DS3.d845.s1.e0" origId="Q8IXH7,H0UI80" charOffset="47-50" type="protein" text="Th1"/>
            <entity id="DS3.d845.s1.e1" origId="12563346" charOffset="51-54" type="compound" text="Th0"/>
            <entity id="DS3.d845.s1.e2" origId="Q16552" charOffset="73-78" type="protein" text="IL-17"/>
            <pair e1="DS3.d845.s1.e1" e2="DS3.d845.s1.e2" id="DS3.d845.s1.i0" interaction="False" />
            <pair e1="DS3.d845.s1.e1" e2="DS3.d845.s1.e0" id="DS3.d845.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d845.s2" origId="9973376-13" text="Thus, IL-17 may define a new subset of T cells, and IL-17 production appears to be a mechanism for Th1/Th0 cells, the most frequent Th subtype present in the rheumatoid synovium, to contribute to the local inflammatory reactions.">
            <entity id="DS3.d845.s2.e0" origId="Q16552" charOffset="6-11" type="protein" text="IL-17"/>
            <entity id="DS3.d845.s2.e1" origId="Q16552" charOffset="52-57" type="protein" text="IL-17"/>
            <entity id="DS3.d845.s2.e2" origId="Q8IXH7,H0UI80" charOffset="99-102" type="protein" text="Th1"/>
            <entity id="DS3.d845.s2.e3" origId="12563346" charOffset="103-106" type="compound" text="Th0"/>
            <pair e1="DS3.d845.s2.e3" e2="DS3.d845.s2.e0" id="DS3.d845.s2.i0" interaction="False" />
            <pair e1="DS3.d845.s2.e3" e2="DS3.d845.s2.e2" id="DS3.d845.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d845.s3" origId="9973376-3" text="The present study was performed to see whether Th cells that produce IL-17 are associated with the Th1, Th2, or Th0 subset.">
            <entity id="DS3.d845.s3.e0" origId="Q16552" charOffset="69-74" type="protein" text="IL-17"/>
            <entity id="DS3.d845.s3.e1" origId="Q8IXH7,H0UI80" charOffset="99-102" type="protein" text="Th1"/>
            <entity id="DS3.d845.s3.e2" origId="12563346" charOffset="112-115" type="compound" text="Th0"/>
            <pair e1="DS3.d845.s3.e2" e2="DS3.d845.s3.e0" id="DS3.d845.s3.i0" interaction="False" />
            <pair e1="DS3.d845.s3.e2" e2="DS3.d845.s3.e1" id="DS3.d845.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d845.s4" origId="9973376-5" text="Thirteen clones were defined as Th1 since they produced IFN-gamma but not IL-4, and four clones were defined as Th0 type that produced both IL-4 and IFN-gamma.">
            <entity id="DS3.d845.s4.e0" origId="Q8IXH7,H0UI80" charOffset="32-35" type="protein" text="Th1"/>
            <entity id="DS3.d845.s4.e1" origId="12563346" charOffset="112-115" type="compound" text="Th0"/>
            <pair e1="DS3.d845.s4.e1" e2="DS3.d845.s4.e0" id="DS3.d845.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d845.s5" origId="9973376-8" text="Three Th1 clones and two Th0 clones produced IL-17.">
            <entity id="DS3.d845.s5.e0" origId="Q8IXH7,H0UI80" charOffset="6-9" type="protein" text="Th1"/>
            <entity id="DS3.d845.s5.e1" origId="12563346" charOffset="25-28" type="compound" text="Th0"/>
            <entity id="DS3.d845.s5.e2" origId="Q16552" charOffset="45-50" type="protein" text="IL-17"/>
            <pair e1="DS3.d845.s5.e1" e2="DS3.d845.s5.e2" id="DS3.d845.s5.i0" interaction="False" />
            <pair e1="DS3.d845.s5.e1" e2="DS3.d845.s5.e0" id="DS3.d845.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d846" origId="9973377">
        <sentence id="DS3.d846.s0" origId="9973377-5" text="Further, analysis of the clonal variants demonstrates that CD4-associated Lck is not essential for the inhibition observed, as anti-CD4 inhibits responses of clonal variants, expressing a form of CD4 unable to associate with Lck (double cysteine-mutated CD4).">
            <entity id="DS3.d846.s0.e0" origId="P06239,Q573B4" charOffset="74-77" type="protein" text="Lck"/>
            <entity id="DS3.d846.s0.e1" origId="P06239,Q573B4" charOffset="225-228" type="protein" text="Lck"/>
            <entity id="DS3.d846.s0.e2" origId="5862,90793998" charOffset="237-245" type="compound" text="cysteine"/>
            <pair e1="DS3.d846.s0.e2" e2="DS3.d846.s0.e0" id="DS3.d846.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d847" origId="9973378">
        <sentence id="DS3.d847.s0" origId="9973378-4" text="IL-4 suppressed activation of DNA binding and tyrosine phosphorylation of the transcription factor Stat5 by IL-2, and suppressed the expression of the IL-2-inducible genes CD25, CIS, the PGE2 receptor, and cytokine responsive (CR) genes CR1 and CR8.">
            <entity id="DS3.d847.s0.e0" origId="P05112,D4HNR6,Q5FC01" charOffset="0-4" type="protein" text="IL-4"/>
            <entity id="DS3.d847.s0.e1" origId="6057,90983769" charOffset="46-54" type="compound" text="tyrosine"/>
            <entity id="DS3.d847.s0.e2" origId="P60568,Q0GK43" charOffset="108-112" type="protein" text="IL-2"/>
            <entity id="DS3.d847.s0.e3" origId="P60568,Q0GK43" charOffset="151-155" type="protein" text="IL-2"/>
            <entity id="DS3.d847.s0.e4" origId="P01589,Q5W005" charOffset="172-176" type="protein" text="CD25"/>
            <entity id="DS3.d847.s0.e5" origId="Q9NSE2" charOffset="178-181" type="protein" text="CIS"/>
            <entity id="DS3.d847.s0.e6" origId="P17927,E9PDY4" charOffset="237-240" type="protein" text="CR1"/>
            <pair e1="DS3.d847.s0.e1" e2="DS3.d847.s0.e0" id="DS3.d847.s0.i0" interaction="False" />
            <pair e1="DS3.d847.s0.e1" e2="DS3.d847.s0.e5" id="DS3.d847.s0.i1" interaction="False" />
            <pair e1="DS3.d847.s0.e1" e2="DS3.d847.s0.e6" id="DS3.d847.s0.i2" interaction="False" />
            <pair e1="DS3.d847.s0.e1" e2="DS3.d847.s0.e4" id="DS3.d847.s0.i3" interaction="False" />
            <pair e1="DS3.d847.s0.e1" e2="DS3.d847.s0.e2" id="DS3.d847.s0.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d847.s1" origId="9973378-7" text="In contrast to suppression of Stat5, proliferative responses to IL-2 were augmented in IL-4-cultured cells, and activation of proliferative pathways leading to activation of mitogen activated protein kinases, induction of expression of Myc, Fos, Pim-1, and cyclin D3, and decreased levels of the cyclin-dependent kinase inhibitor p27 were intact.">
            <entity id="DS3.d847.s1.e0" origId="P60568,Q0GK43" charOffset="64-68" type="protein" text="IL-2"/>
            <entity id="DS3.d847.s1.e1" origId="P05112,D4HNR6,Q5FC01" charOffset="87-91" type="protein" text="IL-4"/>
            <entity id="DS3.d847.s1.e2" origId="P01100,Q6FG41" charOffset="241-244" type="protein" text="Fos"/>
            <entity id="DS3.d847.s1.e3" origId="P11309,A0A024RD25" charOffset="246-251" type="protein" text="Pim-1"/>
            <entity id="DS3.d847.s1.e4" origId="P30281,B3KP19,D6RI00,Q5T8J1" charOffset="257-266" type="protein" text="cyclin D3"/>
            <entity id="DS3.d847.s1.e5" origId="53378893" charOffset="313-329" type="compound" text="kinase inhibitor"/>
            <entity id="DS3.d847.s1.e6" origId="P40305,A8K0H0,A0A087WZF8,Q7Z5R2" charOffset="330-333" type="protein" text="p27"/>
            <pair e1="DS3.d847.s1.e5" e2="DS3.d847.s1.e4" id="DS3.d847.s1.i0" interaction="False" />
            <pair e1="DS3.d847.s1.e5" e2="DS3.d847.s1.e2" id="DS3.d847.s1.i1" interaction="False" />
            <pair e1="DS3.d847.s1.e5" e2="DS3.d847.s1.e1" id="DS3.d847.s1.i2" interaction="False" />
            <pair e1="DS3.d847.s1.e5" e2="DS3.d847.s1.e3" id="DS3.d847.s1.i3" interaction="False" />
            <pair e1="DS3.d847.s1.e5" e2="DS3.d847.s1.e0" id="DS3.d847.s1.i4" interaction="False" />
            <pair e1="DS3.d847.s1.e5" e2="DS3.d847.s1.e6" id="DS3.d847.s1.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d848" origId="9973379">
        <sentence id="DS3.d848.s0" origId="9973379-2" text="Studies with phosphorylated peptides based on the CTLA-4 intracellular domain have suggested that tyrosine phosphorylation of CTLA-4 may regulate its interactions with cytoplasmic proteins that could determine its intracellular trafficking and/or signal transduction.">
            <entity id="DS3.d848.s0.e0" origId="P16410" charOffset="50-56" type="protein" text="CTLA-4"/>
            <entity id="DS3.d848.s0.e1" origId="6057,90983769" charOffset="98-106" type="compound" text="tyrosine"/>
            <entity id="DS3.d848.s0.e2" origId="P16410" charOffset="126-132" type="protein" text="CTLA-4"/>
            <pair e1="DS3.d848.s0.e1" e2="DS3.d848.s0.e0" id="DS3.d848.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d848.s1" origId="9973379-4" text="In this report, we show that CTLA-4 can associate with the Src kinases Fyn and Lck and that transfection of Fyn or Lck, but not the unrelated kinase ZAP70, can induce tyrosine phosphorylation of CTLA-4 on residues Y201 and Y218.">
            <entity id="DS3.d848.s1.e0" origId="P16410" charOffset="29-35" type="protein" text="CTLA-4"/>
            <entity id="DS3.d848.s1.e1" origId="P06241" charOffset="71-74" type="protein" text="Fyn"/>
            <entity id="DS3.d848.s1.e2" origId="P06239,Q573B4" charOffset="79-82" type="protein" text="Lck"/>
            <entity id="DS3.d848.s1.e3" origId="P06241" charOffset="108-111" type="protein" text="Fyn"/>
            <entity id="DS3.d848.s1.e4" origId="P06239,Q573B4" charOffset="115-118" type="protein" text="Lck"/>
            <entity id="DS3.d848.s1.e5" origId="P43403" charOffset="149-154" type="protein" text="ZAP70"/>
            <entity id="DS3.d848.s1.e6" origId="6057,90983769" charOffset="167-175" type="compound" text="tyrosine"/>
            <entity id="DS3.d848.s1.e7" origId="P16410" charOffset="195-201" type="protein" text="CTLA-4"/>
            <pair e1="DS3.d848.s1.e6" e2="DS3.d848.s1.e5" id="DS3.d848.s1.i0" interaction="False" />
            <pair e1="DS3.d848.s1.e6" e2="DS3.d848.s1.e1" id="DS3.d848.s1.i1" interaction="False" />
            <pair e1="DS3.d848.s1.e6" e2="DS3.d848.s1.e0" id="DS3.d848.s1.i2" interaction="False" />
            <pair e1="DS3.d848.s1.e6" e2="DS3.d848.s1.e2" id="DS3.d848.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d848.s2" origId="9973379-5" text="A similar pattern of tyrosine phosphorylation was found in pervanadate-treated Jurkat T cells stably expressing CTLA-4.">
            <entity id="DS3.d848.s2.e0" origId="6057,90983769" charOffset="21-29" type="compound" text="tyrosine"/>
            <entity id="DS3.d848.s2.e1" origId="P16410" charOffset="112-118" type="protein" text="CTLA-4"/>
            <pair e1="DS3.d848.s2.e0" e2="DS3.d848.s2.e1" id="DS3.d848.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d848.s3" origId="9973379-7" text="CTLA-4 phosphorylation induced the association of CTLA-4 with the tyrosine phosphatase SHP-2, but not with phosphatidylinositol 3-kinase.">
            <entity id="DS3.d848.s3.e0" origId="P16410" charOffset="0-6" type="protein" text="CTLA-4"/>
            <entity id="DS3.d848.s3.e1" origId="P16410" charOffset="50-56" type="protein" text="CTLA-4"/>
            <entity id="DS3.d848.s3.e2" origId="6057,90983769" charOffset="66-74" type="compound" text="tyrosine"/>
            <entity id="DS3.d848.s3.e3" origId="Q06124" charOffset="87-92" type="protein" text="SHP-2"/>
            <entity id="DS3.d848.s3.e4" origId="16738692,53477912" charOffset="107-127" type="compound" text="phosphatidylinositol"/>
            <pair e1="DS3.d848.s3.e4" e2="DS3.d848.s3.e3" id="DS3.d848.s3.i0" interaction="False" />
            <pair e1="DS3.d848.s3.e4" e2="DS3.d848.s3.e0" id="DS3.d848.s3.i1" interaction="False" />
            <pair e1="DS3.d848.s3.e2" e2="DS3.d848.s3.e3" id="DS3.d848.s3.i2" interaction="False" />
            <pair e1="DS3.d848.s3.e2" e2="DS3.d848.s3.e0" id="DS3.d848.s3.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d848.s4" origId="9973379-8" text="In contrast, Lck-induced phosphorylation of CD28 resulted in the recruitment of phosphatidylinositol 3-kinase, but not SHP-2.">
            <entity id="DS3.d848.s4.e0" origId="P06239,Q573B4" charOffset="13-16" type="protein" text="Lck"/>
            <entity id="DS3.d848.s4.e1" origId="P10747,B4E0L1" charOffset="44-48" type="protein" text="CD28"/>
            <entity id="DS3.d848.s4.e2" origId="16738692,53477912" charOffset="80-100" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d848.s4.e3" origId="Q06124" charOffset="119-124" type="protein" text="SHP-2"/>
            <pair e1="DS3.d848.s4.e2" e2="DS3.d848.s4.e3" id="DS3.d848.s4.i0" interaction="False" />
            <pair e1="DS3.d848.s4.e2" e2="DS3.d848.s4.e1" id="DS3.d848.s4.i1" interaction="False" />
            <pair e1="DS3.d848.s4.e2" e2="DS3.d848.s4.e0" id="DS3.d848.s4.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d849" origId="9973380">
        <sentence id="DS3.d849.s0" origId="9973380-5" text="Freshly isolated CRTH2+ CD4+ T cells produced Th2- but little or no Th1-type cytokines upon stimulation with PMA and ionomycin.">
            <entity id="DS3.d849.s0.e0" origId="Q8IXH7,H0UI80" charOffset="68-71" type="protein" text="Th1"/>
            <entity id="DS3.d849.s0.e1" origId="122634,22833501,27924,4792" charOffset="109-112" type="compound" text="PMA"/>
            <entity id="DS3.d849.s0.e2" origId="25134244,3733,5353687,6434517,6912226" charOffset="117-126" type="compound" text="ionomycin"/>
            <pair e1="DS3.d849.s0.e2" e2="DS3.d849.s0.e0" id="DS3.d849.s0.i0" interaction="False" />
            <pair e1="DS3.d849.s0.e1" e2="DS3.d849.s0.e0" id="DS3.d849.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d850" origId="9973385">
        <sentence id="DS3.d850.s0" origId="9973385-0" text="Specificity of the SH2 domains of SHP-1 in the interaction with the immunoreceptor tyrosine-based inhibitory motif-bearing receptor gp49B.">
            <entity id="DS3.d850.s0.e0" origId="P97797,E0CYM8,Q6P6I8,E9QPT7,E0CX65" charOffset="34-39" type="protein" text="SHP-1"/>
            <entity id="DS3.d850.s0.e1" origId="6057,90983769" charOffset="83-91" type="compound" text="tyrosine"/>
            <entity id="DS3.d850.s0.e2" origId="Q64281" charOffset="132-137" type="protein" text="gp49B"/>
            <pair e1="DS3.d850.s0.e1" e2="DS3.d850.s0.e0" id="DS3.d850.s0.i0" interaction="False" />
            <pair e1="DS3.d850.s0.e1" e2="DS3.d850.s0.e2" id="DS3.d850.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d850.s1" origId="9973385-10" text="Thus, gp49B signaling involves SHP-1, and this association is dependent on tyrosine phosphorylation of the gp49B ITIMs, and an intact SHP-1 carboxyl SH2 domain.">
            <entity id="DS3.d850.s1.e0" origId="Q64281" charOffset="6-11" type="protein" text="gp49B"/>
            <entity id="DS3.d850.s1.e1" origId="P97797,E0CYM8,Q6P6I8,E9QPT7,E0CX65" charOffset="31-36" type="protein" text="SHP-1"/>
            <entity id="DS3.d850.s1.e2" origId="6057,90983769" charOffset="75-83" type="compound" text="tyrosine"/>
            <entity id="DS3.d850.s1.e3" origId="Q64281" charOffset="107-112" type="protein" text="gp49B"/>
            <entity id="DS3.d850.s1.e4" origId="P97797,E0CYM8,Q6P6I8,E9QPT7,E0CX65" charOffset="134-139" type="protein" text="SHP-1"/>
            <pair e1="DS3.d850.s1.e2" e2="DS3.d850.s1.e1" id="DS3.d850.s1.i0" interaction="False" />
            <pair e1="DS3.d850.s1.e2" e2="DS3.d850.s1.e0" id="DS3.d850.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d850.s2" origId="9973385-4" text="We demonstrate that the tyrosine residues within the ITIMs are phosphorylated and serve for the association and activation of the cytoplasmic tyrosine phosphatase SHP-1.">
            <entity id="DS3.d850.s2.e0" origId="6057,90983769" charOffset="24-32" type="compound" text="tyrosine"/>
            <entity id="DS3.d850.s2.e1" origId="6057,90983769" charOffset="142-150" type="compound" text="tyrosine"/>
            <entity id="DS3.d850.s2.e2" origId="P97797,E0CYM8,Q6P6I8,E9QPT7,E0CX65" charOffset="163-168" type="protein" text="SHP-1"/>
            <pair e1="DS3.d850.s2.e0" e2="DS3.d850.s2.e2" id="DS3.d850.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d850.s3" origId="9973385-6" text="To address the mechanism of binding between gp49B and SHP-1, binding studies involving glutathione S-transferase SHP-1 mutants were performed.">
            <entity id="DS3.d850.s3.e0" origId="Q64281" charOffset="44-49" type="protein" text="gp49B"/>
            <entity id="DS3.d850.s3.e1" origId="P97797,E0CYM8,Q6P6I8,E9QPT7,E0CX65" charOffset="54-59" type="protein" text="SHP-1"/>
            <entity id="DS3.d850.s3.e2" origId="124886,20725278,745" charOffset="87-98" type="compound" text="glutathione"/>
            <entity id="DS3.d850.s3.e3" origId="P97797,E0CYM8,Q6P6I8,E9QPT7,E0CX65" charOffset="113-118" type="protein" text="SHP-1"/>
            <pair e1="DS3.d850.s3.e2" e2="DS3.d850.s3.e1" id="DS3.d850.s3.i0" interaction="False" />
            <pair e1="DS3.d850.s3.e2" e2="DS3.d850.s3.e0" id="DS3.d850.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d851" origId="9973391">
        <sentence id="DS3.d851.s0" origId="9973391-7" text="CD28 coengagement overcomes this sensitivity, as does activation via Ab cross-linking of the TCR or via covalent peptide-MHC complexes, suggesting that phosphatidylinositol 3-kinase is not required per se but rather plays a role in signal amplification.">
            <entity id="DS3.d851.s0.e0" origId="P10747,B4E0L1" charOffset="0-4" type="protein" text="CD28"/>
            <entity id="DS3.d851.s0.e1" origId="16738692,53477912" charOffset="152-172" type="compound" text="phosphatidylinositol"/>
            <pair e1="DS3.d851.s0.e1" e2="DS3.d851.s0.e0" id="DS3.d851.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d852" origId="9973393">
        <sentence id="DS3.d852.s0" origId="9973393-0" text="CD40-CD154 interaction and IFN-gamma are required for IL-12 but not prostaglandin E2 secretion by microglia during antigen presentation to Th1 cells.">
            <entity id="DS3.d852.s0.e0" origId="P27512" charOffset="0-4" type="protein" text="CD40"/>
            <entity id="DS3.d852.s0.e1" origId="P27548,Q0VEI3" charOffset="5-10" type="protein" text="CD154"/>
            <entity id="DS3.d852.s0.e2" origId="285703,6145931" charOffset="68-81" type="compound" text="prostaglandin"/>
            <pair e1="DS3.d852.s0.e2" e2="DS3.d852.s0.e1" id="DS3.d852.s0.i0" interaction="False" />
            <pair e1="DS3.d852.s0.e2" e2="DS3.d852.s0.e0" id="DS3.d852.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d853" origId="9973396">
        <sentence id="DS3.d853.s0" origId="9973396-0" text="Protein interactions of Src homology 2 (SH2) domain-containing inositol phosphatase (SHIP): association with Shc displaces SHIP from FcgammaRIIb in B cells.">
            <entity id="DS3.d853.s0.e0" origId="892" charOffset="63-71" type="compound" text="inositol"/>
            <entity id="DS3.d853.s0.e1" origId="Q92835" charOffset="85-89" type="protein" text="SHIP"/>
            <entity id="DS3.d853.s0.e2" origId="P29353" charOffset="109-112" type="protein" text="Shc"/>
            <entity id="DS3.d853.s0.e3" origId="Q92835" charOffset="123-127" type="protein" text="SHIP"/>
            <entity id="DS3.d853.s0.e4" origId="P31994,P31995" charOffset="133-144" type="protein" text="FcgammaRIIb"/>
            <pair e1="DS3.d853.s0.e0" e2="DS3.d853.s0.e1" id="DS3.d853.s0.i0" interaction="False" />
            <pair e1="DS3.d853.s0.e0" e2="DS3.d853.s0.e2" id="DS3.d853.s0.i1" interaction="False" />
            <pair e1="DS3.d853.s0.e0" e2="DS3.d853.s0.e4" id="DS3.d853.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d853.s1" origId="9973396-1" text="Our recent studies revealed that the inositol phosphatase Src homology 2 (SH2) domain-containing inositol phosphatase (SHIP) is phosphorylated and associated with Shc exclusively under negative signaling conditions in B cells, which is due to recruitment of the SHIP SH2 domain to the FcgammaRIIb.">
            <entity id="DS3.d853.s1.e0" origId="892" charOffset="37-45" type="compound" text="inositol"/>
            <entity id="DS3.d853.s1.e1" origId="892" charOffset="97-105" type="compound" text="inositol"/>
            <entity id="DS3.d853.s1.e2" origId="Q92835" charOffset="119-123" type="protein" text="SHIP"/>
            <entity id="DS3.d853.s1.e3" origId="P29353" charOffset="163-166" type="protein" text="Shc"/>
            <entity id="DS3.d853.s1.e4" origId="Q92835" charOffset="262-266" type="protein" text="SHIP"/>
            <entity id="DS3.d853.s1.e5" origId="P31994,P31995" charOffset="285-296" type="protein" text="FcgammaRIIb"/>
            <pair e1="DS3.d853.s1.e0" e2="DS3.d853.s1.e2" id="DS3.d853.s1.i0" interaction="False" />
            <pair e1="DS3.d853.s1.e0" e2="DS3.d853.s1.e3" id="DS3.d853.s1.i1" interaction="False" />
            <pair e1="DS3.d853.s1.e0" e2="DS3.d853.s1.e5" id="DS3.d853.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d854" origId="9973398">
        <sentence id="DS3.d854.s0" origId="9973398-4" text="Here, we show that profound, specific T cell unresponsiveness to alloantigen was induced by treatment of H-2k mice with H-2b APCs that expressed Fas ligand and that profound T cell unresponsiveness specific for the H-Y Ag was induced by treatment of H-2Db/H-Y TCR transgenic female mice with H-2Db/H-Y APCs that expressed Fas ligand.">
            <entity id="DS3.d854.s0.e0" origId="P01901,Q7JJ15,Q3TH01" charOffset="105-109" type="protein" text="H-2k"/>
            <entity id="DS3.d854.s0.e1" origId="P41047,Q544E9,Q99PH8" charOffset="145-155" type="protein" text="Fas ligand"/>
            <entity id="DS3.d854.s0.e2" origId="11957419" charOffset="252-255" type="compound" text="2Db"/>
            <entity id="DS3.d854.s0.e3" origId="11957419" charOffset="294-297" type="compound" text="2Db"/>
            <entity id="DS3.d854.s0.e4" origId="P41047,Q544E9,Q99PH8" charOffset="322-332" type="protein" text="Fas ligand"/>
            <pair e1="DS3.d854.s0.e2" e2="DS3.d854.s0.e0" id="DS3.d854.s0.i0" interaction="False" />
            <pair e1="DS3.d854.s0.e2" e2="DS3.d854.s0.e1" id="DS3.d854.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d855" origId="9973402">
        <sentence id="DS3.d855.s0" origId="9973402-4" text="Heterokaryons formed by the fusion of anergic murine T cells to normal murine T cells also failed to accumulate intracellular IL-2 protein in response to stimulation either with the combination of CD3 and CD28 mAbs or with ionomycin plus a protein kinase C-activating phorbol ester.">
            <entity id="DS3.d855.s0.e0" origId="P31041,Q8CDB3" charOffset="205-209" type="protein" text="CD28"/>
            <entity id="DS3.d855.s0.e1" origId="25134244,3733,5353687,6434517,6912226" charOffset="223-232" type="compound" text="ionomycin"/>
            <entity id="DS3.d855.s0.e2" origId="27924,70702034" charOffset="268-281" type="compound" text="phorbol ester"/>
            <pair e1="DS3.d855.s0.e1" e2="DS3.d855.s0.e0" id="DS3.d855.s0.i0" interaction="False" />
            <pair e1="DS3.d855.s0.e2" e2="DS3.d855.s0.e0" id="DS3.d855.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d856" origId="9973403">
        <sentence id="DS3.d856.s0" origId="9973403-6" text="Because ROI levels and Deltapsim are regulated by the supply of reducing equivalents from the pentose phosphate pathway (PPP), we studied the impact of transaldolase (TAL), a key enzyme of the PPP, on Fas signaling.">
            <entity id="DS3.d856.s0.e0" origId="167704,1061,644102" charOffset="102-111" type="compound" text="phosphate"/>
            <entity id="DS3.d856.s0.e1" origId="P37837" charOffset="152-165" type="protein" text="transaldolase"/>
            <entity id="DS3.d856.s0.e2" origId="P37837" charOffset="167-170" type="protein" text="TAL"/>
            <pair e1="DS3.d856.s0.e0" e2="DS3.d856.s0.e2" id="DS3.d856.s0.i0" interaction="False" />
            <pair e1="DS3.d856.s0.e0" e2="DS3.d856.s0.e1" id="DS3.d856.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d856.s1" origId="9973403-7" text="Overexpression of TAL accelerated Fas-induced mitochondrial ROI production, Deltapsim elevation, activation of caspase-8 and caspase-3, proteolysis of poly(A)DP-ribose polymerase, and PS externalization.">
            <entity id="DS3.d856.s1.e0" origId="P37837" charOffset="18-21" type="protein" text="TAL"/>
            <entity id="DS3.d856.s1.e1" origId="Q14790,A0A024R3Z8" charOffset="111-120" type="protein" text="caspase-8"/>
            <entity id="DS3.d856.s1.e2" origId="P42574" charOffset="125-134" type="protein" text="caspase-3"/>
            <entity id="DS3.d856.s1.e3" origId="9996708" charOffset="161-167" type="compound" text="ribose"/>
            <pair e1="DS3.d856.s1.e3" e2="DS3.d856.s1.e0" id="DS3.d856.s1.i0" interaction="False" />
            <pair e1="DS3.d856.s1.e3" e2="DS3.d856.s1.e1" id="DS3.d856.s1.i1" interaction="False" />
            <pair e1="DS3.d856.s1.e3" e2="DS3.d856.s1.e2" id="DS3.d856.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d857" origId="9973405">
        <sentence id="DS3.d857.s0" origId="9973405-0" text="A critical tyrosine residue in the cytoplasmic tail is important for CD1d internalization but not for its basolateral sorting in MDCK cells.">
            <entity id="DS3.d857.s0.e0" origId="6057,90983769" charOffset="11-19" type="compound" text="tyrosine"/>
            <entity id="DS3.d857.s0.e1" origId="P15813" charOffset="69-73" type="protein" text="CD1d"/>
            <pair e1="DS3.d857.s0.e0" e2="DS3.d857.s0.e1" id="DS3.d857.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d857.s1" origId="9973405-8" text="CD1d contains a tyrosine-based sorting signal in its cytoplasmic tail that is necessary for internalization.">
            <entity id="DS3.d857.s1.e0" origId="P15813" charOffset="0-4" type="protein" text="CD1d"/>
            <entity id="DS3.d857.s1.e1" origId="6057,90983769" charOffset="16-24" type="compound" text="tyrosine"/>
            <pair e1="DS3.d857.s1.e1" e2="DS3.d857.s1.e0" id="DS3.d857.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d858" origId="9973406">
        <sentence id="DS3.d858.s0" origId="9973406-1" text="It has been shown that a membrane-proximal region within common beta (betac) receptor of IL-3/granulocyte-macrophage CSF/IL-5 (amino acids 450-517) is important for Lyn binding.">
            <entity id="DS3.d858.s0.e0" origId="16122568,16750043,4369303,448383" charOffset="117-120" type="compound" text="CSF"/>
            <entity id="DS3.d858.s0.e1" origId="P07948,Q6NUK7,A8K379" charOffset="165-168" type="protein" text="Lyn"/>
            <pair e1="DS3.d858.s0.e0" e2="DS3.d858.s0.e1" id="DS3.d858.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d858.s1" origId="9973406-6" text="The P--&amp;gt;A mutation in this region abrogated the binding to Lyn, indicating a critical role of proline residues.">
            <entity id="DS3.d858.s1.e0" origId="P07948,Q6NUK7,A8K379" charOffset="62-65" type="protein" text="Lyn"/>
            <entity id="DS3.d858.s1.e1" origId="57240853,614,8988" charOffset="97-104" type="compound" text="proline"/>
            <pair e1="DS3.d858.s1.e1" e2="DS3.d858.s1.e0" id="DS3.d858.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d859" origId="9973408">
        <sentence id="DS3.d859.s0" origId="9973408-5" text="LPS-chelating antibiotic, polymyxin B, suppressed the antiapoptotic activity, indicating the specificity of the effect.">
            <entity id="DS3.d859.s0.e0" origId="O14896,G0Z349" charOffset="0-3" type="protein" text="LPS"/>
            <entity id="DS3.d859.s0.e1" origId="3083714" charOffset="26-35" type="compound" text="polymyxin"/>
            <pair e1="DS3.d859.s0.e1" e2="DS3.d859.s0.e0" id="DS3.d859.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d859.s1" origId="9973408-7" text="An antioxidant, pyrrolidine dithiocarbamate, which blocked LPS-induced NF-kappaB activation, also abolished the antiapoptotic effects of LPS at the same time.">
            <entity id="DS3.d859.s1.e0" origId="65351" charOffset="16-43" type="compound" text="pyrrolidine dithiocarbamate"/>
            <entity id="DS3.d859.s1.e1" origId="O14896,G0Z349" charOffset="59-62" type="protein" text="LPS"/>
            <entity id="DS3.d859.s1.e2" origId="O14896,G0Z349" charOffset="137-140" type="protein" text="LPS"/>
            <pair e1="DS3.d859.s1.e0" e2="DS3.d859.s1.e1" id="DS3.d859.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d859.s2" origId="9973408-8" text="Besides TNF, the apoptosis induced by taxol and okadaic acid was also sensitive to LPS-induced NF-kappaB activation, whereas that induced by H2O2, doxorubicin, daunomycin, vincristine, and vinblastine was NF-kappaB insensitive.">
            <entity id="DS3.d859.s2.e0" origId="36314" charOffset="38-43" type="compound" text="taxol"/>
            <entity id="DS3.d859.s2.e1" origId="11953808,42628599,446512,45356271,4584,5468826,57059112,6102351,6426933,6476659,6917781,90479758" charOffset="48-60" type="compound" text="okadaic acid"/>
            <entity id="DS3.d859.s2.e2" origId="O14896,G0Z349" charOffset="83-86" type="protein" text="LPS"/>
            <entity id="DS3.d859.s2.e3" origId="31703" charOffset="147-158" type="compound" text="doxorubicin"/>
            <entity id="DS3.d859.s2.e4" origId="30323" charOffset="160-170" type="compound" text="daunomycin"/>
            <entity id="DS3.d859.s2.e5" origId="5978" charOffset="172-183" type="compound" text="vincristine"/>
            <pair e1="DS3.d859.s2.e5" e2="DS3.d859.s2.e2" id="DS3.d859.s2.i0" interaction="False" />
            <pair e1="DS3.d859.s2.e3" e2="DS3.d859.s2.e2" id="DS3.d859.s2.i1" interaction="False" />
            <pair e1="DS3.d859.s2.e4" e2="DS3.d859.s2.e2" id="DS3.d859.s2.i2" interaction="False" />
            <pair e1="DS3.d859.s2.e1" e2="DS3.d859.s2.e2" id="DS3.d859.s2.i3" interaction="False" />
            <pair e1="DS3.d859.s2.e0" e2="DS3.d859.s2.e2" id="DS3.d859.s2.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d860" origId="9973410">
        <sentence id="DS3.d860.s0" origId="9973410-3" text="Furthermore, we demonstrate that a mutant H-2Dd molecule that does not interact with TAP due to a Glu to Lys mutation at residue 222 of the H chain (Dd(E222K)) also fails to bind to tapasin.">
            <entity id="DS3.d860.s0.e0" origId="5327104" charOffset="44-47" type="compound" text="2Dd"/>
            <entity id="DS3.d860.s0.e1" origId="5962" charOffset="105-108" type="compound" text="Lys"/>
            <entity id="DS3.d860.s0.e2" origId="Q9R233,Q3TCU5,Q3U9A3,Q9D679,Q8C6N4,O15533,A0A0A0MT98,A0A0A0MSV9,A0A024RCT1" charOffset="182-189" type="protein" text="tapasin"/>
            <pair e1="DS3.d860.s0.e0" e2="DS3.d860.s0.e2" id="DS3.d860.s0.i0" interaction="False" />
            <pair e1="DS3.d860.s0.e1" e2="DS3.d860.s0.e2" id="DS3.d860.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d861" origId="9973413">
        <sentence id="DS3.d861.s0" origId="9973413-0" text="TFEC is a macrophage-restricted member of the microphthalmia-TFE subfamily of basic helix-loop-helix leucine zipper transcription factors.">
            <entity id="DS3.d861.s0.e0" origId="Q9WTW4" charOffset="0-4" type="protein" text="TFEC"/>
            <entity id="DS3.d861.s0.e1" origId="6106" charOffset="101-108" type="compound" text="leucine"/>
            <pair e1="DS3.d861.s0.e1" e2="DS3.d861.s0.e0" id="DS3.d861.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d862" origId="9973416">
        <sentence id="DS3.d862.s0" origId="9973416-7" text="Furthermore, B6 but not A/J mice showed significant up-regulation of splenic IL-12R beta2 mRNA over basal levels by days 3 and 4, coincident with sustained up-regulation of splenic IFN-gamma mRNA levels on days 3-5.">
            <entity id="DS3.d862.s0.e0" origId="71581433" charOffset="80-83" type="compound" text="12R"/>
            <entity id="DS3.d862.s0.e1" origId="P02089,Q549D9" charOffset="84-89" type="protein" text="beta2"/>
            <pair e1="DS3.d862.s0.e0" e2="DS3.d862.s0.e1" id="DS3.d862.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d862.s1" origId="9973416-8" text="However, IL-12R beta1 mRNA levels in the spleen were similarly up-regulated in both mouse strains by day 3.">
            <entity id="DS3.d862.s1.e0" origId="71581433" charOffset="12-15" type="compound" text="12R"/>
            <entity id="DS3.d862.s1.e1" origId="P02088,A8DUK0" charOffset="16-21" type="protein" text="beta1"/>
            <pair e1="DS3.d862.s1.e0" e2="DS3.d862.s1.e1" id="DS3.d862.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d862.s2" origId="9973416-9" text="Taken together, these data suggest that high systemic IL-12 production, accompanied by an early and sustained up-regulation of both IL-12R beta1 and beta2 mRNA levels in the spleen, as occurs in resistant B6 mice, appears to preferentially induce protective Th1 responses against blood-stage malaria.">
            <entity id="DS3.d862.s2.e0" origId="71581433" charOffset="135-138" type="compound" text="12R"/>
            <entity id="DS3.d862.s2.e1" origId="P02088,A8DUK0" charOffset="139-144" type="protein" text="beta1"/>
            <entity id="DS3.d862.s2.e2" origId="P02089,Q549D9" charOffset="149-154" type="protein" text="beta2"/>
            <entity id="DS3.d862.s2.e3" origId="Q922L6" charOffset="258-261" type="protein" text="Th1"/>
            <pair e1="DS3.d862.s2.e0" e2="DS3.d862.s2.e3" id="DS3.d862.s2.i0" interaction="False" />
            <pair e1="DS3.d862.s2.e0" e2="DS3.d862.s2.e2" id="DS3.d862.s2.i1" interaction="False" />
            <pair e1="DS3.d862.s2.e0" e2="DS3.d862.s2.e1" id="DS3.d862.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d863" origId="9973420">
        <sentence id="DS3.d863.s0" origId="9973420-4" text="Oligodeoxynucleotides (ODN) containing CpG motifs activate neonatal APCs to produce IL-12 in vitro and induce adult-like Th1 responses to tetanus toxoid and measles Ags in vivo, with production of IgG2a-specific Abs and adult-like secretion of IFN-gamma and IL-5 by Ag-specific T cells.">
            <entity id="DS3.d863.s0.e0" origId="78673848" charOffset="23-26" type="compound" text="ODN"/>
            <entity id="DS3.d863.s0.e1" origId="Q64279,Q5SQG1" charOffset="121-124" type="protein" text="Th1"/>
            <entity id="DS3.d863.s0.e2" origId="P05113" charOffset="258-262" type="protein" text="IL-5"/>
            <pair e1="DS3.d863.s0.e0" e2="DS3.d863.s0.e2" id="DS3.d863.s0.i0" interaction="False" />
            <pair e1="DS3.d863.s0.e0" e2="DS3.d863.s0.e1" id="DS3.d863.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d863.s1" origId="9973420-6" text="Finally, using Th1-driving CpG-ODN with the boosting dose of a protein vaccine was sufficient to redirect adult but not neonatally primed Th2 responses.">
            <entity id="DS3.d863.s1.e0" origId="Q64279,Q5SQG1" charOffset="15-18" type="protein" text="Th1"/>
            <entity id="DS3.d863.s1.e1" origId="78673848" charOffset="31-34" type="compound" text="ODN"/>
            <entity id="DS3.d863.s1.e2" origId="Q61039" charOffset="138-141" type="protein" text="Th2"/>
            <pair e1="DS3.d863.s1.e1" e2="DS3.d863.s1.e2" id="DS3.d863.s1.i0" interaction="False" />
            <pair e1="DS3.d863.s1.e1" e2="DS3.d863.s1.e0" id="DS3.d863.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d864" origId="9973423">
        <sentence id="DS3.d864.s0" origId="9973423-3" text="Intratracheal challenge with Aspergillus fumigatus conidia in both neutropenic (cyclophosphamide-treated) and nonneutropenic BALB/c mice resulted in the time-dependent increase in lung TNF-alpha levels, which correlated with the histologic development of a patchy, peribronchial infiltration of mononuclear and polymorphonuclear cells.">
            <entity id="DS3.d864.s0.e0" origId="2907" charOffset="80-96" type="compound" text="cyclophosphamide"/>
            <entity id="DS3.d864.s0.e1" origId="P06804,Q3U593" charOffset="185-194" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d864.s0.e0" e2="DS3.d864.s0.e1" id="DS3.d864.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d864.s1" origId="9973423-4" text="Ab-mediated neutralization of TNF-alpha resulted in an increase in mortality in both normal and cyclophosphamide-treated animals, which was associated with increased lung fungal burden as determined by histology and as quantified by chitin content.">
            <entity id="DS3.d864.s1.e0" origId="P06804,Q3U593" charOffset="30-39" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d864.s1.e1" origId="2907" charOffset="96-112" type="compound" text="cyclophosphamide"/>
            <pair e1="DS3.d864.s1.e1" e2="DS3.d864.s1.e0" id="DS3.d864.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d864.s2" origId="9973423-5" text="Depletion of TNF-alpha resulted in a reduced lung neutrophil influx in both normal and cyclophosphamide-treated animals, which occurred in association with a decrease in lung levels of the C-X-C chemokine, macrophage inflammatory protein-2 and the C-C chemokines macrophage inflammatory protein-1alpha and JE.">
            <entity id="DS3.d864.s2.e0" origId="P06804,Q3U593" charOffset="13-22" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d864.s2.e1" origId="2907" charOffset="87-103" type="compound" text="cyclophosphamide"/>
            <pair e1="DS3.d864.s2.e1" e2="DS3.d864.s2.e0" id="DS3.d864.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d864.s3" origId="9973423-6" text="In cyclophosphamide-treated animals, intratracheal administration of a TNF-alpha agonist peptide (TNF70-80) 3 days before, but not concomitant with, the administration of Aspergillus conidia resulted in improved survival from 9% in control mice to 55% in TNF70-80-treated animals.">
            <entity id="DS3.d864.s3.e0" origId="2907" charOffset="3-19" type="compound" text="cyclophosphamide"/>
            <entity id="DS3.d864.s3.e1" origId="P06804,Q3U593" charOffset="71-80" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d864.s3.e0" e2="DS3.d864.s3.e1" id="DS3.d864.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d865" origId="9973425">
        <sentence id="DS3.d865.s0" origId="9973425-1" text="We have studied vascular endothelial activation and increased expression of ICAM-1 and VCAM-1 at the onset of the elicitation phase of oxazolone contact hypersensitivity in mice.">
            <entity id="DS3.d865.s0.e0" origId="P05362" charOffset="76-82" type="protein" text="ICAM-1"/>
            <entity id="DS3.d865.s0.e1" origId="P19320" charOffset="87-93" type="protein" text="VCAM-1"/>
            <entity id="DS3.d865.s0.e2" origId="1712093,1712094,27435" charOffset="135-144" type="compound" text="oxazolone"/>
            <pair e1="DS3.d865.s0.e2" e2="DS3.d865.s0.e0" id="DS3.d865.s0.i0" interaction="False" />
            <pair e1="DS3.d865.s0.e2" e2="DS3.d865.s0.e1" id="DS3.d865.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d866" origId="9973427">
        <sentence id="DS3.d866.s0" origId="9973427-11" text="However, pretreatment with concanamycin A completely inhibited this IL-18- and/or IL-12-augmented NK activity.">
            <entity id="DS3.d866.s0.e0" origId="16211793,16760424,23724569,3649143,5468688,6438151,71308575" charOffset="27-41" type="compound" text="concanamycin A"/>
            <entity id="DS3.d866.s0.e1" origId="P70380,Q2PMY2" charOffset="68-73" type="protein" text="IL-18"/>
            <pair e1="DS3.d866.s0.e0" e2="DS3.d866.s0.e1" id="DS3.d866.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d866.s1" origId="9973427-13" text="These data suggested that NK cells develop and express IL-12R and IL-18R in the absence of IL-12 or IL-18, and that both IL-18 and IL-12 directly and independently augment perforin-mediated cytotoxic activity of NK cells.">
            <entity id="DS3.d866.s1.e0" origId="71581433" charOffset="58-61" type="compound" text="12R"/>
            <entity id="DS3.d866.s1.e1" origId="66563700" charOffset="69-72" type="compound" text="18R"/>
            <entity id="DS3.d866.s1.e2" origId="P70380,Q2PMY2" charOffset="66-71" type="protein" text="IL-18"/>
            <entity id="DS3.d866.s1.e3" origId="P70380,Q2PMY2" charOffset="100-105" type="protein" text="IL-18"/>
            <pair e1="DS3.d866.s1.e1" e2="DS3.d866.s1.e2" id="DS3.d866.s1.i0" interaction="False" />
            <pair e1="DS3.d866.s1.e0" e2="DS3.d866.s1.e2" id="DS3.d866.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d866.s2" origId="9973427-8" text="IL-18R, as well as IL-12R mRNA, was constitutively expressed in splenocytes from SCID mice, which lack T cells and B cells but have intact NK cells, and in those from IL-12 and IL-18 double knockout mice.">
            <entity id="DS3.d866.s2.e0" origId="66563700" charOffset="3-6" type="compound" text="18R"/>
            <entity id="DS3.d866.s2.e1" origId="71581433" charOffset="22-25" type="compound" text="12R"/>
            <entity id="DS3.d866.s2.e2" origId="P97313" charOffset="81-85" type="protein" text="SCID"/>
            <entity id="DS3.d866.s2.e3" origId="P70380,Q2PMY2" charOffset="0-5" type="protein" text="IL-18"/>
            <pair e1="DS3.d866.s2.e0" e2="DS3.d866.s2.e2" id="DS3.d866.s2.i0" interaction="False" />
            <pair e1="DS3.d866.s2.e0" e2="DS3.d866.s2.e3" id="DS3.d866.s2.i1" interaction="False" />
            <pair e1="DS3.d866.s2.e1" e2="DS3.d866.s2.e2" id="DS3.d866.s2.i2" interaction="False" />
            <pair e1="DS3.d866.s2.e1" e2="DS3.d866.s2.e3" id="DS3.d866.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d866.s3" origId="9973427-9" text="NK cells isolated from SCID splenocytes expressed IL-18R on their surface.">
            <entity id="DS3.d866.s3.e0" origId="P97313" charOffset="23-27" type="protein" text="SCID"/>
            <entity id="DS3.d866.s3.e1" origId="66563700" charOffset="53-56" type="compound" text="18R"/>
            <pair e1="DS3.d866.s3.e1" e2="DS3.d866.s3.e0" id="DS3.d866.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d867" origId="9973428">
        <sentence id="DS3.d867.s0" origId="9973428-0" text="Decreased leukotriene C4 synthesis accompanies adherence-dependent nuclear import of 5-lipoxygenase in human blood eosinophils.">
            <entity id="DS3.d867.s0.e0" origId="44563898,5283121" charOffset="10-24" type="compound" text="leukotriene C4"/>
            <entity id="DS3.d867.s0.e1" origId="P09917" charOffset="85-99" type="protein" text="5-lipoxygenase"/>
            <pair e1="DS3.d867.s0.e0" e2="DS3.d867.s0.e1" id="DS3.d867.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d867.s1" origId="9973428-1" text="The enzyme 5-lipoxygenase (5-LO) catalyzes the synthesis of leukotrienes (LTs) from arachidonic acid (AA).">
            <entity id="DS3.d867.s1.e0" origId="P09917" charOffset="11-25" type="protein" text="5-lipoxygenase"/>
            <entity id="DS3.d867.s1.e1" origId="P09917" charOffset="27-31" type="protein" text="5-LO"/>
            <entity id="DS3.d867.s1.e2" origId="444899" charOffset="84-100" type="compound" text="arachidonic acid"/>
            <pair e1="DS3.d867.s1.e2" e2="DS3.d867.s1.e0" id="DS3.d867.s1.i0" interaction="False" />
            <pair e1="DS3.d867.s1.e2" e2="DS3.d867.s1.e1" id="DS3.d867.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d867.s2" origId="9973428-2" text="Adherence or recruitment of polymorphonuclear neutrophils (PMN) induces nuclear import of 5-LO from the cytosol, which is associated with enhanced LTB4 synthesis upon subsequent cell stimulation.">
            <entity id="DS3.d867.s2.e0" origId="P09917" charOffset="90-94" type="protein" text="5-LO"/>
            <entity id="DS3.d867.s2.e1" origId="5280492" charOffset="147-151" type="compound" text="LTB4"/>
            <pair e1="DS3.d867.s2.e1" e2="DS3.d867.s2.e0" id="DS3.d867.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d867.s3" origId="9973428-3" text="In this study, we asked whether adherence of human eosinophils (EOS) causes a similar redistribution of 5-LO and an increase in LTC4 synthesis.">
            <entity id="DS3.d867.s3.e0" origId="P09917" charOffset="104-108" type="protein" text="5-LO"/>
            <entity id="DS3.d867.s3.e1" origId="3907,5280493" charOffset="128-132" type="compound" text="LTC4"/>
            <pair e1="DS3.d867.s3.e1" e2="DS3.d867.s3.e0" id="DS3.d867.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d867.s4" origId="9973428-5" text="Cell stimulation resulted in activation of 5-LO, as evidenced by its translocation to membranes and LTC4 synthesis.">
            <entity id="DS3.d867.s4.e0" origId="P09917" charOffset="43-47" type="protein" text="5-LO"/>
            <entity id="DS3.d867.s4.e1" origId="3907,5280493" charOffset="100-104" type="compound" text="LTC4"/>
            <pair e1="DS3.d867.s4.e1" e2="DS3.d867.s4.e0" id="DS3.d867.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d868" origId="9973430">
        <sentence id="DS3.d868.s0" origId="9973430-1" text="The roles played by resident macrophages (Mphi) and mast cells (MCs) in polymorphonuclear leukocyte (PMN) accumulation and chemokine production within the mouse peritoneal cavity in response to administration of zymosan (0.2 and 1 mg), LPS (1 mg/kg), and thioglycolate (0.5 ml of a 3% suspension) were investigated.">
            <entity id="DS3.d868.s0.e0" origId="64689" charOffset="212-219" type="compound" text="zymosan"/>
            <entity id="DS3.d868.s0.e1" origId="Q9QUK6,L0CL36" charOffset="236-239" type="protein" text="LPS"/>
            <entity id="DS3.d868.s0.e2" origId="1133" charOffset="255-268" type="compound" text="thioglycolate"/>
            <pair e1="DS3.d868.s0.e0" e2="DS3.d868.s0.e1" id="DS3.d868.s0.i0" interaction="False" />
            <pair e1="DS3.d868.s0.e2" e2="DS3.d868.s0.e1" id="DS3.d868.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d868.s1" origId="9973430-5" text="In contrast, MC depletion inhibited PMN accumulation and murine monocyte chemoattractant protein-1 and KC production in the zymosan peritonitis model.">
            <entity id="DS3.d868.s1.e0" origId="P10148,Q5SVU3" charOffset="64-98" type="protein" text="monocyte chemoattractant protein-1"/>
            <entity id="DS3.d868.s1.e1" origId="64689" charOffset="124-131" type="compound" text="zymosan"/>
            <pair e1="DS3.d868.s1.e1" e2="DS3.d868.s1.e0" id="DS3.d868.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d868.s2" origId="9973430-7" text="This was due to an inhibitory action of Mphi-derived IL-10 because there was 1) a time-dependent release of IL-10 in the zymosan exudates; 2) a reduction in IL-10 levels following Mphi, but not MC, depletion; and 3) an increased PMN influx and chemokine production in IL-10 knockout mice.">
            <entity id="DS3.d868.s2.e0" origId="P18893,Q3U879" charOffset="53-58" type="protein" text="IL-10"/>
            <entity id="DS3.d868.s2.e1" origId="P18893,Q3U879" charOffset="108-113" type="protein" text="IL-10"/>
            <entity id="DS3.d868.s2.e2" origId="64689" charOffset="121-128" type="compound" text="zymosan"/>
            <entity id="DS3.d868.s2.e3" origId="P18893,Q3U879" charOffset="108-113" type="protein" text="IL-10"/>
            <entity id="DS3.d868.s2.e4" origId="P18893,Q3U879" charOffset="108-113" type="protein" text="IL-10"/>
            <pair e1="DS3.d868.s2.e2" e2="DS3.d868.s2.e0" id="DS3.d868.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d869" origId="9973431">
        <sentence id="DS3.d869.s0" origId="9973431-4" text="We found that p38-MAPK was constitutively tyrosine phosphorylated and activated during spontaneous apoptosis of neutrophils.">
            <entity id="DS3.d869.s0.e0" origId="Q16539,L7RSM2,B4E0K5,A0A024RD15" charOffset="14-17" type="protein" text="p38"/>
            <entity id="DS3.d869.s0.e1" origId="6057,90983769" charOffset="42-50" type="compound" text="tyrosine"/>
            <pair e1="DS3.d869.s0.e1" e2="DS3.d869.s0.e0" id="DS3.d869.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d869.s1" origId="9973431-5" text="Inhibition of p38-MAPK by SB203580 and an antisense oligonucleotide delayed apoptosis by approximately 24 h. The antioxidants catalase and N-acetylcysteine delayed neutrophil apoptosis, but failed to inhibit phosphorylation and activation of p38-MAPK.">
            <entity id="DS3.d869.s1.e0" origId="Q16539,L7RSM2,B4E0K5,A0A024RD15" charOffset="14-17" type="protein" text="p38"/>
            <entity id="DS3.d869.s1.e1" origId="176155" charOffset="26-34" type="compound" text="SB203580"/>
            <entity id="DS3.d869.s1.e2" origId="44539214,57119183" charOffset="139-155" type="compound" text="N-acetylcysteine"/>
            <entity id="DS3.d869.s1.e3" origId="Q16539,L7RSM2,B4E0K5,A0A024RD15" charOffset="242-245" type="protein" text="p38"/>
            <pair e1="DS3.d869.s1.e2" e2="DS3.d869.s1.e0" id="DS3.d869.s1.i0" interaction="False" />
            <pair e1="DS3.d869.s1.e1" e2="DS3.d869.s1.e0" id="DS3.d869.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d870" origId="9973432">
        <sentence id="DS3.d870.s0" origId="9973432-4" text="The inhibition of PG production by indomethacin led to a 37-60% increase in RANTES, MIP-1alpha, and MIP-1beta but not in GROalpha and IL-8 secretion.">
            <entity id="DS3.d870.s0.e0" origId="3715" charOffset="35-47" type="compound" text="indomethacin"/>
            <entity id="DS3.d870.s0.e1" origId="P13501,D0EI67" charOffset="76-82" type="protein" text="RANTES"/>
            <entity id="DS3.d870.s0.e2" origId="P32246,Q5U003" charOffset="84-94" type="protein" text="MIP-1alpha"/>
            <entity id="DS3.d870.s0.e3" origId="P13236" charOffset="100-109" type="protein" text="MIP-1beta"/>
            <entity id="DS3.d870.s0.e4" origId="P09341" charOffset="121-129" type="protein" text="GROalpha"/>
            <entity id="DS3.d870.s0.e5" origId="P10145,A0A024RDA5" charOffset="134-138" type="protein" text="IL-8"/>
            <pair e1="DS3.d870.s0.e0" e2="DS3.d870.s0.e4" id="DS3.d870.s0.i0" interaction="False" />
            <pair e1="DS3.d870.s0.e0" e2="DS3.d870.s0.e1" id="DS3.d870.s0.i1" interaction="False" />
            <pair e1="DS3.d870.s0.e0" e2="DS3.d870.s0.e5" id="DS3.d870.s0.i2" interaction="False" />
            <pair e1="DS3.d870.s0.e0" e2="DS3.d870.s0.e2" id="DS3.d870.s0.i3" interaction="False" />
            <pair e1="DS3.d870.s0.e0" e2="DS3.d870.s0.e3" id="DS3.d870.s0.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d871" origId="9973438">
        <sentence id="DS3.d871.s0" origId="9973438-6" text="All of the T cell cloids obtained from TIL reacted with HLA-A2+, gp100+ melanoma cell lines as well as with g9-209 and g9-209 2M peptide-pulsed targets.">
            <entity id="DS3.d871.s0.e0" origId="Q15399" charOffset="39-42" type="protein" text="TIL"/>
            <entity id="DS3.d871.s0.e1" origId="3003004" charOffset="65-70" type="compound" text="gp100"/>
            <pair e1="DS3.d871.s0.e1" e2="DS3.d871.s0.e0" id="DS3.d871.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d872" origId="9973441">
        <sentence id="DS3.d872.s0" origId="9973441-5" text="Fibronectin, vitronectin, collagen, or laminin could provide the second signal and was similarly required for the proliferation of FLSs from RA or osteoarthritis patients.">
            <entity id="DS3.d872.s0.e0" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="0-11" type="protein" text="Fibronectin"/>
            <entity id="DS3.d872.s0.e1" origId="P04004,D9ZGG2" charOffset="13-24" type="protein" text="vitronectin"/>
            <entity id="DS3.d872.s0.e2" origId="44342165" charOffset="39-46" type="compound" text="laminin"/>
            <pair e1="DS3.d872.s0.e2" e2="DS3.d872.s0.e0" id="DS3.d872.s0.i0" interaction="False" />
            <pair e1="DS3.d872.s0.e2" e2="DS3.d872.s0.e1" id="DS3.d872.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d872.s1" origId="9973441-6" text="Adhesion to Fibronectin, collagen, or Arg-Gly-Asp peptide down-regulated collagenase expression.">
            <entity id="DS3.d872.s1.e0" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="12-23" type="protein" text="Fibronectin"/>
            <entity id="DS3.d872.s1.e1" origId="104802" charOffset="38-49" type="compound" text="Arg-Gly-Asp"/>
            <pair e1="DS3.d872.s1.e1" e2="DS3.d872.s1.e0" id="DS3.d872.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d873" origId="9973447">
        <sentence id="DS3.d873.s0" origId="9973447-12" text="Furthermore, the data suggest that agents designed to inhibit the OX-40L/OX-40R complex may be useful for treating autoimmune disease.">
            <entity id="DS3.d873.s0.e0" origId="P43488,B6DXE3" charOffset="66-72" type="protein" text="OX-40L"/>
            <entity id="DS3.d873.s0.e1" origId="22460" charOffset="76-79" type="compound" text="40R"/>
            <pair e1="DS3.d873.s0.e1" e2="DS3.d873.s0.e0" id="DS3.d873.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d873.s1" origId="9973447-2" text="When the OX-40R is engaged by the OX-40 ligand (OX-40L), a potent costimulatory signal occurs.">
            <entity id="DS3.d873.s1.e0" origId="22460" charOffset="12-15" type="compound" text="40R"/>
            <entity id="DS3.d873.s1.e1" origId="P43488,B6DXE3" charOffset="34-46" type="protein" text="OX-40 ligand"/>
            <entity id="DS3.d873.s1.e2" origId="P43488,B6DXE3" charOffset="48-54" type="protein" text="OX-40L"/>
            <pair e1="DS3.d873.s1.e0" e2="DS3.d873.s1.e2" id="DS3.d873.s1.i0" interaction="False" />
            <pair e1="DS3.d873.s1.e0" e2="DS3.d873.s1.e1" id="DS3.d873.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d873.s2" origId="9973447-6" text="Therefore, to address the relative contributions of OX-40R/OX-40L and CD28/B7 to the costimulation of myelin-specific T cells, blocking studies were performed using soluble OX-40R and/or soluble CTLA-4.">
            <entity id="DS3.d873.s2.e0" origId="22460" charOffset="55-58" type="compound" text="40R"/>
            <entity id="DS3.d873.s2.e1" origId="P43488,B6DXE3" charOffset="59-65" type="protein" text="OX-40L"/>
            <entity id="DS3.d873.s2.e2" origId="P31041,Q8CDB3" charOffset="70-74" type="protein" text="CD28"/>
            <entity id="DS3.d873.s2.e3" origId="22460" charOffset="176-179" type="compound" text="40R"/>
            <entity id="DS3.d873.s2.e4" origId="P09793,Q6GTR6,Q5SSM0" charOffset="195-201" type="protein" text="CTLA-4"/>
            <pair e1="DS3.d873.s2.e0" e2="DS3.d873.s2.e1" id="DS3.d873.s2.i0" interaction="False" />
            <pair e1="DS3.d873.s2.e0" e2="DS3.d873.s2.e2" id="DS3.d873.s2.i1" interaction="False" />
            <pair e1="DS3.d873.s2.e0" e2="DS3.d873.s2.e4" id="DS3.d873.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d874" origId="9973449">
        <sentence id="DS3.d874.s0" origId="9973449-11" text="Defective T cell activation appeared to result from alterations in transmembrane signaling through the TCR, specifically to lack of tyrosine phosphorylation of the tyrosine kinase, ZAP-70.">
            <entity id="DS3.d874.s0.e0" origId="6057,90983769" charOffset="132-140" type="compound" text="tyrosine"/>
            <entity id="DS3.d874.s0.e1" origId="6057,90983769" charOffset="164-172" type="compound" text="tyrosine"/>
            <entity id="DS3.d874.s0.e2" origId="P43403" charOffset="181-187" type="protein" text="ZAP-70"/>
            <pair e1="DS3.d874.s0.e0" e2="DS3.d874.s0.e2" id="DS3.d874.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d875" origId="9973452">
        <sentence id="DS3.d875.s0" origId="9973452-2" text="Recipients of mouse thyroglobulin (MTg)-primed spleen cells activated in the presence of anti-B7.2 had decreased experimental autoimmune thyroiditis (EAT) severity compared with recipients of cells cultured with control rat Ig or anti-B7.1.">
            <entity id="DS3.d875.s0.e0" origId="75551" charOffset="35-38" type="compound" text="MTg"/>
            <entity id="DS3.d875.s0.e1" origId="P42082,Q61238,Q549Q9" charOffset="94-98" type="protein" text="B7.2"/>
            <entity id="DS3.d875.s0.e2" origId="Q00609,Q549R2" charOffset="235-239" type="protein" text="B7.1"/>
            <pair e1="DS3.d875.s0.e0" e2="DS3.d875.s0.e1" id="DS3.d875.s0.i0" interaction="False" />
            <pair e1="DS3.d875.s0.e0" e2="DS3.d875.s0.e2" id="DS3.d875.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d875.s1" origId="9973452-3" text="Blocking B7.2 during in vivo priming also suppressed the ability of MTg-primed spleen cells to transfer EAT, implicating a role for B7.2 for priming and in vitro activation of EAT effector cells.">
            <entity id="DS3.d875.s1.e0" origId="P42082,Q61238,Q549Q9" charOffset="9-13" type="protein" text="B7.2"/>
            <entity id="DS3.d875.s1.e1" origId="75551" charOffset="68-71" type="compound" text="MTg"/>
            <entity id="DS3.d875.s1.e2" origId="P42082,Q61238,Q549Q9" charOffset="132-136" type="protein" text="B7.2"/>
            <pair e1="DS3.d875.s1.e1" e2="DS3.d875.s1.e0" id="DS3.d875.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d875.s2" origId="9973452-4" text="In contrast, administration of anti-B7.2 or anti-B7.2 Fab to recipients of MTg-activated spleen cells increased the severity of EAT compared with recipients receiving control Ig.">
            <entity id="DS3.d875.s2.e0" origId="P42082,Q61238,Q549Q9" charOffset="36-40" type="protein" text="B7.2"/>
            <entity id="DS3.d875.s2.e1" origId="P42082,Q61238,Q549Q9" charOffset="49-53" type="protein" text="B7.2"/>
            <entity id="DS3.d875.s2.e2" origId="75551" charOffset="75-78" type="compound" text="MTg"/>
            <pair e1="DS3.d875.s2.e2" e2="DS3.d875.s2.e0" id="DS3.d875.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d876" origId="9973453">
        <sentence id="DS3.d876.s0" origId="9973453-0" text="Cutting edge: the CD45 tyrosine phosphatase is an inhibitor of Lck activity in thymocytes.">
            <entity id="DS3.d876.s0.e0" origId="S4R2V1,Q8C6Q7,S4R1S4,S4R1M0" charOffset="18-22" type="protein" text="CD45"/>
            <entity id="DS3.d876.s0.e1" origId="6057,90983769" charOffset="23-31" type="compound" text="tyrosine"/>
            <entity id="DS3.d876.s0.e2" origId="P06240,E9Q696" charOffset="63-66" type="protein" text="Lck"/>
            <pair e1="DS3.d876.s0.e1" e2="DS3.d876.s0.e0" id="DS3.d876.s0.i0" interaction="False" />
            <pair e1="DS3.d876.s0.e1" e2="DS3.d876.s0.e2" id="DS3.d876.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d876.s1" origId="9973453-1" text="A widely accepted model for regulation of the Lck tyrosine kinase is that it is activated by CD45-mediated dephosphorylation of its COOH-terminal negative regulatory tyrosine (Tyr505).">
            <entity id="DS3.d876.s1.e0" origId="P06240,E9Q696" charOffset="46-49" type="protein" text="Lck"/>
            <entity id="DS3.d876.s1.e1" origId="6057,90983769" charOffset="50-58" type="compound" text="tyrosine"/>
            <entity id="DS3.d876.s1.e2" origId="S4R2V1,Q8C6Q7,S4R1S4,S4R1M0" charOffset="93-97" type="protein" text="CD45"/>
            <entity id="DS3.d876.s1.e3" origId="6057,90983769" charOffset="166-174" type="compound" text="tyrosine"/>
            <pair e1="DS3.d876.s1.e1" e2="DS3.d876.s1.e2" id="DS3.d876.s1.i0" interaction="False" />
            <pair e1="DS3.d876.s1.e1" e2="DS3.d876.s1.e0" id="DS3.d876.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d876.s2" origId="9973453-2" text="Previous work from our laboratory, however, found that despite hyperphosphorylation of Tyr505, the activity of Lck from CD45- T cell lines was actually increased due to hyperphosphorylation of the positive regulatory tyrosine, residue 394.">
            <entity id="DS3.d876.s2.e0" origId="P06240,E9Q696" charOffset="111-114" type="protein" text="Lck"/>
            <entity id="DS3.d876.s2.e1" origId="S4R2V1,Q8C6Q7,S4R1S4,S4R1M0" charOffset="120-124" type="protein" text="CD45"/>
            <entity id="DS3.d876.s2.e2" origId="6057,90983769" charOffset="217-225" type="compound" text="tyrosine"/>
            <pair e1="DS3.d876.s2.e2" e2="DS3.d876.s2.e1" id="DS3.d876.s2.i0" interaction="False" />
            <pair e1="DS3.d876.s2.e2" e2="DS3.d876.s2.e0" id="DS3.d876.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d876.s3" origId="9973453-4" text="Lck in thymocytes from CD45-/- mice was hyperphosphorylated on tyrosine residues.">
            <entity id="DS3.d876.s3.e0" origId="P06240,E9Q696" charOffset="0-3" type="protein" text="Lck"/>
            <entity id="DS3.d876.s3.e1" origId="S4R2V1,Q8C6Q7,S4R1S4,S4R1M0" charOffset="23-27" type="protein" text="CD45"/>
            <entity id="DS3.d876.s3.e2" origId="6057,90983769" charOffset="63-71" type="compound" text="tyrosine"/>
            <pair e1="DS3.d876.s3.e2" e2="DS3.d876.s3.e1" id="DS3.d876.s3.i0" interaction="False" />
            <pair e1="DS3.d876.s3.e2" e2="DS3.d876.s3.e0" id="DS3.d876.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d877" origId="9973454">
        <sentence id="DS3.d877.s0" origId="9973454-2" text="These mice expressed strikingly increased nuclear STAT-4 levels in lamina propria CD4+ T lymphocytes upon systemic administration of dinitrophenyl-keyhole limpet hemocyanin and developed chronic transmural colitis characterized by infiltrates of mainly CD4+ T lymphocytes.">
            <entity id="DS3.d877.s0.e0" origId="Q14765" charOffset="50-56" type="protein" text="STAT-4"/>
            <entity id="DS3.d877.s0.e1" origId="53747178" charOffset="133-147" type="compound" text="dinitrophenyl-"/>
            <pair e1="DS3.d877.s0.e1" e2="DS3.d877.s0.e0" id="DS3.d877.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d878" origId="9973462">
        <sentence id="DS3.d878.s0" origId="9973462-5" text="Whereas, previously reported, B cells lacking p50 alone had a severe proliferative defect in response to LPS, a moderate defect in response to CD40 ligand (CD40L), and normal proliferation to Ag receptor cross-linking using dextran-conjugated anti-IgD Abs (alpha delta-dex), B cells lacking both p50 and p65 exhibited severely impaired proliferation in response to LPS, alpha delta-dex, and CD40L.">
            <entity id="DS3.d878.s0.e0" origId="P19838,A0A024RDJ4" charOffset="46-49" type="protein" text="p50"/>
            <entity id="DS3.d878.s0.e1" origId="O14896,G0Z349" charOffset="105-108" type="protein" text="LPS"/>
            <entity id="DS3.d878.s0.e2" origId="P29965" charOffset="143-154" type="protein" text="CD40 ligand"/>
            <entity id="DS3.d878.s0.e3" origId="P29965" charOffset="156-161" type="protein" text="CD40L"/>
            <entity id="DS3.d878.s0.e4" origId="4125253,5460037" charOffset="224-231" type="compound" text="dextran"/>
            <entity id="DS3.d878.s0.e5" origId="P19838,A0A024RDJ4" charOffset="296-299" type="protein" text="p50"/>
            <entity id="DS3.d878.s0.e6" origId="Q04206,A0A087X0W8" charOffset="304-307" type="protein" text="p65"/>
            <entity id="DS3.d878.s0.e7" origId="O14896,G0Z349" charOffset="365-368" type="protein" text="LPS"/>
            <entity id="DS3.d878.s0.e8" origId="P29965" charOffset="391-396" type="protein" text="CD40L"/>
            <pair e1="DS3.d878.s0.e4" e2="DS3.d878.s0.e1" id="DS3.d878.s0.i0" interaction="False" />
            <pair e1="DS3.d878.s0.e4" e2="DS3.d878.s0.e3" id="DS3.d878.s0.i1" interaction="False" />
            <pair e1="DS3.d878.s0.e4" e2="DS3.d878.s0.e2" id="DS3.d878.s0.i2" interaction="False" />
            <pair e1="DS3.d878.s0.e4" e2="DS3.d878.s0.e0" id="DS3.d878.s0.i3" interaction="False" />
            <pair e1="DS3.d878.s0.e4" e2="DS3.d878.s0.e6" id="DS3.d878.s0.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d879" origId="9973464">
        <sentence id="DS3.d879.s0" origId="9973464-2" text="CD38 ligation with anti-CD38 Abs caused rapid, transient, dose-dependent tyrosine phosphorylation of several proteins, including the tyrosine kinase TEC and the adaptor molecule CBL, and association of tyrosine-phosphorylated proteins with phosphatidylinositol 3-kinase p85.">
            <entity id="DS3.d879.s0.e0" origId="P56528,Q4FJL8,P28907" charOffset="0-4" type="protein" text="CD38"/>
            <entity id="DS3.d879.s0.e1" origId="P56528,Q4FJL8,P28907" charOffset="24-28" type="protein" text="CD38"/>
            <entity id="DS3.d879.s0.e2" origId="6057,90983769" charOffset="73-81" type="compound" text="tyrosine"/>
            <entity id="DS3.d879.s0.e3" origId="6057,90983769" charOffset="133-141" type="compound" text="tyrosine"/>
            <entity id="DS3.d879.s0.e4" origId="P22681" charOffset="178-181" type="protein" text="CBL"/>
            <entity id="DS3.d879.s0.e5" origId="6057,90983769" charOffset="133-141" type="compound" text="tyrosine"/>
            <entity id="DS3.d879.s0.e6" origId="16738692,53477912" charOffset="240-260" type="compound" text="phosphatidylinositol"/>
            <pair e1="DS3.d879.s0.e6" e2="DS3.d879.s0.e0" id="DS3.d879.s0.i0" interaction="False" />
            <pair e1="DS3.d879.s0.e6" e2="DS3.d879.s0.e4" id="DS3.d879.s0.i1" interaction="False" />
            <pair e1="DS3.d879.s0.e2" e2="DS3.d879.s0.e0" id="DS3.d879.s0.i2" interaction="False" />
            <pair e1="DS3.d879.s0.e2" e2="DS3.d879.s0.e4" id="DS3.d879.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d879.s1" origId="9973464-4" text="Aggregation was abrogated by addition of the tyrosine kinase inhibitor herbimycin A and was delayed by the phosphatidylinositol 3-kinase inhibitor wortmannin, suggesting a link between biochemical events and cellular effects induced by CD38.">
            <entity id="DS3.d879.s1.e0" origId="6057,90983769" charOffset="45-53" type="compound" text="tyrosine"/>
            <entity id="DS3.d879.s1.e1" origId="53378893" charOffset="54-70" type="compound" text="kinase inhibitor"/>
            <entity id="DS3.d879.s1.e2" origId="16760502,3591" charOffset="71-83" type="compound" text="herbimycin A"/>
            <entity id="DS3.d879.s1.e3" origId="16738692,53477912" charOffset="107-127" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d879.s1.e4" origId="53378893" charOffset="130-146" type="compound" text="kinase inhibitor"/>
            <entity id="DS3.d879.s1.e5" origId="312145" charOffset="147-157" type="compound" text="wortmannin"/>
            <entity id="DS3.d879.s1.e6" origId="P56528,Q4FJL8,P28907" charOffset="236-240" type="protein" text="CD38"/>
            <pair e1="DS3.d879.s1.e1" e2="DS3.d879.s1.e6" id="DS3.d879.s1.i0" interaction="False" />
            <pair e1="DS3.d879.s1.e2" e2="DS3.d879.s1.e6" id="DS3.d879.s1.i1" interaction="False" />
            <pair e1="DS3.d879.s1.e3" e2="DS3.d879.s1.e6" id="DS3.d879.s1.i2" interaction="False" />
            <pair e1="DS3.d879.s1.e5" e2="DS3.d879.s1.e6" id="DS3.d879.s1.i3" interaction="False" />
            <pair e1="DS3.d879.s1.e0" e2="DS3.d879.s1.e6" id="DS3.d879.s1.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d879.s2" origId="9973464-6" text="After 3 days of culture on bone marrow-derived stroma, the mean (+/-SD) cell recovery in the presence of anti-CD38 (T16) was 10.5 +/- 9.2% (n = 7) of that in parallel cultures with an isotype-matched nonreactive Ab.">
            <entity id="DS3.d879.s2.e0" origId="P56528,Q4FJL8,P28907" charOffset="110-114" type="protein" text="CD38"/>
            <entity id="DS3.d879.s2.e1" origId="16740934" charOffset="116-119" type="compound" text="T16"/>
            <pair e1="DS3.d879.s2.e1" e2="DS3.d879.s2.e0" id="DS3.d879.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d879.s3" origId="9973464-7" text="Finally, CD38 ligation in Ba/F3 cells expressing a mutant human CD38 lacking the cytoplasmic domain induced tyrosine phosphorylation with intensity and kinetics similar to those seen with the entire protein.">
            <entity id="DS3.d879.s3.e0" origId="P56528,Q4FJL8,P28907" charOffset="9-13" type="protein" text="CD38"/>
            <entity id="DS3.d879.s3.e1" origId="P56528,Q4FJL8,P28907" charOffset="64-68" type="protein" text="CD38"/>
            <entity id="DS3.d879.s3.e2" origId="6057,90983769" charOffset="108-116" type="compound" text="tyrosine"/>
            <pair e1="DS3.d879.s3.e2" e2="DS3.d879.s3.e0" id="DS3.d879.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d880" origId="9973466">
        <sentence id="DS3.d880.s0" origId="9973466-0" text="Identification of tyrosine phosphorylation sites in the CD28 cytoplasmic domain and their role in the costimulation of Jurkat T cells.">
            <entity id="DS3.d880.s0.e0" origId="6057,90983769" charOffset="18-26" type="compound" text="tyrosine"/>
            <entity id="DS3.d880.s0.e1" origId="P10747,B4E0L1,P31041,Q8CDB3" charOffset="56-60" type="protein" text="CD28"/>
            <pair e1="DS3.d880.s0.e0" e2="DS3.d880.s0.e1" id="DS3.d880.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d880.s1" origId="9973466-1" text="The cytoplasmic domain of CD28 contains four tyrosine residues.">
            <entity id="DS3.d880.s1.e0" origId="P10747,B4E0L1,P31041,Q8CDB3" charOffset="26-30" type="protein" text="CD28"/>
            <entity id="DS3.d880.s1.e1" origId="6057,90983769" charOffset="45-53" type="compound" text="tyrosine"/>
            <pair e1="DS3.d880.s1.e1" e2="DS3.d880.s1.e0" id="DS3.d880.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d880.s2" origId="9973466-2" text="Because signal transduction by CD28 appears to involve its tyrosine phosphorylation, we determined sites of CD28 tyrosine phosphorylation using mutants of mouse CD28 that retained tyrosine at one position, with the remaining three positions mutated to phenylalanine.">
            <entity id="DS3.d880.s2.e0" origId="P10747,B4E0L1,P31041,Q8CDB3" charOffset="31-35" type="protein" text="CD28"/>
            <entity id="DS3.d880.s2.e1" origId="6057,90983769" charOffset="59-67" type="compound" text="tyrosine"/>
            <entity id="DS3.d880.s2.e2" origId="P10747,B4E0L1,P31041,Q8CDB3" charOffset="108-112" type="protein" text="CD28"/>
            <entity id="DS3.d880.s2.e3" origId="6057,90983769" charOffset="113-121" type="compound" text="tyrosine"/>
            <entity id="DS3.d880.s2.e4" origId="P10747,B4E0L1,P31041,Q8CDB3" charOffset="108-112" type="protein" text="CD28"/>
            <entity id="DS3.d880.s2.e5" origId="6057,90983769" charOffset="113-121" type="compound" text="tyrosine"/>
            <entity id="DS3.d880.s2.e6" origId="6140,71567,89654470,994" charOffset="252-265" type="compound" text="phenylalanine"/>
            <pair e1="DS3.d880.s2.e6" e2="DS3.d880.s2.e0" id="DS3.d880.s2.i0" interaction="False" />
            <pair e1="DS3.d880.s2.e1" e2="DS3.d880.s2.e0" id="DS3.d880.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d880.s3" origId="9973466-4" text="Phosphorylation of Tyr170 recruits phosphatidylinositol 3-kinase to CD28.">
            <entity id="DS3.d880.s3.e0" origId="16738692,53477912" charOffset="35-55" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d880.s3.e1" origId="P10747,B4E0L1,P31041,Q8CDB3" charOffset="68-72" type="protein" text="CD28"/>
            <pair e1="DS3.d880.s3.e0" e2="DS3.d880.s3.e1" id="DS3.d880.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d880.s4" origId="9973466-6" text="Consistent with that possibility, mutation of Tyr188 to phenylalanine severely impaired the ability of mouse CD28 to deliver a costimulus for the expression of CD69 and the production of IL-2.">
            <entity id="DS3.d880.s4.e0" origId="6140,71567,89654470,994" charOffset="56-69" type="compound" text="phenylalanine"/>
            <entity id="DS3.d880.s4.e1" origId="P10747,B4E0L1,P31041,Q8CDB3" charOffset="109-113" type="protein" text="CD28"/>
            <entity id="DS3.d880.s4.e2" origId="P37217,Q3U6A8" charOffset="160-164" type="protein" text="CD69"/>
            <pair e1="DS3.d880.s4.e0" e2="DS3.d880.s4.e1" id="DS3.d880.s4.i0" interaction="False" />
            <pair e1="DS3.d880.s4.e0" e2="DS3.d880.s4.e2" id="DS3.d880.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d880.s5" origId="9973466-8" text="Therefore, of the four CD28 tyrosine residues only Tyr188 is required for signaling in Jurkat cells, suggesting that its phosphorylation is a key event in the costimulation of T cells.">
            <entity id="DS3.d880.s5.e0" origId="P10747,B4E0L1,P31041,Q8CDB3" charOffset="23-27" type="protein" text="CD28"/>
            <entity id="DS3.d880.s5.e1" origId="6057,90983769" charOffset="28-36" type="compound" text="tyrosine"/>
            <pair e1="DS3.d880.s5.e1" e2="DS3.d880.s5.e0" id="DS3.d880.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d881" origId="9973469">
        <sentence id="DS3.d881.s0" origId="9973469-4" text="Ligation of CD16 on IL-2-preactivated NK cells resulted in reduction of intracellular peroxide level as well as induction of FasL expression.">
            <entity id="DS3.d881.s0.e0" origId="P08637,M9MML0" charOffset="12-16" type="protein" text="CD16"/>
            <entity id="DS3.d881.s0.e1" origId="17887040" charOffset="86-94" type="compound" text="peroxide"/>
            <entity id="DS3.d881.s0.e2" origId="P48023,Q53ZZ1" charOffset="125-129" type="protein" text="FasL"/>
            <pair e1="DS3.d881.s0.e1" e2="DS3.d881.s0.e0" id="DS3.d881.s0.i0" interaction="False" />
            <pair e1="DS3.d881.s0.e1" e2="DS3.d881.s0.e2" id="DS3.d881.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d881.s1" origId="9973469-5" text="This CD16-induced FasL expression was suppressed by oxidative stress, including thiol deprivation or treatment with hydrogen peroxide (H2O2).">
            <entity id="DS3.d881.s1.e0" origId="P08637,M9MML0" charOffset="5-9" type="protein" text="CD16"/>
            <entity id="DS3.d881.s1.e1" origId="P48023,Q53ZZ1" charOffset="18-22" type="protein" text="FasL"/>
            <entity id="DS3.d881.s1.e2" origId="784" charOffset="116-133" type="compound" text="hydrogen peroxide"/>
            <pair e1="DS3.d881.s1.e2" e2="DS3.d881.s1.e0" id="DS3.d881.s1.i0" interaction="False" />
            <pair e1="DS3.d881.s1.e2" e2="DS3.d881.s1.e1" id="DS3.d881.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d881.s2" origId="9973469-6" text="Addition of thiol-reducing compounds, such as L-cystine, 2-ME, or N-acetyl cysteine, restored FasL expression.">
            <entity id="DS3.d881.s2.e0" origId="595" charOffset="48-55" type="compound" text="cystine"/>
            <entity id="DS3.d881.s2.e1" origId="186100" charOffset="68-83" type="compound" text="acetyl cysteine"/>
            <entity id="DS3.d881.s2.e2" origId="P48023,Q53ZZ1" charOffset="94-98" type="protein" text="FasL"/>
            <pair e1="DS3.d881.s2.e0" e2="DS3.d881.s2.e2" id="DS3.d881.s2.i0" interaction="False" />
            <pair e1="DS3.d881.s2.e1" e2="DS3.d881.s2.e2" id="DS3.d881.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d882" origId="9973473">
        <sentence id="DS3.d882.s0" origId="9973473-9" text="The kinetics of phosphorylation of TCR-associated PDE4B2 correlated with changes in cAMP levels, suggesting that tyrosine phosphorylation of the TCR-associated PDE4B isoform upon engagement of this receptor may be an important regulatory step in PDE4B function.">
            <entity id="DS3.d882.s0.e0" origId="P49913,J3KNB4" charOffset="84-88" type="protein" text="cAMP"/>
            <entity id="DS3.d882.s0.e1" origId="6057,90983769" charOffset="113-121" type="compound" text="tyrosine"/>
            <pair e1="DS3.d882.s0.e1" e2="DS3.d882.s0.e0" id="DS3.d882.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d883" origId="9973475">
        <sentence id="DS3.d883.s0" origId="9973475-3" text="In this report we have studied Ly49-mediated positive and negative signaling in an in vitro cytotoxicity assay using sorted NK cell subsets as effectors and a panel of 51Cr-labeled Con A lymphoblasts as targets in the presence or the absence of Abs to Ly49 and/or class I molecules.">
            <entity id="DS3.d883.s0.e0" origId="104786" charOffset="168-172" type="compound" text="51Cr"/>
            <entity id="DS3.d883.s0.e1" origId="Q91VN6,Q3UAC4,Q9CUY2" charOffset="245-248" type="protein" text="Abs"/>
            <pair e1="DS3.d883.s0.e0" e2="DS3.d883.s0.e1" id="DS3.d883.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d883.s1" origId="9973475-4" text="Our results demonstrate that the activating receptor Ly49D delivers stimulatory signals for target cell lysis upon interacting with H2-Dd, Dr, and Dsp2, but not H2b or H2k class I Ags.">
            <entity id="DS3.d883.s1.e0" origId="Q60651,Q542S4" charOffset="53-58" type="protein" text="Ly49D"/>
            <entity id="DS3.d883.s1.e1" origId="783" charOffset="132-134" type="compound" text="H2"/>
            <entity id="DS3.d883.s1.e2" origId="Q16778" charOffset="161-164" type="protein" text="H2b"/>
            <entity id="DS3.d883.s1.e3" origId="60138166" charOffset="168-171" type="compound" text="H2k"/>
            <pair e1="DS3.d883.s1.e1" e2="DS3.d883.s1.e0" id="DS3.d883.s1.i0" interaction="False" />
            <pair e1="DS3.d883.s1.e1" e2="DS3.d883.s1.e2" id="DS3.d883.s1.i1" interaction="False" />
            <pair e1="DS3.d883.s1.e3" e2="DS3.d883.s1.e0" id="DS3.d883.s1.i2" interaction="False" />
            <pair e1="DS3.d883.s1.e3" e2="DS3.d883.s1.e2" id="DS3.d883.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d883.s2" origId="9973475-5" text="On the other hand, the inhibitory receptor Ly49G2 delivers negative signals for target cell lysis upon interacting with Dd, Dr, and H2k, but not H2b or Dsp2, class I Ags.">
            <entity id="DS3.d883.s2.e0" origId="60138166" charOffset="132-135" type="compound" text="H2k"/>
            <entity id="DS3.d883.s2.e1" origId="Q16778" charOffset="145-148" type="protein" text="H2b"/>
            <pair e1="DS3.d883.s2.e0" e2="DS3.d883.s2.e1" id="DS3.d883.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d884" origId="9973476">
        <sentence id="DS3.d884.s0" origId="9973476-7" text="Results show that paraformaldehyde-fixed CD86+ T cells enhance the proliferation and production of IFN-gamma by anti-CD3 mAb-stimulated naive T cells and induce proliferation of resting allogenic T cells.">
            <entity id="DS3.d884.s0.e0" origId="712" charOffset="18-34" type="compound" text="paraformaldehyde"/>
            <entity id="DS3.d884.s0.e1" origId="P42081,A8K632" charOffset="41-45" type="protein" text="CD86"/>
            <pair e1="DS3.d884.s0.e0" e2="DS3.d884.s0.e1" id="DS3.d884.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d885" origId="9973477">
        <sentence id="DS3.d885.s0" origId="9973477-0" text="Lysophosphatidic acid and sphingosine 1-phosphate protection of T cells from apoptosis in association with suppression of Bax.">
            <entity id="DS3.d885.s0.e0" origId="3988,5311263,5497152,5885531" charOffset="0-21" type="compound" text="Lysophosphatidic acid"/>
            <entity id="DS3.d885.s0.e1" origId="31270,5280335" charOffset="26-37" type="compound" text="sphingosine"/>
            <entity id="DS3.d885.s0.e2" origId="1061,167704,644102" charOffset="40-49" type="compound" text="phosphate"/>
            <entity id="DS3.d885.s0.e3" origId="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0" charOffset="122-125" type="protein" text="Bax"/>
            <pair e1="DS3.d885.s0.e2" e2="DS3.d885.s0.e3" id="DS3.d885.s0.i0" interaction="False" />
            <pair e1="DS3.d885.s0.e1" e2="DS3.d885.s0.e3" id="DS3.d885.s0.i1" interaction="False" />
            <pair e1="DS3.d885.s0.e0" e2="DS3.d885.s0.e3" id="DS3.d885.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d885.s1" origId="9973477-4" text="Apoptosis elicited by C6 ceramide was inhibited by S1P, but not by LPA, in part because ceramide suppressed expression of Edg-2 and Edg-4 surface receptors for LPA without affecting Edg-3 surface receptors for S1P.">
            <entity id="DS3.d885.s1.e0" origId="5702613" charOffset="22-33" type="compound" text="C6 ceramide"/>
            <entity id="DS3.d885.s1.e1" origId="Q92633,Q5VZX0" charOffset="122-127" type="protein" text="Edg-2"/>
            <entity id="DS3.d885.s1.e2" origId="Q9HBW0,A0A024R7M9" charOffset="132-137" type="protein" text="Edg-4"/>
            <entity id="DS3.d885.s1.e3" origId="Q99500" charOffset="182-187" type="protein" text="Edg-3"/>
            <pair e1="DS3.d885.s1.e0" e2="DS3.d885.s1.e1" id="DS3.d885.s1.i0" interaction="False" />
            <pair e1="DS3.d885.s1.e0" e2="DS3.d885.s1.e3" id="DS3.d885.s1.i1" interaction="False" />
            <pair e1="DS3.d885.s1.e0" e2="DS3.d885.s1.e2" id="DS3.d885.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d885.s2" origId="9973477-6" text="Transfections of pairs of antisense plasmids for Edg-2 plus Edg-4 and Edg-3 plus Edg-5, and hygromycin selection of transfectants with reduced expression of the respective Edg R proteins in Western blots, inhibited both protection from apoptosis and reduction in cellular levels of Bax by LPA and S1P.">
            <entity id="DS3.d885.s2.e0" origId="Q92633,Q5VZX0" charOffset="49-54" type="protein" text="Edg-2"/>
            <entity id="DS3.d885.s2.e1" origId="Q9HBW0,A0A024R7M9" charOffset="60-65" type="protein" text="Edg-4"/>
            <entity id="DS3.d885.s2.e2" origId="Q99500" charOffset="70-75" type="protein" text="Edg-3"/>
            <entity id="DS3.d885.s2.e3" origId="O95136,A0A024R7B2" charOffset="81-86" type="protein" text="Edg-5"/>
            <entity id="DS3.d885.s2.e4" origId="127716" charOffset="49-52" type="compound" text="Edg"/>
            <entity id="DS3.d885.s2.e5" origId="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0" charOffset="282-285" type="protein" text="Bax"/>
            <pair e1="DS3.d885.s2.e4" e2="DS3.d885.s2.e0" id="DS3.d885.s2.i0" interaction="False" />
            <pair e1="DS3.d885.s2.e4" e2="DS3.d885.s2.e2" id="DS3.d885.s2.i1" interaction="False" />
            <pair e1="DS3.d885.s2.e4" e2="DS3.d885.s2.e1" id="DS3.d885.s2.i2" interaction="False" />
            <pair e1="DS3.d885.s2.e4" e2="DS3.d885.s2.e3" id="DS3.d885.s2.i3" interaction="False" />
            <pair e1="DS3.d885.s2.e4" e2="DS3.d885.s2.e5" id="DS3.d885.s2.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d885.s3" origId="9973477-7" text="Thus, LPA and S1P protection from apoptosis is mediated by distinct Edg GPCRs and may involve novel effects on Bax regulatory protein.">
            <entity id="DS3.d885.s3.e0" origId="127716" charOffset="68-71" type="compound" text="Edg"/>
            <entity id="DS3.d885.s3.e1" origId="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0" charOffset="111-114" type="protein" text="Bax"/>
            <pair e1="DS3.d885.s3.e0" e2="DS3.d885.s3.e1" id="DS3.d885.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d886" origId="9973478">
        <sentence id="DS3.d886.s0" origId="9973478-4" text="We have examined a second calcium-dependent signaling pathway, mediated by calcium/calmodulin-dependent kinase IV (CaMKIV) in transcriptional activation of TNF family genes.">
            <entity id="DS3.d886.s0.e0" origId="22044544,5460341" charOffset="26-33" type="compound" text="calcium"/>
            <entity id="DS3.d886.s0.e1" origId="Q16566" charOffset="75-113" type="protein" text="calcium/calmodulin-dependent kinase IV"/>
            <entity id="DS3.d886.s0.e2" origId="Q16566" charOffset="115-121" type="protein" text="CaMKIV"/>
            <pair e1="DS3.d886.s0.e0" e2="DS3.d886.s0.e1" id="DS3.d886.s0.i0" interaction="False" />
            <pair e1="DS3.d886.s0.e0" e2="DS3.d886.s0.e2" id="DS3.d886.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d886.s1" origId="9973478-6" text="Furthermore, specific inhibition of CaMKIV by chemical means and by a dominant negative mutant of CaMKIV impairs the ionomycin-induced activity of all three promoters as well as protein expression of CD40L and TNF-alpha.">
            <entity id="DS3.d886.s1.e0" origId="Q16566" charOffset="36-42" type="protein" text="CaMKIV"/>
            <entity id="DS3.d886.s1.e1" origId="Q16566" charOffset="98-104" type="protein" text="CaMKIV"/>
            <entity id="DS3.d886.s1.e2" origId="25134244,3733,5353687,6434517,6912226" charOffset="117-126" type="compound" text="ionomycin"/>
            <entity id="DS3.d886.s1.e3" origId="P29965" charOffset="200-205" type="protein" text="CD40L"/>
            <entity id="DS3.d886.s1.e4" origId="P01375,Q5STB3" charOffset="210-219" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d886.s1.e2" e2="DS3.d886.s1.e3" id="DS3.d886.s1.i0" interaction="False" />
            <pair e1="DS3.d886.s1.e2" e2="DS3.d886.s1.e4" id="DS3.d886.s1.i1" interaction="False" />
            <pair e1="DS3.d886.s1.e2" e2="DS3.d886.s1.e0" id="DS3.d886.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d887" origId="9973479">
        <sentence id="DS3.d887.s0" origId="9973479-3" text="Beta 1 integrin simultaneous cross-linking selectively inhibited CD16-induced phospholipase D (PLD) activation, without affecting either phosphatidylinositol-phospholipase C or cytosolic phospholipase A2 (PLA2) enzymatic activity.">
            <entity id="DS3.d887.s0.e0" origId="P05556" charOffset="0-15" type="protein" text="Beta 1 integrin"/>
            <entity id="DS3.d887.s0.e1" origId="P08637,M9MML0" charOffset="65-69" type="protein" text="CD16"/>
            <entity id="DS3.d887.s0.e2" origId="16738692,53477912" charOffset="137-157" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d887.s0.e3" origId="P14555,A0A024RA96" charOffset="187-203" type="protein" text="phospholipase A2"/>
            <entity id="DS3.d887.s0.e4" origId="P14555,A0A024RA96" charOffset="205-209" type="protein" text="PLA2"/>
            <pair e1="DS3.d887.s0.e2" e2="DS3.d887.s0.e1" id="DS3.d887.s0.i0" interaction="False" />
            <pair e1="DS3.d887.s0.e2" e2="DS3.d887.s0.e4" id="DS3.d887.s0.i1" interaction="False" />
            <pair e1="DS3.d887.s0.e2" e2="DS3.d887.s0.e0" id="DS3.d887.s0.i2" interaction="False" />
            <pair e1="DS3.d887.s0.e2" e2="DS3.d887.s0.e3" id="DS3.d887.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d887.s1" origId="9973479-5" text="The similar effects exerted by specific PLD pharmacological inhibitors (2,3-diphosphoglycerate, ethanol) suggest that in our experimental system, sPLA2 secretion and activation are under the control of a PLD-dependent pathway.">
            <entity id="DS3.d887.s1.e0" origId="61" charOffset="72-94" type="compound" text="2,3-diphosphoglycerate"/>
            <entity id="DS3.d887.s1.e1" origId="702" charOffset="96-103" type="compound" text="ethanol"/>
            <entity id="DS3.d887.s1.e2" origId="P14555,A0A024RA96" charOffset="146-151" type="protein" text="sPLA2"/>
            <pair e1="DS3.d887.s1.e0" e2="DS3.d887.s1.e2" id="DS3.d887.s1.i0" interaction="False" />
            <pair e1="DS3.d887.s1.e1" e2="DS3.d887.s1.e2" id="DS3.d887.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d887.s2" origId="9973479-6" text="By using pharmacological inhibitors (2,3-diphosphoglycerate, wortmannin, ethanol) we also demonstrated that PLD activation is an important step in the CD16-triggered signaling cascade that leads to NK cytotoxic granule exocytosis.">
            <entity id="DS3.d887.s2.e0" origId="61" charOffset="37-59" type="compound" text="2,3-diphosphoglycerate"/>
            <entity id="DS3.d887.s2.e1" origId="312145" charOffset="61-71" type="compound" text="wortmannin"/>
            <entity id="DS3.d887.s2.e2" origId="702" charOffset="73-80" type="compound" text="ethanol"/>
            <entity id="DS3.d887.s2.e3" origId="P08637,M9MML0" charOffset="151-155" type="protein" text="CD16"/>
            <pair e1="DS3.d887.s2.e1" e2="DS3.d887.s2.e3" id="DS3.d887.s2.i0" interaction="False" />
            <pair e1="DS3.d887.s2.e0" e2="DS3.d887.s2.e3" id="DS3.d887.s2.i1" interaction="False" />
            <pair e1="DS3.d887.s2.e2" e2="DS3.d887.s2.e3" id="DS3.d887.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d887.s3" origId="9973479-7" text="Consistent with these findings, fibronectin receptor engagement, by either mAbs or natural ligands, resulted in a selective inhibition of CD16-triggered, but not of PMA/ionomycin-induced, degranulation that was reversed by the exogenous addition of purified PLD from Streptomyces chromofuscus.">
            <entity id="DS3.d887.s3.e0" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="32-43" type="protein" text="fibronectin"/>
            <entity id="DS3.d887.s3.e1" origId="P08637,M9MML0" charOffset="138-142" type="protein" text="CD16"/>
            <entity id="DS3.d887.s3.e2" origId="122634,22833501,27924" charOffset="165-168" type="compound" text="PMA"/>
            <entity id="DS3.d887.s3.e3" origId="25134244,3733,5353687,6434517,6912226" charOffset="169-178" type="compound" text="ionomycin"/>
            <pair e1="DS3.d887.s3.e3" e2="DS3.d887.s3.e1" id="DS3.d887.s3.i0" interaction="False" />
            <pair e1="DS3.d887.s3.e3" e2="DS3.d887.s3.e0" id="DS3.d887.s3.i1" interaction="False" />
            <pair e1="DS3.d887.s3.e2" e2="DS3.d887.s3.e1" id="DS3.d887.s3.i2" interaction="False" />
            <pair e1="DS3.d887.s3.e2" e2="DS3.d887.s3.e0" id="DS3.d887.s3.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d888" origId="9973480">
        <sentence id="DS3.d888.s0" origId="9973480-7" text="Functionally, more potent ligands induce a higher proportion of fully tyrosine phosphorylated zeta-chains and a greater amount of phosphorylated ZAP-70 than less potent ligands, and the number of TCR down-modulated per available ligand is higher with ligands showing this full agonist-like pattern.">
            <entity id="DS3.d888.s0.e0" origId="6057,90983769" charOffset="70-78" type="compound" text="tyrosine"/>
            <entity id="DS3.d888.s0.e1" origId="P43403" charOffset="145-151" type="protein" text="ZAP-70"/>
            <pair e1="DS3.d888.s0.e0" e2="DS3.d888.s0.e1" id="DS3.d888.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d889" origId="9973481">
        <sentence id="DS3.d889.s0" origId="9973481-0" text="IL-2, but not IL-4 and other cytokines, induces phosphorylation of a 98-kDa protein associated with SHP-2, phosphatidylinositol 3'-kinase, and Grb2.">
            <entity id="DS3.d889.s0.e0" origId="Q06124" charOffset="100-105" type="protein" text="SHP-2"/>
            <entity id="DS3.d889.s0.e1" origId="16738692,53477912" charOffset="107-127" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d889.s0.e2" origId="P62993,B0LPF3" charOffset="143-147" type="protein" text="Grb2"/>
            <pair e1="DS3.d889.s0.e1" e2="DS3.d889.s0.e0" id="DS3.d889.s0.i0" interaction="False" />
            <pair e1="DS3.d889.s0.e1" e2="DS3.d889.s0.e2" id="DS3.d889.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d889.s1" origId="9973481-3" text="We now report the identification of a prominent 98-kDa protein (p98) found to be phosphorylated in response to IL-2 stimulation and coprecipitated with SHP-2, the p85 subunit of PI 3'-kinase and Grb2.">
            <entity id="DS3.d889.s1.e0" origId="72193890" charOffset="64-67" type="compound" text="p98"/>
            <entity id="DS3.d889.s1.e1" origId="Q06124" charOffset="152-157" type="protein" text="SHP-2"/>
            <entity id="DS3.d889.s1.e2" origId="P27986" charOffset="163-166" type="protein" text="p85"/>
            <entity id="DS3.d889.s1.e3" origId="P62993,B0LPF3" charOffset="195-199" type="protein" text="Grb2"/>
            <pair e1="DS3.d889.s1.e0" e2="DS3.d889.s1.e1" id="DS3.d889.s1.i0" interaction="False" />
            <pair e1="DS3.d889.s1.e0" e2="DS3.d889.s1.e3" id="DS3.d889.s1.i1" interaction="False" />
            <pair e1="DS3.d889.s1.e0" e2="DS3.d889.s1.e2" id="DS3.d889.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d889.s2" origId="9973481-5" text="p98 can form a multipartite complex with all these proteins as immunodepleting with anti-p85 antiserum substantially reduced the amount of p98 immunoprecipitated by SHP-2 and Grb2; the converse was also true.">
            <entity id="DS3.d889.s2.e0" origId="72193890" charOffset="0-3" type="compound" text="p98"/>
            <entity id="DS3.d889.s2.e1" origId="P27986" charOffset="89-92" type="protein" text="p85"/>
            <entity id="DS3.d889.s2.e2" origId="72193890" charOffset="139-142" type="compound" text="p98"/>
            <entity id="DS3.d889.s2.e3" origId="Q06124" charOffset="165-170" type="protein" text="SHP-2"/>
            <entity id="DS3.d889.s2.e4" origId="P62993,B0LPF3" charOffset="175-179" type="protein" text="Grb2"/>
            <pair e1="DS3.d889.s2.e0" e2="DS3.d889.s2.e3" id="DS3.d889.s2.i0" interaction="False" />
            <pair e1="DS3.d889.s2.e0" e2="DS3.d889.s2.e4" id="DS3.d889.s2.i1" interaction="False" />
            <pair e1="DS3.d889.s2.e0" e2="DS3.d889.s2.e1" id="DS3.d889.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d889.s3" origId="9973481-6" text="Furthermore, phosphorylation of p98 did not occur in cells lacking JAK3, suggesting that it may be a JAK substrate.">
            <entity id="DS3.d889.s3.e0" origId="72193890" charOffset="32-35" type="compound" text="p98"/>
            <entity id="DS3.d889.s3.e1" origId="P52333,A0A024R7M7" charOffset="67-71" type="protein" text="JAK3"/>
            <pair e1="DS3.d889.s3.e0" e2="DS3.d889.s3.e1" id="DS3.d889.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d890" origId="9973482">
        <sentence id="DS3.d890.s0" origId="9973482-0" text="Mitogen-activated protein kinase activation through Fc epsilon receptor I and stem cell factor receptor is differentially regulated by phosphatidylinositol 3-kinase and calcineurin in mouse bone marrow-derived mast cells.">
            <entity id="DS3.d890.s0.e0" origId="P20826" charOffset="78-94" type="protein" text="stem cell factor"/>
            <entity id="DS3.d890.s0.e1" origId="16738692,53477912" charOffset="135-155" type="compound" text="phosphatidylinositol"/>
            <pair e1="DS3.d890.s0.e1" e2="DS3.d890.s0.e0" id="DS3.d890.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d890.s1" origId="9973482-1" text="Aggregation of high affinity FcR for IgE (Fc epsilon RI) on mast cells activates intracellular signal transduction pathways, including the activation of protein tyrosine kinases, phosphatidylinositol 3-kinase (PI3-kinase), and protein kinase C. Binding of stem cell factor (SCF) to its receptor (SCFR, c-Kit) on mast cells also induces increases in intrinsic tyrosine kinase activity and activation of PI3-kinase.">
            <entity id="DS3.d890.s1.e0" origId="P20489" charOffset="42-55" type="protein" text="Fc epsilon RI"/>
            <entity id="DS3.d890.s1.e1" origId="6057,90983769" charOffset="161-169" type="compound" text="tyrosine"/>
            <entity id="DS3.d890.s1.e2" origId="16738692,53477912" charOffset="179-199" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d890.s1.e3" origId="P20826" charOffset="256-272" type="protein" text="stem cell factor"/>
            <entity id="DS3.d890.s1.e4" origId="P20826" charOffset="274-277" type="protein" text="SCF"/>
            <entity id="DS3.d890.s1.e5" origId="P05532,F7DD14" charOffset="296-300" type="protein" text="SCFR"/>
            <entity id="DS3.d890.s1.e6" origId="P05532,F7DD14" charOffset="302-307" type="protein" text="c-Kit"/>
            <entity id="DS3.d890.s1.e7" origId="6057,90983769" charOffset="359-367" type="compound" text="tyrosine"/>
            <pair e1="DS3.d890.s1.e2" e2="DS3.d890.s1.e3" id="DS3.d890.s1.i0" interaction="False" />
            <pair e1="DS3.d890.s1.e2" e2="DS3.d890.s1.e4" id="DS3.d890.s1.i1" interaction="False" />
            <pair e1="DS3.d890.s1.e2" e2="DS3.d890.s1.e6" id="DS3.d890.s1.i2" interaction="False" />
            <pair e1="DS3.d890.s1.e2" e2="DS3.d890.s1.e5" id="DS3.d890.s1.i3" interaction="False" />
            <pair e1="DS3.d890.s1.e2" e2="DS3.d890.s1.e0" id="DS3.d890.s1.i4" interaction="False" />
            <pair e1="DS3.d890.s1.e1" e2="DS3.d890.s1.e3" id="DS3.d890.s1.i5" interaction="False" />
            <pair e1="DS3.d890.s1.e1" e2="DS3.d890.s1.e4" id="DS3.d890.s1.i6" interaction="False" />
            <pair e1="DS3.d890.s1.e1" e2="DS3.d890.s1.e6" id="DS3.d890.s1.i7" interaction="False" />
            <pair e1="DS3.d890.s1.e1" e2="DS3.d890.s1.e5" id="DS3.d890.s1.i8" interaction="False" />
            <pair e1="DS3.d890.s1.e1" e2="DS3.d890.s1.e0" id="DS3.d890.s1.i9" interaction="False" />
        </sentence>
        <sentence id="DS3.d890.s2" origId="9973482-5" text="Wortmannin, an inhibitor of PI3-kinase, inhibited both Fc epsilon RI- and SCFR-mediated JNK activation and partially inhibited Fc epsilon RI, but not SCFR-mediated p38 activation.">
            <entity id="DS3.d890.s2.e0" origId="312145" charOffset="0-10" type="compound" text="Wortmannin"/>
            <entity id="DS3.d890.s2.e1" origId="P20489" charOffset="55-68" type="protein" text="Fc epsilon RI"/>
            <entity id="DS3.d890.s2.e2" origId="P05532,F7DD14" charOffset="74-78" type="protein" text="SCFR"/>
            <entity id="DS3.d890.s2.e3" origId="P20489" charOffset="127-140" type="protein" text="Fc epsilon RI"/>
            <entity id="DS3.d890.s2.e4" origId="P05532,F7DD14" charOffset="150-154" type="protein" text="SCFR"/>
            <entity id="DS3.d890.s2.e5" origId="Q64010,Q3TQV3,Q5ND50,Q5ND51,Q8JZR2" charOffset="164-167" type="protein" text="p38"/>
            <pair e1="DS3.d890.s2.e0" e2="DS3.d890.s2.e5" id="DS3.d890.s2.i0" interaction="False" />
            <pair e1="DS3.d890.s2.e0" e2="DS3.d890.s2.e2" id="DS3.d890.s2.i1" interaction="False" />
            <pair e1="DS3.d890.s2.e0" e2="DS3.d890.s2.e1" id="DS3.d890.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d890.s3" origId="9973482-7" text="Wortmannin and cyclosporin A inhibited Fc epsilon RI-mediated production of TNF-alpha and IL-4 in addition to serotonin release in BMMC.">
            <entity id="DS3.d890.s3.e0" origId="312145" charOffset="0-10" type="compound" text="Wortmannin"/>
            <entity id="DS3.d890.s3.e1" origId="P20489" charOffset="39-52" type="protein" text="Fc epsilon RI"/>
            <entity id="DS3.d890.s3.e2" origId="P06804,Q3U593" charOffset="76-85" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d890.s3.e3" origId="5202" charOffset="110-119" type="compound" text="serotonin"/>
            <pair e1="DS3.d890.s3.e3" e2="DS3.d890.s3.e2" id="DS3.d890.s3.i0" interaction="False" />
            <pair e1="DS3.d890.s3.e3" e2="DS3.d890.s3.e1" id="DS3.d890.s3.i1" interaction="False" />
            <pair e1="DS3.d890.s3.e0" e2="DS3.d890.s3.e2" id="DS3.d890.s3.i2" interaction="False" />
            <pair e1="DS3.d890.s3.e0" e2="DS3.d890.s3.e1" id="DS3.d890.s3.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d891" origId="9973483">
        <sentence id="DS3.d891.s0" origId="9973483-4" text="Inhibition was not restricted to TNF-induced activation, because leflunomide also inhibited NF-kappa B activation induced by other inflammatory agents, including phorbol ester, LPS, H2O2, okadaic acid, and ceramide.">
            <entity id="DS3.d891.s0.e0" origId="3899" charOffset="65-76" type="compound" text="leflunomide"/>
            <entity id="DS3.d891.s0.e1" origId="22833501,70702034" charOffset="162-175" type="compound" text="phorbol ester"/>
            <entity id="DS3.d891.s0.e2" origId="O14896,G0Z349" charOffset="177-180" type="protein" text="LPS"/>
            <entity id="DS3.d891.s0.e3" origId="11953808,42628599,446512,45356271,4584,57059112,5468826,6102351,6476659,6426933,6917781,90479758" charOffset="188-200" type="compound" text="okadaic acid"/>
            <pair e1="DS3.d891.s0.e0" e2="DS3.d891.s0.e2" id="DS3.d891.s0.i0" interaction="False" />
            <pair e1="DS3.d891.s0.e1" e2="DS3.d891.s0.e2" id="DS3.d891.s0.i1" interaction="False" />
            <pair e1="DS3.d891.s0.e3" e2="DS3.d891.s0.e2" id="DS3.d891.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d891.s1" origId="9973483-5" text="Leflunomide blocked the degradation of I kappa B alpha and subsequent nuclear translocation of the p65 subunit, steps essential for NF-kappa B activation.">
            <entity id="DS3.d891.s1.e0" origId="3899" charOffset="0-11" type="compound" text="Leflunomide"/>
            <entity id="DS3.d891.s1.e1" origId="P25963" charOffset="39-54" type="protein" text="I kappa B alpha"/>
            <entity id="DS3.d891.s1.e2" origId="Q9BQQ3,B4E1H8,B3KPY8,A0A024R2U5" charOffset="99-102" type="protein" text="p65"/>
            <pair e1="DS3.d891.s1.e0" e2="DS3.d891.s1.e2" id="DS3.d891.s1.i0" interaction="False" />
            <pair e1="DS3.d891.s1.e0" e2="DS3.d891.s1.e1" id="DS3.d891.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d891.s2" origId="9973483-6" text="This correlated with inhibition of dual specificity-mitogen-activated protein kinase kinase as well as an Src protein tyrosine kinase, p56lck, by leflunomide.">
            <entity id="DS3.d891.s2.e0" origId="6057,90983769" charOffset="118-126" type="compound" text="tyrosine"/>
            <entity id="DS3.d891.s2.e1" origId="P06239,Q573B4" charOffset="135-141" type="protein" text="p56lck"/>
            <entity id="DS3.d891.s2.e2" origId="3899" charOffset="146-157" type="compound" text="leflunomide"/>
            <pair e1="DS3.d891.s2.e2" e2="DS3.d891.s2.e1" id="DS3.d891.s2.i0" interaction="False" />
            <pair e1="DS3.d891.s2.e0" e2="DS3.d891.s2.e1" id="DS3.d891.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d892" origId="9973484">
        <sentence id="DS3.d892.s0" origId="9973484-5" text="In agreement with our molecular analysis, 1) VIP was the most potent peptide among VIP-related peptides (VIP &amp;gt; PACAP &amp;gt; PHM &amp;gt; PHV) to stimulate cAMP production through specific type 1 VIP receptors in both PTEC and LT-TEC; 2) cAMP generation was induced by CGRP in PTEC and by CT in LT-TEC; 3) in frozen thymic sections and by flow cytometry, type 1 VIP-R, CGRP-R, and CT-R were localized in epithelial cells; and 4) in parallel, the transcription of the acetylcholine receptor alpha subunit (the main autoantigen in MG) was induced by CGRP and CT in PTEC and LT-TEC, respectively.">
            <entity id="DS3.d892.s0.e0" origId="P01282" charOffset="45-48" type="protein" text="VIP"/>
            <entity id="DS3.d892.s0.e1" origId="P01282" charOffset="83-86" type="protein" text="VIP"/>
            <entity id="DS3.d892.s0.e2" origId="P01282" charOffset="83-86" type="protein" text="VIP"/>
            <entity id="DS3.d892.s0.e3" origId="P18509" charOffset="114-119" type="protein" text="PACAP"/>
            <entity id="DS3.d892.s0.e4" origId="P19021" charOffset="125-128" type="protein" text="PHM"/>
            <entity id="DS3.d892.s0.e5" origId="446017" charOffset="134-137" type="compound" text="PHV"/>
            <entity id="DS3.d892.s0.e6" origId="6076" charOffset="152-156" type="compound" text="cAMP"/>
            <entity id="DS3.d892.s0.e7" origId="P01282" charOffset="83-86" type="protein" text="VIP"/>
            <entity id="DS3.d892.s0.e8" origId="6076" charOffset="234-238" type="compound" text="cAMP"/>
            <entity id="DS3.d892.s0.e9" origId="P06881,P01258" charOffset="265-269" type="protein" text="CGRP"/>
            <entity id="DS3.d892.s0.e10" origId="P32241,A0A024R2N2,B4DNY6" charOffset="358-363" type="protein" text="VIP-R"/>
            <entity id="DS3.d892.s0.e11" origId="Q16602,D3DPG9" charOffset="365-371" type="protein" text="CGRP-R"/>
            <entity id="DS3.d892.s0.e12" origId="187" charOffset="463-476" type="compound" text="acetylcholine"/>
            <entity id="DS3.d892.s0.e13" origId="P06881,P01258" charOffset="365-369" type="protein" text="CGRP"/>
            <pair e1="DS3.d892.s0.e6" e2="DS3.d892.s0.e3" id="DS3.d892.s0.i0" interaction="False" />
            <pair e1="DS3.d892.s0.e6" e2="DS3.d892.s0.e4" id="DS3.d892.s0.i1" interaction="False" />
            <pair e1="DS3.d892.s0.e6" e2="DS3.d892.s0.e10" id="DS3.d892.s0.i2" interaction="False" />
            <pair e1="DS3.d892.s0.e6" e2="DS3.d892.s0.e0" id="DS3.d892.s0.i3" interaction="False" />
            <pair e1="DS3.d892.s0.e6" e2="DS3.d892.s0.e11" id="DS3.d892.s0.i4" interaction="False" />
            <pair e1="DS3.d892.s0.e6" e2="DS3.d892.s0.e9" id="DS3.d892.s0.i5" interaction="False" />
            <pair e1="DS3.d892.s0.e12" e2="DS3.d892.s0.e3" id="DS3.d892.s0.i6" interaction="False" />
            <pair e1="DS3.d892.s0.e12" e2="DS3.d892.s0.e4" id="DS3.d892.s0.i7" interaction="False" />
            <pair e1="DS3.d892.s0.e12" e2="DS3.d892.s0.e10" id="DS3.d892.s0.i8" interaction="False" />
            <pair e1="DS3.d892.s0.e12" e2="DS3.d892.s0.e0" id="DS3.d892.s0.i9" interaction="False" />
            <pair e1="DS3.d892.s0.e12" e2="DS3.d892.s0.e11" id="DS3.d892.s0.i10" interaction="False" />
            <pair e1="DS3.d892.s0.e12" e2="DS3.d892.s0.e9" id="DS3.d892.s0.i11" interaction="False" />
            <pair e1="DS3.d892.s0.e5" e2="DS3.d892.s0.e3" id="DS3.d892.s0.i12" interaction="False" />
            <pair e1="DS3.d892.s0.e5" e2="DS3.d892.s0.e4" id="DS3.d892.s0.i13" interaction="False" />
            <pair e1="DS3.d892.s0.e5" e2="DS3.d892.s0.e10" id="DS3.d892.s0.i14" interaction="False" />
            <pair e1="DS3.d892.s0.e5" e2="DS3.d892.s0.e0" id="DS3.d892.s0.i15" interaction="False" />
            <pair e1="DS3.d892.s0.e5" e2="DS3.d892.s0.e11" id="DS3.d892.s0.i16" interaction="False" />
            <pair e1="DS3.d892.s0.e5" e2="DS3.d892.s0.e9" id="DS3.d892.s0.i17" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d893" origId="9973485">
        <sentence id="DS3.d893.s0" origId="9973485-4" text="Twenty-one mutant A beta(d) molecules were produced by alanine scanning mutagenesis and assessed for their ability to present species variants of insulin to a panel of beef insulin-specific T cell hybridomas with limited TCR alpha- and/or beta-chain sequence differences.">
            <entity id="DS3.d893.s0.e0" origId="P05067,A0A0A0MRG2,B4DGD0,B4DJT9,E9PG40" charOffset="18-24" type="protein" text="A beta"/>
            <entity id="DS3.d893.s0.e1" origId="5950" charOffset="55-62" type="compound" text="alanine"/>
            <entity id="DS3.d893.s0.e2" origId="P01308,I3WAC9" charOffset="146-153" type="protein" text="insulin"/>
            <entity id="DS3.d893.s0.e3" origId="P01308,I3WAC9" charOffset="173-180" type="protein" text="insulin"/>
            <pair e1="DS3.d893.s0.e1" e2="DS3.d893.s0.e2" id="DS3.d893.s0.i0" interaction="False" />
            <pair e1="DS3.d893.s0.e1" e2="DS3.d893.s0.e0" id="DS3.d893.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d894" origId="9973489">
        <sentence id="DS3.d894.s0" origId="9973489-4" text="Mutagenesis of histidyl 85 and arginyl 82, in the FG loop of domain 1, demonstrated that these residues were essential for the IgA-binding activity of Fc alpha R, while arginyl 87 makes a minor contribution to the binding activity of the receptor.">
            <entity id="DS3.d894.s0.e0" origId="775" charOffset="15-23" type="compound" text="histidyl"/>
            <entity id="DS3.d894.s0.e1" origId="19919009,444288" charOffset="31-38" type="compound" text="arginyl"/>
            <entity id="DS3.d894.s0.e2" origId="P24071,A0A024R4N4,A0A024R4R4" charOffset="151-161" type="protein" text="Fc alpha R"/>
            <entity id="DS3.d894.s0.e3" origId="19919009,444288" charOffset="169-176" type="compound" text="arginyl"/>
            <pair e1="DS3.d894.s0.e0" e2="DS3.d894.s0.e2" id="DS3.d894.s0.i0" interaction="False" />
            <pair e1="DS3.d894.s0.e1" e2="DS3.d894.s0.e2" id="DS3.d894.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d895" origId="9973490">
        <sentence id="DS3.d895.s0" origId="9973490-9" text="In addition, there was an early and increased activation of caspases (caspase-8 and caspase-3) involved in TNFR/TNF signaling pathway, as evident by early cleavage of caspase-8, poly(ADP-ribose) polymerase (PARP), and caspase-3 substrate DEVD-p-nitroamilide NA.">
            <entity id="DS3.d895.s0.e0" origId="Q14790,A0A024R3Z8" charOffset="70-79" type="protein" text="caspase-8"/>
            <entity id="DS3.d895.s0.e1" origId="P42574" charOffset="84-93" type="protein" text="caspase-3"/>
            <entity id="DS3.d895.s0.e2" origId="Q14790,A0A024R3Z8" charOffset="167-176" type="protein" text="caspase-8"/>
            <entity id="DS3.d895.s0.e3" origId="192,44415180,445794" charOffset="183-193" type="compound" text="ADP-ribose"/>
            <entity id="DS3.d895.s0.e4" origId="P42574" charOffset="218-227" type="protein" text="caspase-3"/>
            <pair e1="DS3.d895.s0.e3" e2="DS3.d895.s0.e0" id="DS3.d895.s0.i0" interaction="False" />
            <pair e1="DS3.d895.s0.e3" e2="DS3.d895.s0.e1" id="DS3.d895.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d896" origId="9973500">
        <sentence id="DS3.d896.s0" origId="9973500-9" text="RBL cells, activated through FcepsilonRI in the presence of latrunculin, show increased phospholipase activity as well as increased tyrosine phosphorylation of Syk and increased tyrosine phosphorylation of the receptor itself by the tyrosine kinase Lyn.">
            <entity id="DS3.d896.s0.e0" origId="6057,90983769" charOffset="132-140" type="compound" text="tyrosine"/>
            <entity id="DS3.d896.s0.e1" origId="6057,90983769" charOffset="178-186" type="compound" text="tyrosine"/>
            <entity id="DS3.d896.s0.e2" origId="6057,90983769" charOffset="178-186" type="compound" text="tyrosine"/>
            <entity id="DS3.d896.s0.e3" origId="Q07014" charOffset="249-252" type="protein" text="Lyn"/>
            <pair e1="DS3.d896.s0.e0" e2="DS3.d896.s0.e3" id="DS3.d896.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d897" origId="9973501">
        <sentence id="DS3.d897.s0" origId="9973501-4" text="Immune responses induced by TCR vaccines formulated with various adjuvants: QS-21, IL-12, SAF-1, CD40L, and GM-CSF were compared.">
            <entity id="DS3.d897.s0.e0" origId="60866" charOffset="76-81" type="compound" text="QS-21"/>
            <entity id="DS3.d897.s0.e1" origId="F8VPK3" charOffset="90-95" type="protein" text="SAF-1"/>
            <entity id="DS3.d897.s0.e2" origId="P27548,Q0VEI3" charOffset="97-102" type="protein" text="CD40L"/>
            <entity id="DS3.d897.s0.e3" origId="P01587,Q5SX78" charOffset="108-114" type="protein" text="GM-CSF"/>
            <pair e1="DS3.d897.s0.e0" e2="DS3.d897.s0.e1" id="DS3.d897.s0.i0" interaction="False" />
            <pair e1="DS3.d897.s0.e0" e2="DS3.d897.s0.e2" id="DS3.d897.s0.i1" interaction="False" />
            <pair e1="DS3.d897.s0.e0" e2="DS3.d897.s0.e3" id="DS3.d897.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d897.s1" origId="9973501-5" text="QS-21, IL-12, and SAF-1 biased the humoral immune response toward Th1-type, reflected by the induction of IgG2a and IgG2b anti-C6VL TCR Abs.">
            <entity id="DS3.d897.s1.e0" origId="60866" charOffset="0-5" type="compound" text="QS-21"/>
            <entity id="DS3.d897.s1.e1" origId="F8VPK3" charOffset="18-23" type="protein" text="SAF-1"/>
            <entity id="DS3.d897.s1.e2" origId="Q922L6" charOffset="66-69" type="protein" text="Th1"/>
            <pair e1="DS3.d897.s1.e0" e2="DS3.d897.s1.e1" id="DS3.d897.s1.i0" interaction="False" />
            <pair e1="DS3.d897.s1.e0" e2="DS3.d897.s1.e2" id="DS3.d897.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d898" origId="9973505">
        <sentence id="DS3.d898.s0" origId="9973505-0" text="The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells.">
            <entity id="DS3.d898.s0.e0" origId="46173706" charOffset="4-15" type="compound" text="beta-glucan"/>
            <entity id="DS3.d898.s0.e1" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="45-48" type="protein" text="CR3"/>
            <entity id="DS3.d898.s0.e2" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="50-55" type="protein" text="CD11b"/>
            <entity id="DS3.d898.s0.e3" origId="P05107,B4E0R1" charOffset="56-60" type="protein" text="CD18"/>
            <pair e1="DS3.d898.s0.e0" e2="DS3.d898.s0.e1" id="DS3.d898.s0.i0" interaction="False" />
            <pair e1="DS3.d898.s0.e0" e2="DS3.d898.s0.e3" id="DS3.d898.s0.i1" interaction="False" />
            <pair e1="DS3.d898.s0.e0" e2="DS3.d898.s0.e2" id="DS3.d898.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d898.s1" origId="9973505-4" text="SZP preparations containing primarily mannose or glucose bound to CR3, and the binding of 125I-labeled beta-glucan to CR3 was competitively inhibited by beta-glucans from barley or seaweed, but not by yeast alpha-mannan.">
            <entity id="DS3.d898.s1.e0" origId="18950" charOffset="38-45" type="compound" text="mannose"/>
            <entity id="DS3.d898.s1.e1" origId="206,5793" charOffset="49-56" type="compound" text="glucose"/>
            <entity id="DS3.d898.s1.e2" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="66-69" type="protein" text="CR3"/>
            <entity id="DS3.d898.s1.e3" origId="46173706" charOffset="103-114" type="compound" text="beta-glucan"/>
            <entity id="DS3.d898.s1.e4" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="118-121" type="protein" text="CR3"/>
            <entity id="DS3.d898.s1.e5" origId="870" charOffset="213-219" type="compound" text="mannan"/>
            <pair e1="DS3.d898.s1.e3" e2="DS3.d898.s1.e2" id="DS3.d898.s1.i0" interaction="False" />
            <pair e1="DS3.d898.s1.e0" e2="DS3.d898.s1.e2" id="DS3.d898.s1.i1" interaction="False" />
            <pair e1="DS3.d898.s1.e5" e2="DS3.d898.s1.e2" id="DS3.d898.s1.i2" interaction="False" />
            <pair e1="DS3.d898.s1.e1" e2="DS3.d898.s1.e2" id="DS3.d898.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d898.s2" origId="9973505-5" text="Also, as with human CR3, the lectin site of mouse CR3 was inhibited by alpha- or beta-methylglucoside (but not D-glucose), alpha- or beta-methylmannoside, and N-acetyl-D-glucosamine.">
            <entity id="DS3.d898.s2.e0" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="20-23" type="protein" text="CR3"/>
            <entity id="DS3.d898.s2.e1" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="50-53" type="protein" text="CR3"/>
            <entity id="DS3.d898.s2.e2" origId="445238" charOffset="81-101" type="compound" text="beta-methylglucoside"/>
            <entity id="DS3.d898.s2.e3" origId="79025" charOffset="111-120" type="compound" text="D-glucose"/>
            <entity id="DS3.d898.s2.e4" origId="92333" charOffset="138-153" type="compound" text="methylmannoside"/>
            <entity id="DS3.d898.s2.e5" origId="18897,441477,739" charOffset="168-181" type="compound" text="D-glucosamine"/>
            <pair e1="DS3.d898.s2.e4" e2="DS3.d898.s2.e0" id="DS3.d898.s2.i0" interaction="False" />
            <pair e1="DS3.d898.s2.e3" e2="DS3.d898.s2.e0" id="DS3.d898.s2.i1" interaction="False" />
            <pair e1="DS3.d898.s2.e5" e2="DS3.d898.s2.e0" id="DS3.d898.s2.i2" interaction="False" />
            <pair e1="DS3.d898.s2.e2" e2="DS3.d898.s2.e0" id="DS3.d898.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d898.s3" origId="9973505-6" text="Phagocytosis of zymosan and serum-opsonized zymosan was partially inhibited by anti-CR3 and was reduced to &amp;lt;40% of normal with leukocytes from CR3-/- mice.">
            <entity id="DS3.d898.s3.e0" origId="64689" charOffset="16-23" type="compound" text="zymosan"/>
            <entity id="DS3.d898.s3.e1" origId="64689" charOffset="44-51" type="compound" text="zymosan"/>
            <entity id="DS3.d898.s3.e2" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="84-87" type="protein" text="CR3"/>
            <entity id="DS3.d898.s3.e3" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="146-149" type="protein" text="CR3"/>
            <pair e1="DS3.d898.s3.e0" e2="DS3.d898.s3.e2" id="DS3.d898.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d898.s4" origId="9973505-7" text="As with neutrophils from patients with CD18 deficiency, neutrophils from CR3-/- mice exhibited no phagocytosis of particulate beta-glucan.">
            <entity id="DS3.d898.s4.e0" origId="P05107,B4E0R1" charOffset="39-43" type="protein" text="CD18"/>
            <entity id="DS3.d898.s4.e1" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="73-76" type="protein" text="CR3"/>
            <entity id="DS3.d898.s4.e2" origId="46173706" charOffset="126-137" type="compound" text="beta-glucan"/>
            <pair e1="DS3.d898.s4.e2" e2="DS3.d898.s4.e1" id="DS3.d898.s4.i0" interaction="False" />
            <pair e1="DS3.d898.s4.e2" e2="DS3.d898.s4.e0" id="DS3.d898.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d898.s5" origId="9973505-9" text="beta-Glucan priming for cytotoxicity was inhibited by anti-CR3 and did not occur with leukocytes from CR3-/- mice.">
            <entity id="DS3.d898.s5.e0" origId="46173706" charOffset="0-11" type="compound" text="beta-Glucan"/>
            <entity id="DS3.d898.s5.e1" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="59-62" type="protein" text="CR3"/>
            <entity id="DS3.d898.s5.e2" origId="G5E8F1,Q3U1U4,E9Q604" charOffset="102-105" type="protein" text="CR3"/>
            <pair e1="DS3.d898.s5.e0" e2="DS3.d898.s5.e1" id="DS3.d898.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d899" origId="9973507">
        <sentence id="DS3.d899.s0" origId="9973507-5" text="We further demonstrate that SAg-induced down-modulation of chemokine binding and monocyte hyporesponsiveness to the chemokines MIP-1alpha, monocyte chemotactic protein-1, and MIP-1beta is mediated through cellular protein tyrosine kinases, and the down-modulation can be mimicked by an MHC class II-specific mAb.">
            <entity id="DS3.d899.s0.e0" origId="P32246,Q5U003" charOffset="127-137" type="protein" text="MIP-1alpha"/>
            <entity id="DS3.d899.s0.e1" origId="P13500" charOffset="139-169" type="protein" text="monocyte chemotactic protein-1"/>
            <entity id="DS3.d899.s0.e2" origId="P13236" charOffset="175-184" type="protein" text="MIP-1beta"/>
            <entity id="DS3.d899.s0.e3" origId="6057,90983769" charOffset="222-230" type="compound" text="tyrosine"/>
            <pair e1="DS3.d899.s0.e3" e2="DS3.d899.s0.e2" id="DS3.d899.s0.i0" interaction="False" />
            <pair e1="DS3.d899.s0.e3" e2="DS3.d899.s0.e0" id="DS3.d899.s0.i1" interaction="False" />
            <pair e1="DS3.d899.s0.e3" e2="DS3.d899.s0.e1" id="DS3.d899.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d900" origId="9973508">
        <sentence id="DS3.d900.s0" origId="9973508-4" text="Characterization of these CTL revealed that they contained the granzymes A and B, T cell intracellular Ag-1, and perforin and induced calcium-dependent cytolysis that correlated with the presence of apoptotic nuclei in target cells.">
            <entity id="DS3.d900.s0.e0" origId="H2Q841,H2QQW5" charOffset="63-80" type="protein" text="granzymes A and B"/>
            <entity id="DS3.d900.s0.e1" origId="22044544,5460341" charOffset="134-141" type="compound" text="calcium"/>
            <pair e1="DS3.d900.s0.e1" e2="DS3.d900.s0.e0" id="DS3.d900.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d901" origId="9973510">
        <sentence id="DS3.d901.s0" origId="9973510-3" text="Two rat CXC chemokines (macrophage inflammatory protein (MIP)-2 and cytokine-induced neutrophil chemoattractant (CINC)) as well as three rat CC chemokines (MIP-1alpha, MIP-1beta, and monocyte chemoattractant protein (MCP)-1) were investigated.">
            <entity id="DS3.d901.s0.e0" origId="23994" charOffset="113-117" type="compound" text="CINC"/>
            <entity id="DS3.d901.s0.e1" origId="P50229" charOffset="156-166" type="protein" text="MIP-1alpha"/>
            <entity id="DS3.d901.s0.e2" origId="P50230,G3V7I1" charOffset="168-177" type="protein" text="MIP-1beta"/>
            <pair e1="DS3.d901.s0.e0" e2="DS3.d901.s0.e1" id="DS3.d901.s0.i0" interaction="False" />
            <pair e1="DS3.d901.s0.e0" e2="DS3.d901.s0.e2" id="DS3.d901.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d902" origId="9973512">
        <sentence id="DS3.d902.s0" origId="9973512-0" text="Phosphorylation of cytosolic phospholipase A2 and the release of arachidonic acid in human neutrophils.">
            <entity id="DS3.d902.s0.e0" origId="P47712,B4DZI4" charOffset="19-45" type="protein" text="cytosolic phospholipase A2"/>
            <entity id="DS3.d902.s0.e1" origId="444899" charOffset="65-81" type="compound" text="arachidonic acid"/>
            <pair e1="DS3.d902.s0.e1" e2="DS3.d902.s0.e0" id="DS3.d902.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d902.s1" origId="9973512-10" text="Finally, FMLP increases cPLA2 phosphorylation and arachidonic acid release.">
            <entity id="DS3.d902.s1.e0" origId="P21462" charOffset="9-13" type="protein" text="FMLP"/>
            <entity id="DS3.d902.s1.e1" origId="444899" charOffset="50-66" type="compound" text="arachidonic acid"/>
            <pair e1="DS3.d902.s1.e1" e2="DS3.d902.s1.e0" id="DS3.d902.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d902.s2" origId="9973512-11" text="Interestingly, while the FMLP-induced phosphorylation of cPLA2 is not affected by the inhibitors of the p38 MAP kinase or erk cascades, both inhibitors significantly decrease arachidonic acid release stimulated by FMLP.">
            <entity id="DS3.d902.s2.e0" origId="P21462" charOffset="25-29" type="protein" text="FMLP"/>
            <entity id="DS3.d902.s2.e1" origId="Q16539,L7RSM2,B4E0K5,A0A024RD15" charOffset="104-118" type="protein" text="p38 MAP kinase"/>
            <entity id="DS3.d902.s2.e2" origId="P28482,Q1HBJ4,Q499G7" charOffset="122-125" type="protein" text="erk"/>
            <entity id="DS3.d902.s2.e3" origId="444899" charOffset="175-191" type="compound" text="arachidonic acid"/>
            <entity id="DS3.d902.s2.e4" origId="P21462" charOffset="214-218" type="protein" text="FMLP"/>
            <pair e1="DS3.d902.s2.e3" e2="DS3.d902.s2.e2" id="DS3.d902.s2.i0" interaction="False" />
            <pair e1="DS3.d902.s2.e3" e2="DS3.d902.s2.e1" id="DS3.d902.s2.i1" interaction="False" />
            <pair e1="DS3.d902.s2.e3" e2="DS3.d902.s2.e0" id="DS3.d902.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d902.s3" origId="9973512-3" text="This increase is inhibited by PD 98059, a mitogen-activated protein (MAP)/extracellular signal-regulating kinase (erk) 1 inhibitor, but not by SB 203580, a p38 MAP kinase inhibitor, indicating that this action is mediated through activation of the p42 MAP kinase (erk2).">
            <entity id="DS3.d902.s3.e0" origId="P28482,Q1HBJ4,Q499G7" charOffset="114-117" type="protein" text="erk"/>
            <entity id="DS3.d902.s3.e1" origId="176155" charOffset="143-152" type="compound" text="SB 203580"/>
            <entity id="DS3.d902.s3.e2" origId="Q16539,L7RSM2,B4E0K5,A0A024RD15" charOffset="156-170" type="protein" text="p38 MAP kinase"/>
            <entity id="DS3.d902.s3.e3" origId="P28482,Q1HBJ4,Q499G7" charOffset="264-268" type="protein" text="erk2"/>
            <pair e1="DS3.d902.s3.e1" e2="DS3.d902.s3.e3" id="DS3.d902.s3.i0" interaction="False" />
            <pair e1="DS3.d902.s3.e1" e2="DS3.d902.s3.e2" id="DS3.d902.s3.i1" interaction="False" />
            <pair e1="DS3.d902.s3.e1" e2="DS3.d902.s3.e0" id="DS3.d902.s3.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d902.s4" origId="9973512-5" text="Stimulation by TNF-alpha increases cPLA2 phosphorylation, which is inhibited by SB 203580, but not PD 98059, suggesting a role for p38 MAP kinase.">
            <entity id="DS3.d902.s4.e0" origId="P01375,Q5STB3" charOffset="15-24" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d902.s4.e1" origId="176155" charOffset="80-89" type="compound" text="SB 203580"/>
            <entity id="DS3.d902.s4.e2" origId="Q16539,L7RSM2,B4E0K5,A0A024RD15" charOffset="131-145" type="protein" text="p38 MAP kinase"/>
            <pair e1="DS3.d902.s4.e1" e2="DS3.d902.s4.e0" id="DS3.d902.s4.i0" interaction="False" />
            <pair e1="DS3.d902.s4.e1" e2="DS3.d902.s4.e2" id="DS3.d902.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d902.s5" origId="9973512-6" text="LPS increases cPLA2 phosphorylation and arachidonic acid release.">
            <entity id="DS3.d902.s5.e0" origId="O14896,G0Z349" charOffset="0-3" type="protein" text="LPS"/>
            <entity id="DS3.d902.s5.e1" origId="444899" charOffset="40-56" type="compound" text="arachidonic acid"/>
            <pair e1="DS3.d902.s5.e1" e2="DS3.d902.s5.e0" id="DS3.d902.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d903" origId="9973515">
        <sentence id="DS3.d903.s0" origId="9973515-7" text="Neutrophil activation was not exerted by an anti-ICAM-1 mAb of the IgG1 isotype, by isotype-matched, irrelevant anti-2-phenyloxazolone mAb, or by F(ab')2 fragments of R6.5.">
            <entity id="DS3.d903.s0.e0" origId="P05362" charOffset="49-55" type="protein" text="ICAM-1"/>
            <entity id="DS3.d903.s0.e1" origId="53629811" charOffset="112-134" type="compound" text="anti-2-phenyloxazolone"/>
            <pair e1="DS3.d903.s0.e1" e2="DS3.d903.s0.e0" id="DS3.d903.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d904" origId="9973516">
        <sentence id="DS3.d904.s0" origId="9973516-0" text="Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies.">
            <entity id="DS3.d904.s0.e0" origId="P32648" charOffset="0-29" type="protein" text="Vasoactive intestinal peptide"/>
            <entity id="DS3.d904.s0.e1" origId="6083" charOffset="44-53" type="compound" text="adenylate"/>
            <entity id="DS3.d904.s0.e2" origId="P06804,Q3U593" charOffset="111-120" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d904.s0.e1" e2="DS3.d904.s0.e2" id="DS3.d904.s0.i0" interaction="False" />
            <pair e1="DS3.d904.s0.e1" e2="DS3.d904.s0.e0" id="DS3.d904.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d904.s1" origId="9973516-5" text="In this study we have investigated the effects of VIP and the structurally related neuropeptide pituitary adenylate cyclase-activating polypeptide (PACAP38) on the production of TNF-alpha by endotoxin-activated murine peritoneal macrophages.">
            <entity id="DS3.d904.s1.e0" origId="P32648" charOffset="50-53" type="protein" text="VIP"/>
            <entity id="DS3.d904.s1.e1" origId="6083" charOffset="106-115" type="compound" text="adenylate"/>
            <entity id="DS3.d904.s1.e2" origId="P06804,Q3U593" charOffset="178-187" type="protein" text="TNF-alpha"/>
            <pair e1="DS3.d904.s1.e1" e2="DS3.d904.s1.e0" id="DS3.d904.s1.i0" interaction="False" />
            <pair e1="DS3.d904.s1.e1" e2="DS3.d904.s1.e2" id="DS3.d904.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d904.s2" origId="9973516-6" text="Both neuropeptides rapidly and specifically inhibit the LPS-stimulated production of TNF-alpha, exerting their action through the binding to VPAC1 receptor and the subsequent activation of the adenylate cyclase system.">
            <entity id="DS3.d904.s2.e0" origId="Q9QUK6,L0CL36" charOffset="56-59" type="protein" text="LPS"/>
            <entity id="DS3.d904.s2.e1" origId="P06804,Q3U593" charOffset="85-94" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d904.s2.e2" origId="6083" charOffset="193-202" type="compound" text="adenylate"/>
            <pair e1="DS3.d904.s2.e2" e2="DS3.d904.s2.e1" id="DS3.d904.s2.i0" interaction="False" />
            <pair e1="DS3.d904.s2.e2" e2="DS3.d904.s2.e0" id="DS3.d904.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d905" origId="9973520">
        <sentence id="DS3.d905.s0" origId="9973520-1" text="CD44 is a ubiquitous molecule also known as hyaluronic acid or homing receptor.">
            <entity id="DS3.d905.s0.e0" origId="P16070" charOffset="0-4" type="protein" text="CD44"/>
            <entity id="DS3.d905.s0.e1" origId="24728612,453618" charOffset="44-59" type="compound" text="hyaluronic acid"/>
            <pair e1="DS3.d905.s0.e1" e2="DS3.d905.s0.e0" id="DS3.d905.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d905.s1" origId="9973520-4" text="Using synovial cells from rheumatoid arthritis (RA) patients, we demonstrated that CD44 cross-linking and binding to hyaluronan augmented VCAM-1 expression and subsequently VCAM-1-mediated cell adhesion.">
            <entity id="DS3.d905.s1.e0" origId="P16070" charOffset="83-87" type="protein" text="CD44"/>
            <entity id="DS3.d905.s1.e1" origId="24759,3084050" charOffset="117-127" type="compound" text="hyaluronan"/>
            <entity id="DS3.d905.s1.e2" origId="P19320" charOffset="138-144" type="protein" text="VCAM-1"/>
            <entity id="DS3.d905.s1.e3" origId="P19320" charOffset="173-179" type="protein" text="VCAM-1"/>
            <pair e1="DS3.d905.s1.e1" e2="DS3.d905.s1.e0" id="DS3.d905.s1.i0" interaction="False" />
            <pair e1="DS3.d905.s1.e1" e2="DS3.d905.s1.e2" id="DS3.d905.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d905.s2" origId="9973520-5" text="Briefly, we found that 1) rheumatoid synovial cells highly expressed CD44; 2) cross-linking of CD44 markedly but transiently augmented VCAM-1 expression and its mRNA transcription much more than did IL-1beta and TNF-alpha; 3) hyaluronan, especially when fragmented, also up-regulated VCAM-1; 4) CD44 activated the transcription factor AP-1; and 5) the integrin-dependent adhesive function of RA synovial cells to T cells was also amplified by CD44 cross-linking.">
            <entity id="DS3.d905.s2.e0" origId="P16070" charOffset="69-73" type="protein" text="CD44"/>
            <entity id="DS3.d905.s2.e1" origId="P16070" charOffset="95-99" type="protein" text="CD44"/>
            <entity id="DS3.d905.s2.e2" origId="P19320" charOffset="135-141" type="protein" text="VCAM-1"/>
            <entity id="DS3.d905.s2.e3" origId="P01584" charOffset="199-207" type="protein" text="IL-1beta"/>
            <entity id="DS3.d905.s2.e4" origId="24759,3084050" charOffset="226-236" type="compound" text="hyaluronan"/>
            <entity id="DS3.d905.s2.e5" origId="P19320" charOffset="284-290" type="protein" text="VCAM-1"/>
            <entity id="DS3.d905.s2.e6" origId="P16070" charOffset="95-99" type="protein" text="CD44"/>
            <entity id="DS3.d905.s2.e7" origId="P16070" charOffset="95-99" type="protein" text="CD44"/>
            <pair e1="DS3.d905.s2.e4" e2="DS3.d905.s2.e0" id="DS3.d905.s2.i0" interaction="False" />
            <pair e1="DS3.d905.s2.e4" e2="DS3.d905.s2.e2" id="DS3.d905.s2.i1" interaction="False" />
            <pair e1="DS3.d905.s2.e4" e2="DS3.d905.s2.e3" id="DS3.d905.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d905.s3" origId="9973520-6" text="These results indicate that the adhesion of RA synovial cells to matrices such as hyaluronic acid through CD44 could up-regulate VCAM-1 expression and VCAM-1-mediated adhesion to T cells, which might in turn cause activation of T cells and synovial cells in RA synovitis.">
            <entity id="DS3.d905.s3.e0" origId="24728612,453618" charOffset="82-97" type="compound" text="hyaluronic acid"/>
            <entity id="DS3.d905.s3.e1" origId="P16070" charOffset="106-110" type="protein" text="CD44"/>
            <entity id="DS3.d905.s3.e2" origId="P19320" charOffset="129-135" type="protein" text="VCAM-1"/>
            <entity id="DS3.d905.s3.e3" origId="P19320" charOffset="151-157" type="protein" text="VCAM-1"/>
            <pair e1="DS3.d905.s3.e0" e2="DS3.d905.s3.e1" id="DS3.d905.s3.i0" interaction="False" />
            <pair e1="DS3.d905.s3.e0" e2="DS3.d905.s3.e2" id="DS3.d905.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d906" origId="9973527">
        <sentence id="DS3.d906.s0" origId="9973527-1" text="To determine whether the Th1 response in tuberculosis correlated with IL-12R expression, we measured expression of the IL-12R beta 1 and IL-12R beta 2 subunits, as well as IL-12R beta 2 mRNA expression in tuberculosis patients and healthy tuberculin reactors.">
            <entity id="DS3.d906.s0.e0" origId="Q8IXH7,H0UI80" charOffset="25-28" type="protein" text="Th1"/>
            <entity id="DS3.d906.s0.e1" origId="71581433" charOffset="73-76" type="compound" text="12R"/>
            <entity id="DS3.d906.s0.e2" origId="P42701" charOffset="119-132" type="protein" text="IL-12R beta 1"/>
            <entity id="DS3.d906.s0.e3" origId="71581433" charOffset="122-125" type="compound" text="12R"/>
            <entity id="DS3.d906.s0.e4" origId="71581433" charOffset="122-125" type="compound" text="12R"/>
            <pair e1="DS3.d906.s0.e1" e2="DS3.d906.s0.e2" id="DS3.d906.s0.i0" interaction="False" />
            <pair e1="DS3.d906.s0.e1" e2="DS3.d906.s0.e0" id="DS3.d906.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d906.s1" origId="9973527-2" text="In tuberculosis patients, IFN-gamma production by Mycobacterium tuberculosis-stimulated PBMC was reduced, the percentages of T cells expressing IL-12R beta 1 and IL-12R beta 2 were significantly decreased, and IL-12R beta 2 mRNA expression was also markedly reduced.">
            <entity id="DS3.d906.s1.e0" origId="P42701" charOffset="144-157" type="protein" text="IL-12R beta 1"/>
            <entity id="DS3.d906.s1.e1" origId="71581433" charOffset="147-150" type="compound" text="12R"/>
            <entity id="DS3.d906.s1.e2" origId="71581433" charOffset="165-168" type="compound" text="12R"/>
            <pair e1="DS3.d906.s1.e1" e2="DS3.d906.s1.e0" id="DS3.d906.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d906.s2" origId="9973527-4" text="In M. tuberculosis-stimulated peripheral blood T cells from tuberculosis patients, anti-IL-10 and anti-TGF-beta enhanced IL-12R beta 1 and IL-12R beta 2 expression, and IFN-gamma production.">
            <entity id="DS3.d906.s2.e0" origId="P22301,Q6FGW4" charOffset="88-93" type="protein" text="IL-10"/>
            <entity id="DS3.d906.s2.e1" origId="P42701" charOffset="121-134" type="protein" text="IL-12R beta 1"/>
            <entity id="DS3.d906.s2.e2" origId="71581433" charOffset="124-127" type="compound" text="12R"/>
            <pair e1="DS3.d906.s2.e2" e2="DS3.d906.s2.e1" id="DS3.d906.s2.i0" interaction="False" />
            <pair e1="DS3.d906.s2.e2" e2="DS3.d906.s2.e0" id="DS3.d906.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d906.s3" origId="9973527-5" text="In M. tuberculosis-stimulated peripheral blood T cells from healthy tuberculin reactors, recombinant IL-10 and TGF-beta reduced IL-12R beta 1 and IL-12R beta 2 expression, as well as IFN-gamma production.">
            <entity id="DS3.d906.s3.e0" origId="P22301,Q6FGW4" charOffset="101-106" type="protein" text="IL-10"/>
            <entity id="DS3.d906.s3.e1" origId="P42701" charOffset="128-141" type="protein" text="IL-12R beta 1"/>
            <entity id="DS3.d906.s3.e2" origId="71581433" charOffset="131-134" type="compound" text="12R"/>
            <pair e1="DS3.d906.s3.e2" e2="DS3.d906.s3.e1" id="DS3.d906.s3.i0" interaction="False" />
            <pair e1="DS3.d906.s3.e2" e2="DS3.d906.s3.e0" id="DS3.d906.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d906.s4" origId="9973527-6" text="In combination with prior studies showing increased production of TGF-beta by blood monocytes from tuberculosis patients, this suggests that increased TGF-beta production is the underlying abnormality that reduces IL-12R beta 1 and IL-12R beta 2 expression in tuberculosis.">
            <entity id="DS3.d906.s4.e0" origId="P42701" charOffset="214-227" type="protein" text="IL-12R beta 1"/>
            <entity id="DS3.d906.s4.e1" origId="71581433" charOffset="217-220" type="compound" text="12R"/>
            <pair e1="DS3.d906.s4.e1" e2="DS3.d906.s4.e0" id="DS3.d906.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d906.s5" origId="9973527-7" text="Our findings provide evidence that IL-12R expression correlates well with IFN-gamma production in human tuberculosis, and that expression of IL-12R beta 1 and IL-12R beta 2 may play a central role in mediating a protective Th1 response.">
            <entity id="DS3.d906.s5.e0" origId="71581433" charOffset="38-41" type="compound" text="12R"/>
            <entity id="DS3.d906.s5.e1" origId="P42701" charOffset="141-154" type="protein" text="IL-12R beta 1"/>
            <entity id="DS3.d906.s5.e2" origId="71581433" charOffset="144-147" type="compound" text="12R"/>
            <entity id="DS3.d906.s5.e3" origId="Q8IXH7,H0UI80" charOffset="223-226" type="protein" text="Th1"/>
            <pair e1="DS3.d906.s5.e0" e2="DS3.d906.s5.e1" id="DS3.d906.s5.i0" interaction="False" />
            <pair e1="DS3.d906.s5.e0" e2="DS3.d906.s5.e3" id="DS3.d906.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d907" origId="9973529">
        <sentence id="DS3.d907.s0" origId="9973529-1" text="Engagement of the B-cell antigen receptor (BCR) or the nerve growth factor receptor (NGFR/TrkA) induces activation of multiple tyrosine kinases, resulting in phosphorylation of numerous intracellular substrates.">
            <entity id="DS3.d907.s0.e0" origId="P08138" charOffset="55-83" type="protein" text="nerve growth factor receptor"/>
            <entity id="DS3.d907.s0.e1" origId="P08138" charOffset="85-89" type="protein" text="NGFR"/>
            <entity id="DS3.d907.s0.e2" origId="P04629,X5DR71" charOffset="90-94" type="protein" text="TrkA"/>
            <entity id="DS3.d907.s0.e3" origId="6057,90983769" charOffset="127-135" type="compound" text="tyrosine"/>
            <pair e1="DS3.d907.s0.e3" e2="DS3.d907.s0.e0" id="DS3.d907.s0.i0" interaction="False" />
            <pair e1="DS3.d907.s0.e3" e2="DS3.d907.s0.e1" id="DS3.d907.s0.i1" interaction="False" />
            <pair e1="DS3.d907.s0.e3" e2="DS3.d907.s0.e2" id="DS3.d907.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d907.s1" origId="9973529-2" text="We show that addition of NGF or anti-IgM antibody leads to the early tyrosine phosphorylation of p95(Vav), which is expressed exclusively in hematopoietic cells; NGF, similar to crosslinking the BCR, also results in the rapid activation of Ras.">
            <entity id="DS3.d907.s1.e0" origId="6057,90983769" charOffset="69-77" type="compound" text="tyrosine"/>
            <entity id="DS3.d907.s1.e1" origId="O60934,A0A0C4DG07" charOffset="97-100" type="protein" text="p95"/>
            <entity id="DS3.d907.s1.e2" origId="P15498,Q96D37,A0A0A0MR07,B2R8B5" charOffset="101-104" type="protein" text="Vav"/>
            <pair e1="DS3.d907.s1.e0" e2="DS3.d907.s1.e2" id="DS3.d907.s1.i0" interaction="False" />
            <pair e1="DS3.d907.s1.e0" e2="DS3.d907.s1.e1" id="DS3.d907.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d907.s2" origId="9973529-3" text="The phosphorylation of Vav and activation of Ras triggered by NGF is mediated through Trk tyrosine kinase, whereas signaling through the BCR uses a different tyrosine kinase.">
            <entity id="DS3.d907.s2.e0" origId="P15498,Q96D37,A0A0A0MR07,B2R8B5" charOffset="23-26" type="protein" text="Vav"/>
            <entity id="DS3.d907.s2.e1" origId="54730402" charOffset="86-89" type="compound" text="Trk"/>
            <entity id="DS3.d907.s2.e2" origId="6057,90983769" charOffset="90-98" type="compound" text="tyrosine"/>
            <entity id="DS3.d907.s2.e3" origId="6057,90983769" charOffset="158-166" type="compound" text="tyrosine"/>
            <pair e1="DS3.d907.s2.e1" e2="DS3.d907.s2.e0" id="DS3.d907.s2.i0" interaction="False" />
            <pair e1="DS3.d907.s2.e2" e2="DS3.d907.s2.e0" id="DS3.d907.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d907.s3" origId="9973529-4" text="We also show that NGF induces tyrosine phosphorylation of Shc and its association with Grb2.">
            <entity id="DS3.d907.s3.e0" origId="6057,90983769" charOffset="30-38" type="compound" text="tyrosine"/>
            <entity id="DS3.d907.s3.e1" origId="P29353" charOffset="58-61" type="protein" text="Shc"/>
            <entity id="DS3.d907.s3.e2" origId="P62993,B0LPF3" charOffset="87-91" type="protein" text="Grb2"/>
            <pair e1="DS3.d907.s3.e0" e2="DS3.d907.s3.e1" id="DS3.d907.s3.i0" interaction="False" />
            <pair e1="DS3.d907.s3.e0" e2="DS3.d907.s3.e2" id="DS3.d907.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d908" origId="9973532">
        <sentence id="DS3.d908.s0" origId="9973532-8" text="Cross-linking the intact monomorphic HLA-A,B,C epitope or the polymorphic HLA-B7 epitope induced IL-2 production upon costimulation with PMA.">
            <entity id="DS3.d908.s0.e0" origId="P30443,P04439,Q5SUL5,B1PKY1,B2R7U3,O78126" charOffset="37-44" type="protein" text="HLA-A,B"/>
            <entity id="DS3.d908.s0.e1" origId="P01889,P30460,Q5SS57,E5FQ95" charOffset="74-80" type="protein" text="HLA-B7"/>
            <entity id="DS3.d908.s0.e2" origId="122634,22833501,27924" charOffset="137-140" type="compound" text="PMA"/>
            <pair e1="DS3.d908.s0.e2" e2="DS3.d908.s0.e1" id="DS3.d908.s0.i0" interaction="False" />
            <pair e1="DS3.d908.s0.e2" e2="DS3.d908.s0.e0" id="DS3.d908.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d909" origId="9973537">
        <sentence id="DS3.d909.s0" origId="9973537-7" text="Antibodies against the known murine NK inhibitory receptors Ly-49A, C, G, and I did not affect the inhibitory effect of m144.">
            <entity id="DS3.d909.s0.e0" origId="Q8MHR8" charOffset="60-66" type="protein" text="Ly-49A"/>
            <entity id="DS3.d909.s0.e1" origId="9964188" charOffset="120-124" type="compound" text="m144"/>
            <pair e1="DS3.d909.s0.e1" e2="DS3.d909.s0.e0" id="DS3.d909.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d910" origId="9973539">
        <sentence id="DS3.d910.s0" origId="9973539-6" text="In monocytes, rhIL-4delta2 blocked inhibitory action of hIL-4 on LPS-induced cyclooxygenase-2 expression and subsequent prostaglandin E2 secretion.">
            <entity id="DS3.d910.s0.e0" origId="O14896,G0Z349" charOffset="65-68" type="protein" text="LPS"/>
            <entity id="DS3.d910.s0.e1" origId="P35354" charOffset="77-93" type="protein" text="cyclooxygenase-2"/>
            <entity id="DS3.d910.s0.e2" origId="285703,6145931" charOffset="120-133" type="compound" text="prostaglandin"/>
            <pair e1="DS3.d910.s0.e2" e2="DS3.d910.s0.e1" id="DS3.d910.s0.i0" interaction="False" />
            <pair e1="DS3.d910.s0.e2" e2="DS3.d910.s0.e0" id="DS3.d910.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d911" origId="9973541">
        <sentence id="DS3.d911.s0" origId="9973541-5" text="In this article, we review the fundamental embryological processes involved in closing the neural tube, the relevant epidemiologic data on folic acid supplementation and relative NTD risk, as well as several recent studies of candidate genes for NTD sensitivity that are involved in folate transport and metabolism.">
            <entity id="DS3.d911.s0.e0" origId="6037" charOffset="139-149" type="compound" text="folic acid"/>
            <entity id="DS3.d911.s0.e1" origId="Q9BT04,A0A024QZF7" charOffset="179-182" type="protein" text="NTD"/>
            <entity id="DS3.d911.s0.e2" origId="Q9BT04,A0A024QZF7" charOffset="246-249" type="protein" text="NTD"/>
            <pair e1="DS3.d911.s0.e0" e2="DS3.d911.s0.e1" id="DS3.d911.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d912" origId="9973542">
        <sentence id="DS3.d912.s0" origId="9973542-4" text="The only exceptions were 2 asymptomatic ornithine transcarbamylase (OTC)-deficient females, 1 male with mild OTC deficiency, and 1 patient with citrullinemia (CIT) whose plasma glutamine levels were never above 100 micromol/L.">
            <entity id="DS3.d912.s0.e0" origId="P00480" charOffset="40-66" type="protein" text="ornithine transcarbamylase"/>
            <entity id="DS3.d912.s0.e1" origId="P00480" charOffset="68-71" type="protein" text="OTC"/>
            <entity id="DS3.d912.s0.e2" origId="P00480" charOffset="109-112" type="protein" text="OTC"/>
            <entity id="DS3.d912.s0.e3" origId="5961" charOffset="177-186" type="compound" text="glutamine"/>
            <pair e1="DS3.d912.s0.e3" e2="DS3.d912.s0.e0" id="DS3.d912.s0.i0" interaction="False" />
            <pair e1="DS3.d912.s0.e3" e2="DS3.d912.s0.e1" id="DS3.d912.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d912.s1" origId="9973542-8" text="Plasma ammonia levels showed a positive correlation with glutamine in patients with carbamyl phosphate synthetase I and OTC deficiency and a negative correlation in patients with PA.">
            <entity id="DS3.d912.s1.e0" origId="222" charOffset="7-14" type="compound" text="ammonia"/>
            <entity id="DS3.d912.s1.e1" origId="5961" charOffset="57-66" type="compound" text="glutamine"/>
            <entity id="DS3.d912.s1.e2" origId="278" charOffset="84-102" type="compound" text="carbamyl phosphate"/>
            <entity id="DS3.d912.s1.e3" origId="P00480" charOffset="120-123" type="protein" text="OTC"/>
            <pair e1="DS3.d912.s1.e2" e2="DS3.d912.s1.e3" id="DS3.d912.s1.i0" interaction="False" />
            <pair e1="DS3.d912.s1.e0" e2="DS3.d912.s1.e3" id="DS3.d912.s1.i1" interaction="False" />
            <pair e1="DS3.d912.s1.e1" e2="DS3.d912.s1.e3" id="DS3.d912.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d913" origId="9973543">
        <sentence id="DS3.d913.s0" origId="9973543-10" text="These results suggest that biotin regulates the expression of the catabolic carboxylases (PCC and MCC), that this regulation occurs after the posttranscriptional level, and that pyruvate carboxylase, a key enzyme for gluconeogenesis, Krebs cycle anaplerosis, and fatty acid synthesis, is spared of this control.">
            <entity id="DS3.d913.s0.e0" origId="171548,53700020" charOffset="27-33" type="compound" text="biotin"/>
            <entity id="DS3.d913.s0.e1" origId="P52873,A0A0G2JTL5" charOffset="178-198" type="protein" text="pyruvate carboxylase"/>
            <pair e1="DS3.d913.s0.e0" e2="DS3.d913.s0.e1" id="DS3.d913.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d913.s1" origId="9973543-2" text="We studied the effect of biotin on the genetic expression of rat liver mitochondrial carboxylases: pyruvate carboxylase (PC), propionyl-CoA carboxylase (PCC), and 3-methylcrotonyl-CoA carboxylase (MCC).">
            <entity id="DS3.d913.s1.e0" origId="171548,53700020" charOffset="25-31" type="compound" text="biotin"/>
            <entity id="DS3.d913.s1.e1" origId="P52873,A0A0G2JTL5" charOffset="99-119" type="protein" text="pyruvate carboxylase"/>
            <entity id="DS3.d913.s1.e2" origId="92753" charOffset="126-139" type="compound" text="propionyl-CoA"/>
            <entity id="DS3.d913.s1.e3" origId="439869,9549326,99" charOffset="163-183" type="compound" text="3-methylcrotonyl-CoA"/>
            <pair e1="DS3.d913.s1.e2" e2="DS3.d913.s1.e1" id="DS3.d913.s1.i0" interaction="False" />
            <pair e1="DS3.d913.s1.e0" e2="DS3.d913.s1.e1" id="DS3.d913.s1.i1" interaction="False" />
            <pair e1="DS3.d913.s1.e3" e2="DS3.d913.s1.e1" id="DS3.d913.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d914" origId="9973545">
        <sentence id="DS3.d914.s0" origId="9973545-1" text="Expression patterns of mRNAs coding for the murine folate binding proteins one and two (FBP1 and FBP2) were determined by ribonuclease protection assay (RPA) in highly inbred SWV/Fnn mouse embryos.">
            <entity id="DS3.d914.s0.e0" origId="6037" charOffset="51-57" type="compound" text="folate"/>
            <entity id="DS3.d914.s0.e1" origId="Q9QXD6" charOffset="88-92" type="protein" text="FBP1"/>
            <entity id="DS3.d914.s0.e2" origId="P70695,Q3TKP4" charOffset="97-101" type="protein" text="FBP2"/>
            <pair e1="DS3.d914.s0.e0" e2="DS3.d914.s0.e1" id="DS3.d914.s0.i0" interaction="False" />
            <pair e1="DS3.d914.s0.e0" e2="DS3.d914.s0.e2" id="DS3.d914.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d915" origId="9973546">
        <sentence id="DS3.d915.s0" origId="9973546-3" text="Surfactants consisted of a palmitic acid containing phospholipid mixture (PL) with full-length SP-B peptide (B1-78), one of two SP-B mutants (Bserine and BR236C), the synthetic SP-B mimic KL4 (UCLA-KL4), a natural SP-B (Bbovine), synthetic palmitoylated SP-C peptide (C1-35), a combination of B1-78 + C1-35, a combination of BR236C + C1-35, and the clinical surfactant Survanta.">
            <entity id="DS3.d915.s0.e0" origId="985" charOffset="27-40" type="compound" text="palmitic acid"/>
            <entity id="DS3.d915.s0.e1" origId="P15285" charOffset="95-99" type="protein" text="SP-B"/>
            <entity id="DS3.d915.s0.e2" origId="P15285" charOffset="128-132" type="protein" text="SP-B"/>
            <entity id="DS3.d915.s0.e3" origId="P15285" charOffset="128-132" type="protein" text="SP-B"/>
            <entity id="DS3.d915.s0.e4" origId="P15285" charOffset="128-132" type="protein" text="SP-B"/>
            <pair e1="DS3.d915.s0.e0" e2="DS3.d915.s0.e1" id="DS3.d915.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d916" origId="9973547">
        <sentence id="DS3.d916.s0" origId="9973547-10" text="Modifications and substitutions of 6-amino function, better accepted by the IMP-preferring form than by the AMP-preferring form, indicated that no essential hydrogen bonding is required for catalytic activity.">
            <entity id="DS3.d916.s0.e0" origId="P29218,A0A024R830" charOffset="76-79" type="protein" text="IMP"/>
            <entity id="DS3.d916.s0.e1" origId="783" charOffset="157-165" type="compound" text="hydrogen"/>
            <pair e1="DS3.d916.s0.e1" e2="DS3.d916.s0.e0" id="DS3.d916.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d916.s1" origId="9973547-12" text="Hydrogen bonding potential of N-1 was significant for the hydrolysis rate of the IMP- but not of the AMP-preferring form.">
            <entity id="DS3.d916.s1.e0" origId="783" charOffset="0-8" type="compound" text="Hydrogen"/>
            <entity id="DS3.d916.s1.e1" origId="P29218,A0A024R830" charOffset="81-84" type="protein" text="IMP"/>
            <pair e1="DS3.d916.s1.e0" e2="DS3.d916.s1.e1" id="DS3.d916.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d916.s2" origId="9973547-4" text="Changes in the phosphate moiety reduced significantly hydrolysis by the IMP-preferring form, whereas the AMP-preferring form was less affected.">
            <entity id="DS3.d916.s2.e0" origId="1061,167704,644102" charOffset="15-24" type="compound" text="phosphate"/>
            <entity id="DS3.d916.s2.e1" origId="P29218,A0A024R830" charOffset="72-75" type="protein" text="IMP"/>
            <pair e1="DS3.d916.s2.e0" e2="DS3.d916.s2.e1" id="DS3.d916.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d916.s3" origId="9973547-6" text="Substitutions at the C-8 adenine base reduced the hydrolysis rate of both the enzymes and variations of the syn-anti conformational equilibrium resulted in different effects on catalysis by both forms.">
            <entity id="DS3.d916.s3.e0" origId="190,57060554" charOffset="25-32" type="compound" text="adenine"/>
            <entity id="DS3.d916.s3.e1" origId="P06241" charOffset="108-111" type="protein" text="syn"/>
            <pair e1="DS3.d916.s3.e0" e2="DS3.d916.s3.e1" id="DS3.d916.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d916.s4" origId="9973547-8" text="Hydrogen bonding potential of base N-7 was essential for the binding and catalysis of the IMP- but not of the AMP-preferring form.">
            <entity id="DS3.d916.s4.e0" origId="783" charOffset="0-8" type="compound" text="Hydrogen"/>
            <entity id="DS3.d916.s4.e1" origId="P29218,A0A024R830" charOffset="90-93" type="protein" text="IMP"/>
            <pair e1="DS3.d916.s4.e0" e2="DS3.d916.s4.e1" id="DS3.d916.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d917" origId="9973554">
        <sentence id="DS3.d917.s0" origId="9973554-8" text="(iv) Specific residues, R47 and K49 in NF-YC and N61 in NF-YB, are crucial for CCAAT-binding.">
            <entity id="DS3.d917.s0.e0" origId="44580458" charOffset="24-27" type="compound" text="R47"/>
            <entity id="DS3.d917.s0.e1" origId="Q13952" charOffset="39-44" type="protein" text="NF-YC"/>
            <entity id="DS3.d917.s0.e2" origId="Q9NYF5" charOffset="49-52" type="protein" text="N61"/>
            <entity id="DS3.d917.s0.e3" origId="P25208,A0A024RBG7" charOffset="56-61" type="protein" text="NF-YB"/>
            <pair e1="DS3.d917.s0.e0" e2="DS3.d917.s0.e1" id="DS3.d917.s0.i0" interaction="False" />
            <pair e1="DS3.d917.s0.e0" e2="DS3.d917.s0.e3" id="DS3.d917.s0.i1" interaction="False" />
            <pair e1="DS3.d917.s0.e0" e2="DS3.d917.s0.e2" id="DS3.d917.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d918" origId="9973595">
        <sentence id="DS3.d918.s0" origId="9973595-4" text="EPL cells expressed the pluripotent cell markers Oct4, SSEA1 and alkaline phosphatase.">
            <entity id="DS3.d918.s0.e0" origId="11207678" charOffset="0-3" type="compound" text="EPL"/>
            <entity id="DS3.d918.s0.e1" origId="P20263" charOffset="49-53" type="protein" text="Oct4"/>
            <entity id="DS3.d918.s0.e2" origId="Q11127,Q544B8" charOffset="55-60" type="protein" text="SSEA1"/>
            <pair e1="DS3.d918.s0.e0" e2="DS3.d918.s0.e1" id="DS3.d918.s0.i0" interaction="False" />
            <pair e1="DS3.d918.s0.e0" e2="DS3.d918.s0.e2" id="DS3.d918.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d918.s1" origId="9973595-5" text="However, the formation of EPL cells was accompanied by alterations in Fgf5, Gbx2 and Rex1 expression, a loss in chimaera forming ability, changes in factor responsiveness and modified differentiation capabilities, all consistent with the identification of EPL cells as equivalent to the primitive ectoderm population of the 5.5 to 6.0 days post coitum embryo.">
            <entity id="DS3.d918.s1.e0" origId="11207678" charOffset="26-29" type="compound" text="EPL"/>
            <entity id="DS3.d918.s1.e1" origId="P15656" charOffset="70-74" type="protein" text="Fgf5"/>
            <entity id="DS3.d918.s1.e2" origId="P48031" charOffset="76-80" type="protein" text="Gbx2"/>
            <entity id="DS3.d918.s1.e3" origId="P22227,E9QK22" charOffset="85-89" type="protein" text="Rex1"/>
            <entity id="DS3.d918.s1.e4" origId="11207678" charOffset="256-259" type="compound" text="EPL"/>
            <pair e1="DS3.d918.s1.e0" e2="DS3.d918.s1.e2" id="DS3.d918.s1.i0" interaction="False" />
            <pair e1="DS3.d918.s1.e0" e2="DS3.d918.s1.e1" id="DS3.d918.s1.i1" interaction="False" />
            <pair e1="DS3.d918.s1.e0" e2="DS3.d918.s1.e3" id="DS3.d918.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d918.s2" origId="9973595-6" text="EPL cell formation could be reversed in the presence of LIF and withdrawal of MEDII, which suggested that EPL cell formation was not a terminal differentiation event but reflected the ability of pluripotent cells to adopt distinct cell states in response to specific factors.">
            <entity id="DS3.d918.s2.e0" origId="11207678" charOffset="0-3" type="compound" text="EPL"/>
            <entity id="DS3.d918.s2.e1" origId="P09056,F8WH42" charOffset="56-59" type="protein" text="LIF"/>
            <entity id="DS3.d918.s2.e2" origId="11207678" charOffset="106-109" type="compound" text="EPL"/>
            <pair e1="DS3.d918.s2.e0" e2="DS3.d918.s2.e1" id="DS3.d918.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d919" origId="9973596">
        <sentence id="DS3.d919.s0" origId="9973596-2" text="Additionally, two water-soluble proteins, transketolase (TKT) and aldehyde dehydrogenase class 1 (ALDH1), isolated from rabbit keratocytes showed unexpectedly abundant expression ( approximately 30% of the soluble protein) in transparent corneas and markedly reduced levels in opaque scleral fibroblasts or keratocytes from hazy, freeze injured regions of the cornea.">
            <entity id="DS3.d919.s0.e0" origId="962" charOffset="18-23" type="compound" text="water"/>
            <entity id="DS3.d919.s0.e1" origId="G1TAH7" charOffset="42-55" type="protein" text="transketolase"/>
            <pair e1="DS3.d919.s0.e0" e2="DS3.d919.s0.e1" id="DS3.d919.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d920" origId="9973599">
        <sentence id="DS3.d920.s0" origId="9973599-1" text="Rab3a, a small GTP-binding protein, is believed to mediate Ca2+-dependent exocytosis.">
            <entity id="DS3.d920.s0.e0" origId="P11023" charOffset="0-5" type="protein" text="Rab3a"/>
            <entity id="DS3.d920.s0.e1" origId="6830" charOffset="15-18" type="compound" text="GTP"/>
            <pair e1="DS3.d920.s0.e1" e2="DS3.d920.s0.e0" id="DS3.d920.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d920.s1" origId="9973599-4" text="In chromaffin cells, Rab3a is not exclusively localized on secretory granules since a fraction is present on a previously unidentified subcellular compartment equilibrating at light sucrose density.">
            <entity id="DS3.d920.s1.e0" origId="P11023" charOffset="21-26" type="protein" text="Rab3a"/>
            <entity id="DS3.d920.s1.e1" origId="5988" charOffset="182-189" type="compound" text="sucrose"/>
            <pair e1="DS3.d920.s1.e1" e2="DS3.d920.s1.e0" id="DS3.d920.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d920.s2" origId="9973599-7" text="After stimulation, amounts of both Rab3a-d and the granule marker dopamine-beta-hydroxylase (DbetaH) increase transiently in sucrose gradient fractions enriched in endosomal markers.">
            <entity id="DS3.d920.s2.e0" origId="P11023" charOffset="35-40" type="protein" text="Rab3a"/>
            <entity id="DS3.d920.s2.e1" origId="P15101" charOffset="66-91" type="protein" text="dopamine-beta-hydroxylase"/>
            <entity id="DS3.d920.s2.e2" origId="5988" charOffset="125-132" type="compound" text="sucrose"/>
            <pair e1="DS3.d920.s2.e2" e2="DS3.d920.s2.e1" id="DS3.d920.s2.i0" interaction="False" />
            <pair e1="DS3.d920.s2.e2" e2="DS3.d920.s2.e0" id="DS3.d920.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d920.s3" origId="9973599-8" text="A diaminobenzidine-induced density shift of endosomes alters the distribution of DbetaH and Rab3a-d. At the ultrastructural level, subplasmalemmal pleiomorphic organelles were detected by Rab3a-d-immunogold labelling.">
            <entity id="DS3.d920.s3.e0" origId="21226166" charOffset="2-18" type="compound" text="diaminobenzidine"/>
            <entity id="DS3.d920.s3.e1" origId="P11023" charOffset="92-97" type="protein" text="Rab3a"/>
            <entity id="DS3.d920.s3.e2" origId="P11023" charOffset="188-193" type="protein" text="Rab3a"/>
            <pair e1="DS3.d920.s3.e0" e2="DS3.d920.s3.e1" id="DS3.d920.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d921" origId="9973602">
        <sentence id="DS3.d921.s0" origId="9973602-0" text="Underexpression of the 43 kDa inositol polyphosphate 5-phosphatase is associated with spontaneous calcium oscillations and enhanced calcium responses following endothelin-1 stimulation.">
            <entity id="DS3.d921.s0.e0" origId="892" charOffset="30-38" type="compound" text="inositol"/>
            <entity id="DS3.d921.s0.e1" origId="22044544,5460341" charOffset="98-105" type="compound" text="calcium"/>
            <entity id="DS3.d921.s0.e2" origId="22044544,5460341" charOffset="132-139" type="compound" text="calcium"/>
            <entity id="DS3.d921.s0.e3" origId="P05305,Q6FH53" charOffset="160-172" type="protein" text="endothelin-1"/>
            <pair e1="DS3.d921.s0.e1" e2="DS3.d921.s0.e3" id="DS3.d921.s0.i0" interaction="False" />
            <pair e1="DS3.d921.s0.e0" e2="DS3.d921.s0.e3" id="DS3.d921.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d921.s1" origId="9973602-1" text="The 43 kDa inositol polyphosphate 5-phosphatase (5-phosphatase) hydrolyses the signalling molecules inositol 1,4,5-trisphosphate (Ins(1,4,5)P3) and inositol 1,3,4,5-tetrakisphosphate (Ins(1,3,4, 5)P4) and thereby regulates cellular transformation.">
            <entity id="DS3.d921.s1.e0" origId="892" charOffset="11-19" type="compound" text="inositol"/>
            <entity id="DS3.d921.s1.e1" origId="892" charOffset="100-108" type="compound" text="inositol"/>
            <entity id="DS3.d921.s1.e2" origId="19432134" charOffset="115-128" type="compound" text="trisphosphate"/>
            <entity id="DS3.d921.s1.e3" origId="Q08050,Q53Y49,A0A0D9SFF0,A8K591" charOffset="130-139" type="protein" text="Ins(1,4,5"/>
            <entity id="DS3.d921.s1.e4" origId="892" charOffset="100-108" type="compound" text="inositol"/>
            <entity id="DS3.d921.s1.e5" origId="Q08050,Q53Y49,A0A0D9SFF0,A8K591" charOffset="184-199" type="protein" text="Ins(1,3,4, 5)P4"/>
            <pair e1="DS3.d921.s1.e0" e2="DS3.d921.s1.e3" id="DS3.d921.s1.i0" interaction="False" />
            <pair e1="DS3.d921.s1.e0" e2="DS3.d921.s1.e5" id="DS3.d921.s1.i1" interaction="False" />
            <pair e1="DS3.d921.s1.e2" e2="DS3.d921.s1.e3" id="DS3.d921.s1.i2" interaction="False" />
            <pair e1="DS3.d921.s1.e2" e2="DS3.d921.s1.e5" id="DS3.d921.s1.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d922" origId="9973615">
        <sentence id="DS3.d922.s0" origId="9973615-0" text="The exosome subunit Rrp43p is required for the efficient maturation of 5.8S, 18S and 25S rRNA.">
            <entity id="DS3.d922.s0.e0" origId="P25359" charOffset="20-26" type="protein" text="Rrp43p"/>
            <entity id="DS3.d922.s0.e1" origId="76936801" charOffset="85-88" type="compound" text="25S"/>
            <pair e1="DS3.d922.s0.e1" e2="DS3.d922.s0.e0" id="DS3.d922.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d922.s1" origId="9973615-7" text="Therefore, in addition to the maturation of 5.8S rRNA, Rrp43p is required for the maturation 18S and 25S rRNA.">
            <entity id="DS3.d922.s1.e0" origId="P25359" charOffset="55-61" type="protein" text="Rrp43p"/>
            <entity id="DS3.d922.s1.e1" origId="76936801" charOffset="101-104" type="compound" text="25S"/>
            <pair e1="DS3.d922.s1.e1" e2="DS3.d922.s1.e0" id="DS3.d922.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d923" origId="9973622">
        <sentence id="DS3.d923.s0" origId="9973622-1" text="Eukaryotic translation initiation factor 3 (eIF3) is a large multisubunit protein complex that plays an essential role in the binding of the initiator methionyl-tRNA and mRNA to the 40S ribosomal subunit to form the 40S initiation complex.">
            <entity id="DS3.d923.s0.e0" origId="Q14152" charOffset="0-42" type="protein" text="Eukaryotic translation initiation factor 3"/>
            <entity id="DS3.d923.s0.e1" origId="Q14152" charOffset="44-48" type="protein" text="eIF3"/>
            <entity id="DS3.d923.s0.e2" origId="13091120" charOffset="151-160" type="compound" text="methionyl"/>
            <pair e1="DS3.d923.s0.e2" e2="DS3.d923.s0.e1" id="DS3.d923.s0.i0" interaction="False" />
            <pair e1="DS3.d923.s0.e2" e2="DS3.d923.s0.e0" id="DS3.d923.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d923.s1" origId="9973622-6" text="The protein shows 33% identity and 53% similarity with the Tif35p subunit (YDR 429C) of yeast eIF3.">
            <entity id="DS3.d923.s1.e0" origId="Q04067" charOffset="59-65" type="protein" text="Tif35p"/>
            <entity id="DS3.d923.s1.e1" origId="50909918" charOffset="75-78" type="compound" text="YDR"/>
            <entity id="DS3.d923.s1.e2" origId="Q14152" charOffset="94-98" type="protein" text="eIF3"/>
            <pair e1="DS3.d923.s1.e1" e2="DS3.d923.s1.e0" id="DS3.d923.s1.i0" interaction="False" />
            <pair e1="DS3.d923.s1.e1" e2="DS3.d923.s1.e2" id="DS3.d923.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d924" origId="9973625">
        <sentence id="DS3.d924.s0" origId="9973625-0" text="Binding of the glucose-dependent Mig1p repressor to the GAL1 and GAL4 promoters in vivo: regulationby glucose and chromatin structure.">
            <entity id="DS3.d924.s0.e0" origId="206,5793,64689,79025" charOffset="15-22" type="compound" text="glucose"/>
            <entity id="DS3.d924.s0.e1" origId="P27705" charOffset="33-38" type="protein" text="Mig1p"/>
            <entity id="DS3.d924.s0.e2" origId="P04385" charOffset="56-60" type="protein" text="GAL1"/>
            <entity id="DS3.d924.s0.e3" origId="P04386" charOffset="65-69" type="protein" text="GAL4"/>
            <entity id="DS3.d924.s0.e4" origId="206,5793,64689,79025" charOffset="102-109" type="compound" text="glucose"/>
            <pair e1="DS3.d924.s0.e0" e2="DS3.d924.s0.e3" id="DS3.d924.s0.i0" interaction="False" />
            <pair e1="DS3.d924.s0.e0" e2="DS3.d924.s0.e2" id="DS3.d924.s0.i1" interaction="False" />
            <pair e1="DS3.d924.s0.e0" e2="DS3.d924.s0.e1" id="DS3.d924.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d924.s1" origId="9973625-1" text="Binding of the MIG1 repressor to the glucose-repressible GAL1 and GAL4 promoters was analyzed in vivo by cyclobutane dimer footprinting in two yeast strains that show different glucose repression responses.">
            <entity id="DS3.d924.s1.e0" origId="206,5793,64689,79025" charOffset="37-44" type="compound" text="glucose"/>
            <entity id="DS3.d924.s1.e1" origId="P04385" charOffset="57-61" type="protein" text="GAL1"/>
            <entity id="DS3.d924.s1.e2" origId="P04386" charOffset="66-70" type="protein" text="GAL4"/>
            <entity id="DS3.d924.s1.e3" origId="206,5793,64689,79025" charOffset="177-184" type="compound" text="glucose"/>
            <pair e1="DS3.d924.s1.e0" e2="DS3.d924.s1.e2" id="DS3.d924.s1.i0" interaction="False" />
            <pair e1="DS3.d924.s1.e0" e2="DS3.d924.s1.e1" id="DS3.d924.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d924.s2" origId="9973625-2" text="Mig1p binding to the two promoters in both strains was glucose-induced.">
            <entity id="DS3.d924.s2.e0" origId="P27705" charOffset="0-5" type="protein" text="Mig1p"/>
            <entity id="DS3.d924.s2.e1" origId="5793,206,64689,79025" charOffset="55-62" type="compound" text="glucose"/>
            <pair e1="DS3.d924.s2.e1" e2="DS3.d924.s2.e0" id="DS3.d924.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d924.s3" origId="9973625-3" text="In cells subject to rapid and stringent glucose repression (S288c), long-term Mig1p binding in glucose-grown cells was inhibited by the formation of a competing chromatin structure.">
            <entity id="DS3.d924.s3.e0" origId="5793,206,64689,79025" charOffset="40-47" type="compound" text="glucose"/>
            <entity id="DS3.d924.s3.e1" origId="P27705" charOffset="78-83" type="protein" text="Mig1p"/>
            <entity id="DS3.d924.s3.e2" origId="5793,206,64689,79025" charOffset="95-102" type="compound" text="glucose"/>
            <pair e1="DS3.d924.s3.e0" e2="DS3.d924.s3.e1" id="DS3.d924.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d924.s4" origId="9973625-4" text="Under conditions where glucose repression was only partially effective (gal80 - or low glucose), the chromatin structure did not form and long-term Mig1p binding was observed The same long-term binding of Mig1p was seen in cells of a different strain (W303A) that shows only partial glucose repression of the GAL1 promoter.">
            <entity id="DS3.d924.s4.e0" origId="206,5793,64689,79025" charOffset="23-30" type="compound" text="glucose"/>
            <entity id="DS3.d924.s4.e1" origId="P04387" charOffset="72-77" type="protein" text="gal80"/>
            <entity id="DS3.d924.s4.e2" origId="206,5793,64689,79025" charOffset="87-94" type="compound" text="glucose"/>
            <entity id="DS3.d924.s4.e3" origId="P27705" charOffset="148-153" type="protein" text="Mig1p"/>
            <entity id="DS3.d924.s4.e4" origId="P27705" charOffset="205-210" type="protein" text="Mig1p"/>
            <entity id="DS3.d924.s4.e5" origId="206,5793,64689,79025" charOffset="87-94" type="compound" text="glucose"/>
            <entity id="DS3.d924.s4.e6" origId="P04385" charOffset="309-313" type="protein" text="GAL1"/>
            <pair e1="DS3.d924.s4.e0" e2="DS3.d924.s4.e6" id="DS3.d924.s4.i0" interaction="False" />
            <pair e1="DS3.d924.s4.e0" e2="DS3.d924.s4.e1" id="DS3.d924.s4.i1" interaction="False" />
            <pair e1="DS3.d924.s4.e0" e2="DS3.d924.s4.e3" id="DS3.d924.s4.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d924.s5" origId="9973625-5" text="We conclude from these experiments that Mig1p binding to glucose-repressed promoters is glucose-dependent but transient.">
            <entity id="DS3.d924.s5.e0" origId="P27705" charOffset="40-45" type="protein" text="Mig1p"/>
            <entity id="DS3.d924.s5.e1" origId="5793,206,64689,79025" charOffset="57-64" type="compound" text="glucose"/>
            <entity id="DS3.d924.s5.e2" origId="5793,206,64689,79025" charOffset="88-95" type="compound" text="glucose"/>
            <pair e1="DS3.d924.s5.e1" e2="DS3.d924.s5.e0" id="DS3.d924.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d925" origId="9973627">
        <sentence id="DS3.d925.s0" origId="9973627-6" text="The low level of 8-oxoguanine-DNA glycosylase in CS extracts correlates with the reduced expression of the 8-oxoguanine-DNA glycosylase gene (hOGG1) in CS cells.">
            <entity id="DS3.d925.s0.e0" origId="65154" charOffset="17-29" type="compound" text="8-oxoguanine"/>
            <entity id="DS3.d925.s0.e1" origId="65154" charOffset="107-119" type="compound" text="8-oxoguanine"/>
            <entity id="DS3.d925.s0.e2" origId="O15527,E5KPM6,E5KPM7,E5KPM8,E5KPN1,E5KPN0,E5KPM5,E5KPM9" charOffset="142-147" type="protein" text="hOGG1"/>
            <pair e1="DS3.d925.s0.e0" e2="DS3.d925.s0.e2" id="DS3.d925.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d925.s1" origId="9973627-7" text="Both the levels of expression of the hOGG1 gene and the incision of 8-oxoguanine in DNAincreased markedly after transfection of CS-B cells with the CSB gene.">
            <entity id="DS3.d925.s1.e0" origId="O15527,E5KPM6,E5KPM7,E5KPM8,E5KPN1,E5KPN0,E5KPM5,E5KPM9" charOffset="37-42" type="protein" text="hOGG1"/>
            <entity id="DS3.d925.s1.e1" origId="65154" charOffset="68-80" type="compound" text="8-oxoguanine"/>
            <entity id="DS3.d925.s1.e2" origId="P0DML3,B1A4H9,A6NIT4" charOffset="148-151" type="protein" text="CSB"/>
            <pair e1="DS3.d925.s1.e1" e2="DS3.d925.s1.e2" id="DS3.d925.s1.i0" interaction="False" />
            <pair e1="DS3.d925.s1.e1" e2="DS3.d925.s1.e0" id="DS3.d925.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d925.s2" origId="9973627-8" text="We suggest that the CSB mutation leads to deficient transcription of the hOGG1 gene and thus to deficient repair of 8-oxoguanine in DNA.">
            <entity id="DS3.d925.s2.e0" origId="P0DML3,B1A4H9,A6NIT4" charOffset="20-23" type="protein" text="CSB"/>
            <entity id="DS3.d925.s2.e1" origId="O15527,E5KPM6,E5KPM7,E5KPM8,E5KPN1,E5KPN0,E5KPM5,E5KPM9" charOffset="73-78" type="protein" text="hOGG1"/>
            <entity id="DS3.d925.s2.e2" origId="65154" charOffset="116-128" type="compound" text="8-oxoguanine"/>
            <pair e1="DS3.d925.s2.e2" e2="DS3.d925.s2.e1" id="DS3.d925.s2.i0" interaction="False" />
            <pair e1="DS3.d925.s2.e2" e2="DS3.d925.s2.e0" id="DS3.d925.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d926" origId="9973632">
        <sentence id="DS3.d926.s0" origId="9973632-3" text="Spectral evolution of GCAA and GAAA tetraloops, as formed in very short hairpins with only three G.C base pairs in their stems (T m &amp;gt;60 degreesC), are reported and compared with those previously published on UUCG and UACG tetraloops, for which the syn orientation of the terminal guanine as well as the 2'-endo/anti conformation of the third rC residue have been confirmed by means of vibrational marker bands.">
            <entity id="DS3.d926.s0.e0" origId="P06241" charOffset="251-254" type="protein" text="syn"/>
            <entity id="DS3.d926.s0.e1" origId="764" charOffset="283-290" type="compound" text="guanine"/>
            <pair e1="DS3.d926.s0.e1" e2="DS3.d926.s0.e0" id="DS3.d926.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d927" origId="9973638">
        <sentence id="DS3.d927.s0" origId="9973638-0" text="A human myeloid cell line producing stem cell growth factor, KPB-M15, secretes another growth factor active on murine hematopoietic progenitor cells.">
            <entity id="DS3.d927.s0.e0" origId="Q9Y240,A0A0A6YY95" charOffset="36-59" type="protein" text="stem cell growth factor"/>
            <entity id="DS3.d927.s0.e1" origId="16132126" charOffset="65-68" type="compound" text="M15"/>
            <pair e1="DS3.d927.s0.e1" e2="DS3.d927.s0.e0" id="DS3.d927.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d927.s1" origId="9973638-10" text="This is the first report of a human myeloid cell line, KPB-M15, constitutively producing M-CSF in addition to SCGF and IL-6.">
            <entity id="DS3.d927.s1.e0" origId="16132126" charOffset="59-62" type="compound" text="M15"/>
            <entity id="DS3.d927.s1.e1" origId="P07141" charOffset="89-94" type="protein" text="M-CSF"/>
            <entity id="DS3.d927.s1.e2" origId="O88200" charOffset="110-114" type="protein" text="SCGF"/>
            <entity id="DS3.d927.s1.e3" origId="P08505,A2RTD1" charOffset="119-123" type="protein" text="IL-6"/>
            <pair e1="DS3.d927.s1.e0" e2="DS3.d927.s1.e2" id="DS3.d927.s1.i0" interaction="False" />
            <pair e1="DS3.d927.s1.e0" e2="DS3.d927.s1.e3" id="DS3.d927.s1.i1" interaction="False" />
            <pair e1="DS3.d927.s1.e0" e2="DS3.d927.s1.e1" id="DS3.d927.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d927.s2" origId="9973638-1" text="Human stem cell growth factor (SCGF) produced by a myeloid cell line, KPB-M15, exhibits species-specific hematopoietic activities.">
            <entity id="DS3.d927.s2.e0" origId="Q9Y240,A0A0A6YY95" charOffset="6-29" type="protein" text="stem cell growth factor"/>
            <entity id="DS3.d927.s2.e1" origId="O88200" charOffset="31-35" type="protein" text="SCGF"/>
            <entity id="DS3.d927.s2.e2" origId="16132126" charOffset="74-77" type="compound" text="M15"/>
            <pair e1="DS3.d927.s2.e2" e2="DS3.d927.s2.e0" id="DS3.d927.s2.i0" interaction="False" />
            <pair e1="DS3.d927.s2.e2" e2="DS3.d927.s2.e1" id="DS3.d927.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d927.s3" origId="9973638-6" text="PCR, Northern hybridization and ELISA demonstrated that KPB-M15 cells secreted a significant amount of M-CSF and IL-6.">
            <entity id="DS3.d927.s3.e0" origId="16132126" charOffset="60-63" type="compound" text="M15"/>
            <entity id="DS3.d927.s3.e1" origId="P07141" charOffset="103-108" type="protein" text="M-CSF"/>
            <entity id="DS3.d927.s3.e2" origId="P08505,A2RTD1" charOffset="113-117" type="protein" text="IL-6"/>
            <pair e1="DS3.d927.s3.e0" e2="DS3.d927.s3.e2" id="DS3.d927.s3.i0" interaction="False" />
            <pair e1="DS3.d927.s3.e0" e2="DS3.d927.s3.e1" id="DS3.d927.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d927.s4" origId="9973638-7" text="Anti-M-CSF but not anti-IL-6 antibody abrogated CSA in KPB-M15-CM.">
            <entity id="DS3.d927.s4.e0" origId="P07141" charOffset="5-10" type="protein" text="M-CSF"/>
            <entity id="DS3.d927.s4.e1" origId="P08505,A2RTD1" charOffset="24-28" type="protein" text="IL-6"/>
            <entity id="DS3.d927.s4.e2" origId="16132126" charOffset="59-62" type="compound" text="M15"/>
            <pair e1="DS3.d927.s4.e2" e2="DS3.d927.s4.e1" id="DS3.d927.s4.i0" interaction="False" />
            <pair e1="DS3.d927.s4.e2" e2="DS3.d927.s4.e0" id="DS3.d927.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d927.s5" origId="9973638-9" text="Collectively, M-CSF is a sole CSA for murine hematopoietic progenitor cells in KPB-M15-CM.">
            <entity id="DS3.d927.s5.e0" origId="P07141" charOffset="14-19" type="protein" text="M-CSF"/>
            <entity id="DS3.d927.s5.e1" origId="16132126" charOffset="83-86" type="compound" text="M15"/>
            <pair e1="DS3.d927.s5.e1" e2="DS3.d927.s5.e0" id="DS3.d927.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d928" origId="9973639">
        <sentence id="DS3.d928.s0" origId="9973639-6" text="Partially glycosylated Rh50 (32 kDa) was again isolated from the lysates of K562 cells metabolically labeled with (35S)-methionine or (3H)-mannose using anti-Rh50 antisera.">
            <entity id="DS3.d928.s0.e0" origId="Q02094,Q96E98,Q9QUT0" charOffset="23-27" type="protein" text="Rh50"/>
            <entity id="DS3.d928.s0.e1" origId="6137,84815,876" charOffset="120-130" type="compound" text="methionine"/>
            <entity id="DS3.d928.s0.e2" origId="18950,206" charOffset="139-146" type="compound" text="mannose"/>
            <entity id="DS3.d928.s0.e3" origId="Q02094,Q96E98,Q9QUT0" charOffset="158-162" type="protein" text="Rh50"/>
            <pair e1="DS3.d928.s0.e2" e2="DS3.d928.s0.e0" id="DS3.d928.s0.i0" interaction="False" />
            <pair e1="DS3.d928.s0.e1" e2="DS3.d928.s0.e0" id="DS3.d928.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d929" origId="9973640">
        <sentence id="DS3.d929.s0" origId="9973640-0" text="In vivo administration of granulocyte colony-stimulating factor increases the surface expression of sialyl-Lewis(x) on neutrophils in healthy volunteers.">
            <entity id="DS3.d929.s0.e0" origId="P09919,Q6FH65,Q8N4W3" charOffset="26-63" type="protein" text="granulocyte colony-stimulating factor"/>
            <entity id="DS3.d929.s0.e1" origId="18729306" charOffset="100-106" type="compound" text="sialyl"/>
            <pair e1="DS3.d929.s0.e1" e2="DS3.d929.s0.e0" id="DS3.d929.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d929.s1" origId="9973640-5" text="G-CSF administration decreased the surface expression of L-selectin on neutrophils, whereas it increased the expression of sialyl-Lewisx but not Lewisx on neutrophils.">
            <entity id="DS3.d929.s1.e0" origId="P09919,Q6FH65,Q8N4W3" charOffset="0-5" type="protein" text="G-CSF"/>
            <entity id="DS3.d929.s1.e1" origId="P14151,A0A024R8Z0" charOffset="57-67" type="protein" text="L-selectin"/>
            <entity id="DS3.d929.s1.e2" origId="18729306" charOffset="123-129" type="compound" text="sialyl"/>
            <pair e1="DS3.d929.s1.e2" e2="DS3.d929.s1.e1" id="DS3.d929.s1.i0" interaction="False" />
            <pair e1="DS3.d929.s1.e2" e2="DS3.d929.s1.e0" id="DS3.d929.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d930" origId="9973643">
        <sentence id="DS3.d930.s0" origId="9973643-3" text="Molecular analysis revealed that this quantitative alteration was accompanied by a novel base change at codon 837 (ACG--&amp;gt;GCG) of the AE1 gene, resulting in substitution of alanine for threonine.">
            <entity id="DS3.d930.s0.e0" origId="P01275" charOffset="124-127" type="protein" text="GCG"/>
            <entity id="DS3.d930.s0.e1" origId="P02730" charOffset="136-139" type="protein" text="AE1"/>
            <entity id="DS3.d930.s0.e2" origId="5950,602" charOffset="175-182" type="compound" text="alanine"/>
            <entity id="DS3.d930.s0.e3" origId="194239,6288" charOffset="187-196" type="compound" text="threonine"/>
            <pair e1="DS3.d930.s0.e2" e2="DS3.d930.s0.e1" id="DS3.d930.s0.i0" interaction="False" />
            <pair e1="DS3.d930.s0.e2" e2="DS3.d930.s0.e0" id="DS3.d930.s0.i1" interaction="False" />
            <pair e1="DS3.d930.s0.e3" e2="DS3.d930.s0.e1" id="DS3.d930.s0.i2" interaction="False" />
            <pair e1="DS3.d930.s0.e3" e2="DS3.d930.s0.e0" id="DS3.d930.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d931" origId="9973668">
        <sentence id="DS3.d931.s0" origId="9973668-1" text="To investigate the relationship between leptin levels and IDDM with and without microalbuminuria, fasting serum levels of leptin, insulin, insulin-like growth factor-1 (IGF-1), sex hormone-binding globulin (SHBG), testosterone (SHBG) ratio, blood pressure and body mass index (BMI) were measured in 18 normo- and 11 microalbuminuric females with &amp;gt;5 years of IDDM, and 24 healthy controls in late puberty.">
            <entity id="DS3.d931.s0.e0" origId="P41159,A4D0Y8" charOffset="40-46" type="protein" text="leptin"/>
            <entity id="DS3.d931.s0.e1" origId="P41159,A4D0Y8" charOffset="122-128" type="protein" text="leptin"/>
            <entity id="DS3.d931.s0.e2" origId="P01308,I3WAC9" charOffset="130-137" type="protein" text="insulin"/>
            <entity id="DS3.d931.s0.e3" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="139-167" type="protein" text="insulin-like growth factor-1"/>
            <entity id="DS3.d931.s0.e4" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="169-174" type="protein" text="IGF-1"/>
            <entity id="DS3.d931.s0.e5" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="177-205" type="protein" text="sex hormone-binding globulin"/>
            <entity id="DS3.d931.s0.e6" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="207-211" type="protein" text="SHBG"/>
            <entity id="DS3.d931.s0.e7" origId="6013" charOffset="214-226" type="compound" text="testosterone"/>
            <entity id="DS3.d931.s0.e8" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="228-232" type="protein" text="SHBG"/>
            <pair e1="DS3.d931.s0.e7" e2="DS3.d931.s0.e0" id="DS3.d931.s0.i0" interaction="False" />
            <pair e1="DS3.d931.s0.e7" e2="DS3.d931.s0.e4" id="DS3.d931.s0.i1" interaction="False" />
            <pair e1="DS3.d931.s0.e7" e2="DS3.d931.s0.e5" id="DS3.d931.s0.i2" interaction="False" />
            <pair e1="DS3.d931.s0.e7" e2="DS3.d931.s0.e3" id="DS3.d931.s0.i3" interaction="False" />
            <pair e1="DS3.d931.s0.e7" e2="DS3.d931.s0.e6" id="DS3.d931.s0.i4" interaction="False" />
            <pair e1="DS3.d931.s0.e7" e2="DS3.d931.s0.e2" id="DS3.d931.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d931.s1" origId="9973668-4" text="Including IDDM females only, solely low IGF-1 and high testosterone/SHBG were associated with leptin (R2 = 0.39, p = 0.009).">
            <entity id="DS3.d931.s1.e0" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="40-45" type="protein" text="IGF-1"/>
            <entity id="DS3.d931.s1.e1" origId="6013" charOffset="55-67" type="compound" text="testosterone"/>
            <entity id="DS3.d931.s1.e2" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="68-72" type="protein" text="SHBG"/>
            <entity id="DS3.d931.s1.e3" origId="P41159,A4D0Y8" charOffset="94-100" type="protein" text="leptin"/>
            <pair e1="DS3.d931.s1.e1" e2="DS3.d931.s1.e2" id="DS3.d931.s1.i0" interaction="False" />
            <pair e1="DS3.d931.s1.e1" e2="DS3.d931.s1.e3" id="DS3.d931.s1.i1" interaction="False" />
            <pair e1="DS3.d931.s1.e1" e2="DS3.d931.s1.e0" id="DS3.d931.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d932" origId="9973713">
        <sentence id="DS3.d932.s0" origId="9973713-3" text="Fluoride ion analysis was carried out on 24 AgF samples using the Ion-Selective Electrode technique.">
            <entity id="DS3.d932.s0.e0" origId="28179" charOffset="0-12" type="compound" text="Fluoride ion"/>
            <entity id="DS3.d932.s0.e1" origId="Q8NI99,A0A024R7A9" charOffset="44-47" type="protein" text="AgF"/>
            <pair e1="DS3.d932.s0.e0" e2="DS3.d932.s0.e1" id="DS3.d932.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d933" origId="9973772">
        <sentence id="DS3.d933.s0" origId="9973772-8" text="The type, percentage and diameter of the fibers, as well as the enzymes of glycogen metabolism (glycogen synthase and glycogen phosphorylase), glycolysis (phosphofructokinase and lactate dehydrogenase), oxidative metabolism (succinate dehydrogenase and citrate synthase) and creatine kinase and transaminase (aspartate and alanine aminotransferase) were studied.">
            <entity id="DS3.d933.s0.e0" origId="439177" charOffset="75-83" type="compound" text="glycogen"/>
            <entity id="DS3.d933.s0.e1" origId="439177" charOffset="96-104" type="compound" text="glycogen"/>
            <entity id="DS3.d933.s0.e2" origId="439177" charOffset="96-104" type="compound" text="glycogen"/>
            <entity id="DS3.d933.s0.e3" origId="612" charOffset="179-186" type="compound" text="lactate"/>
            <entity id="DS3.d933.s0.e4" origId="1110" charOffset="225-234" type="compound" text="succinate"/>
            <entity id="DS3.d933.s0.e5" origId="O75390,A0A024RB75" charOffset="253-269" type="protein" text="citrate synthase"/>
            <entity id="DS3.d933.s0.e6" origId="586" charOffset="275-283" type="compound" text="creatine"/>
            <entity id="DS3.d933.s0.e7" origId="5960" charOffset="309-318" type="compound" text="aspartate"/>
            <entity id="DS3.d933.s0.e8" origId="5950,602" charOffset="323-330" type="compound" text="alanine"/>
            <pair e1="DS3.d933.s0.e8" e2="DS3.d933.s0.e5" id="DS3.d933.s0.i0" interaction="False" />
            <pair e1="DS3.d933.s0.e0" e2="DS3.d933.s0.e5" id="DS3.d933.s0.i1" interaction="False" />
            <pair e1="DS3.d933.s0.e6" e2="DS3.d933.s0.e5" id="DS3.d933.s0.i2" interaction="False" />
            <pair e1="DS3.d933.s0.e7" e2="DS3.d933.s0.e5" id="DS3.d933.s0.i3" interaction="False" />
            <pair e1="DS3.d933.s0.e3" e2="DS3.d933.s0.e5" id="DS3.d933.s0.i4" interaction="False" />
            <pair e1="DS3.d933.s0.e4" e2="DS3.d933.s0.e5" id="DS3.d933.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d933.s1" origId="9973772-9" text="RESULTS: Detraining had an adaptation effect, decreasing the cross-sectional area of type I and type II fibers, and decreasing the activities of creatine kinase, citrate synthase, phosphofructokinase, lactate dehydrogenase and aspartate aminotransferase.">
            <entity id="DS3.d933.s1.e0" origId="586" charOffset="145-153" type="compound" text="creatine"/>
            <entity id="DS3.d933.s1.e1" origId="O75390,A0A024RB75" charOffset="162-178" type="protein" text="citrate synthase"/>
            <entity id="DS3.d933.s1.e2" origId="612" charOffset="201-208" type="compound" text="lactate"/>
            <entity id="DS3.d933.s1.e3" origId="5960" charOffset="227-236" type="compound" text="aspartate"/>
            <pair e1="DS3.d933.s1.e2" e2="DS3.d933.s1.e1" id="DS3.d933.s1.i0" interaction="False" />
            <pair e1="DS3.d933.s1.e3" e2="DS3.d933.s1.e1" id="DS3.d933.s1.i1" interaction="False" />
            <pair e1="DS3.d933.s1.e0" e2="DS3.d933.s1.e1" id="DS3.d933.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d934" origId="9973786">
        <sentence id="DS3.d934.s0" origId="9973786-13" text="ACE inhibitors, digitalis and calcium antagonists are to be indicated among the most widely used drugs.">
            <entity id="DS3.d934.s0.e0" origId="P12821,B4DKH4" charOffset="0-3" type="protein" text="ACE"/>
            <entity id="DS3.d934.s0.e1" origId="56840973" charOffset="16-25" type="compound" text="digitalis"/>
            <entity id="DS3.d934.s0.e2" origId="22044544,5460341" charOffset="30-37" type="compound" text="calcium"/>
            <pair e1="DS3.d934.s0.e1" e2="DS3.d934.s0.e0" id="DS3.d934.s0.i0" interaction="False" />
            <pair e1="DS3.d934.s0.e2" e2="DS3.d934.s0.e0" id="DS3.d934.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d935" origId="9973826">
        <sentence id="DS3.d935.s0" origId="9973826-2" text="METHODS: Our series consisted of 161 female subjects (mean age 54 +/- 7 years, disease duration 5 +/- 3 months) subdivided into: a) 13 patients suffering from insulin-dependent diabetes (IDDM) without clinical and instrumental signs of micro- and macro-angiopathy; b) 148 suffering from non insulin-dependent diabetes mellitus (NIDDM) of whom: 1) 52 without vascular complications (28 normal weight, BMI &amp;lt; 25, and 24 obese, BMI &amp;gt; 30); 2) 40 with clinical and instrumental signs of non hypertensive coronary heart disease (CHD); 3) 25 with CHD and hypertension (arterial blood pressure over 160/95 mmHg); 4) 31 with hypercholesterolemia (values over 250 mg/dl).">
            <entity id="DS3.d935.s0.e0" origId="P01308,I3WAC9" charOffset="159-166" type="protein" text="insulin"/>
            <entity id="DS3.d935.s0.e1" origId="P01308,I3WAC9" charOffset="291-298" type="protein" text="insulin"/>
            <entity id="DS3.d935.s0.e2" origId="221493" charOffset="528-531" type="compound" text="CHD"/>
            <entity id="DS3.d935.s0.e3" origId="221493" charOffset="545-548" type="compound" text="CHD"/>
            <pair e1="DS3.d935.s0.e2" e2="DS3.d935.s0.e0" id="DS3.d935.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d936" origId="9973836">
        <sentence id="DS3.d936.s0" origId="9973836-3" text="We report the case of a 81-year-old man with insulin-dependent diabetes mellitus who showed electrocardiographic features of acute myocardial ischemia during an episode of hypoglycemia; these alterations disappeared after glucose administration.">
            <entity id="DS3.d936.s0.e0" origId="P01308,I3WAC9" charOffset="45-52" type="protein" text="insulin"/>
            <entity id="DS3.d936.s0.e1" origId="206,64689,79025" charOffset="222-229" type="compound" text="glucose"/>
            <pair e1="DS3.d936.s0.e1" e2="DS3.d936.s0.e0" id="DS3.d936.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d937" origId="9973840">
        <sentence id="DS3.d937.s0" origId="9973840-6" text="Three linkers (EGS, DST and DSP) were labile in in vitro and in vivo studies.">
            <entity id="DS3.d937.s0.e0" origId="123663" charOffset="15-18" type="compound" text="EGS"/>
            <entity id="DS3.d937.s0.e1" origId="Q91ZU6,S4R1P5" charOffset="20-23" type="protein" text="DST"/>
            <entity id="DS3.d937.s0.e2" origId="E9Q557,E9PZW0" charOffset="28-31" type="protein" text="DSP"/>
            <pair e1="DS3.d937.s0.e0" e2="DS3.d937.s0.e1" id="DS3.d937.s0.i0" interaction="False" />
            <pair e1="DS3.d937.s0.e0" e2="DS3.d937.s0.e2" id="DS3.d937.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d938" origId="9973849">
        <sentence id="DS3.d938.s0" origId="9973849-3" text="Whereas small amounts of NO produced by endothelial constitutive calcium-dependent NOS may act to preserve intestinal mucosa integrity, large amounts of NO synthesised by inducible calcium-independent NOS may play a key role in further aggravation of the inflammation and may be associated with the development of intestinal mucosal injury and amplification of immune response in patients with inflammatory bowel disease (IBD).">
            <entity id="DS3.d938.s0.e0" origId="22044544,5460341" charOffset="65-72" type="compound" text="calcium"/>
            <entity id="DS3.d938.s0.e1" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="83-86" type="protein" text="NOS"/>
            <entity id="DS3.d938.s0.e2" origId="22044544,5460341" charOffset="181-188" type="compound" text="calcium"/>
            <entity id="DS3.d938.s0.e3" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="201-204" type="protein" text="NOS"/>
            <pair e1="DS3.d938.s0.e0" e2="DS3.d938.s0.e1" id="DS3.d938.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d939" origId="9973907">
        <sentence id="DS3.d939.s0" origId="9973907-1" text="PURPOSE: The aim of the study was to examine muscle metabolism in athletes by 31P-spectroscopy (MRS) and to evaluate to what degree the respective resonance spectrum correlates with the kind of muscle exercise.">
            <entity id="DS3.d939.s0.e0" origId="86208097" charOffset="78-81" type="compound" text="31P"/>
            <entity id="DS3.d939.s0.e1" origId="P59665" charOffset="96-99" type="protein" text="MRS"/>
            <pair e1="DS3.d939.s0.e0" e2="DS3.d939.s0.e1" id="DS3.d939.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d940" origId="9973923">
        <sentence id="DS3.d940.s0" origId="9973923-3" text="Using the nonisotopic RNAse cleavage assay (NIRCA), we screened for point mutations and identified an ApaI restriction site polymorphism located in intron 7 within the TP53 gene.">
            <entity id="DS3.d940.s0.e0" origId="173210" charOffset="102-106" type="compound" text="ApaI"/>
            <entity id="DS3.d940.s0.e1" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="168-172" type="protein" text="TP53"/>
            <pair e1="DS3.d940.s0.e0" e2="DS3.d940.s0.e1" id="DS3.d940.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d941" origId="9973953">
        <sentence id="DS3.d941.s0" origId="9973953-1" text="To detect chromosomal abnormalities in prodromal phase of adult T-cell leukemia (ATL), we established a clonal culture method for human T-lymphotropic virus type I (HTLV-I) infected T-cells in methylcellulose containing recombinant human interleukin 2 (rhIL-2).">
            <entity id="DS3.d941.s0.e0" origId="9841438" charOffset="81-84" type="compound" text="ATL"/>
            <entity id="DS3.d941.s0.e1" origId="44263857" charOffset="193-208" type="compound" text="methylcellulose"/>
            <entity id="DS3.d941.s0.e2" origId="P60568,Q0GK43" charOffset="220-251" type="protein" text="recombinant human interleukin 2"/>
            <pair e1="DS3.d941.s0.e0" e2="DS3.d941.s0.e2" id="DS3.d941.s0.i0" interaction="False" />
            <pair e1="DS3.d941.s0.e1" e2="DS3.d941.s0.e2" id="DS3.d941.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d942" origId="9974008">
        <sentence id="DS3.d942.s0" origId="9974008-0" text="(The use of Diprivan in CO2 laser microlaryngosurgery (MLS)).">
            <entity id="DS3.d942.s0.e0" origId="4943" charOffset="12-20" type="compound" text="Diprivan"/>
            <entity id="DS3.d942.s0.e1" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="24-27" type="protein" text="CO2"/>
            <entity id="DS3.d942.s0.e2" origId="P53701,A0A024RBY9" charOffset="55-58" type="protein" text="MLS"/>
            <pair e1="DS3.d942.s0.e0" e2="DS3.d942.s0.e2" id="DS3.d942.s0.i0" interaction="False" />
            <pair e1="DS3.d942.s0.e0" e2="DS3.d942.s0.e1" id="DS3.d942.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d942.s1" origId="9974008-4" text="After comparative assessment with conventional techniques, the inference is reached that Diprivan is a further alternative available, and should be considered in the choice of anesthesiological techniques for MLS.">
            <entity id="DS3.d942.s1.e0" origId="4943" charOffset="89-97" type="compound" text="Diprivan"/>
            <entity id="DS3.d942.s1.e1" origId="P53701,A0A024RBY9" charOffset="209-212" type="protein" text="MLS"/>
            <pair e1="DS3.d942.s1.e0" e2="DS3.d942.s1.e1" id="DS3.d942.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d943" origId="9974084">
        <sentence id="DS3.d943.s0" origId="9974084-0" text="Strength and its relationship to changes in fat-free mass, total body potassium, total body water and IGF-1 in adults with growth hormone deficiency: effect of treatment with growth hormone.">
            <entity id="DS3.d943.s0.e0" origId="5462222" charOffset="70-79" type="compound" text="potassium"/>
            <entity id="DS3.d943.s0.e1" origId="962" charOffset="92-97" type="compound" text="water"/>
            <entity id="DS3.d943.s0.e2" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="102-107" type="protein" text="IGF-1"/>
            <entity id="DS3.d943.s0.e3" origId="P01241,B1A4G6,B1A4G7" charOffset="123-137" type="protein" text="growth hormone"/>
            <entity id="DS3.d943.s0.e4" origId="P01241,B1A4G6,B1A4G7" charOffset="175-189" type="protein" text="growth hormone"/>
            <pair e1="DS3.d943.s0.e1" e2="DS3.d943.s0.e2" id="DS3.d943.s0.i0" interaction="False" />
            <pair e1="DS3.d943.s0.e1" e2="DS3.d943.s0.e3" id="DS3.d943.s0.i1" interaction="False" />
            <pair e1="DS3.d943.s0.e0" e2="DS3.d943.s0.e2" id="DS3.d943.s0.i2" interaction="False" />
            <pair e1="DS3.d943.s0.e0" e2="DS3.d943.s0.e3" id="DS3.d943.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d943.s1" origId="9974084-1" text="The present investigation examined changes in strength in growth hormone deficient (GHD) adults following treatment with recombinant human growth hormone (rhGH), and assessed their relationship to changes in fat-free mass (FFM), total body potassium (TBK), total body water (TBW), the concentration of TBK and TBW per kg FFM, and insulin like growth factor-1 (IGF-1).">
            <entity id="DS3.d943.s1.e0" origId="P01241,B1A4G6,B1A4G7" charOffset="58-72" type="protein" text="growth hormone"/>
            <entity id="DS3.d943.s1.e1" origId="P01241,B1A4G6,B1A4G7" charOffset="121-153" type="protein" text="recombinant human growth hormone"/>
            <entity id="DS3.d943.s1.e2" origId="5462222" charOffset="240-249" type="compound" text="potassium"/>
            <entity id="DS3.d943.s1.e3" origId="962" charOffset="268-273" type="compound" text="water"/>
            <entity id="DS3.d943.s1.e4" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="330-358" type="protein" text="insulin like growth factor-1"/>
            <entity id="DS3.d943.s1.e5" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="360-365" type="protein" text="IGF-1"/>
            <pair e1="DS3.d943.s1.e3" e2="DS3.d943.s1.e1" id="DS3.d943.s1.i0" interaction="False" />
            <pair e1="DS3.d943.s1.e3" e2="DS3.d943.s1.e4" id="DS3.d943.s1.i1" interaction="False" />
            <pair e1="DS3.d943.s1.e3" e2="DS3.d943.s1.e5" id="DS3.d943.s1.i2" interaction="False" />
            <pair e1="DS3.d943.s1.e3" e2="DS3.d943.s1.e0" id="DS3.d943.s1.i3" interaction="False" />
            <pair e1="DS3.d943.s1.e2" e2="DS3.d943.s1.e1" id="DS3.d943.s1.i4" interaction="False" />
            <pair e1="DS3.d943.s1.e2" e2="DS3.d943.s1.e4" id="DS3.d943.s1.i5" interaction="False" />
            <pair e1="DS3.d943.s1.e2" e2="DS3.d943.s1.e5" id="DS3.d943.s1.i6" interaction="False" />
            <pair e1="DS3.d943.s1.e2" e2="DS3.d943.s1.e0" id="DS3.d943.s1.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d944" origId="9974097">
        <sentence id="DS3.d944.s0" origId="9974097-4" text="The temporal profile of CO2 production (VCO2) response was clearly abnormal: VCO2 was always lower than oxygen consumption throughout the test, reflecting the lack of lactate buffering by the bicarbonates due to the absence of lactate production.">
            <entity id="DS3.d944.s0.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="24-27" type="protein" text="CO2"/>
            <entity id="DS3.d944.s0.e1" origId="977" charOffset="104-110" type="compound" text="oxygen"/>
            <entity id="DS3.d944.s0.e2" origId="612" charOffset="167-174" type="compound" text="lactate"/>
            <entity id="DS3.d944.s0.e3" origId="612" charOffset="227-234" type="compound" text="lactate"/>
            <pair e1="DS3.d944.s0.e1" e2="DS3.d944.s0.e0" id="DS3.d944.s0.i0" interaction="False" />
            <pair e1="DS3.d944.s0.e2" e2="DS3.d944.s0.e0" id="DS3.d944.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d945" origId="9974116">
        <sentence id="DS3.d945.s0" origId="9974116-4" text="When performance was stable on the ALCR schedule, six subjects were injected (bilaterally into the CA3 area of the dorsal hippocampus) with 5.0 microliters aggregated A beta in suspension, and the remaining six subjects were injected with 5.0 microliters sterile water.">
            <entity id="DS3.d945.s0.e0" origId="P14141" charOffset="99-102" type="protein" text="CA3"/>
            <entity id="DS3.d945.s0.e1" origId="P08592,Q6P6Q5" charOffset="167-173" type="protein" text="A beta"/>
            <entity id="DS3.d945.s0.e2" origId="962" charOffset="263-268" type="compound" text="water"/>
            <pair e1="DS3.d945.s0.e2" e2="DS3.d945.s0.e0" id="DS3.d945.s0.i0" interaction="False" />
            <pair e1="DS3.d945.s0.e2" e2="DS3.d945.s0.e1" id="DS3.d945.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d945.s1" origId="9974116-8" text="From approximately day 50 post-injection onward, A beta-injected subjects demonstrated significantly higher numbers of incorrect lever response perseverations than did sterile water-injected subjects.">
            <entity id="DS3.d945.s1.e0" origId="P08592,Q6P6Q5" charOffset="49-55" type="protein" text="A beta"/>
            <entity id="DS3.d945.s1.e1" origId="962" charOffset="176-181" type="compound" text="water"/>
            <pair e1="DS3.d945.s1.e1" e2="DS3.d945.s1.e0" id="DS3.d945.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d946" origId="9974117">
        <sentence id="DS3.d946.s0" origId="9974117-7" text="Moreover, intense Bax protein immunoreactivity was detected in the retinal sections at 24 h after ischemia although little immunoreactivity was present in the normal sections.">
            <entity id="DS3.d946.s0.e0" origId="Q9JKL3,G3V8T9" charOffset="18-21" type="protein" text="Bax"/>
            <entity id="DS3.d946.s0.e1" origId="638015" charOffset="67-74" type="compound" text="retinal"/>
            <pair e1="DS3.d946.s0.e1" e2="DS3.d946.s0.e0" id="DS3.d946.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d946.s1" origId="9974117-8" text="These results suggest that apoptosis associated with the expression of Bax is involved in retinal cell loss after ischemic insult.">
            <entity id="DS3.d946.s1.e0" origId="Q9JKL3,G3V8T9" charOffset="71-74" type="protein" text="Bax"/>
            <entity id="DS3.d946.s1.e1" origId="638015" charOffset="90-97" type="compound" text="retinal"/>
            <pair e1="DS3.d946.s1.e1" e2="DS3.d946.s1.e0" id="DS3.d946.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d947" origId="9974119">
        <sentence id="DS3.d947.s0" origId="9974119-1" text="Photochemical thrombotic ischemia model was used to study the possible roles of excision repair cross-complementing group 6 (ERCC6), a DNA repair gene, in the neuroprotection of dextromethorphan (DM), a NMDA antagonist, in ischemic brain injury.">
            <entity id="DS3.d947.s0.e0" origId="D3ZS47,A0A0G2JTU1" charOffset="80-123" type="protein" text="excision repair cross-complementing group 6"/>
            <entity id="DS3.d947.s0.e1" origId="D3ZS47,A0A0G2JTU1" charOffset="125-130" type="protein" text="ERCC6"/>
            <entity id="DS3.d947.s0.e2" origId="5360696,5362449,3008,6916184" charOffset="178-194" type="compound" text="dextromethorphan"/>
            <pair e1="DS3.d947.s0.e2" e2="DS3.d947.s0.e0" id="DS3.d947.s0.i0" interaction="False" />
            <pair e1="DS3.d947.s0.e2" e2="DS3.d947.s0.e1" id="DS3.d947.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d948" origId="9974121">
        <sentence id="DS3.d948.s0" origId="9974121-2" text="In the striatum, dopamine (DA) of the rat seems to be metabolized by MAO A, and DA of the human is largely deaminated by MAO B.">
            <entity id="DS3.d948.s0.e0" origId="681" charOffset="17-25" type="compound" text="dopamine"/>
            <entity id="DS3.d948.s0.e1" origId="G3V9Z3" charOffset="69-74" type="protein" text="MAO A"/>
            <entity id="DS3.d948.s0.e2" origId="P27338,B7Z242" charOffset="121-126" type="protein" text="MAO B"/>
            <pair e1="DS3.d948.s0.e0" e2="DS3.d948.s0.e1" id="DS3.d948.s0.i0" interaction="False" />
            <pair e1="DS3.d948.s0.e0" e2="DS3.d948.s0.e2" id="DS3.d948.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d948.s1" origId="9974121-4" text="Using in vivo microdialysis, we investigated the pharmacological activity of selegiline, a selective irreversible inhibitor of MAO B, in the striatum of marmosets.">
            <entity id="DS3.d948.s1.e0" origId="26757" charOffset="77-87" type="compound" text="selegiline"/>
            <entity id="DS3.d948.s1.e1" origId="P27338,B7Z242" charOffset="127-132" type="protein" text="MAO B"/>
            <pair e1="DS3.d948.s1.e0" e2="DS3.d948.s1.e1" id="DS3.d948.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d949" origId="9974123">
        <sentence id="DS3.d949.s0" origId="9974123-10" text="The capsaicin-induced fragmentation of the CGRP terminal plexus in laminae I and II of the lumbar spinal dorsal horn was also markedly repaired on both sides by the intraplantar NGF injections.">
            <entity id="DS3.d949.s0.e0" origId="2548" charOffset="4-14" type="compound" text="capsaicin-"/>
            <entity id="DS3.d949.s0.e1" origId="P01256,P01257,A0A0G2JSX2" charOffset="43-47" type="protein" text="CGRP"/>
            <pair e1="DS3.d949.s0.e0" e2="DS3.d949.s0.e1" id="DS3.d949.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d949.s1" origId="9974123-11" text="The NGF treatment caused the CGRP nerve terminals in the spinal cord to regain their ability of releasing transmitter upon capsaicin stimulation as shown in tissue slice superfusion experiments.">
            <entity id="DS3.d949.s1.e0" origId="P01256,P01257,A0A0G2JSX2" charOffset="29-33" type="protein" text="CGRP"/>
            <entity id="DS3.d949.s1.e1" origId="1548943" charOffset="123-132" type="compound" text="capsaicin"/>
            <pair e1="DS3.d949.s1.e1" e2="DS3.d949.s1.e0" id="DS3.d949.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d949.s2" origId="9974123-12" text="These results show that within one week, rhNGF-beta can induce a complete reinnervation of skin and spinal cord with intact CGRP-IR nerve terminals after an acute capsaicin lesion.">
            <entity id="DS3.d949.s2.e0" origId="P01256,P01257,A0A0G2JSX2" charOffset="124-128" type="protein" text="CGRP"/>
            <entity id="DS3.d949.s2.e1" origId="1548943" charOffset="163-172" type="compound" text="capsaicin"/>
            <pair e1="DS3.d949.s2.e1" e2="DS3.d949.s2.e0" id="DS3.d949.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d949.s3" origId="9974123-3" text="The present study was aimed at investigating the neurochemical, immunohistochemical and functional recovery of peripheral and central terminals of capsaicin-lesioned afferents following administration of recombinant human NGF-beta (rhNGF-beta).">
            <entity id="DS3.d949.s3.e0" origId="2548" charOffset="147-157" type="compound" text="capsaicin-"/>
            <entity id="DS3.d949.s3.e1" origId="P01138" charOffset="204-230" type="protein" text="recombinant human NGF-beta"/>
            <pair e1="DS3.d949.s3.e0" e2="DS3.d949.s3.e1" id="DS3.d949.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d949.s4" origId="9974123-9" text="In the paw skin, the CGRP-immunoreactive (CGRP-IR) nerve endings were restricted to a fragmentary subepidermal plexus after the capsaicin treatment, whereas the subsequent NGF treatment caused a bilateral recovery of the subepidermal plexus and an intact reinnervation of the epidermis and blood vessels with free nerve terminals.">
            <entity id="DS3.d949.s4.e0" origId="P01256,P01257,A0A0G2JSX2" charOffset="21-25" type="protein" text="CGRP"/>
            <entity id="DS3.d949.s4.e1" origId="P01256,P01257,A0A0G2JSX2" charOffset="42-46" type="protein" text="CGRP"/>
            <entity id="DS3.d949.s4.e2" origId="1548943" charOffset="128-137" type="compound" text="capsaicin"/>
            <pair e1="DS3.d949.s4.e2" e2="DS3.d949.s4.e0" id="DS3.d949.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d950" origId="9974124">
        <sentence id="DS3.d950.s0" origId="9974124-6" text="Reverse-phase HPLC analysis of ODN-LI showed that in control nerve extracts, the major immunoreactive peak co-elutes with triakontatetraneuropeptide (TTN).">
            <entity id="DS3.d950.s0.e0" origId="78673848" charOffset="31-34" type="compound" text="ODN"/>
            <entity id="DS3.d950.s0.e1" origId="P11030,M0RDC5" charOffset="122-148" type="protein" text="triakontatetraneuropeptide"/>
            <pair e1="DS3.d950.s0.e0" e2="DS3.d950.s0.e1" id="DS3.d950.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d951" origId="9974125">
        <sentence id="DS3.d951.s0" origId="9974125-0" text="Net efflux of cysteine, glutathione and related metabolites from rat hippocampal slices during oxygen/glucose deprivation: dependence on gamma-glutamyl transpeptidase.">
            <entity id="DS3.d951.s0.e0" origId="5862,90793998" charOffset="14-22" type="compound" text="cysteine"/>
            <entity id="DS3.d951.s0.e1" origId="124886,20725278" charOffset="24-35" type="compound" text="glutathione"/>
            <entity id="DS3.d951.s0.e2" origId="977" charOffset="95-101" type="compound" text="oxygen"/>
            <entity id="DS3.d951.s0.e3" origId="206,5793,64689,79025" charOffset="102-109" type="compound" text="glucose"/>
            <entity id="DS3.d951.s0.e4" origId="P07314" charOffset="137-166" type="protein" text="gamma-glutamyl transpeptidase"/>
            <pair e1="DS3.d951.s0.e1" e2="DS3.d951.s0.e4" id="DS3.d951.s0.i0" interaction="False" />
            <pair e1="DS3.d951.s0.e0" e2="DS3.d951.s0.e4" id="DS3.d951.s0.i1" interaction="False" />
            <pair e1="DS3.d951.s0.e2" e2="DS3.d951.s0.e4" id="DS3.d951.s0.i2" interaction="False" />
            <pair e1="DS3.d951.s0.e3" e2="DS3.d951.s0.e4" id="DS3.d951.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d951.s1" origId="9974125-2" text="In the present study, we have examined how blockage of gamma-glutamyl transpeptidase, the key enzyme in glutathione degradation, influences the extracellular concentrations of glutathione, cysteine and related metabolites during anoxia/aglycemia of rat hippocampal slices.">
            <entity id="DS3.d951.s1.e0" origId="P07314" charOffset="55-84" type="protein" text="gamma-glutamyl transpeptidase"/>
            <entity id="DS3.d951.s1.e1" origId="124886,20725278" charOffset="104-115" type="compound" text="glutathione"/>
            <entity id="DS3.d951.s1.e2" origId="124886,20725278" charOffset="176-187" type="compound" text="glutathione"/>
            <entity id="DS3.d951.s1.e3" origId="5862,90793998" charOffset="189-197" type="compound" text="cysteine"/>
            <pair e1="DS3.d951.s1.e1" e2="DS3.d951.s1.e0" id="DS3.d951.s1.i0" interaction="False" />
            <pair e1="DS3.d951.s1.e3" e2="DS3.d951.s1.e0" id="DS3.d951.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d951.s2" origId="9974125-4" text="These increases in net efflux of cysteine, cysteine sulfinate, gamma-glutamyl-glutamate and gamma-glutamyl-glutamine were reduced or blocked by acivicin, an inhibitor of gamma-glutamyl transpeptidase.">
            <entity id="DS3.d951.s2.e0" origId="5862,90793998" charOffset="33-41" type="compound" text="cysteine"/>
            <entity id="DS3.d951.s2.e1" origId="1549098,109" charOffset="43-61" type="compound" text="cysteine sulfinate"/>
            <entity id="DS3.d951.s2.e2" origId="439500" charOffset="69-87" type="compound" text="glutamyl-glutamate"/>
            <entity id="DS3.d951.s2.e3" origId="10171586" charOffset="98-116" type="compound" text="glutamyl-glutamine"/>
            <entity id="DS3.d951.s2.e4" origId="294641" charOffset="144-152" type="compound" text="acivicin"/>
            <entity id="DS3.d951.s2.e5" origId="P07314" charOffset="170-199" type="protein" text="gamma-glutamyl transpeptidase"/>
            <pair e1="DS3.d951.s2.e3" e2="DS3.d951.s2.e5" id="DS3.d951.s2.i0" interaction="False" />
            <pair e1="DS3.d951.s2.e4" e2="DS3.d951.s2.e5" id="DS3.d951.s2.i1" interaction="False" />
            <pair e1="DS3.d951.s2.e2" e2="DS3.d951.s2.e5" id="DS3.d951.s2.i2" interaction="False" />
            <pair e1="DS3.d951.s2.e1" e2="DS3.d951.s2.e5" id="DS3.d951.s2.i3" interaction="False" />
            <pair e1="DS3.d951.s2.e0" e2="DS3.d951.s2.e5" id="DS3.d951.s2.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d951.s3" origId="9974125-8" text="The results suggest that gamma-glutamyl transpeptidase may be involved in the regulation of the extracellular concentrations of cysteine, several gamma-glutamyl-containing dipeptides and glutathione but not glutamate during ischemia.">
            <entity id="DS3.d951.s3.e0" origId="P07314" charOffset="25-54" type="protein" text="gamma-glutamyl transpeptidase"/>
            <entity id="DS3.d951.s3.e1" origId="5862,90793998" charOffset="128-136" type="compound" text="cysteine"/>
            <entity id="DS3.d951.s3.e2" origId="193305" charOffset="25-39" type="compound" text="gamma-glutamyl"/>
            <entity id="DS3.d951.s3.e3" origId="124886,20725278" charOffset="187-198" type="compound" text="glutathione"/>
            <entity id="DS3.d951.s3.e4" origId="33032,23327,611,57109091" charOffset="207-216" type="compound" text="glutamate"/>
            <pair e1="DS3.d951.s3.e2" e2="DS3.d951.s3.e0" id="DS3.d951.s3.i0" interaction="False" />
            <pair e1="DS3.d951.s3.e3" e2="DS3.d951.s3.e0" id="DS3.d951.s3.i1" interaction="False" />
            <pair e1="DS3.d951.s3.e1" e2="DS3.d951.s3.e0" id="DS3.d951.s3.i2" interaction="False" />
            <pair e1="DS3.d951.s3.e4" e2="DS3.d951.s3.e0" id="DS3.d951.s3.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d952" origId="9974126">
        <sentence id="DS3.d952.s0" origId="9974126-3" text="In the present study, we investigated the effect of chronic EtOH (4-day inhalation) on the CB1 agonist stimulated guanosine-5'-O-(3-(35S)thio)-triphosphate ((35S)GTP gamma S) binding in SPM from mouse.">
            <entity id="DS3.d952.s0.e0" origId="P47746" charOffset="91-94" type="protein" text="CB1"/>
            <entity id="DS3.d952.s0.e1" origId="6802" charOffset="114-123" type="compound" text="guanosine"/>
            <entity id="DS3.d952.s0.e2" origId="6830" charOffset="162-165" type="compound" text="GTP"/>
            <pair e1="DS3.d952.s0.e2" e2="DS3.d952.s0.e0" id="DS3.d952.s0.i0" interaction="False" />
            <pair e1="DS3.d952.s0.e1" e2="DS3.d952.s0.e0" id="DS3.d952.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d952.s1" origId="9974126-8" text="The pharmacological specificity of CP55,940 stimulated (35S)GTP gamma S binding in SPM was examined with CB1 receptor antagonist, SR141716A and these studies indicated that CP55,940 stimulated (35S)GTP gamma S binding was blocked by SR141716A with a decrease (P &amp;lt; 0.05) in the IC50 values in the SPM from chronic EtOH group.">
            <entity id="DS3.d952.s1.e0" origId="104895" charOffset="35-43" type="compound" text="CP55,940"/>
            <entity id="DS3.d952.s1.e1" origId="6830" charOffset="60-63" type="compound" text="GTP"/>
            <entity id="DS3.d952.s1.e2" origId="P47746" charOffset="105-108" type="protein" text="CB1"/>
            <entity id="DS3.d952.s1.e3" origId="104850" charOffset="130-139" type="compound" text="SR141716A"/>
            <entity id="DS3.d952.s1.e4" origId="104895" charOffset="173-181" type="compound" text="CP55,940"/>
            <entity id="DS3.d952.s1.e5" origId="6830" charOffset="198-201" type="compound" text="GTP"/>
            <entity id="DS3.d952.s1.e6" origId="104850" charOffset="233-242" type="compound" text="SR141716A"/>
            <pair e1="DS3.d952.s1.e1" e2="DS3.d952.s1.e2" id="DS3.d952.s1.i0" interaction="False" />
            <pair e1="DS3.d952.s1.e0" e2="DS3.d952.s1.e2" id="DS3.d952.s1.i1" interaction="False" />
            <pair e1="DS3.d952.s1.e3" e2="DS3.d952.s1.e2" id="DS3.d952.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d953" origId="9974130">
        <sentence id="DS3.d953.s0" origId="9974130-1" text="In this study we examined blood pressure and heart rate responses to intrathecal administration of a synthetic NK1-receptor agonist, H2N-(CH2)4-CO-Phe-Phe-Pro-NmeLeu-Met-NH2 (GR 73,632), in spontaneously hypertensive rats (SHR) and their progenitor strain, the Wistar-Kyoto rat (WKY).">
            <entity id="DS3.d953.s0.e0" origId="P14600" charOffset="111-123" type="protein" text="NK1-receptor"/>
            <entity id="DS3.d953.s0.e1" origId="4069131" charOffset="151-158" type="compound" text="Phe-Pro"/>
            <pair e1="DS3.d953.s0.e1" e2="DS3.d953.s0.e0" id="DS3.d953.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d953.s1" origId="9974130-6" text="Prior administration of the NK1-receptor antagonist (3 aR,7aR)-7,7-diphenyl-2-(1-imino-2(methoxyphenyl)ethyl) perhydroisoindol-4-one (RP 67,580) significantly reduced the pressor response in WKY but not SHR.">
            <entity id="DS3.d953.s1.e0" origId="P14600" charOffset="28-40" type="protein" text="NK1-receptor"/>
            <entity id="DS3.d953.s1.e1" origId="23134249" charOffset="103-108" type="compound" text="ethyl"/>
            <entity id="DS3.d953.s1.e2" origId="19957562" charOffset="110-132" type="compound" text="perhydroisoindol-4-one"/>
            <pair e1="DS3.d953.s1.e2" e2="DS3.d953.s1.e0" id="DS3.d953.s1.i0" interaction="False" />
            <pair e1="DS3.d953.s1.e1" e2="DS3.d953.s1.e0" id="DS3.d953.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d954" origId="9974134">
        <sentence id="DS3.d954.s0" origId="9974134-3" text="We have used optical imaging of the styryl dye, FM1-43, which selectively labels synaptic vesicles, to investigate potential presynaptic effects of BDNF.">
            <entity id="DS3.d954.s0.e0" origId="446659" charOffset="48-51" type="compound" text="FM1"/>
            <entity id="DS3.d954.s0.e1" origId="P23560,A0A0E3SU01" charOffset="148-152" type="protein" text="BDNF"/>
            <pair e1="DS3.d954.s0.e0" e2="DS3.d954.s0.e1" id="DS3.d954.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d954.s1" origId="9974134-6" text="BDNF-dependent enhancement of exocytosis was blocked by the tyrosine kinase inhibitor, K252a, but not by K252b, consistent with signalling via the TrkB receptor.">
            <entity id="DS3.d954.s1.e0" origId="P23560,A0A0E3SU01" charOffset="0-4" type="protein" text="BDNF"/>
            <entity id="DS3.d954.s1.e1" origId="6057,90983769" charOffset="60-68" type="compound" text="tyrosine"/>
            <entity id="DS3.d954.s1.e2" origId="53378893" charOffset="69-85" type="compound" text="kinase inhibitor"/>
            <entity id="DS3.d954.s1.e3" origId="9846716" charOffset="105-110" type="compound" text="K252b"/>
            <pair e1="DS3.d954.s1.e2" e2="DS3.d954.s1.e0" id="DS3.d954.s1.i0" interaction="False" />
            <pair e1="DS3.d954.s1.e3" e2="DS3.d954.s1.e0" id="DS3.d954.s1.i1" interaction="False" />
            <pair e1="DS3.d954.s1.e1" e2="DS3.d954.s1.e0" id="DS3.d954.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d954.s2" origId="9974134-8" text="Addition of the inhibitors of RNA synthesis, actinomycin D, or 5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole (DRB), did not affect the enhancement of exocytosis produced by BDNF.">
            <entity id="DS3.d954.s2.e0" origId="24898154" charOffset="85-112" type="compound" text="ribofuranosyl benzimidazole"/>
            <entity id="DS3.d954.s2.e1" origId="3165,5894,59910845,6610267" charOffset="114-117" type="compound" text="DRB"/>
            <entity id="DS3.d954.s2.e2" origId="P23560,A0A0E3SU01" charOffset="177-181" type="protein" text="BDNF"/>
            <pair e1="DS3.d954.s2.e0" e2="DS3.d954.s2.e2" id="DS3.d954.s2.i0" interaction="False" />
            <pair e1="DS3.d954.s2.e1" e2="DS3.d954.s2.e2" id="DS3.d954.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d954.s3" origId="9974134-9" text="However, the effect of BDNF was blocked by the inhibitors of translation, cycloheximide or anisomycin.">
            <entity id="DS3.d954.s3.e0" origId="P23560,A0A0E3SU01" charOffset="23-27" type="protein" text="BDNF"/>
            <entity id="DS3.d954.s3.e1" origId="6197" charOffset="74-87" type="compound" text="cycloheximide"/>
            <entity id="DS3.d954.s3.e2" origId="253602" charOffset="91-101" type="compound" text="anisomycin"/>
            <pair e1="DS3.d954.s3.e2" e2="DS3.d954.s3.e0" id="DS3.d954.s3.i0" interaction="False" />
            <pair e1="DS3.d954.s3.e1" e2="DS3.d954.s3.e0" id="DS3.d954.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d955" origId="9974143">
        <sentence id="DS3.d955.s0" origId="9974143-4" text="The resulting neurodegeneration is estimated by (a) propidium iodide (PI) uptake, (b) lactate dehydrogenase (LDH) efflux to the culture medium, (c) ordinary Nissl cell staining, (d) staining by the neurodegenerative marker Fluoro-Jade (FJ), (e) neuronal microtubule degeneration by immunohistochemical staining for microtubule-associated protein 2 (MAP2), and (f) Timm sulphide silver staining for heavy metal alterations.">
            <entity id="DS3.d955.s0.e0" origId="4939" charOffset="52-68" type="compound" text="propidium iodide"/>
            <entity id="DS3.d955.s0.e1" origId="612" charOffset="86-93" type="compound" text="lactate"/>
            <entity id="DS3.d955.s0.e2" origId="P11137,A0A024R3Y8,A0A024R407,A0A024R409,Q6NYC5" charOffset="315-347" type="protein" text="microtubule-associated protein 2"/>
            <entity id="DS3.d955.s0.e3" origId="P11137,A0A024R3Y8,A0A024R407,A0A024R409,Q6NYC5" charOffset="349-353" type="protein" text="MAP2"/>
            <entity id="DS3.d955.s0.e4" origId="23954" charOffset="378-384" type="compound" text="silver"/>
            <pair e1="DS3.d955.s0.e0" e2="DS3.d955.s0.e3" id="DS3.d955.s0.i0" interaction="False" />
            <pair e1="DS3.d955.s0.e0" e2="DS3.d955.s0.e2" id="DS3.d955.s0.i1" interaction="False" />
            <pair e1="DS3.d955.s0.e4" e2="DS3.d955.s0.e3" id="DS3.d955.s0.i2" interaction="False" />
            <pair e1="DS3.d955.s0.e4" e2="DS3.d955.s0.e2" id="DS3.d955.s0.i3" interaction="False" />
            <pair e1="DS3.d955.s0.e1" e2="DS3.d955.s0.e3" id="DS3.d955.s0.i4" interaction="False" />
            <pair e1="DS3.d955.s0.e1" e2="DS3.d955.s0.e2" id="DS3.d955.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d955.s1" origId="9974143-9" text="A change in Timm sulphide silver staining in deep central parts of some control cultures, corresponds to areas with loss of cells in cell staining, loss of MAP2 staining, PI uptake, and FJ staining.">
            <entity id="DS3.d955.s1.e0" origId="23954" charOffset="26-32" type="compound" text="silver"/>
            <entity id="DS3.d955.s1.e1" origId="P11137,A0A024R3Y8,A0A024R407,A0A024R409,Q6NYC5" charOffset="156-160" type="protein" text="MAP2"/>
            <pair e1="DS3.d955.s1.e0" e2="DS3.d955.s1.e1" id="DS3.d955.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d956" origId="9974151">
        <sentence id="DS3.d956.s0" origId="9974151-2" text="Evidence is presented for the existence of STTm/STTl, STTc/STTi, STT/SMT, STT/SRT, SCT/DCPS, SST/DCPS, SCT/SST, STT/SHT, STeT/SHT, STeTs and other doubly or multiply projecting spinal neurons that have been anatomically and physiologically identified and named based on the locations of the cells of origin and their terminations in the brain.">
            <entity id="DS3.d956.s0.e0" origId="81801" charOffset="54-58" type="compound" text="STTc"/>
            <entity id="DS3.d956.s0.e1" origId="16448368" charOffset="43-46" type="compound" text="STT"/>
            <entity id="DS3.d956.s0.e2" origId="16448368" charOffset="48-51" type="compound" text="STT"/>
            <entity id="DS3.d956.s0.e3" origId="P09683" charOffset="83-86" type="protein" text="SCT"/>
            <entity id="DS3.d956.s0.e4" origId="Q96C86" charOffset="87-91" type="protein" text="DCPS"/>
            <entity id="DS3.d956.s0.e5" origId="Q96C86" charOffset="97-101" type="protein" text="DCPS"/>
            <entity id="DS3.d956.s0.e6" origId="P09683" charOffset="103-106" type="protein" text="SCT"/>
            <entity id="DS3.d956.s0.e7" origId="16448368" charOffset="48-51" type="compound" text="STT"/>
            <pair e1="DS3.d956.s0.e1" e2="DS3.d956.s0.e4" id="DS3.d956.s0.i0" interaction="False" />
            <pair e1="DS3.d956.s0.e1" e2="DS3.d956.s0.e3" id="DS3.d956.s0.i1" interaction="False" />
            <pair e1="DS3.d956.s0.e0" e2="DS3.d956.s0.e4" id="DS3.d956.s0.i2" interaction="False" />
            <pair e1="DS3.d956.s0.e0" e2="DS3.d956.s0.e3" id="DS3.d956.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d957" origId="9974152">
        <sentence id="DS3.d957.s0" origId="9974152-9" text="However, the role of mGluRs in LTP induction continues to be a source of dispute, and resolution of the question of the exact involvement of mGluRs in the induction of LTP will have to await the production of more selective ligands and of selective gene knockouts.">
            <entity id="DS3.d957.s0.e0" origId="Q9CXJ1" charOffset="21-27" type="protein" text="mGluRs"/>
            <entity id="DS3.d957.s0.e1" origId="56846361" charOffset="31-34" type="compound" text="LTP"/>
            <entity id="DS3.d957.s0.e2" origId="Q9CXJ1" charOffset="141-147" type="protein" text="mGluRs"/>
            <entity id="DS3.d957.s0.e3" origId="56846361" charOffset="168-171" type="compound" text="LTP"/>
            <pair e1="DS3.d957.s0.e1" e2="DS3.d957.s0.e0" id="DS3.d957.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d958" origId="9974153">
        <sentence id="DS3.d958.s0" origId="9974153-3" text="With the genetic linkage of mutations in the superoxide dismutase (SOD-1) gene with familial ALS patients, new avenues for study have become available including transgenic mice and culture models.">
            <entity id="DS3.d958.s0.e0" origId="5359597" charOffset="45-55" type="compound" text="superoxide"/>
            <entity id="DS3.d958.s0.e1" origId="P00441,V9HWC9" charOffset="67-72" type="protein" text="SOD-1"/>
            <pair e1="DS3.d958.s0.e0" e2="DS3.d958.s0.e1" id="DS3.d958.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d959" origId="9974157">
        <sentence id="DS3.d959.s0" origId="9974157-1" text="The expression of group I metabotropic glutamate receptors (mGluR1 and mGluR5) and inositol 1,4,5-trisphosphate receptor type 1 (IP3R1) mRNA was studied by in situ hybridization in the developing rat hippocampus after in utero hypoxia-ischemia.">
            <entity id="DS3.d959.s0.e0" origId="23327,33032,611,57109091" charOffset="39-48" type="compound" text="glutamate"/>
            <entity id="DS3.d959.s0.e1" origId="P97772,Q3V0U2,P23818,Q7TNB5,F6YNQ1" charOffset="60-66" type="protein" text="mGluR1"/>
            <entity id="DS3.d959.s0.e2" origId="Q8C825,Q3UZT1,Q8BRT2,Q8BQZ0" charOffset="71-77" type="protein" text="mGluR5"/>
            <entity id="DS3.d959.s0.e3" origId="892" charOffset="83-91" type="compound" text="inositol"/>
            <entity id="DS3.d959.s0.e4" origId="19432134" charOffset="98-111" type="compound" text="trisphosphate"/>
            <entity id="DS3.d959.s0.e5" origId="P29994,C7E1V2,F1LQX8,Q5BJS8" charOffset="129-134" type="protein" text="IP3R1"/>
            <pair e1="DS3.d959.s0.e4" e2="DS3.d959.s0.e2" id="DS3.d959.s0.i0" interaction="False" />
            <pair e1="DS3.d959.s0.e4" e2="DS3.d959.s0.e5" id="DS3.d959.s0.i1" interaction="False" />
            <pair e1="DS3.d959.s0.e4" e2="DS3.d959.s0.e1" id="DS3.d959.s0.i2" interaction="False" />
            <pair e1="DS3.d959.s0.e0" e2="DS3.d959.s0.e2" id="DS3.d959.s0.i3" interaction="False" />
            <pair e1="DS3.d959.s0.e0" e2="DS3.d959.s0.e5" id="DS3.d959.s0.i4" interaction="False" />
            <pair e1="DS3.d959.s0.e0" e2="DS3.d959.s0.e1" id="DS3.d959.s0.i5" interaction="False" />
            <pair e1="DS3.d959.s0.e3" e2="DS3.d959.s0.e2" id="DS3.d959.s0.i6" interaction="False" />
            <pair e1="DS3.d959.s0.e3" e2="DS3.d959.s0.e5" id="DS3.d959.s0.i7" interaction="False" />
            <pair e1="DS3.d959.s0.e3" e2="DS3.d959.s0.e1" id="DS3.d959.s0.i8" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d960" origId="9974161">
        <sentence id="DS3.d960.s0" origId="9974161-8" text="Among immunopanned cells that responded to FBS by expression of GFAP, both process-bearing (similar to type 2 astroglia) and flattened, polygonal (similar to type 1 astroglia) GFAP+ cells were observed.">
            <entity id="DS3.d960.s0.e0" origId="P47819" charOffset="64-68" type="protein" text="GFAP"/>
            <entity id="DS3.d960.s0.e1" origId="71405072" charOffset="136-145" type="compound" text="polygonal"/>
            <entity id="DS3.d960.s0.e2" origId="P47819" charOffset="176-180" type="protein" text="GFAP"/>
            <pair e1="DS3.d960.s0.e1" e2="DS3.d960.s0.e0" id="DS3.d960.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d961" origId="9974163">
        <sentence id="DS3.d961.s0" origId="9974163-0" text="Neurotrophic factors BDNF and GDNF protect embryonic chick spinal cord motoneurons from ethanol neurotoxicity in vivo.">
            <entity id="DS3.d961.s0.e0" origId="P25429,K4MNE5" charOffset="21-25" type="protein" text="BDNF"/>
            <entity id="DS3.d961.s0.e1" origId="F1NPM2" charOffset="30-34" type="protein" text="GDNF"/>
            <entity id="DS3.d961.s0.e2" origId="702" charOffset="88-95" type="compound" text="ethanol"/>
            <pair e1="DS3.d961.s0.e2" e2="DS3.d961.s0.e0" id="DS3.d961.s0.i0" interaction="False" />
            <pair e1="DS3.d961.s0.e2" e2="DS3.d961.s0.e1" id="DS3.d961.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d961.s1" origId="9974163-6" text="The concurrent delivery of BDNF or GDNF with ethanol to the embryonic chick from E10 to E15 was designed to examine the capacity of these NTFs to provide in vivo neuroprotection for this ethanol-sensitive motoneuron population.">
            <entity id="DS3.d961.s1.e0" origId="P25429,K4MNE5" charOffset="27-31" type="protein" text="BDNF"/>
            <entity id="DS3.d961.s1.e1" origId="F1NPM2" charOffset="35-39" type="protein" text="GDNF"/>
            <entity id="DS3.d961.s1.e2" origId="702" charOffset="45-52" type="compound" text="ethanol"/>
            <entity id="DS3.d961.s1.e3" origId="445974" charOffset="81-84" type="compound" text="E10"/>
            <entity id="DS3.d961.s1.e4" origId="702" charOffset="187-194" type="compound" text="ethanol"/>
            <pair e1="DS3.d961.s1.e3" e2="DS3.d961.s1.e0" id="DS3.d961.s1.i0" interaction="False" />
            <pair e1="DS3.d961.s1.e3" e2="DS3.d961.s1.e1" id="DS3.d961.s1.i1" interaction="False" />
            <pair e1="DS3.d961.s1.e2" e2="DS3.d961.s1.e0" id="DS3.d961.s1.i2" interaction="False" />
            <pair e1="DS3.d961.s1.e2" e2="DS3.d961.s1.e1" id="DS3.d961.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d961.s2" origId="9974163-7" text="Analysis of motoneuron numbers indicated that both BDNF and GDNF provided protection to developing spinal cord motoneurons from ethanol toxicity, restoring motoneuron numbers to control levels.">
            <entity id="DS3.d961.s2.e0" origId="P25429,K4MNE5" charOffset="51-55" type="protein" text="BDNF"/>
            <entity id="DS3.d961.s2.e1" origId="F1NPM2" charOffset="60-64" type="protein" text="GDNF"/>
            <entity id="DS3.d961.s2.e2" origId="702" charOffset="128-135" type="compound" text="ethanol"/>
            <pair e1="DS3.d961.s2.e2" e2="DS3.d961.s2.e0" id="DS3.d961.s2.i0" interaction="False" />
            <pair e1="DS3.d961.s2.e2" e2="DS3.d961.s2.e1" id="DS3.d961.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d962" origId="9974164">
        <sentence id="DS3.d962.s0" origId="9974164-5" text="on postnatal day 7 (P7) and then examined at P14, P45, and P75.">
            <entity id="DS3.d962.s0.e0" origId="P02692" charOffset="45-48" type="protein" text="P14"/>
            <entity id="DS3.d962.s0.e1" origId="24779676" charOffset="50-53" type="compound" text="P45"/>
            <entity id="DS3.d962.s0.e2" origId="P07174,G3V6P1" charOffset="59-62" type="protein" text="P75"/>
            <pair e1="DS3.d962.s0.e1" e2="DS3.d962.s0.e2" id="DS3.d962.s0.i0" interaction="False" />
            <pair e1="DS3.d962.s0.e1" e2="DS3.d962.s0.e0" id="DS3.d962.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d962.s1" origId="9974164-6" text="Using three-dimensional, non-biased cell counting, neuronal loss was observed in the CA3 subfield of the hippocampal formation at P45 and P75 in animals administered 10 nmol KA, as compared to animals administered 5 nmol KA or artificial cerebrospinal fluid.">
            <entity id="DS3.d962.s1.e0" origId="P14141" charOffset="85-88" type="protein" text="CA3"/>
            <entity id="DS3.d962.s1.e1" origId="24779676" charOffset="130-133" type="compound" text="P45"/>
            <entity id="DS3.d962.s1.e2" origId="P07174,G3V6P1" charOffset="138-141" type="protein" text="P75"/>
            <pair e1="DS3.d962.s1.e1" e2="DS3.d962.s1.e0" id="DS3.d962.s1.i0" interaction="False" />
            <pair e1="DS3.d962.s1.e1" e2="DS3.d962.s1.e2" id="DS3.d962.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d963" origId="9974165">
        <sentence id="DS3.d963.s0" origId="9974165-13" text="However, the size of barrels in S1, as measured in tangential sections stained for the GABAA receptor alpha 1 subunit, was enlarged upon chronic, topical blockade of NMDA receptors with MK-801 and was reduced to the same extent upon chronic exposure to BDNF.">
            <entity id="DS3.d963.s0.e0" origId="180081" charOffset="186-192" type="compound" text="MK-801"/>
            <entity id="DS3.d963.s0.e1" origId="P23363,A0A0G2K624,A0A0H2UI28" charOffset="253-257" type="protein" text="BDNF"/>
            <pair e1="DS3.d963.s0.e0" e2="DS3.d963.s0.e1" id="DS3.d963.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d963.s1" origId="9974165-9" text="Slices of Elvax polymer loaded with the N-methyl-D-asparate (NMDA) receptor antagonist MK-801 or with brain derived neurotrophic factor (BDNF) were placed unilaterally over the left parietal cortex in newborn animals.">
            <entity id="DS3.d963.s1.e0" origId="180081" charOffset="87-93" type="compound" text="MK-801"/>
            <entity id="DS3.d963.s1.e1" origId="P23363,A0A0G2K624,A0A0H2UI28" charOffset="102-135" type="protein" text="brain derived neurotrophic factor"/>
            <entity id="DS3.d963.s1.e2" origId="P23363,A0A0G2K624,A0A0H2UI28" charOffset="137-141" type="protein" text="BDNF"/>
            <pair e1="DS3.d963.s1.e0" e2="DS3.d963.s1.e2" id="DS3.d963.s1.i0" interaction="False" />
            <pair e1="DS3.d963.s1.e0" e2="DS3.d963.s1.e1" id="DS3.d963.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d964" origId="9974170">
        <sentence id="DS3.d964.s0" origId="9974170-0" text="Bcl-2 and Bax expression following methylazoxymethanol acetate-induced apoptosis in the external granule cell layer of the developing rat cerebellum.">
            <entity id="DS3.d964.s0.e0" origId="P49950" charOffset="0-5" type="protein" text="Bcl-2"/>
            <entity id="DS3.d964.s0.e1" origId="Q9JKL3,G3V8T9" charOffset="10-13" type="protein" text="Bax"/>
            <entity id="DS3.d964.s0.e2" origId="11606,5363199" charOffset="35-62" type="compound" text="methylazoxymethanol acetate"/>
            <pair e1="DS3.d964.s0.e2" e2="DS3.d964.s0.e0" id="DS3.d964.s0.i0" interaction="False" />
            <pair e1="DS3.d964.s0.e2" e2="DS3.d964.s0.e1" id="DS3.d964.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d964.s1" origId="9974170-1" text="Since Bcl-2 protects a variety of cell types from programmed cell death, whereas Bax promotes apoptosis, the present study examines Bcl-2 and Bax proteins, and Bcl-2 and Bax mRNA expression in the developing cerebellum of the rat following methylazoxymethanol (MAM) acetate administration by using immunohistochemistry, Western blotting and Northern blotting.">
            <entity id="DS3.d964.s1.e0" origId="P49950" charOffset="6-11" type="protein" text="Bcl-2"/>
            <entity id="DS3.d964.s1.e1" origId="Q9JKL3,G3V8T9" charOffset="81-84" type="protein" text="Bax"/>
            <entity id="DS3.d964.s1.e2" origId="P49950" charOffset="132-137" type="protein" text="Bcl-2"/>
            <entity id="DS3.d964.s1.e3" origId="Q9JKL3,G3V8T9" charOffset="142-145" type="protein" text="Bax"/>
            <entity id="DS3.d964.s1.e4" origId="P49950" charOffset="132-137" type="protein" text="Bcl-2"/>
            <entity id="DS3.d964.s1.e5" origId="Q9JKL3,G3V8T9" charOffset="142-145" type="protein" text="Bax"/>
            <entity id="DS3.d964.s1.e6" origId="11554,5460323,6433205" charOffset="240-259" type="compound" text="methylazoxymethanol"/>
            <entity id="DS3.d964.s1.e7" origId="176" charOffset="266-273" type="compound" text="acetate"/>
            <pair e1="DS3.d964.s1.e6" e2="DS3.d964.s1.e0" id="DS3.d964.s1.i0" interaction="False" />
            <pair e1="DS3.d964.s1.e6" e2="DS3.d964.s1.e1" id="DS3.d964.s1.i1" interaction="False" />
            <pair e1="DS3.d964.s1.e7" e2="DS3.d964.s1.e0" id="DS3.d964.s1.i2" interaction="False" />
            <pair e1="DS3.d964.s1.e7" e2="DS3.d964.s1.e1" id="DS3.d964.s1.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d965" origId="9974171">
        <sentence id="DS3.d965.s0" origId="9974171-7" text="Given its predominance in the caudal regions of the striatum, 5-HT neurotransmission at the 5-HT2 receptor is suggested to play a central role in this mechanism.">
            <entity id="DS3.d965.s0.e0" origId="5202" charOffset="62-66" type="compound" text="5-HT"/>
            <entity id="DS3.d965.s0.e1" origId="P28223" charOffset="92-106" type="protein" text="5-HT2 receptor"/>
            <pair e1="DS3.d965.s0.e0" e2="DS3.d965.s0.e1" id="DS3.d965.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d966" origId="9974180">
        <sentence id="DS3.d966.s0" origId="9974180-2" text="Catalepsy, immobility, ataxia, or the impairment of complex behavioral acts are observed after acute administration of either natural and synthetic cannabinoid receptor agonists or the endogenous CB1 ligand anandamide.">
            <entity id="DS3.d966.s0.e0" origId="P21554,V5KA96,S5TLS4" charOffset="196-199" type="protein" text="CB1"/>
            <entity id="DS3.d966.s0.e1" origId="2185,5281969" charOffset="207-217" type="compound" text="anandamide"/>
            <pair e1="DS3.d966.s0.e1" e2="DS3.d966.s0.e0" id="DS3.d966.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d966.s1" origId="9974180-4" text="In the basal ganglia, the functionality of the anandamide-CB1 system is poorly understood.">
            <entity id="DS3.d966.s1.e0" origId="2185,5281969" charOffset="47-57" type="compound" text="anandamide"/>
            <entity id="DS3.d966.s1.e1" origId="P21554,V5KA96,S5TLS4" charOffset="58-61" type="protein" text="CB1"/>
            <pair e1="DS3.d966.s1.e0" e2="DS3.d966.s1.e1" id="DS3.d966.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d966.s2" origId="9974180-5" text="Dual effects are often observed after the administration of CB1 ligands in animal models of pharmacological manipulation of basal ganglia transmitter systems, indicating that the activity of the anandamide-CB1 system depends on the ongoing activation of the different elements of the basal ganglia.">
            <entity id="DS3.d966.s2.e0" origId="P21554,V5KA96,S5TLS4" charOffset="60-63" type="protein" text="CB1"/>
            <entity id="DS3.d966.s2.e1" origId="2185,5281969" charOffset="195-205" type="compound" text="anandamide"/>
            <entity id="DS3.d966.s2.e2" origId="P21554,V5KA96,S5TLS4" charOffset="206-209" type="protein" text="CB1"/>
            <pair e1="DS3.d966.s2.e1" e2="DS3.d966.s2.e0" id="DS3.d966.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d966.s3" origId="9974180-7" text="Additionally, a potential state-dependent bidirectional coupling of the CB1 receptor to the adenylate cyclase transduction system has also been described.">
            <entity id="DS3.d966.s3.e0" origId="P21554,V5KA96,S5TLS4" charOffset="72-75" type="protein" text="CB1"/>
            <entity id="DS3.d966.s3.e1" origId="6083" charOffset="92-101" type="compound" text="adenylate"/>
            <pair e1="DS3.d966.s3.e1" e2="DS3.d966.s3.e0" id="DS3.d966.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d967" origId="9974182">
        <sentence id="DS3.d967.s0" origId="9974182-1" text="Unprecedented developments in cannabinoid research within the past decade include discovery of a brain (CB1) and peripheral (CB2) receptor; endogenous ligands, anandamide, and 2-arachidonylglycerol; cannabinoid drug-induced partial and inverse agonism at CB1 receptors, antagonism of NMDA receptors and glutamate, and antioxidant activity; and preferential CB1 receptor localization in areas subserving spasticity, pain, abnormal involuntary movements, seizures, and amnesia.">
            <entity id="DS3.d967.s0.e0" origId="P21554,V5KA96,S5TLS4" charOffset="104-107" type="protein" text="CB1"/>
            <entity id="DS3.d967.s0.e1" origId="P34972,A0A024RAH7" charOffset="125-128" type="protein" text="CB2"/>
            <entity id="DS3.d967.s0.e2" origId="2185,5281969" charOffset="160-170" type="compound" text="anandamide"/>
            <entity id="DS3.d967.s0.e3" origId="5282280" charOffset="176-197" type="compound" text="2-arachidonylglycerol"/>
            <entity id="DS3.d967.s0.e4" origId="P21554,V5KA96,S5TLS4" charOffset="255-258" type="protein" text="CB1"/>
            <entity id="DS3.d967.s0.e5" origId="23327,33032,611,57109091" charOffset="303-312" type="compound" text="glutamate"/>
            <entity id="DS3.d967.s0.e6" origId="P21554,V5KA96,S5TLS4" charOffset="255-258" type="protein" text="CB1"/>
            <pair e1="DS3.d967.s0.e2" e2="DS3.d967.s0.e1" id="DS3.d967.s0.i0" interaction="False" />
            <pair e1="DS3.d967.s0.e2" e2="DS3.d967.s0.e0" id="DS3.d967.s0.i1" interaction="False" />
            <pair e1="DS3.d967.s0.e3" e2="DS3.d967.s0.e1" id="DS3.d967.s0.i2" interaction="False" />
            <pair e1="DS3.d967.s0.e3" e2="DS3.d967.s0.e0" id="DS3.d967.s0.i3" interaction="False" />
            <pair e1="DS3.d967.s0.e5" e2="DS3.d967.s0.e1" id="DS3.d967.s0.i4" interaction="False" />
            <pair e1="DS3.d967.s0.e5" e2="DS3.d967.s0.e0" id="DS3.d967.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d968" origId="9974194">
        <sentence id="DS3.d968.s0" origId="9974194-6" text="Among ALP, only 7% of the female athletes supplemented iron regularly compared to 37% of male ALP (P &amp;lt; 0.05) Overall, male athletes supplemented mostly on a regular basis and female athletes more on an occasional basis.">
            <entity id="DS3.d968.s0.e0" origId="P05187,B2R7C7" charOffset="6-9" type="protein" text="ALP"/>
            <entity id="DS3.d968.s0.e1" origId="23925,67172434" charOffset="55-59" type="compound" text="iron"/>
            <entity id="DS3.d968.s0.e2" origId="P05187,B2R7C7" charOffset="94-97" type="protein" text="ALP"/>
            <pair e1="DS3.d968.s0.e1" e2="DS3.d968.s0.e0" id="DS3.d968.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d969" origId="9974213">
        <sentence id="DS3.d969.s0" origId="9974213-1" text="Previous investigation has provided evidence for the control of electrogenic chloride secretion by pituitary adenylate cyclase-activating polypeptide (PACAP) across the rat epididymal epithelium using electrophysiological measurement of transepithelial transport in cultured epididymal system.">
            <entity id="DS3.d969.s0.e0" origId="312" charOffset="77-85" type="compound" text="chloride"/>
            <entity id="DS3.d969.s0.e1" origId="P13589" charOffset="99-149" type="protein" text="pituitary adenylate cyclase-activating polypeptide"/>
            <entity id="DS3.d969.s0.e2" origId="P13589" charOffset="151-156" type="protein" text="PACAP"/>
            <pair e1="DS3.d969.s0.e0" e2="DS3.d969.s0.e1" id="DS3.d969.s0.i0" interaction="False" />
            <pair e1="DS3.d969.s0.e0" e2="DS3.d969.s0.e2" id="DS3.d969.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d969.s1" origId="9974213-6" text="Much weaker immunostaining for PACAP, as compared to those found in other regions, was observed in the cauda epididymal tubules which are in close proximity to the vas deferens.">
            <entity id="DS3.d969.s1.e0" origId="P13589" charOffset="31-36" type="protein" text="PACAP"/>
            <entity id="DS3.d969.s1.e1" origId="6323535" charOffset="164-167" type="compound" text="vas"/>
            <pair e1="DS3.d969.s1.e1" e2="DS3.d969.s1.e0" id="DS3.d969.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d969.s2" origId="9974213-8" text="Together with the previous finding, the present results suggest that PACAP may exhibit a regional difference in its expression along the epididymal duct and it may act in a paracrine or autocrine fashion in the regulation of epididymal chloride secretion and hence fluid secretion, thus regulating epididymal and sperm functions along the epididymal duct.">
            <entity id="DS3.d969.s2.e0" origId="P13589" charOffset="69-74" type="protein" text="PACAP"/>
            <entity id="DS3.d969.s2.e1" origId="312" charOffset="236-244" type="compound" text="chloride"/>
            <pair e1="DS3.d969.s2.e1" e2="DS3.d969.s2.e0" id="DS3.d969.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d970" origId="9974214">
        <sentence id="DS3.d970.s0" origId="9974214-7" text="Furthermore, using confocal microscopy of isolated myocytes the authors demonstrate that the association of annexin VI with the sarcolemma is stable even after cells are treated with the intracellular calcium chelator BAPTA-AM, to greatly deplete cytosolic calcium levels.">
            <entity id="DS3.d970.s0.e0" origId="Q6IMZ3" charOffset="108-118" type="protein" text="annexin VI"/>
            <entity id="DS3.d970.s0.e1" origId="22044544,5460341" charOffset="201-208" type="compound" text="calcium"/>
            <entity id="DS3.d970.s0.e2" origId="2293" charOffset="218-226" type="compound" text="BAPTA-AM"/>
            <entity id="DS3.d970.s0.e3" origId="22044544,5460341" charOffset="257-264" type="compound" text="calcium"/>
            <pair e1="DS3.d970.s0.e1" e2="DS3.d970.s0.e0" id="DS3.d970.s0.i0" interaction="False" />
            <pair e1="DS3.d970.s0.e2" e2="DS3.d970.s0.e0" id="DS3.d970.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d971" origId="9974216">
        <sentence id="DS3.d971.s0" origId="9974216-4" text="ELISA quantitation was achieved by the addition of anti-zeta-crystallin antibodies to the DNA-zeta-crystallin complex, using a novel immunochemical avidin-biotin method.">
            <entity id="DS3.d971.s0.e0" origId="O97764" charOffset="56-71" type="protein" text="zeta-crystallin"/>
            <entity id="DS3.d971.s0.e1" origId="O97764" charOffset="94-109" type="protein" text="zeta-crystallin"/>
            <entity id="DS3.d971.s0.e2" origId="53700020" charOffset="155-161" type="compound" text="biotin"/>
            <pair e1="DS3.d971.s0.e2" e2="DS3.d971.s0.e0" id="DS3.d971.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d972" origId="9974223">
        <sentence id="DS3.d972.s0" origId="9974223-2" text="Lovastatin, an indirect inhibitor of protein prenylation, altered the processing of MRas1 protein, blocked the accumulation of MRas3 protein, and caused the MRas1/p20 protein complex to disappear in M. racemosus.">
            <entity id="DS3.d972.s0.e0" origId="53232" charOffset="0-10" type="compound" text="Lovastatin"/>
            <entity id="DS3.d972.s0.e1" origId="Q9BW30,A0A024R702" charOffset="163-166" type="protein" text="p20"/>
            <pair e1="DS3.d972.s0.e0" e2="DS3.d972.s0.e1" id="DS3.d972.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d972.s1" origId="9974223-6" text="Exogenous dibutyryl-cAMP initiated morphogenesis from hyphal (polar) growth to yeast-like (spherical) growth during spore germination and strongly prevented cell death which resulted from lovastatin treatment.">
            <entity id="DS3.d972.s1.e0" origId="P49913,J3KNB4" charOffset="20-24" type="protein" text="cAMP"/>
            <entity id="DS3.d972.s1.e1" origId="53232" charOffset="188-198" type="compound" text="lovastatin"/>
            <pair e1="DS3.d972.s1.e1" e2="DS3.d972.s1.e0" id="DS3.d972.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d972.s2" origId="9974223-7" text="Wortmannin added together with dibutyryl-cAMP showed a synergistic effect in the prevention of fungal cell death.">
            <entity id="DS3.d972.s2.e0" origId="312145" charOffset="0-10" type="compound" text="Wortmannin"/>
            <entity id="DS3.d972.s2.e1" origId="P49913,J3KNB4" charOffset="41-45" type="protein" text="cAMP"/>
            <pair e1="DS3.d972.s2.e0" e2="DS3.d972.s2.e1" id="DS3.d972.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d972.s3" origId="9974223-8" text="These data suggest that the regulation of lovastatin-induced cell death in Mucor requires a signal transduction pathway(s) involving cAMP whose function is specific to a particular developmental stage.">
            <entity id="DS3.d972.s3.e0" origId="53232" charOffset="42-52" type="compound" text="lovastatin"/>
            <entity id="DS3.d972.s3.e1" origId="P49913,J3KNB4" charOffset="133-137" type="protein" text="cAMP"/>
            <pair e1="DS3.d972.s3.e0" e2="DS3.d972.s3.e1" id="DS3.d972.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d973" origId="9974225">
        <sentence id="DS3.d973.s0" origId="9974225-1" text="Angle selective ENDOR of nitroxyl spin-labels is briefly reviewed to illustrate the methodology of structure analysis developed in our laboratory for characterizing catalytically competent intermediates of enzyme catalyzed reactions.">
            <entity id="DS3.d973.s0.e0" origId="8620" charOffset="16-21" type="compound" text="ENDOR"/>
            <entity id="DS3.d973.s0.e1" origId="945" charOffset="25-33" type="compound" text="nitroxyl"/>
            <entity id="DS3.d973.s0.e2" origId="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5" charOffset="34-38" type="protein" text="spin"/>
            <pair e1="DS3.d973.s0.e0" e2="DS3.d973.s0.e2" id="DS3.d973.s0.i0" interaction="False" />
            <pair e1="DS3.d973.s0.e1" e2="DS3.d973.s0.e2" id="DS3.d973.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d973.s1" origId="9974225-2" text="ENDOR structure determination of a reaction intermediate of alpha-chymotrypsin formed with a kinetically specific spin-labeled substrate and of an enzyme-inhibitor complex formed with a spin-labeled transition-state inhibitor analog is briefly described.">
            <entity id="DS3.d973.s1.e0" origId="8620" charOffset="0-5" type="compound" text="ENDOR"/>
            <entity id="DS3.d973.s1.e1" origId="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5" charOffset="114-118" type="protein" text="spin"/>
            <entity id="DS3.d973.s1.e2" origId="P78347,X5DR09,X5D939,Q499G6,A8K9W7,X5D2J9,X5DNP5" charOffset="186-190" type="protein" text="spin"/>
            <pair e1="DS3.d973.s1.e0" e2="DS3.d973.s1.e1" id="DS3.d973.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d974" origId="9974231">
        <sentence id="DS3.d974.s0" origId="9974231-1" text="The impact of performance context on subjective mental workload ratings was assessed with the Subjective Workload Assessment Technique (SWAT) and the NASA Task Load Index (TLX).">
            <entity id="DS3.d974.s0.e0" origId="6433156" charOffset="136-140" type="compound" text="SWAT"/>
            <entity id="DS3.d974.s0.e1" origId="O14649" charOffset="155-159" type="protein" text="Task"/>
            <entity id="DS3.d974.s0.e2" origId="5289474" charOffset="172-175" type="compound" text="TLX"/>
            <pair e1="DS3.d974.s0.e0" e2="DS3.d974.s0.e1" id="DS3.d974.s0.i0" interaction="False" />
            <pair e1="DS3.d974.s0.e2" e2="DS3.d974.s0.e1" id="DS3.d974.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d975" origId="9974375">
        <sentence id="DS3.d975.s0" origId="9974375-2" text="At first thrombin converts fibrinogen to fibrin molecules which in vivo form soluble complexes with fibrinogen.">
            <entity id="DS3.d975.s0.e0" origId="90470996" charOffset="9-17" type="compound" text="thrombin"/>
            <entity id="DS3.d975.s0.e1" origId="P02675,V9HVY1" charOffset="27-37" type="protein" text="fibrinogen"/>
            <entity id="DS3.d975.s0.e2" origId="P02675,V9HVY1" charOffset="100-110" type="protein" text="fibrinogen"/>
            <pair e1="DS3.d975.s0.e0" e2="DS3.d975.s0.e1" id="DS3.d975.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d976" origId="9974378">
        <sentence id="DS3.d976.s0" origId="9974378-3" text="We, therefore, studied the associations between fasting serum oestradiol, plasma cholesterol and triglyceride, and Factor VII activity, PAI activity, t-PA antigen, fibrin D-dimer, and vWF antigen in 10 women, each sampled on 6 occasions between 10 weeks and 35 weeks during normal pregnancy.">
            <entity id="DS3.d976.s0.e0" origId="5997" charOffset="81-92" type="compound" text="cholesterol"/>
            <entity id="DS3.d976.s0.e1" origId="P00750" charOffset="150-154" type="protein" text="t-PA"/>
            <entity id="DS3.d976.s0.e2" origId="P04275" charOffset="184-187" type="protein" text="vWF"/>
            <pair e1="DS3.d976.s0.e0" e2="DS3.d976.s0.e2" id="DS3.d976.s0.i0" interaction="False" />
            <pair e1="DS3.d976.s0.e0" e2="DS3.d976.s0.e1" id="DS3.d976.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d977" origId="9974380">
        <sentence id="DS3.d977.s0" origId="9974380-2" text="Here, RAD30 is shown to encode a DNA polymerase that can replicate efficiently past a thymine-thymine cis-syn cyclobutane dimer, a lesion that normally blocks DNA polymerases.">
            <entity id="DS3.d977.s0.e0" origId="Q04049" charOffset="6-11" type="protein" text="RAD30"/>
            <entity id="DS3.d977.s0.e1" origId="1135" charOffset="86-93" type="compound" text="thymine"/>
            <entity id="DS3.d977.s0.e2" origId="1135" charOffset="94-101" type="compound" text="thymine"/>
            <pair e1="DS3.d977.s0.e1" e2="DS3.d977.s0.e0" id="DS3.d977.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d977.s1" origId="9974380-3" text="When incubated in vitro with all four nucleotides, RAD30 incorporates two adenines opposite the thymine-thymine dimer.">
            <entity id="DS3.d977.s1.e0" origId="Q04049" charOffset="51-56" type="protein" text="RAD30"/>
            <entity id="DS3.d977.s1.e1" origId="1135" charOffset="96-103" type="compound" text="thymine"/>
            <entity id="DS3.d977.s1.e2" origId="1135" charOffset="104-111" type="compound" text="thymine"/>
            <pair e1="DS3.d977.s1.e1" e2="DS3.d977.s1.e0" id="DS3.d977.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d978" origId="9974389">
        <sentence id="DS3.d978.s0" origId="9974389-1" text="An alanyl-alanyl-phenylalanyl-7-amino-4-methylcoumarin-hydrolyzing protease particle copurifying with 26S proteasomes was isolated and identified as tripeptidyl peptidase II (TPPII), a cytosolic subtilisin-like peptidase of unknown function.">
            <entity id="DS3.d978.s0.e0" origId="24753895" charOffset="3-54" type="compound" text="alanyl-alanyl-phenylalanyl-7-amino-4-methylcoumarin"/>
            <entity id="DS3.d978.s0.e1" origId="P29144,Q5VZU9" charOffset="149-173" type="protein" text="tripeptidyl peptidase II"/>
            <entity id="DS3.d978.s0.e2" origId="P29144,Q5VZU9" charOffset="175-180" type="protein" text="TPPII"/>
            <pair e1="DS3.d978.s0.e0" e2="DS3.d978.s0.e2" id="DS3.d978.s0.i0" interaction="False" />
            <pair e1="DS3.d978.s0.e0" e2="DS3.d978.s0.e1" id="DS3.d978.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d979" origId="9974390">
        <sentence id="DS3.d979.s0" origId="9974390-0" text="Role of NADH shuttle system in glucose-induced activation of mitochondrial metabolism and insulin secretion.">
            <entity id="DS3.d979.s0.e0" origId="439153" charOffset="8-12" type="compound" text="NADH"/>
            <entity id="DS3.d979.s0.e1" origId="206,5793,64689,79025" charOffset="31-38" type="compound" text="glucose"/>
            <entity id="DS3.d979.s0.e2" origId="P01308,I3WAC9" charOffset="90-97" type="protein" text="insulin"/>
            <pair e1="DS3.d979.s0.e0" e2="DS3.d979.s0.e2" id="DS3.d979.s0.i0" interaction="False" />
            <pair e1="DS3.d979.s0.e1" e2="DS3.d979.s0.e2" id="DS3.d979.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d979.s1" origId="9974390-1" text="Glucose metabolism in glycolysis and in mitochondria is pivotal to glucose-induced insulin secretion from pancreatic beta cells.">
            <entity id="DS3.d979.s1.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS3.d979.s1.e1" origId="206,5793,64689,79025" charOffset="67-74" type="compound" text="glucose"/>
            <entity id="DS3.d979.s1.e2" origId="P01308,I3WAC9" charOffset="83-90" type="protein" text="insulin"/>
            <pair e1="DS3.d979.s1.e1" e2="DS3.d979.s1.e2" id="DS3.d979.s1.i0" interaction="False" />
            <pair e1="DS3.d979.s1.e0" e2="DS3.d979.s1.e2" id="DS3.d979.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d979.s2" origId="9974390-2" text="One or more factors derived from glycolysis other than pyruvate appear to be required for the generation of mitochondrial signals that lead to insulin secretion.">
            <entity id="DS3.d979.s2.e0" origId="1060" charOffset="55-63" type="compound" text="pyruvate"/>
            <entity id="DS3.d979.s2.e1" origId="P01308,I3WAC9" charOffset="143-150" type="protein" text="insulin"/>
            <pair e1="DS3.d979.s2.e0" e2="DS3.d979.s2.e1" id="DS3.d979.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d979.s3" origId="9974390-4" text="By abolishing the NADH shuttle function, glucose-induced increases in NADH autofluorescence, mitochondrial membrane potential, and adenosine triphosphate content were reduced and glucose-induced insulin secretion was abrogated.">
            <entity id="DS3.d979.s3.e0" origId="439153" charOffset="18-22" type="compound" text="NADH"/>
            <entity id="DS3.d979.s3.e1" origId="206,5793,64689,79025" charOffset="41-48" type="compound" text="glucose"/>
            <entity id="DS3.d979.s3.e2" origId="439153" charOffset="70-74" type="compound" text="NADH"/>
            <entity id="DS3.d979.s3.e3" origId="57476835,60961" charOffset="131-140" type="compound" text="adenosine"/>
            <entity id="DS3.d979.s3.e4" origId="206,5793,64689,79025" charOffset="179-186" type="compound" text="glucose"/>
            <entity id="DS3.d979.s3.e5" origId="P01308,I3WAC9" charOffset="195-202" type="protein" text="insulin"/>
            <pair e1="DS3.d979.s3.e3" e2="DS3.d979.s3.e5" id="DS3.d979.s3.i0" interaction="False" />
            <pair e1="DS3.d979.s3.e0" e2="DS3.d979.s3.e5" id="DS3.d979.s3.i1" interaction="False" />
            <pair e1="DS3.d979.s3.e1" e2="DS3.d979.s3.e5" id="DS3.d979.s3.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d979.s4" origId="9974390-5" text="The NADH shuttle evidently couples glycolysis with activation of mitochondrial energy metabolism to trigger insulin secretion.">
            <entity id="DS3.d979.s4.e0" origId="439153" charOffset="4-8" type="compound" text="NADH"/>
            <entity id="DS3.d979.s4.e1" origId="P01308,I3WAC9" charOffset="108-115" type="protein" text="insulin"/>
            <pair e1="DS3.d979.s4.e0" e2="DS3.d979.s4.e1" id="DS3.d979.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d980" origId="9974395">
        <sentence id="DS3.d980.s0" origId="9974395-0" text="A copper cofactor for the ethylene receptor ETR1 from Arabidopsis.">
            <entity id="DS3.d980.s0.e0" origId="23978" charOffset="2-8" type="compound" text="copper"/>
            <entity id="DS3.d980.s0.e1" origId="108194" charOffset="9-17" type="compound" text="cofactor"/>
            <entity id="DS3.d980.s0.e2" origId="53675528,6325" charOffset="26-34" type="compound" text="ethylene"/>
            <entity id="DS3.d980.s0.e3" origId="P49333" charOffset="44-48" type="protein" text="ETR1"/>
            <pair e1="DS3.d980.s0.e2" e2="DS3.d980.s0.e3" id="DS3.d980.s0.i0" interaction="False" />
            <pair e1="DS3.d980.s0.e0" e2="DS3.d980.s0.e3" id="DS3.d980.s0.i1" interaction="False" />
            <pair e1="DS3.d980.s0.e1" e2="DS3.d980.s0.e3" id="DS3.d980.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d980.s1" origId="9974395-1" text="The ETR1 receptor from Arabidopsis binds the gaseous hormone ethylene.">
            <entity id="DS3.d980.s1.e0" origId="P49333" charOffset="4-8" type="protein" text="ETR1"/>
            <entity id="DS3.d980.s1.e1" origId="53675528,6325" charOffset="61-69" type="compound" text="ethylene"/>
            <pair e1="DS3.d980.s1.e1" e2="DS3.d980.s1.e0" id="DS3.d980.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d980.s2" origId="9974395-5" text="strain 6803 that shows homology to the ethylene-binding domain of ETR1 encodes a functional ethylene-binding protein.">
            <entity id="DS3.d980.s2.e0" origId="53675528,6325" charOffset="39-47" type="compound" text="ethylene"/>
            <entity id="DS3.d980.s2.e1" origId="P49333" charOffset="66-70" type="protein" text="ETR1"/>
            <entity id="DS3.d980.s2.e2" origId="53675528,6325" charOffset="92-100" type="compound" text="ethylene"/>
            <pair e1="DS3.d980.s2.e0" e2="DS3.d980.s2.e1" id="DS3.d980.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d980.s3" origId="9974395-6" text="On the basis of sequence conservation between the Arabidopsis and the cyanobacterial ethylene-binding domains and on in vitro mutagenesis of ETR1, a structural model for this copper-based ethylene sensor domain is presented.">
            <entity id="DS3.d980.s3.e0" origId="53675528,6325" charOffset="85-93" type="compound" text="ethylene"/>
            <entity id="DS3.d980.s3.e1" origId="P49333" charOffset="141-145" type="protein" text="ETR1"/>
            <entity id="DS3.d980.s3.e2" origId="23978" charOffset="175-181" type="compound" text="copper"/>
            <entity id="DS3.d980.s3.e3" origId="53675528,6325" charOffset="188-196" type="compound" text="ethylene"/>
            <pair e1="DS3.d980.s3.e0" e2="DS3.d980.s3.e1" id="DS3.d980.s3.i0" interaction="False" />
            <pair e1="DS3.d980.s3.e2" e2="DS3.d980.s3.e1" id="DS3.d980.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d981" origId="9974399">
        <sentence id="DS3.d981.s0" origId="9974399-2" text="Homozygosity for the C677T mutation in the gene for 5,10-methylenetetrahydrofolate reductase (MTHFR) is frequently associated with hyperhomocysteinemia, particularly in individuals with low levels of serum folate, and has been directly associated with cardiovascular disease in certain populations.">
            <entity id="DS3.d981.s0.e0" origId="P42898,Q8IU67,Q59GJ6" charOffset="57-92" type="protein" text="methylenetetrahydrofolate reductase"/>
            <entity id="DS3.d981.s0.e1" origId="P42898,Q8IU67,Q59GJ6" charOffset="94-99" type="protein" text="MTHFR"/>
            <entity id="DS3.d981.s0.e2" origId="6037" charOffset="76-82" type="compound" text="folate"/>
            <pair e1="DS3.d981.s0.e2" e2="DS3.d981.s0.e1" id="DS3.d981.s0.i0" interaction="False" />
            <pair e1="DS3.d981.s0.e2" e2="DS3.d981.s0.e0" id="DS3.d981.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d982" origId="9974400">
        <sentence id="DS3.d982.s0" origId="9974400-4" text='Flow cytometry performed with monoclonal antibodies (PAC-1, AP-6, and F26) specific for the "activated" GP IIb-IIIa complex revealed large decreases in the expression of activation markers on platelets during therapy, but these decreases were less marked when inhibition of ADP-induced PA was incomplete.'>
            <entity id="DS3.d982.s0.e0" origId="Q99612,D3GC14" charOffset="53-58" type="protein" text="PAC-1"/>
            <entity id="DS3.d982.s0.e1" origId="6022" charOffset="274-277" type="compound" text="ADP"/>
            <pair e1="DS3.d982.s0.e1" e2="DS3.d982.s0.e0" id="DS3.d982.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d982.s1" origId="9974400-6" text="Unblocked GP IIb-IIIa complexes were detected on thrombin-stimulated platelets from the patients by immunoelectron microscopy performed using the monoclonal antibody AP-2.">
            <entity id="DS3.d982.s1.e0" origId="90470996" charOffset="49-57" type="compound" text="thrombin"/>
            <entity id="DS3.d982.s1.e1" origId="Q92664" charOffset="166-170" type="protein" text="AP-2"/>
            <pair e1="DS3.d982.s1.e0" e2="DS3.d982.s1.e1" id="DS3.d982.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d983" origId="9974401">
        <sentence id="DS3.d983.s0" origId="9974401-2" text="We incubated sodium oleate with human umbilical vein endothelial cells for 0 to 72 hours, followed by coincubation of oleate with human recombinant tumor necrosis factor, interleukin (IL)-1alpha, IL-1beta, IL-4, Escherichia coli lipopolysaccharide (LPS), or phorbol 12-myristate 13-acetate for a further 6 to 24 hours.">
            <entity id="DS3.d983.s0.e0" origId="445639,965" charOffset="13-26" type="compound" text="sodium oleate"/>
            <entity id="DS3.d983.s0.e1" origId="P01584" charOffset="196-204" type="protein" text="IL-1beta"/>
            <entity id="DS3.d983.s0.e2" origId="P05112,D4HNR6,Q5FC01" charOffset="206-210" type="protein" text="IL-4"/>
            <entity id="DS3.d983.s0.e3" origId="11970143" charOffset="229-247" type="compound" text="lipopolysaccharide"/>
            <entity id="DS3.d983.s0.e4" origId="27924" charOffset="258-289" type="compound" text="phorbol 12-myristate 13-acetate"/>
            <pair e1="DS3.d983.s0.e0" e2="DS3.d983.s0.e2" id="DS3.d983.s0.i0" interaction="False" />
            <pair e1="DS3.d983.s0.e0" e2="DS3.d983.s0.e1" id="DS3.d983.s0.i1" interaction="False" />
            <pair e1="DS3.d983.s0.e3" e2="DS3.d983.s0.e2" id="DS3.d983.s0.i2" interaction="False" />
            <pair e1="DS3.d983.s0.e3" e2="DS3.d983.s0.e1" id="DS3.d983.s0.i3" interaction="False" />
            <pair e1="DS3.d983.s0.e4" e2="DS3.d983.s0.e2" id="DS3.d983.s0.i4" interaction="False" />
            <pair e1="DS3.d983.s0.e4" e2="DS3.d983.s0.e1" id="DS3.d983.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d984" origId="9974403">
        <sentence id="DS3.d984.s0" origId="9974403-5" text="This enhancement was strongly reduced (1) in the presence of monoclonal antibody PAC1 against activated alphaIIbbeta3, a polyclonal antibody against alphaIIb, and in the presence of the fibrinogen peptides GRGDS and HHLGGAKQAGDV; (2) in alphaIIbbeta3-deficient platelets; and (3) after dissociation of alphaIIbbeta3.">
            <entity id="DS3.d984.s0.e0" origId="Q99612,D3GC14" charOffset="81-85" type="protein" text="PAC1"/>
            <entity id="DS3.d984.s0.e1" origId="P02675,V9HVY1" charOffset="186-196" type="protein" text="fibrinogen"/>
            <entity id="DS3.d984.s0.e2" origId="123811,3611371" charOffset="206-211" type="compound" text="GRGDS"/>
            <pair e1="DS3.d984.s0.e2" e2="DS3.d984.s0.e1" id="DS3.d984.s0.i0" interaction="False" />
            <pair e1="DS3.d984.s0.e2" e2="DS3.d984.s0.e0" id="DS3.d984.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d984.s1" origId="9974403-6" text="In contrast, binding of 125I-LDL to normal platelets in the presence of PAC1, anti-alphaIIb, GRGDS, and HHLGGAKQAGDV, and to alphaIIbbeta3-deficient platelets was normal.">
            <entity id="DS3.d984.s1.e0" origId="Q99612,D3GC14" charOffset="72-76" type="protein" text="PAC1"/>
            <entity id="DS3.d984.s1.e1" origId="123811,3611371" charOffset="93-98" type="compound" text="GRGDS"/>
            <pair e1="DS3.d984.s1.e1" e2="DS3.d984.s1.e0" id="DS3.d984.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d984.s2" origId="9974403-9" text="Inhibition of protein kinase C (bisindolylmaleimide) diminished fibrinogen binding and sensitization by LDL; inhibition of tyrosine kinases (herbimycin A) left fibrinogen binding unchanged but diminished sensitization by LDL.">
            <entity id="DS3.d984.s2.e0" origId="2396" charOffset="32-51" type="compound" text="bisindolylmaleimide"/>
            <entity id="DS3.d984.s2.e1" origId="P02675,V9HVY1" charOffset="64-74" type="protein" text="fibrinogen"/>
            <entity id="DS3.d984.s2.e2" origId="6057,90983769" charOffset="123-131" type="compound" text="tyrosine"/>
            <entity id="DS3.d984.s2.e3" origId="16760502,3591,5311102,6436247" charOffset="141-153" type="compound" text="herbimycin A"/>
            <entity id="DS3.d984.s2.e4" origId="P02675,V9HVY1" charOffset="160-170" type="protein" text="fibrinogen"/>
            <pair e1="DS3.d984.s2.e0" e2="DS3.d984.s2.e1" id="DS3.d984.s2.i0" interaction="False" />
            <pair e1="DS3.d984.s2.e3" e2="DS3.d984.s2.e1" id="DS3.d984.s2.i1" interaction="False" />
            <pair e1="DS3.d984.s2.e2" e2="DS3.d984.s2.e1" id="DS3.d984.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d985" origId="9974404">
        <sentence id="DS3.d985.s0" origId="9974404-4" text="These samples were analyzed by enzyme-linked immunosorbent assay for 2-chain factor VIIa, by prothrombin F1+2 assay, by thrombin-antithrombin (TAT) assay, and for heparin concentration.">
            <entity id="DS3.d985.s0.e0" origId="P00734" charOffset="93-104" type="protein" text="prothrombin"/>
            <entity id="DS3.d985.s0.e1" origId="P00748,Q8IZZ5" charOffset="105-109" type="protein" text="F1+2"/>
            <entity id="DS3.d985.s0.e2" origId="90470996" charOffset="96-104" type="compound" text="thrombin"/>
            <pair e1="DS3.d985.s0.e2" e2="DS3.d985.s0.e1" id="DS3.d985.s0.i0" interaction="False" />
            <pair e1="DS3.d985.s0.e2" e2="DS3.d985.s0.e0" id="DS3.d985.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d985.s1" origId="9974404-7" text="Factor VIIa and both F1+2 and thrombin-antithrombin levels in samples from the aorta, pericardium, and suction fluid were significantly correlated (r=0.57, P&amp;lt;0.001, n=111; and r=0.51, P&amp;lt;0.">
            <entity id="DS3.d985.s1.e0" origId="P00748,Q8IZZ5" charOffset="21-25" type="protein" text="F1+2"/>
            <entity id="DS3.d985.s1.e1" origId="90470996" charOffset="30-38" type="compound" text="thrombin"/>
            <pair e1="DS3.d985.s1.e1" e2="DS3.d985.s1.e0" id="DS3.d985.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d985.s2" origId="9974404-9" text="There was no evidence of factor VIIa generation in the circuit during bypass surgery, and both F1+2 and thrombin-antithrombin levels rose only approximately 2-fold, probably because heparin levels were higher than they were in the pericardium (P&amp;lt;0.05).">
            <entity id="DS3.d985.s2.e0" origId="P00748,Q8IZZ5" charOffset="95-99" type="protein" text="F1+2"/>
            <entity id="DS3.d985.s2.e1" origId="90470996" charOffset="104-112" type="compound" text="thrombin"/>
            <pair e1="DS3.d985.s2.e1" e2="DS3.d985.s2.e0" id="DS3.d985.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d986" origId="9974405">
        <sentence id="DS3.d986.s0" origId="9974405-2" text="Upregulation of metalloproteinase (MMP)-2 and MMP-9 accompanies neointima formation in cholesterol-fed rabbits, in rat and pig models of angioplasty, and in organ cultures of human saphenous veins.">
            <entity id="DS3.d986.s0.e0" origId="P41246,P14780" charOffset="46-51" type="protein" text="MMP-9"/>
            <entity id="DS3.d986.s0.e1" origId="5997" charOffset="87-98" type="compound" text="cholesterol"/>
            <pair e1="DS3.d986.s0.e1" e2="DS3.d986.s0.e0" id="DS3.d986.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d987" origId="9974406">
        <sentence id="DS3.d987.s0" origId="9974406-11" text="In contrast, plasma concentrations of the related cholesteryl ester transfer protein (CETP) were higher in type IIa and type IIb patients than in normolipidemic controls, and significant, positive correlations with total and low density lipoprotein cholesterol levels were noted.">
            <entity id="DS3.d987.s0.e0" origId="P11597,B4DMZ5" charOffset="50-84" type="protein" text="cholesteryl ester transfer protein"/>
            <entity id="DS3.d987.s0.e1" origId="P11597,B4DMZ5" charOffset="86-90" type="protein" text="CETP"/>
            <entity id="DS3.d987.s0.e2" origId="5997" charOffset="249-260" type="compound" text="cholesterol"/>
            <pair e1="DS3.d987.s0.e2" e2="DS3.d987.s0.e1" id="DS3.d987.s0.i0" interaction="False" />
            <pair e1="DS3.d987.s0.e2" e2="DS3.d987.s0.e0" id="DS3.d987.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d987.s1" origId="9974406-18" text="It is proposed that plasma PLTP mass levels are related to glucose metabolism rather than to lipid metabolism.">
            <entity id="DS3.d987.s1.e0" origId="P55058" charOffset="27-31" type="protein" text="PLTP"/>
            <entity id="DS3.d987.s1.e1" origId="206,5793,64689,79025" charOffset="59-66" type="compound" text="glucose"/>
            <pair e1="DS3.d987.s1.e1" e2="DS3.d987.s1.e0" id="DS3.d987.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d988" origId="9974409">
        <sentence id="DS3.d988.s0" origId="9974409-4" text="Incubation of endothelial cells with urokinase-type plasminogen activator (uPA,1 nmol/L) induced a rapid and pronounced increase in tyrosine phosphorylation of several proteins with a molecular weight between 80 to 90 and 130 to 140 kDa.">
            <entity id="DS3.d988.s0.e0" origId="P00749,A0A024QZM9,Q59GZ8" charOffset="37-73" type="protein" text="urokinase-type plasminogen activator"/>
            <entity id="DS3.d988.s0.e1" origId="6057,90983769" charOffset="132-140" type="compound" text="tyrosine"/>
            <pair e1="DS3.d988.s0.e1" e2="DS3.d988.s0.e0" id="DS3.d988.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d988.s1" origId="9974409-6" text="Using coimmunoprecipitation techniques, we demonstrated that the activated urokinase receptor is associated with 2 cytoplasmic tyrosine kinases of the Jak family, viz, Jak1 and Tyk2.">
            <entity id="DS3.d988.s1.e0" origId="6057,90983769" charOffset="127-135" type="compound" text="tyrosine"/>
            <entity id="DS3.d988.s1.e1" origId="P23458" charOffset="168-172" type="protein" text="Jak1"/>
            <entity id="DS3.d988.s1.e2" origId="P29597,A0A024R7E4" charOffset="177-181" type="protein" text="Tyk2"/>
            <pair e1="DS3.d988.s1.e0" e2="DS3.d988.s1.e2" id="DS3.d988.s1.i0" interaction="False" />
            <pair e1="DS3.d988.s1.e0" e2="DS3.d988.s1.e1" id="DS3.d988.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d989" origId="9974410">
        <sentence id="DS3.d989.s0" origId="9974410-1" text="methionine synthase and 5,10-methylenetetrahydrofolate reductase (MTHFR) sequentially catalyze the remethylation of homocysteine to methionine.">
            <entity id="DS3.d989.s0.e0" origId="Q99707" charOffset="0-19" type="protein" text="methionine synthase"/>
            <entity id="DS3.d989.s0.e1" origId="108194,439175,445117,884" charOffset="24-54" type="compound" text="5,10-methylenetetrahydrofolate"/>
            <entity id="DS3.d989.s0.e2" origId="P42898,Q8IU67,Q59GJ6" charOffset="66-71" type="protein" text="MTHFR"/>
            <entity id="DS3.d989.s0.e3" origId="6137,84815,876" charOffset="0-10" type="compound" text="methionine"/>
            <pair e1="DS3.d989.s0.e3" e2="DS3.d989.s0.e2" id="DS3.d989.s0.i0" interaction="False" />
            <pair e1="DS3.d989.s0.e3" e2="DS3.d989.s0.e0" id="DS3.d989.s0.i1" interaction="False" />
            <pair e1="DS3.d989.s0.e1" e2="DS3.d989.s0.e2" id="DS3.d989.s0.i2" interaction="False" />
            <pair e1="DS3.d989.s0.e1" e2="DS3.d989.s0.e0" id="DS3.d989.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d989.s1" origId="9974410-2" text="A point mutation in the encoding region of the methionine synthase gene, which results in substitution of an aspartic acid for a glycine residue (D919G), has been identified in patients of the cblG genetic complementation group; these patients exhibit significantly decreased methionine synthase activity.">
            <entity id="DS3.d989.s1.e0" origId="Q99707" charOffset="47-66" type="protein" text="methionine synthase"/>
            <entity id="DS3.d989.s1.e1" origId="57268516,5960" charOffset="109-122" type="compound" text="aspartic acid"/>
            <entity id="DS3.d989.s1.e2" origId="45934207,750" charOffset="129-136" type="compound" text="glycine"/>
            <entity id="DS3.d989.s1.e3" origId="Q99707" charOffset="193-197" type="protein" text="cblG"/>
            <entity id="DS3.d989.s1.e4" origId="Q99707" charOffset="276-295" type="protein" text="methionine synthase"/>
            <pair e1="DS3.d989.s1.e2" e2="DS3.d989.s1.e3" id="DS3.d989.s1.i0" interaction="False" />
            <pair e1="DS3.d989.s1.e2" e2="DS3.d989.s1.e0" id="DS3.d989.s1.i1" interaction="False" />
            <pair e1="DS3.d989.s1.e1" e2="DS3.d989.s1.e3" id="DS3.d989.s1.i2" interaction="False" />
            <pair e1="DS3.d989.s1.e1" e2="DS3.d989.s1.e0" id="DS3.d989.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d989.s2" origId="9974410-8" text="Furthermore, in patients with ischemic stroke, plasma levels of homocyst(e)ine and folate were similar, irrespective of methionine synthase genotype.">
            <entity id="DS3.d989.s2.e0" origId="69382" charOffset="64-78" type="compound" text="homocyst(e)ine"/>
            <entity id="DS3.d989.s2.e1" origId="6037" charOffset="83-89" type="compound" text="folate"/>
            <entity id="DS3.d989.s2.e2" origId="Q99707" charOffset="120-139" type="protein" text="methionine synthase"/>
            <pair e1="DS3.d989.s2.e0" e2="DS3.d989.s2.e2" id="DS3.d989.s2.i0" interaction="False" />
            <pair e1="DS3.d989.s2.e1" e2="DS3.d989.s2.e2" id="DS3.d989.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d990" origId="9974411">
        <sentence id="DS3.d990.s0" origId="9974411-1" text="The common C-480T transition in the hepatic lipase (HL) promoter has been shown to be associated with lower HL activity and increased high density lipoprotein (HDL) cholesterol.">
            <entity id="DS3.d990.s0.e0" origId="P11150,A6H8L5" charOffset="36-50" type="protein" text="hepatic lipase"/>
            <entity id="DS3.d990.s0.e1" origId="5997" charOffset="165-176" type="compound" text="cholesterol"/>
            <pair e1="DS3.d990.s0.e1" e2="DS3.d990.s0.e0" id="DS3.d990.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d991" origId="9974412">
        <sentence id="DS3.d991.s0" origId="9974412-0" text="tissue factor pathway inhibitor is expressed by human monocyte-derived macrophages : relationship to tissue factor induction by cholesterol and oxidized LDL.">
            <entity id="DS3.d991.s0.e0" origId="P13726" charOffset="0-13" type="protein" text="tissue factor"/>
            <entity id="DS3.d991.s0.e1" origId="P13726" charOffset="101-114" type="protein" text="tissue factor"/>
            <entity id="DS3.d991.s0.e2" origId="5997" charOffset="128-139" type="compound" text="cholesterol"/>
            <pair e1="DS3.d991.s0.e2" e2="DS3.d991.s0.e0" id="DS3.d991.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d991.s1" origId="9974412-4" text="Equally, we investigated the effect of cholesterol and of oxidized LDL (Ox-LDL) on the expression of TFPI and TF by human monocyte-derived macrophages (HMDMs).">
            <entity id="DS3.d991.s1.e0" origId="5997" charOffset="39-50" type="compound" text="cholesterol"/>
            <entity id="DS3.d991.s1.e1" origId="P10646" charOffset="101-105" type="protein" text="TFPI"/>
            <pair e1="DS3.d991.s1.e0" e2="DS3.d991.s1.e1" id="DS3.d991.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d991.s2" origId="9974412-6" text="Gel filtration of HMDM supernatants showed the presence of an active 100-kDa form of TFPI, which was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions; under reducing conditions, however, the immunoblot revealed a 40-kDa form of TFPI.">
            <entity id="DS3.d991.s2.e0" origId="P10646" charOffset="85-89" type="protein" text="TFPI"/>
            <entity id="DS3.d991.s2.e1" origId="5360545" charOffset="114-120" type="compound" text="sodium"/>
            <entity id="DS3.d991.s2.e2" origId="8778" charOffset="121-136" type="compound" text="dodecyl sulfate"/>
            <entity id="DS3.d991.s2.e3" origId="6579" charOffset="137-151" type="compound" text="polyacrylamide"/>
            <entity id="DS3.d991.s2.e4" origId="P10646" charOffset="279-283" type="protein" text="TFPI"/>
            <pair e1="DS3.d991.s2.e2" e2="DS3.d991.s2.e0" id="DS3.d991.s2.i0" interaction="False" />
            <pair e1="DS3.d991.s2.e3" e2="DS3.d991.s2.e0" id="DS3.d991.s2.i1" interaction="False" />
            <pair e1="DS3.d991.s2.e1" e2="DS3.d991.s2.e0" id="DS3.d991.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d991.s3" origId="9974412-7" text="The TFPI in HMDM supernatants possessed heparin-binding affinity, suggesting potential interaction of TFPI with heparan sulfate proteoglycans.">
            <entity id="DS3.d991.s3.e0" origId="P10646" charOffset="4-8" type="protein" text="TFPI"/>
            <entity id="DS3.d991.s3.e1" origId="P10646" charOffset="102-106" type="protein" text="TFPI"/>
            <entity id="DS3.d991.s3.e2" origId="53477715" charOffset="112-127" type="compound" text="heparan sulfate"/>
            <pair e1="DS3.d991.s3.e2" e2="DS3.d991.s3.e0" id="DS3.d991.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d991.s4" origId="9974412-8" text="Stimulation of foam cell formation by incubation of macrophages for 48 hours with exogenous free cholesterol indicated that neither the biological activity nor the de novo synthesis of TFPI protein was affected.">
            <entity id="DS3.d991.s4.e0" origId="5997" charOffset="97-108" type="compound" text="cholesterol"/>
            <entity id="DS3.d991.s4.e1" origId="P10646" charOffset="185-189" type="protein" text="TFPI"/>
            <pair e1="DS3.d991.s4.e0" e2="DS3.d991.s4.e1" id="DS3.d991.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d992" origId="9974413">
        <sentence id="DS3.d992.s0" origId="9974413-2" text="Twenty-five pairs of healthy twins underwent measurements of PAI-1:Ag and other variables, including body mass index, mean blood pressure, plasma renin activity, insulin, and glucose.">
            <entity id="DS3.d992.s0.e0" origId="P00797" charOffset="146-151" type="protein" text="renin"/>
            <entity id="DS3.d992.s0.e1" origId="P01308,I3WAC9" charOffset="162-169" type="protein" text="insulin"/>
            <entity id="DS3.d992.s0.e2" origId="5793,64689,206,79025" charOffset="175-182" type="compound" text="glucose"/>
            <pair e1="DS3.d992.s0.e2" e2="DS3.d992.s0.e1" id="DS3.d992.s0.i0" interaction="False" />
            <pair e1="DS3.d992.s0.e2" e2="DS3.d992.s0.e0" id="DS3.d992.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d992.s1" origId="9974413-5" text="Estimates of genetic variance and heritability were obtained for PAI-1:Ag, and for body mass index, mean blood pressure, plasma renin activity, glucose, and insulin by jointly examining data in a path analysis with TWINAN90.">
            <entity id="DS3.d992.s1.e0" origId="P00797" charOffset="128-133" type="protein" text="renin"/>
            <entity id="DS3.d992.s1.e1" origId="5793,64689,206,79025" charOffset="144-151" type="compound" text="glucose"/>
            <entity id="DS3.d992.s1.e2" origId="P01308,I3WAC9" charOffset="157-164" type="protein" text="insulin"/>
            <pair e1="DS3.d992.s1.e1" e2="DS3.d992.s1.e2" id="DS3.d992.s1.i0" interaction="False" />
            <pair e1="DS3.d992.s1.e1" e2="DS3.d992.s1.e0" id="DS3.d992.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d993" origId="9974414">
        <sentence id="DS3.d993.s0" origId="9974414-0" text="Glucose phosphorylation is essential for the turnover of neutral lipid and the second stage assembly of triacylglycerol-rich apoB-containing lipoproteins in primary hepatocyte cultures.">
            <entity id="DS3.d993.s0.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS3.d993.s0.e1" origId="11146" charOffset="104-119" type="compound" text="triacylglycerol"/>
            <entity id="DS3.d993.s0.e2" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="125-129" type="protein" text="apoB"/>
            <pair e1="DS3.d993.s0.e1" e2="DS3.d993.s0.e2" id="DS3.d993.s0.i0" interaction="False" />
            <pair e1="DS3.d993.s0.e0" e2="DS3.d993.s0.e2" id="DS3.d993.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d993.s1" origId="9974414-10" text="Glucose had no effects on the posttranslational degradation of newly-synthesized apoB-100 or apoB-48.">
            <entity id="DS3.d993.s1.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS3.d993.s1.e1" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="81-85" type="protein" text="apoB"/>
            <entity id="DS3.d993.s1.e2" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="93-97" type="protein" text="apoB"/>
            <pair e1="DS3.d993.s1.e0" e2="DS3.d993.s1.e1" id="DS3.d993.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d993.s2" origId="9974414-15" text="Output of small, dense, apoB-containing particles is relatively unaffected by the glucose and MH-induced changes in TAG synthesis and lipolysis, an observation which suggests that only the bulk lipid addition step of VLDL assembly is affected by changes in glucose metabolism.">
            <entity id="DS3.d993.s2.e0" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="24-28" type="protein" text="apoB"/>
            <entity id="DS3.d993.s2.e1" origId="206,5793,64689,79025" charOffset="82-89" type="compound" text="glucose"/>
            <entity id="DS3.d993.s2.e2" origId="206,5793,64689,79025" charOffset="257-264" type="compound" text="glucose"/>
            <pair e1="DS3.d993.s2.e1" e2="DS3.d993.s2.e0" id="DS3.d993.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d993.s3" origId="9974414-1" text="Primary hepatocytes cultured in a medium supplemented with amino acids and lipogenic substrates responded to increased extracellular glucose by increasing the secretion of VLDL apoB.">
            <entity id="DS3.d993.s3.e0" origId="206,5793,64689,79025" charOffset="133-140" type="compound" text="glucose"/>
            <entity id="DS3.d993.s3.e1" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="177-181" type="protein" text="apoB"/>
            <pair e1="DS3.d993.s3.e0" e2="DS3.d993.s3.e1" id="DS3.d993.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d993.s4" origId="9974414-5" text="Glucose also gave rise to a modest (50% to 60%) increase in the incorporation of 35S methionine into newly synthesized apoB (P&amp;lt;0.05) and to a doubling of newly-synthesized apoB secretion as VLDL (P&amp;lt;0.">
            <entity id="DS3.d993.s4.e0" origId="206,5793,64689,79025" charOffset="0-7" type="compound" text="Glucose"/>
            <entity id="DS3.d993.s4.e1" origId="6137,84815,876" charOffset="85-95" type="compound" text="methionine"/>
            <entity id="DS3.d993.s4.e2" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="119-123" type="protein" text="apoB"/>
            <entity id="DS3.d993.s4.e3" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="175-179" type="protein" text="apoB"/>
            <pair e1="DS3.d993.s4.e1" e2="DS3.d993.s4.e2" id="DS3.d993.s4.i0" interaction="False" />
            <pair e1="DS3.d993.s4.e0" e2="DS3.d993.s4.e2" id="DS3.d993.s4.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d993.s5" origId="9974414-8" text="MH inhibited apoB-48 and apoB-100 synthesis and VLDL secretion at all glucose concentrations.">
            <entity id="DS3.d993.s5.e0" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="13-17" type="protein" text="apoB"/>
            <entity id="DS3.d993.s5.e1" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="25-29" type="protein" text="apoB"/>
            <entity id="DS3.d993.s5.e2" origId="206,5793,64689,79025" charOffset="70-77" type="compound" text="glucose"/>
            <pair e1="DS3.d993.s5.e2" e2="DS3.d993.s5.e0" id="DS3.d993.s5.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d993.s6" origId="9974414-9" text="The effects of glucose and MH on the secretion of newly-synthesized apoB-48 or apoB-100 as small dense particles were less pronounced.">
            <entity id="DS3.d993.s6.e0" origId="206,5793,64689,79025" charOffset="15-22" type="compound" text="glucose"/>
            <entity id="DS3.d993.s6.e1" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="68-72" type="protein" text="apoB"/>
            <entity id="DS3.d993.s6.e2" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="79-83" type="protein" text="apoB"/>
            <pair e1="DS3.d993.s6.e0" e2="DS3.d993.s6.e1" id="DS3.d993.s6.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d994" origId="9974415">
        <sentence id="DS3.d994.s0" origId="9974415-20" text="Serum HDL cholesterol in patients with MI on admission was not significantly different than in controls, and the decrease that occurred by the fifth day after MI did not explain the lower PON1 levels.">
            <entity id="DS3.d994.s0.e0" origId="5997" charOffset="10-21" type="compound" text="cholesterol"/>
            <entity id="DS3.d994.s0.e1" origId="P27169" charOffset="188-192" type="protein" text="PON1"/>
            <pair e1="DS3.d994.s0.e0" e2="DS3.d994.s0.e1" id="DS3.d994.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d995" origId="9974418">
        <sentence id="DS3.d995.s0" origId="9974418-2" text="We describe a novel genetic variant of the apoA1 gene identified in a patient with low concentrations of plasma HDL cholesterol.">
            <entity id="DS3.d995.s0.e0" origId="P02647,A0A024R3E3" charOffset="43-48" type="protein" text="apoA1"/>
            <entity id="DS3.d995.s0.e1" origId="5997" charOffset="116-127" type="compound" text="cholesterol"/>
            <pair e1="DS3.d995.s0.e1" e2="DS3.d995.s0.e0" id="DS3.d995.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d995.s1" origId="9974418-3" text="The proband, a 12-year-old Japanese boy, exhibited markedly low levels of both plasma apoA1 and HDL cholesterol.">
            <entity id="DS3.d995.s1.e0" origId="P02647,A0A024R3E3" charOffset="86-91" type="protein" text="apoA1"/>
            <entity id="DS3.d995.s1.e1" origId="5997" charOffset="100-111" type="compound" text="cholesterol"/>
            <pair e1="DS3.d995.s1.e1" e2="DS3.d995.s1.e0" id="DS3.d995.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d995.s2" origId="9974418-8" text="No measurable plasma apoA1 and HDL cholesterol in a patient with homozygosity for nonsense mutation at residue 84 has been reported previously.">
            <entity id="DS3.d995.s2.e0" origId="P02647,A0A024R3E3" charOffset="21-26" type="protein" text="apoA1"/>
            <entity id="DS3.d995.s2.e1" origId="5997" charOffset="35-46" type="compound" text="cholesterol"/>
            <pair e1="DS3.d995.s2.e1" e2="DS3.d995.s2.e0" id="DS3.d995.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d996" origId="9974422">
        <sentence id="DS3.d996.s0" origId="9974422-12" text="Total cholesterol and HDL levels remained similar in both groups of rats, but plasma ApoA1 Milano levels were elevated in ApoA1 Milano-treated rats.">
            <entity id="DS3.d996.s0.e0" origId="5997" charOffset="6-17" type="compound" text="cholesterol"/>
            <entity id="DS3.d996.s0.e1" origId="P04639,P02647,A0A024R3E3" charOffset="85-90" type="protein" text="ApoA1"/>
            <entity id="DS3.d996.s0.e2" origId="P04639,P02647,A0A024R3E3" charOffset="122-127" type="protein" text="ApoA1"/>
            <pair e1="DS3.d996.s0.e0" e2="DS3.d996.s0.e1" id="DS3.d996.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d996.s1" origId="9974422-13" text="In in vitro studies, incubation of platelets with ApoA1 Milano reduced ADP-induced platelet aggregation by about 50%, but ApoA1 Milano had no direct effect on vasoreactivity.">
            <entity id="DS3.d996.s1.e0" origId="P04639,P02647,A0A024R3E3" charOffset="50-55" type="protein" text="ApoA1"/>
            <entity id="DS3.d996.s1.e1" origId="6022" charOffset="71-74" type="compound" text="ADP"/>
            <entity id="DS3.d996.s1.e2" origId="P04639,P02647,A0A024R3E3" charOffset="122-127" type="protein" text="ApoA1"/>
            <pair e1="DS3.d996.s1.e1" e2="DS3.d996.s1.e0" id="DS3.d996.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d996.s2" origId="9974422-1" text="The mutant form of human ApoA1, known as ApoA1 Milano, is formed as a result of arginine 173 to cysteine substitution and inhibits experimental atherosclerosis in cholesterol-fed animals.">
            <entity id="DS3.d996.s2.e0" origId="P04639,P02647,A0A024R3E3" charOffset="25-30" type="protein" text="ApoA1"/>
            <entity id="DS3.d996.s2.e1" origId="P04639,P02647,A0A024R3E3" charOffset="41-46" type="protein" text="ApoA1"/>
            <entity id="DS3.d996.s2.e2" origId="6322,90867653" charOffset="80-88" type="compound" text="arginine"/>
            <entity id="DS3.d996.s2.e3" origId="5862,90793998" charOffset="96-104" type="compound" text="cysteine"/>
            <entity id="DS3.d996.s2.e4" origId="5997" charOffset="163-174" type="compound" text="cholesterol"/>
            <pair e1="DS3.d996.s2.e3" e2="DS3.d996.s2.e0" id="DS3.d996.s2.i0" interaction="False" />
            <pair e1="DS3.d996.s2.e2" e2="DS3.d996.s2.e0" id="DS3.d996.s2.i1" interaction="False" />
            <pair e1="DS3.d996.s2.e4" e2="DS3.d996.s2.e0" id="DS3.d996.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d997" origId="9974423">
        <sentence id="DS3.d997.s0" origId="9974423-0" text="Cholesterol or triglyceride loading of human monocyte-derived macrophages by incubation with modified lipoproteins does not induce tissue factor expression.">
            <entity id="DS3.d997.s0.e0" origId="5997" charOffset="0-11" type="compound" text="Cholesterol"/>
            <entity id="DS3.d997.s0.e1" origId="P13726" charOffset="131-144" type="protein" text="tissue factor"/>
            <pair e1="DS3.d997.s0.e0" e2="DS3.d997.s0.e1" id="DS3.d997.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d997.s1" origId="9974423-1" text="Macrophages/foam cells localized in cholesterol- and triglyceride-rich regions of atherosclerotic plaques express high levels of tissue factor (TF), the essential cofactor and receptor of factor VIIa.">
            <entity id="DS3.d997.s1.e0" origId="5997" charOffset="36-47" type="compound" text="cholesterol"/>
            <entity id="DS3.d997.s1.e1" origId="P13726" charOffset="129-142" type="protein" text="tissue factor"/>
            <entity id="DS3.d997.s1.e2" origId="108194" charOffset="163-171" type="compound" text="cofactor"/>
            <pair e1="DS3.d997.s1.e2" e2="DS3.d997.s1.e1" id="DS3.d997.s1.i0" interaction="False" />
            <pair e1="DS3.d997.s1.e0" e2="DS3.d997.s1.e1" id="DS3.d997.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d998" origId="9974424">
        <sentence id="DS3.d998.s0" origId="9974424-0" text="Focal increases in vascular cell adhesion molecule-1 and intimal macrophages at atherosclerosis-susceptible sites in the rabbit aorta after short-term cholesterol feeding.">
            <entity id="DS3.d998.s0.e0" origId="Q865F2,G1T1S9" charOffset="19-52" type="protein" text="vascular cell adhesion molecule-1"/>
            <entity id="DS3.d998.s0.e1" origId="5997" charOffset="151-162" type="compound" text="cholesterol"/>
            <pair e1="DS3.d998.s0.e1" e2="DS3.d998.s0.e0" id="DS3.d998.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d998.s1" origId="9974424-10" text="These results suggest that (1) VCAM-1 expression and intimal macrophage densities are influenced by plasma cholesterol and regional factors such as arterial fluid dynamics and (2) VCAM-1 plays a significant role in the localization of macrophages.">
            <entity id="DS3.d998.s1.e0" origId="Q865F2,G1T1S9" charOffset="31-37" type="protein" text="VCAM-1"/>
            <entity id="DS3.d998.s1.e1" origId="5997" charOffset="107-118" type="compound" text="cholesterol"/>
            <entity id="DS3.d998.s1.e2" origId="Q865F2,G1T1S9" charOffset="180-186" type="protein" text="VCAM-1"/>
            <pair e1="DS3.d998.s1.e1" e2="DS3.d998.s1.e0" id="DS3.d998.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d998.s2" origId="9974424-1" text="We tested the hypotheses that vascular cell adhesion molecule-1 (VCAM-1) expression on endothelium at lesion-prone sites in the rabbit aorta correlates with exposure to plasma cholesterol and that macrophage accumulation is associated with endothelial cells expressing VCAM-1.">
            <entity id="DS3.d998.s2.e0" origId="Q865F2,G1T1S9" charOffset="30-63" type="protein" text="vascular cell adhesion molecule-1"/>
            <entity id="DS3.d998.s2.e1" origId="Q865F2,G1T1S9" charOffset="65-71" type="protein" text="VCAM-1"/>
            <entity id="DS3.d998.s2.e2" origId="5997" charOffset="176-187" type="compound" text="cholesterol"/>
            <entity id="DS3.d998.s2.e3" origId="Q865F2,G1T1S9" charOffset="269-275" type="protein" text="VCAM-1"/>
            <pair e1="DS3.d998.s2.e2" e2="DS3.d998.s2.e0" id="DS3.d998.s2.i0" interaction="False" />
            <pair e1="DS3.d998.s2.e2" e2="DS3.d998.s2.e1" id="DS3.d998.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d998.s3" origId="9974424-2" text="After rabbits were fed 0.25% cholesterol for 2 weeks, VCAM-1 expression was selectively increased at the distal and lateral portions of the major abdominal branches.">
            <entity id="DS3.d998.s3.e0" origId="5997" charOffset="29-40" type="compound" text="cholesterol"/>
            <entity id="DS3.d998.s3.e1" origId="Q865F2,G1T1S9" charOffset="54-60" type="protein" text="VCAM-1"/>
            <pair e1="DS3.d998.s3.e0" e2="DS3.d998.s3.e1" id="DS3.d998.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d998.s4" origId="9974424-3" text="In the arch and the celiac, superior mesenteric, and renal artery branches, VCAM-1 expression was positively correlated with the plasma cholesterol integrated over the duration of the experiments.">
            <entity id="DS3.d998.s4.e0" origId="Q865F2,G1T1S9" charOffset="76-82" type="protein" text="VCAM-1"/>
            <entity id="DS3.d998.s4.e1" origId="5997" charOffset="136-147" type="compound" text="cholesterol"/>
            <pair e1="DS3.d998.s4.e1" e2="DS3.d998.s4.e0" id="DS3.d998.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d998.s5" origId="9974424-7" text="In normocholesterolemic rabbits, 23+/-4% (mean+/-SEM) of the macrophages were directly associated with VCAM-1-positive endothelium.">
            <entity id="DS3.d998.s5.e0" origId="5289348" charOffset="49-52" type="compound" text="SEM"/>
            <entity id="DS3.d998.s5.e1" origId="Q865F2,G1T1S9" charOffset="103-109" type="protein" text="VCAM-1"/>
            <pair e1="DS3.d998.s5.e0" e2="DS3.d998.s5.e1" id="DS3.d998.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d999" origId="9974425">
        <sentence id="DS3.d999.s0" origId="9974425-11" text="Our finding was that in postmenopausal Finnish women LDL cholesterol levels in apoE4-negative subjects respond more favorably to HRT than those in apoE4-positive subjects.">
            <entity id="DS3.d999.s0.e0" origId="5997" charOffset="57-68" type="compound" text="cholesterol"/>
            <entity id="DS3.d999.s0.e1" origId="P02649" charOffset="79-84" type="protein" text="apoE4"/>
            <entity id="DS3.d999.s0.e2" origId="P02649" charOffset="147-152" type="protein" text="apoE4"/>
            <pair e1="DS3.d999.s0.e0" e2="DS3.d999.s0.e1" id="DS3.d999.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d999.s1" origId="9974425-2" text="The apolipoprotein E genotype has influence on serum levels of lipids and lipoproteins; ApoE allele epsilon4 (apoE4) is associated with high total and LDL cholesterol levels.">
            <entity id="DS3.d999.s1.e0" origId="P02649" charOffset="4-20" type="protein" text="apolipoprotein E"/>
            <entity id="DS3.d999.s1.e1" origId="P02649" charOffset="88-108" type="protein" text="ApoE allele epsilon4"/>
            <entity id="DS3.d999.s1.e2" origId="P02649" charOffset="110-115" type="protein" text="apoE4"/>
            <entity id="DS3.d999.s1.e3" origId="5997" charOffset="155-166" type="compound" text="cholesterol"/>
            <pair e1="DS3.d999.s1.e3" e2="DS3.d999.s1.e1" id="DS3.d999.s1.i0" interaction="False" />
            <pair e1="DS3.d999.s1.e3" e2="DS3.d999.s1.e2" id="DS3.d999.s1.i1" interaction="False" />
            <pair e1="DS3.d999.s1.e3" e2="DS3.d999.s1.e0" id="DS3.d999.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d999.s2" origId="9974425-8" text="During the follow-up period, serum total cholesterol and LDL cholesterol concentrations decreased in the HRT group in apoE4-negative women (8.1% and 17.1%, respectively; P&amp;lt;0.001) but did not change in the HRT group in apoE4-positive women or in the placebo group.">
            <entity id="DS3.d999.s2.e0" origId="5997" charOffset="41-52" type="compound" text="cholesterol"/>
            <entity id="DS3.d999.s2.e1" origId="5997" charOffset="61-72" type="compound" text="cholesterol"/>
            <entity id="DS3.d999.s2.e2" origId="P02649" charOffset="118-123" type="protein" text="apoE4"/>
            <entity id="DS3.d999.s2.e3" origId="P02649" charOffset="221-226" type="protein" text="apoE4"/>
            <pair e1="DS3.d999.s2.e0" e2="DS3.d999.s2.e2" id="DS3.d999.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d999.s3" origId="9974425-9" text="Serum HDL cholesterol concentrations decreased in the placebo group (apoE4-negative, 3.9%, P=0.015; apoE4-positive, 8.1%, P=0.004) but did not change significantly in the HRT group.">
            <entity id="DS3.d999.s3.e0" origId="5997" charOffset="10-21" type="compound" text="cholesterol"/>
            <entity id="DS3.d999.s3.e1" origId="P02649" charOffset="69-74" type="protein" text="apoE4"/>
            <entity id="DS3.d999.s3.e2" origId="P02649" charOffset="100-105" type="protein" text="apoE4"/>
            <pair e1="DS3.d999.s3.e0" e2="DS3.d999.s3.e1" id="DS3.d999.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1000" origId="9974426">
        <sentence id="DS3.d1000.s0" origId="9974426-4" text="The residual LDL receptor activity, measured in cultured fibroblasts of 32 patients, varied from &amp;lt;2% to 30% of normal and was inversely correlated with the plasma LDL cholesterol level (r=-0.665; P&amp;lt;0.003).">
            <entity id="DS3.d1000.s0.e0" origId="P01130,A0A024R7D5" charOffset="13-25" type="protein" text="LDL receptor"/>
            <entity id="DS3.d1000.s0.e1" origId="5997" charOffset="170-181" type="compound" text="cholesterol"/>
            <pair e1="DS3.d1000.s0.e1" e2="DS3.d1000.s0.e0" id="DS3.d1000.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1000.s1" origId="9974426-5" text="The most severe coronary atherosclerosis was observed in those patients with the lowest residual LDL receptor activity (&amp;lt;/=5% of normal) and the highest plasma LDL cholesterol levels.">
            <entity id="DS3.d1000.s1.e0" origId="P01130,A0A024R7D5" charOffset="97-109" type="protein" text="LDL receptor"/>
            <entity id="DS3.d1000.s1.e1" origId="5997" charOffset="167-178" type="compound" text="cholesterol"/>
            <pair e1="DS3.d1000.s1.e1" e2="DS3.d1000.s1.e0" id="DS3.d1000.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1001" origId="9974427">
        <sentence id="DS3.d1001.s0" origId="9974427-0" text="Resveratrol, a polyphenolic compound found in wine, inhibits tissue factor expression in vascular cells : A possible mechanism for the cardiovascular benefits associated with moderate consumption of wine.">
            <entity id="DS3.d1001.s0.e0" origId="445154,5056" charOffset="0-11" type="compound" text="Resveratrol"/>
            <entity id="DS3.d1001.s0.e1" origId="P13726" charOffset="61-74" type="protein" text="tissue factor"/>
            <pair e1="DS3.d1001.s0.e0" e2="DS3.d1001.s0.e1" id="DS3.d1001.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1001.s1" origId="9974427-3" text="In the present investigation, we examined the effect of resveratrol on induction of tissue factor (TF) expression in vascular cells that were exposed to pathophysiological stimuli.">
            <entity id="DS3.d1001.s1.e0" origId="445154,5056" charOffset="56-67" type="compound" text="resveratrol"/>
            <entity id="DS3.d1001.s1.e1" origId="P13726" charOffset="84-97" type="protein" text="tissue factor"/>
            <pair e1="DS3.d1001.s1.e0" e2="DS3.d1001.s1.e1" id="DS3.d1001.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1001.s2" origId="9974427-4" text="The data presented herein show that resveratrol, in a dose-dependent manner, inhibited the expression of TF in endothelial cells stimulated with a variety of agonists, including interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNFalpha) and lipopolysaccharide (LPS).">
            <entity id="DS3.d1001.s2.e0" origId="445154,5056" charOffset="36-47" type="compound" text="resveratrol"/>
            <entity id="DS3.d1001.s2.e1" origId="P01584" charOffset="178-195" type="protein" text="interleukin-1beta"/>
            <entity id="DS3.d1001.s2.e2" origId="P01584" charOffset="197-205" type="protein" text="IL-1beta"/>
            <entity id="DS3.d1001.s2.e3" origId="P01375,Q5STB3" charOffset="208-235" type="protein" text="tumor necrosis factor-alpha"/>
            <entity id="DS3.d1001.s2.e4" origId="P01375,Q5STB3" charOffset="237-245" type="protein" text="TNFalpha"/>
            <entity id="DS3.d1001.s2.e5" origId="11970143" charOffset="251-269" type="compound" text="lipopolysaccharide"/>
            <pair e1="DS3.d1001.s2.e0" e2="DS3.d1001.s2.e3" id="DS3.d1001.s2.i0" interaction="False" />
            <pair e1="DS3.d1001.s2.e0" e2="DS3.d1001.s2.e1" id="DS3.d1001.s2.i1" interaction="False" />
            <pair e1="DS3.d1001.s2.e0" e2="DS3.d1001.s2.e4" id="DS3.d1001.s2.i2" interaction="False" />
            <pair e1="DS3.d1001.s2.e0" e2="DS3.d1001.s2.e2" id="DS3.d1001.s2.i3" interaction="False" />
            <pair e1="DS3.d1001.s2.e5" e2="DS3.d1001.s2.e3" id="DS3.d1001.s2.i4" interaction="False" />
            <pair e1="DS3.d1001.s2.e5" e2="DS3.d1001.s2.e1" id="DS3.d1001.s2.i5" interaction="False" />
            <pair e1="DS3.d1001.s2.e5" e2="DS3.d1001.s2.e4" id="DS3.d1001.s2.i6" interaction="False" />
            <pair e1="DS3.d1001.s2.e5" e2="DS3.d1001.s2.e2" id="DS3.d1001.s2.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d1001.s3" origId="9974427-6" text="In addition, resveratrol was shown to inhibit the LPS-induced expression of TNFalpha mRNA in endothelial cells and of TNFalpha and IL-1beta mRNA in monocytes.">
            <entity id="DS3.d1001.s3.e0" origId="445154,5056" charOffset="13-24" type="compound" text="resveratrol"/>
            <entity id="DS3.d1001.s3.e1" origId="P01375,Q5STB3" charOffset="76-84" type="protein" text="TNFalpha"/>
            <entity id="DS3.d1001.s3.e2" origId="P01375,Q5STB3" charOffset="118-126" type="protein" text="TNFalpha"/>
            <entity id="DS3.d1001.s3.e3" origId="P01584" charOffset="131-139" type="protein" text="IL-1beta"/>
            <pair e1="DS3.d1001.s3.e0" e2="DS3.d1001.s3.e3" id="DS3.d1001.s3.i0" interaction="False" />
            <pair e1="DS3.d1001.s3.e0" e2="DS3.d1001.s3.e1" id="DS3.d1001.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1001.s4" origId="9974427-8" text="However, resveratrol did not significantly alter the binding of the transcription factors c-Fos/c-Jun and c-Rel/p65, the transcription factors required for the induction of TF promoter in both endothelial cells and monocytes.">
            <entity id="DS3.d1001.s4.e0" origId="445154,5056" charOffset="9-20" type="compound" text="resveratrol"/>
            <entity id="DS3.d1001.s4.e1" origId="P01100,Q6FG41" charOffset="90-95" type="protein" text="c-Fos"/>
            <entity id="DS3.d1001.s4.e2" origId="P05412" charOffset="96-101" type="protein" text="c-Jun"/>
            <entity id="DS3.d1001.s4.e3" origId="Q04864" charOffset="106-111" type="protein" text="c-Rel"/>
            <entity id="DS3.d1001.s4.e4" origId="Q9H4A3,A5D8Z4,F5GWT4" charOffset="112-115" type="protein" text="p65"/>
            <pair e1="DS3.d1001.s4.e0" e2="DS3.d1001.s4.e4" id="DS3.d1001.s4.i0" interaction="False" />
            <pair e1="DS3.d1001.s4.e0" e2="DS3.d1001.s4.e3" id="DS3.d1001.s4.i1" interaction="False" />
            <pair e1="DS3.d1001.s4.e0" e2="DS3.d1001.s4.e1" id="DS3.d1001.s4.i2" interaction="False" />
            <pair e1="DS3.d1001.s4.e0" e2="DS3.d1001.s4.e2" id="DS3.d1001.s4.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1001.s5" origId="9974427-9" text="Similarly, resveratrol had no significant effect on the binding of NF-kappaB in endothelial cells stimulated with IL-1beta, TNFalpha, and LPS.">
            <entity id="DS3.d1001.s5.e0" origId="445154,5056" charOffset="11-22" type="compound" text="resveratrol"/>
            <entity id="DS3.d1001.s5.e1" origId="P01584" charOffset="114-122" type="protein" text="IL-1beta"/>
            <entity id="DS3.d1001.s5.e2" origId="P01375,Q5STB3" charOffset="124-132" type="protein" text="TNFalpha"/>
            <pair e1="DS3.d1001.s5.e0" e2="DS3.d1001.s5.e1" id="DS3.d1001.s5.i0" interaction="False" />
            <pair e1="DS3.d1001.s5.e0" e2="DS3.d1001.s5.e2" id="DS3.d1001.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1002" origId="9974428">
        <sentence id="DS3.d1002.s0" origId="9974428-6" text="However, there was significant evidence (P&amp;lt;0.10) that associations between variation in the probability of having CAC and variation in body mass index, plasma total cholesterol, and plasma ApoB in men and body mass index, plasma triglycerides, plasma ApoA1, and plasma ApoE in women were dependent on ApoE genotype.">
            <entity id="DS3.d1002.s0.e0" origId="5997" charOffset="168-179" type="compound" text="cholesterol"/>
            <entity id="DS3.d1002.s0.e1" origId="P04114,Q7Z7Q0,Q59HB3" charOffset="192-196" type="protein" text="ApoB"/>
            <entity id="DS3.d1002.s0.e2" origId="P02647,A0A024R3E3" charOffset="254-259" type="protein" text="ApoA1"/>
            <entity id="DS3.d1002.s0.e3" origId="P02649" charOffset="272-276" type="protein" text="ApoE"/>
            <entity id="DS3.d1002.s0.e4" origId="P02649" charOffset="304-308" type="protein" text="ApoE"/>
            <pair e1="DS3.d1002.s0.e0" e2="DS3.d1002.s0.e3" id="DS3.d1002.s0.i0" interaction="False" />
            <pair e1="DS3.d1002.s0.e0" e2="DS3.d1002.s0.e1" id="DS3.d1002.s0.i1" interaction="False" />
            <pair e1="DS3.d1002.s0.e0" e2="DS3.d1002.s0.e2" id="DS3.d1002.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1003" origId="9974430">
        <sentence id="DS3.d1003.s0" origId="9974430-3" text="These mice were examined for levels of total plasma cholesterol, HDL cholesterol, VLDL and LDL cholesterol, unesterified cholesterol, autoantibodies, and aortic fatty streak lesions.">
            <entity id="DS3.d1003.s0.e0" origId="5997" charOffset="52-63" type="compound" text="cholesterol"/>
            <entity id="DS3.d1003.s0.e1" origId="5997" charOffset="69-80" type="compound" text="cholesterol"/>
            <entity id="DS3.d1003.s0.e2" origId="Q9Z1P5" charOffset="82-86" type="protein" text="VLDL"/>
            <entity id="DS3.d1003.s0.e3" origId="5997" charOffset="69-80" type="compound" text="cholesterol"/>
            <entity id="DS3.d1003.s0.e4" origId="5997" charOffset="69-80" type="compound" text="cholesterol"/>
            <pair e1="DS3.d1003.s0.e0" e2="DS3.d1003.s0.e2" id="DS3.d1003.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1003.s1" origId="9974430-5" text="The locus on Chr 15 exhibited lod scores of 11.1 for total cholesterol and 6.7 for VLDL and LDL cholesterol in mice fed an atherogenic diet, and it contains a candidate gene, the sterol regulatory element binding protein-2.">
            <entity id="DS3.d1003.s1.e0" origId="5997" charOffset="59-70" type="compound" text="cholesterol"/>
            <entity id="DS3.d1003.s1.e1" origId="Q9Z1P5" charOffset="83-87" type="protein" text="VLDL"/>
            <entity id="DS3.d1003.s1.e2" origId="5997" charOffset="96-107" type="compound" text="cholesterol"/>
            <pair e1="DS3.d1003.s1.e0" e2="DS3.d1003.s1.e1" id="DS3.d1003.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1004" origId="9986706">
        <sentence id="DS3.d1004.s0" origId="9986706-0" text="Ajoene is an inhibitor and subversive substrate of human glutathione reductase and Trypanosoma cruzi trypanothione reductase: crystallographic, kinetic, and spectroscopic studies.">
            <entity id="DS3.d1004.s0.e0" origId="P00390,V9HW90" charOffset="57-78" type="protein" text="glutathione reductase"/>
            <entity id="DS3.d1004.s0.e1" origId="449517,46936689" charOffset="101-114" type="compound" text="trypanothione"/>
            <pair e1="DS3.d1004.s0.e1" e2="DS3.d1004.s0.e0" id="DS3.d1004.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1004.s1" origId="9986706-1" text="Ajoene ((E,Z)-4,5,9-trithiadodeca-1,6,11-triene 9-oxide), a garlic-derived natural compound, is a covalent inhibitor as well as a substrate of human glutathione reductase (GR) and Trypanosoma cruzi trypanothione reductase (TR).">
            <entity id="DS3.d1004.s1.e0" origId="190217" charOffset="50-55" type="compound" text="oxide"/>
            <entity id="DS3.d1004.s1.e1" origId="P00390,V9HW90" charOffset="149-170" type="protein" text="glutathione reductase"/>
            <entity id="DS3.d1004.s1.e2" origId="449517,46936689" charOffset="198-211" type="compound" text="trypanothione"/>
            <pair e1="DS3.d1004.s1.e2" e2="DS3.d1004.s1.e1" id="DS3.d1004.s1.i0" interaction="False" />
            <pair e1="DS3.d1004.s1.e0" e2="DS3.d1004.s1.e1" id="DS3.d1004.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1004.s2" origId="9986706-5" text="The reaction leads also to the formation of single-electron reduced products and concomitantly superoxide anion radicals as shown by coupling the reaction to the reduction of cytochrome c.">
            <entity id="DS3.d1004.s2.e0" origId="5359597" charOffset="95-105" type="compound" text="superoxide"/>
            <entity id="DS3.d1004.s2.e1" origId="P99999,G4XXL9" charOffset="175-187" type="protein" text="cytochrome c"/>
            <pair e1="DS3.d1004.s2.e0" e2="DS3.d1004.s2.e1" id="DS3.d1004.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1005" origId="9986713">
        <sentence id="DS3.d1005.s0" origId="9986713-7" text="Restraining this helix in a linear form (i.e., con-G(A7,E10-K13)) results in a minor reduction in potency.">
            <entity id="DS3.d1005.s0.e0" origId="16181638" charOffset="47-52" type="compound" text="con-G"/>
            <entity id="DS3.d1005.s0.e1" origId="445974" charOffset="56-59" type="compound" text="E10"/>
            <entity id="DS3.d1005.s0.e2" origId="Q9UIX4,Q86Y85" charOffset="60-63" type="protein" text="K13"/>
            <pair e1="DS3.d1005.s0.e0" e2="DS3.d1005.s0.e2" id="DS3.d1005.s0.i0" interaction="False" />
            <pair e1="DS3.d1005.s0.e1" e2="DS3.d1005.s0.e2" id="DS3.d1005.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1005.s1" origId="9986713-9" text="Peptides with the Leu5-Tyr5 substitution also have low potencies (con-G(Y5,A7) and con-G(Y5,K7)) indicating that Leu5 in con-G is important for full antagonist behavior.">
            <entity id="DS3.d1005.s1.e0" origId="O60858,A0A024RDU3,L7MTJ6" charOffset="18-22" type="protein" text="Leu5"/>
            <entity id="DS3.d1005.s1.e1" origId="16181638" charOffset="66-71" type="compound" text="con-G"/>
            <entity id="DS3.d1005.s1.e2" origId="16181638" charOffset="83-88" type="compound" text="con-G"/>
            <entity id="DS3.d1005.s1.e3" origId="O60858,A0A024RDU3,L7MTJ6" charOffset="113-117" type="protein" text="Leu5"/>
            <entity id="DS3.d1005.s1.e4" origId="16181638" charOffset="83-88" type="compound" text="con-G"/>
            <pair e1="DS3.d1005.s1.e1" e2="DS3.d1005.s1.e0" id="DS3.d1005.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1006" origId="9986716">
        <sentence id="DS3.d1006.s0" origId="9986716-0" text="Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.">
            <entity id="DS3.d1006.s0.e0" origId="66764649" charOffset="23-41" type="compound" text="indenoisoquinoline"/>
            <entity id="DS3.d1006.s0.e1" origId="P11387" charOffset="42-57" type="protein" text="topoisomerase I"/>
            <pair e1="DS3.d1006.s0.e0" e2="DS3.d1006.s0.e1" id="DS3.d1006.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1006.s1" origId="9986716-2" text="The two most cytotoxic indenoisoquinolines proved to be cis-6-ethyl-5,6,12,13-tetrahydro-2,3-dimethoxy-8, 9-(methylenedioxy)-5,11-dioxo-11H-indeno(1,2-c)isoquinoline (21) and cis-6-allyl-5,6,12,13-tetrahydro-2,3-dimethoxy-8, 9-(methylenedioxy)-5,11-dioxo-11H-indeno(1,2-c)isoquinoline (22), both of which displayed submicromolar mean graph midpoints when tested in 55 human cancer cell cultures.">
            <entity id="DS3.d1006.s1.e0" origId="O75159" charOffset="56-61" type="protein" text="cis-6"/>
            <entity id="DS3.d1006.s1.e1" origId="23134249" charOffset="62-67" type="compound" text="ethyl"/>
            <entity id="DS3.d1006.s1.e2" origId="79015" charOffset="109-123" type="compound" text="methylenedioxy"/>
            <entity id="DS3.d1006.s1.e3" origId="66534" charOffset="136-139" type="compound" text="11H"/>
            <entity id="DS3.d1006.s1.e4" origId="56996021" charOffset="140-165" type="compound" text="indeno(1,2-c)isoquinoline"/>
            <entity id="DS3.d1006.s1.e5" origId="O75159" charOffset="175-180" type="protein" text="cis-6"/>
            <entity id="DS3.d1006.s1.e6" origId="8252" charOffset="181-186" type="compound" text="allyl"/>
            <entity id="DS3.d1006.s1.e7" origId="79015" charOffset="228-242" type="compound" text="methylenedioxy"/>
            <entity id="DS3.d1006.s1.e8" origId="66534" charOffset="255-258" type="compound" text="11H"/>
            <entity id="DS3.d1006.s1.e9" origId="56996021" charOffset="259-284" type="compound" text="indeno(1,2-c)isoquinoline"/>
            <pair e1="DS3.d1006.s1.e2" e2="DS3.d1006.s1.e0" id="DS3.d1006.s1.i0" interaction="False" />
            <pair e1="DS3.d1006.s1.e9" e2="DS3.d1006.s1.e0" id="DS3.d1006.s1.i1" interaction="False" />
            <pair e1="DS3.d1006.s1.e6" e2="DS3.d1006.s1.e0" id="DS3.d1006.s1.i2" interaction="False" />
            <pair e1="DS3.d1006.s1.e3" e2="DS3.d1006.s1.e0" id="DS3.d1006.s1.i3" interaction="False" />
            <pair e1="DS3.d1006.s1.e1" e2="DS3.d1006.s1.e0" id="DS3.d1006.s1.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d1006.s2" origId="9986716-3" text="Two of the most potent top1 inhibitors were 6-(3-carboxy-1-propyl)-5,6-dihydro-5, 11-dioxo-11H-indeno(1,2-c)isoquinoline (26) and 6-ethyl-2, 3-dimethoxy-8,9-(methylenedioxy)-11H-indeno(1,2-c)isoquinolinium chloride (27), both of which also inhibited top2, unwound DNA, and are assumed to be DNA intercalators.">
            <entity id="DS3.d1006.s2.e0" origId="P11387" charOffset="23-27" type="protein" text="top1"/>
            <entity id="DS3.d1006.s2.e1" origId="66534" charOffset="91-94" type="compound" text="11H"/>
            <entity id="DS3.d1006.s2.e2" origId="56996021" charOffset="95-120" type="compound" text="indeno(1,2-c)isoquinoline"/>
            <entity id="DS3.d1006.s2.e3" origId="23134249" charOffset="132-137" type="compound" text="ethyl"/>
            <entity id="DS3.d1006.s2.e4" origId="79015" charOffset="158-172" type="compound" text="methylenedioxy"/>
            <entity id="DS3.d1006.s2.e5" origId="59429805" charOffset="174-205" type="compound" text="11H-indeno(1,2-c)isoquinolinium"/>
            <entity id="DS3.d1006.s2.e6" origId="312" charOffset="206-214" type="compound" text="chloride"/>
            <entity id="DS3.d1006.s2.e7" origId="P11388" charOffset="250-254" type="protein" text="top2"/>
            <pair e1="DS3.d1006.s2.e4" e2="DS3.d1006.s2.e7" id="DS3.d1006.s2.i0" interaction="False" />
            <pair e1="DS3.d1006.s2.e4" e2="DS3.d1006.s2.e0" id="DS3.d1006.s2.i1" interaction="False" />
            <pair e1="DS3.d1006.s2.e1" e2="DS3.d1006.s2.e7" id="DS3.d1006.s2.i2" interaction="False" />
            <pair e1="DS3.d1006.s2.e1" e2="DS3.d1006.s2.e0" id="DS3.d1006.s2.i3" interaction="False" />
            <pair e1="DS3.d1006.s2.e7" e2="DS3.d1006.s2.e7" id="DS3.d1006.s2.i4" interaction="False" />
            <pair e1="DS3.d1006.s2.e7" e2="DS3.d1006.s2.e0" id="DS3.d1006.s2.i5" interaction="False" />
            <pair e1="DS3.d1006.s2.e7" e2="DS3.d1006.s2.e7" id="DS3.d1006.s2.i6" interaction="False" />
            <pair e1="DS3.d1006.s2.e7" e2="DS3.d1006.s2.e0" id="DS3.d1006.s2.i7" interaction="False" />
            <pair e1="DS3.d1006.s2.e6" e2="DS3.d1006.s2.e7" id="DS3.d1006.s2.i8" interaction="False" />
            <pair e1="DS3.d1006.s2.e6" e2="DS3.d1006.s2.e0" id="DS3.d1006.s2.i9" interaction="False" />
            <pair e1="DS3.d1006.s2.e3" e2="DS3.d1006.s2.e7" id="DS3.d1006.s2.i10" interaction="False" />
            <pair e1="DS3.d1006.s2.e3" e2="DS3.d1006.s2.e0" id="DS3.d1006.s2.i11" interaction="False" />
        </sentence>
        <sentence id="DS3.d1006.s3" origId="9986716-4" text="However, two additional potent top1 inhibitors, 6-allyl-5,6-dihydro-2,3-dimethoxy-8, 9-(methylenedioxy)-5,11-dioxo-11H-indeno(1,2-c)isoquinoline (13c) and 5,6-dihydro-6-(4-hydroxybut-1-yl)-2,3-dimethoxy-8, 9-methylenedioxy-5,11-dioxo-11H-indeno(1,2-c)isoquinoline (19a), did not unwind DNA and did not affect top2.">
            <entity id="DS3.d1006.s3.e0" origId="P11387" charOffset="31-35" type="protein" text="top1"/>
            <entity id="DS3.d1006.s3.e1" origId="8252" charOffset="50-55" type="compound" text="allyl"/>
            <entity id="DS3.d1006.s3.e2" origId="79015" charOffset="88-102" type="compound" text="methylenedioxy"/>
            <entity id="DS3.d1006.s3.e3" origId="66534" charOffset="115-118" type="compound" text="11H"/>
            <entity id="DS3.d1006.s3.e4" origId="56996021" charOffset="119-144" type="compound" text="indeno(1,2-c)isoquinoline"/>
            <entity id="DS3.d1006.s3.e5" origId="79015" charOffset="208-222" type="compound" text="methylenedioxy"/>
            <entity id="DS3.d1006.s3.e6" origId="66534" charOffset="234-237" type="compound" text="11H"/>
            <entity id="DS3.d1006.s3.e7" origId="56996021" charOffset="238-263" type="compound" text="indeno(1,2-c)isoquinoline"/>
            <entity id="DS3.d1006.s3.e8" origId="6096886" charOffset="265-268" type="compound" text="19a"/>
            <entity id="DS3.d1006.s3.e9" origId="P11388" charOffset="309-313" type="protein" text="top2"/>
            <pair e1="DS3.d1006.s3.e2" e2="DS3.d1006.s3.e9" id="DS3.d1006.s3.i0" interaction="False" />
            <pair e1="DS3.d1006.s3.e2" e2="DS3.d1006.s3.e0" id="DS3.d1006.s3.i1" interaction="False" />
            <pair e1="DS3.d1006.s3.e9" e2="DS3.d1006.s3.e9" id="DS3.d1006.s3.i2" interaction="False" />
            <pair e1="DS3.d1006.s3.e9" e2="DS3.d1006.s3.e0" id="DS3.d1006.s3.i3" interaction="False" />
            <pair e1="DS3.d1006.s3.e8" e2="DS3.d1006.s3.e9" id="DS3.d1006.s3.i4" interaction="False" />
            <pair e1="DS3.d1006.s3.e8" e2="DS3.d1006.s3.e0" id="DS3.d1006.s3.i5" interaction="False" />
            <pair e1="DS3.d1006.s3.e3" e2="DS3.d1006.s3.e9" id="DS3.d1006.s3.i6" interaction="False" />
            <pair e1="DS3.d1006.s3.e3" e2="DS3.d1006.s3.e0" id="DS3.d1006.s3.i7" interaction="False" />
            <pair e1="DS3.d1006.s3.e1" e2="DS3.d1006.s3.e9" id="DS3.d1006.s3.i8" interaction="False" />
            <pair e1="DS3.d1006.s3.e1" e2="DS3.d1006.s3.e0" id="DS3.d1006.s3.i9" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1007" origId="9986717">
        <sentence id="DS3.d1007.s0" origId="9986717-0" text="Three-dimensional quantitative structure-activity relationship analyses using comparative molecular field analysis and comparative molecular similarity indices analysis to elucidate selectivity differences of inhibitors binding to trypsin, thrombin, and factor Xa.">
            <entity id="DS3.d1007.s0.e0" origId="90470996" charOffset="240-248" type="compound" text="thrombin"/>
            <entity id="DS3.d1007.s0.e1" origId="P00742,Q5JVE7,Q5JVE8" charOffset="254-263" type="protein" text="factor Xa"/>
            <pair e1="DS3.d1007.s0.e0" e2="DS3.d1007.s0.e1" id="DS3.d1007.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1007.s1" origId="9986717-1" text="Three-dimensional quantitative structure-activity relationship (3D QSAR) methods were applied using a training set of 72 inhibitors of the benzamidine type with respect to their binding affinities (Ki values) toward thrombin, trypsin, and factor Xa to yield statistically reliable models of good predictive power.">
            <entity id="DS3.d1007.s1.e0" origId="2332" charOffset="139-150" type="compound" text="benzamidine"/>
            <entity id="DS3.d1007.s1.e1" origId="90470996" charOffset="216-224" type="compound" text="thrombin"/>
            <entity id="DS3.d1007.s1.e2" origId="P00742,Q5JVE7,Q5JVE8" charOffset="239-248" type="protein" text="factor Xa"/>
            <pair e1="DS3.d1007.s1.e1" e2="DS3.d1007.s1.e2" id="DS3.d1007.s1.i0" interaction="False" />
            <pair e1="DS3.d1007.s1.e0" e2="DS3.d1007.s1.e2" id="DS3.d1007.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1008" origId="9986719">
        <sentence id="DS3.d1008.s0" origId="9986719-0" text="1-aryl-4-((5-methoxy-1,2,3, 4-tetrahydronaphthalen-1-yl)alkyl)piperazines and their analogues: influence of the stereochemistry of the tetrahydronaphthalen-1-yl nucleus on 5-HT1A receptor affinity and selectivity versus alpha1 and D2 receptors. 5.">
            <entity id="DS3.d1008.s0.e0" origId="91066389" charOffset="13-21" type="compound" text="methoxy-"/>
            <entity id="DS3.d1008.s0.e1" origId="P08908,Q5ZGX3,A8K5W4" charOffset="172-187" type="protein" text="5-HT1A receptor"/>
            <entity id="DS3.d1008.s0.e2" origId="P25100,B0ZBE0" charOffset="220-226" type="protein" text="alpha1"/>
            <pair e1="DS3.d1008.s0.e0" e2="DS3.d1008.s0.e1" id="DS3.d1008.s0.i0" interaction="False" />
            <pair e1="DS3.d1008.s0.e0" e2="DS3.d1008.s0.e2" id="DS3.d1008.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1008.s1" origId="9986719-2" text="They were evaluated for in vitro 5-HT1A, D2, and alpha1 receptor affinity by radioligand binding assays, to study the influence of the chiral carbon atom of the tetrahydronaphthalene nucleus on the 5-HT1A affinity and selectivity.">
            <entity id="DS3.d1008.s1.e0" origId="P25100,B0ZBE0" charOffset="49-55" type="protein" text="alpha1"/>
            <entity id="DS3.d1008.s1.e1" origId="5462310" charOffset="142-148" type="compound" text="carbon"/>
            <entity id="DS3.d1008.s1.e2" origId="8404" charOffset="161-182" type="compound" text="tetrahydronaphthalene"/>
            <pair e1="DS3.d1008.s1.e1" e2="DS3.d1008.s1.e0" id="DS3.d1008.s1.i0" interaction="False" />
            <pair e1="DS3.d1008.s1.e2" e2="DS3.d1008.s1.e0" id="DS3.d1008.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1008.s2" origId="9986719-7" text="Furthermore, compounds (S)-(+)-4 and (R)-(-)-4 were submitted to the (35S)GTPgammaS binding assay for a preliminary evaluation of their intrinsic activity on the 5-HT1A receptor.">
            <entity id="DS3.d1008.s2.e0" origId="1764" charOffset="74-83" type="compound" text="GTPgammaS"/>
            <entity id="DS3.d1008.s2.e1" origId="P08908,Q5ZGX3,A8K5W4" charOffset="162-177" type="protein" text="5-HT1A receptor"/>
            <pair e1="DS3.d1008.s2.e0" e2="DS3.d1008.s2.e1" id="DS3.d1008.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1009" origId="9986727">
        <sentence id="DS3.d1009.s0" origId="9986727-4" text="Vezf1 encodes a protein with a predicted molecular mass of 56 kDa and that contains six putative zinc finger domains and shows high homology to a previously identified human gene, DB1, that is believed to be involved in regulating expression of cytokine genes such as interleukin-3.">
            <entity id="DS3.d1009.s0.e0" origId="Q5SXC4" charOffset="0-5" type="protein" text="Vezf1"/>
            <entity id="DS3.d1009.s0.e1" origId="23994" charOffset="97-101" type="compound" text="zinc"/>
            <entity id="DS3.d1009.s0.e2" origId="Q14119" charOffset="180-183" type="protein" text="DB1"/>
            <entity id="DS3.d1009.s0.e3" origId="P08700" charOffset="268-281" type="protein" text="interleukin-3"/>
            <pair e1="DS3.d1009.s0.e1" e2="DS3.d1009.s0.e2" id="DS3.d1009.s0.i0" interaction="False" />
            <pair e1="DS3.d1009.s0.e1" e2="DS3.d1009.s0.e3" id="DS3.d1009.s0.i1" interaction="False" />
            <pair e1="DS3.d1009.s0.e1" e2="DS3.d1009.s0.e0" id="DS3.d1009.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1010" origId="9986728">
        <sentence id="DS3.d1010.s0" origId="9986728-1" text="The Caenorhabditis elegans gene LIN-29 encodes a zinc-finger transcription factor that is required for hypodermal cell terminal differentiation and proper vulva morphogenesis.">
            <entity id="DS3.d1010.s0.e0" origId="G5EGB2,G5EGU6,E6N0V9" charOffset="32-38" type="protein" text="LIN-29"/>
            <entity id="DS3.d1010.s0.e1" origId="23994" charOffset="49-53" type="compound" text="zinc"/>
            <pair e1="DS3.d1010.s0.e1" e2="DS3.d1010.s0.e0" id="DS3.d1010.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1011" origId="9986733">
        <sentence id="DS3.d1011.s0" origId="9986733-6" text="The administration of retinol to the vitamin A-deficient embryo restores GATA-4 expression and completely rescues the vitamin A-deficient phenotype.">
            <entity id="DS3.d1011.s0.e0" origId="445354" charOffset="22-29" type="compound" text="retinol"/>
            <entity id="DS3.d1011.s0.e1" origId="P43694,B6DU75,B3KUF4" charOffset="73-79" type="protein" text="GATA-4"/>
            <pair e1="DS3.d1011.s0.e0" e2="DS3.d1011.s0.e1" id="DS3.d1011.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1012" origId="9986736">
        <sentence id="DS3.d1012.s0" origId="9986736-10" text="The shapes of the excitation spectra suggest the involvement of flavins, NAD(P)H, and at least one other, as yet unidentified, fluorophore.">
            <entity id="DS3.d1012.s0.e0" origId="5326566" charOffset="64-71" type="compound" text="flavins"/>
            <entity id="DS3.d1012.s0.e1" origId="Q16698,A0A024R9D7" charOffset="73-80" type="protein" text="NAD(P)H"/>
            <pair e1="DS3.d1012.s0.e0" e2="DS3.d1012.s0.e1" id="DS3.d1012.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1012.s1" origId="9986736-3" text="Spectral measurements (from one eye) were recorded from five patients with proliferative diabetic retinopathy and five age-matched healthy controls, using a modified commercial scanning fluorophotometer with a mercury arc or a tungsten halogen lamp as excitation light source in combination with interference filters (excitation wavelengths: 365, 405, 420, 430, 436, 440, 450, 470 and 480 nm; bandwidth: 10 nm).">
            <entity id="DS3.d1012.s1.e0" origId="23964" charOffset="227-235" type="compound" text="tungsten"/>
            <entity id="DS3.d1012.s1.e1" origId="Q13449" charOffset="244-248" type="protein" text="lamp"/>
            <pair e1="DS3.d1012.s1.e0" e2="DS3.d1012.s1.e1" id="DS3.d1012.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1013" origId="9986737">
        <sentence id="DS3.d1013.s0" origId="9986737-5" text="Specific antagonists of the adenosine A1 and A2a receptors were injected systemically, prior to ischemia of either 5, 30, or 60 min.">
            <entity id="DS3.d1013.s0.e0" origId="86620451" charOffset="28-40" type="compound" text="adenosine A1"/>
            <entity id="DS3.d1013.s0.e1" origId="P16086,Q6IRK8,A0A0G2K1Y8" charOffset="45-48" type="protein" text="A2a"/>
            <pair e1="DS3.d1013.s0.e0" e2="DS3.d1013.s0.e1" id="DS3.d1013.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1013.s1" origId="9986737-7" text="The adenosine A1 receptor antagonist DPCPX attenuated recovery after retinal ischemia of either 5 or 30 min, while the A2a receptor antagonist CSC dramatically protected retinal function and structure even with ischemia lasting up to 60 min.">
            <entity id="DS3.d1013.s1.e0" origId="P25099" charOffset="4-25" type="protein" text="adenosine A1 receptor"/>
            <entity id="DS3.d1013.s1.e1" origId="1329" charOffset="37-42" type="compound" text="DPCPX"/>
            <entity id="DS3.d1013.s1.e2" origId="638015" charOffset="69-76" type="compound" text="retinal"/>
            <entity id="DS3.d1013.s1.e3" origId="P16086,Q6IRK8,A0A0G2K1Y8" charOffset="119-122" type="protein" text="A2a"/>
            <entity id="DS3.d1013.s1.e4" origId="638015" charOffset="170-177" type="compound" text="retinal"/>
            <pair e1="DS3.d1013.s1.e1" e2="DS3.d1013.s1.e3" id="DS3.d1013.s1.i0" interaction="False" />
            <pair e1="DS3.d1013.s1.e1" e2="DS3.d1013.s1.e0" id="DS3.d1013.s1.i1" interaction="False" />
            <pair e1="DS3.d1013.s1.e2" e2="DS3.d1013.s1.e3" id="DS3.d1013.s1.i2" interaction="False" />
            <pair e1="DS3.d1013.s1.e2" e2="DS3.d1013.s1.e0" id="DS3.d1013.s1.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1014" origId="9986738">
        <sentence id="DS3.d1014.s0" origId="9986738-11" text="The temporal and concentration dependence of IGF-I expression by addition of the PKC activator PMA, to culture medium was similar to that due to the addition of bFGF.">
            <entity id="DS3.d1014.s0.e0" origId="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261" charOffset="45-50" type="protein" text="IGF-I"/>
            <entity id="DS3.d1014.s0.e1" origId="122634,22833501,4792" charOffset="95-98" type="compound" text="PMA"/>
            <entity id="DS3.d1014.s0.e2" origId="P13109" charOffset="161-165" type="protein" text="bFGF"/>
            <pair e1="DS3.d1014.s0.e1" e2="DS3.d1014.s0.e0" id="DS3.d1014.s0.i0" interaction="False" />
            <pair e1="DS3.d1014.s0.e1" e2="DS3.d1014.s0.e2" id="DS3.d1014.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1014.s1" origId="9986738-12" text="The down-regulation of IGF-I expression by bFGF (10 ng ml-1) and PMA (0.1 microM) was blocked by the PKC inhibitors H-7 (30 microM) and calphostin C (1 microM).">
            <entity id="DS3.d1014.s1.e0" origId="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261" charOffset="23-28" type="protein" text="IGF-I"/>
            <entity id="DS3.d1014.s1.e1" origId="P13109" charOffset="43-47" type="protein" text="bFGF"/>
            <entity id="DS3.d1014.s1.e2" origId="122634,22833501,4792" charOffset="65-68" type="compound" text="PMA"/>
            <entity id="DS3.d1014.s1.e3" origId="2533" charOffset="136-148" type="compound" text="calphostin C"/>
            <pair e1="DS3.d1014.s1.e3" e2="DS3.d1014.s1.e0" id="DS3.d1014.s1.i0" interaction="False" />
            <pair e1="DS3.d1014.s1.e3" e2="DS3.d1014.s1.e1" id="DS3.d1014.s1.i1" interaction="False" />
            <pair e1="DS3.d1014.s1.e2" e2="DS3.d1014.s1.e0" id="DS3.d1014.s1.i2" interaction="False" />
            <pair e1="DS3.d1014.s1.e2" e2="DS3.d1014.s1.e1" id="DS3.d1014.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1014.s2" origId="9986738-13" text="Forskolin (5 microM), an adenylate cyclase activator, had activator, had no effect on IGF-I expression.">
            <entity id="DS3.d1014.s2.e0" origId="47936" charOffset="0-9" type="compound" text="Forskolin"/>
            <entity id="DS3.d1014.s2.e1" origId="6083" charOffset="25-34" type="compound" text="adenylate"/>
            <entity id="DS3.d1014.s2.e2" origId="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261" charOffset="86-91" type="protein" text="IGF-I"/>
            <pair e1="DS3.d1014.s2.e0" e2="DS3.d1014.s2.e2" id="DS3.d1014.s2.i0" interaction="False" />
            <pair e1="DS3.d1014.s2.e1" e2="DS3.d1014.s2.e2" id="DS3.d1014.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1014.s3" origId="9986738-14" text="SQ22536 (100 microM), an adenylate cyclase inhibitor, and H-89, a PKA inhibitor, had no inhibitory effect on bFGF-induced down-regulation of IGF-I expression.">
            <entity id="DS3.d1014.s3.e0" origId="6083" charOffset="25-34" type="compound" text="adenylate"/>
            <entity id="DS3.d1014.s3.e1" origId="P13109" charOffset="109-113" type="protein" text="bFGF"/>
            <entity id="DS3.d1014.s3.e2" origId="P08025,F8WFZ5,Q5RK13,A0A0G2JX40,Q63261" charOffset="141-146" type="protein" text="IGF-I"/>
            <pair e1="DS3.d1014.s3.e0" e2="DS3.d1014.s3.e2" id="DS3.d1014.s3.i0" interaction="False" />
            <pair e1="DS3.d1014.s3.e0" e2="DS3.d1014.s3.e1" id="DS3.d1014.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1014.s4" origId="9986738-4" text="Cultured cells were identified by immunocytochemistry using antibodies against vimentin, carbonic anhydrase C, and glutamine synthetase.">
            <entity id="DS3.d1014.s4.e0" origId="P31000" charOffset="79-87" type="protein" text="vimentin"/>
            <entity id="DS3.d1014.s4.e1" origId="5961" charOffset="115-124" type="compound" text="glutamine"/>
            <pair e1="DS3.d1014.s4.e1" e2="DS3.d1014.s4.e0" id="DS3.d1014.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1014.s5" origId="9986738-5" text="Cells of passage 1-4 were treated with bFGF, the PKC inhibitor H-7, calphostin C, the PKC activator PMA or the PKA inhibitor H-89, as well as the adenylate cyclase activator forskolin, or adenylate cyclase inhibitor SQ22536.">
            <entity id="DS3.d1014.s5.e0" origId="P13109" charOffset="39-43" type="protein" text="bFGF"/>
            <entity id="DS3.d1014.s5.e1" origId="2533" charOffset="68-80" type="compound" text="calphostin C"/>
            <entity id="DS3.d1014.s5.e2" origId="122634,22833501,4792" charOffset="100-103" type="compound" text="PMA"/>
            <entity id="DS3.d1014.s5.e3" origId="6083" charOffset="146-155" type="compound" text="adenylate"/>
            <entity id="DS3.d1014.s5.e4" origId="47936" charOffset="174-183" type="compound" text="forskolin"/>
            <entity id="DS3.d1014.s5.e5" origId="6083" charOffset="188-197" type="compound" text="adenylate"/>
            <pair e1="DS3.d1014.s5.e4" e2="DS3.d1014.s5.e0" id="DS3.d1014.s5.i0" interaction="False" />
            <pair e1="DS3.d1014.s5.e1" e2="DS3.d1014.s5.e0" id="DS3.d1014.s5.i1" interaction="False" />
            <pair e1="DS3.d1014.s5.e2" e2="DS3.d1014.s5.e0" id="DS3.d1014.s5.i2" interaction="False" />
            <pair e1="DS3.d1014.s5.e3" e2="DS3.d1014.s5.e0" id="DS3.d1014.s5.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1015" origId="9986739">
        <sentence id="DS3.d1015.s0" origId="9986739-9" text="In glaucoma, enhanced expression of tenascin may be protective to the axons of the retinal ganglion cells by providing a barrier for humoral and/or blood-borne factors that may cause further neural damage.">
            <entity id="DS3.d1015.s0.e0" origId="P24821,F5H7V9,Q4LE33,B4E1W8,E9PC84,J3QSU6" charOffset="36-44" type="protein" text="tenascin"/>
            <entity id="DS3.d1015.s0.e1" origId="638015" charOffset="83-90" type="compound" text="retinal"/>
            <pair e1="DS3.d1015.s0.e1" e2="DS3.d1015.s0.e0" id="DS3.d1015.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1016" origId="9986745">
        <sentence id="DS3.d1016.s0" origId="9986745-2" text="The present experiments were made in order to study whether this phenomenon could be influenced by the tyrosinase inhibitor, alpha-methyl-p-tyrosine.">
            <entity id="DS3.d1016.s0.e0" origId="P14679,L8B082" charOffset="103-113" type="protein" text="tyrosinase"/>
            <entity id="DS3.d1016.s0.e1" origId="68309" charOffset="131-148" type="compound" text="methyl-p-tyrosine"/>
            <pair e1="DS3.d1016.s0.e1" e2="DS3.d1016.s0.e0" id="DS3.d1016.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1016.s1" origId="9986745-3" text="Melanin content, melanin production and tyrosinase activity of cultured uveal melanocytes derived from irides of brown or brown-blue color were measured after adding latanoprost at different molar concentration with or without alpha-methyl-p-tyrosine (10(-5)m).">
            <entity id="DS3.d1016.s1.e0" origId="6325610" charOffset="0-7" type="compound" text="Melanin"/>
            <entity id="DS3.d1016.s1.e1" origId="6325610" charOffset="17-24" type="compound" text="melanin"/>
            <entity id="DS3.d1016.s1.e2" origId="P14679,L8B082" charOffset="40-50" type="protein" text="tyrosinase"/>
            <entity id="DS3.d1016.s1.e3" origId="5311221" charOffset="166-177" type="compound" text="latanoprost"/>
            <entity id="DS3.d1016.s1.e4" origId="68309" charOffset="233-250" type="compound" text="methyl-p-tyrosine"/>
            <pair e1="DS3.d1016.s1.e3" e2="DS3.d1016.s1.e2" id="DS3.d1016.s1.i0" interaction="False" />
            <pair e1="DS3.d1016.s1.e0" e2="DS3.d1016.s1.e2" id="DS3.d1016.s1.i1" interaction="False" />
            <pair e1="DS3.d1016.s1.e4" e2="DS3.d1016.s1.e2" id="DS3.d1016.s1.i2" interaction="False" />
            <pair e1="DS3.d1016.s1.e1" e2="DS3.d1016.s1.e2" id="DS3.d1016.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1016.s2" origId="9986745-4" text="It was shown that latanoprost stimulated melanin content, melanin production and tyrosinase activity in a molar range between 10(-7) and 10(-5)m in uveal melanocytes derived from irides of both brown and brown-blue color.">
            <entity id="DS3.d1016.s2.e0" origId="5311221" charOffset="18-29" type="compound" text="latanoprost"/>
            <entity id="DS3.d1016.s2.e1" origId="6325610" charOffset="41-48" type="compound" text="melanin"/>
            <entity id="DS3.d1016.s2.e2" origId="6325610" charOffset="58-65" type="compound" text="melanin"/>
            <entity id="DS3.d1016.s2.e3" origId="P14679,L8B082" charOffset="81-91" type="protein" text="tyrosinase"/>
            <pair e1="DS3.d1016.s2.e0" e2="DS3.d1016.s2.e3" id="DS3.d1016.s2.i0" interaction="False" />
            <pair e1="DS3.d1016.s2.e1" e2="DS3.d1016.s2.e3" id="DS3.d1016.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1016.s3" origId="9986745-7" text="These results suggest that latanoprost-induced stimulation of melanin production, follows the metabolic pathway involving tyrosinase activity and may be relevant for the therapeutic application of latanoprost in glaucoma in order to reduce its side-effect resulting in increased iris pigmentation.">
            <entity id="DS3.d1016.s3.e0" origId="5311221" charOffset="27-38" type="compound" text="latanoprost"/>
            <entity id="DS3.d1016.s3.e1" origId="6325610" charOffset="62-69" type="compound" text="melanin"/>
            <entity id="DS3.d1016.s3.e2" origId="P14679,L8B082" charOffset="122-132" type="protein" text="tyrosinase"/>
            <entity id="DS3.d1016.s3.e3" origId="5311221" charOffset="197-208" type="compound" text="latanoprost"/>
            <pair e1="DS3.d1016.s3.e0" e2="DS3.d1016.s3.e2" id="DS3.d1016.s3.i0" interaction="False" />
            <pair e1="DS3.d1016.s3.e1" e2="DS3.d1016.s3.e2" id="DS3.d1016.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1017" origId="9986746">
        <sentence id="DS3.d1017.s0" origId="9986746-8" text="Presence of MMP-2, MMP-3 and TIMP-1 in epiretinal and subretinal membranes of PVR but not in normal retina indicates that these molecules may play an important role during the healing process that follows rhegmatogenous retinal detachment.">
            <entity id="DS3.d1017.s0.e0" origId="P08253,A0A024R6R4" charOffset="12-17" type="protein" text="MMP-2"/>
            <entity id="DS3.d1017.s0.e1" origId="P08254" charOffset="19-24" type="protein" text="MMP-3"/>
            <entity id="DS3.d1017.s0.e2" origId="P01033,Q6FGX5,B4DJK3" charOffset="29-35" type="protein" text="TIMP-1"/>
            <entity id="DS3.d1017.s0.e3" origId="638015" charOffset="42-49" type="compound" text="retinal"/>
            <pair e1="DS3.d1017.s0.e3" e2="DS3.d1017.s0.e0" id="DS3.d1017.s0.i0" interaction="False" />
            <pair e1="DS3.d1017.s0.e3" e2="DS3.d1017.s0.e1" id="DS3.d1017.s0.i1" interaction="False" />
            <pair e1="DS3.d1017.s0.e3" e2="DS3.d1017.s0.e2" id="DS3.d1017.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1018" origId="9986765">
        <sentence id="DS3.d1018.s0" origId="9986765-3" text="myo-Inositol, quantified by a separate proton MRS, and readily detectable in 13C MRS, was used as an internal reference.">
            <entity id="DS3.d1018.s0.e0" origId="892" charOffset="4-12" type="compound" text="Inositol"/>
            <entity id="DS3.d1018.s0.e1" origId="1038,5460653" charOffset="39-45" type="compound" text="proton"/>
            <entity id="DS3.d1018.s0.e2" origId="P59665" charOffset="46-49" type="protein" text="MRS"/>
            <entity id="DS3.d1018.s0.e3" origId="P59665" charOffset="81-84" type="protein" text="MRS"/>
            <pair e1="DS3.d1018.s0.e0" e2="DS3.d1018.s0.e2" id="DS3.d1018.s0.i0" interaction="False" />
            <pair e1="DS3.d1018.s0.e1" e2="DS3.d1018.s0.e2" id="DS3.d1018.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1019" origId="9986887">
        <sentence id="DS3.d1019.s0" origId="9986887-3" text="The concentration of routine laboratory parameters, components of the complement system (C3, C4, C5, C1 inhibitor, total hemolytic complement, C3d, and C5a), circulating interleukins (IL-6 and IL-8) and soluble adhesion molecules (sICAM-1 and sE-selectin) were determined.">
            <entity id="DS3.d1019.s0.e0" origId="P01031" charOffset="152-155" type="protein" text="C5a"/>
            <entity id="DS3.d1019.s0.e1" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="184-188" type="protein" text="IL-6"/>
            <entity id="DS3.d1019.s0.e2" origId="P10145,A0A024RDA5" charOffset="193-197" type="protein" text="IL-8"/>
            <entity id="DS3.d1019.s0.e3" origId="4929" charOffset="246-254" type="compound" text="selectin"/>
            <pair e1="DS3.d1019.s0.e3" e2="DS3.d1019.s0.e1" id="DS3.d1019.s0.i0" interaction="False" />
            <pair e1="DS3.d1019.s0.e3" e2="DS3.d1019.s0.e2" id="DS3.d1019.s0.i1" interaction="False" />
            <pair e1="DS3.d1019.s0.e3" e2="DS3.d1019.s0.e0" id="DS3.d1019.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1020" origId="9986907">
        <sentence id="DS3.d1020.s0" origId="9986907-2" text="Properties of the newly discovered factors RF3, eRF1, and eRF3 are described.">
            <entity id="DS3.d1020.s0.e0" origId="1453694" charOffset="43-46" type="compound" text="RF3"/>
            <entity id="DS3.d1020.s0.e1" origId="P62495,B7Z7P8" charOffset="48-52" type="protein" text="eRF1"/>
            <pair e1="DS3.d1020.s0.e0" e2="DS3.d1020.s0.e1" id="DS3.d1020.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1021" origId="9986909">
        <sentence id="DS3.d1021.s0" origId="9986909-8" text="Thus, lucigenin-dependent chemiluminescence of microsomes may be due to some enzymes including lucigenin reductase (NADPH-cytochrome P450 reductase, NADH-cytochrome b5 reductase), generation of O2-.">
            <entity id="DS3.d1021.s0.e0" origId="65100" charOffset="6-15" type="compound" text="lucigenin"/>
            <entity id="DS3.d1021.s0.e1" origId="65100" charOffset="95-104" type="compound" text="lucigenin"/>
            <entity id="DS3.d1021.s0.e2" origId="P00388" charOffset="116-147" type="protein" text="NADPH-cytochrome P450 reductase"/>
            <entity id="DS3.d1021.s0.e3" origId="439153" charOffset="149-153" type="compound" text="NADH"/>
            <pair e1="DS3.d1021.s0.e3" e2="DS3.d1021.s0.e2" id="DS3.d1021.s0.i0" interaction="False" />
            <pair e1="DS3.d1021.s0.e0" e2="DS3.d1021.s0.e2" id="DS3.d1021.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1022" origId="9986915">
        <sentence id="DS3.d1022.s0" origId="9986915-0" text="Kinetic properties of the activator complexes plasmin--staphylokinase and plasmin(ogen)--streptokinase in vitro.">
            <entity id="DS3.d1022.s0.e0" origId="P00747,Q5TEH5" charOffset="46-53" type="protein" text="plasmin"/>
            <entity id="DS3.d1022.s0.e1" origId="P00747,Q5TEH5" charOffset="74-81" type="protein" text="plasmin"/>
            <entity id="DS3.d1022.s0.e2" origId="9815560" charOffset="89-102" type="compound" text="streptokinase"/>
            <pair e1="DS3.d1022.s0.e2" e2="DS3.d1022.s0.e0" id="DS3.d1022.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1022.s1" origId="9986915-1" text="Comparative kinetic and electrophoretic study of the interaction of plasminogen (PG) with equimolar concentrations of staphylokinase (SPK) and streptokinase (SK) at 4 and 37 degreesC showed that the PG--SK complex has fibrinolytic and esterase activities, whereas the PG--SPK complex was inactive.">
            <entity id="DS3.d1022.s1.e0" origId="P00747,Q5TEH5" charOffset="68-79" type="protein" text="plasminogen"/>
            <entity id="DS3.d1022.s1.e1" origId="Q92797,A0A024R0R6" charOffset="134-137" type="protein" text="SPK"/>
            <entity id="DS3.d1022.s1.e2" origId="9815560" charOffset="143-156" type="compound" text="streptokinase"/>
            <entity id="DS3.d1022.s1.e3" origId="Q92797,A0A024R0R6" charOffset="272-275" type="protein" text="SPK"/>
            <pair e1="DS3.d1022.s1.e2" e2="DS3.d1022.s1.e1" id="DS3.d1022.s1.i0" interaction="False" />
            <pair e1="DS3.d1022.s1.e2" e2="DS3.d1022.s1.e0" id="DS3.d1022.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1022.s2" origId="9986915-3" text="The catalytic efficiency of Z-Lys-pNP hydrolysis (kcat/Km) by the preformed PL--SPK complex was twofold lower than that in the case of the PL--SK complex.">
            <entity id="DS3.d1022.s2.e0" origId="5962" charOffset="30-33" type="compound" text="Lys"/>
            <entity id="DS3.d1022.s2.e1" origId="Q92797,A0A024R0R6" charOffset="80-83" type="protein" text="SPK"/>
            <pair e1="DS3.d1022.s2.e0" e2="DS3.d1022.s2.e1" id="DS3.d1022.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1022.s3" origId="9986915-5" text="The PL--SPK complex was considerably more stable than the PG--SK(PL--SK) complex; streptokinase degraded more rapidly than staphylokinase.">
            <entity id="DS3.d1022.s3.e0" origId="Q92797,A0A024R0R6" charOffset="8-11" type="protein" text="SPK"/>
            <entity id="DS3.d1022.s3.e1" origId="9815560" charOffset="82-95" type="compound" text="streptokinase"/>
            <pair e1="DS3.d1022.s3.e1" e2="DS3.d1022.s3.e0" id="DS3.d1022.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1022.s4" origId="9986915-7" text="Probably, unlike streptokinase, staphylokinase which is less susceptible to degradation in the PL--SPK complex and is released from the triple complex alpha2-antiplasmin--PL--SPK, forms a potentially highly active new complex with free molecules of plasminogen in the plasma.">
            <entity id="DS3.d1022.s4.e0" origId="9815560" charOffset="17-30" type="compound" text="streptokinase"/>
            <entity id="DS3.d1022.s4.e1" origId="Q92797,A0A024R0R6" charOffset="99-102" type="protein" text="SPK"/>
            <entity id="DS3.d1022.s4.e2" origId="Q92797,A0A024R0R6" charOffset="175-178" type="protein" text="SPK"/>
            <entity id="DS3.d1022.s4.e3" origId="P00747,Q5TEH5" charOffset="249-260" type="protein" text="plasminogen"/>
            <pair e1="DS3.d1022.s4.e0" e2="DS3.d1022.s4.e1" id="DS3.d1022.s4.i0" interaction="False" />
            <pair e1="DS3.d1022.s4.e0" e2="DS3.d1022.s4.e3" id="DS3.d1022.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1023" origId="9986917">
        <sentence id="DS3.d1023.s0" origId="9986917-7" text="The sea urchin thymidilate kinase can utilize ATP, dCTP, and dTTP as donors of the phosphate group.">
            <entity id="DS3.d1023.s0.e0" origId="65091" charOffset="51-55" type="compound" text="dCTP"/>
            <entity id="DS3.d1023.s0.e1" origId="P47980,B3DN56" charOffset="61-65" type="protein" text="dTTP"/>
            <entity id="DS3.d1023.s0.e2" origId="1061,167704,644102" charOffset="83-92" type="compound" text="phosphate"/>
            <pair e1="DS3.d1023.s0.e2" e2="DS3.d1023.s0.e1" id="DS3.d1023.s0.i0" interaction="False" />
            <pair e1="DS3.d1023.s0.e0" e2="DS3.d1023.s0.e1" id="DS3.d1023.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1024" origId="9986918">
        <sentence id="DS3.d1024.s0" origId="9986918-0" text="Reduction of nitrite by glycosylated amino acids and glycosylated albumin.">
            <entity id="DS3.d1024.s0.e0" origId="946" charOffset="13-20" type="compound" text="nitrite"/>
            <entity id="DS3.d1024.s0.e1" origId="P02768" charOffset="66-73" type="protein" text="albumin"/>
            <pair e1="DS3.d1024.s0.e0" e2="DS3.d1024.s0.e1" id="DS3.d1024.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1024.s1" origId="9986918-1" text="Glycosylated amino acids and glycosylated human serum albumin reduce nitrite to nitric oxide under anaerobic conditions.">
            <entity id="DS3.d1024.s1.e0" origId="P02768" charOffset="54-61" type="protein" text="albumin"/>
            <entity id="DS3.d1024.s1.e1" origId="946" charOffset="69-76" type="compound" text="nitrite"/>
            <entity id="DS3.d1024.s1.e2" origId="145068" charOffset="80-92" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d1024.s1.e1" e2="DS3.d1024.s1.e0" id="DS3.d1024.s1.i0" interaction="False" />
            <pair e1="DS3.d1024.s1.e2" e2="DS3.d1024.s1.e0" id="DS3.d1024.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1024.s2" origId="9986918-3" text="Without preincubation after the addition of sodium nitrite, glucose or a mixture of glucose with amino acid or serum albumin did not cause spectrophotometrically detectible transformation of deoxyHb into nitrosoHb.">
            <entity id="DS3.d1024.s2.e0" origId="23668193" charOffset="44-58" type="compound" text="sodium nitrite"/>
            <entity id="DS3.d1024.s2.e1" origId="206,79025,5793,64689" charOffset="60-67" type="compound" text="glucose"/>
            <entity id="DS3.d1024.s2.e2" origId="206,79025,5793,64689" charOffset="84-91" type="compound" text="glucose"/>
            <entity id="DS3.d1024.s2.e3" origId="P02768" charOffset="117-124" type="protein" text="albumin"/>
            <pair e1="DS3.d1024.s2.e0" e2="DS3.d1024.s2.e3" id="DS3.d1024.s2.i0" interaction="False" />
            <pair e1="DS3.d1024.s2.e1" e2="DS3.d1024.s2.e3" id="DS3.d1024.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1025" origId="9986921">
        <sentence id="DS3.d1025.s0" origId="9986921-10" text="In summary, our data suggest that (1) the blunted CRH-induced release of ACTH and cortisol during SWS is not mimicked by systemic GHRH administration, and (2) CRH enhances sigma EEG activity possibly via modulation of afferent pathways from the median eminence to the thalamus and this effect is reduced by pre-treatment with GHRH.">
            <entity id="DS3.d1025.s0.e0" origId="P06850" charOffset="50-53" type="protein" text="CRH"/>
            <entity id="DS3.d1025.s0.e1" origId="P01189,Q6FHC8" charOffset="73-77" type="protein" text="ACTH"/>
            <entity id="DS3.d1025.s0.e2" origId="5754" charOffset="82-90" type="compound" text="cortisol"/>
            <entity id="DS3.d1025.s0.e3" origId="P01286" charOffset="130-134" type="protein" text="GHRH"/>
            <entity id="DS3.d1025.s0.e4" origId="P06850" charOffset="159-162" type="protein" text="CRH"/>
            <entity id="DS3.d1025.s0.e5" origId="P01286" charOffset="326-330" type="protein" text="GHRH"/>
            <pair e1="DS3.d1025.s0.e2" e2="DS3.d1025.s0.e1" id="DS3.d1025.s0.i0" interaction="False" />
            <pair e1="DS3.d1025.s0.e2" e2="DS3.d1025.s0.e0" id="DS3.d1025.s0.i1" interaction="False" />
            <pair e1="DS3.d1025.s0.e2" e2="DS3.d1025.s0.e3" id="DS3.d1025.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1025.s1" origId="9986921-2" text="Since GHRH is involved in the promotion of SWS in humans and rats, it was examined whether the blunted CRH-induced ACTH and cortisol release during SWS could be mimicked by systemic GHRH.">
            <entity id="DS3.d1025.s1.e0" origId="P01286" charOffset="6-10" type="protein" text="GHRH"/>
            <entity id="DS3.d1025.s1.e1" origId="P06850" charOffset="103-106" type="protein" text="CRH"/>
            <entity id="DS3.d1025.s1.e2" origId="P01189,Q6FHC8" charOffset="115-119" type="protein" text="ACTH"/>
            <entity id="DS3.d1025.s1.e3" origId="5754" charOffset="124-132" type="compound" text="cortisol"/>
            <entity id="DS3.d1025.s1.e4" origId="P01286" charOffset="182-186" type="protein" text="GHRH"/>
            <pair e1="DS3.d1025.s1.e3" e2="DS3.d1025.s1.e2" id="DS3.d1025.s1.i0" interaction="False" />
            <pair e1="DS3.d1025.s1.e3" e2="DS3.d1025.s1.e1" id="DS3.d1025.s1.i1" interaction="False" />
            <pair e1="DS3.d1025.s1.e3" e2="DS3.d1025.s1.e0" id="DS3.d1025.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1025.s2" origId="9986921-4" text="The sleep EEG was recorded during the lights off period and blood samples, collected every 20 min between 22.00 and 07.00 h, were assayed for GH, cortisol and ACTH.">
            <entity id="DS3.d1025.s2.e0" origId="5754" charOffset="146-154" type="compound" text="cortisol"/>
            <entity id="DS3.d1025.s2.e1" origId="P01189,Q6FHC8" charOffset="159-163" type="protein" text="ACTH"/>
            <pair e1="DS3.d1025.s2.e0" e2="DS3.d1025.s2.e1" id="DS3.d1025.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1025.s3" origId="9986921-8" text="Similarly, cortisol was significantly enhanced compared with baseline following CRH during wakefulness only.">
            <entity id="DS3.d1025.s3.e0" origId="5754" charOffset="11-19" type="compound" text="cortisol"/>
            <entity id="DS3.d1025.s3.e1" origId="P06850" charOffset="80-83" type="protein" text="CRH"/>
            <pair e1="DS3.d1025.s3.e0" e2="DS3.d1025.s3.e1" id="DS3.d1025.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1026" origId="9986923">
        <sentence id="DS3.d1026.s0" origId="9986923-0" text="Melatonin modulation of the daily prolactin secretion in intact and ovariectomized ewes. Relation to a phase of the estrous cycle and to the presence of estradiol.">
            <entity id="DS3.d1026.s0.e0" origId="896" charOffset="0-9" type="compound" text="Melatonin"/>
            <entity id="DS3.d1026.s0.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="34-43" type="protein" text="prolactin"/>
            <entity id="DS3.d1026.s0.e2" origId="5757" charOffset="153-162" type="compound" text="estradiol"/>
            <pair e1="DS3.d1026.s0.e0" e2="DS3.d1026.s0.e1" id="DS3.d1026.s0.i0" interaction="False" />
            <pair e1="DS3.d1026.s0.e2" e2="DS3.d1026.s0.e1" id="DS3.d1026.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1026.s1" origId="9986923-1" text="The aim of this study was to investigate whether melatonin might modulate the daily prolactin secretion in the ewe during a period of ovarian activity and, if so, whether this modulatory action of melatonin was related to the presence of estradiol in the organism.">
            <entity id="DS3.d1026.s1.e0" origId="896" charOffset="49-58" type="compound" text="melatonin"/>
            <entity id="DS3.d1026.s1.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="84-93" type="protein" text="prolactin"/>
            <entity id="DS3.d1026.s1.e2" origId="896" charOffset="197-206" type="compound" text="melatonin"/>
            <entity id="DS3.d1026.s1.e3" origId="5757" charOffset="238-247" type="compound" text="estradiol"/>
            <pair e1="DS3.d1026.s1.e0" e2="DS3.d1026.s1.e1" id="DS3.d1026.s1.i0" interaction="False" />
            <pair e1="DS3.d1026.s1.e3" e2="DS3.d1026.s1.e1" id="DS3.d1026.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1026.s2" origId="9986923-3" text="Melatonin was infused into the third brain ventricle (100 microgram/100 microliter/h) from 14.00 to 18.00 h. The concentration of prolactin increased significantly during the infusion of melatonin in late follicular-phase ewes, but not in luteal-phase ewes, as compared to the concentration before the infusion: range from 204.0 +/- 31.7 to 272.2 +/- 50.1 ng/ml vs. range from 68.2 +/- 31.8 to 94.7 +/- 33.1 ng/ml (mean +/- SEM, n = 4, p &amp;lt; 0.01) and to the concentration noted during control infusions: range from 130.0 +/- 58.0 to 179.3 +/- 55.6 ng/ml (mean +/- SEM, n = 4, p &amp;lt; 0.05).">
            <entity id="DS3.d1026.s2.e0" origId="896" charOffset="0-9" type="compound" text="Melatonin"/>
            <entity id="DS3.d1026.s2.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="130-139" type="protein" text="prolactin"/>
            <entity id="DS3.d1026.s2.e2" origId="896" charOffset="187-196" type="compound" text="melatonin"/>
            <entity id="DS3.d1026.s2.e3" origId="5289348" charOffset="424-427" type="compound" text="SEM"/>
            <entity id="DS3.d1026.s2.e4" origId="5289348" charOffset="566-569" type="compound" text="SEM"/>
            <pair e1="DS3.d1026.s2.e0" e2="DS3.d1026.s2.e1" id="DS3.d1026.s2.i0" interaction="False" />
            <pair e1="DS3.d1026.s2.e3" e2="DS3.d1026.s2.e1" id="DS3.d1026.s2.i1" interaction="False" />
            <pair e1="DS3.d1026.s2.e2" e2="DS3.d1026.s2.e1" id="DS3.d1026.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1026.s3" origId="9986923-4" text="In ovariectomized ewes, the concentration of prolactin during infusion of melatonin increased significantly, unrelated to the presence of estradiol, as compared to the concentration before infusion: range from 136.7 +/- 20.3 to 260.0 +/- 11.6 ng/ml vs. range from 41.6 +/- 2.6 to 152.3 +/- 14.6 ng/ml in OVX ewes (mean +/- SEM, n = 4, p &amp;lt; 0.01) and range from 161.5 +/- 66.5 to 250.2 +/- 24.3 ng/ml vs. range from 61.2 +/- 1.7 to 159.2 +/- 43.3 ng/ml in OVX+E2 ewes (mean +/- SEM, n = 4, p &amp;lt; 0.01).">
            <entity id="DS3.d1026.s3.e0" origId="P01236,Q5I0G2,Q5THQ0" charOffset="45-54" type="protein" text="prolactin"/>
            <entity id="DS3.d1026.s3.e1" origId="896" charOffset="74-83" type="compound" text="melatonin"/>
            <entity id="DS3.d1026.s3.e2" origId="5757" charOffset="138-147" type="compound" text="estradiol"/>
            <entity id="DS3.d1026.s3.e3" origId="5289348" charOffset="323-326" type="compound" text="SEM"/>
            <entity id="DS3.d1026.s3.e4" origId="5289348" charOffset="479-482" type="compound" text="SEM"/>
            <pair e1="DS3.d1026.s3.e1" e2="DS3.d1026.s3.e0" id="DS3.d1026.s3.i0" interaction="False" />
            <pair e1="DS3.d1026.s3.e3" e2="DS3.d1026.s3.e0" id="DS3.d1026.s3.i1" interaction="False" />
            <pair e1="DS3.d1026.s3.e2" e2="DS3.d1026.s3.e0" id="DS3.d1026.s3.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1026.s4" origId="9986923-6" text="These results indicate that melatonin may affect the daily secretion of prolactin in ewes during the breeding season, and suggest that the variable response of prolactin to the melatonin signal in intact and ovariectomized ewes relates to the interaction between both ovarian steroids - estradiol and progesterone - and the prolactin-releasing factor.">
            <entity id="DS3.d1026.s4.e0" origId="896" charOffset="28-37" type="compound" text="melatonin"/>
            <entity id="DS3.d1026.s4.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="72-81" type="protein" text="prolactin"/>
            <entity id="DS3.d1026.s4.e2" origId="P01236,Q5I0G2,Q5THQ0" charOffset="160-169" type="protein" text="prolactin"/>
            <entity id="DS3.d1026.s4.e3" origId="896" charOffset="177-186" type="compound" text="melatonin"/>
            <entity id="DS3.d1026.s4.e4" origId="5757" charOffset="287-296" type="compound" text="estradiol"/>
            <entity id="DS3.d1026.s4.e5" origId="5994" charOffset="301-313" type="compound" text="progesterone"/>
            <entity id="DS3.d1026.s4.e6" origId="P01236,Q5I0G2,Q5THQ0" charOffset="160-169" type="protein" text="prolactin"/>
            <pair e1="DS3.d1026.s4.e0" e2="DS3.d1026.s4.e1" id="DS3.d1026.s4.i0" interaction="False" />
            <pair e1="DS3.d1026.s4.e4" e2="DS3.d1026.s4.e1" id="DS3.d1026.s4.i1" interaction="False" />
            <pair e1="DS3.d1026.s4.e5" e2="DS3.d1026.s4.e1" id="DS3.d1026.s4.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1027" origId="9986924">
        <sentence id="DS3.d1027.s0" origId="9986924-0" text="Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study.">
            <entity id="DS3.d1027.s0.e0" origId="P30560" charOffset="39-42" type="protein" text="V1a"/>
            <entity id="DS3.d1027.s0.e1" origId="60943" charOffset="63-71" type="compound" text="SR-49059"/>
            <pair e1="DS3.d1027.s0.e1" e2="DS3.d1027.s0.e0" id="DS3.d1027.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1027.s1" origId="9986924-10" text="In conclusion, our study shows that (3H)SR-49059 is a suitable probe to investigate V1a receptors in the rat brain.">
            <entity id="DS3.d1027.s1.e0" origId="60943" charOffset="40-48" type="compound" text="SR-49059"/>
            <entity id="DS3.d1027.s1.e1" origId="P30560" charOffset="84-87" type="protein" text="V1a"/>
            <pair e1="DS3.d1027.s1.e0" e2="DS3.d1027.s1.e1" id="DS3.d1027.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1027.s2" origId="9986924-1" text="A potent non-peptide vasopressin (AVP) antagonist, SR-49059, displaying high stability and selective affinity for the V1a AVP receptor subtype, has recently been described.">
            <entity id="DS3.d1027.s2.e0" origId="P01186" charOffset="34-37" type="protein" text="AVP"/>
            <entity id="DS3.d1027.s2.e1" origId="60943" charOffset="51-59" type="compound" text="SR-49059"/>
            <entity id="DS3.d1027.s2.e2" origId="P30560" charOffset="118-121" type="protein" text="V1a"/>
            <entity id="DS3.d1027.s2.e3" origId="P01186" charOffset="122-125" type="protein" text="AVP"/>
            <pair e1="DS3.d1027.s2.e1" e2="DS3.d1027.s2.e2" id="DS3.d1027.s2.i0" interaction="False" />
            <pair e1="DS3.d1027.s2.e1" e2="DS3.d1027.s2.e0" id="DS3.d1027.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1027.s3" origId="9986924-5" text="In vitro labelling of rat brain sections with (3H)SR-49059 was similar to that previously detected with (3H)AVP, which confirms that the majority of central AVP binding sites are V1a sites similar to peripheral V1a receptors.">
            <entity id="DS3.d1027.s3.e0" origId="60943" charOffset="50-58" type="compound" text="SR-49059"/>
            <entity id="DS3.d1027.s3.e1" origId="P01186" charOffset="108-111" type="protein" text="AVP"/>
            <entity id="DS3.d1027.s3.e2" origId="P01186" charOffset="157-160" type="protein" text="AVP"/>
            <entity id="DS3.d1027.s3.e3" origId="P30560" charOffset="179-182" type="protein" text="V1a"/>
            <entity id="DS3.d1027.s3.e4" origId="P30560" charOffset="211-214" type="protein" text="V1a"/>
            <pair e1="DS3.d1027.s3.e0" e2="DS3.d1027.s3.e3" id="DS3.d1027.s3.i0" interaction="False" />
            <pair e1="DS3.d1027.s3.e0" e2="DS3.d1027.s3.e1" id="DS3.d1027.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1028" origId="9986926">
        <sentence id="DS3.d1028.s0" origId="9986926-0" text="Estrogens normalize the hypothalamic-pituitary-adrenal axis response to stress and increase glucocorticoid receptor immuno-reactivity in hippocampus of aging male rats.">
            <entity id="DS3.d1028.s0.e0" origId="3001028" charOffset="0-9" type="compound" text="Estrogens"/>
            <entity id="DS3.d1028.s0.e1" origId="P06536" charOffset="92-115" type="protein" text="glucocorticoid receptor"/>
            <pair e1="DS3.d1028.s0.e0" e2="DS3.d1028.s0.e1" id="DS3.d1028.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1028.s1" origId="9986926-7" text="We observed that prolonged estrogen treatment (6 weeks) of old rats normalized the termination of the stress response, restored dexamethasone inhibition of plasma CORT, and increased GR immunoreactivity in CA1 and CA2 hippocampal subfields and subiculum.">
            <entity id="DS3.d1028.s1.e0" origId="5743" charOffset="128-141" type="compound" text="dexamethasone"/>
            <entity id="DS3.d1028.s1.e1" origId="B0BNN3" charOffset="206-209" type="protein" text="CA1"/>
            <entity id="DS3.d1028.s1.e2" origId="P27139" charOffset="214-217" type="protein" text="CA2"/>
            <pair e1="DS3.d1028.s1.e0" e2="DS3.d1028.s1.e2" id="DS3.d1028.s1.i0" interaction="False" />
            <pair e1="DS3.d1028.s1.e0" e2="DS3.d1028.s1.e1" id="DS3.d1028.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1029" origId="9986992">
        <sentence id="DS3.d1029.s0" origId="9986992-4" text="Too much water, hot or cold, is a continued source of cutaneous misery to the soldier in the field.">
            <entity id="DS3.d1029.s0.e0" origId="962" charOffset="9-14" type="compound" text="water"/>
            <entity id="DS3.d1029.s0.e1" origId="Q8IWW8" charOffset="16-19" type="protein" text="hot"/>
            <pair e1="DS3.d1029.s0.e0" e2="DS3.d1029.s0.e1" id="DS3.d1029.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1030" origId="9987007">
        <sentence id="DS3.d1030.s0" origId="9987007-1" text="In the present study in situ hybridization was used to study the effect of kainic acid induced seizures on the expression of the zinc finger immediate-early genes (IEGs) NGFI-A, NGFI-B, NGFI-C, egr-2; egr-3 and Nurr1.">
            <entity id="DS3.d1030.s0.e0" origId="10255" charOffset="75-86" type="compound" text="kainic acid"/>
            <entity id="DS3.d1030.s0.e1" origId="23994" charOffset="129-133" type="compound" text="zinc"/>
            <entity id="DS3.d1030.s0.e2" origId="P18146,Q546S1" charOffset="170-176" type="protein" text="NGFI-A"/>
            <entity id="DS3.d1030.s0.e3" origId="P22736,A0A024R126,F5GXF0,Q6ZMM6" charOffset="178-184" type="protein" text="NGFI-B"/>
            <entity id="DS3.d1030.s0.e4" origId="Q05215,B7ZKU3" charOffset="186-192" type="protein" text="NGFI-C"/>
            <entity id="DS3.d1030.s0.e5" origId="P11161" charOffset="194-199" type="protein" text="egr-2"/>
            <entity id="DS3.d1030.s0.e6" origId="Q06889,B4DH80" charOffset="201-206" type="protein" text="egr-3"/>
            <entity id="DS3.d1030.s0.e7" origId="P43354,F1D8N6,Q53EL4" charOffset="211-216" type="protein" text="Nurr1"/>
            <pair e1="DS3.d1030.s0.e1" e2="DS3.d1030.s0.e7" id="DS3.d1030.s0.i0" interaction="False" />
            <pair e1="DS3.d1030.s0.e1" e2="DS3.d1030.s0.e5" id="DS3.d1030.s0.i1" interaction="False" />
            <pair e1="DS3.d1030.s0.e1" e2="DS3.d1030.s0.e6" id="DS3.d1030.s0.i2" interaction="False" />
            <pair e1="DS3.d1030.s0.e1" e2="DS3.d1030.s0.e4" id="DS3.d1030.s0.i3" interaction="False" />
            <pair e1="DS3.d1030.s0.e1" e2="DS3.d1030.s0.e3" id="DS3.d1030.s0.i4" interaction="False" />
            <pair e1="DS3.d1030.s0.e1" e2="DS3.d1030.s0.e2" id="DS3.d1030.s0.i5" interaction="False" />
            <pair e1="DS3.d1030.s0.e0" e2="DS3.d1030.s0.e7" id="DS3.d1030.s0.i6" interaction="False" />
            <pair e1="DS3.d1030.s0.e0" e2="DS3.d1030.s0.e5" id="DS3.d1030.s0.i7" interaction="False" />
            <pair e1="DS3.d1030.s0.e0" e2="DS3.d1030.s0.e6" id="DS3.d1030.s0.i8" interaction="False" />
            <pair e1="DS3.d1030.s0.e0" e2="DS3.d1030.s0.e4" id="DS3.d1030.s0.i9" interaction="False" />
            <pair e1="DS3.d1030.s0.e0" e2="DS3.d1030.s0.e3" id="DS3.d1030.s0.i10" interaction="False" />
            <pair e1="DS3.d1030.s0.e0" e2="DS3.d1030.s0.e2" id="DS3.d1030.s0.i11" interaction="False" />
        </sentence>
        <sentence id="DS3.d1030.s1" origId="9987007-4" text="However, in the CA1 and CA3 subfields of hippocampus known to be damaged by kainic acid the expression of all the IEGs except egr-2 remained elevated for 24 h. NGFI-A, NGFI-B, NGFI-C and to a lesser extent, Nurr1, remained elevated also in the subcortical region of the temporal lobe.">
            <entity id="DS3.d1030.s1.e0" origId="P00915,V9HWE3" charOffset="16-19" type="protein" text="CA1"/>
            <entity id="DS3.d1030.s1.e1" origId="P07451,V9HWA3" charOffset="24-27" type="protein" text="CA3"/>
            <entity id="DS3.d1030.s1.e2" origId="10255" charOffset="76-87" type="compound" text="kainic acid"/>
            <entity id="DS3.d1030.s1.e3" origId="P11161" charOffset="126-131" type="protein" text="egr-2"/>
            <entity id="DS3.d1030.s1.e4" origId="P18146,Q546S1" charOffset="160-166" type="protein" text="NGFI-A"/>
            <entity id="DS3.d1030.s1.e5" origId="P22736,A0A024R126,F5GXF0,Q6ZMM6" charOffset="168-174" type="protein" text="NGFI-B"/>
            <entity id="DS3.d1030.s1.e6" origId="Q05215,B7ZKU3" charOffset="176-182" type="protein" text="NGFI-C"/>
            <entity id="DS3.d1030.s1.e7" origId="P43354,F1D8N6,Q53EL4" charOffset="207-212" type="protein" text="Nurr1"/>
            <pair e1="DS3.d1030.s1.e2" e2="DS3.d1030.s1.e1" id="DS3.d1030.s1.i0" interaction="False" />
            <pair e1="DS3.d1030.s1.e2" e2="DS3.d1030.s1.e7" id="DS3.d1030.s1.i1" interaction="False" />
            <pair e1="DS3.d1030.s1.e2" e2="DS3.d1030.s1.e0" id="DS3.d1030.s1.i2" interaction="False" />
            <pair e1="DS3.d1030.s1.e2" e2="DS3.d1030.s1.e3" id="DS3.d1030.s1.i3" interaction="False" />
            <pair e1="DS3.d1030.s1.e2" e2="DS3.d1030.s1.e6" id="DS3.d1030.s1.i4" interaction="False" />
            <pair e1="DS3.d1030.s1.e2" e2="DS3.d1030.s1.e5" id="DS3.d1030.s1.i5" interaction="False" />
            <pair e1="DS3.d1030.s1.e2" e2="DS3.d1030.s1.e4" id="DS3.d1030.s1.i6" interaction="False" />
        </sentence>
        <sentence id="DS3.d1030.s2" origId="9987007-5" text="By 24 h incorporation of 14C-leucine decreased in the piriform cortex, amygdala, and in the CA1 and CA3 subfields, but not in CA2 and dentate gyrus.">
            <entity id="DS3.d1030.s2.e0" origId="6106" charOffset="29-36" type="compound" text="leucine"/>
            <entity id="DS3.d1030.s2.e1" origId="P00915,V9HWE3" charOffset="92-95" type="protein" text="CA1"/>
            <entity id="DS3.d1030.s2.e2" origId="P07451,V9HWA3" charOffset="100-103" type="protein" text="CA3"/>
            <entity id="DS3.d1030.s2.e3" origId="P00918,V9HW21" charOffset="126-129" type="protein" text="CA2"/>
            <pair e1="DS3.d1030.s2.e0" e2="DS3.d1030.s2.e2" id="DS3.d1030.s2.i0" interaction="False" />
            <pair e1="DS3.d1030.s2.e0" e2="DS3.d1030.s2.e3" id="DS3.d1030.s2.i1" interaction="False" />
            <pair e1="DS3.d1030.s2.e0" e2="DS3.d1030.s2.e1" id="DS3.d1030.s2.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1031" origId="9987012">
        <sentence id="DS3.d1031.s0" origId="9987012-0" text="Enhanced synaptic transmission and reduced threshold for LTP induction in fyn-transgenic mice.">
            <entity id="DS3.d1031.s0.e0" origId="56846361" charOffset="57-60" type="compound" text="LTP"/>
            <entity id="DS3.d1031.s0.e1" origId="P39688" charOffset="74-77" type="protein" text="fyn"/>
            <pair e1="DS3.d1031.s0.e0" e2="DS3.d1031.s0.e1" id="DS3.d1031.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1031.s1" origId="9987012-10" text="Thus, these results suggest that regulation of fyn tyrosine kinase activity is important for both synaptic transmission and plasticity.">
            <entity id="DS3.d1031.s1.e0" origId="P39688" charOffset="47-50" type="protein" text="fyn"/>
            <entity id="DS3.d1031.s1.e1" origId="6057,90983769" charOffset="51-59" type="compound" text="tyrosine"/>
            <pair e1="DS3.d1031.s1.e1" e2="DS3.d1031.s1.e0" id="DS3.d1031.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1031.s2" origId="9987012-2" text="These fyn-transgenes were driven by the calcium/calmodulin-dependent protein kinase II alpha promoter which turned on in the forebrain neurons including hippocampal pyramidal cells and in late neural development.">
            <entity id="DS3.d1031.s2.e0" origId="P39688" charOffset="6-9" type="protein" text="fyn"/>
            <entity id="DS3.d1031.s2.e1" origId="22044544,5460341" charOffset="40-47" type="compound" text="calcium"/>
            <entity id="DS3.d1031.s2.e2" origId="18648446" charOffset="165-174" type="compound" text="pyramidal"/>
            <pair e1="DS3.d1031.s2.e1" e2="DS3.d1031.s2.e0" id="DS3.d1031.s2.i0" interaction="False" />
            <pair e1="DS3.d1031.s2.e2" e2="DS3.d1031.s2.e0" id="DS3.d1031.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1031.s3" origId="9987012-4" text="A weak theta-burst stimulation, which was subthreshold for the induction of long-term potentiation (LTP) in control slices, elicited LTP in CA1 region of the slices expressing m-fyn.">
            <entity id="DS3.d1031.s3.e0" origId="56846361" charOffset="100-103" type="compound" text="LTP"/>
            <entity id="DS3.d1031.s3.e1" origId="56846361" charOffset="133-136" type="compound" text="LTP"/>
            <entity id="DS3.d1031.s3.e2" origId="P13634" charOffset="140-143" type="protein" text="CA1"/>
            <entity id="DS3.d1031.s3.e3" origId="P39688" charOffset="178-181" type="protein" text="fyn"/>
            <pair e1="DS3.d1031.s3.e0" e2="DS3.d1031.s3.e2" id="DS3.d1031.s3.i0" interaction="False" />
            <pair e1="DS3.d1031.s3.e0" e2="DS3.d1031.s3.e3" id="DS3.d1031.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1031.s4" origId="9987012-5" text="When a relatively strong stimulation was applied, the magnitude of LTP in m-fyn slices was similar to that in control slices.">
            <entity id="DS3.d1031.s4.e0" origId="56846361" charOffset="67-70" type="compound" text="LTP"/>
            <entity id="DS3.d1031.s4.e1" origId="P39688" charOffset="76-79" type="protein" text="fyn"/>
            <pair e1="DS3.d1031.s4.e0" e2="DS3.d1031.s4.e1" id="DS3.d1031.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1031.s5" origId="9987012-6" text="By contrast, the basal synaptic transmission and the threshold for the induction of LTP were not altered in the slices overexpressing wild-type fyn.">
            <entity id="DS3.d1031.s5.e0" origId="56846361" charOffset="84-87" type="compound" text="LTP"/>
            <entity id="DS3.d1031.s5.e1" origId="P39688" charOffset="144-147" type="protein" text="fyn"/>
            <pair e1="DS3.d1031.s5.e0" e2="DS3.d1031.s5.e1" id="DS3.d1031.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1032" origId="9987013">
        <sentence id="DS3.d1032.s0" origId="9987013-4" text="In the A beta-(1-42)-infused rats, spontaneous alternation behaviour in a Y-maze and spatial memory in a water maze task were significantly impaired, as compared with A beta-(40-1)-infused control rats.">
            <entity id="DS3.d1032.s0.e0" origId="P08592,Q6P6Q5" charOffset="7-13" type="protein" text="A beta"/>
            <entity id="DS3.d1032.s0.e1" origId="962" charOffset="105-110" type="compound" text="water"/>
            <entity id="DS3.d1032.s0.e2" origId="P08592,Q6P6Q5" charOffset="167-173" type="protein" text="A beta"/>
            <pair e1="DS3.d1032.s0.e1" e2="DS3.d1032.s0.e0" id="DS3.d1032.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1032.s1" origId="9987013-6" text="Potent antioxidants idebenone and alpha-tocopherol prevented the behavioural deficits in Y-maze and water maze, but not passive avoidance, tasks in A beta-(1-42)-infused rats when they were repeatedly administered by mouth once a day from 3 days before the start of A beta infusion to the end of behavioural experiments.">
            <entity id="DS3.d1032.s1.e0" origId="3686" charOffset="20-29" type="compound" text="idebenone"/>
            <entity id="DS3.d1032.s1.e1" origId="14985" charOffset="40-50" type="compound" text="tocopherol"/>
            <entity id="DS3.d1032.s1.e2" origId="962" charOffset="100-105" type="compound" text="water"/>
            <entity id="DS3.d1032.s1.e3" origId="P08592,Q6P6Q5" charOffset="148-154" type="protein" text="A beta"/>
            <entity id="DS3.d1032.s1.e4" origId="P08592,Q6P6Q5" charOffset="266-272" type="protein" text="A beta"/>
            <pair e1="DS3.d1032.s1.e2" e2="DS3.d1032.s1.e3" id="DS3.d1032.s1.i0" interaction="False" />
            <pair e1="DS3.d1032.s1.e1" e2="DS3.d1032.s1.e3" id="DS3.d1032.s1.i1" interaction="False" />
            <pair e1="DS3.d1032.s1.e0" e2="DS3.d1032.s1.e3" id="DS3.d1032.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1032.s2" origId="9987013-7" text="Lipid peroxide levels in the hippocampus and cerebral cortex of A beta-(1-42)-infused rats did not differ from those in control animals, and neither idebenone nor alpha-tocopherol affected the lipid peroxide levels.">
            <entity id="DS3.d1032.s2.e0" origId="17887040" charOffset="6-14" type="compound" text="peroxide"/>
            <entity id="DS3.d1032.s2.e1" origId="P08592,Q6P6Q5" charOffset="64-70" type="protein" text="A beta"/>
            <entity id="DS3.d1032.s2.e2" origId="3686" charOffset="149-158" type="compound" text="idebenone"/>
            <entity id="DS3.d1032.s2.e3" origId="14985" charOffset="169-179" type="compound" text="tocopherol"/>
            <entity id="DS3.d1032.s2.e4" origId="17887040" charOffset="199-207" type="compound" text="peroxide"/>
            <pair e1="DS3.d1032.s2.e0" e2="DS3.d1032.s2.e1" id="DS3.d1032.s2.i0" interaction="False" />
            <pair e1="DS3.d1032.s2.e3" e2="DS3.d1032.s2.e1" id="DS3.d1032.s2.i1" interaction="False" />
            <pair e1="DS3.d1032.s2.e2" e2="DS3.d1032.s2.e1" id="DS3.d1032.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1032.s3" origId="9987013-8" text="These results suggest that treatment with antioxidants such as idebenone and alpha-tocopherol prevents learning and memory deficits caused by A beta.">
            <entity id="DS3.d1032.s3.e0" origId="3686" charOffset="63-72" type="compound" text="idebenone"/>
            <entity id="DS3.d1032.s3.e1" origId="14985" charOffset="83-93" type="compound" text="tocopherol"/>
            <entity id="DS3.d1032.s3.e2" origId="P08592,Q6P6Q5" charOffset="142-148" type="protein" text="A beta"/>
            <pair e1="DS3.d1032.s3.e1" e2="DS3.d1032.s3.e2" id="DS3.d1032.s3.i0" interaction="False" />
            <pair e1="DS3.d1032.s3.e0" e2="DS3.d1032.s3.e2" id="DS3.d1032.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1033" origId="9987015">
        <sentence id="DS3.d1033.s0" origId="9987015-5" text="Field-evoked, but not KCl-evoked, synaptic vesicle exocytosis monitored by the fluorescent vesicle probe FM2-10 was inhibited by staurosporine.">
            <entity id="DS3.d1033.s0.e0" origId="Q9ESQ4" charOffset="105-111" type="protein" text="FM2-10"/>
            <entity id="DS3.d1033.s0.e1" origId="44259,44299148,451705,44120114,5459111,5279,5311103,6711321,9956178,6419748,9937179" charOffset="129-142" type="compound" text="staurosporine"/>
            <pair e1="DS3.d1033.s0.e1" e2="DS3.d1033.s0.e0" id="DS3.d1033.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1034" origId="9987016">
        <sentence id="DS3.d1034.s0" origId="9987016-4" text="The number of superficial (laminae I-II) and deep (laminae III-VI) spinal dorsal horn cells expressing the c-fos proto-oncogene 2 h after subcutaneous injection of formalin was reduced by 34% and 50%, respectively, in animals with an ipsilateral DRt lesion as compared to non-lesioned rats.">
            <entity id="DS3.d1034.s0.e0" origId="P12841" charOffset="107-112" type="protein" text="c-fos"/>
            <entity id="DS3.d1034.s0.e1" origId="712" charOffset="164-172" type="compound" text="formalin"/>
            <pair e1="DS3.d1034.s0.e1" e2="DS3.d1034.s0.e0" id="DS3.d1034.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1034.s1" origId="9987016-5" text="No differences in c-fos expression were observed after lesioning the DRt contralateral to the formalin injection.">
            <entity id="DS3.d1034.s1.e0" origId="P12841" charOffset="18-23" type="protein" text="c-fos"/>
            <entity id="DS3.d1034.s1.e1" origId="712" charOffset="94-102" type="compound" text="formalin"/>
            <pair e1="DS3.d1034.s1.e1" e2="DS3.d1034.s1.e0" id="DS3.d1034.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1035" origId="9987018">
        <sentence id="DS3.d1035.s0" origId="9987018-0" text="CaMKII-dependent phosphorylation of NR2A and NR2B is decreased in animals characterized by hippocampal damage and impaired LTP.">
            <entity id="DS3.d1035.s0.e0" origId="P15791" charOffset="0-6" type="protein" text="CaMKII"/>
            <entity id="DS3.d1035.s0.e1" origId="Q00959" charOffset="36-40" type="protein" text="NR2A"/>
            <entity id="DS3.d1035.s0.e2" origId="Q00960" charOffset="45-49" type="protein" text="NR2B"/>
            <entity id="DS3.d1035.s0.e3" origId="56846361" charOffset="123-126" type="compound" text="LTP"/>
            <pair e1="DS3.d1035.s0.e3" e2="DS3.d1035.s0.e0" id="DS3.d1035.s0.i0" interaction="False" />
            <pair e1="DS3.d1035.s0.e3" e2="DS3.d1035.s0.e2" id="DS3.d1035.s0.i1" interaction="False" />
            <pair e1="DS3.d1035.s0.e3" e2="DS3.d1035.s0.e1" id="DS3.d1035.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1035.s1" origId="9987018-1" text="The calcium-calmodulin-dependent protein kinase II (CaMKII) subserves activity-dependent plasticity in central neurons.">
            <entity id="DS3.d1035.s1.e0" origId="22044544,5460341" charOffset="4-11" type="compound" text="calcium"/>
            <entity id="DS3.d1035.s1.e1" origId="P15791" charOffset="52-58" type="protein" text="CaMKII"/>
            <pair e1="DS3.d1035.s1.e0" e2="DS3.d1035.s1.e1" id="DS3.d1035.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1035.s2" origId="9987018-2" text="To examine in vivo the implication of CaMKII activity in synaptic plasticity, we used an animal model characterized by developmentally induced targeted neuronal ablation within the cortex and the hippocampus, and showing, at presynaptic level, molecular alterations leading to facilitation of glutamate release in hippocampal synapses (methylazoxymethanol-treated rats, MAM-rats).">
            <entity id="DS3.d1035.s2.e0" origId="P15791" charOffset="38-44" type="protein" text="CaMKII"/>
            <entity id="DS3.d1035.s2.e1" origId="23327,33032,611,57109091" charOffset="293-302" type="compound" text="glutamate"/>
            <entity id="DS3.d1035.s2.e2" origId="11554,5460323,6433205" charOffset="336-355" type="compound" text="methylazoxymethanol"/>
            <entity id="DS3.d1035.s2.e3" origId="P06238,M0R9G2" charOffset="370-373" type="protein" text="MAM"/>
            <pair e1="DS3.d1035.s2.e2" e2="DS3.d1035.s2.e0" id="DS3.d1035.s2.i0" interaction="False" />
            <pair e1="DS3.d1035.s2.e2" e2="DS3.d1035.s2.e3" id="DS3.d1035.s2.i1" interaction="False" />
            <pair e1="DS3.d1035.s2.e1" e2="DS3.d1035.s2.e0" id="DS3.d1035.s2.i2" interaction="False" />
            <pair e1="DS3.d1035.s2.e1" e2="DS3.d1035.s2.e3" id="DS3.d1035.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1035.s3" origId="9987018-7" text="In addition, a treatment able to restore long-term potentiation (LTP) in hippocampal slices from MAM-rats, e.g.">
            <entity id="DS3.d1035.s3.e0" origId="56846361" charOffset="65-68" type="compound" text="LTP"/>
            <entity id="DS3.d1035.s3.e1" origId="P06238,M0R9G2" charOffset="97-100" type="protein" text="MAM"/>
            <pair e1="DS3.d1035.s3.e0" e2="DS3.d1035.s3.e1" id="DS3.d1035.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1035.s4" origId="9987018-8" text="exposure to D-serine, is able to restore CaMKII activity to the control value.">
            <entity id="DS3.d1035.s4.e0" origId="71077" charOffset="12-20" type="compound" text="D-serine"/>
            <entity id="DS3.d1035.s4.e1" origId="P15791" charOffset="41-47" type="protein" text="CaMKII"/>
            <pair e1="DS3.d1035.s4.e0" e2="DS3.d1035.s4.e1" id="DS3.d1035.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1036" origId="9987019">
        <sentence id="DS3.d1036.s0" origId="9987019-1" text="P2X receptors for adenosine 5'-triphosphate (ATP) comprise a family of ligand-gated cation channels with distinct characteristics which are dependent on the receptor subunits (P2X1-7) expressed, and the homomeric or heteromeric assembly of protein subunits in individual cells.">
            <entity id="DS3.d1036.s0.e0" origId="57476835,60961" charOffset="18-27" type="compound" text="adenosine"/>
            <entity id="DS3.d1036.s0.e1" origId="P47824,Q9JIF8,B7U2F3,P49653,A0A0G2K9G8,P49654,Q9R1K3,P51577,P51578,P51579,R9PXR5" charOffset="176-182" type="protein" text="P2X1-7"/>
            <pair e1="DS3.d1036.s0.e0" e2="DS3.d1036.s0.e1" id="DS3.d1036.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1037" origId="9987022">
        <sentence id="DS3.d1037.s0" origId="9987022-8" text="In a second experiment, mice were injected intraperitoneally with saline or endotoxin and killed after 1, 3, 6 or 24 h. In GR-i mice, endotoxin caused an augmented rise in plasma ACTH, but not in corticosterone levels.">
            <entity id="DS3.d1037.s0.e0" origId="P01193" charOffset="179-183" type="protein" text="ACTH"/>
            <entity id="DS3.d1037.s0.e1" origId="5753" charOffset="196-210" type="compound" text="corticosterone"/>
            <pair e1="DS3.d1037.s0.e1" e2="DS3.d1037.s0.e0" id="DS3.d1037.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1038" origId="9987027">
        <sentence id="DS3.d1038.s0" origId="9987027-11" text="We conclude that GABAA receptor alpha 6 subunit-dependent actions in the cerebellar cortex can be compensated by other receptor subtypes; but if not for the alpha 6 subunit, patients on benzodiazepine medication would suffer considerably from ataxic side-effects.">
            <entity id="DS3.d1038.s0.e0" origId="Q16445" charOffset="17-39" type="protein" text="GABAA receptor alpha 6"/>
            <entity id="DS3.d1038.s0.e1" origId="134664" charOffset="186-200" type="compound" text="benzodiazepine"/>
            <pair e1="DS3.d1038.s0.e1" e2="DS3.d1038.s0.e0" id="DS3.d1038.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1039" origId="9987028">
        <sentence id="DS3.d1039.s0" origId="9987028-0" text="Intrastriatal grafting of a GDNF-producing cell line protects striatonigral neurons from quinolinic acid excitotoxicity in vivo.">
            <entity id="DS3.d1039.s0.e0" origId="Q07731,A7UGJ1" charOffset="28-32" type="protein" text="GDNF"/>
            <entity id="DS3.d1039.s0.e1" origId="1066,57058294" charOffset="89-104" type="compound" text="quinolinic acid"/>
            <pair e1="DS3.d1039.s0.e1" e2="DS3.d1039.s0.e0" id="DS3.d1039.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1039.s1" origId="9987028-2" text="GDNF is expressed in the adult striatum, but its signalling tyrosine kinase receptor, c-ret, has not been detected in this structure by in situ hybridization.">
            <entity id="DS3.d1039.s1.e0" origId="Q07731,A7UGJ1" charOffset="0-4" type="protein" text="GDNF"/>
            <entity id="DS3.d1039.s1.e1" origId="6057,90983769" charOffset="60-68" type="compound" text="tyrosine"/>
            <pair e1="DS3.d1039.s1.e1" e2="DS3.d1039.s1.e0" id="DS3.d1039.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1039.s2" origId="9987028-5" text="A fibroblast cell line, engineered to overexpress GDNF, was grafted in adult rats striatum 24 h before quinolinic acid (QUIN) injection.">
            <entity id="DS3.d1039.s2.e0" origId="Q07731,A7UGJ1" charOffset="50-54" type="protein" text="GDNF"/>
            <entity id="DS3.d1039.s2.e1" origId="1066,57058294" charOffset="103-118" type="compound" text="quinolinic acid"/>
            <pair e1="DS3.d1039.s2.e1" e2="DS3.d1039.s2.e0" id="DS3.d1039.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1040" origId="9987029">
        <sentence id="DS3.d1040.s0" origId="9987029-11" text="In the kindling model, compounds with a high affinity for GluR7 (LU 97175) or compounds (LU 115455, LU 136541) which potently bind to AMPA receptors and low affinity kainate receptor subunits were potent anticonvulsants in the kindling model, whereas the AMPA receptor-selective LU 112313 was the least selective compound in this model, indicating that non-NMDA antagonists acting at both AMPA and kainate receptors are more effective in this model than AMPA receptor-selective drugs.">
            <entity id="DS3.d1040.s0.e0" origId="P42264,G3V9I2" charOffset="58-63" type="protein" text="GluR7"/>
            <entity id="DS3.d1040.s0.e1" origId="10255" charOffset="166-173" type="compound" text="kainate"/>
            <entity id="DS3.d1040.s0.e2" origId="10255" charOffset="398-405" type="compound" text="kainate"/>
            <pair e1="DS3.d1040.s0.e1" e2="DS3.d1040.s0.e0" id="DS3.d1040.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1040.s1" origId="9987029-8" text="One compound, LU 97175, bound to native high affinity kainate receptors and rat GluR5-GluR7 subunits, i.e.">
            <entity id="DS3.d1040.s1.e0" origId="10255" charOffset="54-61" type="compound" text="kainate"/>
            <entity id="DS3.d1040.s1.e1" origId="P42264,G3V9I2" charOffset="86-91" type="protein" text="GluR7"/>
            <pair e1="DS3.d1040.s1.e0" e2="DS3.d1040.s1.e1" id="DS3.d1040.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1041" origId="9987030">
        <sentence id="DS3.d1041.s0" origId="9987030-5" text="Following a four-vessel occlusion insult, quantitative in situ hybridization revealed a highly significant and persistent 100% increase of cyclin D1 mRNA in the vulnerable pyramidal neurons of the CA1 hippocampal region.">
            <entity id="DS3.d1041.s0.e0" origId="P39948" charOffset="139-148" type="protein" text="cyclin D1"/>
            <entity id="DS3.d1041.s0.e1" origId="18648446" charOffset="172-181" type="compound" text="pyramidal"/>
            <entity id="DS3.d1041.s0.e2" origId="B0BNN3" charOffset="197-200" type="protein" text="CA1"/>
            <pair e1="DS3.d1041.s0.e1" e2="DS3.d1041.s0.e0" id="DS3.d1041.s0.i0" interaction="False" />
            <pair e1="DS3.d1041.s0.e1" e2="DS3.d1041.s0.e2" id="DS3.d1041.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1041.s1" origId="9987030-8" text="Following kainate-induced seizures, cyclin D1 mRNA was induced in the vulnerable CA3 region, and to a lesser extent, in non-vulnerable regions.">
            <entity id="DS3.d1041.s1.e0" origId="10255" charOffset="10-17" type="compound" text="kainate"/>
            <entity id="DS3.d1041.s1.e1" origId="P39948" charOffset="36-45" type="protein" text="cyclin D1"/>
            <entity id="DS3.d1041.s1.e2" origId="P14141" charOffset="81-84" type="protein" text="CA3"/>
            <pair e1="DS3.d1041.s1.e0" e2="DS3.d1041.s1.e1" id="DS3.d1041.s1.i0" interaction="False" />
            <pair e1="DS3.d1041.s1.e0" e2="DS3.d1041.s1.e2" id="DS3.d1041.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1042" origId="9987037">
        <sentence id="DS3.d1042.s0" origId="9987037-4" text="Twelve percent of the recorded CA1 pyramidal cells were selectively active while the rat was running in the wheel.">
            <entity id="DS3.d1042.s0.e0" origId="B0BNN3" charOffset="31-34" type="protein" text="CA1"/>
            <entity id="DS3.d1042.s0.e1" origId="18648446" charOffset="35-44" type="compound" text="pyramidal"/>
            <pair e1="DS3.d1042.s0.e1" e2="DS3.d1042.s0.e0" id="DS3.d1042.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1043" origId="9987068">
        <sentence id="DS3.d1043.s0" origId="9987068-5" text="Rats were treated with the COX-1/COX-2 inhibitor indomethacin and the selective COX-2 inhibitors meloxicam and SC 58125.">
            <entity id="DS3.d1043.s0.e0" origId="P05503,Q8HIC9" charOffset="27-32" type="protein" text="COX-1"/>
            <entity id="DS3.d1043.s0.e1" origId="P00406,Q8SEZ5" charOffset="33-38" type="protein" text="COX-2"/>
            <entity id="DS3.d1043.s0.e2" origId="3715" charOffset="49-61" type="compound" text="indomethacin"/>
            <entity id="DS3.d1043.s0.e3" origId="P00406,Q8SEZ5" charOffset="80-85" type="protein" text="COX-2"/>
            <entity id="DS3.d1043.s0.e4" origId="54677470" charOffset="97-106" type="compound" text="meloxicam"/>
            <pair e1="DS3.d1043.s0.e4" e2="DS3.d1043.s0.e0" id="DS3.d1043.s0.i0" interaction="False" />
            <pair e1="DS3.d1043.s0.e4" e2="DS3.d1043.s0.e1" id="DS3.d1043.s0.i1" interaction="False" />
            <pair e1="DS3.d1043.s0.e2" e2="DS3.d1043.s0.e0" id="DS3.d1043.s0.i2" interaction="False" />
            <pair e1="DS3.d1043.s0.e2" e2="DS3.d1043.s0.e1" id="DS3.d1043.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1043.s1" origId="9987068-7" text="RESULTS: Indomethacin, to a lesser degree the selective COX-2 inhibitors, enhanced glomerular MCP-1 and RANTES mRNA levels.">
            <entity id="DS3.d1043.s1.e0" origId="3715" charOffset="9-21" type="compound" text="Indomethacin"/>
            <entity id="DS3.d1043.s1.e1" origId="P00406,Q8SEZ5" charOffset="56-61" type="protein" text="COX-2"/>
            <entity id="DS3.d1043.s1.e2" origId="P14844" charOffset="94-99" type="protein" text="MCP-1"/>
            <entity id="DS3.d1043.s1.e3" origId="Q6PED1" charOffset="104-110" type="protein" text="RANTES"/>
            <pair e1="DS3.d1043.s1.e0" e2="DS3.d1043.s1.e3" id="DS3.d1043.s1.i0" interaction="False" />
            <pair e1="DS3.d1043.s1.e0" e2="DS3.d1043.s1.e1" id="DS3.d1043.s1.i1" interaction="False" />
            <pair e1="DS3.d1043.s1.e0" e2="DS3.d1043.s1.e2" id="DS3.d1043.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1044" origId="9987069">
        <sentence id="DS3.d1044.s0" origId="9987069-4" text="To test this hypothesis, we examined changes in activity of the HGF/c-met system in the folic acid model of acute tubular injury and repair.">
            <entity id="DS3.d1044.s0.e0" origId="P14210" charOffset="64-67" type="protein" text="HGF"/>
            <entity id="DS3.d1044.s0.e1" origId="P08581,A0A024R728,A0A024R759,B4DLF5" charOffset="68-73" type="protein" text="c-met"/>
            <entity id="DS3.d1044.s0.e2" origId="6037" charOffset="88-98" type="compound" text="folic acid"/>
            <pair e1="DS3.d1044.s0.e2" e2="DS3.d1044.s0.e0" id="DS3.d1044.s0.i0" interaction="False" />
            <pair e1="DS3.d1044.s0.e2" e2="DS3.d1044.s0.e1" id="DS3.d1044.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1044.s1" origId="9987069-5" text="METHODS: Tissue HGF and c-met mRNA levels were detected by RNase protection assay and Northern blot analysis following acute renal injury induced by a single injection of folic acid.">
            <entity id="DS3.d1044.s1.e0" origId="P14210" charOffset="16-19" type="protein" text="HGF"/>
            <entity id="DS3.d1044.s1.e1" origId="P08581,A0A024R728,A0A024R759,B4DLF5" charOffset="24-29" type="protein" text="c-met"/>
            <entity id="DS3.d1044.s1.e2" origId="6037" charOffset="171-181" type="compound" text="folic acid"/>
            <pair e1="DS3.d1044.s1.e2" e2="DS3.d1044.s1.e0" id="DS3.d1044.s1.i0" interaction="False" />
            <pair e1="DS3.d1044.s1.e2" e2="DS3.d1044.s1.e1" id="DS3.d1044.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1044.s2" origId="9987069-8" text="RESULTS: Extremely rapid induction of renal HGF and c-met mRNA was observed beginning one hour following injection of folic acid.">
            <entity id="DS3.d1044.s2.e0" origId="P14210" charOffset="44-47" type="protein" text="HGF"/>
            <entity id="DS3.d1044.s2.e1" origId="P08581,A0A024R728,A0A024R759,B4DLF5" charOffset="52-57" type="protein" text="c-met"/>
            <entity id="DS3.d1044.s2.e2" origId="6037" charOffset="118-128" type="compound" text="folic acid"/>
            <pair e1="DS3.d1044.s2.e2" e2="DS3.d1044.s2.e0" id="DS3.d1044.s2.i0" interaction="False" />
            <pair e1="DS3.d1044.s2.e2" e2="DS3.d1044.s2.e1" id="DS3.d1044.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1045" origId="9987070">
        <sentence id="DS3.d1045.s0" origId="9987070-0" text="Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cells.">
            <entity id="DS3.d1045.s0.e0" origId="206,5793,79025,64689" charOffset="24-31" type="compound" text="glucose"/>
            <entity id="DS3.d1045.s0.e1" origId="P01015" charOffset="42-57" type="protein" text="angiotensinogen"/>
            <pair e1="DS3.d1045.s0.e0" e2="DS3.d1045.s0.e1" id="DS3.d1045.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1045.s1" origId="9987070-2" text="We have previously reported that high levels of glucose stimulate the expression of rat angiotensinogen (ANG) gene in opossum kidney (OK) proximal tubular cells.">
            <entity id="DS3.d1045.s1.e0" origId="206,5793,79025,64689" charOffset="48-55" type="compound" text="glucose"/>
            <entity id="DS3.d1045.s1.e1" origId="P01015" charOffset="88-103" type="protein" text="angiotensinogen"/>
            <pair e1="DS3.d1045.s1.e0" e2="DS3.d1045.s1.e1" id="DS3.d1045.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1046" origId="9987073">
        <sentence id="DS3.d1046.s0" origId="9987073-0" text="High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1.">
            <entity id="DS3.d1046.s0.e0" origId="206,5793,64689,79025" charOffset="5-12" type="compound" text="glucose"/>
            <entity id="DS3.d1046.s0.e1" origId="P22388" charOffset="80-92" type="protein" text="endothelin-1"/>
            <pair e1="DS3.d1046.s0.e0" e2="DS3.d1046.s0.e1" id="DS3.d1046.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1046.s1" origId="9987073-11" text="In HG, down-regulation of PKC isoforms with phorbol ester prevented the increased stimulation of MAPK by ET-1.">
            <entity id="DS3.d1046.s1.e0" origId="27924,70702034" charOffset="44-57" type="compound" text="phorbol ester"/>
            <entity id="DS3.d1046.s1.e1" origId="P22388" charOffset="105-109" type="protein" text="ET-1"/>
            <pair e1="DS3.d1046.s1.e0" e2="DS3.d1046.s1.e1" id="DS3.d1046.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1046.s2" origId="9987073-2" text="Our purpose was to determine if high glucose alters endothelin-1 (ET-1) or platelet-derived growth factor-B activation of mesangial cell diacylglycerol-sensitive protein kinase C (PKC) isoforms and subsequent stimulation of mitogen-activated protein kinase (MAPK; p42, p44).">
            <entity id="DS3.d1046.s2.e0" origId="206,5793,64689,79025" charOffset="37-44" type="compound" text="glucose"/>
            <entity id="DS3.d1046.s2.e1" origId="P22388" charOffset="52-64" type="protein" text="endothelin-1"/>
            <entity id="DS3.d1046.s2.e2" origId="P22388" charOffset="66-70" type="protein" text="ET-1"/>
            <entity id="DS3.d1046.s2.e3" origId="6026790" charOffset="137-151" type="compound" text="diacylglycerol"/>
            <entity id="DS3.d1046.s2.e4" origId="P21708" charOffset="269-272" type="protein" text="p44"/>
            <pair e1="DS3.d1046.s2.e3" e2="DS3.d1046.s2.e2" id="DS3.d1046.s2.i0" interaction="False" />
            <pair e1="DS3.d1046.s2.e3" e2="DS3.d1046.s2.e1" id="DS3.d1046.s2.i1" interaction="False" />
            <pair e1="DS3.d1046.s2.e3" e2="DS3.d1046.s2.e4" id="DS3.d1046.s2.i2" interaction="False" />
            <pair e1="DS3.d1046.s2.e0" e2="DS3.d1046.s2.e2" id="DS3.d1046.s2.i3" interaction="False" />
            <pair e1="DS3.d1046.s2.e0" e2="DS3.d1046.s2.e1" id="DS3.d1046.s2.i4" interaction="False" />
            <pair e1="DS3.d1046.s2.e0" e2="DS3.d1046.s2.e4" id="DS3.d1046.s2.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1047" origId="9987074">
        <sentence id="DS3.d1047.s0" origId="9987074-4" text="METHODS: MG 63 and SaOS-2 human osteoblastic cell lines were cultured for 6 or 24 hours in media containing calcitriol, the sterols of interest, or 1-34 synthetic PTH.">
            <entity id="DS3.d1047.s0.e0" origId="5280453" charOffset="108-118" type="compound" text="calcitriol"/>
            <entity id="DS3.d1047.s0.e1" origId="1107" charOffset="124-131" type="compound" text="sterols"/>
            <entity id="DS3.d1047.s0.e2" origId="P01270" charOffset="163-166" type="protein" text="PTH"/>
            <pair e1="DS3.d1047.s0.e0" e2="DS3.d1047.s0.e2" id="DS3.d1047.s0.i0" interaction="False" />
            <pair e1="DS3.d1047.s0.e1" e2="DS3.d1047.s0.e2" id="DS3.d1047.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1047.s1" origId="9987074-7" text="RESULTS: We found that calcitriol and paricalcitol behaved in a similar fashion, resulting in increased IL-6 release only at higher concentrations (10(-7) to 10(-9) M).">
            <entity id="DS3.d1047.s1.e0" origId="5280453" charOffset="23-33" type="compound" text="calcitriol"/>
            <entity id="DS3.d1047.s1.e1" origId="5281104" charOffset="38-50" type="compound" text="paricalcitol"/>
            <entity id="DS3.d1047.s1.e2" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="104-108" type="protein" text="IL-6"/>
            <pair e1="DS3.d1047.s1.e0" e2="DS3.d1047.s1.e2" id="DS3.d1047.s1.i0" interaction="False" />
            <pair e1="DS3.d1047.s1.e1" e2="DS3.d1047.s1.e2" id="DS3.d1047.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1048" origId="9987075">
        <sentence id="DS3.d1048.s0" origId="9987075-3" text="METHODS: We morphometrically studied random samples of the left ventricle myocardium and small intramyocardial arteries in subtotally (5/6) nephrectomized (SNx) male Sprague-Dawley rats treated with either the selective ETA receptor antagonist BMS182874 (30 mg/kg/day) or the nonselective ETA/ETB receptor antagonist Ro46-2005 (30 mg/kg/day) in comparison with either sham-operated rats, untreated SNx, or SNx rats treated with the angiotensin-converting enzyme inhibitor trandolapril (0.1 mg/kg/day).">
            <entity id="DS3.d1048.s0.e0" origId="24812721" charOffset="156-159" type="compound" text="SNx"/>
            <entity id="DS3.d1048.s0.e1" origId="P26684,A1Y2B8,A0A0G2JSX5" charOffset="289-305" type="protein" text="ETA/ETB receptor"/>
            <entity id="DS3.d1048.s0.e2" origId="24812721" charOffset="398-401" type="compound" text="SNx"/>
            <entity id="DS3.d1048.s0.e3" origId="24812721" charOffset="398-401" type="compound" text="SNx"/>
            <entity id="DS3.d1048.s0.e4" origId="5484727" charOffset="472-484" type="compound" text="trandolapril"/>
            <pair e1="DS3.d1048.s0.e4" e2="DS3.d1048.s0.e1" id="DS3.d1048.s0.i0" interaction="False" />
            <pair e1="DS3.d1048.s0.e0" e2="DS3.d1048.s0.e1" id="DS3.d1048.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1049" origId="9987076">
        <sentence id="DS3.d1049.s0" origId="9987076-5" text="METHODS: Cycling or quiescent human mesangial cells were incubated in RPMI 1640 containing 10% heat-inactivated fetal calf serum (FCS) in the absence or presence of pravastatin, an inhibitor of HMG-CoA reductase, and mevalonate metabolites.">
            <entity id="DS3.d1049.s0.e0" origId="54687" charOffset="165-176" type="compound" text="pravastatin"/>
            <entity id="DS3.d1049.s0.e1" origId="A7Z064" charOffset="194-211" type="protein" text="HMG-CoA reductase"/>
            <entity id="DS3.d1049.s0.e2" origId="439230,54544985" charOffset="217-227" type="compound" text="mevalonate"/>
            <pair e1="DS3.d1049.s0.e2" e2="DS3.d1049.s0.e1" id="DS3.d1049.s0.i0" interaction="False" />
            <pair e1="DS3.d1049.s0.e0" e2="DS3.d1049.s0.e1" id="DS3.d1049.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1050" origId="9987080">
        <sentence id="DS3.d1050.s0" origId="9987080-10" text="Genistein also reduced PMN spreading on fibronectin.">
            <entity id="DS3.d1050.s0.e0" origId="5280961" charOffset="0-9" type="compound" text="Genistein"/>
            <entity id="DS3.d1050.s0.e1" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="40-51" type="protein" text="fibronectin"/>
            <pair e1="DS3.d1050.s0.e0" e2="DS3.d1050.s0.e1" id="DS3.d1050.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1050.s1" origId="9987080-12" text="fibronectin strongly increased tyrosine phosphorylation of three 102, 63, and 54 kDa proteins.">
            <entity id="DS3.d1050.s1.e0" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="0-11" type="protein" text="fibronectin"/>
            <entity id="DS3.d1050.s1.e1" origId="6057,90983769" charOffset="31-39" type="compound" text="tyrosine"/>
            <pair e1="DS3.d1050.s1.e1" e2="DS3.d1050.s1.e0" id="DS3.d1050.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1050.s2" origId="9987080-8" text="Tests on other matrix substances revealed that the percentage of apoptotic PMNs in the presence of TNF alpha was 8 +/- 1% on PolyHema, 26 +/- 4% on fibronectin, 17 +/- 2% on collagen I, 16 +/- 2% on collagen IV, and 16 +/- 3% on laminin (P &amp;lt; 0.05 for all matrices compared with PolyHema).">
            <entity id="DS3.d1050.s2.e0" origId="P01375,Q5STB3" charOffset="99-108" type="protein" text="TNF alpha"/>
            <entity id="DS3.d1050.s2.e1" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="148-159" type="protein" text="fibronectin"/>
            <entity id="DS3.d1050.s2.e2" origId="44342165" charOffset="229-236" type="compound" text="laminin"/>
            <pair e1="DS3.d1050.s2.e2" e2="DS3.d1050.s2.e1" id="DS3.d1050.s2.i0" interaction="False" />
            <pair e1="DS3.d1050.s2.e2" e2="DS3.d1050.s2.e0" id="DS3.d1050.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1050.s3" origId="9987080-9" text="Preincubation with genistein (50 microM) significantly inhibited TNF alpha-mediated apoptosis on fibronectin (39 +/- 4% to 21 +/- 4%) but not on PolyHema (21 +/- 4% to 16 +/- 4%).">
            <entity id="DS3.d1050.s3.e0" origId="5280961" charOffset="19-28" type="compound" text="genistein"/>
            <entity id="DS3.d1050.s3.e1" origId="P01375,Q5STB3" charOffset="65-74" type="protein" text="TNF alpha"/>
            <entity id="DS3.d1050.s3.e2" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="97-108" type="protein" text="fibronectin"/>
            <pair e1="DS3.d1050.s3.e0" e2="DS3.d1050.s3.e2" id="DS3.d1050.s3.i0" interaction="False" />
            <pair e1="DS3.d1050.s3.e0" e2="DS3.d1050.s3.e1" id="DS3.d1050.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1051" origId="9987085">
        <sentence id="DS3.d1051.s0" origId="9987085-12" text="Although the contribution of endogenous endothelin-1 to resting vascular tone appears to be reduced in CRF, ETA receptor antagonism, and particularly endothelin-converting enzyme inhibition, should be explored as means by which to reduce vascular tone and blood pressure in patients with CRF.">
            <entity id="DS3.d1051.s0.e0" origId="P05305,Q6FH53" charOffset="40-52" type="protein" text="endothelin-1"/>
            <entity id="DS3.d1051.s0.e1" origId="44284481" charOffset="40-50" type="compound" text="endothelin"/>
            <pair e1="DS3.d1051.s0.e1" e2="DS3.d1051.s0.e0" id="DS3.d1051.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1051.s1" origId="9987085-3" text="METHODS: We investigated the contribution of endogenous and exogenous endothelin-1 to the maintenance of vascular tone in patients with CRF (creatinine &amp;gt; or = 200 mumol/liter) and in age- and sex-matched healthy subjects.">
            <entity id="DS3.d1051.s1.e0" origId="P05305,Q6FH53" charOffset="70-82" type="protein" text="endothelin-1"/>
            <entity id="DS3.d1051.s1.e1" origId="588" charOffset="141-151" type="compound" text="creatinine"/>
            <pair e1="DS3.d1051.s1.e1" e2="DS3.d1051.s1.e0" id="DS3.d1051.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1051.s2" origId="9987085-4" text="In a series of experiments, we measured forearm vascular responses to intra-arterial norepinephrine (30 to 240 pmol/min), endothelin-1 (5 pmol/min), the selective endothelin A (ETA) receptor antagonist BQ-123 (3 mg/hr), the mixed endothelin-converting enzyme and neutral endopeptidase inhibitor phosphoramidon (30 nmol/min), and the selective neutral endopeptidase inhibitor thiorphan (30 nmol/min).">
            <entity id="DS3.d1051.s2.e0" origId="439260" charOffset="85-99" type="compound" text="norepinephrine"/>
            <entity id="DS3.d1051.s2.e1" origId="P05305,Q6FH53" charOffset="122-134" type="protein" text="endothelin-1"/>
            <entity id="DS3.d1051.s2.e2" origId="44284481" charOffset="122-132" type="compound" text="endothelin"/>
            <entity id="DS3.d1051.s2.e3" origId="16219006,443289,52943236" charOffset="202-208" type="compound" text="BQ-123"/>
            <entity id="DS3.d1051.s2.e4" origId="44284481" charOffset="163-173" type="compound" text="endothelin"/>
            <entity id="DS3.d1051.s2.e5" origId="445114,46936424,65400,46782752" charOffset="295-309" type="compound" text="phosphoramidon"/>
            <entity id="DS3.d1051.s2.e6" origId="3132" charOffset="375-384" type="compound" text="thiorphan"/>
            <pair e1="DS3.d1051.s2.e6" e2="DS3.d1051.s2.e1" id="DS3.d1051.s2.i0" interaction="False" />
            <pair e1="DS3.d1051.s2.e0" e2="DS3.d1051.s2.e1" id="DS3.d1051.s2.i1" interaction="False" />
            <pair e1="DS3.d1051.s2.e2" e2="DS3.d1051.s2.e1" id="DS3.d1051.s2.i2" interaction="False" />
            <pair e1="DS3.d1051.s2.e3" e2="DS3.d1051.s2.e1" id="DS3.d1051.s2.i3" interaction="False" />
            <pair e1="DS3.d1051.s2.e5" e2="DS3.d1051.s2.e1" id="DS3.d1051.s2.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1052" origId="9987087">
        <sentence id="DS3.d1052.s0" origId="9987087-0" text="Coadministration of albumin and furosemide in patients with the nephrotic syndrome.">
            <entity id="DS3.d1052.s0.e0" origId="P02768" charOffset="20-27" type="protein" text="albumin"/>
            <entity id="DS3.d1052.s0.e1" origId="3440" charOffset="32-42" type="compound" text="furosemide"/>
            <pair e1="DS3.d1052.s0.e1" e2="DS3.d1052.s0.e0" id="DS3.d1052.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1052.s1" origId="9987087-4" text="Urinary volume, sodium, albumin and FU excretion, renal hemodynamics, and plasma atrial natriuretic factor concentration were assessed.">
            <entity id="DS3.d1052.s1.e0" origId="5360545" charOffset="16-22" type="compound" text="sodium"/>
            <entity id="DS3.d1052.s1.e1" origId="P02768" charOffset="24-31" type="protein" text="albumin"/>
            <pair e1="DS3.d1052.s1.e0" e2="DS3.d1052.s1.e1" id="DS3.d1052.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1053" origId="9987089">
        <sentence id="DS3.d1053.s0" origId="9987089-8" text="Patients with elevated CRP or SAA had significantly higher serum levels of Lp(a), higher plasma fibrinogen, and lower serum levels of high-density lipoprotein cholesterol, apo A-I, and Salb than patients with normal CRP or SAA.">
            <entity id="DS3.d1053.s0.e0" origId="P02741" charOffset="23-26" type="protein" text="CRP"/>
            <entity id="DS3.d1053.s0.e1" origId="P02675,V9HVY1" charOffset="96-106" type="protein" text="fibrinogen"/>
            <entity id="DS3.d1053.s0.e2" origId="5997" charOffset="159-170" type="compound" text="cholesterol"/>
            <entity id="DS3.d1053.s0.e3" origId="P02741" charOffset="216-219" type="protein" text="CRP"/>
            <pair e1="DS3.d1053.s0.e2" e2="DS3.d1053.s0.e0" id="DS3.d1053.s0.i0" interaction="False" />
            <pair e1="DS3.d1053.s0.e2" e2="DS3.d1053.s0.e1" id="DS3.d1053.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1054" origId="9987092">
        <sentence id="DS3.d1054.s0" origId="9987092-3" text='METHODS: As a part of a clinical trial in kidney transplant recipients on triple immunosuppressive therapy (CSA, azathioprine and steroid), which includes renal biopsy as "per protocol," 22 patients enrolled between 12 and 24 months posttransplantation underwent renal hemodynamic evaluation by measuring glomerular filtration rate and renal plasma flow by the plasma clearance of unlabeled iohexol and the renal clearance of para-aminohippuric acid, respectively.'>
            <entity id="DS3.d1054.s0.e0" origId="P0DML2,P0DML3,A8K6C2" charOffset="108-111" type="protein" text="CSA"/>
            <entity id="DS3.d1054.s0.e1" origId="2265" charOffset="113-125" type="compound" text="azathioprine"/>
            <entity id="DS3.d1054.s0.e2" origId="3730" charOffset="391-398" type="compound" text="iohexol"/>
            <entity id="DS3.d1054.s0.e3" origId="2148" charOffset="426-449" type="compound" text="para-aminohippuric acid"/>
            <pair e1="DS3.d1054.s0.e2" e2="DS3.d1054.s0.e0" id="DS3.d1054.s0.i0" interaction="False" />
            <pair e1="DS3.d1054.s0.e1" e2="DS3.d1054.s0.e0" id="DS3.d1054.s0.i1" interaction="False" />
            <pair e1="DS3.d1054.s0.e3" e2="DS3.d1054.s0.e0" id="DS3.d1054.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1055" origId="9987093">
        <sentence id="DS3.d1055.s0" origId="9987093-7" text="Infusion of sodium nitroprusside neither decreased platelet activation (P-selectin + platelets) nor affected the number of platelet-leukocyte aggregates (CD41+ neutrophils) as measured by flow cytometry.">
            <entity id="DS3.d1055.s0.e0" origId="5360545" charOffset="12-18" type="compound" text="sodium"/>
            <entity id="DS3.d1055.s0.e1" origId="11963622" charOffset="19-32" type="compound" text="nitroprusside"/>
            <entity id="DS3.d1055.s0.e2" origId="P16109,Q5R341,A0A024R8Y9,Q6NUL9" charOffset="72-82" type="protein" text="P-selectin"/>
            <entity id="DS3.d1055.s0.e3" origId="P08514" charOffset="154-158" type="protein" text="CD41"/>
            <pair e1="DS3.d1055.s0.e1" e2="DS3.d1055.s0.e3" id="DS3.d1055.s0.i0" interaction="False" />
            <pair e1="DS3.d1055.s0.e1" e2="DS3.d1055.s0.e2" id="DS3.d1055.s0.i1" interaction="False" />
            <pair e1="DS3.d1055.s0.e0" e2="DS3.d1055.s0.e3" id="DS3.d1055.s0.i2" interaction="False" />
            <pair e1="DS3.d1055.s0.e0" e2="DS3.d1055.s0.e2" id="DS3.d1055.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1056" origId="9987114">
        <sentence id="DS3.d1056.s0" origId="9987114-6" text="Msn1p and Mss11p act downstream of Mep2p and Ras2p and regulate the transcription of both STA2 and MUC1.">
            <entity id="DS3.d1056.s0.e0" origId="P22148" charOffset="0-5" type="protein" text="Msn1p"/>
            <entity id="DS3.d1056.s0.e1" origId="Q03825" charOffset="10-16" type="protein" text="Mss11p"/>
            <entity id="DS3.d1056.s0.e2" origId="P41948" charOffset="35-40" type="protein" text="Mep2p"/>
            <entity id="DS3.d1056.s0.e3" origId="P01120" charOffset="45-50" type="protein" text="Ras2p"/>
            <entity id="DS3.d1056.s0.e4" origId="5311453" charOffset="90-94" type="compound" text="STA2"/>
            <pair e1="DS3.d1056.s0.e4" e2="DS3.d1056.s0.e0" id="DS3.d1056.s0.i0" interaction="False" />
            <pair e1="DS3.d1056.s0.e4" e2="DS3.d1056.s0.e1" id="DS3.d1056.s0.i1" interaction="False" />
            <pair e1="DS3.d1056.s0.e4" e2="DS3.d1056.s0.e2" id="DS3.d1056.s0.i2" interaction="False" />
            <pair e1="DS3.d1056.s0.e4" e2="DS3.d1056.s0.e3" id="DS3.d1056.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1057" origId="9987137">
        <sentence id="DS3.d1057.s0" origId="9987137-9" text="In contrast, CRD1 expression was not regulated by the phospholipid precursors inositol and choline, and was not altered in the regulatory mutants ino2, ino4 and opi1.">
            <entity id="DS3.d1057.s0.e0" origId="892" charOffset="78-86" type="compound" text="inositol"/>
            <entity id="DS3.d1057.s0.e1" origId="305,57080826" charOffset="91-98" type="compound" text="choline"/>
            <entity id="DS3.d1057.s0.e2" origId="P26798" charOffset="146-150" type="protein" text="ino2"/>
            <entity id="DS3.d1057.s0.e3" origId="P13902" charOffset="152-156" type="protein" text="ino4"/>
            <entity id="DS3.d1057.s0.e4" origId="P21957" charOffset="161-165" type="protein" text="opi1"/>
            <pair e1="DS3.d1057.s0.e0" e2="DS3.d1057.s0.e3" id="DS3.d1057.s0.i0" interaction="False" />
            <pair e1="DS3.d1057.s0.e0" e2="DS3.d1057.s0.e2" id="DS3.d1057.s0.i1" interaction="False" />
            <pair e1="DS3.d1057.s0.e0" e2="DS3.d1057.s0.e4" id="DS3.d1057.s0.i2" interaction="False" />
            <pair e1="DS3.d1057.s0.e1" e2="DS3.d1057.s0.e3" id="DS3.d1057.s0.i3" interaction="False" />
            <pair e1="DS3.d1057.s0.e1" e2="DS3.d1057.s0.e2" id="DS3.d1057.s0.i4" interaction="False" />
            <pair e1="DS3.d1057.s0.e1" e2="DS3.d1057.s0.e4" id="DS3.d1057.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1058" origId="9987177">
        <sentence id="DS3.d1058.s0" origId="9987177-6" text="Gene fusion constructs were generated from DNA encoding Mycobacterium bovis strain BCG Hsp65 and individual fragments of influenza virus nucleoprotein (NP) encompassing H-2Kd- and H-2Db-restricted CTL epitopes.">
            <entity id="DS3.d1058.s0.e0" origId="P63038" charOffset="87-92" type="protein" text="Hsp65"/>
            <entity id="DS3.d1058.s0.e1" origId="16050817" charOffset="171-174" type="compound" text="2Kd"/>
            <entity id="DS3.d1058.s0.e2" origId="11957419" charOffset="182-185" type="compound" text="2Db"/>
            <pair e1="DS3.d1058.s0.e1" e2="DS3.d1058.s0.e0" id="DS3.d1058.s0.i0" interaction="False" />
            <pair e1="DS3.d1058.s0.e2" e2="DS3.d1058.s0.e0" id="DS3.d1058.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1058.s1" origId="9987177-9" text="An NP fusion protein made with glutathione-S-transferase failed to elicit NP-specific CTL, indicating that the phenomenon requires Hsp65 sequences.">
            <entity id="DS3.d1058.s1.e0" origId="124886,20725278,745" charOffset="31-42" type="compound" text="glutathione"/>
            <entity id="DS3.d1058.s1.e1" origId="P63038" charOffset="131-136" type="protein" text="Hsp65"/>
            <pair e1="DS3.d1058.s1.e0" e2="DS3.d1058.s1.e1" id="DS3.d1058.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1059" origId="9987186">
        <sentence id="DS3.d1059.s0" origId="9987186-3" text="Among 13 GAS reference strains, two categories were distinguished on aerobic incubation at 37 degrees C, one expressing similar IgG binding activity at 6 h and 18 h (types M1, M4, M13, M15), and a second one which showed higher binding at 6 h than at 18 h (M9, M14, M22, M25, M48, M49).">
            <entity id="DS3.d1059.s0.e0" origId="16132126" charOffset="185-188" type="compound" text="M15"/>
            <entity id="DS3.d1059.s0.e1" origId="11400707" charOffset="257-259" type="compound" text="M9"/>
            <entity id="DS3.d1059.s0.e2" origId="16044960" charOffset="261-264" type="compound" text="M14"/>
            <entity id="DS3.d1059.s0.e3" origId="16045336" charOffset="266-269" type="compound" text="M22"/>
            <entity id="DS3.d1059.s0.e4" origId="745994" charOffset="271-274" type="compound" text="M25"/>
            <entity id="DS3.d1059.s0.e5" origId="Q60890" charOffset="281-284" type="protein" text="M49"/>
            <pair e1="DS3.d1059.s0.e1" e2="DS3.d1059.s0.e5" id="DS3.d1059.s0.i0" interaction="False" />
            <pair e1="DS3.d1059.s0.e0" e2="DS3.d1059.s0.e5" id="DS3.d1059.s0.i1" interaction="False" />
            <pair e1="DS3.d1059.s0.e2" e2="DS3.d1059.s0.e5" id="DS3.d1059.s0.i2" interaction="False" />
            <pair e1="DS3.d1059.s0.e3" e2="DS3.d1059.s0.e5" id="DS3.d1059.s0.i3" interaction="False" />
            <pair e1="DS3.d1059.s0.e4" e2="DS3.d1059.s0.e5" id="DS3.d1059.s0.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d1059.s1" origId="9987186-4" text="Only one strain (M36) bound less IgG at 6 h than at 18 h. Seven of the strains (M5, M6, M22, M25, M36, M48, M49) showed higher binding of IgG when grown in a 5% CO2 atmosphere than in air, whereas one strain (M14) showed a reverse pattern and in the remaining five strains, no influence was found.">
            <entity id="DS3.d1059.s1.e0" origId="16045336" charOffset="88-91" type="compound" text="M22"/>
            <entity id="DS3.d1059.s1.e1" origId="745994" charOffset="93-96" type="compound" text="M25"/>
            <entity id="DS3.d1059.s1.e2" origId="Q60890" charOffset="108-111" type="protein" text="M49"/>
            <entity id="DS3.d1059.s1.e3" origId="16044960" charOffset="209-212" type="compound" text="M14"/>
            <pair e1="DS3.d1059.s1.e1" e2="DS3.d1059.s1.e2" id="DS3.d1059.s1.i0" interaction="False" />
            <pair e1="DS3.d1059.s1.e3" e2="DS3.d1059.s1.e2" id="DS3.d1059.s1.i1" interaction="False" />
            <pair e1="DS3.d1059.s1.e0" e2="DS3.d1059.s1.e2" id="DS3.d1059.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1060" origId="9987205">
        <sentence id="DS3.d1060.s0" origId="9987205-10" text="In vitro experiments also showed that desipramine increased glucocorticoid receptor mRNA.">
            <entity id="DS3.d1060.s0.e0" origId="2995" charOffset="38-49" type="compound" text="desipramine"/>
            <entity id="DS3.d1060.s0.e1" origId="E9PUR6,E9PYV1" charOffset="60-83" type="protein" text="glucocorticoid receptor"/>
            <pair e1="DS3.d1060.s0.e0" e2="DS3.d1060.s0.e1" id="DS3.d1060.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1060.s1" origId="9987205-7" text="OUTCOME MEASURES: Indicators of depressive disorder in transgenic mice, effect of antidepressant therapy on dexamethasone binding in transgenic mouse hippocampus, mouse behaviour, and glucocorticoid receptor activity.">
            <entity id="DS3.d1060.s1.e0" origId="5743" charOffset="108-121" type="compound" text="dexamethasone"/>
            <entity id="DS3.d1060.s1.e1" origId="E9PUR6,E9PYV1" charOffset="184-207" type="protein" text="glucocorticoid receptor"/>
            <pair e1="DS3.d1060.s1.e0" e2="DS3.d1060.s1.e1" id="DS3.d1060.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1060.s2" origId="9987205-9" text="Treatment with amitriptyline reduced levels of corticotropin and corticosterone, increased glucocorticoid receptor mRNA concentrations and glucocorticoid binding capacity of several brain areas, and reversed behavioural changes.">
            <entity id="DS3.d1060.s2.e0" origId="2160" charOffset="15-28" type="compound" text="amitriptyline"/>
            <entity id="DS3.d1060.s2.e1" origId="5753" charOffset="65-79" type="compound" text="corticosterone"/>
            <entity id="DS3.d1060.s2.e2" origId="E9PUR6,E9PYV1" charOffset="91-114" type="protein" text="glucocorticoid receptor"/>
            <pair e1="DS3.d1060.s2.e0" e2="DS3.d1060.s2.e2" id="DS3.d1060.s2.i0" interaction="False" />
            <pair e1="DS3.d1060.s2.e1" e2="DS3.d1060.s2.e2" id="DS3.d1060.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1061" origId="9987207">
        <sentence id="DS3.d1061.s0" origId="9987207-1" text="OBJECTIVE: To determine the efficacy of substituting moclobemide, a reversible monoamine oxidase-A inhibitor, for fluoxetine to reverse fluoxetine-induced sexual dysfunction in patients with depression.">
            <entity id="DS3.d1061.s0.e0" origId="4235" charOffset="53-64" type="compound" text="moclobemide"/>
            <entity id="DS3.d1061.s0.e1" origId="P21397,Q53YE7,Q49A63" charOffset="79-98" type="protein" text="monoamine oxidase-A"/>
            <entity id="DS3.d1061.s0.e2" origId="3386" charOffset="114-124" type="compound" text="fluoxetine"/>
            <entity id="DS3.d1061.s0.e3" origId="3386" charOffset="136-146" type="compound" text="fluoxetine"/>
            <pair e1="DS3.d1061.s0.e2" e2="DS3.d1061.s0.e1" id="DS3.d1061.s0.i0" interaction="False" />
            <pair e1="DS3.d1061.s0.e0" e2="DS3.d1061.s0.e1" id="DS3.d1061.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1062" origId="9987554">
        <sentence id="DS3.d1062.s0" origId="9987554-6" text="Twenty-three cases had mined Cape crocidolite; three had mined amosite; and three Transvaal crocidolite plus amosite.">
            <entity id="DS3.d1062.s0.e0" origId="O95347,A0A024R158,Q7Z2X1,Q05D74,A8K984,B3KMB1,Q6IPS5,Q05BV1,B7ZLZ7" charOffset="29-33" type="protein" text="Cape"/>
            <entity id="DS3.d1062.s0.e1" origId="86278622" charOffset="34-45" type="compound" text="crocidolite"/>
            <entity id="DS3.d1062.s0.e2" origId="86278622" charOffset="92-103" type="compound" text="crocidolite"/>
            <pair e1="DS3.d1062.s0.e1" e2="DS3.d1062.s0.e0" id="DS3.d1062.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1062.s1" origId="9987554-7" text="A minimum of 22 of the cases had exclusively environmental exposure, 20 were from the NW Cape crocidolite mining area.">
            <entity id="DS3.d1062.s1.e0" origId="O95347,A0A024R158,Q7Z2X1,Q05D74,A8K984,B3KMB1,Q6IPS5,Q05BV1,B7ZLZ7" charOffset="89-93" type="protein" text="Cape"/>
            <entity id="DS3.d1062.s1.e1" origId="86278622" charOffset="94-105" type="compound" text="crocidolite"/>
            <pair e1="DS3.d1062.s1.e1" e2="DS3.d1062.s1.e0" id="DS3.d1062.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1062.s2" origId="9987554-8" text="The relative risks associated with environmental exposure in the NW Cape (crocidolite) were larger than for environmental exposure in the NE Transvaal (amosite and crocidolite): 21.9 vs. 7.1 and 50.9 vs. 12.0 for the cancer control and medical control datasets, respectively.">
            <entity id="DS3.d1062.s2.e0" origId="O95347,A0A024R158,Q7Z2X1,Q05D74,A8K984,B3KMB1,Q6IPS5,Q05BV1,B7ZLZ7" charOffset="68-72" type="protein" text="Cape"/>
            <entity id="DS3.d1062.s2.e1" origId="86278622" charOffset="74-85" type="compound" text="crocidolite"/>
            <entity id="DS3.d1062.s2.e2" origId="86278622" charOffset="164-175" type="compound" text="crocidolite"/>
            <pair e1="DS3.d1062.s2.e1" e2="DS3.d1062.s2.e0" id="DS3.d1062.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1062.s3" origId="9987554-9" text="CONCLUSIONS: The results confirm the importance of environmental exposure in the Cape crocidolite mining area, the relative paucity of cases linked to amosite, the rarity of chrysotile cases and are consistent with a fiber gradient in mesotheliomagenic potential for South African asbestos with crocidolite &amp;gt; amosite &amp;gt; chrysotile.">
            <entity id="DS3.d1062.s3.e0" origId="O95347,A0A024R158,Q7Z2X1,Q05D74,A8K984,B3KMB1,Q6IPS5,Q05BV1,B7ZLZ7" charOffset="81-85" type="protein" text="Cape"/>
            <entity id="DS3.d1062.s3.e1" origId="86278622" charOffset="86-97" type="compound" text="crocidolite"/>
            <entity id="DS3.d1062.s3.e2" origId="86278622" charOffset="295-306" type="compound" text="crocidolite"/>
            <pair e1="DS3.d1062.s3.e1" e2="DS3.d1062.s3.e0" id="DS3.d1062.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1063" origId="9987566">
        <sentence id="DS3.d1063.s0" origId="9987566-8" text="The patient was started on intravenous ampicillin and gentamicin and induction of labor with oxytocin was begun.">
            <entity id="DS3.d1063.s0.e0" origId="6249" charOffset="39-49" type="compound" text="ampicillin"/>
            <entity id="DS3.d1063.s0.e1" origId="441305,57134040,3467" charOffset="54-64" type="compound" text="gentamicin"/>
            <entity id="DS3.d1063.s0.e2" origId="P01178,X5D7M6" charOffset="93-101" type="protein" text="oxytocin"/>
            <pair e1="DS3.d1063.s0.e1" e2="DS3.d1063.s0.e2" id="DS3.d1063.s0.i0" interaction="False" />
            <pair e1="DS3.d1063.s0.e0" e2="DS3.d1063.s0.e2" id="DS3.d1063.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1064" origId="9987616">
        <sentence id="DS3.d1064.s0" origId="9987616-10" text="The extraction efficiency of cyclophosphamide from urine samples was also studied at six different pH values (pH 4, 5, 6, 7, 8, 10).">
            <entity id="DS3.d1064.s0.e0" origId="2907" charOffset="29-45" type="compound" text="cyclophosphamide"/>
            <entity id="DS3.d1064.s0.e1" origId="Q9NXG6" charOffset="110-126" type="protein" text="pH 4, 5, 6, 7, 8"/>
            <pair e1="DS3.d1064.s0.e0" e2="DS3.d1064.s0.e1" id="DS3.d1064.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1065" origId="9987643">
        <sentence id="DS3.d1065.s0" origId="9987643-4" text="The aortoiliac bifurcations were divided into three regions based on the area changes: an apical region corresponding to the bifurcation apex (taper = 2.96 +/- 0.80 mm2/mm), a preapical region (flare = 3.58 +/- 0.87 mm2/mm), and the postapical region (flare = 0.82 +/- 0.80 mm2/mm).">
            <entity id="DS3.d1065.s0.e0" origId="80006" charOffset="15-26" type="compound" text="bifurcation"/>
            <entity id="DS3.d1065.s0.e1" origId="Q9UL42,Q5U5Z3" charOffset="165-168" type="protein" text="mm2"/>
            <entity id="DS3.d1065.s0.e2" origId="Q9UL42,Q5U5Z3" charOffset="216-219" type="protein" text="mm2"/>
            <entity id="DS3.d1065.s0.e3" origId="Q9UL42,Q5U5Z3" charOffset="216-219" type="protein" text="mm2"/>
            <pair e1="DS3.d1065.s0.e0" e2="DS3.d1065.s0.e1" id="DS3.d1065.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1066" origId="9987647">
        <sentence id="DS3.d1066.s0" origId="9987647-2" text="A statistical difference was detected between the different age groups regarding the numbers of gastrin-, somatostatin-, and serotonin-immunoreactive cells.">
            <entity id="DS3.d1066.s0.e0" origId="P48757" charOffset="96-103" type="protein" text="gastrin"/>
            <entity id="DS3.d1066.s0.e1" origId="P60041,Q545V6" charOffset="106-118" type="protein" text="somatostatin"/>
            <entity id="DS3.d1066.s0.e2" origId="5202" charOffset="125-134" type="compound" text="serotonin"/>
            <pair e1="DS3.d1066.s0.e2" e2="DS3.d1066.s0.e1" id="DS3.d1066.s0.i0" interaction="False" />
            <pair e1="DS3.d1066.s0.e2" e2="DS3.d1066.s0.e0" id="DS3.d1066.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1066.s1" origId="9987647-6" text="There was a statistical difference between different age-groups regarding the cell secretory index (CSI) of somatostatin- and gastrin-immunoreactive cells, the CSI of both somatostatin- and serotonin-immunoreactive cells increased significantly in 1-, 12-, and 24-month-old mice, compared with young mice.">
            <entity id="DS3.d1066.s1.e0" origId="P60041,Q545V6" charOffset="108-120" type="protein" text="somatostatin"/>
            <entity id="DS3.d1066.s1.e1" origId="P48757" charOffset="126-133" type="protein" text="gastrin"/>
            <entity id="DS3.d1066.s1.e2" origId="P60041,Q545V6" charOffset="172-184" type="protein" text="somatostatin"/>
            <entity id="DS3.d1066.s1.e3" origId="5202" charOffset="190-199" type="compound" text="serotonin"/>
            <pair e1="DS3.d1066.s1.e3" e2="DS3.d1066.s1.e0" id="DS3.d1066.s1.i0" interaction="False" />
            <pair e1="DS3.d1066.s1.e3" e2="DS3.d1066.s1.e1" id="DS3.d1066.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1067" origId="9987648">
        <sentence id="DS3.d1067.s0" origId="9987648-5" text="In contrast, that of tumor-neighboring mucosa and carcinomas to serotonin and chromogranin-A and to argyrophilia were 11.5% and 1.9%, 32.7% and 17.3%, and 26.9% and 21.2%, respectively.">
            <entity id="DS3.d1067.s0.e0" origId="5202" charOffset="64-73" type="compound" text="serotonin"/>
            <entity id="DS3.d1067.s0.e1" origId="P10645,G5E968,Q86T07" charOffset="78-92" type="protein" text="chromogranin-A"/>
            <pair e1="DS3.d1067.s0.e0" e2="DS3.d1067.s0.e1" id="DS3.d1067.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1068" origId="9987649">
        <sentence id="DS3.d1068.s0" origId="9987649-2" text="After an immunohistochemical reaction using an antibody against arginine-vasopressin, we compared by densitometry the amount of vasopressin immunoreactive material (vasopressin-ir) of these centers in 4 groups of animals: control Wistar Kyoto rats (WKY), spontaneously hypertensive rats (SHR), WKY rats treated with captopril (WKY-T) and SHR rats also treated with the same drug (SHR-T).">
            <entity id="DS3.d1068.s0.e0" origId="P01186" charOffset="64-84" type="protein" text="arginine-vasopressin"/>
            <entity id="DS3.d1068.s0.e1" origId="44093" charOffset="316-325" type="compound" text="captopril"/>
            <pair e1="DS3.d1068.s0.e1" e2="DS3.d1068.s0.e0" id="DS3.d1068.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1068.s1" origId="9987649-5" text="Then, ACE inhibition by captopril influences vasopressin content in brain areas where the hormone is concentrated before being released, which supports the hypothesis that suggests a central modulatory effect of ACE inhibitors, contributing to their therapeutic action on hypertension.">
            <entity id="DS3.d1068.s1.e0" origId="P47820" charOffset="6-9" type="protein" text="ACE"/>
            <entity id="DS3.d1068.s1.e1" origId="44093" charOffset="24-33" type="compound" text="captopril"/>
            <entity id="DS3.d1068.s1.e2" origId="P47820" charOffset="212-215" type="protein" text="ACE"/>
            <pair e1="DS3.d1068.s1.e1" e2="DS3.d1068.s1.e0" id="DS3.d1068.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1069" origId="9987657">
        <sentence id="DS3.d1069.s0" origId="9987657-5" text="We tested whether etoposide, a topoisomerase II inhibitor, could induce apoptosis in androgen-dependent (LNCaP) as well as independent (PC-3 and DU 145) human prostate cancer cell lines.">
            <entity id="DS3.d1069.s0.e0" origId="11758093,17571827,3310,439525,45356822,50989217,5284558,59360017,90657341,9916469,6419930,6610299,6708815" charOffset="18-27" type="compound" text="etoposide"/>
            <entity id="DS3.d1069.s0.e1" origId="P29120" charOffset="136-151" type="protein" text="PC-3 and DU 145"/>
            <pair e1="DS3.d1069.s0.e0" e2="DS3.d1069.s0.e1" id="DS3.d1069.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1070" origId="9987658">
        <sentence id="DS3.d1070.s0" origId="9987658-1" text="To evaluate the cellular origin of follicular dendritic cells (FDC) in lymphoid follicles (LFs), severe combined immunodeficient (SCID) mice (H-2d) were grafted with 5-bromo-2'-deoxyuridine (BrdU)-incorporated bone marrow cells from CB-17 mice (H-2d) and with non-BrdU-incorporated bone marrow cells from C3H mice (H-2k) and Wistar rats (RT1u).">
            <entity id="DS3.d1070.s0.e0" origId="76871876" charOffset="91-94" type="compound" text="LFs"/>
            <entity id="DS3.d1070.s0.e1" origId="P97313" charOffset="97-128" type="protein" text="severe combined immunodeficient"/>
            <entity id="DS3.d1070.s0.e2" origId="P97313" charOffset="130-134" type="protein" text="SCID"/>
            <entity id="DS3.d1070.s0.e3" origId="6035" charOffset="166-189" type="compound" text="5-bromo-2'-deoxyuridine"/>
            <pair e1="DS3.d1070.s0.e3" e2="DS3.d1070.s0.e1" id="DS3.d1070.s0.i0" interaction="False" />
            <pair e1="DS3.d1070.s0.e3" e2="DS3.d1070.s0.e2" id="DS3.d1070.s0.i1" interaction="False" />
            <pair e1="DS3.d1070.s0.e0" e2="DS3.d1070.s0.e1" id="DS3.d1070.s0.i2" interaction="False" />
            <pair e1="DS3.d1070.s0.e0" e2="DS3.d1070.s0.e2" id="DS3.d1070.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1070.s1" origId="9987658-3" text="Secondary LFs in the lymph nodes and spleen of the reconstructed SCID mice were examined morphologically and immunocytochemically.">
            <entity id="DS3.d1070.s1.e0" origId="76871876" charOffset="10-13" type="compound" text="LFs"/>
            <entity id="DS3.d1070.s1.e1" origId="P97313" charOffset="65-69" type="protein" text="SCID"/>
            <pair e1="DS3.d1070.s1.e0" e2="DS3.d1070.s1.e1" id="DS3.d1070.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1070.s2" origId="9987658-6" text="A cell grafting study in SCID mice using bone marrow cells from C3H mice and Wistar rats demonstrated that FDCs in reconstructed LFs exhibited a marker specific for the recipient but not for the donor.">
            <entity id="DS3.d1070.s2.e0" origId="P97313" charOffset="25-29" type="protein" text="SCID"/>
            <entity id="DS3.d1070.s2.e1" origId="76871876" charOffset="129-132" type="compound" text="LFs"/>
            <pair e1="DS3.d1070.s2.e1" e2="DS3.d1070.s2.e0" id="DS3.d1070.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1070.s3" origId="9987658-7" text="These data indicate that functionally active FDCs occur de novo in reconstructed LFs in SCID mice, and do not support the view that FDCs originate from bone marrow cells in short-term reconstructed LFs.">
            <entity id="DS3.d1070.s3.e0" origId="76871876" charOffset="81-84" type="compound" text="LFs"/>
            <entity id="DS3.d1070.s3.e1" origId="P97313" charOffset="88-92" type="protein" text="SCID"/>
            <entity id="DS3.d1070.s3.e2" origId="76871876" charOffset="198-201" type="compound" text="LFs"/>
            <pair e1="DS3.d1070.s3.e0" e2="DS3.d1070.s3.e1" id="DS3.d1070.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1071" origId="9987667">
        <sentence id="DS3.d1071.s0" origId="9987667-5" text="Recent evidence, however, suggests that an intricate process of pulmonary remodeling occurs during the development of emphysema, where a complex network of serine proteases and metalloproteinases capable of degrading different extracellular matrix molecules, primarily, but not exclusively fibrillar collagens and elastin, are implicated in the pathogenesis of this disease.">
            <entity id="DS3.d1071.s0.e0" origId="5951" charOffset="156-162" type="compound" text="serine"/>
            <entity id="DS3.d1071.s0.e1" origId="P15502,G3V0G6,B3KRT8,G5E950,B4E3S4,E7ENM0,Q8NBI4,F8WAH6,E7EN65,Q6ZUN2,Q59H17" charOffset="314-321" type="protein" text="elastin"/>
            <pair e1="DS3.d1071.s0.e0" e2="DS3.d1071.s0.e1" id="DS3.d1071.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1072" origId="9987669">
        <sentence id="DS3.d1072.s0" origId="9987669-0" text="Nitric oxide synthase in skeletal muscle fibers: a signaling component of the dystrophin-glycoprotein complex.">
            <entity id="DS3.d1072.s0.e0" origId="145068" charOffset="0-12" type="compound" text="Nitric oxide"/>
            <entity id="DS3.d1072.s0.e1" origId="P11532,Q4G0X0,A7E212,A1L0U9,Q16484" charOffset="78-88" type="protein" text="dystrophin"/>
            <pair e1="DS3.d1072.s0.e0" e2="DS3.d1072.s0.e1" id="DS3.d1072.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1072.s1" origId="9987669-10" text="Besides acetylcholine, glutamate has also been shown to stimulate nNOS, probably acting through N-methyl-D-aspartate receptors, which are colocalized with nNOS at the junctional sarcolemma.">
            <entity id="DS3.d1072.s1.e0" origId="187" charOffset="8-21" type="compound" text="acetylcholine"/>
            <entity id="DS3.d1072.s1.e1" origId="23327,33032,611,57109091" charOffset="23-32" type="compound" text="glutamate"/>
            <entity id="DS3.d1072.s1.e2" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="66-70" type="protein" text="nNOS"/>
            <entity id="DS3.d1072.s1.e3" origId="83887" charOffset="105-116" type="compound" text="D-aspartate"/>
            <entity id="DS3.d1072.s1.e4" origId="P29475,B3VK56,B4DG68,A0PJJ7" charOffset="155-159" type="protein" text="nNOS"/>
            <pair e1="DS3.d1072.s1.e3" e2="DS3.d1072.s1.e2" id="DS3.d1072.s1.i0" interaction="False" />
            <pair e1="DS3.d1072.s1.e0" e2="DS3.d1072.s1.e2" id="DS3.d1072.s1.i1" interaction="False" />
            <pair e1="DS3.d1072.s1.e1" e2="DS3.d1072.s1.e2" id="DS3.d1072.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1073" origId="9987675">
        <sentence id="DS3.d1073.s0" origId="9987675-3" text="The known elements of cholesterol trafficking machinery include clathrin-coated pits, scavenger receptor type B1, caveolae, phospholipid rafts, Niemann-Pick C disease protein, sterol carrier protein 2, multidrug resistance protein, microsomal triglyceride transfer protein and steroidogenic acute regulation protein.">
            <entity id="DS3.d1073.s0.e0" origId="5997" charOffset="22-33" type="compound" text="cholesterol"/>
            <entity id="DS3.d1073.s0.e1" origId="P22307,B2R761,Q59HG9" charOffset="176-200" type="protein" text="sterol carrier protein 2"/>
            <pair e1="DS3.d1073.s0.e0" e2="DS3.d1073.s0.e1" id="DS3.d1073.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1074" origId="9987677">
        <sentence id="DS3.d1074.s0" origId="9987677-0" text="Opioids, NSAIDs and 5-lipoxygenase inhibitors act synergistically in brain via arachidonic acid metabolism.">
            <entity id="DS3.d1074.s0.e0" origId="P09917" charOffset="20-34" type="protein" text="5-lipoxygenase"/>
            <entity id="DS3.d1074.s0.e1" origId="444899" charOffset="79-95" type="compound" text="arachidonic acid"/>
            <pair e1="DS3.d1074.s0.e1" e2="DS3.d1074.s0.e0" id="DS3.d1074.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1074.s1" origId="9987677-2" text="We further demonstrated that the efficacy of opioids was enhanced synergistically by treatment of brain neurons with inhibitors of the other major enzymes responsible for arachidonic acid metabolism; cyclooxygenase (COX-1) and 5-lipoxygenase.">
            <entity id="DS3.d1074.s1.e0" origId="444899" charOffset="171-187" type="compound" text="arachidonic acid"/>
            <entity id="DS3.d1074.s1.e1" origId="P00395,U5YWV7" charOffset="216-221" type="protein" text="COX-1"/>
            <entity id="DS3.d1074.s1.e2" origId="P09917" charOffset="227-241" type="protein" text="5-lipoxygenase"/>
            <pair e1="DS3.d1074.s1.e0" e2="DS3.d1074.s1.e2" id="DS3.d1074.s1.i0" interaction="False" />
            <pair e1="DS3.d1074.s1.e0" e2="DS3.d1074.s1.e1" id="DS3.d1074.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1075" origId="9987680">
        <sentence id="DS3.d1075.s0" origId="9987680-6" text="In our adhesion assay a significant increase in eosinophil adhesion properties to fibronectin was obtained when eosinophils were PMA stimulated and interacting with platelets, as compared to activated eosinophils without platelets.">
            <entity id="DS3.d1075.s0.e0" origId="P02751,Q6MZF4,Q6N084,B7ZLE5,Q6MZM7,Q9UQS6" charOffset="82-93" type="protein" text="fibronectin"/>
            <entity id="DS3.d1075.s0.e1" origId="122634,22833501,4792" charOffset="129-132" type="compound" text="PMA"/>
            <pair e1="DS3.d1075.s0.e1" e2="DS3.d1075.s0.e0" id="DS3.d1075.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1076" origId="9987681">
        <sentence id="DS3.d1076.s0" origId="9987681-0" text="Cytosolic phospholipase A2, increased and activated in the eosinophils of patients with hypereosinophilic syndrome in vivo, is involved in the augmented release of leukotriene C4.">
            <entity id="DS3.d1076.s0.e0" origId="P47712,B4DZI4" charOffset="0-26" type="protein" text="Cytosolic phospholipase A2"/>
            <entity id="DS3.d1076.s0.e1" origId="5280493,5283121,44563898" charOffset="164-178" type="compound" text="leukotriene C4"/>
            <pair e1="DS3.d1076.s0.e1" e2="DS3.d1076.s0.e0" id="DS3.d1076.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1077" origId="9987682">
        <sentence id="DS3.d1077.s0" origId="9987682-0" text="Temporal relationships between leukocytes, IL-5 and IL-8 in guinea pig lungs, plasma cortisol and airway function after antigen challenge.">
            <entity id="DS3.d1077.s0.e0" origId="O08987" charOffset="43-47" type="protein" text="IL-5"/>
            <entity id="DS3.d1077.s0.e1" origId="P49113" charOffset="52-56" type="protein" text="IL-8"/>
            <entity id="DS3.d1077.s0.e2" origId="5754" charOffset="85-93" type="compound" text="cortisol"/>
            <pair e1="DS3.d1077.s0.e2" e2="DS3.d1077.s0.e0" id="DS3.d1077.s0.i0" interaction="False" />
            <pair e1="DS3.d1077.s0.e2" e2="DS3.d1077.s0.e1" id="DS3.d1077.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1077.s1" origId="9987682-1" text="OBJECTIVE AND DESIGN: The aim was to determine the time courses for the changes in airway function, airway reactivity, influx of inflammatory cells and levels of the pro-inflammatory cytokines, interleukin (IL)-5 and IL-8 in bronchoalveolar lavage fluid (BALF), and the plasma levels of cortisol and ACTH after antigen challenge to determine whether a temporal link could be established between these events.">
            <entity id="DS3.d1077.s1.e0" origId="O08987" charOffset="207-212" type="protein" text="IL)-5"/>
            <entity id="DS3.d1077.s1.e1" origId="P49113" charOffset="217-221" type="protein" text="IL-8"/>
            <entity id="DS3.d1077.s1.e2" origId="5754" charOffset="287-295" type="compound" text="cortisol"/>
            <pair e1="DS3.d1077.s1.e2" e2="DS3.d1077.s1.e0" id="DS3.d1077.s1.i0" interaction="False" />
            <pair e1="DS3.d1077.s1.e2" e2="DS3.d1077.s1.e1" id="DS3.d1077.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1078" origId="9987683">
        <sentence id="DS3.d1078.s0" origId="9987683-0" text="Synergistic protection against cartilage destruction by low dose prednisolone and interleukin-10 in established murine collagen arthritis.">
            <entity id="DS3.d1078.s0.e0" origId="5755" charOffset="65-77" type="compound" text="prednisolone"/>
            <entity id="DS3.d1078.s0.e1" origId="P18893,Q3U879" charOffset="82-96" type="protein" text="interleukin-10"/>
            <pair e1="DS3.d1078.s0.e0" e2="DS3.d1078.s0.e1" id="DS3.d1078.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1078.s1" origId="9987683-10" text="Of great interest, treatment of CIA with prednisolone/IL-10 markedly reduced IL-1 beta and enhanced IL-10 production by synovial tissue.">
            <entity id="DS3.d1078.s1.e0" origId="5755" charOffset="41-53" type="compound" text="prednisolone"/>
            <entity id="DS3.d1078.s1.e1" origId="P18893,Q3U879" charOffset="54-59" type="protein" text="IL-10"/>
            <entity id="DS3.d1078.s1.e2" origId="P10749" charOffset="77-86" type="protein" text="IL-1 beta"/>
            <entity id="DS3.d1078.s1.e3" origId="P18893,Q3U879" charOffset="100-105" type="protein" text="IL-10"/>
            <pair e1="DS3.d1078.s1.e0" e2="DS3.d1078.s1.e2" id="DS3.d1078.s1.i0" interaction="False" />
            <pair e1="DS3.d1078.s1.e0" e2="DS3.d1078.s1.e1" id="DS3.d1078.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1078.s2" origId="9987683-12" text="CONCLUSION: This study demonstrates synergistic effects of combined treatment with prednisolone and IL-10 on suppressing disease activity of CIA as well as reducing cartilage.">
            <entity id="DS3.d1078.s2.e0" origId="5755" charOffset="83-95" type="compound" text="prednisolone"/>
            <entity id="DS3.d1078.s2.e1" origId="P18893,Q3U879" charOffset="100-105" type="protein" text="IL-10"/>
            <pair e1="DS3.d1078.s2.e0" e2="DS3.d1078.s2.e1" id="DS3.d1078.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1078.s3" origId="9987683-3" text="Mice with established CIA were selected and treated for at least 7 days with either prednisolone (0.05-5 mg/kg), IL-10 (0.1-5 micrograms/day) or the combination of prednisolone/IL-10 (0.05/1 and 0.05/5).">
            <entity id="DS3.d1078.s3.e0" origId="5755" charOffset="84-96" type="compound" text="prednisolone"/>
            <entity id="DS3.d1078.s3.e1" origId="P18893,Q3U879" charOffset="113-118" type="protein" text="IL-10"/>
            <entity id="DS3.d1078.s3.e2" origId="5755" charOffset="164-176" type="compound" text="prednisolone"/>
            <entity id="DS3.d1078.s3.e3" origId="P18893,Q3U879" charOffset="177-182" type="protein" text="IL-10"/>
            <pair e1="DS3.d1078.s3.e0" e2="DS3.d1078.s3.e1" id="DS3.d1078.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1078.s4" origId="9987683-7" text="Synergistic effects were seen with the combination of low dose prednisolone and IL-10 (0.05 mg/kg, 1 microgram/day).">
            <entity id="DS3.d1078.s4.e0" origId="5755" charOffset="63-75" type="compound" text="prednisolone"/>
            <entity id="DS3.d1078.s4.e1" origId="P18893,Q3U879" charOffset="80-85" type="protein" text="IL-10"/>
            <pair e1="DS3.d1078.s4.e0" e2="DS3.d1078.s4.e1" id="DS3.d1078.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1078.s5" origId="9987683-9" text="Moreover, COMP levels were significantly decreased after IL-10/prednisolone treatment, confirming decreased cartilage involvement.">
            <entity id="DS3.d1078.s5.e0" origId="Q9R0G6" charOffset="10-14" type="protein" text="COMP"/>
            <entity id="DS3.d1078.s5.e1" origId="P18893,Q3U879" charOffset="57-62" type="protein" text="IL-10"/>
            <entity id="DS3.d1078.s5.e2" origId="5755" charOffset="63-75" type="compound" text="prednisolone"/>
            <pair e1="DS3.d1078.s5.e2" e2="DS3.d1078.s5.e0" id="DS3.d1078.s5.i0" interaction="False" />
            <pair e1="DS3.d1078.s5.e2" e2="DS3.d1078.s5.e1" id="DS3.d1078.s5.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1079" origId="9987684">
        <sentence id="DS3.d1079.s0" origId="9987684-6" text="RESULTS: The bradykinin-induced increase in cytosolic free calcium concentration ((Ca2+)i) and activation of the respiratory burst were significantly enhanced by interleukin-1 beta (100 U/ml) added to cultures of macrophages 24 h before stimulation with bradykinin.">
            <entity id="DS3.d1079.s0.e0" origId="22044544,5460341" charOffset="59-66" type="compound" text="calcium"/>
            <entity id="DS3.d1079.s0.e1" origId="Q9WVG1" charOffset="162-180" type="protein" text="interleukin-1 beta"/>
            <pair e1="DS3.d1079.s0.e0" e2="DS3.d1079.s0.e1" id="DS3.d1079.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1079.s1" origId="9987684-7" text="However, the EC50 values of bradykinin-induced calcium signal of 23 +/- 8 nM and 29 +/- 17 nM and superoxide radical formation of 64 +/- 22 nM and 34 +/- 29 nM in control and interleukin-1 beta-treated cells, respectively, were not changed.">
            <entity id="DS3.d1079.s1.e0" origId="22044544,5460341" charOffset="47-54" type="compound" text="calcium"/>
            <entity id="DS3.d1079.s1.e1" origId="5359597" charOffset="98-116" type="compound" text="superoxide radical"/>
            <entity id="DS3.d1079.s1.e2" origId="Q9WVG1" charOffset="175-193" type="protein" text="interleukin-1 beta"/>
            <pair e1="DS3.d1079.s1.e1" e2="DS3.d1079.s1.e2" id="DS3.d1079.s1.i0" interaction="False" />
            <pair e1="DS3.d1079.s1.e0" e2="DS3.d1079.s1.e2" id="DS3.d1079.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1080" origId="9987687">
        <sentence id="DS3.d1080.s0" origId="9987687-1" text="PURPOSE: Data about the effect of multifetal pregnancy reduction on midtrimester maternal serum levels of alpha-fetoprotein (AFP), human chorionic gonadotropin (hCG), and unconjugated estriol (uE3) are scarce and contradictory.">
            <entity id="DS3.d1080.s0.e0" origId="P02771" charOffset="106-123" type="protein" text="alpha-fetoprotein"/>
            <entity id="DS3.d1080.s0.e1" origId="P02771" charOffset="125-128" type="protein" text="AFP"/>
            <entity id="DS3.d1080.s0.e2" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="131-159" type="protein" text="human chorionic gonadotropin"/>
            <entity id="DS3.d1080.s0.e3" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="161-164" type="protein" text="hCG"/>
            <entity id="DS3.d1080.s0.e4" origId="5756" charOffset="184-191" type="compound" text="estriol"/>
            <pair e1="DS3.d1080.s0.e4" e2="DS3.d1080.s0.e2" id="DS3.d1080.s0.i0" interaction="False" />
            <pair e1="DS3.d1080.s0.e4" e2="DS3.d1080.s0.e0" id="DS3.d1080.s0.i1" interaction="False" />
            <pair e1="DS3.d1080.s0.e4" e2="DS3.d1080.s0.e1" id="DS3.d1080.s0.i2" interaction="False" />
            <pair e1="DS3.d1080.s0.e4" e2="DS3.d1080.s0.e3" id="DS3.d1080.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1080.s1" origId="9987687-6" text="RESULTS: Twenty-four (88.9%) of 27 patients had maternal serum AFP levels above 2.0 MoM (mean, 4.60 +/- 3.48 MoM; range, 1.49-14.85 MoM), however, none of the newborns had structural anomalies.">
            <entity id="DS3.d1080.s1.e0" origId="P02771" charOffset="63-66" type="protein" text="AFP"/>
            <entity id="DS3.d1080.s1.e1" origId="5282188" charOffset="84-87" type="compound" text="MoM"/>
            <entity id="DS3.d1080.s1.e2" origId="5282188" charOffset="109-112" type="compound" text="MoM"/>
            <entity id="DS3.d1080.s1.e3" origId="5282188" charOffset="109-112" type="compound" text="MoM"/>
            <pair e1="DS3.d1080.s1.e1" e2="DS3.d1080.s1.e0" id="DS3.d1080.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1080.s2" origId="9987687-8" text="The mean hCG levels were 1.22 +/- 0.49 MoM (range, 0.14-2.47), and the mean uE3 levels were 1.15 +/- 0.31 MoM (range, 0.56-1.84).">
            <entity id="DS3.d1080.s2.e0" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="9-12" type="protein" text="hCG"/>
            <entity id="DS3.d1080.s2.e1" origId="5282188" charOffset="39-42" type="compound" text="MoM"/>
            <entity id="DS3.d1080.s2.e2" origId="5282188" charOffset="106-109" type="compound" text="MoM"/>
            <pair e1="DS3.d1080.s2.e1" e2="DS3.d1080.s2.e0" id="DS3.d1080.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1081" origId="9987702">
        <sentence id="DS3.d1081.s0" origId="9987702-8" text="The response was not significantly altered in the presence of acute or chronic acetaminophen dosing, as assessed by prothrombin time and factor VII concentrations.">
            <entity id="DS3.d1081.s0.e0" origId="1983" charOffset="79-92" type="compound" text="acetaminophen"/>
            <entity id="DS3.d1081.s0.e1" origId="P00734" charOffset="116-127" type="protein" text="prothrombin"/>
            <pair e1="DS3.d1081.s0.e0" e2="DS3.d1081.s0.e1" id="DS3.d1081.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1082" origId="9987705">
        <sentence id="DS3.d1082.s0" origId="9987705-3" text="A pharmacokinetic interaction with rifampin, an antituberculosis agent and potent inducer of CYP3A4 and P-glycoprotein, and tacrolimus was evaluated in six healthy male volunteers.">
            <entity id="DS3.d1082.s0.e0" origId="16043998,24871024,25141428,5381226,5458213,5702112,57032154,6243627,6842115,6913622" charOffset="35-43" type="compound" text="rifampin"/>
            <entity id="DS3.d1082.s0.e1" origId="P08684,Q6GRK0" charOffset="93-99" type="protein" text="CYP3A4"/>
            <entity id="DS3.d1082.s0.e2" origId="P08183,A4D1D2" charOffset="104-118" type="protein" text="P-glycoprotein"/>
            <entity id="DS3.d1082.s0.e3" origId="445643,90726579" charOffset="124-134" type="compound" text="tacrolimus"/>
            <pair e1="DS3.d1082.s0.e0" e2="DS3.d1082.s0.e1" id="DS3.d1082.s0.i0" interaction="False" />
            <pair e1="DS3.d1082.s0.e0" e2="DS3.d1082.s0.e2" id="DS3.d1082.s0.i1" interaction="False" />
            <pair e1="DS3.d1082.s0.e3" e2="DS3.d1082.s0.e1" id="DS3.d1082.s0.i2" interaction="False" />
            <pair e1="DS3.d1082.s0.e3" e2="DS3.d1082.s0.e2" id="DS3.d1082.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1082.s1" origId="9987705-7" text="Rifampin appears to induce both intestinal and hepatic metabolism of tacrolimus, most likely through induction of CYP3A and P-glycoprotein in the liver and small bowel.">
            <entity id="DS3.d1082.s1.e0" origId="16043998,24871024,5381226,5458213,5702112,25141428,57032154,6243627,6842115,6913622" charOffset="0-8" type="compound" text="Rifampin"/>
            <entity id="DS3.d1082.s1.e1" origId="445643,90726579" charOffset="69-79" type="compound" text="tacrolimus"/>
            <entity id="DS3.d1082.s1.e2" origId="P08183,A4D1D2" charOffset="124-138" type="protein" text="P-glycoprotein"/>
            <pair e1="DS3.d1082.s1.e0" e2="DS3.d1082.s1.e2" id="DS3.d1082.s1.i0" interaction="False" />
            <pair e1="DS3.d1082.s1.e1" e2="DS3.d1082.s1.e2" id="DS3.d1082.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1083" origId="9987734">
        <sentence id="DS3.d1083.s0" origId="9987734-1" text="OBJECTIVE: To evaluate the efficacy of the GnRH agonist (GnRHa) administered in conjunction with human menopausal gonadotropin/human chorionic gonadotropin hMG/hCG and direct intraperitoneal insemination (DIPI) in women with long-standing unexplained infertility.">
            <entity id="DS3.d1083.s0.e0" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="160-163" type="protein" text="hCG"/>
            <entity id="DS3.d1083.s0.e1" origId="47363" charOffset="205-209" type="compound" text="DIPI"/>
            <pair e1="DS3.d1083.s0.e1" e2="DS3.d1083.s0.e0" id="DS3.d1083.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1083.s1" origId="9987734-4" text="Pregnancy rates per cycle and per patient of DIPI were compared between groups of hMG/hCG with (GnRHa(+) controlled ovarian hyperstimulation (COH) group) or without (GnRHa(-) COH group) GnRHa.">
            <entity id="DS3.d1083.s1.e0" origId="47363" charOffset="45-49" type="compound" text="DIPI"/>
            <entity id="DS3.d1083.s1.e1" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="86-89" type="protein" text="hCG"/>
            <pair e1="DS3.d1083.s1.e0" e2="DS3.d1083.s1.e1" id="DS3.d1083.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1083.s2" origId="9987734-7" text="CONCLUSION: The use of GnRHa with hMG/hCG and DIPI treatment significantly increased the pregnancy rate in women with long-standing infertility.">
            <entity id="DS3.d1083.s2.e0" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="38-41" type="protein" text="hCG"/>
            <entity id="DS3.d1083.s2.e1" origId="47363" charOffset="46-50" type="compound" text="DIPI"/>
            <pair e1="DS3.d1083.s2.e1" e2="DS3.d1083.s2.e0" id="DS3.d1083.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1084" origId="9987735">
        <sentence id="DS3.d1084.s0" origId="9987735-0" text="Polycystic ovary syndrome. Insulin resistance and ovulatory responses to clomiphene citrate.">
            <entity id="DS3.d1084.s0.e0" origId="P01308,I3WAC9" charOffset="27-34" type="protein" text="Insulin"/>
            <entity id="DS3.d1084.s0.e1" origId="3033832,60974,6420009" charOffset="73-91" type="compound" text="clomiphene citrate"/>
            <pair e1="DS3.d1084.s0.e1" e2="DS3.d1084.s0.e0" id="DS3.d1084.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1084.s1" origId="9987735-1" text="OBJECTIVE: To evaluate Insulin secretion detected on oral glucose tolerance testing in relation to clomiphene citrate (CC) responses in women with polycystic ovary syndrome (PCOS).">
            <entity id="DS3.d1084.s1.e0" origId="P01308,I3WAC9" charOffset="23-30" type="protein" text="Insulin"/>
            <entity id="DS3.d1084.s1.e1" origId="206,5793,64689,79025" charOffset="58-65" type="compound" text="glucose"/>
            <entity id="DS3.d1084.s1.e2" origId="3033832,60974,6420009" charOffset="99-117" type="compound" text="clomiphene citrate"/>
            <pair e1="DS3.d1084.s1.e2" e2="DS3.d1084.s1.e0" id="DS3.d1084.s1.i0" interaction="False" />
            <pair e1="DS3.d1084.s1.e1" e2="DS3.d1084.s1.e0" id="DS3.d1084.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1084.s2" origId="9987735-3" text="Plasma baseline levels of gonadotropins, sex hormone binding globulin, androstenedione, dehydroepiandrosterone sulfate and testosterone (T) were determined.">
            <entity id="DS3.d1084.s2.e0" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="41-69" type="protein" text="sex hormone binding globulin"/>
            <entity id="DS3.d1084.s2.e1" origId="6128" charOffset="71-86" type="compound" text="androstenedione"/>
            <entity id="DS3.d1084.s2.e2" origId="12594" charOffset="88-118" type="compound" text="dehydroepiandrosterone sulfate"/>
            <entity id="DS3.d1084.s2.e3" origId="6013" charOffset="123-135" type="compound" text="testosterone"/>
            <pair e1="DS3.d1084.s2.e2" e2="DS3.d1084.s2.e0" id="DS3.d1084.s2.i0" interaction="False" />
            <pair e1="DS3.d1084.s2.e1" e2="DS3.d1084.s2.e0" id="DS3.d1084.s2.i1" interaction="False" />
            <pair e1="DS3.d1084.s2.e3" e2="DS3.d1084.s2.e0" id="DS3.d1084.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1084.s3" origId="9987735-4" text="Insulin and glucose serum concentrations were analyzed in all samples after a 75-g oral glucose tolerance test.">
            <entity id="DS3.d1084.s3.e0" origId="P01308,I3WAC9" charOffset="0-7" type="protein" text="Insulin"/>
            <entity id="DS3.d1084.s3.e1" origId="206,5793,64689,79025" charOffset="12-19" type="compound" text="glucose"/>
            <entity id="DS3.d1084.s3.e2" origId="206,5793,64689,79025" charOffset="88-95" type="compound" text="glucose"/>
            <pair e1="DS3.d1084.s3.e1" e2="DS3.d1084.s3.e0" id="DS3.d1084.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1085" origId="9987738">
        <sentence id="DS3.d1085.s0" origId="9987738-7" text="Nuchal cord was associated with increased risks of fetal distress (OR 2.7, 95% CI 2.1-3.4), meconium staining (OR 2.1, 95% CI 1.7-2.6), five-minute Apgar score &amp;lt; 7 (OR 1.6, 95% CI 1.1-2.4) and assisted ventilation &amp;lt; 30 minutes (OR 1.9, 95% CI 1.4-2.6).">
            <entity id="DS3.d1085.s0.e0" origId="5288826" charOffset="92-100" type="compound" text="meconium"/>
            <entity id="DS3.d1085.s0.e1" origId="Q6IFH4" charOffset="111-117" type="protein" text="OR 2.1"/>
            <entity id="DS3.d1085.s0.e2" origId="Q8NGX5" charOffset="168-174" type="protein" text="OR 1.6"/>
            <pair e1="DS3.d1085.s0.e0" e2="DS3.d1085.s0.e2" id="DS3.d1085.s0.i0" interaction="False" />
            <pair e1="DS3.d1085.s0.e0" e2="DS3.d1085.s0.e1" id="DS3.d1085.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1086" origId="9987743">
        <sentence id="DS3.d1086.s0" origId="9987743-3" text="CASE: A woman with an 11.3-week cervical pregnancy was treated with methotrexate, angiographic embolization of the anterior division of the hypogastric artery, dilatation and curettage, and minimal rollerball ablation of bleeding cervical vessels only.">
            <entity id="DS3.d1086.s0.e0" origId="P61962" charOffset="19-24" type="protein" text="an 11"/>
            <entity id="DS3.d1086.s0.e1" origId="126941" charOffset="68-80" type="compound" text="methotrexate"/>
            <pair e1="DS3.d1086.s0.e1" e2="DS3.d1086.s0.e0" id="DS3.d1086.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1087" origId="9987747">
        <sentence id="DS3.d1087.s0" origId="9987747-2" text="The role of cyclic adenosine monophosphate and CRP protein, forming a complex, is shown.">
            <entity id="DS3.d1087.s0.e0" origId="6083" charOffset="19-42" type="compound" text="adenosine monophosphate"/>
            <entity id="DS3.d1087.s0.e1" origId="P02741" charOffset="47-50" type="protein" text="CRP"/>
            <pair e1="DS3.d1087.s0.e0" e2="DS3.d1087.s0.e1" id="DS3.d1087.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1088" origId="9987806">
        <sentence id="DS3.d1088.s0" origId="9987806-10" text="It is suggested that the molecules agrin, ARIA, MuSK and S-laminin have suitable properties according to the dual-constraint hypothesis to subserve this purpose.">
            <entity id="DS3.d1088.s0.e0" origId="O00468" charOffset="35-40" type="protein" text="agrin"/>
            <entity id="DS3.d1088.s0.e1" origId="Q02297,Q7RTW5,A0A024QY88,Q7RTW3,B0FWZ3,B0FYA9,A6MW55,B0FYA8,Q6PK61,B0FYA7,A6MW56,F6RJN6,B7Z1D7" charOffset="42-46" type="protein" text="ARIA"/>
            <entity id="DS3.d1088.s0.e2" origId="O15146,A0A087WSY1" charOffset="48-52" type="protein" text="MuSK"/>
            <entity id="DS3.d1088.s0.e3" origId="44342165" charOffset="59-66" type="compound" text="laminin"/>
            <pair e1="DS3.d1088.s0.e3" e2="DS3.d1088.s0.e2" id="DS3.d1088.s0.i0" interaction="False" />
            <pair e1="DS3.d1088.s0.e3" e2="DS3.d1088.s0.e0" id="DS3.d1088.s0.i1" interaction="False" />
            <pair e1="DS3.d1088.s0.e3" e2="DS3.d1088.s0.e1" id="DS3.d1088.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1089" origId="9987815">
        <sentence id="DS3.d1089.s0" origId="9987815-0" text="A multi-purpose system for water purification and sea-water softening.">
            <entity id="DS3.d1089.s0.e0" origId="962" charOffset="27-32" type="compound" text="water"/>
            <entity id="DS3.d1089.s0.e1" origId="Q7KSQ0" charOffset="50-53" type="protein" text="sea"/>
            <entity id="DS3.d1089.s0.e2" origId="962" charOffset="54-59" type="compound" text="water"/>
            <pair e1="DS3.d1089.s0.e0" e2="DS3.d1089.s0.e1" id="DS3.d1089.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1089.s1" origId="9987815-1" text="A novel technique that can be used for reacting toxic carbon dioxide (CO2) emissions from power plants and other combustion wastes with sea water is described.">
            <entity id="DS3.d1089.s1.e0" origId="280" charOffset="54-68" type="compound" text="carbon dioxide"/>
            <entity id="DS3.d1089.s1.e1" origId="Q7KSQ0" charOffset="136-139" type="protein" text="sea"/>
            <entity id="DS3.d1089.s1.e2" origId="962" charOffset="140-145" type="compound" text="water"/>
            <pair e1="DS3.d1089.s1.e2" e2="DS3.d1089.s1.e1" id="DS3.d1089.s1.i0" interaction="False" />
            <pair e1="DS3.d1089.s1.e0" e2="DS3.d1089.s1.e1" id="DS3.d1089.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1089.s2" origId="9987815-2" text="A chemical interaction between CO2 and the cations in sea water, with the pH electrolytically regulated, can precipitate almost all the calcium and magnesium ions, as well as some sodium and potassium ions, as carbonates and bicarbonates.">
            <entity id="DS3.d1089.s2.e0" origId="Q7KSQ0" charOffset="54-57" type="protein" text="sea"/>
            <entity id="DS3.d1089.s2.e1" origId="962" charOffset="58-63" type="compound" text="water"/>
            <entity id="DS3.d1089.s2.e2" origId="22044544,5460341" charOffset="136-143" type="compound" text="calcium"/>
            <entity id="DS3.d1089.s2.e3" origId="888" charOffset="148-162" type="compound" text="magnesium ions"/>
            <entity id="DS3.d1089.s2.e4" origId="5360545" charOffset="180-186" type="compound" text="sodium"/>
            <entity id="DS3.d1089.s2.e5" origId="5462222" charOffset="191-200" type="compound" text="potassium"/>
            <pair e1="DS3.d1089.s2.e1" e2="DS3.d1089.s2.e0" id="DS3.d1089.s2.i0" interaction="False" />
            <pair e1="DS3.d1089.s2.e2" e2="DS3.d1089.s2.e0" id="DS3.d1089.s2.i1" interaction="False" />
            <pair e1="DS3.d1089.s2.e5" e2="DS3.d1089.s2.e0" id="DS3.d1089.s2.i2" interaction="False" />
            <pair e1="DS3.d1089.s2.e4" e2="DS3.d1089.s2.e0" id="DS3.d1089.s2.i3" interaction="False" />
            <pair e1="DS3.d1089.s2.e3" e2="DS3.d1089.s2.e0" id="DS3.d1089.s2.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d1089.s3" origId="9987815-5" text="The technology and equipment for purification are based on modules that can be used for industrial waste-water, sea water, solutions, and otherwise.">
            <entity id="DS3.d1089.s3.e0" origId="962" charOffset="105-110" type="compound" text="water"/>
            <entity id="DS3.d1089.s3.e1" origId="Q7KSQ0" charOffset="112-115" type="protein" text="sea"/>
            <entity id="DS3.d1089.s3.e2" origId="962" charOffset="116-121" type="compound" text="water"/>
            <pair e1="DS3.d1089.s3.e0" e2="DS3.d1089.s3.e1" id="DS3.d1089.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1090" origId="9987822">
        <sentence id="DS3.d1090.s0" origId="9987822-1" text="Based on the X-ray structure of the complex of Ac-Tyr-Val-Ala-Asp-H (L-709049) and interleukin-1 beta converting enzyme (ICE), we synthesized compounds which were derived from 2-NapCO-Val-Pro-Asp-CH2OPh (1) to obtain a potent inhibitor in the cell assay.">
            <entity id="DS3.d1090.s0.e0" origId="14767562" charOffset="50-57" type="compound" text="Tyr-Val"/>
            <entity id="DS3.d1090.s0.e1" origId="P29452" charOffset="83-119" type="protein" text="interleukin-1 beta converting enzyme"/>
            <entity id="DS3.d1090.s0.e2" origId="3838871" charOffset="188-195" type="compound" text="Pro-Asp"/>
            <pair e1="DS3.d1090.s0.e0" e2="DS3.d1090.s0.e1" id="DS3.d1090.s0.i0" interaction="False" />
            <pair e1="DS3.d1090.s0.e2" e2="DS3.d1090.s0.e1" id="DS3.d1090.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1090.s1" origId="9987822-4" text="Compound 27c also dose dependently inhibited LPS-primed ATP-induced IL-1 beta release in mice.">
            <entity id="DS3.d1090.s1.e0" origId="54669588" charOffset="9-12" type="compound" text="27c"/>
            <entity id="DS3.d1090.s1.e1" origId="Q9QUK6,L0CL36" charOffset="45-48" type="protein" text="LPS"/>
            <entity id="DS3.d1090.s1.e2" origId="5957" charOffset="56-59" type="compound" text="ATP"/>
            <entity id="DS3.d1090.s1.e3" origId="P10749" charOffset="68-77" type="protein" text="IL-1 beta"/>
            <pair e1="DS3.d1090.s1.e0" e2="DS3.d1090.s1.e3" id="DS3.d1090.s1.i0" interaction="False" />
            <pair e1="DS3.d1090.s1.e0" e2="DS3.d1090.s1.e1" id="DS3.d1090.s1.i1" interaction="False" />
            <pair e1="DS3.d1090.s1.e2" e2="DS3.d1090.s1.e3" id="DS3.d1090.s1.i2" interaction="False" />
            <pair e1="DS3.d1090.s1.e2" e2="DS3.d1090.s1.e1" id="DS3.d1090.s1.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1091" origId="9987833">
        <sentence id="DS3.d1091.s0" origId="9987833-0" text="Synthesis of the selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist (+)-(S)-2-chloro-5-methoxy-4-(5-(2-piperidylmethyl)-1,2,4-oxadiazol-3-y l)aniline.">
            <entity id="DS3.d1091.s0.e0" origId="Q13639" charOffset="27-48" type="protein" text="5-hydroxytryptamine 4"/>
            <entity id="DS3.d1091.s0.e1" origId="Q13639" charOffset="50-55" type="protein" text="5-HT4"/>
            <entity id="DS3.d1091.s0.e2" origId="1800613" charOffset="82-90" type="compound" text="2-chloro"/>
            <entity id="DS3.d1091.s0.e3" origId="91066389" charOffset="93-101" type="compound" text="methoxy-"/>
            <entity id="DS3.d1091.s0.e4" origId="6451463" charOffset="126-141" type="compound" text="1,2,4-oxadiazol"/>
            <entity id="DS3.d1091.s0.e5" origId="6115" charOffset="148-155" type="compound" text="aniline"/>
            <pair e1="DS3.d1091.s0.e2" e2="DS3.d1091.s0.e0" id="DS3.d1091.s0.i0" interaction="False" />
            <pair e1="DS3.d1091.s0.e2" e2="DS3.d1091.s0.e1" id="DS3.d1091.s0.i1" interaction="False" />
            <pair e1="DS3.d1091.s0.e3" e2="DS3.d1091.s0.e0" id="DS3.d1091.s0.i2" interaction="False" />
            <pair e1="DS3.d1091.s0.e3" e2="DS3.d1091.s0.e1" id="DS3.d1091.s0.i3" interaction="False" />
            <pair e1="DS3.d1091.s0.e4" e2="DS3.d1091.s0.e0" id="DS3.d1091.s0.i4" interaction="False" />
            <pair e1="DS3.d1091.s0.e4" e2="DS3.d1091.s0.e1" id="DS3.d1091.s0.i5" interaction="False" />
            <pair e1="DS3.d1091.s0.e5" e2="DS3.d1091.s0.e0" id="DS3.d1091.s0.i6" interaction="False" />
            <pair e1="DS3.d1091.s0.e5" e2="DS3.d1091.s0.e1" id="DS3.d1091.s0.i7" interaction="False" />
        </sentence>
        <sentence id="DS3.d1091.s1" origId="9987833-1" text="In a search for novel 5-hydroxytryptamine 4 (5-HT4) agonists focusing on the linker group of benzamide derivatives, 2-chloro-5-methoxy-4-(5-(2-piperidylmethyl)-1,2,4-oxadiazol-3-yl)a niline (2) was prepared and its optical isomers were separated.">
            <entity id="DS3.d1091.s1.e0" origId="Q13639" charOffset="22-43" type="protein" text="5-hydroxytryptamine 4"/>
            <entity id="DS3.d1091.s1.e1" origId="Q13639" charOffset="45-50" type="protein" text="5-HT4"/>
            <entity id="DS3.d1091.s1.e2" origId="2331" charOffset="93-102" type="compound" text="benzamide"/>
            <entity id="DS3.d1091.s1.e3" origId="1800613" charOffset="116-124" type="compound" text="2-chloro"/>
            <entity id="DS3.d1091.s1.e4" origId="91066389" charOffset="127-135" type="compound" text="methoxy-"/>
            <entity id="DS3.d1091.s1.e5" origId="6451463" charOffset="160-175" type="compound" text="1,2,4-oxadiazol"/>
            <pair e1="DS3.d1091.s1.e3" e2="DS3.d1091.s1.e0" id="DS3.d1091.s1.i0" interaction="False" />
            <pair e1="DS3.d1091.s1.e3" e2="DS3.d1091.s1.e1" id="DS3.d1091.s1.i1" interaction="False" />
            <pair e1="DS3.d1091.s1.e4" e2="DS3.d1091.s1.e0" id="DS3.d1091.s1.i2" interaction="False" />
            <pair e1="DS3.d1091.s1.e4" e2="DS3.d1091.s1.e1" id="DS3.d1091.s1.i3" interaction="False" />
            <pair e1="DS3.d1091.s1.e2" e2="DS3.d1091.s1.e0" id="DS3.d1091.s1.i4" interaction="False" />
            <pair e1="DS3.d1091.s1.e2" e2="DS3.d1091.s1.e1" id="DS3.d1091.s1.i5" interaction="False" />
            <pair e1="DS3.d1091.s1.e5" e2="DS3.d1091.s1.e0" id="DS3.d1091.s1.i6" interaction="False" />
            <pair e1="DS3.d1091.s1.e5" e2="DS3.d1091.s1.e1" id="DS3.d1091.s1.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1092" origId="9987835">
        <sentence id="DS3.d1092.s0" origId="9987835-1" text="Starting with 5-S-glutathionyl-beta-alanyl-L-dopa (1) and 5-S-glutathionyl-beta-alanyl-dopamine (2), a series of analogues with truncated glutathionyl and beta-alanyl-dopa moieties were synthesized, and their inhibitory effects on autophosphorylation and substrate phosphorylation reaction by c-Src and by epidermal growth factor receptor (EGFR) were evaluated.">
            <entity id="DS3.d1092.s0.e0" origId="91153497" charOffset="18-31" type="compound" text="glutathionyl-"/>
            <entity id="DS3.d1092.s0.e1" origId="448397,188982" charOffset="36-42" type="compound" text="alanyl"/>
            <entity id="DS3.d1092.s0.e2" origId="6047" charOffset="43-49" type="compound" text="L-dopa"/>
            <entity id="DS3.d1092.s0.e3" origId="91153497" charOffset="62-75" type="compound" text="glutathionyl-"/>
            <entity id="DS3.d1092.s0.e4" origId="22798410" charOffset="80-95" type="compound" text="alanyl-dopamine"/>
            <entity id="DS3.d1092.s0.e5" origId="448397,188982" charOffset="80-86" type="compound" text="alanyl"/>
            <entity id="DS3.d1092.s0.e6" origId="P12931" charOffset="293-298" type="protein" text="c-Src"/>
            <entity id="DS3.d1092.s0.e7" origId="P00533" charOffset="306-338" type="protein" text="epidermal growth factor receptor"/>
            <entity id="DS3.d1092.s0.e8" origId="P00533" charOffset="340-344" type="protein" text="EGFR"/>
            <pair e1="DS3.d1092.s0.e0" e2="DS3.d1092.s0.e7" id="DS3.d1092.s0.i0" interaction="False" />
            <pair e1="DS3.d1092.s0.e0" e2="DS3.d1092.s0.e6" id="DS3.d1092.s0.i1" interaction="False" />
            <pair e1="DS3.d1092.s0.e0" e2="DS3.d1092.s0.e8" id="DS3.d1092.s0.i2" interaction="False" />
            <pair e1="DS3.d1092.s0.e4" e2="DS3.d1092.s0.e7" id="DS3.d1092.s0.i3" interaction="False" />
            <pair e1="DS3.d1092.s0.e4" e2="DS3.d1092.s0.e6" id="DS3.d1092.s0.i4" interaction="False" />
            <pair e1="DS3.d1092.s0.e4" e2="DS3.d1092.s0.e8" id="DS3.d1092.s0.i5" interaction="False" />
            <pair e1="DS3.d1092.s0.e2" e2="DS3.d1092.s0.e7" id="DS3.d1092.s0.i6" interaction="False" />
            <pair e1="DS3.d1092.s0.e2" e2="DS3.d1092.s0.e6" id="DS3.d1092.s0.i7" interaction="False" />
            <pair e1="DS3.d1092.s0.e2" e2="DS3.d1092.s0.e8" id="DS3.d1092.s0.i8" interaction="False" />
            <pair e1="DS3.d1092.s0.e1" e2="DS3.d1092.s0.e7" id="DS3.d1092.s0.i9" interaction="False" />
            <pair e1="DS3.d1092.s0.e1" e2="DS3.d1092.s0.e6" id="DS3.d1092.s0.i10" interaction="False" />
            <pair e1="DS3.d1092.s0.e1" e2="DS3.d1092.s0.e8" id="DS3.d1092.s0.i11" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1093" origId="9987865">
        <sentence id="DS3.d1093.s0" origId="9987865-4" text="Following administration, urine samples (total void volume) were collected ad lib for seven days and pH, specific gravity and creatinine values were determined.">
            <entity id="DS3.d1093.s0.e0" origId="Q8TF66,B3KWI4" charOffset="78-81" type="protein" text="lib"/>
            <entity id="DS3.d1093.s0.e1" origId="588" charOffset="126-136" type="compound" text="creatinine"/>
            <pair e1="DS3.d1093.s0.e1" e2="DS3.d1093.s0.e0" id="DS3.d1093.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1094" origId="9987875">
        <sentence id="DS3.d1094.s0" origId="9987875-3" text='During the course of analyzing over 10,000 individuals for the STR loci CSF1PO, TPOX and THO1 (CTT) using silver staining for allele detection, 42 samples demonstrated alleles that were "off ladder," contained three-banded patterns at a single locus, or exhibited an apparent THO1 "9.3,10" allele pattern.'>
            <entity id="DS3.d1094.s0.e0" origId="P82979" charOffset="89-93" type="protein" text="THO1"/>
            <entity id="DS3.d1094.s0.e1" origId="23954" charOffset="106-112" type="compound" text="silver"/>
            <entity id="DS3.d1094.s0.e2" origId="P82979" charOffset="276-280" type="protein" text="THO1"/>
            <pair e1="DS3.d1094.s0.e1" e2="DS3.d1094.s0.e0" id="DS3.d1094.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1094.s1" origId="9987875-6" text='The only exception was a sample in which a wide band within the THO1 locus was identified as a THO1 "9.3, 10" genotype by silver staining kit and SYBR Green I staining but was verified to be a THO1 "9.3" homozygote by all other allele detection systems.'>
            <entity id="DS3.d1094.s1.e0" origId="P82979" charOffset="64-68" type="protein" text="THO1"/>
            <entity id="DS3.d1094.s1.e1" origId="P82979" charOffset="95-99" type="protein" text="THO1"/>
            <entity id="DS3.d1094.s1.e2" origId="23954" charOffset="122-128" type="compound" text="silver"/>
            <entity id="DS3.d1094.s1.e3" origId="P82979" charOffset="95-99" type="protein" text="THO1"/>
            <pair e1="DS3.d1094.s1.e2" e2="DS3.d1094.s1.e0" id="DS3.d1094.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1095" origId="9987882">
        <sentence id="DS3.d1095.s0" origId="9987882-0" text="Allele distribution at nine STR loci--D3S1358, vWA, FGA, TH01, TPOX, CSF1PO, D5S818, D13S317 and D7S820--in the Japanese population by multiplex PCR and capillary electrophoresis.">
            <entity id="DS3.d1095.s0.e0" origId="P02671" charOffset="52-55" type="protein" text="FGA"/>
            <entity id="DS3.d1095.s0.e1" origId="703907" charOffset="57-61" type="compound" text="TH01"/>
            <pair e1="DS3.d1095.s0.e1" e2="DS3.d1095.s0.e0" id="DS3.d1095.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1095.s1" origId="9987882-1" text="Nine tetranucleotide short tandem repeat (STR) loci, D3S1358, vWA, FGA TH01, TPOX, CSF1PO, D5S818, D13S317 and D7S820, were analyzed in the Japanese population with a newly released kit for personal identification using multiplex PCR with fluorescent-labeled primers following capillary electrophoresis.">
            <entity id="DS3.d1095.s1.e0" origId="P02671" charOffset="67-70" type="protein" text="FGA"/>
            <entity id="DS3.d1095.s1.e1" origId="703907" charOffset="71-75" type="compound" text="TH01"/>
            <pair e1="DS3.d1095.s1.e1" e2="DS3.d1095.s1.e0" id="DS3.d1095.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1096" origId="9987883">
        <sentence id="DS3.d1096.s0" origId="9987883-0" text="LDLR, GYPA, HBGG, D7S8 and GC allele and genotype frequencies in the northwest Italian population.">
            <entity id="DS3.d1096.s0.e0" origId="P02724,A0A0C4DFT7,E9PD10,Q14419" charOffset="6-10" type="protein" text="GYPA"/>
            <entity id="DS3.d1096.s0.e1" origId="125044" charOffset="12-16" type="compound" text="HBGG"/>
            <pair e1="DS3.d1096.s0.e1" e2="DS3.d1096.s0.e0" id="DS3.d1096.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1096.s1" origId="9987883-1" text="Allele and genotype frequencies for five PCR-based DNA markers (LDLR, GYPA, HBGG, D7S8 and GC) were determined in 100 unrelated individuals from Piedmont (Northwest Italy).">
            <entity id="DS3.d1096.s1.e0" origId="P02724,A0A0C4DFT7,E9PD10,Q14419" charOffset="70-74" type="protein" text="GYPA"/>
            <entity id="DS3.d1096.s1.e1" origId="125044" charOffset="76-80" type="compound" text="HBGG"/>
            <pair e1="DS3.d1096.s1.e1" e2="DS3.d1096.s1.e0" id="DS3.d1096.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1097" origId="9987884">
        <sentence id="DS3.d1097.s0" origId="9987884-3" text="Salivary DNase I was extracted from stains using phosphate buffer containing Nonidet P-40.">
            <entity id="DS3.d1097.s0.e0" origId="1061,167704,644102" charOffset="49-58" type="compound" text="phosphate"/>
            <entity id="DS3.d1097.s0.e1" origId="P51665" charOffset="85-89" type="protein" text="P-40"/>
            <pair e1="DS3.d1097.s0.e0" e2="DS3.d1097.s0.e1" id="DS3.d1097.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1098" origId="9987900">
        <sentence id="DS3.d1098.s0" origId="9987900-8" text="In the class II region there is one complete DRB gene called DLA-DRB1 with at least 24 alleles and one full-length DQB gene, DLA-DQB1, with 20 alleles characterized to date.">
            <entity id="DS3.d1098.s0.e0" origId="3165,5894,59910845,6610267" charOffset="45-48" type="compound" text="DRB"/>
            <entity id="DS3.d1098.s0.e1" origId="P18470" charOffset="61-69" type="protein" text="DLA-DRB1"/>
            <entity id="DS3.d1098.s0.e2" origId="5326974" charOffset="115-118" type="compound" text="DQB"/>
            <entity id="DS3.d1098.s0.e3" origId="O78116" charOffset="125-133" type="protein" text="DLA-DQB1"/>
            <pair e1="DS3.d1098.s0.e0" e2="DS3.d1098.s0.e3" id="DS3.d1098.s0.i0" interaction="False" />
            <pair e1="DS3.d1098.s0.e0" e2="DS3.d1098.s0.e1" id="DS3.d1098.s0.i1" interaction="False" />
            <pair e1="DS3.d1098.s0.e2" e2="DS3.d1098.s0.e3" id="DS3.d1098.s0.i2" interaction="False" />
            <pair e1="DS3.d1098.s0.e2" e2="DS3.d1098.s0.e1" id="DS3.d1098.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1099" origId="9987917">
        <sentence id="DS3.d1099.s0" origId="9987917-2" text="To characterize the biochemical and molecular defect in GUSB-deficient MPS VII dogs, we have measured lysosomal enzyme activities, analyzed distribution of glycosaminoglycans (GAGs), and estimated the size and abundance of the GUSB gene product at the mRNA and protein level in normal, homozygous affected, and heterozygous carrier retinal pigment epithelium (RPE) samples.">
            <entity id="DS3.d1099.s0.e0" origId="O18835" charOffset="56-60" type="protein" text="GUSB"/>
            <entity id="DS3.d1099.s0.e1" origId="O18835" charOffset="227-231" type="protein" text="GUSB"/>
            <entity id="DS3.d1099.s0.e2" origId="638015" charOffset="332-339" type="compound" text="retinal"/>
            <pair e1="DS3.d1099.s0.e2" e2="DS3.d1099.s0.e0" id="DS3.d1099.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1099.s1" origId="9987917-4" text="The decrease in GUSB activity resulted in storage of GAGs predominantly heparan sulfate and chondroitin sulfate.">
            <entity id="DS3.d1099.s1.e0" origId="O18835" charOffset="16-20" type="protein" text="GUSB"/>
            <entity id="DS3.d1099.s1.e1" origId="53477715" charOffset="72-87" type="compound" text="heparan sulfate"/>
            <entity id="DS3.d1099.s1.e2" origId="53477707" charOffset="92-103" type="compound" text="chondroitin"/>
            <entity id="DS3.d1099.s1.e3" origId="1117" charOffset="80-87" type="compound" text="sulfate"/>
            <pair e1="DS3.d1099.s1.e2" e2="DS3.d1099.s1.e0" id="DS3.d1099.s1.i0" interaction="False" />
            <pair e1="DS3.d1099.s1.e3" e2="DS3.d1099.s1.e0" id="DS3.d1099.s1.i1" interaction="False" />
            <pair e1="DS3.d1099.s1.e1" e2="DS3.d1099.s1.e0" id="DS3.d1099.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1100" origId="9987920">
        <sentence id="DS3.d1100.s0" origId="9987920-0" text="Strategies for identification of mutations causing hereditary retinal diseases in dogs: evaluation of opsin as a candidate gene.">
            <entity id="DS3.d1100.s0.e0" origId="638015" charOffset="62-69" type="compound" text="retinal"/>
            <entity id="DS3.d1100.s0.e1" origId="P32308" charOffset="102-107" type="protein" text="opsin"/>
            <pair e1="DS3.d1100.s0.e0" e2="DS3.d1100.s0.e1" id="DS3.d1100.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1100.s1" origId="9987920-7" text="We have used two strategies to examine the rod opsin gene for association with inherited retinal disease in dogs: (1) linkage to determine cosegregation of the disease locus with an intragenic polymorphic marker in the opsin gene in those breeds where suitable informative pedigrees were available; and (2) scanning the coding sequence of the gene in cases where only a limited number of affected or obligate heterozygous samples were available for a breed.">
            <entity id="DS3.d1100.s1.e0" origId="P32308" charOffset="47-52" type="protein" text="opsin"/>
            <entity id="DS3.d1100.s1.e1" origId="638015" charOffset="89-96" type="compound" text="retinal"/>
            <entity id="DS3.d1100.s1.e2" origId="P32308" charOffset="219-224" type="protein" text="opsin"/>
            <pair e1="DS3.d1100.s1.e1" e2="DS3.d1100.s1.e0" id="DS3.d1100.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1101" origId="9987933">
        <sentence id="DS3.d1101.s0" origId="9987933-3" text="Gel electrophoresis of three blood proteins (TF, HBB, and SOD) from the putative hybrid, the putative sika deer sire and three axis deer hinds from the herd (not necessarily including the dam) initially verified that hybridization had occurred.">
            <entity id="DS3.d1101.s0.e0" origId="5792" charOffset="49-52" type="compound" text="HBB"/>
            <entity id="DS3.d1101.s0.e1" origId="P00441,V9HWC9" charOffset="58-61" type="protein" text="SOD"/>
            <pair e1="DS3.d1101.s0.e0" e2="DS3.d1101.s0.e1" id="DS3.d1101.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1102" origId="9987964">
        <sentence id="DS3.d1102.s0" origId="9987964-2" text="The study dealt with androgen exchange, the baseline levels of serum sexual steroid hormones and their receptors in the tumor, the blood concentrations of the sexual steroids conjugated globulin and pituitary hormone, the metabolism of arachidonic acid, the expression of epidermal growth factor and its ligands, the amount of calmodulin, cAMP in the osteogenic sarcoma in 300 patients aged 14-56 years.">
            <entity id="DS3.d1102.s0.e0" origId="444899" charOffset="236-252" type="compound" text="arachidonic acid"/>
            <entity id="DS3.d1102.s0.e1" origId="P49913,J3KNB4" charOffset="339-343" type="protein" text="cAMP"/>
            <pair e1="DS3.d1102.s0.e0" e2="DS3.d1102.s0.e1" id="DS3.d1102.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1103" origId="9987989">
        <sentence id="DS3.d1103.s0" origId="9987989-0" text="Spiny calretinin-immunoreactive neurons in the hilus and CA3 region of the rat hippocampus: local axon circuits, synaptic connections, and glutamic acid decarboxylase 65/67 mRNA expression.">
            <entity id="DS3.d1103.s0.e0" origId="P47728" charOffset="6-16" type="protein" text="calretinin"/>
            <entity id="DS3.d1103.s0.e1" origId="33032" charOffset="139-152" type="compound" text="glutamic acid"/>
            <pair e1="DS3.d1103.s0.e1" e2="DS3.d1103.s0.e0" id="DS3.d1103.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1103.s1" origId="9987989-6" text="We next analyzed the expression of glutamic acid decarboxylase (GAD65/67) mRNAs in spiny nonpyramidal neurons that were identified by calretinin immunoreactivity.">
            <entity id="DS3.d1103.s1.e0" origId="33032" charOffset="35-48" type="compound" text="glutamic acid"/>
            <entity id="DS3.d1103.s1.e1" origId="Q05683" charOffset="64-69" type="protein" text="GAD65"/>
            <entity id="DS3.d1103.s1.e2" origId="P47728" charOffset="134-144" type="protein" text="calretinin"/>
            <pair e1="DS3.d1103.s1.e0" e2="DS3.d1103.s1.e1" id="DS3.d1103.s1.i0" interaction="False" />
            <pair e1="DS3.d1103.s1.e0" e2="DS3.d1103.s1.e2" id="DS3.d1103.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1104" origId="9987991">
        <sentence id="DS3.d1104.s0" origId="9987991-10" text="Our results suggest that expression of NBAT may provide specific populations of cNOS-containing forebrain neurons with a unique mechanism for regulating somatodendritic synthesis of nitric oxide.">
            <entity id="DS3.d1104.s0.e0" origId="Q62600" charOffset="80-84" type="protein" text="cNOS"/>
            <entity id="DS3.d1104.s0.e1" origId="145068" charOffset="182-194" type="compound" text="nitric oxide"/>
            <pair e1="DS3.d1104.s0.e1" e2="DS3.d1104.s0.e0" id="DS3.d1104.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1105" origId="9987997">
        <sentence id="DS3.d1105.s0" origId="9987997-2" text="To this end, Sprague-Dawley rats were anaesthetised with Ketamil (100 mg/kg) and Rompun (10 mg/kg), and injections of biotinylated dextran or cholera toxin subunit B (CTB) were made into various dorsal thalamic nuclei, including the primary relay (dorsal lateral geniculate, medial geniculate, ventral posterior), association (lateral dorsal, lateral posterior, posterior thalamic), and intralaminar (central lateral, parafascicular) nuclear groups, by using stereotaxic coordinates.">
            <entity id="DS3.d1105.s0.e0" origId="5707" charOffset="81-87" type="compound" text="Rompun"/>
            <entity id="DS3.d1105.s0.e1" origId="4125253,5460037" charOffset="131-138" type="compound" text="dextran"/>
            <entity id="DS3.d1105.s0.e2" origId="Q9QZC4,A0A096MK76" charOffset="142-165" type="protein" text="cholera toxin subunit B"/>
            <entity id="DS3.d1105.s0.e3" origId="Q9QZC4,A0A096MK76" charOffset="167-170" type="protein" text="CTB"/>
            <pair e1="DS3.d1105.s0.e0" e2="DS3.d1105.s0.e2" id="DS3.d1105.s0.i0" interaction="False" />
            <pair e1="DS3.d1105.s0.e0" e2="DS3.d1105.s0.e3" id="DS3.d1105.s0.i1" interaction="False" />
            <pair e1="DS3.d1105.s0.e1" e2="DS3.d1105.s0.e2" id="DS3.d1105.s0.i2" interaction="False" />
            <pair e1="DS3.d1105.s0.e1" e2="DS3.d1105.s0.e3" id="DS3.d1105.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1105.s1" origId="9987997-6" text="After CTB or dextran injections into the primary relay nuclei, very few cells are labelled in the zona incerta.">
            <entity id="DS3.d1105.s1.e0" origId="Q9QZC4,A0A096MK76" charOffset="6-9" type="protein" text="CTB"/>
            <entity id="DS3.d1105.s1.e1" origId="4125253,5460037" charOffset="13-20" type="compound" text="dextran"/>
            <pair e1="DS3.d1105.s1.e1" e2="DS3.d1105.s1.e0" id="DS3.d1105.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1106" origId="9988018">
        <sentence id="DS3.d1106.s0" origId="9988018-0" text="Beat-to-beat repolarization variability in amplitude and duration in LQTS patients with the SCN5A sodium channel gene mutation.">
            <entity id="DS3.d1106.s0.e0" origId="Q14524,K4DIA1,Q86V90,E9PG18,H9KVD2,E9PHB6" charOffset="92-97" type="protein" text="SCN5A"/>
            <entity id="DS3.d1106.s0.e1" origId="5360545" charOffset="98-104" type="compound" text="sodium"/>
            <pair e1="DS3.d1106.s0.e1" e2="DS3.d1106.s0.e0" id="DS3.d1106.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1107" origId="9988043">
        <sentence id="DS3.d1107.s0" origId="9988043-1" text="Principal mechanisms of bacterial resistance to quinolones are modification of target enzymes, DNA gyrase (gyrA) and topoisomerase IV (parC), or reduction of intracellular concentration due to mutations in the regulatory genes for efflux systems, such as mexR and nfxB.">
            <entity id="DS3.d1107.s0.e0" origId="3036108" charOffset="48-58" type="compound" text="quinolones"/>
            <entity id="DS3.d1107.s0.e1" origId="Q4W1Q6" charOffset="135-139" type="protein" text="parC"/>
            <pair e1="DS3.d1107.s0.e0" e2="DS3.d1107.s0.e1" id="DS3.d1107.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1107.s1" origId="9988043-2" text="We have examined gyrA, parC, mexR, and nfxB genes from 16 quinolone-resistant clinical isolates of Pseudomonas aeruginosa to determine the relation between mutations in DNA replicating enzymes or regulatory genes for efflux systems and to correlate the mutations with minimal inhibitory concentrations (MICs).">
            <entity id="DS3.d1107.s1.e0" origId="Q4W1Q6" charOffset="23-27" type="protein" text="parC"/>
            <entity id="DS3.d1107.s1.e1" origId="6038" charOffset="58-67" type="compound" text="quinolone"/>
            <pair e1="DS3.d1107.s1.e1" e2="DS3.d1107.s1.e0" id="DS3.d1107.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1107.s2" origId="9988043-8" text="The data indicate that gyrA mutation is the most important component of quinolone resistance, and simultaneous presence of parC mutations is associated with high-level resistance.">
            <entity id="DS3.d1107.s2.e0" origId="6038" charOffset="72-81" type="compound" text="quinolone"/>
            <entity id="DS3.d1107.s2.e1" origId="Q4W1Q6" charOffset="123-127" type="protein" text="parC"/>
            <pair e1="DS3.d1107.s2.e0" e2="DS3.d1107.s2.e1" id="DS3.d1107.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1108" origId="9988050">
        <sentence id="DS3.d1108.s0" origId="9988050-0" text="Transmission of vanA-type vancomycin-resistant enterococci and vanA resistance elements between chicken and humans at avoparcin-exposed farms.">
            <entity id="DS3.d1108.s0.e0" origId="D2JBE4" charOffset="16-20" type="protein" text="vanA"/>
            <entity id="DS3.d1108.s0.e1" origId="14969" charOffset="26-36" type="compound" text="vancomycin"/>
            <entity id="DS3.d1108.s0.e2" origId="D2JBE4" charOffset="63-67" type="protein" text="vanA"/>
            <pair e1="DS3.d1108.s0.e1" e2="DS3.d1108.s0.e0" id="DS3.d1108.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1109" origId="9988065">
        <sentence id="DS3.d1109.s0" origId="9988065-8" text="The diagnostic accuracy of the T:NL ratio to differentiate responders and nonresponders was 33.3%, with a cutoff value of 2.5, which was significantly improved to 77.8% when an increased T:NL ratio after dipyridamole was assigned to a nonresponder.">
            <entity id="DS3.d1109.s0.e0" origId="Q6ZTA4,F8W8C1" charOffset="31-35" type="protein" text="T:NL"/>
            <entity id="DS3.d1109.s0.e1" origId="Q6ZTA4,F8W8C1" charOffset="187-191" type="protein" text="T:NL"/>
            <entity id="DS3.d1109.s0.e2" origId="3108" charOffset="204-216" type="compound" text="dipyridamole"/>
            <pair e1="DS3.d1109.s0.e2" e2="DS3.d1109.s0.e0" id="DS3.d1109.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1109.s1" origId="9988065-9" text="Furthermore, all patients with CR showed diminished T:NL ratios after dipyridamole, and all patients with NR showed an increased T:NL ratio after dipyridamole.">
            <entity id="DS3.d1109.s1.e0" origId="Q6ZTA4,F8W8C1" charOffset="52-56" type="protein" text="T:NL"/>
            <entity id="DS3.d1109.s1.e1" origId="3108" charOffset="70-82" type="compound" text="dipyridamole"/>
            <entity id="DS3.d1109.s1.e2" origId="Q6ZTA4,F8W8C1" charOffset="129-133" type="protein" text="T:NL"/>
            <entity id="DS3.d1109.s1.e3" origId="3108" charOffset="146-158" type="compound" text="dipyridamole"/>
            <pair e1="DS3.d1109.s1.e1" e2="DS3.d1109.s1.e0" id="DS3.d1109.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1110" origId="9988094">
        <sentence id="DS3.d1110.s0" origId="9988094-0" text="The expression of neuropeptide-induced excessive grooming behavior in dopamine D1 and D2 receptor-deficient mice.">
            <entity id="DS3.d1110.s0.e0" origId="681" charOffset="70-78" type="compound" text="dopamine"/>
            <entity id="DS3.d1110.s0.e1" origId="P61168" charOffset="86-97" type="protein" text="D2 receptor"/>
            <pair e1="DS3.d1110.s0.e0" e2="DS3.d1110.s0.e1" id="DS3.d1110.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1110.s1" origId="9988094-10" text="In contrast, the systemic administration of the opioid receptor antagonist, naloxone, totally suppressed the residual grooming activity of oxytocin-, prolactin- or ACTH-(1-24)-injected mice and of those treated with beta-endorphin.">
            <entity id="DS3.d1110.s1.e0" origId="5284596" charOffset="76-84" type="compound" text="naloxone"/>
            <entity id="DS3.d1110.s1.e1" origId="P35454,Q545V4" charOffset="139-147" type="protein" text="oxytocin"/>
            <entity id="DS3.d1110.s1.e2" origId="Q3TT66,Q9CPQ2" charOffset="150-159" type="protein" text="prolactin"/>
            <entity id="DS3.d1110.s1.e3" origId="P01193" charOffset="216-230" type="protein" text="beta-endorphin"/>
            <pair e1="DS3.d1110.s1.e0" e2="DS3.d1110.s1.e1" id="DS3.d1110.s1.i0" interaction="False" />
            <pair e1="DS3.d1110.s1.e0" e2="DS3.d1110.s1.e3" id="DS3.d1110.s1.i1" interaction="False" />
            <pair e1="DS3.d1110.s1.e0" e2="DS3.d1110.s1.e2" id="DS3.d1110.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1110.s2" origId="9988094-11" text="In contrast with the behavioral deficit observed in dopamine D1 receptor-deficient mice, dopamine D2 receptor-null animals showed a normal expression of spontaneous novelty-induced grooming and a high level of grooming activity induced by i.c.v.">
            <entity id="DS3.d1110.s2.e0" origId="681" charOffset="52-60" type="compound" text="dopamine"/>
            <entity id="DS3.d1110.s2.e1" origId="681" charOffset="89-97" type="compound" text="dopamine"/>
            <entity id="DS3.d1110.s2.e2" origId="P61168" charOffset="98-109" type="protein" text="D2 receptor"/>
            <pair e1="DS3.d1110.s2.e0" e2="DS3.d1110.s2.e2" id="DS3.d1110.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1110.s3" origId="9988094-9" text="The systemic administration of the dopamine D2 receptor antagonist, sulpiride did not suppress the residual grooming activity shown by animals injected with oxytocin, prolactin or ACTH-(1-24), and did not change the behavioral expression of those injected with beta-endorphin.">
            <entity id="DS3.d1110.s3.e0" origId="681" charOffset="35-43" type="compound" text="dopamine"/>
            <entity id="DS3.d1110.s3.e1" origId="P61168" charOffset="44-55" type="protein" text="D2 receptor"/>
            <entity id="DS3.d1110.s3.e2" origId="3018598,5355" charOffset="68-77" type="compound" text="sulpiride"/>
            <entity id="DS3.d1110.s3.e3" origId="P35454,Q545V4" charOffset="157-165" type="protein" text="oxytocin"/>
            <entity id="DS3.d1110.s3.e4" origId="Q3TT66,Q9CPQ2" charOffset="167-176" type="protein" text="prolactin"/>
            <entity id="DS3.d1110.s3.e5" origId="P01193" charOffset="261-275" type="protein" text="beta-endorphin"/>
            <pair e1="DS3.d1110.s3.e2" e2="DS3.d1110.s3.e3" id="DS3.d1110.s3.i0" interaction="False" />
            <pair e1="DS3.d1110.s3.e2" e2="DS3.d1110.s3.e5" id="DS3.d1110.s3.i1" interaction="False" />
            <pair e1="DS3.d1110.s3.e2" e2="DS3.d1110.s3.e1" id="DS3.d1110.s3.i2" interaction="False" />
            <pair e1="DS3.d1110.s3.e2" e2="DS3.d1110.s3.e4" id="DS3.d1110.s3.i3" interaction="False" />
            <pair e1="DS3.d1110.s3.e0" e2="DS3.d1110.s3.e3" id="DS3.d1110.s3.i4" interaction="False" />
            <pair e1="DS3.d1110.s3.e0" e2="DS3.d1110.s3.e5" id="DS3.d1110.s3.i5" interaction="False" />
            <pair e1="DS3.d1110.s3.e0" e2="DS3.d1110.s3.e1" id="DS3.d1110.s3.i6" interaction="False" />
            <pair e1="DS3.d1110.s3.e0" e2="DS3.d1110.s3.e4" id="DS3.d1110.s3.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1111" origId="9988099">
        <sentence id="DS3.d1111.s0" origId="9988099-0" text="Chronic alnespirone-induced desensitization of somatodendritic 5-HT1A autoreceptors in the rat dorsal raphe nucleus.">
            <entity id="DS3.d1111.s0.e0" origId="178132" charOffset="8-19" type="compound" text="alnespirone"/>
            <entity id="DS3.d1111.s0.e1" origId="P19327" charOffset="63-69" type="protein" text="5-HT1A"/>
            <pair e1="DS3.d1111.s0.e0" e2="DS3.d1111.s0.e1" id="DS3.d1111.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1111.s1" origId="9988099-1" text="The effects of long-term (7, 14 or 21 days) administration of the 5-HT1A receptor agonist alnespirone (5 mg/(kg day), i.p.)">
            <entity id="DS3.d1111.s1.e0" origId="P19327" charOffset="66-72" type="protein" text="5-HT1A"/>
            <entity id="DS3.d1111.s1.e1" origId="178132" charOffset="90-101" type="compound" text="alnespirone"/>
            <pair e1="DS3.d1111.s1.e1" e2="DS3.d1111.s1.e0" id="DS3.d1111.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1111.s2" origId="9988099-3" text="Whatever the treatment duration, the specific binding of (3H)8 hydroxy-2-(di-n-propylamino)tetralin ((3H)8-OH-DPAT), (3H)trans,4-((3Z)3-(2-dimethylaminoethyl) oxyimino-3(2-fluorophenyl) propen-1-yl) phenol hemifumarate ((3H)SR 46349B), and (3H)S-zacopride to 5-HT1A, 5-HT2A and 5-HT3 receptors, respectively, were unaltered in all the brain areas examined.">
            <entity id="DS3.d1111.s2.e0" origId="90285" charOffset="71-99" type="compound" text="2-(di-n-propylamino)tetralin"/>
            <entity id="DS3.d1111.s2.e1" origId="10008" charOffset="172-184" type="compound" text="fluorophenyl"/>
            <entity id="DS3.d1111.s2.e2" origId="996" charOffset="199-205" type="compound" text="phenol"/>
            <entity id="DS3.d1111.s2.e3" origId="P19327" charOffset="259-265" type="protein" text="5-HT1A"/>
            <pair e1="DS3.d1111.s2.e0" e2="DS3.d1111.s2.e3" id="DS3.d1111.s2.i0" interaction="False" />
            <pair e1="DS3.d1111.s2.e1" e2="DS3.d1111.s2.e3" id="DS3.d1111.s2.i1" interaction="False" />
            <pair e1="DS3.d1111.s2.e2" e2="DS3.d1111.s2.e3" id="DS3.d1111.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1111.s3" origId="9988099-4" text="In contrast, in vitro electrophysiological recordings performed 24 h after the last injection of alnespirone showed that the potency of the 5-HT1A receptor agonist, 8-OH-DPAT, to depress the firing of serotoninergic neurons in the dorsal raphe nucleus, was significantly reduced after a 21-day treatment with alnespirone.">
            <entity id="DS3.d1111.s3.e0" origId="178132" charOffset="97-108" type="compound" text="alnespirone"/>
            <entity id="DS3.d1111.s3.e1" origId="P19327" charOffset="140-146" type="protein" text="5-HT1A"/>
            <entity id="DS3.d1111.s3.e2" origId="178132" charOffset="309-320" type="compound" text="alnespirone"/>
            <pair e1="DS3.d1111.s3.e0" e2="DS3.d1111.s3.e1" id="DS3.d1111.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1112" origId="9988100">
        <sentence id="DS3.d1112.s0" origId="9988100-3" text="Immediately following the last self-administration session ('acute drug on board' state), and just before the next scheduled session ('drug expecting' state), the animals were decapitated and the levels of dynorphin A and B, (Met5)- and (Leu5)-enkephalin and substance P were measured in different brain areas.">
            <entity id="DS3.d1112.s0.e0" origId="16129685" charOffset="206-215" type="compound" text="dynorphin"/>
            <entity id="DS3.d1112.s0.e1" origId="P04094" charOffset="244-254" type="protein" text="enkephalin"/>
            <pair e1="DS3.d1112.s0.e0" e2="DS3.d1112.s0.e1" id="DS3.d1112.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1112.s1" origId="9988100-5" text="In contrast, during the 'drug expecting' state, heroin-treated animals had increased levels of dynorphin A, dynorphin B and (Met5)-enkephalin in the caudal striatum as compared to the cocaine- and saline-treated animals, and the level of (Leu5)-enkephalin was increased as compared to the cocaine-treated group.">
            <entity id="DS3.d1112.s1.e0" origId="5462328" charOffset="48-54" type="compound" text="heroin"/>
            <entity id="DS3.d1112.s1.e1" origId="16129685" charOffset="95-104" type="compound" text="dynorphin"/>
            <entity id="DS3.d1112.s1.e2" origId="25075991,25078106,25078261,25081093,53481558" charOffset="108-119" type="compound" text="dynorphin B"/>
            <entity id="DS3.d1112.s1.e3" origId="P04094" charOffset="131-141" type="protein" text="enkephalin"/>
            <entity id="DS3.d1112.s1.e4" origId="446220" charOffset="184-191" type="compound" text="cocaine"/>
            <entity id="DS3.d1112.s1.e5" origId="P04094" charOffset="245-255" type="protein" text="enkephalin"/>
            <entity id="DS3.d1112.s1.e6" origId="446220" charOffset="289-296" type="compound" text="cocaine"/>
            <pair e1="DS3.d1112.s1.e4" e2="DS3.d1112.s1.e3" id="DS3.d1112.s1.i0" interaction="False" />
            <pair e1="DS3.d1112.s1.e0" e2="DS3.d1112.s1.e3" id="DS3.d1112.s1.i1" interaction="False" />
            <pair e1="DS3.d1112.s1.e2" e2="DS3.d1112.s1.e3" id="DS3.d1112.s1.i2" interaction="False" />
            <pair e1="DS3.d1112.s1.e1" e2="DS3.d1112.s1.e3" id="DS3.d1112.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1112.s2" origId="9988100-6" text="In the septum, an increase of (Met5)-enkephalin and substance P was observed in the animals expecting heroin as compared to the saline- and/or cocaine-treated animals.">
            <entity id="DS3.d1112.s2.e0" origId="P04094" charOffset="37-47" type="protein" text="enkephalin"/>
            <entity id="DS3.d1112.s2.e1" origId="5462328" charOffset="102-108" type="compound" text="heroin"/>
            <entity id="DS3.d1112.s2.e2" origId="446220" charOffset="143-150" type="compound" text="cocaine"/>
            <pair e1="DS3.d1112.s2.e2" e2="DS3.d1112.s2.e0" id="DS3.d1112.s2.i0" interaction="False" />
            <pair e1="DS3.d1112.s2.e1" e2="DS3.d1112.s2.e0" id="DS3.d1112.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1112.s3" origId="9988100-8" text="In conclusion, heroin, as compared to cocaine, appears to have a more pronounced effect on dynorphin, enkephalin and substance P levels in the caudal striatum and septum, especially during periods when self-administration of the drug is expected.">
            <entity id="DS3.d1112.s3.e0" origId="5462328" charOffset="15-21" type="compound" text="heroin"/>
            <entity id="DS3.d1112.s3.e1" origId="446220" charOffset="38-45" type="compound" text="cocaine"/>
            <entity id="DS3.d1112.s3.e2" origId="16129685" charOffset="91-100" type="compound" text="dynorphin"/>
            <entity id="DS3.d1112.s3.e3" origId="P04094" charOffset="102-112" type="protein" text="enkephalin"/>
            <pair e1="DS3.d1112.s3.e1" e2="DS3.d1112.s3.e3" id="DS3.d1112.s3.i0" interaction="False" />
            <pair e1="DS3.d1112.s3.e0" e2="DS3.d1112.s3.e3" id="DS3.d1112.s3.i1" interaction="False" />
            <pair e1="DS3.d1112.s3.e2" e2="DS3.d1112.s3.e3" id="DS3.d1112.s3.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1113" origId="9988101">
        <sentence id="DS3.d1113.s0" origId="9988101-0" text="Methamphetamine alters prodynorphin gene expression and dynorphin A levels in rat hypothalamus.">
            <entity id="DS3.d1113.s0.e0" origId="10836" charOffset="0-15" type="compound" text="Methamphetamine"/>
            <entity id="DS3.d1113.s0.e1" origId="F1M7S3" charOffset="23-35" type="protein" text="prodynorphin"/>
            <pair e1="DS3.d1113.s0.e0" e2="DS3.d1113.s0.e1" id="DS3.d1113.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1113.s1" origId="9988101-2" text="To better understand the possible existence of common neuronal pathways shared by different classes of drugs of abuse, we studied the effects of methamphetamine on the gene expression of the opioid precursor prodynorphin and on the levels of peptide dynorphin A in the rat brain.">
            <entity id="DS3.d1113.s1.e0" origId="10836" charOffset="145-160" type="compound" text="methamphetamine"/>
            <entity id="DS3.d1113.s1.e1" origId="F1M7S3" charOffset="208-220" type="protein" text="prodynorphin"/>
            <pair e1="DS3.d1113.s1.e0" e2="DS3.d1113.s1.e1" id="DS3.d1113.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1113.s2" origId="9988101-5" text="for 15 days) methamphetamine markedly raised prodynorphin mRNA levels in the hypothalamus, whereas no effect was observed in the hippocampus.">
            <entity id="DS3.d1113.s2.e0" origId="10836" charOffset="13-28" type="compound" text="methamphetamine"/>
            <entity id="DS3.d1113.s2.e1" origId="F1M7S3" charOffset="45-57" type="protein" text="prodynorphin"/>
            <pair e1="DS3.d1113.s2.e0" e2="DS3.d1113.s2.e1" id="DS3.d1113.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1113.s3" origId="9988101-7" text="These results indicate that methamphetamine affects prodynorphin gene expression in the hypothalamus, which may be an important site (also for its relevant neuroendocrine correlates) for opioidergic mechanisms activated by addictive drugs.">
            <entity id="DS3.d1113.s3.e0" origId="10836" charOffset="28-43" type="compound" text="methamphetamine"/>
            <entity id="DS3.d1113.s3.e1" origId="F1M7S3" charOffset="52-64" type="protein" text="prodynorphin"/>
            <pair e1="DS3.d1113.s3.e0" e2="DS3.d1113.s3.e1" id="DS3.d1113.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1114" origId="9988105">
        <sentence id="DS3.d1114.s0" origId="9988105-15" text="The increased responsiveness to norepinephrine may involve (i) a rapid up-regulation of cardiac beta1-adrenoceptors and cAMP signaling in cardiac pacemaker cells due to the loss of the inhibitory influence of cardiac NO, and (ii) the up-regulation of beta1-adrenoceptor-mediated signal transduction processes in response to the L-NAME-induced withdrawal of cardiac sympathetic nerve activity.">
            <entity id="DS3.d1114.s0.e0" origId="439260" charOffset="32-46" type="compound" text="norepinephrine"/>
            <entity id="DS3.d1114.s0.e1" origId="P08588" charOffset="96-114" type="protein" text="beta1-adrenoceptor"/>
            <entity id="DS3.d1114.s0.e2" origId="39836" charOffset="328-334" type="compound" text="L-NAME"/>
            <pair e1="DS3.d1114.s0.e0" e2="DS3.d1114.s0.e1" id="DS3.d1114.s0.i0" interaction="False" />
            <pair e1="DS3.d1114.s0.e2" e2="DS3.d1114.s0.e1" id="DS3.d1114.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1115" origId="9988110">
        <sentence id="DS3.d1115.s0" origId="9988110-10" text="These results suggest that FR140423, a selective cyclooxygenase-2 inhibitor, is a potent non-steroidal anti-inflammatory drug (NSAID) without gastrointestinal side effects and is a unique compound having morphine-like analgesic effects.">
            <entity id="DS3.d1115.s0.e0" origId="132932" charOffset="27-35" type="compound" text="FR140423"/>
            <entity id="DS3.d1115.s0.e1" origId="P35354" charOffset="49-65" type="protein" text="cyclooxygenase-2"/>
            <entity id="DS3.d1115.s0.e2" origId="5288826" charOffset="204-212" type="compound" text="morphine"/>
            <pair e1="DS3.d1115.s0.e0" e2="DS3.d1115.s0.e1" id="DS3.d1115.s0.i0" interaction="False" />
            <pair e1="DS3.d1115.s0.e2" e2="DS3.d1115.s0.e1" id="DS3.d1115.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1115.s1" origId="9988110-2" text="In recombinant human cyclooxygenase enzyme assays, the inhibition of prostaglandin E2 formation by FR140423 was 150 times more selective for cyclooxygenase-2 than cyclooxygenase-1.">
            <entity id="DS3.d1115.s1.e0" origId="285703,6145931" charOffset="69-82" type="compound" text="prostaglandin"/>
            <entity id="DS3.d1115.s1.e1" origId="132932" charOffset="99-107" type="compound" text="FR140423"/>
            <entity id="DS3.d1115.s1.e2" origId="P35354" charOffset="141-157" type="protein" text="cyclooxygenase-2"/>
            <entity id="DS3.d1115.s1.e3" origId="P23219,A0A087X296" charOffset="163-179" type="protein" text="cyclooxygenase-1"/>
            <pair e1="DS3.d1115.s1.e1" e2="DS3.d1115.s1.e2" id="DS3.d1115.s1.i0" interaction="False" />
            <pair e1="DS3.d1115.s1.e1" e2="DS3.d1115.s1.e3" id="DS3.d1115.s1.i1" interaction="False" />
            <pair e1="DS3.d1115.s1.e0" e2="DS3.d1115.s1.e2" id="DS3.d1115.s1.i2" interaction="False" />
            <pair e1="DS3.d1115.s1.e0" e2="DS3.d1115.s1.e3" id="DS3.d1115.s1.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1116" origId="9988112">
        <sentence id="DS3.d1116.s0" origId="9988112-8" text="MAP kinase kinase (MEK)-1-specific inhibitor, (2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one) (PD98059), blocked the increase in BrdU uptake into SQ-5 cells caused by human recombinant leptin.">
            <entity id="DS3.d1116.s0.e0" origId="Q02750,A4QPA9,B4DFY5" charOffset="0-25" type="protein" text="MAP kinase kinase (MEK)-1"/>
            <entity id="DS3.d1116.s0.e1" origId="10286" charOffset="75-96" type="compound" text="4H-1-benzopyran-4-one"/>
            <entity id="DS3.d1116.s0.e2" origId="P41160,Q544U0" charOffset="189-195" type="protein" text="leptin"/>
            <pair e1="DS3.d1116.s0.e1" e2="DS3.d1116.s0.e2" id="DS3.d1116.s0.i0" interaction="False" />
            <pair e1="DS3.d1116.s0.e1" e2="DS3.d1116.s0.e0" id="DS3.d1116.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1117" origId="9988113">
        <sentence id="DS3.d1117.s0" origId="9988113-0" text="Cloning, expression and functional role of a nociceptin/orphanin FQ receptor in the porcine gastrointestinal tract.">
            <entity id="DS3.d1117.s0.e0" origId="16131448" charOffset="45-55" type="compound" text="nociceptin"/>
            <entity id="DS3.d1117.s0.e1" origId="P79292" charOffset="56-76" type="protein" text="orphanin FQ receptor"/>
            <pair e1="DS3.d1117.s0.e0" e2="DS3.d1117.s0.e1" id="DS3.d1117.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1117.s1" origId="9988113-1" text="The heptadecapeptide nociceptin/orphanin FQ is the cognate ligand for the opioid receptor-like orphanin FQ (OFQ) receptor, a member of the G protein-coupled receptor superfamily.">
            <entity id="DS3.d1117.s1.e0" origId="16131448" charOffset="21-31" type="compound" text="nociceptin"/>
            <entity id="DS3.d1117.s1.e1" origId="P79292" charOffset="95-121" type="protein" text="orphanin FQ (OFQ) receptor"/>
            <pair e1="DS3.d1117.s1.e0" e2="DS3.d1117.s1.e1" id="DS3.d1117.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1118" origId="9988115">
        <sentence id="DS3.d1118.s0" origId="9988115-4" text="Gemcitabine cytotoxicity of glioma cells does not require wild-type p53 activity: (i) there was no difference in the susceptibility to gemcitabine between cell lines with wild-type p53 and cell lines with mutant or deleted p53; (ii) ectopic expression of a temperature-sensitive p53 protein either at wild-type (32.5 degrees C) or at mutant (38.5 degrees C) conformation had no significant influence on gemcitabine-induced cell death.">
            <entity id="DS3.d1118.s0.e0" origId="60750" charOffset="0-11" type="compound" text="Gemcitabine"/>
            <entity id="DS3.d1118.s0.e1" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="68-71" type="protein" text="p53"/>
            <entity id="DS3.d1118.s0.e2" origId="60750" charOffset="135-146" type="compound" text="gemcitabine"/>
            <entity id="DS3.d1118.s0.e3" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="181-184" type="protein" text="p53"/>
            <entity id="DS3.d1118.s0.e4" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="181-184" type="protein" text="p53"/>
            <entity id="DS3.d1118.s0.e5" origId="P04637,K7PPA8,A0A087X1Q1,A0A087WT22,Q53GA5,H2EHT1,A0A087WXZ1" charOffset="181-184" type="protein" text="p53"/>
            <entity id="DS3.d1118.s0.e6" origId="60750" charOffset="403-414" type="compound" text="gemcitabine"/>
            <pair e1="DS3.d1118.s0.e2" e2="DS3.d1118.s0.e1" id="DS3.d1118.s0.i0" interaction="False" />
            <pair e1="DS3.d1118.s0.e0" e2="DS3.d1118.s0.e1" id="DS3.d1118.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1118.s1" origId="9988115-6" text="There was no correlation between the susceptibility to gemcitabine and the endogenous expression of the B cell lymphoma-2 (BCL-2)-family proteins BCL-2, BCL-XL, myeloid cell leukemia-1 (MCL-1), BCL-2-associated X protein (BAX), BCL-2 homologous antagonist/killer (BAK) and BCL-XS.">
            <entity id="DS3.d1118.s1.e0" origId="60750" charOffset="55-66" type="compound" text="gemcitabine"/>
            <entity id="DS3.d1118.s1.e1" origId="Q07817,Q5TE63" charOffset="153-159" type="protein" text="BCL-XL"/>
            <entity id="DS3.d1118.s1.e2" origId="Q07820,C8YZ26,A0A087WT64" charOffset="161-184" type="protein" text="myeloid cell leukemia-1"/>
            <entity id="DS3.d1118.s1.e3" origId="Q07820,C8YZ26,A0A087WT64" charOffset="186-191" type="protein" text="MCL-1"/>
            <entity id="DS3.d1118.s1.e4" origId="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0" charOffset="194-220" type="protein" text="BCL-2-associated X protein"/>
            <entity id="DS3.d1118.s1.e5" origId="Q07812,I6LPK7,Q5ZPJ1,Q5ZPJ0" charOffset="222-225" type="protein" text="BAX"/>
            <entity id="DS3.d1118.s1.e6" origId="Q16611" charOffset="228-262" type="protein" text="BCL-2 homologous antagonist/killer"/>
            <entity id="DS3.d1118.s1.e7" origId="Q16611" charOffset="264-267" type="protein" text="BAK"/>
            <entity id="DS3.d1118.s1.e8" origId="Q07817,Q5TE63" charOffset="273-279" type="protein" text="BCL-XS"/>
            <pair e1="DS3.d1118.s1.e0" e2="DS3.d1118.s1.e8" id="DS3.d1118.s1.i0" interaction="False" />
            <pair e1="DS3.d1118.s1.e0" e2="DS3.d1118.s1.e5" id="DS3.d1118.s1.i1" interaction="False" />
            <pair e1="DS3.d1118.s1.e0" e2="DS3.d1118.s1.e3" id="DS3.d1118.s1.i2" interaction="False" />
            <pair e1="DS3.d1118.s1.e0" e2="DS3.d1118.s1.e4" id="DS3.d1118.s1.i3" interaction="False" />
            <pair e1="DS3.d1118.s1.e0" e2="DS3.d1118.s1.e1" id="DS3.d1118.s1.i4" interaction="False" />
            <pair e1="DS3.d1118.s1.e0" e2="DS3.d1118.s1.e2" id="DS3.d1118.s1.i5" interaction="False" />
            <pair e1="DS3.d1118.s1.e0" e2="DS3.d1118.s1.e6" id="DS3.d1118.s1.i6" interaction="False" />
            <pair e1="DS3.d1118.s1.e0" e2="DS3.d1118.s1.e7" id="DS3.d1118.s1.i7" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1119" origId="9988119">
        <sentence id="DS3.d1119.s0" origId="9988119-5" text="Our hypothesis is that SR-3 exerts its beneficial effects by normalizing the structure and function of the neuronal membrane and by restoring dopamine D2 receptor functions.">
            <entity id="DS3.d1119.s0.e0" origId="Q9HBF4" charOffset="23-27" type="protein" text="SR-3"/>
            <entity id="DS3.d1119.s0.e1" origId="681" charOffset="142-150" type="compound" text="dopamine"/>
            <pair e1="DS3.d1119.s0.e1" e2="DS3.d1119.s0.e0" id="DS3.d1119.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1120" origId="9988122">
        <sentence id="DS3.d1120.s0" origId="9988122-0" text="Region specific expression of NMDA receptor NR1 subunit mRNA in hypothalamus and pons following chronic morphine treatment.">
            <entity id="DS3.d1120.s0.e0" origId="Q05586,Q59GW0,Q5VSF9" charOffset="44-47" type="protein" text="NR1"/>
            <entity id="DS3.d1120.s0.e1" origId="5288826" charOffset="104-112" type="compound" text="morphine"/>
            <pair e1="DS3.d1120.s0.e1" e2="DS3.d1120.s0.e0" id="DS3.d1120.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1120.s1" origId="9988122-2" text="Using in situ hybridization techniques, the effects of chronic morphine treatment on the expression of mRNAs encoding the NMDA receptor subunits NRI, NR2A, and NR2B were investigated.">
            <entity id="DS3.d1120.s1.e0" origId="5288826" charOffset="63-71" type="compound" text="morphine"/>
            <entity id="DS3.d1120.s1.e1" origId="Q05586,Q59GW0,Q5VSF9" charOffset="145-148" type="protein" text="NRI"/>
            <entity id="DS3.d1120.s1.e2" origId="Q12879,Q547U9,Q59EW6" charOffset="150-154" type="protein" text="NR2A"/>
            <entity id="DS3.d1120.s1.e3" origId="Q13224" charOffset="160-164" type="protein" text="NR2B"/>
            <pair e1="DS3.d1120.s1.e0" e2="DS3.d1120.s1.e3" id="DS3.d1120.s1.i0" interaction="False" />
            <pair e1="DS3.d1120.s1.e0" e2="DS3.d1120.s1.e1" id="DS3.d1120.s1.i1" interaction="False" />
            <pair e1="DS3.d1120.s1.e0" e2="DS3.d1120.s1.e2" id="DS3.d1120.s1.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1120.s2" origId="9988122-5" text="No changes were detected in expression of the NRI mRNA in the frontal cortex, caudate-putamen, nucleus accumbens, amygdala, CA1, CA2, and the dentate gyrus of the hippocampus, and in the central grey after morphine treatment.">
            <entity id="DS3.d1120.s2.e0" origId="Q05586,Q59GW0,Q5VSF9" charOffset="46-49" type="protein" text="NRI"/>
            <entity id="DS3.d1120.s2.e1" origId="P00915,V9HWE3" charOffset="124-127" type="protein" text="CA1"/>
            <entity id="DS3.d1120.s2.e2" origId="P00918,V9HW21" charOffset="129-132" type="protein" text="CA2"/>
            <entity id="DS3.d1120.s2.e3" origId="5288826" charOffset="206-214" type="compound" text="morphine"/>
            <pair e1="DS3.d1120.s2.e3" e2="DS3.d1120.s2.e2" id="DS3.d1120.s2.i0" interaction="False" />
            <pair e1="DS3.d1120.s2.e3" e2="DS3.d1120.s2.e0" id="DS3.d1120.s2.i1" interaction="False" />
            <pair e1="DS3.d1120.s2.e3" e2="DS3.d1120.s2.e1" id="DS3.d1120.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1120.s3" origId="9988122-6" text="The expression of NR2A and NR2B subunit mRNAs did not change after morphine treatment in any brain region.">
            <entity id="DS3.d1120.s3.e0" origId="Q12879,Q547U9,Q59EW6" charOffset="18-22" type="protein" text="NR2A"/>
            <entity id="DS3.d1120.s3.e1" origId="Q13224" charOffset="27-31" type="protein" text="NR2B"/>
            <entity id="DS3.d1120.s3.e2" origId="5288826" charOffset="67-75" type="compound" text="morphine"/>
            <pair e1="DS3.d1120.s3.e2" e2="DS3.d1120.s3.e1" id="DS3.d1120.s3.i0" interaction="False" />
            <pair e1="DS3.d1120.s3.e2" e2="DS3.d1120.s3.e0" id="DS3.d1120.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1120.s4" origId="9988122-7" text="These results suggest that changes in gene expression of the NRI subunit of the NMDA receptor are involved in the development of morphine tolerance and dependence.">
            <entity id="DS3.d1120.s4.e0" origId="Q05586,Q59GW0,Q5VSF9" charOffset="61-64" type="protein" text="NRI"/>
            <entity id="DS3.d1120.s4.e1" origId="5288826" charOffset="129-137" type="compound" text="morphine"/>
            <pair e1="DS3.d1120.s4.e1" e2="DS3.d1120.s4.e0" id="DS3.d1120.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1121" origId="9988123">
        <sentence id="DS3.d1121.s0" origId="9988123-0" text="(1S,3R)-ACPD, a metabotropic glutamate receptor agonist, enhances damage after global ischaemia.">
            <entity id="DS3.d1121.s0.e0" origId="Q9NSB8" charOffset="8-12" type="protein" text="ACPD"/>
            <entity id="DS3.d1121.s0.e1" origId="33032,23327,611,57109091" charOffset="29-38" type="compound" text="glutamate"/>
            <pair e1="DS3.d1121.s0.e1" e2="DS3.d1121.s0.e0" id="DS3.d1121.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1121.s1" origId="9988123-1" text="There are opposing results in the literature concerning the influence of (1S,3R)-ACPD ((1S,3R)-1-aminocyclopentane-1,3-dicarboxylate: group I/II metabotropic glutamate receptor agonist) on neurodegeneration, showing both enhancement and reduction of damage.">
            <entity id="DS3.d1121.s1.e0" origId="Q9NSB8" charOffset="81-85" type="protein" text="ACPD"/>
            <entity id="DS3.d1121.s1.e1" origId="1310" charOffset="95-132" type="compound" text="1-aminocyclopentane-1,3-dicarboxylate"/>
            <entity id="DS3.d1121.s1.e2" origId="33032,23327,611,57109091" charOffset="158-167" type="compound" text="glutamate"/>
            <pair e1="DS3.d1121.s1.e1" e2="DS3.d1121.s1.e0" id="DS3.d1121.s1.i0" interaction="False" />
            <pair e1="DS3.d1121.s1.e2" e2="DS3.d1121.s1.e0" id="DS3.d1121.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1122" origId="9988124">
        <sentence id="DS3.d1122.s0" origId="9988124-5" text="Pretreatment of lungs with NS 398 (N-(2-cyclohexyl)-4-nitrophenyl methanesulphonamide), a selective inhibitor of cyclooxygenase-2, did not change basal or antigen-induced 8-iso-prostaglandin F2alpha release at all.">
            <entity id="DS3.d1122.s0.e0" origId="72879" charOffset="66-85" type="compound" text="methanesulphonamide"/>
            <entity id="DS3.d1122.s0.e1" origId="P70682,H0UXH3" charOffset="113-129" type="protein" text="cyclooxygenase-2"/>
            <entity id="DS3.d1122.s0.e2" origId="285703,6145931" charOffset="177-190" type="compound" text="prostaglandin"/>
            <pair e1="DS3.d1122.s0.e0" e2="DS3.d1122.s0.e1" id="DS3.d1122.s0.i0" interaction="False" />
            <pair e1="DS3.d1122.s0.e2" e2="DS3.d1122.s0.e1" id="DS3.d1122.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1123" origId="9988128">
        <sentence id="DS3.d1123.s0" origId="9988128-4" text="The MAP kinase activation was inhibited either by the renin inhibitor pepstatin A or by the angiotensin-converting enzyme inhibitor captopril.">
            <entity id="DS3.d1123.s0.e0" origId="P08424" charOffset="54-59" type="protein" text="renin"/>
            <entity id="DS3.d1123.s0.e1" origId="13040982,44304955,4742,6420001,5464273" charOffset="70-81" type="compound" text="pepstatin A"/>
            <entity id="DS3.d1123.s0.e2" origId="44093" charOffset="132-141" type="compound" text="captopril"/>
            <pair e1="DS3.d1123.s0.e2" e2="DS3.d1123.s0.e0" id="DS3.d1123.s0.i0" interaction="False" />
            <pair e1="DS3.d1123.s0.e1" e2="DS3.d1123.s0.e0" id="DS3.d1123.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1123.s1" origId="9988128-6" text="Pepstatin A inhibited MAP kinase activation induced by renin but not by angiotensin I and angiotensin II.">
            <entity id="DS3.d1123.s1.e0" origId="13040982,44304955,4742,5464273,6420001" charOffset="0-11" type="compound" text="Pepstatin A"/>
            <entity id="DS3.d1123.s1.e1" origId="P08424" charOffset="55-60" type="protein" text="renin"/>
            <entity id="DS3.d1123.s1.e2" origId="P01015" charOffset="90-104" type="protein" text="angiotensin II"/>
            <pair e1="DS3.d1123.s1.e0" e2="DS3.d1123.s1.e2" id="DS3.d1123.s1.i0" interaction="False" />
            <pair e1="DS3.d1123.s1.e0" e2="DS3.d1123.s1.e1" id="DS3.d1123.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1123.s2" origId="9988128-7" text="Captopril inhibited the MAP kinase activation induced by angiotensin I but not by angiotensin II.">
            <entity id="DS3.d1123.s2.e0" origId="44093" charOffset="0-9" type="compound" text="Captopril"/>
            <entity id="DS3.d1123.s2.e1" origId="P01015" charOffset="82-96" type="protein" text="angiotensin II"/>
            <pair e1="DS3.d1123.s2.e0" e2="DS3.d1123.s2.e1" id="DS3.d1123.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1124" origId="9988129">
        <sentence id="DS3.d1124.s0" origId="9988129-4" text="Depletion of the endoplasmic reticulum Ca2+ store by incubation with 0.1 mM BHQ for 6 min abolished the (Ca2+)i increase evoked by bradykinin or ATP, suggesting that BHQ depleted the inositol 1,4,5-trisphosphate (IP3)-sensitive Ca2+ store.">
            <entity id="DS3.d1124.s0.e0" origId="P01042" charOffset="131-141" type="protein" text="bradykinin"/>
            <entity id="DS3.d1124.s0.e1" origId="5957" charOffset="145-148" type="compound" text="ATP"/>
            <entity id="DS3.d1124.s0.e2" origId="892" charOffset="183-191" type="compound" text="inositol"/>
            <entity id="DS3.d1124.s0.e3" origId="19432134" charOffset="198-211" type="compound" text="trisphosphate"/>
            <entity id="DS3.d1124.s0.e4" origId="439456" charOffset="213-216" type="compound" text="IP3"/>
            <pair e1="DS3.d1124.s0.e4" e2="DS3.d1124.s0.e0" id="DS3.d1124.s0.i0" interaction="False" />
            <pair e1="DS3.d1124.s0.e2" e2="DS3.d1124.s0.e0" id="DS3.d1124.s0.i1" interaction="False" />
            <pair e1="DS3.d1124.s0.e1" e2="DS3.d1124.s0.e0" id="DS3.d1124.s0.i2" interaction="False" />
            <pair e1="DS3.d1124.s0.e3" e2="DS3.d1124.s0.e0" id="DS3.d1124.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1125" origId="9988131">
        <sentence id="DS3.d1125.s0" origId="9988131-0" text="Altered ratio of endothelin ET(A)- and ET(B) receptor mRNA in bronchial biopsies from patients with asthma and chronic airway obstruction.">
            <entity id="DS3.d1125.s0.e0" origId="44284481" charOffset="17-27" type="compound" text="endothelin"/>
            <entity id="DS3.d1125.s0.e1" origId="P25101" charOffset="28-32" type="protein" text="ET(A"/>
            <pair e1="DS3.d1125.s0.e0" e2="DS3.d1125.s0.e1" id="DS3.d1125.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1125.s1" origId="9988131-1" text="Using a reverse transcription-polymerase chain reaction (RT-PCR) based assay the ratio of mRNA for the human endothelin ET(A) and ET(B) receptors in bronchial biopsies was assessed.">
            <entity id="DS3.d1125.s1.e0" origId="16132423" charOffset="103-119" type="compound" text="human endothelin"/>
            <entity id="DS3.d1125.s1.e1" origId="P25101" charOffset="120-124" type="protein" text="ET(A"/>
            <pair e1="DS3.d1125.s1.e0" e2="DS3.d1125.s1.e1" id="DS3.d1125.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1125.s2" origId="9988131-2" text="In patients with diagnoses like bronchial cancer, endothelin ET(A) mRNA was the dominating subtype (ratio 3.74 +/- 0.99).">
            <entity id="DS3.d1125.s2.e0" origId="44284481" charOffset="50-60" type="compound" text="endothelin"/>
            <entity id="DS3.d1125.s2.e1" origId="P25101" charOffset="61-71" type="protein" text="ET(A) mRNA"/>
            <pair e1="DS3.d1125.s2.e0" e2="DS3.d1125.s2.e1" id="DS3.d1125.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1125.s3" origId="9988131-3" text="Subjects with the diagnosis of asthma or chronic obstructive pulmonary disease showed significantly higher levels (ratio 0.81 +/- 0.04) of endothelin ET(B) receptor mRNA compared to endothelin ET(A) receptor mRNA.">
            <entity id="DS3.d1125.s3.e0" origId="44284481" charOffset="139-149" type="compound" text="endothelin"/>
            <entity id="DS3.d1125.s3.e1" origId="44284481" charOffset="182-192" type="compound" text="endothelin"/>
            <entity id="DS3.d1125.s3.e2" origId="P25101" charOffset="193-197" type="protein" text="ET(A"/>
            <pair e1="DS3.d1125.s3.e0" e2="DS3.d1125.s3.e2" id="DS3.d1125.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1126" origId="9988132">
        <sentence id="DS3.d1126.s0" origId="9988132-0" text="MGMT- and P450 3A-inhibitors do not sensitize glioblastoma cell cultures against nitrosoureas.">
            <entity id="DS3.d1126.s0.e0" origId="P16455,B4DEE8" charOffset="0-4" type="protein" text="MGMT"/>
            <entity id="DS3.d1126.s0.e1" origId="2981881,91293124" charOffset="15-17" type="compound" text="3A"/>
            <pair e1="DS3.d1126.s0.e1" e2="DS3.d1126.s0.e0" id="DS3.d1126.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1126.s1" origId="9988132-10" text="CONCLUSION: In no case could a significant sensitizing effect of P450 3A- and MGMT inhibitors be demonstrated.">
            <entity id="DS3.d1126.s1.e0" origId="2981881,91293124" charOffset="70-72" type="compound" text="3A"/>
            <entity id="DS3.d1126.s1.e1" origId="P16455,B4DEE8" charOffset="78-82" type="protein" text="MGMT"/>
            <pair e1="DS3.d1126.s1.e0" e2="DS3.d1126.s1.e1" id="DS3.d1126.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1126.s2" origId="9988132-3" text="O6-benzylguanine (BG), an inhibitor of the DNA repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT), was used in parallel experiments, since MGMT is discussed as a main mechanism in nitrosourea resistance.">
            <entity id="DS3.d1126.s2.e0" origId="4578" charOffset="0-16" type="compound" text="O6-benzylguanine"/>
            <entity id="DS3.d1126.s2.e1" origId="P16455,B4DEE8" charOffset="61-99" type="protein" text="O6-methylguanine-DNA-methyltransferase"/>
            <entity id="DS3.d1126.s2.e2" origId="P16455,B4DEE8" charOffset="101-105" type="protein" text="MGMT"/>
            <entity id="DS3.d1126.s2.e3" origId="P16455,B4DEE8" charOffset="148-152" type="protein" text="MGMT"/>
            <entity id="DS3.d1126.s2.e4" origId="105035" charOffset="189-200" type="compound" text="nitrosourea"/>
            <pair e1="DS3.d1126.s2.e4" e2="DS3.d1126.s2.e1" id="DS3.d1126.s2.i0" interaction="False" />
            <pair e1="DS3.d1126.s2.e4" e2="DS3.d1126.s2.e2" id="DS3.d1126.s2.i1" interaction="False" />
            <pair e1="DS3.d1126.s2.e0" e2="DS3.d1126.s2.e1" id="DS3.d1126.s2.i2" interaction="False" />
            <pair e1="DS3.d1126.s2.e0" e2="DS3.d1126.s2.e2" id="DS3.d1126.s2.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1126.s3" origId="9988132-7" text="For cell culture experiments with P450 3A and MGMT inhibitors, early passages of 3 glioblastomas, a late passage of an immortalized cell line derived from a reoccurring glioblastoma, and the human glioblastoma line LN405 were used.">
            <entity id="DS3.d1126.s3.e0" origId="2981881,91293124" charOffset="39-41" type="compound" text="3A"/>
            <entity id="DS3.d1126.s3.e1" origId="P16455,B4DEE8" charOffset="46-50" type="protein" text="MGMT"/>
            <pair e1="DS3.d1126.s3.e0" e2="DS3.d1126.s3.e1" id="DS3.d1126.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1127" origId="9988141">
        <sentence id="DS3.d1127.s0" origId="9988141-2" text="Since we found that both types of patients have increased urinary NO2-/NO3-, metabolites of NO, that correlated with their increased urinary cGMP, second messenger of NO, we examined the possible role of NO system in the pathophysiology of these syndromes.">
            <entity id="DS3.d1127.s0.e0" origId="P41271,A0A087WTY6" charOffset="71-74" type="protein" text="NO3"/>
            <entity id="DS3.d1127.s0.e1" origId="24316" charOffset="141-145" type="compound" text="cGMP"/>
            <pair e1="DS3.d1127.s0.e1" e2="DS3.d1127.s0.e0" id="DS3.d1127.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1128" origId="9988142">
        <sentence id="DS3.d1128.s0" origId="9988142-10" text="Non-users of vitamin D metabolites treated with RenaGel with calcium experienced a significant decrease in PTH (median change -114.5 vs. -22 pg/mL in RenaGel group, P = 0.006).">
            <entity id="DS3.d1128.s0.e0" origId="5280795,5283711" charOffset="13-22" type="compound" text="vitamin D"/>
            <entity id="DS3.d1128.s0.e1" origId="22044544,5460341" charOffset="61-68" type="compound" text="calcium"/>
            <entity id="DS3.d1128.s0.e2" origId="P01270" charOffset="107-110" type="protein" text="PTH"/>
            <pair e1="DS3.d1128.s0.e1" e2="DS3.d1128.s0.e2" id="DS3.d1128.s0.i0" interaction="False" />
            <pair e1="DS3.d1128.s0.e0" e2="DS3.d1128.s0.e2" id="DS3.d1128.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1128.s1" origId="9988142-2" text="PATIENTS AND METHODS: We performed a randomized clinical trial to compare the efficacy of RenaGel alone and RenaGel with calcium, using the serum phosphorus concentration and intact parathyroid hormone (PTH) as the principal outcomes of interest.">
            <entity id="DS3.d1128.s1.e0" origId="22044544,5460341" charOffset="121-128" type="compound" text="calcium"/>
            <entity id="DS3.d1128.s1.e1" origId="P01270" charOffset="182-201" type="protein" text="parathyroid hormone"/>
            <entity id="DS3.d1128.s1.e2" origId="P01270" charOffset="203-206" type="protein" text="PTH"/>
            <pair e1="DS3.d1128.s1.e0" e2="DS3.d1128.s1.e1" id="DS3.d1128.s1.i0" interaction="False" />
            <pair e1="DS3.d1128.s1.e0" e2="DS3.d1128.s1.e2" id="DS3.d1128.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1128.s2" origId="9988142-6" text="RESULTS: Serum phosphorus and PTH rose significantly when patients stopped their phosphate binders during both washout periods.">
            <entity id="DS3.d1128.s2.e0" origId="P01270" charOffset="30-33" type="protein" text="PTH"/>
            <entity id="DS3.d1128.s2.e1" origId="1061,167704,644102" charOffset="81-90" type="compound" text="phosphate"/>
            <pair e1="DS3.d1128.s2.e1" e2="DS3.d1128.s2.e0" id="DS3.d1128.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1128.s3" origId="9988142-9" text="During the treatment phase, the reduction in PTH tended to be greater in the RenaGel with calcium group (median change -67.0 vs. -22.5 pg/mL in RenaGel group, P = 0.07).">
            <entity id="DS3.d1128.s3.e0" origId="P01270" charOffset="45-48" type="protein" text="PTH"/>
            <entity id="DS3.d1128.s3.e1" origId="22044544,5460341" charOffset="90-97" type="compound" text="calcium"/>
            <pair e1="DS3.d1128.s3.e1" e2="DS3.d1128.s3.e0" id="DS3.d1128.s3.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1129" origId="9988183">
        <sentence id="DS3.d1129.s0" origId="9988183-3" text="A marked elevation of interferon (IFN)-gamma levels (&amp;gt;100 pg/mL) was observed in sequential serum samples from all fatal EHF cases compared with patients who recovered or controls.">
            <entity id="DS3.d1129.s0.e0" origId="P01579" charOffset="22-44" type="protein" text="interferon (IFN)-gamma"/>
            <entity id="DS3.d1129.s0.e1" origId="71627424" charOffset="124-127" type="compound" text="EHF"/>
            <pair e1="DS3.d1129.s0.e1" e2="DS3.d1129.s0.e0" id="DS3.d1129.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1129.s1" origId="9988183-4" text="Markedly elevated serum levels of interleukin (IL)-2, IL-10, tumor necrosis factor (TNF)-alpha, and IFN-alpha were also noted in fatal EHF cases; however, they had a greater degree of variability.">
            <entity id="DS3.d1129.s1.e0" origId="P60568,Q0GK43" charOffset="34-52" type="protein" text="interleukin (IL)-2"/>
            <entity id="DS3.d1129.s1.e1" origId="P22301,Q6FGW4" charOffset="54-59" type="protein" text="IL-10"/>
            <entity id="DS3.d1129.s1.e2" origId="P01375,Q5STB3" charOffset="61-94" type="protein" text="tumor necrosis factor (TNF)-alpha"/>
            <entity id="DS3.d1129.s1.e3" origId="P01562,L0N195" charOffset="100-109" type="protein" text="IFN-alpha"/>
            <entity id="DS3.d1129.s1.e4" origId="71627424" charOffset="135-138" type="compound" text="EHF"/>
            <pair e1="DS3.d1129.s1.e4" e2="DS3.d1129.s1.e3" id="DS3.d1129.s1.i0" interaction="False" />
            <pair e1="DS3.d1129.s1.e4" e2="DS3.d1129.s1.e0" id="DS3.d1129.s1.i1" interaction="False" />
            <pair e1="DS3.d1129.s1.e4" e2="DS3.d1129.s1.e1" id="DS3.d1129.s1.i2" interaction="False" />
            <pair e1="DS3.d1129.s1.e4" e2="DS3.d1129.s1.e2" id="DS3.d1129.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1129.s2" origId="9988183-6" text="mRNA quantitation from blood clots of the same patients showed relatively elevated levels of TNF-alpha and IFN-alpha in samples from EHF patients.">
            <entity id="DS3.d1129.s2.e0" origId="P01375,Q5STB3" charOffset="93-102" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d1129.s2.e1" origId="P01562,L0N195" charOffset="107-116" type="protein" text="IFN-alpha"/>
            <entity id="DS3.d1129.s2.e2" origId="71627424" charOffset="133-136" type="compound" text="EHF"/>
            <pair e1="DS3.d1129.s2.e2" e2="DS3.d1129.s2.e0" id="DS3.d1129.s2.i0" interaction="False" />
            <pair e1="DS3.d1129.s2.e2" e2="DS3.d1129.s2.e1" id="DS3.d1129.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1130" origId="9988225">
        <sentence id="DS3.d1130.s0" origId="9988225-8" text="In this assay, bFGF was found to be an essential cofactor with which VEGF as well as HGF/SF were able to synergize independently.">
            <entity id="DS3.d1130.s0.e0" origId="108194" charOffset="49-57" type="compound" text="cofactor"/>
            <entity id="DS3.d1130.s0.e1" origId="P15692,A0A024RD37,A0A024RD33,A2A2V4" charOffset="69-73" type="protein" text="VEGF"/>
            <entity id="DS3.d1130.s0.e2" origId="P14210" charOffset="85-91" type="protein" text="HGF/SF"/>
            <pair e1="DS3.d1130.s0.e0" e2="DS3.d1130.s0.e2" id="DS3.d1130.s0.i0" interaction="False" />
            <pair e1="DS3.d1130.s0.e0" e2="DS3.d1130.s0.e1" id="DS3.d1130.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1131" origId="9988227">
        <sentence id="DS3.d1131.s0" origId="9988227-1" text="The ErbB-4 gene encodes a detected receptor protein that possesses intrinsic tyrosine kinase activity and belongs to the family of the epidermal growth factor receptor (EGFR); ErbB-4 is stimulated by the heregulins and betacellulin, which enables this receptor to form heterodimers with erbB-2, a prerequisite for erbB-2 activation.">
            <entity id="DS3.d1131.s0.e0" origId="Q15303" charOffset="4-10" type="protein" text="ErbB-4"/>
            <entity id="DS3.d1131.s0.e1" origId="6057,90983769" charOffset="77-85" type="compound" text="tyrosine"/>
            <entity id="DS3.d1131.s0.e2" origId="P00533" charOffset="135-167" type="protein" text="epidermal growth factor receptor"/>
            <entity id="DS3.d1131.s0.e3" origId="P00533" charOffset="169-173" type="protein" text="EGFR"/>
            <entity id="DS3.d1131.s0.e4" origId="Q15303" charOffset="176-182" type="protein" text="ErbB-4"/>
            <entity id="DS3.d1131.s0.e5" origId="P35070" charOffset="219-231" type="protein" text="betacellulin"/>
            <entity id="DS3.d1131.s0.e6" origId="P04626,J3QLU9,F5H1T4,X5DNK3" charOffset="287-293" type="protein" text="erbB-2"/>
            <entity id="DS3.d1131.s0.e7" origId="P04626,J3QLU9,F5H1T4,X5DNK3" charOffset="314-320" type="protein" text="erbB-2"/>
            <pair e1="DS3.d1131.s0.e1" e2="DS3.d1131.s0.e6" id="DS3.d1131.s0.i0" interaction="False" />
            <pair e1="DS3.d1131.s0.e1" e2="DS3.d1131.s0.e2" id="DS3.d1131.s0.i1" interaction="False" />
            <pair e1="DS3.d1131.s0.e1" e2="DS3.d1131.s0.e3" id="DS3.d1131.s0.i2" interaction="False" />
            <pair e1="DS3.d1131.s0.e1" e2="DS3.d1131.s0.e0" id="DS3.d1131.s0.i3" interaction="False" />
            <pair e1="DS3.d1131.s0.e1" e2="DS3.d1131.s0.e5" id="DS3.d1131.s0.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1132" origId="9988233">
        <sentence id="DS3.d1132.s0" origId="9988233-3" text="This study immunocytochemically monitors Fos protein within sequential biopsies from primary human breast cancer patients obtained pre-treatment (T1), during tamoxifen therapy (T2, T3) and on disease progression (T5), examining in parallel proliferation (i.e., MIBI (Ki67) immunostaining, mitotic activity), cellularity and endocrine response.">
            <entity id="DS3.d1132.s0.e0" origId="P01100,Q6FG41" charOffset="41-44" type="protein" text="Fos"/>
            <entity id="DS3.d1132.s0.e1" origId="2733526" charOffset="158-167" type="compound" text="tamoxifen"/>
            <entity id="DS3.d1132.s0.e2" origId="5920" charOffset="181-183" type="compound" text="T3"/>
            <pair e1="DS3.d1132.s0.e1" e2="DS3.d1132.s0.e0" id="DS3.d1132.s0.i0" interaction="False" />
            <pair e1="DS3.d1132.s0.e2" e2="DS3.d1132.s0.e0" id="DS3.d1132.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1132.s1" origId="9988233-8" text="Our data indicate that tamoxifen response involves a reduction in both tumor cell proliferation and cell survival, potentially entailing diminished Fos protein expression in better-responding patients.">
            <entity id="DS3.d1132.s1.e0" origId="2733526" charOffset="23-32" type="compound" text="tamoxifen"/>
            <entity id="DS3.d1132.s1.e1" origId="P01100,Q6FG41" charOffset="148-151" type="protein" text="Fos"/>
            <pair e1="DS3.d1132.s1.e0" e2="DS3.d1132.s1.e1" id="DS3.d1132.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1133" origId="9988266">
        <sentence id="DS3.d1133.s0" origId="9988266-2" text="Epigenetic events can also facilitate genetic damage, as illustrated by the increased mutagenicity of 5-methylcytosine and the silencing of the MLH1 mismatch repair gene by DNA methylation in colorectal tumours.">
            <entity id="DS3.d1133.s0.e0" origId="122004" charOffset="104-118" type="compound" text="methylcytosine"/>
            <entity id="DS3.d1133.s0.e1" origId="P40692,A0A024R2S9,Q59EG3" charOffset="144-148" type="protein" text="MLH1"/>
            <pair e1="DS3.d1133.s0.e0" e2="DS3.d1133.s0.e1" id="DS3.d1133.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1134" origId="9988270">
        <sentence id="DS3.d1134.s0" origId="9988270-1" text="The discovery of Rous sarcoma virus (RSV) led to the identification of cellular Src (c-Src), a non-receptor tyrosine kinase, which has since been implicated in the development of numerous human cancers.">
            <entity id="DS3.d1134.s0.e0" origId="P12931" charOffset="85-90" type="protein" text="c-Src"/>
            <entity id="DS3.d1134.s0.e1" origId="90983769" charOffset="108-116" type="compound" text="tyrosine"/>
            <pair e1="DS3.d1134.s0.e1" e2="DS3.d1134.s0.e0" id="DS3.d1134.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1134.s1" origId="9988270-3" text="Studies of the mechanism of c-Src regulation have suggested that c-Src kinase activity is downregulated by phosphorylation of a critical carboxy-terminal tyrosine (Tyr 530 in human c-Src, equivalent to Tyr 527 in chicken Src) and have implied the existence of activating mutations in this C-terminal regulatory region.">
            <entity id="DS3.d1134.s1.e0" origId="P12931" charOffset="28-33" type="protein" text="c-Src"/>
            <entity id="DS3.d1134.s1.e1" origId="P12931" charOffset="65-70" type="protein" text="c-Src"/>
            <entity id="DS3.d1134.s1.e2" origId="90983769" charOffset="154-162" type="compound" text="tyrosine"/>
            <entity id="DS3.d1134.s1.e3" origId="6057" charOffset="164-167" type="compound" text="Tyr"/>
            <entity id="DS3.d1134.s1.e4" origId="P12931" charOffset="65-70" type="protein" text="c-Src"/>
            <entity id="DS3.d1134.s1.e5" origId="6057" charOffset="202-205" type="compound" text="Tyr"/>
            <pair e1="DS3.d1134.s1.e3" e2="DS3.d1134.s1.e0" id="DS3.d1134.s1.i0" interaction="False" />
            <pair e1="DS3.d1134.s1.e2" e2="DS3.d1134.s1.e0" id="DS3.d1134.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1135" origId="9988272">
        <sentence id="DS3.d1135.s0" origId="9988272-0" text="Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the sla mouse.">
            <entity id="DS3.d1135.s0.e0" origId="Q9Z0Z4,A2AI62,Q9BQS7,A0A0C4DG76,E7ES21" charOffset="0-10" type="protein" text="Hephaestin"/>
            <entity id="DS3.d1135.s0.e1" origId="Q61147,G3X8Q5,E9PZD8,Q8BU82" charOffset="14-27" type="protein" text="ceruloplasmin"/>
            <entity id="DS3.d1135.s0.e2" origId="23925,67172434" charOffset="63-67" type="compound" text="iron"/>
            <pair e1="DS3.d1135.s0.e2" e2="DS3.d1135.s0.e1" id="DS3.d1135.s0.i0" interaction="False" />
            <pair e1="DS3.d1135.s0.e2" e2="DS3.d1135.s0.e0" id="DS3.d1135.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1135.s1" origId="9988272-9" text="We suggest that the Hephaestin protein is a multicopper ferroxidase necessary for iron egress from intestinal enterocytes into the circulation and that it is an important link between copper and iron metabolism in mammals.">
            <entity id="DS3.d1135.s1.e0" origId="Q9Z0Z4,A2AI62,Q9BQS7,A0A0C4DG76,E7ES21" charOffset="20-30" type="protein" text="Hephaestin"/>
            <entity id="DS3.d1135.s1.e1" origId="23925,67172434" charOffset="82-86" type="compound" text="iron"/>
            <entity id="DS3.d1135.s1.e2" origId="23978" charOffset="49-55" type="compound" text="copper"/>
            <entity id="DS3.d1135.s1.e3" origId="23925,67172434" charOffset="195-199" type="compound" text="iron"/>
            <pair e1="DS3.d1135.s1.e2" e2="DS3.d1135.s1.e0" id="DS3.d1135.s1.i0" interaction="False" />
            <pair e1="DS3.d1135.s1.e1" e2="DS3.d1135.s1.e0" id="DS3.d1135.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1136" origId="9988274">
        <sentence id="DS3.d1136.s0" origId="9988274-1" text="The yeast protein Set1p, inactivation of which alleviates telomeric position effect (TPE), contains a conserved SET domain present in chromosomal proteins involved in epigenetic control of transcription.">
            <entity id="DS3.d1136.s0.e0" origId="P38827" charOffset="18-23" type="protein" text="Set1p"/>
            <entity id="DS3.d1136.s0.e1" origId="445181" charOffset="85-88" type="compound" text="TPE"/>
            <pair e1="DS3.d1136.s0.e1" e2="DS3.d1136.s0.e0" id="DS3.d1136.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1136.s1" origId="9988274-6" text="Furthermore, restoration of TPE in a Set1delta mutant by overexpression of the isolated SET domain requires Mec3p.">
            <entity id="DS3.d1136.s1.e0" origId="445181" charOffset="28-31" type="compound" text="TPE"/>
            <entity id="DS3.d1136.s1.e1" origId="Q02574" charOffset="108-113" type="protein" text="Mec3p"/>
            <pair e1="DS3.d1136.s1.e0" e2="DS3.d1136.s1.e1" id="DS3.d1136.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1137" origId="9988277">
        <sentence id="DS3.d1137.s0" origId="9988277-3" text="To identify this gene, we introduced an expression cDNA library prepared from mouse NIH3T3 fibroblasts into nonpermissive hamster cells and screened these cells for acquired susceptibility to MCF viruses encoding beta-galactosidase and G418 resistance.">
            <entity id="DS3.d1137.s0.e0" origId="P23780,Q3TAW7" charOffset="213-231" type="protein" text="beta-galactosidase"/>
            <entity id="DS3.d1137.s0.e1" origId="123865" charOffset="236-240" type="compound" text="G418"/>
            <pair e1="DS3.d1137.s0.e1" e2="DS3.d1137.s0.e0" id="DS3.d1137.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1138" origId="9988279">
        <sentence id="DS3.d1138.s0" origId="9988279-1" text="link protein (LP), an extracellular matrix protein in cartilage, stabilizes aggregates of aggrecan and hyaluronan, giving cartilage its tensile strength and elasticity.">
            <entity id="DS3.d1138.s0.e0" origId="Q9QUP5" charOffset="0-12" type="protein" text="link protein"/>
            <entity id="DS3.d1138.s0.e1" origId="24759,3084050" charOffset="103-113" type="compound" text="hyaluronan"/>
            <pair e1="DS3.d1138.s0.e1" e2="DS3.d1138.s0.e0" id="DS3.d1138.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1139" origId="9988280">
        <sentence id="DS3.d1139.s0" origId="9988280-0" text="Increased insulin sensitivity and hypoglycaemia in mice lacking the p85 alpha subunit of phosphoinositide 3-kinase.">
            <entity id="DS3.d1139.s0.e0" origId="P26450,Q80UI5,Q8C7P2,Q3TP23" charOffset="68-77" type="protein" text="p85 alpha"/>
            <entity id="DS3.d1139.s0.e1" origId="16738692" charOffset="89-105" type="compound" text="phosphoinositide"/>
            <pair e1="DS3.d1139.s0.e1" e2="DS3.d1139.s0.e0" id="DS3.d1139.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1139.s1" origId="9988280-2" text="Although a role for phosphoinositide-3-kinase (PI3K) activity in insulin-stimulated glucose transport and glucose transporter isoform 4 (Glut4) translocation has been suggested in vitro, its role in vivo and the molecular link between activation of PI3K and translocation has not yet been elucidated.">
            <entity id="DS3.d1139.s1.e0" origId="16738692" charOffset="20-36" type="compound" text="phosphoinositide"/>
            <entity id="DS3.d1139.s1.e1" origId="206,5793,64689,79025" charOffset="84-91" type="compound" text="glucose"/>
            <entity id="DS3.d1139.s1.e2" origId="206,5793,64689,79025" charOffset="106-113" type="compound" text="glucose"/>
            <entity id="DS3.d1139.s1.e3" origId="P14142" charOffset="137-142" type="protein" text="Glut4"/>
            <pair e1="DS3.d1139.s1.e0" e2="DS3.d1139.s1.e3" id="DS3.d1139.s1.i0" interaction="False" />
            <pair e1="DS3.d1139.s1.e1" e2="DS3.d1139.s1.e3" id="DS3.d1139.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1139.s2" origId="9988280-3" text="To determine the role of PI3K in glucose homeostasis, we generated mice with a targeted disruption of the gene encoding the p85alpha regulatory subunit of PI3K (Pik3r1; refs 3-5).">
            <entity id="DS3.d1139.s2.e0" origId="206,5793,64689,79025" charOffset="33-40" type="compound" text="glucose"/>
            <entity id="DS3.d1139.s2.e1" origId="P26450,Q80UI5,Q8C7P2,Q3TP23" charOffset="124-132" type="protein" text="p85alpha"/>
            <entity id="DS3.d1139.s2.e2" origId="P26450,Q80UI5,Q8C7P2,Q3TP23" charOffset="161-167" type="protein" text="Pik3r1"/>
            <pair e1="DS3.d1139.s2.e0" e2="DS3.d1139.s2.e1" id="DS3.d1139.s2.i0" interaction="False" />
            <pair e1="DS3.d1139.s2.e0" e2="DS3.d1139.s2.e2" id="DS3.d1139.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1139.s3" origId="9988280-4" text="Pik3r1-/- mice showed increased insulin sensitivity and hypoglycaemia due to increased glucose transport in skeletal muscle and adipocytes.">
            <entity id="DS3.d1139.s3.e0" origId="P26450,Q80UI5,Q8C7P2,Q3TP23" charOffset="0-6" type="protein" text="Pik3r1"/>
            <entity id="DS3.d1139.s3.e1" origId="206,5793,64689,79025" charOffset="87-94" type="compound" text="glucose"/>
            <pair e1="DS3.d1139.s3.e1" e2="DS3.d1139.s3.e0" id="DS3.d1139.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1139.s4" origId="9988280-6" text="This isoform switch was associated with an increase in insulin-induced generation of phosphatidylinositol(3,4,5)triphosphate (PtdIns(3,4,5)P3) in Pik3r1-/- adipocytes and facilitation of Glut4 translocation from the low-density microsome (LDM) fraction to the plasma membrane (PM).">
            <entity id="DS3.d1139.s4.e0" origId="53477912" charOffset="85-105" type="compound" text="phosphatidylinositol"/>
            <entity id="DS3.d1139.s4.e1" origId="P26450,Q80UI5,Q8C7P2,Q3TP23" charOffset="146-152" type="protein" text="Pik3r1"/>
            <entity id="DS3.d1139.s4.e2" origId="P14142" charOffset="187-192" type="protein" text="Glut4"/>
            <entity id="DS3.d1139.s4.e3" origId="6398474" charOffset="239-242" type="compound" text="LDM"/>
            <pair e1="DS3.d1139.s4.e0" e2="DS3.d1139.s4.e2" id="DS3.d1139.s4.i0" interaction="False" />
            <pair e1="DS3.d1139.s4.e0" e2="DS3.d1139.s4.e1" id="DS3.d1139.s4.i1" interaction="False" />
            <pair e1="DS3.d1139.s4.e3" e2="DS3.d1139.s4.e2" id="DS3.d1139.s4.i2" interaction="False" />
            <pair e1="DS3.d1139.s4.e3" e2="DS3.d1139.s4.e1" id="DS3.d1139.s4.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1139.s5" origId="9988280-7" text="This mechanism seems to be responsible for the phenotype of Pik3r1-/- mice, namely increased glucose transport and hypoglycaemia.">
            <entity id="DS3.d1139.s5.e0" origId="P26450,Q80UI5,Q8C7P2,Q3TP23" charOffset="60-66" type="protein" text="Pik3r1"/>
            <entity id="DS3.d1139.s5.e1" origId="206,5793,64689,79025" charOffset="93-100" type="compound" text="glucose"/>
            <pair e1="DS3.d1139.s5.e1" e2="DS3.d1139.s5.e0" id="DS3.d1139.s5.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1140" origId="9988309">
        <sentence id="DS3.d1140.s0" origId="9988309-4" text="A peak in IFN-gamma production in the first month of infection may suggest Th1 or Th0 activity at this time and this may be correlated with initial protoscolex death.">
            <entity id="DS3.d1140.s0.e0" origId="P01580" charOffset="10-19" type="protein" text="IFN-gamma"/>
            <entity id="DS3.d1140.s0.e1" origId="Q64279,Q5SQG1" charOffset="75-78" type="protein" text="Th1"/>
            <entity id="DS3.d1140.s0.e2" origId="12563346" charOffset="82-85" type="compound" text="Th0"/>
            <pair e1="DS3.d1140.s0.e2" e2="DS3.d1140.s0.e0" id="DS3.d1140.s0.i0" interaction="False" />
            <pair e1="DS3.d1140.s0.e2" e2="DS3.d1140.s0.e1" id="DS3.d1140.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1141" origId="9988312">
        <sentence id="DS3.d1141.s0" origId="9988312-4" text="In particular, ES-62 acts by modulating activation of the tyrosine kinases Fyn, Lck and ZAP-70 leading to selective disruption of TCR coupling to the phospholipase D, protein kinase C, phosphoinositide-3-kinase and RasMAPkinase signalling cascades.">
            <entity id="DS3.d1141.s0.e0" origId="6057,90983769" charOffset="58-66" type="compound" text="tyrosine"/>
            <entity id="DS3.d1141.s0.e1" origId="P06241" charOffset="75-78" type="protein" text="Fyn"/>
            <entity id="DS3.d1141.s0.e2" origId="P06239,Q573B4" charOffset="80-83" type="protein" text="Lck"/>
            <entity id="DS3.d1141.s0.e3" origId="P43403" charOffset="88-94" type="protein" text="ZAP-70"/>
            <pair e1="DS3.d1141.s0.e0" e2="DS3.d1141.s0.e1" id="DS3.d1141.s0.i0" interaction="False" />
            <pair e1="DS3.d1141.s0.e0" e2="DS3.d1141.s0.e2" id="DS3.d1141.s0.i1" interaction="False" />
            <pair e1="DS3.d1141.s0.e0" e2="DS3.d1141.s0.e3" id="DS3.d1141.s0.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1142" origId="9988328">
        <sentence id="DS3.d1142.s0" origId="9988328-4" text="Serum levels of interleukin-6 (IL-6), IL-6 soluble receptor (IL-6sR), IL-8, IL-10, and elastase-alpha1-antitrypsin complex (E-alpha 1AT) were assayed by ELISAs.">
            <entity id="DS3.d1142.s0.e0" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="16-29" type="protein" text="interleukin-6"/>
            <entity id="DS3.d1142.s0.e1" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="31-35" type="protein" text="IL-6"/>
            <entity id="DS3.d1142.s0.e2" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="38-42" type="protein" text="IL-6"/>
            <entity id="DS3.d1142.s0.e3" origId="P10145,A0A024RDA5" charOffset="70-74" type="protein" text="IL-8"/>
            <entity id="DS3.d1142.s0.e4" origId="P22301,Q6FGW4" charOffset="76-81" type="protein" text="IL-10"/>
            <entity id="DS3.d1142.s0.e5" origId="71576793" charOffset="132-135" type="compound" text="1AT"/>
            <pair e1="DS3.d1142.s0.e5" e2="DS3.d1142.s0.e1" id="DS3.d1142.s0.i0" interaction="False" />
            <pair e1="DS3.d1142.s0.e5" e2="DS3.d1142.s0.e3" id="DS3.d1142.s0.i1" interaction="False" />
            <pair e1="DS3.d1142.s0.e5" e2="DS3.d1142.s0.e4" id="DS3.d1142.s0.i2" interaction="False" />
            <pair e1="DS3.d1142.s0.e5" e2="DS3.d1142.s0.e0" id="DS3.d1142.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1142.s1" origId="9988328-7" text="Significant correlations were found between levels of both IL-8 and IL-10 with those of TNF-alpha as well as between IL-8 and E-alpha 1AT.">
            <entity id="DS3.d1142.s1.e0" origId="P10145,A0A024RDA5" charOffset="59-63" type="protein" text="IL-8"/>
            <entity id="DS3.d1142.s1.e1" origId="P22301,Q6FGW4" charOffset="68-73" type="protein" text="IL-10"/>
            <entity id="DS3.d1142.s1.e2" origId="P01375,Q5STB3" charOffset="88-97" type="protein" text="TNF-alpha"/>
            <entity id="DS3.d1142.s1.e3" origId="P10145,A0A024RDA5" charOffset="117-121" type="protein" text="IL-8"/>
            <entity id="DS3.d1142.s1.e4" origId="71576793" charOffset="134-137" type="compound" text="1AT"/>
            <pair e1="DS3.d1142.s1.e4" e2="DS3.d1142.s1.e2" id="DS3.d1142.s1.i0" interaction="False" />
            <pair e1="DS3.d1142.s1.e4" e2="DS3.d1142.s1.e0" id="DS3.d1142.s1.i1" interaction="False" />
            <pair e1="DS3.d1142.s1.e4" e2="DS3.d1142.s1.e1" id="DS3.d1142.s1.i2" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1143" origId="9988330">
        <sentence id="DS3.d1143.s0" origId="9988330-1" text="Light subunit neurofilament (NFL) and glial fibrillary acidic protein (GFAP) concentrations were determined in cerebrospinal fluid (CSF) of 34 patients with human African trypanosomiasis (HAT), five serologically positive but parasitologically unconfirmed individuals, and four healthy controls without evidence of HAT.">
            <entity id="DS3.d1143.s0.e0" origId="P07196" charOffset="14-27" type="protein" text="neurofilament"/>
            <entity id="DS3.d1143.s0.e1" origId="P07196" charOffset="29-32" type="protein" text="NFL"/>
            <entity id="DS3.d1143.s0.e2" origId="P14136,A7REI1" charOffset="38-69" type="protein" text="glial fibrillary acidic protein"/>
            <entity id="DS3.d1143.s0.e3" origId="P14136,A7REI1" charOffset="71-75" type="protein" text="GFAP"/>
            <entity id="DS3.d1143.s0.e4" origId="16122568,16750043,4369303,448383" charOffset="132-135" type="compound" text="CSF"/>
            <entity id="DS3.d1143.s0.e5" origId="O60235,B4DL57" charOffset="157-186" type="protein" text="human African trypanosomiasis"/>
            <entity id="DS3.d1143.s0.e6" origId="O60235,B4DL57" charOffset="188-191" type="protein" text="HAT"/>
            <entity id="DS3.d1143.s0.e7" origId="O60235,B4DL57" charOffset="315-318" type="protein" text="HAT"/>
            <pair e1="DS3.d1143.s0.e4" e2="DS3.d1143.s0.e3" id="DS3.d1143.s0.i0" interaction="False" />
            <pair e1="DS3.d1143.s0.e4" e2="DS3.d1143.s0.e1" id="DS3.d1143.s0.i1" interaction="False" />
            <pair e1="DS3.d1143.s0.e4" e2="DS3.d1143.s0.e0" id="DS3.d1143.s0.i2" interaction="False" />
            <pair e1="DS3.d1143.s0.e4" e2="DS3.d1143.s0.e2" id="DS3.d1143.s0.i3" interaction="False" />
            <pair e1="DS3.d1143.s0.e4" e2="DS3.d1143.s0.e5" id="DS3.d1143.s0.i4" interaction="False" />
            <pair e1="DS3.d1143.s0.e4" e2="DS3.d1143.s0.e6" id="DS3.d1143.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d1143.s1" origId="9988330-3" text="The astrogliosis observed in HAT and experimental models of HAT is confirmed in our study by the presence of increased GFAP levels in the CSE The abnormal NFL CSF levels reflect structural damage of nerve cells in 33 % of the second-stage patients studied.">
            <entity id="DS3.d1143.s1.e0" origId="O60235,B4DL57" charOffset="29-32" type="protein" text="HAT"/>
            <entity id="DS3.d1143.s1.e1" origId="O60235,B4DL57" charOffset="60-63" type="protein" text="HAT"/>
            <entity id="DS3.d1143.s1.e2" origId="P14136,A7REI1" charOffset="119-123" type="protein" text="GFAP"/>
            <entity id="DS3.d1143.s1.e3" origId="6326983" charOffset="138-141" type="compound" text="CSE"/>
            <entity id="DS3.d1143.s1.e4" origId="P07196" charOffset="155-158" type="protein" text="NFL"/>
            <entity id="DS3.d1143.s1.e5" origId="16122568,16750043,4369303,448383" charOffset="159-162" type="compound" text="CSF"/>
            <pair e1="DS3.d1143.s1.e3" e2="DS3.d1143.s1.e2" id="DS3.d1143.s1.i0" interaction="False" />
            <pair e1="DS3.d1143.s1.e3" e2="DS3.d1143.s1.e4" id="DS3.d1143.s1.i1" interaction="False" />
            <pair e1="DS3.d1143.s1.e3" e2="DS3.d1143.s1.e0" id="DS3.d1143.s1.i2" interaction="False" />
            <pair e1="DS3.d1143.s1.e5" e2="DS3.d1143.s1.e2" id="DS3.d1143.s1.i3" interaction="False" />
            <pair e1="DS3.d1143.s1.e5" e2="DS3.d1143.s1.e4" id="DS3.d1143.s1.i4" interaction="False" />
            <pair e1="DS3.d1143.s1.e5" e2="DS3.d1143.s1.e0" id="DS3.d1143.s1.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d1143.s2" origId="9988330-4" text="To our knowledge, this is the first time neuronal damage in HAT patients is demonstrated by using biochemical markers of brain damage in the CSF.">
            <entity id="DS3.d1143.s2.e0" origId="O60235,B4DL57" charOffset="60-63" type="protein" text="HAT"/>
            <entity id="DS3.d1143.s2.e1" origId="16122568,16750043,4369303,448383" charOffset="141-144" type="compound" text="CSF"/>
            <pair e1="DS3.d1143.s2.e1" e2="DS3.d1143.s2.e0" id="DS3.d1143.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1144" origId="9988331">
        <sentence id="DS3.d1144.s0" origId="9988331-10" text="On the other hand, factor XIII deficiency might reduce protection of the vascular endothelium against HNE and reactive oxygen species, which would promote organ damage.">
            <entity id="DS3.d1144.s0.e0" origId="P08246" charOffset="102-105" type="protein" text="HNE"/>
            <entity id="DS3.d1144.s0.e1" origId="977" charOffset="119-125" type="compound" text="oxygen"/>
            <pair e1="DS3.d1144.s0.e1" e2="DS3.d1144.s0.e0" id="DS3.d1144.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1144.s1" origId="9988331-7" text="The factor X.III levels were inversely correlated with clinical severity, parasitemia, and human neutrophil elastase (HNE), but not with thrombin-antithrombin III levels.">
            <entity id="DS3.d1144.s1.e0" origId="P08246" charOffset="91-116" type="protein" text="human neutrophil elastase"/>
            <entity id="DS3.d1144.s1.e1" origId="P08246" charOffset="118-121" type="protein" text="HNE"/>
            <entity id="DS3.d1144.s1.e2" origId="90470996" charOffset="137-145" type="compound" text="thrombin"/>
            <pair e1="DS3.d1144.s1.e2" e2="DS3.d1144.s1.e0" id="DS3.d1144.s1.i0" interaction="False" />
            <pair e1="DS3.d1144.s1.e2" e2="DS3.d1144.s1.e1" id="DS3.d1144.s1.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1145" origId="9988347">
        <sentence id="DS3.d1145.s0" origId="9988347-1" text="The study assessed immunohistochemically the location and distribution of various non-collagenous matrix proteins (fibronectin, laminin, tenascin-C, osteocalcin, thrombospondin-1, vitronectin and undulin) in musculoskeletal tissues of rat.">
            <entity id="DS3.d1145.s0.e0" origId="F1LST1,A0A096P6L8" charOffset="115-126" type="protein" text="fibronectin"/>
            <entity id="DS3.d1145.s0.e1" origId="44342165" charOffset="128-135" type="compound" text="laminin"/>
            <entity id="DS3.d1145.s0.e2" origId="B2LYI9,A0A0G2K1L0" charOffset="137-147" type="protein" text="tenascin-C"/>
            <entity id="DS3.d1145.s0.e3" origId="Q71SA3" charOffset="162-178" type="protein" text="thrombospondin-1"/>
            <entity id="DS3.d1145.s0.e4" origId="Q3KR94" charOffset="180-191" type="protein" text="vitronectin"/>
            <pair e1="DS3.d1145.s0.e1" e2="DS3.d1145.s0.e3" id="DS3.d1145.s0.i0" interaction="False" />
            <pair e1="DS3.d1145.s0.e1" e2="DS3.d1145.s0.e0" id="DS3.d1145.s0.i1" interaction="False" />
            <pair e1="DS3.d1145.s0.e1" e2="DS3.d1145.s0.e4" id="DS3.d1145.s0.i2" interaction="False" />
            <pair e1="DS3.d1145.s0.e1" e2="DS3.d1145.s0.e2" id="DS3.d1145.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1146" origId="9988349">
        <sentence id="DS3.d1146.s0" origId="9988349-5" text="Binding sites at the apical poles of neuroepithelium of five of these lectins (PNA, LCA, SBA, LPA and GSA-II) disappeared completely during further development.">
            <entity id="DS3.d1146.s0.e0" origId="S4R2V1,Q8C6Q7,S4R1S4,S4R1M0" charOffset="84-87" type="protein" text="LCA"/>
            <entity id="DS3.d1146.s0.e1" origId="C8YR32" charOffset="89-92" type="protein" text="SBA"/>
            <entity id="DS3.d1146.s0.e2" origId="5288473" charOffset="102-105" type="compound" text="GSA"/>
            <pair e1="DS3.d1146.s0.e2" e2="DS3.d1146.s0.e1" id="DS3.d1146.s0.i0" interaction="False" />
            <pair e1="DS3.d1146.s0.e2" e2="DS3.d1146.s0.e0" id="DS3.d1146.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1146.s1" origId="9988349-6" text="The binding sites of four other lectins, WGA, MPA, Con A and BPA, remained expressed during the course of development, being indicative for the carbohydrate side-chains beta-GlcNAc(1-4)Gluc, alpha-Gal(1-3)GalNAc, alpha-D-Man/alpha-D-Gluc and alpha-GalNAc.">
            <entity id="DS3.d1146.s1.e0" origId="Q03001,Q6P0N6,B4DSS9,F8W9J4,E9PHM6,B4DGY0,E9PEB9,F6QMI7" charOffset="51-64" type="protein" text="Con A and BPA"/>
            <entity id="DS3.d1146.s1.e1" origId="11861101,24139,439174,899" charOffset="174-180" type="compound" text="GlcNAc"/>
            <entity id="DS3.d1146.s1.e2" origId="16219440" charOffset="191-200" type="compound" text="alpha-Gal"/>
            <entity id="DS3.d1146.s1.e3" origId="35717" charOffset="205-211" type="compound" text="GalNAc"/>
            <entity id="DS3.d1146.s1.e4" origId="185698" charOffset="213-224" type="compound" text="alpha-D-Man"/>
            <entity id="DS3.d1146.s1.e5" origId="84265" charOffset="242-254" type="compound" text="alpha-GalNAc"/>
            <pair e1="DS3.d1146.s1.e3" e2="DS3.d1146.s1.e0" id="DS3.d1146.s1.i0" interaction="False" />
            <pair e1="DS3.d1146.s1.e2" e2="DS3.d1146.s1.e0" id="DS3.d1146.s1.i1" interaction="False" />
            <pair e1="DS3.d1146.s1.e5" e2="DS3.d1146.s1.e0" id="DS3.d1146.s1.i2" interaction="False" />
            <pair e1="DS3.d1146.s1.e1" e2="DS3.d1146.s1.e0" id="DS3.d1146.s1.i3" interaction="False" />
            <pair e1="DS3.d1146.s1.e4" e2="DS3.d1146.s1.e0" id="DS3.d1146.s1.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1147" origId="9988357">
        <sentence id="DS3.d1147.s0" origId="9988357-6" text="Arterial and mixed venous gas analyses were performed and O2 and CO2 concentrations were calculated, including the carbamate contribute.">
            <entity id="DS3.d1147.s0.e0" origId="P06681,Q8N6L6,B4DQI1,Q5JP69,A0A0G2JL69,Q53HP3,B4DV48" charOffset="65-68" type="protein" text="CO2"/>
            <entity id="DS3.d1147.s0.e1" origId="277" charOffset="115-124" type="compound" text="carbamate"/>
            <pair e1="DS3.d1147.s0.e1" e2="DS3.d1147.s0.e0" id="DS3.d1147.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1148" origId="9988361">
        <sentence id="DS3.d1148.s0" origId="9988361-3" text="Prolactin and cortisol responses to D-fenfluramine challenge, clinical psychobehavioural changes, personality characteristics, including mood, aggressiveness and temperamental aspects, were evaluated 3 weeks after MDMA discontinuation.">
            <entity id="DS3.d1148.s0.e0" origId="P01236,Q5I0G2,Q5THQ0" charOffset="0-9" type="protein" text="Prolactin"/>
            <entity id="DS3.d1148.s0.e1" origId="3337" charOffset="38-50" type="compound" text="fenfluramine"/>
            <pair e1="DS3.d1148.s0.e1" e2="DS3.d1148.s0.e0" id="DS3.d1148.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1148.s1" origId="9988361-7" text="Prolactin responses to D-fenfluramine stimulation area under the curve among MDMA users were negatively correlated with direct aggressiveness scores for Buss Durkee Hostility Inventory; a negative correlation between Prolactin responses and novelty-seeking scores was also evidenced among MDMA users.">
            <entity id="DS3.d1148.s1.e0" origId="P01236,Q5I0G2,Q5THQ0" charOffset="0-9" type="protein" text="Prolactin"/>
            <entity id="DS3.d1148.s1.e1" origId="3337" charOffset="25-37" type="compound" text="fenfluramine"/>
            <entity id="DS3.d1148.s1.e2" origId="P01236,Q5I0G2,Q5THQ0" charOffset="217-226" type="protein" text="Prolactin"/>
            <pair e1="DS3.d1148.s1.e1" e2="DS3.d1148.s1.e0" id="DS3.d1148.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1149" origId="9988364">
        <sentence id="DS3.d1149.s0" origId="9988364-0" text="Neuroendocrine and hypothermic effects of 5-HT1A receptor stimulation with ipsapirone in healthy men: a placebo-controlled study.">
            <entity id="DS3.d1149.s0.e0" origId="P08908,Q5ZGX3,A8K5W4" charOffset="42-57" type="protein" text="5-HT1A receptor"/>
            <entity id="DS3.d1149.s0.e1" origId="56971" charOffset="75-85" type="compound" text="ipsapirone"/>
            <pair e1="DS3.d1149.s0.e1" e2="DS3.d1149.s0.e0" id="DS3.d1149.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1149.s1" origId="9988364-11" text="These results contrast with previous studies, which found no effect of ipsapirone on PRL and GH release in humans, but are in accordance with data using other 5-HT1A agonist drugs.">
            <entity id="DS3.d1149.s1.e0" origId="56971" charOffset="71-81" type="compound" text="ipsapirone"/>
            <entity id="DS3.d1149.s1.e1" origId="P01236,Q5I0G2,Q5THQ0" charOffset="85-88" type="protein" text="PRL"/>
            <entity id="DS3.d1149.s1.e2" origId="P08908,Q5ZGX3,A8K5W4" charOffset="159-165" type="protein" text="5-HT1A"/>
            <pair e1="DS3.d1149.s1.e0" e2="DS3.d1149.s1.e1" id="DS3.d1149.s1.i0" interaction="False" />
            <pair e1="DS3.d1149.s1.e0" e2="DS3.d1149.s1.e2" id="DS3.d1149.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1149.s2" origId="9988364-12" text="The presence of an oxytocin response to ipsapirone suggests that oxytocin is a potential marker for serotonergic function in neuroendocrine challenge studies, but this awaits further study.">
            <entity id="DS3.d1149.s2.e0" origId="P01178,X5D7M6" charOffset="19-27" type="protein" text="oxytocin"/>
            <entity id="DS3.d1149.s2.e1" origId="56971" charOffset="40-50" type="compound" text="ipsapirone"/>
            <entity id="DS3.d1149.s2.e2" origId="P01178,X5D7M6" charOffset="65-73" type="protein" text="oxytocin"/>
            <pair e1="DS3.d1149.s2.e1" e2="DS3.d1149.s2.e0" id="DS3.d1149.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1149.s3" origId="9988364-5" text="We used the 5-HT1A receptor partial agonist ipsapirone (20 mg) as an oral serotonergic challenge drug in a random-order, double-blind placebo-controlled study of 12 healthy men.">
            <entity id="DS3.d1149.s3.e0" origId="P08908,Q5ZGX3,A8K5W4" charOffset="12-27" type="protein" text="5-HT1A receptor"/>
            <entity id="DS3.d1149.s3.e1" origId="56971" charOffset="44-54" type="compound" text="ipsapirone"/>
            <pair e1="DS3.d1149.s3.e1" e2="DS3.d1149.s3.e0" id="DS3.d1149.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1149.s4" origId="9988364-7" text="Ipsapirone caused clear and significant elevations in adrenocorticotrophin (ACTH), cortisol (CORT), prolactin (PRL), and growth hormone (GH) release.">
            <entity id="DS3.d1149.s4.e0" origId="56971" charOffset="0-10" type="compound" text="Ipsapirone"/>
            <entity id="DS3.d1149.s4.e1" origId="O00230,Q8IUV6" charOffset="83-91" type="protein" text="cortisol"/>
            <entity id="DS3.d1149.s4.e2" origId="O00230,Q8IUV6" charOffset="93-97" type="protein" text="CORT"/>
            <entity id="DS3.d1149.s4.e3" origId="P01236,Q5I0G2,Q5THQ0" charOffset="100-109" type="protein" text="prolactin"/>
            <entity id="DS3.d1149.s4.e4" origId="P01236,Q5I0G2,Q5THQ0" charOffset="111-114" type="protein" text="PRL"/>
            <entity id="DS3.d1149.s4.e5" origId="P01241,B1A4G6,B1A4G7" charOffset="121-135" type="protein" text="growth hormone"/>
            <pair e1="DS3.d1149.s4.e0" e2="DS3.d1149.s4.e2" id="DS3.d1149.s4.i0" interaction="False" />
            <pair e1="DS3.d1149.s4.e0" e2="DS3.d1149.s4.e3" id="DS3.d1149.s4.i1" interaction="False" />
            <pair e1="DS3.d1149.s4.e0" e2="DS3.d1149.s4.e5" id="DS3.d1149.s4.i2" interaction="False" />
            <pair e1="DS3.d1149.s4.e0" e2="DS3.d1149.s4.e1" id="DS3.d1149.s4.i3" interaction="False" />
            <pair e1="DS3.d1149.s4.e0" e2="DS3.d1149.s4.e4" id="DS3.d1149.s4.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1150" origId="9988368">
        <sentence id="DS3.d1150.s0" origId="9988368-11" text="Unexpectedly, paraoxon levels occasionally reincreased during treatment and resulted in re-inhibition of AChE, bearing some resemblance to the Intermediate Syndrome.">
            <entity id="DS3.d1150.s0.e0" origId="9395" charOffset="14-22" type="compound" text="paraoxon"/>
            <entity id="DS3.d1150.s0.e1" origId="P22303" charOffset="105-109" type="protein" text="AChE"/>
            <pair e1="DS3.d1150.s0.e0" e2="DS3.d1150.s0.e1" id="DS3.d1150.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1150.s1" origId="9988368-13" text="The paraoxon concentrations measured fitted satisfactorily the values calculated from the kinetic constants previously obtained for AChE inhibition and obidoxime-induced reactivation in vitro.">
            <entity id="DS3.d1150.s1.e0" origId="9395" charOffset="4-12" type="compound" text="paraoxon"/>
            <entity id="DS3.d1150.s1.e1" origId="P22303" charOffset="132-136" type="protein" text="AChE"/>
            <entity id="DS3.d1150.s1.e2" origId="107688" charOffset="152-161" type="compound" text="obidoxime"/>
            <pair e1="DS3.d1150.s1.e2" e2="DS3.d1150.s1.e1" id="DS3.d1150.s1.i0" interaction="False" />
            <pair e1="DS3.d1150.s1.e0" e2="DS3.d1150.s1.e1" id="DS3.d1150.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1150.s2" origId="9988368-14" text="This indicates that diethylphosphoryloxime formation during obidoxime-induced reactivation does not markedly contribute to the re-inhibition of AChE as observed in vitro.">
            <entity id="DS3.d1150.s2.e0" origId="90835160" charOffset="20-42" type="compound" text="diethylphosphoryloxime"/>
            <entity id="DS3.d1150.s2.e1" origId="107688" charOffset="60-69" type="compound" text="obidoxime"/>
            <entity id="DS3.d1150.s2.e2" origId="P22303" charOffset="144-148" type="protein" text="AChE"/>
            <pair e1="DS3.d1150.s2.e1" e2="DS3.d1150.s2.e2" id="DS3.d1150.s2.i0" interaction="False" />
            <pair e1="DS3.d1150.s2.e0" e2="DS3.d1150.s2.e2" id="DS3.d1150.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1150.s3" origId="9988368-2" text="Paraoxon concentration was estimated by means of inhibition kinetics observed with electric eel acetylcholinesterase (AChE) which was determined by a modified Ellman procedure.">
            <entity id="DS3.d1150.s3.e0" origId="9395" charOffset="0-8" type="compound" text="Paraoxon"/>
            <entity id="DS3.d1150.s3.e1" origId="P22303" charOffset="96-122" type="protein" text="acetylcholinesterase (AChE"/>
            <pair e1="DS3.d1150.s3.e0" e2="DS3.d1150.s3.e1" id="DS3.d1150.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1150.s4" origId="9988368-9" text="In poisoning with excessive doses and initial paraoxon concentrations above 500 nM, therapeutic obidoxime concentrations of approximately 10 microM failed to essentially reactivate erythrocyte AChE in vivo, while reactivatability ex vivo was nearly complete.">
            <entity id="DS3.d1150.s4.e0" origId="9395" charOffset="46-54" type="compound" text="paraoxon"/>
            <entity id="DS3.d1150.s4.e1" origId="107688" charOffset="96-105" type="compound" text="obidoxime"/>
            <entity id="DS3.d1150.s4.e2" origId="P22303" charOffset="193-197" type="protein" text="AChE"/>
            <pair e1="DS3.d1150.s4.e1" e2="DS3.d1150.s4.e2" id="DS3.d1150.s4.i0" interaction="False" />
            <pair e1="DS3.d1150.s4.e0" e2="DS3.d1150.s4.e2" id="DS3.d1150.s4.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1151" origId="9988374">
        <sentence id="DS3.d1151.s0" origId="9988374-1" text="A mechanistically based cytodynamic two-stage (CD2) cancer model was shown recently to predict both ecologic US county data and underground-miner data on lung-cancer mortality (LCM) vs radon concentration, indicating biological plausibility of the apparent negative dose-response relation exhibited by the ecologic data.">
            <entity id="DS3.d1151.s0.e0" origId="P06729,Q53F96" charOffset="47-50" type="protein" text="CD2"/>
            <entity id="DS3.d1151.s0.e1" origId="24857" charOffset="185-190" type="compound" text="radon"/>
            <pair e1="DS3.d1151.s0.e1" e2="DS3.d1151.s0.e0" id="DS3.d1151.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1151.s1" origId="9988374-2" text="To further investigate this hypothesis, the CD2 model was fitted to combine age-specific LCM data vs estimated radon-exposure in white females of age 40+ years in 2821 US counties during 1950-1954 using new estimates of county-specific mean residential radon exposure, and in five cohorts of underground nonsmoking miners.">
            <entity id="DS3.d1151.s1.e0" origId="P06729,Q53F96" charOffset="44-47" type="protein" text="CD2"/>
            <entity id="DS3.d1151.s1.e1" origId="24857" charOffset="111-116" type="compound" text="radon"/>
            <entity id="DS3.d1151.s1.e2" origId="24857" charOffset="253-258" type="compound" text="radon"/>
            <pair e1="DS3.d1151.s1.e1" e2="DS3.d1151.s1.e0" id="DS3.d1151.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1152" origId="9988392">
        <sentence id="DS3.d1152.s0" origId="9988392-6" text="MAIN OUTCOME MEASURE(S): Serum testosterone levels, testicular volume, penis length, and sperm count were evaluated after the administration of hCG and FSH.">
            <entity id="DS3.d1152.s0.e0" origId="6013" charOffset="31-43" type="compound" text="testosterone"/>
            <entity id="DS3.d1152.s0.e1" origId="P01215,Q6I9S8,A0A087WYZ4" charOffset="144-147" type="protein" text="hCG"/>
            <entity id="DS3.d1152.s0.e2" origId="P25440,X5CF57,A0A024RCR5" charOffset="152-155" type="protein" text="FSH"/>
            <pair e1="DS3.d1152.s0.e0" e2="DS3.d1152.s0.e2" id="DS3.d1152.s0.i0" interaction="False" />
            <pair e1="DS3.d1152.s0.e0" e2="DS3.d1152.s0.e1" id="DS3.d1152.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1153" origId="9988395">
        <sentence id="DS3.d1153.s0" origId="9988395-0" text="Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels.">
            <entity id="DS3.d1153.s0.e0" origId="5757" charOffset="43-52" type="compound" text="estradiol"/>
            <entity id="DS3.d1153.s0.e1" origId="P01241,B1A4G6,B1A4G7" charOffset="85-99" type="protein" text="growth hormone"/>
            <entity id="DS3.d1153.s0.e2" origId="P01241,B1A4G6,B1A4G7" charOffset="135-149" type="protein" text="growth hormone"/>
            <entity id="DS3.d1153.s0.e3" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="151-179" type="protein" text="insulin-like growth factor-1"/>
            <entity id="DS3.d1153.s0.e4" origId="P17936,B3KPF0" charOffset="239-246" type="protein" text="IGFBP-3"/>
            <pair e1="DS3.d1153.s0.e0" e2="DS3.d1153.s0.e3" id="DS3.d1153.s0.i0" interaction="False" />
            <pair e1="DS3.d1153.s0.e0" e2="DS3.d1153.s0.e4" id="DS3.d1153.s0.i1" interaction="False" />
            <pair e1="DS3.d1153.s0.e0" e2="DS3.d1153.s0.e1" id="DS3.d1153.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1153.s1" origId="9988395-13" text="CONCLUSION(S): The administration of oral, but not transdermal, E2 plus medroxyprogesterone acetate at the usual clinical doses used in postmenopausal women decreased IGF-1 levels and the response of GH to GHRH in older women.">
            <entity id="DS3.d1153.s1.e0" origId="6279" charOffset="72-99" type="compound" text="medroxyprogesterone acetate"/>
            <entity id="DS3.d1153.s1.e1" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="167-172" type="protein" text="IGF-1"/>
            <entity id="DS3.d1153.s1.e2" origId="P01286" charOffset="206-210" type="protein" text="GHRH"/>
            <pair e1="DS3.d1153.s1.e0" e2="DS3.d1153.s1.e2" id="DS3.d1153.s1.i0" interaction="False" />
            <pair e1="DS3.d1153.s1.e0" e2="DS3.d1153.s1.e1" id="DS3.d1153.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1153.s2" origId="9988395-1" text="OBJECTIVE: To determine the effects of menopause and three different formulations of E2 plus medroxyprogesterone acetate on serum concentrations of basal and growth hormone-releasing hormone (GHRH)-stimulated growth hormone (GH), insulin-like growth factor-1 (IGF-1), insulin-like growth factor binding protein (IGFBP)-1, IGFBP-3, insulin, and C peptide.">
            <entity id="DS3.d1153.s2.e0" origId="6279" charOffset="93-120" type="compound" text="medroxyprogesterone acetate"/>
            <entity id="DS3.d1153.s2.e1" origId="P01241,B1A4G6,B1A4G7" charOffset="158-172" type="protein" text="growth hormone"/>
            <entity id="DS3.d1153.s2.e2" origId="P01286" charOffset="192-196" type="protein" text="GHRH"/>
            <entity id="DS3.d1153.s2.e3" origId="P01241,B1A4G6,B1A4G7" charOffset="209-223" type="protein" text="growth hormone"/>
            <entity id="DS3.d1153.s2.e4" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="230-258" type="protein" text="insulin-like growth factor-1"/>
            <entity id="DS3.d1153.s2.e5" origId="P05019,Q5U743,Q13429,Q59GC5" charOffset="260-265" type="protein" text="IGF-1"/>
            <entity id="DS3.d1153.s2.e6" origId="P17936,B3KPF0" charOffset="322-329" type="protein" text="IGFBP-3"/>
            <pair e1="DS3.d1153.s2.e0" e2="DS3.d1153.s2.e4" id="DS3.d1153.s2.i0" interaction="False" />
            <pair e1="DS3.d1153.s2.e0" e2="DS3.d1153.s2.e2" id="DS3.d1153.s2.i1" interaction="False" />
            <pair e1="DS3.d1153.s2.e0" e2="DS3.d1153.s2.e6" id="DS3.d1153.s2.i2" interaction="False" />
            <pair e1="DS3.d1153.s2.e0" e2="DS3.d1153.s2.e5" id="DS3.d1153.s2.i3" interaction="False" />
            <pair e1="DS3.d1153.s2.e0" e2="DS3.d1153.s2.e1" id="DS3.d1153.s2.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1154" origId="9988396">
        <sentence id="DS3.d1154.s0" origId="9988396-6" text="MAIN OUTCOME MEASURE(S): Anthropometry and serum concentrations of glucose, insulin, free T, DHEAS, androstenedione, E2, and sex hormone-binding globulin (SHBG) at fasting, 60 minutes, and 120 minutes after oral glucose loading.">
            <entity id="DS3.d1154.s0.e0" origId="206,5793,64689,79025" charOffset="67-74" type="compound" text="glucose"/>
            <entity id="DS3.d1154.s0.e1" origId="Q06520,A8K015" charOffset="93-98" type="protein" text="DHEAS"/>
            <entity id="DS3.d1154.s0.e2" origId="6128" charOffset="100-115" type="compound" text="androstenedione"/>
            <entity id="DS3.d1154.s0.e3" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="125-153" type="protein" text="sex hormone-binding globulin"/>
            <entity id="DS3.d1154.s0.e4" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="155-159" type="protein" text="SHBG"/>
            <entity id="DS3.d1154.s0.e5" origId="206,5793,64689,79025" charOffset="212-219" type="compound" text="glucose"/>
            <pair e1="DS3.d1154.s0.e2" e2="DS3.d1154.s0.e1" id="DS3.d1154.s0.i0" interaction="False" />
            <pair e1="DS3.d1154.s0.e2" e2="DS3.d1154.s0.e4" id="DS3.d1154.s0.i1" interaction="False" />
            <pair e1="DS3.d1154.s0.e2" e2="DS3.d1154.s0.e3" id="DS3.d1154.s0.i2" interaction="False" />
            <pair e1="DS3.d1154.s0.e0" e2="DS3.d1154.s0.e1" id="DS3.d1154.s0.i3" interaction="False" />
            <pair e1="DS3.d1154.s0.e0" e2="DS3.d1154.s0.e4" id="DS3.d1154.s0.i4" interaction="False" />
            <pair e1="DS3.d1154.s0.e0" e2="DS3.d1154.s0.e3" id="DS3.d1154.s0.i5" interaction="False" />
        </sentence>
        <sentence id="DS3.d1154.s1" origId="9988396-9" text="Increased body mass index and more pronounced abdominal fat localization resulted in basal hyperinsulinemia, markedly exaggerated glucose-induced insulin levels, and hyperandrogenism, as was evident by significantly elevated free T and low SHBG serum levels.">
            <entity id="DS3.d1154.s1.e0" origId="206,5793,64689,79025" charOffset="130-137" type="compound" text="glucose"/>
            <entity id="DS3.d1154.s1.e1" origId="P04278,B0FWH2,I3L145,B4DYU0,B0FWH8" charOffset="240-244" type="protein" text="SHBG"/>
            <pair e1="DS3.d1154.s1.e0" e2="DS3.d1154.s1.e1" id="DS3.d1154.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1155" origId="9988405">
        <sentence id="DS3.d1155.s0" origId="9988405-6" text="The following tests also were carried out: vaginal ultrasound examination; measurement of the ovarian response of 17-hydroxyprogesterone (17-OHP) after the administration of leuprolide acetate, 1 mg SC; and determination of fasting serum LH, FSH, E2, 17-OHP, insulin, and androgen levels.">
            <entity id="DS3.d1155.s0.e0" origId="657181" charOffset="174-192" type="compound" text="leuprolide acetate"/>
            <entity id="DS3.d1155.s0.e1" origId="P25440,X5CF57,A0A024RCR5" charOffset="242-245" type="protein" text="FSH"/>
            <pair e1="DS3.d1155.s0.e0" e2="DS3.d1155.s0.e1" id="DS3.d1155.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1156" origId="9988429">
        <sentence id="DS3.d1156.s0" origId="9988429-4" text="Histamine has been shown to increase the adhesion of leucocytes to the endothelium and to stimulate production of IL-6 and IL-8 by endothelial cells.">
            <entity id="DS3.d1156.s0.e0" origId="774" charOffset="0-9" type="compound" text="Histamine"/>
            <entity id="DS3.d1156.s0.e1" origId="P05231,Q75MH2,B5MC21,B4DNQ5,B4DVM1" charOffset="114-118" type="protein" text="IL-6"/>
            <entity id="DS3.d1156.s0.e2" origId="P10145,A0A024RDA5" charOffset="123-127" type="protein" text="IL-8"/>
            <pair e1="DS3.d1156.s0.e0" e2="DS3.d1156.s0.e1" id="DS3.d1156.s0.i0" interaction="False" />
            <pair e1="DS3.d1156.s0.e0" e2="DS3.d1156.s0.e2" id="DS3.d1156.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1157" origId="9988463">
        <sentence id="DS3.d1157.s0" origId="9988463-6" text="Leukotriene A4 subsequently becomes a substrate for one of two enzymes, leukotriene A4 epoxide hydrolase or LTC4 synthase.">
            <entity id="DS3.d1157.s0.e0" origId="5280383" charOffset="0-14" type="compound" text="Leukotriene A4"/>
            <entity id="DS3.d1157.s0.e1" origId="5280383" charOffset="72-86" type="compound" text="leukotriene A4"/>
            <entity id="DS3.d1157.s0.e2" origId="Q16873" charOffset="108-121" type="protein" text="LTC4 synthase"/>
            <pair e1="DS3.d1157.s0.e0" e2="DS3.d1157.s0.e2" id="DS3.d1157.s0.i0" interaction="False" />
            <pair e1="DS3.d1157.s0.e1" e2="DS3.d1157.s0.e2" id="DS3.d1157.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1158" origId="9988477">
        <sentence id="DS3.d1158.s0" origId="9988477-0" text="Identification of a 47 kDa fibronectin-binding protein expressed by Borrelia burgdorferi isolate B31.">
            <entity id="DS3.d1158.s0.e0" origId="O50835" charOffset="27-54" type="protein" text="fibronectin-binding protein"/>
            <entity id="DS3.d1158.s0.e1" origId="12302171" charOffset="97-100" type="compound" text="B31"/>
            <pair e1="DS3.d1158.s0.e1" e2="DS3.d1158.s0.e0" id="DS3.d1158.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1158.s1" origId="9988477-5" text="Borrelia burgdorferi isolate B31 expressed a 47 kDa (P47) fibronectin-binding protein that was localized to the outer envelope based on susceptibility to proteinase K. The interaction of P47 with fibronectin was specific, and the region of fibronectin bound by P47 mapped to the gelatin/collagen binding domain.">
            <entity id="DS3.d1158.s1.e0" origId="12302171" charOffset="29-32" type="compound" text="B31"/>
            <entity id="DS3.d1158.s1.e1" origId="O50835" charOffset="58-85" type="protein" text="fibronectin-binding protein"/>
            <pair e1="DS3.d1158.s1.e0" e2="DS3.d1158.s1.e1" id="DS3.d1158.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1158.s2" origId="9988477-7" text="A search of protein databases disclosed that the P47 peptide mass profile matched that predicted for the bbk32 gene product of B. burgdorferi isolate B31.">
            <entity id="DS3.d1158.s2.e0" origId="O50835" charOffset="105-110" type="protein" text="bbk32"/>
            <entity id="DS3.d1158.s2.e1" origId="12302171" charOffset="150-153" type="compound" text="B31"/>
            <pair e1="DS3.d1158.s2.e1" e2="DS3.d1158.s2.e0" id="DS3.d1158.s2.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1159" origId="9988481">
        <sentence id="DS3.d1159.s0" origId="9988481-1" text="The YopM virulence protein of Yersinia pestis has been described as binding human alpha-thrombin and inhibiting thrombin-induced platelet aggregation in vitro.">
            <entity id="DS3.d1159.s0.e0" origId="P17778" charOffset="4-8" type="protein" text="YopM"/>
            <entity id="DS3.d1159.s0.e1" origId="90470996" charOffset="88-96" type="compound" text="thrombin"/>
            <entity id="DS3.d1159.s0.e2" origId="90470996" charOffset="112-120" type="compound" text="thrombin"/>
            <pair e1="DS3.d1159.s0.e1" e2="DS3.d1159.s0.e0" id="DS3.d1159.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1159.s1" origId="9988481-7" text="Immunofluorescence localization revealed that YopM, in contrast to YopE, is not only targeted to the cytoplasm but also trafficks to the cell's nucleus by means of a vesicle-associated pathway that is strongly inhibited by brefeldin A, perturbed by monensin or bafilomycin A1 and dependent upon microtubules (decreased by colchicine and nocodazole).">
            <entity id="DS3.d1159.s1.e0" origId="P17778" charOffset="46-50" type="protein" text="YopM"/>
            <entity id="DS3.d1159.s1.e1" origId="2430,5351204,5353446,24123450,71308166,6436187,6364669" charOffset="223-234" type="compound" text="brefeldin A"/>
            <entity id="DS3.d1159.s1.e2" origId="12912923,28263,4243,441145" charOffset="249-257" type="compound" text="monensin"/>
            <entity id="DS3.d1159.s1.e3" origId="2287,53321987,5385089,5458921,5702538,90479784,90656913,6436223" charOffset="261-275" type="compound" text="bafilomycin A1"/>
            <entity id="DS3.d1159.s1.e4" origId="6167" charOffset="322-332" type="compound" text="colchicine"/>
            <entity id="DS3.d1159.s1.e5" origId="4122" charOffset="337-347" type="compound" text="nocodazole"/>
            <pair e1="DS3.d1159.s1.e1" e2="DS3.d1159.s1.e0" id="DS3.d1159.s1.i0" interaction="False" />
            <pair e1="DS3.d1159.s1.e2" e2="DS3.d1159.s1.e0" id="DS3.d1159.s1.i1" interaction="False" />
            <pair e1="DS3.d1159.s1.e5" e2="DS3.d1159.s1.e0" id="DS3.d1159.s1.i2" interaction="False" />
            <pair e1="DS3.d1159.s1.e4" e2="DS3.d1159.s1.e0" id="DS3.d1159.s1.i3" interaction="False" />
            <pair e1="DS3.d1159.s1.e3" e2="DS3.d1159.s1.e0" id="DS3.d1159.s1.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1160" origId="9988527">
        <sentence id="DS3.d1160.s0" origId="9988527-3" text="The peptide containing the sequence Phe-Ser-Trp-Ser-Asp-Trp-Trp-Ser (residues 388-395 in lipoprotein lipase, which include the consensus TSP type I sequence) showed strong binding to heparin.">
            <entity id="DS3.d1160.s0.e0" origId="193508" charOffset="36-43" type="compound" text="Phe-Ser"/>
            <entity id="DS3.d1160.s0.e1" origId="5951" charOffset="40-43" type="compound" text="Ser"/>
            <entity id="DS3.d1160.s0.e2" origId="7020001" charOffset="52-59" type="compound" text="Asp-Trp"/>
            <entity id="DS3.d1160.s0.e3" origId="5951" charOffset="48-51" type="compound" text="Ser"/>
            <entity id="DS3.d1160.s0.e4" origId="P06858" charOffset="89-107" type="protein" text="lipoprotein lipase"/>
            <entity id="DS3.d1160.s0.e5" origId="P07996" charOffset="137-140" type="protein" text="TSP"/>
            <pair e1="DS3.d1160.s0.e0" e2="DS3.d1160.s0.e5" id="DS3.d1160.s0.i0" interaction="False" />
            <pair e1="DS3.d1160.s0.e0" e2="DS3.d1160.s0.e4" id="DS3.d1160.s0.i1" interaction="False" />
            <pair e1="DS3.d1160.s0.e1" e2="DS3.d1160.s0.e5" id="DS3.d1160.s0.i2" interaction="False" />
            <pair e1="DS3.d1160.s0.e1" e2="DS3.d1160.s0.e4" id="DS3.d1160.s0.i3" interaction="False" />
            <pair e1="DS3.d1160.s0.e2" e2="DS3.d1160.s0.e5" id="DS3.d1160.s0.i4" interaction="False" />
            <pair e1="DS3.d1160.s0.e2" e2="DS3.d1160.s0.e4" id="DS3.d1160.s0.i5" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1161" origId="9988528">
        <sentence id="DS3.d1161.s0" origId="9988528-0" text="Amino acid sequence, spectral, oxygen-binding, and autoxidation properties of indoleamine dioxygenase-like myoglobin from the gastropod mollusc Turbo cornutus.">
            <entity id="DS3.d1161.s0.e0" origId="977" charOffset="31-37" type="compound" text="oxygen"/>
            <entity id="DS3.d1161.s0.e1" origId="P02144" charOffset="107-116" type="protein" text="myoglobin"/>
            <pair e1="DS3.d1161.s0.e0" e2="DS3.d1161.s0.e1" id="DS3.d1161.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1161.s1" origId="9988528-11" text="We suggest that a noncatalytic binding site for tryptophan, in which several dissociation groups with pKa &amp;gt; or = 7.6 are involved, remains in Turbo myoglobin as a relic of molecular evolution.">
            <entity id="DS3.d1161.s1.e0" origId="57175189,6305" charOffset="48-58" type="compound" text="tryptophan"/>
            <entity id="DS3.d1161.s1.e1" origId="P02144" charOffset="151-160" type="protein" text="myoglobin"/>
            <pair e1="DS3.d1161.s1.e0" e2="DS3.d1161.s1.e1" id="DS3.d1161.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1161.s2" origId="9988528-4" text="The amino acid sequence of Turbo myoglobin showed no significant homology with any other usual 16-kDa globins, but showed 36% identity with the myoglobin from Sulculus diversicolor (Haliotiidae) and 27% identity with human indoleamine 2,3-dioxygenase, a tryptophan-degrading enzyme containing heme.">
            <entity id="DS3.d1161.s2.e0" origId="P02144" charOffset="33-42" type="protein" text="myoglobin"/>
            <entity id="DS3.d1161.s2.e1" origId="P02144" charOffset="144-153" type="protein" text="myoglobin"/>
            <entity id="DS3.d1161.s2.e2" origId="57175189,6305" charOffset="254-264" type="compound" text="tryptophan"/>
            <entity id="DS3.d1161.s2.e3" origId="4971" charOffset="293-297" type="compound" text="heme"/>
            <pair e1="DS3.d1161.s2.e2" e2="DS3.d1161.s2.e0" id="DS3.d1161.s2.i0" interaction="False" />
            <pair e1="DS3.d1161.s2.e3" e2="DS3.d1161.s2.e0" id="DS3.d1161.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1161.s3" origId="9988528-6" text="The absorbance ratio of gamma to CT maximum (gamma/CT) of Turbo metmyoglobin was 17.8, indicating that this myoglobin probably possesses a histidine residue near the sixth coordination position of heme iron.">
            <entity id="DS3.d1161.s3.e0" origId="P02144" charOffset="67-76" type="protein" text="myoglobin"/>
            <entity id="DS3.d1161.s3.e1" origId="6274" charOffset="139-148" type="compound" text="histidine"/>
            <entity id="DS3.d1161.s3.e2" origId="4971" charOffset="197-201" type="compound" text="heme"/>
            <entity id="DS3.d1161.s3.e3" origId="23925,67172434" charOffset="202-206" type="compound" text="iron"/>
            <pair e1="DS3.d1161.s3.e3" e2="DS3.d1161.s3.e0" id="DS3.d1161.s3.i0" interaction="False" />
            <pair e1="DS3.d1161.s3.e1" e2="DS3.d1161.s3.e0" id="DS3.d1161.s3.i1" interaction="False" />
            <pair e1="DS3.d1161.s3.e2" e2="DS3.d1161.s3.e0" id="DS3.d1161.s3.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1161.s4" origId="9988528-7" text="The Turbo myoglobin binds oxygen reversibly.">
            <entity id="DS3.d1161.s4.e0" origId="P02144" charOffset="10-19" type="protein" text="myoglobin"/>
            <entity id="DS3.d1161.s4.e1" origId="977" charOffset="26-32" type="compound" text="oxygen"/>
            <pair e1="DS3.d1161.s4.e1" e2="DS3.d1161.s4.e0" id="DS3.d1161.s4.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1161.s5" origId="9988528-8" text="Its oxygen equilibrium properties are similar to those of Sulculus myoglobin, giving P50 = 3.5 mm Hg at pH 7.4 and 20 degrees C. The pH dependence of autoxidation of Turbo oxymyoglobin was quite different from that of mammalian myoglobin, suggesting a unique protein folding around the heme cavity of Turbo myoglobin.">
            <entity id="DS3.d1161.s5.e0" origId="977" charOffset="4-10" type="compound" text="oxygen"/>
            <entity id="DS3.d1161.s5.e1" origId="P02144" charOffset="67-76" type="protein" text="myoglobin"/>
            <entity id="DS3.d1161.s5.e2" origId="P25942,Q6P2H9" charOffset="85-88" type="protein" text="P50"/>
            <entity id="DS3.d1161.s5.e3" origId="P02144" charOffset="175-184" type="protein" text="myoglobin"/>
            <entity id="DS3.d1161.s5.e4" origId="4971" charOffset="286-290" type="compound" text="heme"/>
            <entity id="DS3.d1161.s5.e5" origId="P02144" charOffset="175-184" type="protein" text="myoglobin"/>
            <pair e1="DS3.d1161.s5.e0" e2="DS3.d1161.s5.e2" id="DS3.d1161.s5.i0" interaction="False" />
            <pair e1="DS3.d1161.s5.e0" e2="DS3.d1161.s5.e1" id="DS3.d1161.s5.i1" interaction="False" />
            <pair e1="DS3.d1161.s5.e4" e2="DS3.d1161.s5.e2" id="DS3.d1161.s5.i2" interaction="False" />
            <pair e1="DS3.d1161.s5.e4" e2="DS3.d1161.s5.e1" id="DS3.d1161.s5.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1162" origId="9988537">
        <sentence id="DS3.d1162.s0" origId="9988537-9" text="A remarkable finding in the uninvolved skin of patients treated with liarozole or acitretin was the distinct focal expression of SKALP in the granular layer and the expression of E-FABP in the spinous layers, which is not found in normal human skin.">
            <entity id="DS3.d1162.s0.e0" origId="60652" charOffset="69-78" type="compound" text="liarozole"/>
            <entity id="DS3.d1162.s0.e1" origId="5284513" charOffset="82-91" type="compound" text="acitretin"/>
            <entity id="DS3.d1162.s0.e2" origId="P19957" charOffset="129-134" type="protein" text="SKALP"/>
            <entity id="DS3.d1162.s0.e3" origId="Q01469,E7DVW5" charOffset="179-185" type="protein" text="E-FABP"/>
            <pair e1="DS3.d1162.s0.e1" e2="DS3.d1162.s0.e3" id="DS3.d1162.s0.i0" interaction="False" />
            <pair e1="DS3.d1162.s0.e1" e2="DS3.d1162.s0.e2" id="DS3.d1162.s0.i1" interaction="False" />
            <pair e1="DS3.d1162.s0.e0" e2="DS3.d1162.s0.e3" id="DS3.d1162.s0.i2" interaction="False" />
            <pair e1="DS3.d1162.s0.e0" e2="DS3.d1162.s0.e2" id="DS3.d1162.s0.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1163" origId="9988561">
        <sentence id="DS3.d1163.s0" origId="9988561-10" text="Tolbutamide (300 microM) antagonized the effects of diazoxide (300 but not 30 microM aggravated the decline of ATP, UTP and CTP to 51.8, 37.5 and 28.5% of the contents observed at normoxia; GTP levels also showed a tendency to decrease after diazoxide application.">
            <entity id="DS3.d1163.s0.e0" origId="5505" charOffset="0-11" type="compound" text="Tolbutamide"/>
            <entity id="DS3.d1163.s0.e1" origId="3019" charOffset="52-61" type="compound" text="diazoxide"/>
            <entity id="DS3.d1163.s0.e2" origId="5957" charOffset="111-114" type="compound" text="ATP"/>
            <entity id="DS3.d1163.s0.e3" origId="6133" charOffset="116-119" type="compound" text="UTP"/>
            <entity id="DS3.d1163.s0.e4" origId="P53007,B4DP62,D9HTE9" charOffset="124-127" type="protein" text="CTP"/>
            <entity id="DS3.d1163.s0.e5" origId="6830" charOffset="190-193" type="compound" text="GTP"/>
            <entity id="DS3.d1163.s0.e6" origId="3019" charOffset="242-251" type="compound" text="diazoxide"/>
            <pair e1="DS3.d1163.s0.e5" e2="DS3.d1163.s0.e4" id="DS3.d1163.s0.i0" interaction="False" />
            <pair e1="DS3.d1163.s0.e3" e2="DS3.d1163.s0.e4" id="DS3.d1163.s0.i1" interaction="False" />
            <pair e1="DS3.d1163.s0.e0" e2="DS3.d1163.s0.e4" id="DS3.d1163.s0.i2" interaction="False" />
            <pair e1="DS3.d1163.s0.e2" e2="DS3.d1163.s0.e4" id="DS3.d1163.s0.i3" interaction="False" />
            <pair e1="DS3.d1163.s0.e1" e2="DS3.d1163.s0.e4" id="DS3.d1163.s0.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d1163.s1" origId="9988561-3" text="In addition, the effects of the KATP channel activator diazoxide and its antagonist tolbutamide were investigated on ATP, GTP, CTP and UTP levels in slices of the parietal cortex.">
            <entity id="DS3.d1163.s1.e0" origId="3019" charOffset="55-64" type="compound" text="diazoxide"/>
            <entity id="DS3.d1163.s1.e1" origId="5505" charOffset="84-95" type="compound" text="tolbutamide"/>
            <entity id="DS3.d1163.s1.e2" origId="5957" charOffset="33-36" type="compound" text="ATP"/>
            <entity id="DS3.d1163.s1.e3" origId="6830" charOffset="122-125" type="compound" text="GTP"/>
            <entity id="DS3.d1163.s1.e4" origId="P53007,B4DP62,D9HTE9" charOffset="127-130" type="protein" text="CTP"/>
            <entity id="DS3.d1163.s1.e5" origId="6133" charOffset="135-138" type="compound" text="UTP"/>
            <pair e1="DS3.d1163.s1.e3" e2="DS3.d1163.s1.e4" id="DS3.d1163.s1.i0" interaction="False" />
            <pair e1="DS3.d1163.s1.e5" e2="DS3.d1163.s1.e4" id="DS3.d1163.s1.i1" interaction="False" />
            <pair e1="DS3.d1163.s1.e1" e2="DS3.d1163.s1.e4" id="DS3.d1163.s1.i2" interaction="False" />
            <pair e1="DS3.d1163.s1.e2" e2="DS3.d1163.s1.e4" id="DS3.d1163.s1.i3" interaction="False" />
            <pair e1="DS3.d1163.s1.e0" e2="DS3.d1163.s1.e4" id="DS3.d1163.s1.i4" interaction="False" />
        </sentence>
        <sentence id="DS3.d1163.s2" origId="9988561-8" text="UTP and CTP contents were even more decreased (to 60.9 and 41.6%),, probably because the salvage pathway of these pyrimidine nucleotides is less effective than that of the purine nucleotides ATP and GTP.">
            <entity id="DS3.d1163.s2.e0" origId="6133" charOffset="0-3" type="compound" text="UTP"/>
            <entity id="DS3.d1163.s2.e1" origId="P53007,B4DP62,D9HTE9" charOffset="8-11" type="protein" text="CTP"/>
            <entity id="DS3.d1163.s2.e2" origId="5957" charOffset="191-194" type="compound" text="ATP"/>
            <entity id="DS3.d1163.s2.e3" origId="6830" charOffset="199-202" type="compound" text="GTP"/>
            <pair e1="DS3.d1163.s2.e3" e2="DS3.d1163.s2.e1" id="DS3.d1163.s2.i0" interaction="False" />
            <pair e1="DS3.d1163.s2.e0" e2="DS3.d1163.s2.e1" id="DS3.d1163.s2.i1" interaction="False" />
            <pair e1="DS3.d1163.s2.e2" e2="DS3.d1163.s2.e1" id="DS3.d1163.s2.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1163.s3" origId="9988561-9" text="While tolbutamide (30 microM) had no effect on the hypoxia-induced decrease of nucleotides, diazoxide at 300, but not 30 microM aggravated the decline of ATP, UTP and CTP to 51.8, 37.5 and 28.5% of the contents observed at normoxia; GTP levels also showed a tendency to decrease after diazoxide application.">
            <entity id="DS3.d1163.s3.e0" origId="5505" charOffset="6-17" type="compound" text="tolbutamide"/>
            <entity id="DS3.d1163.s3.e1" origId="3019" charOffset="92-101" type="compound" text="diazoxide"/>
            <entity id="DS3.d1163.s3.e2" origId="5957" charOffset="154-157" type="compound" text="ATP"/>
            <entity id="DS3.d1163.s3.e3" origId="6133" charOffset="159-162" type="compound" text="UTP"/>
            <entity id="DS3.d1163.s3.e4" origId="P53007,B4DP62,D9HTE9" charOffset="167-170" type="protein" text="CTP"/>
            <entity id="DS3.d1163.s3.e5" origId="6830" charOffset="233-236" type="compound" text="GTP"/>
            <entity id="DS3.d1163.s3.e6" origId="3019" charOffset="285-294" type="compound" text="diazoxide"/>
            <pair e1="DS3.d1163.s3.e5" e2="DS3.d1163.s3.e4" id="DS3.d1163.s3.i0" interaction="False" />
            <pair e1="DS3.d1163.s3.e3" e2="DS3.d1163.s3.e4" id="DS3.d1163.s3.i1" interaction="False" />
            <pair e1="DS3.d1163.s3.e0" e2="DS3.d1163.s3.e4" id="DS3.d1163.s3.i2" interaction="False" />
            <pair e1="DS3.d1163.s3.e2" e2="DS3.d1163.s3.e4" id="DS3.d1163.s3.i3" interaction="False" />
            <pair e1="DS3.d1163.s3.e1" e2="DS3.d1163.s3.e4" id="DS3.d1163.s3.i4" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1164" origId="9988678">
        <sentence id="DS3.d1164.s0" origId="9988678-6" text="In a cell-free system, Decorin induces autophosphorylation of purified EGF receptor by activating the receptor tyrosine kinase and can also act as a substrate for the EGF receptor kinase itself.">
            <entity id="DS3.d1164.s0.e0" origId="P07585,Q6FH10,A0A024RBG6" charOffset="23-30" type="protein" text="Decorin"/>
            <entity id="DS3.d1164.s0.e1" origId="P00533" charOffset="71-83" type="protein" text="EGF receptor"/>
            <entity id="DS3.d1164.s0.e2" origId="6057,90983769" charOffset="111-119" type="compound" text="tyrosine"/>
            <entity id="DS3.d1164.s0.e3" origId="P00533" charOffset="167-179" type="protein" text="EGF receptor"/>
            <pair e1="DS3.d1164.s0.e2" e2="DS3.d1164.s0.e1" id="DS3.d1164.s0.i0" interaction="False" />
            <pair e1="DS3.d1164.s0.e2" e2="DS3.d1164.s0.e0" id="DS3.d1164.s0.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1165" origId="9988680">
        <sentence id="DS3.d1165.s0" origId="9988680-5" text="These results demonstrate a mitochondrial iron cycle in which Yfh1p regulates mitochondrial iron efflux.">
            <entity id="DS3.d1165.s0.e0" origId="23925,67172434" charOffset="42-46" type="compound" text="iron"/>
            <entity id="DS3.d1165.s0.e1" origId="Q07540" charOffset="62-67" type="protein" text="Yfh1p"/>
            <entity id="DS3.d1165.s0.e2" origId="23925,67172434" charOffset="92-96" type="compound" text="iron"/>
            <pair e1="DS3.d1165.s0.e0" e2="DS3.d1165.s0.e1" id="DS3.d1165.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1166" origId="9988682">
        <sentence id="DS3.d1166.s0" origId="9988682-1" text="A novel human UDP-GlcNAc:Gal/GlcNAcbeta1-3GalNAcalpha beta1, 6GlcNAc-transferase, designated C2/4GnT, was identified by BLAST analysis of expressed sequence tags.">
            <entity id="DS3.d1166.s0.e0" origId="445675" charOffset="14-24" type="compound" text="UDP-GlcNAc"/>
            <entity id="DS3.d1166.s0.e1" origId="25061208" charOffset="29-53" type="compound" text="GlcNAcbeta1-3GalNAcalpha"/>
            <entity id="DS3.d1166.s0.e2" origId="O95395,A0A024R5T9,Q02742,Q86T81" charOffset="93-100" type="protein" text="C2/4GnT"/>
            <pair e1="DS3.d1166.s0.e0" e2="DS3.d1166.s0.e2" id="DS3.d1166.s0.i0" interaction="False" />
            <pair e1="DS3.d1166.s0.e1" e2="DS3.d1166.s0.e2" id="DS3.d1166.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1166.s1" origId="9988682-3" text="Expression of the secreted form of C2/4GnT in insect cells showed that the gene product had UDP-N-acetyl-alpha-D-glucosamine:acceptor beta1, 6-N-acetylglucosaminyltransferase (beta1,6GlcNAc-transferase) activity.">
            <entity id="DS3.d1166.s1.e0" origId="O95395,A0A024R5T9,Q02742,Q86T81" charOffset="35-42" type="protein" text="C2/4GnT"/>
            <entity id="DS3.d1166.s1.e1" origId="6031" charOffset="92-95" type="compound" text="UDP"/>
            <entity id="DS3.d1166.s1.e2" origId="82313" charOffset="96-124" type="compound" text="N-acetyl-alpha-D-glucosamine"/>
            <entity id="DS3.d1166.s1.e3" origId="O95395,A0A024R5T9" charOffset="176-201" type="protein" text="beta1,6GlcNAc-transferase"/>
            <pair e1="DS3.d1166.s1.e1" e2="DS3.d1166.s1.e0" id="DS3.d1166.s1.i0" interaction="False" />
            <pair e1="DS3.d1166.s1.e1" e2="DS3.d1166.s1.e3" id="DS3.d1166.s1.i1" interaction="False" />
            <pair e1="DS3.d1166.s1.e2" e2="DS3.d1166.s1.e0" id="DS3.d1166.s1.i2" interaction="False" />
            <pair e1="DS3.d1166.s1.e2" e2="DS3.d1166.s1.e3" id="DS3.d1166.s1.i3" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1167" origId="9988683">
        <sentence id="DS3.d1167.s0" origId="9988683-0" text="Mitogenic up-regulation of the PRL-1 protein-tyrosine phosphatase gene by Egr-1. Egr-1 activation is an early event in liver regeneration.">
            <entity id="DS3.d1167.s0.e0" origId="Q78EG7" charOffset="31-36" type="protein" text="PRL-1"/>
            <entity id="DS3.d1167.s0.e1" origId="6057,90983769" charOffset="45-53" type="compound" text="tyrosine"/>
            <entity id="DS3.d1167.s0.e2" origId="P08046,Q544D6,Q8CAT6" charOffset="74-79" type="protein" text="Egr-1"/>
            <entity id="DS3.d1167.s0.e3" origId="P08046,Q544D6,Q8CAT6" charOffset="81-86" type="protein" text="Egr-1"/>
            <pair e1="DS3.d1167.s0.e1" e2="DS3.d1167.s0.e0" id="DS3.d1167.s0.i0" interaction="False" />
            <pair e1="DS3.d1167.s0.e1" e2="DS3.d1167.s0.e2" id="DS3.d1167.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1167.s1" origId="9988683-3" text="The expression of the PRL-1 gene, which encodes a unique nuclear protein-tyrosine phosphatase, is rapidly induced in regenerating liver and mitogen-treated cells.">
            <entity id="DS3.d1167.s1.e0" origId="Q78EG7" charOffset="22-27" type="protein" text="PRL-1"/>
            <entity id="DS3.d1167.s1.e1" origId="6057,90983769" charOffset="73-81" type="compound" text="tyrosine"/>
            <pair e1="DS3.d1167.s1.e1" e2="DS3.d1167.s1.e0" id="DS3.d1167.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1168" origId="9988687">
        <sentence id="DS3.d1168.s0" origId="9988687-1" text="To isolate new antioxidant genes, we have searched for activities that would rescue the tert-butyl hydroperoxide (t-BOOH)-hypersensitive phenotype of a Saccharomyces cerevisiae strain deleted for the gene encoding the oxidative stress response regulator Skn7.">
            <entity id="DS3.d1168.s0.e0" origId="90937099" charOffset="88-98" type="compound" text="tert-butyl"/>
            <entity id="DS3.d1168.s0.e1" origId="784" charOffset="99-112" type="compound" text="hydroperoxide"/>
            <entity id="DS3.d1168.s0.e2" origId="P38889" charOffset="254-258" type="protein" text="Skn7"/>
            <pair e1="DS3.d1168.s0.e0" e2="DS3.d1168.s0.e2" id="DS3.d1168.s0.i0" interaction="False" />
            <pair e1="DS3.d1168.s0.e1" e2="DS3.d1168.s0.e2" id="DS3.d1168.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1168.s1" origId="9988687-2" text="We report the characterization of AHP1, which encodes a 19-kDa protein similar to the AhpC/TSA protein family within a small region encompassing Cys-62 of Ahp1p and the highly conserved N-terminal catalytic AhpC/TSA cysteine.">
            <entity id="DS3.d1168.s1.e0" origId="P38013" charOffset="155-160" type="protein" text="Ahp1p"/>
            <entity id="DS3.d1168.s1.e1" origId="5862,90793998" charOffset="216-224" type="compound" text="cysteine"/>
            <pair e1="DS3.d1168.s1.e1" e2="DS3.d1168.s1.e0" id="DS3.d1168.s1.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1168.s2" origId="9988687-5" text="Similar to yeast Tsa1p, Ahp1p forms a disulfide-linked homodimer upon oxidation and in vivo requires the presence of the thioredoxin system but not of glutathione to perform its antioxidant protective function.">
            <entity id="DS3.d1168.s2.e0" origId="P34760" charOffset="17-22" type="protein" text="Tsa1p"/>
            <entity id="DS3.d1168.s2.e1" origId="P38013" charOffset="24-29" type="protein" text="Ahp1p"/>
            <entity id="DS3.d1168.s2.e2" origId="124886,20725278,745" charOffset="151-162" type="compound" text="glutathione"/>
            <pair e1="DS3.d1168.s2.e2" e2="DS3.d1168.s2.e0" id="DS3.d1168.s2.i0" interaction="False" />
            <pair e1="DS3.d1168.s2.e2" e2="DS3.d1168.s2.e1" id="DS3.d1168.s2.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1168.s3" origId="9988687-7" text="Therefore, with respect to substrate specificity, Ahp1p differs from Tsa1p and is similar to prokaryotic alkyl hydroperoxide reductase AhpC.">
            <entity id="DS3.d1168.s3.e0" origId="P38013" charOffset="50-55" type="protein" text="Ahp1p"/>
            <entity id="DS3.d1168.s3.e1" origId="P34760" charOffset="69-74" type="protein" text="Tsa1p"/>
            <entity id="DS3.d1168.s3.e2" origId="784" charOffset="111-124" type="compound" text="hydroperoxide"/>
            <pair e1="DS3.d1168.s3.e2" e2="DS3.d1168.s3.e1" id="DS3.d1168.s3.i0" interaction="False" />
            <pair e1="DS3.d1168.s3.e2" e2="DS3.d1168.s3.e0" id="DS3.d1168.s3.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1168.s4" origId="9988687-8" text="These data suggest that Ahp1p is a yeast orthologue of prokaryotic AhpC and justifies its name of yeast alkyl hydroperoxide reductase.">
            <entity id="DS3.d1168.s4.e0" origId="P38013" charOffset="24-29" type="protein" text="Ahp1p"/>
            <entity id="DS3.d1168.s4.e1" origId="784" charOffset="110-123" type="compound" text="hydroperoxide"/>
            <pair e1="DS3.d1168.s4.e1" e2="DS3.d1168.s4.e0" id="DS3.d1168.s4.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1169" origId="9988688">
        <sentence id="DS3.d1169.s0" origId="9988688-2" text="The beta, gamma, and delta subunits, that contribute the guanine nucleotide exchange activity of EF-1H, are tightly associated with the NH2-terminal polypeptide extension of valyl-tRNA synthetase.">
            <entity id="DS3.d1169.s0.e0" origId="764" charOffset="57-64" type="compound" text="guanine"/>
            <entity id="DS3.d1169.s0.e1" origId="6329" charOffset="136-140" type="compound" text="NH2-"/>
            <entity id="DS3.d1169.s0.e2" origId="P26640,A0A024RCN6" charOffset="174-195" type="protein" text="valyl-tRNA synthetase"/>
            <pair e1="DS3.d1169.s0.e1" e2="DS3.d1169.s0.e2" id="DS3.d1169.s0.i0" interaction="False" />
            <pair e1="DS3.d1169.s0.e0" e2="DS3.d1169.s0.e2" id="DS3.d1169.s0.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1169.s1" origId="9988688-4" text="We show here that the addition of EF-1alpha and GTP in excess in the aminoacylation mixture is accompanied by a 2-fold stimulation of valyl-tRNAVal synthesis catalyzed by the valyl-tRNA synthetase component of the ValRS.EF-1H complex.">
            <entity id="DS3.d1169.s1.e0" origId="P68104,Q6IPS9" charOffset="34-43" type="protein" text="EF-1alpha"/>
            <entity id="DS3.d1169.s1.e1" origId="68290" charOffset="134-139" type="compound" text="valyl"/>
            <entity id="DS3.d1169.s1.e2" origId="P26640,A0A024RCN6" charOffset="175-196" type="protein" text="valyl-tRNA synthetase"/>
            <pair e1="DS3.d1169.s1.e1" e2="DS3.d1169.s1.e2" id="DS3.d1169.s1.i0" interaction="False" />
            <pair e1="DS3.d1169.s1.e1" e2="DS3.d1169.s1.e0" id="DS3.d1169.s1.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1169.s2" origId="9988688-5" text="This effect is not observed in the presence of EF-1alpha and GDP or EF-Tu.GTP and requires association of valyl-tRNA synthetase within the ValRS.EF-1H complex.">
            <entity id="DS3.d1169.s2.e0" origId="P68104,Q6IPS9" charOffset="47-56" type="protein" text="EF-1alpha"/>
            <entity id="DS3.d1169.s2.e1" origId="8977" charOffset="61-64" type="compound" text="GDP"/>
            <entity id="DS3.d1169.s2.e2" origId="P26640,A0A024RCN6" charOffset="106-127" type="protein" text="valyl-tRNA synthetase"/>
            <pair e1="DS3.d1169.s2.e1" e2="DS3.d1169.s2.e2" id="DS3.d1169.s2.i0" interaction="False" />
            <pair e1="DS3.d1169.s2.e1" e2="DS3.d1169.s2.e0" id="DS3.d1169.s2.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1170" origId="9988690">
        <sentence id="DS3.d1170.s0" origId="9988690-0" text="Role of the flavin midpoint potential and NAD binding in determining NAD versus oxygen reactivity of xanthine oxidoreductase.">
            <entity id="DS3.d1170.s0.e0" origId="2016" charOffset="12-18" type="compound" text="flavin"/>
            <entity id="DS3.d1170.s0.e1" origId="5893" charOffset="42-45" type="compound" text="NAD"/>
            <entity id="DS3.d1170.s0.e2" origId="5893" charOffset="69-72" type="compound" text="NAD"/>
            <entity id="DS3.d1170.s0.e3" origId="977" charOffset="80-86" type="compound" text="oxygen"/>
            <entity id="DS3.d1170.s0.e4" origId="P80457" charOffset="101-124" type="protein" text="xanthine oxidoreductase"/>
            <pair e1="DS3.d1170.s0.e0" e2="DS3.d1170.s0.e4" id="DS3.d1170.s0.i0" interaction="False" />
            <pair e1="DS3.d1170.s0.e3" e2="DS3.d1170.s0.e4" id="DS3.d1170.s0.i1" interaction="False" />
            <pair e1="DS3.d1170.s0.e1" e2="DS3.d1170.s0.e4" id="DS3.d1170.s0.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1170.s1" origId="9988690-10" text="However, 1-deaza-XDH does exhibit xanthine/NAD activity, and 8-CN-XO has normal xanthine/oxygen activity.">
            <entity id="DS3.d1170.s1.e0" origId="P80457" charOffset="17-20" type="protein" text="XDH"/>
            <entity id="DS3.d1170.s1.e1" origId="1188" charOffset="34-42" type="compound" text="xanthine"/>
            <entity id="DS3.d1170.s1.e2" origId="5893" charOffset="43-46" type="compound" text="NAD"/>
            <entity id="DS3.d1170.s1.e3" origId="768" charOffset="63-66" type="compound" text="CN-"/>
            <entity id="DS3.d1170.s1.e4" origId="1188" charOffset="80-88" type="compound" text="xanthine"/>
            <entity id="DS3.d1170.s1.e5" origId="977" charOffset="89-95" type="compound" text="oxygen"/>
            <pair e1="DS3.d1170.s1.e5" e2="DS3.d1170.s1.e0" id="DS3.d1170.s1.i0" interaction="False" />
            <pair e1="DS3.d1170.s1.e3" e2="DS3.d1170.s1.e0" id="DS3.d1170.s1.i1" interaction="False" />
            <pair e1="DS3.d1170.s1.e1" e2="DS3.d1170.s1.e0" id="DS3.d1170.s1.i2" interaction="False" />
            <pair e1="DS3.d1170.s1.e2" e2="DS3.d1170.s1.e0" id="DS3.d1170.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1170.s2" origId="9988690-11" text="The binding of NAD to oxidized XO and XDH was investigated by ultrafiltration and isothermal titration calorimetry.">
            <entity id="DS3.d1170.s2.e0" origId="5893" charOffset="15-18" type="compound" text="NAD"/>
            <entity id="DS3.d1170.s2.e1" origId="P80457" charOffset="38-41" type="protein" text="XDH"/>
            <pair e1="DS3.d1170.s2.e0" e2="DS3.d1170.s2.e1" id="DS3.d1170.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1170.s3" origId="9988690-12" text="The Kd for the binding of NAD to XDH was determined to be 280 +/- 145 microM by ultrafiltration and 160 +/- 40 microM by isothermal titration calorimetry.">
            <entity id="DS3.d1170.s3.e0" origId="5893" charOffset="26-29" type="compound" text="NAD"/>
            <entity id="DS3.d1170.s3.e1" origId="P80457" charOffset="33-36" type="protein" text="XDH"/>
            <pair e1="DS3.d1170.s3.e0" e2="DS3.d1170.s3.e1" id="DS3.d1170.s3.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1170.s4" origId="9988690-1" text="xanthine oxidoreductase from bovine milk can be prepared in two interconvertible forms, xanthine oxidase (XO) and xanthine dehydrogenase (XDH), depending on the number of protein cysteines versus cystines.">
            <entity id="DS3.d1170.s4.e0" origId="P80457" charOffset="0-23" type="protein" text="xanthine oxidoreductase"/>
            <entity id="DS3.d1170.s4.e1" origId="1188" charOffset="0-8" type="compound" text="xanthine"/>
            <entity id="DS3.d1170.s4.e2" origId="P80457" charOffset="114-136" type="protein" text="xanthine dehydrogenase"/>
            <entity id="DS3.d1170.s4.e3" origId="P80457" charOffset="138-141" type="protein" text="XDH"/>
            <pair e1="DS3.d1170.s4.e1" e2="DS3.d1170.s4.e2" id="DS3.d1170.s4.i0" interaction="False" />
            <pair e1="DS3.d1170.s4.e1" e2="DS3.d1170.s4.e0" id="DS3.d1170.s4.i1" interaction="False" />
            <pair e1="DS3.d1170.s4.e1" e2="DS3.d1170.s4.e3" id="DS3.d1170.s4.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1170.s5" origId="9988690-2" text="Enzyme forms differ in respect to their oxidizing substrates; XDH prefers NAD to molecular oxygen, whereas XO only reacts significantly with oxygen.">
            <entity id="DS3.d1170.s5.e0" origId="P80457" charOffset="62-65" type="protein" text="XDH"/>
            <entity id="DS3.d1170.s5.e1" origId="5893" charOffset="74-77" type="compound" text="NAD"/>
            <entity id="DS3.d1170.s5.e2" origId="977" charOffset="91-97" type="compound" text="oxygen"/>
            <entity id="DS3.d1170.s5.e3" origId="977" charOffset="141-147" type="compound" text="oxygen"/>
            <pair e1="DS3.d1170.s5.e2" e2="DS3.d1170.s5.e0" id="DS3.d1170.s5.i0" interaction="False" />
            <pair e1="DS3.d1170.s5.e1" e2="DS3.d1170.s5.e0" id="DS3.d1170.s5.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1170.s6" origId="9988690-4" text="Unlike XDH, the midpoint potential of the FAD, the center at which oxygen and NAD react, is too high in XO to efficiently reduce NAD (Hunt, J., Massey, V., Dunham, W.R., and Sands, R.H. (1993) J. Biol.">
            <entity id="DS3.d1170.s6.e0" origId="P80457" charOffset="7-10" type="protein" text="XDH"/>
            <entity id="DS3.d1170.s6.e1" origId="643975" charOffset="42-45" type="compound" text="FAD"/>
            <entity id="DS3.d1170.s6.e2" origId="977" charOffset="67-73" type="compound" text="oxygen"/>
            <entity id="DS3.d1170.s6.e3" origId="5893" charOffset="78-81" type="compound" text="NAD"/>
            <entity id="DS3.d1170.s6.e4" origId="5893" charOffset="129-132" type="compound" text="NAD"/>
            <pair e1="DS3.d1170.s6.e3" e2="DS3.d1170.s6.e0" id="DS3.d1170.s6.i0" interaction="False" />
            <pair e1="DS3.d1170.s6.e2" e2="DS3.d1170.s6.e0" id="DS3.d1170.s6.i1" interaction="False" />
            <pair e1="DS3.d1170.s6.e1" e2="DS3.d1170.s6.e0" id="DS3.d1170.s6.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1170.s7" origId="9988690-7" text="To distinguish between changes in thermodynamics and in substrate binding, samples of both XO and XDH have been prepared in which the native FAD has been replaced with an FAD analog of different redox potential, 1-deaza-FAD or 8-CN-FAD.">
            <entity id="DS3.d1170.s7.e0" origId="P80457" charOffset="98-101" type="protein" text="XDH"/>
            <entity id="DS3.d1170.s7.e1" origId="643975" charOffset="141-144" type="compound" text="FAD"/>
            <entity id="DS3.d1170.s7.e2" origId="643975" charOffset="171-174" type="compound" text="FAD"/>
            <entity id="DS3.d1170.s7.e3" origId="194041" charOffset="212-223" type="compound" text="1-deaza-FAD"/>
            <entity id="DS3.d1170.s7.e4" origId="768" charOffset="229-232" type="compound" text="CN-"/>
            <entity id="DS3.d1170.s7.e5" origId="643975" charOffset="171-174" type="compound" text="FAD"/>
            <pair e1="DS3.d1170.s7.e3" e2="DS3.d1170.s7.e0" id="DS3.d1170.s7.i0" interaction="False" />
            <pair e1="DS3.d1170.s7.e4" e2="DS3.d1170.s7.e0" id="DS3.d1170.s7.i1" interaction="False" />
            <pair e1="DS3.d1170.s7.e1" e2="DS3.d1170.s7.e0" id="DS3.d1170.s7.i2" interaction="False" />
        </sentence>
        <sentence id="DS3.d1170.s8" origId="9988690-8" text="Reductive titrations indicate that both 1-deaza-XO and 1-deaza-XDH have a flavin midpoint potential similar to native XDH and that 8-CN-XO and 8-CN-XDH each have a flavin potential higher than XO.">
            <entity id="DS3.d1170.s8.e0" origId="P80457" charOffset="63-66" type="protein" text="XDH"/>
            <entity id="DS3.d1170.s8.e1" origId="2016" charOffset="74-80" type="compound" text="flavin"/>
            <entity id="DS3.d1170.s8.e2" origId="P80457" charOffset="118-121" type="protein" text="XDH"/>
            <entity id="DS3.d1170.s8.e3" origId="768" charOffset="133-136" type="compound" text="CN-"/>
            <entity id="DS3.d1170.s8.e4" origId="P80457" charOffset="118-121" type="protein" text="XDH"/>
            <entity id="DS3.d1170.s8.e5" origId="2016" charOffset="164-170" type="compound" text="flavin"/>
            <pair e1="DS3.d1170.s8.e3" e2="DS3.d1170.s8.e0" id="DS3.d1170.s8.i0" interaction="False" />
            <pair e1="DS3.d1170.s8.e1" e2="DS3.d1170.s8.e0" id="DS3.d1170.s8.i1" interaction="False" />
        </sentence>
        <sentence id="DS3.d1170.s9" origId="9988690-9" text="Both the low potential 1-deaza-XO and the high potential 8-CN-XDH contain essentially no xanthine/NAD activity.">
            <entity id="DS3.d1170.s9.e0" origId="P80457" charOffset="62-65" type="protein" text="XDH"/>
            <entity id="DS3.d1170.s9.e1" origId="1188" charOffset="89-97" type="compound" text="xanthine"/>
            <entity id="DS3.d1170.s9.e2" origId="5893" charOffset="98-101" type="compound" text="NAD"/>
            <pair e1="DS3.d1170.s9.e1" e2="DS3.d1170.s9.e0" id="DS3.d1170.s9.i0" interaction="False" />
            <pair e1="DS3.d1170.s9.e2" e2="DS3.d1170.s9.e0" id="DS3.d1170.s9.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1171" origId="9988691">
        <sentence id="DS3.d1171.s0" origId="9988691-3" text="Thus, MMP-23 lacks a recognizable signal sequence and has a short prodomain, although it contains a single cysteine residue that can be part of the cysteine-switch mechanism operating for maintaining enzyme latency.">
            <entity id="DS3.d1171.s0.e0" origId="O75900" charOffset="6-12" type="protein" text="MMP-23"/>
            <entity id="DS3.d1171.s0.e1" origId="5862,90793998" charOffset="107-115" type="compound" text="cysteine"/>
            <entity id="DS3.d1171.s0.e2" origId="5862,90793998" charOffset="148-156" type="compound" text="cysteine"/>
            <pair e1="DS3.d1171.s0.e1" e2="DS3.d1171.s0.e0" id="DS3.d1171.s0.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1171.s1" origId="9988691-5" text="Furthermore, MMP-23 is devoid of structural features distinctive of the diverse MMP subclasses, including the specific residues located close to the zinc-binding site in collagenases, the transmembrane domain of membrane-type MMPs, or the fibronectin-like domain of gelatinases.">
            <entity id="DS3.d1171.s1.e0" origId="O75900" charOffset="13-19" type="protein" text="MMP-23"/>
            <entity id="DS3.d1171.s1.e1" origId="23994" charOffset="149-153" type="compound" text="zinc"/>
            <pair e1="DS3.d1171.s1.e1" e2="DS3.d1171.s1.e0" id="DS3.d1171.s1.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1172" origId="9988693">
        <sentence id="DS3.d1172.s0" origId="9988693-2" text="We describe herein the characterization of a monoclonal antibody that selectively recognizes antithrombin in complex with either thrombin, factor Xa, or a synthetic peptide corresponding to residues P14 to P9 of the serpin's reactive center loop (RCL, ultimately cleaved between the P1 and P'1 residues).">
            <entity id="DS3.d1172.s0.e0" origId="P01008,A0A024R944" charOffset="93-105" type="protein" text="antithrombin"/>
            <entity id="DS3.d1172.s0.e1" origId="90470996" charOffset="97-105" type="compound" text="thrombin"/>
            <entity id="DS3.d1172.s0.e2" origId="Q8N726,P42771,K7PML8,G3XAG3" charOffset="199-202" type="protein" text="P14"/>
            <entity id="DS3.d1172.s0.e3" origId="445641" charOffset="247-250" type="compound" text="RCL"/>
            <pair e1="DS3.d1172.s0.e3" e2="DS3.d1172.s0.e2" id="DS3.d1172.s0.i0" interaction="False" />
            <pair e1="DS3.d1172.s0.e3" e2="DS3.d1172.s0.e0" id="DS3.d1172.s0.i1" interaction="False" />
            <pair e1="DS3.d1172.s0.e1" e2="DS3.d1172.s0.e2" id="DS3.d1172.s0.i2" interaction="False" />
            <pair e1="DS3.d1172.s0.e1" e2="DS3.d1172.s0.e0" id="DS3.d1172.s0.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1172.s1" origId="9988693-3" text="Accordingly, this antibody reacts with none of the monomeric conformers of antithrombin (native, latent, and RCL-cleaved) and does not recognize heparin-activated antithrombin or antithrombin bound to a non-catalytic mutant of thrombin (S195A, in which the serine of the charge stabilizing system has been swapped for alanine).">
            <entity id="DS3.d1172.s1.e0" origId="P01008,A0A024R944" charOffset="75-87" type="protein" text="antithrombin"/>
            <entity id="DS3.d1172.s1.e1" origId="445641" charOffset="109-112" type="compound" text="RCL"/>
            <entity id="DS3.d1172.s1.e2" origId="P01008,A0A024R944" charOffset="163-175" type="protein" text="antithrombin"/>
            <entity id="DS3.d1172.s1.e3" origId="P01008,A0A024R944" charOffset="163-175" type="protein" text="antithrombin"/>
            <entity id="DS3.d1172.s1.e4" origId="90470996" charOffset="79-87" type="compound" text="thrombin"/>
            <entity id="DS3.d1172.s1.e5" origId="5951" charOffset="257-263" type="compound" text="serine"/>
            <entity id="DS3.d1172.s1.e6" origId="5950" charOffset="318-325" type="compound" text="alanine"/>
            <pair e1="DS3.d1172.s1.e1" e2="DS3.d1172.s1.e0" id="DS3.d1172.s1.i0" interaction="False" />
            <pair e1="DS3.d1172.s1.e4" e2="DS3.d1172.s1.e0" id="DS3.d1172.s1.i1" interaction="False" />
            <pair e1="DS3.d1172.s1.e6" e2="DS3.d1172.s1.e0" id="DS3.d1172.s1.i2" interaction="False" />
            <pair e1="DS3.d1172.s1.e5" e2="DS3.d1172.s1.e0" id="DS3.d1172.s1.i3" interaction="False" />
        </sentence>
        <sentence id="DS3.d1172.s2" origId="9988693-4" text="The neoepitope encompasses the motif DAFHK, located in native antithrombin on strand 4 of beta-sheet A, which becomes strand 5 of beta-sheet A in the RCL-cleaved and latent conformers.">
            <entity id="DS3.d1172.s2.e0" origId="P01008,A0A024R944" charOffset="62-74" type="protein" text="antithrombin"/>
            <entity id="DS3.d1172.s2.e1" origId="445641" charOffset="150-153" type="compound" text="RCL"/>
            <pair e1="DS3.d1172.s2.e1" e2="DS3.d1172.s2.e0" id="DS3.d1172.s2.i0" interaction="False" />
        </sentence>
        <sentence id="DS3.d1172.s3" origId="9988693-5" text="The inferences on the structure of the antithrombin-protease stable complex are that either a major remodeling of antithrombin accompanies the final elaboration of the complex or that, within the complex, at the most residues P14 to P6 of the RCL are inserted into beta-sheet A.">
            <entity id="DS3.d1172.s3.e0" origId="P01008,A0A024R944" charOffset="39-51" type="protein" text="antithrombin"/>
            <entity id="DS3.d1172.s3.e1" origId="P01008,A0A024R944" charOffset="114-126" type="protein" text="antithrombin"/>
            <entity id="DS3.d1172.s3.e2" origId="Q8N726,P42771,K7PML8,G3XAG3" charOffset="226-229" type="protein" text="P14"/>
            <entity id="DS3.d1172.s3.e3" origId="445641" charOffset="243-246" type="compound" text="RCL"/>
            <pair e1="DS3.d1172.s3.e3" e2="DS3.d1172.s3.e2" id="DS3.d1172.s3.i0" interaction="False" />
            <pair e1="DS3.d1172.s3.e3" e2="DS3.d1172.s3.e0" id="DS3.d1172.s3.i1" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1173" origId="9988695">
        <sentence id="DS3.d1173.s0" origId="9988695-9" text="No changes in either the Vmax or Km values of sphingomyelin or of GM3 synthase were detected after FB1 treatment.">
            <entity id="DS3.d1173.s0.e0" origId="O88829" charOffset="66-78" type="protein" text="GM3 synthase"/>
            <entity id="DS3.d1173.s0.e1" origId="2733487,62314,3431" charOffset="99-102" type="compound" text="FB1"/>
            <pair e1="DS3.d1173.s0.e1" e2="DS3.d1173.s0.e0" id="DS3.d1173.s0.i0" interaction="False" />
        </sentence>
    </document>
    <document id="DS3.d1174" origId="9988697">
        <sentence id="DS3.d1174.s0" origId="9988697-1" text="A protein fraction of mitochondria from human acute lymphocytic leukemia cells, which could be reconstituted into proteoliposomes to have dCTP transport activity, has been partially purified by hydroxyapatite and blue Sepharose chromatography.">
            <entity id="DS3.d1174.s0.e0" origId="Q24117,M9NDP1" charOffset="138-142" type="protein" text="dCTP"/>
            <entity id="DS3.d1174.s0.e1" origId="14781" charOffset="194-208" type="compound" text="hydroxyapatite"/>
            <entity id="DS3.d1174.s0.e2" origId="11966311" charOffset="218-227" type="compound" text="Sepharose"/>
            <pair e1="DS3.d1174.s0.e1" e2="DS3.d1174.s0.e0" id="DS3.d1174.s0.i0" interaction="False" />
            <pair e1="DS3.d1174.s0.e2" e2="DS3.d1174.s0.e0" id="DS3.d1174.s0.i1" interaction="False" />
        </sentence>
</document>
</corpus>
